<SEC-DOCUMENT>0001305253-23-000005.txt : 20230317
<SEC-HEADER>0001305253-23-000005.hdr.sgml : 20230317
<ACCEPTANCE-DATETIME>20230316183446
ACCESSION NUMBER:		0001305253-23-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230317
DATE AS OF CHANGE:		20230316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eiger BioPharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001305253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				361004130
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36183
		FILM NUMBER:		23740189

	BUSINESS ADDRESS:	
		STREET 1:		2155 PARK BOULEVARD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-279-9845

	MAIL ADDRESS:	
		STREET 1:		2155 PARK BOULEVARD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celladon Corp
		DATE OF NAME CHANGE:	20041005
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>eigr-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5bf4cbbb-10e9-4fbc-b4bb-3a741d1bed32,g:0d7ff615-48b4-4d72-96cc-45180aee1521,d:55f26684d5024316bef45166a614e201--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:eigr="http://www.eigerbio.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>eigr-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:AmendmentFlag" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-36">0001305253</ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-37">2022</ix:nonNumeric><ix:nonNumeric contextRef="i10c618b5c7b3487e9779d512b4de6cb1_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-888">0</ix:nonNumeric><ix:nonNumeric contextRef="i6193b2da2c0048398fdfab50bdd10c98_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-889">0</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="eigr-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d807711b4f64b30a7b7788c5e328d70_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5b0214e5e20a40479ca62fa1f0e66c24_I20230313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965b044302dc48988da35b57cfb58274_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6769059acf419584a1d5e087c7d813_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iabac5190f6fd4b358ed63396e06def66_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd62fc9b3a24432b3e2aae65a93e3a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id179859417824997b40e168360961323_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dec7376c9ed41ca8bc576d43df8f8c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib76f8832abac4cfea3d3116b0eeedbe1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2d5cecd217418582eec551acd8d836_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia386820e405b4bf383170b67729d1511_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8cfaed52a2d473ab12f3b5530650c41_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380647f21fbb4f4b88a32a72fa283b95_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f3f456db4f4a55a3d22861cea918c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49673d67a34044e3a750f2b9178048a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1713a9ff0046649a86f61420a19003_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b36575981b4572bcb7ca1dc5769835_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430636db1f0f42f2ac9906c42783a48f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5569a83205404b1ab3e0541a2035e937_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd0e307c2eab47c5a18cefb7aad66078_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5bbf3a04c3844a28b4b670e4ceca7a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7b5637f1bc435fbeb01ba1c65e4e8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad1535391c54ca0a4cf8079da469538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607fa35bf31f4c78b9dd13096251e2ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ea87a513d646d09871aebfe33508a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f351ad36ff44a06a963475dcfb18d78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec887a30f3da48368433567628e641f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63379744fdd040ef8ba43ddec4a1793c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf88f13c190f43639edfd10e3b5f87b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47d708618bb4821bc17b74b8bd55ef1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a49e4c035a341fba613eb1be522b4a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284faebef99d43ad8a30a1beac1378bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b0e05eb8a74058b915db9040827fd8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d24ef6e4884de5be511fe91960c05c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1651d333e874061b4abfcd49f5976e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>eigr:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3c0ff92a272442afaa01f8a3b8e72b36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i243c690d5ce3462c865847425d9c4b48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie052ceb522c94669817dae862de6dd4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e1792926524fcb95997fa9f9ef3f47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606a6b3724044b869c02652034594518_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfcec53252b04308b81a3cceadbdd73f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia328cb20d25e4fab95b8005fa9861f94_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f52fce331b4f66a6e112c7e3be3f98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822a4e7e22674f7bbb06ac44f94c3932_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d8abc424bd4f599a92cdb29f6579f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f285951c75439fabaef052cce22e5c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8e4b3a3c1f4746a43ddffd760f8621_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6001d47ec21d4e1eb84a3b4279669161_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:AutorisationTemporaireDUtlisationMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394cd5e381054e4889a9aad84ab79747_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5d0c2a8148487aa4d0984dc7e1f99a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ac15c5f9d74de499a4fe9278a01e7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f5cc5d592e405dbec8dfa432ab7e43_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca1a86dbf584c8a9e5686d5ab7063c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ffc44f911d84c7e8b5688da7a44b998_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5485fa3aad4734a238db7b097d944e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58d979ab27f4989884fc5e44ee5ba47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad646a38b894ce5a9b00244c2be3b71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca3d92946644292bfe24473fcc4be04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29e2e430ce08456580668540fb412dad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i723c7034a80843358bb376fffac512d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i046e24627cb54f7189bede6e1170857e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552f64c943e64319a4ce95e39943680e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceddcfeabe854c64be9f9598bcbb3de0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe8063b179f430aa2aa6b702e9b306c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eef20e8a0334e0ba1d0d3ca4318cddf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ec97ca82ce4eaab0fe2d816a068638_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afe7b4dbf6b4c01a3a293ce9ee8ddf9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dda2ffdbb7449b99003a29733a4d967_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3710956fd50341c98bf6174e70730c41_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564ce4de58c74e4b8c4230bf90320a01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcbf0466704049dab4b0a5022b8f1e03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97feebbd9cc94ec48c7937f8f4950348_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7631982a357a40a69c633f5518769a9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib532a65e081b47d0a19d3b35f518a757_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab1c22a221540b9a784d77e13b63afd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcaac54148842f482fb9f6ab25e2ed3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ecf5e8208174b24a163cd9c86a1f6a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230066a3071c4132b69848eae00a92eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36a17f8d193244e19ada1c34fd6361e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232fe125fe24498fa3256c6f183ee314_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968a09cb75864d2bbf238de4188016c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cd42c9f677f475ba44a739bbcb8d569_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c955bd8cca416686ce21b475131066_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee904f5f9d1a470abe8bd130514c72f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9339f160d84eebbc7070bc3bddd479_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1af0f8a55164e0eb8dcc387d8ee162c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib672ffc131c141c89ec35e1cdc6d0888_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib149a8ec14b946089462bf96a8cb0335_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d031ec06fa747218f0529c0d926de3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70fa2af8a8064c0b96426610b6658882_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fa03a6d5dbf4539a01f114da77c480a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78913e7ab2e4303a5543c869a3218e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6eb2b8528634735a6af7527a73a9128_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c4688b49a6540e98c724acb8b04a2ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2171cc598bbc4faa9d1dfb89113cc454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0faa0526436449a8d5aedef9fe5142d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5464846d99ce4aafbbb96b5563f1dc1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a60c80d69a4de39ff38d8b55aef975_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide1b1828296e40aeb62b7b75b1921d5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26381ba35f554000928e20baa54aaf82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6182cf377fb42d5b55072fb1f5fcc4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e14c606c1641bb863e16722c0cbc4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4960562ae1a43d5a1836ee70a2a0ced_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia72e03af8e4d4e029c34f04f781a6afe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia401dca885444fa3b7a5f036bf820425_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia921678878f04db6adbca4595688a360_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af19da2c6184c899e48459eaf368c09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a349046f334530a41f51eebfe060e1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice98876375a746198c11b6156223c890_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40856ef0109745e6bca5398e2deb59e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i806febb1a3f14a009905147c299141c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-11</xbrli:startDate><xbrli:endDate>2018-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e9958c1f874287a316e0d40a1ee557_I20180811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215c0c22884741439373b4bb5cf353ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01aaeb68a154d89b511aa445e1f10c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38883ca632644fd93eb6fb8b5632ec4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1093f397da6f4ccbaa4327f49cc99f6b_D20180515-20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-15</xbrli:startDate><xbrli:endDate>2018-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26693b4f07bb413dbe7693e3a8733d02_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312ccf68285749298fc9eaba96fdb15e_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b0cb8cbbf34f3a92bae7940e633560_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b448fdcc72493fa8f472a5547e9c5e_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522fba7c7f6b4899a22248daae63fdef_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c796ad9f4d4cd8b485cdc08c8eea06_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a015d0ea8614264a0d243ef6aad2068_I20100930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b02f365ff984634a4f599eb3ff0b476_D20100901-20100930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-09-01</xbrli:startDate><xbrli:endDate>2010-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31cc6fec54de49cbaac8df50f262c636_D20180515-20180515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-15</xbrli:startDate><xbrli:endDate>2018-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a31c2673294cd7a5b85a7f0ceb46ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424ffec162f345b6805146b3e1859078_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1f282e249c451586adac7467c9a9ae_D20101201-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121466ae35884ba0b24b9f6d9978e273_I20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070111655a2d458abdc58cce6fdf5362_I20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff02c15b30e423587839d54ad95f618_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78240c9a110c474c969a366314c34f1a_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da09837945d43e4865652c607fde425_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d316f19952e4069af11841afd2c9639_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba57b158870e40fdb866d4b2678df531_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6368f25382834801a6682e48b0981e29_D20160322-20160322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-22</xbrli:startDate><xbrli:endDate>2016-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e59300f06d44a9b0494eb5cc7fed9c_I20160322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290212954c99401aae042a9ef1f88723_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6901de3d60ff4db1916a73b9d096e7a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b1a8da043d451197ac210c2a30510d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5c0da13bd14c669d92be3294f92711_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8114b95ec2a24e868a25140a3f0158b2_D20201120-20201120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-20</xbrli:startDate><xbrli:endDate>2020-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f59d99d10d04de492abcac7063c4d9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87cb0850d4c413db472e1cfa4e0516f_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ab44b29d644c6e854e9000bd3ea4dd_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5efa461c8d184d5bbf8fae9a20d47978_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57d9437106f448c83d0afbcf0114df9_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812e7a0b79e5490fbf8cc0469a5ce008_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19f9a06b61e4ddfa40008408ebc9e74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0abd73b32db44aca977bb76f57865f5_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4a7a59d419a456a86819f0db13f903a_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia94b90e55cdc4829a94a8b1e45fbba04_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eigr:VariableRateComponentAxis">eigr:VariableRateComponentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9713023dded64c8ea5adac4bda00c7e2_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="eigr:VariableRateComponentAxis">eigr:VariableRateComponentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f055c598d7454da7696030a389cafe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c422a139a345809437127a7479b57a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBAndCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3899d90a98f843c28f7608b176abbecb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2913f5ce26fd4b958098cf5381ee746d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8c23ec655449c28e8237fc61998863_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24dada1a3b5242b5a75afa813589f088_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788faa633fdf42068abaa39dc2edf9d3_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:InnovatusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16fb4c62472c449a9b7982be7439e638_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:InnovatusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c72d39d32d498788a5ca7d700ec4e8_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c6b12ce519418c8440d547c323d70f_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d31eefba974ecf8d96ae66cc576d69_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ef2a5a94d44cb39fe45dcedfee9769_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442e61d07b494a89af46c51bf3c39c99_I20180803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d5cb28ee524a039c68d61469c0487f_I20190305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87edad638cf242f0a34985f29b06a8ed_D20190305-20190305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-05</xbrli:startDate><xbrli:endDate>2019-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c59ab4e6cc45cab9946e312f152846_I20190305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676ed4dafff44a7db6aea95716fda14c_I20190305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanFifthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-23</xbrli:startDate><xbrli:endDate>2021-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i054ac64c0a9a48f39f0672426b1763f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed09a12b16a48eca75c2639c1883cb0_D20211006-20211006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062780bfd6314b9aa885ba2d25702a18_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911bf9268d42447e85041ca1379f6928_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d011b31a4674517a07eb189e6e48b8a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e876d14531242919ba3e7c51a9f6620_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13530243d7b34f1c827b988b0901189a_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b089476acf40c8a5b5c34b133005bc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd0a96271fe4fe19e51825f3a419589_D20220331-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ff52c712c8d4b55877e2745e77f4a16_D20220325-20220325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b3390cbd84f4e9b830a1dae02e73f6d_D20220325-20220325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-25</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedce0e0e2285449bb203fa52f3e4b81a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ec4a30b09349279833954d224dead9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a28c62f12bf4413a513b312483af157_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eigr:HoldersOfTenPercentOrMoreOfVotingPowerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7aafa6247ea4c65a7c5873f86ff4fd6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09207d695d8c4253a8e427f8c6d035d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4028eb882514f05b6a41d5478817cee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief5a5c4c1ae64fc4ab9b4e7b4056be2a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:InducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2dd632aefc143bb8b84aea6a35fcbaf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:InducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73059116eb97484196f938499f7d5281_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec04d4ad35c443b99bbe1aa326e6d2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c049d0b7ef5404389a868b354fa749a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac2aed31bb54cc18cb6ae41a4a4024c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71407d30e650431da3d0986454f2222a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b3e189eaf243f4af6da3f36cd256b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51aa14a7322841a28eb8b15ffc596162_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79074ea06073434787ed7105b645d332_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09b60b6370048899551663b184c6f48_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdaee817ecba4432b442ecd4baec5196_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03ebee97bdd465fb594bd07b6658cd6_I20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94322c77d52a4ebc957caaa8538856a0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c1d057c3104eb38128ca6d2e56cc34_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d49d00344d4c8d9255a8ab257ddb21_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b559f643dc4ebe82779e55c0713860_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:PerformanceStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4545b7ea67d340b68656d572237dd471_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:PerformanceStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26ed6605602415ead8fa34aa2933308_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5fd9f65a07451c9c163efc7530542c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96530fc320b84544b9696cf29d5efa21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:PerformanceStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4234b3566e684a2bbc69705bd15492d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78457377acd944119ee3cbc487a296cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77186ca2509745eb8c68fb8c32e77418_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891dd7eeeb804b7180c764a60670443b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf58d38de1c412a9467e8c815412e01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e0daa1d8724811b59a7c133d069b57_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea11b6251f7c49fbab31dbf60503d7f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d45e0236dca466d80b365de652362f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c618b5c7b3487e9779d512b4de6cb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6193b2da2c0048398fdfab50bdd10c98_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1c32c7c8074780b2a2e9572bb98ea4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i038017cc1aff4f5b802f302a04651e70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3f6e0f47b76477398971584c280e787_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eigr:OrphanDrugCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd9ad44e31d4bb09abdd6c03737db5d_I20221108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6112fe6606643398b7e891f4e07a185_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i88df8041ee074c629e1deb74604adbcd_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e22fa7313ce40ddbecce4a6177c2baf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:PatheonIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e4723198e54d37b6163a5733e2bfed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:PatheonIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd59ee561b343dab5061b07e80ba9b4_I20230206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f726335e506438cbf098a44665c4473_D20230206-20230206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8892b34c54854c50ad3eda9fa1852d3d_I20230206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4934175f59ca42c484533a305704b3c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1325efe242c2485cb3654887aef1a15d_I20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="account"><xbrli:measure>eigr:account</xbrli:measure></xbrli:unit><xbrli:context id="id907190c69db4635b5b4ed706d83cdfe_I20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eigr:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i55f26684d5024316bef45166a614e201_810"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from   &#160;&#160;&#160;&#160;   to          </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">001-36183</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">Eiger BioPharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">33-0971591</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">2155 Park Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-11">Palo Alto</ix:nonNumeric>, <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-13">94306</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:700;line-height:115%"> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:CityAreaCode" id="f-14">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-15">272 6138</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:37.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:TradingSymbol" id="f-17">EIGR</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9746;</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9746;</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#168;</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2022 totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i5d807711b4f64b30a7b7788c5e328d70_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-28">274,107,513</ix:nonFraction> based on the closing price of $6.30 as reported by the Nasdaq Global Market. This calculation excludes 457,654 shares held by executive officers, directors and stockholders that the Registrant has concluded are affiliates of the Registrant. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the Registrant.</span></div><div style="margin-top:2pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, as of March 13, 2023 was <ix:nonFraction unitRef="shares" contextRef="i5b0214e5e20a40479ca62fa1f0e66c24_I20230313" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">44,158,437</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-30" escape="true"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Part III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2023 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2022.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:AuditorName" id="f-31">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:AuditorLocation" id="f-32">San Francisco, CA</ix:nonNumeric>, Auditor ID: <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="dei:AuditorFirmId" id="f-33">185</ix:nonNumeric></span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EIGER BIOPHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_552">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_552">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_13">ITEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_563">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_563">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_16">ITEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_130">40</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_19">ITEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_591">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_591">81</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_22">ITEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_586">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_586">81</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_25">ITEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_127">81</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_28">ITEM 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_139">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_139">82</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_10">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_10">83</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_34">ITEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17pt;text-indent:-17pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_617">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_617">83</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_37">ITEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_557">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_557">84</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_40">ITEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_67">85</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_85">ITEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_118">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_118">95</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_88">ITEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_13">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_13">95</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 9.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_626">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_626">125</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 9A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_121">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_121">125</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 9B.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_631">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_631">126</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline">PART III</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_124">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 10.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_133">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_133">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 11.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_136">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_136">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 12.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17pt;text-indent:-17pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_142">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_142">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 13.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_671">Certain Relationships and Related Party Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_671">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 14.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_666">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_666">127</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline">PART IV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_642">128</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 15.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_145">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_145">128</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ITEM 16.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_655">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i55f26684d5024316bef45166a614e201_655">132</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_552"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; may contain &#8220;forward-looking statements.&#8221; We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain supply of our commercial and clinical trial materials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to scale our commercial operations;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to finance the continued advancement of our development pipeline products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to research, develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain favorable reimbursement and pricing and the rate and degree of market acceptance of our product candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to manufacture product necessary to support regulatory approvals and timely meet commercial requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential approval of Zokinvy in jurisdictions outside of the U.S., including the European Union;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the performance of our third-party suppliers and manufacturers;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the filing date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div id="i55f26684d5024316bef45166a614e201_563"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Business</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. All five of our rare disease programs have FDA Breakthrough Therapy designation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our HDV platform includes two first-in-class therapies in Phase 3 clinical trials that target critical host processes involved in viral replication. Lonafarnib is a first-in-class, oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III interferon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D-LIVR is the pivotal Phase 3 study of lonafarnib boosted with ritonavir, alone or in combination with peginterferon alfa-2a, for HDV. The study completed enrollment of 407 patients, and we announced topline Week 48 data in December 2022, with Week 72 data expected in mid-2023.  LIMT-2 is the pivotal Phase 3 study of peginterferon lambda for HDV that is currently enrolling and dosing patients with a planned enrollment of 150 patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing avexitide, a first in class, well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs and no approved therapies: congenital hyperinsulinism (HI) and post-bariatric hypoglycemia (PBH). Avexitide has completed Phase 2 for both indications, and we initiated Phase 3 study startup activities for HI in 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approved our first commercial product, Zokinvy (lonafarnib), to reduce risk of mortality of Hutchinson-Gilford progeria syndrome (HGPS) and for treatment of processing-deficient progeroid laminopathies (PL) with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, on November 20, 2020. Collectively known as progeria, these are ultra-rare and rapidly fatal genetic conditions of accelerated aging in children. In July 2022, we announced that the European Commission (EC) granted Eiger a centralized marketing authorization (MA). The EC's centralized MA is valid in all 27 EU member states plus Iceland, Liechtenstein, and Norway. In August 2022, the Medicine and Healthcare products Regulatory Agency (MHRA) granted approval in the UK. We have obtained a reimbursed price in Germany and have applied for a named patient program approvals in Spain and the UK.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercially launched Zokinvy in the U.S. in January 2021 and started to record product revenue in the first quarter of 2021. Our first European sales were recognized in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically incurred operating losses in each year since inception and we expect to incur losses for the foreseeable future. We had a net loss of $96.8 million, $33.9 million and $65.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $437.2 million. Substantially all of our operating losses have resulted from expenses incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations.<br/> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, seek regulatory approval for, and potentially commercialize our product candidates, which will require the addition of new personnel and upgrades to our information technology systems. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve additional regulatory approvals. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a formal program prioritization assessment with a focus on enhancing long-term shareholder value while fulfilling the promise of advancing our high-potential product candidates for patients with serious diseases.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Product Candidates</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Lonafarnib (LNF) for HDV</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNF is a well-characterized, orally bioavailable, first-in-class farnesylation inhibitor in a Phase 3 clinical trial for HDV infection and is our lead program. HDV is the most severe form of viral hepatitis for which there is currently no FDA-approved therapy. Chronic HDV infection can lead to a rapid progression to liver cirrhosis, a greater likelihood of developing liver cancer, and has the highest fatality rate of all the chronic hepatitis infections.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><img src="eigr-20221231_g1.jpg" alt="eigr-20221231_g1.jpg" style="height:258px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed LNF from Merck in 2010. LNF is a small molecule that blocks the production of HDV virus particles by inhibiting a key step, called farnesylation, in the virus life cycle. We have completed five Phase 2 dose-finding studies in 129 HDV-infected patients. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Phase 2 studies have identified two lonafarnib-based regimens, which are in our Phase 3 registration program. Both regimens have achieved clinically meaningful composite endpoints of HDV RNA decline &#8805; 2 logs from baseline and normalized alanine aminotransferase (ALT), a key liver enzyme, at Week 24: all-oral regimen of LNF 50 mg boosted with RTV twice daily and combination regimen of LNF boosted with RTV combined with PEG IFN-alfa-2a. Predominantly grade 1 gastrointestinal (GI) adverse events (AE) were observed in Phase 2 amongst per-protocol treated patients. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 3 registration program consists of a single, pivotal, international trial, called D-LIVR, that is designed to support U.S. and EU regulatory approvals. D-LIVR has the potential to generate data for two distinct lonafarnib-based ritonavir-boosted regimens for approval. The study includes an all-oral arm of lonafarnib boosted with ritonavir and a combination arm of lonafarnib boosted with ritonavir combined with peginterferon-alfa-2a. Each arm is compared to placebo. Topline Week 48 data announced in December 2022 demonstrated that both lonafarnib-based regimens showed statistical significance versus placebo on the primary endpoint. Week 72 data is expected in mid-2023 </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNF for treatment of HDV infection has been granted Orphan Drug designation by the FDA and EMA, Fast Track and Breakthrough Therapy designations by the FDA and PRIME designation by the EMA.</span></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Peginterferon Lambda (lambda) for HDV</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lambda is our second program in clinical development for HDV and is currently in Phase 3. Lambda is a well-characterized, first-in-class, type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed worldwide rights to lambda from Bristol Myers Squibb in April 2016. Lambda has been administered in clinical trials involving over 4,000 patients infected with the Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), and SARS-CoV-2. Lambda has not been approved for any indication. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously completed the Phase 2 LIMT-1 study of 33 HDV-infected patients. Based on the data from LIMT-1, we have agreement with the FDA and EMA on a single pivotal, randomized Phase 3 open-label study, called LIMT-2, of lambda as a monotherapy for treatment of HDV. The primary endpoint, as achieved in Phase 2, is a durable virologic response (DVR), defined as HDV RNA below the limit of quantitation (BLQ) at 24-weeks post-treatment. LIMT-2 is currently enrolling and dosing patients across approximately fifty clinical trial sites in thirteen countries with a target enrollment of 150 patients in by mid-2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lambda for the treatment of HDV infection has received Orphan Drug designation from the FDA and the EMA and Fast Track and Breakthrough Therapy designations from the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Combination Therapy for HDV</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also generated data with the combination of LNF + RTV and lambda for the treatment of HDV. The Phase 2 LIFT-1 study was a single arm investigator sponsored study of lambda combined with LNF boosted with RTV for 24 weeks treatment with 24 weeks follow-up. Primary endpoint was &gt; 2 log decline in HDV RNA at end of treatment. In November 2020, we reported positive end-of-study data from a Phase 2 single arm study called LIFT-1, conducted at the National Institutes of Health&#8217;s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 26 HDV-infected patients. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 LIFT-2 single arm study of 48 weeks treatment with lambda combined with LNF boosted with RTV is planned to initiate in 2023 with an enrollment target of 30 HDV-infected patients. The primary endpoint is a DVR.</span></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Peginterferon Lambda (lambda) for COVID-19</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also generated data with lambda in multiple Phase 2 and Phase 3 investigator sponsored studies of mild and moderate COVID-19 patients. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TOGETHER study was an investigator sponsored Phase 3, multi-center, randomized, placebo-controlled adaptive platform study evaluating therapeutics in newly diagnosed, high-risk, non-hospitalized patients with COVID-19 across twelve clinical trial sites in Brazil and 5 sites in Canada. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint compared the number of emergency setting visits, hospitalizations, and/or deaths in treated patients versus placebo through Day 28. TOGETHER completed enrollment of over 1,900 predominantly vaccinated patients at high risk for developing complications from progression of COVID-19 randomized 1:1 lambda vs. placebo. Following our press release on September 6, 2022, in which we updated on the status of our planned EUA based on recent communications with the FDA, we submitted a pre-EUA meeting request to the FDA as well as additional morbidity and mortality outcomes data and analyses from the investigator-sponsored TOGETHER study. This included further statistical modeling and efficacy analyses of the study's primary and secondary endpoints and long-term follow-up data that we believe continues to support the topline outcomes reported in March. In response, the FDA denied the request for a pre-EUA meeting. Citing its concerns with the conduct of the TOGETHER study, the FDA concluded that any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA suggested that, given lambda's mechanism of action and the ongoing need for improved COVID-19 therapeutics, we should consider requesting an end-of-Phase 2 meeting to discuss a company-sponsored pivotal trial that could support an eventual Biologics License Application (BLA). We continue to explore opportunities for ex-US emergency use of lambda for COVID-19 and other respiratory viral infections.</span></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Avexitide in Congenital Hyperinsulinism (HI)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avexitide is a well-characterized peptide that we are developing as a treatment for congenital hyperinsulinism (HI), an ultra-rare, pediatric metabolic disorder. HI is the most frequent cause of persistent hypoglycemia in neonates and children and is characterized by fasting and protein-induced hypoglycemia and results in permanent brain damage with neurodevelopmental deficits in up to 50% of patients. Near-total pancreatectomy is often indicated and leads to life-long insulin-dependent diabetes (IDDM). Safe and effective therapies are urgently needed to prevent brain damage, IDDM and death.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avexitide binds to the GLP-1 receptor on pancreatic beta-cells and behaves as a GLP-1 antagonist and inverse agonist, reducing fasting and amino-acid induced cAMP accumulation and thereby decreasing calcium-stimulated insulin secretion. Avexitide has demonstrated clinical proof of concept and has been dosed in over 25 patients with HI at Children&#8217;s Hospital of Philadelphia (CHOP). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avexitide has been granted Breakthrough Therapy designation by the FDA for the treatment of HI, Orphan Drug designation by the EMA for the treatment of HI and Orphan Drug designation by the FDA for the treatment of hyperinsulinemic hypoglycemia, which includes HI. Avexitide has also been granted Rare Pediatric Disease designation by the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Avexitide in Post-Bariatric Hypoglycemia (PBH)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing avexitide as a treatment for post-bariatric hypoglycemia (PBH), a debilitating and potentially life-threatening condition for which there is currently no approved therapy. This disorder occurs often in a subset of bariatric surgeries including Roux-en-Y gastric bypass (RYGB) and Sleeve Gastrectomy (SG). PBH patients experience frequent symptomatic hypoglycemia, with blood glucose concentrations often low enough to cause seizures, altered mental status, loss of consciousness and even death. Bariatric procedures are widely performed and are increasing in frequency for medically complicated obesity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five clinical studies have been completed demonstrating clinical proof of concept in over 70 patients suffering from  PBH indicating that avexitide can reduce hypoglycemia and associated symptoms  in affected patients. Avexitide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that competes with endogenous GLP-1 and has been shown to reduce the excessive post-prandial insulin release that characterizes this disorder. These Phase 2 data were generated using intravenous or subcutaneous (SC) formulation delivery. Pharmacokinetics from these Phase 2 SC studies indicate that the SC formulation could enable once or twice a day dosing. We developed a proprietary SC liquid formulation and completed a Phase 1 dose-ranging pharmacokinetics trial in healthy humans. In October 2018, we reported positive topline data from PREVENT, a multi-center, placebo-controlled study investigating the safety and durability of effect of 28-day dosing of SC avexitide in post-bariatric surgical patients. The primary efficacy endpoint of improved postprandial glucose nadir during mixed meal tolerance testing (MMTT) was achieved with statistical significance with fewer participants requiring glycemic rescue during each of the active dosing regimens than during placebo dosing. The secondary endpoint of reduced postprandial insulin peak during MMTT was also statistically significant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avexitide for the treatment of hyperinsulinemic hypoglycemia has been granted Orphan Drug designation by the FDA and for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS) by the EMA. NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels (hyperinsulinemia) and low blood glucose levels (hypoglycemia), which includes PBH. Avexitide for the treatment of PBH has also been granted Breakthrough Therapy designation by the FDA. Following End of Phase 2 and Scientific Advice meetings with regulatory agencies, we have agreement on a single pivotal Phase 3 study. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved Product</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we received FDA approval for Zokinvy to reduce the risk of mortality in HGPS and to treat processing-deficient PL. Collectively known as progeria, these are ultra-rare and rapidly fatal genetic conditions of accelerated aging in children. Zokinvy is our first approved product, and the first approved therapy for these indications. There are approximately 20 identified patients in the U.S. who are eligible for treatment with Zokinvy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2022, we announced that the European Commission (EC) granted Eiger a centralized marketing authorization (MA) under the exceptional circumstances procedure for Zokinvy for the treatment of HGPS and PL, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children. In July 2022, we announced that the European Commission (EC) granted Eiger a centralized marketing authorization (MA). The EC's centralized MA is valid in all 27 EU member states plus Iceland, Liechtenstein, and Norway. In August 2022, the Medicine and Healthcare products Regulatory Agency (MHRA) granted approval in the UK.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zokinvy is a disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with HGPS. In patients with HGPS, Zokinvy reduced the incidence of mortality by 60% (p=0.0064) and increased average survival time by at least 2.5 years. The most commonly reported adverse reactions were gastrointestinal (vomiting, diarrhea, nausea), and most were mild or moderate (Grade 1 or 2) in severity. Many patients with HGPS have received continuous Zokinvy therapy for more than 10 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HGPS is an ultra-rare and rapidly fatal genetic condition of accelerated aging in children. HGPS is caused by a point mutation in the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMNA gene, encoding the lamin A protein, yielding the farnesylated aberrant protein called progerin. Lamin A protein is part of the structural scaffolding that holds the nucleus together. Researchers now believe that progerin may make the nucleus unstable, and that cellular instability may lead to the process of premature aging in HGPS. Children with HGPS die of the same heart disease that affects millions of normally aging adults, arteriosclerosis, but at an average age of 14.5 years if untreated. Disease manifestations include severe failure to thrive, scleroderma-like skin, global </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lipodystrophy, alopecia, joint contractures, skeletal dysplasia, global accelerated atherosclerosis with cardiovascular decline, and debilitating strokes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Processing-deficient progeroid laminopathies are genetic conditions of accelerated aging caused by a constellation of mutations in the LMNA and/or ZMPSTE24 genes yielding farnesylated proteins that are distinct from progerin. While non-progerin producing, these genetic mutations result in disease manifestations with phenotypes that have overlap with, but are distinct from, HGPS. Collectively, worldwide prevalence of progeroid laminopathies is believed to be approximately 200 patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into an amendment to our license agreement with Merck to include not only all uses of LNF related to the treatment of HGPS, but also progeroid laminopathies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Model and Management Team</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our approach to clinical development enables achievement of early clinical signals of efficacy and safety in our Phase 2 programs and potentially reduces clinical risks and costs inherent in the product discovery and development process. We have a highly experienced management team whose members have, in the course of their prior employment, participated in bringing numerous product candidates through regulatory approval and into commercialization. We plan to leverage our management team&#8217;s breadth and depth of experience in clinical and regulatory product development as well as market development and commercialization to identify potentially promising product candidates to address unmet medical needs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current product candidate pipeline has been obtained by in-licensing from pharmaceutical companies and academic institutions. With our focus on HDV and other serious diseases, our strategy is to acquire and retain some or all commercialization rights to our products in significant territories to diversify risk, identify a rapid regulatory pathway to approval and minimize the development investment in order to maximize long-term value for our stockholders. Over time, depending upon the data and potential market opportunity, we expect to develop an integrated commercial organization, which we believe can be targeted and cost effective for selected, promising orphan disease designated programs. We plan to balance these interests with opportunities to out-license assets from our portfolio enhance stockholder value through partnerships and other strategic relationships.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we plan to evaluate in-licensing opportunities in order to enhance our pipeline and leverage our business development, clinical development, regulatory and commercial expertise. We believe our executive management team has the capability and experience to continue to execute this model. Our executive management team has worked in other private and public biotechnology companies such as Alza Corporation, Chiron Corporation, Questcor, Valeant, and Schering-Plough, each of which was acquired by a larger biopharmaceutical industry company. Our executive management team also has previous work experience at biopharmaceutical companies, including Achillion, GlobeImmune, Bristol-Myers Squibb, Rigel, Cytokinetics, BioMarin, Gilead, AbbVie, and Amgen.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions. We currently have a diverse portfolio of well-characterized product candidates with the potential to address life-threatening diseases for which the unmet medical need is high and, primarily focused on the development of therapies to treat and cure HDV infection. We believe we are well-positioned to be a leader in HDV and in the development and commercialization of novel therapeutics for other serious diseases. Our focus to achieve this goal will be to utilize our experience and capabilities to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Advance our existing product candidates through late-stage clinical trials, generating meaningful clinical results;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Work with U.S. and international regulatory authorities for expeditious, efficient development pathways toward registration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Prepare for commercialization of each program;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Use our industry relationships and experience to source, evaluate and in-license well-characterized product candidates to continue pipeline development; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Identify potential commercial or distribution partners for our products in relevant territories.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hepatitis Delta Virus Overview</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">About Hepatitis Delta Virus</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HDV is a small circular ribonucleic acid (RNA) virus that expresses only one protein, the hepatitis delta antigen (HDAg). There are two forms of HDAg &#8211; small and large. These two forms of HDAg and the single-stranded RNA genome are surrounded by a lipid envelope, which is embedded with Hepatitis B Virus (HBV) surface antigen (HBsAg) proteins. HDV does not encode its own envelope proteins and must acquire them from HBV during the final steps of replication. Hence, natural HDV infections always occur in the presence of a co-existing HBV infection. HBsAg is the only element of HBV relied upon by HDV. HDV replication can occur independently of HBV replication.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HDV is the most severe form of viral hepatitis. HDV can be acquired either by co-infection (a simultaneous co-infection with HDV and HBV) or by super-infection (HDV infection of someone already harboring a chronic HBV infection). Both co-infection and super-infection with HDV result in more severe complications compared to infection with HBV alone. These complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in chronic infections. HDV has the highest fatality rate of all the hepatitis infections at up to 20%. Although HDV/HBV simultaneous co-infection in adults usually resolves completely, in some cases it can become fulminant hepatitis, which carries a very high mortality rate. In the case of super-infections, the predominant form of HDV, HDV super-infection leads to a more severe form of disease than chronic HBV mono-infection. In a study published in 1987 in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, histological liver deterioration was observed in 77% of HBV patients co-infected with HDV over a 15-year follow-up period, versus 30% of patients infected with HBV alone (p&lt;0.01). In a 2013 study of chronic HBV patients published in the Journal of Gastroenterology and Hepatology, cirrhosis was present in 73% of HBV patients co-infected with HDV, compared to only 22% of those infected with HBV alone. Patients co-infected with HDV are more than twice-as-likely to develop liver-related complications, cirrhosis, or require liver transplants than matched patients infected with HBV alone.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g2.jpg" alt="eigr-20221231_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:380px"/></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g3.jpg" alt="eigr-20221231_g3.jpg" style="height:194px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HDV is generally spread through exchange of body fluids either sexually or through contact with infected blood. Globally, it is estimated that between 4.3% and 5.7% of the 240 million worldwide chronic HBV population, or 10 to 14 million people, are infected with HDV. The prevalence of HDV in patients infected with chronic HBV is even higher in certain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan. The prevalence of HDV has recently begun to increase in Western Europe and the United States due to migration from countries with high infection rates.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g4.jpg" alt="eigr-20221231_g4.jpg" style="height:260px;margin-bottom:5pt;vertical-align:text-bottom;width:390px"/></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Role of HDV Screening in Identifying Patients Who May Benefit from LNF and/or Lambda</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Active HDV infections are best detected by reverse transcriptase-polymerase chain reaction (RT-PCR) assays for genomic RNA. These assays yield a quantitative assessment of the number of viral particles, or viral load, in serum. A commercial assay for quantitative HDV RNA has been available in Europe (Robogene&#174;) since 2015. Quest Diagnostics and ARUP Laboratories offer commercial assays for quantitative HDV RNA testing in the United States. Both assays are calibrated using the World Health Organization HDV standard provided by the Paul Erhlich Institute in Germany.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial discussions with payors have indicated that they would be willing to reimburse healthcare providers for HDV RNA quantitative assays that are carried out following a positive HBsAg test for HBV. Greater availability of commercial assays will increase the number of assays performed and increase the number of identified patients who can potentially benefit from an HDV therapies such as LNF and lambda.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Therapy for HDV</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there is no FDA-approved therapy for hepatitis delta virus infection. Hepcludex (buleviritide) was conditionally approved in Europe in 2020 for treatment of chronic HDV, and a BLA was submitted to the U.S. FDA in November 2021. In October 2022, the FDA issued a Complete Response Letter (CRL) citing concerns regarding the manufacture and delivery of bulevirtide.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Association for the Study of Liver Diseases (AASLD) guidelines suggest treatment of chronic hepatitis delta infections with IFN-alfa. In clinical trials of IFN-alfa or PEG IFN-alfa, between 25% and 33% of HDV infected patients were able to achieve undetectable HDV RNA after a minimum of 48 weeks of therapy, with some requiring two years of therapy. However, long-term therapy with IFN-alfa is known to be associated with numerous adverse events and tolerability is a significant problem for some of these patients. In addition, rebound of HDV RNA occurs in greater than 50% of patients. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV nucleoside analogs that suppress HBV DNA are ineffective against HDV since they are ineffective in suppressing the expression HBsAg. Current development programs targeting HBV functional cures are in early stages and are not expected to eliminate extra-hepatic reservoirs of HBsAg. Given that HDV only requires small amounts of HBsAg for virion assembly, functional cures, if achieved, will not eradicate HDV. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HDV Replication and Farnesylation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After HDV enters a target cell hepatocyte, the genome is translocated to the nucleus where genome replication occurs and the two forms of HDAg small delta antigen (SHDAg) and large delta antigen (LHDAg) are produced. The newly formed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HDV genome and the small and large delta antigen must acquire a lipid envelope from HBV to complete the assembly process. An important interaction between HDV and HBV proteins has been shown to depend on the presence of the last four amino acids of the large delta antigen, comprising a CXXX box motif, where C represents cysteine and X denotes any other amino acid. This amino acid sequence is required for LHDAg to be farnesylated by a host enzyme which covalently attaches a 15-carbon prenyl lipid (farnesyl-moiety) to the cysteine of the CXXX box. Farnesylation of the large delta antigen renders it more lipophilic, promotes its association with HBsAg and is essential for initiating the HDV particle formation process. Our approach involves targeting this host process called farnesylation, or protein farnesylation, which has been shown to be essential for the last steps in HDV replication, the assembly and release of new virus progeny.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 1980s, farnesyltransferase inhibitors were developed by multiple pharmaceutical companies for oncology indications. Addition of a farnesyl or prenyl lipid group to the Ras protein (Ras) a well-known and important regulator of cellular proliferation, allows for membrane association. Once membrane bound, Ras may then be activated. The importance of activated Ras in tumor development was demonstrated by sequence analyses of tumors from patients where up to 30% have mutations involving Ras. Several farnesylation inhibitors were developed in oncology and taken into the clinic and in some cases through late-stage clinical development. However, these programs did not lead to approvals, due to a lack of compelling efficacy. The class-related, dose-limiting toxicity has been gastrointestinal side effects including nausea, vomiting, diarrhea and weight loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Published studies demonstrate that farnesyltransferase inhibitors block HDV viral production both in cellular experiments and in HDV transgenic mice. Targeting farnesylation or farnesyltransferase, a host target, significantly reduces the likelihood of HDV developing resistance to escape effects of antiviral therapy. Viruses mutate quickly and there is a higher rate of mutations in viral replication compared to mammalian cell division. However, no matter how much HDV may mutate, these changes are unlikely to alter the host process of farnesylation which HDV requires to complete packaging. Thus, targeting a host farnesylation process provides what we believe to be a higher barrier to resistance. Identification of clinic-ready farnesylation inhibitors has allowed us to move rapidly into proof-of-concept studies in humans.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our First HDV Opportunity: Lonafarnib (LNF) for HDV</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lonafarnib (LNF) is a well-characterized, orally active inhibitor of farnesyltransferase. LNF inhibits the farnesylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. Since farnesylation is a host process, not under control of HDV, and LNF inhibits farnesylation, we believe that there is also a potentially higher barrier to resistance with LNF therapy. LNF for the treatment of HDV infection has been granted Orphan Drug designation in Europe and the United States, and LNF in combination with RTV has been granted Fast Track and Breakthrough Therapy designations from the FDA for the treatment of chronic HDV infections.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we have issued patents, U.S. Patent No. 10,076,512; 10,828,283; and 11,311,519, all entitled Treatment of Hepatitis Delta Virus Infection. The issued claims cover a broad range of RTV-boosted LNF doses and durations with and without interferons. The European Patent Office, the Chinese Patent Office and the Japan Patent Office have also granted patents with claims covering a broad range of LNF boosted with RTV dosing regimens for the treatment of chronic HDV infection. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LNF Phase 2 Clinical Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed LNF from Merck in 2010, and have relied upon Merck&#8217;s prior Phase 1, 2 and 3 clinical experience with LNF in over 2,000 patients to understand safety and pharmacokinetics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed five Phase 2 trials (POC, LOWR-1, LOWR-2, LOWR-3, LOWR-4) with LNF in 129 HDV-infected patients. The Phase 2 LOWR HDV (Lonafarnib With Ritonavir in HDV) Program identified dose(s) and regimen(s) for registration.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">POC Study (Placebo-controlled LNF monotherapy) (N=14)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LOWR-1 Study (Combination: LNF with RTV or PEG IFN-alfa-2a) (N=21)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LOWR-2 Study (Dose Finding: LNF + RTV &#177; PEG IFN-alfa-2a) (N=58)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LOWR-3 Study (QD Dosing: LNF + RTV) (N=21)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">LOWR-4 Study (Dose-Escalation: LNF + RTV) (N=15)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 NIH proof-of-concept study demonstrated statistically significant decreases in HDV RNA viral load with two LNF active groups versus placebo for 28-days. A statistically significant correlation between increasing LNF serum levels and decreasing HDV RNA viral loads was also observed, demonstrating that higher serum levels resulted in greater decline in HDV RNA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 LOWR studies demonstrated benefits of twice daily RTV-boosting of LNF for up to 24 weeks of dosing. RTV is a pharmacokinetic (PK) enhancer known to inhibit the metabolism of LNF, allowing lower doses of LNF to be administered, while resulting in higher systemic concentrations of LNF. The Phase 2 LOWR HDV studies identified two LNF-based regimens that can achieve clinically meaningful composite endpoints of HDV RNA decline &#8805; 2 logs from baseline and normalized ALT at Week 24: all-oral regimen of LNF 50 mg BID boosted with RTV twice daily and combination regimen of LNF 50 or 25 mg BID boosted with RTV combined with PEG IFN-alfa-2a (see figures below). These dosing regimens were associated with predominantly grade 1 GI AEs amongst per-protocol treated patient.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g5.jpg" alt="eigr-20221231_g5.jpg" style="height:275px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 D-LIVR Study</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D-LIVR (Delta-Liver Improvement and Virologic Response in HDV) is an international, multi-center, Phase 3 study of LNF-treated patients (total N=407 patients including controls) to evaluate an all-oral arm of LNF boosted with RTV and a combination arm of LNF boosted with RTV and peginterferon-alfa-2a (PEG IFN-alfa-2a), with each arm compared to a placebo arm (background HBV nucleos(t)ide only), in HDV-infected patients. A PEG IFN-alfa-2a alone arm is included to demonstrate contribution of effect only. The LNF containing arms are not required to demonstrate superiority over PEG IFN-alfa-2a alone. The primary endpoint is a composite of a &#8805; 2 log</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decline in HDV RNA and ALT normalization at end of 48 weeks of treatment with LNF-based regimens versus placebo.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D-LIVR is an international study, with over 100 sites across over twenty countries. Week 48 topline data was reported on December 8, 2022, with Week 72 data expected by mid-2023.</span></div><div style="margin-top:12pt"><img src="eigr-20221231_g6.jpg" alt="eigr-20221231_g6.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topline Week 48 results showed that both treatment arms achieved statistical significance over placebo in the composite primary endpoint as well as the component virologic and biochemical responses. Study participants receiving the all-oral therapy and combination therapy showed a composite response of 10.1% (p=0.0044) and 19.2% (p &lt;0.0001), respectively, compared to those receiving placebo (1.9%). A peginterferon alfa comparator arm was included in the study to show contribution of effect. The composite response rate in the all-oral arm was comparable to the peginterferon alfa arm (10.1% vs 9.6%). The composite response rate in the combination arm was twice that of the peginterferon alfa arm (19.2% vs 9.6%).</span></div><div style="margin-top:12pt"><img src="eigr-20221231_g7.jpg" alt="eigr-20221231_g7.jpg" style="height:254px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breaking the composite primary endpoint into its two component parts also showed statistically significant improvements for both parameters. Looking first at virologic response, defined as a greater than or equal to 2 log reduction of HDV RNA, 14.6% of the study participants receiving the all-oral therapy showed improvement with a p-value of 0.0026, and 32.0% of the patients receiving combination therapy showed improvement with a p-value less than 0.0001, compared to 3.8% of those patients receiving placebo. For ALT normalization, 24.7% of the study participants receiving the all-oral therapy </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">showed improvement with a p-value of 0.003, and 34.4% of those patients receiving the combination therapy showed improvement with a p-value less than 0.0001, compared to 7.7% of those patients receiving placebo.</span></div><div style="margin-top:12pt"><img src="eigr-20221231_g8.jpg" alt="eigr-20221231_g8.jpg" style="height:252px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key secondary histological endpoint was defined as &#8805;2-point improvement in histological activity index (HAI) and no worsening of Ishak fibrosis scoring as determined by blinded assessment of paired liver biopsies (n=229) collected at baseline and Week 48. This was demonstrated in 35 of 66 patients (53%, p=0.0139) with statistical significance in the combination arm versus 8 of 30 patients (27%) receiving placebo. Response was demonstrated in 35 of 107 patients (33%, p=0.61) in the all-oral arm versus placebo. Response in the peginterferon alfa comparator arm was 10 of 26 patients (38%).</span></div><div style="margin-top:12pt"><img src="eigr-20221231_g9.jpg" alt="eigr-20221231_g9.jpg" style="height:158px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining secondary endpoints including virologic, biochemical, and composite responses at Week 72 (24-weeks post-treatment), are being collected and are expected to be reported mid-2023. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Second HDV Program: Peginterferon Lambda (lambda) for HDV</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lambda is a well-characterized, late-stage, first in class, type III, well-tolerated interferon (IFN) that we in-licensed from Bristol-Myers Squibb in April 2016. Lambda is being developed as a well-tolerated interferon. Lambda stimulates immune responses that are critical for the development of host protection during viral infections. Lambda targets type III IFN receptors which are distinct from the type I IFN receptors targeted by IFN-alfa. These type III receptors are highly expressed on hepatocytes with limited expression on hematopoietic and central nervous system cells, which has been demonstrated to reduce the off-target effects associated with other IFNs and improve the tolerability of lambda (Chan 2016). Although lambda does not use the IFN-alfa receptor, signaling through either the IFN-lambda or IFN-alfa receptor complexes results in the activation of the same Jak-STAT signal transduction cascade. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials of IFN-alfa or PEG IFN-alfa-2a, after 48-72 weeks of therapy, between 25% and 33% of HDV-infected patients were HDV RNA undetectable 24 weeks after stopping therapy. However, IFN-alfa is known to be associated with numerous adverse events and tolerability is a significant problem for many of these patients. We are developing lambda as a well-tolerated interferon, either as a monotherapy and in a combination with LNF + RTV.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lambda Clinical Data</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIMT-1 Monotherapy Phase 2 Clinical Trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIMT-1 was a 1:1 randomized, open-label Phase 2 study of lambda 120 mcg or 180 mcg subcutaneous injections administered weekly for 48 weeks in 33 patients with chronic HDV. End of treatment was followed by a treatment-free 24-week observation period. The primary objective of the Phase 2 study was to evaluate the safety, tolerability, and efficacy of treatment with two dose levels of lambda in patients with chronic HDV infection. All patients were administered an anti-HBV nucleos(t)ide analog throughout the study. The trial was conducted at four international sites in New Zealand, Israel and Pakistan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Week 48 end-of-treatment data were presented in November 2018 at AASLD. At Week 48, patients in the 180 &#956;g lambda treated group experienced a 2.4 log mean decline in HDV-RNA, with 6 of 10 (60%) experiencing &#8805; 2 log decline, 4 of 10 (40%) patients were HDV-RNA negative at end of treatment. At Week 48, patients in the 120 &#956;g lambda treated group experienced a 1.5 log</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mean decline in HDV RNA, with 6 of 14 (42.9%) experiencing &#8805; 2 log</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decline, 2 of 14 (14.3%) patients were HDV-RNA negative at end of treatment. The most commonly reported AEs were moderate headache, pyrexia, fatigue, and myalgia. Observed ALT flares result from vigorous antiviral immunological response to treatment, not due to direct hepatotoxicity. End of 24-week follow-up data, presented in April 2019 at EASL, demonstrated that 36% of HDV infected patients were able to maintain HDV RNA below limit of quantitation (BLQ) 24-weeks post-treatment, or a Durable Virologic Response (DVR), and achieve ALT normalization. These data are illustrated below.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g10.jpg" alt="eigr-20221231_g10.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:520px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIMT-1 study did not include per-protocol liver biopsies. However pre- and post-treatment liver biopsies were collected for two patients where regression in liver fibrosis from F5 to F1 and F4 to F1 was observed. This is the first demonstration of regression in liver fibrosis with a finite lambda treatment.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g11.jpg" alt="eigr-20221231_g11.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3 LIMT-2 Study</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with the FDA and EMA on a single pivotal Phase 3 study, called LIMT-2, of lambda as a monotherapy for treatment of HDV.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIMT-2 is a randomized, open-label, parallel-arm study that will include 150 patients randomized 2:1 to two different lambda-containing arms. The first arm is 48 weeks of treatment with lambda 180 mcg administered weekly and a 24-week off-treatment follow-up period. The second arm is 12-weeks of no therapy followed by 48 weeks of treatment with weekly lambda 180 mcg and a 24-weeks off-treatment follow-up period. The primary endpoint is a Durable Virologic Response (DVR), or HDV RNA below limit of quantitation (BLQ) or undetectable, 24-weeks post treatment of Arm 1 compared to placebo after 12-weeks of no treatment of Arm 2. All patients will be administered an anti-HBV nucleos(t)ide analog throughout the study. LIMT-2 is currently enrolling a target of 150 patients in across approximately 50 sites in 13 countries.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g12.jpg" alt="eigr-20221231_g12.jpg" style="height:278px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential for Registration in HDV for LNF/RTV and Lambda</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNF/RTV (D-LIVR) and lambda (LIMT-2) form our HDV platform strategy with multiple opportunities to win for HDV patients. While the D-LIVR study has a composite primary endpoint (&gt; 2 log reduction in HDV RNA and ALT normalization) at Week 48, the response rate at 24 weeks post-treatment may support accelerated approval of LNF/RTV for finite therapy. Similarly, the LIMT-2 primary endpoint (DVR at 24 weeks post-treatment) for lambda is intended to support accelerated approval for finite therapy. Our first goal is approval of these treatments for HDV, where there is an urgent, unmet medical need. Key opinion leaders have suggested that combinations of LNF/RTV and lambda with other antiviral agents may demonstrate an even greater antiviral effect. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Proprietary HDV Combination Therapy: Lambda and LNF + RTV</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 LIFT-1 HDV Combination Clinical Trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFT-1 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ambda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eron combination </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herapy) was an open-label, Phase 2 study evaluating lambda in combination with lonafarnib boosted with ritonavir in 26 HDV-infected patients. Patients were dosed for 24 weeks and underwent off-treatment follow-up for 24 weeks. The primary endpoint was &gt;2 log decline in HDV RNA at end of 24-weeks of treatment. The secondary endpoint was an improvement in histology (&gt;2-point improvement in histological activity index and no progression in fibrosis) at end of follow-up. LIFT-1 was conducted within the National Institutes of Health (NIH) at the NIDDK. The final end-of-treatment and end-of-study data were reported in November 2020 at the AASLD conference and are summarized in the figure below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data demonstrated that after 24 weeks of treatment, by per protocol analysis, 77% of patients (17 of 22) achieved the primary efficacy end point of &gt;2 log decline in HDV RNA, with 50% of patients (11 of 22) either HDV RNA BLQ or undetectable. At Week 48 (24 weeks post-treatment), 5 of 22 patients (23%) maintained HDV RNA BLQ or were HDV RNA undetectable, 11 of 20 patients (55%) demonstrated improvement in Histology Activity Index (HAI), and 6 of 20 patients (30%) achieved the secondary endpoint of &gt; 2 point improvement in HAI.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g13.jpg" alt="eigr-20221231_g13.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2 LIFT-2 HDV Combination Clinical Trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIFT-2 (Lambda Interferon combination Therapy) is an open-label, Phase 2 study that will evaluate lambda in combination with lonafarnib boosted with ritonavir in 30 HDV-infected patients. Patients will be dosed for 48 weeks with follow-up for 24 weeks. The primary endpoint is a DVR, or HDV RNA below the limit of quantitation at 24 weeks post-treatment. LIFT-2 will also be conducted within the (NIH) at the NIDDK. If positive, data from LIFT-2 will provide additional support for this combination therapy.</span></div><div style="margin-top:6pt;text-align:center"><img src="eigr-20221231_g14.jpg" alt="eigr-20221231_g14.jpg" style="height:281px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Congenital Hyperinsulinism (HI) Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congenital Hyperinsulinism (HI) is an ultra-rare pediatric metabolic disease. HI presents with severe hypoglycemia in the neonatal period requiring intensive care hospitalization, administration of high rates of intravenous glucose through central lines, continuous intravenous administration of glucagon and in most instances surgical treatment by pancreatectomy during the neonatal period or during infancy. The most common and severe form of HI is refractory to medical treatment with diazoxide and affects approximately 60% of all patients. This form of HI arises out of inactivating mutations in the genes encoding the KATP channel, resulting in focal and diffuse forms of HI. Focal disease, occurring in approximately 50% of patients with KATP HI, resolves in 97% of cases after partial pancreatectomy. Diffuse disease persists in 41% of cases after subtotal (98%) pancreatectomy. However, by the age of 14 years old, data show that 91% of patients undergoing subtotal pancreatectomy develop insulin-dependent diabetes, at which point hyperinsulinism is no longer </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present. Thus, HI is a congenital, rare pediatric disease with life-threatening manifestations of severe hyperinsulinemic hypoglycemia occurring primarily during the neonatal period, infancy, childhood and adolescence. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Data to Date</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, a total of 39 patients with KATP HI enrolled in 3 clinical investigations at Children&#8217;s Hospital of Philadelphia (CHOP) have received avexitide administered by continuous IV infusion: 10 adolescents and adults, 16 children, and 13 neonates. Data generated across all 3 clinical investigations suggest that treatment with avexitide may effectively reduce fasting and postprandial hypoglycemia in patients with HI. Avexitide treatment was well tolerated, with no serious drug-related adverse events (AEs) reported. Data from each of the three studies are presented in the figures below. Avexitide for treatment of HI has been granted Rare Pediatric Disease designation by the FDA.</span></div><div style="margin-top:6pt;text-align:center"><img src="eigr-20221231_g15.jpg" alt="eigr-20221231_g15.jpg" style="height:244px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><img src="eigr-20221231_g16.jpg" alt="eigr-20221231_g16.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><img src="eigr-20221231_g17.jpg" alt="eigr-20221231_g17.jpg" style="height:267px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, Eiger announced it is initiating the Phase 3 registrational program for avexitide in congenital hyperinsulinism (HI) by the end of the year. In connection with our Phase 3, startup activities, we observed low levels of product-related impurities in the finished drug product. Although not unusual for this class of compounds, we are working with our CMO's to control and qualify these materials and plan to initiate dosing when an adequate supply of materials with a sufficient shelf life has been released. Avexitide has been granted Orphan Drug designation in the U.S. by the FDA for the treatment of hyperinsulinemic hypoglycemia (which includes HI) and has also been granted Rare Pediatric Disease designation making it potentially eligible for a priority review voucher upon regulatory approval. Avexitide is the only investigational therapy for HI that has been granted Breakthrough Therapy designation by the FDA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-bariatric Hypoglycemia (PBH) Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the use of bariatric surgical procedures has increased worldwide due to rising obesity and Type 2 diabetes, a new post-surgical complication, hypoglycemia associated with bariatric surgery, has been increasingly diagnosed and reported in the procedures that involve reducing the size of the stomach with a vertical sleeve gastrectomy (SG) or by resecting and re-routing the small intestine to a small stomach pouch (Roux-en-Y gastric bypass). This disorder leads to frequent symptomatic hypoglycemia, often resulting in glucose concentrations low enough to cause seizures, altered mental status, loss of consciousness, cognitive dysfunction, disability and death. Quality of life can be severely diminished, and many patients cannot care for themselves or others, work, drive, or be left alone. There is no approved treatment for this condition. Severe cases have historically been surgically managed with near-total to total pancreatectomy, which results in insulin dependent diabetes and is associated with a greater than 6% surgical mortality risk.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research suggests that elevated GLP-1 may play an important role in mediating the glucose-lowering effect associated with bariatric surgery. Surgically altered nutrient transit, resulting from bariatric surgeries can cause early nutrient sensing by the intestinal &#8220;L&#8221; cells, leading to enhanced secretion of GLP-1 causing elevated insulin secretion. This effect may play a primary role in the early resolution of Type 2 diabetes after surgery. In patients with PBH, excessive secretion of GLP-1 and/or exaggerated sensitivity to GLP-1 results in dysfunctional insulin release, leading to severe, debilitating hypoglycemia. GLP-1 receptor antagonists compete with endogenous GLP-1 and have the potential to prevent dysfunctional insulin release and resultant symptomatic hypoglycemia.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Data to Date</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five clinical studies involving over 70 patients with PBH have demonstrated that pharmacologic blockade of the GLP-1 receptor can reduce hypoglycemia and  associated symptoms. We believe that avexitide may represent the first targeted medical treatment for patients with PBH. In studies completed to date, there have been no significant adverse drug reactions attributed to avexitide.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our Phase 2 study called PREVENT in October 2018. The PREVENT study was a Phase 2, multicenter, randomized, single-blind, placebo-controlled cross-over study to assess the efficacy and safety of 28-day dosing of avexitide in patients with PBH. A total of 18 patients were enrolled and treated with two dosing regimens (once daily and twice daily) of avexitide for 28 days. All patients participated in three 14-day treatment periods, involving placebo SC </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injections, once-daily avexitide SC injections, and twice-daily avexitide SC injections. Patients self-administered injections in the outpatient setting throughout the study duration and additionally underwent in-clinic MMTT provocations with concomitant blood draws and symptom assessments following each 14-day treatment period. Participants' metabolic and clinical outcomes were  assessed in the outpatient setting by electronic diary, self -monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM) and postprandial glucose, insulin, and symptom responses were assessed during MMTT provocation in the in-clinic setting.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoint of improved postprandial glucose nadir during MMTT was achieved with statistical significance with avexitide 30 mg BID and 60 mg QD, with fewer participants requiring glycemic rescue during each of the active dosing regimens than during placebo dosing. The secondary endpoint of reduced postprandial insulin peak during MMTT was also statistically significant with avexitide 30 mg BID and 60 mg QD. The primary and secondary endpoints are shown in the figure below.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g18.jpg" alt="eigr-20221231_g18.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Metabolic and clinical improvements were also monitored during each patients&#8217; daily routine in the outpatient setting and assessed by electronic diary and continuous glucose monitoring (CGM). Patients experienced fewer episodes of Levels 1-3 hypoglycemia during both dosing regimens of avexitide as compared to placebo as shown in the table below. </span></div><div style="margin-top:18pt"><span style="color:#064e7b;font-family:'Times New Roman',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%">METABOLIC AND CLINICAL IMPROVEMENTS</span></div><div style="margin-top:8pt"><span style="color:#1998c9;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reduction in Rates</span><span style="color:#1998c9;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#1998c9;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of Levels 1-3 Hypoglycemia, as Captured by Self-Monitoring of Blood Glucose (SMBG) and eDiary in the Outpatient Setting</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#005480;border-left:0.5pt solid #ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Number of Episodes in 14 Day Period</span></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Placebo</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Avexitide</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">30 mg BID</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Avexitide</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60 mg QD</span></div></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Rate of  Level 1 Hypoglycemia</span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.03</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.81</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.56</span></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000;border-top:1pt solid #ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Change from Placebo</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">NA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">-1.24<br/>(p=0.072)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-2.51<br/>(p=0.001)</span></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Rate of Level 2 Hypoglycemia (Clinically Important Hypoglycemia)</span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.01</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.21</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.81</span></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000;border-top:1pt solid #ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Change from Placebo</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">NA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">-0.77<br/>(p=0.040)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.17</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(p=0.004)</span></div></td></tr><tr><td colspan="3" style="background-color:#005480;border-left:1pt solid #000;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Rate of Level 3 Hypoglycemia (Severe Hypoglycemia)</span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.96</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.50</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.86</span></td></tr><tr><td colspan="3" style="background-color:#005480;border-bottom:1pt solid #000000;border-left:1pt solid #000;border-top:1pt solid #ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Change from Placebo</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">N/A</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">-0.49<br/>(p=0.224)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#160;-1.09<br/>(p=0.014)</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:5pt">Rate is defined as number of episodes in a 14 day period</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:5pt">Level 1 Hypoglycemia is defined as hypoglycemia symptoms confirmed by SBGM concentrations of &lt;70 mg/dL</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:5pt">Level 2 Hypoglycemia (Clinically Important Hypoglycemia) is defined as SMBG&#8197;&lt;&#8197;54 mg/dL (3.0 mmol/L)</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:5pt">Level 3 Hypoglycemia (Severe Hypoglycemia) is defined as a severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery. This applies regardless of whether a patient actually receives external assistance</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avexitide was well tolerated. There were no treatment-related serious adverse events and no participant withdrawals. Adverse events were typically mild to moderate in severity. The most common adverse events were injection site bruising, nausea, and headache, all of which occurred with lower frequency during avexitide dosing periods than during the placebo dosing period. Avexitide has been granted Breakthrough Therapy designation by the FDA. In 2020, we received concurrence with the FDA and EMA on a single Phase 3 trial for avexitide for treatment of PBH.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently contract with third parties for the commercial manufacturing of our FDA-approved product, Zokinvy, and all of our clinical product candidates and intend to do so in the future. We do not own or operate manufacturing facilities for the production of clinical trial materials of our product candidates and have no plans to build our own clinical or commercial scale manufacturing capabilities. We believe that the use of contract manufacturing organizations (CMOs) eliminates the need for us to directly invest in manufacturing facilities, equipment and additional staff. Although we rely on contract manufacturers, our personnel and consultants have extensive manufacturing experience overseeing our CMOs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our third-party manufacturers have met the manufacturing requirements for the product candidates. We expect third-party manufacturers to be capable of providing sufficient quantities of our product candidates to meet anticipated full-scale commercial demands but have not assessed these capabilities beyond the supply of clinical material for products in clinical development. We have identified or plan to identify commercial contract manufacturers as we move our product candidates to Phase 3 clinical trials. We believe there are alternate sources of manufacturing that could be identified and enabled to satisfy our clinical and commercial requirements, however, we cannot be certain that identifying and establishing alternative relationships with such sources can be successful, cost effective, or completed on a timely basis without significant delay in the development or commercialization of our product candidates. All of our third-party manufacturers are subject to periodic audits to confirm compliance with applicable regulations and must pass inspection before we can manufacture our products for commercial sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have qualified and finalized or are in process of finalizing commercial supply agreements with contract manufacturers of Zokinvy (lonafarnib) and have identified commercial manufacturers for lambda and plan to proceed with qualifications.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lonafarnib</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The drug product for completed lonafarnib (LNF) Phase 2 clinical studies for the treatment of HDV and HGPS was manufactured by Merck. We have successfully completed the technology transfer for manufacture of the LNF drug substance and the LNF drug product to our third-party manufacturers. All future HDV clinical trials will be conducted with product manufactured by these CMOs. These manufacturers produce our commercial supply for HGPS and processing-deficient progeroid laminopathies.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lambda</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed the technology transfer from BMS to our CRO for our lambda program. As part of the license agreement, sufficient inventory of product was obtained to complete our Phase 2 and initiate our Phase 3 clinical trials. We have manufactured additional batches of lambda products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both lonafarnib and lambda are GMP products from all CMOs.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avexitide</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The drug substance and drug product used for the production of avexitide clinical trial material for the treatment of HI and PBH is manufactured by our third-party CMOs. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and in-license those proprietary technologies, inventions, and improvements we believe are important to our business. We seek and maintain, where available, patent protection for our product candidates including: composition dosage, formulation, use, manufacturing process, among others. We have also licensed patents and patent applications that cover certain of our product candidates and/or their manufacture, use, or formulation. We also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely, or plan to rely, on regulatory exclusivity, including Orphan Drug designation and New Chemical Entity (NCE) and Biologic License Application (BLA) exclusivities, as well as trade secrets and carefully monitor our proprietary information to protect all aspects of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to expand our intellectual property portfolio by filing patent applications for our product candidates. We file and prosecute patent applications in the United States and Europe and, when appropriate, additional countries, including Japan, Korea, Canada and China.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend significantly upon our ability to: (i) obtain and maintain patents and other exclusivity protections for commercially important technology, inventions and know-how related to our business; (ii) prosecute our patent applications to issue as patents and defend and enforce our patents; (iii) maintain our licenses to use intellectual property owned by others; (iv) preserve the confidentiality of our trade secrets, and (v) operate without infringing the valid and enforceable patents and other proprietary rights of others. In addition to maintaining our existing proprietary assets, we seek to strengthen our proprietary positions when economically reasonable to do so. Our ability to augment our proprietary position relies on its: (i) know-how; (ii) ability to access technological innovations, and (iii) ability to in-license technology when appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical/biotechnology companies like us are generally uncertain and involve complex legal, scientific, and factual issues. In addition, the scope claimed in a patent application can be significantly reduced during the patent prosecution process before any patent issues. After issuance of a patent, if the issued patent is challenged, then the courts or a patent office can redefine the scope of the patent, including by invalidating some or all of the patent claims, or rendering the patent unenforceable in its entirety. Consequently, we do not know with certainty whether patents will issue in each country in which we or our licensors file patent applications, or if those patent applications, if ever issued, will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issue with claims that cover our product candidates, or, even if they do issue, whether the patent or its relevant claims will remain enforceable upon challenge. Accordingly, we cannot predict with certainty whether the patent applications we are currently pursuing will issue as patents in a particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from potential competitors to make any of our products commercially successful. Any of our patents, including already issued in-licensed patents or any patents that may issue to us or our licensors in the future, could be challenged, narrowed, circumvented, or invalidated by third parties. Newly filed patent applications in the United States Patent and Trademark Office (the USPTO) and certain other patent offices are maintained in secrecy for a minimum of 18 months, and publications of discoveries in the scientific or patent literature often lag far behind the actual discoveries themselves. For these reasons, we cannot be certain that inventions claimed in pending patent applications were not invented by another party prior to our invention or disclosed or claimed in a patent application filed before the effective filing date of our applications, in either of which case the claims may not be patentable to us. For certain applications with an effective filing date prior to March 13, 2013, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. Also, while we are not currently participating in any interferences or post-grant challenge proceedings, such as patent oppositions, post-grant reexamination proceedings, inter parties review proceedings and patent litigation, that seek to invalidate claims of pending patent applications or issued patents, we may have to participate in such proceedings in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in the countries where they are issued. In most countries, the standard patent term for inventions relating to human drugs and their formulation and use is 20 years from the date of filing the first non-provisional patent or international application under the Patent Cooperation Treaty of 1970 (PCT).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PCT is an international patent law treaty that provides a single PCT application can be converted into a patent application in any of the more than 154 PCT contracting states, providing a cost-effective means for seeking patent protection in numerous regions or countries. Conversion of a PCT application into an application in any of the contracting states typically occurs about 30 months after a priority application is filed, or about 18 months after the PCT application filing date. An applicant must undertake prosecution within the allotted time in the patent offices of any, or a combination, of the contracting states or in a regional patent office it determines to undertake patent issuance in protection in such country or territory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or in-license a number of patents in the U.S. and foreign countries that cover our products, product candidates, and methods of their use. With respect to our owned or in-licensed issued patents in the U.S. and Europe, we may be entitled to obtain an extension of patent term to extend the patent expiration date. For example, in the U.S., this extended coverage period is known as patent term extension (PTE) and can only be obtained provided we apply for and receive a marketing authorization for a product. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended. In Europe, Supplementary Protection Certificates (SPC) may also be available to patents, which would be available by applying to the member states. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. The exact duration of the extension depends on the time we spend in clinical studies as well as getting marketing approval from the FDA.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Protection of Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exclusivity positions for our clinical-stage product candidates as of December 31, 2022 are summarized below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LNF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have licensed from Merck a portfolio of patents and know how covering the compound, formulations of the compound, and synthesis, but these expire before the anticipated launch date of the LNF product candidate. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States, we have obtained patent protection for the use of LNF in combination with RTV for the treatment of HDV infection. Eiger&#8217;s U.S. Patent Nos. 10,076,512; 10,828,283; and 11,311,519 entitled, Treatment of Hepatitis Delta Virus Infection, include claims covering a broad range of RTV-boosted LNF doses and durations with and without interferons. The patents have terms that extend at least until 2035.  Additional claims are being pursued in a continuation application. The European Patent Office, the Chinese Patent office and the Japanese Patent Office have also granted patents with claims covering a broad range of LNF boosted with RTV dosing regimens for the treatment of HDV infection. These patents will have a term that extends to 2035. In Europe, China and Japan, additional claims are being pursued in divisional applications. We have now obtained patent protection with claims covering treatment of HDV with LNF boosted with RTV  the U.S., Europe, China and Japan, which are key major pharmaceutical markets. A corresponding patent application claiming the use of lonafarnib boosted with ritonavir is pending in Korea. Additionally, US Patent 10,835,496 and a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">European Patent issued claiming particular dosage forms for ritonavir-boosted lonafarnib for the treatment of HDV infections. A Notice of Allowance was also received for an application in South Korea. These patents extend protection until at least 2036.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in-licensed from The Progeria Research Foundation patents covering the methods of treating Hutchinson-Gilford progeria syndrome (HGPS), and progeroid laminopathies. The patents provide protection until at least 2024 and an application for patent term extension (PTE) that could extend the protection for one of the patents until 2029 has been filed. We have also filed a patent application in the U.S. directed to methods of treating HGPS and progeroid laminopathies that if issued would provide further protection until at least 2039. In addition, LNF has been granted Orphan Drug designation by the FDA and the EMA in this indication, which respectively may provide up to seven and ten years of regulatory exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lambda.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in-licensed from BMS a portfolio of patents relating to the manufacture, use, and compositions of interferon lambda modified by polyethylene glycol derivatization (lambda). The key United States composition of matter patent in this portfolio expires in 2025, but we expect to be eligible for the full five years of patent term extension for that patent. In addition, we expect regulatory approval for lambda to be filed under a BLA, which if granted would provide 12 years reference product exclusivity (4 years in filing exclusivity; 12 years for data), as well as Orphan Drug exclusivity for treatment of HDV infection. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and Europe, we have obtained patent protection for the use of lambda for treatment of HDV infection. U.S. Patent No. 10,953,072 issued with claims covering the use of lambda to treat HDV. The term of this patent extends at least until 2037. The European Patent Office has also granted a patent with claims covering use of lambda to treat HDV. Additional claims are being pursued in continuation/divisional applications in the U.S. and Europe. Applications are also pending in China, Japan and Korea. Any patents that issue from these applications will expire in 2037. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also filed a PCT application relating to the use of lambda in HDV that has matured into patent applications in the United States, Europe, Australia, Brazil, Canada, China, Eurasia, Israel, India, Japan, South Korea, Mexico, and South Africa. Any patents that issue from these applications should offer protection until at least 2039.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have filed a  PCT application related to the use of lambda and lonafarnib and ritonavir to treat HDV, that has matured into patent applications in the United States, Europe, Australia, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Russia, Ukraine, and South Africa. Any patents that issue from these applications should offer protection until at least 2040. Lastly, we also filed a PCT application related to the use of lambda to treat COVID-19 that has matured into patent applications in the United States, Europe, Australia, Brazil, Canada, Chile, China, Columbia, Eurasia, Israel, Japan, South Korea, Mexico, New Zealand, Saudi Arabia, Singapore, Ukraine, Vietnam, and South Africa.   </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avexitide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have in-licensed from Stanford two PCT applications that claim the use of avexitide and other agents in the treatment of hypoglycemia associated with bariatric surgery, including in PBH. The USPTO issued US 10,639,354, US 10,660,937, US 10,993,992, and US 10,993,991, which provide protection at least until 2036. Up to five years of patent term extension will be available in the United States. The European Patent Office has also granted two patents with claims covering use of avexitide to treat hypoglycemia, which will expire in 2036. Two Australian patents and a Chilean patent have also issued with similar claims, which will also expire in 2036 Additional claims are being pursued in continuation/divisional applications in the U.S. and Europe. Applications are also pending in Canada, and Chile.  Any patents that issue from these applications will expire in 2036. Additionally, avexitide has been granted Orphan Drug designation in the treatment of hyperinsulinemic hypoglycemia by the FDA and the EMA, which provides seven years and ten years of regulatory exclusivity in the United States and Europe, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we have obtained patent protection for formulations of avexitide and the use of these formulations in the treatment of hypoglycemia associated with bariatric surgery. The USPTO issued US 11,020,484, which will provide protection at least until 2037. Additional claims are being pursued in continuation application. Applications are also pending in Europe, Australia, Brazil, Canada, Chile, China, Hong Kong, Israel, India, and Japan. Any patents that issue from these applications will expire in 2037. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also filed a PCT application related to method of treating HI and PBH, that has matured into patent applications in the United States, Australia, Brazil, Canada, Chile, China, Europe, Israel,  and Japan. If issued, the patents will provide protection until 2039. We have also filed a PCT application related to method of treating congenital hyperinsulinism, which will offer protection until 2042 if issued into patents at the national stage.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have in-licensed patents and patent applications from the Trustees of the University of Pennsylvania (UPenn) and Children's Hospital of Philadelphia (CHOP), relating to hyperinsulinemia hypoglycemia. The in-licensed patents and applications relate to multiple hyperinsulinemic disorders, including PBH and HI. The patents, which are issued in the U.S. and Europe,  provide protection until 2028. There are continuation applications pending from which we are pursuing additional claim coverage.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proprietary Rights and Processes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection for some of our confidential and proprietary information. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business, scientific, development or financial affairs that are either developed or made known to the individual during the course of the individual&#8217;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and disclose our technology. If these events happen, we may not be able to meaningfully protect our trade secrets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or based on the employee&#8217;s use of our confidential information are our exclusive property or that we have an exclusive royalty free license to use such technology.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Given the significant unmet medical need for novel therapies to treat Progeria, chronic hepatitis delta virus infection, congenital hyperinsulinism, post-bariatric hypoglycemia, and COVID-19, these conditions are where various treatments from many companies are used and where many public and private universities and research organizations are actively engaged in the discovery, research and development of product candidates. As a result, there are and will likely continue to be extensive resources invested in the discovery and development of new products to treat these unmet medical needs. We anticipate facing intense and increasing competition as new products enter the market and advanced technologies become available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are numerous multinational pharmaceutical companies and large biotechnology companies currently marketing or pursuing the development of products or product candidates targeting the same indications as our product candidates. Many of our competitors, either alone or with strategic partners, have or will have substantially greater financial, technical and human resources than us. Accordingly, our competitors may be more successful than us in developing or marketing products and technologies that are more effective, safer or less costly. Additionally, our competitors may obtain regulatory approval for their products more rapidly and may achieve more widespread market acceptance. Accelerated mergers and acquisitions activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential competitors and the related stage of development of their product candidates in target indications is as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HDV: Gilead (conditional approval in Europe, BLA submitted in the U.S.), Vir (Phase 2), Janssen Research &amp; Development, LLC (Phase 2), Replicor, Inc. (Phase 2), PharmaEssentia (Phase 2), Albireo (preclinical), Assembly (preclinical)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HGPS and Progeroid Laminopathies: PRG Science &amp; Technology (Phase 1)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HI: Zealand Pharmaceuticals (Phase 3), Rezolute, Inc (Phase 2b), Hamni (Phase 2), Crinetics (Phase 1)</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">PBH: Xeris Pharmaceuticals (Phase 2), Vogenyx (Phase 2)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other therapies that are used or may be used for our targeted indications, and these other products in clinical development or marketed for other indications may be used in competition with our product candidates if we are able to identify potential market opportunities of interest. For example, HDV has not been generally identified as a target for development compared to hepatitis B or hepatitis C, and products on the market or in development for those indications may potentially be tested in HDV as the understanding of the potential medical need for therapies in this indication become more widely understood.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, convenience in dosing, product labeling, cost-effectiveness, price, the level of generic competition and the availability of reimbursement from the government and other third-parties. Our commercial opportunity could be reduced or eliminated for any of our products if our competitors have products that are approved earlier than our product candidates or are superior compared to our product candidates or if our product candidates do not result in an improvement in condition compared to those other products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Asset Purchase Agreements</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Merck</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2010, we entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck, which provides us with the exclusive right to develop and commercialize lonafarnib. As consideration for such exclusive right, we issued Private Eiger convertible preferred stock with a fair value of $0.5 million when the agreement was executed in September 2010. This preferred stock was converted to 27,350 shares of common stock upon the Merger. In addition, we are obligated to pay Merck up to an aggregate of $27.0 million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. Our obligation to pay royalties to Merck expires on a country-by-country and product-by-product basis on the later of the expiration of the last to expire patent assigned to us under the agreement on the tenth anniversary of the first commercial sale of the product. In May 2015, the first regulatory milestone was achieved, and we paid the related milestone payment of $1.0 million to Merck. No additional milestone payments were incurred during the year ended December 31, 2021. Upon completion of D-LIVR, we will owe Merck a $1.0 million milestone. We announced primary topline data of D-LIVR in December 2022, and the study is expected to complete by the end of 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merck License will continue for so long as we owe royalty payments to Merck under the agreement. Each party has the right to terminate the Merck License Agreement for the other party&#8217;s uncured material breach or bankruptcy. Merck also has the right to terminate the agreement if we discontinue development and commercialization of LNF for a specified period of time. In addition, we have the right to terminate the agreement, with notice, for any reason.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, we entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford progeria syndrome (HGPS) in humans at no cost to us. We have the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to The Progeria Research Foundation. Merck will not receive milestone payments in relation to lonafarnib for the treatment of HGPS and progeroid laminopathies or any royalty payments for sales of lonafarnib to treat the currently estimated HGPS and progeroid laminopathies patient population worldwide. On November 3, 2020, we entered into an amendment to the exclusive license agreement with Merck which expanded the definition of HGPS to also include progeroid laminopathies.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement with AbbVie Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, we entered into an asset purchase agreement (the AbbVie Agreement) with AbbVie Inc. (AbbVie) to sell our Rare Pediatric Disease Priority Review Voucher, which was awarded on November 20, 2020 upon approval by the FDA of our new drug application for Zokinvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for HGPS and processing-deficient progeroid laminopathies (the PRV) to AbbVie. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the PRV, AbbVie agreed to pay us $95.0 million. The transaction closed in January 2021. Such consideration was shared equally with The Progeria Research Foundation (the PRF) in accordance with the terms of our Collaboration and Supply Agreement, dated May 15, 2018, with the PRF, pursuant to which we and the PRF will equally share any proceeds from the sale of a priority review voucher that we may receive as the sponsor of a rare pediatric disease product application. We retained approximately $46.5 million of the net proceeds from the sale of the PRV.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement with Eiger Group International, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2010, we entered into an Asset Purchase Agreement with Eiger Group International, Inc. (EGI) dated December 8, 2010 (the EGI APA). Dr. Jeffrey Glenn, a member of our board of directors, is the sole owner of EGI.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the EGI APA, we purchased all the assets including intellectual property rights related to the use of farnesyltransferase inhibitors as anti-viral agents and methods to treat viral infection with those inhibitors. We also purchased all assets including intellectual property rights related to the use of inhibitors of prenylation, prenyl cysteine methyltransferase, and a specified protease as anti-viral agents and methods to treat viral infection with those inhibitors. We are obligated to use commercially reasonable efforts to develop and commercialize the licensed products in major markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the EGI APA, we paid EGI an upfront payment of $0.4 million. Additionally, we are obligated to pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, we may make a one-time payment of $0.5 million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the EGI APA extends until expiration of all payment obligations, and we may terminate the agreement upon notice to EGI. EGI may terminate the EGI APA if we fail to use commercially reasonable efforts to develop and commercialize licensed products. In addition, each party may terminate the EGI APA for the other party&#8217;s uncured material breach or bankruptcy. In the event of any termination, other than termination by us for EGI&#8217;s breach, we will assign the purchased assets back to EGI.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, we entered into an agreement with EGI whereby we sold all of the assets related to the compound clemizole, including any related intellectual property. EGI is obligated to pay to us a high single-digit royalty on future aggregate annual net sales, subject to certain reductions and exceptions. EGI&#8217;s obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either expiration of the last to expire patent sold to EGI under the agreement or the earliest of the tenth anniversary of the first commercial sale of the product. As of December 31, 2022, the product has not achieved regulatory approval.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement with Tracey McLaughlin and Colleen Craig</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an Asset Purchase Agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig (the Sellers) dated September 25, 2015 (the Exendin APA). We also entered into a consulting agreement with the Sellers as part of the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Exendin APA, we purchased all the assets and the intellectual property rights related to the compound avexitide from the Sellers, including an assignment of a license agreement with Stanford which covered exclusive rights with respect to the compound avexitide. Under the assigned Stanford exclusive license agreement, we are obligated to pay Stanford a low, single-digit royalty on net sales after the first commercial sale of any product developed based on avexitide.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Exendin APA, we are obligated to pay development milestone payments in aggregate up to $1.0 million to each of the Sellers and a low, single-digit royalty based on aggregate annual net sales of all products developed based on avexitide subject to certain reductions and exceptions. Our obligation to pay royalties expires on the expiration of the last to expire patent assigned to us under the agreement. We also agreed to retain each of the Sellers as consultants pursuant to consulting agreements, each with a term of one year, subject to annual renewal. The consulting agreements related to the Exendin APA have expired. During the year ended December 31, 2017, upon the successful completion of the Phase 2 trials, the development milestone was achieved, and we paid the related milestone payment of $0.1 million to each of the Sellers.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Bristol-Myers Squibb Company</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2016, we entered into a License Agreement and a Common Stock Purchase Agreement with Bristol-Myers Squibb Company, together BMS, the BMS Purchase Agreement and the BMS License Agreement. Under the BMS License Agreement, BMS granted us an exclusive, worldwide, license to research, develop, manufacture, and sell products </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">containing the proprietary BMS molecule known as PEG-interferon Lambda-1a (peginterferon lambda or the Licensed Product) for all therapeutic and diagnostic uses in humans and animals. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the development and commercialization of the Licensed Product at our sole cost and expense. In April 2016, under the BMS License Agreement we paid an upfront payment of $2.0 million in cash and issued 157,587 shares of our common stock to BMS with an aggregate fair value of $3.2 million. The BMS Purchase Agreement grants BMS certain registration rights with respect to the shares of common stock delivered, and BMS has agreed to certain trading and other restrictions with respect to the shares purchased.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BMS License Agreement, we are obligated to make development and regulatory milestone payments totaling $61.0 million and commercial sales milestones of up to $128.0 million after the achievement of specified milestones. We are also obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. If we grant a sublicense, we are obligated to pay BMS a portion of the sublicensing income received. In the fourth quarter of 2020, we recorded a $3.0 million milestone expense that was triggered on successful demonstration of proof of concept in a Phase 2 clinical trial. In March 2022, we recorded a $5.0 million milestone expense related to the initiation of the Phase 3 LIMT-2 study of lambda for HDV. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with the Trustees of the UPenn and CHOP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the UPenn and the CHOP, under which we obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain GLP-1 receptor antagonist(s) products to treat all human and animal conditions. We also obtained an exclusive, royalty-bearing, sublicensable, worldwide license to certain data developed by CHOP. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the development and commercialization of the licensed products at our sole cost and expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to us under the UPenn/CHOP Agreement, we paid UPenn a one-time, non-refundable issue fee of $1.0 million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, we are obligated to pay UPenn a specified annual license maintenance fee, up to $2.5 million in development milestones upon marketing authorization in one or more countries, and sales milestones of up to $18.0 million. We will also be required to pay UPenn a flat royalty in the low-single digits on our net sales of all licensed products, subject to specified reductions and offsets, and specified minimum annual royalty payments. Our obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. No milestones have been achieved as of December 31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for our failure to achieve the specified diligence milestones within the specified periods, subject to our extension rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations and Product Approvals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current product candidates are subject to regulation in the United States by the FDA under the Federal Food, Drug, and Cosmetic Act (FDC Act) and its implementing regulations. Our lambda product candidate is additionally subject to regulation as a biologic under the Public Health Service Act. The FDA subjects drugs and biologics to extensive pre and post market regulation. Failure to comply with the FDC Act and other federal and state statutes and regulations may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications (NDAs), BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal penalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approval is required before any new biologic, drug or dosage form, including a new use of a previously approved product, can be marketed in the United States. The process required by the FDA before a new product may be marketed in the United States is long, expensive, and inherently uncertain. Product development in the United States typically involves completion of preclinical laboratory and animal tests, submission to the FDA of an IND application, which must become effective before clinical testing may commence, approval by an independent institutional review board (IRB) at each clinical site before each trial may be initiated, performance of adequate and well controlled clinical trials to establish the safety, efficacy, purity and/or potency of the product for each indication for which FDA approval is sought, submission to the FDA of an NDA or BLA, satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced, and FDA review and approval of the NDA or BLA. Developing the data to satisfy FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product, disease or indication.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests include laboratory evaluation of the product&#8217;s chemistry, formulation, and toxicity, as well as animal studies to characterize and assess the potential safety, efficacy, purity and/or potency of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practice (GLP) regulations. These preclinical results are submitted to the FDA as part of an IND along with other information, including information about the product&#8217;s chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical studies including reproductive toxicity and carcinogenicity may be initiated or continue after the IND is submitted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the IND automatically becomes effective and the clinical trial proposed in the IND may begin. If the FDA raises any concerns or questions and places the clinical trial on a clinical hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, a submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug or biologic to human subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations, including good clinical practice (GCP) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials; and (ii) with protocols that detail, among other things, the objectives of the trial, the parameters to be used in monitoring safety, efficacy, purity and/or potency criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to and approved by an IRB at each study site before the study commences at that site and the IRB must monitor the clinical trial until it is completed. An IRB may also require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients, or the IRB may impose other conditions. The study sponsor or the FDA may also suspend or discontinue a clinical trial at any time on various grounds, including a determination that the subjects are being exposed to an unacceptable health risk.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, although there is leeway to overlap or combine these phases.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition, and is tested to assess safety, dosage tolerance, pharmacokinetics and pharmacological activity, and, when possible, to ascertain evidence of efficacy. The product candidate may also be tested in patients with severe or life-threatening diseases to gain an early indication of its effectiveness.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The trials are conducted using a limited patient population for the purposes of preliminarily determining the effectiveness of the product in that particular indication, ascertaining dosage tolerance, discerning the optimal dosage, and identifying possible adverse effects and safety risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If a compound demonstrates evidence of efficacy and has an acceptable safety profile in the Phase 2 clinical trials, then Phase 3 clinical trials are undertaken to obtain additional information from an expanded and diverse patient population, at multiple, geographically dispersed clinical trial sites, in randomized controlled studies often with a double-blind design to maximize the reproducibility of the study results. Typically, a minimum of two positive Phase 3 clinical trials are submitted to support the product&#8217;s marketing application. These Phase 3 clinical trials are intended to provide sufficient data demonstrating evidence of the safety, efficacy, purity and potency of the product such that the FDA can evaluate the overall benefit-risk of the product and provide adequate information for the labeling and package insert for the product. Trials conducted outside of the United States under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to the FDA in support of product approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials for investigational products must publicly disclose certain clinical trial information, including detailed trial design. These requirements are subject to specific timelines and apply to most Phase 3 clinical trials of FDA-regulated products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may condition approval of an NDA or BLA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the product. Such post approval trials are typically referred to as Phase 4 clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. Phase 1, Phase 2, Phase 3 and Phase 4 clinical trials may not be completed successfully within any specified period, or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually finalize a process for manufacturing the product in commercial quantities in accordance with current good manufacturing practice (cGMP) requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA requesting approval to market the drug or biologic for one or more specified indications. FDA review and approval of the NDA or BLA is required before marketing of the product may begin in the United States. The NDA or BLA must include the results of all preclinical, clinical, and other testing, including negative or ambiguous results as well as positive findings, together with other detailed information including compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The application must also contain extensive manufacturing information. The FDA reviews an NDA or BLA to determine, among other things, whether a product is safe and effective for its intended use. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, the submission of most NDAs and BLAs is subject to both a substantial application user fee and annual program user fees. These fees are typically increased annually.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. Once the submission is accepted for filing, the FDA begins an in-depth review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act (PDUFA) guidelines that are currently in effect, the FDA has agreed to certain performance goals in the review of applications. Standard applications are generally reviewed within ten months of filing, or twelve months from submission. Although the FDA often meets its user fee performance goals, it can extend these timelines if necessary, and FDA review may not occur on a timely basis. The FDA usually refers applications for novel products, or products that present difficult questions of safety, efficacy, purity and/or potency, to an advisory committee&#8212;a panel of independent experts, typically including clinicians and other scientific experts&#8212;for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the recommendation of the advisory committee, but it generally follows its recommendations. Before approving an NDA or BLA, the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the product is manufactured. The FDA will not approve an application unless it verifies that compliance with cGMP requirements is satisfactory and that the manufacturing processes and facilities are adequate to assure consistent production of the product within required specifications. The FDA will not approve a product unless the application contains data showing substantial evidence that it is safe and effective in the indication studied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the application and conducts its inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies contained in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application, including potentially significant, expensive and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive, and the FDA may interpret data differently than we do. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the application, the FDA will typically issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of additional information requested. FDA approval is never guaranteed. The FDA may refuse to approve an application if applicable regulatory criteria are not satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. The approval for a product may be significantly more limited than requested in the application, including limitations on the specific diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be included in the product&#8217;s package insert, or labeling.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition of approval, the FDA may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guidelines, communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, including dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS or use of a companion diagnostic with a product can materially affect the potential market and profitability of the product. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance to monitor the product&#8217;s safety, efficacy, purity and/or potency. The FDA may also condition approval on, among other things, changes to proposed labeling or development of adequate controls and specifications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, product approvals may be withdrawn if compliance with regulatory standards are not maintained or problems are identified following initial marketing. In addition, after approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. There also are continuing, annual program user fees for any marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">505(b)(2) NDA Pathway</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative path to FDA approval, an applicant may submit an NDA under Section 505(b)(2) of the Food, Drug and Cosmetic Act. A Section 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness or both for an approved drug product.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drugs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant an Orphan Drug designation to products intended to treat a rare disease or condition&#8212;generally one that affects fewer than 200,000 individuals in the United States. Orphan Drug designation must be requested before submitting the NDA or BLA. After the FDA grants Orphan Drug designation, the FDA publicly discloses the product&#8217;s identity and its intended orphan use. Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first active moiety to be approved to treat a disease with FDA&#8217;s Orphan Drug designation is entitled to a seven-year period of marketing exclusivity in the United States for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same product for the same orphan indication, regardless of patent status, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the Orphan Drug to meet the needs of patients with the disease or condition for which the product was designated. Orphan Drug exclusivity does not prevent the FDA from approving a different chemical/biological entity for the same disease or condition. An Orphan Drug designation also does not preclude the same product from being developed for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research expenses and a waiver of the application user fee.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Pediatric Disease (RPD) designation by the FDA enables priority review voucher (PRV) eligibility upon U.S. market approval of a designated product for rare pediatric diseases. The RPD-PRV program is intended to encourage development of therapies to prevent and treat rare pediatric diseases. The voucher, which is awarded upon NDA or BLA approval to the sponsor of a designated RPD can be sold or transferred to another entity and used by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holder to receive priority review for a future NDA or BLA submission, which reduces the FDA review time of such future submission from ten to six months.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers several expedited development and review programs for qualifying product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. PRIME designation by the EMA confers comparable benefits on qualifying drug product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing application for a biologic submitted to the FDA for approval, including a product with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review). A product is eligible for accelerated approval if the product provides a meaningful therapeutic advantage to patients over available treatments for a serious or life threatening condition, based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such product for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety, efficacy, purity and/or potency as those granted traditional approval and accelerated approval is typically contingent on a requirement to conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval using expedited procedures if, among other things, the sponsor fails to conduct any required post-approval study with due diligence or a such study fails to verify and describe a clinical benefit.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast Track designation, Breakthrough Therapy designation, priority review, accelerated approval do not change the standards for approval but may expedite the development or approval process. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing post-approval regulatory requirements. For instance, the FDA closely regulates the post-approval marketing, labeling, advertising and promotion of products, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Failure to comply with these requirements can result in adverse publicity as well as significant penalties, including the issuance of warning letters directing a company to correct any deviations from the FDA&#8217;s standards. The FDA may also impose a requirement that future advertising and promotional materials be pre-cleared by the FDA, and the Company may face federal and/or state civil and criminal investigations and prosecutions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new application or supplement before the change can be implemented. A supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing NDAs or BLAs. Obtaining new indication is an important part of managing the life cycle of the product.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse Event Reporting and cGMP Compliance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recordkeeping, adverse event reporting and the submission of periodic reports are required following the FDA&#8217;s approval of an NDA or BLA. The FDA also may require post-marketing testing or Phase 4 clinical trials, REMS, or surveillance to monitor the effects of an approved product. In addition, the FDA may place conditions on an approval that could restrict the distribution or use of the product. Furthermore, manufacture, packaging, labeling, storage and distribution procedures must continue to conform to cGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies to assess compliance with ongoing regulatory requirements, including cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall a product from distribution or withdraw approval for that product. Regulatory authorities may also withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals upon discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA. These other agencies include, without limitation, the Centers for Medicare and Medicaid Services, the Office of Inspector General for the U.S. Department of Health and Human Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of laws, including without limitation, anti-kickback and false claims laws, data privacy and security laws, drug price reporting laws, and physician payment transparency laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Anti-Kickback Statute, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. Violations of the federal Anti-Kickback Statute are punishable by imprisonment for up to ten years and statutory fines of up to $100,000. Additional criminal fines can be imposed under federal U.S. criminal procedure laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil penalties include statutory amounts of up to $100,000 (adjusted for inflation) per violation, assessments of up to three times the total payments between the parties to the arrangement, and exclusion from participation in the federal healthcare programs or suspension from future participation in Medicare and Medicaid. Further, violation of the federal Anti-Kickback Statute can also form the basis for False Claims Act liability (discussed below). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes any request or demand for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product or other items or services of value to customers with the expectation that the customers would</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommend the use of certain products or bill federal programs for such products. Companies have been prosecuted for causing false claims to be submitted because of, for example, the alleged marketing of products for unapproved, and thus non-reimbursable, uses, for the alleged submission of incorrect government price reporting data to certain Federal health care programs, for alleged violations of the federal Anti-Kickback Statute, and for other sales and marketing practices. Violations of the False Claims Act can result in civil penalties of up more than $25,000 per false claim or statement (an amount adjusted annually for inflation) plus three times the amount of damages sustained by the government. In addition, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to data privacy and information security laws and regulations, including both foreign and domestic, in the locations in which we conduct our business. HIPAA and its respective implementing regulations imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information and requires the adoption of administrative, physical and technical safeguards to protect such information. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Physician Payments Sunshine Act imposes, among other things, annual reporting requirements for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse midwives and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Covered manufacturers must submit reports by the 90th day of each calendar year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous federal laws and may apply regardless of payer. In addition, state data privacy laws that protect the security of health information may differ from each other and may not be preempted by federal law. In addition, certain states require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. Further, a number of states have enacted legislation designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, several states and local jurisdictions require the registration of sales representatives. These laws may adversely affect our sales, marketing and other activities with respect to any product candidate for which we receive approval to market in the United States by imposing administrative and compliance burdens on us. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the healthcare regulatory laws described above or any other laws that apply to it, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of products. Whether or not we obtain FDA approval for a product, we or our collaborators must obtain approval of the drug by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the product in those countries. The approval process varies from country to country and the time to approve may be longer or shorter than that required for FDA approval. Further, to the extent that any of our products are sold in a foreign country, we may be subject to additional foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application (MAA) either under the so-called centralized or national</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(mutual-recognition or decentralized) authorization procedures. A marketing authorization may be granted only to an applicant established in the EU. In the case of pediatric patients, Regulation (EC) No 1901/2006, as amended, provides that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA&#8209;approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1) a product&#8209;specific waiver, (2) a class waiver, or (3) a deferral for one or more of the measures included in the PIP. The centralized procedure provides for the grant of a single marketing authorization by the European Commission following a favorable opinion by the EMA that is valid in all EU Member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases, other immune dysfunctions and viral diseases. The centralized procedure is optional for other products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health or which contain a new active substance for indications other than those specified to be compulsory. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA grants Orphan Drug designation to promote the development of products for the treatment, prevention or diagnosis of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU. In addition, Orphan Drug designation can be granted if the drug is intended for a life threatening or chronically debilitating condition in the EU and without incentives it is unlikely that sales of the drug in the EU would be sufficient to justify the investment required to develop the drug. Orphan Drug designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing or treating the condition, or if such a method exists, the proposed Orphan Drug will be of significant benefit to patients. Orphan Drug designation provides opportunities for free or reduced-fee protocol assistance, fee reductions for marketing authorization applications and other post-authorization activities and ten years of market exclusivity following drug approval, which can be extended to 12 years if trials are conducted in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance with an agreed-upon pediatric investigational plan. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA may grant eligibility to the Priority Medicines (PRIME) Scheme to support the development of promising medicines that target an unmet medical need, i.e., medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients with no current treatment options for their disease. Through PRIME, the EMA grants proactive support to medicine developers to optimize the generation of robust data on a medicine&#8217;s benefits and risks, and enable accelerated assessment of medicines applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data protection laws, including, without limitation, the EU&#8217;s General Data Protection Regulation (EU GDPR), the EU GDPR as transposed into the national laws of the United Kingdom by virtue of section 3 of the European Union (withdrawal) Act 2018 as the UK GDPR (the EU GDPR and the UK GDPR, together the GDPR), the UK Data Protection, 2018 and European Union (EU) Member State and English data protection legislation, also apply to health-related and other personal information that we process, including, without limitation, personal information relating to clinical trial participants in the EU and/or the UK. The GDPR imposes significant obligations on controllers and processors of personal information, including, among other things, to: (i) implement administrative, physical, technical, and organizational safeguards to protect personal information; (ii) establish an appropriate and valid legal basis for processing personal information; (iii) comply with accountability and transparency requirements regarding the processing of personal information, which require controllers to demonstrate and record compliance with the GDPR and to provide more detailed information to data subjects regarding processing; (iv) comply with data protection rights of data subjects including a right of access to and rectification of personal information a right to obtain restriction of processing or to object to processing of personal information, a right to ask for a copy of personal information to be provided to a third party in a useable format and erasing personal information in certain circumstances; (v) report certain personal data breaches to the relevant supervisory authority without undue delay (and no later than 72, where feasible); (vi), obtain explicit consent for collection of sensitive personal information such as health data; and (vii) consider data protection as any new products or services are developed and to limit the amount of personal information processed. In addition, the GDPR prohibits the international transfer of personal information outside of the EU and/or the UK including to the U.S., unless made to a country deemed to have adequate data privacy laws by the European Commission and/or the UK or a data transfer mechanism in accordance with the GDPR (as applicable) has been put in place. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR allows EU Member States and the UK (as applicable) to make additional laws and regulations further limiting the processing of personal information, including genetic, biometric and health data. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also introduces fines of up to &#8364;20 million (under the EU GDPR) or &#163;17.5 million (under the UK GDPR) or up to 4% of the annual global revenue of the non-compliant company, whichever is greater, for serious violations of certain of the GDPR&#8217;s requirements. The GDPR identifies a list of points to consider when determining the level of fines to impose (including the nature, gravity and duration of the infringement). Data subjects also have a right to compensation for financial or non-financial losses (e.g., distress). Complying with the GDPR may cause us to incur substantial operational and compliance costs or require us to change our business practices. Despite our efforts to bring practices into compliance with the GDPR, we may not be successful either due to internal or external factors such as resource allocation limitations or a lack of vendor cooperation. Non-compliance could result in proceedings against us by governmental entities, regulators, customers, data subjects, suppliers, vendors or other parties. Further, there is a risk that the measures will not be implemented correctly or that individuals within the business will not be fully compliant with the new procedures. If there are breaches of these measures, we could face significant administrative and monetary sanctions as well as reputational damage which may have a material adverse effect on our operations, financial condition and prospects.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Coverage, Pricing and Reimbursement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and many other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover Zokinvy or any of our product candidates once approved could reduce physician utilization of such products and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that 50% to 70% of US patients who are eligible for treatment with Zokinvy will be covered by insurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through a federal healthcare program such as Medicaid, and the remaining patients will be covered by commercial insurance. We have had active engagement with payers that cover the lives of identified patients with Progeria and processing-deficient progeroid laminopathies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Additionally, coverage policies and third&#8209;party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more of our products, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, price transparency measures, inflation rebates, drug price negotiation programs for certain products, and restrictions on coverage and reimbursement and requirements for substitution of generic products. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that third-party payors will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to reform the delivery and payment for healthcare items and services. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the ACA was passed, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. This law was designed to expand access to health insurance coverage for uninsured and underinsured individuals while containing overall healthcare costs. The framework of the ACA and other healthcare reforms continues to evolve as a result of executive, legislative, regulatory, and administrative developments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, Congress has enacted several laws that modify certain provisions of the ACA, such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, the health insurer tax.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, for calendar years 2021 and 2022, the American Rescue Plan Act of 2021 temporarily increased premium tax credit assistance established under the ACA to help eligible individuals cover premiums for health insurance purchased through the health insurance marketplace and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. The Inflation Reduction Act of 2022 extended this increased tax credit assistance and removal of the 400% federal poverty limit through 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2021, President Biden issued an executive order instructing certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. The ACA has also faced various judicial challenges, and on June 17, 2021, the U.S. Supreme Court </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dismissed a challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. It is unclear how any future healthcare reform measures of the Biden administration or other efforts, if any, to repeal, amend or replace the ACA will impact the ACA, and our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in Congressional and federal agency inquiries regarding pricing and related practices, as well as proposed and enacted federal and state legislation and regulation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products For example, the American Rescue Plan Act of 2021 included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Previously, under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. Effective January 1, 2024, manufacturers&#8217; Medicaid Drug Rebate Program rebate liability will no longer be capped, potentially resulting in a manufacturer paying more in Medicaid Drug Rebate Program rebates than it receives on the sale of certain covered outpatient drugs. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drug prices, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, HHS issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. In August 2022, President Biden signed into law the Inflation Reduction Act of 2022, which implements substantial changes to the Medicare program, including drug pricing reforms and changes to the Medicare Part D benefit design.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Among other reforms, the Inflation Reduction Act of 2022 imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that, beginning in 2025, will cap benefit annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, beginning in 2026, establishes a &#8220;maximum fair price&#8221; for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services. Furthermore, the Biden administration continues to direct HHS to consider new healthcare payment and delivery models that would lower drug costs and promote access to innovative therapies for beneficiaries enrolled in the Medicare and Medicaid programs. In addition, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Policy changes, including potential modification or repeal of all or parts of the ACA or the implementation of new health care legislation, could result in significant changes to the health care system, which may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand or lower pricing for our product candidates, or additional pricing pressures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. For example, in the United States, there have been several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products can only be effectively marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials in order to compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross- border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Regulation (EU) 2021/2282 on HTA, or HTA Regulation, was adopted. The HTA Regulation will apply as from 12 January 2025. It particularly replaces the current system based on the voluntary network of national authorities, and the new framework covers joint clinical assessments, joint scientific consultations, the identification of emerging health technologies, and voluntary cooperation for the national authorities. The HTA Regulation aims to provide a transparent and inclusive framework for health technology assessments in the EU, and it will help EU countries determine the effectiveness and value of new technologies and decide on pricing and reimbursement by health insurers or health systems.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses were $75.3 million, $64.4 million and $41.6 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a total of 56 full-time employees in the United States and Europe, 39 of whom were primarily engaged in manufacturing and research and development activities, and 17 of whom were engaged in general management and administration. 11 of our employees have either an M.D. or a Ph.D. None of our employees are represented by a labor union or subject to a collective bargaining agreement. We have never experienced any work stoppage and consider our relations with our employees to be good.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated in California in December 2000 as Celladon Corporation (Celladon). In April 2012, Celladon reincorporated in Delaware and had its initial public offering in February of 2014.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2016, Eiger BioPharmaceuticals, Inc. (Private Eiger) completed its merger (Merger) with Celladon in accordance with the terms of the Merger Agreement. Pursuant to the Merger Agreement, Celladon Merger Sub, Inc., a wholly-owned subsidiary of Celladon (Merger Sub) merged with and into Private Eiger, with Private Eiger becoming a wholly-owned subsidiary of Celladon and the surviving corporation of the Merger. Immediately following the Merger, Celladon changed its name to Eiger BioPharmaceuticals, Inc. In connection with the Merger, our common stock began trading on The Nasdaq Global Market with the ticker symbol EIGR on March 23, 2016. Our principal executive offices are located at 2155 Park Blvd in Palo Alto, California 94306, and our telephone number is 650-272-6138. Our corporate website address is www.eigerbio.com. The contents of our website are not incorporated into this Annual Report on Form 10-K and our reference to the URL for our website is intended to be an inactive textual reference only.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.</span></div><div id="i55f26684d5024316bef45166a614e201_130"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, as well as the other information in this report, and in our other public filings. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should carefully consider the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report as part of your evaluation of an investment in our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a commercial-stage biopharmaceutical company with additional product candidates in clinical development and a limited operating history. We have incurred net losses in each year since our inception. We have one U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved product for commercial sale, Zokinvy (lonafarnib), and prior to 2021, have never generated any product revenue and may never be profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the success of our product candidates, which are in various stages of clinical development. We cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval and without regulatory approval we will not be able to market our product candidates. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prior to the approval of our new drug application (NDA) for Zokinvy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lonafarnib) to reduce the risk of mortality in HGPS, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, we had not submitted an application for approval or obtained FDA approval for any product. We may not be able to obtain FDA approval of any future NDA or Biologics License Application (BLA) for our product candidates, which would prohibit commercialization. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business strategy is based upon obtaining and maintaining Orphan Drug designation for our product candidates. If we are unable to obtain or maintain Orphan Drug designation or regulatory approval, our business would be substantially harmed. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends in part on our ability to attract, retain, and motivate qualified personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on clinical studies of our product candidates in order to obtain regulatory approval. We may find it difficult to enroll patients in our clinical studies given the limited number of patients who have the diseases for which our product candidates are being studied.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical studies of our product candidates fail to demonstrate safety, efficacy, purity and/or potency to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our clinical studies, manufacture our product candidates and perform other services. Our ability to obtain regulatory approval or commercialize our product candidates and our business could be impaired if these collaborations are unsuccessful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have limited marketing and sales capabilities for the commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Sales of our products depend substantially on the extent to which the costs of our product candidates will be paid for or reimbursed by healthcare management organizations or government authorities or third-party payors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently conducting and will continue to conduct clinical trials for our product candidates outside the United States, which could expose us to risks that could have a material adverse effect on our business, including risks in connection with the actions taken by the Russian Federation in Ukraine and surrounding areas.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to develop peginterferon lambda for COVID-19 or file for a temporary use authorization with a foreign regulatory agency.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We intend to rely on a combination of exclusivity from Orphan Drug designation and our patent rights for our product candidates. If we are unable to maintain exclusivity from the combination of these approaches, then our ability to compete effectively in our markets may be harmed. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The annual reassessment by the EMA of the risk-benefit balance for Zokinvy including information on the safe and effective use may not be positive, which could lead to a variation, suspension, revocation of our marketing authorization or requirement to fulfil additional specific obligations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to maintain effective proprietary rights for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to ours.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in any efforts to identify, license, discover, develop or commercialize additional product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent upon information technology systems and any failure or security breach of such systems could result in a material disruption in the development of our product candidates or other business operations as well as result in statutory or contractual obligations or otherwise expose us to liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends in part on our ability to attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The current COVID-19 pandemic has and may continue to adversely affect our financial condition and our business as well as those of third parties on which we rely on significant manufacturing, clinical or other business operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition, Integration and Capital Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company with a limited operating history. We have incurred net losses in each year since our inception. For the years ended December&#160;31, 2022, 2021 and 2020 we reported a net loss of $96.8 million, $33.9 million and $65.1 million, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $437.2 million. Our prior losses, combined with expected future losses, have had and may continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our currently available resources will be sufficient to fund our planned operations for at least the next 12 months following the issuance date of these consolidated financial statements. Our assumption does not reflect the possibility that we may not be able to access a portion of our existing cash, cash equivalents and short-term securities due to market and other conditions. For example, on March 10, 2023, the Federal Deposit Insurance Corporation (FDIC) was appointed receiver of Silicon Valley Bank (SVB), where we maintain an operating account with a balance that exceeded the FDIC insurance limit. Although, in this case the cash in our accounts at Silicon Valley Bank did not impact our operations or our conclusion that we have sufficient capital to fund our operations for at least the next 12 months, we cannot be certain that future market corrections or other conditions will not impact our ability to access our cash, cash equivalents and short-term securities. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC jointly announced enabling actions that fully protect all depositors of SVB and that such depositors would have access to all of their funds starting Monday, March 13, 2023. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and short-term securities may be threatened. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will continue to require substantial additional capital to continue our clinical development, manufacturing and regulatory approval efforts and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amounts and timing of our future funding requirements will depend on many factors, including our ability to achieve regulatory approval and the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including manufacturing of clinical supplies, conducting clinical studies and providing selling, general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities and debt facilities. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect losses to increase as we advance our clinical development programs in various clinical studies, particularly the D-LIVR pivotal study, to support the submission of an NDA for lonafarnib-based regimens for use in an HDV indication. We may need significant additional resources in order to aggressively move lonafarnib-based regimens forward successfully based on the discussions with the FDA. It may be several years, if ever, before we complete pivotal clinical studies and have additional product candidates approved for commercialization. We expect to invest significant funds into our clinical candidates to advance these compounds to potential regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval to market one or more additional product candidates, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products. We have also agreed with The Progeria Research Foundation to make Zokinvy available to progeria (HGPS and processing-deficient progeroid laminopathies) patients under an expanded access program that may not result in payment to us. Future clinical trials of new therapies for progeria conducted by third parties may also result in patients converting from commercially reimbursed Zokinvy to product provided through clinical trials and result in lower revenues received by us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the clinical development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undertake the manufacturing or have manufactured our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our programs into larger, more expensive clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional nonclinical, clinical, or other studies for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize and provide expanded access to Zokinvy for the treatment of HGPS and processing-deficient PL </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify and develop potential commercial opportunities, such as lonafarnib-based regimens, peginterferon lambda for HDV, and avexitide for HI and PBH;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory and marketing approvals and reimbursement for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market ourselves;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire, and/or develop other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone, royalty or other payments under third-party license agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop and educate HDV markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to attract and retain skilled personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and experience any delays or encounter issues with the development and potential for regulatory approval of our clinical candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies, or supportive studies necessary to support marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a representative indication of our future performance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior to 2021, we never generated any product revenue and may never be profitable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one product approved for commercialization in the U.S. and EU for two ultra-rare diseases. The first is Zokinvy, which works to (i) reduce the risk of mortality in HGPS, and (ii) treatprocessing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations. Zokinvy was approved by the FDA in November 2020 and launched commercially in the U.S. in January 2021, under the exceptional circumstances procedure. In July 2022, our MAA for Zokinvy was approved by the EC, based on a recommendation by the EMA. The Marketing Authorization (MA) is subject to the EMA&#8217;s continued review on an annual basis of new efficacy and safety information which may become available. Our ability to generate substantial revenue and achieve profitability depends on our ability to (i)obtain the regulatory and marketing approvals necessary to commercialize Zokinvy in foreign jurisdictions, alone or with strategic collaboration partners, and (ii) to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, more of our product candidates in the U.S. or foreign jurisdictions. We do not anticipate generating significant product revenue for the foreseeable future. Our ability to generate future product revenue depends heavily on our success in many areas, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing research and development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining additional and maintaining current regulatory and marketing approvals for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing, launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gaining market acceptance of our product candidates as treatment options;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in and maintaining any collaboration, licensing, or other arrangements into which we may enter;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining reimbursement or pricing for our product candidates that supports profitability; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain additional product approvals for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our current pipeline of product candidates has been in-licensed from third parties and we will have to develop or acquire manufacturing capabilities in order to continue development and potential commercialization of our product candidates. Additionally, if we are not able to generate sufficient revenue from the sale of any approved products, we may never become profitable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity, including pursuant to the 2022 ATM Facility, debt or other securities convertible into equity, your ownership interest will be diluted, and the terms of these new securities </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may include liquidation or other preferences that adversely affect your rights as a common stockholder such as the Loan and Security Agreement we entered into with Innovatus Life Sciences Lending Fund I, LP (Innovatus) in June 2022 (the Innovatus Loan). The Innovatus Loan was a $75.0&#160;million debt financing arrangement with Innovatus wherein we borrowed the first tranche of $40.0&#160;million upon closing of the debt financing in June 2022. The Innovatus Loan is secured by perfected first priority liens on our assets. The Innovatus Loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be adversely impacted by worsening global economic conditions and continuing disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. We cannot assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially affect our business, financial condition, and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covenants in the Innovatus Loan restrict our business and operations in many ways and if we do not effectively comply with our covenants, our financial conditions and results of operations could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Innovatus Loan provides for up to $75.0&#160;million in term loans due on August 31, 2027, of which $40.5&#160;million in principal is outstanding as of December&#160;31, 2022. All of our current and future assets, secure our borrowings under the Innovatus Loan. The Innovatus Loan requires that we comply with certain covenants applicable to us, including among other things, covenants restricting dispositions, changes in business, management, ownership or business locations, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. Our failure to comply with any of the covenants could result in a default under the Innovatus Loan, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable. If we are unable to repay those amounts, the lenders under the Innovatus Loan could proceed against the collateral granted to them to secure that debt, and our inability to use or dispose of those assets would seriously harm our business. In addition, should we be unable to comply with these covenants or if we default on any portion of our outstanding borrowings, the lenders can also impose a 5.0% penalty, restrict access to additional borrowings under the loan and security agreement, and accelerate the maturity of the debt. Any default under the Innovatus Loan would materially affect our liquidity and ability to fund our operations and complete our planned clinical trials and regulatory filings would be substantially impaired.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development of our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the success of our product candidates, which are in various stages of clinical development. Certain of our product candidates have produced results in academic settings to date or for other indications than those that we contemplate, and we cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have invested substantially all of our efforts and financial resources to identify, acquire, and develop our portfolio of product candidates. Our future success is dependent on our ability to further develop, obtain regulatory approvals for, and commercialize one or more of these product candidates. Our NDA for Zokinvy to reduce the risk of mortality in HGPS, and for treatment of processing-deficient progeroid laminopathies (PL) with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, was approved in November 2020. Prior to the U.S. Zokinvy commercial launch in 2021, we had not generated revenue from sales of any products and may never be able to develop or commercialize additional product candidates. In addition, we have a commitment to provide access to Zokinvy for patients with HGPS and PL with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, for no or minimal cost to those patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to potential commercial products, we currently have three product candidates that are in Phase 3 clinical development, lonafarnib-based regimens for HDV, peginterferon lambda for HDV, and avexitide for HI development program. Avexitide for PBH has completed Phase 2 clinical trials. It may be years before our studies are completed, and new studies initiated, if at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our geographically diverse clinical sites with good clinical practice protocols. We review and monitor the execution of our protocols at our various sites in an effort to understand those protocols are being followed. There can be no assurance that the data we develop for our product candidates in our planned indications will be sufficient or complete enough to obtain regulatory approval. Likewise, there can be no assurance that the data obtained from foreign clinical trial sites in studies not conducted under an investigational new drug application, or IND, will be accepted in support of an application for regulatory approval or authorization for use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. Similarly, data obtained from foreign clinical trial sites may not be accepted by other foreign regulatory authorities in support of an application for regulatory approval or authorization for use in these jurisdictions.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our current product candidates. We cannot be certain that any of our product candidates will be successful in clinical studies or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical studies. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain FDA approval of any future NDA or BLA for our product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing and distribution and other possible activities relating to lonafarnib-based regimens, peginterferon lambda, avexitide and any other product candidate that we may develop in the future are subject to extensive regulation in the United States. Prior to the approval of our NDA for Zokinvy to reduce the risk of mortality in HGPS, and for treatment of PL with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, we had not submitted an application for approval or obtained FDA approval for any product. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of an NDA or a BLA is not guaranteed, and the approval process is an expensive and uncertain process that may take several years. The FDA and foreign regulatory entities also have substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to target and the regulations applicable to any particular product candidate. Data are subject to varying interpretation and the FDA may not agree that our clinical data support that any of our product candidates are safe and effective for the proposed therapeutic use. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage, and we could encounter problems that require us to repeat or perform additional preclinical studies or clinical trials or generate additional chemistry, manufacturing and controls data, including product stability data. In previous studies, ECG abnormalities were observed in our lonafarnib program. The FDA and similar foreign authorities could delay, limit or deny approval of a product candidate, and may ultimately approve the product for narrower indications or with unfavorable labeling that would impede our commercialization of the product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods, including obtaining reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks associated with FDA approval as well as additional, presently unanticipated, risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others, including the risk that our product candidates may not be approved for all indications requested and that such approval may be subject to limitations on the indicated uses for which the product may be marketed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business strategy is based upon obtaining and maintaining Orphan Drug designation for our product candidates, which is an uncertain process. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are unable to obtain or maintain Orphan Drug designation or regulatory approval for our product candidates, our business would be substantially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to identifying and developing product candidates depends, in large part, on our ability to obtain and maintain Orphan Drug designation from regulatory authorities in major markets. Without the potential protection of this regulatory exclusivity upon approval, many of our product candidates would otherwise not justify investment. While we assess the potential for obtaining Orphan Drug designation at the time that we contemplate the acquisition of product candidates and we intend to timely file for such designation, there can be no assurance that we will obtain Orphan Drug designation or be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able to successfully meet the regulatory requirements to maintain that designation with the planned clinical trials for our product candidates. Failure to obtain and maintain Orphan Drug designation would make our product candidates significantly less competitive and potentially not viable investments for further development. Although we currently have Orphan Drug designation for some of our product candidates in multiple targeted indications, failure to demonstrate significant benefit over existing approved products in pivotal clinical trials may lead to marketing approval but without qualifying for Orphan Drug protection in some regions, such as in Europe.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have obtained U.S. and EMA regulatory approval for one product, Zokinvy, and it is possible that none of our current product candidates or any future product candidates we may seek to develop will ever obtain regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design, size or implementation of our clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from our development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical studies of our product candidates may not be sufficient or complete or meet the regulatory requirements to support the submission of an NDA, BLA, or other submission or to obtain regulatory approval in the United States or foreign jurisdictions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may find failures in our manufacturing processes, validation procedures and specifications, or facilities of our third-party manufacturers with which we contract for clinical and commercial supplies that may delay or limit our ability to obtain regulatory approval for our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our NDA, BLA or other submission insufficient for approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy and uncertain regulatory approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain additional regulatory approval to market any of our product candidates or to be significantly delayed from our expectations for potential approval, which would significantly harm our business, results of operations, and prospects. In addition, although we have obtained Orphan Drug designation for five of our development programs to date, there can be no assurance that the FDA or comparable foreign regulatory authorities will grant our similar status for our other proposed development indications or other product candidates in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although the FDA has granted Rare Pediatric Disease designation to avexitide for the treatment of congenital hyperinsulinism, NDA approval for this program may not meet the eligibility criteria for a priority review voucher.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our avexitide compound has received Rare Pediatric Disease (RPD) designation from the FDA for the treatment of Congenital Hyperinsulinism (HI). The FDA defines a &#8220;rare pediatric disease&#8221; as a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect patients under the age of 18 years, that is, a disease or condition that affects fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the product in the United States will be recovered from sales in the United States for that drug or biological product. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease product for which the voucher was awarded is not marketed in the U.S. within </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one year following the date of approval. In addition, the priority review voucher is only awarded to an NCE, thus if a compound is approved first for an indication that is not a rare pediatric disease the compound may not be eligible to receive the voucher. While we obtained and sold the priority review voucher issued upon approval of Zokinvy to reduce the risk of mortality in HGPS, and for treatment of PL with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, there can be no assurance that we will be successful in obtaining approval for avexitide for the treatment of HI, or that a priority review voucher will be issued at the time of any such approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress has only authorized the Rare Pediatric Disease Priority Review Voucher Program until September 30, 2024. However, if a product candidate receives RPD designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026. Avexitide may not be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority review voucher prior to expiration of the program, unless Congress further reauthorizes the program. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance we will receive a rare pediatric disease priority review voucher. Also, although priority review vouchers may be sold or transferred to third parties, there is no guarantee that we will be able to realize any value if we were to sell a priority review voucher.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have received Breakthrough Therapy designations, this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood of receiving marketing approval in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Breakthrough Therapy designation for lonafarnib and peginterferon lambda for the treatment of HDV, and for avexitide for the treatment of HI and PBH. A Breakthrough Therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. The Breakthrough Therapy designations we have obtained may not result in faster development processes, reviews or approvals compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that any of our development programs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for some or all of our future product candidates for the treatment of various conditions, there can be no assurance that we will receive any such Breakthrough Therapy designation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may submit an application for our product candidates under the Accelerated Approval Pathway. If we are unable to obtain approval or licensure of our product candidates through the Accelerated Approval Program in the United States, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing approval. Even if we receive approval from the FDA through the Accelerated Approval Program, if any required confirmatory post-marketing trial does not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw the approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may submit an NDA or BLA for our product candidates under the Accelerated Approval Pathway. If we are unable to obtain approval of our product candidates through the Accelerated Approval Program in the United States, we may be required to conduct additional nonclinical and clinical studies and trials beyond those that we currently contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing approval. Even if we receive approval from the FDA through the Accelerated Approval Program, if any required confirmatory post-marketing trial does not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw the approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek approval under the Accelerated Approval pathway for our lonafarnib and peginterferon lambda products for the treatment of HDV. For any approval to market a product, we must provide the FDA and foreign regulatory agencies with clinical data that adequately demonstrate the safety, efficacy, purity and/or potency of the product for the indication applied for in the NDA, BLA, or other respective regulatory filings. The Accelerated Approval Program is one of several approaches used by the FDA to make prescription drugs and biologics more rapidly available for the treatment of serious or life-threatening diseases. Section 506(c) of the Federal Food, Drug and Cosmetic Act (FDCA) provides that the FDA may grant accelerated approval to &#8220;a product for a serious or life-threatening condition upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.&#8221; Approval through the Accelerated Approval Program is typically subject, however, to the requirement that the applicant conduct additional post-marketing clinical trials to verify and describe the product&#8217;s clinical benefit. Typically, clinical benefit is verified when post-marketing clinical trials show that the product provides a clinically meaningful positive therapeutic effect, that is, an effect on how a patient feels, functions, or survives. If such confirmatory post-marketing trial fails to confirm the product&#8217;s clinical profile or risks and benefits, the FDA may withdraw its approval of the product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion with regard to approval through the Accelerated Approval Program, and even if we believe that the Accelerated Approval Program is appropriate for our product candidates, we cannot assure you that the FDA will ultimately agree. Furthermore, even if we do obtain approval through the Accelerated Approval Program, we may not experience a faster development process, review or approval compared to conventional FDA procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lonafarnib-based regimens and peginterferon lambda products for the treatment of HDV are in Phase 3 studies with endpoints intended to support accelerated approval. The primary endpoint for the D-LIVR study, the Phase 3 study of lonafarnib-based regimens, is a composite of a &gt; 2 log reduction in HDV RNA and ALT normalization and is intended to support accelerated approval. The primary endpoint for the LIMT-2 study, the Phase 3 study of peginterferon lambda, is a durable virologic response (DVR), defined as HDV RNA below the limit of quantitation at 24 weeks post-treatment, and is intended to support accelerated approval for finite therapy. The study endpoints were previously achieved in Phase 2 studies and are consistent with FDA guidance on the development of treatments for HDV. While these proposed endpoints are designed to be consistent with FDA guidance, there is no assurance that approval will be granted on a timely basis, or at all. FDA may disagree that the design of, or results from, our studies support accelerated approval. Additionally, the FDA could require us to conduct further studies or trials prior to granting approval of any type, including by determining that approval through the Accelerated Approval Program is not appropriate and that our clinical trials may not be used to support approval through the conventional pathway. We might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. There also can be no assurance that after subsequent FDA feedback we will continue to pursue approval through the Accelerated Approval Program. A failure to obtain approval through the Accelerated Approval Program could result in a longer time period to obtain approval of our product candidates, could increase the cost of their development, could delay our ability to commercialize our products and could significantly harm our financial position and competitive position in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive approval for one or more of our product candidates through the Accelerated Approval Program, we will be subject to rigorous post-marketing requirements, possibly including the completion of one or more confirmatory post-marketing trials as the FDA may require, to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw the approval for multiple reasons, including if we fail to conduct any required confirmatory post-marketing trial with due diligence, our confirmatory post-marketing trial does not confirm the predicted clinical benefit, other evidence shows that the product is not safe or effective under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, Congress has recently enacted potential changes to the Accelerated Approval Program that could impact our ability to obtain an Accelerated Approval, or increase the burdens associated with post marketing requirements in the event we do obtain an Accelerated Approval. In particular, FDA must specify certain conditions for required post approval studies for products that receive Accelerated Approval, which may include enrollment targets and milestones, including the target date for study completion, by the time the product is approved. FDA may also require post approval studies to be underway at the time of Accelerated Approval or within a specified time period following Accelerated Approval for such products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining, or inability to obtain, approval through the Accelerated Approval Program, or any issues in maintaining approval granted under the Accelerated Approval Program, would delay or prevent commercialization of our products, and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of larger, later-stage controlled clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent clinical studies. Our clinical studies to date have been conducted on a small number of patients in limited numbers of clinical sites and in academic settings or for other indications. We will have to conduct larger, well-controlled studies in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical studies. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical studies we have conducted or may conduct will demonstrate consistent or adequate safety, efficacy, purity and/or potency with respect to the proposed indication for use sufficient to obtain regulatory approval to receive regulatory approval or market our product candidates. For example, in 2018 we announced negative results from two of our Phase 2 clinical trials of ubenimex in two different indications, and as a result we have terminated further development of ubenimex.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical studies given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical studies of our product candidates is essential to our success. The timing of our clinical studies depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical studies if we encounter difficulties in enrollment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The eligibility criteria of our planned clinical studies may further limit the available eligible study participants as we expect to require that patients have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical studies. We may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical studies in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical studies, and the willingness of physicians to participate in our planned clinical studies. . For example, early in the COVID-19 pandemic, certain clinical study sites that were scheduled to open were delayed in activating and other sites suspended randomization of subjects for a period of time. Future pandemic restrictions could result in delays of our clinical trials, including LIMT-2. If patients are unwilling to participate in our clinical studies for any reason, the timeline for conducting studies and obtaining regulatory approval of our product candidates may be delayed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical study of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies would likely increase our overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical studies are costly, time consuming and inherently risky, and we may fail to demonstrate safety, efficacy, purity and/or potency to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data or diagnostics to support the initiation or continuation of clinical studies necessary for product approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining required Institutional Review Board (IRB) approval at each clinical study site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to permit the conduct of a study by regulatory authorities, after review of an investigational new drug (IND) or equivalent foreign application or amendment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting qualified patients, or patients dropping out of, in our clinical studies, including as a result of the evolving COVID-19 global pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">feasibility of continuous trial execution in countries impacted by war, geopolitical conflict and other humanitarian crises;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by clinical sites or our CROs or other third parties to adhere to clinical study requirements or report complete findings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform the clinical studies in accordance with the FDA&#8217;s good clinical practice (GCP) requirements, or applicable foreign regulatory guidelines;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of adverse events associated with our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical studies of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon development programs in other ongoing or planned indications for a product candidate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with third-party manufacturers and the time for manufacture of sufficient quantities of our product candidates for use in clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete clinical development and obtain regulatory approval could result in additional costs to us or impair our ability to generate revenue. Clinical study delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to obtain or maintain Orphan Drug designation exclusivity and to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Given we are not able to receive an Emergency Use Authorization (EUA) from FDA in the U.S., and we may not be able to receive a similar temporary use authorization from foreign regulatory agencies. If we do receive an EUA or similar temporary use authorization, absent a full marketing authorization for that indication, our ability to sell our products would be revoked when the COVID-19 public health emergency terminates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2022, we announced that, following feedback from FDA, we will not submit an EUA application for peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. If we decide to submit a future application for an EUA, we cannot predict whether FDA will grant an EUA. If we do not receive an EUA from FDA, we will not be able to commercialize future products and may be required to conduct additional clinical trials for an EUA. Obtaining such an authorization is dependent upon a number of factors, which are not under our control. Even if an EUA is received, we also cannot predict how long, if ever, an EUA would remain in place.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do intend to pursue similar temporary use authorizations in non-U.S. jurisdictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various regulatory pathways are available in jurisdictions outside the United States to make products available for emergency use. For example, regulatory authorities in certain EU Member States may temporarily authorize the distribution of an unauthorized drug in response to the suspected or confirmed spread of pathogenic agents such as the virus which is causing COVID-19. Obtaining such a temporary authorization is dependent upon a number of factors, which are not under our control. If such authorizations would be granted, they would only apply for a limited period of time. We might thus no longer be authorized to distribute our product under these authorizations if that time limit expired or the pandemic terminates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities in the EU or in other jurisdictions outside the US may grant a conditional marketing authorization for medicinal products intended for the treatment of seriously debilitating or life-threatening diseases prior to the submission of comprehensive clinical data if that treatment is of major therapeutic advantage to the patients concerned or no other authorized treatment is available. In emergency situations, such a conditional marketing authorization may also be granted for these medicinal products where comprehensive pre-clinical or pharmaceutical data have not been supplied. These conditional marketing authorizations are subject to specific conditions (e.g., completing on-going studies or conducting new studies) which must be fulfilled within a timeline specified in the marketing authorization. These marketing authorizations are valid for a short period of time (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, one year) which can usually be renewed. If we would apply for such a conditional marketing authorization the regulatory authority concerned may reject our application because it considers that the benefit-risk balance of our product is not favorable or it judges it unlikely that we would be able to provide comprehensive data. If we would obtain such a conditional marketing authorization we may not be able to complete (timely) the studies which the regulatory authority imposed as a condition for the marketing authorization or the data collected in the course of these studies may indicate that our product does not have a favorable benefit-risk profile. As a result we may not be able to continue distributing our product because the conditional marketing authorization has been revoked or not renewed, or the regulatory authority refused finally to grant a regular marketing authorization.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in the EU or other jurisdictions outside the EU may make a product available for compassionate reasons to a group of patients with a chronically or seriously debilitating disease or whose disease is considered to be life-threatening, and who cannot be treated satisfactorily with an authorized medicinal product provided that the product is subject of an application for marketing authorization or is undergoing clinical trials. If we would request a regulatory authority to make our product available to patient under these conditions the regulatory authority may reject our request if, for example, it considers that the patients concerned can be treated satisfactorily with other products that are already authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Programs which make products available under the conditions mentioned above are usually authorized for a limited period of time (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., one year). Regulatory authorities may not renew expiring authorizations for these programs if we terminate prematurely a clinical trial with our product or decide not to submit or to withdraw an application for marketing authorization in the jurisdiction concerned. That may, for example, happen because pharmacovigilance data or other data collected during our clinical trials indicate that our product does not have the appropriate benefit-risk balance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lonafarnib product candidate has been studied in thousands of oncology patients, and the most common non-hematologic adverse events of any grade were gastrointestinal system disorders (nausea, anorexia, diarrhea and vomiting), weight loss, fatigue and rash. Use of Zokinvy to reduce the risk of mortality in HGPS, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, has been reported to cause ECG abnormalities, but these ECG abnormalities have not resulted in a risk of mortality for these patients. There is no guarantee that additional or more severe side effects or other properties will not be identified through ongoing clinical studies by other uses of lonafarnib for other indications or our own clinical trials. Our peginterferon lambda product candidate is well-characterized and has been studied in thousands of HBV and HCV patients, and the most common adverse events seen are moderate headache, pyrexia, fatigue, and myalgia. ALT flares that were seen result from vigorous antiviral immunological response to treatment, not due to direct hepatotoxicity. There is no guarantee that additional or more severe side effects will not be identified through ongoing clinical studies for other uses of peginterferon lambda. Undesirable side effects, other properties, and negative results for other indications may negatively impact the development and potential for approval of our product candidates for our proposed indications. For example, the ECG abnormalities seen with lonafarnib in HGPS and PL patients has the potential to impact the labeling for lonafarnib-based regimens for HDV. Our avexitide product candidate has been studied in 39 HI patients and over 70 PBH patients, and the most common adverse events are injection site bruising/reaction, nausea, and headache. There is no guarantee that additional or more severe side effects will not be identified through ongoing clinical studies for other uses of avexitide in clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even if one or more of our current product candidates receives marketing approval, and we or others later may identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Risk Evaluation and Mitigation Strategy (REMS) plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing regulatory requirements related to the U.S. and European approvals of Zokinvy, and if we obtain additional regulatory approvals for a product candidate, we will be subject to additional ongoing regulatory requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved, they will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (cGMP) regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA, or MAA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety, efficacy, purity and/or potency of the product candidate. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new legislation addressing product safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm the clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any of our ongoing clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require a product recall.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prescription drugs and biologics may be promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and the value of us and our operating results would be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical studies, manufacture our product candidates and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon investigators and third-party CROs to conduct, monitor and manage our ongoing clinical programs. We rely on these parties for execution of clinical studies and manage and control only certain aspects of their activities. We remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We, our investigators, and our CROs and other vendors are required to comply with all applicable laws, regulations and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our investigators, CROs or vendors fail to comply with applicable laws, regulations and guidelines, the results generated in our clinical studies may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies before approving our marketing applications. We cannot assure you that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical studies, comply with applicable requirements. Our failure to comply with these laws, regulations and guidelines may require us to repeat clinical studies or conduct larger additional studies, which would be costly and delay the regulatory approval process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with investigators or third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical studies relative to those of other customers and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical studies. If investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical studies may be delayed or terminated, and we may not be able to meet our current plans with respect to our product candidates. CROs may also involve higher costs than anticipated, which could negatively affect our financial condition and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we do not currently have, nor do we plan to establish, the capability to manufacture product candidates for use in the conduct of our clinical studies or in support of our commercialization of potential products, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale without the use of third-party manufacturers. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical studies and regulatory approval. There are expected to be a limited number of suppliers for the active ingredients and other materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical studies, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete the study, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate, could delay completion of our clinical studies and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our lonafarnib program, we procured an inventory of product from Merck to supply our initial clinical study needs. In 2016, we transferred the manufacturing of drug substance and drug product to our third-party contractors. The material used for lonafarnib HDV pivotal trials, ongoing progeria clinical studies and expanded access program, and commercial Zokinvy supply are sourced from Eiger-controlled CMOs. These same vendors are currently under development for commercial qualification. Materials used for our avexitide clinical trials are also sourced from CMOs. Our vendors have successfully made GMP batches for our clinical studies, however, our trials could be delayed if quality, stability, or other issues occur in relation to the manufacture of any unique batch. If these CMOs are not able to provide us </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with sufficient quantities of product for our clinical trials or in support of our commercialization of potential products on a timely basis, or at all, whether due to production shortages or other supply interruptions resulting from any delay, our clinical trials or regulatory approval may be delayed, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or could impair our ability to generate revenue from the sale of such product candidate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of product, or fail to do so at acceptable quality levels or prices our product candidates could be stopped, delayed, or made less profitable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to source raw materials and manufacture our clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our contract manufacturers to manufacture our product candidates will be subject to pre-approval inspection by the FDA that will be conducted after we submit our marketing applications to the FDA or comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs, for manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, our future applications may not be approved by regulatory authorities, which would significantly delay our commercialization plans and increase our costs. We have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel, and in the past we have experienced quality control issues with product manufactured by our contract manufacturers. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates, and the actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may not be able to develop additional commercially viable products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party manufacturers exposes us to the following additional risks:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to identify manufacturers on acceptable terms or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract manufacturers may not be able to execute our manufacturing procedures appropriately;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, the approval of any of our product candidates by the FDA or comparable foreign regulatory authorities or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not conducted appropriately and test data is not reliable, patients could be put at risk of serious harm and could result in product liability suits.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of medical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up and validating initial production and absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidates to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our product development principally on treatments for rare and ultra-rare diseases. Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidate. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. For example, although we believe that our lonafarnib-based regimens and peginterferon lambda data are supportive of antiviral activity against HDV, there can be no assurance that our clinical trials will successfully address this condition. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Moreover, we expect that the sales of Zokinvy to patients with progeria will have limited profits given the ultra-rare nature of these diseases.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies that may compete with our product candidates. For example, we have competitors both in the United States and internationally, including multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include Gilead Sciences, Merck, Roche, Holding AG, Actelion Pharmaceuticals US, Johnson &amp; Johnson, Replicor, Arrowhead Pharmaceuticals, Novartis International, Zealand Pharmaceuticals, Xeris Pharmaceuticals, Rezolute, Hanmi Pharmaceutical, and Crinetics Pharmaceuticals as well as other smaller companies or biotechnology startups and large multinational pharmaceutical companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we commercially launched Zokinvy following its FDA approval, we have limited marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although certain of our employees may have marketed, launched and sold other pharmaceutical products in the past while employed at other companies, we have limited recent experience selling and marketing our product candidates and we currently have a small sales and marketing organization. To successfully commercialize Zokinvy and additional products that may result from our development programs, we will need to invest in and expand these capabilities, either on our own or with others, which would be expensive, difficult and time consuming. Any failure or delay in the timely development of our internal commercialization capabilities could adversely impact the potential for success of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, given our recent, limited experience in marketing and selling biopharmaceutical products, we may rely on future collaborators to commercialize our products. If collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, in particular in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies. In addition, we have established an expanded access program in order to make Zokinvy available for patients with progeria, which requires additional resources and costs to support.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the health care providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and other health care providers. The degree of market acceptance of any of our products will depend on a number of factors, including without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of our receipt of any marketing and commercialization licensures;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any licensures and the countries in which licensures are obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety, efficacy, purity and/or potency of the product as demonstrated in clinical studies and potential advantages over competing treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease and any side effects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which approval is granted, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the patients and physicians to accept these therapies or any new methods of administration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the marketing, sales and distribution support for the product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the publicity concerning our products or competing products and treatments; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our physician education programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and availability of third-party insurance coverage and reimbursement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product displays a favorable safety, efficacy, purity and/or potency profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequate level of acceptance by physicians, patients, third-party payors, and other health care providers, we will not be able to generate sufficient revenue to become or remain profitable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or maintain adequate reimbursement or insurance coverage for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that reimbursement will be available for our products and, if coverage and reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the indications for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, coverage and reimbursement of our products must be sufficient to support our commercial efforts and other development programs and the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive treatments, particularly in Orphan Drug designated indications where the eligible patient population is small. Sales of our products will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free or we may not be able to successfully commercialize our products. For example, Zokinvy for patients with HGPS and processing-deficient progeroid laminopathies provided under an expanded access program may not result in reimbursement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS), as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors often follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS and other payors will decide with respect to coverage for products such as ours and what reimbursement our products may receive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover Zokinvy or any of our product candidates once approved could reduce utilization of such products and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that adequate reimbursement will be available. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Additionally, coverage policies and third&#8209;party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more of our products, less favorable coverage policies and reimbursement rates may be implemented in the future. If we are unable to obtain and maintain sufficient third&#8209;party coverage and adequate reimbursement, the commercial success of our products may be greatly hindered and our financial condition and results of operations may be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the potential revenue may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, inadequate coverage or payment for our products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, coverage and reimbursement status of our products, if approved, are provided for by the national laws of the EU Member States. In the EU, pricing and reimbursement schemes vary widely from Member State to Member State. Some Member States provide that products can only be effectively marketed after a reimbursement price has been agreed. Some Member States may require the completion of additional studies in order to compare the cost-effectiveness of a particular drug candidate to currently available therapies (so called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the Company placing the product on the market. Other Member States may allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade (arbitrage between low-priced and high-priced Member States), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with products due to increased and continued efforts to limit or reduce healthcare spending. The downward pressure on healthcare costs in general, particularly prescription drugs, has and is expected to continue to increase in the future. As a result, profitability of our products may be more difficult to achieve even if they receive regulatory approval.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on a combination of exclusivity from Orphan Drug designation as well as patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to focus on product candidates for which Orphan Drug designation may be obtained in the major markets of the world. In addition, we rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors&#8217; ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an Orphan Drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the European Union (the EU), the EMA&#8217;s Committee for Orphan Medicinal Products (COMP) grants Orphan Drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same product for the same indication for a period of seven years, except in limited </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress is considering updates to the Orphan Drug provisions of the FDCA in response to a recent decision by the U.S. Court of Appeals for the 11th Circuit. Any changes to the Orphan Drug provisions could change our opportunities for, or likelihood of success in obtaining, Orphan Drug exclusivity and would materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the Orphan Drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the extent and scope of patent protection for our products may in some cases be limited, Orphan Drug designation is especially important for our products for which Orphan Drug designation may be available. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain or maintain Orphan Drug exclusivity for our drug and biological products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition sooner than if we had obtained Orphan Drug exclusivity and our revenue will be reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we have Orphan Drug designations for each of our development programs in the United States and Europe, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain Orphan Drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products with different active moieties can be approved for the same condition. Even after an Orphan Drug is approved, the FDA or EMA can subsequently approve the same product with the same active moiety for the same condition if the FDA or EMA concludes that the later product is safer, more effective, or makes a major contribution to patient care. Orphan Drug designation neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-licensed may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Although we have licensed a number of patents covering methods of use and certain compositions of matter, we do not have complete patent protection for our product candidates. For example, in connection with the arbitration with PRF described in Part I, Item 3 Legal Proceedings below, PRF is indirectly challenging the validity of our in-license of certain patents covering the methods of treating HGPS and progeroid laminopathies. Likewise, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">most of the patents or applications covering products that we have licensed in from Stanford have limited protection outside of the United States. Therefore, a competitor could develop the same or similar product that may compete with our product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our product licenses are limited to specified indications or therapeutic areas which may result in the same compound being developed and commercialized by a third party whom we have no control over or rights against. This may result in safety data, pricing or off label uses from that third party&#8217;s product that may negatively affect the development and commercialization of our product candidates. If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The annual reassessment by the EMA of the risk-benefit balance, including information on the safe and effective use, for Zokinvy may not be positive, leading to a variation, suspension, revocation of our MA or fulfillment of additional specific obligations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2022, we announced that the European Commission (EC) granted an MA under the exceptional circumstances procedure for Zokinvy to treat patients aged 12 months and older with HGPS and PL. The EC authorization follows the positive opinion granted by the CHMP in May 2022 which found that the risk-benefit balance for Zokinvy is favorable to recommend the granting of a MA although the rarity of the disease means that it was not possible to obtain complete information on Zokinvy during the assessment process. As a result, the MA was issued under the exceptional circumstances procedure and subject to the EMA&#8217;s continued review on an annual basis of new efficacy and safety information which may become available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Article 14(8) Regulation (EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with the requirements laid down in Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the legislation) might be eligible for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess the risk-benefit balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under exceptional circumstances is aimed at the provision of information on the safe and effective use of the product. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the annual reassessment by the EMA of the risk-benefit balance including information on the safe and effective use for Zokinvy may not be positive. This could lead to the variation, suspension, revocation of our MA for Zokinvy in the EU, or lead to additional specific commitments or conditions being fulfilled.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have sufficient patent term protections for our products to effectively protect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. In addition, upon issuance in the United States any patent term can be adjusted based on certain delays caused by the applicant(s) or the United States Patent and Trademark Office (USPTO). For example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of products. With respect to lonafarnib-based regimens, peginterferon lambda and avexitide, a substantial portion of the potential commercial opportunity will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our products for an extended period after regulatory approval, which would negatively impact our business and results of operations. If we do not have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent laws and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that it or our licensors were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (the Leahy-Smith Act) enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the USPTO must still implement various regulations, the courts have yet to address any of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are using or exploiting their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. Even if we conduct freedom to operate analyses, we would expect to do so only with respect to certain of our product candidates as they move through development. Accordingly, there may be third-party patents that would impair our ability to commercialize product candidates and we cannot assure you that we could obtain a license, or even if available, whether such license might be obtained on commercially reasonable terms. Even in those situations where we conduct a freedom to operate analysis, there can be no assurance that we would identify all relevant or necessary patents and patent applications that may apply to the manufacture and commercialization of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe, and if patents issue with respect to any such application and we become aware of such issuance, we would have to determine its impact on our efforts to develop and commercialize our product candidates and the strategy for obtaining a license or contesting any such issued patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, the manufacturing process of any of our product candidates, methods of use, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to obtain a license, then parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in meeting our diligence obligations under our existing license agreements necessary to maintain our product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to the intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain in effect these proprietary rights. For example, we have certain specified diligence obligations under our license agreement for lonafarnib. We may not be able to achieve the required diligence milestones in a timely manner, which may result in the license agreement being terminated, and we may be unable to successfully negotiate an extension or waiver of those termination rights. Any termination of license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collaborate with U.S. and foreign academic institutions to identify product candidates, accelerate our research and conduct development. Typically, these institutions have provided us with an option to negotiate an exclusive license to any of the institution&#8217;s rights in the patents or other intellectual property resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue a program of interest to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates marketed under NDAs may be subject to generic competition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application (ANDA) seeking approval of a generic copy of an approved innovator product marketed under an NDA. Generally, in place of clinical studies intended to demonstrate safety or effectiveness, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form, route of administration and that it is bioequivalent to the branded product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section 505(b)(2) that references the FDA&#8217;s finding of safety and effectiveness of a previously approved drug. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innovative small molecule drugs may be eligible for certain periods of regulatory exclusivity. The FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity (NCE). During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent for other conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers may seek to launch these generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for our drug. Competition that our drug candidates may face from generic versions of our drug candidates could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those drug candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those drug candidates may be substantially limited if our drug candidates, if and when approved, are not afforded the appropriate periods of non-patent exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic applicant that seeks to market its product before expiration of the patents must include in the ANDA or 505(b)(2) what is known as a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are patents listed for our products in the Orange Book after approval by the FDA, ANDAs and 505(b)(2) NDAs with respect to those products would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in securing or maintaining proprietary patent protection in the United States and/or in other countries for products and technologies we develop or license. Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could more immediately face generic competition and its sales would likely decline materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our biological product candidates for which we intend to seek licensure may face competition from biosimilars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated licensure pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have an adverse effect on the future commercial prospects for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a risk that any product candidates we may develop that are licensed as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. In addition, the approval of a biologic product biosimilar to one of our products could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our products. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation, including litigation challenging the constitutionality of the ACA. For example, in December 2018, a federal district court ruled that the ACA, without the &#8220;individual mandate&#8221; penalty (which was repealed by Congress as part of the Tax Cuts and Jobs Act), is unconstitutional in its entirety. In December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court ruling that the individual mandate provisions are unconstitutional and remanded the case back to the district court for further analysis of whether such provisions could be severed from the remainder of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the case without specifically ruling on the constitutionality of the ACA. There may, however, be other efforts to challenge, repeal, or replace the ACA in the future. We continue to evaluate the effect that the ACA and its possible repeal and replacement has (or may have) on our business and exclusivity under the BPCIA. It is uncertain the extent to which any such changes may impact our business or financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates is dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates are controlled by our licensors. This is the case with our agreements with Stanford and Nippon Kayaku, each of whom is primarily responsible for the prosecution of patents and patent applications licensed to us under the applicable collaboration agreements. If they or any of our future licensors fail to appropriately and broadly prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications, we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of intellectual property license and supply agreements that are important to our business and expects to enter into additional license agreements in the future. Our existing agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, purchasing, supply and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, our agreements may be subject to termination by the licensor, in which event we would not be able to develop, manufacture or market products covered by the license or subject to supply commitments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we are not currently involved in any intellectual property litigation, we may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. Although we are not currently involved in any intellectual property litigation, if we or one of our licensing partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants and independent contractors do not use the proprietary information or intellectual property rights of others in their work forums, and we are not currently subject to any claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends in part on our ability to attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2022, David Cory resigned as our President and Chief Executive Officer and a member of our Board, and on January 3, 2023, Sriram Ryali notified the Company of his resignation as the Company&#8217;s Chief Financial Officer, effective January 20, 2023, and on February 17, 2023, Erik Atkisson resigned as our General Counsel, Corporate Secretary and Chief Compliance Officer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has appointed Dr. David Apelian as the Company&#8217;s Interim President and Chief Executive Officer, and Dr. Apelian will remain a member of the Board. We are highly dependent on Dr. Apelian until we hire a full-time non-interim President and Chief Executive Officer, and will need to attract and retain appropriate finance and other personnel. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, including appropriate finance and legal personnel, the loss of the services of Dr. Apelian, or the failure to hire a fulltime President and Chief Executive Officer and other qualified management personnel, may impede the progress of our research, development, and commercialization objectives and would negatively impact our ability to succeed in our in-licensing strategy.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 56 full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, manufacturing, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation of data processing is evolving as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. We and our partners may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (e.g., laws and regulations that address data privacy and data security including, without limitation, health data). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our partners to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our partners&#8217; ability to process or use data in order to support the provision of our products or services, affect our or our partners&#8217; ability to offer our products and services in certain locations, or cause regulators to reject, limit or disrupt our clinical trial activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other personal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information apply to our operations or the operations of our partners. In addition, we may receive unintended health information in error from third parties (including research institutions from which we may obtain clinical trial data) that are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA. On December 10, 2020, the Office of Civil Rights within the Department of Health and Human Services issued proposed revisions to the HIPAA Privacy Rule aimed at reducing regulatory burdens that may exist in discouraging coordination of care and patient access to their health information, among other changes. While a final rule has not yet been issued, if adopted, these proposed changes may require us to update our policies and procedures to comply with the new requirements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, several state laws have recently been passed or amended to significantly expand privacy rights and obligations of businesses that process personal information, including identifiable sensitive health information. For example, in June 2018, California enacted the California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020. The CCPA gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. The California Privacy Rights Act of 2020 (CPRA), which expands the CCPA, was passed in the election on November 3, 2020. The CPRA will, among other things, give consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, and establish the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. Following the CPRA, Virginia and Colorado have enacted similar, but not completely consistent, comprehensive privacy legislation that will also go into effect in January and July 2023, respectively. Many other states are considering similar legislation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aspects of the these new state privacy laws, and their interpretation and enforcement, remain uncertain. The potential effects of these new and evolving state privacy laws are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Although the California, Virginia and Colorado laws include exemptions for certain clinical trials data and HIPAA protected health information, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents, and those health-data related exceptions may evolve through amendment or regulatory interpretation. The state privacy law developments, moreover, have prompted a number of additional proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data protection laws, including, without limitation, the EU GDPR that took effect in May 2018, and EU Member State data protection legislation, may also apply to health-related and other personal information obtained from individuals. The EU GDPR has been transposed into the national laws of the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018 as the UK GDPR (together, the EU GDPR and the UK GDPR, the GDPR). The EU GDPR has direct effect in all EU Member States and has extraterritorial effect where organizations outside of the EU process personal information of individuals in the EU in relation to the offering of goods or services to those individuals (targeting test) or the monitoring of their behavior (monitoring test). The UK GDPR has a similar extraterritorial test for organizations outside of the UK processing personal information of individuals in the UK in relation to the offering of goods or services to those individuals or the monitoring of their behavior. As such, the GDPR applies to us to the extent we are established in an EU Member State or the UK or we meet the requirements of either the targeting test or the monitoring test. These laws impose strict obligations on businesses, including to: (i) implement administrative, physical, technical, and organizational safeguards to protect personal information; (ii) establish an appropriate and valid legal basis for processing personal information; (iii) comply with accountability transparency requirements regarding the processing of personal information, which require controllers to demonstrate and record compliance with the GDPR and to provide more detailed information to data subjects regarding processing; (iv) comply with data protection rights of data subjects including a right of access to and rectification of personal information, a right to obtain restriction of processing or to object to processing of personal information, a right to ask for a copy of personal information to be provided to a third party in a useable format and erasing personal information in certain circumstances; (v) report certain personal data breaches to the relevant supervisory authority without undue delay (and no later than 72 hours, where feasible); (vi) obtain explicit consent for collection of sensitive personal information such as health data; and (vii) consider data protection as any new products or services are developed and to limit the amount of personal information processed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR restricts the transfer of personal information from the European Economic Area (EEA) to the United States and other countries that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws unless the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties to the transfer have implemented an appropriate data transfer mechanism in accordance with the EU GDPR. The UK GDPR has similar restrictions on transfers of personal information from the United Kingdom to countries that the UK does not recognize as having &#8220;adequate&#8221; data protection laws in the United Kingdom (as discussed below) and Switzerland impose similar restrictions. One of the primary mechanisms allowing United States companies to import personal information from Europe had been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the United States Department of Commerce. However, in July 2020, the Court of Justice of the EU (CJEU) invalidated the EU-U.S. Privacy Shield, and subsequent regulatory guidance required additional compliance efforts to analyze international data flows and take steps to ensure adequate protections for personal data transferred to the United States and other certain jurisdictions, including by implementing supplementary measures that provide privacy protections in addition to those provided under the Standard Contractual Clauses (SCCs). Moreover, new versions of the European Commission&#8217;s Standard Contractual Clauses, now the primary mechanism for the lawful transfer of personal information transfers from Europe and/or the United Kingdom to the United States or other countries, have been released requiring additional compliance and implementation efforts. The United Kingdom is also expected to publish its own set of SCCs in early 2022 for transfers of personal data outside of the United Kingdom. Similarly, the Swiss Federal Data Protection and Information Commissioner announced that the Swiss-U.S. Privacy Shield Framework is inadequate for personal information transfers from Switzerland to the United States in light of the CJEU&#8217;s July 2020 decision, and also raised questions about the viability of the older version of the Standard Contractual Clauses. As such, any transfers by us or our vendors of personal information from Europe may not comply with European data protection law, may increase our exposure to the EU GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions and may reduce demand from companies subject to European data protection laws. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, where we rely on SCCs, we must now evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. This evaluation will, in particular, include an assessment as to whether the types of personal data transferred pursuant to SCCs may be subject to government surveillance in the data importer&#8217;s country and an assessment as to whether the data importer can meet its contractual obligations under the SCCs. This may have implications for our cross-border data flows and may result in compliance costs. Inability to import personal information from the EEA, United Kingdom or Switzerland may also restrict our clinical trial activities in Europe; limit our ability to collaborate with CROs, service providers, contractors and other companies subject to European data protection laws; and require us to increase our data processing capabilities in Europe at significant expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, other countries outside of Europe continue to enact or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. For example, Brazil enacted the General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais or LGPD) (Law No. 13,709/2018), which broadly regulates the processing of personal information and imposes compliance obligations and penalties comparable to those of the EU GDPR.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the EU GDPR, regulators may impose substantial fines and penalties for non-compliance. Companies that violate the EU GDPR can face fines of up to the greater of 20 million Euros or 4% of their consolidated worldwide annual turnover (revenue) and restrictions or prohibitions on data processing. The EU also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR. The EU GDPR has increased our responsibility and liability in relation to personal information that we process, requiring us to put in place additional mechanisms to ensure compliance with the EU GDPR and other EU and international data protection rules. There may also be a risk that the measures will not be implemented correctly or that individuals within the business will not be fully compliant with the required procedures. Similarly, the UK GDPR introduces fines of up to the greater of &#163;17.5 million or up to 4% of their consolidated worldwide annual turnover (revenue).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties, fines or sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security or privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Compliance with data protection laws may be time-consuming, require additional resources and could result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments to customers or partners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these matters could materially adversely affect our business, financial condition, or operational results.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure in our information technology and storage systems or our security measures, including without limitation, data breaches, or inadequacy of our business continuity and disaster recovery plans and procedures, could significantly disrupt the operation of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our, and our third-party vendors&#8217;, information technology (IT) systems, and the availability of data related to our products, services and operations. IT systems and data are vulnerable to risks and damages from a variety of sources, including catastrophe or natural disaster, telecommunications or network failures, malicious human acts, breaches of security, cyber-attacks, loss of power or other natural or man-made events. Moreover, despite network security and back-up measures, we and our vendors frequently defend against and respond to data security attacks and incidents, and vendors&#8217; servers are potentially vulnerable to physical or electronic break-ins, computer viruses, software vulnerabilities, ransomware attacks and similar disruptive problems. If our business continuity and disaster recovery plans and procedures were disrupted, inadequate or unsuccessful in the event of a problem, we could experience a material adverse interruption of our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, data security breaches, whether inadvertent or intentional, by employees or others, may expose proprietary information, trade secrets, personal information, clinical trial data or other sensitive data to unauthorized persons, impact the integrity, availability or confidentiality of our IT systems or data (including, but not limited to, data loss), or disrupt or interrupt our IT systems or operations. Our partners and vendors face similar risks and any security breach of their systems could adversely affect our security posture. Malicious attacks by third parties are of ever-increasing sophistication and can be made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and financial motivation prompted by the enormous growth in ransomware over the past several years) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. Foreign, federal, and state laws or regulations allows for the imposition of civil liability, fines and/or corrective action on entities that improperly use or disclose the personal information of individuals, including through a data security breach. Accordingly, data security breaches experienced by us, our collaborators or contractors could lead to significant fines, required corrective action, loss of trade secrets or other intellectual property, or could lead to the public exposure of personally identifiable information (including sensitive personal information) of our employees, collaborators, clinical trial patients, and others. A data security breach or privacy violation that leads to disclosure or modification of or prevents access to personal information, including personally identifiable information, patient information or protected health information, could result in civil liability, harm our reputation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. If we are unable to adequately prevent, detect or respond to data security breaches or privacy violations, or implement satisfactory remedial measures in the wake of a data security incident, our operations could be disrupted, and we may suffer civil liability to our customers or individuals, loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data, or our clinical trials may be adversely impacted from data loss resulting in delayed regulatory approvals or other operational impacts. In addition, these breaches and other inappropriate access events can be difficult to detect, and any delay in identifying and responding to them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices or other remote working activity that access and process confidential information remotely increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures designed to protect our data security and information technology systems, no set of security measures is infallible, and these measures may not prevent such events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2021, we learned we were the victim of a business email compromise during which an unauthorized party gained access to the email account of an employee in our finance department. The incident resulted in a net loss of approximately $0.3 million. Based on our investigation, the incident was financially motivated and impacted a single email account. In response to the incident, we conducted a review of our corporate information technology and email policies and have implemented additional security measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite precautionary measures to prevent anticipated and unanticipated problems, including data breaches, there can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems (or that of our third-party providers). Such events could affect our IT systems, sustained or repeated system failures that interrupt our ability to generate, use and maintain data or our IT systems could adversely affect our ability to operate our business and result in increased costs or loss of revenue, other financial and reputational harm to us, theft of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trade secrets and other proprietary information, legal claims or proceedings, liability under laws that protect the privacy of personal information and regulatory penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in any efforts to identify, license, discover, develop or commercialize additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not succeed in preclinical or clinical testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to reform the delivery and payment for healthcare items and services. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the ACA was passed, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. This law was designed to expand access to health insurance coverage for uninsured and underinsured individuals while at the same time containing overall healthcare costs. The framework of the ACA and other healthcare reforms continues to evolve as a result of executive, legislative, regulatory, and administrative developments. For example, Congress has enacted several laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, the health insurer tax. More recently, for calendar years 2021 and 2022, the American Rescue Plan Act of 2021 temporarily increased premium tax credit assistance established under the ACA to help eligible individuals cover premiums for health insurance purchased through the health insurance marketplace and removed the 400% federal poverty level limit that otherwise applies for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purposes of eligibility to receive premium tax credits. The Inflation Reduction Act of 2022 extended this increased tax credit assistance and removal of the 400% federal poverty limit through 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2021, President Biden issued an executive order instructing certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. There have also been numerous historical challenges and amendments to certain aspects of the ACA, and on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. It is unclear how the healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal, amend or replace the ACA will impact the ACA and our business.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in Congressional and federal agency inquiries regarding pricing and related practices, as well as proposed and enacted federal and state legislation and regulation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the American Rescue Plan Act of 2021 included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Previously, under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. Effective January 1, 2024, manufacturers&#8217; Medicaid Drug Rebate Program rebate liability will no longer be capped, potentially resulting in a manufacturer paying more in Medicaid Drug Rebate Program rebates than it receives on the sale of certain covered outpatient drugs. Additionally, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drug prices, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, HHS issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. In August 2022, President Biden signed into law the Inflation Reduction Act of 2022, which implements substantial changes to the Medicare program, including drug pricing reforms and changes to the Medicare Part D benefit design.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other reforms, the Inflation Reduction Act of 2022 imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that, beginning in 2025, will cap benefit annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, beginning in 2026, establishes a &#8220;maximum fair price&#8221; for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services. The Biden administration continues to direct the Department of Health and Human Services to consider new healthcare payment and delivery models that would lower drug costs and promote access to innovative therapies for beneficiaries enrolled in the Medicare and Medicaid programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict how, or to what extent, the Biden administration&#8217;s drug pricing policies will affect our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Any legislation aimed at further healthcare reform may have the effect of limiting the amounts that government agencies will pay for healthcare products and services. Policy changes, including potential modification or repeal of all or parts of the ACA or the implementation of new health care legislation, could result in significant changes to the health care system, which may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand or lower pricing for our product candidates, or additional pricing pressures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. The increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to foreign, federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, sanctions or other liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations may be subject to various foreign, federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, physician sunshine laws, the EU GDPR and/or the UK GDPR and other regulations. These laws may impact, among other things, our research, sales, marketing, education and patient assistance programs. In addition, we may be subject to patient privacy regulation by foreign, federal, and state governments in which we conduct our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying anything of value as remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA and its implementing regulations impose certain requirements on certain covered entity healthcare providers, health plans, and healthcare clearinghouse and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered subcontractors, relating to the privacy, security, and transmission of individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to HHS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse midwives, as well as ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug, and Cosmetic Act (FDCA), which, among other things, prohibits the adulteration and misbranding of drugs and biological products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payors, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the EU GDPR and/or the UK GDPR (together, GDPR) and other EU Member State or English data protection legislation, which require data controllers and processors to (i) implement administrative, physical, technical, and organizational safeguards to protect personal information; (ii) establish an appropriate and valid legal basis for processing personal information (iii) comply with accountability transparency requirements regarding the processing of personal information, which require controllers to demonstrate and record compliance with the GDPR and to provide more detailed information to data subjects regarding processing; (iv) comply with data protection rights of data subjects including a right of access to and rectification of personal information, a right to obtain restriction of processing or to object to processing of personal information, a right to ask for a copy of personal information to be provided to a third party in a useable format and erasing personal information in certain circumstances; (v) report certain personal data breaches to the relevant supervisory authority without undue delay </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(and no later than 72 hours, where feasible); (vi) obtain explicit consent for collection of sensitive personal information such as health data; and (vii) consider data protection as any new products or services are developed and to limit the amount of personal information processed. In addition, the GDPR prohibits the international transfer of personal information outside of the EU and/or the UK including to the U.S., unless made to a country deemed to have adequate data privacy laws by the European Commission and/or the UK or a data transfer mechanism in accordance with the GDPR (as applicable) has been put in place.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply, we may be subject to penalties, including significant civil, criminal and administrative penalties, damages, disgorgement, fines, sanctions, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, corporate integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The withdrawal of the United Kingdom from the EU, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the electorate in the UK voted in favor of leaving the EU (commonly referred to as &#8220;Brexit&#8221;). Thereafter, in March 2017, the country formally notified the EU of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty and the UK formally left the EU on January 31, 2020. A transition period began on February 1, 2020, during which EU pharmaceutical law remained applicable to the UK. This transition period ended on December 31, 2020. The EU-UK Trade and Cooperation Agreement (TCA) was agreed on December 24, 2020. The UK and EU agreed that the TCA would apply provisionally from January 1, 2021, the TCA was ratified on April 30, 2021 and came into force on May 1, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the regulatory framework in the UK covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the UK, as UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will fully impact regulatory requirements for product candidates and products in the UK in the long-term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At present, the regulatory framework for medicines that existed before the end of the transition period has effectively been preserved in UK domestic legislation as &#8216;retained EU law&#8217; which has prevented substantial divergence to the regulation of medicines so far. However, the UK Government has now introduced the Retained EU Law (Revocation and Reform) Bill 2022 which intends to end the &#8220;special status&#8221; of retained EU law under UK law. If enacted into law, this would facilitate departure from retained EU law, and may lead to greater regulatory divergence between the EU and UK in the future. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In comparison, as matters currently stand, under the terms of the Northern Ireland Protocol (the NIP), implemented by the EU (Withdrawal Agreement) Act 2020, Northern Ireland is treated for the same purposes as if it were still an EU Member State, and must remain aligned to the EU single market and customs rules. The UK government has also introduced a bill &#8216;Northern Ireland Protocol Bill&#8217; which if enacted into law would enable the government to unilaterally disapply parts of the NIP which may lead to changes to the regulatory environment in Northern Ireland, and may trigger retaliatory measures against the UK by the EU. However, on February 27, 2023, the UK government and the EU Commission reached political agreement on a package of proposed amendments to the NIP (Windsor Framework). According to the UK government, if these proposals are implemented, this would lead to a &#8220;carve-out from EU rules&#8221; and, amongst other measures, the UK medicines regulator (MHRA) would be responsible for approving medicines for the whole UK market, meaning that medicinal products available in Northern Ireland will not have to comply with EU law but rather with UK law, so medicinal products would be able to freely circulate between Northern Ireland and Great Britain. Furthermore, the UK government has said that it will withdraw the Northern Ireland Protocol Bill under the Windsor Framework if it is implemented. The future regulatory framework for medicines in Northern Ireland will remain uncertain until the proposals are passed into law. The EU-UK Trade and Cooperation Agreement allows for future deviation from the current regulatory framework and it is not known if and/or when any deviations may occur, which may have an impact on Eiger&#8217;s business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies now need to comply with a separate UK regulatory legal framework in order to commercialize medicinal products in Great Britain (namely, England, Wales and Scotland, as EU law currently applies in Northern Ireland). For instance, Great Britain will no longer be covered by centralized marketing authorizations (as matters stand, under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January 1, 2021. For a period of three years from January 1, 2021, the MHRA may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required. The MHRA has also introduced new procedures aimed at accelerating regulatory approvals and time to market, including &#8216;rolling reviews&#8217; and the Innovative Licensing and Access Pathway (ILAP) although eligibility requirements apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCA and the proposed Bills allow for future deviation from the current regulatory framework and it is not known if and/or when any deviations may occur, which may have an impact on development, manufacture, marketing authorization, commercial sales and distribution of pharmaceutical products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraudulent conduct or other illegal activity by our employees, independent contractors, principal investigators, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, promotion, sales, marketing and certain business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of patient recruitment or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harm patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use or misuse of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs due to related litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management&#8217;s attention from our primary business;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates, if approved for commercial sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current product liability insurance coverage is appropriate in light of our clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to increase our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our licensors and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently conducting and will continue to conduct clinical trials in foreign countries, which could expose us to risks that could have a material adverse effect on the success of our business and the delivery of clinical trial data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted in the past and are currently conducting clinical trials in the United States, Canada, Australia, Turkey, Germany, Pakistan, New Zealand, Mongolia, Spain, France, Bulgaria, Romania, Taiwan, Sweden, Italy, Belgium, Switzerland, United Kingdom, Greece, Moldova, Ukraine, Russia, and Israel, and accordingly, we are subject to risks associated with doing business globally, including commercial, political, and financial risks. Emerging regions, such as Eastern Europe, Latin America, Asia, and Africa, as well as more developed markets, such as the United Kingdom, France, Germany, and Australia, provide clinical study opportunities for us. In addition, we are subject to potential disruption caused by military conflicts; potentially unstable governments or legal systems; civil or political upheaval or unrest; local labor policies and conditions; possible expropriation, nationalization, or confiscation of assets; problems with repatriation of foreign earnings; economic or trade sanctions; closure of markets to imports; anti-American sentiment; terrorism or other types of violence in or outside the United States; health pandemics; and a significant reduction in global travel. For example, both Turkey and Pakistan are key regions for clinical activity relating to Hepatitis Delta Virus, and further </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outbreaks of violence and political instability in the region could disrupt our clinical operations or otherwise limit our ability to access or conduct clinical studies in those regions. Certain countries have closed their borders due to COVID-19 preventing activation of clinical sites. Actions taken by the Russian Federation in Ukraine and surrounding areas have destabilized the region and caused the adoption of comprehensive sanctions by, among others, the EU, the United States and the UK, which restrict a wide range of trade and financial dealings with Russia and Russian persons, as well as certain regions in Ukraine, including by imposing stricter export controls, prohibiting dealings with major Russian banks and credit institutions, and prohibiting trade with the Donetsk, Luhansk, Kherson and Zaporizhzhia regions of Ukraine. In addition, clinical site initiation and patient enrollment may be delayed, and we may not be able to access sites for initiation, monitoring and data collection in regions affected by the Russian invasion of Ukraine, including due to the prioritization of hospital resources away from clinical trials or as a result of government imposed curfews, warfare, violence or other governmental action or events that restrict movement. Some patients may not be able to comply with clinical trial protocols if the conflict impedes patient movement or interrupts healthcare services. We could also experience disruptions in our supply chain or limits to our ability to obtain sufficient materials for our products in certain regions. Our success will depend, in part, on our ability to overcome the challenges we encounter with respect to these risks and other factors affecting U.S. companies with global operations. If our global clinical trials were to experience significant disruption due to these risks or for other reasons, it could have a material adverse effect on our operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon whom we depend may be adversely affected by earthquakes, natural epidemics or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earthquakes, health epidemics or other natural disasters could severely disrupt our operations and have a material adverse effect on our business. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. For example, in December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China. Since certain starting materials of certain of our products obtained from third-party chemical suppliers are manufactured in China and Japan, an outbreak of communicable diseases in the region, or the perception that such an outbreak could occur, and the measures taken by the governments of countries affected, could adversely affect our business, financial condition or results of operations by limiting our ability to manufacture product within or outside for example China, Japan, Italy, Canada, and the United States, forcing temporary closure of facilities that we rely upon or increasing the costs associated with obtaining starting materials and then clinical supplies of our product candidates. The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In addition, our corporate headquarters is located in the San Francisco Bay Area, which has in the past experienced severe earthquakes, other natural disasters, and an outbreak of COVID-19. We do not carry earthquake insurance. We have limited disaster recovery and business continuity plans in place currently and our business would be impaired in the event of a serious disaster or similar event. We may incur substantial expenses to develop and implement any disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is currently adversely affected by and could be materially adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics including the evolving effects of the COVID-19 outbreak. We have a significant number of clinical trial sites in countries that have been directly affected by COVID-19. We depend on manufacturing operations for various stages of our supply chain in countries that have been directly affected by COVID-19. COVID-19 continues to adversely affect our business and could materially and adversely affect our operations and those of our manufacturers and other third parties with whom we conduct business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been adversely affected by COVID-19 and could be materially and adversely impacted by COVID-19 or other health epidemics in regions where we have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. The ongoing effects of the pandemic and government and other responses thereto, including shelter-in-place orders and our work-from-home policies, may continue to negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of any restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our suppliers of certain materials used in the production of our drug products are located in China, Japan, Canada, Italy and the United States. While many of these materials may be obtained by more than one supplier, including suppliers outside of China, Japan, Canada, Italy and the United States, port closures and other restrictions resulting from the coronavirus outbreak in the region may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Site initiation and patient enrollment has been delayed, due to prioritization of hospital resources toward the COVID-19 pandemic, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a result of the COVID-19 pandemic, the extent and length of which is uncertain, we may be required to develop and implement additional clinical study policies and procedures designed to help protect study participants from the COVID-19 virus, which may include using telemedicine visits, remote monitoring of patients and clinical sites, and measures to ensure that data from clinical studies that may be disrupted as result of the pandemic are collected pursuant to the study protocol and consistent with GCPs, with any material protocol deviation reviewed and approved by the site IRB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and EMA have in the past suspended, may continue to suspend, prioritize or delay certain foreign inspections, and if there continues to be a suspension or delay in inspections, our product application reviews and potential approvals could be impacted or delayed. Further, ongoing surges in COVID-19 case numbers with the emergence of new variants and sub-variants have contributed to interruptions in FDA&#8217;s surveillance capabilities, and such disruptions may persist in the future as a result of future surges. We cannot predict whether, and when, FDA will decide to pause or resume inspections due to the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic, including providing guidance regarding the conduct of clinical trials. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, or impact reviews or other regulatory activities, it could significantly impact the ability of the FDA or other foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to adversely affect our business operations, the extent of the impact on our clinical development and regulatory efforts and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19. In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and may continue to be highly volatile, and you may not be able to resell some or all of your shares at a desired market price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results or delays in preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of adverse events in other gene therapy products or clinical trials of such products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in filing an IND, NDA, BLA, or MAA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that IND, NDA, or BLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or the EMA&#8217;s review of that MAA);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain or maintain Orphan Drug designation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and supply agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by our licensors to prosecute, maintain, or enforce our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory authority decisions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products, services, or technologies by our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections we may provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or macroeconomic conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to the hepatitis market generally, including with respect to other products and potential products in such markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies that compete with potential products of ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may also adversely affect the trading price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and will continue to incur significant legal, accounting and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and The Nasdaq Stock Market LLC. These rules and regulations impose significant legal and financial compliance costs and make some activities more time-consuming and costly. For example, our management team consists of certain executive officers who have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. In addition, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15% of our voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders, if any, for the foreseeable future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause our stock price to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. Certain of our existing stockholders, including Columbia Threadneedle Investments, 683 Capital Management, BlackRock Institutional Trust, and The Vanguard Group, and their respective affiliated entities, own substantial ownership interest in our common stock and any decision to sell a significant number of shares may negatively impact the price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ownership of our common stock is highly concentrated, and it may prevent stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders and their affiliates beneficially own or control a significant portion of the outstanding shares of our common stock. Accordingly, these executive officers, directors, 5% stockholders and their affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of us, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our net operating loss carryforwards and certain other tax attributes are now subject to limitations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our federal and state net operating loss (NOL) carry-forwards will begin to expire, if not utilized, beginning in 2030 for federal income tax purposes and 2028 for California state income tax purposes. These NOL carry-forwards could expire unused and be unavailable to offset future income tax liabilities. Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), U.S. federal net operating loss carryforwards generated in tax years beginning after December 31, 2017 may be carried forward indefinitely but, in the case of tax years beginning after December 31, 2020, may only be used to offset 80% of taxable income annually. In addition, California has enacted A.B. 85 which imposed limits on the usability of California state net operating losses and certain tax credits in tax years beginning after 2019 and before 2023. Such limitations could result in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the expiration of portions of our net operating loss and tax credit carryforwards before utilization. On February 9, 2022, Senate Bill No. 113 was signed into California law and reinstates the net operating loss deduction, and removes the above-described temporary limitation on allowable credits, for taxable years beginning on or after January 1, 2022. Moreover, if a corporation undergoes an ownership change within the meaning of Section 382 of the Code (Section 382) the corporation&#8217;s NOL carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the &#8220;ownership change.&#8221; In general, an ownership change occurs if there is a cumulative change in the corporation&#8217;s equity ownership by certain stockholders that exceeds fifty percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Our merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#8217;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. In addition, we assessed whether Eiger had an ownership change, as defined by Section 382 of the Code, as a result of the Merger and other stock issuances that occurred from our formation through December 31, 2020. Based upon this assessment, we have experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to these ownership changes, reductions were made to our NOL and tax credit carryforwards under these rules. Additional ownership changes in the future could result in additional limitations on our net operating loss and tax credit carryforwards. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations. A full valuation allowance has been provided for the entire amount of our remaining net operating losses.</span></div><div id="i55f26684d5024316bef45166a614e201_591"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i55f26684d5024316bef45166a614e201_586"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 2155 Park Blvd in Palo Alto, California 94306 in a facility we lease encompassing 8,029 square feet of office space. The lease commenced on March 1, 2018 and was to expire five years after the commencement date. The lease had one three-year renewal option prior to expiration and included rent escalation clauses through the lease term. In February 2023, the Company amended the lease to extend the lease term for an additional year from March 1, 2023 to February 28, 2024. The amendment also included a one year renewal option. </span></div><div id="i55f26684d5024316bef45166a614e201_127"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not list all routine litigation matters with which we are a party. We discuss below certain pending matters. In determining whether to discuss a pending matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages alleged and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; and whether the action purports to be, or is, a class action the jurisdiction in which the proceeding is pending.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Schoen v. Eiger BioPharmaceuticals, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, Case No. 22-cv-06985</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022 a putative securities class action complaint was filed in the United States District Court for the Northern District of California alleging that the company and two former executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleges generally that between March 2021 and October 2022 material misstatements and omissions were made to shareholders regarding the TOGETHER study of peginterferon lambda for the treatment of COVID-19 as well as the likelihood of FDA approval of an Emergency Use Authorization for peginterferon lambda. The Court appointed a lead plaintiff on March 2, 2023. The litigation is currently ongoing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Progeria Research Foundation, Inc. v. Eiger BioPharmaceuticals, Inc. Arbitration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2022, the Company received a demand for arbitration (Demand) from claimant The Progeria Research Foundation, Inc. (PRF) asserting two claims under a May 15, 2018 Collaboration and Supply Agreement (the PRF Collaboration Agreement) between the parties. PRF has alleged that the Company breached an obligation to supply quantities of a drug as requested by PRF. PRF also has a claim for declaratory relief regarding the grant of licenses under the PRF Collaboration Agreement. On January 18, 2023, the Company filed a response to the Demand denying PRF&#8217;s claims, contesting the arbitrability of PRF&#8217;s claim for declaratory relief, and asserting a counterclaim for declaratory relief related to the contractual provision underlying PRF&#8217;s original drug supply claim. To give the parties an opportunity to discuss a potential negotiated resolution of their dispute, the arbitration has been suspended through the end of 2023. As a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result, all arbitration activities are now on hold, and the final hearing, originally scheduled for May 9 &#8211; 12, 2023, in Boston, Massachusetts, has been taken off calendar.</span></div><div id="i55f26684d5024316bef45166a614e201_139"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i55f26684d5024316bef45166a614e201_617"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2016, Celladon and Private Eiger completed the Merger. Immediately prior to the Merger, Celladon completed a 15-for-1 reverse stock split. Following the Merger, we changed the name of the combined company to Eiger BioPharmaceuticals, Inc. and changed the symbol to &#8220;EIGR.&#8221; Our common stock originally began trading on The Nasdaq Global Market on January 30, 2014. Prior to January 30, 2014, there was no public market for our common stock. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 13, 2023, there were approximately 20 stockholders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends, if permitted, will be made at the discretion of our board of directors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our compensation plans under which our equity securities are authorized for issuance as of December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(a)</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Securities to be</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Issued Upon</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Outstanding</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options, Warrants and Rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(b)</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Outstanding</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options ($/share)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(c)</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Available</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For Issuance Under</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Equity</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Compensation Plans</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Excluding Securities</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Reflected in Column</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(a))</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Plan Category</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity compensation plans approved by stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,784,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,764,517</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equity compensation plans not approved by</span></div><div style="margin-top:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;stockholders</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,784,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,764,517</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The amount shown in column (a) includes <ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-38">6,143,183</ix:nonFraction> outstanding options and <ix:nonFraction unitRef="shares" contextRef="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-39">641,407</ix:nonFraction> restricted and performance stock units.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">The weighted average exercise price in column (b) includes options only as restricted and performance stock units do not have an exercise price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:26.68pt">As of December&#160;31, 2022, the number of securities remaining available for issuance in column (c) includes <ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-40">1,976,460</ix:nonFraction> share available for future issuance in the form of options or restricted stock, restricted or performance stock units, or restricted stock awards under our Amended and Restated 2013 Equity Incentive Plan and 2021 Inducement Plan and <ix:nonFraction unitRef="shares" contextRef="i965b044302dc48988da35b57cfb58274_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-41">788,057</ix:nonFraction> shares remained available for future issuance under our 2013 Employee Stock Purchase Plan (ESPP). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022, in connection with the Innovatus Loan, we entered into a Common Stock Purchase Agreement (the Purchase Agreement) with Innovatus Life Sciences Lending Fund I, LP, Innovatus Life Sciences Offshore Fund I-A, LP, Innovatus Flagship Fund I, LP, and Innovatus Flagship Offshore Fund I, LP (each an Investor, and collectively the Investors) for the sale and issuance of common stock with an aggregate value of $5.0 million. The closing occurred on June 1, 2022, and we sold and issued 749,053 shares of common stock (the Shares) to the Investors at a per share purchase price of $6.6751, the preceding five-day volume-weighted average price per share. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Shares were sold and issued in a private placement in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. The Company relied upon these exemptions from registration based in part on the representations made by the Investors in the Purchase Agreement. The Investors will acquire the Shares for investment for the Investors&#8217; own account and not with a view to or for sale in connection with any distribution thereof, and appropriate legends will be affixed to the Shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the loan proceeds was used to repay in full the approximately $33.5 million of aggregate principal amount, unpaid interest, and exit fees in connection with our loans outstanding owed to Oxford Finance LLC. Refer to Note 8 of our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for additional details.</span></div><div id="i55f26684d5024316bef45166a614e201_557"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Reserved</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis together with our financial statements and related notes included elsewhere in this Annual Report. The following discussion contains forward-looking statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption &#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated, references to the terms the &#8220;combined company,&#8221; &#8220;Eiger,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Eiger BioPharmaceuticals, Inc. (formerly known as Celladon Corporation) and its subsidiaries after the merger described herein. The term &#8220;Private Eiger&#8221; refers to privately-held Eiger BioPharmaceuticals, Inc. prior to its merger with Celladon Merger Sub, Inc. a wholly-owned subsidiary of Celladon Corporation. The term &#8220;Celladon&#8221; refers to Celladon Corporation and its subsidiaries prior to the Merger.</span></div><div id="i55f26684d5024316bef45166a614e201_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. All five of our rare disease programs have FDA Breakthrough Therapy designation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Lonafarnib is a first-in-class, oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III, interferon.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D-LIVR is the pivotal Phase 3 study of lonafarnib boosted with ritonavir, alone or in combination with peginterferon alfa-2a, for HDV. The study completed enrollment of 407 patients, and we announced topline Week 48 data in December 2022, with week 72 data expected in mid-2023. LIMT-2 is the pivotal Phase 3 study of peginterferon lambda for HDV.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing avexitide, a first in class, well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs and no approved therapies: congenital hyperinsulinism (HI) and post-bariatric hypoglycemia (PBH). Avexitide has completed Phase 2 for both indications, and we initiated Phase 3 study start-up activities for HI in 2022. In connection with our Phase 3, start-up activities, we observed low levels of product-related impurities in the finished drug product. Although not unusual for this class of compounds, we are working with our CMO's to control and qualify these materials and plan to initiate dosing in Phase 3 when an adequate supply of materials with a sufficient shelf-life has been released.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approved our first commercial product, Zokinvy (lonafarnib), to reduce the risk of mortality of Hutchinson-Gilford progeria syndrome (HGPS) and for treatment of processing-deficient progeroid laminopathies (PL) with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, on November 20, 2020. Collectively known as progeria, these are ultra-rare and rapidly fatal genetic conditions of accelerated aging in children. On July 20, 2022, we announced that the European Commission (EC) granted Eiger a centralized marketing authorization (MA) under the exceptional circumstances procedure for Zokinvy for the treatment of HGPS and PL, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children. The MA is subject to the EMA&#8217;s continued review on an annual basis of new efficacy and safety information which may become available. The EC's centralized MA is valid in all 27 EU member states plus Iceland, Liechtenstein, and Norway. Regulatory review is ongoing by the UK's Medicine and Healthcare products Regulatory Agency (MHRA) as part of the UK's European Commission Decision Reliance Procedure, which has been extended to apply across Great Britain until December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercially launched Zokinvy in the U.S. in January 2021 and in Europe in November 2022 and started to record product revenue in the first quarter of 2021. Our first European sales were recognized in the fourth quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have historically incurred operating losses in each year since inception and we expect to incur losses for the foreseeable future. We had a net loss of $96.8 million, $33.9 million and $65.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $437.2 million. Substantially all of our operating losses have resulted from expenses incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, and potentially commercialize our product candidates, which will require the addition of new personnel and upgrades to our information technology systems. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve additional regulatory approvals. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a formal program prioritization assessment with a focus on enhancing long-term shareholder value while fulfilling the promise of advancing our high-potential product candidates for patients with serious diseases.</span></div><div id="i55f26684d5024316bef45166a614e201_73"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2022, we announced topline Week 48 data from the Phase 3 D-LIVR study (N=407) evaluating lonafarnib in two regimens in patients with chronic HDV: lonafarnib boosted with ritonavir alone (all-oral) and in combination with peginterferon alfa (combination). The composite primary endpoint was a &#8805;2 log decline in HDV RNA and normalization of alanine aminotransferase (ALT) at the end of 48 weeks of treatment compared to placebo.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topline Week 48 results showed that both treatment arms achieved statistical significance over placebo in the composite primary endpoint as well as the component virologic and biochemical responses. Study participants receiving the all-oral therapy and combination therapy showed a composite response of 10.1% (p=0.0044) and 19.2% (p &lt;0.0001), respectively, compared to those receiving placebo (1.9%). Study participants receiving the all-oral therapy and combination therapy showed statistically significant improved rates of ALT normalization of 24.7% (p=0.003) and 34.4% (p&lt;0.0001), respectively, compared to those receiving placebo (7.7%). A peginterferon alfa comparator arm was included in the study to show contribution of effect. The composite response rate in the all-oral arm was comparable to the peginterferon alfa arm (10.1% vs 9.6%). The composite response rate in the combination arm was twice that of the peginterferon alfa arm (19.2% vs 9.6%).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key secondary endpoint of proportion of patients with improvement in histological response rate demonstrated with statistical significance in combination arm vs placebo.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#151515;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger plans to engage with regulatory agencies, beginning with a request for a pre-NDA meeting with FDA in Q1 2023 with a meeting anticipated in Q2 2023, to discuss pathways for regulatory submissions. T</span><span style="color:#151515;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he full D-LIVR dataset, including analyses of the</span><span style="background-color:#ffffff;color:#151515;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 24-week post-treatment period, would be included in potential regulatory submissions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on Plans for Emergency Use Authorization (EUA) Application Following U.S. FDA Feedback</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2022, we announced that, following feedback from FDA, we will not submit an EUA application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our press release on September 6, 2022, in which we updated on the status of our planned EUA based on recent communications with the FDA, we submitted a pre-EUA meeting request to the FDA as well as additional morbidity and mortality outcomes data and analyses from the investigator-sponsored TOGETHER study. This included further statistical modeling and efficacy analyses of the study's primary and secondary endpoints and long-term follow-up data that we believe continues to support the topline outcomes reported in March. In response, the FDA denied the request for a pre-EUA meeting. Citing its concerns with the conduct of the TOGETHER study, the FDA concluded that any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA suggested that, given peginterferon lambda's mechanism of action and the ongoing need for improved COVID-19 therapeutics, we should consider requesting an end-of-Phase 2 meeting to discuss a company-sponsored pivotal trial that could support an eventual Biologics License Application (BLA), We are evaluating next steps for this program in the U.S., as well as ex-U.S. emergency use authorization pathways, and strategic options for the continued development of peginterferon lambda for COVID-19 and other respiratory viral infections.    </span></div><div id="i55f26684d5024316bef45166a614e201_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenue, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product revenue, net consists of sales of Zokinvy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lonafarnib) for HGPS and processing-deficient progeroid laminopathies in the United States and under a reimbursed early access program, or cohort ATU program, in France. In November 2022, sales of Zokinvy launched commercially in Europe through our wholly owned subsidiary in Ireland. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue consists of milestone payments from the MDA with AnGes, Inc., which was executed in May 2022. </span></div><div id="i55f26684d5024316bef45166a614e201_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, third party logistics costs, write down of inventories, and other period costs. </span></div><div id="i55f26684d5024316bef45166a614e201_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses represent costs incurred to conduct research and development, such as the development of our product candidates. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with consultants, contract research organizations and clinical trial sites that conduct research and development activities on our behalf;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laboratory and vendor expenses related to the execution of clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">contract manufacturing expenses, primarily for the production of clinical trial supplies; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">license fees associated with our license agreements; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">internal costs that are associated with activities performed by our research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated internal research and development costs consist primarily of:</span></div><div style="margin-top:6pt;padding-left:99pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.46pt">personnel costs, which include salaries, benefits and stock-based compensation expense;</span></div><div style="margin-top:6pt;padding-left:99pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.46pt">allocated facilities and other expenses, which include expenses for rent and maintenance of facilities and depreciation expense; and</span></div><div style="margin-top:6pt;padding-left:99pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.46pt">regulatory expenses and technology license fees related to development activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest component of our operating expenses has historically been the investment in clinical trials, including contract manufacturing arrangements, clinical trial material related costs and other research and development activities. However, we do not allocate internal research and development costs, such as salaries, benefits, stock-based compensation expense and indirect costs to product candidates on a program-specific basis. The following table shows our research and development expenses for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Product candidates:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lonafarnib</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Peginterferon Lambda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Avexitide</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Internal research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,436&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,590&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect research and development expenses will continue to be significant and may increase in the future as we advance our product candidates into and through later stage clinical trials and pursue regulatory approvals, which will require a significant investment in regulatory support and contract manufacturing and clinical trial material related costs. In addition, in the future we may evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to license fees and/or milestone payments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commercialization and sale of any of our product candidates. The COVID-19 pandemic presents additional risks and uncertainties associated with developing drugs,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as further described in Item 1A, "Risk Factors".</span></div><div id="i55f26684d5024316bef45166a614e201_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of personnel costs, allocated expenses, expenses for outside professional services, including legal, audit, accounting services, insurance costs and costs associated with being a public company, and commercial related expenses. Personnel costs consist of salaries, benefits and stock-based compensation. Allocated expenses consist of facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation expense and other supplies. Our expenses include costs related to compliance with the rules and regulations of the SEC and Nasdaq, insurance, investor relations, banking fees and other administrative expenses and professional services. We expect our selling, general and administrative expenses to increase in the future due to sales and marketing activities from the commercialization of our product candidates.</span></div><div id="i55f26684d5024316bef45166a614e201_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of interest on our long-term borrowings.</span></div><div id="i55f26684d5024316bef45166a614e201_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our investments in debt securities and cash equivalents.</span></div><div id="i55f26684d5024316bef45166a614e201_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (expense) income, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net primarily consists of the loss on extinguishment of debt recorded during the year ended December&#160;31, 2022. </span></div><div id="i55f26684d5024316bef45166a614e201_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities revenues, and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. We accrue for these costs based on factors such as estimates of the work completed and in accordance with agreements established with our third-party service providers. We make judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, we adjust our accrued liabilities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval of our product candidates, expenses incurred to manufacture products are recorded as research and development expense. We begin capitalizing these expenses as inventory upon regulatory approval. We periodically </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assess the recoverability of our inventory and reduce the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales. We wrote-down $1.0 million of inventories for the year ended December&#160;31, 2022. There were no write-downs in prior periods.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenue when a customer obtains control of our product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is our only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States, and other countries. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. We use the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. We record an accrued liability for unpaid rebates related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt payment discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We provide a discount to a customer if it pays for purchases within 30 days. We expect that our customers will earn prompt payment discounts and use the most likely amount method for estimating such discounts. As a result, when revenues are recognized, we deduct the full amount of the prompt payment discounts from total product revenues and record these discounts as a reduction of accounts receivable.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We provide co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. We use the expected-value method for estimating co-payment assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. We record an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We offer limited product return rights and generally allow for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. We consider several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation costs related to stock options and restricted stock units based on the estimated fair value of the awards on the grant date. We estimate the grant date fair value of stock options, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. We record forfeitures when they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model includes the following assumptions:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise. </span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility for stock options is based on the Company's historical stock price volatility. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the contractual term to determine the non-employee awards&#8217; fair value at the grant date. The contractual term of options granted under the Plan is 10 years. Our Board of Directors determined the fair value of each share of underlying common stock based on the closing price of our common stock as reported by the Nasdaq Global Market on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of restricted stock units based on the closing market price of our common stock on the date of grant and the resulting stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once we have determined that it is probable that performance conditions will be satisfied. </span></div><div id="i55f26684d5024316bef45166a614e201_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes results of operations for the years ended December&#160;31, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ <br/>Change </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% <br/>Change </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,143&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,740)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,939)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,853)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,776)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,917)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,859)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Percentage not meaningful or not material. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product revenue, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net change was flat for the year ended December&#160;31, 2022, from the same period of 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other revenue</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue of $0.8 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 reflects the upfront payment received from AnGes, Inc. under the terms of the MDA, which was executed in May 2022. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased by $1.1 million to $1.8 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from $0.7 million for the same period in 2021. The increase was primarily due to a non-conforming batch of inventory that was written off during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $10.8 million to $75.2 million for the year ended December&#160;31, 2022, from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$64.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the same period in 2021. The increase was primarily due to a $6.6 million increase in headcount related expenses, including stock-based compensation expense and travel expenses related to participation in scientific conferences, a $5.3 million increase in clinical and manufacturing spend for activities related to Avexitide Phase 3 readiness, a $5.0 million milestone related to the Phase 3 LIMT-2 study of peginterferon lambda for HDV under the BMS License Agreement, which occurred in March 2022, a $2.4 million increase in other outside services across programs including consulting and advisory services and a $0.3 million increase in operational overhead cost. These increases were partially offset by a $7.5 million decrease in clinical and contract manufacturing expenditures on Lonafarnib as patients rolled off the study program and a $2.1 million decrease in costs associated with the support of an investigator sponsored study for peginterferon lambda for COVID.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Selling, general and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $5.2 million to $29.1 million for the year ended December&#160;31, 2022, from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the same period in 2021. The increase was primarily due to a $2.9 million increase in outside services, including consulting, advisory and accounting services, a $2.1 million increase in headcount related expenses and a $0.3 million increase in other operating expenses, all to support company growth. The increases were partially offset by a $0.1 million decrease in sales and marketing expense. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased by $0.6 million compared to the same period in 2021. The increase was primarily due to an increase in the outstanding principal balance of our long-term borrowings related to the Innovatus loan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $0.9 million compared to the same period in 2021. The increase was primarily due to an increase in the average balance of money market funds and available-for-sale securities during 2022 along with an increase in interest rates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (expense) income, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net changed by $47.5 million compared to the same period in 2021. The change was primarily due to $46.5 million net proceeds received from the sale of our rare pediatric disease priority review voucher to AbbVie Inc in 2021 and a $1.1 million loss on early extinguishment of the Oxford loan in 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for income taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes decreased by $41,000 compared to the same period in 2021. The change was primarily due to the tax expense related to state taxes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had $98.9 million of cash, cash equivalents and short-term debt securities, comprised of $25.8 million of cash and cash equivalents and $73.1 million of short-term debt securities available-for-sale, and an accumulated deficit of $437.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022, we entered into a loan and security agreement with Innovatus Life Sciences Lending Fund I, LP (Innovatus), providing for up to $75.0 million funded in three tranches with a maturity date of August 31, 2027. We were funded $40.0 million in June 2022 at the closing, of which approximately $33.5&#160;million was used to pay off the Oxford Loan. We recorded a loss of $1.1&#160;million on early extinguishment of the debt which was recognized as a component of Other (expense) income, net in the consolidated statement of operations and comprehensive loss. As part of the agreement with Innovatus, we are required to maintain a cash balance of not less than 5% of the aggregate principal amount of funded and outstanding term loans at all times. We are currently eligible to draw the $17.5 million under Tranche B, but have not done so as of December 31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with entering into the Innovatus Loan, we entered into a Stock Purchase Agreement with Innovatus for the sale of common stock with an aggregate value of $5.0 million. On June 1, 2022, we issued 749,053 shares of common stock to Innovatus at a per share purchase price of $6.6751. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2022, we entered into a new Open Market Sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies, pursuant to which we can sell up to a maximum of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our common stock in offerings that are deemed &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act, under Eiger&#8217;s effective shelf registration statement (the 2022 ATM Facility). In April 2022, we completed offerings from the 2022 ATM facility for a total of 2,686,288 shares of our common stock resulting in net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, after deducting commissions costs. No additional offerings were completed since April 2022. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$28.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remaining under the 2022 ATM Facility for future issuance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, we filed a shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission (SEC), which was declared effective by the SEC on December 31, 2020 and permits the offer, issuance and sale by us up to a maximum aggregate offering price of $200.0 million of our common stock, preferred stock, debt securities and warrants. In connection with the filing of the registration statement, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC (Jefferies), pursuant to which we could sell up to a maximum of $50.0 million of our common stock in offerings that are seemed &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act (2020 ATM Facility). In March 2022, we completed the sale of all shares available under the 2020 ATM Facility, and the 2020 ATM Facility was terminated.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the currently available resources will be sufficient to fund our planned operations for at least the next 12 months following the issuance date of this Annual Report on Form 10-K. However, if our anticipated operating results are not achieved in future periods, we believe that planned expenditures may need to be reduced or we would be required to raise funding in order to fund our operations. Additionally, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic, among other events.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to fund operating expenses, including research and development expenditures and selling, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in outstanding accounts payable and accrued expenses.</span></div><div id="i55f26684d5024316bef45166a614e201_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2021, we had not generated any product revenue. We launched our first commercial product, Zokinvy, in January 2021. We expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture and clinical trials of, and seek regulatory approval for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be, funding the development of our product candidates, sales and marketing costs for commercialization of Zokinvy and other product candidates, compensation and related expenses, hiring additional staff, including clinical, scientific, operational, manufacturing, financial, and management </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel, and costs associated with operating as a public company. We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional collaborations or strategic partnerships with other companies. As a result of economic conditions, general global economic uncertainty, political change and other factors, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we may need to curtail planned development or commercialization activities. The sale of additional equity, including pursuant to the 2022 ATM Facility, or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into a non-cancelable operating facility lease agreement commencing on March 1, 2018 and expiring in February 2023. In February 2023, the Company amended the lease to extend the lease by one year with a one year renewal option. The extended lease will commence on March 1, 2023 and expires on February 28, 2024. We also have additional operating leases that are not considered significant for disclosure. Refer to Note 13 of our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of our contractual obligations as of December 31, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset and License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. Refer to Note 5, Note 6 and Note 7 in our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of our contractual obligations as of December 31, 2022. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Development Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2018, we entered into a Product Development Agreement and a First Project Agreement (the Product Agreements), pursuant to which we will receive development program support services for the HDV program. The services are to be provided from July 1, 2018 through the new drug application (NDA) filing. The Product Agreements can be terminated by either party due to material breach or by us without cause with 90 days prior written notice. Refer to Note 5 of our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for additional details. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovatus Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022, we entered into a term loan and security agreement (Innovatus Loan) with Innovatus, providing for up to $75.0 million funded in three tranches with a maturity date of August 31, 2027. The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) the Prime Rate published in the Money Rates section of the Wall Street Journal (or any successor thereto) and (ii) 3.5%, plus (b) 3.75%; provided that, at the election of the Borrower, up to 2.25% of such rate shall be payable in-kind until the third anniversary of the closing date. We received $40.0 million in June 2022 on the Closing Date under Tranche A. The remaining $35.0 million is divided into two tranches (Tranche B and Tranche C). The $17.5 million under each of Tranche B and Tranche C will be available for a period commencing on the later of (a) the first date that we achieve certain development and regulatory milestones applicable to each Tranche and (b) November 1, 2022. Both Tranche B and Tranche C draw periods end on the earlier of (a) June 30, 2024 or (b) an event of default. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with entering into the Innovatus Loan, we entered into a Stock Purchase Agreement with Innovatus for the sale of common stock with an aggregate value of $5.0 million. On June 1, 2022, we issued 749,053 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock to Innovatus at a per share purchase price of $6.6751, the preceding five-day volume weighted average price per share. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the loan proceeds was used to repay in full the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $33.5&#160;million of aggregate principal amount, unpaid interest, and exit fees in connection with our loans outstanding owed to Oxford Finance LLC. Refer to Note 8 of our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for additional details.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Service Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, we are required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture 80 percent of actual manufacturing volume. If we order more than 20 percent of manufacturing volume from other manufacturers, we are required to pay 70 percent of purchase price to Patheon for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive two-year terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#8217;s notice of termination to the other.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the SEC and do not have any holdings in variable interest entities.</span></div><div id="i55f26684d5024316bef45166a614e201_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:71.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,010)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,342)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,643)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December&#160;31, 2022 was $83.0 million, which primarily consisted of a net loss of $96.8 million, stock-based compensation expense of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, loss on extinguishment of long-term debt of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, inventory write down of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> non-cash interest expense of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization of debt securities discount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amortization of operating lease right-of-use assets of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.6 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depreciation and amortization of $0.3 million. Additionally, cash used in operating activities reflected changes in net operating assets due to an increase of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accounts payable and accrued liabilities primarily due to the timing of payments and a decrease of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8 million in accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increase of $1.4 million in inventories, an increase of $1.3 million in other assets, a decrease of $0.6 million in operating lease liabilities and an increase of $0.2 million in prepaid expenses and other current assets.   </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December 31, 2021 was $71.3&#160;million, which primarily consisted of a net loss of $33.9&#160;million, a $46.5&#160;million gain from the sale of a priority review voucher and $0.3&#160;million income related to an asset purchase agreement which were partially offset by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation expense of $7.9&#160;million, amortization of debt securities premiums and discounts of $1.0&#160;million, non-cash interest expense of $0.8&#160;million, amortization of operating lease right-of-use assets of $0.5&#160;million, depreciation and amortization of $0.3&#160;million, and common stock issued under Product Development Agreement of $0.2&#160;million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cash used in operating activities reflected changes in net operating assets of $1.3&#160;million due to an increase of $2.4&#160;million in inventory, an increase of $2.6&#160;million in accounts receivable, an increase of $0.6&#160;million in other assets, an increase of $0.7&#160;million in prepaid expenses and other current assets, and a decrease of $0.5&#160;million in operating lease liabilities, partially offset by an overall increase of $5.5&#160;million in accounts payable and accrued liabilities primarily due to the timing of payments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the year ended December&#160;31, 2022 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily consisting of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$85.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of proceeds from maturities of debt securities, which were partially offset by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$75.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of purchases of debt securities.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the year ended December 31, 2021 was $61.5&#160;million, primarily consisting of $99.6&#160;million of proceeds from maturities of debt securities, $46.5&#160;million of net proceeds received from the sale of our priority review voucher, which were partially offset by $84.6&#160;million of purchases of debt securities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the year ended December&#160;31, 2022 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$77.0 million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which primarily consisted of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$66.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of proceeds net of commissions from the issuance of common stock under the 2020 and 2022 ATM Facilities, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of proceeds from debt, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million of proceeds from issuance of common stock to lender, $0.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proceeds from issuance of common stock upon stock option exercises and ESPP purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which were partially offset by the $33.3 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repayment of debt, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payment of debt issuance costs and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million of common stock offering costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the year ended December 31, 2021 was $3.2&#160;million, which primarily consisted of $3.0&#160;million of net proceeds from the issuance of common stock under the ATM Facility and $0.7&#160;million of proceeds from the issuance of common stock upon stock option exercises and ESPP purchase, partially offset by $0.3&#160;million payments of common stock offering costs and $0.2&#160;million in debt issuance costs.</span></div><div id="i55f26684d5024316bef45166a614e201_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 to our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of recent accounting pronouncements adopted and not yet adopted for the year ended December&#160;31, 2022.</span></div><div id="i55f26684d5024316bef45166a614e201_118"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.</span></div><div id="i55f26684d5024316bef45166a614e201_13"></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_683"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger BioPharmaceuticals, Inc.:</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Eiger BioPharmaceuticals, Inc. and subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="margin-top:12pt;text-align:center"><img src="eigr-20221231_g19.jpg" alt="eigr-20221231_g19.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:143px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2015.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Francisco, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 16, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-42">25,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-43">22,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">73,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">66,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">2,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-48">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-49">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">9,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">117,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">103,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">17,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-56">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-57">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-58">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-59">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">4,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-62">120,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-63">126,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">8,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">7,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">15,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">13,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-68">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-69">628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">7,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">25,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">29,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net of current portion </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">39,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">23,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-76">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-77">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-78">64,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-79">54,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-81">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022 and 2021; <ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-85">44,074,284</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87">34,568,821</ix:nonFraction></ix:nonFraction> shares issued</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and outstanding as of December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-88">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-89">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-90">492,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-91">412,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-92">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-93">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-94">437,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-95">340,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">55,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">72,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">120,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">126,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabac5190f6fd4b358ed63396e06def66_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-100">12,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd62fc9b3a24432b3e2aae65a93e3a7_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-101">12,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id179859417824997b40e168360961323_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dec7376c9ed41ca8bc576d43df8f8c3_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-103">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76f8832abac4cfea3d3116b0eeedbe1_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2d5cecd217418582eec551acd8d836_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-106">13,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-107">12,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-109">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="f-110">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">75,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">64,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">41,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">29,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">23,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">20,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-118">106,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-119">89,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-120">62,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">92,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">76,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">62,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">4,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">3,559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">3,594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-127">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-128">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-129">704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-130">963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">46,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-132">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-133">96,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">33,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-135">65,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-136">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-137">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">96,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">33,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">65,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-143">2.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-144"><ix:nonFraction unitRef="usdPerShare" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-145">1.00</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-146"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-147">2.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-148"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-149">41,628,207</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150"><ix:nonFraction unitRef="shares" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151">33,944,342</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152"><ix:nonFraction unitRef="shares" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-153">28,143,391</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">96,776</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">33,917</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">65,051</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized loss on available-for-sale debt securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-157">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-158">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-159">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-160">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-163">96,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-164">34,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-165">65,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.683%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accumulated Other Comprehensive Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total Stockholders&#8217; Equity </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ic8cfaed52a2d473ab12f3b5530650c41_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166">24,523,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic8cfaed52a2d473ab12f3b5530650c41_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-167">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i380647f21fbb4f4b88a32a72fa283b95_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">297,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i99f3f456db4f4a55a3d22861cea918c2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i49673d67a34044e3a750f2b9178048a1_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">241,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8c1713a9ff0046649a86f61420a19003_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">56,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon offering at-the-market, net of $<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:StockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-172">3,231</ix:nonFraction> of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-173">9,267,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-174">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-175">96,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-176">96,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon ESPP purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-177">25,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-178">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-179">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon stock option exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-180">61,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-181">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-182">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vesting of common stock under Product Development Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" scale="3" id="f-183">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" scale="3" id="f-184">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-185">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-186">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale debt securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if8b36575981b4572bcb7ca1dc5769835_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-187">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-188">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i430636db1f0f42f2ac9906c42783a48f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">65,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">65,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i5569a83205404b1ab3e0541a2035e937_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-191">33,878,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5569a83205404b1ab3e0541a2035e937_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-192">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifd0e307c2eab47c5a18cefb7aad66078_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">401,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if5bbf3a04c3844a28b4b670e4ceca7a1_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-194">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iac7b5637f1bc435fbeb01ba1c65e4e8b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">306,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">95,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon offering at-the-market, net of $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:StockIssuanceCosts" scale="3" id="f-197">417</ix:nonFraction> of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-198">565,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-199">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-200">2,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-201">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon ESPP purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-202">37,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-203">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-204">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon stock option exercise</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-205">53,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-206">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-207">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock upon release of restricted stock units</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-208">33,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vesting of common stock under Product Development Agreement</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" scale="3" id="f-210">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" scale="3" id="f-211">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-212">7,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-213">7,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale debt securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i607fa35bf31f4c78b9dd13096251e2ce_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-214">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-215">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i74ea87a513d646d09871aebfe33508a1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">33,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">33,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7f351ad36ff44a06a963475dcfb18d78_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-218">34,568,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7f351ad36ff44a06a963475dcfb18d78_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-219">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iec887a30f3da48368433567628e641f8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">412,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i63379744fdd040ef8ba43ddec4a1793c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-221">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="idf88f13c190f43639edfd10e3b5f87b8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">340,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">72,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon offering at-the-market, net of $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:StockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-224">2,068</ix:nonFraction> of commissions and issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-225">8,528,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-226">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-227">66,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-228">66,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-229">47,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-230">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-231">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock to lender</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="INF" name="eigr:StockIssuedDuringPeriodSharesStockIssuedToLender" format="ixt:num-dot-decimal" scale="0" id="f-232">749,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueStockIssuedToLender" scale="3" id="f-233">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueStockIssuedToLender" format="ixt:num-dot-decimal" scale="3" id="f-234">4,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueStockIssuedToLender" format="ixt:num-dot-decimal" scale="3" id="f-235">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of common stock issued under Product Development Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" scale="3" id="f-236">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" scale="3" id="f-237">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon ESPP purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-238">48,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-239">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-240">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-241">132,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">8,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-244">8,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale debt securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic47d708618bb4821bc17b74b8bd55ef1_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-245">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-246">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic47d708618bb4821bc17b74b8bd55ef1_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-247">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-248">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6a49e4c035a341fba613eb1be522b4a3_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-249">96,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-250">96,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i284faebef99d43ad8a30a1beac1378bb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-251">44,074,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i284faebef99d43ad8a30a1beac1378bb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-252">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i78b0e05eb8a74058b915db9040827fd8_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">492,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i42d24ef6e4884de5be511fe91960c05c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-254">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic1651d333e874061b4abfcd49f5976e4_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-255">437,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-256">55,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_28"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i55f26684d5024316bef45166a614e201_7">Table of Contents</a></span></div><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">96,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-258">33,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-259">65,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from sale of priority review voucher</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:GainLossFromSaleOfPriorityReviewVoucher" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:GainLossFromSaleOfPriorityReviewVoucher" format="ixt:num-dot-decimal" scale="3" id="f-261">46,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:GainLossFromSaleOfPriorityReviewVoucher" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income related to asset purchase agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:IncomeLossRelatedToAssetPurchaseAgreement" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:IncomeLossRelatedToAssetPurchaseAgreement" scale="3" id="f-264">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:IncomeLossRelatedToAssetPurchaseAgreement" format="ixt:fixed-zero" scale="3" id="f-265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-266">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-267">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-268">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory write down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-269">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="3" id="f-271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt securities premiums and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-272">682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-273">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-274">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-275">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-278">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-279">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-280">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-281">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-282">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-283">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued under Product Development Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-284">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-285">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="f-286">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-287">8,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-288">7,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-289">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-290">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-291">2,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-293">1,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-294">2,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="f-296">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="f-297">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-298">3,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-299">1,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-300">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-301">1,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-302">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-303">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-304">1,899</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-305">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-306">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-307">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="eigr:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-308">628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="eigr:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-309">576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="eigr:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-310">534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-311">83,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-312">71,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-313">63,185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-314">75,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-315">84,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-316">128,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-317">85,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-318">99,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-319">83,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds related to asset purchase agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:ProceedsRelatedToAssetPurchaseAgreement" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:ProceedsRelatedToAssetPurchaseAgreement" scale="3" id="f-321">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:ProceedsRelatedToAssetPurchaseAgreement" format="ixt:fixed-zero" scale="3" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of priority review voucher</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:ProceedsFromSaleOfPriorityReviewVoucher" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:ProceedsFromSaleOfPriorityReviewVoucher" format="ixt:num-dot-decimal" scale="3" id="f-324">95,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:ProceedsFromSaleOfPriorityReviewVoucher" format="ixt:fixed-zero" scale="3" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to priority review voucher</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:PaymentsRelatedToPriorityReviewVoucher" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:PaymentsRelatedToPriorityReviewVoucher" format="ixt:num-dot-decimal" scale="3" id="f-327">48,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:PaymentsRelatedToPriorityReviewVoucher" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-329">340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-330">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-331">258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-332">9,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-333">61,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-334">44,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon offering at-the-market, net of commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-335">66,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-336">3,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-337">96,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock to lender</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" format="ixt:num-dot-decimal" scale="3" id="f-338">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-341">39,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-344">33,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-347">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-348">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-349">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon ESPP purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-350">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-351">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-352">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-353">1,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-354">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-356">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-357">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-358">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-359">76,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-360">3,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-361">97,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-362">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-363">6,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-364">10,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-365">22,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-366">28,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1713a9ff0046649a86f61420a19003_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-367">39,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-368">25,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-369">22,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-370">28,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-371">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-372">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-373">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-374">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment purchases included in accounts payable and accrual </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-377">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering costs included in accounts payable and accrual </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="eigr:OfferingCostsIncurredNotYetPaid" scale="3" id="f-380">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="eigr:OfferingCostsIncurredNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="eigr:OfferingCostsIncurredNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-383">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-384"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-386"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eiger BioPharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div id="i55f26684d5024316bef45166a614e201_34"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-388" continuedAt="i2c8752f2c3724747b023fb1113f63168" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i2c8752f2c3724747b023fb1113f63168"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on November&#160;6, 2008. Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV), the most severe form of viral hepatitis, and other serious diseases. All five of the Company&#8217;s rare disease programs have been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Lonafarnib is a first-in-class, oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III, interferon.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA approved the Company&#8217;s first commercial product, Zokinvy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (lonafarnib), to reduce risk of mortality of Hutchinson-Gilford progeria syndrome (HGPS) and for treatment of processing-deficient progeroid laminopathies (PL), collectively known as progeria, with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, on November 20, 2020. The Company announced that the European Commission approved its Marketing Authorization Application (MAA) for Zokinvy, under exceptional circumstances procedure on July 20, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing avexitide, a well-characterized peptide, as a treatment for congenital hyperinsulinism (HI), an ultra-rare pediatric metabolic disorder, and post-bariatric hypoglycemia (PBH), a debilitating and potentially life-threatening condition. There are currently no approved therapies for these disorders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal operations are based in Palo Alto, California, with subsidiaries in Delaware, Ireland, England and Wales. The Company operates in <ix:nonFraction unitRef="segment" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-389">one</ix:nonFraction> segment. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-390">98.9</ix:nonFraction> million of cash, cash equivalents and short-term securities, comprised of $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-391">25.8</ix:nonFraction> million of cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-392">73.1</ix:nonFraction> million of short-term debt securities available-for-sale. The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-393">437.2</ix:nonFraction> million and negative cash flows from operating activities as of December&#160;31, 2022. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and until it does, the Company will need to continue to raise additional capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the currently available resources will be sufficient to fund its planned operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if the Company&#8217;s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic, among other events.</span></div></ix:continuation><div id="i55f26684d5024316bef45166a614e201_37"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-394" continuedAt="i2b97e640bd6240168eb3494093280ce7" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i2b97e640bd6240168eb3494093280ce7" continuedAt="i9b6b9cf53fe84370ab2fb592b3a1234a"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-395" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9b6b9cf53fe84370ab2fb592b3a1234a" continuedAt="i143a780960c944fdaab53fb8a7d7d8aa"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:UseOfEstimates" id="f-396" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="f-397" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#8217;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="i3c0ff92a272442afaa01f8a3b8e72b36_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-398">58</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i243c690d5ce3462c865847425d9c4b48_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-399">42</ix:nonFraction> percent of the Company&#8217;s accounts receivable as of December&#160;31, 2022. One customer accounted for approximately <ix:nonFraction unitRef="number" contextRef="ie052ceb522c94669817dae862de6dd4c_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-400">93</ix:nonFraction> percent of product revenue during the year ended December&#160;31, 2022. Two customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="i44e1792926524fcb95997fa9f9ef3f47_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-401">66</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i606a6b3724044b869c02652034594518_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-402">34</ix:nonFraction> percent of the Company&#8217;s accounts receivable as of December 31, 2021. One customer accounted for approximately <ix:nonFraction unitRef="number" contextRef="ibfcec53252b04308b81a3cceadbdd73f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:num-dot-decimal" scale="-2" id="f-403">94</ix:nonFraction> percent of product revenue during the year ended December 31, 2021. The Company did not have accounts receivable or revenue in 2020.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-404" continuedAt="ie9dac86cc87d4fb6a95ded515b0e6f1e" escape="true"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transaction Risk</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger BioPharmaceuticals Europe Limited</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for 2022 were $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="eigr:OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-405">0.1</ix:nonFraction> million. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at the subsidiary. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation Risk</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9dac86cc87d4fb6a95ded515b0e6f1e">The foreign currency translation risk relates to the translation of the foreign consolidated subsidiary's assets, liabilities, revenues and expenses from the subsidiary's functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the foreign subsidiary, which has a functional currency other than the U.S. dollar are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation losses, net of tax, for 2022 were $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-406">0.1</ix:nonFraction> million.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-407" escape="true"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="f-408" continuedAt="i64a5ddd2ff8b4941afa960bdc1d2f9f9" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. Long-term securities consist of debt securities classified as available-for-</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i143a780960c944fdaab53fb8a7d7d8aa" continuedAt="i818cd8e2ac0440359b7648c4dfc6c961"><div style="margin-top:6pt"><ix:continuation id="i64a5ddd2ff8b4941afa960bdc1d2f9f9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale and have maturities greater than 365 days from the date of acquisition. The Company&#8217;s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of accumulated other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net on the accompanying consolidated statements of operations.</span></ix:continuation></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-409" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" id="f-410" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of the property and equipment are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia328cb20d25e4fab95b8005fa9861f94_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-411">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i55f52fce331b4f66a6e112c7e3be3f98_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-412">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of remaining lease term or <ix:nonNumeric contextRef="i822a4e7e22674f7bbb06ac44f94c3932_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-413">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0d8abc424bd4f599a92cdb29f6579f8_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-414">3</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="f-415" continuedAt="ib9292173852f4fde879a69504c731dfb" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9292173852f4fde879a69504c731dfb">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</ix:continuation> Through December&#160;31, 2022, the Company has <ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-416">not</ix:nonFraction> impaired any long-lived assets.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ReceivablesPolicyTextBlock" id="f-417" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent amounts billed to the Company&#8217;s customers, net of an allowance for doubtful accounts. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The expectation of collectability is based on a review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for doubtful accounts.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-418"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-419">no</ix:nonFraction></ix:nonFraction> allowance as of December&#160;31, 2022 and 2021. The Company had <ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="f-420"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="f-421">no</ix:nonFraction></ix:nonFraction> bad debt expense for the years ended December&#160;31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="f-422" continuedAt="i01d705e172ef4b79a58f831f2c8f9056" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval of the Company&#8217;s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01d705e172ef4b79a58f831f2c8f9056">The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i818cd8e2ac0440359b7648c4dfc6c961" continuedAt="i3ef05748130641da9838adbd076e7e9d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company wrote-down $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-423">1.0</ix:nonFraction> million of inventories for the year ended December&#160;31, 2022. There were <ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="f-424"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="f-425">no</ix:nonFraction></ix:nonFraction> write-downs in prior periods.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-426" continuedAt="i6a9b167955f54ac1b296b7a7ca35adac" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021 and in Europe in November 2022 . Prior to 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="i20f285951c75439fabaef052cce22e5c_D20210101-20210331" decimals="0" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-427">no</ix:nonFraction> product revenue. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of <ix:nonNumeric contextRef="i9b8e4b3a3c1f4746a43ddffd760f8621_D20210601-20210630" name="eigr:EarlyAccessProgramTerm" format="ixt-sec:durwordsen" id="f-428">one year</ix:nonNumeric>. The Company has received a one year extension of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy (lonafarnib) through a reimbursed early access program in France. The Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i6001d47ec21d4e1eb84a3b4279669161_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-429">0.2</ix:nonFraction>&#160;million from sales of product under the ATU program for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company&#8217;s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt payment discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3ef05748130641da9838adbd076e7e9d" continuedAt="ib37e1cc8dd82435fbf1dd9eeef42f355"><ix:continuation id="i6a9b167955f54ac1b296b7a7ca35adac" continuedAt="i39e3307a170e44b493afb6a99f71de64"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39e3307a170e44b493afb6a99f71de64">The Company&#8217;s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory milestones.</ix:continuation> </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-430" continuedAt="i529db0138afe4642b3a9f4c1a1acab7d" escape="true">Cost of Sales</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i529db0138afe4642b3a9f4c1a1acab7d">Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="eigr:AccruedResearchAndDevelopmentCostsPolicyTextBlock" id="f-431" continuedAt="i840459f1074e4b4ea1c069fc7d4ae91b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying consolidated balance sheets and within research and development expenses in the accompanying consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-432" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use assets and current and noncurrent lease liabilities, as applicable, in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in selling, general and administrative expenses in the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in selling, general and administrative expenses when incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib37e1cc8dd82435fbf1dd9eeef42f355" continuedAt="i03d554a1d7954843a3fbfe3a56b9242b"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:DebtPolicyTextBlock" id="f-433" continuedAt="ief4b3828c84a4fc49a6f4a29397ef6b1" escape="true">Deferred Financing Costs</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ief4b3828c84a4fc49a6f4a29397ef6b1">Financing costs incurred with securing a term debt are recorded in the Company&#8217;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#8217;s consolidated statements of operations over the contractual life of the loan using the effective interest method.</ix:continuation> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i840459f1074e4b4ea1c069fc7d4ae91b" continuedAt="if00a709cbc9b447ba6902df91f0863c4">Research and Development Costs</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if00a709cbc9b447ba6902df91f0863c4">Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#8217;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</ix:continuation> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-434" continuedAt="ie72f437282284f7c991880d7fd2d59c1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie72f437282284f7c991880d7fd2d59c1">Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Stock-based awards to non-employees are recorded at their fair value as of the grant date, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions for Black-Scholes option pricing model inputs. The Company accounts for forfeitures of stock-based awards when they occur.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-435" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-436" continuedAt="i748fdcd410454471961f9e12018a8144" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i748fdcd410454471961f9e12018a8144">Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#8217;s unrealized gains and losses on debt securities and foreign currency translation adjustment represent the components of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss.</ix:continuation> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-437" continuedAt="i039adeba2d234d888ebeccb680d748cd" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i039adeba2d234d888ebeccb680d748cd">Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i03d554a1d7954843a3fbfe3a56b9242b"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-438" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i394cd5e381054e4889a9aad84ab79747_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-439">6,143,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d5d0c2a8148487aa4d0984dc7e1f99a_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-440">5,262,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ac15c5f9d74de499a4fe9278a01e7d_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-441">3,697,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9f5cc5d592e405dbec8dfa432ab7e43_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-442">641,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ca1a86dbf584c8a9e5686d5ab7063c7_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-443">623,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ffc44f911d84c7e8b5688da7a44b998_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-444">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b5485fa3aad4734a238db7b097d944e_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-445">334,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib58d979ab27f4989884fc5e44ee5ba47_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-446">48,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ad646a38b894ce5a9b00244c2be3b71_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-447">81,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-448">7,119,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-449">5,933,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-450">3,815,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-451" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company does not expect the impact of adopting this standard to be material. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. In October 2021, the Company amended its Oxford Loan to replace its floating interest rate with the LIBOR replacement rate (see Note 8). The Company adopted this standard when LIBOR was about to be discontinued and the adoption did not have a material impact on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i55f26684d5024316bef45166a614e201_40"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="f-452" continuedAt="i9607a8d3aadb4f2c97c39e00bbbb18e9" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i9607a8d3aadb4f2c97c39e00bbbb18e9" continuedAt="ie175b9061bff48b789921d64c47b2158"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). As of December&#160;31, 2022 and 2021, the carrying amount of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimated fair value due to their relatively short maturities. Management believes the terms of its long-term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company&#8217;s debt approximated its fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie175b9061bff48b789921d64c47b2158" continuedAt="ia6a57068d07142af94ea66a88e86f4ed"><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company&#8217;s debt securities and commercial paper consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were <ix:nonFraction unitRef="usd" contextRef="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-453"><ix:nonFraction unitRef="usd" contextRef="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-454"><ix:nonFraction unitRef="usd" contextRef="idca3d92946644292bfe24473fcc4be04_I20211231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-455"><ix:nonFraction unitRef="usd" contextRef="idca3d92946644292bfe24473fcc4be04_I20211231" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-456">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets or liabilities classified as Level 3 as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i29e2e430ce08456580668540fb412dad_D20220101-20221231" decimals="INF" name="eigr:FairValueTransfersBetweenLevelsTransfersAmount" format="ixt:fixed-zero" scale="0" id="f-457"><ix:nonFraction unitRef="usd" contextRef="i723c7034a80843358bb376fffac512d9_D20210101-20211231" decimals="INF" name="eigr:FairValueTransfersBetweenLevelsTransfersAmount" format="ixt:fixed-zero" scale="0" id="f-458">no</ix:nonFraction></ix:nonFraction> transfers into or out of Level 3 of the fair value hierarchy during the periods presented. </span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-459" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046e24627cb54f7189bede6e1170857e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-460">11,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552f64c943e64319a4ce95e39943680e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceddcfeabe854c64be9f9598bcbb3de0_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe8063b179f430aa2aa6b702e9b306c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-463">11,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eef20e8a0334e0ba1d0d3ca4318cddf_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ec97ca82ce4eaab0fe2d816a068638_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-465">8,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afe7b4dbf6b4c01a3a293ce9ee8ddf9_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-467">8,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3710956fd50341c98bf6174e70730c41_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564ce4de58c74e4b8c4230bf90320a01_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-469">28,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcbf0466704049dab4b0a5022b8f1e03_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-471">28,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7631982a357a40a69c633f5518769a9c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib532a65e081b47d0a19d3b35f518a757_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-473">39,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ab1c22a221540b9a784d77e13b63afd_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-475">39,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ecf5e8208174b24a163cd9c86a1f6a2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-476">11,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230066a3071c4132b69848eae00a92eb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-477">77,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-479">88,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a17f8d193244e19ada1c34fd6361e5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-480">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232fe125fe24498fa3256c6f183ee314_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968a09cb75864d2bbf238de4188016c4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-483">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd42c9f677f475ba44a739bbcb8d569_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c955bd8cca416686ce21b475131066_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-485">41,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee904f5f9d1a470abe8bd130514c72f9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-487">41,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1af0f8a55164e0eb8dcc387d8ee162c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib672ffc131c141c89ec35e1cdc6d0888_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-489">42,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib149a8ec14b946089462bf96a8cb0335_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-491">42,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fa2af8a8064c0b96426610b6658882_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-492">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa03a6d5dbf4539a01f114da77c480a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-493">83,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca3d92946644292bfe24473fcc4be04_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-495">97,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-496"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-497">no</ix:nonFraction></ix:nonFraction> financial liabilities measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia6a57068d07142af94ea66a88e86f4ed" continuedAt="i1a92180413a542b28cc87265edcfb6aa"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-498" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the estimated value of the Company&#8217;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized loss </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe8063b179f430aa2aa6b702e9b306c_I20221231" decimals="-3" name="eigr:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-499">11,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe8063b179f430aa2aa6b702e9b306c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-500">11,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78913e7ab2e4303a5543c869a3218e3_I20221231" decimals="-3" name="eigr:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-501">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78913e7ab2e4303a5543c869a3218e3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-502">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-503">15,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-504">15,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-505">39,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-506">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-507">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-508">39,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-509">28,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-511">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-512">28,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-513">4,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-516">4,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-517">73,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-518">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-519">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-520">73,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6eb2b8528634735a6af7527a73a9128_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-521">15,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4688b49a6540e98c724acb8b04a2ad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-522">73,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-523">88,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized loss </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231" decimals="-3" name="eigr:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-524">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-525">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-526">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-527">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-528">41,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-530">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-531">41,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-532">42,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-534">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-535">42,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-536">84,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-538">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-539">83,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2171cc598bbc4faa9d1dfb89113cc454_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-540">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0faa0526436449a8d5aedef9fe5142d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-541">66,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5464846d99ce4aafbbb96b5563f1dc1d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-542">17,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-543">97,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><ix:continuation id="i1a92180413a542b28cc87265edcfb6aa" continuedAt="iee9729a830f44677a0be409d9c049695"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically reviews the available-for-sale securities for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">other-than-temporary</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i) it is more likely </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">than n</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ot that the Company will be required to sell the debt securities before recovery of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">their</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the year ended December&#160;31, 2022, the Company did <ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="0" id="f-544">not</ix:nonFraction> recognize any </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">other-than-temporary</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> impairment losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">T</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iee9729a830f44677a0be409d9c049695">he unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-545">0.2</ix:nonFraction> million as of December&#160;31, 2022 include debt securities with unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="0" id="f-546">21,000</ix:nonFraction> that have been in the loss position for more than 12 months. However, the Company is planning to hold these securities until maturity and expects to recover the amortized cost basis</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-547" continuedAt="ibcd2b224650c4e20b2454a76e17bb1b2" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ibcd2b224650c4e20b2454a76e17bb1b2" continuedAt="id0c3a42217e1498e96c2eb29b37a559e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-548" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-549">1,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-550">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-551">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-552">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-553">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-554">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-555">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-556">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-557" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i62a60c80d69a4de39ff38d8b55aef975_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-558">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide1b1828296e40aeb62b7b75b1921d5c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-559">669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i26381ba35f554000928e20baa54aaf82_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-560">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia6182cf377fb42d5b55072fb1f5fcc4c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-561">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ib5e14c606c1641bb863e16722c0cbc4a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-562">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia4960562ae1a43d5a1836ee70a2a0ced_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-563">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia72e03af8e4d4e029c34f04f781a6afe_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-564">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia401dca885444fa3b7a5f036bf820425_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-565">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia921678878f04db6adbca4595688a360_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-566">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0af19da2c6184c899e48459eaf368c09_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-567">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-568">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-569">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-570">895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-571">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-572">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-573">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-574">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-575">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-576">0.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" id="f-577" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract manufacturing costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:PrepaidContractManufacturingCosts" format="ixt:num-dot-decimal" scale="3" id="f-578">3,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:PrepaidContractManufacturingCosts" format="ixt:num-dot-decimal" scale="3" id="f-579">3,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-580">4,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="f-581">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:PrepaidResearchCosts" format="ixt:num-dot-decimal" scale="3" id="f-582">2,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:PrepaidResearchCosts" format="ixt:num-dot-decimal" scale="3" id="f-583">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-584">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="f-585">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:PrepaidMarketing" scale="3" id="f-586">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:PrepaidMarketing" scale="3" id="f-587">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:OtherPrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-588">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:OtherPrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-589">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-590">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-591">9,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id0c3a42217e1498e96c2eb29b37a559e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities </span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-592" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-593">6,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-594">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract research costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:AccruedContractedResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-595">4,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:AccruedContractedResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-596">4,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:ContractManufacturingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-597">2,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:ContractManufacturingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-598">3,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:ProductRevenueReserves" format="ixt:num-dot-decimal" scale="3" id="f-599">1,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:ProductRevenueReserves" format="ixt:num-dot-decimal" scale="3" id="f-600">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-601">1,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-602">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-603">15,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-604">13,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i55f26684d5024316bef45166a614e201_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="eigr:ProductDevelopmentAgreementTextBlock" id="f-605" continuedAt="i64946cd5d40c4e188641b80fd53d3be5" escape="true">License, Collaboration, and Product Development Agreements</ix:nonNumeric></span></div><ix:continuation id="i64946cd5d40c4e188641b80fd53d3be5" continuedAt="i9eadaa7abf434aabb5fda7464f6c680e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the University of Pennsylvania (UPenn) and the Children&#8217;s Hospital of Philadelphia (CHOP), under which the Company obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain Glucagon Like Peptide-1 (GLP-1) receptor antagonist(s) products to treat all human and animal conditions. The Company also obtained an exclusive, royalty-bearing, sublicensable, worldwide license to certain data developed by CHOP. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the development and commercialization of the licensed products at its sole cost and expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to the Company under the UPenn/CHOP Agreement, the Company paid UPenn a one-time, non-refundable issue fee of $<ix:nonFraction unitRef="usd" contextRef="ic6a349046f334530a41f51eebfe060e1_D20190101-20191231" decimals="-5" name="eigr:NonRefundableIssueFee" format="ixt:num-dot-decimal" scale="6" id="f-606">1.0</ix:nonFraction>&#160;million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, the Company is obligated to pay UPenn a specified annual license maintenance fee, up to $<ix:nonFraction unitRef="usd" contextRef="ice98876375a746198c11b6156223c890_D20190101-20191231" decimals="-5" name="eigr:LicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="6" id="f-607">2.5</ix:nonFraction>&#160;million upon marketing authorization in one or more countries, and up to $<ix:nonFraction unitRef="usd" contextRef="i40856ef0109745e6bca5398e2deb59e6_D20190101-20191231" decimals="-5" name="eigr:MilestoneObligations" format="ixt:num-dot-decimal" scale="6" id="f-608">18.0</ix:nonFraction>&#160;million in commercial milestones. The Company will also be required to pay UPenn a flat royalty in the low-single digits on net sales of all licensed products by the Company, subject to specified reductions and offsets, and specified minimum annual royalty payments. The Company&#8217;s obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. <ix:nonFraction unitRef="usd" contextRef="i806febb1a3f14a009905147c299141c6_D20220101-20221231" decimals="INF" name="eigr:MilestoneObligations" format="ixt:fixed-zero" scale="0" id="f-609">No</ix:nonFraction> milestones have been achieved as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for the Company&#8217;s failure to achieve the specified diligence milestones within the specified periods, subject to the Company&#8217;s extension rights.</span></div><div style="margin-top:18pt;padding-left:23.13pt;text-indent:-23.13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Development Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2018, the Company entered into a Product Development Agreement and a First Project Agreement (the Product Agreements), pursuant to which the Company will receive development program support services for its HDV program. The services are to be provided from July 1, 2018 through the new drug application (NDA) filing. As consideration, the Company has committed to pay fees of approximately $<ix:nonFraction unitRef="usd" contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811" decimals="-5" name="eigr:ProductDevelopmentFees" format="ixt:num-dot-decimal" scale="6" id="f-610">10.0</ix:nonFraction>&#160;million in cash and stock over <ix:nonNumeric contextRef="ic8e9958c1f874287a316e0d40a1ee557_I20180811" name="eigr:PeriodOfCommittedPaymentOfFees" format="ixt-sec:durwordsen" id="f-611">four years</ix:nonNumeric>, including approximately $<ix:nonFraction unitRef="usd" contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811" decimals="-3" name="eigr:ExpertConsultantFeesAndPassThroughCosts" format="ixt:num-dot-decimal" scale="6" id="f-612">0.8</ix:nonFraction>&#160;million for expert consultant fees and pass through costs to vendors, plus certain incentive-based regulatory milestone fees up to $<ix:nonFraction unitRef="usd" contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811" decimals="-5" name="eigr:IncentiveBasedRegulatoryMilestoneFees" format="ixt:num-dot-decimal" scale="6" id="f-613">1.0</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the aggregate payment, the Company issued <ix:nonFraction unitRef="shares" contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-614">115,526</ix:nonFraction> shares of common stock subject to quarterly vesting requirements related to successful performance of the services and achievement of budget timeline set forth in the Product Agreements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Product Agreements can be terminated by either party due to material breach or by the Company without cause with 90 days prior written notice. For the years ended December 31, 2022, 2021 and 2020, the Company recognized research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i215c0c22884741439373b4bb5cf353ab_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-615">19,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie01aaeb68a154d89b511aa445e1f10c5_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-616">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib38883ca632644fd93eb6fb8b5632ec4_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-617">0.2</ix:nonFraction>&#160;million, respectively, related to the shares issued under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2022, the restricted shares were fully vested.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9eadaa7abf434aabb5fda7464f6c680e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progeria Research Foundation (PRF) Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the Company entered into a Collaboration and Supply Agreement (the PRF Collaboration Agreement) with PRF. Under the PRF Collaboration Agreement, the parties agreed to collaborate with respect to the development and pursuit of regulatory approval of lonafarnib for the treatment of HGPS and processing-deficient progeroid laminopathies, collectively called progeria, in humans. PRF granted the Company a non-exclusive, world-wide, royalty-free, sub-licensable license pertaining to all intellectual property and data controlled by PRF to prepare and file any NDA for a product containing lonafarnib for progeria. The Company is obligated to: (i) exclusively supply lonafarnib to PRF for use in clinical trials and non-clinical research in progeria at the Company&#8217;s expense, (ii) prepare and be the sponsor of any NDA submission for lonafarnib for the treatment of progeria to the FDA, (iii) use commercially reasonable efforts to file a NDA for progeria by a specified date, (iv) submit a Rare Pediatric Disease designation and a request for expedited approval in connection with a NDA filing, (v) establish a patient support program in progeria, and (vi) use commercially reasonable efforts to develop a pediatric formulation of lonafarnib for use in progeria.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PRF Collaboration Agreement, the Company is solely responsible for any additional studies necessary for obtaining an NDA for progeria and is also responsible for any additional costs for such studies up to $<ix:nonFraction unitRef="usd" contextRef="ic6a349046f334530a41f51eebfe060e1_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-618">2.0</ix:nonFraction>&#160;million. The PRF Collaboration Agreement continues for an initial term of <ix:nonNumeric contextRef="i1093f397da6f4ccbaa4327f49cc99f6b_D20180515-20180515" name="eigr:CollaborationAgreementInitialTerm" format="ixt-sec:durwordsen" id="f-619">ten years</ix:nonNumeric> and automatically renews for subsequent renewal terms of <ix:nonNumeric contextRef="i1093f397da6f4ccbaa4327f49cc99f6b_D20180515-20180515" name="eigr:CollaborativeArrangementRenewalTerm" format="ixt-sec:durwordsen" id="f-620">two years</ix:nonNumeric> each unless either party terminates earlier.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Bristol-Meyers Squibb License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (peginterferon lambda or the Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $<ix:nonFraction unitRef="usd" contextRef="i26693b4f07bb413dbe7693e3a8733d02_D20160401-20160430" decimals="-5" name="eigr:UpFrontCashPayments" format="ixt:num-dot-decimal" scale="6" id="f-621">2.0</ix:nonFraction> million and issued <ix:nonFraction unitRef="shares" contextRef="i312ccf68285749298fc9eaba96fdb15e_D20160401-20160430" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-622">157,587</ix:nonFraction> shares of its common stock at an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i312ccf68285749298fc9eaba96fdb15e_D20160401-20160430" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-623">3.2</ix:nonFraction> million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="if8b0cb8cbbf34f3a92bae7940e633560_D20160401-20160430" decimals="-5" name="eigr:MilestoneObligations" format="ixt:num-dot-decimal" scale="6" id="f-624">61.0</ix:nonFraction> million and commercial sales milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i98b448fdcc72493fa8f472a5547e9c5e_D20160401-20160430" decimals="-5" name="eigr:MilestoneObligations" format="ixt:num-dot-decimal" scale="6" id="f-625">128.0</ix:nonFraction> million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In the fourth quarter of 2020, the Company recorded in research and development expense a $<ix:nonFraction unitRef="usd" contextRef="i522fba7c7f6b4899a22248daae63fdef_D20160401-20160430" decimals="-5" name="eigr:MilestoneObligations" format="ixt:num-dot-decimal" scale="6" id="f-626">3.0</ix:nonFraction> million milestone, triggered on successful demonstration of proof of concept, as defined by the BMS License Agreement, in a Phase 2 clinical trial. In March 2022, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i53c796ad9f4d4cd8b485cdc08c8eea06_D20220301-20220331" decimals="-5" name="eigr:MilestoneObligations" format="ixt:num-dot-decimal" scale="6" id="f-627">5.0</ix:nonFraction> million milestone expense in research and development, which was related to the initiation of a Phase 3 clinical trial, as defined under the BMS License Agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2010, the Company entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck &amp; Co., Inc. (Merck), which provides the Company with the exclusive right to develop, manufacture, and sell products containing the compounds lonafarnib for the treatment of all human viruses except certain specified viruses such as hepatitis B and hepatitis C alone. As part of consideration, the Company issued <ix:nonFraction unitRef="shares" contextRef="i6a015d0ea8614264a0d243ef6aad2068_I20100930" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-628">27,350</ix:nonFraction> shares of common stock with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i6a015d0ea8614264a0d243ef6aad2068_I20100930" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-629">0.5</ix:nonFraction>&#160;million. The Company is obligated to pay Merck up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6b02f365ff984634a4f599eb3ff0b476_D20100901-20100930" decimals="-5" name="eigr:DevelopmentMilestoneObligations" format="ixt:num-dot-decimal" scale="6" id="f-630">27.0</ix:nonFraction>&#160;million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. In May 2015, the first regulatory milestone was achieved and the Company paid the related milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i31cc6fec54de49cbaac8df50f262c636_D20180515-20180515" decimals="-5" name="eigr:MilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-631">1.0</ix:nonFraction>&#160;million to Merck. <ix:nonFraction unitRef="usd" contextRef="ia0a31c2673294cd7a5b85a7f0ceb46ce_D20220101-20221231" decimals="INF" name="eigr:MilestonePayments" format="ixt:fixed-zero" scale="0" id="f-632">No</ix:nonFraction> additional milestones have been achieved as of December 31, 2022. The next milestone of $<ix:nonFraction unitRef="usd" contextRef="i424ffec162f345b6805146b3e1859078_D20230101-20231231" decimals="-5" name="eigr:MilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-633">1.0</ix:nonFraction>&#160;million is due upon successful completion of the Phase 3 study, which is expected by end of 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the Company entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford progeria syndrome (HGPS) in humans at no cost to the Company. On November 3, 2020, the Company entered into an amendment to the exclusive license agreement with Merck which expanded the indication to also include progeroid laminopathies, collectively called progeria. The Company has the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to the PRF. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria or any royalty payments for sales of a specified quantity of lonafarnib to treat the currently estimated progeria  patient population worldwide.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="eigr:AssetPurchaseAgreementTextBlock" id="f-634" continuedAt="i6d0a141f7f5e491b9ff6d1bc94ed6c9f" escape="true">Asset Purchase Agreements and Related License Agreements </ix:nonNumeric></span></div><ix:continuation id="i6d0a141f7f5e491b9ff6d1bc94ed6c9f" continuedAt="i38379a1e3b2745faa5843b4be3266ed5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EGI Asset Purchase Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2010, the Company entered into an asset purchase agreement with Eiger Group International, Inc. (EGI). Dr. Jeffrey Glenn, a founder and director of the Company, is the sole owner of EGI. Pursuant to the agreement, the Company purchased all of the assets including the intellectual property rights related to the use of farnesyltransferase inhibitors as anti-viral agents and methods to treat viral infections with those inhibitors and inhibitors of prenylation, prenyl cysteine methyltransferase and a protease as anti-viral agents and methods to treat viral infection with those inhibitors. The Company paid EGI an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i4a1f282e249c451586adac7467c9a9ae_D20101201-20101231" decimals="-5" name="eigr:UpFrontCashPayments" format="ixt:num-dot-decimal" scale="6" id="f-635">0.4</ix:nonFraction>&#160;million when the agreement was executed in December 2010. Additionally, the Company will pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, the Company may make a one-time payment of $<ix:nonFraction unitRef="usd" contextRef="i121466ae35884ba0b24b9f6d9978e273_I20101231" decimals="-5" name="eigr:OneTimePaymentToBeMadeOnAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-636">0.5</ix:nonFraction>&#160;million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product. The product is currently not under development.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avexitide Purchase Agreement and Related Stanford License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, the Company entered into an asset purchase agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig, (the Sellers), whereby the Company purchased all of the assets related to the compound avexitide (formerly known as exendin 9-39) including any related intellectual property from the Sellers (the Exendin APA). The Company also entered into a consulting agreement with the Sellers as part of the agreement. The Company issued <ix:nonFraction unitRef="shares" contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" format="ixt:num-dot-decimal" scale="0" id="f-637">15,378</ix:nonFraction> shares of common stock that were valued at $<ix:nonFraction unitRef="usd" contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" format="ixt:num-dot-decimal" scale="6" id="f-638">0.2</ix:nonFraction>&#160;million and with the option to purchase <ix:nonFraction unitRef="shares" contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930" decimals="0" name="eigr:OptionsToPurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-639">46,134</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i070111655a2d458abdc58cce6fdf5362_I20150930" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-640">2.06</ix:nonFraction> per share when the agreement was executed in September 2015.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the <ix:nonFraction unitRef="shares" contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930" decimals="0" name="eigr:OptionsToPurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-641">46,134</ix:nonFraction> options to purchase common stock, <ix:nonFraction unitRef="shares" contextRef="i2ff02c15b30e423587839d54ad95f618_D20150901-20150930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" format="ixt:num-dot-decimal" scale="0" id="f-642"><ix:nonFraction unitRef="shares" contextRef="i78240c9a110c474c969a366314c34f1a_D20150901-20150930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" format="ixt:num-dot-decimal" scale="0" id="f-643"><ix:nonFraction unitRef="shares" contextRef="i9da09837945d43e4865652c607fde425_D20150901-20150930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" format="ixt:num-dot-decimal" scale="0" id="f-644"><ix:nonFraction unitRef="shares" contextRef="i1d316f19952e4069af11841afd2c9639_D20150901-20150930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" format="ixt:num-dot-decimal" scale="0" id="f-645">15,378</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares vest monthly over <ix:nonNumeric contextRef="iba57b158870e40fdb866d4b2678df531_D20150901-20150930" name="eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase" format="ixt-sec:durwordsen" id="f-646">four years</ix:nonNumeric> as services are provided by the Sellers and <ix:nonFraction unitRef="shares" contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930" decimals="0" name="eigr:VestingOfOptionsToPurchaseCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-647">30,756</ix:nonFraction> vest upon the earlier of the first commercial sale of the product or the approval of new drug application by the U.S. FDA (the milestone-vested options).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2016, immediately following the closing of the merger, the Company issued additional top-up options to the Sellers to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6368f25382834801a6682e48b0981e29_D20160322-20160322" decimals="0" name="eigr:OptionsToPurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-648">48,544</ix:nonFraction> shares of common stock, pursuant to the terms of the Exendin APA, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i53e59300f06d44a9b0494eb5cc7fed9c_I20160322" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-649">17.25</ix:nonFraction> per share. The top-up options consist of both time-vested and milestone-vested options.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the time-vested options is recognized as stock-based compensation expense as the awards vest over time. The fair value of the milestone-vested options will be recognized as research and development expense when it is probable that the earliest milestone will be achieved at their fair value as of the ASU 2018-07 adoption date. During the years ended December 31, 2022, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i290212954c99401aae042a9ef1f88723_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-650">0&#160;million</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6901de3d60ff4db1916a73b9d096e7a2_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-651">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic9b1a8da043d451197ac210c2a30510d_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-652">0.1</ix:nonFraction>&#160;million of compensation expense related to the time-vested options, respectively. No expense was recognized for the milestone vested options during the years ended December 31, 2022, 2021, and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also obligated to pay development milestone payments in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i2a5c0da13bd14c669d92be3294f92711_D20150901-20150930" decimals="-5" name="eigr:LicenseAgreementPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-653">1.0</ix:nonFraction>&#160;million to each Seller. Additionally, the Company is obligated to pay each Seller royalties of low single-digits based on aggregate annual net sales of all products developed based on avexitide, subject to certain reductions and exceptions. The Company&#8217;s obligation to pay royalties expires on the expiration of the last to expire patent assigned to the Company under the agreement. Additionally, the Company has assumed the license agreement the Sellers had previously entered into with the Board of Trustees of the Leland Stanford Junior University (Stanford). The Company is obligated to pay a royalty to Stanford in the low single-digits on annual net sales after the first commercial sale of any products developed based on avexitide. As of December 31, 2022, the Company has paid a total of $<ix:nonFraction unitRef="usd" contextRef="i6901de3d60ff4db1916a73b9d096e7a2_D20210101-20211231" decimals="-5" name="eigr:LicenseAgreementMilestonePaymentsPaid" format="ixt:num-dot-decimal" scale="6" id="f-654">0.1</ix:nonFraction>&#160;million in milestone payments to each of the Sellers related to the successful completion of the Phase 2 trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement with AbbVie Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;20, 2020, Eiger entered into the AbbVie Agreement with AbbVie to sell its rare pediatric disease priority review voucher (the PRV), which was awarded on November&#160;20, 2020 upon FDA approval of Zokinvy. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i38379a1e3b2745faa5843b4be3266ed5">In consideration for the PRV, AbbVie agreed to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i8114b95ec2a24e868a25140a3f0158b2_D20201120-20201120" decimals="-5" name="eigr:PaymentForAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-655">95.0</ix:nonFraction> million. The transaction closed in January 2021. Such consideration was shared with the PRF in accordance with the terms of the PRF Collaboration and Supply Agreement, pursuant to which the Company and PRF will equally share any net proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained $<ix:nonFraction unitRef="usd" contextRef="i2f59d99d10d04de492abcac7063c4d9c_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-656">46.5</ix:nonFraction> million of proceeds from the sale of the PRV, net of related payments, and recorded the amount in other (expense) income, net in the consolidated statement of operations for the year ended December 31, 2021.</ix:continuation></span></div><div id="i55f26684d5024316bef45166a614e201_720"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-657" continuedAt="i05cfa7a9c1dc41e1a4b9b3f00964f8cc" escape="true">Sale of Assets</ix:nonNumeric></span></div><ix:continuation id="i05cfa7a9c1dc41e1a4b9b3f00964f8cc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company and Theragene Pharmaceuticals, Inc. (Theragene) entered into an asset purchase agreement (Theragene APA), whereby the Company sold all of the assets related to MYDICAR including any related intellectual property for a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-658">0.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="ib87cb0850d4c413db472e1cfa4e0516f_I20170531" decimals="0" name="eigr:SaleOfAssetsNumberOfCommonStockSharesReceived" format="ixt:num-dot-decimal" scale="0" id="f-659">475,000</ix:nonFraction> shares of common stock of Theragene. At any time after the Theragene APA execution date and until Theragene has received cumulative gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531" decimals="-5" name="eigr:MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" format="ixt:num-dot-decimal" scale="6" id="f-660">4.0</ix:nonFraction>&#160;million (Proceeds Date) from all equity financing transactions occurring after the Theragene APA execution date, if Theragene issues additional shares of its common stock without consideration or for a consideration per share less than $<ix:nonFraction unitRef="usdPerShare" contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531" decimals="2" name="eigr:MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" scale="0" id="f-661">6.00</ix:nonFraction> per share then Theragene will issue additional shares of its common stock to the Company concurrently with such issue, in an amount such that the per share consideration multiplied by the aggregate number of common stock shares issued to the Company will equal $<ix:nonFraction unitRef="usd" contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531" decimals="-5" name="eigr:AggregateCommonStockConsiderationValue" format="ixt:num-dot-decimal" scale="6" id="f-662">2.9</ix:nonFraction>&#160;million. Additionally, the Company may exercise a put option at any time after the Proceeds Date, where upon written notice from the Company, Theragene will repurchase the <ix:nonFraction unitRef="shares" contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531" decimals="0" name="eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" format="ixt:num-dot-decimal" scale="0" id="f-663">225,000</ix:nonFraction> shares of its common stock held by the Company (Option Shares) at an aggregate purchase price equal to the greater of $<ix:nonFraction unitRef="usd" contextRef="id8ab44b29d644c6e854e9000bd3ea4dd_D20170501-20170531" decimals="-5" name="eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" format="ixt:num-dot-decimal" scale="6" id="f-664">1.4</ix:nonFraction>&#160;million or the aggregate fair market value of the Option Shares as of the date of the receipt of such notice. The Company is also eligible to receive contingent consideration up to a maximum $<ix:nonFraction unitRef="usd" contextRef="i5efa461c8d184d5bbf8fae9a20d47978_I20170531" decimals="-5" name="eigr:AssetPurchaseAgreementContingentConsiderationReceivable" format="ixt:num-dot-decimal" scale="6" id="f-665">45.0</ix:nonFraction>&#160;million in cash, based upon Theragene achieving certain specified future milestones. In addition, the Company is also eligible to receive up to <ix:nonFraction unitRef="number" contextRef="if57d9437106f448c83d0afbcf0114df9_D20170501-20170531" decimals="2" name="eigr:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="f-666">8</ix:nonFraction>% royalties on net sales of any future Theragene products covered by or involving the related patents or know-how until the twentieth anniversary of the Theragene APA. To-date, no consideration has been earned or is expected to be earned.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the sale of the MYDICAR assets qualify as an asset sale and not a business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Theragene APA, the Company became the owner of <ix:nonFraction unitRef="shares" contextRef="i812e7a0b79e5490fbf8cc0469a5ce008_I20211231" decimals="0" name="eigr:SaleOfAssetsNumberOfCommonStockSharesReceived" format="ixt:num-dot-decimal" scale="0" id="f-667">475,000</ix:nonFraction> shares of common stock of Theragene and held a put option for <ix:nonFraction unitRef="shares" contextRef="ib19f9a06b61e4ddfa40008408ebc9e74_D20210101-20211231" decimals="0" name="eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" format="ixt:num-dot-decimal" scale="0" id="f-668">225,000</ix:nonFraction> shares of common stock of Theragene, which were recognized as a cost method investment with carrying value of <ix:nonFraction unitRef="usd" contextRef="i812e7a0b79e5490fbf8cc0469a5ce008_I20211231" decimals="0" name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" format="ixt:fixed-zero" scale="0" id="f-669">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Theragene entered into an Asset Purchase Agreement with a third party for the sale of MYDICAR. Under the terms of the Theragene APA between the Company and Theragene, the Company is eligible to receive <ix:nonFraction unitRef="number" contextRef="ib0abd73b32db44aca977bb76f57865f5_D20200901-20200930" decimals="2" name="eigr:UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" scale="-2" id="f-670">25</ix:nonFraction>% of any upfront, licensee fee, milestone or other payment (other than royalty payments) received by Theragene from the sale or sublicense of MYDICAR, within 30 days of receipt of such payments by Theragene. As such, during the year ended December 31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ib19f9a06b61e4ddfa40008408ebc9e74_D20210101-20211231" decimals="-5" name="eigr:ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-671">0.3</ix:nonFraction>&#160;million in other (expense) income, net. The Company expects to receive a de minimis amount subsequent to December 31, 2022.</span></div></ix:continuation><div id="i55f26684d5024316bef45166a614e201_52"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="f-672" continuedAt="if09d5f6c23f64a0b8dffe5fa61e0af83" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="if09d5f6c23f64a0b8dffe5fa61e0af83" continuedAt="i8facb92e140d4878bc3732f8ac330a1c"><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovatus Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022 (Closing Date), the Company entered into a term loan and security agreement (Innovatus Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), providing for up to $<ix:nonFraction unitRef="usd" contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-673">75.0</ix:nonFraction> million funded in three tranches with a maturity date of August&#160;31, 2027. The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) the Prime Rate published in the Money Rates section of the Wall Street Journal (or any successor thereto) and (ii) <ix:nonFraction unitRef="number" contextRef="ia94b90e55cdc4829a94a8b1e45fbba04_D20220601-20220601" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-674">3.5</ix:nonFraction>%, plus (b) <ix:nonFraction unitRef="number" contextRef="i9713023dded64c8ea5adac4bda00c7e2_D20220601-20220601" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-675">3.75</ix:nonFraction>%; provided that, at the election of the Borrower, up to <ix:nonFraction unitRef="number" contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601" decimals="4" name="eigr:DebtInstrumentPercentOfInterestDue" scale="-2" id="f-676">2.25</ix:nonFraction>% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through July 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. <ix:nonFraction unitRef="number" contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601" decimals="4" name="eigr:DebtInstrumentPercentOfInterestDue" scale="-2" id="f-677">2.25</ix:nonFraction>% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to <ix:nonFraction unitRef="number" contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601" decimals="3" name="eigr:DebtInstrumentExitFeePayablePercentage" scale="-2" id="f-678">6.5</ix:nonFraction>% of the aggregate principal amount of the tranches funded under the Innovatus Loan. The Innovatus Loan contains customary representations, warranties, events of default and covenants of the Company and its subsidiaries, including a requirement to maintain a cash balance of not less than <ix:nonFraction unitRef="number" contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601" decimals="2" name="eigr:MinimumCashBalanceOfFaceValueOfLoanPercent" scale="-2" id="f-679">5</ix:nonFraction>% of the aggregate principal amount of funded and outstanding </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8facb92e140d4878bc3732f8ac330a1c" continuedAt="i89a13e902feb4c2e8bf8b764f6b74fb2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan terms at all times. The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was funded $<ix:nonFraction unitRef="usd" contextRef="if6f055c598d7454da7696030a389cafe_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-680">40.0</ix:nonFraction> million in June 2022 on the Closing Date under Tranche A. The remaining $<ix:nonFraction unitRef="usd" contextRef="i98c422a139a345809437127a7479b57a_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-681">35.0</ix:nonFraction> million is divided into two tranches (Tranche B and Tranche C). The $<ix:nonFraction unitRef="usd" contextRef="i3899d90a98f843c28f7608b176abbecb_I20220630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-682">17.5</ix:nonFraction> million under each of Tranche B and Tranche C will be available for a period commencing on the later of (a) the first date that the Company achieves certain development and regulatory milestones applicable to each Tranche and (b) November 1, 2022. Both Tranche B and Tranche C draw periods end on the earlier of (a) June 30, 2024 or (b) an event of default. The Company believes it is currently eligible to draw the $<ix:nonFraction unitRef="usd" contextRef="i2913f5ce26fd4b958098cf5381ee746d_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-683">17.5</ix:nonFraction>&#160;million under Tranche B, but has not done so as of December 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified a number of embedded derivatives that require bifurcation from the Innovatus Loan. These embedded features include mandatory prepayment upon an event of default or change in control and contingent rate increases. However, the fair value of these embedded features was deemed to be immaterial on the date of issuance and at December&#160;31, 2022. At each subsequent reporting period, the Company will reassess the fair value of the embedded features and will record a liability if the fair value of the features becomes material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Innovatus Loan, the Company recorded a debt discount of $<ix:nonFraction unitRef="usd" contextRef="iac8c23ec655449c28e8237fc61998863_I20221231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" format="ixt:num-dot-decimal" scale="6" id="f-684">0.2</ix:nonFraction>&#160;million and capitalized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iac8c23ec655449c28e8237fc61998863_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-685">1.1</ix:nonFraction>&#160;million. The discount and issuance costs will be amortized over the life of the loan. Interest expense for the Innovatus Loan for the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i24dada1a3b5242b5a75afa813589f088_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-686">2.6</ix:nonFraction>&#160;million, and is inclusive of non-cash amortization of the debt discount and debt issuance costs and accretion of final payment. The carrying value of the Innovatus Loan at December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="iac8c23ec655449c28e8237fc61998863_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-687">39.6</ix:nonFraction> million. The carrying amount of the Innovatus Loan approximates fair value given its recent issuance. The effective interest rate for the Innovatus Loan was <ix:nonFraction unitRef="number" contextRef="i24dada1a3b5242b5a75afa813589f088_D20220101-20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-688">12.86</ix:nonFraction>% as of December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with entering into the Innovatus Loan, the Company entered into a Stock Purchase Agreement with Innovatus for the sale of common stock with an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="i788faa633fdf42068abaa39dc2edf9d3_D20220601-20220601" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-689">5.0</ix:nonFraction> million. On June 1, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i788faa633fdf42068abaa39dc2edf9d3_D20220601-20220601" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-690">749,053</ix:nonFraction> shares of common stock to Innovatus at a per share purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i16fb4c62472c449a9b7982be7439e638_I20220601" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-691">6.6751</ix:nonFraction>, the preceding five-day volume weighted average price per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the loan proceeds were used to repay in full the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $<ix:nonFraction unitRef="usd" contextRef="i53c72d39d32d498788a5ca7d700ec4e8_I20220601" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-692">33.5</ix:nonFraction>&#160;million of aggregate principal amount, unpaid interest, and exit fees in connection with loans outstanding owed to Oxford Finance LLC by the Company. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oxford Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into an aggregate $<ix:nonFraction unitRef="usd" contextRef="i92c6b12ce519418c8440d547c323d70f_I20161231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-693">25.0</ix:nonFraction> million loan with Oxford Finance LLC (the Oxford Loan) with a maturity date of July&#160;1, 2021. The Company borrowed $<ix:nonFraction unitRef="usd" contextRef="i19d31eefba974ecf8d96ae66cc576d69_I20161231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-694">15.0</ix:nonFraction> million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan and borrowed $<ix:nonFraction unitRef="usd" contextRef="id8ef2a5a94d44cb39fe45dcedfee9769_I20180531" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-695">5.0</ix:nonFraction> million (Tranche B). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;3, 2018, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowed the remaining $<ix:nonFraction unitRef="usd" contextRef="i442e61d07b494a89af46c51bf3c39c99_I20180803" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-696">5.0</ix:nonFraction> million (Tranche C) under the Oxford Loan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $<ix:nonFraction unitRef="usd" contextRef="i10d5cb28ee524a039c68d61469c0487f_I20190305" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-697">35.0</ix:nonFraction> million and extended the maturity date to March&#160;1, 2024. On March&#160;5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $<ix:nonFraction unitRef="usd" contextRef="i10d5cb28ee524a039c68d61469c0487f_I20190305" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-698">23.3</ix:nonFraction>&#160;million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i87edad638cf242f0a34985f29b06a8ed_D20190305-20190305" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-699">6.7</ix:nonFraction> million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $<ix:nonFraction unitRef="usd" contextRef="i43c59ab4e6cc45cab9946e312f152846_I20190305" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="f-700">30.0</ix:nonFraction>&#160;million (Amended Tranche A). The remaining $<ix:nonFraction unitRef="usd" contextRef="i676ed4dafff44a7db6aea95716fda14c_I20190305" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-701">5.0</ix:nonFraction> million (Amended Tranche B) was available to the Company provided that certain milestones are achieved by February 2021. The Company did not draw down the Amended Tranche B.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;23, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by <ix:nonNumeric contextRef="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223" name="eigr:DebtInstrumentInterestPaymentPeriod" format="ixt-sec:durmonth" id="f-702">17</ix:nonNumeric> months until September 1, 2022, followed by <ix:nonNumeric contextRef="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223" name="eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod" format="ixt-sec:durmonth" id="f-703">19</ix:nonNumeric> equal monthly payments of principal and interest. The Company paid an amendment fee of $<ix:nonFraction unitRef="usd" contextRef="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223" decimals="-5" name="eigr:AmendmentFeesPayment" format="ixt:num-dot-decimal" scale="6" id="f-704">0.2</ix:nonFraction>&#160;million to the lender on the effective date of the fifth amendment, which was recorded as an additional debt discount and was being amortized over the remaining term of the Amended Oxford Loan. Interest expense for the Oxford Loan for the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i054ac64c0a9a48f39f0672426b1763f8_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-705">1.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2021, the Company entered into the sixth amendment to the Oxford Loan, which amended the interest to be the LIBOR replacement rate which is the sum of the alternate benchmark rate and the LIBOR replacement spread. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of final payment, the Company was required to pay an exit fee of <ix:nonFraction unitRef="number" contextRef="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601" decimals="3" name="eigr:DebtInstrumentExitFeePayablePercentage" scale="-2" id="f-706">7.50</ix:nonFraction>% of the original principal balance of borrowed funds, or $<ix:nonFraction unitRef="usd" contextRef="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601" decimals="-5" name="eigr:DebtInstrumentUnamortizedExitFees" format="ixt:num-dot-decimal" scale="6" id="f-707">2.3</ix:nonFraction> million. In addition, the Company was required to pay an additional exit fee of $<ix:nonFraction unitRef="usd" contextRef="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601" decimals="-5" name="eigr:DebtInstrumentUnamortizedAdditionalExitFees" format="ixt:num-dot-decimal" scale="6" id="f-708">1.0</ix:nonFraction> million. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i89a13e902feb4c2e8bf8b764f6b74fb2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $<ix:nonFraction unitRef="usd" contextRef="ifed09a12b16a48eca75c2639c1883cb0_D20211006-20211006" decimals="-5" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-709">0.9</ix:nonFraction> million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022, upon entering into the Innovatus Loan, the Company repaid the Oxford Loan, including (i) the $<ix:nonFraction unitRef="usd" contextRef="i062780bfd6314b9aa885ba2d25702a18_I20220601" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-710">30.0</ix:nonFraction> million outstanding principal balances, (ii) $<ix:nonFraction unitRef="usd" contextRef="i911bf9268d42447e85041ca1379f6928_D20220601-20220601" decimals="-5" name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-711">0.2</ix:nonFraction> million in accrued and unpaid interest, and (iii) other final payments consisting of $<ix:nonFraction unitRef="usd" contextRef="i062780bfd6314b9aa885ba2d25702a18_I20220601" decimals="-5" name="eigr:LineOfCreditFacilityOtherFinalPayments" format="ixt:num-dot-decimal" scale="6" id="f-712">3.3</ix:nonFraction> million, for a total payment of $<ix:nonFraction unitRef="usd" contextRef="i911bf9268d42447e85041ca1379f6928_D20220601-20220601" decimals="-5" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-713">33.5</ix:nonFraction> million. The Company recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="i9d011b31a4674517a07eb189e6e48b8a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-714">1.1</ix:nonFraction>&#160;million on early extinguishment of the debt related to the unamortized debt premium, discount, and cost of issuance, which was recognized as a component of other (expense) income, net in the consolidated statement of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the amortization of the debt discount utilizing the effective interest method. <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-715" continuedAt="ie7e463917c2046c186ff0d72372d1189" escape="true">Debt and unamortized discount balances are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="ie7e463917c2046c186ff0d72372d1189"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-716">40,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-717">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:DebtInstrumentUnamortizedExitFees" format="ixt:num-dot-decimal" scale="3" id="f-718">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:DebtInstrumentUnamortizedExitFees" format="ixt:num-dot-decimal" scale="3" id="f-719">3,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-720">3,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-721">1,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-722">39,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-723">31,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-725">7,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-726">39,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-727">23,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-728" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum payments of principal, exit fee and interest expense under the Innovatus Loan were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-729">3,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-730">3,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-731">4,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-732">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-733">48,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-734">64,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-735">21,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: exit fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="eigr:DebtInstrumentExitFee" format="ixt:num-dot-decimal" scale="3" id="f-736">3,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-737">39,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i55f26684d5024316bef45166a614e201_727"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-738" continuedAt="i82dc428678f14de4bfc00ba7f0d62583" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i82dc428678f14de4bfc00ba7f0d62583" continuedAt="i2391981b76174df788d3b4a063a2e1a2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Company&#8217;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the convertible preferred stockholders. As of December&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="eigr:DividendsDeclared" format="ixt:fixed-zero" scale="0" id="f-739">no</ix:nonFraction> dividends had been declared by the Board of Directors.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by the Company up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i13530243d7b34f1c827b988b0901189a_D20201201-20201231" decimals="-5" name="eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-740">200.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of its common stock, preferred stock, debt securities and warrants. Up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231" decimals="-5" name="eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod" format="ixt:num-dot-decimal" scale="6" id="f-741">50.0</ix:nonFraction>&#160;million of the maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231" decimals="-5" name="eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-742">200.0</ix:nonFraction>&#160;million may be issued and sold pursuant to an ATM financing facility (the 2020 ATM Facility) under a sales agreement with Jefferies. In December 2021, the Company completed ATM offerings for a total of <ix:nonFraction unitRef="shares" contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-743">565,938</ix:nonFraction> shares of common stock under the 2020 ATM Facility. The offerings were made under the Company&#8217;s effective shelf registration statement and resulted in net proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-744">3.0</ix:nonFraction>&#160;million, after deducting commissions. In January and March 2022, the Company completed ATM offerings for a total of <ix:nonFraction unitRef="shares" contextRef="ic3b089476acf40c8a5b5c34b133005bc_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-745">5,841,786</ix:nonFraction> shares of common stock under the 2020 ATM Facility. The offerings were made under the Company&#8217;s </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2391981b76174df788d3b4a063a2e1a2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective shelf registration statement and resulted in net proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="i2cd0a96271fe4fe19e51825f3a419589_D20220331-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-746">45.6</ix:nonFraction>&#160;million, after deducting commissions. As of December 31, 2022, the Company completed the sale of all shares available for sale under the 2020 ATM Facility, and the 2020 ATM Facility was terminated.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2022, the Company entered into a new Open Market Sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies, pursuant to which the Company can sell up to a maximum of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1ff52c712c8d4b55877e2745e77f4a16_D20220325-20220325" decimals="-5" name="eigr:CommonStockValueAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-747">50.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our common stock in offerings that are deemed &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act, under the Company&#8217;s effective shelf registration statement (the 2022 ATM Facility). In April 2022, the Company completed offerings from the 2022 ATM facility for a total of <ix:nonFraction unitRef="shares" contextRef="i8b3390cbd84f4e9b830a1dae02e73f6d_D20220325-20220325" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-748">2,686,288</ix:nonFraction> shares of our common stock resulting in net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8b3390cbd84f4e9b830a1dae02e73f6d_D20220325-20220325" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-749">20.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, after deducting commissions costs. No additional offerings were completed since April 2022. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iedce0e0e2285449bb203fa52f3e4b81a_D20220101-20221231" decimals="-5" name="eigr:CommonStockValueAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-750">28.7</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remaining under the 2022 ATM Facility for future issuance.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="eigr:CommonStockReservedForFutureIssuancesTableTextBlock" id="f-751" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="0" name="eigr:OptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-752">6,143,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="0" name="eigr:OptionsIssuedAndOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-753">5,262,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options available for future grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-754">1,976,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-755">1,327,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted and performance stock units outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="0" name="eigr:RestrictedAndPerformanceStockUnitsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-756">641,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="0" name="eigr:RestrictedAndPerformanceStockUnitsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-757">623,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for issuance under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="0" name="eigr:SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" format="ixt:num-dot-decimal" scale="0" id="f-758">788,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="0" name="eigr:SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" format="ixt:num-dot-decimal" scale="0" id="f-759">671,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-760">9,549,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-761">7,884,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i55f26684d5024316bef45166a614e201_55"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-762" continuedAt="i10edfc1b3f5e43d98123711257dbdac9" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i10edfc1b3f5e43d98123711257dbdac9" continuedAt="i173837c31a9249fdad70cd15bbb93685"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restated 2013 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors adopted and in August 2016 the Company&#8217;s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Under the terms of the Restated 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restated 2013 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than <ix:nonFraction unitRef="number" contextRef="ib1ec4a30b09349279833954d224dead9_D20220101-20221231" decimals="2" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" scale="-2" id="f-763">10</ix:nonFraction>% of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than <ix:nonFraction unitRef="number" contextRef="i0a28c62f12bf4413a513b312483af157_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-764">110</ix:nonFraction>% of fair market value, as determined by the Board of Directors. The terms of options granted under the Restated 2013 Plan may not exceed <ix:nonNumeric contextRef="id7aafa6247ea4c65a7c5873f86ff4fd6_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-765">ten years</ix:nonNumeric>. The vesting schedule of newly issued option grants is generally <ix:nonNumeric contextRef="i09207d695d8c4253a8e427f8c6d035d4_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-766">four years</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2022, the Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="if4028eb882514f05b6a41d5478817cee_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-767">8,127,807</ix:nonFraction> shares under the Restated 2013 Plan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Inducement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company approved the 2021 Inducement Plan to reserve <ix:nonFraction unitRef="shares" contextRef="ief5a5c4c1ae64fc4ab9b4e7b4056be2a_D20210401-20210630" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-768">850,000</ix:nonFraction> shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals&#8217; entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ie2dd632aefc143bb8b84aea6a35fcbaf_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-769">380,000</ix:nonFraction> shares remaining available to be issued under the 2021 Inducement Plan. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i173837c31a9249fdad70cd15bbb93685" continuedAt="i8aba9b43c3b34e33b633b662abba5ee5"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-770" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity, including restricted stock units (RSUs) and performance stock units (PSUs) available for grant activity, under the Company&#8217;s stock-based compensation plans during the year ended December&#160;31, 2022 (in thousands, except option and share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Available for <br/>Grants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-771">1,327,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-772">5,262,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-773">10.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-774">7.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-775">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-776">1,728,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" format="ixt:num-dot-decimal" scale="0" id="f-777">2,061,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-778">2,061,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-779">5.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" format="ixt:num-dot-decimal" scale="0" id="f-780">298,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" format="ixt:num-dot-decimal" scale="0" id="f-781">30,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-782">47,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-783">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" format="ixt:num-dot-decimal" scale="0" id="f-784">1,132,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-785">1,132,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-786">9.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="INF" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" format="ixt:num-dot-decimal" scale="0" id="f-787">126,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="0" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" format="ixt:num-dot-decimal" scale="0" id="f-788">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of  December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-789">1,976,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-790">6,143,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-791">9.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-792">6.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of  December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-794">3,726,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-795">10.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-796">4.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="2" name="eigr:ClosingPriceOfCommonStock" scale="0" id="f-798">1.18</ix:nonFraction> as of December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised in 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-799">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-800">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-801">0.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> weighted-average grant date fair value of options granted were $<ix:nonFraction unitRef="usdPerShare" contextRef="i73059116eb97484196f938499f7d5281_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-802">3.65</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ec04d4ad35c443b99bbe1aa326e6d2a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-803">5.58</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4c049d0b7ef5404389a868b354fa749a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-804">4.78</ix:nonFraction> per share, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of options that vested during the years ended December&#160;31, 2022, 2021 and 2010 was $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-805">7.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-806">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-807">5.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation of stock options granted by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizes the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-808" continuedAt="i3e73c296b57c408f96f43b8b9e7935e9" escape="true">The fair value of stock options was estimated using the following weighted-average assumptions:</ix:nonNumeric></span></div><ix:continuation id="i3e73c296b57c408f96f43b8b9e7935e9" continuedAt="i78468764f9ae430f8629d48b312f2a30"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaac2aed31bb54cc18cb6ae41a4a4024c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-809">5.27</ix:nonNumeric>-<ix:nonNumeric contextRef="i71407d30e650431da3d0986454f2222a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-810">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09b3e189eaf243f4af6da3f36cd256b0_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-811">5.27</ix:nonNumeric>-<ix:nonNumeric contextRef="i51aa14a7322841a28eb8b15ffc596162_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-812">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i79074ea06073434787ed7105b645d332_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-813">5.00</ix:nonNumeric>-<ix:nonNumeric contextRef="ic09b60b6370048899551663b184c6f48_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-814">6.08</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icdaee817ecba4432b442ecd4baec5196_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-815">10.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-816">68.71</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-817">88.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-818">68.96</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-819">71.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-820">73.00</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-821">77.00</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-822">1.76</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-823">4.23</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-824">0.62</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-825">1.35</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-826">0.39</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-827">1.37</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-828">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-829">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-830">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected term represents the number of years the Company estimates, based primarily on historical experience, that the options will be outstanding prior to exercise.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected volatility for stock options is based on the Company's historical stock price volatility.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8aba9b43c3b34e33b633b662abba5ee5" continuedAt="i88af7bdb87ef44d4b628917fe9f2f9bb"><ix:continuation id="i78468764f9ae430f8629d48b312f2a30"><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-831">zero</ix:nonFraction>.</span></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, the Company&#8217;s board of directors adopted and in 2016, upon the merger with Celladon, the Company amended and approved the 2013 Employee Stock Purchase Plan (2013 ESPP). The 2013 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code and is administered by the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock initially reserved for issuance under the 2013 ESPP was <ix:nonFraction unitRef="shares" contextRef="if03ebee97bdd465fb594bd07b6658cd6_I20131231" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-832">100,000</ix:nonFraction> shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) <ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-833">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) <ix:nonFraction unitRef="shares" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-834">165,000</ix:nonFraction> shares of common stock, unless a lower number determined by the board of directors. As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="i965b044302dc48988da35b57cfb58274_I20221231" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-835">948,831</ix:nonFraction> shares are reserved for issuance and <ix:nonFraction unitRef="shares" contextRef="i965b044302dc48988da35b57cfb58274_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-836">788,057</ix:nonFraction> shares available for future issuance under the 2013 ESPP. During the years ended December&#160;31, 2022, 2021 and 2020, employees purchased <ix:nonFraction unitRef="shares" contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-837">48,115</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="f-838">0.2</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="shares" contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-839">37,619</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="f-840">0.3</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-841">25,645</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="f-842">0.2</ix:nonFraction>&#160;million, respectively, under the 2013 ESPP.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company revised its non-employee director compensation policy to approve the granting of RSUs in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for at least <ix:nonNumeric contextRef="i94322c77d52a4ebc957caaa8538856a0_D20200101-20200331" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-843">six months</ix:nonNumeric> during the prior calendar year and continues to serve as a non-employee member of the board of Directors (the Board) is granted RSUs. Each eligible director who has served on the Board for less than <ix:nonNumeric contextRef="i94322c77d52a4ebc957caaa8538856a0_D20200101-20200331" name="us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-844">six months</ix:nonNumeric> during the prior calendar year and who continues to serve as a non-employee member of the Board, is granted RSUs which are pro-rated for the period served during the prior calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director&#8217;s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. The RSUs granted to employees will vest annually on the <ix:nonNumeric contextRef="if1c1d057c3104eb38128ca6d2e56cc34_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-845">one-year</ix:nonNumeric>, <ix:nonNumeric contextRef="ib0d49d00344d4c8d9255a8ab257ddb21_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-846">two-year</ix:nonNumeric>, and <ix:nonNumeric contextRef="i50b559f643dc4ebe82779e55c0713860_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-847">three-year</ix:nonNumeric> anniversaries of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company&#8217;s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSUs are also available for grant pursuant to the Restated 2013 Plan. Each PSU, which is a stock award, is earned through the achievement of performance-based metrics over a defined performance period. The length of the defined performance period, the performance-based metric to be achieved during the defined performance period, and the measure of whether and to what degree such performance-based metric has been achieved will be conclusively determined by the compensation committee of the Company&#8217;s Board, in its sole discretion. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022 and 2021 the Company granted <ix:nonFraction unitRef="shares" contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-848">30,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4545b7ea67d340b68656d572237dd471_D20210101-20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-849">270,000</ix:nonFraction> PSUs, with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-850">6.87</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4545b7ea67d340b68656d572237dd471_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-851">7.92</ix:nonFraction> per share, respectively. The performance-based metrics include the achievement of certain revenue targets and clinical and regulatory milestones. During the year ended December&#160;31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-852">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4545b7ea67d340b68656d572237dd471_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-853">0.2</ix:nonFraction>&#160;million of stock-based compensation expense related to the PSUs as it is expected that all milestones will be achieved by the target dates, respectively. This expense is included in selling, general and administrative expenses. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-854">no</ix:nonFraction> PSUs have vested as the performance-based metrics of the PSUs have not yet been achieved. During the year ended December&#160;31, 2022 and 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="ia26ed6605602415ead8fa34aa2933308_D20211001-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-855">298,150</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-856">371,500</ix:nonFraction> RSUs, respectively, with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia26ed6605602415ead8fa34aa2933308_D20211001-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-857">5.22</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-858">9.16</ix:nonFraction> per share, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to the RSUs granted, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iea5fd9f65a07451c9c163efc7530542c_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-859">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-860">0.9</ix:nonFraction>&#160;million in stock-based compensation expense for the year ended December&#160;31, 2022 and 2021, respectively, which were included in selling, general and administrative expenses. As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested RSUs and PSUs was $<ix:nonFraction unitRef="usd" contextRef="i96530fc320b84544b9696cf29d5efa21_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-861"><ix:nonFraction unitRef="usd" contextRef="i4234b3566e684a2bbc69705bd15492d7_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-862">3.0</ix:nonFraction></ix:nonFraction>&#160;million, which the Company expects to recognize over an estimated weighted-average period of <ix:nonNumeric contextRef="iea5fd9f65a07451c9c163efc7530542c_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-863"><ix:nonNumeric contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-864">2.0</ix:nonNumeric></ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i88af7bdb87ef44d4b628917fe9f2f9bb"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-865" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and PSU activity and weighted average grant date fair value for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares as of  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78457377acd944119ee3cbc487a296cf_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-866">623,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i78457377acd944119ee3cbc487a296cf_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-867">8.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-868">328,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-869">5.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-870">132,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-871">9.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-872">176,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-873">7.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares as of  December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-874">641,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-875">7.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-876" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77186ca2509745eb8c68fb8c32e77418_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-877">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891dd7eeeb804b7180c764a60670443b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-878">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf58d38de1c412a9467e8c815412e01_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-879">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e0daa1d8724811b59a7c133d069b57_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-880">5,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea11b6251f7c49fbab31dbf60503d7f5_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-881">5,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d45e0236dca466d80b365de652362f6_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-882">4,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-883">8,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-884">7,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-885">5,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested options was $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-886">10.1</ix:nonFraction> million, which the Company expects to recognize over an estimated weighted average period of <ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-887">2.70</ix:nonNumeric> years.</span></div></ix:continuation><div id="i55f26684d5024316bef45166a614e201_58"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-890" continuedAt="i86107d127a0542fb86c6d8906362d055" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i86107d127a0542fb86c6d8906362d055" continuedAt="i34ba5cbf989a42debe48db4a5fd8b882"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes was approximately $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-891">23,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-892">64,000</ix:nonFraction> for the year ended December&#160;31, 2022 and 2021 respectively, with an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-893">0.02</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-894">0.19</ix:nonFraction>)% for the year ended December&#160;31, 2022 and 2021. No provision for income taxes was recorded for the years ended December 31, 2020. The effective tax rate in each period differs from the U.S. statutory tax rate primarily due to the valuation allowances on the Company&#8217;s deferred tax assets as it is more likely than not that some or all of the Company&#8217;s deferred tax assets will not be realized. The tax expense recorded for the year ended December&#160;31, 2022 relates to state taxes. </span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-895" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-896">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-897">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-898">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-899">25.99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-900">31.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-901">26.75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-902">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-903">12.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-904">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-905">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-906">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-907">0.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-908">0.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-909">3.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-910">1.00</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-911">0.59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-912">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-913">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-914">0.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="number" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-915">0.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i34ba5cbf989a42debe48db4a5fd8b882" continuedAt="i45b45a95b5f5425fb10ef487e135d6a2"><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-917" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-918">63,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-919">60,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-920">9,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-921">5,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:DeferredTaxAssetDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-922">2,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:DeferredTaxAssetDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-923">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-924">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-925">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Section 174 Capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-926">15,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-928">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-929">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:DeferredTaxAssetsLeaseLiabilities" scale="3" id="f-930">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:DeferredTaxAssetsLeaseLiabilities" scale="3" id="f-931">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-932">96,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-933">71,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-934">96,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-935">71,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-936">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-937">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="eigr:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="f-938">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="eigr:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="f-939">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-940">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-941">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s lack of earnings history, the deferred tax assets have been fully offset by a valuation allowance as of December 31, 2022 and 2021. The net change in the valuation allowance for the years ended December&#160;31, 2022 and 2021 increased by $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="eigr:IncreaseInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-944">25.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="eigr:IncreaseInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-945">10.5</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i5b1c32c7c8074780b2a2e9572bb98ea4_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-946">292.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i038017cc1aff4f5b802f302a04651e70_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-947">25.4</ix:nonFraction>&#160;million, respectively, of federal and state operating loss carryforwards available to reduce future taxable income that will begin to expire in 2030 and 2028, respectively, for federal and state tax purposes. The Company had $<ix:nonFraction unitRef="usd" contextRef="id3f6e0f47b76477398971584c280e787_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-948">10.8</ix:nonFraction>&#160;million of federal Orphan Drug credit carryforwards available to reduce future taxable income that will begin to expire in 12/31/2041.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company also had research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i5b1c32c7c8074780b2a2e9572bb98ea4_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:fixed-zero" scale="6" id="f-949">0&#160;million</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i038017cc1aff4f5b802f302a04651e70_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-950">3.1</ix:nonFraction>&#160;million for federal and state purposes available to offset future taxable income tax, respectively. If not utilized, the state credits can be carried forward indefinitely. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if the Company has experienced an ownership change under Section 382 of the Internal Revenue Code (the Code) of 1986, as amended. The Company&#8217;s merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#8217;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. The Company assessed whether it had an ownership change, as defined by Section 382 of the Code from its formation through December 31, 2021. Based upon this assessment, the Company experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to the April 20, 2016 and October 18, 2018 ownership changes, reductions were made to the Company&#8217;s NOL and tax credit carryforwards under these rules. Additional ownership changes in the future could result in additional limitations on the Company&#8217;s NOL and tax credit carryforwards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i45b45a95b5f5425fb10ef487e135d6a2"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-951" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2022, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-952">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-953">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8c1713a9ff0046649a86f61420a19003_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-954">3,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions based on tax positions related to prior year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions based on tax positions related to current year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-958">1,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-959">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-960">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reductions based on tax positions related to prior year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-961">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-963">2,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reductions based on tax positions related to current year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-967">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-968">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-969">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the $<ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-970">3.5</ix:nonFraction> million of unrecognized tax benefits is recognized, there would not be an effect on the effective tax rate. The Company does not expect the unrecognized tax benefits to change significantly over the next 12 months. As of December&#160;31, 2022, the unrecognized tax benefits for uncertain tax positions were offset against deferred tax assets and would not affect the income tax rate if recognized due to the Company being in a full valuation allowance position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to account for interest and penalties in tax expense on the consolidated statements of operations. The Company files income tax returns in the U.S. federal and state jurisdictions. All periods since inception are subject to examination by U.S. federal and state jurisdictions. There were <ix:nonFraction unitRef="usd" contextRef="ide6769059acf419584a1d5e087c7d813_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-971"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-972"><ix:nonFraction unitRef="usd" contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-973">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> such interest or penalties during the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation><div id="i55f26684d5024316bef45166a614e201_740"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-974" continuedAt="i9781ca0ab67a46e59e99cf2d828e3ef7" escape="true">Legal Matters</ix:nonNumeric></span></div><div style="margin-top:6pt"><span><br/></span></div><ix:continuation id="i9781ca0ab67a46e59e99cf2d828e3ef7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">From time to time in the ordinary course of business, the Company may be involved in various legal claims and litigation, including those pertaining to the defense and enforcement of the Company's patent or other intellectual property rights and contractual rights. The Company is defending all current litigation matters, including the litigation matters discussed below. Although there can be no assurances and the outcome of these matters is currently not determinable, the Company currently believes that none of these claims or proceedings are likely to have a material adverse effect on the Company's financial position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The Company records accruals for outstanding legal proceedings, claims or investigations when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company evaluated developments in legal proceedings, claims or investigations that could affect the amount of any accrual, as well as any developments that would result in a loss contingency to become both probable and reasonably estimable. The Company has not recorded any accrual for loss contingencies associated with such legal claims or litigation discussed herein as they are in the early stages and an estimate of loss, if any, cannot be made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On November 8, 2022 a putative securities class action complaint was filed in the United States District Court for the Northern District of California alleging that the company and <ix:nonFraction unitRef="segment" contextRef="iefd9ad44e31d4bb09abdd6c03737db5d_I20221108" decimals="0" name="eigr:NumberOfFormerExecutives" format="ixt-sec:numwordsen" scale="0" id="f-975">two</ix:nonFraction> former executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleges generally that between March 2021 and October 2022 material misstatements and omissions were made to shareholders regarding the TOGETHER study of peginterferon lambda for the treatment of COVID-19 as well as the likelihood of FDA approval of an Emergency Use Authorization for peginterferon lambda. The Court appointed a lead plaintiff on March 2, 2023. The litigation is currently ongoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On November 15, 2022, the Company received a demand for arbitration (Demand) from claimant The Progeria Research Foundation, Inc. (PRF) asserting two claims under a May 15, 2018 Collaboration and Supply Agreement (the PRF Collaboration Agreement) between the parties. PRF has alleged that the Company breached an obligation to supply quantities of a drug as requested by PRF. PRF also has a claim for declaratory relief regarding the grant of licenses under the PRF Collaboration Agreement. On January 18, 2023, the Company filed a response to the Demand denying PRF&#8217;s claims, contesting the arbitrability of PRF&#8217;s claim for declaratory relief, and asserting a counterclaim for declaratory relief related to the contractual provision underlying PRF&#8217;s original drug supply claim. To give the parties an opportunity to discuss a potential negotiated resolution of their dispute, the arbitration has been suspended through the end of 2023. As a result, all arbitration activities are now on hold, and the final hearing, originally scheduled for May 9 &#8211; 12, 2023, in Boston, Massachusetts, has been taken off calendar.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-976" continuedAt="i33bb7bffaf614a3e97612dd4d991c6bc" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i33bb7bffaf614a3e97612dd4d991c6bc"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into a non-cancelable operating facility lease agreement for <ix:nonFraction unitRef="sqft" contextRef="ie6112fe6606643398b7e891f4e07a185_I20171031" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-977">8,029</ix:nonFraction> square feet of office space located at 2155 Park Blvd. in Palo Alto, California. The lease commenced on March&#160;1, 2018 and was to expire in February 2023. The lease had a <ix:nonNumeric contextRef="ie6112fe6606643398b7e891f4e07a185_I20171031" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-978">three-year</ix:nonNumeric> renewal option prior to expiration. The lease included rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $<ix:nonFraction unitRef="usd" contextRef="ie6112fe6606643398b7e891f4e07a185_I20171031" decimals="-5" name="us-gaap:PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-979">0.3</ix:nonFraction>&#160;million. In February 2023, the Company amended the lease to extend the lease by one year with a <ix:nonNumeric contextRef="i88df8041ee074c629e1deb74604adbcd_I20230228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-980">one year</ix:nonNumeric> renewal option. The extended lease will commence on March 1, 2023 and expire on February 28, 2024. The Company accounted for the amendment as a lease modification in accordance with ASC Topic 842. The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.</span></div><ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-981" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-982">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-983">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-984">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-985">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-986">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-987">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-988">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-989">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense recognized for the Company&#8217;s operating leases was $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-990"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-991"><ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-992">0.6</ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-993"><ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-994"><ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-995">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating cash outflows for the operating lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-996">0.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-997">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-998">0.7</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, the weighted-average remaining lease term and weighted-average discount rate were <ix:nonNumeric contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-999">1.2</ix:nonNumeric> years and <ix:nonFraction unitRef="number" contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1000">12.82</ix:nonFraction>%, respectively. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. However, the amount and timing of these payments are not known. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Service Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, the Company is required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture <ix:nonFraction unitRef="number" contextRef="i9e22fa7313ce40ddbecce4a6177c2baf_D20200101-20201231" decimals="2" name="eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" scale="-2" id="f-1001">80</ix:nonFraction>% of actual manufacturing volume. If the Company orders more than <ix:nonFraction unitRef="number" contextRef="i54e4723198e54d37b6163a5733e2bfed_D20200101-20201231" decimals="0" name="eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" scale="0" id="f-1002">20</ix:nonFraction> percent of manufacturing volume from other manufacturers, the Company is required to pay <ix:nonFraction unitRef="number" contextRef="i9e22fa7313ce40ddbecce4a6177c2baf_D20200101-20201231" decimals="2" name="eigr:PercentageOfPurchasePrice" scale="-2" id="f-1003">70</ix:nonFraction>% of purchase price to Patheon for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive two-year terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#8217;s notice of termination to the other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i55f26684d5024316bef45166a614e201_64"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1004" continuedAt="i68f98017b9b242e98ab8d44fdea0a201" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68f98017b9b242e98ab8d44fdea0a201">As disclosed in Note 6, the Company entered into license agreements with EGI, which is owned by the founder of the Company.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_749"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="f-1005" continuedAt="ie430c352b793409a8006b900c09437f7" escape="true">Subsequent Event</ix:nonNumeric></span></div><ix:continuation id="ie430c352b793409a8006b900c09437f7"><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Departure of Directors or Certain Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, the Company entered into a separation agreement and general release with David Cory, the Company's former President and Chief Executive Officer. Pursuant to the separation agreement, Mr. Cory will be entitled to receive, (i) $<ix:nonFraction unitRef="usd" contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206" decimals="-5" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1006">1.5</ix:nonFraction>&#160;million continuation of his base salary and target bonus for a period of <ix:nonNumeric contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206" name="eigr:BaseSalaryAndTargetBonusContinuationPeriod" format="ixt-sec:durmonth" id="f-1007">18</ix:nonNumeric> months; (ii) $<ix:nonFraction unitRef="usd" contextRef="i2f726335e506438cbf098a44665c4473_D20230206-20230206" decimals="-5" name="us-gaap:PensionAndOtherPostretirementBenefitContributions" format="ixt:num-dot-decimal" scale="6" id="f-1008">0.4</ix:nonFraction>&#160;million cash payment equal to Mr. Cory's target bonus for 2022; (iii) reimbursement for COBRA continuation coverage for Mr. Cory and his eligible dependents for a period of <ix:nonNumeric contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206" name="eigr:COBRAContinuationCoveragePeriod" format="ixt-sec:durmonth" id="f-1009">18</ix:nonNumeric> months; (iv) accelerated vesting of <ix:nonFraction unitRef="number" contextRef="i8892b34c54854c50ad3eda9fa1852d3d_I20230206" decimals="2" name="eigr:PostEmploymentBenefitAcceleratedVesting" scale="-2" id="f-1010">50</ix:nonFraction>% of Mr. Cory's unvested stock options, performance-based restricted stock units, and time-based RSUs outstanding as of the separation date; (v) reimbursement of Mr. Cory's legal fees associated with the negotiation of the Separation Agreement up to $<ix:nonFraction unitRef="usd" contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206" decimals="-3" name="eigr:PostEmploymentBenefitsLegalFeesReimbursementThreshold" format="ixt:num-dot-decimal" scale="0" id="f-1011">10,000</ix:nonFraction>. The Company accrued $<ix:nonFraction unitRef="usd" contextRef="i4934175f59ca42c484533a305704b3c7_I20221231" decimals="-5" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1012">2.0</ix:nonFraction>&#160;million related to David Cory's separation for salary and benefits as of December 31, 2022. Expense related to stock options acceleration will be recorded in Q1 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Silicon Valley Bank Closure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 10, 2023, the Company maintained <ix:nonFraction unitRef="account" contextRef="i1325efe242c2485cb3654887aef1a15d_I20230310" decimals="0" name="eigr:NumberOfAccounts" format="ixt-sec:numwordsen" scale="0" id="f-1013">two</ix:nonFraction> accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at Silicon Valley Bank (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVB) holding</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash deposits of approximately $<ix:nonFraction unitRef="usd" contextRef="id907190c69db4635b5b4ed706d83cdfe_I20230310" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1014">8.3</ix:nonFraction>&#160;million. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (FDIC) was appointed receiver. The FDIC initially announced that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll insured depositors will have full access to their insured deposits no later than, March 13, 2023, with uninsured depositors receiving an advance dividend a receivership certificate for their uninsured funds. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#8217; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its full deposits with SVB. The cash was subsequently moved to another financial institution.</span></div></ix:continuation><div id="i55f26684d5024316bef45166a614e201_626"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i55f26684d5024316bef45166a614e201_121"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. Controls and Procedures</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Evaluation of Disclosure Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our management&#8217;s evaluation (with the participation of our principal executive officer and our principal financial officer) of our disclosure controls and procedures as required by Rule 13a-15 under the Exchange Act, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective to achieve their stated purpose as of December&#160;31, 2022, the end of the period covered by this report. </span></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Management&#8217;s Report on Internal Control over Financial Reporting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance, not absolute assurance, regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are inherent limitations to the effectiveness of any system of internal control over financial reporting. These limitations include the possibility of human error, the circumvention or overriding of the system and reasonable resource constraints. Because of its inherent limitations, our internal control over financial reporting may not prevent or detect </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Changes in Internal Control over Financial Reporting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal year ended December&#160;31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i55f26684d5024316bef45166a614e201_631"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i55f26684d5024316bef45166a614e201_865"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III. OTHER INFORMATION</span></div><div id="i55f26684d5024316bef45166a614e201_133"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, the information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. A current copy of the code is posted on the Investors Corporate Governance section of our website, which is located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.eigerbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of The Nasdaq Global Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span></div><div id="i55f26684d5024316bef45166a614e201_136"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December&#160;31, 2022.</span></div><div id="i55f26684d5024316bef45166a614e201_142"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December&#160;31, 2022.</span></div><div id="i55f26684d5024316bef45166a614e201_671"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. Certain Relationships and Related Party Transactions, and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December&#160;31, 2022.</span></div><div id="i55f26684d5024316bef45166a614e201_666"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. Principal Accountant Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is KPMG LLP, San Francisco, CA, Auditor ID: 185</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2023 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December&#160;31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_642"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i55f26684d5024316bef45166a614e201_145"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Financial Statements and Financial Statement Schedules</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="margin-top:6pt;padding-left:108pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements at Item 8 herein.</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span></div><div style="margin-top:6pt;padding-left:108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312515381300/d19344dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of November 18, 2015, by and among Celladon Corporation, Celladon Merger Sub, Inc., and Eiger BioPharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on November 19, 2015).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex31.htm">Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of Celladon Corporation, filed with the SEC on February 10, 2014).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex32.htm">Amended and Restated Bylaws of Celladon Corporation (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 10, 2014).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on March 23, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex32.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on March 23, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513414057/d578642dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October&#160;29, 2013).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513414057/d578642dex43.htm">Form of Warrant to Purchase Common Stock issued to participants in Celladon Corporation&#8217;s Convertible Debt and Warrant financing, dated October 15, 2013 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020010645/eigr-ex43_1012.htm">Description of Registrant&#8217;s Securities (incorporated by reference to Exhibit 4.3 to the Annual Report on Form 10-K (File No. 001-36183), filed with the SEC on March 13, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513396992/d578642dex101.htm">Form of Indemnity Agreement by and between Celladon Corporation and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513396992/d578642dex102.htm">Celladon Corporation 2001 Stock Option Plan and Form of Notice of Grant of Stock Option, Stock Option Agreement and Stock Option Exercise Notice thereunder (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.204%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513396992/d578642dex103.htm">Celladon Corporation 2012 Equity Incentive Plan and Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459017010695/eigr-ex101_419.htm">Celladon Corporation Non-Employee Director Compensation Policy, amended on April 12, 2017 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183), filed with the SEC on May 12, 2017).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312515401947/d72850dex1044.htm">Eiger BioPharmaceuticals, Inc. 2009 Equity Incentive Plan and Form of Notice of Grant of Stock Option, Stock Option Agreement and Stock Option Exercise Notice thereunder (incorporated by reference to Exhibit 10.44 to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459016028120/eigr-ex102_216.htm">Eiger BioPharmaceuticals, Inc. 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form 10-Q (File No. 001-36183), filed with the SEC on November&#160;8, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459016028120/eigr-ex101_217.htm">Eiger BioPharmaceuticals, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form 10-Q (File No. 001-36183), filed with the SEC on November 8, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312515401947/d72850dex1038.htm">Lease, dated as of March 19, 2015 by and between JTC, a California general partnership and Eiger BioPharmaceuticals, Inc. (incorporated by reference to Exhibit 10.38 to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex109_1145.htm">Asset Purchase Agreement, dated September 25, 2015, by and between Eiger BioPharmaceuticals, Inc. and Tracey McLaughlin and Colleen Craig&#160;(incorporated by reference to Exhibit 10.9 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1010_1144.htm">License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Corporation (incorporated by reference to Exhibit 10.10 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516434995/d72850dex1053.htm">Sublease Agreement, dated as of January 8, 2016, by and between Baker Hughes Oilfield Operations, Inc. and Eiger BioPharmaceuticals, Inc. (incorporated by reference to Exhibit 10.53 to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1012_1143.htm">License Agreement, dated as of April 20, 2016, by and between Eiger BioPharmaceuticals, Inc. and Bristol-Myers Squibb Company (incorporated by reference to Exhibit 10.12 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516625162/d207633dex102.htm">Common Stock Purchase Agreement, dated as of April 20, 2016, by and between Eiger BioPharmaceuticals, Inc. and Bristol-Myers Squibb Company (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-3, as amended (File No. 333-212114) filed with the SEC on June 17, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459017005079/eigr-ex1026_1978.htm">Loan and Security Agreement, dated December 30, 2016, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.26 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 23, 2017).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">129</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018005123/eigr-ex1027_830.htm">Standard Multi-Tenant Office Lease &#8211; Net, dated October 11, 2017, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC, and addendum thereto&#160;(incorporated by reference to Exhibit 10.27 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2018).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018013225/eigr-ex102_344.htm">First Amendment to Lease, dated April 26, 2018, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC (incorporated by reference to Exhibit 10.2 to the Quarterly&#160;report on Form 10-Q (File No. 001-36183) filed with the SEC on May 11, 2018).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1017_1142.htm">Amendment No. 6 to License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp &amp; Dohme Corp (incorporated by reference to Exhibit 10.17 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1018_1141.htm">Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and The Progeria Research Foundation (incorporated by reference to Exhibit 10.18 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018021197/eigr-ex104_259.htm">Second Amendment to Loan and Security Agreement, dated May 11, 2018, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.4 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on August 10, 2018).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018028934/eigr-ex102_530.htm">Common Stock Purchase Agreement, dated September 19, 2018, by and between Eiger BioPharmaceuticals, Inc. and RRD International, LLC (incorporated by reference to Exhibit 10.2 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 9, 2018).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019007830/eigr-ex1038_1121.htm">First Amendment to Loan and Security Agreement, dated August 24, 2017, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC&#160;(incorporated by reference to Exhibit 10.38 to the Annual report on Form 10-K (File No. 001-36183) with the SEC on March 14, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex101_231.htm">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and David A. Cory (incorporated by reference to Exhibit 10.1 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex102_230.htm">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and Sriram Ryali (incorporated by reference to Exhibit 10.2 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex103_229.htm">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and Stephana E. Patton (incorporated by reference to Exhibit 10.3 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex104_227.htm">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and James Shaffer (incorporated by reference to Exhibit 10.4 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex105_228.htm">License Agreement, dated as of May 10, 2019, by and among the Trustees of the University of Pennsylvania and The Children&#8217;s Hospital of Philadelphia and Eiger BioPharmaceuticals, Inc (incorporated by reference to Exhibit 10.5 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019018009/eigr-ex103_436.htm">Third Amendment to Loan and Security Agreement, dated March 5, 2019, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.3 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on May 9, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020022884/eigr-ex101_191.htm">Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Eldon Mayer, dated as of December 3, 2019 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on May 7, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020022884/eigr-ex102_190.htm">Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on May 7, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020037833/eigr-ex101_303.htm">Amendment No. 1, dated June 15, 2020, to the Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and the Progeria Research Foundation (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on August 6, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1031_1140.htm">Asset Purchase Agreement, by and between Eiger BioPharmaceuticals, Inc. and AbbVie Inc., dated as of November 20, 2020 (incorporated by reference to Exhibit 10.31 to the Annual Report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1032_1138.htm">Amendment No. 7 to License Agreement, dated November 3, 2020, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp &amp; Dohme Corp (incorporated by reference to Exhibit 10.32 to the Annual Report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021011758/eigr-ex1033_1139.htm">Amendment No. 5 to Loan and Security Agreement, dated February 23, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC&#160;(incorporated by reference to Exhibit 10.33 to the Annual Report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021025012/eigr-ex102_260.htm">Form of Restricted Stock Unit Award Grant Notice and Award Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on May 6, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021041599/eigr-ex101_82.htm">2021 Inducement Plan (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on August 5, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021054519/eigr-ex101_46.htm">Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Erik Atkisson, dated as of August 26, 2021 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on November 4, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1305253/000156459021054519/eigr-ex102_65.htm">Amendment No. 6 to Loan and Security Agreement, dated October 6, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on November 4, 2021).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1305253/000156459022009697/eigr-ex1038_622.htm">Amendment No. 4 to Loan and Security Agreement, dated March 10, 2020, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1305253/000119312522169283/d328938dex101.htm">Loan and Security Agreement, dated June 1, 2022, among Eiger BioPharmaceuticals, Inc., its domestic subsidiaries and Innovatus Life Sciences Lending Fund I, LP, as collateral agent and lender (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 7, 2022).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1305253/000119312522169283/d328938dex102.htm">Common Stock Purchase Agreement, dated June 1, 2022, among Eiger BioPharmaceuticals, Inc., Innovatus Life Sciences Lending Fund I, LP, Innovatus Life Sciences Offshore Fund I-A, LP, Innovatus Flagship Fund I, LP, and Innovatus Flagship Offshore Fund I, LP (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on June 7, 2022).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41**+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex1041.htm">Separation Agreement and General Release, dated as of February 6, 2023, by and between Eiger BioPharmaceuticals, Inc. and David A. Cory.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42**+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex1042.htm">Offer Letter Agreement, dated as of January 9, 2023, by and between Eiger BioPharmaceuticals, Inc. and David Apelian.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex1043.htm">Second</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex1043.htm"> Amendment to Lease, dated February </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex1043.htm">16,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex1043.htm"> 2023, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC. </a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1305253/000156459022009697/eigr-ex211_10.htm">List of Subsidiaries.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="eigr-2022x12x31ex231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1305253/000156459022009697/eigr-10k_20211231.htm#POWER_ATTORNEY">Power of Attorney. Reference is made to the signature page hereto.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="eigr-2022x12x31ex311.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="eigr-2022x12x31ex312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="eigr-2022x12x31ex321.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, has been formatted in Inline XBRL and is contained in Exhibit 101.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div id="i55f26684d5024316bef45166a614e201_655"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i55f26684d5024316bef45166a614e201_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eiger BioPharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;16, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Apelian</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Apelian</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Interim President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eiger BioPharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;16, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michelle Maynard</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michelle Maynard</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Acting Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Apelian and Michelle Maynard, and each of them, as his or her attorneys-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his or her substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Apelian</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Board of Directors, Interim President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Apelian</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michelle Maynard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, Finance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Acting Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michelle Maynard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas J. Dietz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Dietz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Evan Loh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evan Loh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Glenn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Glenn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">133</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Christine Murray</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Christine Murray</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Amit K. Sachdev</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amit K. Sachdev</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Kim Sablich</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Kim Sablich</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Lisa Kelly-Croswell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lisa Kelly-Croswell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">134</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>2
<FILENAME>eigr-2022x12x31ex1041.htm
<DESCRIPTION>EX-10.41
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i77de262ac2ac43299ad43516392878e4_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.41</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SEPARATION AGREEMENT AND GENERAL RELEASE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Separation Agreement and General Release (&#8220;Agreement&#8221;) is being entered into on the date listed on the signature page hereof by and between David Cory (&#8220;Executive&#8221;) and Eiger BioPharmaceuticals, Inc. (&#8220;Company&#8221;).  Executive and the Company are referred to jointly as the &#8220;Parties&#8221; or individually as a &#8220;Party.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive was employed by the Company as its President and Chief Executive Officer pursuant to that certain Amended and Restated Employment Terms Offer Letter Agreement dated November 1, 2019 (the &#8220;Offer Letter Agreement&#8221;)&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive resigned his employment from the Company, effective December 14, 2022&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties desire to set forth their understandings and mutual agreements with respect to Executive&#8217;s end of employment with the Company, Executive&#8217;s benefits and obligations following Executive&#8217;s end of employment, and all other matters between them&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual promises and undertakings contained herein, and intending to be legally bound hereby, the Parties agree as follows&#58;<br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Separation from Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive resigned his employment with such resignation effective on December 14, 2022 (the &#8220;Separation Date&#8221;).  Executive received Executive&#8217;s regular base salary through the Separation Date, and was paid $48,230.77 for all of his accrued but unused vacation through the Separation Date, but is not and will not be entitled to any other compensation through the Separation Date.  Coverage under any benefit plans ceased as of December 31, 2022.  Executive will be entitled to continue his health plan coverage pursuant to COBRA at his sole expense following the Separation Date, regardless of whether Executive signs this Agreement.    </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Salary Continuation and 2022 Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Company will pay Executive $1,504,800, which is an amount equal to eighteen (18) months of (1)&#160;Executive&#8217;s base salary as of the Separation Date, and (2)&#160;the Bonus (as defined in the Offer Letter Agreement) at the target level as of the Separation Date on a pro-rata basis (i.e., for 18 months) ((1) and (2), collectively, &#8220;Salary Continuation&#8221;), in each case less applicable withholdings and deductions and subject to Section 1(f).  The Salary Continuation will be paid by direct deposit in equal installments on the Company&#8217;s regular payroll schedule over the eighteen (18)-month period following the Separation Date, commencing with the first regular payroll schedule in 2023 occurring at least three (3) business days following the date this Agreement becomes effective and no longer subject to revocation by Executive (as described in Section 17), with the first such payment to include the Salary Continuation that Executive would have received had this Agreement become effective on the Separation Date.  As of the date of this Agreement, the Company&#8217;s current payroll schedule is bi-monthly, such that the payment per pay period for the Salary Continuation, after the first such payment, will be $41,800.  Company will also pay Executive $376,200, which is an amount equal to a bonus for calendar year 2022 at the target level, less applicable withholdings and deductions.  This payment for a 2022 bonus will be made on the first regular payroll schedule in 2023 occurring at least three (3) business days following the date this Agreement becomes effective and no longer subject to revocation by Executive (as described in Section 17) and subject to Section 1(f).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Health Continuation Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive timely elects continued coverage under COBRA for Executive and his covered dependents, then the Company shall reimburse the Executive for (subject to submission of evidence of proof of payment to Matthew Bys (or such other designee of the Company) reasonably acceptable to the Company of the incurrence of such expense and subject to any applicable reimbursement policies or practices of the Company as may be in effect) the COBRA premiums necessary to continue Executive&#8217;s health plan insurance coverage in effect for Executive and his eligible dependents on the Separation Date until the earliest of (i)&#160;the close of the eighteen (18) month period following the Separation Date, (ii) the expiration of Executive&#8217;s eligibility for the continuation coverage under COBRA, or (iii)&#160;the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. If Executive becomes eligible for coverage under another employer's group health plan or otherwise ceases to be eligible for COBRA during the period provided in this Section 1(c), Executive must notify the Company as soon as practicable of such event, and all payments and obligations under this Section 1(c) shall cease. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Separation Date, Executive has been granted stock options to purchase an aggregate of 502,002 shares of the Company&#8217;s common stock that are unvested, and 108,333 unvested performance-based restricted stock units and restricted stock units of the Company (the &#8220;Unvested Awards&#8221;).  As of the Separation Date, Executive has been granted stock options to purchase 1,296,525 shares of the Company&#8217;s common stock that are vested, and 15,667 restricted stock units of the Company have become vested and were settled.  Other than stock options to purchase an aggregate of 1,798,527 shares of the Company&#8217;s common stock, and 124,000 performance-based restricted stock units and restricted stock units of the Company, in each case as described in the immediately preceding two sentences of this Section 1(d), or any publicly-traded stock in the Company owned by Executive, Executive has been granted and holds no equity or similar interests in the Company or any of its affiliates.  Subject to Section 1(f), in each award granted to Executive in which there are unvested awards, fifty percent (50%) of such unvested awards will become vested on the date that this Agreement becomes effective and no longer subject to revocation by Executive (as described in Section 17), such that, in the aggregate, fifty percent (50%) of the Unvested Awards (the &#8220;Accelerated Awards&#8221;) will become vested on the date that this Agreement becomes effective and no longer subject to revocation by Executive (as described in Section 17). As of the Separation Date, any Unvested Awards that are not Accelerated Awards shall be immediately forfeited and cancelled without any further action of the Company. The Parties acknowledge and agree that, subject to Executive&#8217;s compliance with Section 1(f), any vested stock option to purchase shares of common stock of the Company, including any of the  Accelerated Awards that are in the form of stock options, shall remain exercisable until the earlier of (i) the originally stated expiration date of the applicable stock option, and (ii) the first anniversary of the Separation Date&#59; provided however that Executive acknowledges and agrees that any stock option that is intended to be an &#8220;incentive stock option&#8221; under Section 422 of the Internal Revenue Code of 1986, as amended, shall instead be treated as a nonqualified stock option in the event that any such stock option is exercised later than three (3) months following the Separation Date. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section 1(f), the Company will reimburse Executive up to $10,000 for his legal fees associated with the negotiation of this Agreement, following Executive&#8217;s submission (within forty-five (45) days following the date this Agreement becomes effective and no longer subject to revocation by Executive (as described in Section 17)) of a completed W-9 form, bank support (such as a cancelled check or bank letter), and invoice (listing hours spent, legal fees incurred, and general summary of work performed) from Executive&#8217;s counsel.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions on Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To receive the payments and benefits described in Section 1(b), Section 1(c), Section 1(d), and Section 1(e), (i)&#160;Executive must sign and return this Agreement such that it becomes effective and no longer subject to revocation by Executive (as described in Section 17) no later than 60 days following the Separation Date (i.e., no later than February 12, 2023), and (ii) Executive must remain in compliance with Executive&#8217;s obligations under this Agreement (including without limitation under Sections 6, 7, and 8) and any other contractual obligations Executive may have to the Company or any of its affiliates (including without limitation under the EPIIA, as defined below).  If the Company&#8217;s Board of Directors determines in good faith after reasonable investigation that Executive has breached any of his obligations under this Agreement (including without limitation under Sections 6, 7, or 8) or any other contractual obligation Executive may have to the Company or its affiliates (including without limitation under the EPIIA, as defined below), (i)&#160;Executive will immediately return to the Company any portion of the payments that have been paid to Executive pursuant to Section 1(b) and any payments made by the Company pursuant to Section 1(c) and Section 1(e), (ii) the Accelerated Awards shall be immediately forfeited and cancelled without any further action of the Company, and (iii) Executive will be entitled to no further payments or benefits pursuant to Section 1(b), Section 1(c), Section 1(d), or Section 1(e).  Notwithstanding anything to the contrary in this Agreement or otherwise, Executive acknowledges and agrees that any payments or benefits provided hereunder that constitute &#8220;incentive-based compensation&#8221; pursuant to the SEC&#8217;s final clawback rules under &#167;&#160;954 of Dodd-Frank, NASDAQ&#8217;s listing standards and any applicable clawback policy that the Company may implement in connection therewith (such final clawback rules, listing standards and Company policy, together, the &#8220;Clawback Rules&#8221;) shall be subject to repayment by Executive as contemplated and required thereunder. Accordingly, Executive acknowledges and agrees that, to the extent required under the Clawback Rules, Executive shall timely and fully repay any such amounts, on a pre-tax basis, to the Company and agrees that any such repayment shall, in no event, constitute a breach of the Company&#8217;s obligations hereunder.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Other Positions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon the Separation Date, and without further action or notice by Executive or the Company (or its affiliates), Executive will be deemed to have resigned from any position he may hold, as an employee or otherwise, with the  Company or any of its affiliates, including without limitation any position he may hold (as a director or otherwise) on the Board of Directors or other governing bodies of the Company or any of its affiliates. Executive agrees to cooperate with the Company to take all actions requested by the Company to evidence such resignations.  Without limiting the foregoing, Executive&#8217;s execution of this Agreement shall be deemed the grant by Executive to the officers of the Company of a limited irrevocable power of attorney (which is deemed coupled with an interest) to sign in Executive&#8217;s name and on Executive&#8217;s behalf any such documentation as may be required to be executed solely for the limited purposes of effectuating such resignations.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Other Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that Executive has timely received all wages, benefits, expense reimbursements, and other compensation to which Executive was entitled in connection with his employment or other relationship with the Company or any of the Released Parties, or the termination thereof, through the Separation Date, except for reasonable attorneys&#8217; fees incurred by Executive in connection with the investigation predating this Agreement and subject to indemnification by the Company.  Without limiting the foregoing, Executive specifically acknowledges and agrees that he has been timely paid for all bonuses to which he was entitled and reimbursement for all business expenses incurred, in each case through the Separation Date. Except as described in this Section 1, Executive acknowledges and agrees that he is not entitled to any other wages, compensation, bonuses, commissions, equity, severance, benefits, expense reimbursements, or other payments in connection with Executive&#8217;s employment or other relationship, or the termination of Executive&#8217;s employment or other relationship, with the Company or any of the Released Parties, and neither the Company nor any of the Released Parties shall have any liability or obligation to Executive in excess of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amounts specified in this Section 1, including Executive&#8217;s indemnification rights referenced in this Section 1(h).  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Complete General Release of Claims by Executive</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In consideration of the payments and benefits described in Section 1(b), Section 1(c), Section 1(d), Section 1(e), and other good and valuable consideration to which Executive would not otherwise be entitled, Executive unconditionally discharges, releases, and remises the Released Parties (as defined below), jointly and severally, of and from all claims, causes of action, suits, charges, debts, dues, sums of money, attorneys&#8217; fees and costs, accounts, bills, covenants, contracts, torts, agreements, expenses, wages, bonuses, compensation, promises, damages, judgments, rights, demands, or otherwise (&#8220;Claims&#8221;), known or unknown, in law or equity, accrued or un-accrued, contingent or non-contingent, arising at any time up to and including the date Executive signs this Agreement, whether or not capable of proof as of the date of this Agreement, whether common law or statutory, whether or not now recognized, that Executive or anyone claiming by, through, or under him (including without limitation his heirs, executors, personal representatives, administrators, assigns, and spouse(s)) in any way might have, or could have, against any of the Released Parties.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Claims enumerated above (&#8220;Released Claims&#8221;) shall include, without limitation and only by way of example&#58; all Claims arising from or relating to Executive&#8217;s employment with any of the Released Parties, or the termination thereof&#59; all Claims arising from or relating to the Offer Letter Agreement and any other agreements between Executive and any of the Released Parties&#59; all Claims arising from or relating to any options or other equity interests&#47;awards in any of the Released Parties (except to the extent explicitly provided in Section 1(d) of this Agreement)&#59; all Claims for discrimination based on age, sex, race, color, disability status, national origin, religion, or any other protected characteristic, including (without limitation) Claims under the Age Discrimination in Employment Act, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Civil Rights Act of 1866, the Civil Rights Act of 1991, the Rehabilitation Act, the California Fair Employment and Housing Act, the Unruh Civil Rights Act, and all state and local analogues of such statutes&#59; all Claims under the Employee Retirement Income Security Act of 1974, the Family and Medical Leave Act, the Equal Pay Act, the Fair Credit Reporting Act, the Families First Coronavirus Response Act, the California Family Rights Act, the Moore-Brown-Roberti Family Rights Act, the California Worker Adjustment and Retraining Notification Act, the California Labor Code (including without limitation the California political activities discrimination statute, Cal. Labor Code &#167;&#160;1101&#59; California crime victim or domestic violence victim discrimination statute, Cal. Labor Code &#167;&#160;230&#59; and California equal pay law, Cal. Labor Code &#167;&#160;1197.5), the California Voting Leave Law, and all other federal, state, and local statutes, rules, regulations, or ordinances&#59; and all common law Claims, including (without limitation) Claims for breach of contract, defamation, interference with contractual&#47;prospective contractual relations, invasion of privacy, promissory estoppel, negligence, breach of the covenant of good faith and fair dealing, fraud, infliction of emotional distress, wrongful discharge, punitive damages, and any other common law Claims under the laws of any jurisdiction.  It is the intention of the Parties that the language relating to the description of Claims released in this Section shall be given the broadest possible interpretation permitted by law.  Nothing in this Section shall be construed to impair, limit, reduce, alter, or affect Executive&#8217;s rights or claims under this Agreement, any rights to vested equity or as an equityholder in the Company, any rights to indemnification that Executive may have, any rights or claims that cannot be waived as a matter of law, and any rights to any vested benefits under any employee benefit plans, which rights remain subject to the terms of the applicable plan documents.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As used herein, &#8220;Released Parties&#8221; means&#58; (i) Eiger BioPharmaceuticals, Inc.&#59; (ii)&#160;the Company&#8217;s past, present, and future parents, subsidiaries, and affiliates (including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation Eiger, Inc.)&#59; (iii) each of the foregoing entities&#8217;&#47;persons&#8217; successors and assigns&#59; (iv)&#160;each of the foregoing entities&#8217;&#47;persons&#8217; owners, shareholders, officers, directors, managers, members, partners, employees, attorneys, agents, insurers, representatives, and benefit plans (including such plan&#8217;s fiduciaries, administrators, insurers, trustees, and the like), in their individual and official capacities&#59; and (v) all entities&#47;persons claimed to be jointly or severally liable with any of the foregoing entities&#47;persons or through&#47;by which any such entities&#47;persons have acted with respect to the Executive.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Covenant Not to Sue</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive agrees and covenants not to file, initiate, or join any lawsuit (either individually, with others, or as part of a class), in any forum, pleading, raising, or asserting any Claim(s) barred or released by Section 2 of this Agreement.  If Executive does so, and the action is found to be barred in whole or in part by this Agreement, Executive agrees to pay the attorneys&#8217; fees and costs, or the proportions thereof, incurred by the applicable Released Party in defending against those Claims that are found to be barred by Section 2 of this Agreement.  Nothing in this Section 3 or this Agreement precludes Executive from challenging the validity of the release in Section 2 under the requirements of the Age Discrimination in Employment Act, and Executive shall not be responsible for reimbursing the attorneys&#8217; fees and costs of the Released Parties in connection with such a challenge to the validity of the release.  Executive, however, acknowledges that the release in Section 2 applies to all Claims that Executive has under the Age Discrimination in Employment Act, and that, unless the release is held to be invalid, all of Executive&#8217;s Claims under that Act shall be extinguished by execution of this Agreement.  Executive agrees that nothing in this Agreement shall preclude or prevent Executive from filing a charge with, providing information to, speaking with, or cooperating with law enforcement, the U.S. Equal Employment Opportunity Commission, the U.S. Securities and Exchange Commission, the California Department of Fair Employment and Housing, a local commission on human rights, or other government agency, or from speaking with Executive&#8217;s attorneys.  Executive agrees that Executive will not seek or accept any relief obtained on Executive&#8217;s behalf by any government agency, private party, class, or otherwise with respect to any Claims released in this Agreement, provided that this Agreement does not limit Executive&#8217;s right to receive an award for information provided to any government agency.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Extent of General Release by Executive</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees that the general release in Section 2 applies not only to Claims that are presently known, suspected, or disclosed to Executive, but also to Claims that are presently unknown, unsuspected, or undisclosed to Executive.  Executive hereby acknowledges and agrees that Executive is aware of the provisions of Section 1542 of the California Civil Code regarding the effectiveness of this Agreement on unknown or unsuspected Claims and hereby knowingly waives its protection and the protection of any similar law.  Section 1542 provides&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive acknowledges that Executive is assuming the risk that the facts may turn out to be different from what Executive believes them to be and agrees that the release in Section 2 shall be in all respects effective and not subject to termination or rescission because of such mistaken belief.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Acknowledgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party acknowledges that such Party is entering into this Agreement freely and voluntarily and without reliance on any promises not expressly contained herein, that such Party has had adequate time to consider this Agreement and consult with legal counsel of such Party&#8217;s choice, that such Party has consulted with legal counsel of such Party&#8217;s choice, and that this Agreement shall not be deemed void or voidable by any claims of duress, deception, mistake of fact, or otherwise.  Nor shall the principle of construction that all ambiguities are to be construed against the drafter be employed in the interpretation of this Agreement.  Rather, it is agreed that this Agreement should not be construed for or against any Party.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Disparagement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither Executive nor any person acting on Executive&#8217;s behalf shall disparage or cause to be disparaged, whether directly or indirectly, the Company, any of the products or services of the Company or any of its affiliates, or any of the Released Parties (as previously defined) in any forum or through any medium of communication.  Within three (3) days of the date that this Agreement becomes effective and no longer subject to revocation by Executive (as described in Section 17), the Company shall instruct the then-current members of the Board of Directors of the Company and the executive team of the Company to not disparage or cause to be disparaged, whether directly or indirectly, Executive in any forum or through any medium of communication and to not make any statements regarding Executive&#8217;s departure from the Company that are inconsistent with the Form 8-K filed by the Company with the U.S. Securities and Exchange Commission on December 20, 2022.  Nothing in this Agreement or otherwise prevents Executive or any other person or entity from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to believe is unlawful.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Continuing Obligations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Previous Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that he remains bound by, and will abide by, all of Executive&#8217;s obligations under the Employee Proprietary Information and Inventions Agreement (&#8220;EPIIA&#8221;), which remains in effect in accordance with its terms, is hereby assigned to the Company, and will be construed, without limitation, such that all provisions thereof will run for the benefit of the Company, all references to the &#8220;Company&#8221; in the EPIIA will include Eiger BioPharmaceuticals, Inc., and the EPIIA will be enforceable by the Company. Executive agrees that the restrictions contained in Section 6 and in this Section 7, and in the EPIIA, are in addition to, and not in lieu of, any similar obligations (including without limitation any protection of confidential information or intellectual property, non-disparagement, or other restrictive covenants) by which Executive may be bound.     </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive warrants and represents that he has returned to the Company, and has not retained, all property of the Company and its affiliates in Executive&#8217;s possession, custody, or control, including without limitation documents, data, and equipment (and any copies thereof) of any nature and in whatever medium, regardless of whether such documents, data, or equipment contains confidential information.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Protection of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the Company and its affiliates, in the course of performing their business activities, acquire and develop Confidential Information (as defined below) that provides the Company and its affiliates with a business advantage and that Executive has developed and been provided with such Confidential Information during employment.  Executive agrees that Executive will not, directly or indirectly, at any time, use (whether on Executive&#8217;s own behalf or on behalf of any other person or entity) or disclose (to any person or entity) any Confidential Information, except as may be required by law.  &#8220;Confidential Information&#8221; means all confidential, proprietary, and non-public information (whether in written, electronic, or other form) of the Company or any of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its affiliates (including without limitation any predecessors thereof), or third parties with whom the Company or its affiliates do business, including without limitation trade secrets&#59; business information&#59; information regarding the assets and affairs of the Company or its affiliates&#59; financial information&#59; operating methods or strategies&#59; marketing plans or strategies&#59; competitive know-how&#59; processes&#59; designs&#59; formulas&#59; developmental or experimental work&#59; forecasts&#59; client lists or other client-related information of any kind&#59; and any other information of a similar nature not already in the public domain.  Confidential Information also includes any information in relation to which the Company or any of its affiliates owes a duty of confidentiality.  Confidential Information shall not include any information that is in or enters the public domain, or is or becomes generally known in the industry in which the Company operates, other than by disclosure by the Executive or any other person or entity in violation of any confidentiality or other obligation.  In the event Executive is required by law to disclose Confidential Information, Executive will (unless prohibited by law) (i) immediately (and prior to such disclosure) notify the Company and cooperate with the Company in any efforts by the Company to oppose such disclosure, and (ii) disclose only that portion of the Confidential Information that Executive is advised by written opinion of counsel is legally required to be disclosed and exercise best efforts to ensure that such Confidential Information will be afforded confidential treatment.    </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Section 7, this Agreement, the EPIIA, or otherwise shall prohibit Executive, the Company, or any other person or entity from (i)&#160;reporting possible violations of federal law or regulation to any government agency or entity or self-regulatory organization or making disclosures that are protected under the whistleblower provisions of federal law or regulation, or (ii) supplying truthful information to any government authority or in response to any lawful subpoena or other legal process or making any disclosures required by law.  In addition, notwithstanding anything in this Section 7, this Agreement, the EPIIA, or otherwise, in accordance with the U.S. Defend Trade Secrets Act of 2016, (i) Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (a) is made (I) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (II) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal, and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to Executive&#8217;s attorney and use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal and does not disclose the trade secret except pursuant to court order.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that in the event that Executive breaches any of the provisions in Section 6 or this Section 7 (or under the EPIIA), the Company and its affiliates shall suffer immediate, irreparable injury and will, therefore, be entitled to seek injunctive relief, in addition to any other damages to which it or they may be entitled, as well as the costs and reasonable legal fees it or they incur in enforcing its or their rights.  Executive further acknowledges and agrees that any claim Executive may have against the Company or any of its affiliates, whether under this Agreement or otherwise, will not be a defense to enforcement of the restrictions set forth in Section 6 and this Section 7 (or under the EPIIA).  If any covenants set forth in this Agreement are deemed invalid or unenforceable for any reason, it is the intention of the Executive and the Company that such covenants be equitably reformed or modified only to the extent necessary to render them valid and enforceable in all respects.  Executive further agrees that the each of the Company&#8217;s affiliates is a beneficiary of the restrictions set forth in Section 6 and this Section 7 and may enforce Section 6 and this Section 7.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 8. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cooperation Following Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees that following the Separation Date, Executive will  reasonably cooperate with the Company and its affiliates as to any and all claims, controversies, disputes, or complaints of which Executive has any knowledge or that may relate to Executive or his employment or other relationship with the Company or its affiliates.  Company will reimburse Executive for any reasonable out-of-pocket expenses incurred, following the Separation Date and with the advance written approval of the Company, pursuant to providing cooperation under this Section 8.  Such cooperation includes but is not limited to providing the Company and its affiliates with all information known to Executive related to such claims, controversies, disputes, or complaints.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Admission of Wrongdoing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nothing in this Agreement constitutes or should be construed to constitute an admission or evidence of any liability or fault or wrongdoing on the part of any Party or any Released Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law and Dispute Resolution</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement shall be governed by, subject to, and construed under the laws of the State of Delaware irrespective of any otherwise applicable principles of conflicts of law.  Executive and the Company agree that any disputes or claims arising under or related to this Agreement shall be resolved in accordance with the Arbitration section of the Offer Letter Agreement&#59; provided that, for the avoidance of doubt, (i)&#160;any other agreement between Executive and the Company or any of its affiliates, whether or not referenced in this Agreement, will be subject to the governing law, dispute resolution, and related provisions of such agreement, and (ii)&#160;nothing in this Agreement is intended to prevent any Party or other person or entity from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration.  Any action or claim that is determined cannot be subject to arbitration as a matter of law must be brought exclusively in the state or federal courts covering the State of Delaware, and each Party consents to the exclusive jurisdiction of such courts (and of the appropriate appellate courts) in any such proceeding and waives any objection to venue laid therein.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 11. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE PARTIES HERETO HEREBY WAIVE THE RIGHT TO A TRIAL BY JURY (AND WITH RESPECT TO ANY DISPUTE OR CLAIM SUBJECT TO ARBITRATION UNDER SECTION 10, ALSO WAIVE THE RIGHT TO A TRIAL IN COURT) WITH RESPECT TO ANY DISPUTES OR CLAIMS (WHETHER STATUTORY, COMMON LAW, OR OTHERWISE) ARISING OUT OF, IN CONNECTION WITH, OR RELATING TO THIS AGREEMENT.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Inurement and Assignment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement shall inure to the benefit of, and be binding upon, the Parties&#8217; heirs, executors, assigns, successors, and legal representatives.  Company, but not Executive, shall have the right to assign this Agreement or its rights under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Severability</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any provision of this Agreement (other than the general release in Section 2) is adjudged to be invalid for whatever reason, such invalidity shall not affect any other clause of this Agreement, and such clauses shall remain in full force and effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Entire Agreement&#59; Prior Agreements&#59; Amendment&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement contains the entire agreement of the Parties with respect to the subject matter hereof and supersedes any and all prior or contemporaneous agreements, oral or written, regarding the subject matter hereof.  This Agreement may not be changed, altered, waived, or otherwise amended except by mutual agreement in writing signed by the Parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 15.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Counterparts and Headings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be signed in counterparts and all counterparts taken together constitute one document.  The headings of the sections, subsections, paragraphs, subparagraphs, clauses, and subclauses of this Agreement are for convenience of reference only and shall not in any way affect the meaning or interpretation of any of the provisions hereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 409A</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties intend that this Agreement be interpreted in the least restrictive manner necessary to be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (&#8220;Section 409A&#8221;), to the extent applicable, and without resulting in any increase in the amounts owed hereunder by the Company.  Notwithstanding the foregoing or anything else herein to the contrary, neither the Company nor any of its affiliates nor any of their respective directors, officers, partners, members, employees, and advisors shall be held liable for any taxes, interest, or other amounts owed by Executive as a result of Section 409A.  Notwithstanding anything herein to the contrary, any &#8220;deferred compensation&#8221; (as defined in Section 409A) payable hereunder as a result of Executive&#8217;s termination of employment shall not be paid unless and until Executive has undergone a &#8220;separation from service&#8221; (as defined in Section 409A).  No reimbursement or in-kind benefit provided hereunder shall be subject to liquidation or exchange for another benefit and the amount available for reimbursement, or in-kind benefits provided, during any calendar year shall not affect the amount available for reimbursement, or in-kind benefits to be provided, in a subsequent calendar year.  Any reimbursement to which Executive is entitled hereunder shall be made no later than the last day of the calendar year following the calendar year in which such expenses were incurred.  If any right to payment hereunder is deemed a right to an installment payment, such right shall be treated as a right to a series of separate payments and, accordingly, each installment payment shall at all times be considered a separate and distinct payment for purposes of Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Consideration and Expiration of Offer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive is hereby advised to consult with counsel before executing this Agreement.  Executive hereby acknowledges and understands that he has the right to consider this Agreement for a period of at least twenty-one (21) days prior to execution.  Executive agrees that changes made to this Agreement, whether material or immaterial, do not restart the aforementioned twenty-one (21) day period.  Executive further acknowledges and understands that for seven (7) days following Executive&#8217;s execution of this Agreement, Executive may revoke this Agreement by providing written notice to the Company to be received within this seven-day period.  Any such revocation must be sent to Erik Atkisson, General Counsel and Chief Compliance Officer, Eiger BioPharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, CA 94306, or eatkisson&#64;eigerbio.com.  This Agreement shall not become effective or enforceable until the seven-day revocation period has expired without revocation.  Executive understands that the offer contained in this Agreement is considered withdrawn if Executive has not signed and returned to the Company a signed original of this Agreement such that it becomes effective and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="padding-right:6pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no longer subject to revocation by Executive (as described in this Section) no later than 60 days following the Separation Date (i.e., no later than February 12, 2023).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THE UNDERSIGNED, INTENDING TO BE LEGALLY BOUND BY THE FOREGOING TERMS, HEREBY APPLY THEIR SIGNATURES VOLUNTARILY AND WITH FULL UNDERSTANDING OF THE TERMS OF THIS AGREEMENT AND EXECUTE THIS AGREEMENT AS OF THE DATES SET FORTH BELOW.  EXECUTIVE UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, EXECUTIVE IS WAIVING ALL LEGAL CLAIMS THAT EXECUTIVE MAY HAVE AGAINST THE COMPANY AND RELATED PERSONS&#47;ENTITIES, AS DESCRIBED IN SECTIONS 2 AND 4 OF THIS AGREEMENT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David Cory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">02&#47;04&#47;23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Cory&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dated</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Thomas Dietz</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">02&#47;06&#47;23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Eiger BioPharmaceuticals, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dated</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Thomas Dietz</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">____________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">Chairman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">______________________</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>3
<FILENAME>eigr-2022x12x31ex1042.htm
<DESCRIPTION>EX-10.42
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia02edf29388342c6a7ebb6c16359f015_1"></div><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.42</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 9, 2023</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIA ELECTRONIC MAIL (davidapelian&#64;gmail.com)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Apelian, MD, PhD, MBA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3 Old Beach Glen Road<br>Boonton, New Jersey 07005</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Interim CEO Employment Terms</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Dr. Apelian,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eiger BioPharmaceuticals, Inc. (&#8220;Eiger&#8221; or the &#8220;Company&#8221;) is pleased to offer employment to you on the following terms of this Offer Letter Agreement (&#8220;Agreement&#8221;)&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Duties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be employed as the Interim Chief Executive Officer of the Company, reporting to the Board of Directors of the Company (&#8220;Board&#8221;).  During the Term of Employment, unless agreed to otherwise by the Company and you, you will be permitted to work primarily from your home located in New Jersey, provided that you may be required to travel in connection with your duties to the Company, including without limitation to the Company&#8217;s facility located in Palo Alto, California, and international locations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Term of Employment, you shall have the duties, authorities, and responsibilities as are required by your position, and such other duties, authorities, and responsibilities as may reasonably be assigned to you that are not inconsistent with your position as Interim Chief Executive Officer of the Company.  You must devote, full time, your effort, attention, and energies to the performance of your duties on behalf of the Company during the Term of Employment (as defined below).  During the Term of Employment, you may not directly or indirectly (i)&#160;engage, undertake, or, except as described at the end of this sentence, have an economic or ownership interest in any other employment or business, or (ii)&#160;become a director, officer, employee, agent, consultant, member, or partner of any other person or entity, provided that you may (w)&#160;participate in charitable, social, and civic activities, (x)&#160;manage personal investments for yourself and your immediate family members (subject to any then-in-effect applicable policies, rules, regulations, and codes of the Company), (y)&#160;hold (for investment purposes only and subject to any then-in-effect applicable policies, rules, regulations, and codes of the Company) marketable securities quoted at the time of acquisition on a recognized stock exchange in the United States or elsewhere being collectively not more than 2% of the issued share capital or units of a listed company or trust, and (z)&#160;retain the ownership interest (current stock options or stock of the company when exercised) you hold in BlueSphere Bio as of the date of this Agreement (subject to any capitalization modification that may occur). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compensation and Benefits</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your salary will be $627,000 per year ($52,250 monthly), less applicable payroll deductions and withholdings, during the Term of Employment. You will be paid semi-monthly, or in accordance with the Company&#8217;s compensation practices for other employees in place at the time.  Your base </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">salary shall serve as full compensation for your services to the Company during the Term of Employment.  Without limiting the foregoing, you will remain a director on the Board during the Term of Employment, but, in accordance with the Company&#8217;s policies, will not be entitled to any director fees or additional compensation for your role as a director. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, beginning with respect to calendar year 2023, you will be eligible for an annual bonus, targeted at 60% of your base salary, subject to applicable payroll deductions and withholdings (&#8220;Bonus&#8221;).  Whether you receive this Bonus, and the amount of any such Bonus, will be determined by the Company in its sole discretion based upon your performance, the Company&#8217;s performance, and such other criteria that the Board (or committee thereof) deems relevant in its sole discretion and will be prorated for any partial year during which you are employed (determined by multiplying the amount of such Bonus that would be due for the full year by a fraction, the numerator of which is the number of days during the year of termination that you are employed by the Company and the denominator of which is 365).  Except as provided below, any Bonus shall be paid within thirty (30) days after the Company&#8217;s determination that a Bonus shall be awarded or, if later, at the same time bonuses for such year are paid to other senior executives of the Company.  Notwithstanding the foregoing, in no event will the Bonus be paid later than March 15 of the year following the year to which the Bonus relates.  To be eligible for a Bonus, you must remain employed by the Company as of the date on which the applicable Bonus is paid or, with respect to the Bonus associated with  the Company&#8217;s 2023 year only, have been terminated by the Company without Cause, have resigned your employment for Good Reason, or have resigned due to the Company&#8217;s appointment of a full-time non-interim Chief Executive Officer.  If you are terminated or resign in 2023 under any of the circumstances described in the immediately preceding sentence, your Bonus for 2023 will be calculated based on your pro-rata target bonus and paid within thirty (30) days of the date of termination of your employment.  You will not be eligible for a Bonus if there exists a basis (as determined by the Board in its reasonable judgment) to terminate your employment for Cause as of the date the Bonus is awarded or paid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As an exempt salaried employee, you will be expected to be available and working during the Company&#8217;s regular business hours, and, without additional compensation, for such extended hours or additional time as appropriate to manage your responsibilities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During your employment, you will be entitled to participate in such benefit plans or programs of the Company, if any, as may be made available from time to time by the Company to its employees generally, subject to the terms of any applicable benefit plan or program documents.  Standard Company benefits currently include&#58; medical insurance, paid time off (PTO), 401(k), Employee Stock Purchase Plan (ESPP), and holidays.  Details about these benefits are provided in the Employee Handbook, Summary Plan Descriptions, and other benefit plan or program documents, which are available for your review.  Eiger may change your compensation and benefits from time to time in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will grant to you nonstatutory stock options to purchase up to 170,000 shares of the Company&#8217;s common stock pursuant to and in accordance with the Company&#8217;s Amended and Restated 2013 Equity Incentive Plan (the &#8220;Plan&#8221;), and applicable award agreement containing the terms and conditions of the grant (the &#8220;Options&#8221;).  The exercise price of the Options will be the last closing price of the Company&#8217;s common shares immediately prior to the approval of the grant by the Compensation Committee of the Board.  Provided that you remain employed by the Company in good standing as of such date, Options covering 113,900 shares of the Company&#8217;s common stock will vest upon the earlier to occur of (i) the six (6)-month anniversary of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective Date or (ii) the Company&#8217;s appointment of a full-time non-interim Chief Executive Officer of the Company.  The remaining Options covering 56,100 shares of the Company&#8217;s common stock will vest in six (6) equal monthly installments, following the Effective Date, in each case subject to your Continuous Service (as defined in the Plan) through the applicable vesting date.  The terms of the Plan and the Options award agreements provide that so long as you have no interruption in your Continuous Service (as defined in the Plan), your Options will continue to vest.  Company acknowledges that your continuing service on the Board without interruption following the termination of your employment as Interim Chief Executive Officer of the Company constitutes Continuous Service without interruption (the &#8220;Modified Service Rule&#8221;).  Notwithstanding the foregoing, upon the consummation of a Change in Control (as defined in the Plan) within one (1) year of the Effective Date and prior to any termination of your Continuous Service (as defined in the Plan but subject to the Modified Service Rule), all of the then-unvested portion of the Options shall vest.  In the event of your termination of employment by the Company for any reason other than for Cause and the termination of your Continuous Service (as defined in the Plan), both of which occur prior to the two (2)-year anniversary of the Effective Date, notwithstanding anything to the contrary in the Plan, the vested portion of the Options shall remain exercisable until the earliest of (y) one (1) year following the date of your termination of Continuous Service (as defined in the Plan), and (z) the expiration of the stated term of the Options pursuant to the applicable award agreement.  Except as otherwise provided herein, in the event of your termination of employment for any reason, the portion of the Options that have not then become vested and exercisable shall be automatically forfeited and cancelled for no value without any consideration being paid therefor and otherwise without any further action of the Company whatsoever.  The Options shall be subject to the terms and conditions in the Plan and the applicable award agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Term of Employment </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be employed by the Company pursuant to the terms of this Agreement for a term of six (6) months (&#8220;Initial Term&#8221;), commencing as of December 14, 2022 (the &#8220;Effective Date&#8221;).  Upon the expiration of the Initial Term and each Renewal Term, provided that your employment has not previously terminated, the term of this Agreement shall be automatically extended for successive three (3)-month periods (each, and together, a &#8220;Renewal Term&#8221;)&#59; provided, however, that either you or the Company may elect not to extend this Agreement by giving written notice to the other party at least one (1) week prior to any such renewal date, in which case this Agreement shall terminate at the end of the Initial Term or such Renewal Term, as applicable.  Notwithstanding the foregoing, you or Eiger may terminate your employment with Eiger at any time.  The period of time between the Effective Date and the termination of your employment hereunder (including the Initial Term and any Renewal Term) shall be referred to in this Agreement as the &#8220;Term of Employment.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Payments upon Termination</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon termination of your employment for any reason, you shall be paid all accrued but unpaid base salary through the date your employment terminates, reimbursement for ordinary and necessary business expenses incurred by you but not yet paid to you as of the date your employment terminates, and all accrued but unused vacation as of the date your employment terminates. Except as otherwise provided in this Agreement with respect to continued vesting subject to your Continuous Service, any unvested Company equity awards that you hold, including, but not limited to, any unvested options, shall terminate as of your termination date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, solely in the event that your employment is terminated by the Company without Cause or by you with Good Reason, subject to the immediately succeeding paragraph, you will be entitled to severance pay in an amount equal to your then-current base salary for a period equal to the Term of Employment, up to a maximum of twelve (12) months and subject to a minimum of six (6) months (&#8220;Severance&#8221;).  The Severance will be paid in the form of salary continuation, less applicable payroll deductions and withholdings, in accordance with the Company&#8217;s regular payroll schedule.  For the avoidance of doubt, in no event will you be entitled to any severance if there exists a basis (as determined by the Board in its reasonable judgment) to terminate your employment for Cause as of the date of termination.  The Severance is in lieu of, and not in addition to, any severance or similar payments or benefits to which you may be entitled in the event of termination of employment pursuant to any plan, program, policy, or practice of the Company or any of its affiliates. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your receipt of the Severance is conditional upon your compliance with your obligations to the Company and its affiliates (including without limitation under this Agreement and any other agreement with the Company or any of its affiliates) and your delivering to the Company a general release of claims in favor of the Company and related persons and entities in a form acceptable to the Company (including without limitation such provisions as nondisclosure and non-disparagement as the Company deems advisable) such that it becomes effective (with all revocation periods having expired without exercise) within 30 days following your termination date.  If you breach any of your obligations to the Company or any of its affiliates (including without limitation under this Agreement or any other agreement with the Company or any of its affiliates), in addition to any other remedies that may be available, you (i)&#160;will immediately return to the Company any portion of the Severance that has been paid to you, and (ii) will be entitled to no further Severance.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;Cause&#8221; shall mean that in the reasonable determination of the Board, you (i)&#160;commit, are indicted for, plead guilty to, or plead nolo contendere to any crime involving moral turpitude or any felony, (ii)&#160;participate in any fraud against the Company or any of its affiliates, (iii)&#160;willfully breach your duties to the Company or any of its affiliates, (iv)&#160;wrongfully disclose any trade secrets or other confidential information of the Company or any of its affiliates, or (v)&#160;breach any provision of this Agreement, any other agreement entered into with the Company or any of its affiliates, or any policy, rule, regulation, or code of the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean the occurrence of any of the following without your prior written consent&#58; (i) during the Initial Term, relocation of your principal place of employment of over 35 miles from your then-current principal place of employment immediately prior to such relocation&#59; (ii)&#160;a reduction in your base salary or Bonus target percentage of base salary, unless the salaries or bonus target percentages of all other senior executive officers of the Company are correspondingly and proportionately reduced&#59; or (iii)&#160;</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Change in Control (as defined in the Plan) occurs and the Company or its successor, as applicable, expressly repudiates and fails to perform this Agreement.</font><font style="background-color:#ffffff;color:#333333;font-family:'Cambria',sans-serif;font-size:14pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You cannot terminate your employment for Good Reason unless (i)&#160;you have provided written notice to the Company of the existence of the circumstances that you allege provide grounds for termination for Good Reason within thirty (30) days after the existence of such event, (ii)&#160;the Company has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances but fails to materially cure such circumstances, and (iii)&#160;you resign and actually terminate your employment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">within thirty (30) days after the end of such cure period.  Failure to comply with the immediately preceding sentence shall result in any claim of Good Reason to be irrevocably waived by you.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Protection of Confidential Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge and agree that the Company and its affiliates, in the course of performing their business activities, acquire and develop Confidential Information (as defined below) that provides the Company and its affiliates with a business advantage and that you have developed and been provided with, and will develop and be provided with, such Confidential Information during employment or other relationship with the Company or its affiliates.  You agree that you will not, directly or indirectly, at any time, use (whether on your own behalf or on behalf of any other person or entity) or disclose (to any person or entity) any Confidential Information, except as may be required to perform your duties in good faith to the Company during your employment or other engagement with the Company or as may be required by law.  &#8220;Confidential Information&#8221; means all confidential, proprietary, or non-public information (whether in written, electronic, or other form) of the Company or any of its affiliates (including without limitation any predecessors thereof), or third parties with whom the Company or its affiliates do business, including without limitation trade secrets&#59; business information&#59; information regarding the assets and affairs of the Company or its affiliates&#59; financial information&#59; operating methods or strategies&#59; marketing plans or strategies&#59; competitive know-how&#59; processes&#59; designs&#59; formulas&#59; developmental or experimental work&#59; forecasts&#59; client lists or other client-related information of any kind&#59; and any other information of a similar nature not already in the public domain.  Confidential Information also includes any information in relation to which the Company or any of its affiliates owes a duty of confidentiality.  Confidential Information shall not include any information that is in or enters the public domain, or is or becomes generally known in the industry in which the Company operates, other than by disclosure by you or any other person or entity in violation of any confidentiality or other obligation.  You will take all reasonable and necessary precautions to prevent disclosure of Confidential Information to unauthorized persons or entities and will use your best efforts to ensure that a third party does not disclose any Confidential Information.  In the event you are required by law to disclose Confidential Information, you will (unless prohibited by law) (i) immediately (and prior to such disclosure) notify the Company and cooperate with the Company in any efforts by the Company to oppose such disclosure, and (ii)&#160;disclose only that portion of the Confidential Information that you are advised by written opinion of counsel is legally required to be disclosed and exercise best efforts to ensure that such Confidential Information will be afforded confidential treatment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, in your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality.  Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have no duties or obligations to any person or entity, by agreement or otherwise, that will prevent or impair your ability to enter into, and fully perform your duties and responsibilities under, this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Protection of Intellectual Property</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You represent and warrant that there are no Inventions that you have, alone or jointly with others, made prior to the commencement of your employment or other relationship with the Company or its affiliates that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (collectively, &#8220;Prior Inventions&#8221;).  Notwithstanding the foregoing, if, in the course of your employment or other relationship with the Company or its affiliates, you incorporate a Prior Invention into a product, process, or machine of the Company or its affiliates, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, fully transferable, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, sell, and otherwise use such Prior Invention, in any manner, for any purpose, and in any medium. Notwithstanding the foregoing, you agree that you will not incorporate, or permit to be incorporated, Prior Inventions in any Company IP (defined below) without the Company&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to your agreement below to assign all of your right, title, and interest in and to any particular Company IP to a third party (including without limitation the United States) as directed by the Company, and except for the Prior Inventions and those Inventions that qualify fully under the provisions of California Labor Code 2870 (as set forth in Exhibit 1), you agree that all Inventions and Proprietary Rights that (i) are created or otherwise arise during the term of your employment or other engagement with the Company, (ii) are created as a result of, or otherwise arise in connection with, use of the Company&#8217;s or its affiliates&#8217; facilities, equipment, trade secrets, or other resources, or (iii)&#160;otherwise relate to your employment or the work that you perform for the Company or its affiliates, whether before, on, or after the Effective Date (all such Inventions and Proprietary Rights, collectively, the &#8220;Company IP&#8221;), shall be the sole and exclusive property of the Company.  All Company IP that is created by you and that is copyrightable subject matter shall be considered a &#8220;work made for hire&#8221; to the extent permitted under applicable copyright law and will be considered the sole property of the Company.  With respect to that Company IP that is not considered a &#8220;work made for hire,&#8221; you hereby assign to the Company and agree to assign to the Company in the future (when any such Company IP is first reduced to practice or first fixed in a tangible medium, as applicable), without any requirement of further consideration, all your right, title, and interest in and to any and all such Company IP and all moral rights in connection therewith.  To the extent such moral rights cannot be assigned under applicable law, you hereby waive such moral rights and consent to any action of the Company that would violate such moral rights in the absence of such consent. You will, at the Company&#8217;s request, promptly execute a written assignment to the Company of any such Company IP and take any and all other actions that the Company deems necessary or desirable to permit the Company to further evidence or perfect the assignments.  If any Company IP incorporates any technology or right that is owned or licensed by you and that is not assigned to the Company under this Agreement (the &#8220;Excluded IP&#8221;), you hereby grant to the Company a nonexclusive, royalty-free, irrevocable, perpetual, fully transferable, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, sell, and otherwise use such Excluded IP, in any manner, for any purpose and in any medium.  You also will preserve all Company IP as part of the Confidential Information of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will promptly and fully disclose in writing to the Company all Inventions and Proprietary Rights during your employment or other engagement with the Company or any of its affiliates and for one (1) year after such employment or other engagement concludes, including any that may be considered Excluded IP.  You agree to assist in every proper way and to execute those documents and take such acts as are reasonably requested by the Company to obtain, sustain, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from time to time enforce patents, copyrights, and other rights and protections relating to Company IP in the United States or any other country.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You also agree to assign all of your right, title, and interest in and to any particular Company IP to a third party, including without limitation the United States, as directed by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You represent and warrant that (i) the Company IP assigned or licensed by you hereunder will be entirely created by and wholly original with and to you, or shall be in the public domain, (ii) the Company IP assigned or licensed by you hereunder does not and will not infringe upon, misappropriate, or otherwise violate any third party&#8217;s intellectual property or other rights, (iii)&#160;the use of the Company IP assigned or licensed by you hereunder, by the Company, its affiliates, or their respective employees, representatives, distributors, or agents will not infringe, misappropriate, or otherwise violate any intellectual property or other right of any third party, and (iv) you shall obtain any authorizations necessary to allow the Company to, and the Company shall possess all rights necessary to, fully exploit the Company IP.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;Proprietary Rights&#8221; shall mean all trade secret, patent, copyright, trademark, mask work, and other intellectual property rights throughout the world.  For purposes of this Agreement, &#8220;Inventions&#8221; shall mean all trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Return of Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the termination of the Term of Employment, or upon the earlier request of the Company, you will return to the Company all property of the Company or any of its affiliates in your possession, custody, or control, including without limitation documents, data, and equipment (and any copies thereof) of any nature and in whatever medium and will not keep any such property, whether or not it contains or pertains to any Company IP or Confidential Information.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Disparagement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During and after the Term of Employment, neither you nor any person acting on your behalf shall disparage or cause to be disparaged, whether directly or indirectly, the Company or its affiliates, or any of their products, services, officers, directors, partners, members, owners, or employees, in any forum or through any medium of communication.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Permitted Disclosures</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing in this Agreement or otherwise shall prohibit you from (i)&#160;reporting possible violations of federal law or regulation to any government agency or entity or self-regulatory organization or making disclosures that are protected under the whistleblower provisions of federal law or regulation, (ii) supplying truthful information to any government authority or in response to any lawful subpoena or other legal process, (iii)&#160;disclosing the details relating to a claim of discrimination, retaliation, or harassment, or (iv)&#160;disclosing or discussing conduct with respect to a sexual assault dispute or sexual harassment dispute (to the extent prohibited by the Speak Out Act).  In addition, notwithstanding anything in this Agreement or otherwise, in accordance with the Defend Trade Secrets Act of 2016, (i) you shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (a) is made (I)&#160;in confidence to a federal, state, or local government official, either directly or indirectly, or to an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">attorney, and (II)&#160;solely for the purpose of reporting or investigating a suspected violation of law&#59; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal, and (ii) if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose a trade secret to your attorney and use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal and do not disclose the trade secret except pursuant to court order. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Remedies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You acknowledge and agree that in the event that you breach any of the provisions in the sections of this Agreement labeled Protection of Confidential Information, Protection of Intellectual Property, Return of Property, or Non-Disparagement (collectively, &#8220;Specified Sections&#8221;), the Company and its affiliates shall suffer immediate, irreparable injury and will, therefore, be entitled to injunctive relief, in addition to any other damages to which it or they may be entitled, as well as the costs and reasonable legal fees it or they incur in enforcing its or their rights.  You further acknowledge and agree that any claim you may have against the Company or any of its affiliates, whether under this Agreement or otherwise, will not be a defense to enforcement of the restrictions set forth in the Specified Sections, and the circumstances of the termination of your employment or other relationship with the Company will have no impact on your obligations under the Specified Sections.  If any covenants set forth in this Agreement are deemed invalid or unenforceable for any reason, it is the intention of you and the Company that such covenants be equitably reformed or modified only to the extent necessary to render them valid and enforceable in all respects.  You further agree that each of the Company&#8217;s affiliates is a beneficiary of the restrictions set forth in the Specified Sections and may enforce the Specified Sections.  You further agree that the restrictions set forth in the Specified Sections are in addition to, and not in lieu of, any non-competition, non-solicitation, protection of confidential information or intellectual property, return of property, non-disparagement, or other restrictive covenants by which you may be bound in favor of the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Cooperation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You agree that during and following the Term of Employment, you will cooperate fully with the Company and its affiliates as to any and all claims, controversies, disputes, or complaints of which you have any knowledge or that may relate to you or your employment or other relationship with the Company or its affiliates.  Company will reimburse you for any reasonable out-of-pocket expenses incurred, following the Term of Employment and with the advance written approval of the Company, pursuant to your duties under this paragraph.  Such cooperation includes but is not limited to providing the Company and its affiliates with all information known to you related to such claims, controversies, disputes, or complaints.  Company will consider your reasonable professional and personal commitments made known to it by you and endeavor to schedule such cooperation required under this paragraph (to the extent it is able to control such scheduling) at times that will not unreasonably interfere with such commitments. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 409A</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5), and 1.409A-1(b)(9), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and this Agreement will be construed to the greatest extent possible as consistent with those provisions.  For purposes of Code Section 409A (including without limitation for purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)), your right to receive any installment payments under this Agreement (whether severance payments, reimbursements, or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.  Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your &#8220;separation from service&#8221; within the meaning of Code Section 409A to be a &#8220;specified employee&#8221; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon such separation from service set forth herein or under any other agreement with the Company are deemed to be &#8220;deferred compensation,&#8221; then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to you prior to the earliest of (i) the expiration of the six (6)-month period measured from the date of your &#8220;separation from service&#8221; (within the meaning of Code Section 409A) with the Company, (ii)&#160;the date of your death, or (iii)&#160;such earlier date as permitted under Section 409A without the imposition of adverse taxation.  Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement.  No interest shall be due on any amounts so deferred.  In no event whatsoever shall the Company be liable for any additional tax, interest, or penalty that may be imposed on you by Code Section 409A or damages for failing to comply with Code Section 409A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notice</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any notice, request, or other communication required or permitted to be delivered under this Agreement must be in writing and will be considered received as of the date delivered if delivered in person or by e-mail (or similar electronic transmission), on the next business day if sent by a nationally recognized overnight courier service, and on the second business day if mailed by registered mail, return receipt requested, postage prepaid.  If to you, the notice, request, or other communication must be addressed and sent to you at your residential or e-mail address as then on file with the Company.  If to the Company, the notice, request, or other communication must be addressed to the General Counsel, Eiger BioPharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, California 94306 and legal&#64;eigerbio.com.  You or the Company may change your or its, as applicable, address(es) provided in this paragraph by notice provided in accordance with this paragraph.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall be governed by, subject to, and construed under the laws of the State of Delaware irrespective of any otherwise applicable principles of conflicts of law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Arbitration</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, interpretation, or otherwise of this Agreement, your employment or other relationship with the Company or any of its affiliates (including without limitation any disputes or claims arising out of state or federal discrimination laws (excluding any sexual assault dispute </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or sexual harassment dispute to the extent prohibited by the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021), and any disputes or claims against any officers, directors, managers, partners, members, owners, employees, or other representatives of the Company or any of its affiliates), or the termination of your employment or other relationship with the Company or any of its affiliates, whether arising before, on, or after the Effective Date, shall be resolved, to the fullest extent permitted by law, by final, binding, and confidential arbitration conducted by JAMS or its successor, under JAMS&#8217; then-applicable rules and procedures for employment disputes before a single neutral arbitrator (available upon request and also currently available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  In addition, all claims, disputes, or causes of action covered under this paragraph, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class, collective, or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative, collective, or class proceeding.  To the extent that the preceding sentences regarding class, collective, or representative claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought as a class, collective, or representative proceeding shall proceed in a court of law (as described in the following paragraph) rather than by arbitration.  This paragraph shall not apply to any action or claim that is determined cannot be subject to mandatory arbitration as a matter of law.  In the event you or the Company intends to bring multiple claims, including one or more claims that are determined cannot be subject to mandatory arbitration as a matter of law, the claim or claims that are determined cannot be subject to mandatory arbitration as a matter of law may be publicly filed with a court (as described in the following paragraph), while any other claims will remain subject to mandatory arbitration.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall&#58; (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law, and (ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based.  The arbitrator shall be authorized to award all relief that you or the Company would be entitled to obtain in a court of law.  The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law.  The parties shall be responsible for paying their own attorneys&#8217; fees and all other costs they incur related to any arbitration proceeding, except to the extent that applicable law provides for the shifting or the recovery of such fees and costs.  Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  The arbitration will be conducted in accordance with the Federal Arbitration Act, and any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any action or claim that is determined cannot be subject to arbitration as a matter of law, and any claim for injunctive relief to prevent irreparable harm pending the conclusion of any arbitration, must be brought exclusively in the state or federal courts covering the State of Delaware, and each of you and the Company consents to the exclusive jurisdiction of such courts (and of the appropriate appellate courts) in any such proceeding and waives any objection to venue laid therein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, any other agreement between you and the Company or any of its affiliates, whether or not referenced in this Agreement, will be subject to the governing law, dispute resolution, and related provisions of such agreement.  Without limiting the foregoing, the Employee Confidential Information and Inventions Assignment Agreement that you sign as a condition of your employment (as described below) will be subject to the governing law, dispute resolution, and related provisions of such agreement, except that, notwithstanding anything therein to the contrary, if you and the Company or any of its affiliates are or become involved in or file any proceeding arising under any non-competition, non-solicitation, protection of confidential information or intellectual property, return of property, non-disparagement, or other restrictive covenant obligations in any federal or state court located in Delaware, any similar claims or claims arising under similar provisions of any agreement (including without limitation any claims under the Employee Confidential Information and Inventions Assignment Agreement) may be brought in (and each party agrees, upon the request of the other party, to bring or further pursue such claims only in) such state or federal court located in Delaware.  You and the Company agree that a federal or state court located in Delaware is an appropriate forum for any such claims.  You and the Company hereby consent to the jurisdiction of such courts (and of the appropriate appellate courts) in any such proceeding and waive any objection to venue laid therein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">WAIVER OF JURY TRIAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">YOU AND THE COMPANY HEREBY WAIVE THE RIGHT TO A TRIAL BY JURY (AND WITH RESPECT TO ANY DISPUTE OR CLAIM SUBJECT TO ARBITRATION UNDER THIS AGREEMENT, ALSO WAIVE THE RIGHT TO A TRIAL IN COURT) WITH RESPECT TO ANY DISPUTES, CLAIMS, OR CAUSES OF ACTION (WHETHER STATUTORY, COMMON LAW, OR OTHERWISE) ARISING FROM OR RELATING TO THE ENFORCEMENT, BREACH, PERFORMANCE, INTERPRETATION, OR OTHERWISE OF THIS AGREEMENT, YOUR EMPLOYMENT OR OTHER RELATIONSHIP WITH THE COMPANY OR ANY OF ITS AFFILIATES, OR THE TERMINATION OF YOUR EMPLOYMENT OR OTHER RELATIONSHIP WITH THE COMPANY OR ANY OF ITS AFFILIATES.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This offer is contingent upon satisfactory proof of your right to work in the United States.  You will also be expected to abide by the policies, rules, regulations, and codes of the Company and its affiliates as they may be in effect from time to time, including without limitation the Company&#8217;s Employee Handbook, as a condition of your employment.  You acknowledge that you are aware of Section 304 (Forfeiture of Certain Bonuses and Profits) of the Sarbanes-Oxley Act of 2002 and the right of the Company to be reimbursed for certain payments to you in compliance therewith. You acknowledge and agree that you will be subject to any other clawback policy that may be adopted by the Board before or during the Term of Employment.  As a condition of your employment, you are also required to sign the Company&#8217;s Employee Confidential Information and Inventions Assignment Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, together with your Employee Confidential Information and Inventions Assignment Agreement, and any agreements governing your equity awards, forms the complete and exclusive statement of your employment agreement with the Company.  It supersedes any other agreements or promises made to you by anyone, whether oral or written, including but not limited to the Consulting Agreement between the Company and Medallion Biopharma </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Consulting, LLC dated October 24, 2022 except as to those provisions which survive termination.  Changes in your employment terms, other than those changes expressly reserved to the Company&#8217;s discretion in this Agreement, require a written modification signed by an authorized officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement (i) may be modified or waived only by a writing signed by both you and an authorized officer of the Company, (ii) shall be binding upon and inure to the benefit of you and the Company and your and its respective heirs, executors, administrators, personal representatives, successors, and permitted assigns, (iii) is not assignable or transferable by you, but is assignable and transferable (in whole or in part) by the Company to an affiliate or successor of the Company, and (iv) may be executed in counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument.  The terms of this Agreement are severable, and the invalidity of any provision of this Agreement shall not affect the validity of any other provision.  All invalid provisions shall be deemed severed.  This Agreement should not be construed for or against any party.  The headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please sign and date this Agreement below if you wish to accept these terms to govern your employment at Eiger.  We look forward to your favorable reply and to a productive and enjoyable work relationship.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Tom Dietz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tom Dietz, Ph.D.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chair, Board of Directors </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and agreed&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; David Apelian, M.D., Ph.D.</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:105pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:105pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">01&#47;09&#47;2023</font></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">David Apelian</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Date</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:109.44pt;width:100%"><div style="margin-bottom:12pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">California Labor Code &#167; 2870</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) Relate at the time of conception or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) Result from any work performed by the employee for the employer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>4
<FILENAME>eigr-2022x12x31ex1043.htm
<DESCRIPTION>EX-10.43
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i12abbefe132342628abcab443c129105_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#4f81bd;font-family:'Cambria',sans-serif;font-size:13pt;font-weight:700;line-height:100%">Second Amendment to Lease</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Second Amendment to Lease (&#8220;Amendment&#8221;) is made and entered January 23, 2023 (the &#8220;Amendment Effective Date&#8221;) by and between McDonald Family Co. LLC (&#8220;Lessor&#8221;) and Eiger Pharmaceuticals, Inc. (&#8220;Lessee&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Lessor and Lessee are parties to that certain Standard Multi-Tenant Office Lease &#8211; Net dated October 17, 2017, as amended with Addendum to Lease dated December 8, 2017 and as amended with First Amendment to Lease dated April 26, 2018 (the &#8220;Lease&#8221;) for the premises commonly known as 2171 Park Blvd. Palo Alto, California (the &#8220;Premises&#8221;)&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in accordance with Paragraph 39 of the Lease, Lessor and Lessee now desire to amend the Lease by extending the Term and changing the Expiration Date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in consideration of the Premises and mutual covenants herein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">set forth and for other good and valuable consideration, Lessor and Lessee hereby agree to amend the Lease as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Effective as of the Amendment Effective Date, Paragraph 1.3, the Term of the Lease is hereby extended for an additional year, amending the Expiration Date from February 28, 2023 to February 28, 2024.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Effective as of March 1, 2023, Paragraph 51, Base Rent (NNN) in the Lease is hereby amended to add the following Base Rent for the extended term of the Lease&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RENT&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Total rent for the period from March 1, 2023 to February 28, 2024 will be $496,192.20 or Four Hundred Ninety Six Thousand One Hundred and Ninety Two Dollars and Twenty Cents.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:53.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Months</font></div></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SF</font></div></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NNN Rate</font></div></td><td colspan="3" style="border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:36.12pt;padding-right:36.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Monthly Total</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1-12</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font><br></font></div><div style="padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8029</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5.15</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font><br></font></div><div style="padding-left:29.75pt;padding-right:29.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$41,349.35</font></div></td></tr></table></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All rents shall be paid to Lessor or his authorized agent, at the following address McDonald Family Co. LLC.  At P.O. Box 60233 Station A, Palo Alto, CA 94306, or at such other places as may be designated by Lessor from time to time. </font></div><div><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Effective as of March 1, 2023, Paragraph 55.1 is amended to include the following Operating Expenses for the extended term of the Lease&#58;</font></div><div style="padding-left:54pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OPERATING EXPENSES&#58;  $.95&#47;sqft. X 8029 sqft or $7,627.55 per month.</font></div><div><font><br></font></div><div style="padding-left:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COST OF LIVING ADJUSTMENT&#58;  3% </font></div><div style="padding-left:58.5pt"><font><br></font></div><div style="padding-left:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OPTION TO RENEW&#58;  1 Year</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">All other terms and conditions to the Lease shall remain in full force and effect except to the extent modified in this Amendment.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ENTIRE AGREEMENT&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The foregoing constitutes the entire agreement between the parties and may be modified only in writing and signed by both parties. ____________________________________________________________________ </font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ACCEPTANCE</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The parties hereto have executed this Amendment on the dates specified above their respective signature.</font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:47.500%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;2&#47;16&#47;2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY LESSOR&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Brion McDonald&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Brion McDonald&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Its Manager for McDonald Family Co LLC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY LESSEE&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; David Apelian &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">David Apelian&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Eiger Biopharmaceuticals Inc. CEO    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;2&#47;14&#47;2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="display:inline-block;max-width:5.000%;min-width:4.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:47.500%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>eigr-2022x12x31ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i83256c483c1f4ee8bbad44af2349934d_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.696%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:35.45pt;text-indent:-35.45pt"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 23.1</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We consent to the incorporation by reference in the registration statements (No. 333-251497) on Form S-3 and (Nos.333-263460, 333-258509, 333-254039, 333-237156, 333-230287, 333-224872, 333-219936, 333-211009, 333-203154, 333-193662) on Form S-8 of our report dated March&#160;16,&#160;2023, with respect to the consolidated financial statements of Eiger BioPharmaceuticals, Inc.</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; KPMG LLP&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">San Francisco, California<br>March&#160;16,&#160;2023</font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.902%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">KPMG LLP, a Delaware limited liability partnership and a member firm of<br>the KPMG global organization of independent member firms affiliated with<br>KPMG International Limited, a private English company limited by guarantee.</font></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>eigr-2022x12x31ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id0c5b6f51da648a8841ba369b23fb5a7_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Interim President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Apelian, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Eiger BioPharmaceuticals, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;16, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Apelian</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Apelian</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Interim President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>eigr-2022x12x31ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifcd71effe43a440baaeae40ce2b1da56_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michelle Maynard, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Eiger BioPharmaceuticals, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; March&#160;16, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Michelle Maynard</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michelle Maynard</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Vice President, Finance</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Acting Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>eigr-2022x12x31ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6654b9e36ada4a149d97b80e421b6162_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Apelian Interim President and Chief Executive Officer of Eiger BioPharmaceuticals, Inc. (the &#8220;Company&#8221;), and Michelle Maynard, Acting Principal Accounting Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; March&#160;16, 2023</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Apelian</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Apelian</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director, Interim President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Michelle Maynard</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Michelle Maynard</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Vice President, Finance </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Acting Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Eiger BioPharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#8221;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>eigr-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5bf4cbbb-10e9-4fbc-b4bb-3a741d1bed32,g:0d7ff615-48b4-4d72-96cc-45180aee1521-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eigr="http://www.eigerbio.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eigerbio.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eigerbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.eigerbio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.eigerbio.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000009 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.eigerbio.com/role/DescriptionofBusiness">
        <link:definition>0000010 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.eigerbio.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.eigerbio.com/role/BalanceSheetComponents">
        <link:definition>0000013 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandProductDevelopmentAgreements" roleURI="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreements">
        <link:definition>0000014 - Disclosure - License, Collaboration, and Product Development Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetPurchaseAgreementsandRelatedLicenseAgreements" roleURI="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreements">
        <link:definition>0000015 - Disclosure - Asset Purchase Agreements and Related License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofAssets" roleURI="http://www.eigerbio.com/role/SaleofAssets">
        <link:definition>0000016 - Disclosure - Sale of Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.eigerbio.com/role/Debt">
        <link:definition>0000017 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.eigerbio.com/role/StockholdersEquity">
        <link:definition>0000018 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.eigerbio.com/role/StockBasedCompensation">
        <link:definition>0000019 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.eigerbio.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.eigerbio.com/role/LegalMatters">
        <link:definition>0000021 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.eigerbio.com/role/CommitmentsandContingencies">
        <link:definition>0000022 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosures" roleURI="http://www.eigerbio.com/role/RelatedPartyDisclosures">
        <link:definition>0000023 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.eigerbio.com/role/SubsequentEvents">
        <link:definition>0000024 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.eigerbio.com/role/FairValueMeasurementsTables">
        <link:definition>0000027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsTables">
        <link:definition>0000028 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.eigerbio.com/role/DebtTables">
        <link:definition>0000029 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.eigerbio.com/role/StockholdersEquityTables">
        <link:definition>0000030 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.eigerbio.com/role/StockBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.eigerbio.com/role/IncomeTaxesTables">
        <link:definition>0000032 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail">
        <link:definition>0000034 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000035 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails" roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>0000037 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail" roleURI="http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail">
        <link:definition>0000038 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" roleURI="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail">
        <link:definition>0000039 - Disclosure - Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofInventoryDetail" roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail">
        <link:definition>0000040 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000041 - Disclosure - Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail">
        <link:definition>0000042 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail" roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail">
        <link:definition>0000043 - Disclosure - Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail">
        <link:definition>0000044 - Disclosure - License, Collaboration, and Product Development Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail">
        <link:definition>0000045 - Disclosure - Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofAssetsAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail">
        <link:definition>0000046 - Disclosure - Sale of Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/DebtAdditionalInformationDetail">
        <link:definition>0000047 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail" roleURI="http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail">
        <link:definition>0000048 - Disclosure - Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofMaturitiesofLongtermDebtDetail" roleURI="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail">
        <link:definition>0000049 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>0000050 - Disclosure - Stockholders&#8217; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockReservedForFutureIssuancesDetails" roleURI="http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails">
        <link:definition>0000051 - Disclosure - Stockholders&#8217; Equity - Common Stock Reserved For Future Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetail" roleURI="http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail" roleURI="http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail">
        <link:definition>0000054 - Disclosure - Stock-Based Compensation - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail" roleURI="http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail">
        <link:definition>0000055 - Disclosure - Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail" roleURI="http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail">
        <link:definition>0000056 - Disclosure - Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>0000057 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail">
        <link:definition>0000058 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail">
        <link:definition>0000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail" roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail">
        <link:definition>0000060 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMattersDetails" roleURI="http://www.eigerbio.com/role/LegalMattersDetails">
        <link:definition>0000061 - Disclosure - Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000062 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail" roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail">
        <link:definition>0000063 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1" roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1">
        <link:definition>0000063 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetail" roleURI="http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail">
        <link:definition>0000064 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="eigr_OtherRevenueMember" abstract="true" name="OtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" abstract="false" name="StockIssuedDuringPeriodSharesStockIssuedToLender" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_PurchaseAgreementMember" abstract="true" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ProductDevelopmentAgreementAbstract" abstract="true" name="ProductDevelopmentAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_BaseSalaryAndTargetBonusContinuationPeriod" abstract="false" name="BaseSalaryAndTargetBonusContinuationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_ShareBasedPaymentArrangementTrancheFourMember" abstract="true" name="ShareBasedPaymentArrangementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AssetPurchaseAgreementContingentConsiderationReceivable" abstract="false" name="AssetPurchaseAgreementContingentConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_PRFCollaborationAgreementMember" abstract="true" name="PRFCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_IncentiveBasedRegulatoryMilestoneFees" abstract="false" name="IncentiveBasedRegulatoryMilestoneFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AmendedTrancheBMember" abstract="true" name="AmendedTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" abstract="true" name="AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_PrepaidResearchCosts" abstract="false" name="PrepaidResearchCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DebtInstrumentExitFeePayablePercentage" abstract="false" name="DebtInstrumentExitFeePayablePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eigr_AvexitidePurchaseAgreementMember" abstract="true" name="AvexitidePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_BMSTransactionMember" abstract="true" name="BMSTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_GainLossFromSaleOfPriorityReviewVoucher" abstract="false" name="GainLossFromSaleOfPriorityReviewVoucher" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" abstract="false" name="OneTimePaymentToBeMadeOnAssetPurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_OfferingCostsIncurredNotYetPaid" abstract="false" name="OfferingCostsIncurredNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_InnovatusStockPurchaseAgreementMember" abstract="true" name="InnovatusStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_SecuredDebtTrancheAMember" abstract="true" name="SecuredDebtTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_IncomeLossRelatedToAssetPurchaseAgreement" abstract="false" name="IncomeLossRelatedToAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_AssetPurchaseAgreementTextBlock" abstract="false" name="AssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="eigr_SharesAvailableForGrantAbstract" abstract="true" name="SharesAvailableForGrantAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_DebtInstrumentExitFee" abstract="false" name="DebtInstrumentExitFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ClosingPriceOfCommonStock" abstract="false" name="ClosingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="eigr_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AmendedOxfordLoanMember" abstract="true" name="AmendedOxfordLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_NumberOfFormerExecutives" abstract="false" name="NumberOfFormerExecutives" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eigr_COBRAContinuationCoveragePeriod" abstract="false" name="COBRAContinuationCoveragePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_FairValueTransfersBetweenLevelsTransfersAmount" abstract="false" name="FairValueTransfersBetweenLevelsTransfersAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ExpertConsultantFeesAndPassThroughCosts" abstract="false" name="ExpertConsultantFeesAndPassThroughCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_MasterManufacturingServicesAgreementMember" abstract="true" name="MasterManufacturingServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ProceedsRelatedToAssetPurchaseAgreement" abstract="false" name="ProceedsRelatedToAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_PerformanceStockUnitsPSUMember" abstract="true" name="PerformanceStockUnitsPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" abstract="false" name="MaximumEquityDebtWarrantsIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_PercentageOfPurchasePrice" abstract="false" name="PercentageOfPurchasePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eigr_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_PaymentForAssetPurchaseAgreement" abstract="false" name="PaymentForAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_NonRefundableIssueFee" abstract="false" name="NonRefundableIssueFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_SecuredDebtTrancheBAndCMember" abstract="true" name="SecuredDebtTrancheBAndCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_VestingOfOptionsToPurchaseCommonStock" abstract="false" name="VestingOfOptionsToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_InnovatusLoanMember" abstract="true" name="InnovatusLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_RestrictedAndPerformanceStockUnitsOutstanding" abstract="false" name="RestrictedAndPerformanceStockUnitsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_VariableRateComponentOneMember" abstract="true" name="VariableRateComponentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_UpFrontCashPayments" abstract="false" name="UpFrontCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" abstract="true" name="AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_LicenseAgreementPotentialMilestonePayments" abstract="false" name="LicenseAgreementPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_OxfordLoanAmendmentMember" abstract="true" name="OxfordLoanAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_PatheonIncMember" abstract="true" name="PatheonIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_CollaborationAgreementInitialTerm" abstract="false" name="CollaborationAgreementInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_DebtInstrumentPercentOfInterestDue" abstract="false" name="DebtInstrumentPercentOfInterestDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eigr_SecuredDebtTrancheBMember" abstract="true" name="SecuredDebtTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" abstract="false" name="IncreaseInDeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ProceedsFromSaleOfPriorityReviewVoucher" abstract="false" name="ProceedsFromSaleOfPriorityReviewVoucher" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DebtInstrumentInterestPaymentPeriod" abstract="false" name="DebtInstrumentInterestPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" abstract="false" name="StockIssuedDuringPeriodValueProductDevelopmentAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_NumberOfAccounts" abstract="false" name="NumberOfAccounts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" abstract="false" name="ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AbbvieAssetPurchaseAgreementMember" abstract="true" name="AbbvieAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" abstract="false" name="ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_MilestoneObligations" abstract="false" name="MilestoneObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" abstract="false" name="OtherPrepaidExpenseAndOtherAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_CommonStockValueAvailableForFutureIssuance" abstract="false" name="CommonStockValueAvailableForFutureIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DebtInstrumentUnamortizedAdditionalExitFees" abstract="false" name="DebtInstrumentUnamortizedAdditionalExitFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" abstract="false" name="MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="eigr_DevelopmentPhaseThreeMember" abstract="true" name="DevelopmentPhaseThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" abstract="true" name="RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" abstract="false" name="PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eigr_CollaborativeArrangementRenewalTerm" abstract="false" name="CollaborativeArrangementRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_LicenseAgreementMilestonePaymentsPaid" abstract="false" name="LicenseAgreementMilestonePaymentsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_OptionsIssuedAndOutstanding" abstract="false" name="OptionsIssuedAndOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" abstract="false" name="AccruedResearchAndDevelopmentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" abstract="false" name="EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AutorisationTemporaireDUtlisationMemberMember" abstract="true" name="AutorisationTemporaireDUtlisationMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_CashEquivalentsAmortizedCost" abstract="false" name="CashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_SecuredDebtTrancheCMember" abstract="true" name="SecuredDebtTrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_PostEmploymentBenefitAcceleratedVesting" abstract="false" name="PostEmploymentBenefitAcceleratedVesting" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandThirteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" abstract="true" name="CashEquivalentsAndInvestmentSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" abstract="false" name="MinimumCashBalanceOfFaceValueOfLoanPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_AggregateCommonStockConsiderationValue" abstract="false" name="AggregateCommonStockConsiderationValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_RoyaltyReceivablePercentageOnNetSales" abstract="false" name="RoyaltyReceivablePercentageOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eigr_PrepaidContractManufacturingCosts" abstract="false" name="PrepaidContractManufacturingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_OxfordLoanFifthAmendmentMember" abstract="true" name="OxfordLoanFifthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" abstract="true" name="OptionsGrantedToEmployeesAndNonEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_OrphanDrugCreditCarryforwardMember" abstract="true" name="OrphanDrugCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_OxfordLoanMember" abstract="true" name="OxfordLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_DevelopmentMilestoneObligations" abstract="false" name="DevelopmentMilestoneObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ProductRevenueReserves" abstract="false" name="ProductRevenueReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DevelopmentAndRegulatoryMilestonesMember" abstract="true" name="DevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_EarlyAccessProgramTerm" abstract="false" name="EarlyAccessProgramTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" abstract="true" name="RestrictedStockUnitsAndPerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_MYDICARMember" abstract="true" name="MYDICARMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_StockIssuedDuringPeriodValueStockIssuedToLender" abstract="false" name="StockIssuedDuringPeriodValueStockIssuedToLender" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DebtInstrumentUnamortizedExitFees" abstract="false" name="DebtInstrumentUnamortizedExitFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DeferredTaxAssetDepreciationAndAmortization" abstract="false" name="DeferredTaxAssetDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" abstract="false" name="MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_AmendedTrancheAMember" abstract="true" name="AmendedTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" abstract="false" name="ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_ContractManufacturingCostsCurrent" abstract="false" name="ContractManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ProductDevelopmentAgreementMember" abstract="true" name="ProductDevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" abstract="true" name="AssetPurchaseAgreementAndRelatedLicenseAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="eigr_TheragenePharmaceuticalsIncMember" abstract="true" name="TheragenePharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_OptionsToPurchaseOfCommonStock" abstract="false" name="OptionsToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" abstract="false" name="SaleOfAssetsNumberOfCommonStockSharesReceived" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" abstract="true" name="HoldersOfTenPercentOrMoreOfVotingPowerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_DevelopmentPhaseTwoMember" abstract="true" name="DevelopmentPhaseTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_DividendsDeclared" abstract="false" name="DividendsDeclared" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_LegalMattersAbstract" abstract="true" name="LegalMattersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_ProductDevelopmentFees" abstract="false" name="ProductDevelopmentFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_PrepaidMarketing" abstract="false" name="PrepaidMarketing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ProductDevelopmentAgreementTextBlock" abstract="false" name="ProductDevelopmentAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" abstract="true" name="UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_LineOfCreditFacilityOtherFinalPayments" abstract="false" name="LineOfCreditFacilityOtherFinalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_LicenseMaintenanceFee" abstract="false" name="LicenseMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_EIGTransactionMember" abstract="true" name="EIGTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" abstract="false" name="ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_CommonStockReservedForFutureIssuancesTableTextBlock" abstract="false" name="CommonStockReservedForFutureIssuancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="eigr_SecuredDebtAmendedTrancheAMember" abstract="true" name="SecuredDebtAmendedTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eigr_SiliconValleyBankMember" abstract="true" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" abstract="false" name="VestingPeriodOfOptionsIssuedForCommonStockPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_FormerCEOMember" abstract="true" name="FormerCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_PaymentsRelatedToPriorityReviewVoucher" abstract="false" name="PaymentsRelatedToPriorityReviewVoucher" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_CashEquivalentsAndInvestmentSecuritiesTable" abstract="true" name="CashEquivalentsAndInvestmentSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" abstract="false" name="PostEmploymentBenefitsLegalFeesReimbursementThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_USGovernmentBondsMember" abstract="true" name="USGovernmentBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_VariableRateComponentTwoMember" abstract="true" name="VariableRateComponentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_MerckTransactionMember" abstract="true" name="MerckTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_CommercialSalesMember" abstract="true" name="CommercialSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" abstract="false" name="UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eigr_AmendmentFeesPayment" abstract="false" name="AmendmentFeesPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_UPennCHOPAgreementMember" abstract="true" name="UPennCHOPAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_InducementPlan2021Member" abstract="true" name="InducementPlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" abstract="false" name="SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eigr_AccruedContractedResearchCostsCurrent" abstract="false" name="AccruedContractedResearchCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_PeriodOfCommittedPaymentOfFees" abstract="false" name="PeriodOfCommittedPaymentOfFees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" abstract="false" name="DebtInstrumentPrincipalAndInterestPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eigr_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>eigr-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5bf4cbbb-10e9-4fbc-b4bb-3a741d1bed32,g:0d7ff615-48b4-4d72-96cc-45180aee1521-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_18a80591-5b1a-4e6e-9db8-61b300ac19c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0980bcd1-c78a-42eb-8ea5-88cc83903397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a80591-5b1a-4e6e-9db8-61b300ac19c8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0980bcd1-c78a-42eb-8ea5-88cc83903397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_26ea8d07-3743-49f9-ab70-cdcde62649fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a80591-5b1a-4e6e-9db8-61b300ac19c8" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_26ea8d07-3743-49f9-ab70-cdcde62649fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_16cbc3f1-9322-4a53-b001-208dbf08d464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a80591-5b1a-4e6e-9db8-61b300ac19c8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_16cbc3f1-9322-4a53-b001-208dbf08d464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5be58a0e-87f1-47fd-bd63-20bb27e584cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a80591-5b1a-4e6e-9db8-61b300ac19c8" xlink:to="loc_us-gaap_InventoryNet_5be58a0e-87f1-47fd-bd63-20bb27e584cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5626eb01-b1c1-4ae4-9e24-03224dd9aa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a80591-5b1a-4e6e-9db8-61b300ac19c8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5626eb01-b1c1-4ae4-9e24-03224dd9aa93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_62aa8675-f677-47f0-adae-0fdd9111475b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a62b67c9-0776-46e6-8d5c-2ef7cc1c034e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62aa8675-f677-47f0-adae-0fdd9111475b" xlink:to="loc_us-gaap_LiabilitiesCurrent_a62b67c9-0776-46e6-8d5c-2ef7cc1c034e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ba040119-8f76-48ee-8ba3-1e86f3e3637c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62aa8675-f677-47f0-adae-0fdd9111475b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ba040119-8f76-48ee-8ba3-1e86f3e3637c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eff208e1-8d8a-459c-bf92-1a665156c308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62aa8675-f677-47f0-adae-0fdd9111475b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eff208e1-8d8a-459c-bf92-1a665156c308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ce404140-f56a-44f2-8041-1d8e47baefcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3d584028-8f71-46ba-8cb9-007d3f2023f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce404140-f56a-44f2-8041-1d8e47baefcb" xlink:to="loc_us-gaap_AccountsPayableCurrent_3d584028-8f71-46ba-8cb9-007d3f2023f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c2d3dccc-5867-4839-8908-6e05e42f6351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce404140-f56a-44f2-8041-1d8e47baefcb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c2d3dccc-5867-4839-8908-6e05e42f6351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_73f2f24a-0123-403c-bb78-141d92f9d80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce404140-f56a-44f2-8041-1d8e47baefcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_73f2f24a-0123-403c-bb78-141d92f9d80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9f2999e0-2aee-4034-8689-d24aaa0dd2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce404140-f56a-44f2-8041-1d8e47baefcb" xlink:to="loc_us-gaap_LongTermDebtCurrent_9f2999e0-2aee-4034-8689-d24aaa0dd2a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e18245d-3935-4567-84fd-b9027a1e7ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a2ee4f7e-2500-4b6f-a573-7f2eb7ef442b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8e18245d-3935-4567-84fd-b9027a1e7ee7" xlink:to="loc_us-gaap_CommonStockValue_a2ee4f7e-2500-4b6f-a573-7f2eb7ef442b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ef11f75-1c81-44ca-91a9-b04fba58a07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8e18245d-3935-4567-84fd-b9027a1e7ee7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ef11f75-1c81-44ca-91a9-b04fba58a07b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7a18d274-b809-49e3-b64c-81901f0d7f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8e18245d-3935-4567-84fd-b9027a1e7ee7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7a18d274-b809-49e3-b64c-81901f0d7f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fb28f16-c16a-4c22-a72e-19deb66a831c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8e18245d-3935-4567-84fd-b9027a1e7ee7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fb28f16-c16a-4c22-a72e-19deb66a831c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69f74a60-dea5-4530-8776-288fef5effa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_53b4ba35-70d1-4875-9c46-a265a3190761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69f74a60-dea5-4530-8776-288fef5effa4" xlink:to="loc_us-gaap_AssetsCurrent_53b4ba35-70d1-4875-9c46-a265a3190761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_eb6c25b4-4e9c-4d8b-a655-c1cafa64da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69f74a60-dea5-4530-8776-288fef5effa4" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_eb6c25b4-4e9c-4d8b-a655-c1cafa64da9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a10d4c49-10ce-4fa6-b97c-c1c4ff7da764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69f74a60-dea5-4530-8776-288fef5effa4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a10d4c49-10ce-4fa6-b97c-c1c4ff7da764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_91dd7f6e-72a5-4efb-bab8-68b67188427d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69f74a60-dea5-4530-8776-288fef5effa4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_91dd7f6e-72a5-4efb-bab8-68b67188427d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d77f085e-c81d-4241-895a-40053b70b096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69f74a60-dea5-4530-8776-288fef5effa4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d77f085e-c81d-4241-895a-40053b70b096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0589f14f-0b7b-49e7-a93f-a30ca15bc0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c5e1c7fa-396c-41cb-90bc-e763f9d0e40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0589f14f-0b7b-49e7-a93f-a30ca15bc0be" xlink:to="loc_us-gaap_Liabilities_c5e1c7fa-396c-41cb-90bc-e763f9d0e40a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d53b07f7-5248-49f2-a1b2-2c2644efe565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0589f14f-0b7b-49e7-a93f-a30ca15bc0be" xlink:to="loc_us-gaap_StockholdersEquity_d53b07f7-5248-49f2-a1b2-2c2644efe565" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eb6bfca6-938d-4008-ba74-74f0ac69f844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8d9d9dbf-bdd1-496d-b63b-61a5139d44ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eb6bfca6-938d-4008-ba74-74f0ac69f844" xlink:to="loc_us-gaap_Revenues_8d9d9dbf-bdd1-496d-b63b-61a5139d44ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_18d141e8-b508-46ff-a932-9c44b0cae2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eb6bfca6-938d-4008-ba74-74f0ac69f844" xlink:to="loc_us-gaap_CostsAndExpenses_18d141e8-b508-46ff-a932-9c44b0cae2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94f98954-ad10-4e70-a71a-0d241859a6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2f1be4f4-5aeb-4218-b34b-214f912898b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94f98954-ad10-4e70-a71a-0d241859a6b4" xlink:to="loc_us-gaap_OperatingIncomeLoss_2f1be4f4-5aeb-4218-b34b-214f912898b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0a112b08-ffe6-4f31-8143-0c75991ccdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94f98954-ad10-4e70-a71a-0d241859a6b4" xlink:to="loc_us-gaap_InterestExpense_0a112b08-ffe6-4f31-8143-0c75991ccdf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b0d1eee9-5974-4114-a0fd-8f449dea9c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94f98954-ad10-4e70-a71a-0d241859a6b4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b0d1eee9-5974-4114-a0fd-8f449dea9c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a8f5f1e4-a24c-4f80-9935-a888a1c983fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94f98954-ad10-4e70-a71a-0d241859a6b4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a8f5f1e4-a24c-4f80-9935-a888a1c983fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2bc24bef-4b72-44fc-a8fd-4c3a172723e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fea5ba14-9042-438c-be64-b20cc76c416a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2bc24bef-4b72-44fc-a8fd-4c3a172723e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fea5ba14-9042-438c-be64-b20cc76c416a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_07fc1003-a962-4398-94fb-30bb10a974cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2bc24bef-4b72-44fc-a8fd-4c3a172723e3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_07fc1003-a962-4398-94fb-30bb10a974cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_03aea0b1-3f62-4d2c-8811-8bc6e4ff7e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a4473415-0f37-45c5-b6cb-6ed99b21060e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_03aea0b1-3f62-4d2c-8811-8bc6e4ff7e4e" xlink:to="loc_us-gaap_CostOfRevenue_a4473415-0f37-45c5-b6cb-6ed99b21060e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cd43b48a-579f-49b8-8c72-055745dfc169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_03aea0b1-3f62-4d2c-8811-8bc6e4ff7e4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cd43b48a-579f-49b8-8c72-055745dfc169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b0cc2e6-8a2b-4b28-a233-edbc72191194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_03aea0b1-3f62-4d2c-8811-8bc6e4ff7e4e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0b0cc2e6-8a2b-4b28-a233-edbc72191194" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c91cec6-6ed0-4314-a315-347ee3137fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3af24834-0837-4c45-b2c9-5e8256a632d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c91cec6-6ed0-4314-a315-347ee3137fe5" xlink:to="loc_us-gaap_NetIncomeLoss_3af24834-0837-4c45-b2c9-5e8256a632d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9595701b-2a33-47f3-bd94-744d3e6fa0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c91cec6-6ed0-4314-a315-347ee3137fe5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9595701b-2a33-47f3-bd94-744d3e6fa0bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bee38ce2-4790-42fc-8898-fe5e4d5be470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c91cec6-6ed0-4314-a315-347ee3137fe5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bee38ce2-4790-42fc-8898-fe5e4d5be470" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc63a425-4183-4b4e-a309-fabd9414acc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e7e62b2-0528-44da-950d-912cb0c74be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc63a425-4183-4b4e-a309-fabd9414acc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e7e62b2-0528-44da-950d-912cb0c74be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3cc0dc15-4c08-4408-b9f9-ccf75e1a7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc63a425-4183-4b4e-a309-fabd9414acc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3cc0dc15-4c08-4408-b9f9-ccf75e1a7dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd0d5ede-b084-416d-984a-ff46273fa488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc63a425-4183-4b4e-a309-fabd9414acc7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd0d5ede-b084-416d-984a-ff46273fa488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c4698bf-b120-4fca-840c-103b261c2966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c4698bf-b120-4fca-840c-103b261c2966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_367316ff-766a-4051-9823-c4e096b3895e" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_367316ff-766a-4051-9823-c4e096b3895e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31b94acd-ce6d-440f-952d-3ad083bb3d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_31b94acd-ce6d-440f-952d-3ad083bb3d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b5cd6d2f-2706-46c6-be9e-2cadd5be4fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b5cd6d2f-2706-46c6-be9e-2cadd5be4fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_468d0caf-d74a-46b9-b099-eec7f1a1629c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_468d0caf-d74a-46b9-b099-eec7f1a1629c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_ebb86d17-ecb0-41c0-9cd5-48e9a421e446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_ProceedsFromStockPlans_ebb86d17-ecb0-41c0-9cd5-48e9a421e446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_98e6485f-4e1b-43de-bbb8-846cfe539e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_98e6485f-4e1b-43de-bbb8-846cfe539e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_fde6b546-9cfe-4d91-8803-ac5c3178b923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b50f5ff-af27-4cf4-8c1f-cffe601244e6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_fde6b546-9cfe-4d91-8803-ac5c3178b923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fe86c456-3b33-45fb-8d48-845c43a3544f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fe86c456-3b33-45fb-8d48-845c43a3544f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eeb6c260-c7da-43e8-9a73-6a34a65f5a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_NetIncomeLoss_eeb6c260-c7da-43e8-9a73-6a34a65f5a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28395035-e8f1-4fcd-87cc-99def3a9fac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28395035-e8f1-4fcd-87cc-99def3a9fac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0bdf6e34-c552-4980-b315-675b86121deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0bdf6e34-c552-4980-b315-675b86121deb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ea3705ab-cef9-4133-a6d3-ce15fc6c520a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ea3705ab-cef9-4133-a6d3-ce15fc6c520a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncomeLossRelatedToAssetPurchaseAgreement_0f7ce9e6-b5c9-4407-a567-93ccc616d08a" xlink:href="eigr-20221231.xsd#eigr_IncomeLossRelatedToAssetPurchaseAgreement"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_eigr_IncomeLossRelatedToAssetPurchaseAgreement_0f7ce9e6-b5c9-4407-a567-93ccc616d08a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_58b83410-5e26-463b-b37e-c015f75e9a72" xlink:href="eigr-20221231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_58b83410-5e26-463b-b37e-c015f75e9a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_GainLossFromSaleOfPriorityReviewVoucher_aacfe830-4454-4f0a-a2a7-ac8b50a52759" xlink:href="eigr-20221231.xsd#eigr_GainLossFromSaleOfPriorityReviewVoucher"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_eigr_GainLossFromSaleOfPriorityReviewVoucher_aacfe830-4454-4f0a-a2a7-ac8b50a52759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_0e5ee7cb-7c77-4468-8058-89549ed5ca8b" xlink:href="eigr-20221231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_0e5ee7cb-7c77-4468-8058-89549ed5ca8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_809b5f9d-c3fb-416d-bde1-afe2765f5c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_809b5f9d-c3fb-416d-bde1-afe2765f5c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4ee81aa7-3e5d-4da6-871b-fbd0dcd6c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4ee81aa7-3e5d-4da6-871b-fbd0dcd6c4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d0babce-3735-4c3e-84fc-84b3ea64cd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d0babce-3735-4c3e-84fc-84b3ea64cd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2d168517-bebc-44c9-9164-a4825d48b319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2d168517-bebc-44c9-9164-a4825d48b319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6e85c5f2-dff9-466f-8f98-40d2f1948ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_ShareBasedCompensation_6e85c5f2-dff9-466f-8f98-40d2f1948ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_78727f9b-c43f-48a5-8620-60bc9bd9628c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_78727f9b-c43f-48a5-8620-60bc9bd9628c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_dee872dc-fcc3-4d14-ba76-b01bceed814f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_dee872dc-fcc3-4d14-ba76-b01bceed814f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d007610a-309f-4a18-8cb3-7d0e2ecd4b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d007610a-309f-4a18-8cb3-7d0e2ecd4b2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_438e17f1-481c-4c6f-9e8a-3ce80d0f3797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_00a73d36-364c-4683-9835-5d4cb4d68029" xlink:to="loc_us-gaap_InventoryWriteDown_438e17f1-481c-4c6f-9e8a-3ce80d0f3797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromSaleOfPriorityReviewVoucher_9058f70b-cc45-40b5-979b-0cfb9be1ed44" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromSaleOfPriorityReviewVoucher"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:to="loc_eigr_ProceedsFromSaleOfPriorityReviewVoucher_9058f70b-cc45-40b5-979b-0cfb9be1ed44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_861c1dd1-dce3-4d3e-b7c3-ae4f5c6b0b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_861c1dd1-dce3-4d3e-b7c3-ae4f5c6b0b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a6ccdfed-d005-41f5-b83f-b736bf242001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a6ccdfed-d005-41f5-b83f-b736bf242001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_efd48970-fed8-4270-ac6b-d75f8e53fc34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_efd48970-fed8-4270-ac6b-d75f8e53fc34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsRelatedToAssetPurchaseAgreement_91889bfd-315c-4b01-9b7c-9f3d5f52789b" xlink:href="eigr-20221231.xsd#eigr_ProceedsRelatedToAssetPurchaseAgreement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:to="loc_eigr_ProceedsRelatedToAssetPurchaseAgreement_91889bfd-315c-4b01-9b7c-9f3d5f52789b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PaymentsRelatedToPriorityReviewVoucher_5130dc60-912c-4230-8fdd-560b752289b7" xlink:href="eigr-20221231.xsd#eigr_PaymentsRelatedToPriorityReviewVoucher"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_afc10fbc-8ecf-4eff-ae0e-4edac365dd14" xlink:to="loc_eigr_PaymentsRelatedToPriorityReviewVoucher_5130dc60-912c-4230-8fdd-560b752289b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e8bfd4b8-b04b-4ce5-8a63-925df547675b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_db0a565b-b129-4c55-a287-ac86c6182a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e8bfd4b8-b04b-4ce5-8a63-925df547675b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_db0a565b-b129-4c55-a287-ac86c6182a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8222de06-7ba0-4981-af51-bb91f949fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e8bfd4b8-b04b-4ce5-8a63-925df547675b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8222de06-7ba0-4981-af51-bb91f949fa08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ed65f0ac-89a3-4545-b982-bc76b65e4cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e8bfd4b8-b04b-4ce5-8a63-925df547675b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ed65f0ac-89a3-4545-b982-bc76b65e4cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3c5f6406-2dd6-4922-a3b3-505eeddb8a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dbb0a476-584b-4daa-af4d-c531fbfbee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3c5f6406-2dd6-4922-a3b3-505eeddb8a6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dbb0a476-584b-4daa-af4d-c531fbfbee6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80f15dc1-9df3-4cdd-83c3-12ab7ff58167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3c5f6406-2dd6-4922-a3b3-505eeddb8a6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80f15dc1-9df3-4cdd-83c3-12ab7ff58167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAmortizedCost_d2176082-aa8f-4897-9d8f-837155d99eb8" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f96bddd2-b4ca-46f7-9d98-ebefb6473b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eigr_CashEquivalentsAmortizedCost_d2176082-aa8f-4897-9d8f-837155d99eb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f96bddd2-b4ca-46f7-9d98-ebefb6473b50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofInventoryDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_41843781-d435-4cbc-b68a-f27412e00864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_82a12c98-8e70-4220-9dd2-0a26f35ed838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_41843781-d435-4cbc-b68a-f27412e00864" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_82a12c98-8e70-4220-9dd2-0a26f35ed838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_351d41d8-62b3-4868-ad1e-665640c142b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_41843781-d435-4cbc-b68a-f27412e00864" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_351d41d8-62b3-4868-ad1e-665640c142b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be2a3144-9f39-4237-95d8-5adc947f05d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_41843781-d435-4cbc-b68a-f27412e00864" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be2a3144-9f39-4237-95d8-5adc947f05d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e43d9120-837f-4ced-a038-767866d39b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d159806d-8142-474f-8a03-368006ce65e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e43d9120-837f-4ced-a038-767866d39b20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d159806d-8142-474f-8a03-368006ce65e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa0f1a02-dd83-48cf-8c2b-b12b643b15ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e43d9120-837f-4ced-a038-767866d39b20" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa0f1a02-dd83-48cf-8c2b-b12b643b15ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidContractManufacturingCosts_113b9ff7-0003-409b-a4e3-2bb143a64979" xlink:href="eigr-20221231.xsd#eigr_PrepaidContractManufacturingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:to="loc_eigr_PrepaidContractManufacturingCosts_113b9ff7-0003-409b-a4e3-2bb143a64979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidResearchCosts_e2cdf746-a2b6-4c34-8a2b-02ccc4c8d2bc" xlink:href="eigr-20221231.xsd#eigr_PrepaidResearchCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:to="loc_eigr_PrepaidResearchCosts_e2cdf746-a2b6-4c34-8a2b-02ccc4c8d2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidMarketing_ca15b6fc-51b4-4f6d-ba6a-ca3ba65583f1" xlink:href="eigr-20221231.xsd#eigr_PrepaidMarketing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:to="loc_eigr_PrepaidMarketing_ca15b6fc-51b4-4f6d-ba6a-ca3ba65583f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_2eac3fd6-dbc5-488d-91f9-67bc5337414d" xlink:href="eigr-20221231.xsd#eigr_OtherPrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:to="loc_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_2eac3fd6-dbc5-488d-91f9-67bc5337414d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_f48c9caf-7b66-4925-acad-a77ece893bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:to="loc_us-gaap_PrepaidInsurance_f48c9caf-7b66-4925-acad-a77ece893bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_ce4175e9-94cb-4aaf-9828-1bed20251d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2da7c24-7ac4-48d4-82b8-1a184ef52114" xlink:to="loc_us-gaap_DepositsAssetsCurrent_ce4175e9-94cb-4aaf-9828-1bed20251d42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d4c859c5-feed-4a21-96b7-288d8b75e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AccruedContractedResearchCostsCurrent_569a7995-a52b-4a64-af9d-53c09b3ddb42" xlink:href="eigr-20221231.xsd#eigr_AccruedContractedResearchCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d4c859c5-feed-4a21-96b7-288d8b75e6bb" xlink:to="loc_eigr_AccruedContractedResearchCostsCurrent_569a7995-a52b-4a64-af9d-53c09b3ddb42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_cc38d9d3-a092-4574-a05a-dee717bc6099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d4c859c5-feed-4a21-96b7-288d8b75e6bb" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_cc38d9d3-a092-4574-a05a-dee717bc6099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ContractManufacturingCostsCurrent_fc62b7a6-9e7b-4b0e-a325-638c4ec97b5c" xlink:href="eigr-20221231.xsd#eigr_ContractManufacturingCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d4c859c5-feed-4a21-96b7-288d8b75e6bb" xlink:to="loc_eigr_ContractManufacturingCostsCurrent_fc62b7a6-9e7b-4b0e-a325-638c4ec97b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductRevenueReserves_df9d5766-1eca-476b-b6c3-b13c8b4da2b8" xlink:href="eigr-20221231.xsd#eigr_ProductRevenueReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d4c859c5-feed-4a21-96b7-288d8b75e6bb" xlink:to="loc_eigr_ProductRevenueReserves_df9d5766-1eca-476b-b6c3-b13c8b4da2b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd1f0a94-8aa7-4212-bca2-78cdc21eb383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d4c859c5-feed-4a21-96b7-288d8b75e6bb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd1f0a94-8aa7-4212-bca2-78cdc21eb383" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d6e76bf0-f4a2-45c8-9a3f-63bfe8914ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f2d4f11b-5c30-42dc-a9c8-1fdecef1b90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d6e76bf0-f4a2-45c8-9a3f-63bfe8914ec3" xlink:to="loc_us-gaap_LongTermDebtCurrent_f2d4f11b-5c30-42dc-a9c8-1fdecef1b90e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d2f02893-6982-41ec-8675-9e3a8b10931b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d6e76bf0-f4a2-45c8-9a3f-63bfe8914ec3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d2f02893-6982-41ec-8675-9e3a8b10931b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtScheduleofMaturitiesofLongtermDebtDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b555a200-d640-4d1b-8c7c-9f45574ce148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d1f52423-aa49-43d4-8f12-65aadb1b4e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b555a200-d640-4d1b-8c7c-9f45574ce148" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d1f52423-aa49-43d4-8f12-65aadb1b4e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1550f3f0-632b-4c1d-822f-7e7f326724c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b555a200-d640-4d1b-8c7c-9f45574ce148" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1550f3f0-632b-4c1d-822f-7e7f326724c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_42920360-8b28-46f1-a643-0c42f5949dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b555a200-d640-4d1b-8c7c-9f45574ce148" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_42920360-8b28-46f1-a643-0c42f5949dfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_464fb6c5-214e-4b9f-b8a7-6899ba7ac5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b555a200-d640-4d1b-8c7c-9f45574ce148" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_464fb6c5-214e-4b9f-b8a7-6899ba7ac5e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_353d7575-36f5-4330-812b-59e3f090527a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b555a200-d640-4d1b-8c7c-9f45574ce148" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_353d7575-36f5-4330-812b-59e3f090527a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f2fec2c6-c9ec-4d0d-9a77-b7e83e7d2faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_780aba1d-b732-4eac-96c7-0d972565bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_f2fec2c6-c9ec-4d0d-9a77-b7e83e7d2faf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_780aba1d-b732-4eac-96c7-0d972565bcfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8c223b31-6d22-479c-a24d-7c8f55b72424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_f2fec2c6-c9ec-4d0d-9a77-b7e83e7d2faf" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8c223b31-6d22-479c-a24d-7c8f55b72424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFee_a6800579-fa65-4a4b-9420-e3974e723391" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFee"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_f2fec2c6-c9ec-4d0d-9a77-b7e83e7d2faf" xlink:to="loc_eigr_DebtInstrumentExitFee_a6800579-fa65-4a4b-9420-e3974e723391" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockholdersEquityCommonStockReservedForFutureIssuancesDetails"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0feb1c8e-edd5-46aa-97b7-7439b18162af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_57f85e7c-9474-4de2-960f-74b923396d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0feb1c8e-edd5-46aa-97b7-7439b18162af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_57f85e7c-9474-4de2-960f-74b923396d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_98cfc7f5-1a2a-400a-897e-e0a34d4838b1" xlink:href="eigr-20221231.xsd#eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0feb1c8e-edd5-46aa-97b7-7439b18162af" xlink:to="loc_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_98cfc7f5-1a2a-400a-897e-e0a34d4838b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestrictedAndPerformanceStockUnitsOutstanding_f8444841-ec42-4ad2-8895-e4f14bbeb10d" xlink:href="eigr-20221231.xsd#eigr_RestrictedAndPerformanceStockUnitsOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0feb1c8e-edd5-46aa-97b7-7439b18162af" xlink:to="loc_eigr_RestrictedAndPerformanceStockUnitsOutstanding_f8444841-ec42-4ad2-8895-e4f14bbeb10d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsIssuedAndOutstanding_160e58b5-73f2-44de-86fb-85704f63eb50" xlink:href="eigr-20221231.xsd#eigr_OptionsIssuedAndOutstanding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0feb1c8e-edd5-46aa-97b7-7439b18162af" xlink:to="loc_eigr_OptionsIssuedAndOutstanding_160e58b5-73f2-44de-86fb-85704f63eb50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_18b3ed51-a779-47ce-b059-59750342befa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_18b3ed51-a779-47ce-b059-59750342befa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c1ab98d2-abe3-438d-86da-4e4f4ba9383e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c1ab98d2-abe3-438d-86da-4e4f4ba9383e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4ef07331-c99a-447e-bdc4-4ddf75650a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4ef07331-c99a-447e-bdc4-4ddf75650a73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0d0ccec9-9370-4cc4-a135-53acaf0b75bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0d0ccec9-9370-4cc4-a135-53acaf0b75bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6aa196f9-9b26-46c2-ad98-1085a89bdf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6aa196f9-9b26-46c2-ad98-1085a89bdf7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a1541110-0b71-4727-912e-46ec9cc5bb85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e04b4188-46dd-4fb6-a67e-ee8dc941239a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a1541110-0b71-4727-912e-46ec9cc5bb85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b105f423-4b77-403f-aecf-0d3c6888193f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxLiabilitiesRightOfUseAssets_91e27010-ebee-48e2-a86a-5425d144933d" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b105f423-4b77-403f-aecf-0d3c6888193f" xlink:to="loc_eigr_DeferredTaxLiabilitiesRightOfUseAssets_91e27010-ebee-48e2-a86a-5425d144933d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f8f423fd-5229-493b-812a-a63abd33e3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_027f89c2-7423-4795-97c7-651ff07359ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f8f423fd-5229-493b-812a-a63abd33e3fd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_027f89c2-7423-4795-97c7-651ff07359ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2ff81040-2c74-45b2-8313-9a5195277c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_f8f423fd-5229-493b-812a-a63abd33e3fd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2ff81040-2c74-45b2-8313-9a5195277c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxAssetsLeaseLiabilities_93b7f932-e658-4851-863c-77f3aafcfd0a" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_eigr_DeferredTaxAssetsLeaseLiabilities_93b7f932-e658-4851-863c-77f3aafcfd0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ec748436-adab-4448-8ed5-b271edb752ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ec748436-adab-4448-8ed5-b271edb752ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxAssetDepreciationAndAmortization_9dc90a79-7549-45bd-9a36-61e57b11b71b" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxAssetDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_eigr_DeferredTaxAssetDepreciationAndAmortization_9dc90a79-7549-45bd-9a36-61e57b11b71b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fa5a6500-6f27-4dbc-8be1-f349bf8a8379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fa5a6500-6f27-4dbc-8be1-f349bf8a8379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_5683c90b-abeb-439c-82ba-d5b4914f61bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_5683c90b-abeb-439c-82ba-d5b4914f61bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7dfb054b-b795-4d49-9d29-6046a7bbd87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7dfb054b-b795-4d49-9d29-6046a7bbd87e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_369ff6c1-89b3-40dc-b881-7c99b2e71bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a3cd3f81-421b-4086-a20a-a7051947b1f1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_369ff6c1-89b3-40dc-b881-7c99b2e71bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_16d9ca24-8850-48ce-80dd-e9def9986682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_574ff987-8346-4c2a-adcc-1cb449fa1c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_16d9ca24-8850-48ce-80dd-e9def9986682" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_574ff987-8346-4c2a-adcc-1cb449fa1c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_558dfada-36f4-4cc6-96ea-fb5b461964a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_16d9ca24-8850-48ce-80dd-e9def9986682" xlink:to="loc_us-gaap_DeferredTaxLiabilities_558dfada-36f4-4cc6-96ea-fb5b461964a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b87bbd97-2d2c-4dbd-a2c3-abaedbad8794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42dcb6b6-f073-47d4-be5a-170107c48fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b87bbd97-2d2c-4dbd-a2c3-abaedbad8794" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_42dcb6b6-f073-47d4-be5a-170107c48fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3c22fcf-9287-4016-8b23-0e4d6513bd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b87bbd97-2d2c-4dbd-a2c3-abaedbad8794" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b3c22fcf-9287-4016-8b23-0e4d6513bd35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_45cab8c1-4e39-4b38-987f-71b9bbf9145c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_738c6466-1830-4f25-b1a1-6975a0170bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_45cab8c1-4e39-4b38-987f-71b9bbf9145c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_738c6466-1830-4f25-b1a1-6975a0170bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4a82772-c72a-4754-a0ae-fe951bf87cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_45cab8c1-4e39-4b38-987f-71b9bbf9145c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a4a82772-c72a-4754-a0ae-fe951bf87cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b6698e81-710c-4e7a-ba89-38c47e286083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_45cab8c1-4e39-4b38-987f-71b9bbf9145c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b6698e81-710c-4e7a-ba89-38c47e286083" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75da958b-e176-45c0-9863-6ac22fe73edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9c3f652c-c46d-43a5-86e7-e0cfaf61bed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75da958b-e176-45c0-9863-6ac22fe73edf" xlink:to="loc_us-gaap_OperatingLeaseLiability_9c3f652c-c46d-43a5-86e7-e0cfaf61bed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14a9f383-4050-46b4-8c89-84d00ba44c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75da958b-e176-45c0-9863-6ac22fe73edf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14a9f383-4050-46b4-8c89-84d00ba44c64" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>eigr-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5bf4cbbb-10e9-4fbc-b4bb-3a741d1bed32,g:0d7ff615-48b4-4d72-96cc-45180aee1521-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i7c5bdc06ff9f4091b500a0045f48302f_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b8a09448-f2b0-460d-8170-42ee0d34b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_RevenuesAbstract_b8a09448-f2b0-460d-8170-42ee0d34b9cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ea959718-119b-4bfd-ab72-fbeae4e02fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_b8a09448-f2b0-460d-8170-42ee0d34b9cc" xlink:to="loc_us-gaap_Revenues_ea959718-119b-4bfd-ab72-fbeae4e02fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a2167022-4e43-4fdb-9832-466cd04ebf63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_CostOfRevenue_a2167022-4e43-4fdb-9832-466cd04ebf63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b86c5b0-4b20-4385-b530-685f2d646710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b86c5b0-4b20-4385-b530-685f2d646710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08b6c04f-09d1-44e5-ac52-337b78216985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08b6c04f-09d1-44e5-ac52-337b78216985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9cc12ed5-e3ed-487f-bd0c-df22140c92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_CostsAndExpenses_9cc12ed5-e3ed-487f-bd0c-df22140c92dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b038b2c5-7691-4ec9-b127-b3c9e7ec4f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_OperatingIncomeLoss_b038b2c5-7691-4ec9-b127-b3c9e7ec4f3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_96030678-40c2-4b84-acb8-f6f83bbff5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_InterestExpense_96030678-40c2-4b84-acb8-f6f83bbff5be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_080ca895-69b6-46bf-9b42-739a783e45b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_080ca895-69b6-46bf-9b42-739a783e45b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_232c7e1f-eec6-44b0-978f-81582ea68fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_232c7e1f-eec6-44b0-978f-81582ea68fe5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ce4fcdd-2095-4355-a98c-77253b071722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ce4fcdd-2095-4355-a98c-77253b071722" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3305a13-27b1-449d-a698-fa2fd14e3ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3305a13-27b1-449d-a698-fa2fd14e3ad7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_191ad50a-a1c4-4b4d-a911-66c897213cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_NetIncomeLoss_191ad50a-a1c4-4b4d-a911-66c897213cb3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c3cdc08c-8e8a-4401-a5ce-90215c24e274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:to="loc_us-gaap_EarningsPerShareBasic_c3cdc08c-8e8a-4401-a5ce-90215c24e274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_605771f3-5100-4fde-b6e7-f1759e0b3f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_605771f3-5100-4fde-b6e7-f1759e0b3f1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7989739d-430f-4aad-b572-ed97de544277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7989739d-430f-4aad-b572-ed97de544277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_976161d7-e1f7-49aa-bbe2-01a86ca78038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_976161d7-e1f7-49aa-bbe2-01a86ca78038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:to="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7ad4663-6743-441e-a03e-33e5520a2573_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:to="loc_srt_ProductsAndServicesDomain_d7ad4663-6743-441e-a03e-33e5520a2573_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:to="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_afccd6f9-d7ee-4d19-8e79-6518c83aa32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:to="loc_us-gaap_ProductMember_afccd6f9-d7ee-4d19-8e79-6518c83aa32a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherRevenueMember_786688d9-c5b2-4511-8d28-82b6211d32e5" xlink:href="eigr-20221231.xsd#eigr_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:to="loc_eigr_OtherRevenueMember_786688d9-c5b2-4511-8d28-82b6211d32e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ib2bf864a05bf4fdeafd2603be98174d0_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ea016a0-837a-4101-a0e4-4ab5c5c08cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7ea016a0-837a-4101-a0e4-4ab5c5c08cd1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28ad413d-f0da-410b-8fa6-ecd6c3353ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_28ad413d-f0da-410b-8fa6-ecd6c3353ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_490d21c7-a37f-49eb-925d-0b97d28c50a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockholdersEquity_490d21c7-a37f-49eb-925d-0b97d28c50a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aec70fbe-8ce1-447f-8db7-c35a520eba4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aec70fbe-8ce1-447f-8db7-c35a520eba4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_433ad8f0-e725-4b04-9dfd-3b145e28eb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_433ad8f0-e725-4b04-9dfd-3b145e28eb7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ecc48bd8-3b8f-4cb2-81fd-1922ca225acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ecc48bd8-3b8f-4cb2-81fd-1922ca225acf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c0f5a645-be2a-46af-bb1d-389a9ed77ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c0f5a645-be2a-46af-bb1d-389a9ed77ce2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9336ac0-0be8-48bb-bfb7-dce8588483c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9336ac0-0be8-48bb-bfb7-dce8588483c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3efb4c63-87d8-4677-ab77-919be5ca3fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3efb4c63-87d8-4677-ab77-919be5ca3fe1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_dfeef72d-a4fc-424e-8a72-135e9cadc395" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_dfeef72d-a4fc-424e-8a72-135e9cadc395" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df4af244-0545-4484-8fc2-6a88abd81b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df4af244-0545-4484-8fc2-6a88abd81b92" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4dd0319d-cb11-4de7-8703-0f8b72cdf3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4dd0319d-cb11-4de7-8703-0f8b72cdf3ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_de853b40-6065-4d8b-ac75-5b616bcc3fdc" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodSharesStockIssuedToLender"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_de853b40-6065-4d8b-ac75-5b616bcc3fdc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_a4769c1e-f3d9-49a1-86d8-7508926d95f6" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodValueStockIssuedToLender"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_a4769c1e-f3d9-49a1-86d8-7508926d95f6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0f9e89c9-be22-4814-a2c1-3e723cb222a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0f9e89c9-be22-4814-a2c1-3e723cb222a0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2279f8b9-0687-40b7-a666-901901e20c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2279f8b9-0687-40b7-a666-901901e20c87" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_28bfe74d-c00a-476c-8029-440970d97d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_28bfe74d-c00a-476c-8029-440970d97d5b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb44505c-6790-48c3-bf2f-6e3fd8506edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_NetIncomeLoss_eb44505c-6790-48c3-bf2f-6e3fd8506edf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0a8eab6a-ff58-4c8a-bf82-870604a5f435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd8b0dda-6397-4217-9db2-2351b3b4f776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7ea016a0-837a-4101-a0e4-4ab5c5c08cd1" xlink:to="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_529cf8be-f8ac-4dff-a918-33e4f2b35786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:to="loc_us-gaap_EquityComponentDomain_529cf8be-f8ac-4dff-a918-33e4f2b35786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:to="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07696dfa-630d-42d2-94fb-309e10e4c011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_CommonStockMember_07696dfa-630d-42d2-94fb-309e10e4c011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8db84b39-6abb-4fe4-b060-35355b22df84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8db84b39-6abb-4fe4-b060-35355b22df84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e52b719b-fb9a-4c46-aa10-aac96852689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e52b719b-fb9a-4c46-aa10-aac96852689d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_03950589-8fda-441d-94e3-ddd7c1eaceea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_RetainedEarningsMember_03950589-8fda-441d-94e3-ddd7c1eaceea" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="icd0bb1da54194918a917effacf697b24_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_31fac634-eb27-4356-bd60-320f29d9d936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_31fac634-eb27-4356-bd60-320f29d9d936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_c2eb394b-613f-4802-9db6-510c2cfe2237" xlink:href="eigr-20221231.xsd#eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_c2eb394b-613f-4802-9db6-510c2cfe2237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be81b141-cb37-4593-8906-ccb104b2a297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be81b141-cb37-4593-8906-ccb104b2a297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_214028d0-59c3-4357-8908-5c66f43b56da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_214028d0-59c3-4357-8908-5c66f43b56da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b26d3b28-64af-43fb-8922-e749e99e5274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b26d3b28-64af-43fb-8922-e749e99e5274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_55f5db01-1814-4218-a1a6-81d763814830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_InventoryWriteDown_55f5db01-1814-4218-a1a6-81d763814830" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EarlyAccessProgramTerm_ea57e391-cb87-4ca0-8ba2-1dc5e820f12d" xlink:href="eigr-20221231.xsd#eigr_EarlyAccessProgramTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_eigr_EarlyAccessProgramTerm_ea57e391-cb87-4ca0-8ba2-1dc5e820f12d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_77d17332-c17b-4d43-9833-68ba5f1aa2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_Revenues_77d17332-c17b-4d43-9833-68ba5f1aa2f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7de33d53-14e2-4b14-97e5-1bfa5ff43053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7de33d53-14e2-4b14-97e5-1bfa5ff43053" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4318c2e0-5dcc-41f7-a5a0-160ce2245b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4318c2e0-5dcc-41f7-a5a0-160ce2245b6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:to="loc_srt_ProductsAndServicesDomain_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:to="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c68470bd-55c4-4589-9c15-56825c784909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:to="loc_us-gaap_ProductMember_c68470bd-55c4-4589-9c15-56825c784909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AutorisationTemporaireDUtlisationMemberMember_880654e6-76f1-4698-9035-ac795bc5c9fa" xlink:href="eigr-20221231.xsd#eigr_AutorisationTemporaireDUtlisationMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:to="loc_eigr_AutorisationTemporaireDUtlisationMemberMember_880654e6-76f1-4698-9035-ac795bc5c9fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_15aa53cc-07ac-4ba2-a59e-853332b874b7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_15aa53cc-07ac-4ba2-a59e-853332b874b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CustomerAMember_e9fa2e23-6de7-4f96-91f8-54138034c344" xlink:href="eigr-20221231.xsd#eigr_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:to="loc_eigr_CustomerAMember_e9fa2e23-6de7-4f96-91f8-54138034c344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CustomerBMember_d47d8079-8ad2-46c0-9ede-a738841d0276" xlink:href="eigr-20221231.xsd#eigr_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:to="loc_eigr_CustomerBMember_d47d8079-8ad2-46c0-9ede-a738841d0276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5c7a68ac-3432-473e-b082-86eab6d2ab5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5c7a68ac-3432-473e-b082-86eab6d2ab5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ae926743-e14a-4226-9551-0b90f06ae87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ae926743-e14a-4226-9551-0b90f06ae87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_473ecbfe-8d4c-40f1-9472-7f2e4d0a5b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ae926743-e14a-4226-9551-0b90f06ae87b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_473ecbfe-8d4c-40f1-9472-7f2e4d0a5b0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23c6e408-bd85-48a8-9b47-4921d3045c81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_23c6e408-bd85-48a8-9b47-4921d3045c81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_7aa62690-ab3f-46ef-8cb3-b8a23e7738ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:to="loc_us-gaap_FinanceReceivablesMember_7aa62690-ab3f-46ef-8cb3-b8a23e7738ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_5e0633ee-5a92-4b45-96ac-e462bf5ac244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:to="loc_us-gaap_SalesRevenueNetMember_5e0633ee-5a92-4b45-96ac-e462bf5ac244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_730acd09-e049-4797-875a-f6167552fe60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_730acd09-e049-4797-875a-f6167552fe60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_d6010b3d-071b-45f6-897e-84af5b4b8c6a" xlink:href="eigr-20221231.xsd#eigr_OptionsGrantedToEmployeesAndNonEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:to="loc_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_d6010b3d-071b-45f6-897e-84af5b4b8c6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2de417d5-b760-4eb6-b826-2a24f5f670d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2de417d5-b760-4eb6-b826-2a24f5f670d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EmployeeStockPurchasePlanMember_ab7ccff3-5b90-4945-beaf-c4143e62084f" xlink:href="eigr-20221231.xsd#eigr_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:to="loc_eigr_EmployeeStockPurchasePlanMember_ab7ccff3-5b90-4945-beaf-c4143e62084f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended" id="i4d9e4b0633554612a5b2dc683923dfd8_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edde70ac-7905-4bf6-b7a6-c708807cd363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89975597-b43e-44a8-a7e0-1f89a28c6582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edde70ac-7905-4bf6-b7a6-c708807cd363" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89975597-b43e-44a8-a7e0-1f89a28c6582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edde70ac-7905-4bf6-b7a6-c708807cd363" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876f66c-175e-44db-84c2-ebdfafc7045b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6876f66c-175e-44db-84c2-ebdfafc7045b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LabEquipmentMember_8b496c9b-4b4f-45ac-a58e-7660a03327ca" xlink:href="eigr-20221231.xsd#eigr_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_eigr_LabEquipmentMember_8b496c9b-4b4f-45ac-a58e-7660a03327ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_30be593c-1c70-4982-85c5-1f0ce8394b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_30be593c-1c70-4982-85c5-1f0ce8394b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_91c3c0b2-754f-4eb2-bcb6-63540f3d362c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_91c3c0b2-754f-4eb2-bcb6-63540f3d362c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ComputerEquipmentAndSoftwareMember_6be52fde-aa3f-407e-91da-853bb67fdb94" xlink:href="eigr-20221231.xsd#eigr_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_eigr_ComputerEquipmentAndSoftwareMember_6be52fde-aa3f-407e-91da-853bb67fdb94" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i938db3d8d0574ea386524c437947a178_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_396718aa-4321-4101-8368-8cd05dfaa6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_396718aa-4321-4101-8368-8cd05dfaa6aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b50250c6-18c5-4558-918a-5e36e6cd07e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b50250c6-18c5-4558-918a-5e36e6cd07e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_FairValueTransfersBetweenLevelsTransfersAmount_1d59148b-0d27-4926-ac16-53f9f10b4018" xlink:href="eigr-20221231.xsd#eigr_FairValueTransfersBetweenLevelsTransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_eigr_FairValueTransfersBetweenLevelsTransfersAmount_1d59148b-0d27-4926-ac16-53f9f10b4018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_e5eb8a58-4591-456d-8173-33349a4cc9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_ImpairmentOfInvestments_e5eb8a58-4591-456d-8173-33349a4cc9d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_074d51cd-37cf-4963-9426-2d7145036d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_074d51cd-37cf-4963-9426-2d7145036d23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_def34fb9-f5e7-4bd4-a89b-3ce8135f580f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_def34fb9-f5e7-4bd4-a89b-3ce8135f580f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a727af0-b6dd-4fc9-8981-d8a6657e701a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a727af0-b6dd-4fc9-8981-d8a6657e701a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_52bedf0a-a5da-44fa-9801-c3ad6bb7d544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a727af0-b6dd-4fc9-8981-d8a6657e701a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_52bedf0a-a5da-44fa-9801-c3ad6bb7d544" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="extended" id="ieb2b76663c954e1690d4d934519cd94a_FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_496cc107-de9c-4647-9f13-9e00110042bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_abee73f0-7dad-49d1-b2f9-d7302b2ab375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_496cc107-de9c-4647-9f13-9e00110042bd" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_abee73f0-7dad-49d1-b2f9-d7302b2ab375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cd4b36b0-1fc4-4ce3-a7d2-f583b083461b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_abee73f0-7dad-49d1-b2f9-d7302b2ab375" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cd4b36b0-1fc4-4ce3-a7d2-f583b083461b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_496cc107-de9c-4647-9f13-9e00110042bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fec52963-a42d-4e59-858b-5af70d973c5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fec52963-a42d-4e59-858b-5af70d973c5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0cb259c8-fec7-4a62-9fc0-35b92150ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0cb259c8-fec7-4a62-9fc0-35b92150ff2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ef817306-308c-4228-b4fb-9929f14c5333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ef817306-308c-4228-b4fb-9929f14c5333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8503e421-570e-468c-ba13-bc37f696b5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8503e421-570e-468c-ba13-bc37f696b5c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00fd09a3-3ec2-4e61-90ae-45f085ab11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00fd09a3-3ec2-4e61-90ae-45f085ab11d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_33b14762-2ec3-4c59-9a0f-36594a2c1055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00fd09a3-3ec2-4e61-90ae-45f085ab11d5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_33b14762-2ec3-4c59-9a0f-36594a2c1055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19ca15af-f089-4043-bd21-d1dcf4f0f0fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19ca15af-f089-4043-bd21-d1dcf4f0f0fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5bc30854-531b-4a00-9667-9b77ad6f9738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5bc30854-531b-4a00-9667-9b77ad6f9738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_611bb45f-fd73-478b-9a6a-8ea8a755eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:to="loc_us-gaap_CommercialPaperMember_611bb45f-fd73-478b-9a6a-8ea8a755eafd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_USGovernmentBondsMember_00edd1a2-6953-4e84-bb82-d5a438410adb" xlink:href="eigr-20221231.xsd#eigr_USGovernmentBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:to="loc_eigr_USGovernmentBondsMember_00edd1a2-6953-4e84-bb82-d5a438410adb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended" id="i4ff57ff9b9584a20a69921536925a1e9_FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAmortizedCost_e256361d-818e-4ce4-8c11-4d880897bef1" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_eigr_CashEquivalentsAmortizedCost_e256361d-818e-4ce4-8c11-4d880897bef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb9261c5-b3b9-440e-8c99-ba956af279a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb9261c5-b3b9-440e-8c99-ba956af279a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48da829d-c3b2-43cf-b3ac-94ecb4901f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48da829d-c3b2-43cf-b3ac-94ecb4901f3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_552bf7a2-1d22-48a9-a764-df420f036026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_552bf7a2-1d22-48a9-a764-df420f036026" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0d6fa6cb-c18e-41f9-82f4-74676eb79f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0d6fa6cb-c18e-41f9-82f4-74676eb79f0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22206d99-d56d-417c-bd53-8d0bbce60653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22206d99-d56d-417c-bd53-8d0bbce60653" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_27222019-baee-4caf-bb1b-472e74adbf24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_27222019-baee-4caf-bb1b-472e74adbf24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f4bfd109-7b67-4f71-a756-0a94841b7283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f4bfd109-7b67-4f71-a756-0a94841b7283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_629c558a-0ec1-4c73-aae2-27e8d0967790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_629c558a-0ec1-4c73-aae2-27e8d0967790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f707e3c3-3960-4405-95fd-8e0cd529168d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:to="loc_us-gaap_CashEquivalentsMember_f707e3c3-3960-4405-95fd-8e0cd529168d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bade4ecf-89d6-42a8-b350-8884bf9acf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:to="loc_us-gaap_CommercialPaperMember_bade4ecf-89d6-42a8-b350-8884bf9acf7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf289b24-e42c-4e50-8789-fe590d4c8ef6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf289b24-e42c-4e50-8789-fe590d4c8ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a1a6eaa0-546a-4d54-84db-b663239c06d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a1a6eaa0-546a-4d54-84db-b663239c06d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_31a837fa-8460-4e55-8452-d12e092211a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_CommercialPaperMember_31a837fa-8460-4e55-8452-d12e092211a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_USGovernmentBondsMember_e768744a-7a12-4c57-ad63-2e3bf460c602" xlink:href="eigr-20221231.xsd#eigr_USGovernmentBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_eigr_USGovernmentBondsMember_e768744a-7a12-4c57-ad63-2e3bf460c602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtMember_66a5960e-b93b-4a5f-bf85-063400158161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_ShortTermDebtMember_66a5960e-b93b-4a5f-bf85-063400158161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_9dde0f28-4d71-47bf-b6a1-fa9598410940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_LongTermDebtMember_9dde0f28-4d71-47bf-b6a1-fa9598410940" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i6b5c533c8ac94ab7b802bd0a655d331f_BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7cc5763-f2bd-402c-9da4-073d440cfffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7cc5763-f2bd-402c-9da4-073d440cfffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fcabee26-5b79-469b-98af-033fed6e7f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fcabee26-5b79-469b-98af-033fed6e7f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_48893171-591d-41db-841d-ce3fade34fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_48893171-591d-41db-841d-ce3fade34fac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b67dfa64-e7be-4a68-aaa2-4e03b2da50f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_Depreciation_b67dfa64-e7be-4a68-aaa2-4e03b2da50f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_109461e1-8f71-4896-b8b0-80e83bb9fe27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_109461e1-8f71-4896-b8b0-80e83bb9fe27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ComputerEquipmentAndSoftwareMember_0a114150-7823-47c2-9af2-289b7218c66c" xlink:href="eigr-20221231.xsd#eigr_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_eigr_ComputerEquipmentAndSoftwareMember_0a114150-7823-47c2-9af2-289b7218c66c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e6b92172-3662-4229-bda6-a8564d066fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e6b92172-3662-4229-bda6-a8564d066fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b6b0aef0-2eeb-40c1-bb50-32ef04991fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b6b0aef0-2eeb-40c1-bb50-32ef04991fbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LabEquipmentMember_c158ba9c-e160-4eea-ad13-86c852559cd0" xlink:href="eigr-20221231.xsd#eigr_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_eigr_LabEquipmentMember_c158ba9c-e160-4eea-ad13-86c852559cd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_297a4316-2763-4654-bf25-e70189bee52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_us-gaap_ConstructionInProgressMember_297a4316-2763-4654-bf25-e70189bee52f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail" xlink:type="extended" id="i1b3057bc491a4330b3dc80da75ab4df1_LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NonRefundableIssueFee_1436737b-aa7e-4c9c-a9cc-fa6cf28cd90b" xlink:href="eigr-20221231.xsd#eigr_NonRefundableIssueFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_NonRefundableIssueFee_1436737b-aa7e-4c9c-a9cc-fa6cf28cd90b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseMaintenanceFee_3f53de6a-a006-478e-b9e5-fff0732ca02a" xlink:href="eigr-20221231.xsd#eigr_LicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_LicenseMaintenanceFee_3f53de6a-a006-478e-b9e5-fff0732ca02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MilestoneObligations_4aa2490c-4ee0-4884-a1f3-079d0b04e11b" xlink:href="eigr-20221231.xsd#eigr_MilestoneObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_MilestoneObligations_4aa2490c-4ee0-4884-a1f3-079d0b04e11b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentFees_9ad97e77-dee7-4417-a09b-a0136148d456" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_ProductDevelopmentFees_9ad97e77-dee7-4417-a09b-a0136148d456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PeriodOfCommittedPaymentOfFees_964959c5-1e5d-44ad-a32d-25a208d870a1" xlink:href="eigr-20221231.xsd#eigr_PeriodOfCommittedPaymentOfFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_PeriodOfCommittedPaymentOfFees_964959c5-1e5d-44ad-a32d-25a208d870a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ExpertConsultantFeesAndPassThroughCosts_11290ff0-0b0d-42f7-b7d7-5df8a7e3075b" xlink:href="eigr-20221231.xsd#eigr_ExpertConsultantFeesAndPassThroughCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_ExpertConsultantFeesAndPassThroughCosts_11290ff0-0b0d-42f7-b7d7-5df8a7e3075b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncentiveBasedRegulatoryMilestoneFees_4d11e66d-75f6-4753-9613-1759224ef7ae" xlink:href="eigr-20221231.xsd#eigr_IncentiveBasedRegulatoryMilestoneFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_IncentiveBasedRegulatoryMilestoneFees_4d11e66d-75f6-4753-9613-1759224ef7ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_9e253e25-2341-4a47-b7d3-51b123f7052e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_9e253e25-2341-4a47-b7d3-51b123f7052e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_35fdc2f4-c056-444b-88e1-5e32f63d027f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_35fdc2f4-c056-444b-88e1-5e32f63d027f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CollaborationAgreementInitialTerm_09ce7f66-6a86-45c8-bc56-7e6d08212f46" xlink:href="eigr-20221231.xsd#eigr_CollaborationAgreementInitialTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_CollaborationAgreementInitialTerm_09ce7f66-6a86-45c8-bc56-7e6d08212f46" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CollaborativeArrangementRenewalTerm_7667d62a-28b2-43a2-90d3-1103d72ae7d2" xlink:href="eigr-20221231.xsd#eigr_CollaborativeArrangementRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_CollaborativeArrangementRenewalTerm_7667d62a-28b2-43a2-90d3-1103d72ae7d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpFrontCashPayments_caeddf03-7b1e-41a6-a580-8bab82f0e36d" xlink:href="eigr-20221231.xsd#eigr_UpFrontCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_UpFrontCashPayments_caeddf03-7b1e-41a6-a580-8bab82f0e36d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb29557-55fd-4fb9-a33e-5dabe2883190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb29557-55fd-4fb9-a33e-5dabe2883190" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4e138301-ed29-4b7a-aee8-bdd8dff246fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4e138301-ed29-4b7a-aee8-bdd8dff246fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_390f1657-2878-4f15-8e95-59b1ac4e2f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_CommonStockSharesIssued_390f1657-2878-4f15-8e95-59b1ac4e2f8d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_83c5fa7f-c288-4ded-8fb7-dada7e89c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_CommonStockValue_83c5fa7f-c288-4ded-8fb7-dada7e89c3ac" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentMilestoneObligations_51cea4c4-eea3-4179-a978-fdb9d2ecbab8" xlink:href="eigr-20221231.xsd#eigr_DevelopmentMilestoneObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_DevelopmentMilestoneObligations_51cea4c4-eea3-4179-a978-fdb9d2ecbab8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MilestonePayments_dd570d17-77f4-444e-adae-bd94e18c9282" xlink:href="eigr-20221231.xsd#eigr_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_MilestonePayments_dd570d17-77f4-444e-adae-bd94e18c9282" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_c371b925-71c3-406c-aa51-e5a9344560ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:to="loc_us-gaap_TransactionDomain_c371b925-71c3-406c-aa51-e5a9344560ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_2cdd08f4-4492-4ee9-8310-9d4a8455d66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:to="loc_us-gaap_TransactionDomain_2cdd08f4-4492-4ee9-8310-9d4a8455d66e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_BMSTransactionMember_53d13b68-e585-4e32-8aa8-91b5948d4d86" xlink:href="eigr-20221231.xsd#eigr_BMSTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_2cdd08f4-4492-4ee9-8310-9d4a8455d66e" xlink:to="loc_eigr_BMSTransactionMember_53d13b68-e585-4e32-8aa8-91b5948d4d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1c44697b-d8a0-4009-9a8a-359c0cf04ee6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1c44697b-d8a0-4009-9a8a-359c0cf04ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e207126e-2107-46a0-8a11-1df22ac6cbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:to="loc_us-gaap_LicensingAgreementsMember_e207126e-2107-46a0-8a11-1df22ac6cbfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_985d7236-bad2-41df-bc06-3dde601dbf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_985d7236-bad2-41df-bc06-3dde601dbf3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99be2adb-b327-4fb2-9057-ec9c66327130_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:to="loc_us-gaap_EquityComponentDomain_99be2adb-b327-4fb2-9057-ec9c66327130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b44a72a-6852-440a-a803-40f0d035b763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:to="loc_us-gaap_EquityComponentDomain_9b44a72a-6852-440a-a803-40f0d035b763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_54e977cc-da08-4873-b562-0b3420cc232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b44a72a-6852-440a-a803-40f0d035b763" xlink:to="loc_us-gaap_CommonStockMember_54e977cc-da08-4873-b562-0b3420cc232d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_349680f7-542e-42d8-a070-32a30eba1127_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_349680f7-542e-42d8-a070-32a30eba1127_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46dc8f9a-0210-4306-a98d-5d98eb1e8417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46dc8f9a-0210-4306-a98d-5d98eb1e8417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PurchaseAgreementMember_1c1b1a28-3a0b-4cd8-a331-9ae5672e194d" xlink:href="eigr-20221231.xsd#eigr_PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46dc8f9a-0210-4306-a98d-5d98eb1e8417" xlink:to="loc_eigr_PurchaseAgreementMember_1c1b1a28-3a0b-4cd8-a331-9ae5672e194d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d720a950-5fb5-424c-af2a-09f8f24eca49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d720a950-5fb5-424c-af2a-09f8f24eca49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentAndRegulatoryMilestonesMember_785261b9-1434-4172-a9ac-e564360efdeb" xlink:href="eigr-20221231.xsd#eigr_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_DevelopmentAndRegulatoryMilestonesMember_785261b9-1434-4172-a9ac-e564360efdeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommercialSalesMember_e74439eb-fd9d-43fd-bb88-8c07a2c2a904" xlink:href="eigr-20221231.xsd#eigr_CommercialSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_CommercialSalesMember_e74439eb-fd9d-43fd-bb88-8c07a2c2a904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentPhaseTwoMember_e025e228-f400-40f2-b464-1ec0086fbc48" xlink:href="eigr-20221231.xsd#eigr_DevelopmentPhaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_DevelopmentPhaseTwoMember_e025e228-f400-40f2-b464-1ec0086fbc48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentPhaseThreeMember_656c1e5b-338e-4847-9539-dd83e61bf0c4" xlink:href="eigr-20221231.xsd#eigr_DevelopmentPhaseThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_DevelopmentPhaseThreeMember_656c1e5b-338e-4847-9539-dd83e61bf0c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_327c43fd-b631-4d43-99aa-d22bcfb40512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_327c43fd-b631-4d43-99aa-d22bcfb40512" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55173c31-d613-42e3-9ede-e4263ef5fa79_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:to="loc_srt_RangeMember_55173c31-d613-42e3-9ede-e4263ef5fa79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebf6abad-d8a2-4ab3-87db-afff8f96b0db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:to="loc_srt_RangeMember_ebf6abad-d8a2-4ab3-87db-afff8f96b0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4b5c9cc6-8389-46fc-a202-f076f84b6bb6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ebf6abad-d8a2-4ab3-87db-afff8f96b0db" xlink:to="loc_srt_MaximumMember_4b5c9cc6-8389-46fc-a202-f076f84b6bb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UPennCHOPAgreementMember_d5b42fbc-f27c-467f-a7ff-694939c92d22" xlink:href="eigr-20221231.xsd#eigr_UPennCHOPAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_UPennCHOPAgreementMember_d5b42fbc-f27c-467f-a7ff-694939c92d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementMember_d99ca16e-6a9e-429b-ab06-cf0a7ea8ecfd" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_ProductDevelopmentAgreementMember_d99ca16e-6a9e-429b-ab06-cf0a7ea8ecfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PRFCollaborationAgreementMember_fa548eb8-dddf-426a-b5f7-297206fae15e" xlink:href="eigr-20221231.xsd#eigr_PRFCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_PRFCollaborationAgreementMember_fa548eb8-dddf-426a-b5f7-297206fae15e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MerckTransactionMember_5fdcfa39-4e7b-4796-aba7-37057a67203c" xlink:href="eigr-20221231.xsd#eigr_MerckTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_MerckTransactionMember_5fdcfa39-4e7b-4796-aba7-37057a67203c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_cf732cdb-95ec-4c20-beaa-e7642f61c523_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_cf732cdb-95ec-4c20-beaa-e7642f61c523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_7bd8e0a6-330d-4a2f-824f-4db2feb668da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_7bd8e0a6-330d-4a2f-824f-4db2feb668da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fef2e26b-27ed-4377-938e-f8eb1db9413f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fef2e26b-27ed-4377-938e-f8eb1db9413f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8e50d8f0-3907-4885-9d5c-851dbae2bebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8e50d8f0-3907-4885-9d5c-851dbae2bebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a6c566c4-9399-4239-a684-ee41f591087f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8e50d8f0-3907-4885-9d5c-851dbae2bebb" xlink:to="loc_us-gaap_SubsequentEventMember_a6c566c4-9399-4239-a684-ee41f591087f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail" xlink:type="extended" id="i954d8327f9784182b4b95c229ec9c412_AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpFrontCashPayments_20882ecd-df31-475b-a1d3-bf9d65a570f5" xlink:href="eigr-20221231.xsd#eigr_UpFrontCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_UpFrontCashPayments_20882ecd-df31-475b-a1d3-bf9d65a570f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_a0af8d8e-65de-428d-85ca-5d0da03c166d" xlink:href="eigr-20221231.xsd#eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_a0af8d8e-65de-428d-85ca-5d0da03c166d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_b16eed1a-ae07-455b-b2ac-1bea85de1d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_b16eed1a-ae07-455b-b2ac-1bea85de1d91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_499d13f6-9199-433b-b279-945843ec3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_499d13f6-9199-433b-b279-945843ec3a04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsToPurchaseOfCommonStock_fcd58e77-209c-4d55-864f-7bc7b8dccaaa" xlink:href="eigr-20221231.xsd#eigr_OptionsToPurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_OptionsToPurchaseOfCommonStock_fcd58e77-209c-4d55-864f-7bc7b8dccaaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_798962ee-bd3b-4087-b96a-2f4e48d14a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_798962ee-bd3b-4087-b96a-2f4e48d14a28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_aac8265d-4e62-492e-8ad2-20686f99c177" xlink:href="eigr-20221231.xsd#eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_aac8265d-4e62-492e-8ad2-20686f99c177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VestingOfOptionsToPurchaseCommonStock_70572b3f-e153-4a2c-a0b0-3af7ca6aad51" xlink:href="eigr-20221231.xsd#eigr_VestingOfOptionsToPurchaseCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_VestingOfOptionsToPurchaseCommonStock_70572b3f-e153-4a2c-a0b0-3af7ca6aad51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e003c92-ec12-4c4b-95ea-6f53f75cbca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e003c92-ec12-4c4b-95ea-6f53f75cbca2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseAgreementPotentialMilestonePayments_13f4e2a1-9645-43b3-a894-0646098f1c0c" xlink:href="eigr-20221231.xsd#eigr_LicenseAgreementPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_LicenseAgreementPotentialMilestonePayments_13f4e2a1-9645-43b3-a894-0646098f1c0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseAgreementMilestonePaymentsPaid_78ef37b5-1a50-48fa-ab9d-40a8bce5a61d" xlink:href="eigr-20221231.xsd#eigr_LicenseAgreementMilestonePaymentsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_LicenseAgreementMilestonePaymentsPaid_78ef37b5-1a50-48fa-ab9d-40a8bce5a61d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PaymentForAssetPurchaseAgreement_612cd4b1-a86a-450a-869c-d2cc963d1c00" xlink:href="eigr-20221231.xsd#eigr_PaymentForAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_PaymentForAssetPurchaseAgreement_612cd4b1-a86a-450a-869c-d2cc963d1c00" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_e415f5f6-0af1-4024-a809-ef0b9f1f67f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_e415f5f6-0af1-4024-a809-ef0b9f1f67f8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1cf41f0-e90e-415c-a549-93d829195470_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1cf41f0-e90e-415c-a549-93d829195470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AbbvieAssetPurchaseAgreementMember_fd129685-378d-4335-b027-8c68738cab92" xlink:href="eigr-20221231.xsd#eigr_AbbvieAssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:to="loc_eigr_AbbvieAssetPurchaseAgreementMember_fd129685-378d-4335-b027-8c68738cab92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementMember_3ce75b84-8e6f-4bb6-a833-e0c3efbc665b" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:to="loc_eigr_AssetPurchaseAgreementMember_3ce75b84-8e6f-4bb6-a833-e0c3efbc665b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AvexitidePurchaseAgreementMember_9a54af0a-925e-460e-a030-d89482b65aa2" xlink:href="eigr-20221231.xsd#eigr_AvexitidePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:to="loc_eigr_AvexitidePurchaseAgreementMember_9a54af0a-925e-460e-a030-d89482b65aa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bef68bbb-1415-4340-ae61-3df816386726_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bef68bbb-1415-4340-ae61-3df816386726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134fe113-fc98-4098-bde3-cd3f9db3ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134fe113-fc98-4098-bde3-cd3f9db3ab68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PRFCollaborationAgreementMember_c5c037ff-2877-45df-bc4e-8578b4de4287" xlink:href="eigr-20221231.xsd#eigr_PRFCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134fe113-fc98-4098-bde3-cd3f9db3ab68" xlink:to="loc_eigr_PRFCollaborationAgreementMember_c5c037ff-2877-45df-bc4e-8578b4de4287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fc1d11ab-924e-4930-b169-75af4bf14324_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fc1d11ab-924e-4930-b169-75af4bf14324_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2f7c3b4e-b198-4f74-9d44-57a69692a81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2f7c3b4e-b198-4f74-9d44-57a69692a81c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EIGTransactionMember_7363fe94-3bba-46a1-8785-4181adcb7e60" xlink:href="eigr-20221231.xsd#eigr_EIGTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2f7c3b4e-b198-4f74-9d44-57a69692a81c" xlink:to="loc_eigr_EIGTransactionMember_7363fe94-3bba-46a1-8785-4181adcb7e60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_107a081e-e092-4f80-9c2d-aa6f072f66f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:to="loc_us-gaap_VestingDomain_107a081e-e092-4f80-9c2d-aa6f072f66f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:to="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_be3ec805-f628-414e-aec4-865403d2fe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_be3ec805-f628-414e-aec4-865403d2fe81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_03e41f96-2a7c-469e-a51c-6f0aaab84350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_03e41f96-2a7c-469e-a51c-6f0aaab84350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cbfe5281-70e4-430b-872f-9f3ddf50d567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cbfe5281-70e4-430b-872f-9f3ddf50d567" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedPaymentArrangementTrancheFourMember_e61835f2-158f-4e8e-a956-d534f2b1d4a9" xlink:href="eigr-20221231.xsd#eigr_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_eigr_ShareBasedPaymentArrangementTrancheFourMember_e61835f2-158f-4e8e-a956-d534f2b1d4a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d94fac35-3cae-40d4-9551-7e5e167c8d35_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:to="loc_srt_RangeMember_d94fac35-3cae-40d4-9551-7e5e167c8d35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4142db09-730a-4076-adfa-cdaaffb2a777" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:to="loc_srt_RangeMember_4142db09-730a-4076-adfa-cdaaffb2a777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34892c7b-66b6-471a-a5c4-89005296f2da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4142db09-730a-4076-adfa-cdaaffb2a777" xlink:to="loc_srt_MaximumMember_34892c7b-66b6-471a-a5c4-89005296f2da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#SaleofAssetsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail" xlink:type="extended" id="i85fbed20e690496d88348c31b2d701b9_SaleofAssetsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_2abaa6ac-de59-4519-b99f-227f20cb2c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_2abaa6ac-de59-4519-b99f-227f20cb2c76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_bb9e0946-e185-4f35-8455-b094f95c100a" xlink:href="eigr-20221231.xsd#eigr_SaleOfAssetsNumberOfCommonStockSharesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_bb9e0946-e185-4f35-8455-b094f95c100a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_c0efa331-245b-4b98-b970-a92de63c0853" xlink:href="eigr-20221231.xsd#eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_c0efa331-245b-4b98-b970-a92de63c0853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_8aa19c50-9f80-44ee-bada-07a6fb9ac1b7" xlink:href="eigr-20221231.xsd#eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_8aa19c50-9f80-44ee-bada-07a6fb9ac1b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AggregateCommonStockConsiderationValue_4ddf8f29-9840-4419-b3c2-809cd84ac91c" xlink:href="eigr-20221231.xsd#eigr_AggregateCommonStockConsiderationValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_AggregateCommonStockConsiderationValue_4ddf8f29-9840-4419-b3c2-809cd84ac91c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_a2c8a521-3c98-498c-81f0-bb1e5e6dac09" xlink:href="eigr-20221231.xsd#eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_a2c8a521-3c98-498c-81f0-bb1e5e6dac09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_9ad535b5-d486-49a8-9472-358195969315" xlink:href="eigr-20221231.xsd#eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_9ad535b5-d486-49a8-9472-358195969315" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_0805b44e-8f57-4356-a15d-e967d9e9b446" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementContingentConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_0805b44e-8f57-4356-a15d-e967d9e9b446" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RoyaltyReceivablePercentageOnNetSales_a73b1982-8ddd-426e-b945-aef93b821e9b" xlink:href="eigr-20221231.xsd#eigr_RoyaltyReceivablePercentageOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_RoyaltyReceivablePercentageOnNetSales_a73b1982-8ddd-426e-b945-aef93b821e9b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_08305ab0-ea99-4b0d-8ae1-7dc943e681c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_08305ab0-ea99-4b0d-8ae1-7dc943e681c6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_47b1bee6-1e4b-4811-8f0e-9a5ad42f6c60" xlink:href="eigr-20221231.xsd#eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_47b1bee6-1e4b-4811-8f0e-9a5ad42f6c60" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_51d26d60-dc85-43b9-8112-fe39255f7e86" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_51d26d60-dc85-43b9-8112-fe39255f7e86" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_95bb74ad-3063-4d00-863e-56138db8af59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_95bb74ad-3063-4d00-863e-56138db8af59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_668a1a5c-6f46-4c54-9c06-5bc8ae2d656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_668a1a5c-6f46-4c54-9c06-5bc8ae2d656e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_c6486161-b64f-40d4-8f95-bbd44cbb5f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_668a1a5c-6f46-4c54-9c06-5bc8ae2d656e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_c6486161-b64f-40d4-8f95-bbd44cbb5f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eea11648-85e4-4e01-9227-3a8fb446db82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eea11648-85e4-4e01-9227-3a8fb446db82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MYDICARMember_2c3e50de-4343-47e0-b514-98a65cccffba" xlink:href="eigr-20221231.xsd#eigr_MYDICARMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eea11648-85e4-4e01-9227-3a8fb446db82" xlink:to="loc_eigr_MYDICARMember_2c3e50de-4343-47e0-b514-98a65cccffba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5639f16f-eb27-489c-93d2-3091b437b71f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5639f16f-eb27-489c-93d2-3091b437b71f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a8c6a8e1-1c3c-4595-9045-622028d753af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a8c6a8e1-1c3c-4595-9045-622028d753af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_TheragenePharmaceuticalsIncMember_0849ca86-4ae2-4993-95c3-532a760c2302" xlink:href="eigr-20221231.xsd#eigr_TheragenePharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a8c6a8e1-1c3c-4595-9045-622028d753af" xlink:to="loc_eigr_TheragenePharmaceuticalsIncMember_0849ca86-4ae2-4993-95c3-532a760c2302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e39555bc-6a28-4400-ade3-eee44e32b059_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:to="loc_srt_RangeMember_e39555bc-6a28-4400-ade3-eee44e32b059_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:to="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ee06d24-8038-44e9-afd9-9949e3fcf2ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:to="loc_srt_MinimumMember_6ee06d24-8038-44e9-afd9-9949e3fcf2ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87270ba0-9db8-4544-ba86-36087f0a02ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:to="loc_srt_MaximumMember_87270ba0-9db8-4544-ba86-36087f0a02ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/DebtAdditionalInformationDetail" xlink:type="extended" id="ied156adb0c8f49458a9585778f086497_DebtAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_69bd0e40-dd80-4688-be3f-f86aa648dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_69bd0e40-dd80-4688-be3f-f86aa648dd48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1dd758dc-7b74-4b89-9e31-50cd025cfc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1dd758dc-7b74-4b89-9e31-50cd025cfc39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentPercentOfInterestDue_4dfed00a-d462-49e3-9f1f-9c06ef342d49" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentPercentOfInterestDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentPercentOfInterestDue_4dfed00a-d462-49e3-9f1f-9c06ef342d49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFeePayablePercentage_c322a56b-967d-4be1-9b81-20bbbaa60dba" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFeePayablePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentExitFeePayablePercentage_c322a56b-967d-4be1-9b81-20bbbaa60dba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_63e5918c-ec55-4171-a779-4d2ae566a6b1" xlink:href="eigr-20221231.xsd#eigr_MinimumCashBalanceOfFaceValueOfLoanPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_63e5918c-ec55-4171-a779-4d2ae566a6b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d9dd9aa3-aa07-4508-879a-99849d558863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d9dd9aa3-aa07-4508-879a-99849d558863" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_07b85730-388d-4324-9248-5e1810cbc003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_07b85730-388d-4324-9248-5e1810cbc003" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_646baf24-f4b8-4b85-8359-1ca3b7cd74ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_646baf24-f4b8-4b85-8359-1ca3b7cd74ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4ef9f687-db80-4b83-a439-d26da0d3ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_InterestExpense_4ef9f687-db80-4b83-a439-d26da0d3ac37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d369e04-65d0-4c29-ab24-45e79352ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d369e04-65d0-4c29-ab24-45e79352ac8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_03b2bc2b-5d48-47d7-842e-2492517e2bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_03b2bc2b-5d48-47d7-842e-2492517e2bfe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28cf4509-fb6b-42ac-83ac-e02b76586526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28cf4509-fb6b-42ac-83ac-e02b76586526" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee628e35-d993-46f3-a791-17743b6dbb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee628e35-d993-46f3-a791-17743b6dbb54" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f1b6b66b-39aa-4a59-9b48-c6d9a42ad050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f1b6b66b-39aa-4a59-9b48-c6d9a42ad050" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_07cd8043-7258-4be4-9172-c97cacb51eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCredit_07cd8043-7258-4be4-9172-c97cacb51eab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_672b16cd-7e96-437c-9b34-28c3b6c5855f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_672b16cd-7e96-437c-9b34-28c3b6c5855f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ccdfe95a-c42e-42f0-b506-edf73ebaf46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ccdfe95a-c42e-42f0-b506-edf73ebaf46f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentInterestPaymentPeriod_cd235646-39d6-40e6-ab90-41d1ca8a5009" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentInterestPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentInterestPaymentPeriod_cd235646-39d6-40e6-ab90-41d1ca8a5009" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_74aa47c7-3afe-42c6-b54a-53a4d85eb50e" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_74aa47c7-3afe-42c6-b54a-53a4d85eb50e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendmentFeesPayment_ca38807f-64e1-4f3b-a690-282e3436486c" xlink:href="eigr-20221231.xsd#eigr_AmendmentFeesPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_AmendmentFeesPayment_ca38807f-64e1-4f3b-a690-282e3436486c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedExitFees_bd377145-c07d-4132-93c3-4d29c436cbd4" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedExitFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentUnamortizedExitFees_bd377145-c07d-4132-93c3-4d29c436cbd4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedAdditionalExitFees_d3d87363-81ea-45fd-820c-90889c7bc3a4" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedAdditionalExitFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentUnamortizedAdditionalExitFees_d3d87363-81ea-45fd-820c-90889c7bc3a4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_38de1f99-df56-436b-9fa6-ea08effbc506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_38de1f99-df56-436b-9fa6-ea08effbc506" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_46f12233-eba7-4efa-a573-2864abb266f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_46f12233-eba7-4efa-a573-2864abb266f2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a58e98c2-aa9f-4355-81d1-593ef030bb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a58e98c2-aa9f-4355-81d1-593ef030bb9a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LineOfCreditFacilityOtherFinalPayments_0de1ad8a-e560-440d-b738-edbeeee98814" xlink:href="eigr-20221231.xsd#eigr_LineOfCreditFacilityOtherFinalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_LineOfCreditFacilityOtherFinalPayments_0de1ad8a-e560-440d-b738-edbeeee98814" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c7d3facb-fc9c-474a-b29e-b120d6f49d11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c7d3facb-fc9c-474a-b29e-b120d6f49d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7de0a5d5-b637-423f-bef1-99bb51e0641e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7de0a5d5-b637-423f-bef1-99bb51e0641e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_22e4b610-ebca-406d-8c78-69524e5ea8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7de0a5d5-b637-423f-bef1-99bb51e0641e" xlink:to="loc_us-gaap_LineOfCreditMember_22e4b610-ebca-406d-8c78-69524e5ea8ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_229759a4-dc6f-4aef-8f66-7427e1d8b01d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_229759a4-dc6f-4aef-8f66-7427e1d8b01d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusLoanMember_de830acb-6dc6-4c0b-a254-3bb4576f940b" xlink:href="eigr-20221231.xsd#eigr_InnovatusLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_InnovatusLoanMember_de830acb-6dc6-4c0b-a254-3bb4576f940b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanMember_fe0ea84f-17d3-4c15-aaa2-5fbe84f634a2" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_OxfordLoanMember_fe0ea84f-17d3-4c15-aaa2-5fbe84f634a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanAmendmentMember_2ce04f5a-6e0e-42b0-9fd4-9e2e3a4189b8" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_OxfordLoanAmendmentMember_2ce04f5a-6e0e-42b0-9fd4-9e2e3a4189b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedOxfordLoanMember_b0aa0047-b79e-4937-9564-0af9cac10b0b" xlink:href="eigr-20221231.xsd#eigr_AmendedOxfordLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_AmendedOxfordLoanMember_b0aa0047-b79e-4937-9564-0af9cac10b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanFifthAmendmentMember_9a71843e-258f-4a28-9ec7-956771edf3fb" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanFifthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_OxfordLoanFifthAmendmentMember_9a71843e-258f-4a28-9ec7-956771edf3fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:to="loc_us-gaap_CreditFacilityDomain_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b1c07d87-bac9-4019-812b-ddf82b897249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:to="loc_us-gaap_CreditFacilityDomain_b1c07d87-bac9-4019-812b-ddf82b897249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b1c07d87-bac9-4019-812b-ddf82b897249" xlink:to="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheAMember_e249ab22-f78c-4df0-9e45-843e9d869aac" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheAMember_e249ab22-f78c-4df0-9e45-843e9d869aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtAmendedTrancheAMember_524c59e4-681d-4149-8a97-bd00c33357b3" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtAmendedTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_SecuredDebtTrancheAMember_e249ab22-f78c-4df0-9e45-843e9d869aac" xlink:to="loc_eigr_SecuredDebtAmendedTrancheAMember_524c59e4-681d-4149-8a97-bd00c33357b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheBMember_6339ede0-461d-421c-b40e-64a3c0d42cb6" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheBMember_6339ede0-461d-421c-b40e-64a3c0d42cb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedTrancheBMember_ba5685e3-5826-428f-aa79-eb4ecc3840ff" xlink:href="eigr-20221231.xsd#eigr_AmendedTrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_SecuredDebtTrancheBMember_6339ede0-461d-421c-b40e-64a3c0d42cb6" xlink:to="loc_eigr_AmendedTrancheBMember_ba5685e3-5826-428f-aa79-eb4ecc3840ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheCMember_a59a41a1-8de0-42b2-a4e4-4ad2734e5ed3" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheCMember_a59a41a1-8de0-42b2-a4e4-4ad2734e5ed3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheBAndCMember_e1ef6d95-faf9-4344-8999-17b54c368409" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheBAndCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheBAndCMember_e1ef6d95-faf9-4344-8999-17b54c368409" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentDomain_f102c95b-d3d7-4527-8077-181d65743f3b_default" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:to="loc_eigr_VariableRateComponentDomain_f102c95b-d3d7-4527-8077-181d65743f3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:to="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentOneMember_df87fbb1-1cc9-4ee7-ab72-59050848b58a" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:to="loc_eigr_VariableRateComponentOneMember_df87fbb1-1cc9-4ee7-ab72-59050848b58a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentTwoMember_d7611e98-4e09-4b27-85d5-e710668fead6" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:to="loc_eigr_VariableRateComponentTwoMember_d7611e98-4e09-4b27-85d5-e710668fead6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14e82bb2-6616-49ba-b514-2c81b6f93610_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:to="loc_srt_RangeMember_14e82bb2-6616-49ba-b514-2c81b6f93610_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb1caa7c-1af2-47c1-9035-52dd62da42e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:to="loc_srt_RangeMember_fb1caa7c-1af2-47c1-9035-52dd62da42e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4465b67-2918-4097-9dfd-bbd100b274c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb1caa7c-1af2-47c1-9035-52dd62da42e0" xlink:to="loc_srt_MinimumMember_e4465b67-2918-4097-9dfd-bbd100b274c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6106eba6-9ee3-4764-8e79-0c7cc0d01398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6106eba6-9ee3-4764-8e79-0c7cc0d01398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d298839-3c4d-4dce-8015-3b1f69cb762f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d298839-3c4d-4dce-8015-3b1f69cb762f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusStockPurchaseAgreementMember_9717fc9d-eba9-4022-9e4f-8e9cd18bab04" xlink:href="eigr-20221231.xsd#eigr_InnovatusStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d298839-3c4d-4dce-8015-3b1f69cb762f" xlink:to="loc_eigr_InnovatusStockPurchaseAgreementMember_9717fc9d-eba9-4022-9e4f-8e9cd18bab04" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtScheduleofMaturitiesofLongtermDebtDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail" xlink:type="extended" id="i234e88be69254351b89d99ebf1cdde16_DebtScheduleofMaturitiesofLongtermDebtDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e3c30ca3-9d95-4089-ae54-ff68ae7235c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e3c30ca3-9d95-4089-ae54-ff68ae7235c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_febb544f-f601-4ce8-aae6-77f800577778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_febb544f-f601-4ce8-aae6-77f800577778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dc773c08-517a-4c92-926f-be44381de4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dc773c08-517a-4c92-926f-be44381de4b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4cf8cac4-4d6b-4e0b-8725-5b92e2e8f38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4cf8cac4-4d6b-4e0b-8725-5b92e2e8f38b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_47244359-f02c-48b4-98c5-6bd7cbf9f228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_47244359-f02c-48b4-98c5-6bd7cbf9f228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6a9f674a-1a3c-420e-9785-d6ee85ebb038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6a9f674a-1a3c-420e-9785-d6ee85ebb038" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6bc075a7-6160-4b7e-9b82-28f67d8866ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6bc075a7-6160-4b7e-9b82-28f67d8866ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFee_abc76d95-c195-4452-94f7-3330a988861a" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_eigr_DebtInstrumentExitFee_abc76d95-c195-4452-94f7-3330a988861a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_439dfe43-cfcc-454f-a6d8-e6bca20ccc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_439dfe43-cfcc-454f-a6d8-e6bca20ccc4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:to="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_982c1835-1b0f-4f08-931f-63cbe8f9f724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:to="loc_us-gaap_CreditFacilityDomain_982c1835-1b0f-4f08-931f-63cbe8f9f724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_73e01dea-c5c6-47dd-9986-a85a6fab417e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:to="loc_us-gaap_CreditFacilityDomain_73e01dea-c5c6-47dd-9986-a85a6fab417e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedTrancheAMember_4d461683-2e56-4573-958d-401c61a217f8" xlink:href="eigr-20221231.xsd#eigr_AmendedTrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_73e01dea-c5c6-47dd-9986-a85a6fab417e" xlink:to="loc_eigr_AmendedTrancheAMember_4d461683-2e56-4573-958d-401c61a217f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:to="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c08cbae7-2afc-4cfc-a58d-6dc6a656897a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c08cbae7-2afc-4cfc-a58d-6dc6a656897a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80e1bf83-32c7-4bde-aee0-b2671d9603f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80e1bf83-32c7-4bde-aee0-b2671d9603f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusLoanMember_8296f41f-9dcf-4701-92be-6ed3857bc6bb" xlink:href="eigr-20221231.xsd#eigr_InnovatusLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80e1bf83-32c7-4bde-aee0-b2671d9603f8" xlink:to="loc_eigr_InnovatusLoanMember_8296f41f-9dcf-4701-92be-6ed3857bc6bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" id="i2c17477dcfab4cd98f9dc897ebe9d8ef_StockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DividendsDeclared_ccd3f9f6-70bb-438c-8f09-2e4298855b94" xlink:href="eigr-20221231.xsd#eigr_DividendsDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_DividendsDeclared_ccd3f9f6-70bb-438c-8f09-2e4298855b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_5254fcbd-ca66-41c9-9344-578169349bfa" xlink:href="eigr-20221231.xsd#eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_5254fcbd-ca66-41c9-9344-578169349bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_eb199d9f-0a87-46fd-951d-7f8e56c31210" xlink:href="eigr-20221231.xsd#eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_eb199d9f-0a87-46fd-951d-7f8e56c31210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5aaf1a3-6820-4c13-9f2b-5a3f8963487a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5aaf1a3-6820-4c13-9f2b-5a3f8963487a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2a55c8b-9abe-4968-977d-56c57358d9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2a55c8b-9abe-4968-977d-56c57358d9e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommonStockValueAvailableForFutureIssuance_ca01315c-d0c2-4f31-bd73-a5c4d0293c66" xlink:href="eigr-20221231.xsd#eigr_CommonStockValueAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_CommonStockValueAvailableForFutureIssuance_ca01315c-d0c2-4f31-bd73-a5c4d0293c66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1eaffa99-eb54-4259-a188-afc34f1fb3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1eaffa99-eb54-4259-a188-afc34f1fb3d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e521d38-4d3e-4117-9add-a140996ffa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e521d38-4d3e-4117-9add-a140996ffa5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_671c9e88-425b-402d-ba1e-de2178c6e80d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_671c9e88-425b-402d-ba1e-de2178c6e80d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_398bd265-9e64-446c-9a63-f331466b4184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_398bd265-9e64-446c-9a63-f331466b4184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AtTheMarketOfferingMember_a04291a2-4043-4c0d-953a-96de64b396e4" xlink:href="eigr-20221231.xsd#eigr_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_398bd265-9e64-446c-9a63-f331466b4184" xlink:to="loc_eigr_AtTheMarketOfferingMember_a04291a2-4043-4c0d-953a-96de64b396e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:to="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9025f92-5b95-41aa-98e4-1796406ff207_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:to="loc_srt_RangeMember_c9025f92-5b95-41aa-98e4-1796406ff207_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b9b286a-baf9-413a-bbdc-8f22017456b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:to="loc_srt_RangeMember_5b9b286a-baf9-413a-bbdc-8f22017456b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dae9b6a5-8369-4017-a81b-1af085089035" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b9b286a-baf9-413a-bbdc-8f22017456b6" xlink:to="loc_srt_MaximumMember_dae9b6a5-8369-4017-a81b-1af085089035" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i9f08428638b546f99458957b07178146_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_9e2c4012-b479-4823-bd9d-a80046626989" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_9e2c4012-b479-4823-bd9d-a80046626989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_87da4748-2b93-4b8c-9617-4c2c127f05b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_87da4748-2b93-4b8c-9617-4c2c127f05b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f7f162a-6bd8-4d15-9ac4-d370b3786c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f7f162a-6bd8-4d15-9ac4-d370b3786c5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0eeee1df-0942-4b14-af7d-24b6cb571b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0eeee1df-0942-4b14-af7d-24b6cb571b59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6c46c887-77f8-4e5e-adc7-d2276e592f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6c46c887-77f8-4e5e-adc7-d2276e592f56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ced5f96d-545d-4cbb-be37-253148930355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ced5f96d-545d-4cbb-be37-253148930355" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3778ce44-fb88-44ae-be43-2ecec2fd9c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3778ce44-fb88-44ae-be43-2ecec2fd9c21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ClosingPriceOfCommonStock_87923fec-cc55-4bd7-ba3e-edd7ae2274ca" xlink:href="eigr-20221231.xsd#eigr_ClosingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_eigr_ClosingPriceOfCommonStock_87923fec-cc55-4bd7-ba3e-edd7ae2274ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a383e85f-2390-4554-bffa-7f5f0e593f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a383e85f-2390-4554-bffa-7f5f0e593f06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3cf1e1b7-9a4f-4cd3-82f7-a7299d7b2a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3cf1e1b7-9a4f-4cd3-82f7-a7299d7b2a00" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_750a8d6c-7445-42fb-ade4-eb4c535e99a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_750a8d6c-7445-42fb-ade4-eb4c535e99a1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c73f92d-5caa-406f-929a-84040fb9ff16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c73f92d-5caa-406f-929a-84040fb9ff16" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_629b063f-e733-45ea-88f9-94c74135fc13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_629b063f-e733-45ea-88f9-94c74135fc13" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_49c132bf-6231-4c20-a5b1-7d2588076735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_49c132bf-6231-4c20-a5b1-7d2588076735" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81b09bbc-5159-4b33-8de0-316d2a27224b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81b09bbc-5159-4b33-8de0-316d2a27224b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7f8c7d52-1fca-4328-b442-1b60a4405cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7f8c7d52-1fca-4328-b442-1b60a4405cb8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_34ec174f-683b-4842-9e7b-d058d186b3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_34ec174f-683b-4842-9e7b-d058d186b3b1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_6ed42078-8df4-4687-aa6a-439e37f9567d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_6ed42078-8df4-4687-aa6a-439e37f9567d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a5381d4b-7c17-41be-ac75-99befa0a9a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a5381d4b-7c17-41be-ac75-99befa0a9a69" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f964018c-6d00-4279-ae7b-468cdcc59c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f964018c-6d00-4279-ae7b-468cdcc59c22" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5380d3b1-049c-4e9a-a7a6-760fa5328ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5380d3b1-049c-4e9a-a7a6-760fa5328ea6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbf93135-2f94-405c-87ed-ed2f8732d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbf93135-2f94-405c-87ed-ed2f8732d6a0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20200abf-85a0-4393-a411-a670d612bafe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:to="loc_srt_RangeMember_20200abf-85a0-4393-a411-a670d612bafe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:to="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e903ab73-944f-40e5-b99d-9c21e68b1a29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:to="loc_srt_MinimumMember_e903ab73-944f-40e5-b99d-9c21e68b1a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b0c8b65-e50a-411c-aa13-e61f1248812c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:to="loc_srt_MaximumMember_0b0c8b65-e50a-411c-aa13-e61f1248812c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_203647b6-6ace-4649-9745-897ad856b554_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:to="loc_us-gaap_PlanNameDomain_203647b6-6ace-4649-9745-897ad856b554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:to="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_35a4562a-a198-4240-9520-b5d82a0d12b5" xlink:href="eigr-20221231.xsd#eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:to="loc_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_35a4562a-a198-4240-9520-b5d82a0d12b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InducementPlan2021Member_154b4ee3-fe35-4a20-81de-7587a68f5968" xlink:href="eigr-20221231.xsd#eigr_InducementPlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:to="loc_eigr_InducementPlan2021Member_154b4ee3-fe35-4a20-81de-7587a68f5968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_d381df57-ed87-4fb4-bd47-5f3d06917394" xlink:href="eigr-20221231.xsd#eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:to="loc_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_d381df57-ed87-4fb4-bd47-5f3d06917394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5540b299-e73c-4699-8019-b82443442e99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:to="loc_us-gaap_ClassOfStockDomain_5540b299-e73c-4699-8019-b82443442e99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd636401-795c-45d7-bda4-4c904ba33bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:to="loc_us-gaap_ClassOfStockDomain_dd636401-795c-45d7-bda4-4c904ba33bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_b1c68635-b7bc-41f9-a847-e994b55d2d40" xlink:href="eigr-20221231.xsd#eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dd636401-795c-45d7-bda4-4c904ba33bec" xlink:to="loc_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_b1c68635-b7bc-41f9-a847-e994b55d2d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704dc899-101d-46f3-a661-f89159dbba47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704dc899-101d-46f3-a661-f89159dbba47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_4ef7b4e0-e07c-440a-8915-c299c1fab92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:to="loc_us-gaap_StockOptionMember_4ef7b4e0-e07c-440a-8915-c299c1fab92b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PerformanceStockUnitsPSUMember_2dc5ea5d-d90a-4663-b101-e278113b52bf" xlink:href="eigr-20221231.xsd#eigr_PerformanceStockUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:to="loc_eigr_PerformanceStockUnitsPSUMember_2dc5ea5d-d90a-4663-b101-e278113b52bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0dc3021d-4ed2-4ebf-a6eb-3c7b7372b19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0dc3021d-4ed2-4ebf-a6eb-3c7b7372b19a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b417ed1a-fc4c-408d-950c-22314e2546b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:to="loc_us-gaap_EquityComponentDomain_b417ed1a-fc4c-408d-950c-22314e2546b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:to="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7ee25bb5-0fd7-4bd9-8ad3-8c420ee4f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:to="loc_us-gaap_CommonStockMember_7ee25bb5-0fd7-4bd9-8ad3-8c420ee4f1ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_55dcda58-f6d7-4be6-af61-57791df1b925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_55dcda58-f6d7-4be6-af61-57791df1b925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6c6e5ec2-611b-4412-8fea-66e7198a527a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:to="loc_us-gaap_VestingDomain_6c6e5ec2-611b-4412-8fea-66e7198a527a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:to="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bc53460b-b17a-47fa-af61-8c5a49e1cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bc53460b-b17a-47fa-af61-8c5a49e1cc91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b5148b45-ea02-41f3-821a-3e4fd9a65cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b5148b45-ea02-41f3-821a-3e4fd9a65cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_98041ad1-75f4-4461-b87a-104453357051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_98041ad1-75f4-4461-b87a-104453357051" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail" xlink:type="extended" id="i2f620c6164634e70aec234d58baa04a3_StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5848c-61ec-470f-841d-b230b94b2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5848c-61ec-470f-841d-b230b94b2bd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3e36310a-bae2-4ec1-a502-e1494b8d2e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3e36310a-bae2-4ec1-a502-e1494b8d2e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_587c46d1-542b-44a1-bff0-20035a5f745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_587c46d1-542b-44a1-bff0-20035a5f745e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fb23acf8-fa19-44c8-b86a-5fa472610a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fb23acf8-fa19-44c8-b86a-5fa472610a25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8ade04fb-fd58-49b9-b329-2cd5038596ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8ade04fb-fd58-49b9-b329-2cd5038596ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47c81fae-41e3-49fa-9b5d-37aa3c2239d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47c81fae-41e3-49fa-9b5d-37aa3c2239d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7074a71-78fd-4524-96c4-5ce7bf0a820c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7074a71-78fd-4524-96c4-5ce7bf0a820c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:to="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d198516-31dd-4a57-88bd-a7d863a19c0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d198516-31dd-4a57-88bd-a7d863a19c0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2dae5fc6-5b0f-46db-9d45-ce17b7cec235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2dae5fc6-5b0f-46db-9d45-ce17b7cec235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NonEmployeeStockOptionMember_57836d4b-a378-4834-8a97-192f34281f2b" xlink:href="eigr-20221231.xsd#eigr_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:to="loc_eigr_NonEmployeeStockOptionMember_57836d4b-a378-4834-8a97-192f34281f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:to="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ac73124-f61a-4f96-8655-04098927cbfb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:to="loc_srt_RangeMember_9ac73124-f61a-4f96-8655-04098927cbfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:to="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cbff82b5-36b9-44f0-8edc-b73c0e19c1f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:to="loc_srt_MinimumMember_cbff82b5-36b9-44f0-8edc-b73c0e19c1f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a602760b-ed99-41f8-9aa7-0f27a29043b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:to="loc_srt_MaximumMember_a602760b-ed99-41f8-9aa7-0f27a29043b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail" xlink:type="extended" id="idef69675ed704ce28bacc7c301410422_StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ebbff3-ae66-48fc-a6f6-2d37278310f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ebbff3-ae66-48fc-a6f6-2d37278310f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8792d83-0759-46ea-91d4-2e17358f1594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8792d83-0759-46ea-91d4-2e17358f1594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25203561-1603-42d4-8a81-c2b077d8163e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25203561-1603-42d4-8a81-c2b077d8163e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a9277ba0-97e5-4feb-9c10-65fbb549f2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a9277ba0-97e5-4feb-9c10-65fbb549f2db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7f0f6b2-f6a5-4e18-846f-3e568055c880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c392419-8e75-43de-a75e-1e148643144f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c392419-8e75-43de-a75e-1e148643144f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_72c88696-64cd-42ce-a913-1ee0e168f1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_72c88696-64cd-42ce-a913-1ee0e168f1f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e32277ed-5a64-4f93-bd16-dbe9f6c95a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e32277ed-5a64-4f93-bd16-dbe9f6c95a0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6ce2837b-d4ea-4a8c-b3ba-84dc16ba27cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6ce2837b-d4ea-4a8c-b3ba-84dc16ba27cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f5b802d-21e4-481d-b43e-c9c2451331a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:to="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2850f98d-ef96-429e-af87-07991cc5a2a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2850f98d-ef96-429e-af87-07991cc5a2a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_269d4f5b-2d0a-452c-91f8-cdf266b12bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_269d4f5b-2d0a-452c-91f8-cdf266b12bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_a51b1242-5399-4abe-ac77-033d3bab5961" xlink:href="eigr-20221231.xsd#eigr_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_269d4f5b-2d0a-452c-91f8-cdf266b12bf0" xlink:to="loc_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_a51b1242-5399-4abe-ac77-033d3bab5961" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail" xlink:type="extended" id="id1508db54d054529989435b26d50d5d0_StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce43c95b-57c6-4933-8828-87e7836f545a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1bd50a41-766b-4ab8-9542-b60699e03505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce43c95b-57c6-4933-8828-87e7836f545a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1bd50a41-766b-4ab8-9542-b60699e03505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce43c95b-57c6-4933-8828-87e7836f545a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65324be9-caad-4462-b122-bc9eb0eec37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65324be9-caad-4462-b122-bc9eb0eec37a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9226028-67ff-4f02-aac2-11729d1b3d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9226028-67ff-4f02-aac2-11729d1b3d05" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="ifbcb543fd0b84f0d83aaf7241af28c4e_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6b5b3491-e6a5-47af-91fc-b64844a226d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6b5b3491-e6a5-47af-91fc-b64844a226d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f8ba1506-05ca-4fba-9666-877c4f14e804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f8ba1506-05ca-4fba-9666-877c4f14e804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d2f2b142-dbcd-45e9-a293-09d31d7fa295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d2f2b142-dbcd-45e9-a293-09d31d7fa295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_db708867-007b-48da-bd3d-8f4f45df15b3" xlink:href="eigr-20221231.xsd#eigr_IncreaseInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_db708867-007b-48da-bd3d-8f4f45df15b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b45328ad-4f47-443d-ab21-1d0c6745b0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b45328ad-4f47-443d-ab21-1d0c6745b0db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_50b43e25-fad9-41da-be06-0e25c7f850a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4c93aa76-bee1-41e4-b2e2-9e50d8003077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4c93aa76-bee1-41e4-b2e2-9e50d8003077" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7b512027-c642-44a8-81aa-523d2cefaf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7b512027-c642-44a8-81aa-523d2cefaf6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2e2ddf67-f0d6-402b-aa28-00a00637ba85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2e2ddf67-f0d6-402b-aa28-00a00637ba85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e70e4b0c-01bd-42f6-9469-17145cbb29c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e70e4b0c-01bd-42f6-9469-17145cbb29c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_633b8fb6-0bf4-424a-a85c-9bc3e1ad8a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_633b8fb6-0bf4-424a-a85c-9bc3e1ad8a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_161f590b-853d-4bb3-9832-9885674712ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:to="loc_us-gaap_DomesticCountryMember_161f590b-853d-4bb3-9832-9885674712ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e11a79f6-c988-424b-ba65-c6ace2cb382b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e11a79f6-c988-424b-ba65-c6ace2cb382b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0229bd4-7836-4d6d-a82b-1f97d70c239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0229bd4-7836-4d6d-a82b-1f97d70c239b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OrphanDrugCreditCarryforwardMember_3bed638c-3b83-4040-8afb-48b6dd6e4e5b" xlink:href="eigr-20221231.xsd#eigr_OrphanDrugCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0229bd4-7836-4d6d-a82b-1f97d70c239b" xlink:to="loc_eigr_OrphanDrugCreditCarryforwardMember_3bed638c-3b83-4040-8afb-48b6dd6e4e5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i4fa6a1777b6a4748a926c2d62546cb75_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_944eada1-a836-40f5-b3f5-9be3c4643e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_944eada1-a836-40f5-b3f5-9be3c4643e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d384a1f5-f06e-444c-8cfb-aec6b70c007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d384a1f5-f06e-444c-8cfb-aec6b70c007d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_b1c447fe-0f23-4f98-a37f-a575e073d2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_b1c447fe-0f23-4f98-a37f-a575e073d2a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8bd1e20c-f902-4db7-ad0d-1379c873774c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeaseExpense_8bd1e20c-f902-4db7-ad0d-1379c873774c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6f0bde4f-884e-4a18-8533-570a4d05fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_VariableLeaseCost_6f0bde4f-884e-4a18-8533-570a4d05fc25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_41703128-e917-4a60-9514-51f584fcd2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeasePayments_41703128-e917-4a60-9514-51f584fcd2c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ae96ce5a-0e4b-4c94-8cf0-69a9418218d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ae96ce5a-0e4b-4c94-8cf0-69a9418218d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9bf58e6a-febe-4002-909a-1b9cb750c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9bf58e6a-febe-4002-909a-1b9cb750c06b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_e5fc9b3d-b9e7-468f-94ff-73c54844a51f" xlink:href="eigr-20221231.xsd#eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_e5fc9b3d-b9e7-468f-94ff-73c54844a51f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PercentageOfPurchasePrice_38dc2495-1c1e-4753-91ce-c77f1fa7ed34" xlink:href="eigr-20221231.xsd#eigr_PercentageOfPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_eigr_PercentageOfPurchasePrice_38dc2495-1c1e-4753-91ce-c77f1fa7ed34" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_94176c65-03a9-44e0-8a40-f880ba624b5b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:to="loc_srt_SegmentGeographicalDomain_94176c65-03a9-44e0-8a40-f880ba624b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f446d19c-291c-4804-a79c-aa3d7ec51a39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:to="loc_srt_SegmentGeographicalDomain_f446d19c-291c-4804-a79c-aa3d7ec51a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_7cc7eaa0-84cf-4c15-a6cc-3dee65c358b5" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f446d19c-291c-4804-a79c-aa3d7ec51a39" xlink:to="loc_stpr_CA_7cc7eaa0-84cf-4c15-a6cc-3dee65c358b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3658da1c-1fb1-4884-a2a2-5613382bd28f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3658da1c-1fb1-4884-a2a2-5613382bd28f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0010cc6e-3268-49f7-8e72-fe475802435b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0010cc6e-3268-49f7-8e72-fe475802435b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PatheonIncMember_1b3a305f-f276-43bf-93c5-b6ff71e82f40" xlink:href="eigr-20221231.xsd#eigr_PatheonIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0010cc6e-3268-49f7-8e72-fe475802435b" xlink:to="loc_eigr_PatheonIncMember_1b3a305f-f276-43bf-93c5-b6ff71e82f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44b7f199-a0c5-4f08-8395-001b77aa0ea7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44b7f199-a0c5-4f08-8395-001b77aa0ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9be8939c-2c77-41ec-8469-50fee1e6f76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9be8939c-2c77-41ec-8469-50fee1e6f76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MasterManufacturingServicesAgreementMember_234f7a0d-69c2-4cd1-a9b8-a4ee284bc450" xlink:href="eigr-20221231.xsd#eigr_MasterManufacturingServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9be8939c-2c77-41ec-8469-50fee1e6f76a" xlink:to="loc_eigr_MasterManufacturingServicesAgreementMember_234f7a0d-69c2-4cd1-a9b8-a4ee284bc450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1abbdb4a-1432-4829-a5c5-6038d3563e28_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:to="loc_srt_RangeMember_1abbdb4a-1432-4829-a5c5-6038d3563e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dafa5646-8158-4a41-b8ab-090f0dd058a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:to="loc_srt_RangeMember_dafa5646-8158-4a41-b8ab-090f0dd058a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e72b481-f64d-4786-ae8d-9adf7d002281" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dafa5646-8158-4a41-b8ab-090f0dd058a6" xlink:to="loc_srt_MaximumMember_9e72b481-f64d-4786-ae8d-9adf7d002281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c810485c-7007-4929-9410-9f14c31f636e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c810485c-7007-4929-9410-9f14c31f636e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df51b03b-44a2-4b65-bacb-4ea557d26b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df51b03b-44a2-4b65-bacb-4ea557d26b75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6ccf201c-54b4-4610-be27-70c659abd922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df51b03b-44a2-4b65-bacb-4ea557d26b75" xlink:to="loc_us-gaap_SubsequentEventMember_6ccf201c-54b4-4610-be27-70c659abd922" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#SubsequentEventsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended" id="ic9d90ef2857f4362ba25185f13b4280c_SubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_801748ce-e204-4195-a312-47e75ae344d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_801748ce-e204-4195-a312-47e75ae344d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_BaseSalaryAndTargetBonusContinuationPeriod_4f242750-20d6-4510-8354-79227abcc542" xlink:href="eigr-20221231.xsd#eigr_BaseSalaryAndTargetBonusContinuationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_BaseSalaryAndTargetBonusContinuationPeriod_4f242750-20d6-4510-8354-79227abcc542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_c82522f0-7c6a-4f9d-acc3-722b4f33171e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_c82522f0-7c6a-4f9d-acc3-722b4f33171e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_COBRAContinuationCoveragePeriod_5b331ff0-c44c-46c1-917d-3fbb430fc50b" xlink:href="eigr-20221231.xsd#eigr_COBRAContinuationCoveragePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_COBRAContinuationCoveragePeriod_5b331ff0-c44c-46c1-917d-3fbb430fc50b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PostEmploymentBenefitAcceleratedVesting_c82864ab-f0b5-42d9-878e-f792f167955b" xlink:href="eigr-20221231.xsd#eigr_PostEmploymentBenefitAcceleratedVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_PostEmploymentBenefitAcceleratedVesting_c82864ab-f0b5-42d9-878e-f792f167955b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_5c772fd4-42fe-4963-a185-732d4d5bf2cb" xlink:href="eigr-20221231.xsd#eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_5c772fd4-42fe-4963-a185-732d4d5bf2cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NumberOfAccounts_71ef9571-7cd2-4c7b-918e-0839ed1d4d92" xlink:href="eigr-20221231.xsd#eigr_NumberOfAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_NumberOfAccounts_71ef9571-7cd2-4c7b-918e-0839ed1d4d92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f5747aa-a245-4f63-906f-83a9a9ab0b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f5747aa-a245-4f63-906f-83a9a9ab0b8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00a84940-fc15-49a7-ba89-1332ecba8b59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00a84940-fc15-49a7-ba89-1332ecba8b59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1784d605-0b2c-4df7-9dd1-0e85522d186e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1784d605-0b2c-4df7-9dd1-0e85522d186e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_250581b5-e551-4737-a90c-f42b30a8cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1784d605-0b2c-4df7-9dd1-0e85522d186e" xlink:to="loc_us-gaap_SubsequentEventMember_250581b5-e551-4737-a90c-f42b30a8cd91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12afcd3a-9137-4208-add3-5c1afa9527e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12afcd3a-9137-4208-add3-5c1afa9527e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_53f630bd-a9d6-46de-8dc8-7aec613a797d" xlink:href="eigr-20221231.xsd#eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12afcd3a-9137-4208-add3-5c1afa9527e6" xlink:to="loc_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_53f630bd-a9d6-46de-8dc8-7aec613a797d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5f0891be-3c0d-429a-8ad8-563f3bea5a2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5f0891be-3c0d-429a-8ad8-563f3bea5a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_FormerCEOMember_eb813686-277a-46f7-bb61-8437d9dbe869" xlink:href="eigr-20221231.xsd#eigr_FormerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5f0891be-3c0d-429a-8ad8-563f3bea5a2d" xlink:to="loc_eigr_FormerCEOMember_eb813686-277a-46f7-bb61-8437d9dbe869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_2f3a6aeb-a671-436f-a8c4-711d67b268a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_2f3a6aeb-a671-436f-a8c4-711d67b268a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_84716f01-0afa-4d57-9ccc-da362440c143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_84716f01-0afa-4d57-9ccc-da362440c143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SiliconValleyBankMember_10aaba91-510a-4984-82c1-cdd2e9c19112" xlink:href="eigr-20221231.xsd#eigr_SiliconValleyBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_84716f01-0afa-4d57-9ccc-da362440c143" xlink:to="loc_eigr_SiliconValleyBankMember_10aaba91-510a-4984-82c1-cdd2e9c19112" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>eigr-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5bf4cbbb-10e9-4fbc-b4bb-3a741d1bed32,g:0d7ff615-48b4-4d72-96cc-45180aee1521-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_eigr_OfferingCostsIncurredNotYetPaid_e921ee79-be9e-44b3-8b2f-5d20046db6de_terseLabel_en-US" xlink:label="lab_eigr_OfferingCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offering costs included in accounts payable and accrual</link:label>
    <link:label id="lab_eigr_OfferingCostsIncurredNotYetPaid_label_en-US" xlink:label="lab_eigr_OfferingCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred, Not Yet Paid</link:label>
    <link:label id="lab_eigr_OfferingCostsIncurredNotYetPaid_documentation_en-US" xlink:label="lab_eigr_OfferingCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred, Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OfferingCostsIncurredNotYetPaid" xlink:href="eigr-20221231.xsd#eigr_OfferingCostsIncurredNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OfferingCostsIncurredNotYetPaid" xlink:to="lab_eigr_OfferingCostsIncurredNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_db83cf51-7839-45d5-b28e-bb28772df89f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b83bd080-e1c5-4332-9c12-7b4f885faac4_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_031acfb8-cfe7-4d09-945b-0d10af862043_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_22b11c40-1451-4240-8b51-e8fe2b8f010e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2740acb4-1ef4-449a-9b27-e375f6f0f0ce_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25168d4f-bd5a-4bd1-956a-8a6454c737a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e9b13219-85f6-4cd4-b64e-ed569e9e4d9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed6c0886-2d9c-4f38-98ce-5a77287709c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e3f02f53-bb05-4f9e-abb8-53221fe04304_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d751a774-ac04-4144-8ef2-52feca149f54_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_92831363-5f67-4eb1-84ad-c777524d35a1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_d5561482-9d88-4084-8e3c-6e2187b6df71_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7fda86ff-354e-4007-83d9-b0b329d6c16f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ClosingPriceOfCommonStock_5b11446f-5d80-4753-8a42-8ece5aee6182_terseLabel_en-US" xlink:label="lab_eigr_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of common stock (in usd per share)</link:label>
    <link:label id="lab_eigr_ClosingPriceOfCommonStock_label_en-US" xlink:label="lab_eigr_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_eigr_ClosingPriceOfCommonStock_documentation_en-US" xlink:label="lab_eigr_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ClosingPriceOfCommonStock" xlink:href="eigr-20221231.xsd#eigr_ClosingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ClosingPriceOfCommonStock" xlink:to="lab_eigr_ClosingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8aaf0f75-b3b8-4957-8cd1-89665be9d15a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_59d98c08-0444-4ba1-91ae-7de68d577e5b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MasterManufacturingServicesAgreementMember_6f719caf-cf29-4499-ab59-9a1b4258feb3_terseLabel_en-US" xlink:label="lab_eigr_MasterManufacturingServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Manufacturing Services Agreement</link:label>
    <link:label id="lab_eigr_MasterManufacturingServicesAgreementMember_label_en-US" xlink:label="lab_eigr_MasterManufacturingServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Manufacturing Services Agreement [Member]</link:label>
    <link:label id="lab_eigr_MasterManufacturingServicesAgreementMember_documentation_en-US" xlink:label="lab_eigr_MasterManufacturingServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Manufacturing Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MasterManufacturingServicesAgreementMember" xlink:href="eigr-20221231.xsd#eigr_MasterManufacturingServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MasterManufacturingServicesAgreementMember" xlink:to="lab_eigr_MasterManufacturingServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7160566d-7f68-487e-b2b5-05b07205d2f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ceda0c30-bd94-4787-97de-97e8d8c8c020_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited_2eec9a39-59ca-4505-baf9-8b5acef078db_terseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Restricted Stock Units Forfeited</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of restricted stock units forfeited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_cba67084-9e34-45a5-88a1-2088f9e509ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ce4aa575-ee16-445c-b530-a2b51886c3f0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_37134e63-9db5-4372-9f8a-b180363039cd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_50f19e24-93e1-47c7-87a4-210a17ad74a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of options forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_65bd5cae-7c60-429b-9027-ece3e6586983_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d5297773-c82e-415a-b635-25e54e7a5b6a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_99ffd93b-f6da-445b-a4c8-8df4679385ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_109122ca-aa68-459b-8020-ed2e91d511f0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4cb42337-16f5-483e-a1d7-f6d2aeeff945_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_NumberOfAccounts_d4a2aac2-6fbb-4b8c-b264-775a9570e7e5_terseLabel_en-US" xlink:label="lab_eigr_NumberOfAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of accounts</link:label>
    <link:label id="lab_eigr_NumberOfAccounts_label_en-US" xlink:label="lab_eigr_NumberOfAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Accounts</link:label>
    <link:label id="lab_eigr_NumberOfAccounts_documentation_en-US" xlink:label="lab_eigr_NumberOfAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NumberOfAccounts" xlink:href="eigr-20221231.xsd#eigr_NumberOfAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_NumberOfAccounts" xlink:to="lab_eigr_NumberOfAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PatheonIncMember_1c3682e7-3e42-46dc-a69c-6c95bb133a33_terseLabel_en-US" xlink:label="lab_eigr_PatheonIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patheon Inc</link:label>
    <link:label id="lab_eigr_PatheonIncMember_label_en-US" xlink:label="lab_eigr_PatheonIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patheon Inc [Member]</link:label>
    <link:label id="lab_eigr_PatheonIncMember_documentation_en-US" xlink:label="lab_eigr_PatheonIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patheon Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PatheonIncMember" xlink:href="eigr-20221231.xsd#eigr_PatheonIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PatheonIncMember" xlink:to="lab_eigr_PatheonIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_016e791e-7d5e-4d69-a225-82e895416f49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_USGovernmentBondsMember_a8c886bd-31c8-4e3d-9d8a-1c4a315ce95e_terseLabel_en-US" xlink:label="lab_eigr_USGovernmentBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government bonds</link:label>
    <link:label id="lab_eigr_USGovernmentBondsMember_label_en-US" xlink:label="lab_eigr_USGovernmentBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U S Government Bonds [Member]</link:label>
    <link:label id="lab_eigr_USGovernmentBondsMember_documentation_en-US" xlink:label="lab_eigr_USGovernmentBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government bonds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_USGovernmentBondsMember" xlink:href="eigr-20221231.xsd#eigr_USGovernmentBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_USGovernmentBondsMember" xlink:to="lab_eigr_USGovernmentBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled_d6205466-ac7d-47e1-8bdd-5bf627424325_terseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units cancelled (in shares)</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Cancelled</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_395c06ca-c792-424f-8e05-0e2d15e13fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ecbe51af-238f-4687-a890-8002ab31555f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6f2479a4-4fb3-4028-bf2e-45455e73fca1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3d80b715-8db9-4cbb-bae0-cc3daec21bec_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4273c7bd-7b97-4e9a-b115-0bec2ef8f10c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b6676cb9-6b16-4add-85d5-709d91dab568_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_e362be94-0cf5-403e-bb67-eaadd5f5a840_terseLabel_en-US" xlink:label="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="eigr-20221231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_01ce45c1-e630-4ca6-9e77-bcc92923c342_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_daaeb700-edd1-4358-a19b-c1c446659d17_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_01d49dd2-26ca-477f-9455-60e9b76824af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DevelopmentMilestoneObligations_5a809080-e20f-4a5f-a0fd-e53eb0c284e3_terseLabel_en-US" xlink:label="lab_eigr_DevelopmentMilestoneObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone obligations</link:label>
    <link:label id="lab_eigr_DevelopmentMilestoneObligations_label_en-US" xlink:label="lab_eigr_DevelopmentMilestoneObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Obligations</link:label>
    <link:label id="lab_eigr_DevelopmentMilestoneObligations_documentation_en-US" xlink:label="lab_eigr_DevelopmentMilestoneObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentMilestoneObligations" xlink:href="eigr-20221231.xsd#eigr_DevelopmentMilestoneObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DevelopmentMilestoneObligations" xlink:to="lab_eigr_DevelopmentMilestoneObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_67eabd85-4046-4285-8584-b59b346c9d13_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9160e4dd-e376-4aa3-8a14-fb35509f0b79_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_a8433f2a-3c58-4bec-a077-f8dfdada4316_terseLabel_en-US" xlink:label="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consideration per share of counter party for issuance of additional shares (in usd per share)</link:label>
    <link:label id="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_label_en-US" xlink:label="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Consideration Per Share Of Counter Party For Issuance Of Additional Shares</link:label>
    <link:label id="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_documentation_en-US" xlink:label="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consideration per share of counter party for issuance of additional shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" xlink:href="eigr-20221231.xsd#eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" xlink:to="lab_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_4026d1ae-3cdc-42f6-a493-759d4c0e0e78_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8b8bab40-1fc7-4abe-8183-f1053dcce89f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_f8024a92-837b-4b33-af32-95e7beda7317_terseLabel_en-US" xlink:label="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense And Other Assets Current</link:label>
    <link:label id="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_documentation_en-US" xlink:label="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of other prepaid expense and other assets current classified as other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:href="eigr-20221231.xsd#eigr_OtherPrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef8a955e-d6c1-418b-b011-b113a0f1fb0e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_50b2dffa-3e79-4246-83fa-e6a5239f902d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of loan agreement exit fee</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PrepaidContractManufacturingCosts_c5578d66-31a7-46b9-98e9-04a951f85a90_terseLabel_en-US" xlink:label="lab_eigr_PrepaidContractManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid contract manufacturing costs</link:label>
    <link:label id="lab_eigr_PrepaidContractManufacturingCosts_label_en-US" xlink:label="lab_eigr_PrepaidContractManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Contract Manufacturing Costs</link:label>
    <link:label id="lab_eigr_PrepaidContractManufacturingCosts_documentation_en-US" xlink:label="lab_eigr_PrepaidContractManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid contract manufacturing costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidContractManufacturingCosts" xlink:href="eigr-20221231.xsd#eigr_PrepaidContractManufacturingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PrepaidContractManufacturingCosts" xlink:to="lab_eigr_PrepaidContractManufacturingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_cb1b4c0a-d1b1-4c2f-aa9e-b5d64671a269_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_5a5a4253-545e-4973-9d5a-c323acbe3412_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease payments for operating leases</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8db0f2ba-9505-485d-bc8f-94c08e0f6887_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7a0e373a-919a-42a3-99c8-bc39616f0799_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a7ac37b2-a769-4d00-bf33-753a2fa52595_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fbbdc3c6-1ec6-4999-9c9d-e0b9b9e2fc8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_22172565-7e41-43b7-bffb-3faf02d5bfb4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_29669831-deeb-4b1e-995f-9c096d925dab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of service threshold</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1f742efc-3f61-4c45-ad2b-bcb0ee909e77_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_e1bc9f3d-d6ac-408d-a91d-85eca1ecdd8c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9bd6246c-6b37-42c9-9fb6-308591e6939e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c0c04558-36d0-471e-95de-e2f1bddbd72b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of employee option grants (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_6957678a-abb4-4424-8967-86a32817a151_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b3fb4591-5ef9-4342-960d-efca31df6162_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale debt securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7afe9631-6af8-4bd9-85fc-c6147fc963e5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain/(loss) on available-for-sale debt securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1e4dbccd-2a0c-4709-aba3-951fb015c18f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58695617-0116-4dad-877e-686d182581b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_448b4f82-424a-4d9f-bd76-7c04b657fb4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c63b32e0-964c-41d5-a881-bd11e1e29fa3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d4ca852e-965d-47dc-8074-c6603caec4a3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_88f97597-ffad-40fb-b970-08fa141fd614_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_0dd19a19-4799-4916-9ea8-1dfbed1a2511_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_448ec547-53b5-43d1-9222-7420b7098d94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_62145a62-7106-4898-96b8-eaf852d658c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b9bc71fc-d5b5-4b30-b3e7-8355af064593_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ContractManufacturingCostsCurrent_a335ada0-b17e-4952-9b55-64ac44391f0e_terseLabel_en-US" xlink:label="lab_eigr_ContractManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract manufacturing costs</link:label>
    <link:label id="lab_eigr_ContractManufacturingCostsCurrent_label_en-US" xlink:label="lab_eigr_ContractManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Costs Current</link:label>
    <link:label id="lab_eigr_ContractManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_eigr_ContractManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract manufacturing costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ContractManufacturingCostsCurrent" xlink:href="eigr-20221231.xsd#eigr_ContractManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ContractManufacturingCostsCurrent" xlink:to="lab_eigr_ContractManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_46d119ec-ebfc-4f57-b1e0-d026e006e52e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2a7318c9-51ef-4117-939e-5a7de9bbc5cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MilestonePayments_4fb9b010-3e8a-41a1-bfee-38774124da8e_terseLabel_en-US" xlink:label="lab_eigr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_eigr_MilestonePayments_label_en-US" xlink:label="lab_eigr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_eigr_MilestonePayments_documentation_en-US" xlink:label="lab_eigr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MilestonePayments" xlink:href="eigr-20221231.xsd#eigr_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MilestonePayments" xlink:to="lab_eigr_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_9a70049f-e9eb-419e-86e2-7e780def2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_96752c01-b0ef-4d9a-92c3-1cbe4b555d45_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cdb47570-8ee8-4694-9fe8-70a7c684cfc7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e695bd1b-d099-4200-80c5-fb45335f4c52_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e55e135-8d75-4112-a82b-7e3585e21bb8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_595f55d5-4bdb-48e0-bf84-b540bdd03d93_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ComputerEquipmentAndSoftwareMember_a4b9e6bb-aac8-446c-af00-38d7e6933cbb_terseLabel_en-US" xlink:label="lab_eigr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_eigr_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_eigr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_eigr_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_eigr_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ComputerEquipmentAndSoftwareMember" xlink:href="eigr-20221231.xsd#eigr_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ComputerEquipmentAndSoftwareMember" xlink:to="lab_eigr_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9713156a-37e6-4b67-9bd1-7cf81e1ccbb0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_ef553361-85df-4df0-8be5-037c51fbbe11_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued stocks (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PercentageOfPurchasePrice_3a930000-7f08-4949-b5c5-e3d83b1941af_terseLabel_en-US" xlink:label="lab_eigr_PercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price</link:label>
    <link:label id="lab_eigr_PercentageOfPurchasePrice_label_en-US" xlink:label="lab_eigr_PercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Purchase Price</link:label>
    <link:label id="lab_eigr_PercentageOfPurchasePrice_documentation_en-US" xlink:label="lab_eigr_PercentageOfPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PercentageOfPurchasePrice" xlink:href="eigr-20221231.xsd#eigr_PercentageOfPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PercentageOfPurchasePrice" xlink:to="lab_eigr_PercentageOfPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AmendedTrancheAMember_b78c54a5-164d-4c2f-8a77-2dc91d4ea870_terseLabel_en-US" xlink:label="lab_eigr_AmendedTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Tranche A</link:label>
    <link:label id="lab_eigr_AmendedTrancheAMember_label_en-US" xlink:label="lab_eigr_AmendedTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Tranche A [Member]</link:label>
    <link:label id="lab_eigr_AmendedTrancheAMember_documentation_en-US" xlink:label="lab_eigr_AmendedTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended tranche A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedTrancheAMember" xlink:href="eigr-20221231.xsd#eigr_AmendedTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AmendedTrancheAMember" xlink:to="lab_eigr_AmendedTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_a15ed0c7-9045-4336-bb55-16d2758c3dcb_terseLabel_en-US" xlink:label="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label id="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:href="eigr-20221231.xsd#eigr_IncreaseInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:to="lab_eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_InducementPlan2021Member_bbe9a867-5661-4f90-868b-543dc0e52ca3_terseLabel_en-US" xlink:label="lab_eigr_InducementPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan 2021</link:label>
    <link:label id="lab_eigr_InducementPlan2021Member_label_en-US" xlink:label="lab_eigr_InducementPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan2021 [Member]</link:label>
    <link:label id="lab_eigr_InducementPlan2021Member_documentation_en-US" xlink:label="lab_eigr_InducementPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement plan 2021.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InducementPlan2021Member" xlink:href="eigr-20221231.xsd#eigr_InducementPlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_InducementPlan2021Member" xlink:to="lab_eigr_InducementPlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProductDevelopmentAgreementTextBlock_8eee36df-3161-4b28-bec4-fcf5a1e422b5_terseLabel_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration, and Product Development Agreements</link:label>
    <link:label id="lab_eigr_ProductDevelopmentAgreementTextBlock_label_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Development Agreement [Text Block]</link:label>
    <link:label id="lab_eigr_ProductDevelopmentAgreementTextBlock_documentation_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementTextBlock" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProductDevelopmentAgreementTextBlock" xlink:to="lab_eigr_ProductDevelopmentAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_df1031f4-721c-4b64-8820-36b7d049a20f_terseLabel_en-US" xlink:label="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage</link:label>
    <link:label id="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_label_en-US" xlink:label="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Licensee Fee Milestone And Other Payments Excluding Royalty Payments Received Percentage</link:label>
    <link:label id="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_documentation_en-US" xlink:label="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" xlink:href="eigr-20221231.xsd#eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" xlink:to="lab_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_BMSTransactionMember_3e306c39-9bc4-4275-975f-10001f9956fa_terseLabel_en-US" xlink:label="lab_eigr_BMSTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Transaction</link:label>
    <link:label id="lab_eigr_BMSTransactionMember_label_en-US" xlink:label="lab_eigr_BMSTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Transaction [Member]</link:label>
    <link:label id="lab_eigr_BMSTransactionMember_documentation_en-US" xlink:label="lab_eigr_BMSTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_BMSTransactionMember" xlink:href="eigr-20221231.xsd#eigr_BMSTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_BMSTransactionMember" xlink:to="lab_eigr_BMSTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_8f108348-29c0-4d02-8a09-df57fcc700d1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c0c61be1-6663-4ef0-a3db-47183fe35513_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_24149084-00ab-4f81-bb85-763549e6a92b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases included in accounts payable and accrual</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CashEquivalentsAmortizedCost_808cebe1-2139-4336-a0d9-8b5d066451af_totalLabel_en-US" xlink:label="lab_eigr_CashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Amortized cost</link:label>
    <link:label id="lab_eigr_CashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_eigr_CashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Amortized Cost</link:label>
    <link:label id="lab_eigr_CashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_eigr_CashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAmortizedCost" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CashEquivalentsAmortizedCost" xlink:to="lab_eigr_CashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c275d447-5d4b-4548-bf9e-7c2731b63312_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_26b164e0-06cc-4273-a151-8fc27894f7f7_terseLabel_en-US" xlink:label="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Thirteen Employee Stock Purchase Plan</link:label>
    <link:label id="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Thirteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Thirteen Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:href="eigr-20221231.xsd#eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:to="lab_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7b0bbf02-98c6-4e28-bda9-5555b97db125_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_41ed5381-4436-4ff1-9c53-0f236a873ced_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9c4c1a93-f1ec-47e8-9d97-cbca2ded9163_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_InnovatusStockPurchaseAgreementMember_4946ac66-1f52-4038-ad55-e8f77c948dac_terseLabel_en-US" xlink:label="lab_eigr_InnovatusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Stock Purchase Agreement</link:label>
    <link:label id="lab_eigr_InnovatusStockPurchaseAgreementMember_label_en-US" xlink:label="lab_eigr_InnovatusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_eigr_InnovatusStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_eigr_InnovatusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusStockPurchaseAgreementMember" xlink:href="eigr-20221231.xsd#eigr_InnovatusStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_InnovatusStockPurchaseAgreementMember" xlink:to="lab_eigr_InnovatusStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtMember_4914a7a7-19a7-416f-a8dc-e8b6ea05ffec_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtMember_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtMember" xlink:to="lab_us-gaap_ShortTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_RoyaltyReceivablePercentageOnNetSales_af5f63fe-19c8-4013-bbee-b3d5567a6451_terseLabel_en-US" xlink:label="lab_eigr_RoyaltyReceivablePercentageOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable percentage on net sales</link:label>
    <link:label id="lab_eigr_RoyaltyReceivablePercentageOnNetSales_label_en-US" xlink:label="lab_eigr_RoyaltyReceivablePercentageOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Receivable Percentage On Net Sales</link:label>
    <link:label id="lab_eigr_RoyaltyReceivablePercentageOnNetSales_documentation_en-US" xlink:label="lab_eigr_RoyaltyReceivablePercentageOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable percentage on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RoyaltyReceivablePercentageOnNetSales" xlink:href="eigr-20221231.xsd#eigr_RoyaltyReceivablePercentageOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_RoyaltyReceivablePercentageOnNetSales" xlink:to="lab_eigr_RoyaltyReceivablePercentageOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentExitFeePayablePercentage_38735128-adcf-4dea-a535-7534f30ad963_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentExitFeePayablePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of exit fee on principal balance</link:label>
    <link:label id="lab_eigr_DebtInstrumentExitFeePayablePercentage_label_en-US" xlink:label="lab_eigr_DebtInstrumentExitFeePayablePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Exit Fee Payable Percentage</link:label>
    <link:label id="lab_eigr_DebtInstrumentExitFeePayablePercentage_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentExitFeePayablePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument exit fee payable percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFeePayablePercentage" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFeePayablePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentExitFeePayablePercentage" xlink:to="lab_eigr_DebtInstrumentExitFeePayablePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SecuredDebtTrancheCMember_20260257-c958-4b53-9906-b8bc2b1740c8_terseLabel_en-US" xlink:label="lab_eigr_SecuredDebtTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche C</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheCMember_label_en-US" xlink:label="lab_eigr_SecuredDebtTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche C [Member]</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheCMember_documentation_en-US" xlink:label="lab_eigr_SecuredDebtTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche C.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheCMember" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SecuredDebtTrancheCMember" xlink:to="lab_eigr_SecuredDebtTrancheCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_e917c625-2f45-42d3-a01f-79856804e425_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PaymentForAssetPurchaseAgreement_823231df-ec5f-46e3-9351-2cf938185d8d_terseLabel_en-US" xlink:label="lab_eigr_PaymentForAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for asset purchase agreement</link:label>
    <link:label id="lab_eigr_PaymentForAssetPurchaseAgreement_label_en-US" xlink:label="lab_eigr_PaymentForAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Asset Purchase Agreement</link:label>
    <link:label id="lab_eigr_PaymentForAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_eigr_PaymentForAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for asset purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PaymentForAssetPurchaseAgreement" xlink:href="eigr-20221231.xsd#eigr_PaymentForAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PaymentForAssetPurchaseAgreement" xlink:to="lab_eigr_PaymentForAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_LegalMattersAbstract_label_en-US" xlink:label="lab_eigr_LegalMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Abstract]</link:label>
    <link:label id="lab_eigr_LegalMattersAbstract_documentation_en-US" xlink:label="lab_eigr_LegalMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LegalMattersAbstract" xlink:href="eigr-20221231.xsd#eigr_LegalMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_LegalMattersAbstract" xlink:to="lab_eigr_LegalMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4ad4cc28-f1a4-4471-9ddb-d8f9c841ed74_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_bb9cf336-6664-4edb-bacd-08cdd98e7690_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_902390c3-d964-4875-a10a-d61b398bc55f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3d2b00c7-cc8a-4dfa-a383-dce315f745b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_421b04de-a457-497b-8214-9eff2c882eb3_terseLabel_en-US" xlink:label="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchase by counterparty based on exercise of put options</link:label>
    <link:label id="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_label_en-US" xlink:label="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase By Counterparty Based On Exercise Of Put Option Share</link:label>
    <link:label id="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_documentation_en-US" xlink:label="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase by counterparty based on exercise of put option share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" xlink:href="eigr-20221231.xsd#eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" xlink:to="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_fe1f770a-160e-4f07-bfdc-d6e7a4c45272_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense recognized for company's operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_981ba535-38a0-4691-998a-52f2c2f2ec4b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_f111c562-5d1e-4722-9ec7-304330ad1579_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae910d1b-ff98-4b7c-921a-9bbb93efaa84_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adc1bedd-cdbc-418c-8190-d49529abe44d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CollaborationAgreementInitialTerm_62a0af24-3526-478a-b900-de4145ac933f_terseLabel_en-US" xlink:label="lab_eigr_CollaborationAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement initial term</link:label>
    <link:label id="lab_eigr_CollaborationAgreementInitialTerm_label_en-US" xlink:label="lab_eigr_CollaborationAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Initial Term</link:label>
    <link:label id="lab_eigr_CollaborationAgreementInitialTerm_documentation_en-US" xlink:label="lab_eigr_CollaborationAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CollaborationAgreementInitialTerm" xlink:href="eigr-20221231.xsd#eigr_CollaborationAgreementInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CollaborationAgreementInitialTerm" xlink:to="lab_eigr_CollaborationAgreementInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4ef0ac64-3ca9-47c0-b23e-081e69424940_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_50b99896-5530-41e0-a2d5-8394d4dd4552_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0622f3d0-031b-4145-9a74-ab56549645ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement_b081010a-c2e9-4e64-9015-0afcdf5995ff_negatedLabel_en-US" xlink:label="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income related to asset purchase agreement</link:label>
    <link:label id="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement_label_en-US" xlink:label="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss Related To Asset Purchase Agreement</link:label>
    <link:label id="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) related to asset purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncomeLossRelatedToAssetPurchaseAgreement" xlink:href="eigr-20221231.xsd#eigr_IncomeLossRelatedToAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_IncomeLossRelatedToAssetPurchaseAgreement" xlink:to="lab_eigr_IncomeLossRelatedToAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentExitFee_bc759fec-2904-4838-83fd-332647db3557_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: exit fee</link:label>
    <link:label id="lab_eigr_DebtInstrumentExitFee_label_en-US" xlink:label="lab_eigr_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:label id="lab_eigr_DebtInstrumentExitFee_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFee" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentExitFee" xlink:to="lab_eigr_DebtInstrumentExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AggregateCommonStockConsiderationValue_6c2d02fc-6011-4601-b1ec-68fe7739d2f6_terseLabel_en-US" xlink:label="lab_eigr_AggregateCommonStockConsiderationValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate common stock consideration value</link:label>
    <link:label id="lab_eigr_AggregateCommonStockConsiderationValue_label_en-US" xlink:label="lab_eigr_AggregateCommonStockConsiderationValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Common Stock Consideration Value</link:label>
    <link:label id="lab_eigr_AggregateCommonStockConsiderationValue_documentation_en-US" xlink:label="lab_eigr_AggregateCommonStockConsiderationValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate common stock consideration value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AggregateCommonStockConsiderationValue" xlink:href="eigr-20221231.xsd#eigr_AggregateCommonStockConsiderationValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AggregateCommonStockConsiderationValue" xlink:to="lab_eigr_AggregateCommonStockConsiderationValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_NumberOfFormerExecutives_d2ad5341-eb75-4b8d-bb0d-4171a14ecfa5_terseLabel_en-US" xlink:label="lab_eigr_NumberOfFormerExecutives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of former executives</link:label>
    <link:label id="lab_eigr_NumberOfFormerExecutives_label_en-US" xlink:label="lab_eigr_NumberOfFormerExecutives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Former Executives</link:label>
    <link:label id="lab_eigr_NumberOfFormerExecutives_documentation_en-US" xlink:label="lab_eigr_NumberOfFormerExecutives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Former Executives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NumberOfFormerExecutives" xlink:href="eigr-20221231.xsd#eigr_NumberOfFormerExecutives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_NumberOfFormerExecutives" xlink:to="lab_eigr_NumberOfFormerExecutives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4aee2b60-5483-4d88-a9ad-ee336f815e3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_38dd693c-2559-4884-b0ed-d873e44195c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0b86019d-309c-468c-a1d0-de1905d25c47_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_68662f20-7fce-4fb0-b909-49d20f469340_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e2a18b79-f544-4b2b-aaf9-05b483f0271f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available to be issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DividendsDeclared_1909f690-1426-4507-ac27-2fe6067b73ea_terseLabel_en-US" xlink:label="lab_eigr_DividendsDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_eigr_DividendsDeclared_label_en-US" xlink:label="lab_eigr_DividendsDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared</link:label>
    <link:label id="lab_eigr_DividendsDeclared_documentation_en-US" xlink:label="lab_eigr_DividendsDeclared" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DividendsDeclared" xlink:href="eigr-20221231.xsd#eigr_DividendsDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DividendsDeclared" xlink:to="lab_eigr_DividendsDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_f11003f5-b9f8-4921-97a8-77e624783f00_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_f46c4110-ffdc-43dc-ab04-772620c0d43e_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c56bb0db-dc61-4319-b415-4e144e8af67c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_91c6d093-a1c7-4d6c-813e-d693603d5edf_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AuditInformationAbstract_label_en-US" xlink:label="lab_eigr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_eigr_AuditInformationAbstract_documentation_en-US" xlink:label="lab_eigr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AuditInformationAbstract" xlink:href="eigr-20221231.xsd#eigr_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AuditInformationAbstract" xlink:to="lab_eigr_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_4e7a8423-c578-42c6-90e2-17f076f31aaf_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c9c4b1c3-512e-4aeb-ba2c-b1b45910e3ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5d78b7aa-fa29-4424-87eb-5b13b1fc3abb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_915dcf29-00a3-43a1-bd27-1c33bddf4179_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a6a09747-2ae9-4e0d-833e-8f6e56fbd9ac_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ef259b17-2242-4519-a580-67f064b1738b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6475fdb2-5215-4187-a335-bc33b1228504_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7c3b6abc-18a0-49f6-9b29-37c381c518cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8cd38b76-58d7-4607-8eb9-c154f251eb8f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_899c7bb3-0a71-459f-bd5b-28a7f38c1382_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DevelopmentAndRegulatoryMilestonesMember_ff039ed4-ec4d-4890-8f8c-64e7c158044c_terseLabel_en-US" xlink:label="lab_eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones</link:label>
    <link:label id="lab_eigr_DevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_eigr_DevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:href="eigr-20221231.xsd#eigr_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_5aeec4b5-f862-4ba3-9f49-da66c6ec48ee_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary impairment losses</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments" xlink:to="lab_us-gaap_ImpairmentOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_f7e7279d-b44a-48dc-92dd-8ea90d2fc4f8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f4af3111-cae2-40ea-8ce8-d42a8a44796f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ca7e0fdb-7608-4d2e-a245-3e9218745d7b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1b610203-16fb-4c0c-abff-6c6804c06900_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_dae22dc7-c087-4fe7-8e3d-3289c6e0269c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2a99bd5c-a744-41c8-9423-79ceaa4b33be_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2d1836e0-846b-4f1f-864a-d3a9f9e849aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_51627592-2dff-4253-9139-171b09799725_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_EarlyAccessProgramTerm_615dafc8-833d-4027-b81b-c7b7c43b3d63_terseLabel_en-US" xlink:label="lab_eigr_EarlyAccessProgramTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early access program term (in years)</link:label>
    <link:label id="lab_eigr_EarlyAccessProgramTerm_label_en-US" xlink:label="lab_eigr_EarlyAccessProgramTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Access Program Term</link:label>
    <link:label id="lab_eigr_EarlyAccessProgramTerm_documentation_en-US" xlink:label="lab_eigr_EarlyAccessProgramTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Access Program Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EarlyAccessProgramTerm" xlink:href="eigr-20221231.xsd#eigr_EarlyAccessProgramTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_EarlyAccessProgramTerm" xlink:to="lab_eigr_EarlyAccessProgramTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_012b2a31-e480-40cf-b279-28d561490397_terseLabel_en-US" xlink:label="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of product manufactured on the basics of annual forecasts</link:label>
    <link:label id="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_label_en-US" xlink:label="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Product Manufactured On The Basics Of Annual Forecasts</link:label>
    <link:label id="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_documentation_en-US" xlink:label="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Product Manufactured On The Basics Of Annual Forecasts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:href="eigr-20221231.xsd#eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:to="lab_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_27561af4-ea63-43f6-b74c-9cca9c5d8d1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost_e56fd9bd-cfc3-444c-ba8b-095ecb713b5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost method investment with carrying value</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments and Securities, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:to="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b8fbed0e-b904-4c5a-8687-3611b05f0b50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OrphanDrugCreditCarryforwardMember_d0cdfff0-1795-4f53-a1bc-a0658a2a7d7c_terseLabel_en-US" xlink:label="lab_eigr_OrphanDrugCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Credit Carryforward</link:label>
    <link:label id="lab_eigr_OrphanDrugCreditCarryforwardMember_label_en-US" xlink:label="lab_eigr_OrphanDrugCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Credit Carryforward [Member]</link:label>
    <link:label id="lab_eigr_OrphanDrugCreditCarryforwardMember_documentation_en-US" xlink:label="lab_eigr_OrphanDrugCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Credit Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OrphanDrugCreditCarryforwardMember" xlink:href="eigr-20221231.xsd#eigr_OrphanDrugCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OrphanDrugCreditCarryforwardMember" xlink:to="lab_eigr_OrphanDrugCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c6c4580a-dc3f-4c38-a4d8-afacef761acc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_b1a22bd7-3855-4439-8a92-7a4f26457af0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_VestingOfOptionsToPurchaseCommonStock_bd2f4c96-3ab8-411f-8bab-731a2e4f37e0_terseLabel_en-US" xlink:label="lab_eigr_VestingOfOptionsToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of options to purchase common stock (in shares)</link:label>
    <link:label id="lab_eigr_VestingOfOptionsToPurchaseCommonStock_label_en-US" xlink:label="lab_eigr_VestingOfOptionsToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Of Options To Purchase Common Stock</link:label>
    <link:label id="lab_eigr_VestingOfOptionsToPurchaseCommonStock_documentation_en-US" xlink:label="lab_eigr_VestingOfOptionsToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Of Options To Purchase Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VestingOfOptionsToPurchaseCommonStock" xlink:href="eigr-20221231.xsd#eigr_VestingOfOptionsToPurchaseCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_VestingOfOptionsToPurchaseCommonStock" xlink:to="lab_eigr_VestingOfOptionsToPurchaseCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d7f06e9b-543c-4847-a7bf-3466f03e1b44_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f2c230ac-7449-4a78-81fd-c04bdebaf1ea_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits impact on effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_44bf920d-6fa8-45b1-b2b1-08b65aa7f2cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CommercialSalesMember_10778667-74d3-4e0f-9d14-681e0774af5f_terseLabel_en-US" xlink:label="lab_eigr_CommercialSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Sales</link:label>
    <link:label id="lab_eigr_CommercialSalesMember_label_en-US" xlink:label="lab_eigr_CommercialSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Sales [Member]</link:label>
    <link:label id="lab_eigr_CommercialSalesMember_documentation_en-US" xlink:label="lab_eigr_CommercialSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommercialSalesMember" xlink:href="eigr-20221231.xsd#eigr_CommercialSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CommercialSalesMember" xlink:to="lab_eigr_CommercialSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DeferredTaxAssetDepreciationAndAmortization_4ee69ab6-c980-4ce7-9d65-00c33232b175_terseLabel_en-US" xlink:label="lab_eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_eigr_DeferredTaxAssetDepreciationAndAmortization_label_en-US" xlink:label="lab_eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset Depreciation And Amortization</link:label>
    <link:label id="lab_eigr_DeferredTaxAssetDepreciationAndAmortization_documentation_en-US" xlink:label="lab_eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxAssetDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:to="lab_eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0c3b67ac-fe4f-4482-9a81-a95fe0e8dc93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c0c61d04-85c4-484a-8ea0-34a90d8461a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MilestoneObligations_d040d06e-a54c-49cd-a38a-5fb63c214135_terseLabel_en-US" xlink:label="lab_eigr_MilestoneObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone obligations</link:label>
    <link:label id="lab_eigr_MilestoneObligations_label_en-US" xlink:label="lab_eigr_MilestoneObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligations</link:label>
    <link:label id="lab_eigr_MilestoneObligations_documentation_en-US" xlink:label="lab_eigr_MilestoneObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MilestoneObligations" xlink:href="eigr-20221231.xsd#eigr_MilestoneObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MilestoneObligations" xlink:to="lab_eigr_MilestoneObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ddf7b8f4-1451-4592-9c90-8d7f34dc842d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84530728-b4c9-42dc-8718-08243bfbd619_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d23d46a0-cce2-4149-a949-de52112cd2de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon stock option exercise</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_49f0bb17-2fa1-4174-8180-7f4c149758dc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_VariableRateComponentDomain_616bfcf7-5a5e-40cd-9229-87435d546c8a_terseLabel_en-US" xlink:label="lab_eigr_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_eigr_VariableRateComponentDomain_label_en-US" xlink:label="lab_eigr_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_eigr_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_eigr_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentDomain" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_VariableRateComponentDomain" xlink:to="lab_eigr_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SiliconValleyBankMember_b451801b-4f0a-46f5-b880-0239c04c1d18_terseLabel_en-US" xlink:label="lab_eigr_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:label id="lab_eigr_SiliconValleyBankMember_label_en-US" xlink:label="lab_eigr_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
    <link:label id="lab_eigr_SiliconValleyBankMember_documentation_en-US" xlink:label="lab_eigr_SiliconValleyBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SiliconValleyBankMember" xlink:href="eigr-20221231.xsd#eigr_SiliconValleyBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SiliconValleyBankMember" xlink:to="lab_eigr_SiliconValleyBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5e7e8da3-d684-4ee9-bfd5-c21308d233ab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_30ee864c-2946-4e36-a637-d855a228d262_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2c89c210-9e70-4d51-968d-4e466ac25157_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_47bec0ca-7242-4a8a-9116-3858f3c05e21_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b99f7cf2-0d87-422c-a231-0b009772be15_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_a9a15cd3-8acf-4d32-8cc8-aec6ac3f6435_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment received for sale of assets under asset purchase agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_03f53554-3641-4a77-92d9-3454de31ed37_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_75020a71-f12c-4ddb-afbf-6659f873f8c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dd4c3c95-2a90-423a-a4ab-b2904c4faed3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4f997f96-b022-47e0-86a5-028c89e603d0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, Unrealized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e4a8cd5a-bcff-486b-bac3-5cd5917d9378_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_9ef8f665-6497-47e4-b541-f4504cf10765_terseLabel_en-US" xlink:label="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum cumulative cash proceeds of counter party for issuance of additional shares</link:label>
    <link:label id="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_label_en-US" xlink:label="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Cumulative Cash Proceeds Of Counter Party For Issuance Of Additional Shares</link:label>
    <link:label id="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_documentation_en-US" xlink:label="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum cumulative cash proceeds of counter party for issuance of additional shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" xlink:href="eigr-20221231.xsd#eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" xlink:to="lab_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e87f0df8-4a41-4597-b86f-bfdf57a20a60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized loss position for more than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7e20b3f7-c2dd-4617-99e9-9c8e4bc12aa0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dd77e9c3-d45a-487d-93cd-5b8a9b44f5fd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bce1ab4e-0d31-410d-8035-d6fd0ef84386_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_831733fc-98fb-48fb-a959-57689b18454a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_69d19135-6d7f-4836-9934-69678298dde3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of common stock issued during period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d5b35b29-1417-4323-9526-e9f6b3417a8b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f040666c-9f87-4844-8d05-84e59a1db6ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_5b68c359-c3e4-40fa-94bb-8b2200c9e58c_terseLabel_en-US" xlink:label="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount</link:label>
    <link:label id="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_label_en-US" xlink:label="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Debt Warrants And Units Maximum Aggregate Offering Amount</link:label>
    <link:label id="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_documentation_en-US" xlink:label="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Debt Warrants And Units Maximum Aggregate Offering Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:href="eigr-20221231.xsd#eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:to="lab_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ac4bf42b-fca6-4ab9-a28f-30543088c4ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_56d584a2-930d-4b53-b197-ea9ce3209c74_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon release of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_ea9551f0-ec7d-4e34-ae5d-c2c192dc6e54_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_96cccaf9-c006-4620-aec0-7ef34573ff3a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted_d8f566a6-c538-4179-a87e-f6bda67b6a5f_negatedTerseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units granted (in shares)</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Granted</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of performance stock units granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_InnovatusLoanMember_d27ff1a0-edba-4837-9752-010b9fcd46c4_terseLabel_en-US" xlink:label="lab_eigr_InnovatusLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan</link:label>
    <link:label id="lab_eigr_InnovatusLoanMember_label_en-US" xlink:label="lab_eigr_InnovatusLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan [Member]</link:label>
    <link:label id="lab_eigr_InnovatusLoanMember_documentation_en-US" xlink:label="lab_eigr_InnovatusLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusLoanMember" xlink:href="eigr-20221231.xsd#eigr_InnovatusLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_InnovatusLoanMember" xlink:to="lab_eigr_InnovatusLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0099ae68-db3c-43ce-bf76-75c3190fc617_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_491d0d52-9155-44cb-9fe4-506a11accfea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_da3c5984-b1e9-40eb-b3c6-dbd86c889ae6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9e227317-7b46-4082-9854-016ec45427af_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fd3659e9-6e12-40af-9872-83bb2ebaf304_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, beginning balance (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5b0d20d4-c3ba-4dae-baa8-19c694146348_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, ending balance (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e9dbd27b-022e-46b7-820b-fbc485a61907_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_5d88f50f-0a00-44c3-958d-88e02e190bc2_negatedLabel_en-US" xlink:label="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="eigr-20221231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_ec817b6d-6986-4156-8847-e4d3c52315fd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_63470f52-d925-431d-bd85-32010da0d72b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3fc41c4a-96ef-4b06-897a-15d3a0f63435_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PerformanceStockUnitsPSUMember_6554f2ac-e876-41f7-8583-077c3984458c_terseLabel_en-US" xlink:label="lab_eigr_PerformanceStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units (PSU)</link:label>
    <link:label id="lab_eigr_PerformanceStockUnitsPSUMember_label_en-US" xlink:label="lab_eigr_PerformanceStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units P S U [Member]</link:label>
    <link:label id="lab_eigr_PerformanceStockUnitsPSUMember_documentation_en-US" xlink:label="lab_eigr_PerformanceStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units PSU member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PerformanceStockUnitsPSUMember" xlink:href="eigr-20221231.xsd#eigr_PerformanceStockUnitsPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PerformanceStockUnitsPSUMember" xlink:to="lab_eigr_PerformanceStockUnitsPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d7d3c8c6-900d-458e-9ec7-45738cfd0108_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b442027d-3ff4-45fb-a95d-6c773d0601e5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_04a3f322-381a-41a7-875d-3400075e9b1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2022 and 2021; 44,074,284 and 34,568,821 shares issued and outstanding as of December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e8c240dc-ca69-4dca-a3c4-e7cd561e8751_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fbf3f0cf-afb0-4776-8d21-842d55f8b223_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of options beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f98478a7-0628-4abe-8e2d-e0f0ec1ed72f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of options ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b43b37a8-0c66-48be-a097-6981844f4b8a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_587204ad-fb9a-479b-9367-66c2992dca6c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5167da46-ad82-471d-9111-4eb498a6fa66_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b63d7c2e-78eb-499f-9a06-6b5cc2182818_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e4dfd1c4-e2b4-4c00-affc-7583e44fe028_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_dec9d056-ea38-4d96-b891-0647619f5754_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_c4ae3294-50c8-47f7-98dd-d162f1f05fc0_terseLabel_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement contingent consideration receivable</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_label_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement Contingent Consideration Receivable</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_documentation_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement contingent consideration receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementContingentConsiderationReceivable" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementContingentConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AssetPurchaseAgreementContingentConsiderationReceivable" xlink:to="lab_eigr_AssetPurchaseAgreementContingentConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1fe078c2-8ee3-47f7-82b8-627d87465634_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_858f9699-0d69-41d6-9c5c-f22fe5f00b8d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain_9d1cea49-358b-439d-9cbc-9def9e098ca6_terseLabel_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement, Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain_label_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement, Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_904b3363-cd36-48d9-ac15-0e7c0720a190_terseLabel_en-US" xlink:label="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of options</link:label>
    <link:label id="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_label_en-US" xlink:label="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Of Options Issued For Common Stock Purchase</link:label>
    <link:label id="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_documentation_en-US" xlink:label="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Of Options Issued For Common Stock Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:href="eigr-20221231.xsd#eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:to="lab_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_2d92f8d4-4fba-44fe-aaa6-941dd0df2725_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4f6d59e4-45d0-4dbc-bda1-89070c075fad_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ExpertConsultantFeesAndPassThroughCosts_5d72941a-4378-4fd1-bda0-da75d9a09693_terseLabel_en-US" xlink:label="lab_eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expert consultant fees and pass through costs</link:label>
    <link:label id="lab_eigr_ExpertConsultantFeesAndPassThroughCosts_label_en-US" xlink:label="lab_eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expert Consultant Fees And Pass Through Costs</link:label>
    <link:label id="lab_eigr_ExpertConsultantFeesAndPassThroughCosts_documentation_en-US" xlink:label="lab_eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expert consultant fees and pass through costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:href="eigr-20221231.xsd#eigr_ExpertConsultantFeesAndPassThroughCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:to="lab_eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_2e4f121b-fc37-47b2-a04e-2ca0723997aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_678f2516-63b9-467e-b8c7-9d63424100f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AccruedContractedResearchCostsCurrent_c8e92f3a-80b3-4cf5-8f57-5d2aaf0b2002_terseLabel_en-US" xlink:label="lab_eigr_AccruedContractedResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract research costs</link:label>
    <link:label id="lab_eigr_AccruedContractedResearchCostsCurrent_label_en-US" xlink:label="lab_eigr_AccruedContractedResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contracted Research Costs Current</link:label>
    <link:label id="lab_eigr_AccruedContractedResearchCostsCurrent_documentation_en-US" xlink:label="lab_eigr_AccruedContractedResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contracted research costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AccruedContractedResearchCostsCurrent" xlink:href="eigr-20221231.xsd#eigr_AccruedContractedResearchCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AccruedContractedResearchCostsCurrent" xlink:to="lab_eigr_AccruedContractedResearchCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PurchaseAgreementMember_c5ed92e4-65ae-45ec-b3b4-618cd7c9f929_terseLabel_en-US" xlink:label="lab_eigr_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_eigr_PurchaseAgreementMember_label_en-US" xlink:label="lab_eigr_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement [Member]</link:label>
    <link:label id="lab_eigr_PurchaseAgreementMember_documentation_en-US" xlink:label="lab_eigr_PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PurchaseAgreementMember" xlink:href="eigr-20221231.xsd#eigr_PurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PurchaseAgreementMember" xlink:to="lab_eigr_PurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_9c2a30aa-b934-42b3-8110-43c1edcd3792_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1f0b4af1-6c2c-4c7e-bb45-71d548b13f71_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions_b83c361d-3524-4cf2-b551-fc6a8ffcdd9c_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension and Other Postretirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_72ad42a3-50b4-4dc8-90bd-79d1d6898952_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_125a9e5f-b120-474a-800e-d432165a522b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_39e22459-48df-4bde-b9ae-915606119ea7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_35d43be6-f33d-482d-9ab2-4271ab3c986d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_7c1ab400-c5f5-48e1-8b4a-e050a64c793a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_41e3dff4-9096-4df6-8f53-23056f455b51_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_7e1d2243-982d-4d36-9353-2c65b474f852_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9dfd6524-e21f-4a3e-aeaf-55b058cfbc10_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_133a9419-d907-4a6f-98b7-96ebafc3457c_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Palo Alto, California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_959e9609-717e-4463-902e-fb5716cb9dc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_a8475be0-69f8-4808-be7f-7786970d59bf_negatedTerseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares available for grant options granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_56a92301-041b-40db-8973-0b7c4f0f6a69_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_72887252-32bc-43c9-a722-82c2804cd1a4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_VariableRateComponentTwoMember_54d4779e-6dce-41a5-82d9-a78f18f95109_terseLabel_en-US" xlink:label="lab_eigr_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:label id="lab_eigr_VariableRateComponentTwoMember_label_en-US" xlink:label="lab_eigr_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two [Member]</link:label>
    <link:label id="lab_eigr_VariableRateComponentTwoMember_documentation_en-US" xlink:label="lab_eigr_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentTwoMember" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_VariableRateComponentTwoMember" xlink:to="lab_eigr_VariableRateComponentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_99e72ae1-055c-4c99-828e-70aaf9012359_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d21966a6-b1e4-478b-a0c8-a1a4be40a1d0_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_dba8e823-e19d-4f44-be14-719d5da618c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_61437a59-a3a7-4716-ad9e-5c651eed2dd3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CollaborativeArrangementRenewalTerm_1ac7690b-dbec-4424-94ed-b5b98643c01a_terseLabel_en-US" xlink:label="lab_eigr_CollaborativeArrangementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement renewal term</link:label>
    <link:label id="lab_eigr_CollaborativeArrangementRenewalTerm_label_en-US" xlink:label="lab_eigr_CollaborativeArrangementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Renewal Term</link:label>
    <link:label id="lab_eigr_CollaborativeArrangementRenewalTerm_documentation_en-US" xlink:label="lab_eigr_CollaborativeArrangementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CollaborativeArrangementRenewalTerm" xlink:href="eigr-20221231.xsd#eigr_CollaborativeArrangementRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CollaborativeArrangementRenewalTerm" xlink:to="lab_eigr_CollaborativeArrangementRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_14f912c2-e268-42e9-b42b-c5d0b4eab5a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1676d4a1-a5f4-4493-90ea-1dfc9eacd592_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_08f9e48d-73e5-4e47-b21f-a9e7b7dca7bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited_f8f6557e-6e3c-4a9b-aae0-f5b2ce1d194d_terseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares available for grant forfeited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0dd3b00d-6957-49ad-a1ec-7e356db6f18f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4be0bac1-72b4-44c2-958b-7a32b5998505_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f1aff9e8-cf9e-4ddc-bef5-3288faff5410_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c97a6442-d7ec-4698-b6e2-0ff91efdbda4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_6c06791f-9458-473d-9af9-333c45afd891_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PaymentsRelatedToPriorityReviewVoucher_a7b175f8-7d9b-4508-aadf-ead2eda29893_negatedLabel_en-US" xlink:label="lab_eigr_PaymentsRelatedToPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to priority review voucher</link:label>
    <link:label id="lab_eigr_PaymentsRelatedToPriorityReviewVoucher_label_en-US" xlink:label="lab_eigr_PaymentsRelatedToPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related To Priority Review Voucher</link:label>
    <link:label id="lab_eigr_PaymentsRelatedToPriorityReviewVoucher_documentation_en-US" xlink:label="lab_eigr_PaymentsRelatedToPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to priority review voucher.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PaymentsRelatedToPriorityReviewVoucher" xlink:href="eigr-20221231.xsd#eigr_PaymentsRelatedToPriorityReviewVoucher"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PaymentsRelatedToPriorityReviewVoucher" xlink:to="lab_eigr_PaymentsRelatedToPriorityReviewVoucher" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e04ad269-d799-47c6-bc2c-8c95efbb83f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ba27869f-9b51-40e0-afd2-992cf44b9f9f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b0b56f28-5f3d-4593-9635-4394a9426ebf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_73540a43-24cb-4e4c-b5e8-ad73c4ed8ac6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_3e74118d-68e1-49f4-9312-9fef758a06ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_370b5157-32e5-49ec-bef6-249582790f3e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MerckTransactionMember_dbb99439-e18a-4d39-83ad-cfefe3e73e39_terseLabel_en-US" xlink:label="lab_eigr_MerckTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Transaction</link:label>
    <link:label id="lab_eigr_MerckTransactionMember_label_en-US" xlink:label="lab_eigr_MerckTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Transaction [Member]</link:label>
    <link:label id="lab_eigr_MerckTransactionMember_documentation_en-US" xlink:label="lab_eigr_MerckTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MerckTransactionMember" xlink:href="eigr-20221231.xsd#eigr_MerckTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MerckTransactionMember" xlink:to="lab_eigr_MerckTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2191034b-6afa-47c4-84e0-8756fd462586_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_71d80f25-18db-400d-894e-a193bbe4d22b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_027b61f5-3d6a-43ed-a370-9fd4c2990ca5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4c3caaa7-9058-49e0-909d-9f587af1567e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_62e37590-978c-41cc-b304-5549f038a6b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt securities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AutorisationTemporaireDUtlisationMemberMember_221ecbb9-ca1d-4f28-b719-66cce2672c09_terseLabel_en-US" xlink:label="lab_eigr_AutorisationTemporaireDUtlisationMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Autorisation Temporaire D Utlisation Member</link:label>
    <link:label id="lab_eigr_AutorisationTemporaireDUtlisationMemberMember_label_en-US" xlink:label="lab_eigr_AutorisationTemporaireDUtlisationMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Autorisation Temporaire D Utlisation Member [Member]</link:label>
    <link:label id="lab_eigr_AutorisationTemporaireDUtlisationMemberMember_documentation_en-US" xlink:label="lab_eigr_AutorisationTemporaireDUtlisationMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Autorisation Temporaire D Utlisation Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AutorisationTemporaireDUtlisationMemberMember" xlink:href="eigr-20221231.xsd#eigr_AutorisationTemporaireDUtlisationMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AutorisationTemporaireDUtlisationMemberMember" xlink:to="lab_eigr_AutorisationTemporaireDUtlisationMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3eef991b-4a3a-43f5-8434-c79c78ab61c4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_10806db0-bd7f-4ec6-977e-9cf328edd107_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ebf25f15-b1de-4723-8468-ce8fe5566d5c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_56eacdda-a64b-4a94-a2bb-2a3e31d173b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0ff5c9c6-0a37-4766-96bd-409f12995890_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e8798baf-d9f1-40f5-a579-d200ca3c1d07_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60431acf-5bf9-4243-ab2a-083801a24e20_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_eeb5b0c3-d3c4-466f-bba6-93283a354048_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_8632df71-8f2c-4dbb-b4e6-bb8bdc6f2a82_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings from loan agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DevelopmentPhaseTwoMember_4e88f25d-6f6b-41a8-a78d-fe29707f5e77_terseLabel_en-US" xlink:label="lab_eigr_DevelopmentPhaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Phase Two</link:label>
    <link:label id="lab_eigr_DevelopmentPhaseTwoMember_label_en-US" xlink:label="lab_eigr_DevelopmentPhaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Phase Two [Member]</link:label>
    <link:label id="lab_eigr_DevelopmentPhaseTwoMember_documentation_en-US" xlink:label="lab_eigr_DevelopmentPhaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Phase Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentPhaseTwoMember" xlink:href="eigr-20221231.xsd#eigr_DevelopmentPhaseTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DevelopmentPhaseTwoMember" xlink:to="lab_eigr_DevelopmentPhaseTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6f7a236c-1988-4d26-b6d5-c11c67a00521_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_8bbd7dc3-6bfd-4d58-b0b6-f323db75c0ac_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal and interest payment period</link:label>
    <link:label id="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_label_en-US" xlink:label="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Principal And Interest Payment Period</link:label>
    <link:label id="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument principal and interest payment period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:to="lab_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PRFCollaborationAgreementMember_dc05f198-9ef1-4716-8d66-f89870c9d41c_terseLabel_en-US" xlink:label="lab_eigr_PRFCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progeria Research Foundation (PRF) Collaboration Agreement</link:label>
    <link:label id="lab_eigr_PRFCollaborationAgreementMember_label_en-US" xlink:label="lab_eigr_PRFCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">P R F Collaboration Agreement [Member]</link:label>
    <link:label id="lab_eigr_PRFCollaborationAgreementMember_documentation_en-US" xlink:label="lab_eigr_PRFCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRF collaboration agreement .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PRFCollaborationAgreementMember" xlink:href="eigr-20221231.xsd#eigr_PRFCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PRFCollaborationAgreementMember" xlink:to="lab_eigr_PRFCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_acfe3f47-f8a2-4c55-a4ea-4c54c2c7f2de_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_76c4107b-3929-40b6-91b5-ad3ccc1d4da0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5b4c65da-b3d1-4ee6-aa95-d94f595b1ca4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember_72e4fecf-b61f-4924-ab29-f149a9c23403_terseLabel_en-US" xlink:label="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four</link:label>
    <link:label id="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember_label_en-US" xlink:label="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:label id="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember_documentation_en-US" xlink:label="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedPaymentArrangementTrancheFourMember" xlink:href="eigr-20221231.xsd#eigr_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedPaymentArrangementTrancheFourMember" xlink:to="lab_eigr_ShareBasedPaymentArrangementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_05164325-917c-43ef-afe0-6c6a76b576c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AmendedOxfordLoanMember_5dc65db2-fbe5-4305-b959-2c503065d1c8_terseLabel_en-US" xlink:label="lab_eigr_AmendedOxfordLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Oxford Loan</link:label>
    <link:label id="lab_eigr_AmendedOxfordLoanMember_label_en-US" xlink:label="lab_eigr_AmendedOxfordLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Oxford Loan [Member]</link:label>
    <link:label id="lab_eigr_AmendedOxfordLoanMember_documentation_en-US" xlink:label="lab_eigr_AmendedOxfordLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Oxford loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedOxfordLoanMember" xlink:href="eigr-20221231.xsd#eigr_AmendedOxfordLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AmendedOxfordLoanMember" xlink:to="lab_eigr_AmendedOxfordLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MYDICARMember_cf1b4a16-3411-4bde-858d-77d54906634c_terseLabel_en-US" xlink:label="lab_eigr_MYDICARMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYDICAR</link:label>
    <link:label id="lab_eigr_MYDICARMember_label_en-US" xlink:label="lab_eigr_MYDICARMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M Y D I C A R [Member]</link:label>
    <link:label id="lab_eigr_MYDICARMember_documentation_en-US" xlink:label="lab_eigr_MYDICARMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYDICAR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MYDICARMember" xlink:href="eigr-20221231.xsd#eigr_MYDICARMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MYDICARMember" xlink:to="lab_eigr_MYDICARMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_29ebaf02-eb05-416c-9e36-90a07e010885_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_7b12a2c3-98ba-4a72-9ecf-6ad782eca84e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_28b6f737-eb0f-4129-ba5f-7c94e9ec3b14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_99f7fd89-5b04-4826-80fa-0f23492b67ba_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_98ca657c-a77b-403d-93d2-469a8bfabe41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e970b90e-a537-44a9-a0c6-62e94ce83ddf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6982ecac-f879-44c4-b879-f6e9a4b46246_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6662955c-482d-416b-9ec5-34dc18f6b9d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OtherRevenueMember_f55b9676-1620-4e44-8c68-5ac41122208a_terseLabel_en-US" xlink:label="lab_eigr_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_eigr_OtherRevenueMember_label_en-US" xlink:label="lab_eigr_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:label id="lab_eigr_OtherRevenueMember_documentation_en-US" xlink:label="lab_eigr_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherRevenueMember" xlink:href="eigr-20221231.xsd#eigr_OtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OtherRevenueMember" xlink:to="lab_eigr_OtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2f30e24e-841d-4c5d-ab7e-35a4ad4c58d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Operating Leases Liabilities and Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_917aa8d0-5cc4-46a6-ba3c-7be5155a3776_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ef108405-900a-483d-b3f4-3ff2a967831b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ed345cc4-8b1e-4933-ba86-fa7fa6aaa628_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_69560eae-48b9-41f4-9d83-ccfb68e4ef31_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_bb1f72d3-3161-4be1-ba48-fb6adca8c5a3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f2ecb138-30cd-49e1-b742-de31dfcfabee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2132f173-9773-4fe3-9def-631cb262f838_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_16f5dc6c-b7c6-4a83-aec4-eec33835a330_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher_4d4ef5a3-5821-4aee-a246-3df6cbcebc6b_negatedLabel_en-US" xlink:label="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sale of priority review voucher</link:label>
    <link:label id="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher_label_en-US" xlink:label="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Loss From Sale Of Priority Review Voucher</link:label>
    <link:label id="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher_documentation_en-US" xlink:label="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from sale of priority review voucher.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_GainLossFromSaleOfPriorityReviewVoucher" xlink:href="eigr-20221231.xsd#eigr_GainLossFromSaleOfPriorityReviewVoucher"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_GainLossFromSaleOfPriorityReviewVoucher" xlink:to="lab_eigr_GainLossFromSaleOfPriorityReviewVoucher" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3ebec3af-e78b-4e91-af39-20f9a4d61c69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f5a6a298-846c-4d60-9c30-d90fd20d07d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets_ecb24c79-df51-4ac2-b56f-c50c24af2eef_negatedTerseLabel_en-US" xlink:label="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:label id="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_048df030-78f2-4305-b78c-92170edaf802_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_UpFrontCashPayments_a574aabf-7bd6-40b3-92d6-56625f1d7ba9_terseLabel_en-US" xlink:label="lab_eigr_UpFrontCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up front cash payments</link:label>
    <link:label id="lab_eigr_UpFrontCashPayments_label_en-US" xlink:label="lab_eigr_UpFrontCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Cash Payments</link:label>
    <link:label id="lab_eigr_UpFrontCashPayments_documentation_en-US" xlink:label="lab_eigr_UpFrontCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Cash Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpFrontCashPayments" xlink:href="eigr-20221231.xsd#eigr_UpFrontCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_UpFrontCashPayments" xlink:to="lab_eigr_UpFrontCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_62f7607e-056d-41e2-a431-c7837002ae53_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AvexitidePurchaseAgreementMember_4b20d00f-8eff-4874-940e-6503d0385058_terseLabel_en-US" xlink:label="lab_eigr_AvexitidePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avexitide Purchase Agreement</link:label>
    <link:label id="lab_eigr_AvexitidePurchaseAgreementMember_label_en-US" xlink:label="lab_eigr_AvexitidePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avexitide Purchase Agreement [Member]</link:label>
    <link:label id="lab_eigr_AvexitidePurchaseAgreementMember_documentation_en-US" xlink:label="lab_eigr_AvexitidePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avexitide Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AvexitidePurchaseAgreementMember" xlink:href="eigr-20221231.xsd#eigr_AvexitidePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AvexitidePurchaseAgreementMember" xlink:to="lab_eigr_AvexitidePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_11074d96-a432-4208-b15b-4247311d3fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_914e54cd-d3d4-4048-865d-5509aac190a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_995b615f-5ef9-4bb8-8f62-a28d28354ec4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06061969-5609-4b4e-8a02-1160543a453b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ed10a5ca-2890-4a6c-8e6c-e85c2ccf00ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face value of term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9681b364-fe50-4c74-acba-42b003c99aaa_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_dd001b7f-d27a-4eda-bbb6-2c7b713dce67_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face value of term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ab766fa1-589d-415e-adf7-8a94bf8d20d7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_816d731e-209f-4529-8c32-e207053d893f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_028eb6d9-4046-47c5-b162-de360c4ed467_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_812857dc-039c-49ad-987b-a84b80027556_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under Product Development Agreement</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_22a788bc-d478-40ce-8792-b1889a9d5c40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_212afdd1-312b-4afd-a8d0-fcc73b9418f5_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_StockIssuanceCosts_41824ce7-72d8-4c90-937b-9264fde496a0_terseLabel_en-US" xlink:label="lab_eigr_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_eigr_StockIssuanceCosts_label_en-US" xlink:label="lab_eigr_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_eigr_StockIssuanceCosts_documentation_en-US" xlink:label="lab_eigr_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuanceCosts" xlink:href="eigr-20221231.xsd#eigr_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_StockIssuanceCosts" xlink:to="lab_eigr_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher_beab1bf8-2dc7-4481-92f5-c5d17ddb7712_terseLabel_en-US" xlink:label="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of priority review voucher</link:label>
    <link:label id="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher_label_en-US" xlink:label="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Priority Review Voucher</link:label>
    <link:label id="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher_documentation_en-US" xlink:label="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of priority review voucher.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromSaleOfPriorityReviewVoucher" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromSaleOfPriorityReviewVoucher"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProceedsFromSaleOfPriorityReviewVoucher" xlink:to="lab_eigr_ProceedsFromSaleOfPriorityReviewVoucher" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34027a0f-d787-458f-a692-27babc29a4fe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ba528f25-5bc1-4f36-b48d-6bd15e7868d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual terms of options granted under the Plan</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_21330e4b-1590-4072-8a4b-4537a0362812_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units (unvested)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ea358e37-c79c-48a2-82ef-e65f5d36deba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6b32d666-3632-4140-93da-13d47a3b6b4b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon ESPP purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c1206830-0d83-4731-adf3-7be2b1b67f57_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4f7254a7-7783-4b85-b139-4670b5a563de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3446ad8f-eeca-47bc-bf38-d18141936ddc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3323f106-e0f0-40fe-9355-048a08a1f254_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AmendedTrancheBMember_38737cc3-5c31-4590-807d-70203e6da456_terseLabel_en-US" xlink:label="lab_eigr_AmendedTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Amended Tranche B</link:label>
    <link:label id="lab_eigr_AmendedTrancheBMember_label_en-US" xlink:label="lab_eigr_AmendedTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Tranche B [Member]</link:label>
    <link:label id="lab_eigr_AmendedTrancheBMember_documentation_en-US" xlink:label="lab_eigr_AmendedTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended tranche B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedTrancheBMember" xlink:href="eigr-20221231.xsd#eigr_AmendedTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AmendedTrancheBMember" xlink:to="lab_eigr_AmendedTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_6fa1fe22-0cd0-412b-a78e-c65175dff51a_terseLabel_en-US" xlink:label="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time payment</link:label>
    <link:label id="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_label_en-US" xlink:label="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Payment To Be Made On Asset Purchase Agreement</link:label>
    <link:label id="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Payment To Be Made On Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:href="eigr-20221231.xsd#eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:to="lab_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3475ca58-3ab7-4fb1-8099-fa9198e5dc8d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_c01cc3ab-254f-4d29-bf97-f7ff3a85ee51_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AssetPurchaseAgreementTextBlock_48c9f629-feca-4112-ab75-006ef7af4de1_terseLabel_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreements and Related License Agreements</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementTextBlock_label_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Text Block]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementTextBlock_documentation_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for asset purchase agreement and related license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementTextBlock" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AssetPurchaseAgreementTextBlock" xlink:to="lab_eigr_AssetPurchaseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_091ba52f-a487-4003-8a16-73bb5f443955_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f510804a-2361-418e-97c7-8d5c72f6c9e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fbcebd7-3dbc-4a02-89ff-76aaa173639e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b1743b2e-dc81-4002-b1e3-fa8ff601ed7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a7cbe055-dbe9-489c-96a0-01faa04cb223_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fca99649-9961-4dc2-ad32-f93fcf279527_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e018d231-aa27-4eed-ae69-0f002f220bbc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fd943df3-ef00-4dac-9a35-f9ad10952e7b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b13cbfc9-bfdd-431d-b2cc-b52ee1e76df8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5884493c-2497-463f-bd9e-e42d5e3e24be_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f19397ee-fb52-4f3c-bed6-42f175809fb9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6d50fefd-4adf-473b-96e5-05c506a55711_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_67cb8478-cdc5-4f53-8faa-0ed64f814219_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_54b595ba-3af6-4b0f-b981-ae0ca8d7a6a9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_163b3d8f-75e3-48ab-8282-4c4d3eb15972_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_39d40988-2703-447b-8797-c83894b8d0d9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_92d3ba7e-7930-427b-878a-6a7e93ff19ae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d1a003c0-c168-446a-9064-35f6ab8423da_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a942fcf-586b-4ca8-add4-948642717be1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_94fd2ee6-18c9-4d97-8bb1-0eb0b016c3a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod_889e674a-4436-41f6-be68-3ddc6301385c_terseLabel_en-US" xlink:label="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base salary and target bonus continuation period</link:label>
    <link:label id="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod_label_en-US" xlink:label="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Salary And Target Bonus Continuation Period</link:label>
    <link:label id="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod_documentation_en-US" xlink:label="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Salary And Target Bonus Continuation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_BaseSalaryAndTargetBonusContinuationPeriod" xlink:href="eigr-20221231.xsd#eigr_BaseSalaryAndTargetBonusContinuationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_BaseSalaryAndTargetBonusContinuationPeriod" xlink:to="lab_eigr_BaseSalaryAndTargetBonusContinuationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1944c9e9-6192-45fc-8fc7-e6184ca65c73_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e354c084-890b-4851-a42f-91f2b0fdebcf_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9b1c0b9e-efa8-46e8-9cd2-6a48734c305f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2adf5bf-9497-42b4-894d-d686bcdc56c1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6df1635e-3fc1-450d-8a21-09a05fd0cb76_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_18385178-1105-45f6-a83d-fe41b0076592_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7ce2f327-7fed-4788-8d10-bd2f76c0420a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_6f974afb-0824-4068-80fb-78c894d2a3fa_terseLabel_en-US" xlink:label="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum cash balance of face value of loan (in percent)</link:label>
    <link:label id="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_label_en-US" xlink:label="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Cash Balance Of Face Value Of Loan, Percent</link:label>
    <link:label id="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_documentation_en-US" xlink:label="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Cash Balance Of Face Value Of Loan, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" xlink:href="eigr-20221231.xsd#eigr_MinimumCashBalanceOfFaceValueOfLoanPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" xlink:to="lab_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_a82d42ea-4034-4e13-a214-0f54b8929075_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ed7801e9-ed0d-4211-9752-e0c623b4d53f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of employee option grants (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9a732aec-62de-4818-bda5-7d6951fe4cb5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_7910cb42-1382-4230-930b-c54c84d0e98b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions based on tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f5f2e351-928d-4906-a2c8-313344e54876_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_57fe1775-b703-4c30-9798-be334c461e06_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f58aadcc-3319-4cf8-86a5-550e772971bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1d27c216-5dec-48c1-b8cc-c768b454230e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OptionsIssuedAndOutstanding_58460c78-4ecb-4828-bc44-b2c603362d95_terseLabel_en-US" xlink:label="lab_eigr_OptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding (in shares)</link:label>
    <link:label id="lab_eigr_OptionsIssuedAndOutstanding_label_en-US" xlink:label="lab_eigr_OptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Issued And Outstanding</link:label>
    <link:label id="lab_eigr_OptionsIssuedAndOutstanding_documentation_en-US" xlink:label="lab_eigr_OptionsIssuedAndOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Issued And Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsIssuedAndOutstanding" xlink:href="eigr-20221231.xsd#eigr_OptionsIssuedAndOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OptionsIssuedAndOutstanding" xlink:to="lab_eigr_OptionsIssuedAndOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8aaebf21-9b33-4b28-9035-a69a4778059c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_518132a9-ea71-4218-81ad-4dc83209c7c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued subject to quarterly vesting requirements (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SecuredDebtTrancheBAndCMember_99158f1c-f241-4851-8df6-8b683e2417f1_terseLabel_en-US" xlink:label="lab_eigr_SecuredDebtTrancheBAndCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche B and C</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheBAndCMember_label_en-US" xlink:label="lab_eigr_SecuredDebtTrancheBAndCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche B and C [Member]</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheBAndCMember_documentation_en-US" xlink:label="lab_eigr_SecuredDebtTrancheBAndCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche B and C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheBAndCMember" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheBAndCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SecuredDebtTrancheBAndCMember" xlink:to="lab_eigr_SecuredDebtTrancheBAndCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_LicenseAgreementPotentialMilestonePayments_fedb8f71-2209-4de9-8f50-7d6d496fa0be_terseLabel_en-US" xlink:label="lab_eigr_LicenseAgreementPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement potential milestone payments</link:label>
    <link:label id="lab_eigr_LicenseAgreementPotentialMilestonePayments_label_en-US" xlink:label="lab_eigr_LicenseAgreementPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Potential Milestone Payments</link:label>
    <link:label id="lab_eigr_LicenseAgreementPotentialMilestonePayments_documentation_en-US" xlink:label="lab_eigr_LicenseAgreementPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseAgreementPotentialMilestonePayments" xlink:href="eigr-20221231.xsd#eigr_LicenseAgreementPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_LicenseAgreementPotentialMilestonePayments" xlink:to="lab_eigr_LicenseAgreementPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_57fbba2c-4a99-4dc6-9f5c-7b7cf5d1926d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_VariableRateComponentOneMember_23c90143-5251-4926-80a2-22f391b5c342_terseLabel_en-US" xlink:label="lab_eigr_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:label id="lab_eigr_VariableRateComponentOneMember_label_en-US" xlink:label="lab_eigr_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One [Member]</link:label>
    <link:label id="lab_eigr_VariableRateComponentOneMember_documentation_en-US" xlink:label="lab_eigr_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentOneMember" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_VariableRateComponentOneMember" xlink:to="lab_eigr_VariableRateComponentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_603fce03-da66-4591-a771-25651a98ff78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_90d8d0eb-754b-41be-a8f2-d9717f42d712_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AbbvieAssetPurchaseAgreementMember_27f3ca9f-0904-4b32-bea2-ad70e4a4df3f_terseLabel_en-US" xlink:label="lab_eigr_AbbvieAssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Asset Purchase Agreement</link:label>
    <link:label id="lab_eigr_AbbvieAssetPurchaseAgreementMember_label_en-US" xlink:label="lab_eigr_AbbvieAssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbvie Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_eigr_AbbvieAssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_eigr_AbbvieAssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbvie asset purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AbbvieAssetPurchaseAgreementMember" xlink:href="eigr-20221231.xsd#eigr_AbbvieAssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AbbvieAssetPurchaseAgreementMember" xlink:to="lab_eigr_AbbvieAssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9143c7a3-427d-44c0-9299-afde7a828941_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_20cd739e-d5c2-48db-91a8-13a7cebb25b8_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4af77be-5bf5-4dee-b583-b0dc18e6199e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d266cff0-b2d8-4a0b-adea-0115e175f60f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AssetPurchaseAgreementMember_0110f421-6713-4df1-9f3c-1d2487bf1f43_terseLabel_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementMember" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AssetPurchaseAgreementMember" xlink:to="lab_eigr_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_30dd1943-b460-4cde-9d6f-a96450b05ee5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a2ae06ef-5478-4267-a199-880a6c2a4c92_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PeriodOfCommittedPaymentOfFees_84655241-52ca-40c0-9640-313a0fe6c016_terseLabel_en-US" xlink:label="lab_eigr_PeriodOfCommittedPaymentOfFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of committed payment of fees</link:label>
    <link:label id="lab_eigr_PeriodOfCommittedPaymentOfFees_label_en-US" xlink:label="lab_eigr_PeriodOfCommittedPaymentOfFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Committed Payment Of Fees</link:label>
    <link:label id="lab_eigr_PeriodOfCommittedPaymentOfFees_documentation_en-US" xlink:label="lab_eigr_PeriodOfCommittedPaymentOfFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Committed Payment Of Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PeriodOfCommittedPaymentOfFees" xlink:href="eigr-20221231.xsd#eigr_PeriodOfCommittedPaymentOfFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PeriodOfCommittedPaymentOfFees" xlink:to="lab_eigr_PeriodOfCommittedPaymentOfFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_fb64fbd3-264f-4964-b764-effce2b71ac4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee holding percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OxfordLoanFifthAmendmentMember_e41f4367-012d-44f8-bc26-68b5a8ef76d9_terseLabel_en-US" xlink:label="lab_eigr_OxfordLoanFifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amended Oxford Loan</link:label>
    <link:label id="lab_eigr_OxfordLoanFifthAmendmentMember_label_en-US" xlink:label="lab_eigr_OxfordLoanFifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Fifth Amendment [Member]</link:label>
    <link:label id="lab_eigr_OxfordLoanFifthAmendmentMember_documentation_en-US" xlink:label="lab_eigr_OxfordLoanFifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford loan fifth amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanFifthAmendmentMember" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanFifthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OxfordLoanFifthAmendmentMember" xlink:to="lab_eigr_OxfordLoanFifthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_e2518d31-d00c-4fd9-a2b9-ea6d04e3da8f_terseLabel_en-US" xlink:label="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]</link:label>
    <link:label id="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:href="eigr-20221231.xsd#eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="lab_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_888be122-0bee-440a-99b5-fbe251550317_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_356accd7-c981-442a-a5df-5809aa084316_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_EmployeeStockPurchasePlanMember_f8265889-2e69-4024-8c88-3afea15eb641_terseLabel_en-US" xlink:label="lab_eigr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_eigr_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_eigr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_eigr_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_eigr_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EmployeeStockPurchasePlanMember" xlink:href="eigr-20221231.xsd#eigr_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_EmployeeStockPurchasePlanMember" xlink:to="lab_eigr_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fe336437-4bd8-4450-bbb8-c800dc8ddde4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_81388c13-f5d5-4b9a-b6e6-8ecbfed008e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_d4df193a-ac25-46d8-83c8-48e32c6bf60c_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SecuredDebtAmendedTrancheAMember_ae9db8ac-ac47-49d1-83e9-eb9d1ac70d65_terseLabel_en-US" xlink:label="lab_eigr_SecuredDebtAmendedTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Tranche A</link:label>
    <link:label id="lab_eigr_SecuredDebtAmendedTrancheAMember_label_en-US" xlink:label="lab_eigr_SecuredDebtAmendedTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Amended Tranche A [Member]</link:label>
    <link:label id="lab_eigr_SecuredDebtAmendedTrancheAMember_documentation_en-US" xlink:label="lab_eigr_SecuredDebtAmendedTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended tranche A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtAmendedTrancheAMember" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtAmendedTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SecuredDebtAmendedTrancheAMember" xlink:to="lab_eigr_SecuredDebtAmendedTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a61b8ade-fbe6-4cb0-9eba-79f9fc9caeb5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement_dce8f322-e3f4-4936-b7ce-0b6d2a03e28c_terseLabel_en-US" xlink:label="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds related to asset purchase agreement</link:label>
    <link:label id="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement_label_en-US" xlink:label="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Related To Asset Purchase Agreement</link:label>
    <link:label id="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds related to asset purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsRelatedToAssetPurchaseAgreement" xlink:href="eigr-20221231.xsd#eigr_ProceedsRelatedToAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProceedsRelatedToAssetPurchaseAgreement" xlink:to="lab_eigr_ProceedsRelatedToAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ad7a0963-19e1-424e-8cc2-5fea2e5aedc0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e880994a-0d54-4bb0-9f03-d5d8aedab293_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e4d3a080-c02d-4d59-aef2-bff0bf5bd994_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AmendmentFeesPayment_b02a2c90-2cf8-4b8f-a20f-ac4c9e6063f8_terseLabel_en-US" xlink:label="lab_eigr_AmendmentFeesPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment fees payment</link:label>
    <link:label id="lab_eigr_AmendmentFeesPayment_label_en-US" xlink:label="lab_eigr_AmendmentFeesPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Fees Payment</link:label>
    <link:label id="lab_eigr_AmendmentFeesPayment_documentation_en-US" xlink:label="lab_eigr_AmendmentFeesPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment fees payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendmentFeesPayment" xlink:href="eigr-20221231.xsd#eigr_AmendmentFeesPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AmendmentFeesPayment" xlink:to="lab_eigr_AmendmentFeesPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_52de5be8-77bc-4f8b-bf73-0ace32b5ed8b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_TheragenePharmaceuticalsIncMember_b34696a9-c8a4-48d3-9e38-958300e39e5c_terseLabel_en-US" xlink:label="lab_eigr_TheragenePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theragene Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_eigr_TheragenePharmaceuticalsIncMember_label_en-US" xlink:label="lab_eigr_TheragenePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theragene Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_eigr_TheragenePharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_eigr_TheragenePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theragene Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_TheragenePharmaceuticalsIncMember" xlink:href="eigr-20221231.xsd#eigr_TheragenePharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_TheragenePharmaceuticalsIncMember" xlink:to="lab_eigr_TheragenePharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_12633748-9dc2-4f31-8dfe-21feadd3e4d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-cash Stock Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_9d72436b-4765-4023-a49d-bd6b0e1697e8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a62f5676-0f22-4213-bbe6-9f28985ebf6a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3a3c0f8c-8481-4bf9-9b8b-36c5f927d360_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon offering at-the-market, net of commissions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e41625c8-fcb7-4bc8-a076-f05f43775736_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProductRevenueReserves_f6ca4257-5d8b-4b98-8983-491cfecd2a1e_terseLabel_en-US" xlink:label="lab_eigr_ProductRevenueReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue reserves</link:label>
    <link:label id="lab_eigr_ProductRevenueReserves_label_en-US" xlink:label="lab_eigr_ProductRevenueReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue Reserves</link:label>
    <link:label id="lab_eigr_ProductRevenueReserves_documentation_en-US" xlink:label="lab_eigr_ProductRevenueReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductRevenueReserves" xlink:href="eigr-20221231.xsd#eigr_ProductRevenueReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProductRevenueReserves" xlink:to="lab_eigr_ProductRevenueReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b1387dd3-b953-469e-89ad-ab50743281e7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_UPennCHOPAgreementMember_552135bc-ee4c-4c3b-b36f-837e2e895715_terseLabel_en-US" xlink:label="lab_eigr_UPennCHOPAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPennCHOPAgreement</link:label>
    <link:label id="lab_eigr_UPennCHOPAgreementMember_label_en-US" xlink:label="lab_eigr_UPennCHOPAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPennCHOPAgreement [Member]</link:label>
    <link:label id="lab_eigr_UPennCHOPAgreementMember_documentation_en-US" xlink:label="lab_eigr_UPennCHOPAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPennCHOPAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UPennCHOPAgreementMember" xlink:href="eigr-20221231.xsd#eigr_UPennCHOPAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_UPennCHOPAgreementMember" xlink:to="lab_eigr_UPennCHOPAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c2f2e981-36e7-4f11-aa1a-98ca2aa716ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_7e18d6e3-3705-413f-8685-b2bf08bdcff8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f3ce2097-8f02-4d30-a1ae-b2b15fa7cce5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_6fa80946-b1aa-4b02-8193-ac87ccacf2c3_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DeferredTaxAssetsLeaseLiabilities_52eeea59-e43d-4860-a7d7-49cbe3e08c27_terseLabel_en-US" xlink:label="lab_eigr_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_eigr_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_eigr_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label id="lab_eigr_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_eigr_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxAssetsLeaseLiabilities" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_eigr_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_070cbfd4-474c-43ce-b854-ccc94f95267d_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1961190d-f232-4713-a51c-63c7ddd0b7cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2e601c54-ed19-4a4b-bdef-41a5f832decb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d00ff6c4-7575-4013-a6f9-7d36a48bbd94_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ca022fa5-e81c-4605-9206-c46d89f8638e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis_02e8436e-f8c0-4c65-a67a-b92d5c4cbf28_terseLabel_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</link:label>
    <link:label id="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis_label_en-US" xlink:label="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_9ce4749c-e78d-44c8-8ce3-945d1f3ad649_terseLabel_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to lender (in shares)</link:label>
    <link:label id="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_label_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Issued To Lender</link:label>
    <link:label id="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_documentation_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Issued To Lender</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodSharesStockIssuedToLender"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" xlink:to="lab_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_d9acc017-6b59-4155-bb41-7576fd5751cf_terseLabel_en-US" xlink:label="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance Stock Unit</link:label>
    <link:label id="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_label_en-US" xlink:label="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance Stock Unit [Member]</link:label>
    <link:label id="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_documentation_en-US" xlink:label="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units and performance stock unit member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:href="eigr-20221231.xsd#eigr_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:to="lab_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_34bd745b-2230-4be0-8952-e9c2db46b907_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_29a3b54c-71ca-4b4b-b819-977cd659c27f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_EIGTransactionMember_abf52a81-c474-46f9-be4f-739c85268ab1_terseLabel_en-US" xlink:label="lab_eigr_EIGTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIG Transaction</link:label>
    <link:label id="lab_eigr_EIGTransactionMember_label_en-US" xlink:label="lab_eigr_EIGTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIG Transaction [Member]</link:label>
    <link:label id="lab_eigr_EIGTransactionMember_documentation_en-US" xlink:label="lab_eigr_EIGTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIG Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EIGTransactionMember" xlink:href="eigr-20221231.xsd#eigr_EIGTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_EIGTransactionMember" xlink:to="lab_eigr_EIGTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d8c0531-18e7-41d7-9a0f-f30de430a7c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_ab8c493c-c236-49f9-b47c-4ae3c4d398ac_terseLabel_en-US" xlink:label="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs</link:label>
    <link:label id="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_label_en-US" xlink:label="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs [Policy Text Block]</link:label>
    <link:label id="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:href="eigr-20221231.xsd#eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:to="lab_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_70f6254e-6172-4be1-93ba-59b4389d7770_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_f3e10459-503f-4f79-9934-6249f3c8028d_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary continuation</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa8005c4-2bf3-4ea5-a3a3-26f39623f957_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1164d9cc-5bb9-4a7a-b8f6-23d4073f2da2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_eb602c5a-194c-4c13-a046-683fd5392dbc_terseLabel_en-US" xlink:label="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of assets number of common stock shares received</link:label>
    <link:label id="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_label_en-US" xlink:label="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Assets Number Of Common Stock Shares Received</link:label>
    <link:label id="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_documentation_en-US" xlink:label="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of assets number of common stock shares received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" xlink:href="eigr-20221231.xsd#eigr_SaleOfAssetsNumberOfCommonStockSharesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" xlink:to="lab_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_273641a9-9934-416a-a3e3-92237dee3749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt and Unamortized Discount Balances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cdfd7a39-bce0-408b-ac1d-cddcfa69052d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d99e180b-138f-4bba-b8f2-23b1d8913312_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_635f4226-d107-48f2-99c3-7b5965f5ed8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock_4b211f68-060d-4f23-b270-24ac1c781dd8_terseLabel_en-US" xlink:label="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock_label_en-US" xlink:label="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets Table [Table Text Block]</link:label>
    <link:label id="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock_documentation_en-US" xlink:label="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" xlink:href="eigr-20221231.xsd#eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" xlink:to="lab_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_ff6c997d-0c09-4970-93b5-21c192aeeab5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6d853ba6-4b05-4aa2-8221-b04d35caf94e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_e80555a4-6d0f-498f-b0f7-3d93985d471d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_7e2f50ee-93bf-4928-a1d0-3ff5357651d4_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit of collateral for lease</link:label>
    <link:label id="lab_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_label_en-US" xlink:label="lab_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Assets Separately Reported, Securities Pledged as Collateral, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:to="lab_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedExitFees_cc18c08d-b1f8-4a6b-a5cc-19daa367113f_verboseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedExitFees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan final repayment exit fees payable</link:label>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedExitFees_d254356c-bfde-4778-9384-35f2c3810f1d_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedExitFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee</link:label>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedExitFees_label_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedExitFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Unamortized Exit Fees</link:label>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedExitFees_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedExitFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument unamortized exit fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedExitFees" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedExitFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentUnamortizedExitFees" xlink:to="lab_eigr_DebtInstrumentUnamortizedExitFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f95d4b1-73cd-45d2-b268-09c4b79c79fe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a36c73e9-439a-4435-a08f-f99acfd2bb66_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_bc7a24a7-ef22-4778-a284-0a6c379c5fd4_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProductDevelopmentFees_24f0de80-1af7-4c37-8990-629a037aa233_terseLabel_en-US" xlink:label="lab_eigr_ProductDevelopmentFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development fees</link:label>
    <link:label id="lab_eigr_ProductDevelopmentFees_label_en-US" xlink:label="lab_eigr_ProductDevelopmentFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Development Fees</link:label>
    <link:label id="lab_eigr_ProductDevelopmentFees_documentation_en-US" xlink:label="lab_eigr_ProductDevelopmentFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentFees" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProductDevelopmentFees" xlink:to="lab_eigr_ProductDevelopmentFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e82e8746-5cb6-4720-bad4-a6e2faaa1839_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_599f414f-64cb-4e90-8c97-2f072535462b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a87f3a78-c2d1-46e4-aa5a-2af327ea6415_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in the carrying amount of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_5c83cb18-ad73-4e4d-98f8-f7dd54932673_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CustomerBMember_b2f95ed8-73b7-4f0d-862b-1ecbbdafb2bf_terseLabel_en-US" xlink:label="lab_eigr_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_eigr_CustomerBMember_label_en-US" xlink:label="lab_eigr_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_eigr_CustomerBMember_documentation_en-US" xlink:label="lab_eigr_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CustomerBMember" xlink:href="eigr-20221231.xsd#eigr_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CustomerBMember" xlink:to="lab_eigr_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_8a20b2ab-bdb9-414f-b61c-2b526cef2b12_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_a5207b28-58bd-40b9-882f-7c707678ab9d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3ddd2605-21cd-4dc7-9cf6-1894f0e9de8b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_c9f09bc3-371f-4e70-a581-c87c8a2d73a6_terseLabel_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to lender</link:label>
    <link:label id="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_label_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Issued To Lender</link:label>
    <link:label id="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_documentation_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Issued To Lender</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodValueStockIssuedToLender" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodValueStockIssuedToLender"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_StockIssuedDuringPeriodValueStockIssuedToLender" xlink:to="lab_eigr_StockIssuedDuringPeriodValueStockIssuedToLender" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f5857c0e-9ed3-41e9-ac8f-fc60a61b6df3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_89bac5e4-2c5a-40d9-901c-a3b3c685192d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_3e39a839-5750-4335-9c82-c93c7956d304_terseLabel_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement And Related License Agreement [Line Items]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_label_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement And Related License Agreement [Line Items]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_documentation_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement and related license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProductDevelopmentAgreementMember_f1c9764e-7138-415e-a03a-eaaf6c1a2cc9_terseLabel_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Development Agreement</link:label>
    <link:label id="lab_eigr_ProductDevelopmentAgreementMember_label_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Development Agreement [Member]</link:label>
    <link:label id="lab_eigr_ProductDevelopmentAgreementMember_documentation_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementMember" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProductDevelopmentAgreementMember" xlink:to="lab_eigr_ProductDevelopmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_269521df-ec9d-47fb-9494-60a083019282_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fe72fbda-3a25-4c56-b392-9142fed07a96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_8c0463f5-73d6-48dd-b702-249790e1ca51_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_f308f9ef-c462-41d7-846d-62e46d0b74ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22605858-d96c-4d5d-9893-32f66716606f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of new grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_354ca27c-b682-44b2-988b-fd00d0daaea9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrent" xlink:to="lab_us-gaap_DebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_2b392fe5-dc07-4863-b5c2-a1965e891df3_terseLabel_en-US" xlink:label="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal fees reimbursement threshold</link:label>
    <link:label id="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_label_en-US" xlink:label="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Employment Benefits, Legal Fees Reimbursement Threshold</link:label>
    <link:label id="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_documentation_en-US" xlink:label="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Employment Benefits, Legal Fees Reimbursement Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" xlink:href="eigr-20221231.xsd#eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" xlink:to="lab_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5d04787e-93f4-4b86-8e90-4da9e681194c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_83c57692-9d1e-4803-934c-9178532f4aaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9003c79b-6700-4e30-a9e5-3289a83add93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_07bc648f-ae4b-4c9b-961d-2ddb18755310_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_03c24ca1-f897-4756-9b7d-9bc81654787d_terseLabel_en-US" xlink:label="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received</link:label>
    <link:label id="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_label_en-US" xlink:label="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Upfront Licensee Fee Milestone And Other Payments Excluding Royalty Payments Received</link:label>
    <link:label id="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_documentation_en-US" xlink:label="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" xlink:to="lab_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable_b9ad928d-a940-4b88-9d91-1c40229a6b9c_terseLabel_en-US" xlink:label="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Investment Securities [Table]</link:label>
    <link:label id="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable_label_en-US" xlink:label="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Investment Securities [Table]</link:label>
    <link:label id="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable_documentation_en-US" xlink:label="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and investment securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="lab_eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_dfff2257-c20a-4522-9502-5b072b747f45_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ed8653fe-15a2-48d6-80e1-7f4ca1892c9b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a7ffe289-9ad3-49ba-8cad-68ca9581123d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SharesAvailableForGrantAbstract_9d074097-ed57-49c1-8a68-c8b61fec7e6c_terseLabel_en-US" xlink:label="lab_eigr_SharesAvailableForGrantAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grants</link:label>
    <link:label id="lab_eigr_SharesAvailableForGrantAbstract_label_en-US" xlink:label="lab_eigr_SharesAvailableForGrantAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant [Abstract]</link:label>
    <link:label id="lab_eigr_SharesAvailableForGrantAbstract_documentation_en-US" xlink:label="lab_eigr_SharesAvailableForGrantAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SharesAvailableForGrantAbstract" xlink:href="eigr-20221231.xsd#eigr_SharesAvailableForGrantAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SharesAvailableForGrantAbstract" xlink:to="lab_eigr_SharesAvailableForGrantAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CustomerAMember_9e6b6676-6a3c-4a2a-b158-885789e9b884_terseLabel_en-US" xlink:label="lab_eigr_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_eigr_CustomerAMember_label_en-US" xlink:label="lab_eigr_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_eigr_CustomerAMember_documentation_en-US" xlink:label="lab_eigr_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CustomerAMember" xlink:href="eigr-20221231.xsd#eigr_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CustomerAMember" xlink:to="lab_eigr_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ca436ca7-9ed6-498b-9d8b-b247111137f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b60305c-e140-416b-a8dc-e846cfe29bcc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_NonRefundableIssueFee_c585374e-bc49-40a0-b2dd-b0f9edc9c4f2_terseLabel_en-US" xlink:label="lab_eigr_NonRefundableIssueFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable issue fee</link:label>
    <link:label id="lab_eigr_NonRefundableIssueFee_label_en-US" xlink:label="lab_eigr_NonRefundableIssueFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Issue Fee</link:label>
    <link:label id="lab_eigr_NonRefundableIssueFee_documentation_en-US" xlink:label="lab_eigr_NonRefundableIssueFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Issue Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NonRefundableIssueFee" xlink:href="eigr-20221231.xsd#eigr_NonRefundableIssueFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_NonRefundableIssueFee" xlink:to="lab_eigr_NonRefundableIssueFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e19a6437-ec9d-4549-988a-ed16cc05d1d4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentInterestPaymentPeriod_d4296f45-fa3e-431e-a965-a5d7d42cef83_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payment period</link:label>
    <link:label id="lab_eigr_DebtInstrumentInterestPaymentPeriod_label_en-US" xlink:label="lab_eigr_DebtInstrumentInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Payment Period</link:label>
    <link:label id="lab_eigr_DebtInstrumentInterestPaymentPeriod_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentInterestPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payment period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentInterestPaymentPeriod" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentInterestPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentInterestPaymentPeriod" xlink:to="lab_eigr_DebtInstrumentInterestPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bb462e67-36bf-4ebd-baa4-3b6222cd883f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9c130bcd-5901-4ff9-b198-58027d4f0e0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b20ca6e2-b235-4867-a063-e05404e92c20_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ac56118-5c1c-4ea4-88cb-532cdced3459_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProductDevelopmentAgreementAbstract_544e6f54-78a8-4329-b796-40e356a586ec_terseLabel_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Development Agreement [Abstract]</link:label>
    <link:label id="lab_eigr_ProductDevelopmentAgreementAbstract_label_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Development Agreement [Abstract]</link:label>
    <link:label id="lab_eigr_ProductDevelopmentAgreementAbstract_documentation_en-US" xlink:label="lab_eigr_ProductDevelopmentAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementAbstract" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProductDevelopmentAgreementAbstract" xlink:to="lab_eigr_ProductDevelopmentAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PrepaidMarketing_4d4ee1af-d640-40e8-ad6e-6c72a57be36b_terseLabel_en-US" xlink:label="lab_eigr_PrepaidMarketing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid marketing</link:label>
    <link:label id="lab_eigr_PrepaidMarketing_label_en-US" xlink:label="lab_eigr_PrepaidMarketing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Marketing</link:label>
    <link:label id="lab_eigr_PrepaidMarketing_documentation_en-US" xlink:label="lab_eigr_PrepaidMarketing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidMarketing" xlink:href="eigr-20221231.xsd#eigr_PrepaidMarketing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PrepaidMarketing" xlink:to="lab_eigr_PrepaidMarketing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c1ef20f0-2fc5-441f-afc7-f9afb5a46853_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_0ec75354-e6c0-44a7-8b15-014f3e3ddd42_terseLabel_en-US" xlink:label="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchase by counterparty based on exercise of put option value</link:label>
    <link:label id="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_label_en-US" xlink:label="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase By Counterparty Based On Exercise Of Put Option Value</link:label>
    <link:label id="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_documentation_en-US" xlink:label="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase by counterparty based on exercise of put option value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" xlink:href="eigr-20221231.xsd#eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" xlink:to="lab_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_COBRAContinuationCoveragePeriod_eaade8bf-c559-4125-96a3-d803d2728baf_terseLabel_en-US" xlink:label="lab_eigr_COBRAContinuationCoveragePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA continuation coverage period</link:label>
    <link:label id="lab_eigr_COBRAContinuationCoveragePeriod_label_en-US" xlink:label="lab_eigr_COBRAContinuationCoveragePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA Continuation Coverage Period</link:label>
    <link:label id="lab_eigr_COBRAContinuationCoveragePeriod_documentation_en-US" xlink:label="lab_eigr_COBRAContinuationCoveragePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COBRA Continuation Coverage Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_COBRAContinuationCoveragePeriod" xlink:href="eigr-20221231.xsd#eigr_COBRAContinuationCoveragePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_COBRAContinuationCoveragePeriod" xlink:to="lab_eigr_COBRAContinuationCoveragePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentPercentOfInterestDue_04a97dea-8800-4573-86b4-87d19729e57f_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentPercentOfInterestDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, percent of interest due (in percent)</link:label>
    <link:label id="lab_eigr_DebtInstrumentPercentOfInterestDue_label_en-US" xlink:label="lab_eigr_DebtInstrumentPercentOfInterestDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percent Of Interest Due</link:label>
    <link:label id="lab_eigr_DebtInstrumentPercentOfInterestDue_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentPercentOfInterestDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percent Of Interest Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentPercentOfInterestDue" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentPercentOfInterestDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentPercentOfInterestDue" xlink:to="lab_eigr_DebtInstrumentPercentOfInterestDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_80bcea0d-7a9f-4dc1-ab63-ef5251dd6201_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_LicenseMaintenanceFee_6c1f372c-26be-460e-977e-aca9a1a657af_terseLabel_en-US" xlink:label="lab_eigr_LicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fee</link:label>
    <link:label id="lab_eigr_LicenseMaintenanceFee_label_en-US" xlink:label="lab_eigr_LicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fee</link:label>
    <link:label id="lab_eigr_LicenseMaintenanceFee_documentation_en-US" xlink:label="lab_eigr_LicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseMaintenanceFee" xlink:href="eigr-20221231.xsd#eigr_LicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_LicenseMaintenanceFee" xlink:to="lab_eigr_LicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_LicenseAgreementMilestonePaymentsPaid_88df1640-b250-4840-82f4-67f29d3b71e0_terseLabel_en-US" xlink:label="lab_eigr_LicenseAgreementMilestonePaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement milestone payments paid</link:label>
    <link:label id="lab_eigr_LicenseAgreementMilestonePaymentsPaid_label_en-US" xlink:label="lab_eigr_LicenseAgreementMilestonePaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payments Paid</link:label>
    <link:label id="lab_eigr_LicenseAgreementMilestonePaymentsPaid_documentation_en-US" xlink:label="lab_eigr_LicenseAgreementMilestonePaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payments Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseAgreementMilestonePaymentsPaid" xlink:href="eigr-20221231.xsd#eigr_LicenseAgreementMilestonePaymentsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_LicenseAgreementMilestonePaymentsPaid" xlink:to="lab_eigr_LicenseAgreementMilestonePaymentsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b155c521-8e5d-4d32-98d4-fdea6b20706c_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3938af64-1953-4bf4-ad7f-0bdac3df675e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_f68eb408-c48a-4ff6-82f6-1ddfef8b380c_terseLabel_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreements And Related License Agreements [Abstract]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_label_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreements And Related License Agreements [Abstract]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreements and related license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:to="lab_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_cc299540-245b-460f-bb4f-5b6cd4073122_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_IncentiveBasedRegulatoryMilestoneFees_5f137c61-4d23-446b-aa3e-c17953062625_terseLabel_en-US" xlink:label="lab_eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive-based regulatory milestone fees</link:label>
    <link:label id="lab_eigr_IncentiveBasedRegulatoryMilestoneFees_label_en-US" xlink:label="lab_eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Based Regulatory Milestone Fees</link:label>
    <link:label id="lab_eigr_IncentiveBasedRegulatoryMilestoneFees_documentation_en-US" xlink:label="lab_eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive-based regulatory milestone fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:href="eigr-20221231.xsd#eigr_IncentiveBasedRegulatoryMilestoneFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:to="lab_eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c82ddd2e-c89f-478d-a5f9-4a847131709c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d1efb802-bfc3-4fca-b907-20d0157d6b2f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c0423e2c-9dcc-48f4-a6b7-8fad7a8b2878_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f8176695-a949-4707-b8fc-713f200a112d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2a02e3ad-c303-485c-9033-51adafdeadb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d85e531d-2118-47a2-8b63-847cda7de1d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions based on tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_296c41d5-f843-4b52-aa91-832856a15fbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional options authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_VariableRateComponentAxis_16562cee-723b-4f94-b19c-9ff5d33c2efa_terseLabel_en-US" xlink:label="lab_eigr_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_eigr_VariableRateComponentAxis_label_en-US" xlink:label="lab_eigr_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_eigr_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_eigr_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentAxis" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_VariableRateComponentAxis" xlink:to="lab_eigr_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1ca5b9d1-1d29-48e6-bc05-29dff3f8c1bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_26cda91f-2c12-4bc0-aae6-bdb05d2d59cd_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_LabEquipmentMember_2d304c50-0076-4acd-9cbc-462d1152a2cc_terseLabel_en-US" xlink:label="lab_eigr_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_eigr_LabEquipmentMember_label_en-US" xlink:label="lab_eigr_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_eigr_LabEquipmentMember_documentation_en-US" xlink:label="lab_eigr_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LabEquipmentMember" xlink:href="eigr-20221231.xsd#eigr_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_LabEquipmentMember" xlink:to="lab_eigr_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AtTheMarketOfferingMember_f7104aa4-5a5e-465e-91e4-de4b96b33692_terseLabel_en-US" xlink:label="lab_eigr_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_eigr_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_eigr_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_eigr_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_eigr_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AtTheMarketOfferingMember" xlink:href="eigr-20221231.xsd#eigr_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AtTheMarketOfferingMember" xlink:to="lab_eigr_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_29b64eff-ec9e-47f7-a5b8-5e7cdc09b9a4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8676d6c1-fc31-4bd0-a43b-952ef98c9a0d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_9f617f00-3b82-42b6-9066-055d4d2ddc1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5b05971a-7229-41c4-b2c0-92a25339bee6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding_58042b8e-d772-4629-8001-64ba65d0394a_terseLabel_en-US" xlink:label="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and performance stock units outstanding (in shares)</link:label>
    <link:label id="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding_label_en-US" xlink:label="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted And Performance Stock Units Outstanding</link:label>
    <link:label id="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding_documentation_en-US" xlink:label="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted And Performance Stock Units Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestrictedAndPerformanceStockUnitsOutstanding" xlink:href="eigr-20221231.xsd#eigr_RestrictedAndPerformanceStockUnitsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_RestrictedAndPerformanceStockUnitsOutstanding" xlink:to="lab_eigr_RestrictedAndPerformanceStockUnitsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2a681677-b303-4cd2-8281-f990d3634248_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_98f9a17a-2310-48e0-b472-294a10342aa9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_FormerCEOMember_115a7a25-f3b4-414e-83d8-92132fb59147_terseLabel_en-US" xlink:label="lab_eigr_FormerCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former CEO</link:label>
    <link:label id="lab_eigr_FormerCEOMember_label_en-US" xlink:label="lab_eigr_FormerCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former CEO [Member]</link:label>
    <link:label id="lab_eigr_FormerCEOMember_documentation_en-US" xlink:label="lab_eigr_FormerCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former CEO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_FormerCEOMember" xlink:href="eigr-20221231.xsd#eigr_FormerCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_FormerCEOMember" xlink:to="lab_eigr_FormerCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_cd9bbd12-2ac3-4915-abf8-bb5a1848d5bc_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock_830f4f1b-1cb8-4f82-9ba7-683675f45d13_terseLabel_en-US" xlink:label="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Reserved For Future Issuances</link:label>
    <link:label id="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock_label_en-US" xlink:label="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Reserved For Future Issuances [Table Text Block]</link:label>
    <link:label id="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock_documentation_en-US" xlink:label="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Reserved For Future Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:href="eigr-20221231.xsd#eigr_CommonStockReservedForFutureIssuancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:to="lab_eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_a435da47-088d-4e21-b316-c0bc6f582e5e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_NonEmployeeStockOptionMember_50360e1b-4b28-495a-a524-eeb2f237c5cc_terseLabel_en-US" xlink:label="lab_eigr_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employees Stock Option</link:label>
    <link:label id="lab_eigr_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_eigr_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_eigr_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_eigr_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NonEmployeeStockOptionMember" xlink:href="eigr-20221231.xsd#eigr_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_NonEmployeeStockOptionMember" xlink:to="lab_eigr_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_6cfdffeb-cc58-4c46-97f2-93269da8216a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SecuredDebtTrancheAMember_ef609448-ef0b-4a7a-b249-514a9cfec29f_terseLabel_en-US" xlink:label="lab_eigr_SecuredDebtTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche A</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheAMember_label_en-US" xlink:label="lab_eigr_SecuredDebtTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche A [Member]</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheAMember_documentation_en-US" xlink:label="lab_eigr_SecuredDebtTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheAMember" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SecuredDebtTrancheAMember" xlink:to="lab_eigr_SecuredDebtTrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_83d4ed99-0c7c-4387-9246-3a5c02c12a44_terseLabel_en-US" xlink:label="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated transaction gains</link:label>
    <link:label id="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_label_en-US" xlink:label="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction Adjustment, Net of Tax</link:label>
    <link:label id="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" xlink:href="eigr-20221231.xsd#eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" xlink:to="lab_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_b0cf9c91-85f1-40bf-a71d-0b0a01b1feaf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0bc4714-b087-45e8-8388-d4eddb3f7984_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, outstanding, beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fcf8aee8-e414-4e5a-bae6-854e28945884_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, outstanding, ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6263db9b-e7ef-45d3-8d58-f563181cb743_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c6ef1512-4b18-4165-a3fa-e05be1d69eb8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_d2cc94ff-500c-4b25-a443-54429e28b058_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_34025091-27d0-4a7b-a506-28614842d6c8_terseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number Of Shares Outstanding [Abstract]</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b5b74685-e2ca-4584-9804-e902e8226e22_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_08c34c75-8cf1-41f7-bb05-90c103680c98_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_c6bb822b-6e02-4982-a00e-7646e4ab8392_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cc765cb5-e197-4872-bd9a-738fe5be6ff3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c563f439-a950-4d45-bf7c-2603c6b67cc5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PostEmploymentBenefitAcceleratedVesting_93d94035-2a6e-4958-a3e5-3e41e24dd133_terseLabel_en-US" xlink:label="lab_eigr_PostEmploymentBenefitAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated vesting</link:label>
    <link:label id="lab_eigr_PostEmploymentBenefitAcceleratedVesting_label_en-US" xlink:label="lab_eigr_PostEmploymentBenefitAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Employment Benefit, Accelerated Vesting</link:label>
    <link:label id="lab_eigr_PostEmploymentBenefitAcceleratedVesting_documentation_en-US" xlink:label="lab_eigr_PostEmploymentBenefitAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Employment Benefit, Accelerated Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PostEmploymentBenefitAcceleratedVesting" xlink:href="eigr-20221231.xsd#eigr_PostEmploymentBenefitAcceleratedVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PostEmploymentBenefitAcceleratedVesting" xlink:to="lab_eigr_PostEmploymentBenefitAcceleratedVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4903c70e-5c12-49bd-9561-f194a0818620_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c4317f4-6727-4f8b-844c-1c4f4deefb8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6aaefcdb-c44b-4ca6-969a-a7d0cafa490c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OxfordLoanAmendmentMember_3cb8cd7a-bca6-439c-9dac-da0b85b0b540_terseLabel_en-US" xlink:label="lab_eigr_OxfordLoanAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment</link:label>
    <link:label id="lab_eigr_OxfordLoanAmendmentMember_label_en-US" xlink:label="lab_eigr_OxfordLoanAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Amendment [Member]</link:label>
    <link:label id="lab_eigr_OxfordLoanAmendmentMember_documentation_en-US" xlink:label="lab_eigr_OxfordLoanAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford loan amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanAmendmentMember" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OxfordLoanAmendmentMember" xlink:to="lab_eigr_OxfordLoanAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bea90593-ac75-4082-9454-007d518c058f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7e691a2-c888-45bf-904b-b5f2cf29453c_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c3d29bfb-4cc9-4639-bbfd-4a798a032626_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt securities premiums and discounts</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_LineOfCreditFacilityOtherFinalPayments_20de2957-6e49-4f27-899e-883f993c8bbc_terseLabel_en-US" xlink:label="lab_eigr_LineOfCreditFacilityOtherFinalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other final payments</link:label>
    <link:label id="lab_eigr_LineOfCreditFacilityOtherFinalPayments_label_en-US" xlink:label="lab_eigr_LineOfCreditFacilityOtherFinalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Other Final Payments</link:label>
    <link:label id="lab_eigr_LineOfCreditFacilityOtherFinalPayments_documentation_en-US" xlink:label="lab_eigr_LineOfCreditFacilityOtherFinalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Other Final Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LineOfCreditFacilityOtherFinalPayments" xlink:href="eigr-20221231.xsd#eigr_LineOfCreditFacilityOtherFinalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_LineOfCreditFacilityOtherFinalPayments" xlink:to="lab_eigr_LineOfCreditFacilityOtherFinalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bf1fc5dd-a7ea-4696-a278-e55fd519657a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4cb05f87-d3ae-4e76-baf0-c6d636248883_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_cda81052-1efa-495d-b8cc-60db50edeb6a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b9ef898-ae9f-4ba0-9245-f50e488df27a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8600f8ed-e166-4823-9b6f-338336844eca_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_2b12ba3d-2bcd-430d-b14c-3829a3dac050_terseLabel_en-US" xlink:label="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_label_en-US" xlink:label="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Granted To Employees And Non Employees [Member]</link:label>
    <link:label id="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_documentation_en-US" xlink:label="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted to employees and non employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:href="eigr-20221231.xsd#eigr_OptionsGrantedToEmployeesAndNonEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:to="lab_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_b3641049-2c40-4c27-8cf0-b9e2c5f68b9d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1b0f282f-a3d4-4580-bee5-9a58ffd84f88_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_b614583d-f0e9-4421-8dcf-ec3c8195daff_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_193fc1f6-17ab-4112-b7ac-25c07ce2929b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DevelopmentPhaseThreeMember_59a4f0f1-5b32-4168-9b41-1e6c28d32bc9_terseLabel_en-US" xlink:label="lab_eigr_DevelopmentPhaseThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Phase Three</link:label>
    <link:label id="lab_eigr_DevelopmentPhaseThreeMember_label_en-US" xlink:label="lab_eigr_DevelopmentPhaseThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Phase Three [Member]</link:label>
    <link:label id="lab_eigr_DevelopmentPhaseThreeMember_documentation_en-US" xlink:label="lab_eigr_DevelopmentPhaseThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Phase Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentPhaseThreeMember" xlink:href="eigr-20221231.xsd#eigr_DevelopmentPhaseThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DevelopmentPhaseThreeMember" xlink:to="lab_eigr_DevelopmentPhaseThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SecuredDebtTrancheBMember_a4e0e0b6-5a55-41a6-a4eb-6318c98ac8ce_terseLabel_en-US" xlink:label="lab_eigr_SecuredDebtTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche B</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheBMember_label_en-US" xlink:label="lab_eigr_SecuredDebtTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt, Tranche B [Member]</link:label>
    <link:label id="lab_eigr_SecuredDebtTrancheBMember_documentation_en-US" xlink:label="lab_eigr_SecuredDebtTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheBMember" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SecuredDebtTrancheBMember" xlink:to="lab_eigr_SecuredDebtTrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_741fb3c2-dd8e-482c-9ef8-e5604960b6a9_terseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold ownership percentage of shareholder for grant of options at pre determined exercise price</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c6046c91-982e-45f1-b144-90f59b46d543_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_11ba8037-c731-4dae-a878-415c5a81e447_terseLabel_en-US" xlink:label="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Investment Securities [Line Items]</link:label>
    <link:label id="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_label_en-US" xlink:label="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Investment Securities [Line Items]</link:label>
    <link:label id="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_documentation_en-US" xlink:label="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and investment securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="lab_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c1c5757e-a16e-4949-9785-10687bd496a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b2cc6d88-1553-4959-a7fe-39c559e23cd0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2106f9d8-d2df-4889-8052-7a5d1ce90e53_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c1eeb872-c569-4d99-8077-ecd3e7c383a6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_PrepaidResearchCosts_d9c0f048-6c9f-4a18-adbc-534962a68249_terseLabel_en-US" xlink:label="lab_eigr_PrepaidResearchCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research costs</link:label>
    <link:label id="lab_eigr_PrepaidResearchCosts_label_en-US" xlink:label="lab_eigr_PrepaidResearchCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research Costs</link:label>
    <link:label id="lab_eigr_PrepaidResearchCosts_documentation_en-US" xlink:label="lab_eigr_PrepaidResearchCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of consideration paid in advance for research that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidResearchCosts" xlink:href="eigr-20221231.xsd#eigr_PrepaidResearchCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_PrepaidResearchCosts" xlink:to="lab_eigr_PrepaidResearchCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_07ca54e7-397f-404a-a904-6ca159b12a62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_0c9ce029-4f1a-4c42-be4b-a76614a916cb_terseLabel_en-US" xlink:label="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under ESPP (in shares)</link:label>
    <link:label id="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_label_en-US" xlink:label="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available For Issuance Under Employee Stock Purchase Program</link:label>
    <link:label id="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_documentation_en-US" xlink:label="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available For Issuance Under Employee Stock Purchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" xlink:href="eigr-20221231.xsd#eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" xlink:to="lab_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_d4088732-0d27-4b53-bba1-69b5d13161b4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ef5415fa-bc02-4803-96e4-ba82dfbbfc28_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cf507ecb-4edf-4d50-bb83-6f9d7e21a020_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6a514c0-fded-409a-89aa-578aec13cfdc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bc53703c-0273-4652-8883-06a746b2a48c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f2685b62-4007-41f9-af84-499b7993178c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_3583cab8-6ba2-48c7-9aa6-b3ea153ba32c_terseLabel_en-US" xlink:label="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs</link:label>
    <link:label id="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_label_en-US" xlink:label="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs [Member]</link:label>
    <link:label id="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_documentation_en-US" xlink:label="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" xlink:href="eigr-20221231.xsd#eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" xlink:to="lab_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees_c1027a41-1956-49dd-bbe1-a4e5f65d0d9c_terseLabel_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan final repayment additional exit fees payable</link:label>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees_label_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Unamortized Additional Exit Fees</link:label>
    <link:label id="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees_documentation_en-US" xlink:label="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument unamortized additional exit fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedAdditionalExitFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:to="lab_eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_df7788ac-987a-40d6-a5db-be10547f078d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_8b7a9520-d35f-4090-af17-b24d3caa444a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_882f2b98-543a-4978-911b-5d2652d3e78a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1773897f-ac1f-467f-bc2a-cb1946497774_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4fcbfec9-367c-41dc-ab33-5b9a13f97b4f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum prime rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_809a6de2-b531-4906-bb23-c063eb740ca9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_b8307100-2092-4d8c-ae67-1837ee2f8661_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_6da4f600-6ed1-466b-9d81-c5676e60536d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and unpaid interest</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Increase, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OptionsToPurchaseOfCommonStock_974ec286-f359-4755-b6f7-b39645565376_terseLabel_en-US" xlink:label="lab_eigr_OptionsToPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase of common stock (in shares)</link:label>
    <link:label id="lab_eigr_OptionsToPurchaseOfCommonStock_label_en-US" xlink:label="lab_eigr_OptionsToPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options To Purchase Of Common Stock</link:label>
    <link:label id="lab_eigr_OptionsToPurchaseOfCommonStock_documentation_en-US" xlink:label="lab_eigr_OptionsToPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options To Purchase Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsToPurchaseOfCommonStock" xlink:href="eigr-20221231.xsd#eigr_OptionsToPurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OptionsToPurchaseOfCommonStock" xlink:to="lab_eigr_OptionsToPurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b385ee02-6b2c-447f-b8e5-246e268f8043_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8e62b94f-4440-469c-9099-68e6ddd9377b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2c5a6733-6621-40b7-b182-04d46487cd37_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_0cd10d5d-7c55-4017-98dc-60da219e329f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dc9d89d2-cffc-4bf8-bea0-59cd911c443f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_68356019-5538-42d3-b073-c397b01f76c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_65ea5199-8b77-4b5d-97d6-970f1c2f98d7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_858e2b7d-7e41-4002-9a18-71d935b3f0f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6af0b31f-833b-4361-a1be-240c40bea8f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5840e07e-a451-44b5-b357-3dcb9b204123_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon ESPP purchase</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_CommonStockValueAvailableForFutureIssuance_3f03ce5d-bf05-48d6-985b-ba2002f32c9a_terseLabel_en-US" xlink:label="lab_eigr_CommonStockValueAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for future issuance</link:label>
    <link:label id="lab_eigr_CommonStockValueAvailableForFutureIssuance_label_en-US" xlink:label="lab_eigr_CommonStockValueAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Available For Future Issuance</link:label>
    <link:label id="lab_eigr_CommonStockValueAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_eigr_CommonStockValueAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommonStockValueAvailableForFutureIssuance" xlink:href="eigr-20221231.xsd#eigr_CommonStockValueAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_CommonStockValueAvailableForFutureIssuance" xlink:to="lab_eigr_CommonStockValueAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ecc80685-ece3-4f7d-85a0-928a7e0fcb78_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f6e8965e-1f21-498d-87c9-78ea94874ae0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 Capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90cc53d9-14a4-486c-8a2b-5a2d10f8b699_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of options vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_8b9df397-44f5-4ad6-87c1-d001ca96acc0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0727176e-0133-4611-b4fa-15fb4440221d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_OxfordLoanMember_385f5097-0518-44af-87ed-ad31bdaf0bfd_terseLabel_en-US" xlink:label="lab_eigr_OxfordLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan</link:label>
    <link:label id="lab_eigr_OxfordLoanMember_label_en-US" xlink:label="lab_eigr_OxfordLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan [Member]</link:label>
    <link:label id="lab_eigr_OxfordLoanMember_documentation_en-US" xlink:label="lab_eigr_OxfordLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanMember" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_OxfordLoanMember" xlink:to="lab_eigr_OxfordLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c888f3f2-83d6-4f4c-9a34-1002b4fcef10_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_24cffe09-6b0d-49db-a971-f4d0679dd26f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_acf455ae-aac3-4e3a-8c9f-a79323174ef0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount_29163cc8-2357-4bb7-82aa-0e5f8fc020d5_terseLabel_en-US" xlink:label="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers in or out of level 3</link:label>
    <link:label id="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount_label_en-US" xlink:label="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Transfers Between Levels Transfers Amount</link:label>
    <link:label id="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount_documentation_en-US" xlink:label="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value transfers between levels transfers amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:href="eigr-20221231.xsd#eigr_FairValueTransfersBetweenLevelsTransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:to="lab_eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_115da63b-2190-4e2b-b393-727ea7e38b87_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement, aggregate borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_956a5354-763c-4a8f-927d-1dc3d2e4d92a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_26ee0204-a242-4153-9cd1-50ee493bfee6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in number of shares of common stock reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9c9968ff-878a-41e7-9d2f-8fc9bfb44b47_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_fc76a701-f9a9-402a-accb-948424aa1f1a_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_12d9a6d2-7686-489f-aaba-01f2e08bb649_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d247b998-42e1-4dbd-b3a7-8420594def79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_2cd546af-92da-49c0-8266-41180dd73384_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon ESPP purchase</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e0c9c27b-6fcc-4a1c-8dfb-96ba4ef35ee2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_04dfa4d8-6fd4-4889-a4a7-ae997216e671_terseLabel_en-US" xlink:label="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated Two Thousand Thirteen Equity Incentive Plan Member</link:label>
    <link:label id="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_label_en-US" xlink:label="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated Two Thousand Thirteen Equity Incentive Plan Member [Member]</link:label>
    <link:label id="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_documentation_en-US" xlink:label="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated Two Thousand Thirteen Equity Incentive Plan Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" xlink:href="eigr-20221231.xsd#eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" xlink:to="lab_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cf9782be-3e29-4fc8-ae9c-7a4c2907d502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7941684f-1f77-495c-83ae-408b2381d6b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_58137a38-c2fd-4638-adde-db1a45bdde1f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4e9dcbdb-a739-4502-8b7a-ac5bf124316b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cf068cc9-bd4a-492a-b6b9-b73b09b6af93_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_b4f3ac53-3a67-4ace-9c30-264f9be91b8f_terseLabel_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement And Related License Agreement [Table]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_label_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement And Related License Agreement [Table]</link:label>
    <link:label id="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_documentation_en-US" xlink:label="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement And Related License Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="lab_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_883b553a-2c29-4a01-8814-f0b28eee065b_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bde393ec-7bb2-4a1f-9836-e8bda2e9503b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fcbec92c-faee-4fd8-9562-59a35303e60e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_4e8e87dd-85e7-4314-a99c-a5e7e2aff846_terseLabel_en-US" xlink:label="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holders Of Ten Percent Or More Of Voting Power</link:label>
    <link:label id="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_label_en-US" xlink:label="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holders Of Ten Percent Or More Of Voting Power [Member]</link:label>
    <link:label id="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_documentation_en-US" xlink:label="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holders Of Ten Percent Or More Of Voting Power</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:href="eigr-20221231.xsd#eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:to="lab_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_6af94ab1-f531-42d5-a5ed-083ee5475258_terseLabel_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of common stock under Product Development Agreement</link:label>
    <link:label id="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_label_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Product Development Agreement</link:label>
    <link:label id="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_documentation_en-US" xlink:label="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value product development agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:to="lab_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_57f9148d-aeed-4809-8d89-3a3be62215b2_terseLabel_en-US" xlink:label="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares issued during the period</link:label>
    <link:label id="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_label_en-US" xlink:label="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Equity Debt Warrants Issued During The Period</link:label>
    <link:label id="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Equity Debt Warrants Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:href="eigr-20221231.xsd#eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:to="lab_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_042205fe-6b66-4196-ba58-0e3d26741862_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba188184-7b64-4cb8-9ae9-2f246102cd71_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1f7a1688-0075-423c-b3d2-43e87eda8cbf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_2cb87d39-d3d0-42ba-9195-a778f411cccd_negatedTerseLabel_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_label_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Restricted Stock Units Granted</link:label>
    <link:label id="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_documentation_en-US" xlink:label="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of restricted stock units granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:to="lab_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_3cb3c1eb-6249-462d-aa23-fe0fb4c64c65_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased space</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_2f4b6188-9d82-468d-b32f-49fe15c6a2fb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8a2b1083-bc7c-4e99-bfea-6a76260edbed_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ce0ff00d-a9d0-4b22-870e-a6d07846baa7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_51bb1391-ff3d-4cb0-be8a-4a5ea9a31b75_terseLabel_en-US" xlink:label="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock to lender</link:label>
    <link:label id="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_label_en-US" xlink:label="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock In Connection With Debt</link:label>
    <link:label id="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_documentation_en-US" xlink:label="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock In Connection With Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" xlink:to="lab_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a2da0596-1bbb-43e2-a335-5d7b96226416_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>eigr-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5bf4cbbb-10e9-4fbc-b4bb-3a741d1bed32,g:0d7ff615-48b4-4d72-96cc-45180aee1521-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eigerbio.com/role/Cover" xlink:type="simple" xlink:href="eigr-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1adbf5b5-96ae-4484-9886-95ba9b99f0a0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentType_1adbf5b5-96ae-4484-9886-95ba9b99f0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_fd0cc3a3-d76f-4831-8d80-fc3bca81d9d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentAnnualReport_fd0cc3a3-d76f-4831-8d80-fc3bca81d9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a79af41-553d-4b7a-8139-0b0d0b616fb7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentPeriodEndDate_0a79af41-553d-4b7a-8139-0b0d0b616fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_adce0703-deef-45cd-9b60-15db1c0d0a6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_CurrentFiscalYearEndDate_adce0703-deef-45cd-9b60-15db1c0d0a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a472eb3c-1126-46fa-89fa-a12608a0e972" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentTransitionReport_a472eb3c-1126-46fa-89fa-a12608a0e972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_babda978-998d-4bcb-8a83-43df0625d6aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityFileNumber_babda978-998d-4bcb-8a83-43df0625d6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9b0a8a0f-1d98-45cb-9be0-c1deb86d5623" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityRegistrantName_9b0a8a0f-1d98-45cb-9be0-c1deb86d5623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_309e001e-1a0e-41da-8e04-f08de22e077d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_309e001e-1a0e-41da-8e04-f08de22e077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c33f3aec-98a2-4e8e-8ba1-2d939cf4950f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityTaxIdentificationNumber_c33f3aec-98a2-4e8e-8ba1-2d939cf4950f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2ffaa258-458a-4b19-a6a2-d002a17df1f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityAddressAddressLine1_2ffaa258-458a-4b19-a6a2-d002a17df1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_542a8f8b-a4d5-44e0-ab93-6979013dc7ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityAddressCityOrTown_542a8f8b-a4d5-44e0-ab93-6979013dc7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d2d9a199-aa0c-4ee3-87f8-5f30d9d340a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityAddressStateOrProvince_d2d9a199-aa0c-4ee3-87f8-5f30d9d340a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0f7d1b60-3791-417d-93f3-e38e2b0bd42f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityAddressPostalZipCode_0f7d1b60-3791-417d-93f3-e38e2b0bd42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9b063a34-a812-45f4-a20b-30a24fb3a83d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_CityAreaCode_9b063a34-a812-45f4-a20b-30a24fb3a83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a3a81061-7a5f-44b2-98e7-0790ca83d77f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_LocalPhoneNumber_a3a81061-7a5f-44b2-98e7-0790ca83d77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a96e61c7-a17e-43ec-a371-a3c90bcb06a0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_Security12bTitle_a96e61c7-a17e-43ec-a371-a3c90bcb06a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_72bd81bb-ae30-43ca-8b82-7d15bf7760dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_TradingSymbol_72bd81bb-ae30-43ca-8b82-7d15bf7760dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6ce09bad-d2ba-40f9-b1c0-9d97d10970b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_SecurityExchangeName_6ce09bad-d2ba-40f9-b1c0-9d97d10970b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f8cc0a3f-317a-4ea7-bbf7-bd55d3a646a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f8cc0a3f-317a-4ea7-bbf7-bd55d3a646a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_50c4599d-4c95-4a6c-85df-7ecbb6ead85b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityVoluntaryFilers_50c4599d-4c95-4a6c-85df-7ecbb6ead85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_375dcc15-e202-4cf4-8b66-6a2688973f00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityCurrentReportingStatus_375dcc15-e202-4cf4-8b66-6a2688973f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6dff1527-5bd6-4b05-b8c2-16bc5a88b3b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityInteractiveDataCurrent_6dff1527-5bd6-4b05-b8c2-16bc5a88b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9c904f81-df09-45be-a117-6e99936f1b6f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityFilerCategory_9c904f81-df09-45be-a117-6e99936f1b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9f1459b7-fd40-40ee-b3c8-e9f0b23fbdb2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntitySmallBusiness_9f1459b7-fd40-40ee-b3c8-e9f0b23fbdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e8fc84ba-513d-4e9e-b344-35231ba3cf9c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityEmergingGrowthCompany_e8fc84ba-513d-4e9e-b344-35231ba3cf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a95a150d-92ba-4f35-90e6-377cbee642bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a95a150d-92ba-4f35-90e6-377cbee642bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e4dff1e3-c21d-498d-8729-e0a7bba67970" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityShellCompany_e4dff1e3-c21d-498d-8729-e0a7bba67970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f4fd33d0-e972-4261-90f0-5c48db7ff196" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityPublicFloat_f4fd33d0-e972-4261-90f0-5c48db7ff196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2924b8b5-a84d-4e1e-98d1-cff4f5c65a4b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2924b8b5-a84d-4e1e-98d1-cff4f5c65a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f22ebc54-1466-4373-904a-05859ce20463" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f22ebc54-1466-4373-904a-05859ce20463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1c738146-d99f-4dd1-bfab-2379c93fbe91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_AmendmentFlag_1c738146-d99f-4dd1-bfab-2379c93fbe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bc453fe2-480e-4d0b-8d8a-69dc00a829d6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bc453fe2-480e-4d0b-8d8a-69dc00a829d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6f8dcbbd-f7de-4f09-a65e-24481398a3ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_EntityCentralIndexKey_6f8dcbbd-f7de-4f09-a65e-24481398a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1632c728-27d5-4a3e-8aa0-6df42d82d1a6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bbbefaf-9f8e-40e3-b9a6-306b730dd1dd" xlink:to="loc_dei_DocumentFiscalYearFocus_1632c728-27d5-4a3e-8aa0-6df42d82d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/AuditInformation" xlink:type="simple" xlink:href="eigr-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AuditInformationAbstract_3d503b2e-1bf8-4bd3-8749-c47e2f904ab3" xlink:href="eigr-20221231.xsd#eigr_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_5bc287b7-dacf-4e7c-8faf-2c48a5dc5848" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AuditInformationAbstract_3d503b2e-1bf8-4bd3-8749-c47e2f904ab3" xlink:to="loc_dei_AuditorFirmId_5bc287b7-dacf-4e7c-8faf-2c48a5dc5848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_67c44a12-70fc-4ab4-b0d0-d1b8d9a8ee8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AuditInformationAbstract_3d503b2e-1bf8-4bd3-8749-c47e2f904ab3" xlink:to="loc_dei_AuditorName_67c44a12-70fc-4ab4-b0d0-d1b8d9a8ee8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_c60c5be2-6cd1-47e5-ac10-c53bb8f82592" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AuditInformationAbstract_3d503b2e-1bf8-4bd3-8749-c47e2f904ab3" xlink:to="loc_dei_AuditorLocation_c60c5be2-6cd1-47e5-ac10-c53bb8f82592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fd0ccc5f-08ca-46ee-80c0-ebeef0e90024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd0ccc5f-08ca-46ee-80c0-ebeef0e90024" xlink:to="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97f97dca-d0db-4dbd-aece-bc278b43e121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97f97dca-d0db-4dbd-aece-bc278b43e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrent_7822bfde-c681-4bef-a0ee-21047133e942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:to="loc_us-gaap_DebtSecuritiesCurrent_7822bfde-c681-4bef-a0ee-21047133e942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_39539c73-0b1e-489e-9ee6-cd3432071e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_39539c73-0b1e-489e-9ee6-cd3432071e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_667c9855-1bd9-48bc-b22c-48665fffbcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:to="loc_us-gaap_InventoryNet_667c9855-1bd9-48bc-b22c-48665fffbcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9a47019c-ec91-4c75-a429-9e4a6f0059a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9a47019c-ec91-4c75-a429-9e4a6f0059a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_69d935d2-b8c9-4fd2-a5cf-e88d59a2973a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6000d51d-c95e-4bc3-bd21-743cd5c39e9a" xlink:to="loc_us-gaap_AssetsCurrent_69d935d2-b8c9-4fd2-a5cf-e88d59a2973a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrent_b6fda247-24a0-41ba-b24f-374ca3540565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrent_b6fda247-24a0-41ba-b24f-374ca3540565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_29a98fe5-6438-4670-a791-be2f8f1be838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_29a98fe5-6438-4670-a791-be2f8f1be838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a7bac85-011b-489b-9486-ec1a852a4622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6a7bac85-011b-489b-9486-ec1a852a4622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_00b64470-152f-449c-8759-91b1f9f74c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_00b64470-152f-449c-8759-91b1f9f74c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5435389d-77f0-4247-8eba-fe88bf8f26be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d8fb18bd-00f8-4980-b450-07a29555d541" xlink:to="loc_us-gaap_Assets_5435389d-77f0-4247-8eba-fe88bf8f26be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd0ccc5f-08ca-46ee-80c0-ebeef0e90024" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_733b4ef4-b7ad-4a27-8289-1e9b0e51a3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:to="loc_us-gaap_AccountsPayableCurrent_733b4ef4-b7ad-4a27-8289-1e9b0e51a3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2ab2dd75-f86a-4154-bbc8-591fe09f0d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2ab2dd75-f86a-4154-bbc8-591fe09f0d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8cfc1ded-59ac-44ad-8002-c61343b86e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8cfc1ded-59ac-44ad-8002-c61343b86e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b9a481d1-5785-4283-8c3d-db4b8f9daf63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:to="loc_us-gaap_LongTermDebtCurrent_b9a481d1-5785-4283-8c3d-db4b8f9daf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2473ef94-7357-409a-b0dd-8da113a57ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c9b05ab-21db-4e13-8afb-e12c86d86e33" xlink:to="loc_us-gaap_LiabilitiesCurrent_2473ef94-7357-409a-b0dd-8da113a57ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aad81575-1a28-4c4b-a12c-660e020b54ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aad81575-1a28-4c4b-a12c-660e020b54ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3fe16fcf-95fb-4786-81fd-cba4796f49fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3fe16fcf-95fb-4786-81fd-cba4796f49fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_555c4054-22bb-4f73-a0e4-4b89372fb2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:to="loc_us-gaap_Liabilities_555c4054-22bb-4f73-a0e4-4b89372fb2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_73be0c12-9b77-46be-a968-5f2078fb7105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:to="loc_us-gaap_CommonStockValue_73be0c12-9b77-46be-a968-5f2078fb7105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_03ffad13-2651-4240-835a-5e186e519311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_03ffad13-2651-4240-835a-5e186e519311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_101483d9-3c8f-4600-83a6-c58cfcf890e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_101483d9-3c8f-4600-83a6-c58cfcf890e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4337244b-8416-48c5-a479-b0b199dda5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4337244b-8416-48c5-a479-b0b199dda5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1cda5fd7-91c5-40fd-a12c-a046cc63d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a54be0e1-d9c9-4247-bf9d-3853988ee316" xlink:to="loc_us-gaap_StockholdersEquity_1cda5fd7-91c5-40fd-a12c-a046cc63d20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_05c36510-2e1e-453a-abb8-02fdb266b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5f29f112-eec6-4acf-9ba8-29dde33ab65e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_05c36510-2e1e-453a-abb8-02fdb266b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d12d63c2-6bd8-426b-9716-2da3d97390c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d12d63c2-6bd8-426b-9716-2da3d97390c6" xlink:to="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:to="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d7ad4663-6743-441e-a03e-33e5520a2573" xlink:to="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_afccd6f9-d7ee-4d19-8e79-6518c83aa32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:to="loc_us-gaap_ProductMember_afccd6f9-d7ee-4d19-8e79-6518c83aa32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherRevenueMember_786688d9-c5b2-4511-8d28-82b6211d32e5" xlink:href="eigr-20221231.xsd#eigr_OtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_622a504f-e80f-4065-aa66-49e772175ac7" xlink:to="loc_eigr_OtherRevenueMember_786688d9-c5b2-4511-8d28-82b6211d32e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2802c567-95a2-4f71-baeb-c66a462969d7" xlink:to="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b8a09448-f2b0-460d-8170-42ee0d34b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_RevenuesAbstract_b8a09448-f2b0-460d-8170-42ee0d34b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ea959718-119b-4bfd-ab72-fbeae4e02fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b8a09448-f2b0-460d-8170-42ee0d34b9cc" xlink:to="loc_us-gaap_Revenues_ea959718-119b-4bfd-ab72-fbeae4e02fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a2167022-4e43-4fdb-9832-466cd04ebf63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_CostOfRevenue_a2167022-4e43-4fdb-9832-466cd04ebf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b86c5b0-4b20-4385-b530-685f2d646710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b86c5b0-4b20-4385-b530-685f2d646710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08b6c04f-09d1-44e5-ac52-337b78216985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08b6c04f-09d1-44e5-ac52-337b78216985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9cc12ed5-e3ed-487f-bd0c-df22140c92dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_2333662b-c019-452a-8b7b-9f097cda29c7" xlink:to="loc_us-gaap_CostsAndExpenses_9cc12ed5-e3ed-487f-bd0c-df22140c92dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b038b2c5-7691-4ec9-b127-b3c9e7ec4f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_OperatingIncomeLoss_b038b2c5-7691-4ec9-b127-b3c9e7ec4f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_96030678-40c2-4b84-acb8-f6f83bbff5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_InterestExpense_96030678-40c2-4b84-acb8-f6f83bbff5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_080ca895-69b6-46bf-9b42-739a783e45b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_080ca895-69b6-46bf-9b42-739a783e45b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_232c7e1f-eec6-44b0-978f-81582ea68fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_232c7e1f-eec6-44b0-978f-81582ea68fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ce4fcdd-2095-4355-a98c-77253b071722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ce4fcdd-2095-4355-a98c-77253b071722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3305a13-27b1-449d-a698-fa2fd14e3ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3305a13-27b1-449d-a698-fa2fd14e3ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_191ad50a-a1c4-4b4d-a911-66c897213cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_NetIncomeLoss_191ad50a-a1c4-4b4d-a911-66c897213cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c3cdc08c-8e8a-4401-a5ce-90215c24e274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:to="loc_us-gaap_EarningsPerShareBasic_c3cdc08c-8e8a-4401-a5ce-90215c24e274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_605771f3-5100-4fde-b6e7-f1759e0b3f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_4e9511b2-a13b-4abd-82e3-dfdee0ffd1b1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_605771f3-5100-4fde-b6e7-f1759e0b3f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baef41e-ddb0-4078-a64d-328d9722b8e1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7989739d-430f-4aad-b572-ed97de544277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7989739d-430f-4aad-b572-ed97de544277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_976161d7-e1f7-49aa-bbe2-01a86ca78038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_31211c81-d348-461b-9aa5-24b22a5a547b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_976161d7-e1f7-49aa-bbe2-01a86ca78038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c9d4a1c-964c-4e47-9507-ec8c51126131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87f20ae1-60b3-4bbe-932f-0487a6624bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c9d4a1c-964c-4e47-9507-ec8c51126131" xlink:to="loc_us-gaap_NetIncomeLoss_87f20ae1-60b3-4bbe-932f-0487a6624bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_248837c4-23cd-45ab-a5d6-45572827c213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c9d4a1c-964c-4e47-9507-ec8c51126131" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_248837c4-23cd-45ab-a5d6-45572827c213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c7b6dad0-6836-4249-a7c0-458e6a6e94b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_248837c4-23cd-45ab-a5d6-45572827c213" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c7b6dad0-6836-4249-a7c0-458e6a6e94b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_43320e96-0279-4bc3-9670-227ef0720d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_248837c4-23cd-45ab-a5d6-45572827c213" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_43320e96-0279-4bc3-9670-227ef0720d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef11d50c-fbe8-4f11-a4db-eea27fb01d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c9d4a1c-964c-4e47-9507-ec8c51126131" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef11d50c-fbe8-4f11-a4db-eea27fb01d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_da3f2d86-d93e-4fc3-ab97-b9d092a99c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_da3f2d86-d93e-4fc3-ab97-b9d092a99c98" xlink:to="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_529cf8be-f8ac-4dff-a918-33e4f2b35786" xlink:to="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07696dfa-630d-42d2-94fb-309e10e4c011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_CommonStockMember_07696dfa-630d-42d2-94fb-309e10e4c011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8db84b39-6abb-4fe4-b060-35355b22df84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8db84b39-6abb-4fe4-b060-35355b22df84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e52b719b-fb9a-4c46-aa10-aac96852689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e52b719b-fb9a-4c46-aa10-aac96852689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_03950589-8fda-441d-94e3-ddd7c1eaceea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bbf1ffa2-db7a-420a-9d2b-210a9d5fdbe6" xlink:to="loc_us-gaap_RetainedEarningsMember_03950589-8fda-441d-94e3-ddd7c1eaceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7ea016a0-837a-4101-a0e4-4ab5c5c08cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_333a3567-afe1-4c8b-907c-10ba17f47d92" xlink:to="loc_us-gaap_StatementLineItems_7ea016a0-837a-4101-a0e4-4ab5c5c08cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7ea016a0-837a-4101-a0e4-4ab5c5c08cd1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28ad413d-f0da-410b-8fa6-ecd6c3353ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_28ad413d-f0da-410b-8fa6-ecd6c3353ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_490d21c7-a37f-49eb-925d-0b97d28c50a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockholdersEquity_490d21c7-a37f-49eb-925d-0b97d28c50a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aec70fbe-8ce1-447f-8db7-c35a520eba4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aec70fbe-8ce1-447f-8db7-c35a520eba4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_433ad8f0-e725-4b04-9dfd-3b145e28eb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_433ad8f0-e725-4b04-9dfd-3b145e28eb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ecc48bd8-3b8f-4cb2-81fd-1922ca225acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ecc48bd8-3b8f-4cb2-81fd-1922ca225acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c0f5a645-be2a-46af-bb1d-389a9ed77ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c0f5a645-be2a-46af-bb1d-389a9ed77ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9336ac0-0be8-48bb-bfb7-dce8588483c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9336ac0-0be8-48bb-bfb7-dce8588483c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3efb4c63-87d8-4677-ab77-919be5ca3fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3efb4c63-87d8-4677-ab77-919be5ca3fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_dfeef72d-a4fc-424e-8a72-135e9cadc395" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_dfeef72d-a4fc-424e-8a72-135e9cadc395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df4af244-0545-4484-8fc2-6a88abd81b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df4af244-0545-4484-8fc2-6a88abd81b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4dd0319d-cb11-4de7-8703-0f8b72cdf3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4dd0319d-cb11-4de7-8703-0f8b72cdf3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_de853b40-6065-4d8b-ac75-5b616bcc3fdc" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodSharesStockIssuedToLender"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender_de853b40-6065-4d8b-ac75-5b616bcc3fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_a4769c1e-f3d9-49a1-86d8-7508926d95f6" xlink:href="eigr-20221231.xsd#eigr_StockIssuedDuringPeriodValueStockIssuedToLender"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_eigr_StockIssuedDuringPeriodValueStockIssuedToLender_a4769c1e-f3d9-49a1-86d8-7508926d95f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0f9e89c9-be22-4814-a2c1-3e723cb222a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0f9e89c9-be22-4814-a2c1-3e723cb222a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2279f8b9-0687-40b7-a666-901901e20c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2279f8b9-0687-40b7-a666-901901e20c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_28bfe74d-c00a-476c-8029-440970d97d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_28bfe74d-c00a-476c-8029-440970d97d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb44505c-6790-48c3-bf2f-6e3fd8506edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_NetIncomeLoss_eb44505c-6790-48c3-bf2f-6e3fd8506edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0a8eab6a-ff58-4c8a-bf82-870604a5f435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0a8eab6a-ff58-4c8a-bf82-870604a5f435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd8b0dda-6397-4217-9db2-2351b3b4f776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b07a7212-6c08-48ae-af76-c721ef69d4e7" xlink:to="loc_us-gaap_StockholdersEquity_dd8b0dda-6397-4217-9db2-2351b3b4f776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c961e73d-923f-4227-bb65-b79b8bacecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_StockIssuanceCosts_edad9a9c-3cdf-40a7-8047-a73dc2b7ee8a" xlink:href="eigr-20221231.xsd#eigr_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c961e73d-923f-4227-bb65-b79b8bacecf6" xlink:to="loc_eigr_StockIssuanceCosts_edad9a9c-3cdf-40a7-8047-a73dc2b7ee8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f1cbc7a-cf36-4bd5-9679-f965c643ece1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f1cbc7a-cf36-4bd5-9679-f965c643ece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5df21808-0a3a-4518-91d1-fc615d2dd0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f1cbc7a-cf36-4bd5-9679-f965c643ece1" xlink:to="loc_us-gaap_NetIncomeLoss_5df21808-0a3a-4518-91d1-fc615d2dd0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f1cbc7a-cf36-4bd5-9679-f965c643ece1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_GainLossFromSaleOfPriorityReviewVoucher_a2c136c9-b39e-40af-8d00-1da196d64971" xlink:href="eigr-20221231.xsd#eigr_GainLossFromSaleOfPriorityReviewVoucher"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_eigr_GainLossFromSaleOfPriorityReviewVoucher_a2c136c9-b39e-40af-8d00-1da196d64971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncomeLossRelatedToAssetPurchaseAgreement_c970f5d4-c6db-4b10-a1fa-af04e63c4fd1" xlink:href="eigr-20221231.xsd#eigr_IncomeLossRelatedToAssetPurchaseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_eigr_IncomeLossRelatedToAssetPurchaseAgreement_c970f5d4-c6db-4b10-a1fa-af04e63c4fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_94241461-4cb8-4db1-8121-785f4c80bdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_94241461-4cb8-4db1-8121-785f4c80bdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_7ff60b67-75a7-430d-8725-391d9c6341e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_InventoryWriteDown_7ff60b67-75a7-430d-8725-391d9c6341e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0292ea55-5f1d-4770-8bf0-6013d0142597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0292ea55-5f1d-4770-8bf0-6013d0142597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d0a59742-5fa9-4abd-b06b-80a1a07cebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d0a59742-5fa9-4abd-b06b-80a1a07cebcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f8589df6-37e7-4360-8edc-0006fe326356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f8589df6-37e7-4360-8edc-0006fe326356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_413e2ff9-58ce-42eb-bb64-cc969a531778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_413e2ff9-58ce-42eb-bb64-cc969a531778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_a712cb4a-88fb-4036-b708-a2f808288d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_a712cb4a-88fb-4036-b708-a2f808288d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7e1c3887-06c8-4e10-b074-104372f86989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0dfc1126-24ab-4081-8c9d-db19401c373a" xlink:to="loc_us-gaap_ShareBasedCompensation_7e1c3887-06c8-4e10-b074-104372f86989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f1cbc7a-cf36-4bd5-9679-f965c643ece1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2caecba2-5b1d-4533-a9cb-19b1389a1765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2caecba2-5b1d-4533-a9cb-19b1389a1765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_41c20993-ca83-45ac-af63-c7929013ebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_41c20993-ca83-45ac-af63-c7929013ebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_999e82f1-f6e7-42e9-a33d-12789fb1f84a" xlink:href="eigr-20221231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_999e82f1-f6e7-42e9-a33d-12789fb1f84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e9a07c67-21f0-4318-9ece-e8ce1381363b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e9a07c67-21f0-4318-9ece-e8ce1381363b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6af06dba-3802-444e-b8d8-d9295be5442f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6af06dba-3802-444e-b8d8-d9295be5442f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c33549fd-50cc-4463-b727-f21a63a135cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c33549fd-50cc-4463-b727-f21a63a135cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_c6267be7-e760-4aee-bdd6-91d7d83bd59e" xlink:href="eigr-20221231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_eigr_IncreaseDecreaseInOperatingLeaseLiabilities_c6267be7-e760-4aee-bdd6-91d7d83bd59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a296f71c-cf4b-4df2-8af1-2c3c30dd20df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d7c04c92-e9fa-4953-8941-33c5408ccbc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a296f71c-cf4b-4df2-8af1-2c3c30dd20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_075642fa-35d1-419b-8be4-de4775524aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_075642fa-35d1-419b-8be4-de4775524aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4aa57418-7d78-487e-9f95-87431488c70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4aa57418-7d78-487e-9f95-87431488c70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsRelatedToAssetPurchaseAgreement_316fcc18-599a-472d-a821-a0987f10ee22" xlink:href="eigr-20221231.xsd#eigr_ProceedsRelatedToAssetPurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_eigr_ProceedsRelatedToAssetPurchaseAgreement_316fcc18-599a-472d-a821-a0987f10ee22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromSaleOfPriorityReviewVoucher_c3ee16d0-4e2b-49f1-8bd3-17318c9dca0b" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromSaleOfPriorityReviewVoucher"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_eigr_ProceedsFromSaleOfPriorityReviewVoucher_c3ee16d0-4e2b-49f1-8bd3-17318c9dca0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PaymentsRelatedToPriorityReviewVoucher_56cbff5a-9f6c-4e02-bf35-c558d4a21342" xlink:href="eigr-20221231.xsd#eigr_PaymentsRelatedToPriorityReviewVoucher"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_eigr_PaymentsRelatedToPriorityReviewVoucher_56cbff5a-9f6c-4e02-bf35-c558d4a21342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e42836d7-e092-49f0-a16d-6dc363ebc371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e42836d7-e092-49f0-a16d-6dc363ebc371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_807dcb8b-7a70-4a6b-a00e-8eec8e98fc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f8838ef-5eb0-4bc9-8df7-5bbf83d55bea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_807dcb8b-7a70-4a6b-a00e-8eec8e98fc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6a8b15f9-43d0-4381-a4bf-7f6ed1155f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6a8b15f9-43d0-4381-a4bf-7f6ed1155f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_46c1e8d8-8857-4b3f-b033-ccc00cc492e6" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt_46c1e8d8-8857-4b3f-b033-ccc00cc492e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2b49eeee-7afc-4944-9912-45d2b4a383bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2b49eeee-7afc-4944-9912-45d2b4a383bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bc9c9ae6-709d-4826-a200-45e2dc62fb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bc9c9ae6-709d-4826-a200-45e2dc62fb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9b83e08b-f253-4116-9a57-fc901b6cf1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9b83e08b-f253-4116-9a57-fc901b6cf1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_9f1863f6-bee2-4932-a38b-39841e4de64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_ProceedsFromStockPlans_9f1863f6-bee2-4932-a38b-39841e4de64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_84c958d9-208c-4c81-b9cf-deb52bc78db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_84c958d9-208c-4c81-b9cf-deb52bc78db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3f70f8c4-d7d3-4a95-ab93-972905cf90fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3f70f8c4-d7d3-4a95-ab93-972905cf90fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31293255-80e4-4a76-89a3-658ef813c4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad83b229-3edc-4dec-a1b8-6357627c223f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31293255-80e4-4a76-89a3-658ef813c4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fbc2f0e-adec-4601-b4f2-7c70d93af1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7fbc2f0e-adec-4601-b4f2-7c70d93af1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea104b47-0b78-4d40-ab4a-1298b733c83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea104b47-0b78-4d40-ab4a-1298b733c83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_113818cb-51a9-4bb8-bba7-844918f9245e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_113818cb-51a9-4bb8-bba7-844918f9245e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9120c4bd-2391-4ead-b832-2c69e086079a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_21713e4e-9db1-487c-973f-491d488a0c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:to="loc_us-gaap_InterestPaidNet_21713e4e-9db1-487c-973f-491d488a0c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_96fbe707-1dfb-42a4-b288-e025e7818a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:to="loc_us-gaap_IncomeTaxesPaid_96fbe707-1dfb-42a4-b288-e025e7818a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08186b53-072f-4527-9a00-d21e3cd5c429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_08186b53-072f-4527-9a00-d21e3cd5c429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OfferingCostsIncurredNotYetPaid_388d18f6-d58c-4f91-930c-c3c3baf55e08" xlink:href="eigr-20221231.xsd#eigr_OfferingCostsIncurredNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:to="loc_eigr_OfferingCostsIncurredNotYetPaid_388d18f6-d58c-4f91-930c-c3c3baf55e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e33e00cf-949f-4c96-96eb-bef48923887e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7ffae0e-5b68-4b66-bcb2-857ea55bbf3a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e33e00cf-949f-4c96-96eb-bef48923887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="eigr-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_820eafc0-3316-489e-bcb4-a89cd102eaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8e37fb49-aa33-408b-a23b-35e6f3e2bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_820eafc0-3316-489e-bcb4-a89cd102eaf1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8e37fb49-aa33-408b-a23b-35e6f3e2bd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fe97801e-5a19-480f-b094-ce712b11e0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_820eafc0-3316-489e-bcb4-a89cd102eaf1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fe97801e-5a19-480f-b094-ce712b11e0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f83e22c6-6c35-4d36-941c-b153003e7968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_820eafc0-3316-489e-bcb4-a89cd102eaf1" xlink:to="loc_us-gaap_CommonStockSharesIssued_f83e22c6-6c35-4d36-941c-b153003e7968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d37da37d-ba7c-4ec7-b184-fd02f8aa2c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_820eafc0-3316-489e-bcb4-a89cd102eaf1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d37da37d-ba7c-4ec7-b184-fd02f8aa2c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="eigr-20221231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_edbcfef1-eb33-4ebf-a2f9-d08aec7ba5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9d8802ff-136c-4526-86cd-d77502ea9bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_edbcfef1-eb33-4ebf-a2f9-d08aec7ba5a1" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9d8802ff-136c-4526-86cd-d77502ea9bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77d580e3-ccf6-46e7-9695-035c6b3a999c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d717e804-8b29-4f3e-a6d7-716681eeb630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77d580e3-ccf6-46e7-9695-035c6b3a999c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d717e804-8b29-4f3e-a6d7-716681eeb630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_53ee3659-8f89-4554-a4c8-858323b3819f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a5eb61bf-e8c0-4b19-803f-df440b9a7e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_53ee3659-8f89-4554-a4c8-858323b3819f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a5eb61bf-e8c0-4b19-803f-df440b9a7e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6d8ce8c0-d368-4951-8510-b1dcb6e86976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9c3ec2a3-6623-47ef-93f7-fdfe94bf82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6d8ce8c0-d368-4951-8510-b1dcb6e86976" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_9c3ec2a3-6623-47ef-93f7-fdfe94bf82fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreements" xlink:type="simple" xlink:href="eigr-20221231.xsd#LicenseCollaborationandProductDevelopmentAgreements"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementAbstract_fae4b313-8d92-4007-b041-cdd51cfc999f" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementTextBlock_cbd63742-04c6-4468-ad84-7263a58b4b27" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ProductDevelopmentAgreementAbstract_fae4b313-8d92-4007-b041-cdd51cfc999f" xlink:to="loc_eigr_ProductDevelopmentAgreementTextBlock_cbd63742-04c6-4468-ad84-7263a58b4b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreements" xlink:type="simple" xlink:href="eigr-20221231.xsd#AssetPurchaseAgreementsandRelatedLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_b3985aa7-4c5c-4ffe-9332-b925957e0a11" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementTextBlock_705a31dd-de72-4f62-97b6-25fee363a73d" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_b3985aa7-4c5c-4ffe-9332-b925957e0a11" xlink:to="loc_eigr_AssetPurchaseAgreementTextBlock_705a31dd-de72-4f62-97b6-25fee363a73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SaleofAssets" xlink:type="simple" xlink:href="eigr-20221231.xsd#SaleofAssets"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SaleofAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_07754ebc-3d12-4a44-8435-02d29b936064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c119e2c2-1b23-4073-ba2a-ffed0e673cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_07754ebc-3d12-4a44-8435-02d29b936064" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c119e2c2-1b23-4073-ba2a-ffed0e673cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/Debt" xlink:type="simple" xlink:href="eigr-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5ae5d9ac-d988-41bd-8627-8852a522f435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6b069fe3-9b9e-4bb9-816f-a07edbc6612a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5ae5d9ac-d988-41bd-8627-8852a522f435" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6b069fe3-9b9e-4bb9-816f-a07edbc6612a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5af7ff76-5edf-4b68-81f7-067de2855942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_62417e22-f325-40eb-8954-07144758d559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5af7ff76-5edf-4b68-81f7-067de2855942" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_62417e22-f325-40eb-8954-07144758d559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d271913b-3a52-4b50-8b93-19725578eb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b84a1120-0c25-4fe2-91f3-17842986f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d271913b-3a52-4b50-8b93-19725578eb28" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b84a1120-0c25-4fe2-91f3-17842986f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_780741d9-94e9-48ab-9aa8-c3e1d97dc51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_209253dc-49a9-4947-bce0-25b9c68cf70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_780741d9-94e9-48ab-9aa8-c3e1d97dc51d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_209253dc-49a9-4947-bce0-25b9c68cf70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/LegalMatters" xlink:type="simple" xlink:href="eigr-20221231.xsd#LegalMatters"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LegalMattersAbstract_04da35b3-2e28-4fec-b839-fb07b891967b" xlink:href="eigr-20221231.xsd#eigr_LegalMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_13e0efda-78ac-429c-936f-4f7e9f0f01b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_LegalMattersAbstract_04da35b3-2e28-4fec-b839-fb07b891967b" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_13e0efda-78ac-429c-936f-4f7e9f0f01b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2616170a-31a7-464e-a249-b81cc2e00e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_cd86c158-963a-48ad-bc1d-7ea6a2c1f6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2616170a-31a7-464e-a249-b81cc2e00e5f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_cd86c158-963a-48ad-bc1d-7ea6a2c1f6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="eigr-20221231.xsd#RelatedPartyDisclosures"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/RelatedPartyDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1163300c-593e-4506-bc1c-25e8f1424e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f592a83b-e57a-4698-9a71-125e57e8da93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1163300c-593e-4506-bc1c-25e8f1424e5c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f592a83b-e57a-4698-9a71-125e57e8da93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="eigr-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5f205866-8492-4666-9d2f-bb9ac4fa5caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_493f1956-d338-4d1e-a484-341c76349e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5f205866-8492-4666-9d2f-bb9ac4fa5caf" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_493f1956-d338-4d1e-a484-341c76349e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_def4da2a-59f2-48ce-b813-55e2c89c46a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_def4da2a-59f2-48ce-b813-55e2c89c46a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b32f9a1b-ace9-44f6-a04c-e01d2cdf9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_UseOfEstimates_b32f9a1b-ace9-44f6-a04c-e01d2cdf9b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d844e6b0-d990-4700-9480-406147b403b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d844e6b0-d990-4700-9480-406147b403b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c0600888-00bb-4d9c-b2f3-d1502599fe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c0600888-00bb-4d9c-b2f3-d1502599fe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ce21c5dd-a186-485f-8cac-d37e1e094ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ce21c5dd-a186-485f-8cac-d37e1e094ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_553de60c-cc81-4805-9bc9-6728c39ed4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_553de60c-cc81-4805-9bc9-6728c39ed4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_494aed2a-f9f1-4b31-8bb3-c03328a2c160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_494aed2a-f9f1-4b31-8bb3-c03328a2c160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_053ef729-b030-45c1-88b3-70108c373413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_053ef729-b030-45c1-88b3-70108c373413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_93b9cbb7-919d-430c-af9e-cf29c0294daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_93b9cbb7-919d-430c-af9e-cf29c0294daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6179d2bd-a63e-4ced-8264-624704973945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6179d2bd-a63e-4ced-8264-624704973945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_73015db1-475f-4a7e-bc41-c616ac78ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_73015db1-475f-4a7e-bc41-c616ac78ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_3e022196-f7b7-471f-9346-c6844b6aae1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_3e022196-f7b7-471f-9346-c6844b6aae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_739ce707-c493-47b5-8f12-83447dc7df9b" xlink:href="eigr-20221231.xsd#eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_739ce707-c493-47b5-8f12-83447dc7df9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_34eebfae-686c-47bd-9388-41644cef94b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_34eebfae-686c-47bd-9388-41644cef94b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_56882654-3429-4ff8-bc1a-0d5c6e186ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_DebtPolicyTextBlock_56882654-3429-4ff8-bc1a-0d5c6e186ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_80ad1c76-96f3-4d69-bdf5-d16629471b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_80ad1c76-96f3-4d69-bdf5-d16629471b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_71cc39ad-1a11-4c8d-9aa9-0d16b965327b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_71cc39ad-1a11-4c8d-9aa9-0d16b965327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_55578c74-bf03-4c4f-9114-4e42f09d74e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_55578c74-bf03-4c4f-9114-4e42f09d74e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3e9fe582-6a93-4e6d-9c31-ff6c2e77bf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3e9fe582-6a93-4e6d-9c31-ff6c2e77bf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f0d22699-c47d-4efe-994d-26dd9341826d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a4a07f0-2a62-4da0-b44c-2c0990814f87" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f0d22699-c47d-4efe-994d-26dd9341826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d9c9a52-b0e3-435d-a021-13194c3c61e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_ddff2608-ba98-40f0-afd8-35409e46cc0c" xlink:href="eigr-20221231.xsd#eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d9c9a52-b0e3-435d-a021-13194c3c61e2" xlink:to="loc_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_ddff2608-ba98-40f0-afd8-35409e46cc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b9690a35-ff8b-4b54-866a-ef5856bf76cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d9c9a52-b0e3-435d-a021-13194c3c61e2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b9690a35-ff8b-4b54-866a-ef5856bf76cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0a61679b-98c4-48b5-b3ea-9f6ddc72da86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_600f229b-c2f9-4c5e-8855-ea2702e00547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0a61679b-98c4-48b5-b3ea-9f6ddc72da86" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_600f229b-c2f9-4c5e-8855-ea2702e00547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2afb1e27-66eb-42bc-b918-379d5d5bb79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0a61679b-98c4-48b5-b3ea-9f6ddc72da86" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2afb1e27-66eb-42bc-b918-379d5d5bb79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_87702665-9a4f-49fc-9dbd-74eb060e4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6d3e721a-a83d-427b-a67e-71a110e0376c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_87702665-9a4f-49fc-9dbd-74eb060e4da5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6d3e721a-a83d-427b-a67e-71a110e0376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a86961dd-0df1-42b4-9850-152abbcd84cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_87702665-9a4f-49fc-9dbd-74eb060e4da5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a86961dd-0df1-42b4-9850-152abbcd84cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock_959085a9-9793-4b87-8e81-86d14b0e9d44" xlink:href="eigr-20221231.xsd#eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_87702665-9a4f-49fc-9dbd-74eb060e4da5" xlink:to="loc_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock_959085a9-9793-4b87-8e81-86d14b0e9d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ad3fea2a-d823-4e2a-8c85-5f9456dad07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_87702665-9a4f-49fc-9dbd-74eb060e4da5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ad3fea2a-d823-4e2a-8c85-5f9456dad07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d1bb5b1-e137-48f3-8173-ac7146bd4fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_98ad4f0a-6b74-424e-a44e-9d3a17ade9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d1bb5b1-e137-48f3-8173-ac7146bd4fdb" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_98ad4f0a-6b74-424e-a44e-9d3a17ade9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ab7cfda0-4030-4843-b748-2749b36c35d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d1bb5b1-e137-48f3-8173-ac7146bd4fdb" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ab7cfda0-4030-4843-b748-2749b36c35d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5d19aab-e048-4f84-b312-3260db733ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommonStockReservedForFutureIssuancesTableTextBlock_01ad3c78-71a8-4eac-8ac4-4db5a5127f2d" xlink:href="eigr-20221231.xsd#eigr_CommonStockReservedForFutureIssuancesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5d19aab-e048-4f84-b312-3260db733ac9" xlink:to="loc_eigr_CommonStockReservedForFutureIssuancesTableTextBlock_01ad3c78-71a8-4eac-8ac4-4db5a5127f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c890debb-7bd3-497c-94dd-73340f5ea82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6a135b3a-1f3c-4f2a-9380-4d2db52de1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c890debb-7bd3-497c-94dd-73340f5ea82d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6a135b3a-1f3c-4f2a-9380-4d2db52de1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fea5f412-8fd8-4b25-9be9-cd80197704a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c890debb-7bd3-497c-94dd-73340f5ea82d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fea5f412-8fd8-4b25-9be9-cd80197704a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6f73ee7d-f41e-433a-a979-b80394820239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c890debb-7bd3-497c-94dd-73340f5ea82d" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6f73ee7d-f41e-433a-a979-b80394820239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d5b2364-64b2-473b-9403-9e72703a4730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c890debb-7bd3-497c-94dd-73340f5ea82d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d5b2364-64b2-473b-9403-9e72703a4730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aa696084-1b5b-4c7d-a056-6fe9d1f7a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4351bc6b-99fa-4bdc-b462-7148fe9d2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa696084-1b5b-4c7d-a056-6fe9d1f7a9a3" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4351bc6b-99fa-4bdc-b462-7148fe9d2be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_197f3f4a-267b-4e13-8581-c5374d941c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa696084-1b5b-4c7d-a056-6fe9d1f7a9a3" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_197f3f4a-267b-4e13-8581-c5374d941c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_740609e7-45e8-4480-87e1-f5449cad01d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa696084-1b5b-4c7d-a056-6fe9d1f7a9a3" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_740609e7-45e8-4480-87e1-f5449cad01d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bbe74aac-ff52-40f4-9e56-1e4aca6cc004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_14324712-078a-474a-b172-267f75aff4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbe74aac-ff52-40f4-9e56-1e4aca6cc004" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_14324712-078a-474a-b172-267f75aff4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DescriptionofBusinessAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ac24cd8-1365-4f1e-ac1b-9dfe747c5cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c99c8258-859c-491c-8f7d-bc9f1b15a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ac24cd8-1365-4f1e-ac1b-9dfe747c5cb8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c99c8258-859c-491c-8f7d-bc9f1b15a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8b02c0ff-f04c-403b-8b90-1a6e62395f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ac24cd8-1365-4f1e-ac1b-9dfe747c5cb8" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_8b02c0ff-f04c-403b-8b90-1a6e62395f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74c3bdc1-efbb-432a-aad8-4c7db863046c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ac24cd8-1365-4f1e-ac1b-9dfe747c5cb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74c3bdc1-efbb-432a-aad8-4c7db863046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_59e72812-ce93-474b-a218-4b57369d0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ac24cd8-1365-4f1e-ac1b-9dfe747c5cb8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_59e72812-ce93-474b-a218-4b57369d0fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b600234e-ba20-4c19-b7f4-37b33c7e1936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ac24cd8-1365-4f1e-ac1b-9dfe747c5cb8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b600234e-ba20-4c19-b7f4-37b33c7e1936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_825ff9ec-0d0d-4b36-9f9b-2a822cf156f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_825ff9ec-0d0d-4b36-9f9b-2a822cf156f3" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a1a8180-6a0e-4f62-bd6b-5e0ed8311e06" xlink:to="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c68470bd-55c4-4589-9c15-56825c784909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:to="loc_us-gaap_ProductMember_c68470bd-55c4-4589-9c15-56825c784909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AutorisationTemporaireDUtlisationMemberMember_880654e6-76f1-4698-9035-ac795bc5c9fa" xlink:href="eigr-20221231.xsd#eigr_AutorisationTemporaireDUtlisationMemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_005a7d39-8a6e-4495-9917-c498454d1469" xlink:to="loc_eigr_AutorisationTemporaireDUtlisationMemberMember_880654e6-76f1-4698-9035-ac795bc5c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_15aa53cc-07ac-4ba2-a59e-853332b874b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CustomerAMember_e9fa2e23-6de7-4f96-91f8-54138034c344" xlink:href="eigr-20221231.xsd#eigr_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:to="loc_eigr_CustomerAMember_e9fa2e23-6de7-4f96-91f8-54138034c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CustomerBMember_d47d8079-8ad2-46c0-9ede-a738841d0276" xlink:href="eigr-20221231.xsd#eigr_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_de0399b8-a42a-443b-8c82-bfe00bb7b2ef" xlink:to="loc_eigr_CustomerBMember_d47d8079-8ad2-46c0-9ede-a738841d0276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ae926743-e14a-4226-9551-0b90f06ae87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5c7a68ac-3432-473e-b082-86eab6d2ab5b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ae926743-e14a-4226-9551-0b90f06ae87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_473ecbfe-8d4c-40f1-9472-7f2e4d0a5b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ae926743-e14a-4226-9551-0b90f06ae87b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_473ecbfe-8d4c-40f1-9472-7f2e4d0a5b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_23c6e408-bd85-48a8-9b47-4921d3045c81" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_7aa62690-ab3f-46ef-8cb3-b8a23e7738ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:to="loc_us-gaap_FinanceReceivablesMember_7aa62690-ab3f-46ef-8cb3-b8a23e7738ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_5e0633ee-5a92-4b45-96ac-e462bf5ac244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a41ae13f-0f16-422a-b182-60ded3c4995c" xlink:to="loc_us-gaap_SalesRevenueNetMember_5e0633ee-5a92-4b45-96ac-e462bf5ac244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_730acd09-e049-4797-875a-f6167552fe60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_d6010b3d-071b-45f6-897e-84af5b4b8c6a" xlink:href="eigr-20221231.xsd#eigr_OptionsGrantedToEmployeesAndNonEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:to="loc_eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_d6010b3d-071b-45f6-897e-84af5b4b8c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2de417d5-b760-4eb6-b826-2a24f5f670d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2de417d5-b760-4eb6-b826-2a24f5f670d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EmployeeStockPurchasePlanMember_ab7ccff3-5b90-4945-beaf-c4143e62084f" xlink:href="eigr-20221231.xsd#eigr_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_638bbe41-c985-4708-a673-d3163025c104" xlink:to="loc_eigr_EmployeeStockPurchasePlanMember_ab7ccff3-5b90-4945-beaf-c4143e62084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_8a5cce53-c45a-4a85-8f1f-30336c144806" xlink:to="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_31fac634-eb27-4356-bd60-320f29d9d936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_31fac634-eb27-4356-bd60-320f29d9d936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_c2eb394b-613f-4802-9db6-510c2cfe2237" xlink:href="eigr-20221231.xsd#eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax_c2eb394b-613f-4802-9db6-510c2cfe2237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be81b141-cb37-4593-8906-ccb104b2a297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be81b141-cb37-4593-8906-ccb104b2a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_214028d0-59c3-4357-8908-5c66f43b56da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_214028d0-59c3-4357-8908-5c66f43b56da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b26d3b28-64af-43fb-8922-e749e99e5274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b26d3b28-64af-43fb-8922-e749e99e5274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_55f5db01-1814-4218-a1a6-81d763814830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_InventoryWriteDown_55f5db01-1814-4218-a1a6-81d763814830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EarlyAccessProgramTerm_ea57e391-cb87-4ca0-8ba2-1dc5e820f12d" xlink:href="eigr-20221231.xsd#eigr_EarlyAccessProgramTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_eigr_EarlyAccessProgramTerm_ea57e391-cb87-4ca0-8ba2-1dc5e820f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_77d17332-c17b-4d43-9833-68ba5f1aa2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_Revenues_77d17332-c17b-4d43-9833-68ba5f1aa2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7de33d53-14e2-4b14-97e5-1bfa5ff43053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7de33d53-14e2-4b14-97e5-1bfa5ff43053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4318c2e0-5dcc-41f7-a5a0-160ce2245b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_98adaaa4-b767-4c48-88f8-9be69285230d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4318c2e0-5dcc-41f7-a5a0-160ce2245b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a7d7449d-b994-4755-898a-c044d633d3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a7d7449d-b994-4755-898a-c044d633d3f8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6876f66c-175e-44db-84c2-ebdfafc7045b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LabEquipmentMember_8b496c9b-4b4f-45ac-a58e-7660a03327ca" xlink:href="eigr-20221231.xsd#eigr_LabEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_eigr_LabEquipmentMember_8b496c9b-4b4f-45ac-a58e-7660a03327ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_30be593c-1c70-4982-85c5-1f0ce8394b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_30be593c-1c70-4982-85c5-1f0ce8394b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_91c3c0b2-754f-4eb2-bcb6-63540f3d362c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_91c3c0b2-754f-4eb2-bcb6-63540f3d362c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ComputerEquipmentAndSoftwareMember_6be52fde-aa3f-407e-91da-853bb67fdb94" xlink:href="eigr-20221231.xsd#eigr_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8690a766-b526-411c-8bf4-e384529d7dd4" xlink:to="loc_eigr_ComputerEquipmentAndSoftwareMember_6be52fde-aa3f-407e-91da-853bb67fdb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edde70ac-7905-4bf6-b7a6-c708807cd363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e9d1c5b5-0206-45dd-ac33-f64925a8ce10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edde70ac-7905-4bf6-b7a6-c708807cd363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89975597-b43e-44a8-a7e0-1f89a28c6582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edde70ac-7905-4bf6-b7a6-c708807cd363" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89975597-b43e-44a8-a7e0-1f89a28c6582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c7993177-58c8-490d-900c-598d9844d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c7993177-58c8-490d-900c-598d9844d5c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a727af0-b6dd-4fc9-8981-d8a6657e701a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6f5b3ae2-b02c-4908-ac66-e8bf4457fb57" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a727af0-b6dd-4fc9-8981-d8a6657e701a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_52bedf0a-a5da-44fa-9801-c3ad6bb7d544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a727af0-b6dd-4fc9-8981-d8a6657e701a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_52bedf0a-a5da-44fa-9801-c3ad6bb7d544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f5e79e5-040e-4078-adb1-9e1a5c797313" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_396718aa-4321-4101-8368-8cd05dfaa6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_396718aa-4321-4101-8368-8cd05dfaa6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b50250c6-18c5-4558-918a-5e36e6cd07e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b50250c6-18c5-4558-918a-5e36e6cd07e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_FairValueTransfersBetweenLevelsTransfersAmount_1d59148b-0d27-4926-ac16-53f9f10b4018" xlink:href="eigr-20221231.xsd#eigr_FairValueTransfersBetweenLevelsTransfersAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_eigr_FairValueTransfersBetweenLevelsTransfersAmount_1d59148b-0d27-4926-ac16-53f9f10b4018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_e5eb8a58-4591-456d-8173-33349a4cc9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_ImpairmentOfInvestments_e5eb8a58-4591-456d-8173-33349a4cc9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_074d51cd-37cf-4963-9426-2d7145036d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_074d51cd-37cf-4963-9426-2d7145036d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_def34fb9-f5e7-4bd4-a89b-3ce8135f580f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_47d32125-c53e-4a57-bcce-bf5c94cdd3c3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_def34fb9-f5e7-4bd4-a89b-3ce8135f580f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71299e04-2a64-47a3-bdda-d734c769f7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71299e04-2a64-47a3-bdda-d734c769f7b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fec52963-a42d-4e59-858b-5af70d973c5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0cb259c8-fec7-4a62-9fc0-35b92150ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0cb259c8-fec7-4a62-9fc0-35b92150ff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ef817306-308c-4228-b4fb-9929f14c5333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ef817306-308c-4228-b4fb-9929f14c5333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8503e421-570e-468c-ba13-bc37f696b5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0687ff02-c32f-4769-9b79-6d3c2c382494" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8503e421-570e-468c-ba13-bc37f696b5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00fd09a3-3ec2-4e61-90ae-45f085ab11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_e0a4777f-0e8a-4918-8d72-e7d1c7f895d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00fd09a3-3ec2-4e61-90ae-45f085ab11d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_33b14762-2ec3-4c59-9a0f-36594a2c1055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_00fd09a3-3ec2-4e61-90ae-45f085ab11d5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_33b14762-2ec3-4c59-9a0f-36594a2c1055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_19ca15af-f089-4043-bd21-d1dcf4f0f0fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5bc30854-531b-4a00-9667-9b77ad6f9738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5bc30854-531b-4a00-9667-9b77ad6f9738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_611bb45f-fd73-478b-9a6a-8ea8a755eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:to="loc_us-gaap_CommercialPaperMember_611bb45f-fd73-478b-9a6a-8ea8a755eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_USGovernmentBondsMember_00edd1a2-6953-4e84-bb82-d5a438410adb" xlink:href="eigr-20221231.xsd#eigr_USGovernmentBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8637f46-bfe8-4381-9101-3981af66b64f" xlink:to="loc_eigr_USGovernmentBondsMember_00edd1a2-6953-4e84-bb82-d5a438410adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_496cc107-de9c-4647-9f13-9e00110042bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0134066e-4ad0-4a53-97f6-9e1de67e4ec9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_496cc107-de9c-4647-9f13-9e00110042bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_abee73f0-7dad-49d1-b2f9-d7302b2ab375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_496cc107-de9c-4647-9f13-9e00110042bd" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_abee73f0-7dad-49d1-b2f9-d7302b2ab375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cd4b36b0-1fc4-4ce3-a7d2-f583b083461b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_abee73f0-7dad-49d1-b2f9-d7302b2ab375" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cd4b36b0-1fc4-4ce3-a7d2-f583b083461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0666d5b6-6dfc-46da-b170-47a4e534d846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0666d5b6-6dfc-46da-b170-47a4e534d846" xlink:to="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f4bfd109-7b67-4f71-a756-0a94841b7283" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_629c558a-0ec1-4c73-aae2-27e8d0967790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_629c558a-0ec1-4c73-aae2-27e8d0967790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_f707e3c3-3960-4405-95fd-8e0cd529168d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:to="loc_us-gaap_CashEquivalentsMember_f707e3c3-3960-4405-95fd-8e0cd529168d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bade4ecf-89d6-42a8-b350-8884bf9acf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4e85daec-9fd7-40aa-bc28-bbe99c3d1c8c" xlink:to="loc_us-gaap_CommercialPaperMember_bade4ecf-89d6-42a8-b350-8884bf9acf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cf289b24-e42c-4e50-8789-fe590d4c8ef6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a1a6eaa0-546a-4d54-84db-b663239c06d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a1a6eaa0-546a-4d54-84db-b663239c06d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_31a837fa-8460-4e55-8452-d12e092211a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_CommercialPaperMember_31a837fa-8460-4e55-8452-d12e092211a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_USGovernmentBondsMember_e768744a-7a12-4c57-ad63-2e3bf460c602" xlink:href="eigr-20221231.xsd#eigr_USGovernmentBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_eigr_USGovernmentBondsMember_e768744a-7a12-4c57-ad63-2e3bf460c602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtMember_66a5960e-b93b-4a5f-bf85-063400158161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_ShortTermDebtMember_66a5960e-b93b-4a5f-bf85-063400158161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_9dde0f28-4d71-47bf-b6a1-fa9598410940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ffbf786-488c-47bf-83e1-c3efad6df27b" xlink:to="loc_us-gaap_LongTermDebtMember_9dde0f28-4d71-47bf-b6a1-fa9598410940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesTable_34a49c6b-33bf-4da8-85c3-3443dce516a9" xlink:to="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CashEquivalentsAmortizedCost_e256361d-818e-4ce4-8c11-4d880897bef1" xlink:href="eigr-20221231.xsd#eigr_CashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_eigr_CashEquivalentsAmortizedCost_e256361d-818e-4ce4-8c11-4d880897bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb9261c5-b3b9-440e-8c99-ba956af279a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_eb9261c5-b3b9-440e-8c99-ba956af279a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48da829d-c3b2-43cf-b3ac-94ecb4901f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_48da829d-c3b2-43cf-b3ac-94ecb4901f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_552bf7a2-1d22-48a9-a764-df420f036026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_552bf7a2-1d22-48a9-a764-df420f036026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0d6fa6cb-c18e-41f9-82f4-74676eb79f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0d6fa6cb-c18e-41f9-82f4-74676eb79f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22206d99-d56d-417c-bd53-8d0bbce60653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_22206d99-d56d-417c-bd53-8d0bbce60653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_27222019-baee-4caf-bb1b-472e74adbf24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_9a956909-9caf-43ab-8d97-f2c90353d645" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_27222019-baee-4caf-bb1b-472e74adbf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofInventoryDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3c40ad9-136b-478b-ad36-3d8a8ce03121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f6014791-40e8-4005-83f6-cf2f12e7aa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3c40ad9-136b-478b-ad36-3d8a8ce03121" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f6014791-40e8-4005-83f6-cf2f12e7aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3472d59d-8a09-4106-bc9c-bf53df9fb4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3c40ad9-136b-478b-ad36-3d8a8ce03121" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3472d59d-8a09-4106-bc9c-bf53df9fb4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_36cb2bc1-7150-498f-a22b-6b4af46fc737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3c40ad9-136b-478b-ad36-3d8a8ce03121" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_36cb2bc1-7150-498f-a22b-6b4af46fc737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_546a8c08-6d94-4b34-a7e6-1aece0d2ec58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3c40ad9-136b-478b-ad36-3d8a8ce03121" xlink:to="loc_us-gaap_InventoryNet_546a8c08-6d94-4b34-a7e6-1aece0d2ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_64427a1c-7a19-405a-b294-d927dd3cf2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_64427a1c-7a19-405a-b294-d927dd3cf2a0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_109461e1-8f71-4896-b8b0-80e83bb9fe27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ComputerEquipmentAndSoftwareMember_0a114150-7823-47c2-9af2-289b7218c66c" xlink:href="eigr-20221231.xsd#eigr_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_eigr_ComputerEquipmentAndSoftwareMember_0a114150-7823-47c2-9af2-289b7218c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e6b92172-3662-4229-bda6-a8564d066fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e6b92172-3662-4229-bda6-a8564d066fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b6b0aef0-2eeb-40c1-bb50-32ef04991fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b6b0aef0-2eeb-40c1-bb50-32ef04991fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LabEquipmentMember_c158ba9c-e160-4eea-ad13-86c852559cd0" xlink:href="eigr-20221231.xsd#eigr_LabEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_eigr_LabEquipmentMember_c158ba9c-e160-4eea-ad13-86c852559cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_297a4316-2763-4654-bf25-e70189bee52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_aaa1c904-13f9-4a80-9a6f-a4f8b57131b9" xlink:to="loc_us-gaap_ConstructionInProgressMember_297a4316-2763-4654-bf25-e70189bee52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c0fa2a0-f05e-4c7f-9dcd-123ef11ac4d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7cc5763-f2bd-402c-9da4-073d440cfffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7cc5763-f2bd-402c-9da4-073d440cfffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fcabee26-5b79-469b-98af-033fed6e7f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fcabee26-5b79-469b-98af-033fed6e7f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_48893171-591d-41db-841d-ce3fade34fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_48893171-591d-41db-841d-ce3fade34fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b67dfa64-e7be-4a68-aaa2-4e03b2da50f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40e3c0a3-6c3e-4ad5-897e-e882220edb11" xlink:to="loc_us-gaap_Depreciation_b67dfa64-e7be-4a68-aaa2-4e03b2da50f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidContractManufacturingCosts_995f752e-437e-4dbe-803e-68c2b9ec7d7b" xlink:href="eigr-20221231.xsd#eigr_PrepaidContractManufacturingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_eigr_PrepaidContractManufacturingCosts_995f752e-437e-4dbe-803e-68c2b9ec7d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_28e7f6e2-9cf1-4c45-9d97-428f26bc6404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_us-gaap_DepositsAssetsCurrent_28e7f6e2-9cf1-4c45-9d97-428f26bc6404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidResearchCosts_0bd8c3d5-b08c-4bd8-9b3a-995adb2883ec" xlink:href="eigr-20221231.xsd#eigr_PrepaidResearchCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_eigr_PrepaidResearchCosts_0bd8c3d5-b08c-4bd8-9b3a-995adb2883ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_b90f44d5-1454-436c-909c-e89a80eb63fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_us-gaap_PrepaidInsurance_b90f44d5-1454-436c-909c-e89a80eb63fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PrepaidMarketing_5c973bc6-acde-421d-83b1-8d2f321a95bd" xlink:href="eigr-20221231.xsd#eigr_PrepaidMarketing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_eigr_PrepaidMarketing_5c973bc6-acde-421d-83b1-8d2f321a95bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_54c0b2d8-1d1e-4487-adba-e9ba14589920" xlink:href="eigr-20221231.xsd#eigr_OtherPrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_54c0b2d8-1d1e-4487-adba-e9ba14589920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_629aee61-0e1c-44e4-9459-da9ff89278a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2f9eec33-c534-4c2e-8e51-027b4503ef85" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_629aee61-0e1c-44e4-9459-da9ff89278a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f4d7e722-5eae-483b-a04c-f15e1823a1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f4d7e722-5eae-483b-a04c-f15e1823a1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AccruedContractedResearchCostsCurrent_c59eba95-1d6f-4355-80b4-5c4adc730f3f" xlink:href="eigr-20221231.xsd#eigr_AccruedContractedResearchCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:to="loc_eigr_AccruedContractedResearchCostsCurrent_c59eba95-1d6f-4355-80b4-5c4adc730f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ContractManufacturingCostsCurrent_4d64d9aa-8b84-4d4a-bf17-6eb7e7e00520" xlink:href="eigr-20221231.xsd#eigr_ContractManufacturingCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:to="loc_eigr_ContractManufacturingCostsCurrent_4d64d9aa-8b84-4d4a-bf17-6eb7e7e00520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductRevenueReserves_a98bc387-1c4a-4cbf-b8a5-1349a2480f00" xlink:href="eigr-20221231.xsd#eigr_ProductRevenueReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:to="loc_eigr_ProductRevenueReserves_a98bc387-1c4a-4cbf-b8a5-1349a2480f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_308487da-e967-4d69-9217-64853d8e499f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_308487da-e967-4d69-9217-64853d8e499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f4fd2c8a-bba7-487e-bba7-fcd234528bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2e612a63-c3d5-438a-84c0-8b6e036945a1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f4fd2c8a-bba7-487e-bba7-fcd234528bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementAbstract_7e474480-413c-4f70-a4bb-2c7e1fbacb1a" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ProductDevelopmentAgreementAbstract_7e474480-413c-4f70-a4bb-2c7e1fbacb1a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_2cdd08f4-4492-4ee9-8310-9d4a8455d66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_c371b925-71c3-406c-aa51-e5a9344560ad" xlink:to="loc_us-gaap_TransactionDomain_2cdd08f4-4492-4ee9-8310-9d4a8455d66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_BMSTransactionMember_53d13b68-e585-4e32-8aa8-91b5948d4d86" xlink:href="eigr-20221231.xsd#eigr_BMSTransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_2cdd08f4-4492-4ee9-8310-9d4a8455d66e" xlink:to="loc_eigr_BMSTransactionMember_53d13b68-e585-4e32-8aa8-91b5948d4d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1c44697b-d8a0-4009-9a8a-359c0cf04ee6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e207126e-2107-46a0-8a11-1df22ac6cbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:to="loc_us-gaap_LicensingAgreementsMember_e207126e-2107-46a0-8a11-1df22ac6cbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_985d7236-bad2-41df-bc06-3dde601dbf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_86a71cf7-f5b5-44d1-8992-310d2f78b7f1" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_985d7236-bad2-41df-bc06-3dde601dbf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b44a72a-6852-440a-a803-40f0d035b763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99be2adb-b327-4fb2-9057-ec9c66327130" xlink:to="loc_us-gaap_EquityComponentDomain_9b44a72a-6852-440a-a803-40f0d035b763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_54e977cc-da08-4873-b562-0b3420cc232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b44a72a-6852-440a-a803-40f0d035b763" xlink:to="loc_us-gaap_CommonStockMember_54e977cc-da08-4873-b562-0b3420cc232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46dc8f9a-0210-4306-a98d-5d98eb1e8417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_349680f7-542e-42d8-a070-32a30eba1127" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46dc8f9a-0210-4306-a98d-5d98eb1e8417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PurchaseAgreementMember_1c1b1a28-3a0b-4cd8-a331-9ae5672e194d" xlink:href="eigr-20221231.xsd#eigr_PurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46dc8f9a-0210-4306-a98d-5d98eb1e8417" xlink:to="loc_eigr_PurchaseAgreementMember_1c1b1a28-3a0b-4cd8-a331-9ae5672e194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d720a950-5fb5-424c-af2a-09f8f24eca49" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentAndRegulatoryMilestonesMember_785261b9-1434-4172-a9ac-e564360efdeb" xlink:href="eigr-20221231.xsd#eigr_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_DevelopmentAndRegulatoryMilestonesMember_785261b9-1434-4172-a9ac-e564360efdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommercialSalesMember_e74439eb-fd9d-43fd-bb88-8c07a2c2a904" xlink:href="eigr-20221231.xsd#eigr_CommercialSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_CommercialSalesMember_e74439eb-fd9d-43fd-bb88-8c07a2c2a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentPhaseTwoMember_e025e228-f400-40f2-b464-1ec0086fbc48" xlink:href="eigr-20221231.xsd#eigr_DevelopmentPhaseTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_DevelopmentPhaseTwoMember_e025e228-f400-40f2-b464-1ec0086fbc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentPhaseThreeMember_656c1e5b-338e-4847-9539-dd83e61bf0c4" xlink:href="eigr-20221231.xsd#eigr_DevelopmentPhaseThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_eigr_DevelopmentPhaseThreeMember_656c1e5b-338e-4847-9539-dd83e61bf0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_327c43fd-b631-4d43-99aa-d22bcfb40512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b753420a-5ef9-49ac-ab2d-1b7ae2532e16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_327c43fd-b631-4d43-99aa-d22bcfb40512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebf6abad-d8a2-4ab3-87db-afff8f96b0db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_55173c31-d613-42e3-9ede-e4263ef5fa79" xlink:to="loc_srt_RangeMember_ebf6abad-d8a2-4ab3-87db-afff8f96b0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4b5c9cc6-8389-46fc-a202-f076f84b6bb6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ebf6abad-d8a2-4ab3-87db-afff8f96b0db" xlink:to="loc_srt_MaximumMember_4b5c9cc6-8389-46fc-a202-f076f84b6bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7940fc2a-c1d9-4acf-ae47-3b7bd7ae77b2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UPennCHOPAgreementMember_d5b42fbc-f27c-467f-a7ff-694939c92d22" xlink:href="eigr-20221231.xsd#eigr_UPennCHOPAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_UPennCHOPAgreementMember_d5b42fbc-f27c-467f-a7ff-694939c92d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentAgreementMember_d99ca16e-6a9e-429b-ab06-cf0a7ea8ecfd" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_ProductDevelopmentAgreementMember_d99ca16e-6a9e-429b-ab06-cf0a7ea8ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PRFCollaborationAgreementMember_fa548eb8-dddf-426a-b5f7-297206fae15e" xlink:href="eigr-20221231.xsd#eigr_PRFCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_PRFCollaborationAgreementMember_fa548eb8-dddf-426a-b5f7-297206fae15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MerckTransactionMember_5fdcfa39-4e7b-4796-aba7-37057a67203c" xlink:href="eigr-20221231.xsd#eigr_MerckTransactionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f04204d-a2e6-4d87-b461-dcf6c278a0b6" xlink:to="loc_eigr_MerckTransactionMember_5fdcfa39-4e7b-4796-aba7-37057a67203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_7bd8e0a6-330d-4a2f-824f-4db2feb668da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis_cf732cdb-95ec-4c20-beaa-e7642f61c523" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_7bd8e0a6-330d-4a2f-824f-4db2feb668da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8e50d8f0-3907-4885-9d5c-851dbae2bebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fef2e26b-27ed-4377-938e-f8eb1db9413f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8e50d8f0-3907-4885-9d5c-851dbae2bebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a6c566c4-9399-4239-a684-ee41f591087f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8e50d8f0-3907-4885-9d5c-851dbae2bebb" xlink:to="loc_us-gaap_SubsequentEventMember_a6c566c4-9399-4239-a684-ee41f591087f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2810bb58-6c2e-4328-943e-b0853ec74622" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NonRefundableIssueFee_1436737b-aa7e-4c9c-a9cc-fa6cf28cd90b" xlink:href="eigr-20221231.xsd#eigr_NonRefundableIssueFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_NonRefundableIssueFee_1436737b-aa7e-4c9c-a9cc-fa6cf28cd90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseMaintenanceFee_3f53de6a-a006-478e-b9e5-fff0732ca02a" xlink:href="eigr-20221231.xsd#eigr_LicenseMaintenanceFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_LicenseMaintenanceFee_3f53de6a-a006-478e-b9e5-fff0732ca02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MilestoneObligations_4aa2490c-4ee0-4884-a1f3-079d0b04e11b" xlink:href="eigr-20221231.xsd#eigr_MilestoneObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_MilestoneObligations_4aa2490c-4ee0-4884-a1f3-079d0b04e11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProductDevelopmentFees_9ad97e77-dee7-4417-a09b-a0136148d456" xlink:href="eigr-20221231.xsd#eigr_ProductDevelopmentFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_ProductDevelopmentFees_9ad97e77-dee7-4417-a09b-a0136148d456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PeriodOfCommittedPaymentOfFees_964959c5-1e5d-44ad-a32d-25a208d870a1" xlink:href="eigr-20221231.xsd#eigr_PeriodOfCommittedPaymentOfFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_PeriodOfCommittedPaymentOfFees_964959c5-1e5d-44ad-a32d-25a208d870a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ExpertConsultantFeesAndPassThroughCosts_11290ff0-0b0d-42f7-b7d7-5df8a7e3075b" xlink:href="eigr-20221231.xsd#eigr_ExpertConsultantFeesAndPassThroughCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_ExpertConsultantFeesAndPassThroughCosts_11290ff0-0b0d-42f7-b7d7-5df8a7e3075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncentiveBasedRegulatoryMilestoneFees_4d11e66d-75f6-4753-9613-1759224ef7ae" xlink:href="eigr-20221231.xsd#eigr_IncentiveBasedRegulatoryMilestoneFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_IncentiveBasedRegulatoryMilestoneFees_4d11e66d-75f6-4753-9613-1759224ef7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_9e253e25-2341-4a47-b7d3-51b123f7052e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_9e253e25-2341-4a47-b7d3-51b123f7052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_35fdc2f4-c056-444b-88e1-5e32f63d027f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_35fdc2f4-c056-444b-88e1-5e32f63d027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CollaborationAgreementInitialTerm_09ce7f66-6a86-45c8-bc56-7e6d08212f46" xlink:href="eigr-20221231.xsd#eigr_CollaborationAgreementInitialTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_CollaborationAgreementInitialTerm_09ce7f66-6a86-45c8-bc56-7e6d08212f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CollaborativeArrangementRenewalTerm_7667d62a-28b2-43a2-90d3-1103d72ae7d2" xlink:href="eigr-20221231.xsd#eigr_CollaborativeArrangementRenewalTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_CollaborativeArrangementRenewalTerm_7667d62a-28b2-43a2-90d3-1103d72ae7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpFrontCashPayments_caeddf03-7b1e-41a6-a580-8bab82f0e36d" xlink:href="eigr-20221231.xsd#eigr_UpFrontCashPayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_UpFrontCashPayments_caeddf03-7b1e-41a6-a580-8bab82f0e36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb29557-55fd-4fb9-a33e-5dabe2883190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bdb29557-55fd-4fb9-a33e-5dabe2883190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4e138301-ed29-4b7a-aee8-bdd8dff246fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4e138301-ed29-4b7a-aee8-bdd8dff246fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_390f1657-2878-4f15-8e95-59b1ac4e2f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_CommonStockSharesIssued_390f1657-2878-4f15-8e95-59b1ac4e2f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_83c5fa7f-c288-4ded-8fb7-dada7e89c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_us-gaap_CommonStockValue_83c5fa7f-c288-4ded-8fb7-dada7e89c3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DevelopmentMilestoneObligations_51cea4c4-eea3-4179-a978-fdb9d2ecbab8" xlink:href="eigr-20221231.xsd#eigr_DevelopmentMilestoneObligations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_DevelopmentMilestoneObligations_51cea4c4-eea3-4179-a978-fdb9d2ecbab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MilestonePayments_dd570d17-77f4-444e-adae-bd94e18c9282" xlink:href="eigr-20221231.xsd#eigr_MilestonePayments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0e96015c-83a7-41bd-a9cb-4243392d5cc9" xlink:to="loc_eigr_MilestonePayments_dd570d17-77f4-444e-adae-bd94e18c9282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_a3ca1216-3959-4ca4-8444-53eb8dbbfc97" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_a3ca1216-3959-4ca4-8444-53eb8dbbfc97" xlink:to="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1cf41f0-e90e-415c-a549-93d829195470" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AbbvieAssetPurchaseAgreementMember_fd129685-378d-4335-b027-8c68738cab92" xlink:href="eigr-20221231.xsd#eigr_AbbvieAssetPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:to="loc_eigr_AbbvieAssetPurchaseAgreementMember_fd129685-378d-4335-b027-8c68738cab92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementMember_3ce75b84-8e6f-4bb6-a833-e0c3efbc665b" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:to="loc_eigr_AssetPurchaseAgreementMember_3ce75b84-8e6f-4bb6-a833-e0c3efbc665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AvexitidePurchaseAgreementMember_9a54af0a-925e-460e-a030-d89482b65aa2" xlink:href="eigr-20221231.xsd#eigr_AvexitidePurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a1c62dd9-7f82-4a2a-87b1-a3285b489dbd" xlink:to="loc_eigr_AvexitidePurchaseAgreementMember_9a54af0a-925e-460e-a030-d89482b65aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134fe113-fc98-4098-bde3-cd3f9db3ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bef68bbb-1415-4340-ae61-3df816386726" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134fe113-fc98-4098-bde3-cd3f9db3ab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PRFCollaborationAgreementMember_c5c037ff-2877-45df-bc4e-8578b4de4287" xlink:href="eigr-20221231.xsd#eigr_PRFCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_134fe113-fc98-4098-bde3-cd3f9db3ab68" xlink:to="loc_eigr_PRFCollaborationAgreementMember_c5c037ff-2877-45df-bc4e-8578b4de4287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2f7c3b4e-b198-4f74-9d44-57a69692a81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fc1d11ab-924e-4930-b169-75af4bf14324" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2f7c3b4e-b198-4f74-9d44-57a69692a81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EIGTransactionMember_7363fe94-3bba-46a1-8785-4181adcb7e60" xlink:href="eigr-20221231.xsd#eigr_EIGTransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2f7c3b4e-b198-4f74-9d44-57a69692a81c" xlink:to="loc_eigr_EIGTransactionMember_7363fe94-3bba-46a1-8785-4181adcb7e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_107a081e-e092-4f80-9c2d-aa6f072f66f8" xlink:to="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_be3ec805-f628-414e-aec4-865403d2fe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_be3ec805-f628-414e-aec4-865403d2fe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_03e41f96-2a7c-469e-a51c-6f0aaab84350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_03e41f96-2a7c-469e-a51c-6f0aaab84350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cbfe5281-70e4-430b-872f-9f3ddf50d567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_cbfe5281-70e4-430b-872f-9f3ddf50d567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedPaymentArrangementTrancheFourMember_e61835f2-158f-4e8e-a956-d534f2b1d4a9" xlink:href="eigr-20221231.xsd#eigr_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_740208a4-e38f-4736-a496-f4cb43d52bef" xlink:to="loc_eigr_ShareBasedPaymentArrangementTrancheFourMember_e61835f2-158f-4e8e-a956-d534f2b1d4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4142db09-730a-4076-adfa-cdaaffb2a777" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d94fac35-3cae-40d4-9551-7e5e167c8d35" xlink:to="loc_srt_RangeMember_4142db09-730a-4076-adfa-cdaaffb2a777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34892c7b-66b6-471a-a5c4-89005296f2da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4142db09-730a-4076-adfa-cdaaffb2a777" xlink:to="loc_srt_MaximumMember_34892c7b-66b6-471a-a5c4-89005296f2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_62fa66c9-33b4-497e-a10b-8b49b9023c54" xlink:to="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpFrontCashPayments_20882ecd-df31-475b-a1d3-bf9d65a570f5" xlink:href="eigr-20221231.xsd#eigr_UpFrontCashPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_UpFrontCashPayments_20882ecd-df31-475b-a1d3-bf9d65a570f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_a0af8d8e-65de-428d-85ca-5d0da03c166d" xlink:href="eigr-20221231.xsd#eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_a0af8d8e-65de-428d-85ca-5d0da03c166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_b16eed1a-ae07-455b-b2ac-1bea85de1d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_b16eed1a-ae07-455b-b2ac-1bea85de1d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_499d13f6-9199-433b-b279-945843ec3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_499d13f6-9199-433b-b279-945843ec3a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsToPurchaseOfCommonStock_fcd58e77-209c-4d55-864f-7bc7b8dccaaa" xlink:href="eigr-20221231.xsd#eigr_OptionsToPurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_OptionsToPurchaseOfCommonStock_fcd58e77-209c-4d55-864f-7bc7b8dccaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_798962ee-bd3b-4087-b96a-2f4e48d14a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_798962ee-bd3b-4087-b96a-2f4e48d14a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_aac8265d-4e62-492e-8ad2-20686f99c177" xlink:href="eigr-20221231.xsd#eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_aac8265d-4e62-492e-8ad2-20686f99c177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VestingOfOptionsToPurchaseCommonStock_70572b3f-e153-4a2c-a0b0-3af7ca6aad51" xlink:href="eigr-20221231.xsd#eigr_VestingOfOptionsToPurchaseCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_VestingOfOptionsToPurchaseCommonStock_70572b3f-e153-4a2c-a0b0-3af7ca6aad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e003c92-ec12-4c4b-95ea-6f53f75cbca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e003c92-ec12-4c4b-95ea-6f53f75cbca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseAgreementPotentialMilestonePayments_13f4e2a1-9645-43b3-a894-0646098f1c0c" xlink:href="eigr-20221231.xsd#eigr_LicenseAgreementPotentialMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_LicenseAgreementPotentialMilestonePayments_13f4e2a1-9645-43b3-a894-0646098f1c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LicenseAgreementMilestonePaymentsPaid_78ef37b5-1a50-48fa-ab9d-40a8bce5a61d" xlink:href="eigr-20221231.xsd#eigr_LicenseAgreementMilestonePaymentsPaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_LicenseAgreementMilestonePaymentsPaid_78ef37b5-1a50-48fa-ab9d-40a8bce5a61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PaymentForAssetPurchaseAgreement_612cd4b1-a86a-450a-869c-d2cc963d1c00" xlink:href="eigr-20221231.xsd#eigr_PaymentForAssetPurchaseAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_eigr_PaymentForAssetPurchaseAgreement_612cd4b1-a86a-450a-869c-d2cc963d1c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_e415f5f6-0af1-4024-a809-ef0b9f1f67f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_8bfe93a8-316d-4e0c-960a-b8089c531d89" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_e415f5f6-0af1-4024-a809-ef0b9f1f67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#SaleofAssetsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cea36080-de20-49cb-ae6a-fa0452dc0e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cea36080-de20-49cb-ae6a-fa0452dc0e03" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_668a1a5c-6f46-4c54-9c06-5bc8ae2d656e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_95bb74ad-3063-4d00-863e-56138db8af59" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_668a1a5c-6f46-4c54-9c06-5bc8ae2d656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_c6486161-b64f-40d4-8f95-bbd44cbb5f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_668a1a5c-6f46-4c54-9c06-5bc8ae2d656e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationsMember_c6486161-b64f-40d4-8f95-bbd44cbb5f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eea11648-85e4-4e01-9227-3a8fb446db82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_49c9a2eb-3db4-4feb-87d7-f60ee0e2543c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eea11648-85e4-4e01-9227-3a8fb446db82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MYDICARMember_2c3e50de-4343-47e0-b514-98a65cccffba" xlink:href="eigr-20221231.xsd#eigr_MYDICARMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_eea11648-85e4-4e01-9227-3a8fb446db82" xlink:to="loc_eigr_MYDICARMember_2c3e50de-4343-47e0-b514-98a65cccffba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a8c6a8e1-1c3c-4595-9045-622028d753af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5639f16f-eb27-489c-93d2-3091b437b71f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a8c6a8e1-1c3c-4595-9045-622028d753af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_TheragenePharmaceuticalsIncMember_0849ca86-4ae2-4993-95c3-532a760c2302" xlink:href="eigr-20221231.xsd#eigr_TheragenePharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a8c6a8e1-1c3c-4595-9045-622028d753af" xlink:to="loc_eigr_TheragenePharmaceuticalsIncMember_0849ca86-4ae2-4993-95c3-532a760c2302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e39555bc-6a28-4400-ade3-eee44e32b059" xlink:to="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ee06d24-8038-44e9-afd9-9949e3fcf2ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:to="loc_srt_MinimumMember_6ee06d24-8038-44e9-afd9-9949e3fcf2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87270ba0-9db8-4544-ba86-36087f0a02ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3dfd6f2b-7fef-4fe9-9d53-7325ecd1cf87" xlink:to="loc_srt_MaximumMember_87270ba0-9db8-4544-ba86-36087f0a02ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8bbd64e1-273e-4f95-b62f-33ce36555ba3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_2abaa6ac-de59-4519-b99f-227f20cb2c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_2abaa6ac-de59-4519-b99f-227f20cb2c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_bb9e0946-e185-4f35-8455-b094f95c100a" xlink:href="eigr-20221231.xsd#eigr_SaleOfAssetsNumberOfCommonStockSharesReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived_bb9e0946-e185-4f35-8455-b094f95c100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_c0efa331-245b-4b98-b970-a92de63c0853" xlink:href="eigr-20221231.xsd#eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares_c0efa331-245b-4b98-b970-a92de63c0853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_8aa19c50-9f80-44ee-bada-07a6fb9ac1b7" xlink:href="eigr-20221231.xsd#eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares_8aa19c50-9f80-44ee-bada-07a6fb9ac1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AggregateCommonStockConsiderationValue_4ddf8f29-9840-4419-b3c2-809cd84ac91c" xlink:href="eigr-20221231.xsd#eigr_AggregateCommonStockConsiderationValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_AggregateCommonStockConsiderationValue_4ddf8f29-9840-4419-b3c2-809cd84ac91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_a2c8a521-3c98-498c-81f0-bb1e5e6dac09" xlink:href="eigr-20221231.xsd#eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare_a2c8a521-3c98-498c-81f0-bb1e5e6dac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_9ad535b5-d486-49a8-9472-358195969315" xlink:href="eigr-20221231.xsd#eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue_9ad535b5-d486-49a8-9472-358195969315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_0805b44e-8f57-4356-a15d-e967d9e9b446" xlink:href="eigr-20221231.xsd#eigr_AssetPurchaseAgreementContingentConsiderationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_AssetPurchaseAgreementContingentConsiderationReceivable_0805b44e-8f57-4356-a15d-e967d9e9b446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RoyaltyReceivablePercentageOnNetSales_a73b1982-8ddd-426e-b945-aef93b821e9b" xlink:href="eigr-20221231.xsd#eigr_RoyaltyReceivablePercentageOnNetSales"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_RoyaltyReceivablePercentageOnNetSales_a73b1982-8ddd-426e-b945-aef93b821e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_08305ab0-ea99-4b0d-8ae1-7dc943e681c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_08305ab0-ea99-4b0d-8ae1-7dc943e681c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_47b1bee6-1e4b-4811-8f0e-9a5ad42f6c60" xlink:href="eigr-20221231.xsd#eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage_47b1bee6-1e4b-4811-8f0e-9a5ad42f6c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_51d26d60-dc85-43b9-8112-fe39255f7e86" xlink:href="eigr-20221231.xsd#eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2895a98a-8d45-4877-825c-8dcb894c081e" xlink:to="loc_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived_51d26d60-dc85-43b9-8112-fe39255f7e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/DebtAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f08d989-7136-488c-a30d-74ed6c68827c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f08d989-7136-488c-a30d-74ed6c68827c" xlink:to="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7de0a5d5-b637-423f-bef1-99bb51e0641e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7d3facb-fc9c-474a-b29e-b120d6f49d11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7de0a5d5-b637-423f-bef1-99bb51e0641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_22e4b610-ebca-406d-8c78-69524e5ea8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7de0a5d5-b637-423f-bef1-99bb51e0641e" xlink:to="loc_us-gaap_LineOfCreditMember_22e4b610-ebca-406d-8c78-69524e5ea8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_229759a4-dc6f-4aef-8f66-7427e1d8b01d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusLoanMember_de830acb-6dc6-4c0b-a254-3bb4576f940b" xlink:href="eigr-20221231.xsd#eigr_InnovatusLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_InnovatusLoanMember_de830acb-6dc6-4c0b-a254-3bb4576f940b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanMember_fe0ea84f-17d3-4c15-aaa2-5fbe84f634a2" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_OxfordLoanMember_fe0ea84f-17d3-4c15-aaa2-5fbe84f634a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanAmendmentMember_2ce04f5a-6e0e-42b0-9fd4-9e2e3a4189b8" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanAmendmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_OxfordLoanAmendmentMember_2ce04f5a-6e0e-42b0-9fd4-9e2e3a4189b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedOxfordLoanMember_b0aa0047-b79e-4937-9564-0af9cac10b0b" xlink:href="eigr-20221231.xsd#eigr_AmendedOxfordLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_AmendedOxfordLoanMember_b0aa0047-b79e-4937-9564-0af9cac10b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OxfordLoanFifthAmendmentMember_9a71843e-258f-4a28-9ec7-956771edf3fb" xlink:href="eigr-20221231.xsd#eigr_OxfordLoanFifthAmendmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4f854d1f-45cf-49d1-b250-e5ef6eddf01f" xlink:to="loc_eigr_OxfordLoanFifthAmendmentMember_9a71843e-258f-4a28-9ec7-956771edf3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b1c07d87-bac9-4019-812b-ddf82b897249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_06a64e2a-26cb-485c-88ca-3af6cdc2cbc6" xlink:to="loc_us-gaap_CreditFacilityDomain_b1c07d87-bac9-4019-812b-ddf82b897249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b1c07d87-bac9-4019-812b-ddf82b897249" xlink:to="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheAMember_e249ab22-f78c-4df0-9e45-843e9d869aac" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheAMember_e249ab22-f78c-4df0-9e45-843e9d869aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtAmendedTrancheAMember_524c59e4-681d-4149-8a97-bd00c33357b3" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtAmendedTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SecuredDebtTrancheAMember_e249ab22-f78c-4df0-9e45-843e9d869aac" xlink:to="loc_eigr_SecuredDebtAmendedTrancheAMember_524c59e4-681d-4149-8a97-bd00c33357b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheBMember_6339ede0-461d-421c-b40e-64a3c0d42cb6" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheBMember_6339ede0-461d-421c-b40e-64a3c0d42cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedTrancheBMember_ba5685e3-5826-428f-aa79-eb4ecc3840ff" xlink:href="eigr-20221231.xsd#eigr_AmendedTrancheBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SecuredDebtTrancheBMember_6339ede0-461d-421c-b40e-64a3c0d42cb6" xlink:to="loc_eigr_AmendedTrancheBMember_ba5685e3-5826-428f-aa79-eb4ecc3840ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheCMember_a59a41a1-8de0-42b2-a4e4-4ad2734e5ed3" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheCMember_a59a41a1-8de0-42b2-a4e4-4ad2734e5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SecuredDebtTrancheBAndCMember_e1ef6d95-faf9-4344-8999-17b54c368409" xlink:href="eigr-20221231.xsd#eigr_SecuredDebtTrancheBAndCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredDebtMember_2c3c5afd-2433-40eb-adc4-58a0c672964c" xlink:to="loc_eigr_SecuredDebtTrancheBAndCMember_e1ef6d95-faf9-4344-8999-17b54c368409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_VariableRateComponentAxis_f102c95b-d3d7-4527-8077-181d65743f3b" xlink:to="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentOneMember_df87fbb1-1cc9-4ee7-ab72-59050848b58a" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:to="loc_eigr_VariableRateComponentOneMember_df87fbb1-1cc9-4ee7-ab72-59050848b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_VariableRateComponentTwoMember_d7611e98-4e09-4b27-85d5-e710668fead6" xlink:href="eigr-20221231.xsd#eigr_VariableRateComponentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_VariableRateComponentDomain_8dec686f-ce7a-4742-9f61-b66927155b91" xlink:to="loc_eigr_VariableRateComponentTwoMember_d7611e98-4e09-4b27-85d5-e710668fead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb1caa7c-1af2-47c1-9035-52dd62da42e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14e82bb2-6616-49ba-b514-2c81b6f93610" xlink:to="loc_srt_RangeMember_fb1caa7c-1af2-47c1-9035-52dd62da42e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e4465b67-2918-4097-9dfd-bbd100b274c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb1caa7c-1af2-47c1-9035-52dd62da42e0" xlink:to="loc_srt_MinimumMember_e4465b67-2918-4097-9dfd-bbd100b274c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d298839-3c4d-4dce-8015-3b1f69cb762f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6106eba6-9ee3-4764-8e79-0c7cc0d01398" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d298839-3c4d-4dce-8015-3b1f69cb762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusStockPurchaseAgreementMember_9717fc9d-eba9-4022-9e4f-8e9cd18bab04" xlink:href="eigr-20221231.xsd#eigr_InnovatusStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d298839-3c4d-4dce-8015-3b1f69cb762f" xlink:to="loc_eigr_InnovatusStockPurchaseAgreementMember_9717fc9d-eba9-4022-9e4f-8e9cd18bab04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a21c1b7-d88b-444c-a80e-8af76c67b755" xlink:to="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_69bd0e40-dd80-4688-be3f-f86aa648dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_69bd0e40-dd80-4688-be3f-f86aa648dd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1dd758dc-7b74-4b89-9e31-50cd025cfc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1dd758dc-7b74-4b89-9e31-50cd025cfc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentPercentOfInterestDue_4dfed00a-d462-49e3-9f1f-9c06ef342d49" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentPercentOfInterestDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentPercentOfInterestDue_4dfed00a-d462-49e3-9f1f-9c06ef342d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFeePayablePercentage_c322a56b-967d-4be1-9b81-20bbbaa60dba" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFeePayablePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentExitFeePayablePercentage_c322a56b-967d-4be1-9b81-20bbbaa60dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_63e5918c-ec55-4171-a779-4d2ae566a6b1" xlink:href="eigr-20221231.xsd#eigr_MinimumCashBalanceOfFaceValueOfLoanPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent_63e5918c-ec55-4171-a779-4d2ae566a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d9dd9aa3-aa07-4508-879a-99849d558863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d9dd9aa3-aa07-4508-879a-99849d558863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_07b85730-388d-4324-9248-5e1810cbc003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_07b85730-388d-4324-9248-5e1810cbc003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_646baf24-f4b8-4b85-8359-1ca3b7cd74ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_646baf24-f4b8-4b85-8359-1ca3b7cd74ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4ef9f687-db80-4b83-a439-d26da0d3ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_InterestExpense_4ef9f687-db80-4b83-a439-d26da0d3ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d369e04-65d0-4c29-ab24-45e79352ac8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d369e04-65d0-4c29-ab24-45e79352ac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_03b2bc2b-5d48-47d7-842e-2492517e2bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_03b2bc2b-5d48-47d7-842e-2492517e2bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28cf4509-fb6b-42ac-83ac-e02b76586526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_28cf4509-fb6b-42ac-83ac-e02b76586526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee628e35-d993-46f3-a791-17743b6dbb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee628e35-d993-46f3-a791-17743b6dbb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f1b6b66b-39aa-4a59-9b48-c6d9a42ad050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f1b6b66b-39aa-4a59-9b48-c6d9a42ad050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_07cd8043-7258-4be4-9172-c97cacb51eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCredit_07cd8043-7258-4be4-9172-c97cacb51eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_672b16cd-7e96-437c-9b34-28c3b6c5855f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_672b16cd-7e96-437c-9b34-28c3b6c5855f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ccdfe95a-c42e-42f0-b506-edf73ebaf46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_ccdfe95a-c42e-42f0-b506-edf73ebaf46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentInterestPaymentPeriod_cd235646-39d6-40e6-ab90-41d1ca8a5009" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentInterestPaymentPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentInterestPaymentPeriod_cd235646-39d6-40e6-ab90-41d1ca8a5009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_74aa47c7-3afe-42c6-b54a-53a4d85eb50e" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_74aa47c7-3afe-42c6-b54a-53a4d85eb50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendmentFeesPayment_ca38807f-64e1-4f3b-a690-282e3436486c" xlink:href="eigr-20221231.xsd#eigr_AmendmentFeesPayment"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_AmendmentFeesPayment_ca38807f-64e1-4f3b-a690-282e3436486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedExitFees_bd377145-c07d-4132-93c3-4d29c436cbd4" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedExitFees"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentUnamortizedExitFees_bd377145-c07d-4132-93c3-4d29c436cbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedAdditionalExitFees_d3d87363-81ea-45fd-820c-90889c7bc3a4" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedAdditionalExitFees"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_DebtInstrumentUnamortizedAdditionalExitFees_d3d87363-81ea-45fd-820c-90889c7bc3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_38de1f99-df56-436b-9fa6-ea08effbc506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_38de1f99-df56-436b-9fa6-ea08effbc506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_46f12233-eba7-4efa-a573-2864abb266f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_46f12233-eba7-4efa-a573-2864abb266f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a58e98c2-aa9f-4355-81d1-593ef030bb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a58e98c2-aa9f-4355-81d1-593ef030bb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LineOfCreditFacilityOtherFinalPayments_0de1ad8a-e560-440d-b738-edbeeee98814" xlink:href="eigr-20221231.xsd#eigr_LineOfCreditFacilityOtherFinalPayments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_646993c7-3232-4374-b2da-f929941d0f4b" xlink:to="loc_eigr_LineOfCreditFacilityOtherFinalPayments_0de1ad8a-e560-440d-b738-edbeeee98814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4bde94c3-97cc-4773-a367-61f278d4fd47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4bde94c3-97cc-4773-a367-61f278d4fd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentUnamortizedExitFees_a1b8e01e-51c8-4ef1-af25-def7cf63bff6" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentUnamortizedExitFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:to="loc_eigr_DebtInstrumentUnamortizedExitFees_a1b8e01e-51c8-4ef1-af25-def7cf63bff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1e693d13-724e-4adf-9505-1171849e3ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1e693d13-724e-4adf-9505-1171849e3ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_77575fba-6ccf-4cfd-8f21-40eef902cf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:to="loc_us-gaap_LongTermDebt_77575fba-6ccf-4cfd-8f21-40eef902cf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_14914231-250c-43b7-aa21-ebb0f4abd981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:to="loc_us-gaap_LongTermDebtCurrent_14914231-250c-43b7-aa21-ebb0f4abd981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_195cf092-060f-42fc-933d-6241cff36722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0bd10db0-5fad-478a-9c1c-1c46bf725009" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_195cf092-060f-42fc-933d-6241cff36722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#DebtScheduleofMaturitiesofLongtermDebtDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8a4312a9-71ce-421d-b37b-8874d2fa0c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8a4312a9-71ce-421d-b37b-8874d2fa0c51" xlink:to="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:to="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_73e01dea-c5c6-47dd-9986-a85a6fab417e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_982c1835-1b0f-4f08-931f-63cbe8f9f724" xlink:to="loc_us-gaap_CreditFacilityDomain_73e01dea-c5c6-47dd-9986-a85a6fab417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AmendedTrancheAMember_4d461683-2e56-4573-958d-401c61a217f8" xlink:href="eigr-20221231.xsd#eigr_AmendedTrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_73e01dea-c5c6-47dd-9986-a85a6fab417e" xlink:to="loc_eigr_AmendedTrancheAMember_4d461683-2e56-4573-958d-401c61a217f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:to="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80e1bf83-32c7-4bde-aee0-b2671d9603f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c08cbae7-2afc-4cfc-a58d-6dc6a656897a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80e1bf83-32c7-4bde-aee0-b2671d9603f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InnovatusLoanMember_8296f41f-9dcf-4701-92be-6ed3857bc6bb" xlink:href="eigr-20221231.xsd#eigr_InnovatusLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_80e1bf83-32c7-4bde-aee0-b2671d9603f8" xlink:to="loc_eigr_InnovatusLoanMember_8296f41f-9dcf-4701-92be-6ed3857bc6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_833df432-0c86-47ca-a237-14101d61fe94" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e3c30ca3-9d95-4089-ae54-ff68ae7235c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e3c30ca3-9d95-4089-ae54-ff68ae7235c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_febb544f-f601-4ce8-aae6-77f800577778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_febb544f-f601-4ce8-aae6-77f800577778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dc773c08-517a-4c92-926f-be44381de4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dc773c08-517a-4c92-926f-be44381de4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4cf8cac4-4d6b-4e0b-8725-5b92e2e8f38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4cf8cac4-4d6b-4e0b-8725-5b92e2e8f38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_47244359-f02c-48b4-98c5-6bd7cbf9f228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_47244359-f02c-48b4-98c5-6bd7cbf9f228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6a9f674a-1a3c-420e-9785-d6ee85ebb038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6a9f674a-1a3c-420e-9785-d6ee85ebb038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6bc075a7-6160-4b7e-9b82-28f67d8866ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6bc075a7-6160-4b7e-9b82-28f67d8866ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DebtInstrumentExitFee_abc76d95-c195-4452-94f7-3330a988861a" xlink:href="eigr-20221231.xsd#eigr_DebtInstrumentExitFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_eigr_DebtInstrumentExitFee_abc76d95-c195-4452-94f7-3330a988861a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_439dfe43-cfcc-454f-a6d8-e6bca20ccc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c04117f6-38ce-4325-b904-b6c125fd75f2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_439dfe43-cfcc-454f-a6d8-e6bca20ccc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_766aece7-f84c-405c-a99b-f7d21d2c2648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_766aece7-f84c-405c-a99b-f7d21d2c2648" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_398bd265-9e64-446c-9a63-f331466b4184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_671c9e88-425b-402d-ba1e-de2178c6e80d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_398bd265-9e64-446c-9a63-f331466b4184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_AtTheMarketOfferingMember_a04291a2-4043-4c0d-953a-96de64b396e4" xlink:href="eigr-20221231.xsd#eigr_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_398bd265-9e64-446c-9a63-f331466b4184" xlink:to="loc_eigr_AtTheMarketOfferingMember_a04291a2-4043-4c0d-953a-96de64b396e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:to="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b9b286a-baf9-413a-bbdc-8f22017456b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c9025f92-5b95-41aa-98e4-1796406ff207" xlink:to="loc_srt_RangeMember_5b9b286a-baf9-413a-bbdc-8f22017456b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dae9b6a5-8369-4017-a81b-1af085089035" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b9b286a-baf9-413a-bbdc-8f22017456b6" xlink:to="loc_srt_MaximumMember_dae9b6a5-8369-4017-a81b-1af085089035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ccc8065-5a1a-4820-b7f5-b19fce946c0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DividendsDeclared_ccd3f9f6-70bb-438c-8f09-2e4298855b94" xlink:href="eigr-20221231.xsd#eigr_DividendsDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_DividendsDeclared_ccd3f9f6-70bb-438c-8f09-2e4298855b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_5254fcbd-ca66-41c9-9344-578169349bfa" xlink:href="eigr-20221231.xsd#eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_5254fcbd-ca66-41c9-9344-578169349bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_eb199d9f-0a87-46fd-951d-7f8e56c31210" xlink:href="eigr-20221231.xsd#eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_eb199d9f-0a87-46fd-951d-7f8e56c31210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5aaf1a3-6820-4c13-9f2b-5a3f8963487a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5aaf1a3-6820-4c13-9f2b-5a3f8963487a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2a55c8b-9abe-4968-977d-56c57358d9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c2a55c8b-9abe-4968-977d-56c57358d9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_CommonStockValueAvailableForFutureIssuance_ca01315c-d0c2-4f31-bd73-a5c4d0293c66" xlink:href="eigr-20221231.xsd#eigr_CommonStockValueAvailableForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_eigr_CommonStockValueAvailableForFutureIssuance_ca01315c-d0c2-4f31-bd73-a5c4d0293c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1eaffa99-eb54-4259-a188-afc34f1fb3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1eaffa99-eb54-4259-a188-afc34f1fb3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e521d38-4d3e-4117-9add-a140996ffa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1aa05ee2-67c3-4efa-982f-769c48cb85e8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e521d38-4d3e-4117-9add-a140996ffa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockholdersEquityCommonStockReservedForFutureIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4a3300a-b454-4dbc-9daa-c5bdc20ca627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OptionsIssuedAndOutstanding_9424ff1e-4f05-4170-a806-4ad8d54dcb99" xlink:href="eigr-20221231.xsd#eigr_OptionsIssuedAndOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4a3300a-b454-4dbc-9daa-c5bdc20ca627" xlink:to="loc_eigr_OptionsIssuedAndOutstanding_9424ff1e-4f05-4170-a806-4ad8d54dcb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_861fb213-886b-4d04-a873-9cdb8bd33a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4a3300a-b454-4dbc-9daa-c5bdc20ca627" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_861fb213-886b-4d04-a873-9cdb8bd33a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestrictedAndPerformanceStockUnitsOutstanding_ca4b632a-41af-41a4-ad80-7a80d334fbfe" xlink:href="eigr-20221231.xsd#eigr_RestrictedAndPerformanceStockUnitsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4a3300a-b454-4dbc-9daa-c5bdc20ca627" xlink:to="loc_eigr_RestrictedAndPerformanceStockUnitsOutstanding_ca4b632a-41af-41a4-ad80-7a80d334fbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_b725b9b1-de58-4a62-a819-9a9fabc66dc8" xlink:href="eigr-20221231.xsd#eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4a3300a-b454-4dbc-9daa-c5bdc20ca627" xlink:to="loc_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram_b725b9b1-de58-4a62-a819-9a9fabc66dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5970404c-1ae5-4a06-9e0a-b224c1b15b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c4a3300a-b454-4dbc-9daa-c5bdc20ca627" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5970404c-1ae5-4a06-9e0a-b224c1b15b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27d6acbf-6fc1-4f28-a909-040bbbc408b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27d6acbf-6fc1-4f28-a909-040bbbc408b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_20200abf-85a0-4393-a411-a670d612bafe" xlink:to="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e903ab73-944f-40e5-b99d-9c21e68b1a29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:to="loc_srt_MinimumMember_e903ab73-944f-40e5-b99d-9c21e68b1a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b0c8b65-e50a-411c-aa13-e61f1248812c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86b8b450-267c-4d2e-906a-26736860095e" xlink:to="loc_srt_MaximumMember_0b0c8b65-e50a-411c-aa13-e61f1248812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_203647b6-6ace-4649-9745-897ad856b554" xlink:to="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_35a4562a-a198-4240-9520-b5d82a0d12b5" xlink:href="eigr-20221231.xsd#eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:to="loc_eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember_35a4562a-a198-4240-9520-b5d82a0d12b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_InducementPlan2021Member_154b4ee3-fe35-4a20-81de-7587a68f5968" xlink:href="eigr-20221231.xsd#eigr_InducementPlan2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:to="loc_eigr_InducementPlan2021Member_154b4ee3-fe35-4a20-81de-7587a68f5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_d381df57-ed87-4fb4-bd47-5f3d06917394" xlink:href="eigr-20221231.xsd#eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9d546a53-93be-4d78-b33a-a0e97d88f039" xlink:to="loc_eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_d381df57-ed87-4fb4-bd47-5f3d06917394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dd636401-795c-45d7-bda4-4c904ba33bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5540b299-e73c-4699-8019-b82443442e99" xlink:to="loc_us-gaap_ClassOfStockDomain_dd636401-795c-45d7-bda4-4c904ba33bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_b1c68635-b7bc-41f9-a847-e994b55d2d40" xlink:href="eigr-20221231.xsd#eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dd636401-795c-45d7-bda4-4c904ba33bec" xlink:to="loc_eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_b1c68635-b7bc-41f9-a847-e994b55d2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_704dc899-101d-46f3-a661-f89159dbba47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_4ef7b4e0-e07c-440a-8915-c299c1fab92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:to="loc_us-gaap_StockOptionMember_4ef7b4e0-e07c-440a-8915-c299c1fab92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PerformanceStockUnitsPSUMember_2dc5ea5d-d90a-4663-b101-e278113b52bf" xlink:href="eigr-20221231.xsd#eigr_PerformanceStockUnitsPSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:to="loc_eigr_PerformanceStockUnitsPSUMember_2dc5ea5d-d90a-4663-b101-e278113b52bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0dc3021d-4ed2-4ebf-a6eb-3c7b7372b19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a656c9d-7f9f-41d1-9c49-dadcf3cb9ede" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0dc3021d-4ed2-4ebf-a6eb-3c7b7372b19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b417ed1a-fc4c-408d-950c-22314e2546b2" xlink:to="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7ee25bb5-0fd7-4bd9-8ad3-8c420ee4f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:to="loc_us-gaap_CommonStockMember_7ee25bb5-0fd7-4bd9-8ad3-8c420ee4f1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_55dcda58-f6d7-4be6-af61-57791df1b925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_646860f2-921a-4907-b2ff-911c02ca257d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_55dcda58-f6d7-4be6-af61-57791df1b925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_6c6e5ec2-611b-4412-8fea-66e7198a527a" xlink:to="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bc53460b-b17a-47fa-af61-8c5a49e1cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_bc53460b-b17a-47fa-af61-8c5a49e1cc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b5148b45-ea02-41f3-821a-3e4fd9a65cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b5148b45-ea02-41f3-821a-3e4fd9a65cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_98041ad1-75f4-4461-b87a-104453357051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f1d6cbcd-cc9e-46e2-93ff-94e77e034a57" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_98041ad1-75f4-4461-b87a-104453357051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb4d1751-8973-4a1e-97d9-7589db1feb22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_9e2c4012-b479-4823-bd9d-a80046626989" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_9e2c4012-b479-4823-bd9d-a80046626989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_87da4748-2b93-4b8c-9617-4c2c127f05b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_87da4748-2b93-4b8c-9617-4c2c127f05b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f7f162a-6bd8-4d15-9ac4-d370b3786c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5f7f162a-6bd8-4d15-9ac4-d370b3786c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0eeee1df-0942-4b14-af7d-24b6cb571b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0eeee1df-0942-4b14-af7d-24b6cb571b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6c46c887-77f8-4e5e-adc7-d2276e592f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6c46c887-77f8-4e5e-adc7-d2276e592f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ced5f96d-545d-4cbb-be37-253148930355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ced5f96d-545d-4cbb-be37-253148930355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3778ce44-fb88-44ae-be43-2ecec2fd9c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3778ce44-fb88-44ae-be43-2ecec2fd9c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ClosingPriceOfCommonStock_87923fec-cc55-4bd7-ba3e-edd7ae2274ca" xlink:href="eigr-20221231.xsd#eigr_ClosingPriceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_eigr_ClosingPriceOfCommonStock_87923fec-cc55-4bd7-ba3e-edd7ae2274ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a383e85f-2390-4554-bffa-7f5f0e593f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a383e85f-2390-4554-bffa-7f5f0e593f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3cf1e1b7-9a4f-4cd3-82f7-a7299d7b2a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3cf1e1b7-9a4f-4cd3-82f7-a7299d7b2a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_750a8d6c-7445-42fb-ade4-eb4c535e99a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_750a8d6c-7445-42fb-ade4-eb4c535e99a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c73f92d-5caa-406f-929a-84040fb9ff16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5c73f92d-5caa-406f-929a-84040fb9ff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_629b063f-e733-45ea-88f9-94c74135fc13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_629b063f-e733-45ea-88f9-94c74135fc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_49c132bf-6231-4c20-a5b1-7d2588076735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_49c132bf-6231-4c20-a5b1-7d2588076735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81b09bbc-5159-4b33-8de0-316d2a27224b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81b09bbc-5159-4b33-8de0-316d2a27224b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7f8c7d52-1fca-4328-b442-1b60a4405cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7f8c7d52-1fca-4328-b442-1b60a4405cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_34ec174f-683b-4842-9e7b-d058d186b3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_34ec174f-683b-4842-9e7b-d058d186b3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_6ed42078-8df4-4687-aa6a-439e37f9567d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1_6ed42078-8df4-4687-aa6a-439e37f9567d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a5381d4b-7c17-41be-ac75-99befa0a9a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a5381d4b-7c17-41be-ac75-99befa0a9a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f964018c-6d00-4279-ae7b-468cdcc59c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f964018c-6d00-4279-ae7b-468cdcc59c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5380d3b1-049c-4e9a-a7a6-760fa5328ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5380d3b1-049c-4e9a-a7a6-760fa5328ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbf93135-2f94-405c-87ed-ed2f8732d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cc77fc1-bd26-4720-a910-7413f43a1f78" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dbf93135-2f94-405c-87ed-ed2f8732d6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963f677d-20fd-46c8-bf64-d8a782aa49b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_963f677d-20fd-46c8-bf64-d8a782aa49b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:href="eigr-20221231.xsd#eigr_SharesAvailableForGrantAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:to="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8c90ef9c-7fc2-4515-b7bd-153a2f990ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8c90ef9c-7fc2-4515-b7bd-153a2f990ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8f53b351-dae7-47fd-8447-e17d7678fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8f53b351-dae7-47fd-8447-e17d7678fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_6e036027-5b8b-472d-9837-557a7530ac6d" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_6e036027-5b8b-472d-9837-557a7530ac6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_18bb30da-6d49-4966-bfc3-131920940ec6" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_18bb30da-6d49-4966-bfc3-131920940ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted_9aa0b64b-05aa-436e-8e75-c7c78aae00e9" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted_9aa0b64b-05aa-436e-8e75-c7c78aae00e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited_e568d6b6-66be-4052-a8e3-4c645271fcbd" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited_e568d6b6-66be-4052-a8e3-4c645271fcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited_58155002-5630-425a-a572-2a4c18155124" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited_58155002-5630-425a-a572-2a4c18155124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled_4f2b1c85-fe6b-43a8-bf22-61e94d513a39" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled_4f2b1c85-fe6b-43a8-bf22-61e94d513a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60c357f1-be0f-4f7c-ad6a-0a66f2cca291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_SharesAvailableForGrantAbstract_1974dd78-4fd0-4117-8a54-9f8f477b3313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60c357f1-be0f-4f7c-ad6a-0a66f2cca291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:href="eigr-20221231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:to="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_97950532-3b03-4142-8cea-9c23448661d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_97950532-3b03-4142-8cea-9c23448661d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1d07187e-0d37-4e46-b1e5-0cafdad0a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1d07187e-0d37-4e46-b1e5-0cafdad0a95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55cbaa47-f7bd-4066-9bdf-6280b09fb6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55cbaa47-f7bd-4066-9bdf-6280b09fb6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cd3fe487-4a23-4811-8f87-0a99fb2841cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cd3fe487-4a23-4811-8f87-0a99fb2841cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_522e043e-a928-4c76-9c65-0029547a23b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract_95c58f91-5dc4-4190-9d03-3828c35731f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_522e043e-a928-4c76-9c65-0029547a23b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae7056b2-0243-4581-aa90-92a7c22892e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ae7056b2-0243-4581-aa90-92a7c22892e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_805a8a2a-c73a-4a71-b9c3-11c8535fa0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_805a8a2a-c73a-4a71-b9c3-11c8535fa0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_039dd785-ef92-482a-b203-d84757643ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_039dd785-ef92-482a-b203-d84757643ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_55044eda-d43a-43c0-8aca-682232dfd17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_55044eda-d43a-43c0-8aca-682232dfd17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6181d4d9-ec05-4bbb-b4db-1b8506de7eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6181d4d9-ec05-4bbb-b4db-1b8506de7eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96f59ab8-158b-472d-96b3-5a28159c3623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5d27f3e5-c026-43c5-935e-239eb3eaa4c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96f59ab8-158b-472d-96b3-5a28159c3623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d4b5e4a8-eaf2-4e6d-aa2a-bbabc44cde89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d4b5e4a8-eaf2-4e6d-aa2a-bbabc44cde89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a55d8501-31a0-4311-8df5-3b402cbbba83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_766ca50f-c621-47a1-9f07-630eae6b3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_766ca50f-c621-47a1-9f07-630eae6b3f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_02885262-6c1a-41bb-bc4d-1cc8f1b846ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_02885262-6c1a-41bb-bc4d-1cc8f1b846ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ce520d55-3dc2-4d72-bb97-36d0104c256d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ce520d55-3dc2-4d72-bb97-36d0104c256d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1a404617-20b6-459c-96f3-db61a007df5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1a404617-20b6-459c-96f3-db61a007df5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_84a3da33-433e-42e3-88d6-77e3e82b4525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_84a3da33-433e-42e3-88d6-77e3e82b4525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8085247b-20e8-4e72-8a68-57d31f28d194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d255754f-d334-4877-9c59-00b729d206a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8085247b-20e8-4e72-8a68-57d31f28d194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8094bf21-b1c5-449e-9c9f-c7eeec4268ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8094bf21-b1c5-449e-9c9f-c7eeec4268ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:to="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2d198516-31dd-4a57-88bd-a7d863a19c0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2dae5fc6-5b0f-46db-9d45-ce17b7cec235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2dae5fc6-5b0f-46db-9d45-ce17b7cec235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NonEmployeeStockOptionMember_57836d4b-a378-4834-8a97-192f34281f2b" xlink:href="eigr-20221231.xsd#eigr_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0ebd1fd-eece-45ea-905c-1d99da6e4657" xlink:to="loc_eigr_NonEmployeeStockOptionMember_57836d4b-a378-4834-8a97-192f34281f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:to="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ac73124-f61a-4f96-8655-04098927cbfb" xlink:to="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cbff82b5-36b9-44f0-8edc-b73c0e19c1f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:to="loc_srt_MinimumMember_cbff82b5-36b9-44f0-8edc-b73c0e19c1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a602760b-ed99-41f8-9aa7-0f27a29043b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aeca548f-a07f-4fe7-b308-7ed08e549367" xlink:to="loc_srt_MaximumMember_a602760b-ed99-41f8-9aa7-0f27a29043b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7704bfe-ee38-4971-9fd3-e7dc766a51c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5848c-61ec-470f-841d-b230b94b2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5848c-61ec-470f-841d-b230b94b2bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3e36310a-bae2-4ec1-a502-e1494b8d2e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3e36310a-bae2-4ec1-a502-e1494b8d2e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_587c46d1-542b-44a1-bff0-20035a5f745e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_587c46d1-542b-44a1-bff0-20035a5f745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fb23acf8-fa19-44c8-b86a-5fa472610a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_fb23acf8-fa19-44c8-b86a-5fa472610a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8ade04fb-fd58-49b9-b329-2cd5038596ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8ade04fb-fd58-49b9-b329-2cd5038596ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47c81fae-41e3-49fa-9b5d-37aa3c2239d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_47c81fae-41e3-49fa-9b5d-37aa3c2239d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7074a71-78fd-4524-96c4-5ce7bf0a820c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9375562f-8d2a-446f-915b-67fde589123c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b7074a71-78fd-4524-96c4-5ce7bf0a820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7560e240-9a4f-4929-a249-8fd502b56901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7560e240-9a4f-4929-a249-8fd502b56901" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:to="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_269d4f5b-2d0a-452c-91f8-cdf266b12bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2850f98d-ef96-429e-af87-07991cc5a2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_269d4f5b-2d0a-452c-91f8-cdf266b12bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_a51b1242-5399-4abe-ac77-033d3bab5961" xlink:href="eigr-20221231.xsd#eigr_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_269d4f5b-2d0a-452c-91f8-cdf266b12bf0" xlink:to="loc_eigr_RestrictedStockUnitsAndPerformanceStockUnitMember_a51b1242-5399-4abe-ac77-033d3bab5961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdb605ac-88ac-4766-80b0-230d04cfca64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ebbff3-ae66-48fc-a6f6-2d37278310f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_34ebbff3-ae66-48fc-a6f6-2d37278310f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8792d83-0759-46ea-91d4-2e17358f1594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f8792d83-0759-46ea-91d4-2e17358f1594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25203561-1603-42d4-8a81-c2b077d8163e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25203561-1603-42d4-8a81-c2b077d8163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a9277ba0-97e5-4feb-9c10-65fbb549f2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a9277ba0-97e5-4feb-9c10-65fbb549f2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7f0f6b2-f6a5-4e18-846f-3e568055c880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_86a9fede-6bd7-475a-96b6-11960c28fd29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7f0f6b2-f6a5-4e18-846f-3e568055c880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c73175d-b05d-4c6e-ace9-3f1d13e1acc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c392419-8e75-43de-a75e-1e148643144f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c392419-8e75-43de-a75e-1e148643144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_72c88696-64cd-42ce-a913-1ee0e168f1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_72c88696-64cd-42ce-a913-1ee0e168f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e32277ed-5a64-4f93-bd16-dbe9f6c95a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e32277ed-5a64-4f93-bd16-dbe9f6c95a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6ce2837b-d4ea-4a8c-b3ba-84dc16ba27cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6ce2837b-d4ea-4a8c-b3ba-84dc16ba27cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f5b802d-21e4-481d-b43e-c9c2451331a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ae8288a0-11b9-488b-b73b-518a8a4a151c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f5b802d-21e4-481d-b43e-c9c2451331a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c834540-0187-4ecd-a59a-e6d0942f0fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c834540-0187-4ecd-a59a-e6d0942f0fa2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5bf379f-3dd7-4dfa-82a7-ce43d89e788b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65324be9-caad-4462-b122-bc9eb0eec37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65324be9-caad-4462-b122-bc9eb0eec37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9226028-67ff-4f02-aac2-11729d1b3d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ac8382fe-50d6-4d3b-a405-558467f37480" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9226028-67ff-4f02-aac2-11729d1b3d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce43c95b-57c6-4933-8828-87e7836f545a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_402a38bf-95af-4737-a7ec-c472caf6382d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce43c95b-57c6-4933-8828-87e7836f545a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1bd50a41-766b-4ab8-9542-b60699e03505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce43c95b-57c6-4933-8828-87e7836f545a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1bd50a41-766b-4ab8-9542-b60699e03505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29e6b634-f28c-4081-9235-5a7e213fa8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29e6b634-f28c-4081-9235-5a7e213fa8cd" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e70e4b0c-01bd-42f6-9469-17145cbb29c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_633b8fb6-0bf4-424a-a85c-9bc3e1ad8a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_633b8fb6-0bf4-424a-a85c-9bc3e1ad8a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_161f590b-853d-4bb3-9832-9885674712ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_94b0b9ae-e72a-48b6-a051-63d166221eb0" xlink:to="loc_us-gaap_DomesticCountryMember_161f590b-853d-4bb3-9832-9885674712ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0229bd4-7836-4d6d-a82b-1f97d70c239b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_e11a79f6-c988-424b-ba65-c6ace2cb382b" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0229bd4-7836-4d6d-a82b-1f97d70c239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_OrphanDrugCreditCarryforwardMember_3bed638c-3b83-4040-8afb-48b6dd6e4e5b" xlink:href="eigr-20221231.xsd#eigr_OrphanDrugCreditCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f0229bd4-7836-4d6d-a82b-1f97d70c239b" xlink:to="loc_eigr_OrphanDrugCreditCarryforwardMember_3bed638c-3b83-4040-8afb-48b6dd6e4e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_2912e3ae-b403-4b91-841a-1a9bd4cfd1e6" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6b5b3491-e6a5-47af-91fc-b64844a226d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6b5b3491-e6a5-47af-91fc-b64844a226d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f8ba1506-05ca-4fba-9666-877c4f14e804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f8ba1506-05ca-4fba-9666-877c4f14e804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d2f2b142-dbcd-45e9-a293-09d31d7fa295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d2f2b142-dbcd-45e9-a293-09d31d7fa295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_db708867-007b-48da-bd3d-8f4f45df15b3" xlink:href="eigr-20221231.xsd#eigr_IncreaseInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_eigr_IncreaseInDeferredTaxAssetsValuationAllowance_db708867-007b-48da-bd3d-8f4f45df15b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b45328ad-4f47-443d-ab21-1d0c6745b0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b45328ad-4f47-443d-ab21-1d0c6745b0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_50b43e25-fad9-41da-be06-0e25c7f850a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4c93aa76-bee1-41e4-b2e2-9e50d8003077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4c93aa76-bee1-41e4-b2e2-9e50d8003077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7b512027-c642-44a8-81aa-523d2cefaf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7b512027-c642-44a8-81aa-523d2cefaf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2e2ddf67-f0d6-402b-aa28-00a00637ba85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f2e91cd4-db57-4f8b-a8fb-d39729d2a663" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2e2ddf67-f0d6-402b-aa28-00a00637ba85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c4204918-e7e5-43aa-ad53-c3045a03ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c4204918-e7e5-43aa-ad53-c3045a03ad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0d1a665-5dbe-4a83-98fa-d4493eb16b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0d1a665-5dbe-4a83-98fa-d4493eb16b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1ce20669-8c52-4944-9fa7-c0a578194b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1ce20669-8c52-4944-9fa7-c0a578194b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_88e61563-b71b-4f8b-85ea-176e74e43602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_88e61563-b71b-4f8b-85ea-176e74e43602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_140dfbf9-58b9-47c4-8604-f3fde6850eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_140dfbf9-58b9-47c4-8604-f3fde6850eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e068ff42-852b-4dc0-aacd-50cedaa9c74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e068ff42-852b-4dc0-aacd-50cedaa9c74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34c84f91-a912-4d7d-9edf-fb2af57350f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1efd139-f84d-4066-91d3-6e32af85a8f5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34c84f91-a912-4d7d-9edf-fb2af57350f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5e700a04-baa7-409f-9730-cd2b25d82e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5e700a04-baa7-409f-9730-cd2b25d82e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_3a2cc43e-4e75-451c-8b07-359814759180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_3a2cc43e-4e75-451c-8b07-359814759180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxAssetDepreciationAndAmortization_d2c73c74-1c6a-440b-a69f-f31a3e4caf62" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxAssetDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_eigr_DeferredTaxAssetDepreciationAndAmortization_d2c73c74-1c6a-440b-a69f-f31a3e4caf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_509f0c6b-a5e4-48fe-8a56-1c1e2083fd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_509f0c6b-a5e4-48fe-8a56-1c1e2083fd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a5ee2ddc-1d0a-4e9d-b191-240cf863e2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a5ee2ddc-1d0a-4e9d-b191-240cf863e2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_eba7fc2f-ea4c-4030-9bf1-f5f33c5cb102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_eba7fc2f-ea4c-4030-9bf1-f5f33c5cb102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxAssetsLeaseLiabilities_a3a6682b-32a2-46d4-889e-808a421f16e1" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_eigr_DeferredTaxAssetsLeaseLiabilities_a3a6682b-32a2-46d4-889e-808a421f16e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9dc5327b-3a62-40c6-92f8-a3dc883873cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9dc5327b-3a62-40c6-92f8-a3dc883873cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_976e2d20-2988-4df6-ac29-822099b98831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_976e2d20-2988-4df6-ac29-822099b98831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_6c1eb4c5-99bc-4551-8c07-8d4b8017f310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_6c1eb4c5-99bc-4551-8c07-8d4b8017f310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_DeferredTaxLiabilitiesRightOfUseAssets_5cc9c6b2-b4ff-45dc-bb53-753deacb2e6c" xlink:href="eigr-20221231.xsd#eigr_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_eigr_DeferredTaxLiabilitiesRightOfUseAssets_5cc9c6b2-b4ff-45dc-bb53-753deacb2e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3d59feb9-6ca1-4673-90e2-bcb6de28d286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3d59feb9-6ca1-4673-90e2-bcb6de28d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8b348e06-2278-4f0e-9167-7d979fe1235a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b7c66d0-4c70-46ba-8f23-5eaa99976174" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8b348e06-2278-4f0e-9167-7d979fe1235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c03ff8b6-7541-4e0c-a0a1-1186d7b6a7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c03ff8b6-7541-4e0c-a0a1-1186d7b6a7a3" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a20858be-4788-485d-9c5d-a31424f43c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a20858be-4788-485d-9c5d-a31424f43c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2c88e1da-ab4e-4a51-aad8-ebb68bf6cca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2c88e1da-ab4e-4a51-aad8-ebb68bf6cca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c717de0e-d5ab-4394-9003-268143c809c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c717de0e-d5ab-4394-9003-268143c809c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b4a97605-b225-426c-a211-409f04f8ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b4a97605-b225-426c-a211-409f04f8ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_fe7f8f11-6dba-47df-949d-a90e5c2adc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_fe7f8f11-6dba-47df-949d-a90e5c2adc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_999a2f53-1c96-4091-bebb-cd4e73d2336b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c604ac43-9ca9-47f6-9bcb-427c5720c8bd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_999a2f53-1c96-4091-bebb-cd4e73d2336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="eigr-20221231.xsd#LegalMattersDetails"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/LegalMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eigr_LegalMattersAbstract_c029dd1b-f6be-4951-87c4-84ee19db7d7e" xlink:href="eigr-20221231.xsd#eigr_LegalMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NumberOfFormerExecutives_697466bd-53db-450c-9532-7903c96f729d" xlink:href="eigr-20221231.xsd#eigr_NumberOfFormerExecutives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eigr_LegalMattersAbstract_c029dd1b-f6be-4951-87c4-84ee19db7d7e" xlink:to="loc_eigr_NumberOfFormerExecutives_697466bd-53db-450c-9532-7903c96f729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5fbf2833-8ab7-422c-a947-1393d8115132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5fbf2833-8ab7-422c-a947-1393d8115132" xlink:to="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f446d19c-291c-4804-a79c-aa3d7ec51a39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_94176c65-03a9-44e0-8a40-f880ba624b5b" xlink:to="loc_srt_SegmentGeographicalDomain_f446d19c-291c-4804-a79c-aa3d7ec51a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_7cc7eaa0-84cf-4c15-a6cc-3dee65c358b5" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f446d19c-291c-4804-a79c-aa3d7ec51a39" xlink:to="loc_stpr_CA_7cc7eaa0-84cf-4c15-a6cc-3dee65c358b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0010cc6e-3268-49f7-8e72-fe475802435b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3658da1c-1fb1-4884-a2a2-5613382bd28f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0010cc6e-3268-49f7-8e72-fe475802435b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PatheonIncMember_1b3a305f-f276-43bf-93c5-b6ff71e82f40" xlink:href="eigr-20221231.xsd#eigr_PatheonIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0010cc6e-3268-49f7-8e72-fe475802435b" xlink:to="loc_eigr_PatheonIncMember_1b3a305f-f276-43bf-93c5-b6ff71e82f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9be8939c-2c77-41ec-8469-50fee1e6f76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44b7f199-a0c5-4f08-8395-001b77aa0ea7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9be8939c-2c77-41ec-8469-50fee1e6f76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_MasterManufacturingServicesAgreementMember_234f7a0d-69c2-4cd1-a9b8-a4ee284bc450" xlink:href="eigr-20221231.xsd#eigr_MasterManufacturingServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9be8939c-2c77-41ec-8469-50fee1e6f76a" xlink:to="loc_eigr_MasterManufacturingServicesAgreementMember_234f7a0d-69c2-4cd1-a9b8-a4ee284bc450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dafa5646-8158-4a41-b8ab-090f0dd058a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1abbdb4a-1432-4829-a5c5-6038d3563e28" xlink:to="loc_srt_RangeMember_dafa5646-8158-4a41-b8ab-090f0dd058a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e72b481-f64d-4786-ae8d-9adf7d002281" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dafa5646-8158-4a41-b8ab-090f0dd058a6" xlink:to="loc_srt_MaximumMember_9e72b481-f64d-4786-ae8d-9adf7d002281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_df51b03b-44a2-4b65-bacb-4ea557d26b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c810485c-7007-4929-9410-9f14c31f636e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_df51b03b-44a2-4b65-bacb-4ea557d26b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6ccf201c-54b4-4610-be27-70c659abd922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_df51b03b-44a2-4b65-bacb-4ea557d26b75" xlink:to="loc_us-gaap_SubsequentEventMember_6ccf201c-54b4-4610-be27-70c659abd922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_0ec2485a-66ad-4ed4-a9b8-4eee84a0e160" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_944eada1-a836-40f5-b3f5-9be3c4643e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_944eada1-a836-40f5-b3f5-9be3c4643e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d384a1f5-f06e-444c-8cfb-aec6b70c007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d384a1f5-f06e-444c-8cfb-aec6b70c007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_b1c447fe-0f23-4f98-a37f-a575e073d2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_b1c447fe-0f23-4f98-a37f-a575e073d2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8bd1e20c-f902-4db7-ad0d-1379c873774c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeaseExpense_8bd1e20c-f902-4db7-ad0d-1379c873774c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6f0bde4f-884e-4a18-8533-570a4d05fc25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_VariableLeaseCost_6f0bde4f-884e-4a18-8533-570a4d05fc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_41703128-e917-4a60-9514-51f584fcd2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeasePayments_41703128-e917-4a60-9514-51f584fcd2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ae96ce5a-0e4b-4c94-8cf0-69a9418218d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ae96ce5a-0e4b-4c94-8cf0-69a9418218d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9bf58e6a-febe-4002-909a-1b9cb750c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9bf58e6a-febe-4002-909a-1b9cb750c06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_e5fc9b3d-b9e7-468f-94ff-73c54844a51f" xlink:href="eigr-20221231.xsd#eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_e5fc9b3d-b9e7-468f-94ff-73c54844a51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PercentageOfPurchasePrice_38dc2495-1c1e-4753-91ce-c77f1fa7ed34" xlink:href="eigr-20221231.xsd#eigr_PercentageOfPurchasePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a218786d-e0ba-435f-b127-6a9ef33a7c08" xlink:to="loc_eigr_PercentageOfPurchasePrice_38dc2495-1c1e-4753-91ce-c77f1fa7ed34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4400b9d-7999-4101-bf5f-5ca38a0fed17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4400b9d-7999-4101-bf5f-5ca38a0fed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e214a0ef-3674-47c2-b855-2d66ba711630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e214a0ef-3674-47c2-b855-2d66ba711630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_404ec0fb-494f-4b47-b769-22de4593e572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_404ec0fb-494f-4b47-b769-22de4593e572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_682debcc-6c33-4342-926f-2f5a921c6bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_682debcc-6c33-4342-926f-2f5a921c6bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d878367b-4ce8-4b66-a8f8-4a6cbb567b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d878367b-4ce8-4b66-a8f8-4a6cbb567b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_933efb53-1aa0-49f3-982d-9edbe24c78f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_OperatingLeaseLiability_933efb53-1aa0-49f3-982d-9edbe24c78f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b09dca92-3ae0-4fd2-817f-b4c7a6a63830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b09dca92-3ae0-4fd2-817f-b4c7a6a63830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_934127aa-702b-4e4a-b24e-34363fd5aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_21cbf73b-49a4-43b5-834a-f62e2074be5f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_934127aa-702b-4e4a-b24e-34363fd5aae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1" xlink:type="simple" xlink:href="eigr-20221231.xsd#CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="simple" xlink:href="eigr-20221231.xsd#SubsequentEventsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d7f06280-c2b3-4f21-b42d-e015b2e96157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d7f06280-c2b3-4f21-b42d-e015b2e96157" xlink:to="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1784d605-0b2c-4df7-9dd1-0e85522d186e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_00a84940-fc15-49a7-ba89-1332ecba8b59" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1784d605-0b2c-4df7-9dd1-0e85522d186e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_250581b5-e551-4737-a90c-f42b30a8cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1784d605-0b2c-4df7-9dd1-0e85522d186e" xlink:to="loc_us-gaap_SubsequentEventMember_250581b5-e551-4737-a90c-f42b30a8cd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12afcd3a-9137-4208-add3-5c1afa9527e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a2c0b80c-7f3a-40b9-bfb0-856ee54f6d19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12afcd3a-9137-4208-add3-5c1afa9527e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_53f630bd-a9d6-46de-8dc8-7aec613a797d" xlink:href="eigr-20221231.xsd#eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12afcd3a-9137-4208-add3-5c1afa9527e6" xlink:to="loc_eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember_53f630bd-a9d6-46de-8dc8-7aec613a797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5f0891be-3c0d-429a-8ad8-563f3bea5a2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1b6f572c-315b-4352-a7f0-3d5ed3efbc3b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5f0891be-3c0d-429a-8ad8-563f3bea5a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_FormerCEOMember_eb813686-277a-46f7-bb61-8437d9dbe869" xlink:href="eigr-20221231.xsd#eigr_FormerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5f0891be-3c0d-429a-8ad8-563f3bea5a2d" xlink:to="loc_eigr_FormerCEOMember_eb813686-277a-46f7-bb61-8437d9dbe869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_84716f01-0afa-4d57-9ccc-da362440c143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_2f3a6aeb-a671-436f-a8c4-711d67b268a4" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_84716f01-0afa-4d57-9ccc-da362440c143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_SiliconValleyBankMember_10aaba91-510a-4984-82c1-cdd2e9c19112" xlink:href="eigr-20221231.xsd#eigr_SiliconValleyBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_84716f01-0afa-4d57-9ccc-da362440c143" xlink:to="loc_eigr_SiliconValleyBankMember_10aaba91-510a-4984-82c1-cdd2e9c19112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e2e9bb9b-26eb-4739-aef1-d1ab38c225b0" xlink:to="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_801748ce-e204-4195-a312-47e75ae344d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_801748ce-e204-4195-a312-47e75ae344d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_BaseSalaryAndTargetBonusContinuationPeriod_4f242750-20d6-4510-8354-79227abcc542" xlink:href="eigr-20221231.xsd#eigr_BaseSalaryAndTargetBonusContinuationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_BaseSalaryAndTargetBonusContinuationPeriod_4f242750-20d6-4510-8354-79227abcc542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_c82522f0-7c6a-4f9d-acc3-722b4f33171e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitContributions_c82522f0-7c6a-4f9d-acc3-722b4f33171e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_COBRAContinuationCoveragePeriod_5b331ff0-c44c-46c1-917d-3fbb430fc50b" xlink:href="eigr-20221231.xsd#eigr_COBRAContinuationCoveragePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_COBRAContinuationCoveragePeriod_5b331ff0-c44c-46c1-917d-3fbb430fc50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PostEmploymentBenefitAcceleratedVesting_c82864ab-f0b5-42d9-878e-f792f167955b" xlink:href="eigr-20221231.xsd#eigr_PostEmploymentBenefitAcceleratedVesting"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_PostEmploymentBenefitAcceleratedVesting_c82864ab-f0b5-42d9-878e-f792f167955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_5c772fd4-42fe-4963-a185-732d4d5bf2cb" xlink:href="eigr-20221231.xsd#eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold_5c772fd4-42fe-4963-a185-732d4d5bf2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eigr_NumberOfAccounts_71ef9571-7cd2-4c7b-918e-0839ed1d4d92" xlink:href="eigr-20221231.xsd#eigr_NumberOfAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_eigr_NumberOfAccounts_71ef9571-7cd2-4c7b-918e-0839ed1d4d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f5747aa-a245-4f63-906f-83a9a9ab0b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9d1783c3-f139-455c-857f-ebca4db27cff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f5747aa-a245-4f63-906f-83a9a9ab0b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>eigr-20221231_g1.jpg
<TEXT>
begin 644 eigr-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '4!*L# 2(  A$! Q$!_\0
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MF=!TD&5''TR/0FNIHG"5.7++<*=2-6//';[OS"BBBH- HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN7^)7C9?AWX-O\
M7FLS?_9=@%N)/+W%G"_>P<=?0U<(2J24([O3[R)SC3@YRV2N_1'445X]I_Q]
MO+6]T(>)_",_A[3M;V_8M02^2ZC;< 5W!5&T?,.O//3BO8:VK8>IA[>T6_FG
MMOJCGP^*HXJ_LG>UNC3UVT:3UZ!1117,=84444 %%%% !1110 4444 %%%%
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M5B;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-%O\ \E$^-_\
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M;;5O1.R>_H?/?C+PGH_PKO\ P#JO@NYF35=0O8HY52[>3^T(F RS*2002>P
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MVW_QVC_AZ]\._P#H4?$__?-O_P#':_+JE"T?V=0\P_M&OY'ZB_\ #UWX=_\
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MO_\ &J//U7_GRL__  +?_P"-5HT4 9WGZK_SY6?_ (%O_P#&J//U7_GRL_\
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M?_'*/^"G'_)*/"O_ &&__:$E?G!7TF P%'$4>>=[GS688^MAZW)3M:Q^C_\
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M)/&3ZUO*C.,.=[7M^"?Y,PC6A*?(M[7^YV_-&G117@WB+XF>)M<_:LT#X?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NM^)W_(R6?\
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M\2?^!-O_ /&*/^&"_A__ -!CQ)_X$V__ ,8KZ2HH]K/N'LX=CYM_X8+^'_\
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ME6%-]6E][L9U)>SIRGV3?W*Y]#>&?B3X1\;7$MOX>\4Z+KT\2[I(M,U&&Y9
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M,']VC^P8/[M'U>0>V@?J_P#\+X^&G_10_"G_ (.[;_XNC_A?'PT_Z*'X4_\
M!W;?_%U^4']@P?W:/[!@_NT?5Y![:!^K_P#POCX:?]%#\*?^#NV_^+H_X7Q\
M-/\ HH?A3_P=VW_Q=?E!_8,']VC^P8/[M'U>0>V@?J__ ,+X^&G_ $4/PI_X
M.[;_ .+H_P"%\?#3_HH?A3_P=VW_ ,77Y0?V#!_=H_L&#^[1]7D'MH'ZO_\
M"^/AI_T4/PI_X.[;_P"+H_X7Q\-/^BA^%/\ P=VW_P 77Y0?V#!_=H_L&#^[
M1]7D'MH'ZO\ _"^/AI_T4/PI_P"#NV_^+H_X7Q\-/^BA^%/_  =VW_Q=?E!_
M8,']VC^P8/[M'U>0>V@?J_\ \+X^&G_10_"G_@[MO_BZ/^%\?#3_ **'X4_\
M'=M_\77Y0?V#!_=H_L&#^[1]7D'MH'ZO_P#"^/AI_P!%#\*?^#NV_P#BZ/\
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M^)OVE?%VIZ/J%KJVFS_8_*O+&=9H9-MG K;74D'#*0<'J"*J_$[_ )&2R_[
MFD?^FZVKA[738K5LJ,5W/Q._Y&2S_P"P)I'_ *;K:MZ<'"23[/\ 0SJ24X-K
MNOU.2HHHKJ.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#]U?#O_(OZ9_UZQ?\ H K1K.\._P#(OZ9_UZQ?^@"M&OS(_4 K
M\3?V[A_QEI\0_P#KZ@_])8:_;*OQ/_;N_P"3L_B'_P!?4'_I+#7K9;_&?I^J
M/*S+^"O7]&>"5>T/5)]!UFPU.VV_:;*>.YB\P97<C!AD>F15,"EKZ9-IW1\R
M_>5F>G?%G]H3Q)\8_BK:?$#6+33+/6[46XCBT^&1;?\ <MN0E7=FZ]?F_*NE
MUS]L3X@ZQ\<(/BK;MINC>)H[5;)HM/@?[++" 04>.1W+ YY^;J 1@@&O#L4N
M*RC1IQ226BO;Y[_>;.K4DVV]7:_RV^X]J^)?[5>O?$CPOJ.@1>$?!7A"QU21
M9=1?POHBVDUZ5<.OFR,SL?G ;@@D]:^FOCY^V%%\/M)^$:^#AX)\<BU\/P2R
M)J5O'J#Z7>HD8#H4</#*!D8)[=*_/VMC7O!NO^%8;"76]$U+1XM0A%S9O?VD
MD N8CC$D9<#>O(^89'-92P]/W5LKW]=&OZ]#6.(J7E)N[M;TU3_X'S/5O"/[
M8'Q!\+?$#Q7XLF?3/$5SXIC\G5]/UNT\ZRNHP"$0QJRX55)4 '&#@YH^*W[6
M/BGXN?#NS\$W^A^&=$\/V5^+^TM]!T]K06Y",HB11(5"?.Q^[NR?O5XI2A:U
M]A2T?+M:WRV^XR^L5=?>WO?Y[_>>[^,/VQ?%_C[2_"\.NZ#X5OM6\/S6LMOX
M@?2S_:4H@?>D;S;^$+<L$"Y_$TQ?VQO'D/QZN/BU;0Z3:>(;JW6TN+.*WD-E
M-"$5-C(TA?!V*>'!R."*\,IP6J5"FOL]_P =_O)]M4M:_;\-ON/<]._:Z\2:
M+JOCF\TGPKX0T6/Q=IHTN]LM-TQ[>WAC"NI>)$E&)#YC$LQ;)Q]*O^#_ -M?
MQIX'\/:=9:=X?\'G6--L%TVR\43Z*K:K;VZJ%5%FW $!1CYE.>^:^?J<%I?5
MZ35N7^E?_-E?6*M^;F_K3_)?<2WEW/J5Y/=W4K3W,\C2RRN<L[,<EC[DDU%2
MT5T)65D<[DV[L*4+0%IX6J($"TZBBF 44H6G4Q"8Q2TH%+3$ %+BE"TM,FX4
MH%*%I:H0E."TH%+0!^N?_!//_DUGPW_U]7O_ *4O7TE7S3^P3;KK'[,?AF>X
M+QNLMU"!:NUNFU)G4$K&5!; Y8C<QR22237T+_85M_SUO/\ P.F_^+KX#$_Q
MY^K_ #/O</\ P8>B_(T:*SO["MO^>MY_X'3?_%T?V%;?\];S_P #IO\ XNN8
MZ#1HK._L*V_YZWG_ ('3?_%T?V%;?\];S_P.F_\ BZ -&BL[^PK;_GK>?^!T
MW_Q=']A6W_/6\_\  Z;_ .+H T:*SO["MO\ GK>?^!TW_P 71_85M_SUO/\
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MF_\ BZ -&BL[^PK;_GK>?^!TW_Q=']A6W_/6\_\  Z;_ .+H T:*SO["MO\
MGK>?^!TW_P 71_85M_SUO/\ P.F_^+H T:*SO["MO^>MY_X'3?\ Q=']A6W_
M #UO/_ Z;_XN@#1HK._L*V_YZWG_ ('3?_%T?V%;?\];S_P.F_\ BZ -&BL[
M^PK;_GK>?^!TW_Q=']A6W_/6\_\  Z;_ .+H ^2?^"G'_)*/"O\ V&__ &A)
M7YP5^E'_  40OY?"/PS\-7-BL,\DNK^6RZI E^@'DR'(2X#JIXZ@ ]LU\"?\
M+.UC_GS\/?\ A-:=_P#(]?996Y_5E9=7U_X!\9FJA]9=V]ET_P""<E176_\
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MX)R5%=;_ ,+.UC_GS\/?^$UIW_R/1_PL[6/^?/P]_P"$UIW_ ,CT7J=E]_\
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M>'?^1?TS_KUB_P#0!6C6=X=_Y%_3/^O6+_T 5HU^;GZ6%?BA^W9_R=E\0_\
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M>M(!]&:J6^HVUU=7-M%,LDUN5$J#JF1D9_"K/% #LT;AZTVF,RKPQ R<#)H
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M*8@IP6C%*!3L(*<JTJK4BK5DW$5:>JTJK4BK3)/UD_X)]_\ )K_AW_KZO/\
MTH>OHZOG+_@G[Q^S#X>_Z^KS_P!*'KZ-K\[Q7^\5/5_F?H6%_@4_1?D%,=F7
M[HS]3BGTAZ5RG2<#X^\0>*-+U*UCT:T$EO)$Y:18Q)AP#C.<8'2O,9-4\1^(
M+J"V\8WUS%:BZBD@@CM!;(9 > 67[XYZ$X_I[Y>6AD;_ %NS/O7-Z]HB74*I
M).DHW#:K?-\W8CWJTUV(:=]SY\F\&:!?ZYK>Y[>:2&=Y3#Y5Z,1!7+@[6VL>
M!C;P2& &:N?\(CH36T%KY%F)V,3S_P"BW;[6!/FJ&QDY##&3VZ'MZH/#<:R2
M*DT:L 2P& <#/7]:4>']K;1<H#GD9%(.7R/*X?!>C6:01K%;B18YHI2MI=G=
MG)0CT R V2<@''I4$/@>#=F"/38[=Y3&NZQNRP'& >1WW'.,=*];;P\3G-PI
M_$5&OA?=TDSSC/OZ4#Y5V.+TWX3W%GF20:(+A,>4T4,H4$<]#)_>Q^OK6'^T
M):ZKH7P@>YTF15\01W</[[38RORESG"_,<;2 :]5_P"$+F]'_*DF\)F&/,^T
M)G_EHHQ433E!Q3L=>$G"CB*=6<.9)IM=_+YGQ+HGQ7^(7@F:X;1=3OUOKW9)
M?%X%E8L$ &0R'''\ZV_^&E/C(/\ F+WG_@NB_P#C5?56B^$[2W\775^7M8F:
M'RW<*!N'RX![$C'6NQ&F6&/^/RV_):\26"K2=U7:/T>GQ-@(1Y997"7F[=]O
MAZ;'Q)_PTM\9.?\ B<7@_P"X=%_\:K8^$WQF^(?Q"^,?A32O%6IW%UI4=\+B
M.*6RCA'FK&X!W*BD\,W&:^P_[,T__G[MOR'^%9=]X;TW4-6T9_-BFGM;P3P"
M+ *OL=<G'488_G3A@ZT))NNWY$UN),OK49TX9;&#<9)26Z;35_A/3$]13ZKV
MJLJ@-Z58KVS\Q"BBB@ HHHH *QO%W@_1/'F@W.B>(=,M]6TJXQYMK<KN4X.0
M?4$'D$<BMFB@#RSX?_LO?"[X7ZXFL^&_"-M9:I'_ *NZFGFN7BX(RAE=MAP2
M,K@\UZG7SV?BQXH_X;2'@'^T5_X13^P?M?V'[/'GSL$[_,V[\]L;L>U>H?$K
MXR^"_@_96]UXPU^WT6.X)$*.KR2RXQDK&BL[ 9&2!@9YKJJQK3<'-N3DM-V]
MVOT.2E*C#G4$HJ+UV2V3_4[2BO/] ^/G@'Q1X%U3QCI7B."]\/:6C27MU'#+
MOMPHR=\17S!QR!MR>U<]:?M>?!Z^U>PTR+QUI_VJ^1)(?,CE2(!AE0\C($C;
M'578$'@@&H]A5NX\CNM]&:>WI64N=6?FCV&BO.? ?[1'PZ^)WB2[T'PQXIM=
M6U:V4N]O&DB;E!P3&SJ%D ]4)]:^?/A)^TQHW@'XE?&9?B/XWN(;.'Q ;?2[
M6]EGNC%&LDP*PPJ&*H $!VJ!TS5PPU27,K--*]K:O5+3[R)XFG!1=TTW:]]M
M&]?N/LFBN/NOB]X,L?A^GC>;Q%9)X5=!(FI[R8V!.   -Q;.1M W9!&,U\TZ
MU^T39?$C]JCX31>!/&5U?>&+F*>.^LK66:"*20"3B:!PI)P 1N7MD44L-4JS
MY+6M>^FUDWK]P5L33HT^>Z>UM=[M+3[S[&HKR;Q9^U9\*/ _B:3P_K/C*TM=
M6BD\J6&.&:98GS@J[QHR(0>H8C'?%>HV%_;:I8V][9SQW5I<1K+#/"P9)$89
M5E(Z@@@YK%TYQBIN+L^ILJD)2<$U=="Q11169H%%%% !1110!Q/Q$_X^],_W
M)OYQURM=5\1/^/O3/]R;^<=<K7T>!_@GR^8?Q_D%%%%>@>8%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7#?'7_DB/Q"_P"Q=U'_ -)I*[FN&^.O_)$?B%_V+NH_^DTE
M S\IM*_X]5^E7*IZ5_QZK]*N5[$?A1YD_B844451 4444 %%%% !1110 444
M4 %%%% !76_$[_D9+/\ [ FD?^FZVKDJZWXG?\C)9_\ 8$TC_P!-UM63_B+T
M?Z&J_AOU7ZG)4445J9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?NKX=_Y%_3/^O6+_P! %:-9WAW_ )%_3/\ KUB_] %:
M-?F1^H!7XL_MS#_C*[X@_P#7U!_Z315^TU?BU^W-_P G7?$'_KZ@_P#2:*O8
MRO\ COT_5'D9G_!7K^C/":4"E"TM?4'S(444H6JL3< M."TH6EIB"BBE"T"$
MIV*6E IB$IV,44X+3$)BG44X+5$B!:=13@*8"!:6EIU "!:6BG 4Q"!:=13U
M6JL2-5:D5:55J15JB1JK4BK2JM/5:JPA%6GXHIZK56(;/U?_ ."?_P#R;#X>
M_P"OJ\_]*'KZ,KYT_8!_Y-C\/_\ 7U>?^E#U]%U^<8O_ 'BI_B?YGZ)A?]WI
M_P"%?D%(RY[XI:*Y3J*=SIZ73AG).*CBT>"-L[><YK0HH H?V/;YD(1/WF=Q
MVC)SUH71X% _=QD@8R4&:OT4 4?[(@/6./U^X*%TF%< (@P=WW1U]:O44 0?
M9CW;/X57O]'AU*U,$PRA.35^B@:;3NCGF\%6#8^3I2?\(38?\\ZZ*BHY(]C=
M8BJOM,YW_A"=/_N5+8^$K*QNTN(TQ(AR#6[11RQ[ \15DK.3&J,4ZBBK.<**
M** "BBB@ HHHH ^)_B-\1_#OPG_;V&O^*]0.E:0/#JQ?:#;RR_,RD*-L:LW4
M'G&.*O\ QX_:4^W:]X#UCPCX@L_#/@O4X+E?^%A3>''OYK>17*O!'')'N7)C
M4$;>=P/1:^R:*[XXB'[MRA=Q5M]&M>EO/T\C@EAY_O%&=E-WVU3T6]_+U\S\
MYOA-<7=Q\.?VIY;N^GU.6>S6X:]N+#["]SO6X83&W_Y9[P0VWT(JY\6M'L(/
MV&?@\8[&VC,FJ6SN5A4;F=9MY/'); R>^.:_0VBM_K_OJ:CLX/?^16MMU]-#
M#ZA[LHN6ZFMOY[:ZOIZZ]SY/\>V$.E_MX?"1+2W2T@_L">)5A0(NU8[D!0!Q
M@#'';BO+_AO\4O!OPI^(_P"T!=^,K&80:IJUW9VMZ+!YXYF#S%[4NJG:S[E.
M&PIVDD\5^@%%8+%+D]G.-URN+UUUES7V^7]6-WA7S^TA*SYE):=H\O?Y_P!7
M/S:F^'/BKP[^R'X$U#6M)OKC1K#Q7_;-[I+0LSQV!& SH>0I(<\\8E![UWNM
M>/O#?Q5_;(^$/B'PA9W$FD&*6V_M1]/>VCNWCCD)5"ZJSB-652<8&<"ONBBN
MAYAS3YY1UNVM>ZMKIKL<_P#9_+3]G&6Z2>G:3EIKIJ_,_-SXO_%KQ/XEM?BE
MX:U/7HO!<R7=PL?@;3O"8F?4X@Y8W,EUMRA(&XR9YP6 K[4_9A9G_9[^'Q8E
MC_8UN,D_[(KT^BN:IB5.BJ2C;;\%;M?7S;.BGAI0KNLY7W_%I][:6Z)!1117
M"=X4444 %%%% 'B/[47Q>T?X*Z'HFNZW:WUW:3W$EFL>GQH\F]E#@D.ZC&(S
MW[CBOFIO^"A_P[1B/[ \6'Z6EM_\D5WG_!3CGX4>%?\ L-_^T)*_-WR4_NU]
M;EM%3PZ?FSX_,ZO)B6O)'W)_P\2^'?\ T+_BS_P#MO\ Y(H_X>)?#O\ Z%_Q
M9_X!VW_R17PWY"?W11Y"?W17J?5UW/*]OY'W)_P\2^'?_0O^+/\ P#MO_DBC
M_AXE\._^A?\ %G_@';?_ "17PWY"?W11Y"?W11]77</;^1]R?\/$OAW_ -"_
MXL_\ [;_ .2*/^'B7P[_ .A?\6?^ =M_\D5\-^0G]T4>0G]T4?5UW#V_D?<G
M_#Q+X=_]"_XL_P# .V_^2*/^'B7P[_Z%_P 6?^ =M_\ )%?#?D)_=%'D)_=%
M'U==P]OY'W)_P\2^'?\ T+_BS_P#MO\ Y(H_X>)?#O\ Z%_Q9_X!VW_R17PW
MY"?W11Y"?W11]77</;^1]R?\/$OAW_T+_BS_ , [;_Y(H_X>)?#O_H7_ !9_
MX!VW_P D5\-^0G]T4>0G]T4?5UW#V_D?<G_#Q+X=_P#0O^+/_ .V_P#DBC_A
MXE\._P#H7_%G_@';?_)%?#?D)_=%'D)_=%'U==P]OY'W)_P\2^'?_0O^+/\
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M/[HH\A/[HH^KKN'M_(^Y/^'B7P[_ .A?\6?^ =M_\D4?\/$OAW_T+_BS_P
M[;_Y(KX;\A/[HH\A/[HH^KKN'M_(^Y/^'B7P[_Z%_P 6?^ =M_\ )%<[\2/V
M[/ GC+X=^*?#]EH?B:*\U72KJQADN+6W$:O+"R*6(G)"Y89P"<=C7Q[Y"?W1
M1Y*?W11]77</;^1!IL9CMU!ZXJU0!C@45UI65CE;N[A1113$%%%% !1110 4
M444 %%%% !1110 5UOQ._P"1DL_^P)I'_INMJY*NM^)W_(R6?_8$TC_TW6U9
M/^(O1_H:K^&_5?J<E1116ID%%%% !1110 4444 %%%% !1110 4444 %%%%
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M ")1_P (7H__ $/WA[_OQJ/_ ,B4>TCY_<_\@]E+NOO7^9R5%=;_ ,(7H_\
MT/WA[_OQJ/\ \B4?\(7H_P#T/WA[_OQJ/_R)1[2/G]S_ ,@]E+NOO7^9R5%=
M;_PA>C_]#]X>_P"_&H__ ")1_P (7H__ $/WA[_OQJ/_ ,B4>TCY_<_\@]E+
MNOO7^9R5%=;_ ,(7H_\ T/WA[_OQJ/\ \B4?\(7H_P#T/WA[_OQJ/_R)1[2/
MG]S_ ,@]E+NOO7^9R5%=;_PA>C_]#]X>_P"_&H__ ")1_P (7H__ $/WA[_O
MQJ/_ ,B4>TCY_<_\@]E+NOO7^9R5%=;_ ,(7H_\ T/WA[_OQJ/\ \B4?\(7H
M_P#T/WA[_OQJ/_R)1[2/G]S_ ,@]E+NOO7^9R5%=;_PA>C_]#]X>_P"_&H__
M ")1_P (7H__ $/WA[_OQJ/_ ,B4>TCY_<_\@]E+NOO7^9R5%=;_ ,(7H_\
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MG)45UO\ PA>C_P#0_>'O^_&H_P#R)1_PA>C_ /0_>'O^_&H__(E'M(^?W/\
MR#V4NZ^]?YG)45UO_"%Z/_T/WA[_ +\:C_\ (E'_  A>C_\ 0_>'O^_&H_\
MR)1[2/G]S_R#V4NZ^]?YG)45UO\ PA>C_P#0_>'O^_&H_P#R)1_PA>C_ /0_
M>'O^_&H__(E'M(^?W/\ R#V4NZ^]?YG)45UO_"%Z/_T/WA[_ +\:C_\ (E'_
M  A>C_\ 0_>'O^_&H_\ R)1[2/G]S_R#V4NZ^]?YG)45UO\ PA>C_P#0_>'O
M^_&H_P#R)1_PA>C_ /0_>'O^_&H__(E'M(^?W/\ R#V4NZ^]?YG)45UO_"%Z
M/_T/WA[_ +\:C_\ (E'_  A>C_\ 0_>'O^_&H_\ R)1[2/G]S_R#V4NZ^]?Y
MG)45UO\ PA>C_P#0_>'O^_&H_P#R)1_PA>C_ /0_>'O^_&H__(E'M(^?W/\
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M ")1_P (7H__ $/WA[_OQJ/_ ,B4>TCY_<_\@]E+NOO7^9R5%=;_ ,(7H_\
MT/WA[_OQJ/\ \B4?\(7H_P#T/WA[_OQJ/_R)1[2/G]S_ ,@]E+NOO7^9R5%=
M;_PA>C_]#]X>_P"_&H__ ")1_P (7H__ $/WA[_OQJ/_ ,B4>TCY_<_\@]E+
MNOO7^9R5%=;_ ,(7H_\ T/WA[_OQJ/\ \B4?\(7H_P#T/WA[_OQJ/_R)1[2/
MG]S_ ,@]E+NOO7^9R5%=;_PA>C_]#]X>_P"_&H__ ")1_P (7H__ $/WA[_O
MQJ/_ ,B4>TCY_<_\@]E+NOO7^9R5%=;_ ,(7H_\ T/WA[_OQJ/\ \B4?\(7H
M_P#T/WA[_OQJ/_R)1[2/G]S_ ,@]E+NOO7^9R5%=;_PA>C_]#]X>_P"_&H__
M ")1_P (7H__ $/WA[_OQJ/_ ,B4>TCY_<_\@]E+NOO7^9R5%=;_ ,(7H_\
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MFZVKDJZWXG?\C)9_]@32/_3=;5R59TOX<?1&E;^)+U84445J9!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5UOQ._P"1DL_^P)I'
M_INMJY*NM^)W_(R6?_8$TC_TW6U9/^(O1_H:K^&_5?J<E1116ID%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^ZOAW_ )%_
M3/\ KUB_] %:-9WAW_D7],_Z]8O_ $ 5HU^9'Z@%?B3^WB/^,MOB)_U]0?\
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M-JQAW1F)68$GGJ#A><<8]\CZ8TG4H=8T^"\MW#PS+N5E.14L"W1114@%%%%
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M44 %%%% !1110 4444 %%%% !1110!Q/Q$_X^],_W)OYQURM=5\1/^/O3/\
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M507C%N!5S1%*Z;"#UQ_6@"_1112 **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#1-/\ RN__ '-1_P /'[G_ *)I_P"5W_[FKY0VCTHVCTH^KQ[A[=]CZO\
M^'C]S_T33_RN_P#W-1_P\?N?^B:?^5W_ .YJ^4-H]*-H]*/J\>X>W?8^K_\
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M/^[+U9\1FW^\OT04445[!XP4444 %%%% !1110 4444 %%%% !1110 4444
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M?;PW_P"$MI?_ ,C4[_A<GB/_ )]O#G_A+:7_ /(]<0%I=M/V<>PO:3[G;_\
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M'MJG\S^\]3^(GQ$U6S\06D<=IH3*=(TN3][X?L)#EK"W8C+0$XR3@=%&
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M!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV_\ \8H_X8+^'_\ T&/$G_@3;_\ QBCZQ /8S/@NBOO3_A@OX?\ _08\2?\
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M[$TC_P!-UM7)TZ7\./HA5OXDO5A1116ID%%%% !1110 4444 %%%% !1110
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M#3_HH?A3_P '=M_\71_POCX:?]%#\*?^#NV_^+H [JBN%_X7Q\-/^BA^%/\
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M7J4?X<?1'GUOXLO5A1116IB%%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\$7)3[/[_\ @'J'_"L=4_Z"?A?_ ,*O2_\ Y)IW_"L=4_Z"?A?_ ,*O2_\
MY)KRX+3MM/GJ=U]W_!%R4^S^_P#X!ZA_PK/5/^@GX7_\*O2__DBE_P"%9:I_
MT$_"_P#X56E__)%>7[:=MI^TJ=U]W_!%R4NS^_\ X!Z?_P *SU3_ *"?A?\
M\*K2_P#Y(IW_  K/4_\ H)^%_P#PJM+_ /DBO+PM+MI\]7NON_X(N6GV?W_\
M ]0_X5GJG_03\+_^%5I?_P D4O\ PK/4_P#H)^&/_"JTS_Y(KS#;2A:?/4[K
M[O\ @AR4^S^__@'IX^&FJ?\ 03\,?^%5IG_R13A\,]2_Z"?AC_PJ=,_^2*\P
MVTNVG[2KW7W?\$GDI=G]_P#P#U%?AKJ7_03\,?\ A4Z9_P#)%.'PVU'_ *"?
MAC_PJ=,_^2*\NVTH6G[2KW7W?\$7)2[/[_\ @'J8^&^H_P#03\,?^%3IG_R1
M3_\ A7.H?]!3PS_X5.F?_)%>5[:4+3]I5[K[O^"+V=+L_O\ ^ >JCX=:C_T$
M_#/_ (5&F?\ R13A\.]0[ZIX9_\ "HTS_P"2*\IVTM5[2KW7W/\ S%[.EV?W
MK_(]8'P[O_\ H*>&?_"HTW_Y(IP^'M]_T%/#/_A4:;_\D5Y-BE"T_:5>Z^Y_
MYD^SI=G]Z_R/V-_8@9?#W[.VAV5PRW$J7-V3)IQ%["<SN>)8-Z'WPW!X/->\
M_P!NVW_/.\_\ 9O_ (BOGK_@G7Q^RGX:_P"OJ]_]*9*^E'=8T9W8*JC)9C@
M>M?"8F[KS;[O\S[K#V5&"79?D4/[=MO^>=Y_X S?_$4?V[;?\\[S_P  9O\
MXBI?[8L/^?VW_P"_J_XT?VQ8?\_D'_?P?XUS'01?V[;?\\[S_P  9O\ XBC^
MW;;_ )YWG_@#-_\ $5+_ &Q8_P#/Y!_W\%+_ &M9?\_</_?P4 0_V[;?\\[S
M_P  9O\ XBC^W;;_ )YWG_@#-_\ $5-_:UE_S]P_]_!1_:ME_P _</\ W\%
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MVV_YYWG_ ( S?_$5HT4 9W]NVW_/.\_\ 9O_ (BC^W;;_GG>?^ ,W_Q%:-%
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M%8ZQ_P _GA[_ ,*73O\ Y(KDJ*+5.Z^[_@A>GV?W_P# .M_X5CK'_/YX>_\
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M^?SP]_X4NG?_ "11_P *QUC_ )_/#W_A2Z=_\D5R5%:6J=U]W_!,KT^S^_\
MX!UO_"L=8_Y_/#W_ (4NG?\ R11_PK'6/^?SP]_X4NG?_)%<E11:IW7W?\$+
MT^S^_P#X!UO_  K'6/\ G\\/?^%+IW_R11_PK'6/^?SP]_X4NG?_ "17)446
MJ=U]W_!"]/L_O_X!UO\ PK'6/^?SP]_X4NG?_)%'_"L=8_Y_/#W_ (4NG?\
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M*?\ Y4K3_P".T?\ #(GQ:_Z%/_RI6G_QVCVD.X<DNQX]17L/_#(GQ:_Z%/\
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M_KZ@_P#26&OVUK\3?V[E_P",M/B'_P!?4'_I+#7JY;_&?I^J/+S+^"O7]&>
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M."UZU\,_V5?BI\8-".M>$?!]SJ6DEV1+R6X@MHY"#@[#,Z;\$$$KG!!%>?\
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M/1]447+7C;<HQ# ,A''&SKWR1TKT#X;^%X?A[XO%G8WBWMC<@H]ZY7]YE<J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<+\>/^2'?$3_L7-1_])I*[JN%^/'_)#OB)
M_P!BYJ/_ *324#6YZ)^SS_R(NF_]>\?_ *"*]6KRG]GG_D1=-_Z]X_\ T$5Z
MM7QA]T%?BM^W2/\ C+#XA?\ 7U!_Z30U^U-?BS^W./\ C*[XA?\ 7U!_Z315
MZ^5_QGZ?JCR<S_@KU_1G@NVEVT_;2A?:OJ+'S T+2[:?MHI@(%I=M+BG!:=A
M7&T;:DVTM,0P+3MM+2[:8A*,4[;3MM.PKC-M.V^U."T[;3L3<9MIP6G!?:G;
M:=A7&;:=MIP6EVTQ#=M+MI^VEVTP&A:7;3\4NVG85QF*=MIP7VIXCJK"N1[:
M<%-2K'4BQT[$W(1'3UCJ98Z>(ZJQ-S]8O^"?8V_LO>'1_P!/5Y_Z4/7T#K1Q
MI-X?^F+_ ,C7@'_!/[C]F'P]_P!?5Y_Z4/7ONO'&B7Y_Z8/_ .@FOSO%?[Q4
M]7^9^A87^!3]%^1Y5K%NMYI5W#A09(V7/U%>/ZC\&]!UJ8M=:-8W4F>7:$;O
M^^L9_6O6GD+1D9[54C 4YKGC)QU3.M2:V/+8?@%X:CQLT"Q4>Z9K4L_@GX?A
MD7_B0Z2@SRPLHRWY[:]%7YN:F6M'6J/=CYY/J'@[2K72;.:WAMH8(%<+''$@
M154 #@"LK5-'M;C4[B<PW 9V^]#.P!QQ]W.!^5=!;OL7CBH&4%CWK.^MR3GI
M-#M6X=+Z08Z>>5_52*Z:QT^TAT)4%O@+&0%9B3WZDGFH]HZ9JQNQ#L[8I-W$
M<S!HEE$0J"\@^DI?_P!"S4MCH]C]OAD*W,LB.&!EE(7KZ# /XBM;9[TL:_O%
M/H:0%#QYX9T[Q!I\-O<6,-Q'OW%9%![5YI=? _PS-G?H49S_ ')9%_DPKUZZ
MEW!<U4+5E*E"?Q*YE*G">LD>06/P,T+2[[[;:"]TTQJRD0S!PP8$%2)%;((/
M>M;2?AGI6GVL,(DOKB.(;462?:% [80*#^(->AS*)(RO3-4S&%8 < 4X4X4U
M:"L$*4*?PJQKV-G%:V=O$@VJD:J .V!5*XQ_PENA8_Z:_P#LE65G_=J,]JSQ
M)YGB[1.^/,_]DK0V/=[?_4I]*DJ.W_U*?2I*!!1110!Q/BSQ;KB^*K/PSX8L
MK&;4I+1M0N;O4Y'6"WA#[% 5!N=W;.!D !6)/0'(7QKXYU;4DT*Q\/Z5INMV
MEHMWJ4NHWK26RJ\LL<(A\L;G$GD2-EMI10,J2<5T_B;P)!XBU:QU>#4K_0M9
MLXW@CU#36CWM"Y!:)UE1T=<JI&Y201D$9.<6#X-V.FR6USI6O:YI&J1Q217&
MI07$<LUZKR-(WG":-T8AW=@0H*[B%P.*WBX6UW_K^OZUPDIW\OZ_K^M.1T?X
MT>,/$VJ:5HEAX9TVTUJ[EU:&Y^V7CM!9_89X(F?*KF0,9B  %SE3P,XEUCXU
M:[HK?V7J5IH^C:M:7CVM_J5S)/+IL8\E)86#*@9?-63C>0%,<@RWR[EC_9[C
MT?Q=X8GT75M6T^QTR#5IWU%;M9+O[7=36KY/F(RR*PCGR'5AD@]<$=;;?"6"
MP43V7B/7;36'N);FYU=9H7GNFD5$82*\31%0L404",;0@VXYSM)T=++^KOUZ
M&456UO\ IV7ZC?!_Q&NO$DFLI/9VL+:?IME>@VMR+B-VFB=V"R+PR@IPPZ@Y
MKS'2_CU>6L<^J7$UG;W.O)I+6D.J7CQV-B9M/^T2MG!.T8.%4 LQ7D9)'H?_
M  HO2+.V6#2=7UG0HWTY-+N_L$\>;V%2Y'F&2-L/F23YX]C?.>>!BY-\&]#5
MFDL)[[1[A)+66UN+&55>S:" P1^7N5@08BRE7# ACD5"=)7\RFJK2\C@V_:(
MO7M?LT2Z+)<0WZVUUKT+SS:5%$T+21R$HNY2S*8RK$!2,ECE0>OU[XEZII_P
MKL/$=I9V5WJ-U-!"?L+R:A9JK2A'F5H%+/&%!88&>0#SFM'_ (5:JK'.GBCQ
M FL+<M=-JPGA,TA:,1E&C,1AV;0N%$8 (W##$DV5^&MG!X5L=%M-3U2R:SNF
MOHM2@F7[3]H:1Y'D;*%&WM))E60K\Q^48&$W3TLBDJFMV<G-\4O$FI6"OX;M
M]"UN6RTA=8OYO/ECAG#23(D$'!*N3;S EQ\I4 CDXZ36/BI9Z=I?A2ZM=*U+
M5Y_$VT:=:62Q!R3 T_SF1U50$5B23VK/G^!^EOI_V:WUO6[%IK::TO[BVN(Q
M+J$<TSS2"4F,X)DEF8-&$9?-8*0#@=3=>"M,NKWPU<*CV_\ PC\C26,,) 0;
MH'@VL,<@)(<8QR!2DZ=]$-*IU.(M_P!HK0UL(]0U'1]:T;39K2ZNH+J\AB(F
M-L0)H@D<C.'#$@ J Q!VD\$ZUG\8+-=2O[+6M$U7PS-9:5)K4K:D("@M4;!;
M=%*XW#G*GD8YZC,.O?!71]3\,QZ9$/.:UMM0AM4OR7A9KH,7\T)M8J&;C:RD
M8X.>:X[0_@#J^J:EJ%UXJU:65+FPM=-:%M2DU!I8([E9I4+O%%M5P@3&UF(=
MRS,<8M*C)7V(;JIVW-1/&WQ#L=+\%W$]OH=Q-X@N+>)K21)4N(?-#32C@[<0
MPJ_/<Q^];/PC^).H>/)+]=5%C8W42K(NEI!<0W4*EF&9%F4;AP!N3*YR,UV%
MUX5L[[Q5I^OSM+)>:?;36MM&6'E()60N^W'WR(U7.> 6'<UD>$_AG9>$]6&H
MC4]3U:YBLQIUJVI3(_V6V#;O*0JBELD+EI"S'8OS5FY0<7IJ6HS4EKH<];_'
MB#4+RW@L/"7B&]%Y>7=A93(MJB7,]L[K,JEYQM \N0AGV@["!S@%;?X_:5J5
MC]KTG0M;UB.#3UU._6UBA5K")C( L@>5=TF8I/DCWG"$]USTFC_#72=#_L?[
M.]T?[+O;V_@\QP<R73RM*&^7D SO@<8P.O?S3Q=\ -3C22T\)W*VME=:6^G7
M,CZI-9S29EE<&;RXG69!YS8"B)Q\P\PAOETC[*3M:W]?Y?B1+VL5?^OZN>T>
M']:@\1Z#INK6RR);7]M'=1+* '"N@8!@"1G![$U?K-\,Z*GAOPWI6D1R--'I
M]I%:+(PP7$:!02/?%:5<KM?0Z5>VI\M?M_?$7Q)\,?A_X;U7POJ/]EZA-J;6
MKS>1'-F,Q,Q7$BL.J*<XSQ7P<W[6WQIW''C7 _[!=E_\9K[/_P""G'_)*/"O
M_8;_ /:$E?G!7V&5TXRPR;75GQN:5)1Q+2[(]._X:V^-7_0Z_P#E+LO_ (S1
M_P -;?&K_H=?_*79?_&:\QHKU?8P['D^VD>G?\-;?&K_ *'7_P I=E_\9H_X
M:V^-7_0Z_P#E+LO_ (S7F-%'L8=@]M(]._X:V^-7_0Z_^4NR_P#C-'_#6WQJ
M_P"AU_\ *79?_&:\QHH]C#L'MI'IW_#6WQJ_Z'7_ ,I=E_\ &:/^&MOC5_T.
MO_E+LO\ XS7F-%'L8=@]M(]._P"&MOC5_P!#K_Y2[+_XS1_PUM\:O^AU_P#*
M79?_ !FO,:*/8P[![:1Z=_PUM\:O^AU_\I=E_P#&:/\ AK;XU?\ 0Z_^4NR_
M^,UYC11[&'8/;2/3O^&MOC5_T.O_ )2[+_XS1_PUM\:O^AU_\I=E_P#&:\QH
MH]C#L'MI'IW_  UM\:O^AU_\I=E_\9H_X:V^-7_0Z_\ E+LO_C->8T4>QAV#
MVTCT[_AK;XU?]#K_ .4NR_\ C-'_  UM\:O^AU_\I=E_\9KS&BCV,.P>VD>G
M?\-;?&K_ *'7_P I=E_\9H_X:V^-7_0Z_P#E+LO_ (S7F-%'L8=@]M(]._X:
MV^-7_0Z_^4NR_P#C-'_#6WQJ_P"AU_\ *79?_&:\QHH]C#L'MI'IW_#6WQJ_
MZ'7_ ,I=E_\ &:/^&MOC5_T.O_E+LO\ XS7F-%'L8=@]M(]._P"&MOC5_P!#
MK_Y2[+_XS1_PUM\:O^AU_P#*79?_ !FO,:*/8P[![:1[7XS_ &G_ (R:+K%O
M;V_C/9&^G6%R1_9EF?FEM(97/,/=G)_&L+_AK;XU?]#K_P"4NR_^,USWQ._Y
M&2S_ .P)I'_INMJY*LZ=&#A%OL:5*LE.27<]._X:V^-7_0Z_^4NR_P#C-'_#
M6WQJ_P"AU_\ *79?_&:\QHK3V,.QG[:1Z=_PUM\:O^AU_P#*79?_ !FC_AK;
MXU?]#K_Y2[+_ .,UYC11[&'8/;2/3O\ AK;XU?\ 0Z_^4NR_^,T?\-;?&K_H
M=?\ REV7_P 9KS&BCV,.P>VD>G?\-;?&K_H=?_*79?\ QFC_ (:V^-7_ $.O
M_E+LO_C->8T4>QAV#VTCT[_AK;XU?]#K_P"4NR_^,T?\-;?&K_H=?_*79?\
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M;]@?X+QNR-X8N RG! U2ZZ_]]T_[6H?RO\/\P_LJO_,OQ_R/R=VT[;7ZO_\
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M\*[\1?\ 05;_ +]1_P#Q->E_V9<_]!>\_P"^(?\ XW1_9ES_ -!>\_[XA_\
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M+G_H+WG_ 'Q#_P#&Z/[,N?\ H+WG_?$/_P ;H \P_P"%9Z]C']IM_P!^D_\
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M_%T?VQA_Y7^'^8?V-B/YH_C_ )'Y1T5^KG_# ?P8_P"A?O/_  9W'_Q='_#
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M/^A?O/\ P9W'_P 71_;&'_E?X?YA_8V(_FC^/^1^4=%?JY_PP'\&/^A?O/\
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MP_\ *_P_S#^QL1_-'\?\C\HZ*_5S_A@/X,?]"_>?^#.X_P#BZ/\ A@/X,?\
M0OWG_@SN/_BZ/[8P_P#*_P /\P_L;$?S1_'_ "/>?#O_ "+^F?\ 7K%_Z *T
M:AL[5+&S@MHRQ2&-8U+=2 ,#/Y5-7QY]D%%%% '.WF/M<V!CYC4-%% !34;<
MN3ZD?D2/Z444 :VCW#L3$3E0,CVZ5J444 %%%% !6+K2A+J$@ &16+?@5Q_/
M]!110!1HHHH **** "K+1*VEV\A'SJ[J/H6.?Y"BB@"UHJ#=*^/F  K5HHH
M**** "FNBR(R.H=&&"K#((]*** .6B_U2?0=23_.GT44 %26\:S3)&WW6.#B
MBB@#7UA%;3;AR,F-#(OL0,C_  ^A-8\,C1RJRG!!HHH Z2EHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>eigr-20221231_g10.jpg
<TEXT>
begin 644 eigr-20221231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &^ Y@# 2(  A$! Q$!_\0
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M?Z;:VNM'49GAF02!IO\ 1HEC."A"J7ZG.,8KQ[_@J6NW]AKXB$X)\S3><?\
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M>OF3PS)_PRK_ ,%.];T-C]D\$?&:Q6_@9ODBBU13(_S.XY=IA<@(AQF^B]
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MI'BS1/A^]YIDFO:[XOUN6#%C9AV2."V29PCW$CI@[P0J$L$;^$ ^I?.&[!#
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M!;X9_%#4-/\ $NNWFG:=I6JI8:?>)JZ3A9)+F='M]@VVL5S<DPB(81L*?E4
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M4;'4?B/KD/@+Q3\-OC4GQ8\*W.N647B.U&G:9@6<DA69X'MX5:)5)&^.3?(
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M+$H;G!_=95&;Y\<#/3FOT3\GYLCI^OYT+&58<\#H!0!\#?\ !2/XO>"H=1^
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M^9Y(MC:$YY<6^7P!P^$Z9:OU'%OSS^')X_#_ #T%*(3G.<,3DD<9]/KCW]*
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M_#1W[$\FN^ XKS7+*PU6WU=1#93)++!'YD,C+$Z!R%\W>>/NJS= :YK]M/\
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M_P ZE&'+J.XRT8_X&*YS5?'GC[Q#\8O$_A/P]JFDZ;!I-O%<1_;K,N&S'&S
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MB!K-'PQ R._6C[.ORX50HZ =!4HC9< 'CO2B,@8H;;5KDJG%._*M=R,0A1M
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M]PY(+H5UMPORA1MI3;KNR<$]"3W^M3^72;#@\<]J:;3W%[.*2BD0-:JP9,@
MCJO!'T]*D:+<N&VYZ^N*=L;KQN[T[:>:=VWN/E79$4<.S &-H& !4P^]2 'T
M IV*&[E^HM%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***9)((P"<\G'% #Z*X_P[\6O"WBK5UTS2]1DN+N2.26WWVDT45TB'#M
M!*Z!)E!ZF-F KK'F6,9/3_&@"2BLIO%.DQZFNFMJ-JNHL,K:&91*1Q_#G/<?
MG6CYP/0<^E5*+CNB(U(5+\C3L244P2 L13@<U)8M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY4(.KO97]22BBBH.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O//V@-%&N_!WQ3;E2QCLGN% _O1_O!^J"O0ZH:YIZ:MH]Y92C
M,=S"\+#U#*0?YUM0G[.K&?9HY,93]MAZE/NF<I\&=877?A7X5O$8LS:;#&[-
M_?1-K?\ CP-=M'[]>E>,?LG:C+<?".*RF3RYM+O+BS=?0AR^/_'Z]GCYK7%P
M]GB*D?,YLLJ^WP=*?DO\B2BBBN0]0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&/B;0/#/B+1;?^VM4L+CR]<L=7EO!<F(QM()8I$3R\AEP5W#((R,\^ZJ^XX
M/O[=./UH =3)1N0T^FOVHV$]M3PWX ^9HWQ ^*GA^0@"/5_[0C3T6=2>/^ J
MGYU[BF.U>%Z6J>&?VM-6B9F"Z]H*7 ]#(CA,?]\Q$_C7N4>=QSZFO2S!7JQJ
M?S13_ \+)O=H2H_R2DOQNOS):***\T]X**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO(WN#^?!&00:ZA3GG%>'*#@W"2M8^NI5(UH*I!W31)129I:DU"BBB@ HHHH
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MY/5F.2:^'QG%D(MPP\+^?0_4\N\/ZU1*>85>7RCJ_O/KS5OVK?"%BQ2SAO\
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MU89# C!%?<87&4,7#GH2N?E6.R[%9=4]EBH.+)J*:&SFEKN/.%HHHH ****
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M)%D1D#*Z,"&![CVKD?C%9VUY\+_$J7UD-1@6PFD-O@Y8JA9<8Z'('(Z5\E?
M3XZ^+M/\7>'-"N;^34M%N)([%;>95_=JQP"K8R=O QGIQV&?HJ>#GF6'=>/Q
MP5GYKI\SX>MF-'(<;'"5+^SJOW?[K>Z]'T/NO=S2]Z@AE##&#Q[5,K9:OG.K
M1]PG=)CJ***8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IK'&*=37;;CZT (6QBH+FXC@C+RN(XU!8LQP% [DTZ28+&S-\JC
M^]7R9\>_C9+XDO9_#^B3D:5$Q2YN(VQ]H;H5!'\(_6O*S+,*>7474EOT/=R7
M**^=8A4:.BZOLC3^,'[2DUY+/HWA*8PP+E)M23[S'H1&3V_VO\CY^;=)(7<F
M0DY)8DL2>I)/)_&@YSGKV'L/;THK\9QV85\=5=2K+_*Q_3&5Y/A<GHJGAHI=
MWU; =2?RI::S;>V:7/M7FGO"T4F[YL8HW<XH\A"T4T,"Q [4*P;/K32;=D%T
M.I&P>"*6DSSBI4EOT ;EL\=N^,_F.]>H?"KX[:I\.IXK6[+ZAH6=IMV)=X%]
M8R3T_P!DG\>,'S*D(W<'CT(X-=F&Q=;!3]I0E8\S'Y=A<RI.EB:::?W_ "/T
M-\-^*-/\6:1;ZGI5REU:S+N1U/Y@^A'O6O&Q+#Z<U\)?"?XIZA\,M:\U2UUI
MD[8N;7/W@?XE'3</Y9K[:\-Z_9>)-*M=3T^47%I<QB2.1>A4]/\ /M7[%E.:
M4\QAROXUN?S;Q%P_6R.O:_-2E\,OT9L44@;/%&><5] ?)"T444 (3@9I/,!S
MCD XXYKGOB-XJ_X07P'K_B+[(;[^RK*:]^RK)Y9EV(6VAL';G'7!KRC3?VI+
M;4/@U>^,CH,D>KV]^-+7P^+H-)+<.ZB)5DV@X:-A)DKT#<<<@'O"R!NU.KR#
MP_\ M,>%)OAWX;\4^()SH+:W!)/#IZ)+>2JL98.W[N/=M&TDL5 &1S6MKW[1
MGP\\,_8#?^(XTCO[:.]MYH8)9HF@D.$D+HA55)XRQ% 'I-)7G7B3]H?X?>$?
M$%SHFK^(4M-2MI(XYH?LL[B,NB.A9E0J 5D3YB<?,!FI?C1\4I_A5X=TV_L]
M&77;N_U2WTN*U>[%JN^;<$8R%6P,@#IW]L$ ] W#I^-!..V:\G\-?'F'^U?$
M&E>-M%_X0G6-%T]=5G62[6Z@ELRQ7SHYE5=P#  @J#DBM.T_:"^'^I>'=5UV
M'Q'"FFZ2\:W<MQ!+$\1<X3$;J';?D!2JD-GC- 'H?F#C&3GI@$C\Z59-S8Q[
M]J\*\1?M$)/XL\-6WAN>PGT34]-U6YFOM1M+F-H9;./> RD*X4$?,-A/IR16
MEI_[3'@[0?#>AS^+?$NGQ:K>Z3#JKG2[6ZDMWAD+ 2Q@H7V91OO $ 98"@#V
M6BO/_$WQZ\!^$1IYU/Q!%']OM5O8/(AEGS;MC9*QC5A&C9&'?:#ZUW5K=PWD
M,4UO*D\,J"2.2-@RNI (8$<$$$<T 34444 %%%% !1110 4444 %-:G4C9H
MBN(EGC*.H9&X96&01W%>->//V9_#.J:7>77ANRA\/^)0XN;2_M2R%)EY'KM!
M/H/0\D5[20>U,>/<N"!US6]&O5P\KTY6.+%8&AC8<E>*:_%>AY;\%?BD_C2U
MN]'UR'[!XOT=C;ZA:D8WX.!*H_NG^OH17J,3;F^Z1]:\;^-?PWU)+RU\=^$<
MQ>+-+&7CB!VWL./FC91]X\# [XQZ5VGPK^)&F?$SPM!K.GML+$QW-KD%K><?
M?0X]SU[@@]ZZL53A47UFBK1>Z_E?7Y/H>;@,15IS^I8MWG'9_P RZ/U74[:B
MF"4'I2ALD\5YQ[XZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***0G&* %J.4[5!Q3M_M65XHUZW\-Z!?:I=,4@M8FE8\9X!Z>]1.2A
M%R;V*C"522A'=GC'[2GQ4D\.::/#FFS[=0NTS-(K?-%&<\>Q)QCVS7RHN=N"
M,8^Z!V]?SK3\4>)+KQ=XBOM6O6+7%U)YI_V00-J_0+A1_NUF?Q5^(YMF$\PQ
M$JE_=6B1_5/#V40RC!0I6]]ZR?F+2&EHKPSZ<2F&8>WYBK%I#]HN8H]ZQM(Z
MJ'?[JY(&3[5[-XB^''A?P#K7AG2;U+C69-8($L\5[L,9)5050+R,L.]=V%P+
MQ4)3O9)VOYGB8[-*. J1IRBY2E=I+LMSQ(2 KN[=:T-'T'4?$D_DZ793WT@P
M2((RV >A)["O1OBY\&XO OBG2-/TJZ:2'5F,<"7'+QOE5Y/I\XKT_P"(WA.Q
M\$^#M'\+:3K%IX:@O&*W%U<,PEN  !MRHSU8D\CH.>:]>CDU5U*BJ_8_JQ\_
MBN)\.J=&6%5Y5=KWT2W;ZZ=D?-&N:+>>'+XVEY"$N@,M'&ZRD>QV$\^U;<GP
MI\31PF=M*<,(3<F$2Q^=Y8(!;RMV_&2.U;GBCX7ZA\(-<T34-22'4]+$\<JS
M6L?R.%;<R%2#@D ]^?45ZO9^+="N/B]_PEB:W93:3-I(ABA2=6G\PLH\I8<[
M\GK]WJ0.]7ALKIRG.%6\9<VWEW]#'%Y]6IT:=3!6FN5MRL]6OL^1\X:9HMYX
M@U"'3[&W>XNYC\D:X&<<DY/ &.<D\5!<6S6-U-:R%3-"Y1PCAP"/<$@C\:]B
MUGP]J>@V^I6_A_2Y6UG4YF:^G@4%+%9#N6U0GCS,;=P!/0>M>/7EG<:;>R6E
MU!);3P_*T,BE2GH.@X]!V]:\S&8/ZKIN^_2Q[^69E+,)75E&UTNOFWY=B.FL
M"<8IU%>3:^A]&-93U'6O9_V</BF_A/Q -"OIL:5?R?NMYP(ICCGV#=,=B!ZG
M'C(SWI&9D^=3@KR,=<CD8KT,'C*N$KQKTWMOYGCYKEU+-,+/#5EOL^S/TCCD
MW[2O2I>]>:_ ?QZ/'7@>"6:3S;^T/V6Y;NS*!A_^!#GZY]*])7K7[KAZ\<13
MC4@]&KG\G8O"U,%7G0JK6+L/HHHKI.4Y;XI^%;KQQ\-_$_A^QEAAO=3TZ>TA
MDN"1&KO&5!8@$@9/8&O&++]EW5+?XC:3K#:E9_V##I=L]WIJN_[W5H+9K:.9
M1LQL"L&W9W9'W:^CV8+R3BN;\"?$'1_B-X1M/$NCRNVE71E$<DRA#^[D:-R1
MG@!D;\* /G*X_9%\11^'_ @2;1=2U+0M,GTRZM+K4+VVMW5IVE22.:W"R$_-
M@J0 1[@$/^('[*_C3Q%I-II.EW^BPZ.NB1V"Z;-JFHQ6UE.I8NT2*6\U6SMW
M2Y;!)() KZ@M]=TZ\LWNK>]MY[:,D--'*I12.H)SC_\ 72:;K^FZT'.GWUM?
M!-NXVTR2 9SC.#QT/Y4 >!^*OV;_ !#KNE_%VVAO=*23QA;Z/#9,\DJK&;2)
M%E\W"<9*D@KG(QG&*[GXV_#?Q#X\\(^&K70)].BU?1]8LM5!U"62.%S!D[=R
MH[#+$=NF:T+?X[^%+CP'9>,%FNAH=W?+I\4I@.[S3,81D=AO'6LO7OVE_!OA
MK7=5TW4%UB*/2KE;2^U%-+FDL[>1E5@&E4$#AA^1/09H XGQ5^SCXK^*5OXR
MU+Q=K6DVGB#6-*ATBQBTE9GM;.&*Y%R-S/AW+2*N2 O&<5DP_LM^()/#NHR+
M;^'=%\3)>V%_8RVVI:E?0SO;-(=ERUPQ;:=YQM7Y<_Q8%>ZZ#\4_#WB36M?T
MRQNF>XT2*"XNF9,(8IH_,CD1OXD*@\^U4S\9O#:_"MOB&TMROAE8#=><T!$A
MBW[ P3K@GD>H- '!>)?A#XX\=>(M UO6I_#]K=6>F:O87$.GS7&S-S%Y<!4L
MGS8Y+,0O7@'OD^'?V<?$VEM$;G4=+8K\.W\(YCEE.+MI6<R ;!F,@C+?>R/N
MUW=C^T?X/NM+U^[G&JZ9+HEH+^[LM2TZ6WN/LYX65%8#>I) !!QSVK6TGXV>
M%M:A\'RV=S-,GBIY8]-(A/S/&I:17_NE=K Y[J: /"]8_9+\171\.RDZ%KGV
M;PU:Z%?66HZC?6L2O"" \;6P4NASRK@?A7TWX9T4>']!TW3E6*-+.UCMUCA+
M;%VJ!A=Q)(X&,Y(]:YJS^-'A:^^)MWX"BO)/^$AM;?[1)&8R(\;5<J'Z%@KJ
MQ7L*[D-GMB@!:**1CM[9^E "T5C>*/&&C^"M%N-7UR_BTW3K?[\TISWP  ,E
MB>P )-6M)UJSUS3;34+*4S6EW"D\,FPJ61U#*=K $$@C@C([@4 7Z*Y3P;\3
MM!\?/_Q)3J<\+1>>EW<:/>6UM(F0,I-+$L;G)'"L21D] :ZK- "T444 %%%%
M !37IU(W:@"&;]XNW.":^?\ XC:#J'P5\:2_$7P[;&;0KLA?$&EPX"[<_P"O
M4= 03DGU))X+$?0;(6/;%5[VS2\M9(9XDFCE4QO&XRK*1@@CN,=JZL/6]C+7
M5/='F8[!K&023M*.L6NC_P BCH&NV'B?1[35=-G%U97<:R12)W!]1U!'0@]#
MQ6I'CS#@FOG.Q>?]F?QT+*9Y6^'&N7'[F60D_P!FSOCY2Q/W#S^G<<_1-O*L
MFUU(<%1\P.?Q_&GB,/[&SB[QEJG^AG@,8\1%PK*U2+LUY]UY,LT4TMBEW=*Y
M#UQ:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^GDO^&/?H]9A\8?"SPC:Z9>QQ:G8:O%+?QR3!)8R2[/,26&26<D]22WY\?\
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M_!Z7MQKSF!@%L;B2T=)X<$\!W5)!C^*5AQW^FQ\^<9YR-V<>W%.V_,3G]/\
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M/N6**;N'% ;->;<]T=1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.FQ^,>(E=<M"@GU;_(N4445^E'XH%%%% !1110 4444 %%%% !1110 4444
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MF?2]%1^:.>#3E;/:O#ZV/LQU%%% !1110 4444 %%%% !1110 4444 %%%%
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M^1F.2W.>OMV_*H>=V>U-7.#GK2YKQW9/LXWYU'7^KB@MMQD\\M@GDGJ>O?\
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MB@ HHHH **** "BBB@ HI&8*,GI3?,'7MZT /HIJMGC!!]Z=0 4444 %%%%
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M?[JYSGN.*Y)X6M3CSR6G^1ZU+,L+6FJ=.5Y=O+^D=K1117(>J%%%% !1110
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MKJ'@^ROH=&N'9=4LX)GDB7&TQDJ22 /GSG@94#K7=AZ.#QU6-.+=.3^:_P"
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M]E_PAHA5KE+K5F4[O],E^7_OE0JD?4&O3M-\/V&B6JVVG6-M96Z](X(E1?R
MK25/\YI=M>[1P6'PZM3@D?*XS,,7CWS8FK*3]2)?E(!(QZ5*.M)L[THSGVKN
MTV1Y_H.HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD*D*=F_! /...E-1P-1I<TH_)-?H*4LVHIM1A.WFT7?$W[37@71+6?[#J?\
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MCAB4*J*.@  X IXC&SQ$$IK71?)7)P>40P593I2]W5^=W8MT445YQ] %%%%
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M/_0=UG_P*'_Q-'_"&G_H.ZS_ .!0_P#B:Z%6#$CTIU '.?\ "&G_ *#NL_\
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MG_P*'_Q-'_"&G_H.ZS_X%#_XFN@259,8.<C/4=.QI] '.?\ "&G_ *#NL_\
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M9_\  H?_ !-'_"&G_H.ZS_X%#_XFNCHH YS_ (0T_P#0=UG_ ,"A_P#$T?\
M"&G_ *#NL_\ @4/_ (FNCHH YS_A#3_T'=9_\"A_\31_PAI_Z#NL_P#@4/\
MXFNCHH YS_A#3_T'=9_\"A_\32'P:1_S'=9_\"A_\3724C<B@#C]8T&#1]+N
M+V[U_6([6!/,D9KH< >GR]?;OT[U+X#T2?3;&6]OGFEU/4'\V5KA]SQJ!A(2
M>^P9!]3D]ZOZ]H<^MWFFQR2H-,@F^TSQ9.Z:12#$I'3:#\QYZHO%0^+-6FL[
M.*SL&']JZA((+0==AP2TA'HH!;GJ<#OF@1D3:2_CC7FG%Y<6NGZ2YB@EMW"M
M-<;2DKYP>%4[!Z$L>JBM?_A#3S_Q/-8'_;T/R^[6IHNDVVB:;;V5H-MO"FQ<
M\D^Y/<DY)/<DFK] '.?\(:?^@[K/_@4/_B:/^$-/_0=UG_P*'_Q-=$6V]:3<
M*!G/?\(:?^@[K/\ X%#_ .)H_P"$-/\ T'=9_P# H?\ Q-= ) <XY(YP.:59
M W3D=<T <]_PAI_Z#NL_^!0_^)H_X0T_]!W6?_ H?_$UT=% &'8^%S8W4<QU
M;4[G:<^7<7&Y3^&!6VN>]+10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !37[?6G4R0,5^7&?0\9X]>W- 'S6K-)HZ>-%O
M[F7Q;_PG7]F>6MX4 A_M(VOV39G:4%M\^,9YW=J^DD_UIXQ@?Y_E^E<W_P *
MS\-#Q)_PD']CVC:SO\PW;)\Q?&TR8!V[RO&[&:Z58RLF<_+C&/?N??\ ^M0!
M)1110!3U:ZBL=-N;F?/DPQM(^U-QV@$GCOQFOGOX0>.E\1?&XW]YJER][K>A
M27!TR02!++$Z>3!M90-RQ#+-TWF3!((KZ.=2PX.*S_[!L_[<_M8V\?\ : @-
MJ+C'S^46W;,^F[G\30!H*X;ITIU-5<<^V*=0 5Q'QMU!M+^%'B>=-5N-%F-F
M\4-]: F6.1\(FS!!#%F"@@@@L""",UV]4M8T>S\0:;/I^HVL-[8W"[);>= Z
M./0@C!YP?PH \B^!376E^,/%6D:EILWAB]^RV5W%X>-^U[!'$1(K7,<K,>9'
M5E90!@P@G);->U5SWA/P%H7@G[5_8NF6U@USM\YXD^=PN0@+$EB%!. 3@9.
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M[.5XW=?RKIXU89+8S[4 /J"\94MV9CM506)QG@#GCOQ4]-D4LI .">X.,>]
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MEC$>[# ' XZ=ZZU%*<<8[8XQ[4 /HHHH **** "BBB@ HHHH **** "BBB@
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MP_?:79O=0K-+)/%J<<212E&=<O"ZKG+$$$ !%!->UT4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>eigr-20221231_g11.jpg
<TEXT>
begin 644 eigr-20221231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '& VP# 2(  A$! Q$!_\0
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M-H SEB/S..@]_8T 345&LO3(P2<8SS3STZ9H 6D)V@D]*A6Z![8XSZY],>O
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M4TV\TB\UK1O$WB[5=^JI'*DM_:F"X<Q3,8H)R?LJ;0<*VV)R*ZGP3\ _B/\
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M"XN'DE>-HX$+12,0K2Y0J-RMYS\-_!GBC5OVYOC+\*U^+OQ$M?!6G:99ZA'
MWB&:ZN4\Y(9F@BGN/,,,8,C+O0"?:J8F&&W^IZ;\*?%GQH_;(\/?&+7]!U'P
M9X-\&:/)9:!9ZE=1?;-4N90ZR7,D";_(B"3NNQV60E(V(7YE&)\*?!OQ+TS]
MO+X@?$S4_A;K6E>"_%VE6FGPW=UJFE/-9R010QEYH8;R0F,F-^4W,,K\O)V@
M#/V7O%6O_#[]LSXP?!"\\7>)?&OAO3M/L=:TR\\5ZF;^\M7>&%IHQ*R[F1O.
M3"DX7R\X+,S'ZH^*GC^'X8?#+Q9XOG@6ZCT+2[G4?LS3>5YQBC9Q'OVMM+,
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MU'2_MFB^(/%$6IVEQI\Y"?:+>*\N84N3EI6";I<H(<J3DFM;XD_"CX@_"?\
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MR*H5BC#<T3DKC@$FLF_^ L7Q"_::^%?Q#\*?".Y^&S>'[Z[O?$FJZE'969O
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M^$]W\-O'/@J\T6XT[4KNYBUZ*^LY["^1C&$";)O.#,"Q :(+M7E@QV  O_\
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M7P@\"^*=1C@@O]<T*QU*YBM5*Q+)/;I(ZH"20H+< D].IKY<^*W@GXG>,OV
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MT[=.@I3"&&&^<>_?Z^M2T4 1>3\P(; !SC'?U_S[TGV<#OWSWZ^O^>W%344
M1F'<V2V?S_Q^M((< #<3T[^E2T4 1>2=I&[KW[_S^E2T44 1^2O'L,5)110
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MYAM^4#BOJA/FYZ5PXJA'#U'3B[GN99C*F.HJO.-KW_#1_B24M%%<1[ 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2'I2TE '%_$[X7Z9\4]!@TO4Y[N"&&Y6Z2
M2TE$<BNH8 Y(/9CVK+\(_ S0O">N#6GN-1U[6UA:W35-9NC<W$<;8RBDX '!
MZ#/)&<'%>C[?4T;:Z%B*T8<D9:?YG!/ X>I4]K.%WI^!YSI_P1\*VOP_A\&7
M%M+JFC0RM*/MLF9?,,C/NW*%P06(XQQP<UE>$_V<?#WAC6-,OY=1UG7CI@Q8
M6^LW?G0VAXP8U"@ C"X!R!@8 (!'K!B/F;MW&,8_&G!*7UBLDUS;D2RW"2<7
M*FKQM;0XO3/A?I&C_$#6?&,+7#:KJ<$=O,K./+54"C*X&03M7.2>E1_$#X5V
M/Q"73)I=2U31M0T]G-MJ&DW/DS(KJ Z9((P=J]L_+P1SGN-AYY^E)Y9*X+9_
M"I]K.ZE?5&WU2C[.5)1M%ZV\^YY6W[.OA4?#^7PA$;Z"PFN5O)[J.Y/GRS *
M&=F.1E@HR -O/ !P:G\:? O3_&7BF/7TUO7="U!;);$S:-=BW+QA]X#':3UQ
MW["O3%AVY /RGM2^5\N.U;?6:U[N7],YY9;A90Y.333\-O,\FOOV=],OX;"1
MO$OB:+5[2&2V_MJ+4?\ 3)H7D:3RI'*D,BLYP,9  &378^!/A_HWP\T)-&T2
MV%M:(69@V6:1V.6=V/))_+H!@  =3L[=*#'^=92K5)Q]FWH:TL#AZ,U4IP2:
M.)\'_"W2?!7B/Q)K%@UT][KT_P!INGFDRH;+'"  8&7;\ZM:5\.],TGQKK?B
MB*6>34=6@A@GCD8&-5B7:-@QD$C&<D]*ZSR^<]Z9Y)YR0?PINM4DW*4M;6^1
M<<)1@DH05D[V\^YYI8_ 'PM9^"=1\(R)=7VC7-T]W%#=2[C9N0 /(( \L Y/
M'4LQ.=QS4\,_LY^'-%\06VM:A>ZMXFU&SV?9)-<NS<?9MI8@IP.[9PV0" 5
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M3F^9[G13I1HP4(*RN_Q=R2BDS1FI-A:*3-&: %HI,T9H 6BDS1F@!:*3-&:
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MH_X7A\1_^A_\4?\ @ZN?_CE/_5C$?SH/[+G_ #'[,^8OJ/SH\Q?4?G7XS?\
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MO#XC_P#0_P#BC_P=7/\ \<I?ZLU_^?B%_9L[7YC]F?,7U'YT>8OJ/SK\9O\
MA>'Q'[^/_% YQ\VLW0PWH?WGUH_X7A\1_P#H?_%'_@ZN?_CE/_5FNU=5$5_9
M<[)\Q^S/F+ZC\Z/,7U'YU^,__"\/B/U/C_Q0!ZG6KD#VY,@'3'YT@^.'Q';C
M_A/_ !1G@8_MFZS],;\],?G1_JSB+VY_P?0G^S)7:YC]F?,7U'YT>8OJOYU^
M,W_"\/B.<X\?>*>^,ZU<]NIQYF>.^ ?Q['_"\/B/_P!#_P"*/_!U<_\ QRE_
MJS7_ .?B'_9D]/>/V9W@=<#\:3S@>!U],U^,_P#PO#XC_P#0_P#BC_P=7/\
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MZY4@_3G\ZZZF.H4Z4JBFFHJ[]#DHY-7=:G&%TY:*ZW9\T:5X$\:ZQI+>!O\
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M'!.L9,BM"C*N5(V#@# P?NG/Q-KB6%KK>IQ:5.]UIB7$@L[B;/F2V^\^6[Y
M;<5 YVCN.HQ7VGX9^/7@*VO_  +J=E\5+KPOX?T32X[2Y\"6_A^>6"=]O^D>
M8\:[&9CT8J<'+ Y8U\XZY^T3XOF\/Z]X1T;4TT_P->R7B0:.NG6T9CMI9'(C
M8[-ZMA^SG&/3BO.RUXSVLN:+?JY+\T]?P.;#^UYFSK])_8K\::NNEK'K?A>&
MYU:PCU#3;6?4F2:\C:/S&6-/+W%D4KNXVY8?,>2.8\<?LU^)O O@B7Q1+J6@
MZS96UTEC?0:-J*W$UA<,0OE3# 7<'(0A&8@GN/FKU;PK\</!6F_M*?#_ ,67
M&ME=!TWPC;:5>7GV6?"7"6\B-%MV;W^9EY *^]<$OQ/T"'P'\8[9=1+:AK7B
MBTU33K=8Y5%U!%=R2LQ;;A/D(X?;UZ44\1F/,G).VGV7U>OX:EQJXB^I);?L
M;^-9K6WBDU3PW:>)+BR-]%X3N-2V:NR88@>24P&(4G!88P0<$$#$T7]FS7;[
MP79^)M7U_P -^#K*^FFM[6#Q)?/:S2O%NWC'ELH.4<8)!RN" :]U7XO?!^'X
MU)\:O^$TO8M6:Q+S>$1I4QD:Y-N4\M+K"H<@KC.0<'G!P,[X2_&[PI%IUPGC
MCQM8ZGX7UF:]O[OP-J>@W%X+"XEF:2)8+@(ZMR0V20JDDA03N&7UW,.6UGW^
M%[]5M_P/,S5?$=?R/ECP3X7N_'?BK1= L9(8+O5;J.SBDNBR1I([;5#X!8<_
M[->K>)_V1_&'A?PKXCUJ35/#NH/X=4R:IIFGZCYMW:QC)WNFP!04'F $ABO0
M9^6N;^ [6LO[1W@>6SMVM[-_$5N]M#,YD>.+SAM3<.I5<<GTS7LWB?6OA5\-
M5^-EUI?BW4=:\4^)(KS2ET*XTUXOLCR3,9/,E*^7(HD!8-D8C&,,:[L=B\73
MQ'LJ%UMT\S:M5G&IRHX#P[^R)XJUW3="N)_$'A30[[6XEGL-'U75#'>W$;<J
M4C5&!W C SGG!Q6#X7_9VU[7M#U+6-3UOPYX/T^QU1]%>?Q#J7DJ]XAQ)$IC
M5_N=V.!CD%ADCV=?'7PC\8^.OAQ\1M2\=S>&]2\.Z?8PW/AU?#T\@,EJ2P42
MQY15;)*#)&W:>,8JO\-?CUHEUXF\0:YXF\<V=CX9U[6[B?4O!6K>'9KV.6TV
M;(G1XPZ"9P$5ANVY0L=P 4\/US,.5NST_NLS]O7_ *1D>'/V3-%UKX ZIXL;
MQKI-OKD.HR6L5T^KI'HX1)5C D;RRV]\,4Y^8/$>,\>#?#C2+/7_ !]X8T[4
M+?SK.\O[>.5'.S<CR#(!..#D]/3C.:^@O"_Q/^&_B;X%_$'X>:KKDG@FWU+Q
M%)JVFR2Z;+=J8&E21(@D>1E1"%89PNX8SBO._#?[2'BW4+SPCHWBC7UD\*Z;
M>V+FW>PMP8$@D7:5=8@V5V#OS77A)X[][&5W9WUOMY:%TIU5S<R*/[0W@/2O
M!_Q^\2^$_#\,.EZ9;W4$-O#<W9\J(/!$Q+2RL=HW,Q.6'6M37OV7-<TOP/K?
MBK2_%?A#Q?IVC1K+?)X;U4W<L*'G>WR!0  S<L"0I(!Z5W'QGU#X-^+OBS>?
M$1?'LWB"WO-1M)KKPO#H5W;M-;KY4,X%RY09$:,V/EZ8[UV.N?'+X;:7X+^+
MFBZ;KVB,GB+39HM)L]"\+2:;'$JQ%42>0H&:1S,Q#-\BA"VY-VP<_P!=Q:IT
M8TE)M6YO=?3Y$>VJ1C#E3OUT/+-$_8Q\9:W_ &(!KOA:SEUS3X]1TNWNM29)
M[Q&C\QDCB\O>6C4KOXVC>N"><87C+]EWQ7X)\%:IXAO=2T"Z.DF!=5TK3[_[
M1>Z<TI 59T"[5/.>&/0D9'->@:Q\9_"%U\4_@7JT>L_\2[PYI5C::M*()QY$
MD:IN4KMS)@@_=W#U!'%8NG_%?PO#X1_:&L9-4 NO%6I>?HJ_9Y?])7SKALDA
M $XD0_/CKSD\TXULQNFT^G1_S?Y:E>UQ'4ZWQO\ LKWOQ$O/A])X7N_"GAO[
M=X0TYX;.ZN%M)]2NEB=[AXHHT+.RJT99\ C<.3SCR;P7^S7XE\6Z-K&K7>J>
M'_"NGZ5J+Z3//XAU$6ZM=H</"I56^93M!S@'>-I;G'M^D^._@Q?>,OAAXUU/
MXAWEAJOA?1+"QNM*BTNZ833PQ911($^7#E@V0593C(R:Y.3XF> ?C%\-M4\-
M^*O%5SX%EA\77?B&S=M*EO3-!.93Y)$1XD7S6#8( RF-WS8Y*6(QU.+IV=EU
MY7H90K5XZ=/0@^/WP:MI/BUX5\+VTWAKP)<1>#K.:\DU2XBT^V^T!I$DRZ#Y
MY"PQ\H)."1D D>6?%/X)ZO\ "G3]#U*ZU71M?TC6A+]CU/0+IKFV8QD!P9"B
MKUST)SM/<$#W75OBO\(-?^-&DZI>7$5WX=M/!,&EZ;-KFDO>166H1E]GVFW4
M+YI$;%3M#*7QM*D!JXWX_?$[PQXF^#O@7PSI&O6>M:KHUQ/)>R:?I3:;:$R*
M908XA'&@0&39G"L=I.T%C75@:V+C4I4W%VZZ,UHU*L7%26AI?LKZ1\,/B=K&
MF>#M?^''VO5TM;B>?7AKMU'YQ7>X'D(5 ^7"_>/3/M2_"*P^&GQ?\2>(I;#X
M13QVFB^%[S4H] MM>O;F2_NEDA\L*XPRDAF48#9WY[8/$_LI>/\ 0?AK\6(=
M;\0WWV#3$LKB%IQ!+*-S1':,(I/.?2JG[/GQ"L?AJGCZXN=5N-'U#4/"=UI^
ME7%N)%D-Z[1-"J,@RC94X)*J,=36V*P]>,ZWLW/I;675Z]15:<^:3C<]%^,G
MP=\(K\./ &L:=X8?X4^(]>UDV,NC^(-4D:,0@L/M4HES*JH1'E]J%1*Q*G<I
M/ >*OV8?%_@?3?&&HZ])8Z78^&WAB:XG$^S47E7*+:,(B)3DJK9*A"PW$8..
MI\3?$;PA\:_A1X+C\7>(%T[XA:-J,>GW>K36L]Q/=Z6TF/,)B4>84#YP6#DP
MRD$&0Y['XY_'_P !_&CX7^(?"EOJ,^DOX>O[:X\,&=9V_M.WCA\IUE;;*=S
MS[3(8R=T6[:5<UST*F.HN%%IVYM=&]+]Q0G6CRJQ\D5^A7[!'_(DV9[YE_\
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MUU:,1W2+,@&,-G\\YSG\:]# XR6!K>UBKG30K.A/F1^+G_"O?%7_ $+6L?\
M@OF_^)I3\/\ Q6?^9:UGMUL)B.,= 5('_P!>OV*_X5YH?_/E%_WR*/\ A7NA
M_P#/E%_WR*^C_P!9ZZ^&"_$]+^U)=8GXZ/\ #SQ3)][PSK#CKAM/FQ[<;<8I
MW_"O_%?RX\,ZQ\IR/^)?-P<8!'R]:_8G_A7FA_\ /E%_WR*/^%>Z'_SY1?\
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MHH **** "BBB@ HHHH **** "BBB@ I*"<#UJ$W(7J-H_O9XI7 E)VC-0M*
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MNHYF883$FZ7C&?XOPY]ZO7TQM;811PF-9.MOM. <'IQUR#R<>M'M(?\ /O\
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MN\DM2T4\C22@Q>9EY&9I)F B<<21D;E #=!RWA_XG:UX86=?$/A&Z^TR,;E
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M7)SR,@8K6M1EAZG),YZ&(AB*?/ FJIJH+:7>!<9,+XST^Z:M9/I575@6TF]
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M:>21 %G;IM9D5'.,;=Y&#T6E%V]W4#MYKBY;R%BM--GN3<YD:XM3^ZVQ@(X
M)(;!R.V 5)^8,.2BU#6M-\3:3;:/XAAUBSO=,DU&<20&-&6-BNX3C=S*S,S
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M_P#ZP4=N0_9G=[4;O:OQE_X7_P#$?!(^(7B@CU_MRXQ_Z'P?8XI?^%^?$C(
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M$,1W!BK9 &.1@CH.F#P*_0#]D7]KF/QFUGX+\;WF?$H'E:=JTYPNH =(I#@
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M*&,2K@95BJ@F_+!_:ZV/BBSA6<RRRJK6-NT$UW82PE8WDD1R_&$PQ&5R3LR
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M(EVG!12X&%^4'&<8K_V=<ZAXNAMM5U1[G4HM(N5.J%(X)(MTJQGRP)&(5LL
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MB8Z_MM>Q)1114'GA1110 4444 %%%% !1110 4444 %%%% !1110 4GUI:*
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MB"'3)(K:+S$5L.075,;AU;G-1]0RSVBIZ7]7_F7_ &GG/(ZG,[+R7^1SK_%
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MY76X!!R <YSGO5[4/V1?VD]7U[^W;[P_JE[K@(8:G<>(K5[@,, 'S#<[L
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M]H&IVT"[YIK66-%R!EBA &3[U4=T3+6+/P/@QY,7^Z/Y5ZC^S&0O[1?PW/\
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M=_ED8\O.)-@?$H KPK6/V+/VA?$6H2W^J^%+S4[^7&^ZO=<LII6P  2SSGD
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M_P#A6S10!C?\)AI'_/W_ .0G_P */^$PTC_G[_\ (3_X5LT4 8W_  F&D?\
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M)=I/_/X?^_3_ .%;6*,4OZV#^MS%_P"$NTG_ )_#_P!^G_PI/^$NTC_G[/\
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MVO;R98B-[*B(Q"@D L0"!DCDU\L>$KCXCWMUI]_KUIX;L]+O%D>?2X?.6\L
M?]4HGW,EPZCY779&!NR"V*TC%/<ERL?HA_PL+PM_T,FC_P#@?%_\51_PL3PI
MC)\3:,/7_3XO_BJ^+8SMP"H_6HY,J7. PQT;./Q]JI40YC[1A^)GA.XC62+Q
M-HSQG^(:A%C_ -"^OY5+_P +#\+=O$FD'_M_B_\ BJ^&KR/5$\16JP/:_P!B
M""47,<F?/WY3RBF.-O#?G6@W&" !^=:>QOU&M3[5_P"%A>%_^ACTG_P/B_\
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M(68XPHR_)Y''O7YL-K)TZ&]O9='\ZPN+J/3]2BCL?E@PH$394.6(./G;:G3
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MHW2-F"CC'7O09RM(J6EE]E*A)) R,6$K-MW@^A.,_I71?V;%>6Z2P3!)A_K
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MCB;KC Q^0J\/LS/$[Q/HRBBBNDY HHHH **** "BBB@ HHHH **** "BBB@
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M;RF23 0+]FDXX3+9Y+-P1P<XR=+A2Y>PFU32XAI36LA=M/D66#YEV,]S)GS
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MQ9(]K@;'"@G 8G+DYQ5*ZE$T,R6>E7=U:7DD-M=:5O:: Q.BJ9 \9D2-AF/
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MM(AD9HIEE+A0A)3*D9[>]>.Y.0V3N]<D>W;V[#_ZU!.[ .& S]X=\ 9QTR0
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MR6;/]GOVA"&*(H_RAHW C1A@C<%X!!)!+&L[4+*\23[?:M?,\<WE-/'F;YE
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M3<HC1K_:=P0"SG:"PR 7^;KGK7<:II.F#1[16"RV$2ET:&YC ;R@ X48(PH
MX4 CDC%>@_ ']F.\^+W@W4O$=UXB@TBYFUF^B:S@M#<1IMDP"',BELC':OJ^
M&\91P6*E4KRM&S6U]?D?!<8Y=B<RP,:.%CS2NG:Z6GS/']W0$9 '&0/\@5OV
MOC_Q!8VFCVUOJ3Q1:1.UU8[43=#*W#-NQELCC!S7T;_PPB__ $.R_P#@J_\
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M\B&...)R22_EA=I8YZD'OZU9\1?'3QMXIT\65_K(:U69+D1PVD$6)4;<KY5
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MO#@MF#B,7/E'S=[J@MIN#@<CYAQ[=:_1FN66YX6,_BCJ***DX0HHHH ****
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MA:^)[V.V62.50(+B"SF1F-N48J5E+!2Q<E>J\H-N.-W9:YI<_BJXL(+^PNM
MN[FUFL8?)N#-M5PK(Y=<(I4!L*.2"V2>!7FMC)K5EI\8DE^R3:;--9FVDC,3
M/)'D@L-C!F=/G&X':Q4CJ:Y*LI4U>QV4>6I[M]232_#=U+>VD&G1"XL+*4P3
MK9621W#+)@R( A+!W8JSL7 .X]=N:V]:\92:U9M#+I]MJXL8VL-/O(;AKJ0(
M3CS697"#JB[FP"-Q5P!7"WFGM->WU_91"UM[B?[.\S; D.6<X,D@4%N<9;H,
MJ >M=OJEGH_BAK:Y^P^1IS!;J6..Z9!<RE2)%9G?RSM.YNQVG "X!8IRYU=[
MERCRRNS'76=8N+&%;2]^U>9.DEK)<W"02," &#XP2P W%1\O)P>,G(N;$S+Y
ML>][>R19)8)'5FM99(V;8@)\P!@PRH89P2%.,!]U_9DUE),^J?VA86YA_P!%
MCD8JQ13Y89F54+GD##'H,@]*N:YJUFMV;:XN?M%Q;H\;+-<YE1E#>8PC'R,"
M2/5\9*KN&1G+VDE\)I>*V9'H6DW%A+IDBN\QU?RY$M]-B13:.N3YGEC 9QT!
M;D\YSWSK[3[JYCGAAFNKQ_,2[NTV-YJR(.6EQ'\J@@]N#SSS6M?:?%J%O;W-
M[(9K:S7[,C2.5@6V<APBR+M<;@I.YUR&(!QD"M2?PG;V^BK=W,QU339YC=76
MEJS&\$0/R*0V_$H)P02,XP,DYJXQ9G(H1V^KZ;I<MS8+#>7^8KJ6260227*2
M*S+MC1=TAV97(8G!/ !R/3M UE=+\/C74M8%FF$EN+6QC>2.%C)DA0[*!DDY
M)*@' RW?E--U2]UC3;31[>WM;G2U4S6S6RO'BWC8$*6,N"0RX8E&P!G:>*K?
M\)5KWB#4!JFE"+[;=3F6*..(W!5#M4PN Q0$*HSO ;!!'/%="C;H<[M+=G4>
M*[:]71[/7M*BATR3S<VJW5IYMU+*_52H0^400=K$L.?FQQ4<-G8^)=:CU:PT
MFYAUNUNMEU?M<QNRR",JNZ'=U ()3:A"X /88S>-?$V@WUE%JM@^C:3/="$Z
MGB2XA64,2\DCR?. <[%)"@<_,0 :GUKQ+J]SX?E;2K(:U$DK/<:OJF&@3=G"
MQ@>7YW8;U#8(_B(--7C'F:,;%^XNKBPU32?(TNSC!DE5K[69!-).I(#JKM(2
MBDDE1YFWY@.O%?8_[#=Y_:'P9O[A(OL\<GB/4R(=^_8!.1MW #T]*^')/%!T
MCPK)I4L<$^LWX^U7!PI^RD#:$.Q5W*!][GC(ZU]I?\$^[=++]GU;=)8YXX];
MU$"2)2J,/._A!)X_&KHS3YD@Q$>7E?R/INBBBMSF"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *S?$G_(NZI_UZR_\ H!K2JMJ5I_:&G75J'\LS
M1-'OQG;D$9Q^-5%V:;(J)R@TC\S/AK\/-7^)FO6ND:-%N=E#S7#@B*WC&,NY
M[#T'4_6OT#^%WPOT?X5^'8]*TM=TG#W5TZ_O+B3NS'^0Z ?B:=\*_A1I/PG\
M,Q:3I8WR'#7-XZXDN),<LW]!T _.NT\ODGC\J^BSC.*F8R4(NU..R[GQ7#G#
M=/)X>WJ^]6EN^R[(=5+7?^0'J/\ U[R?^@FKU4==_P"0)J'./]'D_P#037S9
M]RMS\FS=B\LTB#2,IP&CMU/ZY.34C0QWC(GEEMG)/S;PO<]!FB''DI%LF$>0
M3<*X'YG%275L;H.X#/(#A6!905[C<<?RJCZ"-T17GE>65\PR3\JJG[B^G)Y.
M>.]59;$Z;9;I9HC&VX_)M=5].,$_K5V[9I+*V@DBA+*NXY&[<>WS<8QSVJ+4
MF:%MEU;(L6T(3<+M#;NZCY<XIZEQYD0:>Q\Y(%G+6S\O.<;@V,8*^AZ[LU<O
M+>*STM9+=HS'L)ECC@8X ; R!@G-4[J,Z3#:S1+;1PR,"R",HS'M@Y.0/0XK
M8GLK.Q6VDB.R6\^4,%7"*#G##%5KV$W;8IZ?)$?ML,:R,CX:/S'VJP(&0  ,
M_=_B]*==74370'RR3[_,1#,1O7;G"\\]2*K7L,[6\Z;XU+G*ELN=H]1QSU_.
MM&X6.#3X=\R*\, &7@&8#_O]Q[X%5ROL-6BKL@.FI+^YEM8K25BP.[:'[_,P
MQ@@Y'.*;%K5I#J MW=(I<[DGDB=0Z]R"/]8?H*DEC\ZQD\RW:2\,B.ES''G*
M?Q#(8@@9/&:-41M+W0RB&5HR!CG:I.=V!SN/'0YZ]:DSZV(3:7$DMU#;R[0$
MW,8[=L"1NA;CO@9VYICQC<HNVECX&2TOWF SD[<9^@Y]J2#2Y4W6R"7#)YC^
M7$SJ$/7:%'&?8\436J6]N&G=($0@$;6+1=\$8^]V['_:H-+Z\HIOIY!<0VUM
M&^$5HY!E%93UR2#\U6M,U Q6;0RP-:SK(0A=5Y[[PP(!XYS5>&WDDMXX9;DW
M,3*HEV6[Q@CVPQP??-0R6OEPS0:G(YT_Y@HA(41D <*",D$'&,]J5QJS)H;K
M;?-+"P<7"*Y5F*M,0/G(.W'3:>2N<U!8WC/!<VTJ)>&.0ND+1J"HR2>,]RPY
MZ>]6YM)FGA0VUS#=^=&93"Q,,G ^4)$3R0,#!;M2LX16L;F.$SL=S2-L23:<
M\9.,]_;GIQ3)YH]P-FES*#<@7###Q01JW[OKR& Z'/3':I'AD\/Z;)* R;I1
ME9#O8@+VSGJ2!^M5;>6"_C=+"6W$P& T:J?E]B/\14,=U<ZEJ8WRV\T;(8H+
M:0D2-C 9\]_E8@8SG&:?(^PW&+V8Z.6V\Z/B%+6 >8\49 SR3\__ 'T.I%/E
MDMX[ZW$ENJ.828Q%,#M ).3C_>QG_:-7EB>0?9UN+;A_+6$HA##+#"XS@]>F
M!S[5EVT;ZA#+=7L[/Y;.'+R/&RL.H P,KTX]J17,BS]LM]0L5FF^2-9&2*-0
MTJ%0P7?\@/.XD>V,'!XI]PL<$+RWEQ]FL4P[FWA502>^[.?TI/L);3[6UD=;
MV(2EHGE1B57!8 _-V)Z]L8&!Q3HH;>.WDDAMX;8,I7?( ZR%3C;\S'&0"<X[
M'\37L3?2XYM#@A66*XC6YD;9(\]U(Q;Y>  5QCCYN_I52ZCAM[PI"%BEQYI5
MF:Y8MU4[6+$'&X_PCGI5R:]20>6BR/;VX6)BIP)23SR1Z<5GKI3,CG<UM JR
M>6UC((0$3A3B/"EL #:0>_/-5'05-O[1I:?=3M9Q+J"+;1R$>5)/((Q-G[OR
MDABWMCCUIRLDD\-QY0@C6&6.01X#9\P <^N-QQ_M=:@CM!>/$;@27<L(81R2
M6OF%CSO503N'W3@=.GS5!':II=K=R);OY<FT_+*/,8'J2A/RG/?)I6%[EKW/
M7?V4XW_X: \,N<_9I$NL)<(QDW?99.CX*L/]UC7Z(GM7Y\?LGM&WQR\/#<TC
MHETH;YU/_'M)P=W4^YS7Z"[P<5G(\G%-.HFGNKCZ6DI:DXPHHHH **** "BB
MB@ HHHH **** "BBB@ IK?=/:G4C<C% $+(K1X."#Q@CBN%^(/P>T#X@VA2_
MLTEDY*S8PX..H/\ 7K7?;#MQG]*-G&,U=.I*F^:#LS&K1IXB/)6BI+SV/B7Q
MQ^R7JVES22:)<^?#G(AGZ@?[WI^%>3:M\+?%.B[S<Z//L4X\R+#@_0 Y_2OT
MR:(,,'G\*H7?AVPOB3+;1,3U.P GZFOI\-Q)C,.OYO4^%QO!.68J5Z:]GZ'Y
MA_\ "-ZN#@Z5>C_MW?\ PJ6W\)ZS>2B.+3+HM_MPLOZD8K](9OAOH<[9:SC'
MT44L7PYT.%MRV<7_ 'P*]'_6S$?\^XGCKP]PE_XTOP/@'0_@WXCUEHP;;[+N
MS]X%B/R_QKVCX??LM-Y\<]]$7; ):3H/H,U]66OAZQL<>3;QI]%Q5]8PJ@#
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MD@?*FT9Y/KT!K&T7X>ZMKGA37O$MNL::5H[*L\DI"M*S,HVQX'S$;E+9(&2
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M,Y;RS4ZC7+OJO_D3NI<=YW[DHT8/G=E[KU_'S/,+7PI?Z1#;1K;6=[I\D?\
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M4M> ?5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.5ZYMHVT?VAC/^?\O_ G_F']AY9_T"P_\!7^1Y'_ ,,I_#'_ *%MO_!A<_\
MQRC_ (93^&/_ $+;?^#"Y_\ CE>N;:-M']H8S_G_ "_\"?\ F']AY9_T"P_\
M!7^1Y'_PRG\,?^A;;_P87/\ \<H_X93^&/\ T+;?^#"Y_P#CE>N;:-M']H8S
M_G_+_P "?^8?V'EG_0+#_P !7^1Y'_PRG\,?^A;;_P &%S_\<H_X93^&/_0M
MM_X,+G_XY7KFVC;1_:&,_P"?\O\ P)_YA_8>6?\ 0+#_ ,!7^1Y'_P ,I_#'
M_H6V_P#!A<__ !RC_AE/X8_]"VW_ (,+G_XY7KFVC;1_:.,_Y_R_\"?^8?V'
MEG_0+3_\!7^1Y'_PRG\,?^A;;_P87/\ \<H_X93^&/\ T+;?^#"Y_P#CE>N;
M:-M']HXS_G]+_P "?^8_[#RS_H%I_P#@*_R/(_\ AE/X8_\ 0MM_X,+G_P".
M4?\ #*?PQ_Z%QQ]-0N?_ (Y7KFVC;1_:.,_Y_2_\"?\ F+^P\L_Z!:?_ ("O
M\CR)?V5/A@O3PZWX:A<@_B?,YI?^&5?AA_T+9_\  ^Z_^.UZX%/K1MK/^T,;
M]JM+[W_F6LERSIAH?^ Q_P CR+_AE7X8]O#1_P#!A=?_ !VA?V5/ACNR/#C)
MV(74+D9^N)*]=VG'6D\OUJO[0QJTC6E][_S#^Q<KV>&A_P" Q_R/)?\ AE/X
M8;=O_".';G./M]UC/K_K*/\ AE/X8?\ 0MG_ ,#[K_XY7KFVC%5_:6-_Y_2_
M\"?^8?V+EO\ T#0_\ C_ )'D2_LJ_#!N?^$<8?\ <0N?_CE=UX/\"Z/X!T>/
M2M!M?L=A&S.L9E>0AF.2<NQ-="J$=Z/+YR:YJF)KUH\E2HVO-G10R[!X67/1
MHQB_**0^BBBN<]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "HKFWCNK>6"5=T4BE'7.,@C!%2T4">NC/(%_91^&"J /#;8' _XF
M%S_\<I?^&4_AC_T+;?\ @PN?_CE>N;:-M>C_ &CC/^?TO_ G_F>+_8F6?] M
M/_P%?Y'D?_#*?PQ_Z%MO_!A<_P#QRC_AE/X8_P#0MM_X,+G_ ..5ZYMHVT?V
MAC/^?\O_  )_YB_L/+/^@6'_ ("O\CR/_AE/X8_]"VW_ (,+G_XY1_PRG\,?
M^A;;_P &%S_\<KUS;1MH_M#&?\_Y?^!/_,/[#RS_ *!8?^ K_(\C_P"&4_AC
M_P!"VW_@PN?_ (Y1_P ,I_#'_H6V_P#!A<__ !RO7-M&VC^T,9_S_E_X$_\
M,/[#RS_H%A_X"O\ (\C_ .&4_AC_ -"VW_@PN?\ XY1_PRG\,?\ H6V_\&%S
M_P#'*]<VT;:/[0QG_/\ E_X$_P#,/[#RS_H%A_X"O\CR/_AE/X8_]"VW_@PN
M?_CE'_#*?PQ_Z%MO_!A<_P#QRO7-M&VC^T,9_P _Y?\ @3_S#^P\L_Z!8?\
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M=67--W9Z.'PM#"Q<:--15[V2L.I:**R.L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>eigr-20221231_g12.jpg
<TEXT>
begin 644 eigr-20221231_g12.jpg
M_]C_X  02D9)1@ ! 0$ A@"&  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +Q!OH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N%^+'Q./PQTRRNQIO]I?:
M93'L\_RMN!G.=K9KNJ\,_:N!_P"$9T4XX^U-_P"@U4=63)V5SUOPCX@_X2KP
MOIFL>1]E^VVZ3^3OW[-PSC.!G\JV*XWX.DGX7^&LG/\ H4?\J[*D]QK8****
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BDI:
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M>_2O5F^Z?I7R]^S.3'\4-84C!-E,#G_KM'5):,B3U1]14445)84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XA^U7_P B
MGI/_ %]G_P!!KV^O$_VJE!\&Z8W<7F/S4U4=R)?"SMO@Q*'^%_AS) Q:J/RK
MM-Z^H_.ODKPC^SOK'C#P[9:Q;:E8PPW2;UCEW[ASCG"UK_\ #*.O_P#07TW_
M ,B?_$U32ON)2=MCZ>W+_>'YT;U_O#\Z^8?^&4=?_P"@OIO_ )$_^)H_X91U
M_P#Z"^F_^1/_ (FE9=PYGV/I[<O]X?G1O7^\/SKYA_X91U__ *"^F_\ D3_X
MFC_AE'7_ /H+Z;_Y$_\ B:++N',^Q]/;E_O#\Z-Z_P!X?G7S#_PRCK__ $%]
M-_\ (G_Q-'_#*.O_ /07TW_R)_\ $T67<.9]CZ>W+_>'YT;U_O#\Z^8?^&4=
M?_Z"^F_^1/\ XFC_ (91U_\ Z"^F_P#D3_XFBR[AS/L?3VY?[P_.C>O]X?G7
MS#_PRCK_ /T%]-_\B?\ Q-'_  RCK_\ T%]-_P#(G_Q-%EW#F?8^GMR_WA^=
M&]?[P_.OF'_AE'7_ /H+Z;_Y$_\ B:/^&4=?_P"@OIO_ )$_^)HLNX<S['T]
MN7^\/SHWK_>'YU\P_P##*.O_ /07TW_R)_\ $T?\,HZ__P!!?3?_ ")_\319
M=PYGV/I[<O\ >'YT;U_O#\Z^8?\ AE'7_P#H+Z;_ .1/_B:/^&4=?_Z"^F_^
M1/\ XFBR[AS/L?3VY?[P_.C>O]X?G7S#_P ,HZ__ -!?3?\ R)_\31_PRCK_
M /T%]-_\B?\ Q-%EW#F?8^GMR_WA^=&]?[P_.OF'_AE'7_\ H+Z;_P"1/_B:
M/^&4=?\ ^@OIO_D3_P")HLNX<S['T]N7^\/SHWK_ 'A^=?,/_#*.O_\ 07TW
M_P B?_$T?\,HZ_\ ]!?3?_(G_P 319=PYGV/I[<O]X?G1O7^\/SKYA_X91U_
M_H+Z;_Y$_P#B:/\ AE'7_P#H+Z;_ .1/_B:++N',^Q]/;E_O#\Z-Z_WA^=?,
M/_#*.O\ _07TW_R)_P#$T?\ #*.O_P#07TW_ ,B?_$T67<.9]CZ>W+_>'YT;
MU_O#\Z^8?^&4=?\ ^@OIO_D3_P")H_X91U__ *"^F_\ D3_XFBR[AS/L?3VY
M?[P_.C>OJ/SKYA_X91U__H+Z;_Y$_P#B:/\ AE'7_P#H+Z;_ .1/_B:++N',
M^Q]/;E]1^=.KYDM?V5==@NH93JVFD1R*Y \SL0?[M?32\ "I=NA2;>Z%KE?B
M?X^LOAGX%U?Q%?.H2SA9HHV90993PB*&90Q)QQN!-=57QG\5?B)X6^-GQ\T?
MPUK6IZ7IO@;PO/+)=W6J7ULEO?3 ;6$;;U;'+1':Q.=^Y %R1*X-V/0/V9_V
M@O&'Q:\7:OHWBC3=.TYK"PCN"MK:36\AD9E&2))&(4JP(XZ$'.*Q_$GQH^(G
MQ<^)&N> OAA<:3H2:4S-+XA^T1W.]$91N&Z-U7+[HRHCD((^\M97P+\6>&+?
M]J;X@O::QI4>FZE%#:Z2T-S&(;G:(@L<&#A\!2 JYP%]JYWQMK6I:A^TU>WO
MP06ZU76UMI/[;>.=6LYI00A'[Q@A5<8.6 #J G.ZKMJ1=V/3?@-^T1XC\2?$
MK5_AYX[MM/M-?L0T4$EFC!II(@#('VED.5*R!@4'S8VYX'T;D#KQ7QK^R'J'
MA^Q^)FL:9XIL-4G^+$TURTFI:G%Y@4+CS$5NL<A7!)("E=H0[<+7UMXJ\.VO
MBSPWJ>C7L4,]M?6[P.ES"LT?S# )0\-@X./:IEN7'8U P/(.10K!N0<U\*?"
M'XM0_#7]GSXF:0U]ILD^FWLEKIXDMY&DN9)F:)Y)41B0K.I ;A5Z%C3_ -FG
MXC:I\*/!_P 4-)U"RO8_[%L$U%$ANDG-M*RA%2.(GR^=R2$AN>A!-/E%S'W1
MN![YK%TOQQX<US7-1T73=>TS4-8TX@7NGVMY')/;9X'F1J2R?B!7P3)JGB'X
M8_LT&^MI+F#5?B!J4TL]TMU$J-#'&<%%1,J)N=PW*5YQ@<5R&L>,_A>O@_18
M_"MAXN\+>,=/12VL&ZMO+E?9A\LESNBQD[7B12.ZFCE%SGZ?Y ]A6)X9\;^'
M?&JW;>'M?TS75LY3!<MIMY'<"&0=4?83M;V/-?%7[17Q<\4WGPE^'6@ZY!<6
M3:II<>H:U'"YB>X02!#&5FR<[1O!=\,V-P(KSGQ9\0O T.H:3J/PFT_Q9X6\
M1VH$7DW5Q&\=\VY2JEH;II0S,JJ43Y7!QA>M"B',?57Q@U[5;+]JGX4Z=:ZO
MJ5IIMS$YN+&WO98[><CS/]9$K!7Z#[P/0>E?1FX;L9&?2OC7]ICQM-X-^,GP
MQ\4W\.R[L](:XDA$?"S,'4 JS X#L,C<#@'G-=I^RW\+[;Q-&OQ7\4:K#XK\
M6ZH[21S$ATL",J4 Z+(HRNT !!\H[EAK2XT]6CZ$U+Q-I&BZAIUAJ&JV5C?:
ME(T5E;7-PD<ETZKN98U)RY"\D#.!6D#GD<BOSWTQ="MOB+XM_P"&@--U^VU.
M^CD:TU23S#Y81V4&.*!#YG!78R>9'\NW8,$M]O?"G2M#T/X;^&]/\,WYU30+
M:QCCLKQG1S-$%^5B455R?8#Z"I:L-.YU=)N ZD"EKPOXH_ '5O'?C2\UFTU&
MRMX)DC41S;]PVJ >BGTH7F-Z;'N6Y?[P_.C>O]X?G7S#_P ,HZ__ -!?3?\
MR)_\31_PRCK_ /T%]-_\B?\ Q-59=R.9]CZ>W+_>'YT;U_O#\Z^8?^&4=?\
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M"^F_^1/_ (FC_AE'7_\ H+Z;_P"1/_B:++N',^Q]/;E_O#\Z-Z_WA^=?,/\
MPRCK_P#T%]-_\B?_ !-'_#*.O_\ 07TW_P B?_$T67<.9]CZ>W+_ 'A^=&]?
M[P_.OF'_ (91U_\ Z"^F_P#D3_XFC_AE'7_^@OIO_D3_ .)HLNX<S['T]N7^
M\/SHWK_>'YU\P_\ #*.O_P#07TW_ ,B?_$T?\,HZ_P#]!?3?_(G_ ,319=PY
MGV/I[<O]X?G1O7^\/SKYA_X91U__ *"^F_\ D3_XFC_AE'7_ /H+Z;_Y$_\
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M_P")J;+N5S/L?3VY?[P_.C>O]X?G7S#_ ,,HZ]_T%]-_\B?_ !-'_#*.O?\
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M%%%>8>P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&_\  V/_ !H_X6UX)_Z&S1O_  -C_P :/K5#_GXOO0?4\5_SZE]S.MHKDO\
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M7@G_ *&S1O\ P-C_ ,:/K5#_ )^+[T'U/%?\^I?<SK:*Y+_A;7@G_H;-&_\
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MY^+[T'U/%?\ /J7W,ZVBN2_X6UX)_P"ALT;_ ,#8_P#&C_A;7@G_ *&S1O\
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M%_\ %4?\+/\ !_\ T-.C_P#@=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\
M%4?\+/\ !_\ T-.C_P#@=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\
M+/\ !_\ T-.C_P#@=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\
M!_\ T-.C_P#@=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\
MT-.C_P#@=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\ T-.C
M_P#@=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\ T-.C_P#@
M=%_\50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\ T-.C_P#@=%_\
M50%T=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\ T-.C_P#@=%_\50%T
M=/17,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\ T-.C_P#@=%_\50%T=/17
M,?\ "S_!_P#T-.C_ /@=%_\ %4?\+/\ !_\ T-.C_P#@=%_\50%T=/17,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D;I2TC=* /SZ^(W_)0/$?_7_-_P"AFN=K
MHOB-_P E \1_]?\ -_Z&:YVOY[Q7\>IZO\S^P\O_ -SH_P"&/Y(****YCT H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\,\^!?^@0__ ($R?_%5Z111S,+(\W_X9Y\"_P#0(?\ \"9/_BJ/^&>? O\
MT"'_ / F3_XJO2**.9A9'F__  SSX%_Z!#_^!,G_ ,51_P ,\^!?^@0__@3)
M_P#%5Z111S,+(\W_ .&>? O_ $"'_P# F3_XJC_AGGP+_P! A_\ P)D_^*KT
MBBCF861YO_PSSX%_Z!#_ /@3)_\ %4?\,\^!?^@0_P#X$R?_ !5>D44KL.5'
MF_\ PSSX%_Z!+_\ @3)_\51_PSSX%_Z!+_\ @3)_\57I%%%V+E78\W_X9Y\"
M_P#0)?\ \"9/_BJ/^&>? O\ T"7_ / F3_XJO2**+L.5=CS?_AGGP+_T"7_\
M"9/_ (JC_AGGP+_T"7_\"9/_ (JO2**+L.5=CS?_ (9Y\"_] E__  )D_P#B
MJ/\ AGGP+_T"7_\  F3_ .*KTBBB[#E78\W_ .&>? O_ $"7_P# F3_XJC_A
MGGP+_P! E_\ P)D_^*KTBBB[#E78\W_X9Y\"_P#0)?\ \"9/_BJ/^&>? O\
MT"7_ / F3_XJO2**+L.5=CS?_AGGP+_T"7_\"9/_ (JC_AGGP+_T"7_\"9/_
M (JO2**+L.5=CS?_ (9Y\"_] E__  )D_P#BJ/\ AGGP+_T"7_\  F3_ .*K
MTBBB[#E78\W_ .&>? O_ $"7_P# F3_XJC_AGGP+_P! E_\ P)D_^*KTBBB[
M#E78\W_X9Y\"_P#0)?\ \"9/_BJ/^&>? O\ T"7_ / F3_XJO2**+L.5=CR#
MQA\"?!FD^$]:O;;2WCN;:RFFB;[1(<,J$@X+>HK5_9W_ .24:5_UTF_]&-75
M?$'_ )$/Q'_V#;C_ -%-7*_L[?\ )*-*_P"NDW_HQJKH*R3T/2J\O\5?\C!>
M?[R_^@BO4*\O\5?\C!>?[R_^@BO2R[^*_0\;-OX*]3)HHHKZ,^3"O5O#_P#R
M!;/_ *YC^5>4UZMX?_Y MG_US'\J\?,O@B>_E'\27H:%%%%?/GU(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!8 FOR@_9_\ A[IWPF_X*>Z#X+TF6>?3-!\3W5A;R714RNJ6LPRQ4 9)ST%
M'[AT444 %%%% !2-TI:1NE 'Y]?$;_DH'B/_ *_YO_0S7.UT7Q&_Y*!XC_Z_
MYO\ T,USM?SWBOX]3U?YG]AY?_N='_#'\D%%%%<QZ 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<WC2;Q'I<7A ^+;R[&NO=H++R6@E59/.SMVDD '.,D5^Q?Q9^#G@[XY>%/\
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MO**X.Z^.'@^Q^)4/@&;4)E\43.L:6OV.8H6:$S#]Z$V?<!/WO;KQ7>4AA17
M^-OCGX.^'?BK2_#FNZC-:ZOJ9@%K#'9S2A_.F\F/+(A5<OQR1CJ>.:U?B)\3
M/#_PKT6#5O$EW)96,]RMHDD=O),3(RLP&U%)'"-SC'% CJ:*X#7/CIX-\.?#
MW1?&U_J4T7AS6!";*Y6SF=I/-C:1,QA"ZY52>0,8P:Q/$7[5'PS\+ZY>:1?^
M(&6^LVV3+#9SS*&P"5#(A4D9P0#P00>1BG9A='K5%8?@OQIHWQ"\-V>O:!?)
MJ&F7:[HY5!5@0<,KJ0&1U((*L 0000#6Y2&%%%% !1110 4444 %%%% !111
M0!S_ ,0?^1#\1_\ 8-N/_135RO[.W_)*-*_ZZ3?^C&KJOB#_ ,B'XC_[!MQ_
MZ*:N5_9V_P"24:5_UTF_]&-5=">IZ57E_BK_ )&"\_WE_P#017J%>7^*O^1@
MO/\ >7_T$5Z>7?Q7Z'BYM_!7J9-%%%?1GR85ZMX?_P"0+9_]<Q_*O*:]6\/_
M /(%L_\ KF/Y5X^9?!$]_*/XDO0T****^?/J0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***K:E
MJ5IHVGW-_?W,-E96T;33W%PX2.)%&69F/   SDT 6:*^-+?_ (*L_!?4OBEI
MO@[3%UW4[:_NXK*/Q!;V0%EYLC;5&UF$I&XA=PC(YR,CFOK#QKXTT3X=>$]4
M\2^(]1ATG0],@:XN[R<X2-!_,DX  Y)( Y- &W17YR2?\%G/"L?B^<?\*WU^
M7P4J%8=5CFB%Y)+QQY#$(%///F[NGR]0/K[Q'^U1\/O"_P  ;7XP7^JM%X0O
M+2.ZLR8R+BY:1<QP)&>3(Q!&WM@DX )H ]=HK\Y_#?\ P68\)3^);N/Q)\/-
M=T7PU),JZ?J=O+'/*T9;#23Q':%PN&Q$TIZ@=L_H?INH6^K:?;7MK()K:YC6
M:*0=&5AD'\C0!9HHHH *1NE+2-TH _/KXC?\E \1_P#7_-_Z&:YVNB^(W_)0
M/$?_ %_S?^AFN=K^>\5_'J>K_,_L/+_]SH_X8_D@HHHKF/0"BBB@ HHHH **
M** "BBB@#Z$CM/#EY^SAX-7Q+J%UIUJ+VX,4EI"969_-GX([#&?RKC=<\?\
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ME"[BBD\MM[X&3COBOD,P<:N.JN#T<F?H^3QGA\JH*I%IQ@KKKHNQ['^SO_R
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M][=-MFM3:_:6_>:GX1G0;H'T2(+(/NGYF/!_$?G1\ 9%C\*_$XL<#^R!^J3
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M]W+]AE"C.1+\JY]@Y0GTQ7;>$?#[_#7Q5\3]5;R[9=!M9H;-6YPT[9MCGW0
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M2Z+_ -@T?REKW"O#]=_Y.ET7_L&C^4M>X5^X/H?RS'J%%%%26%%%% !1110
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MTU37+^)7DG81PFYF\Q&.6./E4 A=Q)  &:-E9AN[H\B\%_\ )@?B[_K^O/\
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MUJ_N'O[VW$XF2!V"JJ!@,9"(@;!8;MQ#$8KUNIEN7'1!1114E!1110 4444
M%%%% !1110!S_P 0?^1#\1_]@VX_]%-7*_L[?\DHTK_KI-_Z,:NJ^(/_ "(?
MB/\ [!MQ_P"BFKE?V=O^24:5_P!=)O\ T8U5T)ZGI5>7^*O^1@O/]Y?_ $$5
MZA7E_BK_ )&"\_WE_P#017IY=_%?H>+FW\%>IDT445]&?)A7JWA__D"V?_7,
M?RKRFO5O#_\ R!;/_KF/Y5X^9?!$]_*/XDO0T****^?/J0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@#\E/CC^U
M;\?;_P#;M\2_#OX>^)8K"::Z'A?2K"2-/LL2LJ2?:"'ROG ECO.>!C:>E5/
M_P 9_C-^QG^V)HGP]^)7Q-?Q7HFKW-M-K'F/-?P!;G<J&+S%$D;!MORIA!G[
MIQQFZQX7UG2O^"OEI<7FE7MM;W7BV*[@FEMW5)(6M\+(K8P5)4C/L:M_\%!_
M 7B76/\ @H9X1EL- U*]BU'^Q_L<EO:NZS^5-F780,'8.OI0!^OU?"NN>.OV
M]X]<U%-*^'?@*72UN95M))IX][PASY;-_IHY*X/05]TU\*ZY_P $X/'^L:YJ
M-_%^U'X]LHKJYEG2UA>Y"0J[E@BXO!PH..@Z4 >@_LZ>*OVL]7^)45O\8O!W
MA/1/!9M)F>[T>5&G$XQY:X%U(<'YL_+VZBO>OB[\+M'^-7PVU_P1K\EU%H^M
M6_V:Y>RD5)@NX-E696 .5'4&O!?V=/V+_%WP-^)47BC6?CMXL^(-BEI-;'1=
M8:8P,SXQ)\]Q(,K@X^7OUKW?XQ_$^R^"_P ,?$'C;4K"]U.QT6W^TS6FG(K3
MR+N"X0,0"?F[D=* /QQ_:U^'/A[X2_M[>#_"GA73(=)T/39?#L4%O".O[R/+
MN>KNQY+'))ZU]I?\%@OB"WAK]G72/#<)OXI_$6KHIFM7VP^5"N]XYL$$AMRX
M7!!*\]!7P#^TM\>K/XV?M9:?\5M)\,>(+#1;:;2Y&LKZU N2+5U9\!69>=O'
MS?7%??W[3^M7_P"WC^P?=^(/A]X=UBWN(M62ZCT2_MLWUP+>5D=(XXB^6);(
MYZ ]* .8UCP;H>E_\$<$^SZ9;CS/#EOJQ\Q3)MO))T9YEW9VL2S'*XQN.,5^
M;_B+XX7^K_LS>&_A@1=06^A:Y>ZDDD)*V]Q',BL%E&[YY$D,A&5 56&#DFOH
MYOVVKG5/V+U_9RD\$:Q>>.WA308VA@"1) LP\OY-S2/-\JJ1L4%B>1WZ#XX?
ML'^/? ?[#O@:*+03=^)K'6;O6/$.GZ6);JX"W$05&8*"H\F*)5<C"C Y;DT
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M"ZW9OUT?3X+ 71C\LR^6@3?MR<9QG&37244"\Q*6BB@84444 %%%% !1110
M4444 %%%% '/_$'_ )$/Q'_V#;C_ -%-7*_L[?\ )*-*_P"NDW_HQJZKX@_\
MB'XC_P"P;<?^BFKE?V=O^24:5_UTF_\ 1C570GJ>E5Y?XJ_Y&"\_WE_]!%>H
M5Y?XJ_Y&"\_WE_\ 017IY=_%?H>+FW\%>IDT445]&?)A7JWA_P#Y MG_ -<Q
M_*O*:]6\/_\ (%L_^N8_E7CYE\$3W\H_B2]#0HHHKY\^I"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *0TM% 'QAXX^"OC34O&6N7=MH4\MM/>2R1R C#*6
M)!ZUB?\ "A_'?_0OW'YC_&ONJBOC:G"^%J3<W)ZNY^E4>/,QHTXTHPC:*2Z]
M/F?"O_"A_'?_ $+]Q^8_QH_X4/X[_P"A?N/S'^-?=5%9_P"JF$_G?X&W_$0<
MR_Y]Q^Y_YGPK_P *'\=_]"_<?F/\:/\ A0_CO_H7[C\Q_C7W511_JIA/YW^
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M *%^X_,?XU]U44?ZJ83^=_@'_$0<R_Y]Q^Y_YGPK_P *'\=_]"_<?F/\:/\
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M?Q,\/^+[7XO6GB;P[I']H+;V*1*S_<W9D!!&0>C"I/\ A-OC!_T*EG_WR?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V218D9W(55&23
MTH =14%G>1:A;K/"=T;9P?7G%3T]M&)--704444AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>7^*O^1@
MO/\ >7_T$5ZA7E_BK_D8+S_>7_T$5ZN7?Q7Z'AYM_!7J9-%%%?1GR85ZMX?_
M .0+9_\ 7,?RKRFO5O#_ /R!;/\ ZYC^5>/F7P1/?RC^)+T-"BBBOGSZD***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y#XC_%;P[\*;"UO/
M$=U+:V]U(8HFBMWE)8#)X4'% '7T5F>&?$5CXN\/Z?K6F2-+I]]"MQ [H4+(
MPR"5/(_&M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7E_BK_D8+S_>7_P!!%>GE@N2>E>4:W=+>ZM=3*<JS
M\'U X'\J];+4_:-^1X6;->RBO,HT445]$?*!7JWA_P#Y MG_ -<Q_*O*:]8T
M-#'H]F#_ ,\E/Z5XV9?!$]_)_CGZ%ZBBBO /J0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KY@_;P_P"1+\-_]?K_ /H KZ?KYE_;N _X0+0#
MCG[>?_0*N/Q(B?PL]6_9YD,GP1\&$]M-A7\EQ7HE>;?LXR"3X'^#R!C%@B_E
MQ7I-2]RH[(***I:QK>G^'M.GO]3O(+"RA1GDGN) B*JJ6))/H 3^%(9=HK$\
M*>-M!\=6,UYX>U>TUFUAD\F2:SE$BJ^T-M)'?#*?Q%<_\1/CAX+^%JS)X@UN
M&WO8HDG_ +/A!ENG1FVAEB7+,,YZ#H">U,#NZ*YCX?\ Q*\.?%#1!JGAO4X]
M0MP$$L8RLMNS('"2H?F1P&&5(R*Z>D 4444 %%%% !1110 45YW\2_C-9_#3
MQ9X*T*YTJ\U";Q1>_8X9K9HPEN?-ACW/N8$C]^#\H)PI]J]#H 6BBB@ HHI*
M (KM0UK,I&048$?A7Q/^P7)_Q7FO1XY;2MV?I+'_ (U]M7'_ ![R_P"Z?Y5\
M0_L-S+!\4/$*G"QC2)&)Z8 GB_QK2.S,I?$C[BKS;Q]^TE\+/A7KPT3Q?\0/
M#_AS5_)6?[%J%_'%+Y;$A6*DY .T_E7R???\%@/A=IOQWOO"LMI<R^ +:)H1
MXPM@THDNE))VPJ-S0'&T.,DG!QM.ZOAG_@JYI?AW_AJ2#Q-X9OAJ=AXN\.V.
MN->13K+#,S&2!7B('W#';Q]SSN.><#,U/W/T#7]-\5:+8ZQH]];ZGI5]"MQ:
MWEK()(IHV&596'!!%:%?GO\ #G]I[0?V%/\ @G[\,H_$JV^H>-;O39+C2_#=
MK<J9)_M$SW,;R%<^7&(YXF9B,C<  2<5[_\ L4_MA:3^U]\.;K64LH-!\1Z;
M<M;ZCHBW:S-$IYCF7@-Y;@D D#YD<=@2 ?1-%%17%Q':PM+*X1%&2S4]]$)M
M)78L\\=M"TDK!$49+&O.O$GB636)#%$2EHIX'=O<TWQ'XDDUJ8QIE+13\J_W
MO<UB5]#A,'[/]Y4W/E,=CW5_=TOA_,****]8\,]%\+ZC;0Z';))/&C@'*LW/
M4UK?VM9?\_47_?0KR2BO(EE\92<N;<]VGFLH14>78];_ +6LO^?J+_OH4?VM
M9?\ /U%_WT*\DHJ/[-C_ #&G]L3_ )3UO^UK+_GZB_[Z%']K67_/U%_WT*\D
MHH_LV/\ ,']L3_E/6_[6LO\ GZB_[Z%']K67_/U%_P!]"O)**/[-C_,']L3_
M )3UO^UK+_GZB_[Z%']K67_/U%_WT*\DHH_LV/\ ,']L3_E/6_[6LO\ GZB_
M[Z%']K67_/U%_P!]"O)*SO$NK'P_X:UC5EA6X;3[*>\$+-M#F.-GVDXXSMQG
MWI/+8I7<AK-IR=E ]L_M:R_Y^HO^^A1_:UE_S]1?]]"OQ4\'_P#!0?\ :4^)
M]QK#>#O"&D:Y%IL1NKJ.PT:6<VL.3AG(DZ#!YQSBO;OV4_\ @HM<_%SXA:5\
M/O'/AB/1=?O4\BWO['?LGN@"Q5XF&8@5'')P1S7#"E0FTN9Z^1Z4Z^)IQ<N1
M.WF?I[_:UE_S]1?]]"C^UK+_ )^HO^^A7DPC9N0I(]A7D/[3&O>.8?@CXBG^
M$MO_ &UXO5HX8?[.E22>W4L"[QIA@[@ #9C.&8]J[)Y?&$7)R."GFE2I)1Y5
MJ?6_]K67_/U%_P!]"C^UK+_GZB_[Z%?$W[%M[\9-2^%]X_QGM;J#7?M[BQ_M
M"!8;M[? R9$4#'S9"\#CUZU[S>74&G0F:[FBM(0=OF7#B-<GH,D@9I4\#"<5
M/FL.IF<Z<W#E3MV/8/[6LO\ GZB_[Z%']K67_/U%_P!]"O(V*JA=B%15WEB<
M +C.<^F.]1VMU!>P+/;317,#$@2PN'0XZX(XJ_[-C_,9_P!K3WY#V#^UK+_G
MZB_[Z%']K67_ #]1?]]"O(9YHK6!YYY$@@3EY96"HOU)X%1V=]:ZA&TEI<P7
M<:G:SV\BR*#UP2">:/[.C>W,']K3M?D/8O[6LO\ GZB_[Z%']K67_/U%_P!]
M"O)50MT4GZ"H5N[>2\:T6>%KM5WFW$BF0+QR5SG'(YQWH_LV/\P?VM-_8/8/
M[6LO^?J+_OH4?VM9?\_47_?0KR5D*\%<'W%+Y;;=VTX]<4_[-C_,+^UY_P A
MZS_:UE_S]1?]]"C^UK+_ )^HO^^A7DT<8DD5>FX@5^6VB?\ !0S]H?XH>.=6
MT;P#X/TC5I86FN(M+L]+DNYH;=9 N68."P7<@+8&21P,US5L)3HVYI/7R.NA
MCJV(OR16G=G[1?VM9?\ /U%_WT*/[6LO^?J+_OH5^>/[*?Q:_:,\=?$B\T_X
MM>!/^$9\,IIDLT5Y_8\EINN1)$$3>SD'*M(<8_A]J^M?+;CY#STXZU=/ PJQ
MYE)HSK9E4HRY7%/T9ZS_ &M9?\_47_?0H_M:R_Y^H_\ OH5XY9ZE9ZEYGV.[
MM[OR\;_L\RR;,],[2<=#U]*G=ECC>1RJ1HI=W8@!5 R23V ]:U_LZ._,8_VM
M43LX'KG]K6?_ #\Q?]]"C^UK+_GZB_[Z%?GY_P %#OC!XG^$_P  M(\1^ _$
M#:1?W'B&"S-]9>7*)(3;W+,F6#+C=&O3G*UVW[$?CSQ!\4?V9O!_B3Q1J4NL
MZ[?&\^T7DJJ'DV7DR+D* .%11P.U8+!P=3V?-TN=,L?5C159Q5KV/LW^UK+_
M )^HO^^A1_:UE_S]1?\ ?0KQ^\NK?38A)>3PVD9;8)+AUC7=C.,DCG%/C=)H
MTDC99(Y%#(Z$%64]"".H]ZW_ +-C_,<W]K3WY#UW^UK+_GZB_P"^A1_:UE_S
M\Q?]]"O'KR\MM/A$MW<0VD+-M$EQ(L:D\\9) SP?RIUO<0WD"3V\L=Q ^=LL
M+!T;!P<$<'GBC^SH[<P?VM4M?D/7_P"UK/\ Y^HO^^A1_:UE_P _47_?0K\S
M?VH-?_:HA_:'TNV^%>BZC_PAD<5FL4EO#'/87<A<F1[IRN81N)1EW#"(KY&[
M-?;/EELD*2/7%90P4)RE&[T-ZF8SIQC*R=_,]9_M:R_Y^HO^^A1_:UE_S]1?
M]]"O'/[0L_MWV+[7;_;?^?7S5\WIG[F<].>G3FN,^.7Q<T[X#_"[6?'.K6%U
MJ6G:7Y(EMK+;YK>;,D0QN('!D!Y/0&M'E\(IR<]$91S2K*2BH:L^EO[6LO\
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MO^?J+_OH4?VM9?\ /U%_WT*\E52QP!D^PJ&6ZMK>YAMY[B&":8XCBD=5=_\
M=4G)_"AY=%;R!9M-[0/8/[6L_P#GZB_[Z%']K67_ #]1?]]"OS/\+Z_^U->_
MMC20ZAHFH6/PK_M-UEBFACDTU+$+C?'<;06<CYE&XG<<8.,5]H75U!8P--<S
M16T*D RS.$4$]!DG%8T\%"HF[M6.BMF-2DTK)W['L']K67_/U%_WT*/[6LO^
M?J+_ +Z%>0PRQW,"3PNDT$@RDL;!E;Z$<&H[R^M=-C22\N8+2-SA7N)%C#'T
M!8C-;?V=#?F.?^UJE[<A[%_:UE_S]1?]]"C^UK+_ )^HO^^A7D,,T5S"DT,B
M30R#*21L&5AZ@C@U((R1D*2/7%/^S8_S"_M>?\AZU_:UE_S]1?\ ?0H_M:R_
MY^HO^^A7CD>H6DEZ]FEU;O>)G=;+*IE7'7*YR/RJQ266Q>TAO-IK>!ZW_:UE
M_P _47_?0H_M:R_Y^HO^^A7DE%/^S8_S"_MB?\IZW_:UE_S]1?\ ?0H_M:R_
MY^HO^^A7DE%']FQ_F#^V)_RGK?\ :UE_S]1?]]"C^UK+_GZB_P"^A7DE%']F
MQ_F#^V)_RGK?]K67_/U%_P!]"C^UK+_GZB_[Z%>244?V;'^8/[8G_*>M_P!K
M67_/U%_WT*/[6LO^?J+_ +Z%>244?V;'^8/[8G_*>M_VM9?\_47_ 'T*/[6L
MO^?J+_OH5Y)11_9L?Y@_MB?\IZW_ &M9?\_47_?0H_M:R_Y^HO\ OH5Y)11_
M9L?Y@_MB?\IZW_:UE_S]1?\ ?0H_M:R_Y^HO^^A7DE%']FQ_F#^V)_RGK?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_$NG27L9@O)EU"X#1$V\9D7:BJ[+$"I8!%/3*XKT'_@L1_R+'PO_ .O[4O\
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MB:;K7BU/$?@C4M1S]DL#,UK97<:2&+(D4!&=9KD@)][:Y/05]$^'=8U#P_\
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M'I=YJ W*S;Q:ZI-<LBA02680E1[D9K1TE&52E':U_F9*LYPI5I;\UOD>-?\
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M:VMY^)/LTD]FL;,O52WEL0#S@J>]=-^R@?\ C6+\7_\ N-_^D4%$HNI)*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH.G^%]'M-)TJTCL-.M(Q%!;PC"HH_GZDGDDDFM"BF(****0QLG^K;Z&OA_\
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MS?\ ?-'_  C^I?\ /C-_WS7JU%']I5/Y4']D4OYF>4_\(_J7_/C-_P!\T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M +X7_"O,GQ9@I2<N66IZ]/P]S2$%'GAIYO\ R/N?-&:^&?\ A?GCS_H/2_\
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M>E_[X7_"C_6O!_RR#_B'^:?SP^]_Y'W-FC-?#/\ POSQY_T'I?\ OA?\*/\
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MO_(^YLT9KX9_X7YX\_Z#TO\ WPO^%'_"_/'?_0>E_P"^%_PH_P!:\'_+(/\
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MRR#_ (A_FG\\/O?^1]S9HS7PS_POSQY_T'I?^^%_PH_X7YX[_P"@]+_WPO\
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MQZFK/_")_&/_ *&6T_)?_B:^PL?G/-Y'N%%>'_\ ")_&/_H9;3\E_P#B:/\
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M3'_)6+W_ *]X?Y&O*Z_!<V_W^M_B9_6?#W_(IPW^%!1117E'T04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>A_L_?\ )6M"_P!Y_P#T UYY7H?[/_\ R5K0
MO]Y__0#7I9;_ +[2_P 2/!S[_D5XG_ _R/=+7_DZJ\_[!J_^BTKW&O#K7_DZ
MJ\_[!J_^BTKW&OWUG\D1ZA1114E!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!QGQF_Y);XF_Z\G_ *55^!?_ "2K0/\ KB?_ $(U:^,W_)+?$W_7
MD_\ 2JOP+_Y)7H'_ %Q/_H1JNA/VCO:***DH**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXKB!Q+#*@D1UZ,I&01^%2UR_PO\ !L?P]^'7AOPU'+<S)I5A#:>9>3F>4E4
M.Z0\L<YYKJ* "BBB@ KAOC=_R2OQ#_UQ7_T8M=S7#?&[_DE?B'_KBO\ Z,6F
MMQ/8=\%/^26^'?\ KV%=O7$?!3_DEOAW_KV%=O0]PCL@HHHI#"BBB@ HHI*
M%HHHH **** "BBB@ HHHH **** "BBB@!&^Z?I7B7[.'_(6\=_\ 807_ -"E
MKVUONGZ5XE^SA_R%O'?_ &$%_P#0I:I;,E[H\9_:8_Y*Q>_]>\/\C7E=>J?M
M,?\ )6+W_KWA_D:\KK\%S;_?ZW^)G]9\/?\ (IPW^%!1117E'T04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ6LC;FB8@$CZ8=?UKSBOGL7AIX.M*C/='V.78ZGF6%CBJ2LI=_+3\STKX=?
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MP7K7BI?$M]X=L[G7EGAN1?.I\P2Q;?*;KU78F/\ =%*+L.2N)\:O^2.>._\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F^6O7:,_2G44U)K9DN*EN@HHHI#"BBB@84444 %%%% !1110
M4444 %%%% !1110 4444 %>A_L_?\E:T+_>?_P! ->>5Z'^S]_R5K0O]Y_\
MT UZ66_[[2_Q(\'/O^17B?\  _R/=+7_ ).JO/\ L&K_ .BTKW&O#K7_ ).J
MO/\ L&K_ .BTKW&OWUG\D1ZA1114E!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!QGQF_Y);XF_Z\G_I57X%_\DKT#_KB?_0C5KXS?\DM\3?]>3_T
MJK\"_P#DE>@?]<3_ .A&JZ$_:.]HHHJ2@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *2EHH **** "BBB@ KAOC=_P DK\0_]<5_]&+7<UPW
MQO\ ^25>(?\ KBO_ *,6FMQ/8=\%/^26^'?^O85V]>(?"_XT>$O#O@+1M.OM
M2\F[MX DD?EDX/I74_\ #07@?_H+_P#D)J;3N2I*QZ-17G/_  T%X'_Z"_\
MY":C_AH+P/\ ]!?_ ,A-2LQ\R[GHU%><_P##07@?_H+_ /D)J/\ AH+P/_T%
M_P#R$U%F',NYZ-17G/\ PT%X'_Z"_P#Y":C_ (:"\#_]!?\ \A-19AS+N>C4
M5YS_ ,-!>!_^@O\ ^0FH_P"&@O __07_ /(3468<R[GHU%><_P##07@?_H+_
M /D)J/\ AH+P/_T%_P#R$U%F',NYZ-17G/\ PT%X'_Z"_P#Y":C_ (:"\#_]
M!?\ \A-19AS+N>C45YS_ ,-!>!_^@O\ ^0FH_P"&@O __07_ /(3468<R[GH
MU%><_P##07@?_H+_ /D)J/\ AH+P/_T%_P#R$U%F',NYZ-17G/\ PT%X'_Z"
M_P#Y":C_ (:"\#_]!?\ \A-19AS+N>BM]T_2O$OV</\ D+>._P#L(+_Z%+73
MM^T%X'VG_B;_ /D)JY3]F>YCO+SQK<0MNBEO4D1O5292#^5/HQ73:L>._M,?
M\E8O?^O>'^1KRNO4_P!IC_DK%[_U[Q?R->5YK\&S;_?ZW^)G]:<//_A)PW^%
M"T4F:,UY)]#="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4
MF:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!=
M"T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,
MT!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4
MF:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!=
M"T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,T!="T4F:,
MT!="T4F:,T!="UZ'^S]_R5K0O]Y__0#7G>:]$_9__P"2M:%_O/\ ^@&O2RW_
M 'VE_B1X6?/_ (2\3_@?Y'NEK_R=5>?]@U?_ $6E>XU\\Z[XHTWP?^TI?:CJ
ML_V:T6P2,OC/S&-,#]*] _X:"\#_ /07_P#(35^_-,_D=-:GHU%><_\ #07@
M?_H+_P#D)J/^&@O _P#T%_\ R$U39CYEW/1J*\Y_X:"\#_\ 07_\A-1_PT%X
M'_Z"_P#Y":BS#F7<]&HKSG_AH+P/_P!!?_R$U'_#07@?_H+_ /D)J+,.9=ST
M:BO.?^&@O __ $%__(34?\-!>!_^@O\ ^0FHLPYEW/1J*\Y_X:"\#_\ 07_\
MA-1_PT%X'_Z"_P#Y":BS#F7<]&HKSG_AH+P/_P!!?_R$U'_#07@?_H+_ /D)
MJ+,.9=ST:BO.?^&@O __ $%__(34?\-!>!_^@O\ ^0FHLPYEW/1J*\Y_X:"\
M#_\ 07_\A-1_PT%X'_Z"_P#Y":BS#F7<]&HKSG_AH+P/_P!!?_R$U'_#07@?
M_H+_ /D)J+,.9=ST:BO.?^&@O __ $%__(34?\-!>!_^@O\ ^0FHLPYEW/1J
M*\Y_X:"\#_\ 07_\A-1_PT%X'_Z"_P#Y":BS#F7<]&HKSG_AH+P/_P!!?_R$
MU'_#07@?_H+_ /D)J+,.9=ST:BO.?^&@O __ $%__(34?\-!>!_^@O\ ^0FH
MLPYEW/1J*\Y_X:"\#_\ 07_\A-1_PT%X'_Z"_P#Y":BS#F7<]&HKSG_AH+P/
M_P!!?_R$U'_#07@?_H+_ /D)J+,.9=ST:BO.?^&@O __ $%__(34?\-!>!_^
M@O\ ^0FHLPYEW/1J*\Y_X:"\#_\ 07_\A-1_PT%X'_Z"_P#Y":BS#F7<]&HK
MSG_AH+P/_P!!?_R$U'_#07@?_H+_ /D)J+,.9=ST:BO.?^&@O __ $%__(34
M?\-!>!_^@O\ ^0FHLPYEW/1J*\Y_X:"\#_\ 07_\A-1_PT%X'_Z"_P#Y":BS
M#F7<T_C-_P DM\3?]>3_ -*J_ O_ ))7H'_7$_\ H1KD/B7\:?"/B#P#KFFV
M.I^;=W-LT<4?ED;F/:NO^!7_ "2K0/\ KB?_ $(T^@KWEH=[1114EA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56U'3
M;75[*6SO8$N;648>*095AG//Y59HH Y3_A5?A#_H7K#_ +]"C_A5?A#_ *%Z
MP_[]"NKHIW8K(Y3_ (57X0_Z%ZP_[]"C_A5?A#_H7K#_ +]"NKHHNPLCE/\
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M^_5'_"H/!O\ T+MC_P!^J[&BCZK0_D7W(/KV*_Y^R^]G'?\ "H/!O_0NV/\
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M_P!^A75T47861RG_  JOPA_T+UA_WZ%'_"J_"'_0O6'_ 'Z%=711=A9'*?\
M"J_"'_0O6'_?H4?\*K\(?]"]8?\ ?H5U=%%V%D<I_P *K\(?]"]8?]^A1_PJ
MOPA_T+UA_P!^A75T47861RG_  JOPA_T+UA_WZ%=#INEVFCV,5G96Z6UK$,)
M%&,*H]A5JBD 4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#YT\&^,=<N_P!H:YTJ?5;J731=W:"U9\QX5'*C
M'L0/RKZ+KY<\&1F/]IZY!Y_TZ[/YQN:^HZN1$0HHHJ"PHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^&G/!?][4/_  %_^O7DS:'8^)/VBK_3-1C,MG<7LJR(K%2?W9(Y'OBO:/\
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M)/\ P(?_ !H]T/>*'_#3G@O^]J'_ ("__7H_X:<\%_WM0_\  7_Z]7_^&=_
M_P#T#)/_  (?_&C_ (9W\#_] R3_ ,"'_P :/=#WBA_PTYX+_O:A_P" O_UZ
M/^&G/!?][4/_  %_^O5__AG?P/\ ] R3_P "'_QH_P"&=_ __0,D_P# A_\
M&CW0]XH?\-.>"_[VH?\ @+_]>C_AISP7_>U#_P !?_KU?_X9W\#_ /0,D_\
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M_P"&=_ __0,D_P"_[_XT>Z'O%#_AISP7_>U#_P !?_KT?\-.>"_[VH?^ O\
M]>K_ /PSOX'_ .@9)_W_ '_QH_X9W\#_ /0,D_[_ +_XT>Z'O%#_ (:<\%_W
MM0_\!?\ Z]'_  TYX+_O:A_X"_\ UZO_ /#._@?_ *!DG_?]_P#&C_AG?P/_
M - R3_O^_P#C1[H>\4/^&G/!?][4/_ 7_P"O1_PTYX+_ +VH?^ O_P!>K_\
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MX'_Z!DG_ ($/_C1[H>\4/^&G/!?][4/_  %_^O1_PTYX+_O:A_X"_P#UZO\
M_#._@?\ Z!DG_@0_^-'_  SOX'_Z!DG_ ($/_C1[H>\4/^&G/!?][4/_  %_
M^O1_PTYX+_O:A_X"_P#UZO\ _#._@?\ Z!DG_@0_^-'_  SOX'_Z!DG_ ($/
M_C1[H>\4/^&G/!?][4/_  %_^O1_PTYX+_O:A_X"_P#UZO\ _#._@?\ Z!DG
M_@0_^-'_  SOX'_Z!DG_ ($/_C1[H>\4/^&G/!?][4/_  %_^O1_PTYX+_O:
MA_X"_P#UZO\ _#._@?\ Z!DG_@0_^-'_  SOX'_Z!DG_ ($/_C1[H>\4/^&G
M/!?][4/_  %_^O1_PTYX+_O:A_X"_P#UZO\ _#._@?\ Z!DG_@0_^-'_  SO
MX'_Z!DG_ ($/_C1[H>\4/^&G/!?][4/_  %_^O1_PTYX+_O:A_X"_P#UZO\
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MMYD$D<L3!D=2,A@1P01SD4I#B4]'\2:3XA5SI6J66IA%5F-G<)+M5L[2=I.
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MX'_Z!DG_ ($/_C1[H>\4/^&G/!?][4/_  %_^O1_PTYX+_O:A_X"_P#UZO\
M_#._@?\ Z!DG_@0_^-'_  SOX'_Z!DG_ ($/_C1[H>\4/^&G/!?][4/_  %_
M^O7 _%;X@_#SXE6"N9-0M-6@4B"Z%IGWV,,\@_I7IO\ PSOX'_Z!DG_@0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444E 'R[I:>7^U#*.O\ I[G\X\U]1U\[6_@CQ!'^T,VL'2;@:6;W?]KP
M-FW8!GK7T35R(CU"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+QAX%\/\ Q TV&P\1
MZ1:ZS90SBYC@NTWJL@5E#@>H#,/Q-;M% 'A7Q6_9?\*ZMX U6T\'^$]'T_Q'
M((_LESL\K81*A?Y@#CY PZ=Z-+_9DTI?@A<>&4L[+0/%&K:59VVJZI91AS-/
M PD!8G[Z^9O]#AVQ@U[K13NR>5'R;H?BKX__  _T?3O EIX MM16Q@CT^VU^
M%U:"-" L;DEQD1@J&)3G8>#W];_9L^$%Y\&OA\VF:E=I<ZG?7)OKF.'F*W=D
M1/+0XRP 098]23C P*]6I:+ARG&?&3P.?B/\+_$GAY(_-N;NU+6J&8PJ;B,B
M2$,PZ+YB)GVR*\5^"?[,&N:'IOC-O&EW;#4]9T?^P+*[LW\Z>RM3$8WVNP Q
M@0 +CC[.O6OIREHOI8=E>Y\O?LM_LSZ]\*?&&I:_XE:V1Q:&WL[>UG$Z;I7#
M2N<J"C#8,;>OFR9H\9?!_P 9?!SXH:E\2/AI:?\ "1QZD+A]1T*YES(SSRJ[
MB/)&5\S$@Y!0(RC*MBOJ&BGS.]Q<JM8\=^$.O_%OQ5XB35?&>AV'AGPW)ITB
M+I:.&NDNUG 5WZD!DW\!B,!3C)./*[?X6_$+]EOQ%JUY\-='_P"$U\,:HD,"
MZ;/+NN+=D,C(3EER$!==^<MYB;@2N:^MJ*5PL>9_!S4/B5K%QK&H^/K"PTFS
MNX;273--M'#26I*-YZ2G&=V=AY9L$L <"O(?!G[(^HW_ ,"=2\'>*9[?3]9&
ML/JFGW5G)YT:'[-%$!(,#<C;7#+_ +I'(&/JJDHN%NYX/X?T7XT^%OA'X;T>
MRCT%_$&DZC#;,);@M'/I4<) 5W*Y\S>%0D<[1NSDFN,T/X?_ !%^/'Q'\,^*
M_'&@6O@;3/#UXEVEI&B&ZN9XI(I5)Y;*MLC7);Y1$P !;-?5E%.X<H4445)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>8?M&@_P#"KKWC/[Z//YUZ?7!?&[0M0\2?
M#V^L=,M7O+QW0K#&0"<'GJ151W%+8Q?V9V'_  K&$9Y%U-_Z$:]7KS;X!>'-
M3\+^ Q9:M926-U]HD?RI""<$\'@FO2:3W%'8****104444 %%%% !1110 44
M44 %%%% !7C7[37@KQQ\2/"=MX8\*0Z:VE7Q9M6DOIS')A'C:&-, Y5B&+?[
M@'(8U[+13V$]3X]\"_"G]I#X;^&X-!T'7/#]OIL+R2(LL<4CY=V<Y8QY/+8&
M>@ ':O>?^%(^$O&"Q:[XO\&:)/XKOX()-4D2/S5-PL*(P5SRRJ$"@GLHKTFB
MBXDK'S=KG[*>FW'QR\/ZG8>&]'B^'\-BT>H:?G;YD^VXPWEXPW+0<Y_A]J^A
M-&T>Q\.Z/8:5IMK'9:;8P1VMK:PKM2&)%"HBCL H 'TJY2T7N-)(^;OVG/@#
MXF^)'C'1?$'A PPWO]FSZ;J$UQ>M$/)R?+15VD899[I7/&00/IE?&+]D_4_$
M'PQ^'FA>&I;5=0\-QR07$:O]FMYGF"23W*G#,)#/$& S_P M7).0*^IJ*?,Q
M<J/,?A[\&;30O@5%X UAGGCO;">WU-H'".S7 8RJKJ ?EWE%;KA5KQ30]!^,
M'[,;ZEH7A;PTGQ \.W]XUU:W"N!)!A$5C(N]=A8;1M&5S&S#&[%?7-%*X6/'
MXOASXI^+'PL\1^&_BC+;VMW?ZBTUHVBR#%O"C1RVXS@;BDBG(;.X#GK7E_@N
M;XY?!.WL/ 6G^#K/Q3I<<[_9=;\X^1#%)*V!(=X90#N<C#%5< 9Q7UA11<+'
MAWCOX?\ C_XC?LVMX;UM]/G\<W#Q-<.D@CMVV78<$%5P/W:CH.O%<KX^_9CU
MO4+#P'XF\-7=O:>//#EAI]K+!<29M9F@488-CAE;=SC#K\IZ#'TW2478<J/G
MGQIXJ^._AJZOI8O!VC^+-)OOLT$5C:R!VMB;93.6!*[H_-\P L2<!>.3C>_9
ML^"^L?"ZU\1ZMXCO+>?Q#XBN%GNX+-%$$.QI"-N /O&5C@  < #@Y]IHHN%M
M;B4M%%(H**** "BBB@ HHHH **** "N1\5_"OP[XTUBSU+5K-KBYMAM7$A57
M&<X8#J*ZZB@".&&.VA2*)%CB0;511@ #L!7D'[4:;O %LV?NWB?R->QUYG^T
M!X9U/Q5X&6TTFRDOKM;F-Q%&0#M&<GDBJCN3+8M? -@WPKT7!S\K#_QXUZ%7
M#_!?0[_P[\/--L=2M7L[R/=OAD()&6]B:[BD]PCL%%%%(H**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6DR*:S5
M&TGO0!-NIN^JS3BF_:1ZT 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;Z
MJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T
M6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH
M^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJ
MI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!
M;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C
M[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^J
MGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %
MO?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/
MM'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ
M?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6
M]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^
MT>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI
M]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;
MWT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[
M1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JG
MVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O
M?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M
M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?
M:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]
M]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T
M>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]
MH]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;W
MT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1
M[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGV
MCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?
M1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'
MO0!;WT;ZJ?:/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:
M/>C[1[T 6]]&^JGVCWH^T>] %O?1OJI]H]Z/M'O0!;WT;ZJ?:/>C[1[T 6]]
M&^JGVCWH^TCUH N!J7=51;@5(LH- %BBHU:G@T +1110 4QFIS5#(V* (Y)=
MN:I2W6WO27<VW/-9L,<FIW#Q1.JLJ[OF_+^M $TVH!>]56U4#^*EF\*W\F<3
MQ?B#523P3J;'BYA'X&@"8ZN/[U)_; _O55/@75/^?J#]:3_A!=5_Y^H/UH M
M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U
M7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H
M/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _
MO54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=
M5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U'
M]L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J
M#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_V
MP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (07
M5?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ
M@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53
M_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A
M!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4
M?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH
M_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M
M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U
M7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H
M/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _
MO54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=
M5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U'
M]L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J
M#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_V
MP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (07
M5?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ
M@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53
M_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A
M!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4
M?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH
M_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M
M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U
M7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H
M/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _
MO54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=
M5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U'
M]L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J
M#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_V
MP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (07
M5?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ
M@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53
M_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A
M!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4
M?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH
M_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M
M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U
M7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H
M/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _
MO54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=
M5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U'
M]L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J
M#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_V
MP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (07
M5?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ
M@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53
M_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A
M!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4
M?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH
M_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M
M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U
M7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H
M/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _
MO54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=
M5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U'
M]L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J
M#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_V
MP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (07
M5?\ GZ@_6C_A!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ
M@_6@"W_; _O4?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53
M_A!=5_Y^H/UH_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A
M!=5_Y^H/UH M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4
M?VP/[U5/^$%U7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH
M_P"$%U7_ )^H/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH M
M_P!L#^]1_; _O54_X075?^?J#]:/^$%U7_GZ@_6@"W_; _O4?VP/[U5/^$%U
M7_GZ@_6C_A!=5_Y^H/UH M_VP/[U']L#^]53_A!=5_Y^H/UH_P"$%U7_ )^H
M/UH M_VP/[U']L#^]53_ (075?\ GZ@_6C_A!=5_Y^H/UH MC5Q_>J1=6']Z
MJ/\ P@NJ?\_4'Y&GIX)U-<9NH/R- &G%J0;O5V&\#=\UDP^$M0CQFXA/YU+<
MVLVD^4)G5]^<;?;% &_#-NJPK5CV=QNQS6G"V10!:HIJTZ@!K55N&PIJRU5+
MKI0!BZE,54U7\)S^9K4Z_P#3$G_QX4W5F(4U5\#ONU^Y'_3 _P#H2T =Y113
M)IEA0NW2@!]%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX
M/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W1
M53^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_
M*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[
M3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U
M;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54
M_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH
M MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX
M/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_
M*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[
M3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +
M=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U
M;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH
M_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX
M/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W1
M53^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_
M*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[
M3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U
M;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54
M_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH
M MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX
M/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_
M*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[
M3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +
M=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U
M;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH
M_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX
M/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W1
M53^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_
M*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[
M3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54_M.#U
M;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH MT54
M_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX/5ORH
M MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_*C^TX
M/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[3@]6_
M*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +=%5/[
M3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U;\J +
M=%5/[3@]6_*C^TX/5ORH MT54_M.#U;\J/[3@]6_*@"W153^TX/5ORH_M.#U
M;\J +=%5/[3@]6_*I8+I+C=LS\O7- $U<KXXF,+:?@XR7_\ 9:ZJN+^(K;6T
MSW,G_LM $FF3;@M=#;-\M<EHS95:ZFS^Z* -!:?4:U)0 QZIW7>KCU3NN] '
M,:P?E:JO@,_\5%=?]>Y_]"6K.L?<:JG@'_D8KK_KW/\ Z$M 'H55=2_X]&^H
M_G5JJNI?\>C?4?SH QJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***RD\7:%)XDD\.IKFFOXA
MCB^T/I"WD9O%CP#O,.[>%P1\V,<CUH U:*** "BBB@ HIR1O)G8K-CKM&:;0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%.2-Y,[$9L==HS0 VB@@
MJ2",$=:* "BBB@ HHIWEOLW[&V?WL<4 -HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***5068 #)]* $HJKI^J66L0--87MO?PI(T326LRRJKJ<,A*D@
M,#P1U%6J "BBB@ HHHH **** "BBB@ HHJA=>(-*L=4M-,NM4L;;4KL9MK*:
MY1)YQSRD9.YONMT!Z'TH OT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 455L]5L=0N;VWM+VVNKBQD$5W#!,KO;N1D+(H.48CG#8.*
MM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%.*,JABI
M"^N*;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15:^U2RTPV
MPO+RWLS<S+;P?:)EC\Z5L[8TR1N<X.%')P:LT %%%% !1110 4444 %%%% !
M1110 45GZ7XATK7)+J/3-5L=2DM'\JY2SN4F,#\_*X4G:>#P<'@^E:% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %:.C_ /+7\/ZUG5HZ/_RU_#^M &E7#_$H_/I7^])_[+7<5PWQ
M,^_I7UD_]EH KZ*?E6NML_N"N1T7[J5UUG]P4 :"5)4:5)0 QZIW7>KCU3NN
M] '+ZQ]QJJ> ?^1BNO\ KW/_ *$M6]8^XU5/ /\ R,5U_P!>Y_\ 0EH ]"JK
MJ7_'HWU'\ZM55U+_ (]&^H_G0!C4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\_P#[=&I>,M(_
M9UUNZ\#>,M.\":S',DDFK:A?BR)@1)'>&"4@D3N44*%P3\PR.:_'GP_^UYXW
MM?C)JOQ L)M)T#QCX@TA=#O->6!XUB9Q$LM^0@.)F$>YF53RS%5SC'[E_&SX
M,>&OC]\/;SP;XKMC<:3=30SEHPOFQ/&X;=&Q!V,5W)N'(61L$$YKXZM?^"7N
MD7?Q^\3W.I:1X=M_A#>^'VTK3+/3'E34;.<+$(K@^8'S,I1BTI?YR3E<,5H
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M".>1G\S/^"//B;4]&_:(\;>$H+K_ (DEYHDMW<0,BDO+;W$:1/NQD86>3(&
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M  C9BV<C(YK\G_VO/ ,GQ6_X*9:_X+BU$Z2WB'6]+THWH0OY(FM+:,MMR-P
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MQ+X2\7>#-'T37+W2+.ZBN+BX^P2F%Y72:%%RZ_,5VR-\N<'(/85YG\3F\?\
MA_QGX<U;XN:?'XBTO2[PP6LJ?9((+_<JRM$NR,DI^[!;=$#A& QP:Z/]L_4(
M-6\<?#:^M)?M%K=:9<3PS8(WH\]JRM@\C((///-7;5$WT9]DS ":0 8&X_SK
MYD^-GQ6\9>*OB<OPP^'5VEA=B-DOKZ.4Q3&0QEF02%<Q+&A5R\>YCN&#P5/T
M[)_Q]-G^_P#UKX[_ &5?^*E^/GCG5=3_ .)I?VK7Y@O;D^9)$?MIA^5SR/W7
M[O\ W1CI41[ER['0ZO\  KXR6?AX7=M\5]1O-2C1)'L1>7,8! !=1*'8OCG'
MR#?CMFO1_P!GWXV#XN:#/!J$'V'Q)IH5;VW8",R@\>:L9^9>1AE(PK''? ]9
MC_UB?45\?_L>DO\ &CXAM)S+MO1ENN/[1/\ ]:G\2#X6K'U]7C?[5'CK4_!?
MPYM[?1+N\L-9UB]CLK>ZLPH91]YUWD@QEE& PY!/4=:]DKY$^)&L6'Q!_:VT
MG1]:OK>S\/\ A\K')%K%O&MN[1J)IDW%@")"8PK.>"IPOK,=QR>AVG[(7Q,U
M3Q5I_B+P]XAU.?4=8TRX,J->S23W&S<8Y5>0DJ0DBA0 >YZ]:W_VI/B(?"OP
MTU*TT?7[:Q\0R2V\;VL-Q']K^SR,0Y"9WJ"N?F ]<&O(M;\76_PP_:N&N:;K
M4%UX;UZ6)KZY2Y2X@VR#9(@2 YS&RH5W@_,Q/(''8?MC?#+0(?"]_P".A:S#
MQ/YMG8FX^TR>7Y08KM\K=LS@GG&:JWO(B[Y6/^!?PP\"_#^;1?%DOQ"L[K5X
M;5_MZ_VA;1VV;@!45U)+(4'R+ELDYSG@#JOA#^T-:>-(_$K^)]2\/Z"-/OV@
MLR;M8!/"-W[P^;(=W0<KQS4?A7]EGX<W?A*WCETJ]9-6M;.:[ U2Y&]UVR@C
MY_E^8D\8].E>3_L\? GP9\1O^$O/B#39KX:5JQM+5!>2HOE O\KA6 <?*,[L
MY_&GH[W#562/K:^U[2]+TV/4+W4[.ST^39LO+BX2.%M_W,.Q"G=VYY[54T[Q
MIX=UB^2QT_Q!I5_?.K.MK:WT4LK*OWB$5B2!W..*^./CA\2-%U?XS3Z!XOMM
M5C\ >&I#81Z3HLD:%G2-0'7F/:&R!PVY0H"G!KA/'7C7X=Q^)=%UWX:Z=XCT
M74;6X$\]O/.D8<KC:("LLC*[8V$+A3N)P2:7(/G/T-NM=TRQU*UTZYU*SM]1
MNAFWLYKA$FF[?(A.YOP!JM8^,- U34!I]EKVEWE^=Q%I;WL4DWR_>^0-NX[\
M<=Z^3/VPM5O)OB!\/[^U,VC:A>:.HC(R)+1YIU4@]#E?,((XS@CBO?O /[.?
M@OX:Z]9ZWI=A,NNVUN]NUTUW,Z-O4+(1&SE0&*YQVI<J2N.[;L>FJNY@,X!.
M,U\>_&SXJ_%76-%O]8M+'4/ 7A.SF%HKQS>3=7$X=UW+)A9-ORYQA4*D?>/-
M?8->'_ME'_BR%S_V$+;_ -GHCN$MCV307:;1=+>5V9GMH6>1CDDE%))/<U\Z
M-X'^.OQ*U#4M4O\ Q,_@*"(S)I^FVUPR>9AVVJZPMA5("D2,SMAN5&,5]$>'
M_P#D7]*_Z\X?_1:USOQ6^)VE_"KPG<:M?SQK=NK1Z?:LN]KFXVY50@()4'!8
MY&!W!(R;/0;U6IXG^S#\5/%">-]6^'7C6ZO+W5HEFN('O9/M$T$D;#SXGFW'
M<GS*5'/4C(&!7T[7S#^QWX)U#4I-5^)6MS17T^K!X;.:>-WN<^83-*)7YV/\
MJC&=P0'<>@^GJ4MQ1O8^;/"_CCQ%X;_:UUSPSKOB2:31=3,S6.FR3//$K.HE
MMD0$?NCY?F$@87C!)P*U/VQ/B!JO@OP?H%KI%Y?:3<:A?.[:E87;6[QK$@S&
M=O+!_,'<8V#KVY+]K!HOAG\4O!'Q"M)8;6[8LMQ'!:H\\XM\&1\L<.WD2>6H
M(XP.1QB3XB:/9?&K]JC1- O=*CFT6RT96O8[R8C[3:R1-*2B@?+(K7" <]5W
M!@0!5Z:,G6S1ZU^S?XX?Q[\)](N+BY>ZU.SS8WC37?VBX>1#@22'[P:1<. W
M.&')ZUY[\/O'&O\ Q&_:?\12:7K-^O@W2HGBDM[>^2XL92FV*-@AR )2KR;H
MQD%2-V"<\M^SMXEN/A!'\6O#]Y-HUM=Z&DE]"9KDXFNHU:()N9E+Q@I O #9
M?&>153X#-+\+/@%X[^)D-I%)J5T1;6BP3G"(LHB&Y&!0%)Y9&Z'<H )]"VX7
MV/JS4/&?A[2;V2SO_$&DV-Y& 7M[F^BCD4$9!*LP(R"",CD&KNDZQ8:]8K>Z
M9?VNI6;,R+<V<ZS1%E)5@&4D$@@@C/!!%? /@_QM\*&LM1N/B1IGBCQ%XJOY
M9#=7=O,@C"EU92C"XC8.0@)8C<-[J#M.*[#]ECXB0>$=?^(,>CV6JZKX<ATN
MYUB&.ZG5!']FR4$P0&-)ID(7</\ GC_%CA.(U(^Q=5\5:'H-REOJ>MZ;IMPZ
M>:L-Y>1PNR9(W!68$C((STR#4NC^(-*\10S2Z3JECJL4,GE2R6-RDZQO@-M8
MH3AL$'!YP0>]? GAOXD^ ]:UK5]=^+%GXA\1ZY>,?L_V%HQ!'"T17IYL9##>
M0HP578C+M(KI_P!F_P 6Z-IG[1)M/!=KK<GAG6(Y+86M[,#);H$\T33JA<,L
M;(T2,S9_?#+9."<@*6ITWP5N)6_;/\9QM+(T8_MS"%B5&+V#'%?54GBC18-9
MCT>36=.CU>0@)I[W<8N&)4N (RVX_*"W3H,]*^"=8^)&H?"K]H;Q]KFEP0SW
M\ESK-C"92#Y+/=1MY@3'SD",@*<#+ G(!!^J_@%\&[/P;9KXIU:]C\1^*]90
M7%QK"R>>HCDPVV%_X@>"7ZN<= % )+J*,NAZ)?>-_#>EW\UC>^(M(L[V';YM
MK<7\,<L>Y0R[D+ C*D$9'((-:&EZM8ZW8QWNFWMMJ-G(6"7-G,LL;%6*L RD
M@X8$'G@@BOA_P?I>@^#OBEXLL?CE8B36-6A9A=PQ%K<-*96GNE*8(#$1B-T3
M<C9 V'=CZF^!7@GPAX/\%O-X)O)=0T36;J34EN99FDSN 0(-V"NQ$6/! ;*$
MOERQ*:L5%W-[XG:U>>&_AGXOUC3I1!J&GZ->WEM*R!PDL<#NC;2"#AE!P1@U
M\C?L]?'[6]#\=1#QAXEU*]\-7ZFSEO-:NGDM[6<*KI()'!VXWA6 *@"56<X4
M5]6?&S_DB_Q _P"Q=U'_ -)9*^1?AW\,Q\1/V:O%\UM;?:-7T;7)+VU58]SR
MQBSMO/A ",QW(,A%&6>.,9Q3C:VHI7NK'O'[87B;6/"_PTTBZT/5[[1KF76H
MHGN-/N6A=HS;7#%2RD$KE5./51Z5[I'EE0#DD"OA_P"(WQ,/Q$_9@\,QWER;
MC6])UZ&RO&DDW22@6ESY4S99F8NF,N<9=9,# KU7]LSXG:CX(\%Z5H^GO+:K
MK27+W=U#(%/V>%$WP],_.9ERP(X0J<AS1R] YM;GM/\ PLKP?Y?F?\);H)CQ
MG?\ VI!MQZYWUTC*5.""#[U\]P_L8^#&\(K 1+_PE!T[R/[4^U7(M?M?E;?/
M^S>;MV[_ )O+STXSWK._8C\>7&O>$=8\.31,8='>*[MYR5_U=RTK&/ &21)'
M(VXDY\W' 44K*UT.[O9GK_Q7\%Z[XZ\/VMAX?\577A"\BNUN)+VS+AY(Q&ZF
M(['4X)96ZX^0<5\J>.[7XA^!_BWH?@5_BAXAO9=42S<7RWLZ+']HN)( "GF'
M.TQ[NHSG''6ON"OD/X^?\G@^!/\ KAHO_IRN:<7T%/N>L?#SX0^/O!?BRTU/
M4_BC?>(]*59$NM,OHI)%F4HVW:7E8(P?8VX#.%9>C&O!/@+'\2OV@+75+YOB
MCK>C7%O';7$JI/*8W:<2,0B)(BQJ"APH& "   *^WF^Z?I7P%^RGXH\?>&]%
MOQX&\*P>)C/:6/VTSNJBWVK)Y9&94SNW2>OW>W=QUN*6ECV#X)_$3XA^$?BM
M;_#+QR[:P\T3%+R:9Y6B;RGN-Z7#HK7"'F,Y^Z4PI&QE/TC8:WINK3W<-CJ-
MI>S6;^7<QVUPDC0-DC:X4DJ<JW!Q]T^E?*W[+-LOQ ^*GB+Q9XKO[B;QQIVS
M;;R1I;;@83;O*8UVG<H7RV38%0LI.6<;5^,>G:O^S[\:8/B/H5BL_A_57VW5
MJMQY,<MPZOYT+JH'#A?.5FW_ +T.S#Y5#)J[L";2N?5$NN:;!JT.ER:C9QZI
M,GF16+W"">1!GYEC)W$?*W('\)]#5VOF[]EOP?/XPU+6?BMXEMQ<ZOJ%Y*NE
MRS%G\A/F25XBSL0G)@4, RK"P!*OS](U#T9HG='S'XJDU/XI?M=:-H<D%Q;:
M1X->.\\R%HR<B..X,IW+G8\AMX2HW$8+ KN)'TVS;59L$A1G ZU\H?LTZ7)_
MPTC\2;X75L(8GU.!K:2;_2':345<.J8YC4(P9L_*7C'\7'I7[6WC"7PM\';V
MVMWFBN=:G33%DCA610C!GF5]WW0T,<JA@"0S+C'44]TB$]&SYZ\._M#>)X_B
M[IWB;4M?U(>#]1U281VM]*PMELPR*X^S1,</#%/"W0@N0?F.:^ZW_=[MWR[>
MN3TKXQ\6>&/#T?[*/AV+3M<TRY\06<T6NS6]C<6\$T[39$@EC9MY:*"100,,
M3;K@?PU[_P# ?Q[+\1/@W8W]Y<K=:K:QRV%\ZA\^;&/E+,_+.T31.S D%G;I
MT#DA1?1G:KXW\-OIJ:BOB+2&TYY/)2\%_"86DV[M@?=M+;><9SCFG6'C+P]J
MMS!;V.OZ5>W$\;2PPVU]%(\B*6#.JJQ+*"C@D< HWH:^*OV2OA;I7Q=M]3M?
M$;SW6B:+:6S0Z?'/+#MN+@9\U61QCY;<J1CYLKS\O-KXK> ]*\)?M">$?!>B
M&ZTK1;JSL-+_ -'N&,R0W5Y<B8;VR3GSGX.1@XZ4<JO8?,[7/LK3/&OAS6KJ
M*VT[Q#I.H7,P+1PVE_%*[@#)*JK$D  GCL*34/&_AO2;R:TO_$6D6-U"P66"
MYOX8Y(R0" RLP()!'7U%?*?[17P/\-_"/3_#FL^#VU#1[VYU+[*3]NEEV$HS
MK(K.Q9"NS "D##'/;'0?$C]DGPMX/^$.IWUE+<2^(M*LA-+J%Q-*T<XC.Z11
M!OV+N4%%."5&"=Q!)7*@YGM8^IB"I((P16+XUOM7TSPAK-WX?L1J>N0VDCV5
MFV,33!3L7EE')]6 ]ZY;]GO5KS6_@IX1N[Z43W)M&B+A OR1RO&@P..$11[X
MR>:]#J=B]T?*&N?#/X\W7A'4O$EUXWOH]:8"8^'].OWA_=!%W;64K''(!N_=
MJNW<OW_FS7HG[*GQ;O/B9X+N[75;A[S6-#DBAEO&3'GQ.I,+LV?FDPC[C@9P
MIY))JO\ M5?&6U^'_@B\T.PU+[/XGU2$*BPLPEM;=CAYMRL#&Q&X(><MV(!Q
ML?LR_#*;X;?#A/M\5LFK:M(M],8;=HI$B*#RH9-P#%D!;J!M+E<<9-]-2%\6
MAY[\.U3X2_M6>)O#3.EOI7B2,W=K&;XE%9\R(SJX^:5G65%4'@. ">E?3M?.
M?QNTNSC_ &EOA%=):Q)=W-P#-<*@#R>7*GEACWV[VQZ;CZU]&5,NC''J@HHH
MJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *T='_P"6OX?UK.K1T?\ Y:_A_6@#2KAOB9]_2OK)_P"RUW-<
M-\3/OZ5]9/\ V6@"MHOW4KKK/[@KD=%^ZE==9_<% &@E25&E24 ,>J=UWJX]
M4[KO0!R^L?<:JG@'_D8KK_KW/_H2U;UC[C54\ _\C%=?]>Y_]"6@#T*JNI?\
M>C?4?SJU574O^/1OJ/YT 8U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@_[=VAZEXF_9
M%^)FEZ/IUWJVIW5C"D%E8P-/-*PNH20J*"S' )X'0$UX1_P24^&^M>#?@GXR
MM?%OA6^T2]E\0^;##K6G/;R/']FB&Y1*H)7((R.,@U]W]*4DGJ<T /MR!<1$
MG ##^=?DK_P3#^%/C?P9^USXBU7Q!X-\0:%IDNBZA&E[J>ESVT+,UQ"54.Z
M$D D#/.#7ZS4NXGJ2: /SO\ ^"PGP]\4_$#P[\*X_"_AG6/$DEK=:FUPND6$
MMT80R6NTOY:G;G:V,]<'TJE^UA\._%>N?\$Q_@YX=TWPOK6H>(+-M%^TZ3:Z
M?-+=0;+&X5]\2J67:Q .1P2!WK]'0Q7H<4;CUSS0!^<GA?X=^*[?_@C[J_A6
M3PQK,?B=TF"Z(VGS"];.LJXQ!MWGY/FZ=.>E=Y_P2(\$^(O /P+\3V7B;0-4
M\.7DOBAYX[?5K.2UD>/[+;C>%D4$KE2,],@U]O[CG.>:0DGJ<T ?D[_P2O\
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MM4<)/')91P;A*B2!2&5_E(S\O0 @U]E49-$78&KGR!\0_'?Q&_:"_LKP;9>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU*U&F@3&YV$.JK@-N1@>=O)'0U9_9Q\9MXX^$.BW4KR2W5D&TZ>62)(P[Q8
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MB6&W)S@RE96**2,9QQG)P,D>RZOK5AX?TFYU34KN*STZVC\V:YD;Y%7U]\Y
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M: <_.5XP1Z\9KQ?]B'PNEOX/U+Q1.\%SJ6K7[0O,MN$EC6)L.A<'E6D+/@
M$]*:6EQ7UL>R:A\2O!^DWT]E?>+=!LKR!S'-;7.J01R1L.JLK."I]B*UM'US
M3?$6GK?:3J-IJMBS,BW5C.D\193A@'0D9!ZC/%?$7[+/PL\._%3Q-XKM?$=A
M)?PV:F:%8[B2(JS7,@))1@3P!UKI_#_A^Z^%'[7T'ACPFVH6NASM";NWP9E:
MV>!I&5L@X1'VX=OF!/WN>7RHGF9]9:QXCTCP^UJ-5U6QTLW<GDVXO;E(?.DX
M^1-Q&YN1P,GD5HU\@_M9?-^T+\.P>@M+4X]_[0/-?7MU<0VJSSW,T=M;1!I)
M9Y6"I&@R69B>   22>@%*VA2>K11UKQ!I7AFS6\UC4[+2+-I!"MQ?W*01ESG
M"!G(&XX.!UX-9MC\1?"6J:A;V%EXJT.\OKEMD%K;ZE!)+*P!)"(')8X!. .@
M-?)?@?PC)^U=\6/$NM^([W4K72;#9]FCM]LD:Q&4[+6.;9L "J6;:N]A*&R#
M\Q]%^*W[*OA71_!^H:YX32ZT36-'@DOXF-_(T;^7AR69][*557*[-IW8R<='
MRK9D\SW1](HI=E4=2<5P7PJ^-'A[XP0:H^ABZA?3IA#+!?")96!'$BJDCYC)
MRH8XR58=JP_V:_BM=_%;X?M<ZF6DU?3I_L=U<"((D_RAT<8)R2C+N.%&[.!B
MO.O#=XWPS_;#UW2/]/.G>*AYBM);)MDF=#.NU\+^ZC/GI\N3D@-DC(5MT/FV
M9].T45YG\6OVA/"GP9U'3['7UOY)[R%KC_0X4988PQ4,[.Z ;F#  $GY3D 8
MRMRMCTRBO&/ _P"UQ\/?'WB"TTFQNKNTDNCY<-U>I$MNTN0%BWK(V';/&1@G
MC.2 ?,?CA^TQ9/X_TC3-"U/6=,7POK,T.O1P3+$ERD<L:LH"2?.O[N7APOWN
MV3347>Q+DK7/K6BO.OA+\=?#_P :9-4_X1^RU6.WT\1^9=7D"+ [/N_=HZ2,
M"ZA067C =#WKM?$%C=:KX?U2RL;UM-O;JTE@@O4!+6\C(5608(.5)#<$'CJ.
MM(KI=%+5?'WA?0KZ:RU/Q+HVFWL(!EMKS4(898\@,-RLP(R"#R.A!K6L+^UU
M6QM[VQN8;VSN(UF@N;>0212HPRKHRDAE((((.#FOG5?V,_">F^ ]135=?N#K
MGD><WB*X<16]DR(I9O)R%\G*L2)&9@K-^\&%*T?V(->U:?2_%&AS12-H=C)#
M<6=RP<H)93)YT2$G8 /+23:O(,Q8YW"JLK71/,[V9]-W5U#8VLUS<S1V]M"C
M2RS3.$2-%&69F/   ))/  JEH?B/2/$UJ]UHVJV.L6R2>4\VGW*3HK@ E2R$
M@'#*<=<$>M>!?M->+K[Q9XI\._"'0IH1<Z]+'_:3,D<C(NX21J,R#!1(I)W3
M 9E6/:WS$'B_V"79M<\=;CDFPTMC@8&=]YDXHY=+AS:V/L*L_1/$6D^)K5[K
M1]4L=7M4D,33V%RDZ*X )4LA(#88''7D>M:*G# U\G_LKV8\!_&SX@^#8[*\
M:-8V"7E[\DGEVMPT<;,FP!O-6Y#AQ@8 (!##"2NAMV:/ICQ!XPT#PGY']N:[
MI>B>>&,7]I7L5OY@7&XKO89QN7..FX>M:]?$7[:GBP:K\2;72DF:\L-#LXH[
MB%;8XL[BX<%F=]OW71K,9R5!90,,2*^D_AY\5HM4^ UIXYU1;RZ-EI<UQJ&V
M"-)IY+4.MPT:*P7YWB<H,J"&7.WH#ET3$I:M'=:9XBTG6[J^MM.U6QU"YL9/
M*NX;2Y25[9\L-DBJ24;*L,-@Y4^AK0KYB_8NTDZ])XS\;ZA<6]_KEY??89I%
MME26.0JMQ.P9> LIFA)0  >4IYXQU^O_ +87P^\/ZQJE@SZE?KI_,U[8PQ/;
ME=R)O5S(/D\R18]Q 4L0 3N4D<==!J6EV>W45QGPO^+GAWXNZ//?:%-*DEM)
MY=S87BJES;DD[&=%9AM<*2K D'!&=RLJ\IXX_:D\#^ _%%UH%VVH7][:1O)<
M/IT4<D<116>5"6D4YC1"SX!"@')!5@JLQW1Z]7)>'OBOX3\5^*;_ ,-Z3K*7
MFMV(F-S9K#*IC$,JQ2_,R!3M=E7@G.<C(YK(^%/QX\*?&*2]AT.:X@O;3YS9
M7ZI'-)"0N)XPKL&CRP4D'(.,@;D+>!?LX?\ )VGC_C_EEKG_ *=(*=A<VUC[
M!HKSSPI\<O#_ (Z\;7OAS0+74M6^Q9-SJ]M#&;", '!\SS-S!F!1=JG<02,H
M"PXO_ALSP+)9:A?1:?XBFTZQD5);U;",0@.Y2)R6E&P2$?('"L>F <@+E8<R
M/=ZAO+VWTVSGN[RXBM+2WC:6:XG<)'&BC+,S$X4  DD\"L?P+XVTOXB^$].\
M1Z+)))IU\K%/.0HZ,CM'(C#LRNCJ<$C*G!(P3YG^V-_R0'61_P!/^F_^ET%"
M5W8;>ESOF^+G@->6\<>&0,XYUFV_^+KK64JV&!!]#7RI\*OV:_!OQ(^".BZI
M=Q76GZW>+*\FI6MP0P\NYD4#8^Z, J@4_+G!)&#S6O\ L4ZGJ9T/Q7HMYJD.
MHV&E7,(M1:S">VC9_.,K02XRT3L@8=N2P +-FG%="%)Z7/I.BO"?$'[:'PV\
M-ZU=Z=/<7]QY$AB6ZMXX3!.1C)B9I5++G(SC!QD9&"?1/AC\6_#OQ<T^XNM
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MI7UD_P#9: *VB_=2NNL_N"N1T7[J5UUG]P4 :"5)4:5)0 QZIW7>KCU3NN]
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M("QE6.3PFX-QD,..YC[)?VCM/BIJ^AZ#\-_$>H^)K%M2\/V]FSWUG&BNTL7
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M%?"?PC^//@;0X-&T+Q?H-AI<#.\=OL27:7<NWS/:ECEF)Y/>DOAL#TE<P?\
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M <FO#_A/#-#^QS\3&E@EA25-4>)I$*B5?L<8W(3]Y=P9<CC*L.H-9NN_#_\
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M8_E7 R"<9))\D\#H/"O[:&N^'=-D:STW5);R&>)CYC2J]G]K8!GR1^^^88/
M&W[O%7=+\(_'_P"#6EOH?A]+?Q-I<Z7$=L;-X&%@Q==LX%R4*L1EA%F6,$OD
M,<$^L?!WX+W_ (-NM9\2>)]6.K>-M962*YO(96:&&,L" F0N3\J'.!M "J
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M640N&*\,I((8 ,!DX# $D@FOEK]CW_DM7Q#_ .W_ /\ 3D:^OU.U@3V->"?
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M3[7?^>=M_P!^S_C0!Z=17F/_  GVN_\ /.V_[]G_ !H_X3[7?^>=M_W[/^-
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M >G45YC_ ,)]KO\ SSMO^_9_QH_X3[7?^>=M_P!^S_C0!Z=17F/_  GVN_\
M/.V_[]G_ !H_X3[7?^>=M_W[/^- 'IU%>8_\)]KO_/.V_P"_9_QH_P"$^UW_
M )YVW_?L_P"- 'IU%>8_\)]KO_/.V_[]G_&C_A/M=_YYVW_?L_XT >G45YC_
M ,)]KO\ SSMO^_9_QH_X3[7?^>=M_P!^S_C0!Z=17F/_  GVN_\ /.V_[]G_
M !H_X3[7?^>=M_W[/^- 'IU%>8_\)]KO_/.V_P"_9_QH_P"$^UW_ )YVW_?L
M_P"- 'IU%>8_\)]KO_/.V_[]G_&C_A/M=_YYVW_?L_XT >G45YC_ ,)]KO\
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M3[7?^>=M_P!^S_C0!Z=17F/_  GVN_\ /.V_[]G_ !H_X3[7?^>=M_W[/^-
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M >G45YC_ ,)]KO\ SSMO^_9_QH_X3[7?^>=M_P!^S_C0!Z=17F/_  GVN_\
M/.V_[]G_ !H_X3[7?^>=M_W[/^- 'IU%>8_\)]KO_/.V_P"_9_QH_P"$^UW_
M )YVW_?L_P"- 'IU%>8_\)]KO_/.V_[]G_&C_A/M=_YYVW_?L_XT >G45YC_
M ,)]KO\ SSMO^_9_QH_X3[7?^>=M_P!^S_C0!Z=17F/_  GVN_\ /.V_[]G_
M !H_X3[7?^>=M_W[/^- 'IU%>8_\)]KO_/.V_P"_9_QH_P"$^UW_ )YVW_?L
M_P"- 'IU%>8_\)]KO_/.V_[]G_&C_A/M=_YYVW_?L_XT >G45YC_ ,)]KO\
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MZ* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH
M9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSV
MHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[
M4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z*
M &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L
M]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV
M>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^
MB@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &
M;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J
M-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U
M/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@
M!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/
M:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-G
MM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/H
MH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!F
MSVHV>U/HH 9L]J-GM3Z* &;/:C9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C
M9[4^B@!FSVHV>U/HH 9L]J-GM3Z* &;/:C;[4^B@!FVEVTZB@!*6BB@ HHHH
M **** "BBB@ I&8*I). .232U\S_ /!1/XY3_ ?]EGQ-J6FZG_97B+6FCT/2
MK@"8.LTY(D>-XB#'(D"SR(Y8 -&O4X4@'O'@_P"(7A;XA:/-J_A7Q)I'B?2H
M96ADO=%OHKR%)%4,R%XV8!@&4[<YPP]:XW3?VGOAGK'@SP1XLL_$PF\/^-=6
M30] O/L-R/MMZ\DD:Q;#'NCRT,@W2!5^7K@C/P9_P3Y^*W@CX=_M'^*OA)X"
M\9VWB;X>>(O#]M?Z3(EKJ$3-J]M:1I>'RK@ 0-,([F=Q\R[5@59,KLJ#X9_\
MF7_L/_\ 96+/_P!+]1H _4RBOGW]O3XH^*_@U^R[XK\6>"M4&C>);.>PCM;Q
MK>*<)YM[#$_R2HRG*NPY4XSD<UY=X3\3?'CX+_M&_"KP3\2/BOI_Q"L/'6DZ
MM)=P1>&[>R72I[2V2;=!+$%:8;CMRZ@%0?D!(V@'VG4<\R6T,DTC;8XU+LV,
MX &2:_,+P3^UY\2(?C#\,K;0_C;J_P 9/!?B+Q%:^'[[5+GX:0Z)HZO/N5XH
M[O*R&ZC!201A=N&!)8!D*?\ !-_PKXYM_CE^T/>2_$!;C3]&U^Y@\06#:)!C
MQ!<DWJI<;\YM@LBM)Y: J=VT\"@#]&_AK\2O#GQ?\$:7XO\ ".I?VOX=U-7>
MTO1#)#Y@5VC8[)%5QAD8<@=*Z>OR?TS]K'XGZ+\!_P!G'POX(N-2T'4_$EAJ
M^HZE-X&^'UMJ-PRPW4RQ16MD%AM2OWFE$>'3:KMC=B3L8?VI?VB]#_8^^*6M
M>)H?$/ASQMH>OZ?!H7B;Q-X9ATR2]L[FZ2+;]C:#R@553N(,F#-C=\H) /TO
MHKX$NM8_:5^&_P 9M"^&?C3XOZ3XHMO'7A+5I;;4H/#EM%)H]_;VQD9T1403
M*K% "YPZELHA -?.G['^I?&GP#^P7XV\:?#3Q3J-R5UI;2Q\,:5X:@U"XM9O
M/M#<WBNRNTH,!93&R[5 +9!YH _8:BOF_P#8=^+DGQ?^&^H:E+\8;7XOR1W"
M;K@^&TT.^TXL@8P7$"2%6Y^ZZJ 2'P\@&1P7COXG_$WXW?M>>)/A)\+OBO;?
M#?3O".@Q7VI72>&(=3EGO))4!A?[20 %1XV#1\?.P.3]T ^S:*_+Z/\ ;"^.
M'CGP9H_@;PYXVM=/^)=C\3&\$7WB>?1;5+>_@=+CR96A*2JC9A8L$1< (!G+
M&OHO]FWQM\8O#O[3_CSX1_%#QQI_Q"L[#0;;7M-UB#28M/G"R2^7L:.)55>=
MV0=_12&&2M 'TO)\0/"\/C&/PD_B32$\5RP?:8]":^B%\\6"?,$&[>5P#\V,
M<&H[/XD>$M2U_5]"M/%&BW6MZ/'YNI:;#J$+W-DF =TT8;=&,$<L .17YZ_'
MCQ1XM\'_ /!5O0]3\$>"O^%@^((_!P6+0_[5BTWS$*SAV\^4%1M'.".>E4/V
M5M<\0>)/VROVIM3\4^&O^$.\07'AIFO-#^WQWWV1MD0"^?& KY !R!WQVH ^
M]]!_:.^$WBC6+32=%^*'@O5]5O)!%;6-AX@M)YYG/1419"S'V KIO"OQ \+^
M.I-1C\-^)-(\0/ILYMKY=+OHKDVLHSF.4(QV-P?E;!X-?AI\+X;FP_91\.:U
MJ?PLTG3_  99>,H9=5^+,26EWJT"+-&1;0P;XY\!L G>5*L0 *^S=/\ BC:_
MLH?M*?&J\LA?/X'\;^$F\>:+_9FBQ00"X2+<[*9"N]@#N(X!:3YE!Y(!]_>%
M?B!X7\=2:BGAOQ)I'B%]-G^S7JZ5?Q7)M91G,<NQCL;@_*V#P:J?#GXH>&/B
MSHUYJOA34_[5L+2^GTV>;R)8=EQ"VV5,2*I.T\9 P>Q->2_L&_#G4?AW^S3X
M<.N&X_X2+Q \WB+5!.\+8N+IO,8KY0"A2-K!1G&XCV'Q-\+9/CK\/?@#\8_B
M=X/^*]GX:\(^&_$^L7EOX5;P];7S7SI<GSA+/(H>(,2 -I;C/W30!^KM%?$_
M[4'QZ\1Z-IWPXFT3XRZE\/\ Q-XAT)+Z#P=X;\ +XCO-;G=48BW\P[4*[BH1
MG&1SGBO*?"G[9GQ8^)GP[^#G@RS\:V_A;XD>,/$]_I%SX@N/#<;W4=E:L5$S
MVK'R$E9OE=!C'\.,9(!^@GB_XH>&? >O>%]&UW4_L.I>)[QM/TF#R)9/M,X0
MN4W(I"?*"<N0/>NJK\\?VJ+WQY\ +WX"ZW\0O$]U\9M4TCQ;=W\,FB>'(]/O
M)HELV/DF&*1D?!YWJ%PH)(;%6/$G[3WQC\-_L5R?&35_%VCZ7>^,];L_[)%K
MI*W$?AG3)W*' (!N)5"ECY@;G(&<C !^@U%?ECX?_:F^,E_X9^-WB?PY\=IO
MB/X0\&^&XY]/U\>![;3(9M1E=!LP\.0T2Y.UMP8/G P#7H7Q!^*/Q[^ 7P9\
M+:AXK^-VGZ_XV^(MYINF:-;Q^$[=(M',KAKB:.1%59V5'3 F51UP#V /T,HK
MX#\3?&SXQ?LQ_'*R^'OCGXHK\38?%?A;4;[2[Y/"]IILFFWT$<KQG$38=#Y9
MW;@W10%ZFNEU_P#:*^(5C^Q?\#?'D.O[/%?B76=#M-5O_L5N?M$5Q*5F7RS'
ML3<!U501VQ0!]KT5^>&O^-/VF_B%XJ_:+U;P9\8=/\+>&_AYJ=S;Z=H]SH%G
M</.(HO.:,RM 611'T8[R6X( ^:MK3_CK\:/V@-?^"'A7PMX]T_X97WB?P(WB
MW5-6M?#T.I&:82+&8EBG<JJ<[A@Y!SR1@  ^R_!?Q0\,?$34O$UAX>U/^T+O
MPUJ+:3JL?D2Q_9KI5#-'EU ? 8?,N5YZUU5?&'_!-_3O$^DW7Q\LO&FJV^N>
M*X/'D\>I:E:1"**YG$$6Z14"J%!ZX"C%4?'^N?M"_%+]KKXD^ OAM\5['P%X
M<\,:)87T<-WH=K>F2XGARB O"6",ZMN<L2HQM1N@ /MVBO@7X*_M6?%'QM8_
MLP_VYK5K]K\4:]KNC^(S9V,2IJ*V4;K&YRG[MBR;B8M@)/0#BI?VDOVRO&/P
M1\7_ +1\,6N6Z6_AW3- @\*V=U8)(D-]>QNTIRB;F.U)''FL4!0#&#M(!]R^
M(=>L/"N@:GK6J3_9=,TVVEO+J?8S^7#&A=VVJ"3A5)P 2<<"JO@OQEH_Q"\)
M:1XF\/WG]H:'JUK'>V5UY;Q^;"ZAD;:X#+D$<, ?:OFN;P'\8/#'P)^)NI?$
M#XR6WQ)TF_\ !E^\5@_A.WTN6UE-I(VY)H)<,""05=#G"D%>=WRI)^TM\4/"
MO@_X!?#7X=:EXJT:W3X<V6KWTWA'P*GB*_GD8*J@17#)&T"KC,D3':[%6R>%
M /U9HK\P_ /[67[0/Q D^%OP=UC6M2^&'Q3U[6=2^W^(/$'A%1=S:;% TUK/
M':2Q10!&82PD+N;, ;<,D-ZCX%^/WQ9\'_%+XZ_!#Q)XMF^)'CC0?"<GB'PQ
MX@LO#MO9RM-]D5O(:WB+*Q$DT&Q=CECYFXXVK0!]Q:EJ5IHVG76H:A=0V-A:
MQ-/<75S((XH8U!9G=B0%4 $DG@ 5R7P9^*^G?&[X<:1XUTG2]6TG2]4#R6T&
MM6ZP7#QJ[*LNU68%'"AT8,0R,I[U^9FK?M(^.O'?['_QIM_%/QMN=7\<V>BV
M\.K>!=0\)IH.K:)*;^&"<)/"ZB:%E9XY%*$XDC#"(L4;;_;Q^%NK^!O%7['7
MA;PSXON+#2[*XM-#T4W5A#<2V-U%+:*+YVPHF)#09B("?N/]LX /T/OOCEX1
MTOXU6?PKO]1^P>+[_25UFPM[@!8[Z'S)4=(FS\TJ>2S%" =IW+N"OMU? OQ0
M\,_$J;Q)#X;U/^TI/#NK3:'JB^1+%]GO8@IDB^=5W8#K\RY4YX)KX_\ VRK;
MQ3\/_'_[(&MS^,]/U+Q1I?BF+0[^]E@BM[K53>"W@N9XK4*R*A190^T_NS/'
MMY((Y"^^.GCWPSX9^)5CX/U'1_"^N:]^T"W@F#6K?0+0M9V\X0F=HE1%N)OE
M ,D^]F4D%L[64 ^[W^*'AB/XH1_#MM3QXRDT@ZZNF^1+S9";R3+YFWR_]9\N
MW=N[XQS755^:-YJGQ0_9S_; ^(/B3XA>-;?XGZUHGP:OM2T74H=!^S;HEO8_
M+BGM;5>%%P)-S!CB,[V= #LQ/@#^U%^TWKOQ&^$FHW\7Q$\=>#M?N8$UZ&\^
M'-OI.F6\-PJHEQ!?P)*TT,;2^;YA$098EZ!SM /U)HK\^? ?[1?Q(7]LK7_!
M7Q ^+\W@&T7Q5<P>&_!OB/P/$+/Q#I3331P&WU%3$ZN?+*H[$AG\K!F+-'7Z
M"T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YK\4/@
M'X>^+WC?X?>(_$%]K##P5J#:M8:1:WIBL;B\POE3W$8&7:$J2F&7&]P=RLRG
MTJB@#RCXJ?LYZ%\6OB5\.O'%]K>OZ-K/@:XGGL%T:ZC@BN1,8O-BN,QLSQNL
M00JK+E7<'.>.9T/]B[P3X?\ AC\*_ MOJNOOI/PY\0Q>)=)FDN(#//<QS32A
M+@B$*T>ZX<$(J' 7YNI/OM% 'S/_ ,%'?!NM?$#]D'QEH/A_1]0U[5;JXTT1
MV.EVSW%PZK?P,Y5$!8[5#,>. "3P*S_A9_P3Y\)^ O%":KXB\9^+_B9:Z=87
M.CZ#I/B_4!=V>E6$]LD$T*Q;0KEE61>@CV.J^7N0.?JBB@#Y/\$_\$]]%\)G
MP%9W?Q+\:ZSX<^'^LKK'A?0)'LH;6V8,LA%SLM@URYE,Q\PE2J2[%"_,S=#X
M)_8C\/?#;X_:]\2?"_B[Q1I%AXA:[N=8\)1WV=.O+R92HF8$9(7S)W"/NP\B
ME2BKL;Z/HH ^5]?_ ."?GA=OA7X$\+^$_&OB[P=X@\!Q7L?AWQ98WRB]A^TL
M[RI.J+&LL;,PRJB-BJ!=X!;/1WG['.G^*O@_KG@;QM\0_&WC*?7K^VU/4=:O
M]24R+/#*DP2T@9&AM8/,4D1(G"MMW':I'T+10!YWXP^!N@>./BOX/^(&HW.H
M+JWA>TO[*TM8946VFCNXQ'+YH*%R0!\I5EP>N:^>_"O_  37TOX>W6K6_@OX
MT_%3P5X;GF^UV.@Z#KP@M[2<EBY8%")D($2@, V(SN=]WR_9%% 'DOP!_9WT
M[X%0^([YM?U;Q=XN\474=_K_ (AUB0>9>7"IM&R) $AB7+;(U!VJ0NY@JXXK
M]HG]C6+XT>+X_&OA;XC>*_A7XZ^QQZ9/J_AR]D2.[LUE#^5-$KH3C+;2KJ 6
MRP? %?1]% 'SWX:_8A\!^%?#_@72K34_$4S>%/$[>+TO[R^2>YU+46!#R73M
M&0P8'D($Z YR23Z)I_P5T33?CAJ_Q3BNM0;Q!J>BPZ%-:O(GV18(Y3(K*NS<
M'R>27(QVKT"B@#R"\_9A\+7O[2UC\<'U#5QXKM-+.DI9K-%]A,15UW%/+W[L
M.>=^.!Q53PS^R?X2\*_&#XC_ !'M-2UJ36_'=G]AU*WFGA-M"FU5S"HB#*<(
M/O,PZ\5[510!\:>%O^"6?PW\-:59:#+XZ^)&M^#+>]6_E\(:CKL7]D74BL&S
M+!' F<D#)!!XZUZ9^T/^Q%\-?VEKGPA/XEAU#39/"^([%=&ECBB:WRI^SO$\
M;QF+Y5X"@X&,XXKW^B@""SL[?3;."TM(([6UMXUBA@A0(D:*,*JJ.     .F
M*^-+S_@EWX0.L:P=/^)WQ%TSPUXBOIK[Q%X<M]6CCM-4+L6$;".)0%!)!W!R
M5X!4_-7VE10!\_\ Q%_8]T?Q5X^\+^-/"OBC5OASXDT33?["^W:';VLLEQIQ
M7:8BT\4C>8% 5)224Y."3FN;N/\ @GQX+C^#^E^"--\7>,M.U#1M7N=>TGQ9
M'J:C5;2]F!WR&1$17!SSE0Q&<,"<U]244 ?/'A_]B_0K.R\$?\)+XY\;>.M4
M\+ZH^KK?^)-6^VF[F> PO$Z2JP2#:6Q&FT\_,S'FOGG]J?\ 8?'P]^&D:?#?
M2?$GB7P<GB6/7;[PKI=U&VI:*F<M)H),#/$Y8@O&2^X*-H!^8?H;10!^=7P+
M^!/Q(^,6M>/] \17WQ8MO@-XFT1=/9OBMJ@_X2..[60,S6T!+I$N1R\D7S+C
M!-?8OQ7_ &>?#'QB^$]IX UNXU2VTZR^RR66HZ;=>1>VLUN!Y4R2!=N\8[J1
MSTZ8]0HH ^8?@K^PSI_P^US4?$/CGXA>+?BYXFNM.NM%COO$FH2F.UL)V.^&
M)-[,&92 S%SDC*JF:XW3O^"7OA&'7-#EU'XG?$75_#WAJ_@OO#GAZ[U6.2TT
MSRRK&,*\3 J64#Y A"X!)/S5]H44 >5>'?V<O#?AJV^*D%K?:K(GQ&O+B]U4
MS2Q$P/-#Y+BWQ&-H"\C?OY[GI7F/C/\ 8%\.:QX7\"67A?QWXS\">(/!NE)H
M6G^)-$U+RKN:PWJSPS[%56R V"@3#$$A@H6OJ.B@#QG]F3]ECPO^RIX<US1O
M"^JZYK$.L:@=2N;C7KB*:;SBBH<-'%'P0H/()R3S73>'/@KHGA?XQ^,/B3:W
M>H2:YXHL[.RO+>:1#;1I;*5C,:A P)#'.YF]@*] HH ^7M<_X)_^#[KX3Z!X
M0T+Q9XL\-:KX;U"_U70?%-C?K'?V5S=EVER8T17C)8 J K;5P'7))K^!?^"=
M/P]\)>&_B3I.J>(O%WC%OB#:PP:[>Z]J4<EQ))&[2+.DB1*P?S&W?.7!V@$$
M9!^J:* /G;X8_L<IX%T'Q9I>O?%CXB^/8->T^ZT=(_$&NR30V-G*&0"*$YC,
MPC*J964C*Y54#,IQ_&G[">EWFA^ Y/ ?C_Q1\/?&G@C1H=!TCQ+9SK,9[..1
M'6*]MP$2X3*DE!L#%OF#* M?4-% 'S)XP_86TGQ;\/\ 1=*E^)GQ$_X3/0KN
MZU'2O'=SK\LVJ6UQ/%Y;J#PJP$!!Y48CX4X8%W9IOAK^Q'I_@+P+XNT^Z^)G
MCS5O&_B^&SCUKQ\NL-%JQ^S[?+6V<[_)08< -O;;(5+L N/I6B@#X]\5?\$\
M;/Q1X)^($>M_$/Q5XY\;:[X>/AW3-:\1WJ 6-I%.L]K"0D1W9>&W\^5E9Y"L
MCJ$:1LUK']F>/]KS]E;X3KXYN/&G@;XD>$;0+9ZY>>9;ZG:ZC"HA>X=)#NDC
M>6".96)21E5"KQEC7V710!\>_$K]GO7?B#^T=^S[H%WINH^(O _PNTUM9U#Q
M?K^H2&?4;Q@(K:,LJ@RW"RVD4[G=M(;YP-RB3N_$7[#O@3Q+X5\7:)/JWB6T
M?Q#XR;QXNJ6.H)!>:7JAV@26KK& JJ%( =7(WDYW!2OT/10!\K?"'_@GQX4^
M'?B37O$_B3QIXP^)/B;Q+X<E\-:]=^(]0#QWMO,L2R[=J^='\L2JN9F*J<9)
M -6OA#^Q/??"GQ)I@_X79\1=;\#:#/%/H7A*XU4PQ0;8DC:&ZFBVM<P Q1-'
M !'&@5E*N))-WT_10!\PZ/\ L+V:>,O#FI>*/BS\1?B!H'AO5(M?TK0?$^KK
M<)'J:;@)Y9EC621$"PF.+*K&RRG+"=UKZ>HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>eigr-20221231_g13.jpg
<TEXT>
begin 644 eigr-20221231_g13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )&!$H# 2(  A$! Q$!_\0
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MGN-3BL6BNRP15>.5MV5(P<QJ.>.36DJ<H.SZF=.I&:<ET/8::S8YZ5\"Q_\
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M*D@]1GBMN@ HHHH **** "BBFLP49)Q0 ZBF>:I. ><9Q2JP;H<]Z '4444
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M8E_;N^!?PC^$NJZ-XL\=KI.I3^)=5OXX&TJ]E+033EXGW1P,!N7G!.1W Z4
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M/"TID\1>%]4OYW^WPJ^\(^Y7,Z!2WRRR;<D'' (^:_BSXR^&'PR_;<^"^H_
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MKE89=2C$MVY:"-R&DPGS$*"0.3@5^D'V41@A8UPW50,=.E)]C$;ATBC!7I@
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MI]VWE)<:)=*?[52Z8JIB2S0/+,VY\#R5D!YP3@FOHX0?($*C8!C;QM_*L9?
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MY74C!!SU&,CD5B>$_A[X=\!VDUKX:\/:7H%O,^^2+2[..U21CU8B, 9_#^=
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M9O\ $C36U6]MM!#*UZS%"\4D<#<S+G;]T,,G!ZXK!_X)X?&/X3:)X/\ $OQ
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M%#1L,<@J>&!]#69X3\ ^'O 6GM8^&M TSP]9%S)]ETJTCMHMQZMM0 9/KUH
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MH"V^CR:="UI"%.0$A*[%P23P.M=+IVGP:7:P6MK;QVMM!&(XX845410, *
M  !VH F93M/.3GOQFOS7_:Z^&/BS]EO]K#2_VG_!NA7/B/PVZ[O$UG NZ2!?
M+$,KY.=JO%CY@N$*9/!X_2PYJ-HMP.0#GJ.N1[T > ^%_P!NSX"^*O!8\5I\
M3] TVT$+22V.J7J6U_%@ LGV9CYK,.GR*P8_=+<5R=U9^-/VN?AS\4=LESX8
M^'_B?0'TKPGIVIV:?:KTLK,=5E5E62*-\HL49?[N78*64#WJQ^#?@?3?&$OB
MJU\$^';7Q++DOK,.F0+>,3P<RA-Q^N>U=:MN<Y QSD4 ?$G[ ?QX\-?#SX$V
M_P ,/B-JVE?#OQOX%N)].OM'\0:C'9S-$9&E6=?-VJZ'S&'R%EPH.[#BL7X)
MZ?=?M'?\%"/$OQMTH,/ASX0TQM!TG6XXB;;69-CHYB=MNY5,LQWH&7Y%Y^<$
M_:WB?X=^'/''V0^(_#FD:^;.3SK;^TK..X\E_P"^A<'!Z<@9XK>@M1;QJD2K
M&B*%550 8&,  < 4 ?FKXT^-'@&'_@K=X1\1-XTT'^P+3PW)IEQJHU&(VL-U
MY=TGDO+NVJ^YU&">"15K_@L!\3O"5YH'PV\)V_B+3KCQ)9>)8M0N]-BN%>:V
MMQ$P\R4#_5@[UQNP2#D9 )'Z/_88N1Y,>/\ ='X_Y]Z:UF"<^4A.",$ CUR>
M!WH ^-?^"E?Q=\#:M^QAXA2P\8Z#?OX@2%]'2TU*&9M15+F-9&MPK'S50\,R
MY"]\4GP%^(7AKQ1_P3;FM]&UW3]4N]&\'7$&I6MK<H\UE)LEPLT8.Z,G:Q&X
M#(&1D5]F-9HRA3$I7^Z5&![8S@54U;P[9:]I5WI>IV5OJ&EWL30W=E=0H\5P
MC##*ZD$,"#@@\']* /A#_@F1^T#\/O"'[-EOX/\ %7BG3/!GB71+F26ZT_Q%
M=I8.\,X$L,Z><5W(R'JN<#!. RYF^ _@[4?VD/VYO%OQ\9Y#\-]"M)- \,W;
M1[$U5?+>&5H^TD*O)<'S <$LF/XL?:&L_"KPCXDL--L-7\*:+JEAI>W[!:7E
MA#+#:[ %C\I64B/:  -N, "NE6V*K&,*0G"KL&![_A[>O2@#\[?V0[?1_P!A
MK]HCXK_#OXB26?@[2O%UTNJ^$]8O+A8],NK6)YL0+.^ LJI.H*-@@KC^)-TO
M[5-G9?MT_M'?"[X;^ ]4C\0^#?#=P=6\5Z]H\Z36EHI("1K=()%\\HDH"D8W
M,F>A(^_/$/A/2_%NE3:9KFE66M:9/CS;/4(%GA?'(RCY4\@'G/3\IO#_ (9T
MOPMIMMIVCZ;::5I]NNV&ULX$ABB'/"HH '4]* -"-6#$D;<\X!X'^-2T44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%)NH+ 8H 6BF^8H.*/,7@?C0
M ZBF[AUHWC&:5T ZBF>8N,]OI0)5*YSQ5!TN/HIGF+@'/!I68*I)Z4@V'44U
M9%89'2C<* '44FX4C.%&30 ZBH_M";MN><9_"G!@:5T ZBFB12<9YHWBGL Z
MBF[Q@'- <'O2NK7 =131(#2[A1= +39 2,"EW"D\P?Y%,!FQLKVXZ9)_K2[3
MG_Z]+YBXSGCK2JX;I0 +G(S^G2G4TL!1N% KH=12;A2;A_2@8ZBFE@*-XVY[
M4 .HIGG+N SR>11YBT"'T4Q9%89%.W#.*!BT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)XSSBO#?@;X&\.:Y\8/B99:AHFGWME97S);P36RLD.)Y5 53D#@#G%<C\6_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,'E\,+*512<IRLFY.[LB2BBBN4]8**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEL[B[.O:8+6WD\F:<WD>R)\9VLV<!L=CS2MXS\/QZ2NJMKNFKI;/Y:WQNXQ
M6R1M#YVYR#QGM2 V,T;AG'>N(\7_ !B\*^$M!T_5KG5(+S3[^\2QAFL9HY5+
ML<$D[@-J_P 1SQWK8D\<>'+.!;B?Q!I<%LR+(LDE]$J,C<(P);H<'!Z'%.S"
MZ.@HK(L_%^A:E?I8VFM:==7KIYJVT-W&\C)_>"@Y(YZTV+QGX?GUAM)CUS39
M-55MC6*W<9G5O0QYW ^V*0S8)Q0&!X!S6$WCCPY+)##'K^E23RMB*(7L19SN
MVX W<\Y''<8K(\'_ !8\.>,_$>LZ'IEZKW^ES&&1'>/][CJT8#$LHS@G%,#M
M:***0!1110 4444 %%%% !1110 4444 %%%)0 M%)N%)O'% #J*3<*-PH%<6
MBDW"C<* N+12;A1N% 7%HI-PHW"@+BT4FX4;A0%Q:*3<*-PH"XM%)N%&X4!<
M6BDW"C<* N+12;A1N% 7%HI-PHW"@+BT4FX4;A0%Q:*3<*-PH"XM%)N%&X4!
M<6BDW"C<* N+12;A1N% 7%HI-PHW"@+BT4FX4;A0%Q:*3<*-PH"XM%)N%&X4
M!<6BDW"C<* N+12;A1N% 7%HI-PHW"@+BT4FX4;A0%Q:*3<*-PH"XM%)N%&X
M4!<6BDW"C<* N+12;A1N% 7%HI-PHW"@+BT4FX4;A0%Q:*3<*-PH"XM%)N%&
MX4!<6BDW"C<* N+12;A2;A0%QU%)N%&:5T,6BBBF 4444 %%%% !1129Q0 M
M%)N%&: %HHHH **** ,'Q]HL_B3P/X@TFU9$N;_3[BTB:4D('DC9%W$=LL*^
M;;WQ1KFN_!2T^%UMX'U^/Q6+.+1R;FV_T)?**AG-Q]W:4CW9[%L D@9^K9%W
MKC&?]D]Z8R%@,C/XTR6?+MU\'0OBKQM:W>BR:M#IW@R"RT^ZFM]RR3K;%%*
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M-R4B.#E@R1Y"YPRCBLG1OAGJ6GO\-9- TJXT?6;[PG>6NHWD4;19G>VRAN'
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MG'RL >Q_*JK$+U('U-)<+Y?))J_WCEQUFT)<LDD_0^W/^&TO O\ SY:S_P"
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M/:IGPSEM-7FVO5HJGQOG%9\M.*;\E<^QO^&TO O_ #Y:S_X#)_\ '*/^&TO
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M (Y7Q)_^O_Z]&#C(&?\ )_P-'^JN \_O)_U\S5;\OW'VW_PVEX%_Y\M9_P#
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MY\M9_P# 9/\ XY1_PVEX%_Y\M9_\!D_^.5\244?ZJX#S^\/]>\U_N_<?;?\
MPVEX%_Y\M9_\!D_^.4']M+P+M)^QZSTS_P >R?\ QROB2D(W C&<\5+X6P-M
M+_>5'CK-6TGR_<?J#X5\467BS2K+4;%F^SW4*SQI(-K*K $ @9YK=R*\!_9E
MOYKCPWI\;N65+:)5R>P05[Y@^E?E]:$85ITUT=C]XP]6I6P].K-:R2>A+111
M6!V!1110 4444 %9FL:J-/NM*MS&7^WW1M@P.-A$,DN?_(>/QK3KDO'ETUC>
M>%ITM9[UDU1B(+95,C_Z'<\+N91GZF@#J$^\W..?\*>,#O7,_P#"772M_P B
MOKA[G]W!_P#':7_A,+G_ *%;7/\ OW!_\=H Z;</6C</6N:_X3"Y_P"A6US_
M +]P?_':/^$PN?\ H5M<_P"_<'_QV@#I=P]:-P]:YK_A,+G_ *%;7/\ OW!_
M\=H_X3"Y_P"A6US_ +]P?_': .EW#UHW =ZYK_A,+G_H5M<_[]P?_':1O%]U
M_P!"MKG'/^K@_P#CM '3;A7/>(/B%H'A;4(+/5;XV<TVPAF@D,:AWV*7D"E4
M!88RQ K6CEDN;-)6@>$R("89L!E)[-@D>G0UY3\8M<TS6KM/!NHIJ$&EW(BG
MU2]BL+B5&B20,($:)#\[%5R>BIG')X /2M8\7Z/H.J:3IU_?QVU]JTC164#
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MECMI#%.)H7@>)L!L,LBJPX(/(Z&G^&O%VD>,-'&J:->K?V!>2,31HP!9&*L
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M_K;_ -"-?"E?=?[97_)&)O\ K^MO_0C7PI7ZSPM_N#_Q/\D?SUQY_P C:/\
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M096(N+PL(QQT.T$\_2O0_CA)HNM:M::KI/B'3]6BCT^ULWMX?,$N^--K'!4
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MPV;B-;J1V8<<#:0><=:S_&?B;3-2^'GPPT^UNTEO=)CO1>Q*#F$O<*Z9XQR
M3Q6<'C).,=4KVV6W(GV[Z?@*M3P"C*<HIOEYOB>[J<K6C_EU_'8RM3^'\'AC
MQ9K^C>(]:AT=]+! F6V:8W6<% B@C!*Y;D_C5Z[^%!74O!D6GZY;W^F^*F"6
M=_Y!3;^\5'#QD]%+#@'GI[UZ%KOC;PS??$OXB:YI>L:=#K%PML=$U2_@9[4@
M1QK,,%3AR 5!V\#=4/B;QYI%QK?PB>?Q+;:M/HMV[ZK>P1NL<>Z6*0$ J,J
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MOR'T445R'<%%%% !1110 5XG^V5_R;SX@_Z_-,_].-M7ME>)_ME?\F\^(/\
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M:2@#PO\ ;*_Y(Q-_U_6W_H1KX4K[K_;*_P"2,3?]?UM_Z$:^%*_6.%O]P?\
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MM'\36NJ66K:=?I:WFN76LJ]E<()8_-"!8AN!7  8DXSD#&.:\\]<\?Y_7_\
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MXN@N8HRQ))AB9AGL26/:L3QC;ZCJFI>#K&_N+/5?%OGO%=?V>4=F4RH80S(
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MW(T@4C/WAD9%>P^"_BGI6O?$&Y&I^'X;*/Q.9+'4+A;Z4DI., G<<;0<'';
MQ7E$UBND^(9+(SI<?9;PP^>A&Q]C[=Z]MI'->IE\JT.>E7O=J]_S_P#)MO)G
MC9I3P\ITJV'M;X7Z1U3?JK)^A]):_P"#_#M]\6=9\'3>!K+1_#5M&\G_  D5
MO#)"\>VW\T.)?N ;\+^=>+>&]%L+SX/^,M7GMEDU&SN[ 07(7F-'>0,H;N"!
MS[U[SXIO]9LOB]=:_/XWTN'P(9XVFM'U$29MQ&@=/) .2Q#?GGO7FW@W3+?Q
MAX'^)>FZ-=:=IGVW5K:>R@U"=;;]TLLC@'/3"%>!_C7A82M.G37-)\ON-[VO
M?6_G;?H?29AAZ5:JX0BN9^U2VO9Q]VWEV\SF/A_H&F6/A#Q'XRURQ&IQZ2T%
MO:6,C%(;BXD(&6_O*H +*.H)KH?#\7AOXP6^M:+'X5L?#NOP6LMUIDVDLR+,
MZ*&:-T)^8E5//IFK.A^&AI_A7Q!\.]7UW1[?5+LV^IZ3.MV)+<2*Y$D9E'W6
M<!>O')J]\,?AWJ/P_NM<U<7.FZEXE@TVX72--TR\2>5Y6 5WP,810X^7KWKL
MKUZ51U:SF^>ZY5TZ?*W<\_#86I3=&GR15-I^T5DW=7OYWM\-NIX?I>GW6N7U
MI8V:>=>7<JQ11Q]&D<@ #/\ #FO0+CX'W>V[LK/Q!I.I>(;%));W1;.5O/B1
M=V[8V,.P&WY1C!^E<O\ #[4H/"?CS0[Z^5A;:?>PF82*=\85R22O7</F.#[5
M[!X5T*W^'/Q(U;X@:QKFCRZ' ;Z[@2VO5EN+DS"4(JH.=QW@G/3@5Z&.Q5>C
M**IOE]V]M^9]KGDY7@,/6BE6C=\UM[<L;;O:]CS/0?A7>ZMX?M/$&J:II^A^
M'KKS(_M]PQ;;(IVA/+ Y9NH(Z ,:Y?0=)N?$FL:=I=JJB[OKB.",2M\N]VVC
M..@R>?8UV?B:\A7X+>!M/6Z626"[O/,MUD!*ME0&8>N,@>S&L#X=ZE;:/X^\
M.7][.MK96NH033S/]U(UD!9C[ 9KLA.LJ52M5>JYK+TO;[S@E2PGMZ%"BM':
M[;WO:_IN%GX#U74KSQ'9Q>09M!MYY[X--@!8GVN5('S-Z=.*V])^$EU=>'](
MU_5M;TG0-#U3>EM<W4A9F=2XQY:KG.Y#DYP-V>V*](C\,P>%]0^+&JW^OZ2Z
MZMI>I"PM;>[62697?S-QQTP,#'7+&N&^(%U:7'PK^%4,<T;SV\.H">!6!,6Z
MX1OF&<@GJ,]B:\N.-Q&(:C"5KM*]O[K?YH]F66X3#TISJ1YG9NW-UYTNCOMJ
M9$/PE\0R^-M2\*[+>'4=/C:6ZDFG MXH@@82/)CA2"O_ 'T*[1_ ]MX=^"_C
MN\MM5TSQ%8S7FG"TU"S!#<2,'!5AN3EE4<\XK176+"\^*_C>PEU.V@;Q!X<7
M2[2[E<>29WM+? =NPR,?4UFGPVO@7X-^,[6_UK2[G5KJ[T^46-E<B9D5)6.[
M(Z]6^4= N3UK.KBL16<8U)V=X.UM[M-N_D=E'!82BZDX1O=55=O96:5E>VJU
MVO?8YS3?@Q<:A;VEO/K^E6/B:]C6:UT*[=A-(CXV[W PA((.T\GCCFH=%^']
MI?> M9U6\U.QL]4M;RWC$=W<2(UJK>8'CE4)@,WEJ5Z\#G%>K>,-4U;Q)XHA
M\6^%;CP@UC<I#>17&H)"MU:2)&H(<M\Q92IP1ZX_A%>>^&K>X\>>&_'5F;_3
M4UB^U.UO7^T3K;QRC=.970L.1EQ@>A%13Q.)J4_:3E:W+?NM;/H34PF"I5?9
M4XW=I)/HTE=/?=OR.?T'X9M?:'::OK&N:;X:LKQ)?[/^W,SM=21LJMM"@[5!
M.TL?0\4EO\)]:_X2S5M!O_(TI])0R:A>7#D16\> 0^1]\8<$ <DD"O1K'4KG
MQ;X!\(#0#X6FN=-MFM;VQU9(@\4GF%DD0R=1(-S-CO4.GZU<^,[CXE^&]>UO
M2D\2:T+-H]0C<)9RR6I#&(, -I9 !GIE6Z\5K]>Q47/:VJ\TN9*^U]M=6_(S
MEE^"DJ:FM;)VO9-\C=KWMOHK6MUU,SX<_!W2=;^)FEZ5<Z]INMZ)=I-(DMC.
M\4DOEQL=H3&5PV#@X! .">E<)IO@F*\U1[6;Q)H<-M&B27%^MP[1A68*>J!G
M;.&VXZ'K7H'PKTFV^%'Q>\)W&MZOIKR3-/#)'8SK,+8/#Y<;._  +.<XZ8J/
MP1\/[70?[?M-4?P_JGB>+3HIM(M[J]22T<&8I*Q<\%U 4JI]<4WC*E*K.3K-
MKEC;3S?RTZBC@Z5:E"G[)1ESSOKK9132O?KJEYF9H?P_F\)_$OP+(;NWUO1=
M5U*%[/4;?/EW*).JRC:1D;3@%3Z]:T?'?PBDNO$WBV73M<T>[U&UN[N]DT2W
MD;S(K8.9 V0-NX*P!C'(Y]#75^(M3MX[OX'P7-YI/VS3]2N%O5TF1$MX"+N$
M\@<+QR<<;LX)J+3M%MO ?Q,U_P"(%SKVC7^A12:A>6\,-RK2WCS"15A\L<@@
MN5).0<>]<L<97YXUW*TE%I:?$^9I+;2Z]#TIX'!QA+#J/N\R=[ZQ3BFWOK9O
MS^;.-\6:6^I?"GX0VMA;_:-1O&U**-50*T\GVI4C5CZ<@9)[UF:O\(IK"PU#
M[)KVEZMJ^DI)-J6DVKL9;6&-@C.&( ;&1NQTQWKL+;Q9I?AWPG\"K^>2WN/[
M,GOI;V/=N:%?M2$L5'.0/F'N!4WC*3Q%IEOXIO;2[\&KHE]#<(;JV$0N+NVE
M; 7"C=YC C(Z!B#6M/$8BFXTT[*\K7Z^^_+ML<E?"X*ISUI^\[1VV7[N+OOW
MWT/"Z*#G=G.2<@MW.3G] %HKZ]7:3/@';51[A1115 %"_>%%"_>%3+9E+='V
MM^RY_P B_8_]>T?_ *"*^AZ^>/V7?^1?L?\ KVC_ /017T-D5^"8K_>:C\S^
MN\!IAJ=_Y4++G;QSZU\7^#<^ /V>YM8BD_XD'BG2M5T^^9\D07RM<K:S]#Q(
MJ^4V<#<(J^T)5W+CJ.E<^O@70H_"[^&UT:U&@LK*VG^6/)P6WD;>_P W/U-<
MR.Q[G#^,O$6M:9J4$5C=>(88/LZ$)INB07<6< 'YV.2?:CXA>)HD\)66DPV?
M]J^-/$.FFUM+2YMXXY\-%B2:X'(BB0G<XY&1@9->IQP^2H1/D5<   <#T^E<
MWX@^&?AKQ7J@U#5]#M;Z]6 6R7$@.X198[,@@[<LQ^K4 >4WWAG7]-^(O@OP
MGHVHV<%KI7A)X['4M0M1,&F26".1D7.#((TBZ\ .V*]2^%>OS^)O",-[<BS$
MRW-W;,VG_P"HD,5S)%YB>S>7N_X%4M_\-?#6H:38:9<:-!-8V)_T:)MW[G(P
M=ISG'/KVK;T71[70=/MK"QM8K*SMXQ%%;PJ%2-0,!5 [=:!V-"O$_P!LK_DW
MGQ!_U^:9_P"G&VKVRO$_VRO^3>?$'_7YIG_IQMJZL'_O-/\ Q+\SSLR_W*M_
MAE^1\%+_ $'\J6D7^@_E2U^_2W9_(JV"NG^%\:3?$GPLDBJZ-J=NK(V,,#(H
M(Y]JYBKNB:Q<^'M8LM4LBJWMG,L\#. 5#J002#U'M6%:+E3E&.[3.BA*,*L9
M3V35S:\%>'M/U[4=5GU:::+3-+LY=2N(X%_>3*KJ@B4X^4LSH-W8;C78Z)\/
M_#/C[Q+X9&BOJ&D6>K7%Y:SVT[B5[:6"!9?E?^(-O!]LD5RVF_$R^TG5XK^S
MTS2;0>5);W,%O:+''>0N%#12J.H.T=.AY'2IF^+&JVVO:1J6CVEAH<6D(XL=
M/M8<P0O(A61R#R[-GJ>RBO!G1QU5VIRL[*VNWX:W?4^CHXC+803J+FU>G+OK
MIUTLNA?OO!NBZMX7TC7/#]GJ$5O_ &HNA7%G/*KSW<K1JPDC. $9P^W;]T$+
M76VWPUT>WOO"/B!=,N]+L9/$4&DW&FS7D=VTS,P>.7>"0HY =>X'&,\^8Z+X
M^U?P_I=KI]E-%%:6FJ+J\(:$.PN%545B>XP!\OUK1N/BKJ(M;:STS3]/T;3K
M?5$UF.SMXMP%VH^\SMRRYQ\IX   ^[653#XZ35.,]-;ZO^OS-*>-RN,I3J1]
M[39+==O+[CN?$.@Z5KGQ%\774F@:]KD-OJ$UNSMJ$-O%#(SO@([XQ@JQ5,G@
MG(Z5S$/A/PWX9UCQ:VM_VEJ%AH>J1Z;#:VT@CEN QG +M_#CR3RO7&.]9L'Q
M4OGM=4@U'3K#6(K[4GUAH[J(A$NW!!D"@X8;3C;TSS6'JGBS4-:?5VN3&3JU
MZ+ZZVQ@$R+YI7![#]])@>XK6AAL5&\)2M&R6[Z6O^I&(Q>!J152$+S;D]4OE
M?\-[GIV@_"WPK?7?A;0ISJ;:MXITI;^VO%D18+%MLC;=F/G'[LKSV/%+\.=%
M6QO_ (?W-WJEP]G>1ZP'B"KB!4CG0LG&22 6PQ/-<#8_$K7+'6O#NJ13P"]T
M&T6QL6, VI$ R@,/XCAVYHTGXE:WHTV@26\D&[1&N#9[X%8+Y[,92W][(=L"
MHJ8+'24HJ5T_/R?EZ&E/,<N7+)4^5K;3II>^N][FGXD\,Z-?>!+?Q5X>M[NR
MM;>^_LFZM[R42O))Y0=9E*CY<C.Y1QD#'6MSP-KT>I^%=$\-:3X@30?$!OIR
M?,L\QWCRL@AC,@SMY&W./XCGBN+\2^.KCQ!I-IID.GV6D6$+>?+;V$6U)[DA
M0\S#/7 "J!P #5CPYX]C\,V$21>'M(GU*VG$]KJMQ 9)X"&# XSASD?Q=/PI
M_5,0\,HR5Y7TU_JY@L9AHXSGB[1<;-VM?NDELSI[]M4^$OP_T*XMC'9Z]>ZM
M=C4?.B21M]LZ(D#$Y&P$L2.Y;Z53\?>$;3_A>,VA6\B16E]J4$1>VQB'SF7(
M4= 5+L,>JUD:+\2KG3[6YMM4TC3O$L4LLMVHU-"QCN9,!I W4\*AP>":PV\3
M:BWBA/$+3+)JZWBW_G/&-K3>8'R5Z 9 XZ5IA\+B85)MO6SU\]+?<&*QN"J0
MA!7Y4UI_*EW=];GHUWX9^'VAVNN-=PZU=2^'-1%I,B3HHU-I&DV]OW0'DL>.
M2,9YIMQ\,=,L=:U^6UT_4O$-AIRV$T6G0N%EFCNXRS*S ;OEXP5Y)(SQFO/M
M2\3W^I)K"2O&PU2Z2\G&P+F5#(5((Z#,K\?2NY\(_$07RZW_ &IJ-E87UY]B
M6&>\LFFB\J"*2+!52,/AEY],^M8UL/BZ,'*%1N_F_+_@G1A\9@*]11G34;;.
MR5]]]>UMSD_B=X?TSPKXJU+2M&O)+^WM<1FXE923)@%^5X^4DKC_ &*]R^)>
MDR7[>/+&/5]+U7[/81W=KX>ABVW5JT9B9YE;: H"%\J"<[O:O!_'-YIFH^()
MI=*6$6OD01EH+?R$:58U$CHA)PI?<0">YK7O_B]K^H75_=F+3K:_O[<VES>V
MMFB7$D+;0R^9U!*KC/TIUL+6Q$*$H/6*UO\ (6'QN%PDJ\)1]V3TMM:S[/\
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M23(S;BS8.<]<GOS3"J,JY3Y1QM/) ] :^K/^&2+3^[/_ -_31_PR3:?W9_\
MOZ:I\48%KE496]$1_J'FO-SJ4;^K_P CY4P S>A_NC&?<BD\M OW%.WL% _+
M-?5G_#)%I_=G_P"_IH_X9(M/[L__ ']-*7$^ DN7EE_7S*7 N;QUYH_^!/\
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M .M0JXZ'@G^+O_\ 6_\ K5]5_P##)-IZ3_\ ?TT?\,DVGI/_ -_32_UHP/\
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MO@__ ,]]<_\ !6W_ ,51]2Q/\C^X/[2PG_/Q?>?57'^11Q_D5\K?\/(O@_\
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M4\3_ "/[@_M+"?\ /Q?>?5/'^11Q_D5\J_\ #R+X/_\ /?7/_!6W_P 52_\
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M>VN?^"MO_BJ/^'D'P?\ ^>VN?^"MO_BJ:P6*>JIO[B?[3P?_ #\7WH^J>/\
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MY_X*V_\ BJ/^'D7P>_Y[ZY_X*V_^*H^IXG^1_<']I83_ )^+[SZIX_R*./\
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M>_\ R)<7_7U)_,5]XU^6XW_>)^I^V9;_ +G3]!]%%%<!WA1110 4C>]+2-0
MAKQ[]K72;[Q!\!M?L=-M)+^]:XT]UMXBH9@M] S8W$#A5)Z]J]>D8JI/I7Q#
M_P %)OC0-%\,:;\.]-O E[JS+?:CL;YH[5&_=K[;I%W _P#3*NW!4Y5*\%#>
MYYF95*=/"U/:O1IGE7_"I_B&R@_\*_\ $C9Z'[$O P!_?H_X5+\0_P#HGWB;
M_P  E_\ BZ^QOV0?C-_PNSX-:7JEU.)M;L!_9VJ<_,TZ ?O#_OH4?V+,.U>W
M<],5]14XEQE*HXN$=-.I^?4.!LMQ%*-6,Y6:\O\ (_,S_A4OQ#_Z)[XE_P#
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MIG@^AHP?0T?ZT8O^2/X_YA_J!EO_ #\E^'^1^9G_  J7XA_]$]\2_P#@$O\
M\71_PJ7XA_\ 1/?$O_@$O_Q=?IG@^AHY]*/]:,7_ "1_$?\ J!EO_/R7X?Y'
MYF?\*E^(?_1/?$O_ (!+_P#%UV/P7^&/C?2/C-X(U/4_!FMZ5IEAJ$EQ=7M[
M;K'#"GV6=-S'<?XG4?C7Z LPY[>M>*_M5?$8>#?AS+IMM((]3UK=:H.ZQ;?W
MK?EA?^!U2SS&9C_LG+'W].O4B7"V69*O[1]I+]W[W3I\CY:_; _9I^(WQ:^+
MUQK7A?P\;_2VA"K<"95#_,3QD\C!KP__ (89^-'_ $*1_P# E/\ &OT"_9'^
M)7_"6>"6T*ZDSJ&BA85RVXO;G_5MGVP5_P" YKWU5Z\YK@J8[%9;-X1I>YH>
M]AL!@<YI1QT6_?U/R _X89^,_P#T*9_\"4_QH_X89^,__0IG_P "4_QK]@=I
M]31M/J:C^V\5Y'1_JYA.[/Q^_P"&&?C/_P!"F?\ P)2C_AAGXS_]"F?_  )2
MOV!VGU-&T^II?VWBO(/]7,)W9^/W_##/QG_Z%,_^!*4?\,,_&?\ Z%,_^!*5
M^P.T^IHVGU-']MXKR#_5S"=V?C]_PPS\9_\ H4S_ .!*4?\ ##/QG_Z%,_\
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M,_\ @2E'_##/QG_Z%,_^!*5^P&T^IHVGU-']MXKR#_5S"=V?C_\ \,,_&?\
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M/C]\1I/",GA7_A--6;PVUJ;)M-WH(S;E"OE?=R5V\8]Z^A=4\7?!?]I#X;^
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M:;J.MZ#IT^HW$((:ZD\@-O?G&=TCG(_O&O;P,5YS^SG_ ,D!^&W_ &+>G?\
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MZ[??%_0/ =GKVEW,6NZ>^IZ3K\ >2RNH5B>0L,?,"#&RE>W![BN#^(GP_L_
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M9D^\?K6F8?[Y5_Q,PR7_ )%V'_PK\B2BBBO//;"BBB@ HHHH **** "BBB@
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MR;XE''&7'H:S/&;Z?XZ_9J^%,6EZUI27G@^+5TU6QNKQ8KE#/=))%Y:$9D+
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MP\5I"L2;I99-OS%F_AQQSS7++')-PE%W.R.7N24U)6/#?XB.I_R:.F*]?_:
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MN6_X'S%R*-I+8[YQ7L%G^R]XKDM] GU+4?#^AIX@LH;W18]0U6.)[\R@&)%
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M?O79>>.9%4^Z5\S0^([?0[:9K41$R?<>9!(0G(X!'!SCGZU[;^U+\,;?P?\
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ML30SK$-RN,'..]?1X155&U0^0SBGAKJ6'^9Z+1117>?,A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7E?[4'_ "0WQ3_UQC_]&I7JE>5_
MM0?\D-\4_P#7&/\ ]&I79@O]YI_XE^9Y>:?[C7_PO\C)_9%_Y(AI/_7Q=?\
MH]Z]F3[Q^M>,_LB_\D0TG_KXNO\ T>]>S)]X_6M,P_WRK_B9ADO_ "+L/_A7
MY$E%%%>>>V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UNE.I&
MH \B_:9\ R_$CX<SZ1%(8C(_+#']>M?$\G[$/B3PS<QZAX>DMKUG 9V:18Y8
MV[_[U???Q>DNH_"LK6@;SLC;M'>N \"Q^(V2(WL2M'@')'->OA<1[&E9,\C%
M82&(J7DCS_Q1=:S\$/V-]?AUG40GB*2&2*.56WE9)G^5-P_B"[N:_-K4KS3W
MGCF\]KB?&6RP"1IV ]_6OTW_ &RO .I>-/@3?VUG.T2VUQ%=3J%S^[4G)_#(
MK\T)X_!FBZE;Z=.LVLZI(X2381'$N<=?I7S&91GB*ES]&X=JT,#A7S:%1_%=
ME<74T<L<?E[,+Y9";".F>.M>Z_"/Q5;ZIXT\,:%ITOFW1FB,LCDXCVC<2Q'0
M94BO/?$WAG1/AK%:ZA+X>C,[OF""*[63=D?>*YZ#^M=/X?\ '7A^W\"ZUJ<%
MS:Z)XKU:$Z?:PH KPQ'_ %LC[1CD?*!WKY^O1J1P[<%[ST/I_P"TL/BERQD>
MD:W^UP=+^+6OWF@WS6>FO=EQ,5)W,/E8GMM)'0YK[3^ ?[0-G\5/]#G,8U)8
MA('B;,<BXZCTK\DX?AA?^8'M=8LVM\DX9FZ8ZCC\@.U?:?["'@_6-/\ %"W#
M0@V<,85IH263/U(ZUZF!AB*=E5=SP,RA@Y8?W%[R/T&HI.]+7N'Q 4C4M-8X
M'/% 'YQ?\%3/^1^\"_\ 8,G_ /1PKY%^'OQ!USX6^,++Q+X=O/L.J69.R0KN
M5E(PRLO\2GN*^NO^"IG_ "/W@7_L&3C_ ,BBOB/86)["OT;+(QJ8&G&6VMS\
MFSB;IYC4DG9Z?H==\4/BGXC^,GBB7Q%XIOQ>:@Z+&D<8VPVZ#I'&F?E'?OG/
M)KD%R64#KF@K[YI!GMP>V:]B%.$(<E-61XDJDJDN>3NSZ6^$&J>(/&7[-?B7
MP9X1ULZ5XET_68M46T@OQ:3WULRX?#[E/RMCY0>>E8G[36H&V\._#7PWJFJ6
M^N>,]$TJ2#6+F.Y^T/$[/N2&24$[F"G.23CI7@<D:2J-R CH5?)X]/<4J0JH
M !QWZ<9]:X(X22K>U3ZM_>>A/&*5%4FNB7W'M7@?_BWO[./B_P 4EO+U'Q;=
M+X:TYGC# 6Z#S+IU(Y5N@![YKQ>&-Y7CAB&)'(C0,V "3@ GMSW[5T?B/Q]J
MOBGPWX:T*[^S1:;H$,D5I%;1&/)=MS/+S\\AZ;L#BN;91)D,,J>H-:X>E*"D
MWNV85ZT9N*2T1]GC]G/Q;\/_ (;)HGP_N]%N->\0VR_V_P"(9M;A@DCA.&%C
M;@MN5,_??[S9P.*\]T+PC>_%#]G(>!=$N+ ^+/!_B:ZO+S3[B[2-YX91Y6^%
MB0K;6&#V(QCK7S;]EB+$LB;NK,$&3[U))#')@.%8#MC/].G]:XHX&K\4I:WO
M_6IVRQU.W+&.EK'M_P"TE)::)H?PR\#?;K:[UKPKHTMOJYL9A-%#<2S"01B0
M<'"XR!TR*[71?AOJ7Q,_8Q\,6>CW5@FK6GBF_N8]-NIUA:\ A <1%B 64'>1
MW .*^7>%5@..<\ 8SZBNQU3XEW&J?!_1?A^^G0K9Z7JT^K1WGFL6D:5-IC*8
MQ@=<YJJN%DH0A!ZIW;%2Q<.>I.:T<;+\#Z570?!>O>/O@M\,O%MY8ZG/X7T"
M[AU.S^UJEL]\[>=!:F4?*2QP&"GC(&:R_&VGWFA_LF_$JRU;0?#7A'4+K7--
MGBT30YM\HB\Q@&D!D<GI\IXR 3BODP*BPX W>BG 'UZ41Q11L&1%5E!P0.G/
M3^O%8_V:TXKGTO?\;FCS)6E[G=?^2I?H?4/[1'AF[UWQ;\/?'VG7-E>^%!H^
MA6?VV&[C8K+&P1UVYW9#=?3!KTKQ5K5EXK^('[1'@C3(= U/Q)J>KV.J:=:Z
MXP-I>QV\:>8BL'7]X,Y W=B>U?"<<2(W"J"01N(Z ]J/*C\H(% &<X89Q[>_
MKFM'E][)2V_SO^@_[0<9S?+N[_@T?67@^_\ &/AGXD?!CP_XDTCPOX4T >)A
MJMMIVCE%D20J4D>4>:Y7(/?&>*XOX3W5LO[0GQ%GNWA\F:T\0J))'&UP5FVC
M)/T^O&*\ 6&-4QMPOH /E'7 'UI^U63:XX[J!^F.F.O2KC@4KWZJQRRQ\M+=
M&>]0Z//XQ_8RT:VTF2WN;K0?$]Y?ZE"9U#PP-;X60J3G!YQ7:7FAZMXM^&,@
M^+FG:&NGZ7H"/HOC:TO8_MT'RYM[5D0G[0S-M4H5!1<YZYKY/>)68%@KMQDX
MQ],<=AQ3?)57,BA0Y_CVX)/<^O3UIO!2;6NS;^\N.-5G==$ON/2OV;+Z&U^/
MOP\GNI5MHEUFW$CR, J9;&2<\"M[P?X?\=6_QL\9O\/M4CTOQ#HEW?.DDUQ'
M!,\9F='6,2##L1R1UQTKQVWD>UN(YHFVRQL'0XX# Y!/XBMSXA>,KWXE>,-1
M\2:K%#_:.HR+)<&- J,ZHJ%@!TW;<D>I-:5,/*51]FC&GB(PIJ-MG<^F?B5X
MYU'P;H?PIU[X@76GZC\6-*U\W;744D4LZ:4 "JW#Q\??R=I^;CZY-/\ A'_P
M@O[1L_Q,GU[3C\.K'4&\30:TUU&3<HY,JP+&&W>8TC;,8R,!C7R/&BQY"C;S
MQP.?TZ4GDQ[MP51)U\S&6S['M7+]0<8V3WW^9U/,(RDI26JM^"/;O 'B)FG\
M7>/O$&H30>$UU&>[@\*_VA((=5U"=FECMVB1OF0'#2,1C:F,]*]H\$:QI7C#
MP[X:\4ZP-#N]!U+3]:G\>7-U%%G[:P(MU)8&1,+M$:QD8P!VKXI5%P >!C'3
MD?EZ9/XT-"C-O=5<XR>.?3UZUK4R]2?NNQ%/'NGI)76Y[EX3NCH/['/CUKY&
MA77_ !!I=G8,!GSI+<-+,OMA?7UJM^S!X1\-^+O&'B%=;L+'6]0LM'GO-&T3
M4+K[/!?WH VH7R.BY/![5Y[K7CV^UCP3H7A3R8+72=(FFNE6W# W-Q+@-/+D
MG<^U0F> !VKF)(T8[6 =<]QFM50G*%2+T<Y?D92Q$%.FTKJ"MZ]?U/LS4O$"
M?#+X1?"B^\1:5H.DW.D?$(7]]HN@,NV*(6V?WBF1\2;2"<GNN:\M^.7P!URV
M\4>./%KZQHMSX4E>XUJSU;^T$D6[69V>*"-<EC(Q=5 [=>E>"K&D:Y50K=,8
MX'T'I[4GDQ(^515[;D!!Z]?;C^584LOG1ES*1M5QZK+EE'16M\E8^L/'&I6B
M_M1? J^%S"(H-!\.^;(L@"H4W9W'H,9]>YS69J&H6L?PA_::A\^$M-XRLGBC
M$BDRJ-0E)*C/S#!^E?,GEHNX +M/HHQ[\4GEKP0!E> <<@?7'\O2JC@6XQ5]
MK+[G<3Q_-*4VM[_C&Q]G^*/^$E\7>*/!7C/X?:#X+\16CZ58+;ZMJ'RSZ7<P
M1*C12DSKL$9&X':!\Q],GD/@5);?&2Z^(7PW\7:WI^ESZIJH\1VVI>8)(DNX
M;@M=+;J?E(DC,G(/*J.#FOE]H8]^2JL>H)4'G],4NQ2@7 VJ<J,?=^F??FH6
M ]QJ^O0?]HMR4VM-;KU5CZY\$_%"Q^+GC_XSV=E'HD%[XELTMO#EOK#,+&XM
M[=U6.R&738LD<88#(523UZ5S6I>)/%7PWM_A\GC/PUX7T+P=9^*(]9&AZ2%\
M^:5%"RNR&1_W>T[<G R!7S9M5U*-PN,8 XQSQS^&,4@A2%L($5?[J#:!^7MC
M\J<<OY&FV*6/<TU+1_I>Y]S?#GX67_A']K+4O'6I>(M%O/#6IRZC=:;J"ZE&
MS7OVJWG:)$7.[<J,0<]AGH:^&=/E6 VLC@E(=CLR]< Y./>F?9XER /E_P!E
M<'ZCU(/3/:I%[ D 9SM P 3G@8[5T8?"2HMW?1+[M3+$XOV]G;JW]Y]>^+O#
M-VW[8'@SXD"2S'A+7M?T62RNX[J/<P:WB^5XP=R$>2^=W3Y?[U<-X0U2*V^,
MOQW;[5''#=:?XD"AI@(YLM,5YSAL\$#W&*^>3#&N["*5/\..,=P>Y/8>Q-*
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MX1X5\(^$-";PEK-CHPL[GS+R]A0H%<DRDO&XV,<*,.P4>_@7QBNX;C]G_P"
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M7\4/B9-\4KCPK)=Z?#8-X?\ #]GH,+1R&4RBW#;)CD#:QWMD<XKB-J[2NWY
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M@?LBVV@S(\*PY4Y#A>0:^D?"^DMHFCV]HS!S&N"U:NT>E*.OM02Y.6XM%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRO]J#_ )(;
MXI_ZXQ_^C4KU2O*_VH/^2&^*?^N,?_HU*[,%_O-/_$OS/+S3_<:_^%_D9/[(
MO_)$-)_Z^+K_ -'O7LR?>/UKQG]D7_DB&D_]?%U_Z/>O9D^\?K6F8?[Y5_Q,
MPR7_ )%V'_PK\B2BBBO//;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]6_\#!_\17WGY8]!1Y8]!5_VAB_^?C^\R_LO!?\ /F/W'P9_P[M\-_W]6_\
M P?_ !%'_#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O\ Y^/[P_LO!?\ /F/W
M'P9_P[L\-_W]6_\  P?_ !%'_#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O\
MY^/[P_LO!?\ /F/W'P9_P[M\-_W]6_\  P?_ !%'_#NWPW_?U;_P,'_Q%?>?
MECT%'ECT%']H8O\ Y^/[P_LO!?\ /F/W'P9_P[L\-_W]6_\  P?_ !%'_#NW
MPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O\ Y^/[P_LO!?\ /F/W'P9_P[L\-_W]
M6_\  P?_ !%'_#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O\ Y^/[P_LO!?\
M/F/W'P9_P[L\-_W]5_\  L?_ !%'_#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H
M8O\ Y^/[P_LO!?\ /F/W'P9_P[M\-_W]6_\  P?_ !%'_#NWPW_?U;_P,'_Q
M%?>?ECT%'ECT%']H8O\ Y^/[P_LS!?\ /F/W'P9_P[M\-_W]6_\  P?_ !%'
M_#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O\ Y^/[P_LS!?\ /F/W'P9_P[M\
M-_W]6_\  P?_ !%'_#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O\ Y^/[P_LS
M!?\ /F/W'P9_P[M\-_W]6_\  P?_ !%'_#NWPW_?U;_P,'_Q%?>?ECT%'ECT
M%']H8O\ Y^/[P_LS!?\ /F/W'P9_P[L\-_W]6_\  P?_ !%'_#NWPW_?U;_P
M,'_Q%?>?ECT%'ECT%']H8O\ Y^/[Q?V7@O\ GS'[CX,_X=V^&_[^K?\ @8/_
M (BC_AW;X;_OZM_X&#_XBOO/RQZ"CRQZ"C^T,7_S\?WA_9>"_P"?,?N/@S_A
MW;X;_OZM_P"!@_\ B*/^'=OAO^_JW_@8/_B*^\_+'H*/+'H*/[0Q?_/Q_>/^
MS,%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NWPW_?U;_P,'_Q%?>?ECT%'
MECT%']H8O_GX_O#^S,%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NWPW_?U
M;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[/#?\ ?U;_ ,#!
M_P#$4?\ #NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?
M\.[?#?\ ?U;_ ,#!_P#$4?\ #NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX
M_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NWPW_?U;_P,'_Q%?>?E
MCT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NWP
MW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[/#?\ ?U;_
M ,#!_P#$4?\ #NSPW_?U;_P+'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]
MQ\&?\.[/#?\ ?U;_ ,#!_P#$4?\ #NSPW_?U;_P,'_Q%?>?ECT%'ECT%']H8
MO_GX_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NWPW_?U;_P,'_Q%
M?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\
M#NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[?#?\
M?U;_ ,#!_P#$4?\ #NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_
MSYC]Q\&?\.[/#?\ ?U;_ ,#!_P#$4?\ #NSPW_?U;_P,'_Q%?>?ECT%'ECT%
M']H8O_GX_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NSPW_?U;_P,
M'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$
M4?\ #NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[/
M#?\ ?U;_ ,#!_P#$4?\ #NSPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^
MR\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!_P#$4?\ #NSPW_?U;_P,'_Q%?>?ECT%'
MECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[/#?\ ?U;_ ,#!_P#$4?\ #NSPW_?U
M;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?\.[?#?\ ?U;_ ,#!
M_P#$4?\ #NWPW_?U;_P,'_Q%?>?ECT%'ECT%']H8O_GX_O#^R\%_SYC]Q\&?
M\.[?#?\ ?U;_ ,#!_P#$4?\ #NWPW_?U;_P,'_Q%?>?ECT%(8QC[M']H8O\
MG?WB_LO!?\^HG@WP%_9_M_@_8KI]@9C:"1Y09VW-DD=^*]XV'UI<;<8'%.R?
M2N*<I5'S3>IZ-.$:45"&R'4444BPHHHH **** "BBB@ HHHH **** "BBB@
MHHI,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !129%&10 M%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%(3B@!&;;4;3>],FF^4\UD7>H"+J<]Z -=K
M@>OZTS[4O]X?G7*W&OHIQN_6JC>(DS][]:5T!VOVI?[P_.C[4O\ >_6N)_X2
M-!T;]:/^$D7U_6F!VWVI?[WZT?:E_O?K7$_\)(OK^M'_  DB^OZT =M]J7^]
M^M'VI?[WZUQ/_"2+Z_K1_P )(OK^M ';?:E_O?K1]J7^]^M<3_PDB^OZT?\
M"2+Z_K0!VWVI?[WZT?:E_O?K7$_\)(OK^M'_  DB^OZT =M]J7^]^M'VI?[W
MZUQ/_"2+Z_K1_P )(OK^M ';?:E_O?K1]J7^]^M<3_PDB^OZT?\ "2+Z_K0!
MVWVI?[WZT?:E_O?K7$_\)(OK^M'_  DB^OZT =M]J7^]^M>7?M.SAO@;XHP<
MXBC_ /1R5M_\)(OK^M><_M$:Y]K^"OBF) TCM#$ J\D_OX^U=F#_ -YI^J/+
MS6+E@*R76+-?]DB8?\*/TDD_\O%U_P"CWKV>.<9'/:OG#]EG6OL?P8TB)PT;
M?:+H[6!!P9W(.#7L]MKB28^;]:TQ[7UNKKU9&41=/+Z*EIHOR.M\W/>EWFLF
MVOED7Y3S5O[1GOVKSSURTTF*C:X'K6;<WXCSDUC7.N(C'+8_&CS ZG[0/[WZ
MTGVI?[WZUQ;>)4W8W_K2-XD3LWZT =K]J7^]^M'VI?[WZUQ'_"2K_>_6C_A)
M5_O?K0!V_P!J7^]^M'VI?[WZUQ'_  DJ_P![]:/^$E7^]^M ';_:E_O?K1]J
M7^]^M<1_PDJ_WOUH_P"$E7^]^M ';_:E_O?K1]J7^]^M<1_PDJ_WOUH_X25?
M[WZT =O]J7^]^M'VI?[WZUQ'_"2K_>_6C_A)5_O?K0!V_P!J7^]^M'VI?[WZ
MUQ'_  DJ_P![]:/^$E7^]^M ';_:E_O?K1]J7^]^M<1_PDJ_WOUH_P"$E7^]
M^M ';_:E_O?K1]J7^]^M<1_PDJ_WOUH_X25?[WZT =O]J7^]^M+]I'][]:X?
M_A)5_O?K1_PDJ_WL?C0!\<?!9MO_  4N\>D^FI?^@Q5]_?:%S]X?G7YX_"6:
M6U_X*%>.=0:&987_ +1 E9"$.1'C!QBOM?\ X25?[WZUZN8M2G!Q=_=C^1X>
M4WC3J*6GO2_,[?[4O][]:/M2_P![]:XC_A)5_O?K2KXD3/+?K7E'N';K=+G[
MWZT];@$_>_6N'_X22/CY_P!:O6^M+)SNX^M.S>PKG7J^[O3ZQ;6^#8YYZ5J0
MR!L9/-(9-1110 4444 %%%% !36('4XIU1S8\LY!(_V>M ">8A8@$9H5OFY8
M?2O!VGUSQ5\3/&]HWBS7-+L]+FM8;6UTUX$0;XF9B=\+DG(]:W%^'^M2?-_P
MG'B\'_KXM?\ Y&I<RV.*GB)U(N4(W5['K^X>M&X>M>0_\*]UO_H>?%__ ($V
MO_R-1_PKW6_^AY\7_P#@3:__ "-1H:>TK?\ /O\ %'KVX>M&X>M>0_\ "O=;
M_P"AY\7_ /@3:_\ R-1_PKW6_P#H>?%__@3:_P#R-1H'M*W_ #[_ !1Z]N'K
M1N'K7D/_  KW6_\ H>?%_P#X$VO_ ,C4?\*]UO\ Z'GQ?_X$VO\ \C4:![2M
M_P ^_P 4>O;AZT;AZUY#_P *]UO_ *'GQ?\ ^!-K_P#(U'_"O=;_ .AY\7_^
M!-K_ /(U&@>TK?\ /O\ %'KVX>M&X>M>0_\ "O=;_P"AY\7_ /@3:_\ R-1_
MPKW6_P#H>?%__@3:_P#R-1H'M*W_ #[_ !1Z]N'K1N'K7D/_  KW6_\ H>?%
M_P#X$VO_ ,C4?\*]UO\ Z'GQ?_X$VO\ \C4:![2M_P ^_P 4>O;AZT;AZUY#
M_P *]UO_ *'GQ?\ ^!-K_P#(U'_"O=;_ .AY\7_^!-K_ /(U&@>TK?\ /O\
M%'KVX>M&X>M>0_\ "O=;_P"AY\7_ /@3:_\ R-1_PKW6_P#H>?%__@3:_P#R
M-1H'M*W_ #[_ !1Z]N'K1N'K7D/_  KW6_\ H>?%_P#X$VO_ ,C4?\*]UO\
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M_P *]UO_ *'GQ?\ ^!-K_P#(U'_"O=;_ .AY\7_^!-K_ /(U&@>TK?\ /O\
M%'KVX>M&X>M>0_\ "O=;_P"AY\7_ /@3:_\ R-1_PKW6_P#H>?%__@3:_P#R
M-1H'M*W_ #[_ !1Z]N'K1N'K7D/_  KW6_\ H>?%_P#X$VO_ ,C4?\*]UO\
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M\#H/_BJ/^&7?B/\ ] :#_P #H/\ XJN;V^3]XG=]7XB_DJ?>SF?^%O\ C/\
MZ&"X_P"_4?\ \31_PM_QG_T,%Q_WZC_^)KIO^&7?B/\ ] :#_P #H/\ XJC_
M (9=^(__ $!H/_ Z#_XJCV^3]XA]7XB_DJ?>SF?^%O\ C/\ Z&"X_P"_4?\
M\31_PM_QG_T,%Q_WZC_^)KIO^&7?B/\ ] :#_P #H/\ XJC_ (9=^(__ $!H
M/_ Z#_XJCV^3]XA]7XB_DJ?>SF?^%P>,_P#H8+C_ +]1_P#Q-'_"X/&?_0P7
M/_?J/_XFNF_X9=^(_P#T!H/_  .@_P#BJ/\ AEWXC_\ 0&@_\#H/_BJ/;Y/W
MB'U?B+^2I][.9_X7!XS_ .A@N?\ OU'_ /$T?\+@\9_]#!<_]^H__B:Z;_AE
MWXC_ /0&@_\  Z#_ .*H_P"&7?B/_P! :#_P.@_^*H]OD_>(?5^(OY*GWLYG
M_A<'C/\ Z&"X_P"_4?\ \31_PN#QG_T,%Q_WZC_^)KIO^&7?B/\ ] :#_P #
MH/\ XJC_ (9=^(__ $!H/_ Z#_XJCV^3]XA]7XB_DJ?>SF?^%P>,_P#H8+C_
M +]1_P#Q-'_"X/&?_0P7'_?J/_XFNF_X9=^(_P#T!H/_  .@_P#BJ/\ AEWX
MC_\ 0&@_\#H/_BJ/;Y/WB'U?B+^2I][.9_X7!XS_ .A@N/\ OU'_ /$T?\+@
M\9_]#!<?]^H__B:Z;_AEWXC_ /0&@_\  Z#_ .*H_P"&7?B/_P! :#_P.@_^
M*H]OD_>/X!]7XB_DJ?>SF?\ A<'C/_H8+C_OU'_\31_PN#QIP1K]P<'/^JBZ
M]CRO8X/X5TW_  R[\1_^@-!_X'0?_%4G_#+WQ''_ #!8#_V^P?\ Q5"Q&3]X
MA]7XA>\)_>SFS\9/&S$D^(KG/4DQQGGOG*^OI4B?&SQU"PQXCN@5P>(HA_[)
M70?\,P_$<<_V)!]3>PX'_CQS7EDL;0M+&WRLK,A53QD=3QU%=.'IY=B)/V2C
M*QYV*KYS@;?69SC?;<^Z?@5XJO\ Q%\.](O=4NFO+]P^^9\ GYO08'Z5Z@US
M^YS7AG[.\N/AOI _ZZ?^AFO8S*?)/TK\@QJ4<3.-K*^A_2V4SE5R^E.3NVE>
MY\^_ML?$CQ#\._A%'JGAC59='U-M6MX#<1*C,8V24LN&4CDJO;M7PE)^U=\7
M95^;QU?-W_X][?\ ^-5]=_\ !0.;S/@K"O\ U&;8_P#D.:O@_P"&W@+4?B?X
MXTCPKI,D$6HZI(T4+W#%8U*HSG) /9#7T^44J7U-SJQ32>Y\=G=;$+'*G2DU
M=+0ZYOVI/BPW7QM?'_MA;_\ QJF_\-1?%;_H=;[_ +\0?_&J];_X=Q_$_P#Y
M_M!!ST^U-CZ_=H_X=Q?$_P#Y_P#0?_ IO_B:[_;Y;W7W'G?5\V[2^\\D_P"&
MHOBM_P!#K??]^(/_ (U1_P -1?%;_H=;[_OQ!_\ &J]:_P"'<7Q/_P"@AH/_
M (%-_P#$T?\ #N+XG_\ 00T'_P "F_\ B:/K&7=U]P_JV;=I?>>2_P##47Q6
M_P"AUOO^_$'_ ,:H_P"&HOBM_P!#K??]^(/_ (U7K7_#N+XG_P#00T'_ ,"F
M_P#B:/\ AW%\3_\ H(:#_P"!3?\ Q-'UC+NZ^X/JV;=I?>>2_P##47Q6_P"A
MUOO^_$'_ ,:H_P"&HOBM_P!#K??]^(/_ (U7K7_#N+XG_P#00T'_ ,"F_P#B
M:/\ AW%\3_\ H(:#_P"!3?\ Q-'UC+NZ^X/JV;=I?>>2_P##47Q6_P"AUOO^
M_$'_ ,:H_P"&HOBM_P!#K??]^(/_ (U7K7_#N+XG_P#00T'_ ,"F_P#B:/\
MAW%\3_\ H(:#_P"!3?\ Q-'UC+NZ^X/JV;=I?>>2_P##47Q6_P"AUOO^_$'_
M ,:H_P"&HOBM_P!#K??]^8/_ (U7K7_#N+XG_P#00T'_ ,"F_P#B:/\ AW%\
M3_\ H(:#_P"!3?\ Q-'UC+NZ^X/JV;=I?>>2_P##47Q6_P"AUOO^_,'_ ,:H
M_P"&HOBM_P!#K??]^8/_ (U7K7_#N+XG_P#00T'_ ,"F_P#B:/\ AW%\3_\
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M3Q7O$9TII@)MQ3>%V^I7G'I6UXT\=>'OA[H<NK^)=9L]$TR,A6N;V81IN)P
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MCD^]4E1R?>_"@#G]<^Z_^>U?(G[6!'G>'/7-Q_**OKK7/NO_ )[5\A_M7?\
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M%$\>6Q@\QMCYP#S@4BC[?]/?I0>.#[_IUKX]\&?MY:EJ'B+P)<^)O =KX?\
M OCRZ^Q:)K=MK<5[=([D"W-Y;(O[KS >Y)&<=CC?\$_M=^,?BUX^U9/AU\*9
MO%'PVTK6UT2\\3-K$%O=,P95DDBM6 ,D:EMV<YVANAXH ^H^V>V,T=\=Z^,_
M%'[?'B9K'QIXP\%_"=O%/PH\)WYLM1\43ZQ':33;75)I(+9E+2*"_P N#_O!
M<$#J/''[96M2>.O!'A?X9_#V?XC3>,_"X\2:7*+X604&4K_I&\;4B"J3O)SO
M*C!W9H ^I#PI8]!U-1_:8?M'D&:,3XW>5O&_'KCKCD5\BVG_  4(L[_]FL_$
M:W\(R77BK^WE\+CPI!>AO^)@S$(GG;1N0J <A?XEXKSOX>^.O&?B+_@HHFI^
M-/AY/X4\3V/@"[9M"MKR*]%RHV/'Y4PVJ[.#M(.W#$@F@#] O3WZ48-?+'AS
M]KGQW9_&3P=X+^(/PQT_PI9>*KN>QLKZQ\4V^I3QS)'Y@6:*+A!MP#R>3@9Y
MIUK^UE\0_%'Q*^(?AOPI\(1J^D^!M0O;+4-<EU?R8CY43O$L:"/,DKE1F-0V
MW>IYS0!]2]\=Z!\V,<\9KY8T[]M\>)/AU\&M:\.^$3J_B3XA:N=(;1OM1A73
MY(?^/O=*R N8AR!M&<'GU9_P4H\2W7A7]GFPN[37M6\/0MXJTVWO-1T6XDMK
MH6K&7S IC.3\N2%]0..E 'U6RLHR00/<4G3/^SU]J^(OAC\2/AY\(O@7\5/B
MW\-/%OCWXH0:';0P7.G^/-4N/+5PZ%1%YL"E&(D!)"L. .*Z[X??MI>*M<^+
MW@'PKXR^%-[X(T'QY;-<>'M6GOO/FE;9N"S0J/W1(!.UFR 02.> #ZLGFCM8
MWDFD2&./[[R,%5?J3TZBG*0W0Y^E?G/^TO\ M;>+_C+^SC\7O[*^$E^?AB&E
MT6'Q:MZK2^;'.G[U[8J"(0R%6=20I*YKVK7OVK/$O@[QUX7^$O@WX;3>.?$U
MUX3L=1L&&HI:PM^Z7S/.9^(T5<'=R22!@=: /J^D5@R@@Y![U\>V?_!1+1M0
M^!MMXJB\,&3QS<:[_P (LO@U+] 3J.[ 'GD8,0&UM^,C<.*W-#_:K\0:KX@\
M=?#GXG> +GX?>-;?PW=ZU96VG:J+R*^M4@<R;+M%Q'(O8X.#[\4 ?4_I[G H
MSCK7Q1X9_:JO/A+\$_@#9^'? ^M>-=0\>V4BVMC=ZT;N^\X E!)/(B^8">6;
M"!%!(&!BJGQ(_;(^(>K_ +.'QCN=*\'KX-^)/@6\33=5ABU.&Z33XV(+744C
M)ME(X0QXYW9!.* /N+/\\?C17FO[/?B[QQXV^&.DZGX_\-0^&=<>&/$4.I)>
M_:8C&I6X9D "E\Y\O^'->E4F-"&ORW_X*#?\G+ZE_P!@NR_]%M7ZD&ORW_X*
M#?\ )R^I?]@NR_\ 1;5]%DG^^/T/E.(O]R7J?8?[)?\ R0[P/_V#D_\ 0FKZ
M0TWM7S=^R;_R0WP/_P!@Y/\ T)J^D-,[5X^(_CU/G^9]!A/]WI_X8_D;"?=%
M.IJ?=%.KF.H**** "BBB@ I&Z4M(W2D]@/#?!G_)8/B9_P!?MC_Z(:O<(?\
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M.[&*]\4>(=-\/VDS;(YM1N4A5V] 6(S5;P7\6/!?Q&^U#PMXITGQ";5@L_\
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MXN(I)S!+;QW$TC1IF(-YFV1<9&TD'FOLK^'=_#ZT?Y_7% 'S#XN_9.U_Q/\
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M.*\EN[?5OV$_VBO%?BV\\,ZEXA\ ^*ED-O>Z61)):N\@D,;A@JAC(6^7(RK
M@D@BNAT#]I#XD_M*?&[PO#\,-.UKPGX&T^0?V]<ZE9Q212@G<1)P=ORC"[9
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M+J\AL;>6XN)4AMXT,CR.0 J@9))]*Y_5/B!HUEX3U/7K:\CU*RL$9Y39N'Y
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M_P!?DW_I+-7U5^W]_P D9B_[#-M_Z!-7RK^QO_R<]\/?^OR;_P!)9J^CP/\
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MT_QBL)[GQ;_;NK)-DM':-ME(7.0X&W@>_:O;OB^I7X7>*< 9.GS#_P =-4/
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M']*^?=9_Y/*N?^Q'3_TX"OH+3?\ CUC^E1#9GEX#_E[_ (F6Z***L]0****
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MQ] LP4$L0 .I)IV#Z5Y;\65V_"72L#'EW&EJ-PQ@;T&,@^YZ^M>IR1A9" .
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M'UFA_.OO1Z%17GO_  T%\,?^A_\ #?\ X-(?_BJ/^&@OAC_T/_AO_P &D/\
M\51</K-#^=?>CT*BO/?^&@OAC_T/_AO_ ,&D/_Q5'_#07PQ_Z'_PW_X-(?\
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MA2#3[6"SMQ_RRAC5 /P KC5^/_PS'_-0/#G_ (-(?_BJ5?V@?ACGGQ]X;_\
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M*/\ A6.D_P#0)TW_ ,!(O_B*[G%&*?+$/8TOY5]R.&_X5CI/_0)TW_P$B_\
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M_ 2+_P")H_X5CI/_ $"=-_\  2+_ .)KN,48HY8]@]C3_E7W(X?_ (5CI/\
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M ,31_P *QTG_ *!.F_\ @)%_\37<446B'L:?\J^Y'#_\*QTG_H$Z;_X"1?\
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MI31&FX\*03UVCGOWY[FOHJ;]D<Q$_P#%2NW_ &X8_P#:M5F_92=3QXA?_P
M?_MM?I3S[+);S_ _#H<(YY3ORPMZ,^?_ "H_[J_]\BCRH_[J_P#?(KW_ /X9
M5E_Z&!__  !_^VT?\,JR_P#0P/\ ^ /_ -MI?VYE?\R^XO\ U5SS^27_ ($>
M >5'_=7_ +Y%'E1_W5_[Y%>__P##*LO_ $,#_P#@#_\ ;:/^&59?^A@?_P
M?_MM']N97_,ON#_57//Y)?\ @1X!Y4?]U?\ OD4>5'_=7_OD5[__ ,,JR_\
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M>_\ _#*LG_0P/_X ?_;:/^&59/\ H8'_ / #_P"VT?VYE?=?<'^JN>?R2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/R11Y(H YS^PU_N?I2KH:_W/TKHO)%'DB@#GO[%7^Y5B/2PN!MQ6SY(H$8%
M%2&S"C&*N1KM%*%Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HH[J
M&8N$EC<H</M8':< X/IP1^8I9D+[<=CG]"/ZU\\_%G]GC3;'X:ZUI_AG2_[0
MN-;U;P[%<6>I6IU"W6WM]5MF8>3\I%K&AE<VJ,D"*)"B1[Y"P!]$[AZBC<,9
MR,5\XZ'X3\:?#'Q)H7@VW\2:IIWAK[/8R6%SI/ALW=A)=-J-S/J%F45)386B
M6WV>WMQ)*J1(ZA7E,1%:OC[PSXJUW]DOXDV5U+JOB#Q1K7AG5#!8W%I%'.DT
MMI(%M(XX8H\C<=HW!F)8DD]  >\;UZ[A^=*&!Z$'C/6OF+1_A+XZ^''B;0M
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MP(NBJ%E<!2H7@Y!K^#]+\8^'?!]L;:TUKPLL^J:5%?RZ#H4!FBMOL C8I;O
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M6OIN&,JV=NT$>I- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!',<1
ML22 !GBH;&-(C,$14R^6"J!\QY)SW^IYZT44 6J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!K G&/6JFFV\-E!';P0QV\2+
MA(X5"JJYX ';Z444 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>eigr-20221231_g14.jpg
<TEXT>
begin 644 eigr-20221231_g14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )K!$X# 2(  A$! Q$!_\0
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M )*AX/\ ^PS9_P#H]*\/-O\ ?Z?HOS9]3P]_R*JWK+_TF)]C_M2?\D(\3_\
M;K_Z515\=_ 7P/I?Q$^)^GZ'K"226$T4SNL,A1LK&S#GZBOL3]J3_DA'B?\
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MG@6V\<:1;^$/AOH>J1FXT?2?$&F76KWMQ <^7--)%=6RP[Q@A0LA .<GI1\
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M_P!@*^_])WK\XO@'_P EN\$?]A:W_P#0Q7Z._&;_ )(_XZ_[ 5]_Z3O7YQ?
M/_DMW@C_ +"UO_Z&*QK?Q(G7A/X,_P"NA^IU>>?M ?$+4?A3\(]>\4Z3#:W&
MH6'V?RH[U&:([[B.,[@K*>CG&".<5Z'6)XS\&:/\0O#=YH&OV?V_2+S9Y]OY
MKQ[]CJZ_,A###*IX/:NT\H^#&_X*'_$=?^8+X7_\!+G_ .2*A;_@HK\2%_Y@
MGA;_ ,!+G_Y(KZH/[%_P;;KX._\ *G>?_'J8?V*_@R>O@W_RJ7O_ ,>K:,H+
M=&<U)_"?*C_\%'/B4O31/"O_ ("7/_R17Z-5X<?V)O@NW7P9_P"52]_^/5[C
M3J2A*W(K$4XSC?G=SSOX[?&K1_@3X"NO$.J8N+@GR;&P#[7NIR"0@/. ,9+8
MX ]< _E9?77CC]I_XM%MDNM>)-6EQ'$F1%;Q@\*,\1Q(/7IR3DDD^G_MZ_$2
M\\8?'?4-':5O[+\/1I9VT.[Y=[(KROCLQ9MOTC6O7OV-?B-\&?@M\/!>ZQXK
ML[;QEJQ+W_F03,\$88B.$$(1C #''5F[X%>SAX_5:/M8QO)GAXB7UJO[*4K1
M1]$?LW?LVZ'^SWX5\BWV:AXCO$4ZCJQ7!D/7RX\\K&#T'?J>P'L5>-0?MA_!
MRYGCAB\<V;RR,$51;S\DG '^KKV6O&K>U<N:JG=]SVZ/LE'DI-678*Y[XA_\
MB!XF_P"P9<_^BFKH:\V^/'B#Q5I/@74K'PCX U3QWJVI6=Q;Q16-]8VD-NY3
M:IF>YGC(4[CCRU<_*<@<9X,0G*C.*W:?Y'=0:56+?1H_+_\ X)9?LC_"?]H[
MP#XWU+XB>%/^$AO=-U.&WM9?[1N[7RXVB+$8@E0'GN037ZA_"/\ 9U^&GP'M
M9(? 7@S2_#;2HL4MS;1;KF5!C"O.Y:1QQGYF/.3U)KXP_P"";?PD^-?[*-CX
MF\.^-?@]JLNG:[?6]Q'J>EZWI,WV8JI1O-C:\4E "&RFYN#A3Q7Z*UZ%5JZ<
M-FE^2O\ B<--.S4][O\ -V_ _,/_ (*N:I=V_P"T9^SI!=:A<:7H4=[Y_P!L
MA5&,$GVNW#RJ)%:,LJA"-ZL/4$<'[CN/@GXJO+>2&7XZ>/Y(95*.IL?#V&4C
M!'_(*]*Y']MG]D33OVO/AC!HIOUT7Q)I4QN]'U-DW)'(5PT<@'/EN,9QR"JG
MG&#YQ\)O&W[8'P]T"Q\&>)O@YH/CJXL8EM8/&<?B^WLH)$5,*\T11Y7(X!*H
MI..G.ZN6G;V3HR6O,WY-2_#3;4Z:E_:*I':R7HU_GOZEV/\ X)O^#_!O[,_Q
M+^%/A#Q%K0C\7&.[^VZ_-#,(+F(JT1Q#%'A"R+NX)QG%<_\ L?\ Q\N?AG^S
M9:^"=3\&^)_$/B?P>UQHUK)X3T.ZU73-89)6\MK>_@1K<#Y@KF61-I5LXP0/
M3]:\)6WPK^!_Q,\0?&/XB0:9K'B^UDBUG7K4R1V>F[X6A@M[&(DN5C#?+_RT
MD8DGJ /DK]GOQ-^VA\+_ (6:3X9^&'P_\+_$+X?60;^Q-?UJ Z=-<VKL71A%
M/=VLFTAMP+1G[WWF'-.[DZD6]U&]N^JWZ-+1=&MMA67+"26SEOV=KZ=4WJ^J
MLK[GT3_P3G_9C\6? /P?XP\0>.XX;'Q9XUU(:C<:3!()%L8QO*(S#(+DRN2
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M-L1%M*RQI<F3!VC!17.6Y '-??5=U9IN+7:/X)(PCO+UD_O;:/"?VZO^3/\
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MS'C'FEW,N<=]Y;-=KJ'[.W@K4/@')\'CIQB\&'2QI26ZOF1$ ^60,?\ EH&
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M?#7XD?"SX#R_"?XC?#K4O"_EF\>/7(M5T^ZMI4F;.S$-PTB2#><?(5PN2P.
M9AS1=>V_*K>;3;+J6E"BG_,V_)-)&5^SSXV\"^-/C5\1W_9N^'>F6;271_X2
M?XB:U/,;22X9V8):VH8O,&;<Q57MT^7.>5)\CURSU"P_X+)>!(=4UI]<OO['
M9I)C;);QQ9L;LB.-%&0@!!&YG;YCECP!M_LF_!/]I/\ 8C\0^*_!VC?#;1?B
M7X+U>]6ZMM<'B2#3%A8 H)'#J\N"@7<@B."/E8\T_P"*'[,_[1/A?]KSP?\
M'[1=%T/XH:K'!Y>HZ)8WL6E0668I(?)CDG8,Z+'(,2G<Q?)* 84:4^6,Z+3]
MU*WWQ:M;HDWVM;K<BI>4*T7N[V\]5K?J[?._2Q]%_P#!1K_DROXI?]>$7_I1
M%3_^"=?_ "97\*_^P=)_Z42UD_MG:3\3_BQ^S'J/@GP[\,;K5?%?B:QA6[2S
MUFQ%EI;B6-W1IIY87E/RD*4BP>I*]#/^PGIOQ%^&OP7\+?#?Q[\,=4\+76AV
MLL7]L_VIIUW93#S6=1B&Y:56(?IY97Y3\PXJ::M[5/O'\%*_YKUZ!4_Y=O\
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M&]_]!BKVGXE^)/B?XH_9QU6U;X1W4GCKQ#IEYI[:!I>O6,\.GM)&R(\UU-)
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M6#4%O>7XR;7X';!I8Q3>R4/PW+__  3L_P"3*OA9_P!@Z3_THEKYP_X)&_\
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M?:OT$HHK&MB:F(M[1WL:T,-2P]_9JUPHHHKF.H**** "BBB@#YT_;L_9=O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+*00/ER"AY& 0>G%6/VC?%?B3P3X-M-7\.7_ -A:.[6.Y/DQR;D93C[ZG'S
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MO[8TSQ?I<%KYK0[+NVB5]RXSPMNPQSZUO_#GPY_PC_[+^KR,NV;4-/O+U_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **;O7?LW#?C.W/./6G4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ5ZL9*2O%W1X,HRIR<9JS044451 4444 %%%% !1110 4444 %%%% !1110
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MXV7_ ()1_P#'J/\ A'O&O_0XV7_@E'_QZ@#LJ*XW_A'O&O\ T.-E_P""4?\
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M&O\ T.-E_P""4?\ QZC_ (1[QK_T.-E_X)1_\>H [*BN-_X1[QK_ -#C9?\
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MO;C3[A)[6>6VG0Y66%RC+]".17J?@_\ :4\6>&RD5]*FN6B\%;KB4#VD'/\
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MX-9/_D2C_AXYKO\ T1C4/_!K)_\ (E>344?V)@_Y?Q?^8?ZR8[O^"_R/6?\
MAXYKO_1&-0_\&LG_ ,B4?\/'-=_Z(QJ'_@UD_P#D2O)J*/[$P?\ +^+_ ,P_
MUDQW?\%_D>L_\/'-=_Z(QJ'_ (-9/_D2C_AXYKO_ $1C4/\ P:R?_(E>344?
MV)@_Y?Q?^8?ZR8[O^"_R/6?^'CFN_P#1&-0_\&LG_P B4?\ #QS7?^B,:A_X
M-9/_ )$KR:BC^Q,'_+^+_P P_P!9,=W_  7^1ZS_ ,/'-=_Z(QJ'_@UD_P#D
M2C_AXYKO_1&-0_\ !K)_\B5Y-11_8F#_ )?Q?^8?ZR8[O^"_R/6?^'CFN_\
M1&-0_P#!K)_\B4?\/'-=_P"B,:A_X-9/_D2O)J*/[$P?\OXO_,/]9,=W_!?Y
M'K/_  \<UW_HC&H?^#63_P"1*/\ AXYKO_1&-0_\&LG_ ,B5Y-11_8F#_E_%
M_P"8?ZR8[O\ @O\ (]9_X>.:[_T1C4/_  :R?_(E'_#QS7?^B,:A_P"#63_Y
M$KR:BC^Q,'_+^+_S#_63'=_P7^1ZS_P\<UW_ *(QJ'_@UD_^1*/^'CFN_P#1
M&-0_\&LG_P B5Y-11_8F#_E_%_YA_K)CN_X+_(]9_P"'CFN_]$8U#_P:R?\
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M=_8]/^9G#_;-7^5'ZB?\-W^'/^?32_\ P?1__&Z/^&[_  Y_SZ:7_P"#Z/\
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M'Y=LI[S-PG'?!^8^RFNLKY?_ &MO%AN=8TKPY$^8[6/[7.!T\QLJ@/N%!/\
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M<U]\-?$VGZ='I,UWKGV2XM8)9)(B4D0JZ^8S,#@D$;B..U0WVDZ%XV\2>/\
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MS5\,U]S>#?\ DU?X/?\ <8_]+FKX9KXO+_XU?U_5GZ5F'\&AZ?H@HHHKVSQ
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MF6QL8//:V5BIF)8  D<[1G)Q[59\1>(+CP7X^GL]=\&Z1'H0N&B6S;28HRT
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M-7B<,Z<J;M)!1115F84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2?[Z_E^2"BBBO?/E HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO#L8[U0N7.0,#&1U/>N_O_B%X7U#QYXVNY-4>/3=6T--/@N8[:1B9"D*GY"
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M/?\ <8_]+FKX9KXO+_XU?U_5GZ5F'\&AZ?H@HHHKVSQ HHHH **** "BBB@
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M&=,TG1-8\*?9,AHK")S"P0$L)PN]OFXR6/WL"N1UCX?>#M#^/1T+4+Q;+PV
MLS))/M5&*;A$TA.5!/?.<$#.>:]#M]#T'P]9R6/A3XG^'/#5G)@/)"D$MU+C
MO),T^2<_W0H'8"O'_$WPIN]0\8QZ9X9UV+QY>W-NUW/=6\L8VG<0=[F1AGIR
M6S\PKHQ49PC3_=*<E)OH[WN^5)-R:7GVV.3+ZE.I6G;$2IP=/EU4D[K[<FTH
MJ7HWZGHG@*'P]XM^+7B#PU'I&BZKX72%WMIH;&)'C"E!\LR*'898C))SP0:\
M:^)WA^P\*^/=:TK3)3-8VL^R,EMQ7@$KGOM)*_A7K?P/\732>(QX!U+0+/2F
M>&2WFN].5[2]+QJ3F61&RQX/3%>9_&3P/#\/O'5WI=M.]Q:LBW$32MEPK=F/
M<@@\^F*X,?%3P5*M%)ZM.6SOOR^B/4RR3HYK/#SDU[BLKW4DM.>ZTN^UM=SB
M****^;/MPHHHH **** +>EPFXOHE SSFOM+X-Z3]C\,Q97&X U\F?#[26U/6
MH5"YRP%?</A73QINC6\0&,**_5.'\.Z."4GO)W_1?D?@G%V+6)S.4(O2"4?G
MN_Q=OD;%%%%?2'Q04444 %%%% !1110!\1?\%'/^1K^#'_7[>_\ HRSKR:O6
M?^"CG_(U_!C_ *_;W_T99UY-7Z3DG^YQ^?YL_)^)/]]?R_)!1117OGR@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUA1110 4444 %%%% !1110 5TOP_\?:E\./$"ZKIGENY0Q2PS E)4)!*G'N
M<^U<U16M*K.C-5*;LT8UJ-/$4Y4JJO%Z-'J&C_&+3_#OB/4O$FG^'))?$-ZT
MC_:=0O\ SHHF<DMLC2)..>[$XXS7 ^(O$5_XKUJZU74YS<WMPVYW(P.F  .P
M P /:LVBM*F)JUHJ$WHNFB7X'-0P.'P]1U:<?>:2NVV[+IJW9>2"BBBN8[PH
MHHH *5068 =3Q25K^&M)DU34(D52<M@5W8+"RQE>-&/7?R74\O,\?#+<)/$S
MZ+3S?1'LGP!\(FYOTN73*IWQ7U+&@CC51T KA_A7X53P_H<64P[#)KNZ_9X0
MC3BH16BT/YGJ5)5IRJ3=VW=^K"BBBK,PHHHH **** "BBB@#X?\ ^"D4T=OX
MF^#<LKK'$EY?,[N<*H#V9))["O$_^$NT+_H-:?\ ^!4?^-?H?\4O@7X'^-7]
MF?\ "9Z)_;/]F^;]D_TN>#R_,V;_ /5.N<^6G7.,<=37!?\ #"WP/_Z$C_RK
M7W_Q^OJ\OS>E@Z"I2BVU_GZGQN9Y'5Q^(=9227_ ]#XM_P"$NT+_ *#6G_\
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MH_UAH_R/\/\ ,/\ 56K_ ,_%^/\ D?%O_"7:%_T&M/\ _ J/_&C_ (2[0O\
MH-:?_P"!4?\ C7VE_P ,+? __H2/_*M??_'Z/^&%O@?_ -"1_P"5:^_^/T?Z
MPT?Y'^'^8?ZJU?\ GXOQ_P CXM_X2[0O^@UI_P#X%1_XT?\ "7:%_P!!K3__
M  *C_P :^TO^&%O@?_T)'_E6OO\ X_1_PPM\#_\ H2/_ "K7W_Q^C_6&C_(_
MP_S#_56K_P _%^/^1\6_\)=H7_0:T_\ \"H_\:/^$NT+_H-:?_X%1_XU]I?\
M,+? _P#Z$C_RK7W_ ,?H_P"&%O@?_P!"1_Y5K[_X_1_K#1_D?X?YA_JK5_Y^
M+\?\CXM_X2[0O^@UI_\ X%1_XT?\)=H7_0:T_P#\"H_\:^TO^&%O@?\ ]"1_
MY5K[_P"/T?\ #"WP/_Z$C_RK7W_Q^C_6&C_(_P /\P_U5J_\_%^/^1\6_P#"
M7:%_T&M/_P# J/\ QH_X2[0O^@UI_P#X%1_XU]I?\,+? _\ Z$C_ ,JU]_\
M'Z/^&%O@?_T)'_E6OO\ X_1_K#1_D?X?YA_JK5_Y^+\?\CXM_P"$NT+_ *#6
MG_\ @5'_ (T?\)=H7_0:T_\ \"H_\:^TO^&%O@?_ -"1_P"5:^_^/T?\,+?
M_P#Z$C_RK7W_ ,?H_P!8:/\ (_P_S#_56K_S\7X_Y'Q;_P )=H7_ $&M/_\
M J/_ !H_X2[0O^@UI_\ X%1_XU]I?\,+? __ *$C_P JU]_\?H_X86^!_P#T
M)'_E6OO_ (_1_K#1_D?X?YA_JK5_Y^+\?\CXM_X2[0O^@UI__@5'_C1_PEVA
M?]!K3_\ P*C_ ,:^TO\ AA;X'_\ 0D?^5:^_^/T?\,+? _\ Z$C_ ,JU]_\
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M?^5:^_\ C]'_  PM\#_^A(_\JU]_\?H_UAH_R/\ #_,/]5:O_/Q?C_D?%O\
MPEVA?]!K3_\ P*C_ ,:/^$NT+_H-:?\ ^!4?^-?:7_#"WP/_ .A(_P#*M??_
M !^C_AA;X'_]"1_Y5K[_ ./T?ZPT?Y'^'^8?ZJU?^?B_'_(^+?\ A+M"_P"@
MUI__ (%1_P"-'_"7:%_T&M/_ / J/_&OM+_AA;X'_P#0D?\ E6OO_C]'_#"W
MP/\ ^A(_\JU]_P#'Z/\ 6&C_ "/\/\P_U5J_\_%^/^1\6_\ "7:%_P!!K3__
M  *C_P :/^$NT+_H-:?_ .!4?^-?:7_#"WP/_P"A(_\ *M??_'Z/^&%O@?\
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M_P ?H_X86^!__0D?^5:^_P#C]'^L-'^1_A_F'^JM7_GXOQ_R/BW_ (2[0O\
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M_'Z3X@HM6Y7^'^8X\+UHM/G7X_Y'SSX-_P"35_@]_P!QC_TN:OC3_A!_$?\
MT+^J?^ 4G_Q-?L79_ 3P)I_A71_#=OH7EZ+H_G?8;7[9.?*\V3S)/F,FYLL<
M_,3CM@5'_P ,^^ ?^@#_ .3EQ_\ '*^=I9A["I4G"-^9W_%_YGUM;+O;TZ<)
MRMRJWX+_ "/QX_X0?Q'_ -"_JG_@%)_\31_P@_B/_H7]4_\  *3_ .)K]A_^
M&?? /_0!_P#)RX_^.4?\,^^ ?^@#_P"3EQ_\<KJ_MF?\AR?V+'^<_'C_ (0?
MQ'_T+^J?^ 4G_P 31_P@_B/_ *%_5/\ P"D_^)K]A_\ AGWP#_T ?_)RX_\
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M4_\  *3_ .)K]A_^&?? /_0!_P#)RX_^.4?\,^^ ?^@#_P"3EQ_\<H_MF?\
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M.7'_ ,<H_MF?\@?V+'^<_'C_ (0?Q'_T+^J?^ 4G_P 31_P@_B/_ *%_5/\
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M*YZL!4^J8A_NY/1_RO\ R?7MOW/EFBE(*D@C!I*_,S]O"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P7Q^_P"2
M$?$?_L6]2_\ 262OGC_@F3_R2/Q1_P!AP_\ I/%7T/\ '[_DA'Q'_P"Q;U+_
M -)9*^>/^"9/_)(_%'_8</\ Z3Q5ZM/_ '*IZH\JI_OU/T9]B4445Y1ZH444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%\?O^
M2$?$?_L6]2_])9*^>/\ @F3_ ,DC\4?]AP_^D\5?0_Q^_P"2$?$?_L6]2_\
M262OGC_@F3_R2/Q1_P!AP_\ I/%7JT_]RJ>J/*J?[]3]&?8E%%%>4>J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!?'[_DA
M'Q'_ .Q;U+_TEDKYX_X)D_\ )(_%'_8</_I/%7T/\?O^2$?$?_L6]2_])9*^
M>/\ @F3_ ,DC\4?]AP_^D\5>K3_W*IZH\JI_OU/T9]B4445Y1ZH4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%\?O^2$?$?_
M +%O4O\ TEDKYX_X)D_\DC\4?]AP_P#I/%7T/\?O^2$?$?\ [%O4O_262OGC
M_@F3_P DC\4?]AP_^D\5>K3_ -RJ>J/*J?[]3]&?8E%%%>4>J%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Z_^-T?\*!^)_P#T3CQ=_P""*Z_^-U^U-%']LU/Y$']BT_YV?BM_PH'XG_\
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M'C*$8X(8$Y])^"WPDM_@GX&@\,6OB;Q-XL@AD:1-0\5ZD;Z["D ",/M4*B@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_1\%?I;H'^J6LLU_WE^B-<I_W9>K.HAZ5)4</2I*\<]D**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+:-8HYO.EC.P=%;8PW ?[6>M:'B?X7^%/&7A^UT35]#M;K3+0!;:!08_( &
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]NO_ (Y1_8U3^=!_;5/^1G[4T5^*W_"_OB?_ -%'\7?^#VZ_^.4?\+^^)_\
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)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>eigr-20221231_g15.jpg
<TEXT>
begin 644 eigr-20221231_g15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )E!.0# 2(  A$! Q$!_\0
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M](M?[2MYA:PW/FQQ$/-%LE1U):,/CC.<<BG4?LX>TEM_5_NZ]107M)^S6_\
MGM]Y[%17E_[,OQGM?V@?@7X0\=6Y03:I9+]LBCZ17292=.G02*V/;%>H5I.#
MIR<'NC.$E.*DNH4445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGZ?\1/B_X5M;7X@3.+.3PSH\X\E[QY)/*C60/,%7RTWL=SXP<9.!7DG[-O\
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M47@/]CSX86,<?EO=:6NIR\_>>Y9IR?RD'Y5P7_!6*WGN/V*?%30D[8K[3WE
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MK_XCZC;I!)::#I!?S[Q9)$7*%(Y&PJN7X0\*>G4?(O\ P\>^-_\ T9?\0/\
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M'I.,9QNK]!Z*J5I.\MK)6Z:>1,;Q5H]V[]=3P[X3_LC>#?AA^S6_P8D\[7-
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MO_'GB&>_4X.6AC9E!Y[>:T_Y5]U5S/PS^'^E?"GX?^'O!^AQ>5I6BV45E ,
M%@B@%F_VF.6)[DDUTU=%1QYK0^%62]$K+\$8T^:W-/=MM^K=PHHHK(T"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHKE?BAXU'P]\#ZIK@6.2>! L$<F=KRL0J@X(.,G)QV!JX0E4DH
M1W>A$YQIQ<Y;+5_(ZJBO'/@=\:-7^(6LZMH_B*QM-.U*UB2XBCMHW3<A^]D,
MS<C<A_X%5CPE\7-8OOC-K?@G6[6RMXX!(UE+;HZO(!AEW;F(.8SG@#D&NZ>
MK0G.#6L5S?+NCS:>9X>I3A53=I2Y=NO9]CUNBO,OCE\4M0^&NF:2NCVMO>:O
MJ5UY$,-TK,NT#DX5@<Y91U[USGQ2^,/C'PCXVT/PQH6F:7J&H7]I&Y6X5QNF
M9F4JI\Q0J_+W/XU-' UJRBXV]Z]M>VY6(S"AAW-3O[MKV7\SLOF>X45Y=X!U
M[XJZEKIA\5>&])TK2_)<BXMY S"3C:,"=R1USQ^(JA\*_C-JGB'QAKGA7Q9:
MV6FZS8%FB^RJZ1R*OW_OLW;# ]P3Z42P=1<SBU+E5W9IZ?\  ZA',*3Y.:,H
M\SY5=-:_/OT[GL%%>3_"WXL:S\3?&/B 6UG9Q^$M/)C@NMC^?,^?E^;=MP0&
M8C;P"M8?@?XP^./B!X1\276D:/I=WK>GW<4-M; -'&Z,3N+;Y1R /[P^E4\!
M6BVI65N6^NW-M?\ 7L2LRH2LXW?,Y)66_*KNW?;3NSW2BOFFZ^-WQ;L_%]MX
M7F\,:$FNW">9%:\G<N&.=XN-HX5NI[5UOB+XG>/O!7PLO=>\0Z)I=AKD=\D$
M-NI,D+0L!\QV2MSG</O=NE:2RVK'E7-'WK6]Y:W=ON,H9M0GS^[)<M[WB]+*
M^OG8]IHKQCXF?&G6?!GPS\*^(;&TL9;[5EB:9+A',2;H=YV@.#U]2>*P[[XQ
M?%CPC8IJ_B+P1I[Z+M#/)8R'<JG')*RR;1@]U[TH9=6G&Z:6K2NTKM=KCJ9M
MAZ<N6TGHI:1;LGU=CZ#HKSG5/B[;W7P?OO&N@(LQBAW)!=J?DD#!2KA3V)['
MGCGFO/O#?Q2^-'B[1;?5M)\):%=Z?<;O+FW[-V&*GAKD$<@]144\!6FI2E:/
M*[.[MKVU+J9G0IN"BG+F5URIO3OH?0]%5-)DNYM*LI-0B2"_:%&N(HSE4D*C
M<H.3P#GN:\WOOBIJMK\>+'P2MM9G2I[?S6F9'\\-Y3OP=VW&5'\-<U.A.K*4
M8?93?R6YUU<33HPC.=TI-+YO8]3HKP#XF?M#:[X$^)5WHT&EV-UHUBL,EP[(
M_G['";B&#;1RX ^4UWGQ>^)5SX(^'*^)-$6UO6D>'R3<*S1,C\[OE8'I[UT/
M UDJ3M_$V^??MN<ZS'#MU8WUIZOY=N^QZ'17 >,OBY9> _A_I_B'4HO.NKV&
M,PV<)V^;(R!B 3G"CG)YQ[FO/[7XQ?%0:>OB"X\ V\GALJ)=L+,+GR^N[&\M
MC'.?+QBBG@:U1.2LE>VK2N^RN*IF6'I.,=6VKV2;LN[ML>_T5X9\3OC=XGT/
MQEH&A^%=+L+V35K**YBCOU8.7D9@%SYB*O '7\ZAT/X[>+=!\<:=X<\?>'+7
M2WU%U2">R8X4L=JG[[AANX.&&,UI'+:\H*:MJF[75]-]#*6;8:%1PE>RM=V=
ME?:[^9[S17A_Q0^,7B_P]\3;3PEX7TK3=0GN;=)(UO V]W.XD;O,10,+WKIO
MAQKOQ-U+7)8O&7AW3=)TL0,R3V<BLYEW+A<"9^,;NW;K6;P52-)5I2235TKJ
M[^1LLPI2KNA&,FT[-J+LGYL]*HKQOXY?&C5_AYJVG:5X>L;34+Z6VEO+E;I'
M<1Q*"<@*R]E<G/9:[OX8^-!\0/ ^EZX5CCFN(R)XX\[4D4E7 R2<9&1GL16<
ML)5A0CB&O=?_  ?\F:1QM&>)EA4_?2O^77YHZFBO!+GXY>-?&'B75=/^'OAF
MSU.TTR0QS7-])]_D@,,R( "5.!DD@9XKKKKXD>(M-^#^I^)M3T./2M=LPP^Q
M7 ;RR0X4-C(.TYSP>W6M)8&M!1YK7=M+J^NUT9T\QH5)24;V5];.VF]GL>FT
M5\\>&_BE\:/%VBV^K:3X2T*[T^XW>7-OV;L,5/#7((Y!ZBN@^,GQ?\3?#?3_
M  FEIIVGR:KJD9%U#<AG1)0(\JFUQQN<C))Z"M'EU95513BY-M636EN_8PCF
MU"5&6(<9*"5[N+2:?;ON>ST5\_:E\:/B;X!$=]XR\$V::0S!7FT^3E,G&2PD
MD ]@<9Z9KVWPSXDL?%V@V6L:;(9;*[C\R,L,$=B".Q!!!]Q6%;"5*$54=G%]
M4TU?MH=6'QU'$3=*-U):V::=N^IJ45Y-\>OBMK?PR704T2TLKN?4I9(R+U78
M?+LP!M=<9+=S3_ WB+XM7_B:U@\4>%])T[1&#^?<VTJF1<*2N )WZM@?=[U4
M<'4E15=M).]KM)NV]D3/'TXU_JZC)R5KV3:5]KOH>K45X'\9/V@==\#^+[K2
M?#^G6-];Z?;1S7TMU'(YC9V  RKJ /F3KGEJ]DT?Q-9ZMX5M=?5PEE-:+=EN
MNU=NXY^G/Y5%3"5:5*-:2]V6Q=+&T:U>>&@_>CO_ %Y=38HKY[TWXX?$;QVU
MYJ'@SP=976A6TIB+74F96QSQ^\3G!' #8SWKJ]?\7_%.?3-#O/#GA&Q=KFT\
MR]M]0DVO;S9(V8:6,XQ@]#UK:67U:;49RBGYR6FE]>QSPS2C53E3C*27:+UU
MMIW/6:*^:?"7QN^+?CIKY=#\,:%>M8N([CK'L8YP/GN!G[IZ9Z5W%[\6?$&F
M_%KPKX1NK&PBCU&QCFO?E8R1S%9"RHP?;@%/0_6KGEM:G+D;5[-VNKV2O^1%
M/-L/4A[1*2C>UW%VNW;\]SUZBO!/BY\?]?\ A[\0'TBPTNQO=-M[>*XG,JOY
MVUC\V&# #J!]TUWGQ,^),OACX6R^+-#%M>%D@DM_M"LT;+(ZC)"D'HWKUK%X
M&LE3E;2IHO\ @]CH684'*K"^M-7?HM[=SOZ*X/4OBM9>%_AAIGBO6P%DN[2&
M1;:W',LSH&V(">!UZG@"O/+#XL_%SQ1:+J^A>!+$:,XWQBZD/FNO7*YE0MD=
M"$Y]Z=/ UJG,]$D[7;25^VI-3,J%/E6LG)722;=N]EL>_P!%<A\,?'%UX\\/
MS7=_I$VAZA:W#6MS9S9RKJJG(R <$,.H_/K5KXA>/M,^&_AN;5]39BBGRXH8
M_OS2'.$7\B<]@#7-*C4C4]C;WOO.R.(I3I>W3]W>[T];W.EHKP"P^+/Q<\46
MBZOH7@2Q&C.-\8NI#YKKURN94+9'0A.?>NTTOXK:CJGPM\0^(9M%;1]9TA)T
MEL+P,5$L<8<9'RMM.X<<'W[UU5,!6I+5KL[--KU.*CF5"L[135]4W%I/T;1Z
M717$?!OQQ??$3P%9ZWJ,-O!=S22HR6JLL?RN0,!F)Z#UKG_#OQ8U;6/CCK7@
MV:VLUTNRB9XYD1Q,2 A^8EMN/F/11VK/ZI5YZE/K!-OY&OUZC[*E6OI4:2]7
MM^1ZO17EGQ\^*NJ_"O1])NM*MK.XEN[AHG%XCLH4+GC:R\UL?%#XL6'PO\,P
M:C=PM=WEU\MM9QMM,C8R23@X4=S@]14QPM6<82BK\[:7R*EC*-.<X3=N1)OT
M9W=%>!0?&+XI:?9)KVJ^ H#X;($C"V8BY2,\[B"[-@#)Y0#Z5UGQ4^.$/@*;
M3M,TS3I-:\0:@JO#9*2NQ6.%+8!))/ 4>AY'?:67UU.,(V;?9I[;W[6\SGCF
MF&E3E4DW%+75-:/9K36_D>HT5\]:I\:/BEX&@BU/Q7X)L4T9B [V;D,F2,;F
M$DFWT^8#FN_\5?&S2-!^&-OXQM(VOH+S:EK;EMC-(<Y5CSC;M;/7[M$\!7CR
MVM)2=DTTU?L.GF>'J<RDW%Q5VI)IV[Z]#T:BO#_#7Q*^*][?:3=:EX)L_P"P
M-0EB EM&)EBC=AB1@)&( 4Y.4'X4?%#XQ>+_  ]\3;3PEX7TK3=0GN;=)(UO
M V]W.XD;O,10,+WJO[/K.I[---Z]596WOV(_M2@J3K-225OLN[OM;O<]PHKS
M7X<:[\3=2UR6+QEX=TW2=+$#,D]G(K.9=RX7 F?C&[MVZUZ57'6I.C+E;3]'
M='?0KK$0YU%KU33^YA17+_$SQ3<^"? >L:W9Q1375G$'C2<$H26 Y (..?45
MXWH?Q@^,&N>'X?$%IX.TG4-&?<V^VW>8ZJQ5MJ>>6SD'^$_2NBA@ZE>#J1:2
M3MJTM?F<V(Q]+#5%2DFY-7T3>G?0^C**\^^$_P 8+#XIZ/=316SV&I66!=64
MC;MN<X96P,J<'L""#[$^6>$OCA\6/'XO9/#OAG0[^"UD"2$DQE2<D#Y[A<\#
MM5QR^O*4XRM'DM>[2WVU,YYIAXPISC>7/>UDV]-]-]#Z4HKS^W^(&J^$OAO-
MX@\?V,&EZA S!K2Q8,'RV(U7YV&3_O>_%>>Z9\9OBEXGM#KFB> [6;P]RRJ[
MDSR*"<[#O4M_P%#TJ88&K4YFFK)VO=6OY/J54S*C2Y5)2YI*_+RMRMW:Z'T%
M17A7Q*^/VM>'_#O@_4=#TJV6?75D+VVI*[-$RE%V##)_$QY/H.E9]Y\>/'WP
M_P!6T]?'OA2RLM-NWVB:Q?YE&?F((DD4D YVG!-:PRS$3BFK7=TE=7=M'8QJ
M9OA:<FG>R2;=G9*6JOVN?0M%>0_';XO:S\-V\/1Z%:6-Y)JC2#_3%=AQLV[=
MKKC._N:7PCXD^,5YXDL(?$'A31['1GDQ<W$$JET7!Y %PW.<?PFLHX*I*BJS
M:2=[7:3=MS:>8THUG0492DK7LFTK[7:/7:*\S^-WQ1U'X=6.D0:):6]_K>IW
M/DP6]PK,"H')PK*<Y*@<]ZM_!'XF3?%'P<=1O(H+?48)W@N(K<$(",%2 22
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M!346O)JS^YA11161N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<)*Z_/M#;FZX#9R<@8%>E>)/@[K6K_%/PCXECU"UFL]'MX(KEKAW$\S(S$L
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MLU>]KZWN<\'C*V(4N248V?,GR\M[67+;7<9^R[_R1W3/^N\__HPUQ?@HB/\
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M=/QP_P"AW_\ *38__&*/['Q'\R_'_(/[9P_\K_#_ #/ULHK\D_\ ANGXX?\
M0[_^4FQ_^,4?\-T_'#_H=_\ RDV/_P 8H_L?$?S+\?\ (/[9P_\ *_P_S/UL
MHK\D_P#ANGXX?]#O_P"4FQ_^,4?\-T_'#_H=_P#RDV/_ ,8H_L?$?S+\?\@_
MMG#_ ,K_  _S/ULHK\D_^&Z?CA_T._\ Y2;'_P",4?\ #=/QP_Z'?_RDV/\
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MS+\?\@_MG#_RO\/\S];**_)/_ANGXX?]#O\ ^4FQ_P#C%'_#=/QP_P"AW_\
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M\R_'_(/[9P_\K_#_ #/ULHK\D_\ ANGXX?\ 0[_^4FQ_^,4?\-T_'#_H=_\
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M_P",5Z6&P%7%0<X-6O;7_ACS,5F%+"S4)IWM?3_AS];**_)/_ANGXX?]#O\
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MA_T._P#Y2;'_ .,4?\-T_'#_ *'?_P I-C_\8H_L?$?S+\?\@_MG#_RO\/\
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M_MG#_P K_#_,_6RBOR3_ .&Z?CA_T.__ )2;'_XQ1_PW3\</^AW_ /*38_\
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M_P#MQ_\ 2ZWKJPO^\4_5?F<N*_W>IZ/\C\DZ***_0S\Y"BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /TP_X)G_\
M)"->_P"QDG_]);6OK:ODG_@F?_R0C7O^QDG_ /26UKZVKX''?[S/U/T' ?[M
M#T.3U#_D?+'_ *Y_T:NLKD]0_P"1\L?^N?\ 1JZRN [SP7]NG_DU?QO_ -N/
M_I=;U^2=?K9^W3_R:OXW_P"W'_TNMZ_).OL,G_W>7K^B/C<Y_P!XCZ?JPHHH
MKW3P0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3\.^%]9
M\7ZD-/T+2+[6K]E+BUTZV>XE*CJ=B G ]<52N[2?3[J:UNH9+:YA=HY89D*O
M&X."K \@@@@@U]._\$Y?^3AG_P"P/<_^A1UK^$?V<_#GQM\9?'C5]>UR^T)O
M#^L7$L5Q;JKQ(AEG:1Y$VEG 6/A5*GWKAK8I4:KC/X5'F;_[>L=]'"NO24H?
M$Y<J7_;MSY%HKZ7\2?L]_#WQ-\ ];^(WPUUOQ%<'0+K[/?VOB&.%?. * O&(
MP-HQ(& )8XX.#6@/V;?AOX ^$?@_Q9\0]6\7/)XG@6>.Y\-VL,EGIRNJLGGE
MU)/#K]TY)# #C-5];IV>][VM;6[5U^ OJ=5M6M:S=[Z66C^YGRQ17T-X0_9\
M\*>)?V?/B5X^35M3NKSPYJ$EMISPE(K>YA'E;))(VC+@D.3C<,<54M_@)X?F
M_9%NOBF;S4AX@BU(68MA+']DV><J9*^7NS@G^/KVIO%4U=/HXKYRM;\R5A*C
M2:MKS/?^7?\ (X?4/V?OB!I3>$!=>'9(SXMV_P!B@7,+&ZW!".CG9PZGY]O7
MV-<[X\^'_B#X8^)KGP]XFTYM+U>W56DMVD23 90RD,A*D$'L37W!\<]#/B;0
M_P!E;2A?WFEF\-M!]MT^7RKB#=%:C?&_\+CL>QKD?^&3]&^('[5/CGP7K'BG
MQ)J,6GZ/%?PZI?WB3WLLS)"%$TC1G>HWD8 !P ,\5R1QNK=31+G^Z+.N6"3B
MN3=J'7K(^+**^J]'_9G^&7Q&\"^.9/ 7BCQ%?^*?"$!FN9M3MH8;&^PKG]R@
M&]5/EL 7;(/4$&OE2NZG7A5;C'=6_';[SAJX>=%*4NM_O6Z^045^@7PYA^&G
M_#!&K'4$\3_\(S]JC;5S;BV^V_;/,@#FWW?)Y>_;C?\ -MSGFO"? G[/O@F3
MX8ZQ\5/&VKZ[IW@07[VFD6.F1PMJ5VN\JI9FS&K<8(Q@E6.0,9P6,CS34E;E
M=O5NUOF[[?,W^IR<*<HN_,F_2U[_ "26OW'SG17T%\8_V>_#.C_"/1?BE\.M
M9U+4_"5],+6>TUI(Q>6DF2OS&,!3\RE2 .,C!8'->'^&M%?Q)XBTK28VV27]
MU%:JWH7<*#^M=5&I&M?EZ.S\F<E:E*A;FV:NO0L^&? _B/QK-+%X>\/ZIKTL
M0S(FF64ERR#U(13BG>(? ?B7PC=06VN^'M5T2XG.(HM2LI+=G^@=1FOM#]HO
M5/&7@GQIX1^ _P &?M&@PKIZ7 73+E+2YO9CO)9IRRX.V(L3N&XDYSP*\=^+
MWAWX^^%_#?AZS^*4NH3>'#JT1M6U#4+:^?[1AL?O%=Y/NE^IQ^0KDHXKVTH/
M11D]+O5J]K_Y+\3LK87V$9)IN45=V6B=KV_S9Y'\2OA+XL^#^L6VE^+M).D7
MUS;BZBB,\4VZ,L5#;HV8=5/!.>*Y"OT3_:8^%FD_&;]KKX?^$];N+RUTZ\\/
MRO)+8.B3 HT[C!=6'51VKY_^#/[-?AGXB?M*>,OA[J5]JT&BZ-]M^SSVLT2W
M#>3.L:[V:,J<ACG"CGTK/#XY3I*53>SEIV3:_0TQ&!=.HXT]5>,=>\HI_J?-
ME%?0OP@_9NT+Q5I/CGQCXQUJ^T7P%X6N9+9Y+)%:[NG5ON(6&T'!09VG)<#
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M\4_5?F<N*_W>IZ/\C\DZ***_0S\Y"BBB@ HHHH **** "BBB@ HHHH ****
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M!8Y@3)&#N49(Z@=17R;152P:G/VDI:WB_P#P%6_$F.,<(>SC'2TU_P"!-/\
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M9XC%2Q/Q>N[:^2>P4445VG"%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?IA_P3/\ ^2$:]_V,D_\ Z2VM?6U?)/\
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MO#FC_L7_ !7T*_UW3;+6[RXD-MIMQ=(EQ.&BA4&.,G<W(/0'H:[G]F/Q5/\
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MF$L/F"KE0#UR*^5Z*W6%46[2TDK-=].7Y:&,L8Y)7CJFVGVN[_,^X_AOX?\
MA_\  KXSZ]\5+_XK^%]9T'%U-IVFZ3>"YU&9I\D))"H^0@,1GGG&=M<K\#_&
MGB+4->U[QMX:^,'A7P/=ZQK<UUJ?AGQ3<""!HV?>'3<")"0Q7Y=I&W[U?(U%
M3'!VU<KNRBKI;)WVZW*EC&]%&R;<G9O=JU[]#[_TW]I;X8>$OVNM8U/2[JUL
M_#NL:.FGWVMVEO\ N#?"3>)A@9*D84MC!(!/ S6!\1/B3\1=+\+^)6U3]I7P
M5J^D26D\=K8Z);VEU>WNY2%B:.. &'<#@N'.W.>U?#]%9?V=32BKWLK:I/\
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M0DG&1S7S911#"1A)-/2+;2\W?_-V"6,E*#5O>:46_)6_R5PHHHKO//"BBB@
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M86^!_P#T)'_E6OO_ (_1_P ,+? __H2/_*M??_'Z]ZHH^M8C_GX_O8?5</\
M\^U]R/!?^&%O@?\ ]"1_Y5K[_P"/T?\ #"WP/_Z$C_RK7W_Q^O>J*/K6(_Y^
M/[V'U7#_ //M?<CP7_AA;X'_ /0D?^5:^_\ C]'_  PM\#_^A(_\JU]_\?KW
MJBCZUB/^?C^]A]5P_P#S[7W(\%_X86^!_P#T)'_E6OO_ (_1_P ,+? __H2/
M_*M??_'Z]ZHH^M8C_GX_O8?5</\ \^U]R/!?^&%O@?\ ]"1_Y5K[_P"/T?\
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M "K7W_Q^C_AA;X'_ /0D?^5:^_\ C]>]44?6L1_S\?WL/JN'_P"?:^Y'@O\
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MU[U11]:Q'_/Q_>P^JX?_ )]K[D>"_P##"WP/_P"A(_\ *M??_'Z/^&%O@?\
M]"1_Y5K[_P"/U[U11]:Q'_/Q_>P^JX?_ )]K[D>"_P##"WP/_P"A(_\ *M??
M_'Z/^&%O@?\ ]"1_Y5K[_P"/U[U11]:Q'_/Q_>P^JX?_ )]K[D>"_P##"WP/
M_P"A(_\ *M??_'Z/^&%O@?\ ]"1_Y5K[_P"/U[U11]:Q'_/Q_>P^JX?_ )]K
M[D>"_P##"WP/_P"A(_\ *M??_'Z/^&%O@?\ ]"1_Y5K[_P"/U[U11]:Q'_/Q
M_>P^JX?_ )]K[D>"_P##"WP/_P"A(_\ *M??_'Z/^&%O@?\ ]"1_Y5K[_P"/
MU[U11]:Q'_/Q_>P^JX?_ )]K[D>"_P##"WP/_P"A(_\ *M??_'Z/^&%O@?\
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MUX%T/XE>%;[PWXDL?[1T6]V?:+7S9(M^R19%^9&5AAD4\'MZ5Y)_PPM\#_\
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M86^!_P#T)'_E6OO_ (_1_P ,+? __H2/_*M??_'Z]ZHH^M8C_GX_O8?5</\
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M  23[#FD\772NZCMZL?U2@W94U]R/"?^&%O@?_T)'_E6OO\ X_1_PPM\#_\
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M_'Z]ZHH^M8C_ )^/[V'U7#_\^U]R/!?^&%O@?_T)'_E6OO\ X_1_PPM\#_\
MH2/_ "K7W_Q^O>J*/K6(_P"?C^]A]5P__/M?<CP7_AA;X'_]"1_Y5K[_ ./T
M?\,+? __ *$C_P JU]_\?KWJBCZUB/\ GX_O8?5</_S[7W(\%_X86^!__0D?
M^5:^_P#C]'_#"WP/_P"A(_\ *M??_'Z]ZHH^M8C_ )^/[V'U7#_\^U]R/!?^
M&%O@?_T)'_E6OO\ X_1_PPM\#_\ H2/_ "K7W_Q^O>J*/K6(_P"?C^]A]5P_
M_/M?<CP7_AA;X'_]"1_Y5K[_ ./T?\,+? __ *$C_P JU]_\?KWJBCZUB/\
MGX_O8?5</_S[7W(\%_X86^!__0D?^5:^_P#C]>F?#/X3^%?@[H,^C>$-*_LC
M39[EKR2#[1+/NE9$0MND=B/EC08SCCIUKKJ*B=>K47+.;:\VRX4*5-\T()/R
M2"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /'OVO/B\OP-_9P\=^+UE$-]:Z>\%B2>MU+B*'\G=3]
M:^$OV1]>\)?LZ?M+?#_PMX1\6^'-?L?B'X*M[/5FTC5(KY+;7X5:3=,(G.-Q
M8H 2I.\XZ&ON;]IC]G%/VE+'P;H^I:ZNG>&='UV#6=3TIK$7 U=(L[;=F,BA
M$.YLY5\Y''%</\:_V!? GCZ/PG?> -.\/?"3Q/X<UJ#6+?6=!\.0!I?+R?)D
M2)H2REMIY;C;TYI4O=FY2ZM+_MVS5_\ R9OUBM!U/>ARQZ)O_MZZ:7_DJ_\
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MQ1^+7C'1=1T+Q3X^\0S2QZ?JUJ]M<VNFVY,=K&T;@,IQN/(Y&PUI^&?V-?\
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MHHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .3U#_D?+'_ *Y_T:NLKD]0_P"1\L?^N?\ 1JZR@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 5QGB;_D<M*_[9?^C#79UQGB;_D<M*_[9?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \J_:,^-$WP3\"'4K#0K_ ,1:U>LUMI]E8P&3,WELX:0C
M[J *22?2L/X"?'*X\1?LSZ9\1_'5U;6DHM);J_FC011H$9A@#/MCZUZQXRM&
MO/"FLQQQ&:=K*=8T5=S%C&P  ]3G%?(7AO\ 9T\<?$S]C_P'X-@OSX-O;.^-
MWJ-CK%D_[^-9'98I(SM;&[:V#UQ0!/\ !?\ ;:UKQMX;^-'B_7=-2RT;PHBS
MZ9ISQ>7+L9"4$C'J7.T^VZM+X"_M-?$76/B=X1\._$/3]*6Q\;Z'_;NB7&F
MAH$VAA%(#U.TCGWKR+P[^SC\7/$5[^T3H.L-#]EUBV2-'73'M8=4N$C1H6MG
M.%"#8%(!(R:Z+]G?0_&/Q$^-7PHO;_P-KGA+3/AUX5_L:_NM:MC +BY"+'B'
M/WU^3.?<T#/O>C-5M4T]-6TN[L96=(KF%X7:-BK ,I!((Z'GK7P_H_AVZ^"'
M[?W@#P/H'B/79O#>KZ#<7M[9:AJ$EPLL@2YVD[CT'EJ1[B@1]U4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQM2.+1+954>@ ' J7_A6GQ+_ .BKS?\ @FMZ!'K=-;[M>3?\*T^)?_15YO\
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M0!X_\=+^VTSQI\([F\N(;2VC\1R;YIW"(N;"Z')/ YKT#_A87A;_ *&71_\
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M69F( 'N:\6\*?&+P%>_&[Q)]G\;>'9_MEI906WEZK WG298;$P_S-D@8'/-
M'J?Q T:PU_P5K=EJ=E;ZC926DA>WNHEEC;"DC*L"#@@'\*X[]E_1[#1?V?\
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M]8Z'8P:E?C5+^.%5GO!"(A,^.6V G;GTS7#_ +1G_)(=8_Z[V7_I7#7HT/\
MJ4_W10!)17F=YJ'BQ?C-;:1%K5NF@261OFM3:*9,!]A3?UYZYKT2_OK?2[*>
M[NY5@MH$,DDC=%4#))H L45S_A'Q]X=\>07$WA[5[75XK=MDKVK[@C9(P??(
M/Y5T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7#>,KC['XEL9]N_RHT?;G&<.QQ7<T4 <9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &-=G10!QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
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M^U>R6<+VUG!#+.]U)'&J-/(%#2$#!8A0!D]> !STKR#Q]_R=1\(/^P%XD_\
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MH3A<]/\ "CX8_MP2Z+XA_P"$+^.>A'X<>*8QA+ZXS]@N^OS+)RJYQGDX]":
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M5'*@,@^5AD,".*T? FNZQK_A;3+OQ)H2^%?$,\/FW>A_;H[PVK;B,>:F%<<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^.?VV/A+XDUOXD>$?'.E?"30?C7IEGI-WHT_A[7+Z&U%I+++
M&Z72&;Y&X1E/<9R,=1]C5^>/_!3";X9V7QD^$4WQEU#4K[X>O9ZA'+X?T>=U
MG6X^39=LJD9C&=A(8-G& 1NK*=N:"\W_ .DN_P!ZNO5WTW-(_#+T_5?D]?\
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MV":QI\UB)U0$1;U*[@/;- 7/SQ^"?_!2:]USX[21/X%@A7QKJ>FV+L-3)^R
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MU\?!OA?3?#AOM@N?[/A$?F[<[=WKC<?SKM:** "BBB@ HHHH **** "BBB@
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M^)B6\)\*6_@]M&DG\]?,%R;B23'E]<;6'-?0%% 'PI'\'?CK#^TYX@^)&I>
MO#WC&&74BFA3:]K._P#L:Q$F%-O &V))L56+ 9W;L'+,3]UT44 ?!O[;GP+B
M\-_$CX-^*_!-EX>\,7.I>.].M)KBWTN%;J74IIGDCN9)1&6= 48LI;#$@E6(
M!'WE7S5^VU_S0/\ [*SH'_M>OI6@"KJFJ6>AZ9=ZCJ%S%96%I$\]Q<SN$CBC
M4%F=F/   ))]J^.?@'X%UC]JKXL3?';X@13'P?8SO'X$\-W080I$K$+?/$>-
MS8R"1DL<]$CI?BOI6M_MF_M!3?#JRU&:U^"_@MXV\3W-C(R#5M0/S?8A(I^;
M8-H8#[AWD_-Y>/LFRL[?3;."TM(8[:UMXUBBAB4*D:*,*J@<    "@":O-/V
MFO\ DVWXK_\ 8I:M_P"D<M>EUY1^U+K%K9_ 3QWI3-)+JNNZ%J.EZ7I]O$\U
MQ>W4EI*$BBC0%G8]>!P 2< $T <U^T)\+A\8/V/]8\.1P"XOSH$-Y8KCYOM,
M$:RQA3V+%-GT<CO74?LL>-)_B#^SG\.M>N[AKN]N=%MTN;A_O231KY<C'W+H
MQ/UKH_A/XJTKQ7X%TM],NUN#9V\5G=PLC1S6TZQ)NBEC<!HW (.U@#@@]"*\
M;_9!UZ+1/%7QD^%V5A_X1/Q3<76GV@7:(=/O29XD4=-H<R].@9?;(!]*T45C
MQ>,M GUQM%BUS39-84D'3UNXS< @;B/+SNX'/3I0!L5XU^SS_P C-\;O^Q]F
M_P#39IU=[\2_&I^'_@V[UB.T_M"[\ZWL[.S+^6)[JXGCM[>-GP=BM++&"V#M
M!)[5Y1X5FU#]G;Q!XCO/'>L:7<Z-XPOKOQ%<:K9VKVL.EW,5I"KP,'ED,D9A
MMMRN-IW1N"OSJ  >P^.O$FD^$O"&JZKKFJ66C:7!"1+>ZA<)!#&6^10SN0HR
MS*HR>2P'4UYC\,_%FE_$3P#\.M)\+>+/#6J+;Z=9W&M:;OBOGFLE@:)E"JWR
M,)T5=S @&-QC(K0\<?%K2_%$-GX1\&OIOBWQ!XBL4NH8?M86VMK&:-V2^F8*
MQ\HA1M"J2S,@X!+#-_9FL=8\,Z?JO@[QBNF3>,?#*P6R7FG6J1)-I3AOL;*V
M=[*3%,IWA3YD<G! #L >VCC@<"N-\:>*-*\'^+/"5SJ_B&YTV/5;F30K+2TA
M\R&^O)@LD9<JA92BV\H!)5?WC9YQ79UC>,M%OO$?A?4],TW6)O#^H74#10:I
M;1K)):N1Q(JMP2/>@#B+CXX^5\=#\,8?"&MW5ZMA%JDFKQM;"SCM9&9!*<RB
M3'F(\> A.5SC'->H5\S?#+Q=I'C?]KRYU71-:3Q%8-\-[2W_ +3C7:)Y(M6O
M(I&P !G>C9P,9!QQ7TS0 5B>./\ D2]?_P"P?<?^BVK;K@_BAJCWQTKP=I^L
MVFEZMX@E>WD+A);B.T$,KRR1Q%AG[@C#$%5,@)!Q@@' _LTVEMK7P^^$-Q%K
M.M6UWH/@+2EGTJ-FCTZZ2ZM8MDD@*[9)$-L^TJV4W,#][%>]5Y1\!_A]??!^
MWU7P1)X@O/$>C:?':3Z1+J!'FV=J8S MIQP53[+N#<9\TC'&3ZO0 4444 %-
M6-$9BJJI;DD#K3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OC+]O+XW_$#P=X@TKP=X%\8V/P\>3PWJOB6XUF[M8YYKPVB K9
M6XD^4.^221\P'(Z$'[-KYH_:M;X-^/?$FD_#OXL^%'UVT31=0\4'5-YA72K>
MUV"1S*DB2+OR!A,@D $8Z8U;V5G;?\(MW^7Q6ZVL]S:G:^JOM^:7X[>5[K5%
M#]G[X^Z[X\^.%AX2D\06_B+1_P#A7&EZ[>^2D1>RU.1PLBNZ#.9%8/L8\=@
M:^IJ^)O^">'Q"^$5U/KOA;X<_"G6/A?+<V4>NP2:T6EEUJP,C1)<+*[,S*K9
M&W)4;OE)YK[9KMJVNFE:]W]\F_P^'Y=-CCIW5TW>UE]T4OQ^+Y]=PKQW]J_X
MMZU\%/@SJ?B;0+6"XU1)H+>.2[1F@M_,D"&60 @[5!R>:]BKYX_;J\%^*_'7
MP)N=.\*64^JRK?6\U_IEJ^V2\M%?,D2\\Y&./2L#8\U^'O[7_BG1]'^*\GBW
M4/#OB^'PCI4.I6NM>'0R6DLDF56W<DGYMVWIV-:7P'_:+^*%S\5/!OACXEPZ
M+):^-M!.N:7)I4+Q/:\!O*DW,<G:1^)ZUY#X0^!/B#XE6OQDM_"W@#4OAMX)
MUKP[#:VFAZ@Y7[1J$3!PZJ2<9*!2:[;X#>'O'OQ*^.7PTUWQ'X+U'PG8^ _#
M+:5=7&H*%%U=%50^6!V^4'\:!GW,6"KDG KXN^(TT<__  5 ^%#1NLB_\(M<
MC*D$?=O*^QM8TN+6M(O=.G>2.&[@>W=H6VN%92I*GL<'@U^?VB_!?1?@=_P4
M>^&6BZ'?:OJ%K<^'[N[>36;UKJ4,8KI<!B.%PHX]2: /T-HHHH$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !28I:* .6^)'@U_'7A6;38+E;&^2>"\L
M[EX]ZQ7$$JRQ,RY&Y=Z+D9&1GFN?L/"_C#Q)XBT_4?%3:3IT.E+(;2#1YI+@
MRS.NWSG:2--N!G" -R>6->DT4 >!W'ANR7Q=I_AKXD^(9-?L[72O,MI-3*V\
M%],9&\R1T7"%T78%!Z#GKS6E\.?B1I7A.T73+V_O+G2M0\0R:5X<NI5DN#/'
ML1@#)@_(K^:JLQ^Z@YKUC7/#6D>*+46NLZ59:M;!@XAOK=)D##H=K C-6H["
MWAM4MHH8X8$78D<:A51<8P .G% 'SSJ6LZ-)\83XS71]=G\+V:-:W6M1S2BR
M2Z63:9/+W_,BC(+A"HP<GBOHQ7#J&!RIY!KQB;P;XZM?">H^!+.STU]'NO/@
MCUR2?YH;:5V+ PXRT@#L <X/&:T?$'CS_A#_  ;?VOC2&;0([F\DTG2#H\C7
M%S<QE<0NN%^65N>#P#B@#U>EKP?]F.2^T.UU+1O$U_XED\33S372V_B-PW^B
M"9Q"T)  _P!6T8<==U>[T +117.V/Q#\,:EKTFAVGB#3;G68RP?3X;I&G7;R
M<H#D8^E '14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <GJ'_ "/EC_US_HU=97)ZA_R/
MEC_US_HU=90 4444 %%%% !1110 4444 %%%% 'RM^V=\*=7\?>*/ ][X&\<
M:!X5^)J6>J:;INF>(C_H^L6<\*B[B  +!T4*P90<<YXY'F7_  3]\+RZG\0)
MM4\2_%7PAXW\2>"O#<7A#3="\'RO)#I]BCKNED=T0R.S1*"R@K[\@#JO^"AW
M@W7;>/PI\1/#WQ \*^ +S2;34="FO/%DSQ1^3?1JC/;E$9C.HC. %S@D]N<;
M]C'X3_#ZS^*'ASQ'\)?$WA;7/"OAKP4?#VK7.DR%=1O]2EN$E:>YBV A"$8J
MS$GD@<"GAM&_G\G:?W)IV]:CMU"O\,?E\]8_CI?T@KZ62^Y:***0!17C'[0G
MQB\6?#[6O _A;P'X<LO$GB[Q7<W*6\.I7#06T,-O$))I'91G@,H_'N< Z7[-
M'QGNOCM\*[?Q'J6CKX?UJ&\N=-U'34E,BP7$$A1@&(&00%/MG&3C) /5:*^6
M;S]M7^T/VN= ^$&@Z#]HTB:XNK'4=<O$DC_TJ"*1Y(X!P&"%%5F/=CC@ GZF
MH ^:OVVO^:!_]E9T#_VO67^V#\1?%_B7Q+X>^!7PQN7LO%WBF%KK5=7A8@Z1
MI:MM>4D<J7(89R#Q@<NIKY/_ &_OVP/&=C\=CX&M]/T6/2_ GB33?$.EW7D2
MFYDN8K=9%$Q,NQDW3OPJJ<!>>N?JW_@G%X=6Z^ ,/Q#U*[N-7\7>-;VZO=5U
M2];?,YBN)8(XPW78!%N"] 7;'&  9[M\&OA'H7P-^'6D^#_#T;"QL4^>XEP9
M;J9N9)I#W=FR3V' &  *[:J5QK6GV>HVVGSWMO%?W2/);VCRJ)IE3&\HF=S!
M=PS@'&1ZUR4%QXF\<3:->111Z-X,U;1)&OK&_CE@UJWN)54Q*NUML156<,"2
MP8#'>@1M^+O&EAX/TG4KN9+C4KNRLI+\:3IJ">^N8T!)$,.0SL2,#WXS7':]
M)X[_ .$]T7Q1I.CZ?J_A5=)-NVDR.UKJT4TSJ[R!G/E$*L4*^62IR7._@*>X
MT?PGIFBKISQVXN;ZQL4TZ/4KS]]>-"H'RO,WSMDJ&.3RW)YK8H \JT;Q3<^%
M_%.H:WX\BTSP?%XCO+#1=#M6OA++<38EV1R84)Y[L[8"LV551GY:\+^*CGX(
M_P#!03X=>+U9;70OB+ILGAS46P55KN,@0LQ'!9B;5!GG"MSZ?8TD,<VSS(U?
M8P==P!VL.A'O7R#^WU\-?$.K_ C4;;0M->[L_#BS>*H_$5SJ;?;+*YBG,KI&
M,%BODR3E2" GEHO3! ,^P:\ NM/M8_V[M)E2VA65OAW>R%UC 8M_:5JNXGUP
M2,^AKV/P-XB3QAX)\/Z]&08]4T^WOE*],2QJXQ_WU7DEY_R?1H__ &3B]_\
M3G:T"/2?BA,/^$5:UD\*W/C"VOKB&TGTZU*!EC=P#,2S# C^_D'<-H(Y%0^%
MOA3I7AF]%Y+>ZIX@NXX/LMO/KUXUX]M"0 Z1E^F_ W,<LV!N)  $^CS7VM>/
M-8DU/PO/I<>BJ+72M9>]22/48IUCDF*Q*V4VO%&I\P9R/E.,UUM '&_$3P+:
M^)=/2_@O+K0M=TQ6GL=8TW8MQ 0K H0ZLDD9!(,;JRG.<!@I&=\$?#:67@^S
M\1W=[=ZOXA\26EKJ&I:E?.ID=C$"L2*H58XH]S!(U  W,3EF9F[;6O\ D#W_
M /UPD_\ 036!\)?^25>#/^P+9?\ HA* )_&7Q.\'?#G['_PEGBS0_"_VS?\
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MOD(+G 8ACW-=Q10!P'B;QMXF\*VOC+4;CPPMYI6D62W.G-9W0::_8(6D4H0
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M^$__ &*US_Z#>T#/L^BBB@04444 %%%% !1110 4444 %%%% !1110 4444
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M\G[)1J)R3:VEKI==^[ZBT445ZY\Z%%%% !1110 4444 %%%% !1110 4444
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M2.] '<4444""BBB@#S3_ (9E^#W_ $2CP/\ ^$Y9_P#QNO2E4(H50%51@ #
M%+10 4444 ?,?[9WP3\3^)(_#WQ5^&L[V_Q*\#%Y[6WC3=_:5J>9;8@<L<;L
M+_$&=>K@BCXK^-6F?'S]F7PIXLT^%K*>7Q;X?M[_ $Z4_O+*Z35[5986'7@\
MC(!*E3@9KZJK\A/^"@GCO7OA-^U-XGM?"6I2:):ZO#I.K7UO BF*>[@9989B
MK C>KQJV<<\YR"009^O=>,?$!EC_ &I?A"S$*JZ%XD)8G  SIM?-7[/G[<?Q
M7USX0Z$'^#7C+XG:^4N&E\20PK96%Z1<R!0DJPF/Y$VH<#.Z-N.IK\J* /V$
M_:C\;7G[64\GP&^%$]GK%O<2PS^+/$W^ML=*MXI4D2-9%.'F,B+\JY^[MX^8
MIYCH_P#P2N\8?"?4X/%W@#XO0GQAI)-QIJW&A?9XWDP1L:3SY,!E+*<HP(."
M,&ONKX0_#?PY\*/A[H_AWPMI<.E:7;P(WEQ#YI'*@M([=7=CU8\UV= 'S-\)
MOVT_#\MG-X<^,$UM\,/B+I'[G4K+66%K:7+#CSK65F*O&W!QNR,\;AACZ)^S
MO\4_!WCSX>>'=-\.>*-)US4-,T:R6]M=/O(YI+8^2JXD522O*D<]P:\"_P""
MIGPW\0_$3X.>%(O"_A?4O$VJ6NO*S1Z1827<\4)MY@Q(C4L$+!,GIG;GM7RS
M^Q=X;_:'_9]UCQ1XDT/X0ZGJ.F^1 FJ:7K=E-875S""Y!M#(%WNI!R%5S@@;
M>10!^O%%>"_#']M3X;_$*Z73-2NKSP!XDP2VB>,;<Z=/P<'8SGRW^@;=CJHK
MW:WN(KN%)H)4FA<962-@RL/4$=:!'C?COQ!\0(?VBO!/AK0]?TFP\+ZGIMSJ
M=Y:W6EM/<,MI<6RS1I*)5VF1+H ':=A0G#9P/:*\B\5?\G4?#C_L5M?_ /2C
M2ZG_ &HO'UCX ^ OC^\E\16_AW57\/Z@NF3M>BVG-T;=Q"(&W!O,WE=NWG.,
M<T 8?P'_ .2S?'__ +&2R_\ 37:U\X_\%:/B)X7U+X-Z!X7L_$&FWGB*'Q)#
M=RZ7;W*27$426MTC.Z*25&Z1!SC.>.AKX=^ _BWX@_%;XQ:/X0F^)OBW3(?&
M&I16^K7<&KW!DN5*A"T@,G[QO+4("^> !T&*_8[X*?LQ_#OX Z!_9OA3P_!'
M-(JK=:E>*)KRZ([R2$=,Y.U<*,\ 4#/RU_X)U_'"V^!OC_Q3J5]X8\2>)+&\
MTZ."9O#EA]K:T E!\V5=PPG7GK[&O?OVL/\ @I)X?U+1[WP3X;\)7NJ6>H6E
MO-+J6H32:?-;2K/O,1MY("6XC7Y@^/G_ -DU^C-O8VUHQ,%O%"6X)C0+G\J^
M1OVM/^"?(_:B^)UKXO'CW_A&?)TR+3C9_P!C_:]VR21]^_SX\9\S&,?P]>>
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MW7B#4/$I6,2Q%1';QL(ML9.[<6?( VC'.:C1S46O3ULW^2_0O51<D_\ AO\
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MB@ HHHH *\N_:6_Y)#JO_76#_P!&K7J->7?M+?\ )(=5_P"NL'_HU:\[,?\
M<ZW^%_D>QDW_ ",L/_CC^:.D^$O_ "3'PO\ ]@Z'_P! %=;7)?"7_DF/A?\
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M)=TLGEPH[A$7EG(VJ.I%(#NJ*P_!7C;0OB-X7L/$?AG5+?6=$OD+V][:ME)
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MU:.NI6<EJ^\173<*X!(PPY^M 'Z&4444""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#XE_:,_P"2R>(?^W?_ -)XJ\VKTG]HS_DLGB'_ +=__2>*O-J_
M%LP_WRM_BE^;/Z:RC_D78;_!#_TE!1117 >L%%%% !13HT,DBHOWF.!76^)O
MAAJOA/QE9>&;R:T>_O/*\N2%V,0\QMJY)4'@]>/SK:-&I47-%75TOF]D85,1
M2IR4)RLVF_DMW\KHY"BN]O/@QK=G<^*H7NM/+>'(4FNR)FPX9-X$>5R3CUQS
M7!45*-2C95%:_P#G;\T30Q-'$INC*]K?BDU]Z:845V&K?#TZ5\-M%\6&_P#-
M_M*Y> 6?DX\O:7&[?NYSLZ8'6N/I5*4Z,N2:L]']ZNOP*HUZ>(3E3=TFU\T[
M/\0HHHK(W"BN[TGX9VTWP[F\6:MKT>D0/*]O96_V9YFN954G:2I^3)4C)!Z<
M]L\)6U2C.C;G5KI/Y/;T^9S4<12Q#FJ;ORNST>_KL[=;!115^;0=1M?L)N;*
M>TCO@#;2W,9C2521\RLP *\CD<<U$8RE\*-Y2C'1LH45T'CKP3??#_Q!)H^H
MRV\UU&BR%K5RR889') .?PKGZ)QE3DX25FM"*56%:$:E-WB]4_(****@U"BN
MC^'G@\^/O&&GZ$+O[#]J+_Z1Y?F;=J,WW<C/W<=>]9.MZ;_8^M7]AYGG?9;B
M2#S-NW=M8KG&3C.*U=*<::JM:.Z7RM?\T8*O3=9T$_>23MY-M+\F4J***R-P
MHHHH **** "BBB@ HHHH *]M_9)_Y*/J7_8)D_\ 1T->)5[;^R3_ ,E'U+_L
M$R?^CH:];*?]^I>I\]Q!_P BK$?X3ZVHHHK]B/YP"BBB@ HHHH **** .3U#
M_D?+'_KG_1JZRN3U#_D?+'_KG_1JZR@ HHHH **** "BBB@ HHHH *1ONG/2
MEHI/56 _*'QQXP_9DU[2K7PUJ7ACXYM;:1J>H7D<EK;ON::YE5IOG\SYDS&-
MOXGDDFO8OV";?X'0_&#5#\-='^*&GZ[_ &-*)9/&B,+0P>=#N"Y8_O-VS'L&
MKZ6_:&\._'+7I-#/P;\5^&?#*1";^TQXBM&G\XG9Y7E[8VQC#YZ=17E7[/OC
MSXXZ'^TUJ7PU^,_B_P -ZR[>&SK>F0^']/").OVA8F=I"JLC(01L*X8/D'Y<
M56'T:CL[/RV3_1?<%;5.72Z?>UY?YL^NZ^1/VBO$&E> OVN_ 'B3Q5>V^C>%
MV\(:M9#4-08);&X/)BW'C>5(PO4Y &:^NZQ/%G@CP[X^TQ=-\3Z!I?B/3ED$
MRVFK6<=U$) " X212-P!/.,\FD!\F_L!?$#0?A=^S#\--&\7ZK'H&I^*-1O$
MT*TOMR/?;KD*OE#'0M*F.@.\$<'-?+_@NZ^V?#C]GKX?13++\2])^)LUQJ>B
M\O?6FRY+22S(/F   8L3R%)S\IQ^INK_  ]\+>(+K1+K5/#6CZE<Z&XETJ:\
ML(I7T]P4(:!F4F(@QQG*8^XOH*?;> _#5GXIN?$UOX=TF#Q)<Q^5/K$=E$MY
M*@  5I@N]A@#@GL*!GYLS>/O$WP[USQT]K\2[2QUVQ^*LZ)\-I;&WEEU>&XO
M$+3G>ID8NL@VLN0JQ\$,<C]0ZYJY^&?@^\\61^*+CPIH<_B:/ 36I-.A:\7
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M_>@_U%Q/_/Z/W,^_Z*^ /^%F>,/^AKUO_P &,W_Q5'_"S/&'_0UZW_X,9O\
MXJC_ %GH_P#/M_>@_P!1<3_S^C]S/O\ HKX _P"%F>,/^AKUO_P8S?\ Q5'_
M  LSQA_T->M_^#&;_P"*H_UGH_\ /M_>@_U%Q/\ S^C]S/O^O"OVJO\ D&^%
M/^PC_P"RBOG7_A9GC#_H:];_ /!C-_\ %51U7Q=KFO+$NI:UJ&HK"V^,75U)
M*$;U&XG!^E<.-X@I8K#RHJFTW_F>IEG"-? 8N&)E534;Z6?9H_0VBO@#_A9G
MC#_H:];_ /!C-_\ %4?\+,\8?]#7K?\ X,9O_BJ[O]9Z/_/M_>CR_P#47$_\
M_H_<S[_HKX _X69XP_Z&O6__  8S?_%4?\+,\8?]#7K?_@QF_P#BJ/\ 6>C_
M ,^W]Z#_ %%Q/_/Z/W,^_P"BO@#_ (69XP_Z&O6__!C-_P#%4?\ "S/&'_0U
MZW_X,9O_ (JC_6>C_P ^W]Z#_47$_P#/Z/W,^_Z*^ /^%F>,/^AKUO\ \&,W
M_P 51_PLSQA_T->M_P#@QF_^*H_UGH_\^W]Z#_47$_\ /Z/W,^_Z*^ /^%F>
M,/\ H:];_P#!C-_\51_PLSQA_P!#7K?_ (,9O_BJ/]9Z/_/M_>@_U%Q/_/Z/
MW,^_Z*^ /^%F>,/^AKUO_P &,W_Q5'_"S/&'_0UZW_X,9O\ XJC_ %GH_P#/
MM_>@_P!1<3_S^C]S/O\ HKX _P"%F>,/^AKUO_P8S?\ Q5'_  LSQA_T->M_
M^#&;_P"*H_UGH_\ /M_>@_U%Q/\ S^C]S/O^BO@#_A9GC#_H:];_ /!C-_\
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M<#BOKNBBJO[JCT7ZMO\ -D):N7?]$E^2"BBBD4%%%% !7QA\3/\ E*%\)_\
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M10 4451OM2%M\D8#2>_04 7J*@L[I;R$.!@]&7.<&IZ "BBB@ HHHH ****
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M72;:769)(=*E2>T#11DQN@(4D[<M@$_>)JG_ ,*S\8?]"IK?_@NF_P#B:/\
MA6?C#_H5-;_\%TW_ ,35<^.;<FYW=N_35?<]49QIY7&*C&--):_9ZJWY:>A9
MTKXL>+-$UK4-6LM9D@OK]]]RPCC*2MZE"NW/X5'/\4/%-UXHM_$4VKRRZQ;@
MK#<.B$1@@@A4V[0,$\8[U%_PK/QA_P!"IK?_ (+IO_B:/^%9^,/^A4UO_P %
MTW_Q-+FQMDKRLM5OH^Z*Y<LYG*U.[5OL[;6]+:6(;7QSKEG!K<,-]LCUHYOU
M\I#YQR3W7Y>6/W<=:TM<^+WC#Q)HG]D:CKDUQI^ &BV(I<#H&95#-^)-4_\
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M  73?_$UG4CBJSO54I/SNS6C/ 8>ZHN$;[VY5?[CFZ]M_9)_Y*/J7_8)D_\
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M0C?HW7RG'^P;]A^)>O\ C32_B]XYT*^UW5&U34+;2;P6L-PQD+B-PF-R#<5
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M0 4444 %?2/['/\ S-W_ &Y_^UZ^;J^D?V.?^9N_[<__ &O7O9%_R,:7S_\
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M7PG_ .Q6N?\ T&]K[/KXP^)G_*4+X3_]BM<_^@WM S[/HHHH$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!R>H?\CY8_P#7/^C5UE<GJ'_(^6/_ %S_ *-7
M64 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-7[;7_-
M_P#LK.@?^UZ^E:^:OVVO^:!_]E9T#_VO7TK0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!^;E%??W_"L_"'_0J:)_X+H?_B:/^%9^$/\
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M?]"IHG_@NA_^)H_X5GX0_P"A4T3_ ,%T/_Q-'^K%;_GXON8?Z]8;_GS+[T?
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M!YK_ ,/'OV=O^BA_^434?_D>C_AX]^SM_P!%#_\ *)J/_P CUZ5_PS+\'O\
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MX/?]$H\#_P#A.6?_ ,;H_P"&9?@]_P!$H\#_ /A.6?\ \;H \U_X>/?L[?\
M10__ "B:C_\ (]'_  \>_9V_Z*'_ .434?\ Y'JTG[$WP_7X]2>-3X2\(GPJ
MWAS^R!X6_P"$?M_(%W]I$OVS;MV;]@\O.W=@]<<5Z!_PS+\'O^B4>!__  G+
M/_XW0!YK_P /'OV=O^BA_P#E$U'_ .1Z/^'CW[.W_10__*)J/_R/7I7_  S+
M\'O^B4>!_P#PG+/_ .-T?\,R_![_ *)1X'_\)RS_ /C= 'FO_#Q[]G;_ **'
M_P"434?_ )'H_P"'CW[.W_10_P#RB:C_ /(]>E?\,R_![_HE'@?_ ,)RS_\
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MH,U+4=Q"+BWDB;[LBE3^(Q0(_,Z/XV_$G3!I7QOO?'FI'1KOQT_AV7PRTO\
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M0!R>H?\ (^6/_7/^C5UE<GJ'_(^6/_7/^C5UE !1110 4444 %%%% !1110
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MV  'X4X.T6GO:"_\ 35_G?\ ,4TG)-=YO_P)II?*WY%RBBBD,**** "BBB@
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M?I7ZDUY]\+_@CX?^#^M^,[[PY-?6]KXIU/\ MBYTJ21#:6UTRA97@4(&3S"
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MNVW][N%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,P52QX &32
MU!?2+':2EN5VX_/B@#G57:H&2V.,GJ:6BB@ K0TO4/+=;>4_*QQ&WH?0_P!/
MKCTJG;PM<3+&O!/?'0>M27=C):_>&Y"<!A_6@#H**S-.U(R,(9>O\+YZ^Q]_
M\_73H **** *NHVWVBW.!EUY%8-=16!J4(@NB%X5@&  P![?I0!6HHHH ***
M* &3?ZI_]TU:OMBWLZH?NM\WU(!_K56;_5/_ +IJ]JP1;]@N=[(KMZ<Y _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %96LWC1R16ZC
MD5F)^A Q^OZ444 9E%%% &KH85HYFV_,'V9]L _UK290RD$9!X(-%% &9?:;
M&BM*A*>J]14NDWK7<<JN.8F";L]> ?ZT44 7Z*** "L76?\ C[7_ '!_,T44
M 4:*** "BBB@!DW^J?\ W36KK4*B2.4#YV&TGV'(_F:** -&U01V\:CIM%2T
M44 %%%% !6?K2DVJ$-@!P2/7@\?Y]*** ,>BBB@ K:TF$1VV_C<YY./3M_.B
MB@"]7.WD:PW4J+]U3Q^(!_K110!H:/=-(LD)&?+ (;/KGC]/UK2HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>eigr-20221231_g16.jpg
<TEXT>
begin 644 eigr-20221231_g16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )]!/H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOKFG:/XC6'3;34;Z6>*RC^T7B[(4=B(UPB#:H ^4>E<Y\%?^4OWQJ_[%B/\
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MO[*_Q/U?1=1NM(U6ST.XEMKZQF:&>!PO#(ZD,K#U!S67^QYXBU7Q=^QW\/\
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MX?\ B'\=_$"EO$'Q$UR9XBS;O)LH&*1QKZ ,77Z1K7VY7BW[%OAF/PC^R?\
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&+'IS33_ 'DI=XM??*+_ "3.=1:I0AU33^Z,E^J/E3_@FW_R<S^UM_V-"_\
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MS; >N%YX[ GL:^I/V9_V8_"O[*O@G4?"_A*]U:_T^^U&34Y9-9FBEE$KHB$
MQQQC;B-<#&>O-<!^TM_P3Q^$_P"U)XJB\3>)%UC1?$(C2&?4= NHX7ND4$*)
M5DBD5B!QN"AL #. !71.?[^%6*O:/+]\4K_)HEQ4J<X-VO+F7RDW^*/8/BE;
M_#KQQX/;PSX\N=#O?#WB%FLDL]3NXXTO)%RQ2(E@3(NPM\AW*4R,8S7Y^_M+
M?!75/^"<?AVU^)'P7^*NJZ/HXU".*;X?^(+P7-I>J[C<($;&[;WRI<*682#'
M/UKXP_8-^%/CCX$^&?A-J-GJ@\->&V:33+B"^*W<,K!]TA?!5F)D8X92N<<8
MXKS?X7_\$E/@1\-/%%KKDT?B#QA-:R+-!:>([V*2V1U.0QCAABW\X^5]RG'(
MK)1M5;B[:[]UYK[U9E<UZ:4E?3;L_7[MCZY\':\WBGPCHFM/;-9OJ5C!>-;O
M]Z(R1J^P^XSC\*^7_P#@JEH<VM?L4>,VA5G:QN+&[8+_ '5NHPQ_ -G\*^MP
M H  P!7%_&OX<V_Q>^$?C#P7<[0FN:7<62NW1'="$?\ X"VUOPK'%>]"4H+S
M2]'=(O#>Y**F_)OUT9SG[)>M1>(/V8?A5?18V2>&=/4@=F6!%8?FIKY?^%?_
M "E^^+W_ &)\'_H&GUUO_!*WQW<:O^SC/X&U<M#XD\!:M=:+>V<HQ)"OF,\>
M1Z9:1!_US([5[AH'[,WA;PY^T;XC^--M>:L_BK7=-32[FUEFC-DD2B(!D01A
MPV($Y+D=>*[ZDE];]LOA:D__  ..GYG+23CAW1>ZLO\ P&2O^3/'?^"KG_)D
MOC'_ *^]/_\ 2N*O1'T;XA^(/V/?"UA\*M>T_P ,^.I?#VE?V?J>J1B2WAQ'
M"9-P,4HYC#@?(W)'3J.S_:"^!.@?M(_"W4_ 7B:ZU&RT?4)(9))]*ECCN%,4
MBR+M9T=>JC.5/&:['PKX=M?!_A?1]!L6E>RTNSALH&F8,YCC0(I8@ $X49P!
M7+!6IU(O[4HM?)6-Y/\ >4YK[*:^]IGPK_PIO_@H9_T7;X?_ /@##_\ *JO4
M/V<?AU^USX:^)<-[\8OBEX2\5^"A;2K+INDVB)<-,0/+8,MC!@ ]?G/T/4?5
M]%7&7*[D27,K#9/]6WTK\\O^"/?_ " /C3_V-/\ [*]>Q_M)?\$X/AI^U%\2
M#XU\5:YXLT_539Q67DZ1>VZ0;(]VTA9;>0@_,<X./;.<^6?\.5?@A_T-/Q _
M\&-C_P#(=9T[QE*3ZJW_ ),G?\/Q-)V:45T:?X-6_'\#N_\ @J]X'O?&7['6
MO7%C$T\FAW]KJLB*,GRD8QNWT592Q]E->S?LP_&#PS\5/V??"'B32-6LI;6'
M2+>._"RHOV*:.("6.4 _NRI5NN.!D<8KT6P\(Z;9^#[;PQ+!_:.D0V*:<T-_
MB;SX5C$>V3(P^5'.1SDU\;>)O^"//P#\0>)'U6VD\5:!;.^\Z3IFI1?9?O$D
M#S89) #G& XP!QCK51_=NI".JDT[^:5MNS5B7[ZA.6CBFK>3U^^YY_\ LE:G
MIGQ0_P""G7QL\<>" MQX+ATHVDVH6G_'M<7)-LI8$<-O>&9P><A2W?-='_P6
M8O3+\ /!6B1+YEUJ7BN 11C[S;8)QQSZNH_&OL'X+_ OP1^SYX.C\,>!-"AT
M32P_FR[6:26XD( ,DLC$L[<=SP.!@ "OC_\ :GM1^T/_ ,% O@K\+;5VN=*\
M&QOXGUQ8\[8CN5T5S[B*%?\ MN/6FHQ<L/AUM%K7RB^=O\'^!2G*/MJ_5IZ>
MJY4O/H?=^@6']EZ#IMEC;]FMHX<>FU0/Z5?HHIRDY-R?4RA%0BHKH%%%%26%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5YWXN_9\^'_CSXG>&_B%K_ (>34_%W
MAQ=FE7\MU.%ML,S B$.(F(9B0S*2#CG@8]$HHV:DMT&Z<>C"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .%\'_  0\$^ /'GBOQGX?T1=,
M\1^*6C?6+J*YF*7;)G:QB+F-6Y/*J"=QSG)KNJ**.B71!U;ZL**** "BBB@
MHHHH **** "N$\*_ _P3X)^(OBCQYH^B"W\7>)@BZKJDEU--).J8"J!([+&H
MP/E0*/E'' KNZ*%H[K<-U9[!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?&WQ7MK[XE>*?'/B:RF?['X8,-O#L[@.58@^Q#O\
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M<];".,L+3J*+DU)OF=E=V;V.[^-GPA@'PJTJ;0))IKKPS$)+:8N&DD@X+<J
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MA7QCR\[<^^<=ZY+7O#5UX8_9.M8KV-H;BZODNS&PP55V.W([?* ?QKLOA?\
MLW^&8[#PMXI%]JW]H>5;ZAY?G1>5YF%?&/+SMS[YQWK:I4AAZ%14JG(O:2M9
M7Z+3T..G3J8K$4?;4E4E[*.[M]IZ[/4]\KX_^$_P?T?XL^)O&;:Q=7\#65[^
M[-G(B[M[R9W;D;/W1^M?8%?'WPE^#NC?%?Q)XR.KW-_;_8;S]W]BD1<[WDSG
M<C?W1TQ7F97/V=*O+GY;):I7MKV/:SFG[6KAX<BG>3T;LG[KZGN'B*UL?@/\
M%=3M]+N+ATMHI$MI+IU:3S96('*@#@MGIT%>*?".SO/A'\3/"37LC"T\4:<I
M?=P TARJGW#!/^^ZU/C=H3Z3#X-^%GA=;C4VC+W?D7$J[Y2S,4#,-JX_UA[<
M8K)^,D/Q/U+1].U?Q'X8L-&M-#<-#=:?*I:/<5 ! F<XR%Z#BO6PE-.%IS3]
MLY7;LFUJHM+S>IXF.J/VB]G3:=",;))N*E=2DFUT458]%_:P\3:MHNAZ%9V=
MU/8:??7#K>7-N2&PH7"9'.""QQWVU/\ "GX->%M-U73O$G@_Q;>W]I&&%S 9
M4=)MR, K!0I0@MG# GC\:Z6X^('@;QGX-T./Q3<V,=OK=KYZP7YVIN7"OA^B
ME6)&<@^E>))IVC>!?CIX9A^'6MMJ-O>RHMU;V\XGC1"V'0NO#+MRV#DKC.>E
M<F&C4EAWA%>$ES7=O=EWN_+:_P"IVXR=)8B..=JD'R:7M*-]4XKSNFU^@GQ\
M^!.@?#/PM;:MI=WJ4]S/>K RWDL;(%*.Q(VHISE1WKT[P;\!] \":+<>(]/O
M-2EOI=(E!CN)8S&-\63@*@/TYJO^V!_R3?3O^PG'_P"BY*]/?_DFS?\ 8)_]
MHUC5QF(E@8-S>K:?I9'51P&%CFDE&FO=C%KR=WJ>)_ &1D_9Y\9,K%65KP@@
M\C_1EKD?V>]:N?A[X@\/W%S(W]A^*5DM26/R1W"2%5X]?NCZ.?2NM^ ?_)N_
MC3ZWO_I,M,\$^ C\0/V8H+6!?^)G:SSW=DXX82K(QV@_[0R/Q'I7IUJD(5,0
MJGPRE%/T:>OR>OR/%H4JE6CA'2^.,9R7JI+3Y[?,W9F/_#74 SQ_96/_ "&:
MPM6OM?\ V@?B?J_ARRU:;1?"FCLT=P;<D--ABI) /S%F!P#P ,XSUS/A7XQ/
MCKX^:'JDN1=G1S#=!A@B9(V5_P R,_C4_P /O$%K\$_C+XLT?Q&YL;#5)/,@
MO'4[<;V:-B1_"0Y&>Q'/>LG1E1E9*]2%-66^O,[M>BV-EB(UX.3E:E.K[SVT
MY(Z/LK[G70_LQ_\ "(WEMJ'@WQ1J>G7L4J/)'>2!HYU!Y4E%7C&>H85[I7Q;
M\0O!_@WPGXR\*OX3\0'6WNKT/<_Z9%<"+$B;<&-1C.6ZDGBOM*O)S*-3DI5)
MS<KWWC9Z6_I'N95*DJM:E2IJ'+R[2YD[W^[S_P" >&?M)7<OB._\)>!+65DE
MUB]62X*<E8E. 2/3)9O^ 5!^RWJL^E+XF\%7['[7H]XSQJW]TDJ^/8,H/_ Z
MXB36O&'C+XY:[XE\':/;:ZVCL;*$7DBK%$F&0,,R)DDB0\'^(U%I.L>*? /Q
M[TW7?&&E0Z(^O'R)H[616B96"IN&'?&&",<FO6AA_P#9/JEU=QYK77-S;VMO
M\.AXE7%_[;]>M*T9\M[/EY/A;OM\3N'QZT>_U[XW7J:=+*E_9:4M[;^6V&!B
M4N0/0X#$8[XKN/B=XVC\??LQRZU&0)9OLZ7"+_!*LR!Q],C(]B*DG ;]KJ$$
M9!THY_[]-7G'Q7M'^%\7C3PAAET;6F@U/3!_"K"9=Z#Z#/X(OK12M6^K4OM1
M4)+_ ,"]Y?=9_)CK.5!XO$?9DYP?_@"<7][:^9N?'IV_X4-\.UW'#);DC/7_
M $:M35_V98/#_A=M=\):]JUGK4%M]I59)EQ)A0Q12BJ5/''7G'UK)^/7_)"/
MAS_USM__ $FKU3Q1\;/"?AOP&\L.NV&H7_V/RX+6SN$F=I-F "%)VC/4G'0U
M$ZF)IT8+#7NYSNM[ZK<JE1PE:N_K=K*G#5NUM.A/^S[\1+OXC> UN=282:G9
MS-:SRA0OF8 *O@<9((S[@UQ?[8TC#P7H:!B%;4.5SP<1MBM?]E'PU=Z'\-Y;
MN[C:$ZE=-<0HPP3&%55;\2"?I@UC_MD?\B=H/_7^?_1;5RPA3AFZC36G-_P_
MXG:YU:F1.=5^\X_\-^!PWQ,^&,7P/T/0O%/A?7=2M[V:9(WCFE4Y)0OD;57*
M_+@J0<YJ]\<(O^$\\>?#.#4#)!'JUE;>>L)P8_-D&[;D'!Y[CL*[+1/V9SK$
M^FWWBOQAJ?B:UA17BLYMRJH(!V[FD<[>G"XZ5S?[2&AV^O?%[P/H\Q>&TNXX
MK9_)P&5&F*G;D$ X/'%>C0Q,*F(IPY^>2YKRM;2VWF>17PE2E@ZU3V?)"2@N
M6][OF6NFBN9'BCPF/@/\3O"T'A'7+RY?4)D6XT^:56<C>J@.% !5@QQD9&,B
MNO\ B_XFUWQU\5M/^'&B:E)I-KM5[VX@8AFRAD.2""0$Q\N>2>>U<LGA6S_9
MW^-FBF9$U'0-1&R"[OHU:6V).TL&  #*2,D#[K>M:7C/44^&/[4%MX@U0-%I
M&HQ _:,$@*8O*8_\!8 D#L:-*LZ<_C?))QDU\4NBM_=&^:A3K0M[.//!2BG\
M,7NT_P"\/\>_LZQ?#;PO=>)?">OZM!J>G)YTOF2*/,0$%MI15*XZX.<X_&MW
M0/ ^E?M*>#=#\1>(KN_@U2UB>RE^P21HCLKGYB&1L$@@\8ZUK_&[XQ>%8_AO
MJUG8:W8ZI?:C;M;0P64ZS$;A@LVTG: "3SCTK8_9S\-77ACX4Z;%>QM#<73O
M=F-A@JKGY<CM\H!_&O/GB,0L'[>JVIJ5HO9[:KT/4CA<(\<L-02=.4;R2=UH
MU9^IX+\#_@CH7Q,F\2)JEWJ$ TVX2*'[))&NX$OG=N1LGY1TQ6O\=?#FEM\7
M?!GA_4;Z2ST2/3;>UDNI)E1HXP[KN+L-H. ,DC%=7^R7_P ?7CK_ *_(OYRU
MB?'VSTK4/C_X5MM<:)=(DM85NFFE,2"/S9,Y?(VCWR*]+V]269N$I.RC=?\
M@"V/*^JT890ZD8KF<K-^2J-*_D=[\(_A/X!\,^)9-5\+>)I-;O886C>);^WN
M%16[D1J".G&37.?LZL3\4OB=DG_C[;_T?+7H7PVT/X:^'=3N4\&7>EM?W,>)
M8[35#<NR*<_=,C8 )ZBO//V=?^2I?$W_ *^V_P#1\M>9*I*K3Q,I.3]U?$K/
MXD>LJ4:,L+&,8KWW\+NOA?<\J^%NLWG@'Q!:^,C)(VDR:K)IFHC)P%=0P8^O
M5F^J>]>Q_%V3?\>OADR-E2V00>""]8'P'\'V_CSX4^-M$N< 7.H,(Y"/]7($
M4HWX$"N3\/\ B2ZU;XC?#32M3#)J^@W3:;<J_7Y)/D/_ 'S@?\!KUJB5;%.2
M^*FFGZ.#:?R=U\T>-%RP^"Y7\-5IKRDJB37S5G\F?8M?/7Q:8_\ #2OP^Y/^
MKB_]&R5TOB;PS\9+KQ%?3:)XLT>ST=YB;:WFA4ND?8'_ $=N?^!&N6^*H=?V
MD/AV)"&D\J'<RC )\V3->%@**IUE)33O&6BOI[O70^BS2NZF'G!PE&THZNUG
M[RVU9R7QZT>_U[XW7J:=+*E_9:4M[;^6V&!B4N0/0X#$8[XKN/B=XVC\??LQ
MRZU&0)9OLZ7"+_!*LR!Q],C(]B*DG ;]KJ$$9!THY_[]-7G'Q7M'^%\7C3PA
MAET;6F@U/3!_"K"9=Z#Z#/X(OK7J4K5OJU+[45"2_P# O>7W6?R9Y%9RH/%X
MC[,G.#_\ 3B_O;7S-SX].W_"AOAVNXX9+<D9Z_Z-6IJ_[,L'A_PNVN^$M>U:
MSUJ"V^TJLDRXDPH8HI15*GCCKSCZUD_'K_DA'PY_ZYV__I-7JGBCXV>$_#?@
M-Y8==L-0O_L?EP6MG<),[2;, $*3M&>I..AJ)U,33HP6&O=SG=;WU6Y5*CA*
MU=_6[65.&K=K:=#A8_B->?$3]F/Q)<ZB_F:G9K]EGE"A?,PR%6P.,D-S[@UZ
M#^S>2?@SX?SZ3?\ HYZ\M^'7@;4X_P!F3Q5N@D%QJF^[MX=OS-&@3! _VMC8
M]1CUKI?V>/BIX6TWX76>G:EK5GIEYI[2B6*\F6-F!=G#(#][@]!DY%9XRE%T
M*].@KI5$[+I[O^>AI@*TE6PU7$RLW3DKOK[RM^&IF?!>0_\ #1?Q$+,<8N,Y
M/I<+6+H]IJG[3GCK6_MVKW>G^$=-<*EI:MC<"QV#!^7<0I8L0<< #TT_V>Y/
M^$G^+WC[Q!9JYTJX\U4F92,^9,&7\=JDX[<5E_L^^*K+X4^,O%/A?Q//'I,L
MLR[)[IMD>Y"PP6/ #*P8$\8'N*Z9QE&525-?O(PA;NN^G=(YHRC.,(U'^YG5
MG=]'_+KV;/1-(^$]W\+-,\3?V=X@N[SPY+I%QLL;QLR03A<AU( 7!&[. .W7
MJ/#O@_\ #?X?^+_#5Q>>*O%']BZ@ETT26_\ :%O;[HPJD-MD4GJ6&>G%?3.N
M_$'PWXBT3Q#I>E:U9ZG>II5Q.R6<@E4($P3N7*]6'&<U\_? CPI\,M<\(W4_
MC*?38]36\9(Q>:HUL_E;$(PHD7(R6YQ66$K5O8UJE9R4O=U2UZ^GWF^/P^']
MMAZ5!1<??T;?*M(^MO0ZS]H;P_8^$?@7X=TC2;J6ZTV&^3R9I)%<R*R2N"64
M $<\8'I3(_V8;6'P?:ZYX9UW5;'7S9I=)NE78S% Q12BJRY/0Y...M7_ -J!
M]-?X.Z"-'FAN-+2^BCMY+>42QE%BD4 ,"<XQCKVKL/\ A='A+PG\.+"=M=L+
MN\AT^)$L[6X665I!& %*J21SP2<8K*-;%1PL94+N3G*^F^VZ-98?!SQKAB4E
M&-.-M=%J]G^0S]G/XD7WQ"\%S#59/.U33IO(EF*X,BD91C[]0?IGO6%^V 3_
M ,*WT[_L)Q_^BY*7]DOP]>Z;X+U+5;R-HAJMUYD*L,;D48WCV)+?E3?VP/\
MDF^G?]A./_T7)6+C"&;J-/;F7_!_$Z(3J5,CE*J[OEEOO;6WX6.C?XB^%O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Y/P]_P C=J__  +_ -"%=97)^'O^1NU?_@7_ *$*ZR@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_MQ_P#2&WKP6OT3"_[O3]%^1^<XK_>*GJ_S"BBBNDY0HHHH **** "BBB@
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MWBD90S0!BAF:,,2RKTVD9Y&<SXY? W5O@;XD;3=1NK>[MY9IDM) \:3R1HP
ME> .S1!\@KN/(K15Z3E&'-J]C-X>JHRGRZ+?^OZ_$\UHKTOX ?!2X^.OC>70
MUU1=#L;6SEO[W4I(/.6WB0#G9N7.6*C[PX)/;%>=WL<,-Y/';3-<6ZR,L<S)
ML+J#PQ7)QD<XR<>M:<\>?V?6U_EK_DS/DER>TMI>WS_ID%%%%69A17KGPU_9
MF\2_$CPA)XK?5_#WA/PT)_LT6J>)M1^R0SRYP40A6).?4 '! )(-;&E_LI:Q
M9_'+2OAKXMU:W\/7&JPM-8ZK:Q_;+>Y&UBA3YD.&*,O."#CCFL'7I1DXN6J_
M17^^W3<W5"K**FHZ/_.WW7Z['A=%:OBKPW>>#O$VJZ%J";+[3;J2TF Z;T8J
M<>W%95:QDI)2CLS*47"3C):H****HD**** "BBB@ HHHH **** "BBB@#O?@
M#_R7?X<?]C)IO_I5'7[4U^*WP!_Y+O\ #C_L9--_]*HZ_:FOE,Y_B0]#ZW)?
MX<_4****^=/HPHHHH *_)/\ ;I_Y.H\;_P#;C_Z0V]?K97Y)_MT_\G4>-_\
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M(Q)9D^93R2QYSRQQUKA?B-\1M5^*'B5M:U=+.";RDMXK?3[9;>"")!A41%Z
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M[^4DMNZ?S"KBJ/M)N,;I_P"'LN\7U\SZY_8Q_P"2)?M!?]@(?^B+JK7[%_\
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MML?17BJQNO!7Q2^%_B6+P!\-KK1-0UQ;*QU_PK!FQN(I754#P9PMPF&=9 2
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MGIGE^$?C=^R[\1?$"_#_ ,/>$-2\*W4?]FW&AVYCE,1*869R=TIP6!9N#D'
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MPCD0O& H!?<[9;Y1TP/:MU0JSG>ILY7M?IR6_/H<_P!8HTX6IZM0M>W7GO\
MEU/L*3X9>#Q\=_V?-/'A/0Q8:IX<EGO[7^SH?*NY!:E@\J[<.V><MDYK)\.:
M9X%^+4WQL\$GX;>&_#]IX5MKJ33-3TZWQ?B2)I%W/,>6!90P484#Y<$5X"W[
M77C%O&?@?Q,=-T/[?X0L&TZPC\B;RI(VC\LF4>;DMC^Z5&>U8O@[]I#Q+X)\
M0>.M7L;'29;GQC'/%?K<0RLD0E9F;R@) 007.-Q;MUK&IA:TD[/6TK:]7-M?
M@S>GBZ$91NM+POIT44I?B?4?[/?PGLO^%.?#;6=!^''ACQ@VLWTK>*-2\401
MR26ELDI0O )6  "@\H&S@9!SD?+W[4>MZ!K/QL\0)X6T[1=.T&QD%E:C0;5;
M>"4)UD(0[68L6&X8!"BOJ;P7XP\)Z]\%_ACIMCK_ ,*M7&DVIBU6'XH8-Y:%
MBI>.U0@<#YP,\$+'R:^5OVFKKP#=_%[5'^&\4<7AL)&O^CJ5@:8#]X8E/1,X
M]L@D<$4Z/,\9)ROO+Y:Z7^7PBJ\JP45&VT;^>CO;SO\ %Z=#Z7N/#?@_Q-^P
M_P#"J#QKXQ?P9I4>HR2K=QZ;+>M,P>Y'E!8^4)4L=Q! QT->%_M;_'31_C9X
MST;_ (1R&Y30=#L5L;:>\0)+<'.6D*CH#A0 >>,X&<#BO$7QQ\0>)OA#X=^'
M%W;Z>FA:'<M=6TT43BY=F,AP[%RI \UNBCMUKSVNNCAN6O*M-_:DTO7KZV.2
MIBOW$*4%]F,6_1WMZ7UVN?7/_!1'_D8OAS_V+J?^AT? ?_DQGXT?]?2_^@PU
MX5\9/CGK_P <+K0[C7[73[:72+(6$/\ 9\3H'0'.Y]SMEOI@>U'A'XZ:_P"#
M?A7XH\ 65KI\NB^(762ZEN(G-Q&0%'[M@X4?='536/U:I]4='K>__D]_R-%B
M:?UR%;[*27_DG+^96^$'Q@UCX-^(CJFD1P,9FB6X+11^>8ED#,D4K*QB+@%2
MRCH?88O_ !R^.FJ_'+Q&=1U&TM[2"*:9[6,(CSQQR,"(I)PBM*$QA=PX%>:4
M5Z+I0E-5&O>74\^-:I&#II^Z_P"OZ_X!]8?L<?\ $O\ @W\?M6@8+?0: (HV
MYRJF*X)/Y@=^U3_!&T\*^'/V//%OCC5O!&A^*M8TO7@EJVJ6P;EE@55=P-S1
M@R%C'D!OQKE/V+?'VB^'_$GB_P *>)=2M-'T3Q9HLUBU]?3+%#%*%;879B%
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M#4X2W27Y'+CIQJ8FI*.UW_P_SW"BBBNLX0HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/P]_R-VK_P# O_0A
M765R?A[_ )&[5_\ @7_H0KK* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!*6DQR3ZTM !17QI_P4+^*7B;PWJWPJ\!Z3X]_X5/H/C/4
M+F#6/&WW391Q1H5C63<OEERY^8,I^4?,!NKQ3Q)^RGX8\"Z!>^)]+_;9US3=
M6M83<1ZA=>(XY(G<#(!59PSAC@8!).<8/2HYURN;^%7_  WT+<7=16[5_P 6
MOT/TVI*\(_8;^*OB7XT_LO>"?%OB[]YKUW%-%/=",1_:A%,\2S;0  75 3@
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M_P#"L/"G_0!LO^_='_"L/"G_ $ ;+_OW0!H?\)AHG_03M_\ ONC_ (3#1/\
MH)V__?=9_P#PK#PI_P! &R_[]T?\*P\*?] &R_[]T :'_"8:)_T$[?\ [[H_
MX3#1/^@G;_\ ?=9__"L/"G_0!LO^_='_  K#PI_T ;+_ +]T :'_  F&B?\
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M] &R_P"_='_"L/"G_0!LO^_= &A_PF&B?]!.W_[[H_X3#1/^@G;_ /?=9_\
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MBC_A"M6_Z''5?^_</_Q% '845Q__  A6K?\ 0XZK_P!^X?\ XBC_ (0K5O\
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MO^AQU7_OW#_\10!V%%<?_P (5JW_ $..J_\ ?N'_ .(H_P"$*U;_ *''5?\
MOW#_ /$4 =A17'_\(5JW_0XZK_W[A_\ B*/^$*U;_H<=5_[]P_\ Q% '845Q
M_P#PA6K?]#CJO_?N'_XBC_A"M6_Z''5?^_</_P 10!V%%<?_ ,(5JW_0XZK_
M -^X?_B*/^$*U;_H<=5_[]P__$4 =A17'_\ "%:M_P!#CJO_ '[A_P#B*/\
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MLVXY^%MAG_K^O/\ X]7T5HNCV?AW1K#2M.@%MI]C!':VT*DD1QHH5%R22<
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MW1H?#OC'PO);C4+"UO\ [;;/%.A>&:&8QQLZ,%8?-&C J1CH3I./+.45TO\
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M8Z]>7M7D/[5'_))YO^O^R_\ 2F.O7E[4 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** (YI%BC9G(51U+' K._X2+2_^@C:_]_E_QJ;6M-75
M],N+-F*+,A4LO45XJW[+=DV3_;%WDG)^=O\ &L9RJ)^Y&_S.2M.O%KV4+_.Q
M[,/$.E_]!&T_[_K_ (TO_"0Z5_T$;3_O^O\ C7C _9:L/^@S=_\ ?;?XTO\
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M"H). !FOK^HKJUAO;>6WN(HY[>52DD4JAE=2,$$'@@CM55&YW;ZN3^<H\K_
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M<N/Z5Z%7GOPA_P"9M_[#EQ_2H+/0J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Q_P#:H_Y)/-_U_P!E_P"E,=>O+VKR']JC
M_DD\W_7_ &7_ *4QUZ\O:@!U%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P S;_V'+C^E 'H5%%% !1110 4444 %%%% !1110 4444 %%%% !117SO\
M$WX(_%[XO^-]4\_XPWGPZ\!1,L>G:9X,MECU&X78NZ6>[?)1MV\!8QC&"><T
MM;V0]+79]$45\1:E\&_&'P;^(N@>%O _[4'C&]\=ZO;SW^G^'/B,CZW8ZE#
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M#O[5GPH\$_LX6%]'XT\*ZG'J/C'7H=1GN(;&U1D^6X=G*+,P$@\M N=VTCG
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MPC^S)\$O!]_XY\02>)/"*V;1B?Q59:YJ,M[$\CK&C#87)8NRCA"/7BDK]?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&[GCLK3R$8LA+[I/-7/WB%V@@*,%@Y4>X?\ "57/]Q/R/^-'_"57/]Q/R/\
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MYN=NWWSBN+TG]ISX/:]JEIINF?%CP/J.HWDJP6UG:>([.6::1B J(BR$LQ)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\]^$/\ S-O_
M &'+C^E>A5Y[\(?^9M_[#EQ_2@#T*BBB@ HHHH **** "BBB@ HHHH ****
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M@<)AL3&3KXA4[=TW?[D?30E']Y3^-'FCU'YU\RC]F;XA@?\ )4-2_P"^G_\
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M=>^E]S.;Y(IO=V_'\[6UML?HE7"Q_P#);KC_ +%Z+_TIDKNJX6/_ )+=<?\
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MJ* /%_V;_ OAW1_#=_J%CHEA:7XU;4(1<PVZK)L%RX"[@,X  XKVBO,_V?\
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M/.R2=V1OH1_.OH;- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>.-&T_\ :N\/Z-/?0QZA/I)5(BX'.YCCZX%>L?$3QOI_PY\&ZMX@U.80VMC
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M-2*E!W3'.$J<G&:LT.HIH8'I3JL@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 1J\^L?\ DNFI_P#8#A_]'-7H+5Y]8_\ )=-3_P"P'#_Z.:@#T*BBB@#D
M_#W_ "-VK_\  O\ T(5UE<GX>_Y&[5_^!?\ H0KK* .#^/7C?4?AK\$_'7BO
M2+=+K5-%T6[O[6*12RM)'$S+N ZC(!(]!7YM:U\=I[KQ)J'Q/^$?@?X6&R\
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MXCP-^<U]#JN<'H,5Y+^U1C_A4T__ %_V7_I1'7K6<+2&2TM1K(<<TJD[NO%
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MEUMWMN9>TC>QZ_146\GD5(O(KD-!:*** "BBB@ HHHH **** "BBB@ HHHH
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M]4U6UTBQFO+J98;>%2[R,> !7BGAJQN?C9XP'B34HWB\+Z?*5T^U<8\]P?\
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M/X UTF:\&_9W\"^'K"X\17UMHMG!>P:K<QQ3QP*&5-PP%..!7NPS0!)1110
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MG'Z@URG@?3/ _A.S31O!UIX?T:TR673]#C@@CR!R1'$ .GM75UT3ES)+M?\
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MWD<>)R^AA9).M=-732=F>A&0=B/SHWYZ5Y]_PK/48S^Y\7ZJGM^[_P#B:/\
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MI:* /)/@"O\ H_BG''_$YN?_ $(5ZUM%>3? '_CW\4_]AFZ_]"%>M4 %%%%
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M'#_Z.:O6/FST*BBB@#D_#W_(W:O_ ,"_]"%=97)^'O\ D;M7_P"!?^A"NLH
M^9?VU/V4/!/QO\$Z]XNU+P9)XN\=:'H-S'HENM]<PAY%5Y(X]D,B;\N>G4],
MU^;5UI_[+&I?"#PYH7@7P'XEU?\ :!#V,1TFZ2_+3WJR)]HCG0R>4(CB0'8
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M[/\ _P B5?\ _8:U'_TI>O2Z\S_9_P#^1)OO^PUJ/_I2]>F4 %%%% !1110
M4444 %)145Q=0VD+RSRQPQ*,L\C!5'U)Z4 >5_ __D/^//\ L)+_ .@FO65Z
M5XI\"?$6EW'B3QQ%%J5G)++J*>7&EPC,_P AY !YKVI&W=L4 .HHHH ****
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M^VN@W(\F57_D:OFC/2]S>G65U*G+5=CC_ OP9\/> II)[2%KJ[8\3W1+LH[
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M=C:Q6\*[(8U"(N<X JQ0 M%%% !1110!YG^S_P#\B3??]AK4?_2EZ],KS/\
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M)U@OPRD@$Y"M^!;-?MG8WT&J65O=6T@F@F021R#H01D&@"Y12+TI:!!1110
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M1110 4444 %)BEHH 3;WHVCTI:* $VBC;2T4 )MHVCTI:* &E12>6O7%/HH
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MN/DT#3P?>W0_TI_O/(/W_D<W)^T-X$7[NMQ2C_IF0W]:KR?M&>"U^Y=7,O\
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MD_\ SX_\FE_\D?2/_#8W_4H_^5/_ .TT?\-C?]2C_P"5/_[37S=11_;N8_\
M/S\(_P"0?ZJY/_SX_P#)I?\ R1](_P##8W_4H_\ E3_^TT?\-C?]2C_Y4_\
M[37S=11_;N8_\_/PC_D'^JN3_P#/C_R:7_R1](_\-C?]2C_Y4_\ [31_PV-_
MU*/_ )4__M-?-U%']NYC_P _/PC_ )!_JKD__/C_ ,FE_P#)'TC_ ,-C?]2C
M_P"5/_[31_PV-_U*/_E3_P#M-?-U%']NYC_S\_"/^0?ZJY/_ ,^/_)I?_)'T
MC_PV-_U*/_E3_P#M-'_#8W_4H_\ E3_^TU\W44?V[F/_ #\_"/\ D'^JN3_\
M^/\ R:7_ ,D?2/\ PV-_U*/_ )4__M-'_#8W_4H_^5/_ .TU\W44?V[F/_/S
M\(_Y!_JKD_\ SX_\FE_\D?2/_#8W_4H_^5/_ .TT?\-C?]2C_P"5/_[37S=1
M1_;N8_\ /S\(_P"0?ZJY/_SX_P#)I?\ R1](_P##8W_4H_\ E3_^TT?\-C?]
M2C_Y4_\ [37S=11_;N8_\_/PC_D'^JN3_P#/C_R:7_R1](_\-C?]2C_Y4_\
M[31_PV-_U*/_ )4__M-?-U%']NYC_P _/PC_ )!_JKD__/C_ ,FE_P#)'TC_
M ,-C?]2C_P"5/_[31_PV-_U*/_E3_P#M-?-U%']NYC_S\_"/^0?ZJY/_ ,^/
M_)I?_)'TC_PV-_U*/_E3_P#M-'_#8W_4H_\ E3_^TU\W44?V[F/_ #\_"/\
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M'_G[^$?\@_U5R?\ Y\?^33_^2/I'_AL;_J4?_*G_ /::/^&QO^I1_P#*G_\
M::^;J*/[=S'_ )^?A'_(/]5<G_Y\?^32_P#DCZ1_X;&_ZE'_ ,J?_P!IKT[X
M/?&&'XLVVJ,NER:7<6#QAXS,)497#;2&PISE&R,>G)SQ\05](_L<_P#,W?\
M;G_[7KU\IS;&8G&0I59WB[]%V;Z(^=X@X?RW!9;5Q&'I<LXVL[R>\DNK?<^D
M6KSZQ_Y+IJ?_ & X?_1S5Z"U>?6/_)=-3_[ </\ Z.:OT,_'3T*BBB@#D_#W
M_(W:O_P+_P!"%=97)^'O^1NU?_@7_H0KK* "BBB@ HHHH **** ,OQ1_R+>K
M?]>DW_H!KB_V??\ DF.G?[[UVGBC_D6]6_Z])O\ T UQ?[/O_),=._WWH ](
MKC?B1\5M%^%UM8RZLEU,]X[+##9QAG(4 LQW%0 -RCKGYA@'G'95\V_MC?\
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M:V\'G_F&ZY_WXA_^.T#]K7P>/^8;KG_?B'_X[7R511_K#CNZ^X/]3LJ[2_\
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MNQ%<W2@9S&F.<CU(ZBD\._!76O$&DV5^]_I&DB_S]AM]3O!#-=\X_=K@YR<
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MEE_\B<Q173_\(G_U!?''_A-I_P#)-'_")_\ 4%\<?^$VG_R31_868_\ /O\
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M"<C;RK7G&[LM;_<[?^36*O:,K;]/O5_PN?/NO?\ !0+5YOV=OB=<3Z(GP_\
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MV;_O_%_\77YA_9^,_P"?,O\ P%_Y'[I_:^7?]!,/_ X_YGGU%>@_\*!\?_\
M0NS?]_XO_BZ/^% ^/_\ H79O^_\ %_\ %T?V?C/^?,O_  %_Y!_:^7?]!,/_
M  ./^9Y]17H/_"@?'_\ T+LW_?\ B_\ BZ/^% ^/_P#H79O^_P#%_P#%T?V?
MC/\ GS+_ ,!?^0?VOEW_ $$P_P# X_YGGU%>@_\ "@?'_P#T+LW_ '_B_P#B
MZ/\ A07C[_H79O\ O_%_\71_9^,_Y\R_\!?^0?VOEW_03#_P./\ F8WPX\=2
M_#OQ*FK1V4.H#RFADAE)7*-UVL/NGCK@]36YXC^*MG=>$;GPUX<\-Q^'-,O)
MEGNQ]LDNGE92"/F<# RJ_E5#3?@QXTUB!IK/0I9HU=HRWFQC#*2K#ENQ%7/^
M% ^/_P#H79O^_P#%_P#%UUQI9E&E[%4Y<O\ AUUW5[7L^USSZE?):M98B=>#
MDK?\O%;3:ZYK.W2ZT//J*]!_X4#X_P#^A=F_[_Q?_%T?\*!\?_\ 0NS?]_XO
M_BZY/[/QG_/F7_@+_P CT/[7R[_H)A_X''_,\^K1\.:P?#_B#3=4$7GFRN8[
MCRBVW?L8-C..,XKL/^% ^/\ _H79O^_\7_Q='_"@?'__ $+LW_?^+_XNKA@\
M=3DIQI2NM?A?^1$\TRRI%PEB(6>GQQ_S.=\>>*O^$W\7:EKGV7[%]L</Y'F>
M9LPH7&[ ST]*P*]!_P"% ^/_ /H79O\ O_%_\71_PH'Q_P#]"[-_W_B_^+I2
MP.-G)RE1E=_W7_D*EF65T:<:4,1!1BDE[\=E\SSZBO0?^% ^/_\ H79O^_\
M%_\ %T?\*"\??]"[-_W_ (O_ (NI_L_&?\^9?^ O_(T_M?+O^@F'_@<?\S.O
M/B$;OX7V7@\V&W[+>F\%YYWWLAOEV;?]KKGMTKCZ[/3_ (-^,M4N+N"UT.66
M6T<1S*)8QL8C('+<_A5[_A0/C[_H79O^_P#%_P#%UK4PF/K-2G2DVDE\+V2L
MNG8PHYAE5!25.O!7;;]];O?J>?45Z#_PH'Q__P!"[-_W_B_^+H_X4#X__P"A
M=F_[_P 7_P 767]GXS_GS+_P%_Y&_P#:^7?]!,/_  ./^9Y]17H/_"@?'_\
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MH_L_&?\ /F7_ ("_\@_M?+O^@F'_ (''_,\^HKT'_A0/C_\ Z%V;_O\ Q?\
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MA;'7 Q6AY8_N+^5244 ,$:XY10?I2^6G]U?RIU% #?+3^ZOY4>6G]U?RIU%
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MT4 -Y]*49I:* .>T?2KJU\1:C=2Q;8)MVQMP.?F!Z9S70T44 %%%% !1110
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M H20K$T:^<H5?D9O/AW,@XPVW&1CTSX ^(?BK^R_^V=I'P+\>_$O4?BMX?\
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M53X;PO\ ^ N_G>]N?Y&E7F]I/V?Q6G;[U;RM:_(>A?LA^-OB9\'_ -J[Q?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM4/_ #VC_P"^A1]JA_Y[1_\ ?0H EHJ+[5#M8^:F%QD[AQGI2K<Q,P E0D]
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MY!KTO_@G#J%W\4/V'?'_ (6\5WDVLZ3I][J>A0?;'+LEF;6-A'DGHID;'H,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W
M5PMK"7/)Z 9QD^E35S]]=-<W#Y&!&S(!GT.,_I0!#)(\TC.YRS<GT_"FT44
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>eigr-20221231_g17.jpg
<TEXT>
begin 644 eigr-20221231_g17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )[!*0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **P_%/CKPWX'CL9/$GB'2O#Z7UPMI:-JE[%;"XG;[L49=AO<XX49)K<
MH **** "BBB@ HHHH **** "BBL/Q+XZ\-^"YM,B\0>(=*T*74[@6E@FI7L5
MNUW.>D40=AO<Y^ZN30!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (>AK\6_@K^V%\6?A)\?KSQUXS\6Z_XC^$UYXMO/
M#6IV^HW\MU;V1+;U:.-B5B**P90@&5C=<8K]I&^Z:_+S]C;X%:7^T=^SO^TE
MX%U/;&U]XRNGLKIER;6Z10T,H^C8SCJI8=ZB,G"JZB5^6+=N_O137W-V\RVE
M*GR2=N:25^WNR:?WI'Z;75XD^BS7=K,LD;V[2Q31MD,"N58'TZ&OD'_@E/\
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M!6LHOVGLXZWCS)]+>[^DOOTZD)_NW4EI:7*UYZ_JK?.Y^MM%?E'\4/@)?_\
M!,KXO?"[QA\-/&>OWO@CQ#K4>DZWI&LSHZR;B,[_ "UC1P8]Y4E 4:,')SQ^
MC'Q]^%NI_&CX7:IX1TKQAJ7@6XU!X0^LZ3N^T)$LBM)&I#H1O0,A.>C<@C@R
M_@4XZZV]&K?A9I_H-?'R2TTO\M?U31Z)17Y6_$3]@?\ 9P\$PZI=K^TO=:-\
M3;>!KF*[UCQ7IJ2?:=I(9HMJ3?,1CB3//4UZ_P#LF6;_ +?O[!!\*?$_7=6N
MGCU)M-NM6L9D2]F6WDCFA9I)$=6;!12Q4E@,GYLFB/OQDXZN-G\F[7OY=@E[
MLH\VBE=?.U]CUO\ 8]_:;\3?M">+?C)I?B#3])L;?P;XC?2-/;38I4:6$/,H
M,N^1P7Q&.5"CD\5],5^,W['?_!._X<?M!^+?C)I?B+6O%-E;^#?$3Z1I[:7=
MVT;RPAYE#2E[=PS8C7E0HY/%?7/[>GQHU7]EWX+_  W^%_@#75T'6O$+PZ!:
M^(M4N4C;3[*!(XWN'E("HWSQYDP H+L,$# VE3A;634+>=TM?+N^UWV"*<JD
MUT3E?RLWIYVV^7F?<%%?E W[%O[-S:=_;C_M?6[_ !/\OS3XD_X3'3?*-UC&
M_9N\[';_ %^['?M7T)^Q-^TQXW^*'[*/Q EO;F/Q;\0? AOM/M[Z%A.-5>.
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M(/\ A-M%V71T>;Q7IMW_ &I&K#="L< 0N<%CL97#<C SFOI']L']I?QGJ?\
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M2\T_PDOU/B']OGPCJ7[,/QV\)_M/>$+)I+"9QH_B^RMQCSXW78LA[9=/DR>
M\<1YS73?\$>HQ?\ [)VOH"56;Q->C/<9@@_QK[8\;>"=#^(WA74_#7B73(-8
MT+4H3!=V5P"4E0]N.000""""" 0016#\'?@CX)^ /A#_ (1?P%H::!H9N'NC
M;+<33EI7 #,7E=W)(51R> !BE22C"I3EJI*R\DVFUZ;V]1U6YN$H[IW?G9-)
M^NMGZ'Y*?LI_!_\ 9R\.^._B#\,OVE=)M=)\;Z3J[BPU+6M6N]-M9K; &T21
MS1QCH)%+XW+(,$XP/JC0?@G^P%H/C_PM;Z%-X7U/Q/<ZC;KI4&E>*;[5-UUY
M@\H,L=S(F-P'^L&WUXKZH^,O[+?PI_:",3^/_!.G>(+J)!&E\=]O=*@.0@GA
M9)-N?X=V.3ZFN>^&'[#7P*^#NMVVL^%/ASIMEJUK+Y]O>W<L]]-!)C :-KB1
MRA';;C!YZU=.33BYZ-6VZVZ^3?SU)J^]S..M[[]+]/-?H?*7[<>I/^SI^WA\
M&?CMK%G<2^"C:'1[^[@0OY#XG1N!W$=QO ZMY;8Z5]2>+_V\/@-X2\#W7B8_
M$_PWJT4<!EBT[2]1BN+Z9L$JBVZL9 Q/'S* ,\D5['XR\$Z!\0_#MWH/B?1K
M'7M&NEVS6.H0+-$_H=K#J.H/4'D5X1HG_!.3]G#P_P"(!K5K\+--DO YD$=Y
M=W5U;9)S_P >\LK18SVV8'0#%9QYO9^R;TN[/KJ[_G>Q<FG/VEM;)-=--OPW
M/'_^"3/@?68O ?Q$^)NL6,FFKX^UYKZRMY!C=;HTA\P?[)>9U!QSLST(J'_@
MGO\ \G6_M>?]C1'_ .E%[7WG:VL-E;Q6]O%'!;Q*$CBB4*J*!@* .  .U<1\
M/_@9X'^%OBKQ?XD\+Z&NEZUXMNA>ZU="YFE^US!G8-M=V5.9'.$"CYNE;<R5
M2Z5DH<J_\EM^$=3-WE2<7\3DI/[VW^>A\C?\%=O^2<?"7_L=[7_T5+6Y_P %
M;/''BSP5^RY"OAJZNM/M-4UB"PU>\LRRNEJR2-M++RJNZHIY&0=O\6*^G?BW
M\#? _P =--TBP\<Z&-<M-)OTU.SC-U-!Y5P@(5\Q.I;AC\K9!SR*ZCQ/X7T?
MQIH%[H>OZ7::SH]]&8KFQOH5EAF0]F5@0>WY5SRC>FX?WN;RM:&C]>5W\F;1
MERU5/^[;YWEK\N9?,_,:Z^#O_!/WP#\$TUR\UW2_%^I+IX=&C\2W4FJ7$YC^
M4&S@G0QDMV:-0N?F(%>N?\$:/^34M5QT_P"$GN__ $3;U[=X)_X)_P#[/OP]
M\4)XAT3X9:9'JL<GG1R7D]Q>1Q/NW!DBGD=$(/(*J,8&,5Z?\*?@WX/^".@W
MNC>"M&&B:9>7TNI3P+<2S;[B3&]\RNQ&=HX!P,< 5TQGRNI)_:5K=%JG_GKZ
M:',X-QA'^5WOU>C7^7XGP/\ L'_&KP+\&_C9^TUH7CSQ5I/@W4)_%LUY NN7
MD=HDR+/<!@C2, S#<IVCDA@0#S5O_@K-X8LO%_A7X,_%(6+>*OA[I.H;M62R
M9L36-R8'5@Z%2JNL94,",&1>037UC\5/V)?@C\;/%P\4>,O %EJNO';YE['<
MW%JTV  #*(9$$N H'S@\#'2O6O\ A$]%;PPOAQ]*LY= 6U%C_9DL"O;F +M$
M1C(*E=HQ@C&*YTG[.G?XH<MNSY5;7U7ZG1=*I-KX9<WJN;MZ-O\  _/[PY\$
M?^"=/B;PY;:U;WOA&TMYXO-^SZCXVO;2Z3C)5H)+Q9 PZ8V]>F:^@OV=M0_9
MP^#'P7\8>+/A-<VFF_#W3[N6;6M3MI+V[4311IO.9B\CA49<;,KR<<YJ*_\
M^":O[->I:TVJ2_"ZS2Y:02&.WU&]A@R,8 A2<1@<?="X/.1S7LF@_!3P%X8^
M'UWX%TKPCI%AX0O$DCN=&AM56WG$@P^]<?,2.I.3P/05KS/EERZ-KY?/NO\
M@&5ES1OJD_G\O,^(_P!I?P7^Q?\ %SPOK'CNR^(?A+PEXTCA>^MM:\+ZS%#?
MM<KEE9[-&W2.7 S^[$AZAAUKW+_@FY\2/&7Q2_90\-ZUXWN+K4-46XN+6#4K
MPDS7MO&^V.5V/+'[R[N2=F22<U8MO^";/[-EKKPU=/A;8M=B4S>7)J%X]MN/
M;[.TQBV\_=V[1Z5]':7I=GHFFVNGZ=:06%A:QK#;VMK&L<4,:C"HBJ %4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !69XD\+Z-XST2ZT;Q!I-CKNCW0"
MW&GZE;)<6\P!# /&X*L 0#R.H%:=%+?<>VJ*6BZ'IWAO2;32M(T^UTK3+.,0
MVUE90K##"@X"(B@*JCT Q5VBBJ;;U8MM$%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH P_%/@7PWXXCL8_$GA[2O$"6-PMW:+JEE%<BWG7[LL8=3
ML<9X88(K<HHH **** "BBB@ HHHH **** "L+Q-X#\->-)],F\0^'=)UV;2[
M@7=A)J=C%<-:3#&)8BZG8XP/F7!XK=HH **** "BBB@ HHHH **** "BBB@
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MPE#_ /%41ISFKQBV$ZM.F[3DEZLZ>BLG6/%NA^'6B75=9T_3&F!:,7EU'$7
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MV,3XC^+KGQO^R_HVJ7K%[TWL<,TA_C9"Z[OJ0 ?J:]Z^&O\ R3?PQ_V"[?\
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M]V[[PSUJQ\.$USX0_'P:9XEGMIYO$,9,L]KQ$\CL61@-J\[U*XP,;C71S?\
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MT^QZ2]L[J!N*[_*48PN<$]JY:G-_9]/V2G:T_AVM=_%\OU.J"C_:=3V[A?\
M=_$M;\J^'7>_Z'@WC70[Z\^*GC_6M+9EU+P_<1ZE%MY^574-Q[9#?137=?M$
M>*;?QK\'_!^MVI'E7E_&Y4'.QO+D#+^# C\*U_A?"EQ^T-\2HI462*2(JRL,
M@@LH(->0?%:QN/A_]L\"2J[6$>K)JFFR-R/)='4K^!VCZAJ[J%JU>A3?Q04&
MO1I)K\G]YP8A/#T<567PSE4B_5-N+_-?<?0/Q<^$?A/5O#OB/Q+=:3YNMKI\
MDPNOM$J_.D6$.T/MXVCMVKB?V=/A'X3\4>!;'7=3TG[5JL=W(5G^T2KC8P*_
M*KA>/I7LWQ*_Y)CXE_[!5Q_Z*:N)_95_Y)':_P#7W/\ ^A5XE+$5HX"I:;TE
M%+5Z*ST/?K87#RS"CS4T^:,F]%J]-7W/6-0_X\+G_KDW\C7S=^S?_P D8\=?
M6?\ ])Q7TCJ'_'A<_P#7)OY&OF[]F_\ Y(QXZ^L__I.*QP?^Z8CUA^;.O&_[
M_A/^XG_I*/+/AW-)X E\*>.5W?9#J<UC=XZ!=B9_-7?_ +YKWK]IC5Y]8L_#
MG@K33ON]>NT+;3TB4C&?8L0?^ &N!\!^$CXP_9=U^WCC\RZM=0EO( !D[HTC
M) ]RNX?C5C]G/^T?B1\18_$.J_O8O#^FQV<#<XW[=B_CCS&/N:^CQ/)4JRQ,
MMZ+?SZQ_%GR&#]I1H1PL-L0E;R=[3_\ )=32_9NL8]+D^)]E#GRK=Q"F[KM7
MSP/T%<U\!_A?X2\:?#[Q%J7B*#9+:SLB7WVEXO(01ALXW;3@DGY@:ZWX ?\
M(5^+/_7PW_H4]<7^S_\  _0/BAH-_J.KW.H12VMV(5CM941&7:K<Y0GOV(K.
MI.SQ,Y3<=*>JWV^1O3IW6$IQIJ?O5O=>V_H]BY\)=2O[KX _$>TFEDETZUA/
MV7?T4LA+@>W"G'O[UE^%?#/PTNO@G<ZCK5Y:V_BD)/Y>R^;[1O#'RAY&[!!X
M_AZ'.>]>_>/O"6D^"?@?XETO1K1;.SCL)6VJ22S$<LQ/))]37B'A7X*Z7XP^
M ;:_96SQ^)H3-,LR2.?.6-S\FPG;]T<$ '(%13Q5*LJE;F<(N<=5OMU]=WN7
M4P5;#NAA^6-2483T>V]]/39;?(VO"_C?7? _[+LU\99(KJ:[:TTV5\[HXF(^
M9?IB3'X5T/PK_9S\+ZSX'L-5\1VT^J:KJD0NFE>YD3RPXR,;6&3@@DMGFLF;
M4;WXX?LWRQPI]JU[1Y4\V&-!ND\OH5 [F-CTZD$"M;X4_M'>$]+\!Z;INO7<
MVFZEIT"VS1FWDD$H084J54XX R&QS6=?ZQ[.L\.FJG/KR[VMIMK8TPSPWM,.
ML3).E[/W>;;FOKOI=+0YSX<Z:_@'XV:[\.&N);OP[J<$B"&9L\-#O5N. VW*
MD]_RK<_9=O)O#6O>+_!%ZY\^QN3/$I[X/EN1]<1G\:I?"&&\^*/QPU7X@"SE
MM=%@#);O,N-[;!$JCL3MR3C."0*@^,UY+\(OC=IWC&VB9K?4K21947H\BH4(
M/YQ-^%.K>M-X67QSIJ_^..OWVW"BE1IK&T_X=.J[?]>Y63MY7V-GPI&/B-^T
MSKFL_P"MT_P[%]FA;J/, *#_ ,>,K?@*\STG_A _^%O^-_\ A/O^/#[9<?9_
M^/C_ %GG'/\ J>>F>O%>W?LO^&7T?X<_VI<@_;=:N'NW9NI3.U/Y%O\ @5>0
M^$==\&:#\9?'<OC6*SELGNKA8!>6)NE\SSR>%"-@XSS5496K5:4+M0@HKEWT
M:O;SO<C$1YL/1KU+)U*G-[VUFG:_E:QZC>:;X+M?@-XON_ T>W2KJVF+ONF.
MYU&T\2G<,?E7C/PBN&^&_BCP+XA9F&G:\DUE<,3P&$S(?P'[IOP->Y>(?%'A
M'Q)\$?&"^#FMAIUK:2H\5K:-;(CE<_=*KU]0*\QD\*-XB_9-TN]A0M=Z3<37
M:%>NSSG5_P!#N_X#4X6IRPG&M>TIJ+YM[.+6OX&F,I*I*E*ARWA"4ER_#>,D
M]/Q1V?[0UQ+XT\8>$_A_:DD7,WVZ\*G[L8W#]%$A_*N7^!JA?@/\1P.@6Y _
M\!ZT?V<UU#Q]XN\1^.M7&^9+=+&%L';NV#=M^BJO_?9K/^!__)"/B1]+G_TG
MI2C]7PT\)_)R7]7*[_"R*IS^M8RECK:3<TO\,8V_%W9RGPG_ .%/_P#")C_A
M-_\ D-^>_P#S^?ZOC;_JOE]?>O1/VFM+TW2?A7X4L=*B\O2H[^-8(PS']V8G
M(Y8YZ'OS7*_!#Q=\+=%\$BV\7P:7)J_VF1MUWI+7+^6<;?G$;<=>,UUO[3VK
MV&O?##PMJ&ER+-IUQJ$;P.J% 4\I\84@$?0BNBMSO,:::G;FZ_#_ -NG'AO9
M_P!EU6G#FY'\/Q_]O:^AJ_ /4)_!VO\ B/X=:@_SV$C7>GLW_+2!L$X_-6_X
M$WI7/_LZ>#M'\<^ _$FF:W9_;;+^V/-\KS'C^8(,'*$'N>]=3\=-(F\-WWA[
MXBZ=&6N=%D6*^5!S):L<'/TW$?\  _:LW]D.03>$_$,B_=;4RP_%%KSY3<\+
M5Q<'9OEO_B3U?ST?S/3A!4\91P517BN9J_6,HO3Y.Z]+'$2?"OPNO[2D7A4:
M7_Q(6MO,-I]HE^]Y!?._=N^\,]:UOVD/!MMX#\%:#IV@V4MGX7-^\U]##*[Y
MD(4*2SDGH&QDXSBM6;_D\6#_ *\__;9J].^(GQ0\+^![JSTOQ.)%MM2B<[FM
MO.AVJ0"K@9)SNZ;35SQ->-7#.-Y^XG:[U>NOKYBIX/#2HXQ2M#WW'FLM$U'3
MTN]O,X?X3^%?A3KFLZ;KG@]Y+75; ,[6;W+^;\R%3OCD)R!NZIQG'->XU\AA
M?#6M?'?PO+\,8IEB69)KUH8WCA50WSE58 JNS(/ '( ZU]>5YN9TW&4)N4G=
M;2^):[?Y'IY/4C*-2G&,5RM:P^&6GY]PHHHKQ3Z(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"CJ^AZ=X@M1:ZII]KJ5L&#^3>0K*FX=#A@1GD_
MG5N&%+>)(HD6.-%"JB# 4#@ #L*?13YG:U]">57YK:F;#X;TFWU>758M+LHM
M4E&V2^2W03N.!@N!N/0=^PJ*\\(Z%J&J)J=UHNG7.I1E62\FM(WF4K]TAR,C
M';GBM>BJ]I-.Z9+IP::<5KK\R.XMXKJ"2&>-)H9%*/'(H964C!!!Z@BN<_X5
M?X-_Z%'0O_!;#_\ $UT]%$:DX?"[!.G"I\<4_4QF\&^'VDL9#H6FF2Q 6T<V
MD>;< Y C./E //&*O:II-CK=F]IJ-G;W]HY!:"ZB62-L'(RK @\U;HH<Y-IM
M[ J<$FDEJ8\W@W0+BULK:70]-DMK(YM87M(RD!SG*#&%Y]*TKRSM]1M9;6[@
MCNK:92DD,R!T=3U!4\$?6IJ*'.3W8U",=D5=-TNRT6SCL]/L[>PM(\[+>VB6
M.-<G)PJ@ <DG\:AM?#VE66J7&I6^F6<&HW VS7D5NBS2#CAG R>@ZGL*T**7
M-*[=]PY(V2MHMCG+GX;^$KRXEN+CPOHL\\K%Y)9-/A9G8G)))7))/>MK3]-M
M-)M4MK&UAL[9.%AMXQ&@^@ Q5FBJE4G)6DVT*-.$7S1BD_0Q-6\$^'=>N_M6
MIZ!I>HW6T+YUW9QRO@=!N92<5)HW@_0?#LSS:3HFG:9-(NQY+.TCA9ESG!*@
M9&:UZ*/:3Y>7F=A>RI\W/RJ_>Q7O]/M=5LY;2]MH;RUE&V2"XC#HX]"IX-,L
M-)L=+L$L;*SM[.R0%5MK>)4C4$DD!0,<DG\ZMT5',[<M]"^57YK:F+;>"_#U
MGIMSI]OH.F06%R09[6.SC6*4CH64+AN@ZBJ7_"K_  ;_ -"CH7_@MA_^)KIZ
M*T5:HM5)_>9.A2:2<%IY(R=6\):'KRVZZGHVGZBMN"L*W=K'*(P<9"[@<#@=
M/04FC^#]!\/S-+I>B:=ILK<,]G:1Q,?J5 ]:UZ*7M)\O+S.Q7LJ?-S<JOZ!6
M%<> _#-W?&]G\.Z3->%@YN)+&)I-PZ'<5SFMVBIC*4=8NQ4H1FK25Q%4(H50
M%4#  & *R]8\*Z)XB9&U71[#4V3A#>6J3%?IN!Q6K10I.+NGJ.48R7+)71F0
M^&='M]+DTR+2K&/39%VO9I;((6'H4Q@C\*R_^%7^#?\ H4="_P#!;#_\373T
M5:JU([2?WF;HTI))Q6GD9.I>$M#UJVMK?4-&T^_M[4;8(KFUCD2(8 PH8$+P
M ./2F:3X,\/Z!<&?3-"TW3IR,&2TLXXF_-0/4ULT4O:3MR\SL/V5._-RJ_H%
M)2T5F:G/R?#WPM)>?:W\-:.]UN#^>UA$7W#H=VW.:U+[1]/U/3S87EC;7=@P
M"FUGA5XB!@@;2,<8'Y5<HK1U)NUV]#-4X1O:*UW.;A^&OA"WFCEB\*Z)%+&P
M9)$TZ$,K Y!!"\&M;5M"TW7[<0:IIUKJ4 .1%=P+*N?HP(J]10ZDY--R>@HT
MJ<4U&*2?D9VC^'=*\.Q/%I6F6>F1N<LEG;I$"?4A0*NS0QW,+Q31K+$XPR.H
M*D>A!J2BI<G)W;U+C&,5RQ5D86G^ _#6DW0NK'P[I-E<CI-;V44;CG/4+GJ*
MT]1TRSUBU>UO[2"]MG^]#<1K(C?4$8JU13<YR=V]28TX1344DC(T?PAH/AZ9
MI=*T33M,E889[.TCB8CW*@59U;0]-UZW\C4]/M=1@Z^5=PK*OY,".U7J*'.3
M?,WJ"IPC'E25C.T?PWI/AV-X]*TNRTQ'.66SMTB#'U(4#-5-4\"^&]<O'N]1
M\/:5J%VX :>ZLHI)" ,#+,I/ K<HI^TFI<UW<7LJ?+R<JMVL96B^$]#\-R2O
MI.C:?I;R@+(UE:I"7 Z E0,UJ,H92",@\$&EHJ92E)WD[EQC&"M%61F:?X7T
M;2+&XLK'2;&RL[C/G6]O;)'')D8.Y0,'(XY[58TO2;'0[-+33K*WL+1"2L%K
M$L<:Y.3A5  R:MT4W.4KW8E"$;66QF6WAC1[/5I=4M])L8-3FSYE[';(LSYZ
MY<#)S@=3VI]KX>TJRU2XU*WTRS@U&X&V:\BMT6:0<<,X&3T'4]A6A11SR[^7
MR%[.'9;W^??U"L/4/ OAO5KPW=]X>TJ]NSUGN+**1_7[Q7-;E%*,I1=XNPY0
MC-6DKH9%#'!$L4:+'&HVJBC  ] *Q/\ A ?#'VW[9_PC>D_;-V[[1]AB\S/K
MNVYS6]13C.4=8NP2IPFDI*Y4U+2;+6K)[/4+.WO[1\;[>YB62-L'(RK @X(%
M2V=G;Z?:Q6MK!';6T*A(X84"(BCH !P![5-14\SMRWT'RJ_-;4P)?A_X7GO3
M>2>&](DNRP?[0UA$9-PZ'=MSFMY5"*%4!5 P !P!2T54IREI)W%&G"+;BK7*
M&DZ#IF@Q2QZ9IUIIT<K^9(EI L0=O[Q"@9/O4<OAC1YM835I-)L9-53A;YK9
M#.N!@8?&X<<=:TZ*.>5[WU#V<+<MM K.TWPYI.BW-S<:?I=G8W%TVZ>6VMTC
M>4Y)RY4 L<DGGU-:-%2I-)I,;BFTVMC'NO!^@WVH37USHFFW%],ACDN9;2-I
M'4KM*LQ&2"O&#VXJ[I>DV.AV:6FG65O86B$E8+6)8XUR<G"J !DU;HJG.37*
MWH2J<$^9)7,Z_P##>DZI?6U]>Z797E[:D&"YN+='DB(.1M8C*\\\4O\ PCVE
M'6!JQTRS.JA=@OOLZ>?MQC&_&[&..M:%%'/*UKC]G!N[11U?0].\06HM=4T^
MUU*V#!_)O(5E3<.APP(SR?SK)A^&OA"WFCEB\*Z)%+&P9)$TZ$,K Y!!"\&N
MDHIQJ3BK1DT3*E3F[SBF_0QM6\%^']>N!/J>A:;J,XX$EW9QRM^;*?05IVEG
M!I]NEO:P1VT$8PD4*!54>@ X%344G.37*WH4H14G)+5A618^$="TW4Y-1L]%
MTZTU"0L7NX+2-)6W<MEP,G/?GFM>BDI2C>SW'*,96YE>QDZQX3T/Q%-%+JNC
M:?J<L0VQR7EK'*R#.< L#BM&:VAN+=[>6))8)%*/$Z@JRD8*D'@C':I:*.:3
M23>B!1BFY):LI:3HNGZ#9BUTRPMM.M0Q80VD*Q)D]3M4 9ID?A[2H]8?5DTR
MS359%V/?+;H)V7 &"^-Q& ._85H44<TKMWW%R1LE;1&=K'AW2?$*Q+JNEV>I
MK"VZ-;RW24(?4;@<'Z5:O+*WU"TEM;J"*YM95*20S('1U/4%3P1[5/11S.R5
M]A\L;MVW*FF:39:+9I9Z=9V]A:)DI!:Q+'&N3DX50 .:AUGP[I/B.&.+5M+L
M]4BC;<B7ENDRJ<8R P.#6C11S2YN:^HN2/+R6T[&)I?@GP[H=S]HTW0-+T^X
MQCS;6SCB?\U4&MNBBB4I3=Y.X1A&FK05C"U+P)X:UB[:ZO\ P]I5]<MUFN;*
M*1S_ ,"*DULP6\5K"D4,:0Q(,+'&H50/0 5)13<Y223>B!4X1;DEJS"N? ?A
MF\OOMEQX=TF>\W!OM$EC$TF1T.XKG-:=]I=EJ5@]C>6=O=63J%:VGB5XV Z
MJ1@C@?E5JBASD[7>PE3@KM16NYS'_"K_  ;_ -"CH7_@MA_^)KI8XUAC5$4(
MBC:JJ,  = !3J*<JDY_$VPA2A3^"*7HC-UKPSH_B18EU;2K'5%B),:WMLDP0
MGKC<#C.!^50:3X,\/Z!<&?3-"TW3IR,&2TLXXF_-0/4ULT4*I-1Y4W8'3@Y<
M[BK][%74]*LM:LWL]1L[>_M),;[>ZB62-L'(RK @\@&L+_A5_@T<CPEH0/\
MV#8?_B:Z>BB-2<%:,FA3I4ZCO.*?JC-O?#>D:E?6M[=Z7975Y:X^SW$UNCR0
MX.1L8C*\\\5I445+DVK-EJ,8MM+<P]4\"^&]<O'N]1\/:5J%VX :>ZLHI)"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-[=K?U_E8^ROB-^TYX8^'OB\^%8M*\0^+?$44/VBYTWPQIWVR6UB(!#R_,H
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M=Z\[3_"VY[ O[6GA&Y\87&B6.D^)M4L;6_&F77B*QTII=+M[@L%\MY@V1\Q
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MY&*]-\%^,M(^(/A?3O$.@W:WVDW\7FP3*",C.""#R""""#T(-?#?B+X1^(?
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M5M3@ATOQ-K.CZ5<?9=1\1Z5I1FTRSD!P5DFW \''13G(QFN'^/.K6VM?M/\
M[.][8W*W5A=-<7$$T;91T8(58?48KP_0?@GKW@G3-=\#>*M%^,MZ);N46\/@
MNZC.A7\3'"O+N4JA; W;L\8R!C%>R^*?AAK6D?%7]FN'3_#NL'2] M##>R,I
MNQ8?)&-L\\:!,@@C=A0<< "NBG1H4:M*4)7WU[W@_P!?\GJ85:U>K2JPG&WE
MVM./Z?YK0^O****\ ]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?B-X%A^)/A&]
M\/7&K:MHD%WM#WFB77V>Y"@@E0^"-K#*D$$$$BNFHI[.X>1R_P -?ASHGPG\
M&:?X7\/P/#IEDK!/-;?([,2S.[=V))/\@!744454I2J2<I.[9$(1IQ48JR04
M445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %-=2R,H8H2,;EZCWIU% 'G_P '?@IH?P3TG5++1KK4-0EU
M2]?4+R^U25);B:5@ <LJ*,<'MU)]:] HHJYSE4?-)W9$81IKEBM HHHJ"PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI&[QE48_1B#^%=K143BIQ<7U+A)PDI+H?._PV\ :U\5-"^!OBWQ*EYX4\1^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO7^\* '44W>O]X4;U_O"@!U%-WK_ 'A1O7^\* '44W>O]X4H8'H<T +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;^)]WY,ZRBBBOJ3X8**** "BBB@ K8_X)N_\C9XL_P!RT_G-6/6Q_P $W?\
MD;/%G^Y:?SFKY[//]T?]=4?7<-_[W_79GZ.K]T4M(OW12U^<'ZJ%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+:I-KNLZM>/?ZEJMQ&(VN)FZD("0HZ\9/4UZ'157:O;K_P #[MEMV):O:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** &3;?)DWML3:<MG&!CKFOS_ ->\)_"32_!-CXQ;QO\
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M6G\YJ^>SS_='_75'UW#?^]_UV9^CJ_=%+2+]T4M?G!^JA1110 4444 %%%%
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M/$MA\3IO!GB&YT@67]GZ;H U"XE@$K,7D)<+MR.-PR-IQWKIPT(U*JA+K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYO\ B]+X_P#AK\<D
M\>>'?"J^/M*N]$72_P"S5U);66R<2ERZA@<AN.0IZ')'&?I"OE#]J/0_ASJ'
MQ%MY?%7PD\;^-]3_ +/C5=3\/0SM;B/>^(R4E4;@<D\?Q"NK"_Q5=7W_ "?F
MOS.7%?P7\OS7D_R9Z7^RUX7\3>'/ NKS^*+:+3+O5]:NM4@T>&X$Z:=#*5(A
M# D<$,< \;NQR![)7S[^Q-X3U#PC\*-2MKSPY>>&;2XUJZN=.M-24I=FU;9Y
M;3*>C8&WH,A0?<_05/%Z5FEY?DO-_F3A&W13?G^;UV6^^P4445R'8%%%>(?M
M.^/M5\ Z9I%Q:^/+/P#87!F22\DT=]2N)Y@H:.*--I15(#Y9L8XQ4RDHJ[*C
M'F=D>WT5\?:)\=OB7XP\'_"SP_;:SINF>*_%UU="77H;>&Y\JV@P=WE F/S"
M,Y7 QC&%)X]7_9K^(_B3Q?'XR\/>+KJ'4M=\+:L^GR:A#"L(N4YVN44!0?E;
MIVQ]3IRN[\OTLG]S9GS;>?\ P;??9GM5%%%24%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7C'[8WQ"U/X8_LW^,]:T2X-IK3P1:
M?8W*]89KF9+=9![J9=P]UKV>O*?VIOA=??&3X!^+_"NDF,:U<VRW&G>:<+]J
MAD6:$$]@7C49]ZSG;E][;KZ=?P-*=^=6W_7H>?WVK^*?@SXX^$OP/^&UIX?M
M=+O/#M]++JFM6\T[6K6I@'G>7'+'YQ=I7W(64LS[MXP0TNB_M)>)-%TWXF:?
MXM?P+;:]X'UFVTV35M4UB3P]HU[%<0I-$Y>1;IH)-K[?+)D!8<,,\=3X3\'7
M7Q0\9?#/XP7XOO#=_IWAV[L+KPUJ6G/#<)-<F R!R[ IY;0,,;2&# @XQGIO
MA_\ "7_A!?B+\2?%7]J_;O\ A,;ZTO?LGV?R_LGDVJ0;=^\^9NV;LX7&<8/6
MNB7-=J;U]Z_KSZ?^2W_X>QA"UE9::6_\!UO_ -O'#?"[]H:/XO>)G\,RZQ\*
M[N*YM92\?@OXDMJVHX"\E(5LH& YY<2 KP17F?C;X=^"?"O[1'PJ\)?![0K+
M1?'>FZF-8\4:EI*8FCT7RW$J:C/G?,T[L@1969B1N[9KZV\16>H:AH&I6NDZ
M@ND:I/;21VNH/;B<6TI4A)3&2 X5B#M)&<8R*\#^!_[.?Q$^!]G-;6?C_P (
MZQ)J-]]OUO5[_P &W;:IJTK-EWEN/[5*[]N57";4XPF.#,+>T4MK6^;OI\N_
M=:=6U4O@:WO=>B:U?KV[/5[)-?@G,? /[4/Q>^'5J^W0+JVLO&.GVB@[;22Z
M:2.[5>P5Y8A)@=Y&]:^C*\#^"_AG6-?_ &@OBS\2]6TJ[TBQN1:>&=$BO[9X
M)YK6TWM+<;' /ER32ML/\2H&Z$$^^4E\$/3\/L_^2V7J.7\2?K^-ES?^37"B
MBBD 4444 %%%% !1110!\9_\%,/^27:!_P!AN/\ ])YZ^:?A7_R(6E_]M?\
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M "1+5]_ZW_S84445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MME90>8Q=;>-H(CA%)X7<[M@8&68]237ZQR?ZMOI7Y.?M0?\ )X6M?]A#3_\
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M_2J6OI:ORK%?QZGJ_P S]EPO^[T_1?D%%%%<QU!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDVL&G_M(>&H;6&.VA37--VQPH%5?GA/ 'O7["Z2=VGPG_9%?C_:_\G+>'?\
ML-Z;_P"A0U^O^C_\@Z#_ '17Y]GG\:/S_,_5N'_]V?R_(NT445\T?4A1110
M4444 ?&?_!3#_DEV@?\ 8;C_ /2>>OFGX5_\B%I?_;7_ -&O7TM_P4P_Y)=H
M'_8;C_\ 2>>OFGX5_P#(A:7_ -M?_1KU]_D/\'[S\UXF_B?=^3.LHHHKZD^&
M"BBB@ HHHH *V/\ @F[_ ,C9XL_W+3^<U8];'_!-W_D;/%G^Y:?SFKY[//\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^1OVHO&FGV_P 3X]/C^'/A'Q+-IMI8SZKJGB2U6:86\]UY*1P+P206
M)R20-W3U^MII!#"\C=%4L?PK\XO&FL77QUUKPCX]^(=EX8N/!FJZN-'M[+3[
MUH-6L+=YF17D(QN4%2WS%NIP%W9KT<!3YZZD]E:_SO9?,\['SY:$DMW^FK?R
M/L;]G;6M(U#2_&&FZ+X?TGP]::)XCN]-\O18A'!<; A$N /O%2H/NM>M5R'P
MK\&^$? /@^WT7P5%:Q:) [$?99_/W2'EF9\DLQXZGT[8KKZY:TE*;<;]-]]M
M_F=5&+C#WK==MEKM\M@HHHK W"BBB@ HHHH **** "BBB@ ICS)']Y@*5CA2
M:_,S_@H'J%_XF^/&@Z.+IS FFPQV\$DC>3'))<2JSA>@+!8P2!DA%ZX%=F$P
M_P!:JJE>QQ8S$K"4G5:N?I?]LA_YZ+^='VR'_GHOYU^,/_"D==_Y^]/_ ._D
MG_Q%'_"D==_Y^]/_ ._DG_Q%?0?V!/\ G_#_ ()\W_K)1_E_'_@'[/?;(?\
MGHOYT?;(?^>B_G7XP_\ "D==_P"?O3_^_DG_ ,11_P *1UW_ )^]/_[^2?\
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M;_Z%#7Z_Z/\ \@Z#_=%?GF>_QH_/\S]:X>_W;[OR+M%%%?-'U(4444 %%%%
M'QG_ ,%,/^27:!_V&X__ $GGKYI^%?\ R(6E_P#;7_T:]?2W_!3#_DEV@?\
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MYYGO\:/S_,_6N'O]V^[\B[1117S1]2%%%% !1110!\9_\%,/^27:!_V&X_\
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MQ?L!_P#)O6@?[]U_Z52U]+5\T_L!_P#)O6@?[]U_Z52U]+5^38K_ 'BIZO\
M,_;\+_N]/T7Y!1117*=04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI_Z+DK*K\#.K#?QHGW3^P-_R;EX<_P!^[_\ 2J:OH^OG#]@;_DW+PY_OW?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_#"O@__ *#WB'_P93?_ !=?2=%'U[%?\_']X?V?A/\ GU'[D?-G_#"O@_\
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MJ.LV?F8W_9[R1-V,XSAN>I_.K?\ PPKX/_Z#WB'_ ,&4W_Q=?2=%=OUW$_\
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M?_T'O$/_ (,IO_BZ^DZ*U^O8K_GX_O,?[/PG_/J/W(^;/^&%?!__ $'O$/\
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M_@RF_P#BZ^DZ*Z?KV*_Y^/[SE_L_"?\ /J/W(^;/^&%?!_\ T'O$/_@RF_\
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M+_P%_P#LJ/L>J?\ 03B_\!?_ +*M.BD,;&&6-0[;F Y;&,GUQ3J** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 8&G0NVH1%3@1DE^>HVD?S(K?K&TBS>&\;+?+$AC(R>3D8/Z'\ZV:
M "BBB@ HHHH Y_4)%DO)2H[[3QU(X_I5>AK@W1\XC:9/FVGMGM10 4L<;S,$
MCVAVX&[IGWI*O:/'NN2W.%'IQ0!L1QK%&J(-J*, #L!6=JUGN_?H.1P_^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %.PM6MI+DDY#R%AQZDG^OZ5
M<I*6@ HHHH *AO&>.SG:+_6*C%?KCBIJI:N?]!9=^PLRX]\$''Y T 8E%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K,UMT\N%#]\L77GT&#_Z%6G61K4A\
MR-,?*!NS0!G4444 3V*AKN($[1NS70URWM6SI=\TR>5,<RKT;^\/\?\ ]?L
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M!TU%5K&[%W#DXWKPP_K5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>AKEHV+1J3U(S6]I9/V-!G(' H N4444 %%%% !1110 4444 %%%% !1110
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>eigr-20221231_g18.jpg
<TEXT>
begin 644 eigr-20221231_g18.jpg
M_]C_X  02D9)1@ ! 0$ A0"%  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .-!NT# 2(  A$! Q$!_\0
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MHR/6LN.^C\1>'OM-A-F.ZAW12K[C@U^3OQI^.7Q3\ _%;6])'BF[CMK:X.Q
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MKO0/%.LRZF;L9@\X\J1Z5[,<HK3P_MT^E['AU,\H4\3]7:ZVN?H=245\"_\
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M>!K8-KVBT?4]? YE0QR?LWJNA;HHHKSSU0HHHH **** "BBB@ HHHH ****
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M/$X;$8>EA\,N:2\O+8_4W]F6ZN;OX+>&7N00_P!D4#=W&.M? O\ P46\"_\
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M';#2;;_4VD*Q+^ KY)_X*2>!O[5^'-MKT<>Z:SD"9 YP:^:HXE1S)5H[-O\
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M)TMXAY/V5%=/7Y1FLW5?A'X)L+.ZO9="M?D1G9B@]*[NSA%O:Q1+T10OY"N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***:[!5+'@ 4GH@/SA_X*:>,#<>*M$T6.3,:1EI%'K7DO[-/[)-[^T+I>HWR
M:BNG16KA 7&=V169^VEXN;Q5\;]:3=N6S<Q)@U]Z?L#^#T\/?!>SO=FV2_\
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M'U?E_7F?$YW6GB\1#+J/S]?^ ?/'A/\ :T^(?@?0[;2-(O!;V5N,(HC-</\
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MQ&,Q4JE72+9C1SC#8'!PITW>27XF#X;T^]^)'Q#M(!&TUSJ-V-^T9ZFOVO\
MACX7'@WP+H^D 8^RVZH?KBOD/]A_]D6Z\(31^,O%5OY>H2+_ */:R#F/W/O7
MW(!@8HSK%PDHX6D]([^H9#@ZBG/&5EK+;_,6BDKY#_;=_:$\3_ C5_#=UX?:
M,B=B)8Y1E6&:^;HTW6JQI1WD?6UJBHTY59;(^L]2TRUUBSEM+V".YMI 5>.1
M<@@U^:G[=?[+^E?#%H_%7AY?(L[R4B6V[*WM7=^'_P#@I]91Z>@U?1)'N]OS
M&$?+FO ?VGOVN]0^/L4&G0VWV+1X6WJG\1/O7OX/ 8W#XF+BK+KVL?-XS,LO
MQ6&DIN^FBZW.C_X)X>+KS1?BY-IT<C&SN8MK19^7/KBOT"_:4\4+X5^#^OW)
M?8TENT:GW(KXV_X)T?!75&\27/C+4+5[>P\O9!O7&X^HKU__ (*.^+CH_P )
M8M.B?;+<S#(SSBM<[4*^-ITH[NR?WF'#_/0PE6M/X5=K[C\\?A)X<D\<_$[2
M;!E\WSKM7<$=1NYK]@=/_9_\"QV%NC^'K-F6-06\L<\5^0OP2^)$7PG\>6GB
M*6W^TB <)UYKZ\_X>>%5XT7@#TKULUH8BLJ<,/LMSQ,GQ&&HSJ5,2]7M<^U_
M#_PC\)^%]06]TS1;:UNEZ2(@!%>(_P#!0"UFN/@Q.\6=D9R^/2MW]EO]I2X_
M:"CU.9K#[)#:D ''7->A_'+X>K\3OAKK.A#B:>$B,_[0KXS$1K8:M%5]XM,^
M]PU2AB:,GA]I77S/RD_9!O8+/XY>'#,RH&N% +5^S$;!HU(Y!'%?A3J^EZU\
M(_'CV\L4ECJ>FSYB+C&<'@U]A_#_ /X*73Z3H,%KXBTLW-Y$H7S(1][ ZFOK
M\VPT\=3IU:&ME^9\/DV*AEE:K1Q.EW^1^BM9'BY6?POJRI]XVLF,?[IKX!U+
M_@I-KNO^)-+T_P /Z9#;PW-RL3M.N3M)QQ7W_H\S:UX=MWN.6N(!O_$<U\CB
ML#7PU-3JJUS[;"YCA\55]G2=[:GX;^*HY+?Q]>+/D,M^2V[_ 'J_9G]G^X@N
MOA3H#V[K)']G7E>G2OS+_;0^">I?#3XH7VIK;.=&OW\R&95X4YK?_9U_;DU;
MX.Z''H6J6W]H:3#_ *HCEQ7UM:']HY=#V.ZL?&1J?V;FTY5U[KO^)^J\TJ01
M-([!$49+$X K\E?VZOBY!\2/BM+:V$OF6&GCR>#P6'%=A\:O^"A^N^.-%FTK
MPU;?V7;7"[)9FX<#VKQ;X#? GQ#\>/&D"1V\S:<TN^[OF!QC///K7'EF6RH5
M?K.)T43NS;-H5Z/U;"^\Y;_Y'V-_P39^&<FE^%;[Q-=0F.:Y?RXMPZKZUE?\
M%-O&'DZ;I&@+)Q-^]9<^AK[4\!^#;+P#X5L-$L(UCM[6)8Q@=<#K7Y>?\%!O
M%Q\3?&,V:ON%BAB"@]ZY(U?[2S6,E\*>GHMCL5!Y7D\XOXFM?5GM/_!,;PGL
MT_7]7EC^;S%2-R.V*V?^"E7PU_M;POIWB6"/YK(D3,!V->J?L*^%!X>^".F7
M!CV27J^:W%>C_M!^"%^('PIUS2"F]Y(2R\=P":SS3%..9>UC]AK_ ()>3853
MRSV<E\=_^ ?FS^SO\;H_!OPC\<Z%<S[#<6^+92>Y':L3]C?PN_C#X\:5<%=X
MMI_/?\Z\3U2SDTG4KVR;<A@E:,KTZ'%?:G_!,WPBUQXJUO6I(_W:PA4;'&<U
M]A4Y*4*N,CNX_H?#P=2I.E@'LI?KJ?H;KU^NBZ#>7;':L$+/GZ"OQ)^*FHR>
M,OBYK<VXR&[OF5/SK]>/VE/$P\+_  =\17.[8[6S(OU(K\9-%UK[#XDM-6G7
MS?*N/.9?7!S7S/#U.]>I6?2R/K^)JG)AJ=%:-N_W'[/?LW^&?^$5^#OANR*[
M9%M5+?4USG[6GQDLOA/\+M1=IU&I7<9B@AS\QR,$U\G77_!2G4-/\/Q66BZ1
M&D\,8C5I5XX&*^8?'?Q*\9?'_P 5+-?M-J-]*V(K6$$JN3V%)Y57Q6)E4JZ1
M;N33SC#8/"1IT=9)6^9F?#OPS>?$?XC:?I]O&TMS>W0D( SU;)K]9?BUX^L_
M@#\"Q*76*[BLUA@CZ$OM ->.?L2_LGS?#BW'C#Q1"$U61=\$+#!A&.IKP']O
MWXX_\)]XZ7PU83[M-TUN2AX9^]=682CC\13P-'6,=SDRV$LOH5<QQ"U>R/E[
M7-<N/$.N7FK71>6XNI3,V<G&3FO6=!_;$^)7AG2;73-/O1!:6R!(T$9Z"OJ'
M]@?]FW3-0\+S^*?$VEQ7ANLQPPW*9  [U]<?\*&\ =?^$5TW_OR*Z<;F&'PT
MOJLH<RB<F RW%8M?7(SY7(_%SQUX[U?XBZM)JVM2F:];JV,5^JW["^JC4/@=
MI<0;<8%V'VKXJ_X*">"]+\&_$^PATBPAT^UE@),<*X!-?3W_  3@U@WGPQU&
MW9@1;S #\JG$U*>)REU:<;)6T^96&I5<)G,:567,W?7Y'G__  4X\8%!H&BQ
M/D/EI%%>*?L?_LSZ=\?+C6CJSR16]G'F,J<98]*3]OCQ@?$7QMOK$/NCL1M7
MFOK3_@G/X/&C_"EM7*X>_;KCL*QPK>$RAU%I)[?-G3CTL9G,*+UC'3[C\\?B
MYX!G^$_Q&O=#E4XMI<Q[NZ9XK]7?V2_%&B>+/A%I-WI%K;VSQQB&80H 2P')
M-?*'_!2GX6_V?K.G^,+>/_CY_<RE1TQ5'_@G%\7!HOB:[\)7EP$M;A=T"L>-
M]:<TLSRN]_>C^FYG*$<IS=67N2_4_2BO"?VSKNQM/@;K#7P4H>%!_O8.*]UK
MXQ_X*4>+%L?AQ:Z,LNV6ZD#;<\D"OC*,'4K0@NK1]Y6J*E2G4?1,^#O@/X*3
MX@_%/2-'D0O"\X=E'=0:_:SPSH=IX;T.STZRA6"W@C5%C48 P*_+[_@G?X3.
ML?%Y-4,>Z*SC8%L=#VK]5!\HQ7U7$%1J5.BGHE<^+X:HJ7M<1;K86BBBOD3[
MDYCXEZT/#_@36K\MM\BV=@?PK\4IW?QM\4F;[YU"_P 9]<MBOU9_;2\7CPI\
M%-5PX1KI3"/Q%?DOX#\0Q^$_%6FZQ-'YPM)EFV>N#FOK>':?OU*SZ:'Q?%%7
M]U2H=[O]#]@/A]^SQX,L?!6D6UYH-K-<) N^1HQDDBNKTOX*^#-&OH[RST&U
MAN(SE9%C (KXNC_X*<"&-(TT7"J .E>S_LT?M=7/Q\\236":;]F@A&7?%<5?
M"8Z\ZLM%J]SLPV,RY0A15F]%MU/5OVBO$J^$?A#KU\&\LI 57\1BORL_9ET-
MO&7[0&C%D\R.2[,KY&>^:^[O^"B'C#^P_A&VFA]K7S;<9ZXKYP_X)M>$_P"U
MOB)?ZB\>Y+*,%6([FNS)%[*A7Q+_ *T_S.3B%NK5P^%75_FS[[^-?@:/QG\)
M]8T81AF:U81C'0@<5^3'P9\22_!WXX63RN85L[SRI^WR@U^U,T8EB9",AA@U
M^/'[97P^?X??&K40B&.*^8W"MC'4URY)6Y<1.C+::.K/\,I82%6*UIM?<87[
M0'BQ/BA\;;ZYMG\V"XG5(N<]:_6#]GOPY_PBWPC\.V#+M>.V7<,=\5^0/P1\
M/R>*?BIX?M54RG[7&S=^,U^VNGPII.C0HHVI#"!^0KT,ZY<+A*6'CMJ_N/+R
M*4\;CJF*GO:WWGYO?\%+/%QU+QMI.DI)E;1274&NZ_X)D^#FM[+7=;D3Y9MJ
MHU?+G[7OBA_%7QT\02;]T43[$YKT+X _MI1_ _P*NA0Z9]HG4DF3'4UOAJ%2
M.4>SIJ\I+\SGQF(IRSI3J/W8/\D?J/X@URT\-Z/=:C?3+;VUO&7=W. ,"OQE
M_:8^*!^+7Q7U/58R7MXW,,/NH.,UTWQL_;*\;?&:%M-FD&GZ8QP(;;@O[&MW
M]E/]DO7?BIXEL]7UBSDLO#]NXD9IE(\WV%8Y=E_U&3Q6*=K'1FF9_7XK"81-
MW>I]B_L!_#:?P3\)$N[N$QSZ@_G+N'.TCBOGS_@IAXO-UXPT;1HY,Q1Q;G7W
MK]%])TNV\/:1;V5J@BMK:,(BCLH%?CY^V5XN;Q5\;M;&[<MI(8EY]Z\_#3>8
M9K[6VFK_ $1ZF(I?V;E#I7UV^_<V_P!FO]D6\_:$T>_OUU)-.BM7"#>,[J^D
M?!__  3)T6SN$;7]6-[$IR5AR":]2_8.\()X=^"]C=A</?CS6KZ4K?,LRKT\
M3.G2E9(Y,HRK#U<)"K6C>3.,^&OPC\-?"G1X].\/Z?':QJ,&3 +M]37Q[_P5
M!@F.A^'I &\H3<^E?>E> ?MF?!V;XM?"NZ2SC,M_8@S0HHY8^E>!2KR6*A7J
MN]GJ?3U<+%X6>'I*UT?'7_!-JXAA^+>IK(ZJS6V%#=^:_405^%_@?QIKWP9\
M<1:C:!K34[&3$D4@(SCL:^S;3_@IVJ:"J3:*QU79C<H^3=7U><8.IBYQKT=5
M:Q\7DF.I8)3H8CW7<^E_VM/BU9_"WX4ZG+)*OVR[C,$48/S'(QFOR@^%?A6\
M^(_Q.TS3X%:6:XNA*W&>-V36S\8/CAXL_:"\3I-J):5BVVWLX 2/;BOMS]A+
M]ENX\#VH\8>([4Q:I.O^C0R#YHU/K58&BLHP\\17^)]/R0LPQ#SK$0PV&7NK
MK^;/JV.WA\%?#XQ+A([.S(_$+7XL?$#59O&/Q.U*<_.\U\4'TW5^N?[57BH>
M$?@GK]ZK;'\K8O..M?E!\"]#/C;XR:):$;Q<W0=OSS7'D$?:8BKB)]/^'9W<
M12]CA*6&I_U;1'Z]_ 7PTGA7X6:#9(NP_9D=A[D9K\_O^"D7B\ZG\4+/2HY-
MT-O""5!Z&OTRT^W31]#AB^ZEO"%_ "OQK_:2\02^/OCGK"AO,9;DP)CZUR9;
M%XO-.=^;^_8[,P:P64>S6FB7^9][_P#!/'PB?#_PC>Z>/:UY-Y@..HKY]_X*
M2_#4Z1XPL/$-M%MAND(F<#^*ON?]G?P^/#?PA\-VNSRW%HA8>Y%>??MQ_#L^
M.O@S?M#%ONK0^:I YP.M9XC&..:?6.BE;Y;&F#P7/E*P[W<;_/<^(=-^.4=Q
M^RIJ?@Z6?%S"X$2YY(KJ/^";OA'^V/B)>ZJR9^PKP3ZFOD%F:-9$W$8)!7/I
M7Z5_\$V/!ITOP+J&M,F#>L &QUQ7UN*C##8?$5X[S_70^)PDIXK$8?#3V@_R
MU/M*OEC_ (*$^,!X;^#_ -D5\/>R>7@&OJBOSK_X*:>+A<:II.@+)S%^]*YK
M\_PE/VV)IT_/\C]/QE7V.&JU.R?XZ'BG[#OA'_A*?C98AEW+9XG/'I7Z^QC:
MBCT%?G;_ ,$S/"'G:MJOB!DR GDAOQK]%*][B"IS8B--?97YGS/#5*U"=;^9
M_D%9'BCPKI?C'29]-U>SCO+292K)(H/7TKXO_:F_:P\6? KXM6EGI7E7&FRI
MNEAF&?RJII__  5 TE;#%WH<QN\=5'RYKR:67UZU&-:FKIGMULSPV'KRP]5V
M:/G[]L_]G:S^!OBR*?26QI&HL3'&>J'TKV;_ ()D^,;V34M=T&25VLXHQ(B$
M\ DU\W?M&_M%:K^T'XBAGN(?)LH#BV@4<U]D_P#!.SX+:EX-\/WOB?5;=K63
M4%"QQ2##;1SFOJW[2CE4XXM^]:R^_0^,?LJ^;PE@EI=?\$^U*6BN>\?>+[3P
M+X3U'6KR14BM86D^8XR0.E? MGZ4M3Y"_P""B7QT&A:!#X+TV?;>7GSS,AZ+
MZ&OSS\*^*K[P7K<&JZ:/],A.49D)&?6NL^(WB[4?CE\6;F\!>9]0NO+@3KM4
MG K]0O@A^S!X2\*_#G2;/5]!L[[4O)#3RS1@G<:^YP_)D^#C.HO>G_7X'YYB
M^?.\>Z5)^Y#^OQ/SKO\ ]M#XH:E8RV<^HY@D0QL/+/3&*\W\ ZH]K\0M,U!V
MQ(;I9&;W+<U^Q^K? GP%'I-Z4\*Z<&\E\$0C(^4U^.OC2V&@?$Z_BB01+#?X
M1!T WUTY5C:&(KN%.GRLY<VRW%4<.IU:O,KV/UY^+'F:G^SOJK0Y9Y=+##'^
MZ*_'[P5(MA\1M)>X.T17@W[O]ZOV<\"VL7B_X0Z9:S<Q76GI&W_? %?D?^T/
M\*=5^$?Q*U.TNX)(K:6=I;:;!P5)R.:\O)ZD:.-JTIZ7?Y'K9S3EB,MHU8:V
MW^:/V3\$7$=UX3TN6)@T;6Z%2/H*W*_,+X'_ /!0C5?A]X>M]%\067V^UM4$
M<,D8^;:/6NL\7_\ !3J]GM=GAW1UBN&X#7"Y KBQ&4XGVS4%=-[G?@\ZPGU>
M//*S2V/T1KX*_P""G'BXV^FZ#HT4G^M8F1<U]7_ 'QQJ'Q$^%>B>(-4""]O(
MO,D\L86OSC_X*">+SKWQHN=.#[H[%<+7-@L+)9C&C+>+=_E_P3MQF+C++9XB
MGM):?/\ X!M_\$]/A;IWCSQ?J]SK%DEY9VL:E5D7(R:_04_ /P)DG_A';//_
M %S%?/?_  3?\'C2_AG/K17#WK[<X[ U]<ZQ?KI>EW5VYPL,9<Y]A77GF)DL
M5*,'I%6/.X?PL'A%.<;N39^1?[;4>CV/QBFLM$M(K.TMX]C)"N!NK[!_X)P>
M#_[%^%M[?NF'NKC<I/\ =Q7Y\?&769?&'Q:\03!MYFO&6/GMFOUP_9A\,KX8
M^#'AN#9L=[57?ZD5Z>)<L/E$82=W*W^9Y=",<3GDI07NQN_T1XY_P4:\7?V3
M\)1I*/MDO) <9["ODW]@7P@WB#XW6%ZR;H;-6+'M7H7_  4Q\8&^\9:+I$<G
M[N",EUS76?\ !,?PEMM_$&LR)SO58V^M9Y7_ +/EE6OWO^.AIG'^TYI1PZZ6
M_P V?:_Q&UQ/#7@;5K]F"B&W8Y/TK\3I89O&GQ)N(P3))?7S8[]6K]6OVV?%
MG_",_ O6@K;9;A-B\U^3WP]\4)X1\8Z9KL\?GBUE$K)US6?#L/?J5GY+]3;B
MBI:E2H+=W?Z(_7[P%^SYX+M_!>C176@6LMPMM'YCM&,EL#-=3I?P5\&:/>Q7
M=GH-K#<1G<DBH,@U\6P_\%-A;PI&FBX50 .*]I_9E_:ZN/C]XHN--73?LL,,
M1D,F*XJV$QUYU7=+5[G;AL9EW+"BK-Z+;J?4'05^3O\ P4$TO[#\9YIPA0SC
M=D]Z_6*OS)_X*7:;]E^(FB7 4@2QG)[5R93+EQ]/Y_D>AG$>;+ZOR_,R_B!\
M9'T']D?PKX6M9_WVH*1*5/( K0_X)[? P^+/%S>+-1A)LM.(,!<<.U?+6DQZ
MGXXU+2=!BWW!\Q4BC7G )P:_9;]G[X86WPI^&>E:- @$BQAY6QR6(!-?5XZ:
MR^A4G'XZC?\ 7W'Q67TY9G7I4I?!37]?B>CX$<> ,!17Y(?MZ>+3XF^-\Z))
MOBM8_*P.@/2OUBU[4%TG1[N[<@+#&SDGV%?A_P#&#7'\2_$SQ%>R-N#7C[>>
MV:^<R.G[3&\S^ROS/J\_JJE@''^9I'WQ^PC\#- U+X52ZCKNE0WL]S-N1ID!
M(6OI8? +P&&!_P"$=L\_]<Q7P7\*?V^XOACX(T_0(=(\S[*@4OCJ:](\&_\
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M/]",5H4E8R?,[LVC%02C'9'QW??\$QOAU>7<\_\ :VJ)YKERJD8&3GUKZ/\
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MX:\*V'A+P_;Z/IL7D6<">6BKV%?.'Q"_X)[^"?B/XOO?$6HZOJ:WETVYU0C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5*5.-]9I,YZ<W-U--(-H]NHKYO\ B;_P4$^"_P *=>_L?6?$R27FT,5M%\T
M'U(KU3X2_&WPA\;?#Z:QX3U6+4+1NP(#K]1VK&*<XN4=4C2346E+J=W2UP/Q
M:^.7@[X)Z&VJ^+-7AT^W'1207/T%>&Z#_P %.O@1XAUBVTZW\22)/</L1IH"
MJY/N:F#51\L=65).*YI;'U?17*:Q\3M T/P)=>+[F[_XD=O";A[A!GY!W%<'
M\#OVN/AW^T-J-Y9>#=3DO;BU&95>,KBJ47*3@MUOY$N24%4>ST3/:*QO%_BJ
MQ\$^';[6M29ELK.-I9649(4#)KSKXZ?M2^ ?V=H[5O&>HO8BZXB"1EB?RK-^
M)7Q T;XI_LTZWXDT&?[3I5]ITDD,C#&X;3VKDKU''#SK4]>7\SHIP3JPISTY
MC+^!/[<7PV_:&\37&A>%)[Q[Z#)9;B'8./2M'XY?MC?#K]GSQ!IFC>*[Z:*^
MU!@L:0)OVY.,MZ"OS;_X)'J/^%X:Z0.?F_K7T%^W_P"$?@1XF^*6A2_$#QA>
M>'-:MV4^3;Q;Q,N1P?2O0K0]G/#);3W_ !V.2A+VCQ"E]C;_ ()^@VAZU:^(
MM)M-2LI!+:W4:RQL.ZD9%7J\UTSQQX2^&7P5M/$"W;+X6TZQ21;@C),048.*
MXSPU^W)\(/%/@>]\5VOB>&/2[1BDGG_(^1UPIK.IRQG.,?LCI<TJ<)2Z_F>_
M4E?,_P /_P#@HE\%/B1XHAT'2?$F+Z9MJ?:(RBL?J:^E8)X[J%)8G62-AE64
MY!%'+))2MHQ\RYN6^H^N;U;XE>$]!O'M-2\1Z98W2?>AN+I$8?4$UT;?=-?A
MG^W-X>E\8?MMZCH7]H3V<5]=)$9%<X3.!D#/O6"E*6(A0BM9'0HQ]C4K2=E!
M7/VBM/BQX+O[A(+;Q5I$\SG"QQWD98_09KJHY%D4,C!E/((/%?CW\=/^":>H
M? CX5R_$/PSX[OKZ\TV-;IHVRNT8SD'-?1G_  2S_:6U_P"+WA/4O#GB:ZDU
M#4-+Y6YDY)7.,5UTH1K>TC%^]#=')4E*G&%1KW9Z)^9]\TM>5_&?]IGX?_ 6
MS6?Q=K<5D3TA4[I/^^:X'X9?\%!O@Q\6/$46B:+XDVWTOW%ND,8/XFL:?[UV
MAJ:S_=J\M#Z1HJ%KR%;4W/F*8 N_S >,>M?.7Q&_X*%?!?X7ZV=)UCQ)F\7[
MR6T9DV_7%2Y14N5O4I1;CS+8^E*X7XQ?&+P_\#O!=YXI\2R2QZ9:C,C0KN;\
M!7$_!?\ ;*^%OQYO'L_"NOI/=+_RQG'EL?H#7G__  4NPW[+7B?N/*XK#&3J
M8>ESI=OS-,-&%>IR7/5OV?\ ]IKP;^TEHEQJGA"6XEMH'*/]HCV$$>U>LU^=
M?_!'( ?"753C'^D-G\Z^E/BI^W)\*/A!XRC\+:[K;'67( M[6,R$$G !QWKT
M\33A2JQI1W:7Y'!AZDJL9REM%L^@:*S/#FO6WBC1+/5+/?\ 9KJ,21^8NUL'
MU%:5<S3B[,Z$U)70M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5\N_\ !2#_ )-5\5_]<Q_.OJ*OEW_@I$0/V5?%>3CY!_.N#'?P
M7ZK\SOP'^\P]3YV_X(W_ /(E^)_]X?SKY._;BT.7Q#^VS/IUM*UM-=211^;%
MPPR?45]8_P#!&YA_PA?B@9_B'\Z^>/VD"A_X*+:<&VD?:H<@_4U[6)BI9MAH
MO;E7Y(\;#R<<!BI+HW^;/I#XZ?\ !/?X7>&_V8+SQ#::=)'XGM=/%U)J$DI9
MI)-N3D5\Q_\ !-[]G:Q_:'\17]CXON+B_P#"E@"_]F^<0CN.E?J!^U9A?V5?
M$_8?V4?_ $&OB7_@C0P^W>)1GG)XK'!VJ8O%1ELE=+HBL0W' X=K=R2;ZVT/
M$_\ @H'^SSX=_9G^-'AF;P/%)I5G=;9EA20DHP8=#7Z"?$K6KGQ-^P8M_?-Y
MUQ-IBEV;G/RU\G_\%AF ^*G@G)_Y9#_T.OJ'Q4<_\$^;?'/_ !*Q_*O.E)SR
M2MS:VG_F>DHJ.;89QZPN_O1\#?\ !-O]FS0/V@/'FNQ>*#+<Z%8\R6"2%5E)
M)QG%;?\ P42_9GT+]EGQUX9\1?#]9-%M+J0!88Y#E&7'.:R/^":7[2GA;X"_
M$;6X/%MS_9VFZD=OVUE)2,@GKBM__@I%^TIX>_:4\<>&?#?@2?\ MNVM)1BX
M@4D2,V!@"O1Q/-[7"_5]]+V_&YQX>U\3[;;7?]#ZV^-'C"X^('_!.^35KY_.
MN7TY5=VYR0.M?!_["_[+6K_M5-/HVI:_/IO@_3W\^2UC)Q*_IBON_P",O@^?
MP#_P3M?2;L>7<+IRNZMP02.E>4?\$96_XE_B%<]^E:484Y8_&V5TM5ZG)*I4
MA@,*GNW;Y7/:/BMX#TK]@_\ 9;\3Q>"RT<M]E?._B5BN,U\J_P#!./\ 9,\-
M_M+KXA\9?$>";746<HD<LI&YCR3FOT(_;B^%EW\6/@#KVEV*&6[BB:>.->K$
M \5\"?\ !-/]JCPO^SY#XB\%_$2^_P"$>/GEXY+E2 "."#7-A)JIB,3*L[SY
M5RW[=;'?B8\F%HJEMS/FM^%SC/VX?@E8_L:?&[POKWP[EFT>RNG61;=)#A<$
M9'N*]3_X*">$)OC)^SQX$^,%A;*;NSA3[;*J_,>!R?QKS+]OOXV:5^UI\:O"
MWA_X?,VN6UJXC%Q A(8DCGZ5^CH^ 2W'[(O_  K^\CWR?V;RI'1]N<?G7/\
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M=-2\<2S.IQL8_>%>FY0J9M!U5;W.O\UD>?&,HY=6]D]>;IV_X<^C?V^/V#_
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MB?3H%^SV6G[B55!T/M7J7_!9-1!\-?"T1(^6Y _\=KWG_@F:V[]FW2OFR/\
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MADO)))O+;@C+DXK]K5^Z*]:I?ZKA^;?E_4\U6^N5^7:Z_(^;_P!O_P#Y-O\
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M@CWE0,,0.E?H%^S6OB'Q%^PI"FL>=+J#Z9*$,V2[#:<9S7P3_P $[?C1X3^
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M21#D$'WJQ7GN]]3LC9I<NP4444B@HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1124 +17RU\;?V[--^$?Q,A\"VG@_5_$^O3)YB0Z>N<
MBJW@O]OS1M2\36^C>,O".K^ 9;I@D$NKKM61CT XI4_WR3AUV\QU/W3:GT/J
MZBHK>XCN[>.:)P\4BAE9>A!&0:EIDIW5T%)7%_%CXM>'_@WX4N->\072P6T8
M^5,_-(W]T>]?.&B?\%%=.N=4L3K7@'7O#_A^]E\N'6KQ,0,">&SCI2@U4ERQ
MW*DG&/,]C[$HJEH^L6>OZ7;:A83I<V=P@DBEC.0RGO7._%'XI:#\(?"=UX@\
M072VME .,GEV[*/<T3:I_'H$%[2W)K<Z^BOCC2_^"C6G37UI-JG@#7M&\-74
MOE1Z[<QXMSD\'..E?6^@Z[9>)-)MM2TZX2YL[A \<B'(((J^5\O-T(YDI<O4
MOTM>%?M.?M=>$_V7M)L;K7TEO;F\E$<5I:D>8??'I7JG@7QE;>.O!^E^(;:-
MH+6_MUN463JJL,\U,??@ZD=D[?,J7N.,9;O5'0TE?,GQ1_;[^'OPW^)6D>"H
MVEUO5;^Y6U8V?*PN3CYC7NWC+QA+X7\(SZW:Z7<:M)'%YBV=L,R/QG I7_=*
MM]E]2N5^T]D_B.EHKX[D_;U\3(S#_A1OB_"D\^5_]:NE_9Z_;FTGX^>/+_PE
M#X4U70M5L1FX2]7&SV-7"+J/ECO:_P C.<E3CS2V/J"BBBI*"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYCDD"O+O^"B]XNN>*/A_X4G=C:7E['+)%GY6PW0UM? _QYH_[%_[)WAS6_B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#P-H>F^%8_#EOIT*:)'%Y*V>W*!/3%>7_P##8?PW_P"?V^_\ VH_X;#^&_\
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M_;[_ , VKR?]J7]L;PQ#\$O$4OA75+ZVU](2UI*;9E"M[F@#[&HK\??V:?\
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MZ'80Z=8PJ%6*% HX]:VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@##\8>"=$\>Z--I6O:=!J5E,I5HYT#=?3/2OS[_:._X)&>'/$[2:I\
M.+D:'<@^8]E)\RR<\@>E?I!10!YA\%/A79>#_A=X>T35-(LFOK&U6&5C I+,
M!UZ5V_\ PA^A?] >Q_\  =?\*V** ,?_ (0_0O\ H#V/_@.O^%'_  A^A?\
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M Q_^$/T+_H#V/_@.O^%'_"'Z%_T!['_P'7_"MBB@#'_X0_0O^@/8_P#@.O\
MA1_PA^A?] >Q_P# =?\ "MBB@#'_ .$/T+_H#V/_ (#K_A1_PA^A?] >Q_\
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M ,!U_P *V** ,?\ X0_0O^@/8_\ @.O^%'_"'Z%_T!['_P !U_PK8HH Q_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M15:^U*TTN'S;RZAM(O[\\@1?S-*]@+-%9VG^(M*U=RECJ=G>N.JV\Z2$?D:T
M&8*I). .I-/8!:*RH_%6BR77V9-8L'N<X\E;E"^?3&<UJ4>8>0M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E-FE6&)Y'
M.%49)I-V5V&XZEKYE\4_\%$/@_X3\37^@W%_J5UJ5B^RXCL[)I=A]\&N^^#_
M .U+\/\ XW.T7AS5&%TO6UO(_)E_[Y/-5#]XKQU%/]V[2T/7****0PI*\U^,
M7[0W@KX%V,=SXIU(P-(?DMX%\R5OHHYK"^#O[7'P[^.&I3:?X=U&>._C&?LU
M_"8)&'J >M$/WE^36P2]Q)RTN>T445Q'Q4^,GA;X-:"VK>*-16RMOX4'S2/[
M*O>IE)1U948N3LCMZ2O!?A;^VU\,/BYXB71-'U&ZMM0?F./4+8P"3_=)/->H
M?$3XG>'?A7X=FUOQ%J$=C8QC.YB-S>RCN:J7[M*4M$R8^]+ECN=517SS\/OV
M[OA3\2/$T.A:=J-Y:WLYQ$U_:F&.3Z,3S7O]Q?6]K:M=331Q6ZKN:5V 4#US
M3DG&/-+82:<N5;D]+7DW@;]J'X>?$;Q[?>#_  ]K2ZCK-GGS5B&4XZX;O7JL
MTR6\;22NL<:C+,QP *3TBI/9ZA?WG'JB2DKR31OVI_ASXB^)DG@/3-<2^\0H
M<-%"-R9]-P->MT[>ZI='L%US./5;BT444AA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !163=>+-#L9S#<ZSI]O,.L<MTBM^1-
M:4%Q%=1++#(LL;#*NC @_0BCI<.MB2BJ>H:Q8:3&'OKVWLD/ :XE6,?F33M/
MU6RU:+S;*\@O(_[]O*KC\P:-]@+5%,FFC@C:25UC11DLQP!^-9]GXGT?4;CR
M+35K&ZF_YYPW*.WY T>0>9IT444 %%%% !1110 4444 %%%% !1110 4444
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M-DV;LN[K]XK7H0LZV*PWV86<?+I8X):X?#8I_'-M/STN?T'?\)%I7_03L_\
MP(3_ !H_X2+2O^@G9_\ @0G^-?S(_P#":>,_^@SK7_@1+_C44OC[Q;"V)-?U
M:,^C74@_K7"=A_3[:WUM?*6MKB*X4<$Q.& _*IZ_.[_@C1K6I:Y\)?&,NHZA
M<W[KJ:A3<RF0J-G09K]$: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M30P6UQ<$?+&<#KZ4L'K*/M/A]IIZ\O\ F:XJ_(O9?%[-[=KGLO[?7P@T>W^
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M0[BJKD8S^%?'_P +?$7Q[T7P#XOMO@_I5[+\-)Y9=TBQ[]L>3D@D\<5]<_\
M!,BY\&+\+?%:::/*\=F*0WZ2G]X6P<X_&O7C)0C6<%:"A=1>Z?<\ZM%SY%)W
MFZEN9;6['DWQ@UCQQ^W=^U;J/PTTS7)O#_AW27=#+$QQ\O<@=:L?!+Q!XW_8
M?_:JL/ACK?B2;6O"NH.%624D@DX (STYJ;_@G<TLG[9WC=I\^=YLV[/7O5C_
M (*%;H_VR/A\T('F?:(^G7[XK#")8>>!IQVK+WO.]S7%/VRQG-_RZ^'RM8]E
M_P""G/[1WB+P5HOA_P $>$IFMK_Q&0C7$;895;CBOE3XD_LS_$S]C/PCX;^+
M&E^.+K4;NY9);NU+-A P#$'GGK7:_P#!0R2XD_:2^&:S9\H);E0>F>*^G_\
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M^N:=$<1WHN]OF>^,U#X+_:*^.FN>)K"QUGX(/H^F32!9[XW>[RE[MC-3>/\
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MHH^>RFOI>&&.WB6*-0D:C"JHP *X7_A?7P\_Z&[2_P#O]1_POKX>?]#=I?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYG_X*!?"G7/BS^S_K&G: C37L*&46Z]9<#H*^
MF*1E#*01D'M7/7HJO#D;_I&U&JZ,U-'XP_L[_M]1?LP_!W5OAEXG\&W[ZXID
M2': J@L, ,#U_"O4?^"77PE\4ZM\1/%7Q%U;3)M)TC51(L<3KM#[L]!^-?HK
MJ_P-\ :]J#7^H^$-(O+QCDSS6J,Q/UQ76Z5H]EH=E'::?:Q6=K&,+%"@51]
M*[HU+RG6J*\Y1Y7VL<DH>XJ--V@I<WG<_('Q;JFN_P#!/W]L+6/&NJ:+<:GX
M3U:1V5H!C(;MGIFK'P_O];_;T_;#TKQO:Z#>:?X-TYPX><<+MP>O2OUC\5>
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MK7P1K4$NHZ=:Q".*XG;=.N.C;_6M3_A?7P\_Z&[2_P#O]1_POKX>?]#=I?\
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M_P#T*.G?]^__ *]'_#.GPW_Z%'3O^_?_ ->O1Z* /./^&=/AO_T*.G?]^_\
MZ]'_  SI\-_^A1T[_OW_ /7KT>B@#SC_ (9T^&__ $*.G?\ ?O\ ^O1_PSI\
M-_\ H4=._P"_?_UZ]'HH \X_X9T^&_\ T*.G?]^__KT?\,Z?#?\ Z%'3O^_?
M_P!>O1Z* /./^&=?AO\ ]"CIW_?O_P"O1_PSI\-_^A1T[_OW_P#7KT.XG6UM
MY)I#A(U+L?8#)KX&^*O_  4X/AWQQ?Z9X3T&'5]*M6\HW4S%6,@.&&/3-?0Y
M-D&89_5E2R^GS.*N^B7S9R8C%4<*E*J[7/K;_AG7X;_]"CIW_?O_ .O1_P ,
MZ?#?_H4=._[]_P#UZ^'/^'J/B7_H3K3_ +^FC_AZCXE_Z$ZT_P"_IKZ__B&W
M$G_/A?\ @2_S/._MG!_S'W'_ ,,Z_#?_ *%'3_\ OW_]>O@']J+_ ()RZ_\
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MNH2/]7+CE:]1K\ZQ6%K8*O/#XB/+.+LT>S"<:D5.+NF%%%%<I84444 %%%%
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M_P"^31_PS3\-_P#H5[/_ +Y->O\ V?G'_00OZ^1\?_K)P1_T*W]__!/D5O\
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M (9T^&__ $*.G?\ ?O\ ^O7H]% 'G'_#.GPW_P"A1T[_ +]__7H_X9T^&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN!XVN1_VQ%?H'2UY'_$0N)/^@I_='_(Z?[)P?\AY_P#!3X+Z#\#?!=OX?T&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[O#T04445X!UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^=O_!03_DJ.F?]>?\ 6OL[]GW_ )([X7_Z\TKXQ_X*"?\ )4=,_P"O
M/^M?9W[/O_)'?"__ %YI7Q.5_P#(VQ)^Y\4_\D9E/J_R/1****^V/PP****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_%?_@LS_P G#Z#_ -@@?^A5^U%?BO\ \%F?^3A]!_[!
M _\ 0J /HO\ X(J_\D?\9?\ 847_ - K]':_.+_@BK_R1_QE_P!A1?\ T"OT
M=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ,_:^_Y.*\<?\
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M%9/Z5^W?[ ?_ ":/\.O^O ?^A&OQ$_;._P"3HOB-_P!A63^E?MW^P'_R:/\
M#K_KP'_H1H ^A**** "BBB@ HHHH **** "BBB@ HHHH **** *VI?\ (/N?
M^N;?R-?E/\#_ /DZW3?^PQ+_ .A-7ZL:E_R#[G_KFW\C7Y3_  /_ .3K=-_[
M#$O_ *$U?(9Y_'P_K_D?!\2?[QA?\7ZH_6!?NBEI%^Z*6OKS[P**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BDKF_'GQ%\/?#/0+C6?$FIPZ9I\"[GDF8#\A
MWJ9245>3*C%R=DCI:*\'^''[<'P<^*WB!-$\.>+K>[U%^%B<;,_0FO;-4U>S
MT73YKZ]N([>TA7>\KL H'KFKE[D>:6B(3YI<JW+E%?/6G_M[_!'5/%R^&K?Q
MG;-JK2^2(R,+N]-W2O?[6ZAOK>.>"19HG&Y70Y!'KFBS<5/HP;2ERO<FK\5_
M^"S/_)P^@_\ 8('_ *%7[45^*_\ P69_Y.'T#_L$#_T*D,^B_P#@BK_R1_QE
M_P!A1?\ T"OT=K\XO^"*O_)'_&7_ &%%_P#0*_1V@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_$S]K[_DXKQQ_P!?)K]LZ_$S]K[_ ).*\<?]
M?)K]V\(_^1M7_P 'ZGRW$'\"'J?IU^P__P FU^$?^N!_F:]YKP;]A_\ Y-K\
M(_\ 7 _S->\U^49__P C;%?XY?FSWL)_N\/1!1117@'6%%%% !1110 4444
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MQQP3@<U51QQ&'A&+]U5$I)]]]/)DT8NGB>:2U=.3B_1=?,U?%7_!/_P;X?\
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MCCI.-)/3N>ME^<4,RDXT4].Z.QHHHKUSW0HHHH **** "BBB@ HHHH ****
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M7G/_  T1\._^AIL?^^Z/^&A_AW_T--C_ -]T?7,-_P _%]Z#^Q\Q_P"@>?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 )7YW?M]?LC^,;SQUIOQ=^&8:37=-P\MI$,O(0<\#O
MTK]$J*RE!N<:D7:4=F:QGRJ4)*\9:-'XUZIX1_:/_;K\8^'='\=>'I?#FC:8
MR^9++;F%& (R3ZG%?;G[3/[&%M\1?V:;#P5HAVZGH<"FQD;NZCG\Z^MZ6M*J
MC4H^QBK:\U_/N94W*%95F[V5DO+JC\5Q-^U/XI^'\/P(N?"EQ'H7F?96U.2V
M(^0'J7]*_1S]F[]D7PY\,?@KHWA'Q-I%AK]Q;DS2&ZA$BK(W7&:^BZ6MU5:C
M)?:E\3[V,I4TY1_ECLNBN>=?\,Z?##_H1-"_\ D_PK\A/^"N7@W0/!/QXT*R
M\/:/::-:MI0=XK.,(K-NZD#O7[@5^*__  69_P"3A]!_[! _]"K$U/HO_@BK
M_P D?\9?]A1?_0*_1VOSB_X(J_\ )'_&7_847_T"OT=H **** "BBB@ HHHH
M **** "DI:* ,'7/ GA[Q-=)<ZKH]GJ$ZKM62XA5R!Z<BL[_ (5#X+_Z%G3/
M_ 9?\*Z^BL71IR=W%?<82P]&3O*";]#D/^%0^"_^A9TS_P !E_PH_P"%0^"_
M^A9TS_P&7_"NOHI>PI?R+[B?JM#^1?<C\H_VM='L=%_:(OK'3[2*SLUDA @A
M4*O)&>!7Z+>$/A1X-N?"NDROX:TUF>UC))MU)/RCOBOST_;(_P"3E]0_ZZ0?
MS%?IKX(_Y$_1O^O2/_T$5\GE-.$L7B$XK<^'R.C3ECL4I132?;S,S_A4/@O_
M *%G3/\ P&7_  H_X5#X+_Z%G3/_  &7_"NOHKZSV%+^1?<?<?5:'\B^Y'*6
M_P *?!]I<1SP^'--BFC8,DBVZ@J1W'%=4%"]!BEHK2,(P^%6-84X4_@BD%%%
M%6:!1110 4444 %%%% !1110 45RWQ0\4W'@GX>Z_KMI$LUSI]H\\<;]&8=C
M7YR1_P#!4;X@LI)\.:;U(^\?6OL,CX4S3B*G.I@()J#L[M(\[%8^C@VE5>Y^
MHE%?E[_P]$^('_0N:;_WT:/^'HGQ _Z%S3?^^C7T_P#Q#'B/_GU'_P "1Q?V
MW@_YC]0J*_+W_AZ)\0/^A<TW_OHT?\/1/B!_T+FF_P#?1H_XACQ'_P ^H_\
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M5HVMR3NR<<U]85^?9KE>)R;%RP6+5IQWL[[GK4*\,1!5*>S"BBBO).@****
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M_P G#Z#_ -@@?^A5^U%?BO\ \%F?^3A]!_[! _\ 0J /HO\ X(J_\D?\9?\
M847_ - K]':_.+_@BK_R1_QE_P!A1?\ T"OT=H **** "BBB@ HHHH ****
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MV[_8#_Y-'^'7_7@/_0C7XB?MG?\ )T7Q&_["LG]*_;O]@/\ Y-'^'7_7@/\
MT(T ?0E%%% !1110 4444 %%%% !1110 4444 %%%% %;4O^0?<_]<V_D:_*
M?X'_ /)UNF_]AB7_ -":OU8U+_D'W/\ US;^1K\I_@?_ ,G6Z;_V&)?_ $)J
M^0SS^/A_7_(^#XD_WC"_XOU1^L"_=%+2+]T4M?7GW@4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!S?Q \?:5\-?#-SKNLR-%86^-[*
MN3S[5XZO[<WPR8 B_GP>G[DUZ;\9OAG'\7/ =[X;ENFLDN2,S*,E<5\SQ_\
M!.6P1 O_  E$_ Q_JZ^>S"IF<*B6#@G'S_X<_2.',+PK6PLI9W6G"I?11O:W
MW,],_P"&Y/AG_P _]Q_WY-'_  W)\,_^?^X_[\FO-/\ AW/8_P#0T3_]^Z/^
M'<]C_P!#1/\ ]^Z\KV^??\^X_A_F?5_4/#S_ *"JGW/_ .1/2O\ AN3X9_\
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MGZ-_UZ1_^@BOS)_;(_Y.7U#_ *Z0?S%?IMX(_P"1/T;_ *](_P#T$5\AD_\
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M.Z%HHHKR#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X_XO?\
M),_$G_7C)_*O@K]A'_DMTO\ U[2?S-?>OQ>_Y)GXD_Z\9/Y5\%?L(_\ );I?
M^O:3^9KXK-O^1IA?ZZG[EP?_ ,DIG'I^A^DM%%%?:GX:%%%% !1110 4444
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MY(_XR_["B_\ H%?H[7YQ?\$5?^2/^,O^PHO_ *!7Z.T %%%% !1110 4444
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MS?\ )4==_P"O+^M>IEF:8ROBX4ZD[IL]G)\ZQ^)QU.E4J-IL_1>BBBOT\_9
MHHHH **** //?V@O^2*^,O\ L&R_RK\-+?[A_P!X_P Z_<O]H+_DBOC+_L&R
M_P J_#2W^X?]X_SK^HO!_P#W/%_XE^1\+Q%\</0EHHHK^@SXX**** "BBB@
MHHHH **** "BBB@ HHHH **** /NS_@E/_R,7CC_ *Y1_P#H0K]'*_./_@E/
M_P C%XX_ZY1_^A"OT<K^)O$;_DI,1_V[^2/U#)O]SB%%%%?F9[84444 %>5_
MM/?\D1\3_P#7JU>J5Y7^T]_R1'Q/_P!>K5Q8[_=:GH_R/;R/_D:8;_''\T?E
M;:?\>Z?2IJAM/^/=/I4U?SQ+<_T0"BBBD 4444 %%%% !1110 4444 %%%%
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M/_0I0?\ ?XT?\/*-9_Z%*#_O\:/[>P'\_P"##_6;+/\ GY^#/O74O^0?<_\
M7-OY&ORG^!__ "=;IO\ V&)?_0FKV";_ (*1ZS-"\?\ PB5N-RD9\X]Z^9_!
MGQ&G\&_%"W\:16J3SPW;78MF.%)8DX_6OG,TS/#8FK1E3E=1>OX'R>=9Q@\7
M6P\Z4KJ+UT]#]F!]T4M? /\ P\GUG_H4H/\ O\:/^'E&L_\ 0I0?]_C7T?\
M;V _G_!GUG^LV6?\_/P9]_45\ _\/*-9_P"A2@_[_&C_ (>4:S_T*4'_ '^-
M']O8#^?\&'^LV6?\_/P9]_45\ _\/*-9_P"A2@_[_&C_ (>4:S_T*4'_ '^-
M']O8#^?\&'^LV6?\_/P9]_45\ _\/*-9_P"A2@_[_&D/_!2G65Y_X1*#_O\
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M=U/1I[OP7;!1(SV^2T8ZDMUZ5PT>6K.27NM-*_J=U3GIPA+XE*^GH=OX??\
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M .@FNG#?QX>J_,SJ? _0_)C]AO\ Y.RT_P#Z[W'\S7["U^/7[#?_ "=EI_\
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MYU\75^09Y_O\_P"NA^#<2?\ (SJ?+\@HHHKP3Y@**** "BBB@ HHHH ****
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M4O5'RG%?_(BQG^"1^FU%%%?OQ_G^%%%% !1110 4444 %%%% !1110 4444
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M\B3KO_7G+_Z":WJP?'O_ ").N_\ 7E+_ .@FNG#?QX>J_,SJ? _0_)C]AO\
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MXX>A+1117]!GQP444JQO(P6.-Y7/147)/X4-VU8Q**G_ ++U'_H&7G_?AO\
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MCH.?I0(=1358-T/-.H&%%%% !7M7[&O_ "7S2_\ KDU>*U[5^QK_ ,E\TO\
MZY-7KY1_OU+U1\IQ7_R(L9_@D?IM1117[\?Y_A1110 4444 %%%% !1110 4
M444 %%%% !1110 E<?\ $*ST+QEX7U3P[?ZM;VL=["T,G[Y590?QKKV^92*_
M,[]H3]@SXP_$?XIZOKNA>+;JQTZYE+QPK.P"CZ9KGJ>])4W&Z9O322<^:S6Q
MT\W_  2P^#UQ([R>)D9F8L6,ZYY]\TV/_@E=\'8Y$=?$ZAE8$?Z0O^->)?\
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M?SI],D^Z/J/YTX[HJ/Q(_9#X%?\ )'_"?_7A'_*N[KA/@5_R1_PG_P!>$?\
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M9?Y5^&EO]P_[Q_G7[E_M!?\ )%?&7_8-E_E7X:6_W#_O'^=?U%X/_P"YXO\
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MD[H<LHQC>?*[O_(_.M?NBEI%^Z*6OW0^184444"/NS_@E/\ \C%XX_ZY1_\
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MD]79]&^MB'P#X+O?B#XJL]$L 3-.P!([+GK7U?JGPU^#'P7M[;3O$K?;-9=
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_%?\
MX+,_\G#Z#_V"!_Z%7[45^*__  69_P"3A]!_[! _]"H ^B_^"*O_ "1_QE_V
M%%_] K]':_.+_@BK_P D?\9?]A1?_0*_1V@ HHHH **** "OFW]OK_D@MY_U
M\1_SKZ2KYM_;Z_Y(+>?]?$?\Z\W,O]SJ^C/(S?\ W"M_A9^8\?W!]*=38_N#
MZ4ZOQ0_G=A1110(*2EHH 3:!01FEHH&)TZ4M%% A-HI:** $VBEHHH ****
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M-'^'7_7@/_0C0!]"4444 %%%% !1110!\$?\%*?^0YX/_P"N4G\Z^+J^T?\
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MFQUQ0KANAS7VQXBLO@O\"UMM#U73X]2U,J!<2=2/7-<;\</@;X8UKX?Q^/\
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M?$?\Z\W,O]SJ^C/(S?\ W"M_A9^8\?W!]*=38_N#Z4ZOQ0_G=A1110(****
M"BBB@ HHHH **** "BBB@ HHHH *^L?^"<O_ "5+7?\ KR_K7R=7UC_P3E_Y
M*EKO_7E_6O:R;_?J?J?0\/\ _(RI>I^B]%%%?L9^_A1110 4444 >>_M!?\
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M!^LOT/LN'=ZATU%%%?S.?;A1110 4444 ?F[^W)_R6X?]>J_SKP&O?OVY/\
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M(>LYWMVCV^84?9RQDIT=H0=WWDEO\CS[Q%_P3WT;PO\ LDK\4+;5-0_X3N&
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MG_'NGTJ:H;3_ (]T^E35_/$MS_1 ****0!1110 4444 %%%% !1110 4444
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M_P#7%?Y5?K^BZ?P(_P XJW\27JPHHHJS(**** "BBB@ HHHH **** "BBB@
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M_!*?_D8O''_7*/\ ]"%?HY7\3>(W_)28C_MW\D?J&3?[G$****_,SVPHHHH
M*\K_ &GO^2(^)_\ KU:O5*\K_:>_Y(CXG_Z]6KBQW^ZU/1_D>WD?_(TPW^./
MYH_*VT_X]T^E35#:?\>Z?2IJ_GB6Y_H@%%%%( HHHH **** "BBB@ HHHH *
M*** "BBB@ KVK]C7_DOFE_\ 7)J\5KVK]C7_ )+YI?\ UR:O7RC_ 'ZEZH^4
MXK_Y$6,_P2/TVHHHK]^/\_PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?BO_ ,%F?^3A]!_[! _]"K]J*_%?_@LS_P G#Z#_ -@@?^A4
M ?1?_!%7_DC_ (R_["B_^@5^CM?G%_P15_Y(_P",O^PHO_H%?H[0 4444 %%
M%% !7S;^WU_R06\_Z^(_YU])5\V_M]?\D%O/^OB/^=>;F7^YU?1GD9O_ +A6
M_P +/S'C^X/I3J;']P?2G5^*'\[L****!!1110 4444 %%%% !1110 4444
M%%%% !7UC_P3E_Y*EKO_ %Y?UKY.KZQ_X)R_\E2UW_KR_K7M9-_OU/U/H>'_
M /D94O4_1>BBBOV,_?PHHHH **** //?V@O^2*^,O^P;+_*OPTM_N'_>/\Z_
M<O\ :"_Y(KXR_P"P;+_*OPTM_N'_ 'C_ #K^HO!__<\7_B7Y'PO$7QP]"6BB
MBOZ#/C@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^[/^"4__ ",7CC_K
ME'_Z$*_1ROSC_P""4_\ R,7CC_KE'_Z$*_1ROXF\1O\ DI,1_P!N_DC]0R;_
M '.(4445^9GMA1110 5Y7^T]_P D1\3_ /7JU>J5Y7^T]_R1'Q/_ ->K5Q8[
M_=:GH_R/;R/_ )&F&_QQ_-'Y6VG_ ![I]*FJ&T_X]T^E35_/$MS_ $0"BBBD
M 4444 %%%% !1110 4444 %%%% !1110 5[5^QK_ ,E\TO\ ZY-7BM>U?L:_
M\E\TO_KDU>OE'^_4O5'RG%?_ "(L9_@D?IM1117[\?Y_A1110 4444 %%%%
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MK^BZ?P(_SBK?Q)>K"BBBK,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_%?_@LS_P G#Z#_ -@@?^A5^U%?
MBO\ \%F?^3A]!_[! _\ 0J /HO\ X(J_\D?\9?\ 847_ - K]':_.+_@BK_R
M1_QE_P!A1?\ T"OT=H **** "BBB@ KYM_;Z_P"2"WG_ %\1_P Z^DJ^;?V^
MO^2"WG_7Q'_.O-S+_<ZOHSR,W_W"M_A9^8\?W!]*=38_N#Z4ZOQ0_G=A1110
M(**** "BBB@ HHHH **** "BBB@ HHHH *^L?^"<O_)4M=_Z\OZU\G5]8_\
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MX?AG_P D]\._]>,/_H(K^<O&'^'@_67Z'VG#N]0Z:BBBOYG/MPHHHH ****
M/S=_;D_Y+</^O5?YUX#7OW[<G_);A_UZK_.O :_!<Z_W^KZG]\\&_P#)/X/_
M  (****\0^R"BBB@ HHHH **** "BBB@ HHHH **** "KF@_\C+HW_7Y%_Z$
M*IU<T'_D9=&_Z_(O_0A6]#^+'U.;%?P*GH_R/V%T'_D"V/\ UQ7^57ZH:#_R
M!;'_ *XK_*K]?T73^!'^<5;^)+U844459D%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XK_ /!9G_DX?0?^
MP0/_ $*OVHK\5_\ @LS_ ,G#Z#_V"!_Z%0!]%_\ !%7_ )(_XR_["B_^@5^C
MM?G%_P $5?\ DC_C+_L*+_Z!7Z.T %%%% !1110 5\V_M]?\D%O/^OB/^=?2
M5?-O[?7_ "06\_Z^(_YUYN9?[G5]&>1F_P#N%;_"S\QX_N#Z4ZFQ_<'TIU?B
MA_.["BBB@04444 %%%% !1110 4444 %%%% !1110 5]8_\ !.7_ )*EKO\
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M )&71O\ K\B_]"%4ZN:#_P C+HW_ %^1?^A"MZ'\6/J<V*_@5/1_D?L+H/\
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M'^[I'_@4*/\ AT'\<?[ND?\ @4* /LW_ (?)_!__ * ^N?\ ?M:/^'R?P?\
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M%"C_ %<P/9_>'^J>6]G]YYC_ ,-#>'O^?6XH_P"&AO#W_/K<5Z=_PZ#^./\
M=TC_ ,"A1_PZ#^./]W2/_ H4?ZN8'L_O#_5/+>S^\\Q_X:&\/?\ /K<5[?\
MLG_MW^!?@?XRU/5=;T[4)H+JW\I/LX!(.<USW_#H/XX_W=(_\"A1_P .@_CC
M_=TC_P "A73A\CPF&J*K33NO,ZL+PY@<'6C6I)\R\S[-_P"'R?P?_P"@1KG_
M '[6C_A\G\'_ /H#ZY_W[6OC+_AT'\<?[ND?^!0H_P"'0?QQ_NZ1_P"!0KWS
MZ@^S?^'R?P?_ .@/KG_?M:/^'R?P?_Z ^N?]^UKXR_X=!_''^[I'_@4*/^'0
M?QQ_NZ1_X%"@#[-_X?)_!_\ Z ^N?]^UH_X?)_!__H#ZY_W[6OC+_AT'\<?[
MND?^!0H_X=!_''^[I'_@4* /J;XH?\%;?A/XR^'OB#1+32-9%U?VCP1F1%"[
MB.,U^;L7Q<TB-<&";J3^M>^?\.@_CC_=TC_P*%'_  Z#^./]W2/_  *%?:9#
MQ9F/#E.=/ M)3=W=7/-Q>7T<:TZO0\&_X6_I'_/":C_A;^D?\\)J]Y_X=!_'
M'^[I'_@4*/\ AT'\<?[ND?\ @4*^I_XBAQ!_-'_P$\_^P<'V?WG@W_"W](_Y
MX34?\+?TC_GA-7O/_#H/XX_W=(_\"A1_PZ#^./\ =TC_ ,"A1_Q%#B#^:/\
MX"/^PL'V?WG@W_"W](_YX34?\+?TC_GA-7O/_#H/XX_W=(_\"A1_PZ#^./\
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M\-->&O\ GTN_TKN/^'0?QQ_NZ1_X%"C_ (=!_''^[I'_ (%"C_5;+NS^\/\
MB*7$'\T?_ ?^"</_ ,-->&O^?2[_ $H_X::\-?\ /I=_I7<?\.@_CC_=TC_P
M*%'_  Z#^./]W2/_  *%'^JV7=G]XO\ B*7$'\T?_ ?^"<1_PTUX:_Y];O\
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M)L?L=>//V6]0\7S>,?L8CU2.)8!:RASE3SF@#[MHHHH **** "BBB@ HHHH
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M!_\ /M'Y6?\ "XM6_P"></\ WS1_PN+5O^></_?-?JG_ ,.6?AS_ -#;K/\
MWRM'_#EGX<_]#;K/_?*T?ZZ\0?\ 07(/[,P?_/M'Y6?\+BU;_GG#_P!\T?\
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MGO$?_/O:_P#?%?I;_P .6?AS_P!#;K/_ 'RM'_#EGX<_]#;K/_?*T?V+E_\
MSY0?ZZ\0?]!<OP/S2_X:>\1_\^]K_P!\4?\ #3WB/_GWM?\ OBOTM_X<L_#G
M_H;=9_[Y6C_ARS\.?^AMUG_OE:/[%R__ )\H/]=>(/\ H+E^'^1^:7_#3WB/
M_GWM?^^*EL_VIO$MC?6UTEO:F2WE6504XR#D5^E'_#EGX<_]#;K/_?*T?\.6
M?AS_ -#;K/\ WRM-9-E\7=4D3+C3/Y)Q>+E9^G^1\T6O_!9#XMVMO%"ND:&5
MC4*,PGL*E_X?+_%W_H#Z'_WX-?27_#EGX<_]#;K/_?*T?\.6?AS_ -#;K/\
MWRM>RM-#XMMR=V?-O_#Y?XN_] ?0_P#OP:/^'R_Q=_Z ^A_]^#7TE_PY9^'/
M_0VZS_WRM'_#EGX<_P#0VZS_ -\K3$?-O_#Y?XN_] ?0_P#OP:/^'R_Q=_Z
M^A_]^#7TE_PY9^'/_0VZS_WRM'_#EGX<_P#0VZS_ -\K0!\V_P##Y?XN_P#0
M'T/_ +\&I[#_ (+(?%RZOK:$Z-H9$DBH0(2.I KZ+_X<L_#G_H;=9_[Y6I+?
M_@B_\.K>XBE'BS6&,;!L;5YP<T ??OA'59==\*Z-J4ZJL]Y9PW#JO0,Z!B!^
M)K6JAH.DQZ!H>GZ9$Q>*RMX[=&;J0BA03^57Z "BBB@ HHHH **** "BBB@
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M]\)/%UIXF\+^$H--UFUSY-RC$E<C!KW:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /@;_ (+),%_9NT@$@$ZN@'O\M?%W
M_!(5E7]JZ)2<$Z9/@>O%?LA\7O@GX0^.GAV+0_&FDQZQID4HF6&0D .._%<=
M\)_V.?A/\$?% \1>#_"\.DZL(FA^T1L2=IZCF@#VNBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%)1D>M "TE%<A\5/BCH?PA\'7WB/7[E;:RM4+G<<%CZ"HG.--<TGH5&
M+F^6*U.PHK\U/$'_  56\2^:^O:1\.;^7P9"^&OF0X=<]<XK[0_9O_:0\-_M
M)>!X?$&@R;'X$]JQ^>)O0UM&$IQ<DMM_(SG)0DHM[GK=%%%04%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C,%!).!ZF
M@!:0D+R3@5E:EXAM[/1[^_MF6^%HC.T<#!B2!G''>OS.\=_MO?%+]I3XH77P
MR^%EE_PC,Z.T4\UU]\ '!-9\SE45&"O+>WEW-.5*#JS=HKJ?J"MY [;5FC9O
M[H8$U-7Y&?$O]GG]I_\ 9OTP>/K?QW+XG-N?.N+2)F8(.IR*^U?V&/VM(?VF
M/A_NO]L/B33P([V(<9/KBNBG%58R<'=QW1SU).FX\R]V6S/IZBBBLS0****
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M^C74@076S!Y.-P;TJ_\ \%$OAJ=+O/"W[07P^?\ =*T<UU-;?Q X.>*^D_\
M@I-\%]*^)?P%U/4988TU32U\^"YQ\R@<XS7FG[ ,I_: _9%U7P5XAC^V6]JC
M6L32<]N#1&4ZU.=2*M5H-._>+')1HS@I:TZUXM=GW/IW]F/XV:?\??@GI?B
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M7-)LN$>6*CV%HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_*2&%*G^^FZ<-_ZT'4_=P]I+8^QOCA^TOX,^ NFB?7[MIKMQ^[L;4;YW_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "DKP']J[]K/2_V7=(TR[O\
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MFFJBQJ%50JCH .*=4RM?38<;I:[A1114E!1110 4444 %%%% !1110 4444
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M9^,'QXN_A;\'Y5TS^SP?M-TXR6(K/^ ?[:OQ)^#?QF7X8_'-2SW,@CM;]AM
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>eigr-20221231_g19.jpg
<TEXT>
begin 644 eigr-20221231_g19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !> < # 2(  A$! Q$!_\0
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M I^VOV2O^"5?AOX.ZU;^*_B1>6?C;Q-'&K6^EQ0?\2NQE!!WC>-T[KC"NP4
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M;]J:XUVXLVFA\-Z-/<)*3@074C+%&".O,9G'3M[C(!^VF-W'WCGVS_D57O\
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M*:-2Z%",MLV*5(=W))!SG.?:/^"KWQA7X1_LSVG@S27:VO?%DRZ;'Y:_<LX
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M2?[97_!.#QE^SS'=>(_##3>,O B.\CWT<2B^TV+J!=(@^=0@R9AQ\K$K'_$
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MH Y?P#\.O#GPST2#1?"V@6'A[2X551;Z? L:MA0 6QRQP,98D\=:Z?'-+10
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MR[K7[,?PAO;/Q,(U\1ZW>+>W,$,WFI JQJJINQUY;(Y'/6@#ZPHHHH ****
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6>W%"KM__ %YIU% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>eigr-20221231_g2.jpg
<TEXT>
begin 644 eigr-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'J U # 2(  A$! Q$!_\0
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M\4?%;X8_$:U&L?$+X<VKZG$VB6R)+XDT\1>9%/%;K(P6=U,1:,$*'G0#'(4
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M,/"7C*&R;3X_$&E6^J+9F3S&A66-7V;L#=C=C.!GTKX5TG_@I)92Z???#/\
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M$SJ54XY^; XZU\O? ?\ ;B^(/[1VDZSJ/@WX(0S0:/>G3[P7GB^*!HY@H8@
MVW(P1R._YU]?,PFV$K\N00><^W\OY5^6O_!.?XX'X5^$/BQ;?\*\\>>-UD\5
MSW/F>%-&6^6,A%&UMTBXDXSM SC'7L ?7/PM_:V\5^+/VB)/A'XS^$EW\/\
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MC"#;*-K!EVGYNF:]Z_:"^+'BKX0>"7\2>&O :^.[:S$L^IQ#6X=.-I;HA8S
MRJ1(.#E1@^F:^4O^"B&CS?!+XS?!S]H7381'#H^I)I.O3"/]W]F=CM>781)(
M=K2 #D#8OT/T%^T9>V_Q+TGP3\-]/3[;9^/+Q)KV9T1D72;<)<7#$2,.6!A7
M&ULAVR* .-U_]I;XV:S^S#<?$;PO\$)K'Q3-/;MIWAN]O&OYY[*0C=<-#$L4
M@/I'][!W'C(KZ;\/ZA=WFB:?<W\'V:]FMHI)[<G BD* L@SSP21SZ=:^8?\
M@H1XO^)OP=^!<OC+X7^*K'PO!HICBN;!M'@N&DB9@H,3R[E0*,#:(SD=QBM+
M]J[QY\1_"?[(;_$#P3XPA\-ZYI6D6^I7DTVE0W9O Z1AE7?\D1W.6SL8=L"@
M#Z>$O3*D'N#36N=JDE2N!GYN*^0_">J?M0^(?'7P=\227.AS_#K6+-7\2Z-8
M6\"RV2-'N2:2:1@\SMD']PL8!.WRR!NJUHNL_'+XLV_Q;O\ 4-1U;X'S>&KJ
M:T\/0Q:;8RVVH1)$76YN9;J"43+G W0/&@'8D&@#Z0\?1^*+_P +W'_"%7VC
MV/B!!YEN^MV,EY;L0I.QDCGA92QP ^X[>NUNE>6_L5_&WQ3\?O@R_B;QE9Z5
M8:_#J][IL\.BQR);?N)-F5$CNQ)YYW<^@I/V*/CMK'[1?P"TKQ7K]M9V^M)<
MW&G7<FGR;[>YD@;89TX^4/UV@D>AQTXK_@FG_P F^:N>_P#PEVM?^E)H ^A/
MBAXD\3^$_!]WJ?A#PD/&^MPLOEZ+_:4=@TZY^;;+(I4,!R V,^M>!_LE_MH^
M(/VIO$NO6D?PMD\+:)H,KV>I:I<:]'</#=CI (!$K-G#9;.!CO7U)+_!QD;A
M7Y=?\$]?C#=_#*[^-UI;?#?QQXY%UXOFD:X\*V5O/'!@N-DAEN(B&/7@$8[T
M ?27[3G[;GC#]F?Q5I]EJ/P;;6= UB^73]%UJ#Q/!&+Z8@'88?*+Q')Q\WR^
M]?2W@G7-9USPOI][XBT)/#6MS1AKK24ODO!:R'_EF9D 5S[@8K\UO^"B'QEO
M?B9<?!2UNOAMXW\$+:^+H95N/%=C;6\4^2@V1F*XD)8=3D#CO7V=^V-^T<_[
M-_PWLK_3+>QO_%NO:A#I&B6>I&06[SR, 7DV?,40'<0"I/0&@#W;[1C *X)!
M/+#M1]I!; 7/&<Y&*^//CMX^^*7[(O@?PS\1?$'Q"'C[38M1M[+Q1HM]IUI:
MVJ+.VWS+%K>V69/+/3S7DRHY!)KF/VAOCS\7O"/[5GP9T#P7XUTNY\&^/7$U
MOIMWH\:HL>%QYLQ#2LK!@XV>4W\)]0 ?=:W"L,@$_3G/O]*'N%C7<2,=!R.3
MZ"OA_P"*GQ.^./['7BCP]XP\>>.[+XK_  NUB_73]6CC\.P:7/H1D?\ =R0^
M7(=R\[?WLAX&#D_-7K_QD\=?$G5_BK\./!W@*UU"R\'^(89+[6?'&DV45PUA
M$@!1$DG1K=#(&!&]'8C[J$\T ?02S%NJ%?KTKD;7XO>%+SXH7OP[BU,MXRL[
M!-4GTW[/*-ML[%5?S-OEG)'0-GVKY]^$_P 8O&FC_M7>./@?XB\:1>+K>+15
MUC0];NM.@CO[=GX,$_V<1Q2!!\W^K4G(!->)Z)X!^,#_ /!03Q3I,/Q>TN+Q
M2/!UK+-KY\'QM%+;^80L(M?M("L#SOW\^@H ^F?VE/C%\6OA[XV^'.G_  X^
M&"^.]&U;4/)UK4/,(^QQYQLR.(,C+>=)E/EVXR0:],^(OQH\'_"*;P_'XLU?
M^RW\07XTS3/]&FF^T7)!(3]TC;>!U; ]Z^:/VP/B+\7/@KXV^#D^D_$.W&A^
M(-:M-$U#3(] MP\L@3,LWG2F0JKD<(J@KG[YKS__ (*5^&O'$?C;X/W<7C6S
M31[OQA!#I.FMH:L^G7'E']\\OG?OQ_L%5^M 'V1^T1XT\7> ?@UXH\0> _#G
M_"5^*K&U,MEI)BDE\Y\X_P!4F'DP,G8I!;& :T_@[XE\1^*_AGX=UGQAX=_X
M1/Q/>V<<FH:,)!(+64C[H;W&&VG)7=M))!KQ']H9OC1\)/V7?%7B*V^+&GW/
MBS0(Y]4DU:+PI%&+BW5!MMUA>>1(VSSYAW^FVN*@_:P\7>#_ /@G?X6^+FKW
M%KK7C'58H+6;4;Z)(H(Y)KIX1</%$%5A&N&V+MW;>HY- 'VL)?E8D$;?0$_I
MBE5]W;'&:^6;?3OBK<ZA\,_$O@'XTGXI^"+K5+:'Q']HL=**S6Y8"2:UFM8(
M]JJ0=T;%G Z,2,'ZDC<LQ!["@"6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#-\0^(M+\)Z1<ZMK6I6>D:7:IYEQ?:A<)!!"O=G=R%4>Y-?G#_P $
M\_C!X(TW]K;]I^TN/%>CQ2^+O%:W&@-)>QJFJI]MU#!MGSME)^T0D*IW,'R
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MI3U; YS_ ()$^.O"^K?L]7G@S^V[!O$D.K7T\^AM<A+W[,WE_O1%D.4RZKO
MQDE<Y&*^_/L_]YLX.1]?6A+?83\[8)SC)[?RZ=OZG(!\(?L)^.-*_9?\"^*?
MA/\ %[Q+H?@77]!UVXGT\:Q?"QM]0TZ8[H[JUEFV+<(THG&4R0% 8*2*YOX7
MZQ<^)OC?^TS^UCX9L)_^$;T_PU<:;X8O-0C*V6L26=H#--C<LAB$EC" 1C(D
M9<[D;;^A=YHUKJ*1+=PQW8C=94\^-7VNIR'&1PP/0CIGBK'V<*H"'9M/RX'
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M@BD:4+\N<G\:2!:[$ZMGJ,4;JBW$<=!2(RR<@'\_\*+VW%<FW4;JB9]H/?\
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M;:SILVFR7&K--$+@ %E,: ,.>F0:X#2/@=XIUSX&:KI#6\FDZPFL2:C;0W(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD,%!YX&,GU-(UN6_C Y].U5?[23U_6C^TD]?UI-)BL6UMR."^5].O\Z1K?+
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MD_[Z7_&O0-OO1M]Z //_ +'KO_/A)_WTO^-'V/7?^?"3_OI?\:] V^]&WWH
M\_\ L>N_\^$G_?2_XT?8]=_Y\)/^^E_QKT#;[T;?>@#S_P"QZ[_SX2?]]+_C
M1]CUW_GPD_[Z7_&O0-OO1M]Z //_ +'KO_/A)_WTO^-'V/7?^?"3_OI?\:]
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M7_&O0-OO1M]Z //_ +'KO_/A)_WTO^-'V/7?^?"3_OI?\:] V^]&WWH \_\
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MC_PF%\/>/_T!:[#3&S&*XW5#_P 5E?#WC_\ 0%KL=+_U8H TJ6DI: "BBB@
MHHHH **** $JO<=ZL57N.] '"^*O]4_XUV/AO_D7M,_Z]H__ $$5QWBK_5/^
M-=CX;_Y%[3/^O:/_ -!% &E1110 4444 %%%% !1110 4444 %%%% !1110
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MIS7GWPR^$P^'OBSXA:X=4&H-XMU9=4\H6_E_90L*1!,[VWGY,[L+UZ=Z]$%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<5>Y[4,2Y)7/)+JU=!\P/N:Q;BXCMBY)P5&>M=SXLA6U@? YKR?7;PS7$44
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M.#6'8_LI^&M/\.FQFU?6=3U.YU^W\2:CKE[+&UWJ%Y"<IYNU%0)CY0B*H
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M7)7)'- 'L_PF^$^F_"70[NQLKV]U:]OKN2_U'5M29'NKZYD.6DD9%5>P 55
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M-_\ (O:9_P!>T?\ Z"*X[Q5_JG_&NQ\-_P#(O:9_U[1_^@B@#2HHHH ****
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MO%7^J?\ &NQ\-_\ (O:9_P!>T?\ Z"* -*BBB@ HHHH **** "BBB@ HHHH
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M_(O:9_U[1_\ H(KCO%7^J?\ &NQ\-_\ (O:9_P!>T?\ Z"* -*BBB@ HHHH
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M*** "BBB@ HHHH *2EI* /.]4_Y'2_\ K'_Z M=EI?\ JQ7&ZI_R.E_]8_\
MT!:[+2_]6* -*EI*6@ HHHH **** "BBB@!*KW'>K%5[CO0!POBK_5/^-=CX
M;_Y%[3/^O:/_ -!%<=XJ_P!4_P"-=CX;_P"1>TS_ *]H_P#T$4 :5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 GXT4M% "4M%% !1110 4444 %
M%%% !24M% #=OX5EZGX7TW5N;FU1F_OJ-K?F*UJ* //]2^&)3+V%UGTBF_\
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M=4_Y'2_^L?\ Z M=EI?^K% &E2TE+0 4444 %%%% !1110 E5[CO5BJ]QWH
MX7Q5_JG_ !KL?#?_ "+VF?\ 7M'_ .@BN.\5?ZI_QKL?#?\ R+VF?]>T?_H(
MH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *SM7AW6K\UHU!>)YENPH ^;/BU8';,1USZ5\-
M^-Y3X8^*238\N*Y4-GU[']:_1'XG:69K>9@.WI7P7^TEX>>WM[?58DP;24+(
MWHK?_7R:\K-*'ML.WV/5RRK[/$<KZG-ZUXRCMS(9KA855&?S&. N.^>U><>$
M/B!#\4_B!':B9/#^FVD+W#7$D7G37>S[QPQVJ._'.#7)_%+Q<+C2]/TB M',
MR>;>2@X.T_=3ITQR?7I7<?!/]G^+48;37=;M]P<"2TLNBXZK(_J<=N,>]>!@
M,#&<;R6I]+CG["BVI:O8WM*\:2:MKM[IQ2SALF(6*>%'7;SU(9CDD>F*B\5>
M"[5)C$US/=QR?-M$!BC^F[)W?D*]R\-_!S3;6Y,]IHUK!*Q)#)%@C/)Q^->N
M>&_A/]M6-9[594Q@B10<U[='*Z5.?/8^/^NXE.W-H?(?ANUU;1].FL=-N[FQ
MLKA=DL-NY5''X5:M_ ERZX$3$?[H%?==M^S'H5^@D6VDLIC_ !PGY?Q%17G[
M,]_IZEK18=0C]4^5_P 17MPITXWLMSGG4E/=GQYHWPWF=E4Q-C^5>M>$?AJD
M01GBP1[5ZHGP_.DR;+BV:"4<;9%(K9M-)CME"JOS=>E=D::Z&$I,Q=*\*0VJ
MK^[ _"MN/3XX1C8OY5<4 =#39,YSFNA1Y3*[>Y4DC Z#%5I.]6Y.]5).]#"R
M*DG6JLM6I.M59:AE&)XE_P"0'>_]<S7,^#V"6=WGH74]<=C72^)CC1+W_KD:
MXS0[P6NGW9)Q\X'Z&OBL9_R/:"_N/\S]%R]?\8QBO\:_(V;SQ))HUPMQ;7$E
MM/'RLT#F-U^C#D5;L?VN-9T]H[+4X6UD,=J26R@7/IR ,.?K@^]>,>,/$DES
M=?9H&9Y9'"H%..>V:]%^'W@ZR\.6Z3W=HUSJLR[GF?("L1GY:]+,L=' PYK7
MD]D?,9;EE3,'H^6"W9Z3J?CN_P!29<I-:%U$A6XPK("/XADXK ?4+NY8L9V*
MYY*'G^?7VJ6W>'[0S2B(V[#]ZT@+-GVYJ/[5;0S2RPAG4J5#[.<=B0>OZ5\/
M+,\1B):Z'Z70RO!82*25_,EATC^T+=93,ZLQXCG8*W7H1GBJM_IFE*Q2X6U5
MU(#?>8CWZ\_A56T\23Z2KE!/&9/E R,'_:.!FL#Q=XHN85@NH;Y;2:%2TH62
M5XY%'7&,X;KQQTZ]J[*.(JM^_(F>&I7]V*-J:UO=$D8Z7K0N;<N"5DD#%<]
M "3CVZ^U:%C\0UMYKNU?5EU*_MW"-#9K\R@C(W$,P['CJ.^.E?/_ (D^(E_#
M'#HN@W%U)J^K1AWOF))@@.<-&"."W.6Z@?7CO_AMH<7A'3XH;6)+O4)%!FD*
M8,C$98DCOTZ\\<YS7;]<J+2+T*>4X><>:K'4]RTS6M<NAN >&%@"AFR"V?;%
M2:IXHUG1X3).C/&O4QL&_2N,_P"$X6S9RKI!.%QY,D;#&/X2^\_RZUFW7B[6
M-:A2>'3IF@C/[X28 A/;> ,D$>]#Q]>*T9Y<\CPS?,HZ?,[BU^(%_>1HP=86
M<95)V*L?R!JG)\6KFSDQ(LK+E1OB4L#GJ>G;%9.@>(K34+4K"L;R-C:JNNT$
M\9Y.X#KQBL?5/$MI'-*C$P,8?)CDA+A 0>I96&TGW!K98[$6N<\<IP7-RRC^
M9Z'I?QG#1&9WECC"@Y92.._.,#'O77Z%\8K6^8".[CD]0LJDCT)P37RKJ;2V
M%X;BTBCC60%A$ &\SGD>YS[_ (5RVI>(-:13*(Y@8Y=S",LICX./DSM'UKHI
MYC+[:+EPS1K7Y*G+V/T8T+QQ%?A0).#QDUXA^UK<K=:KX;=>?]&G_P#0DKR?
MX1?%+5VU".QU(O,<X2Y"\C&#M;\/\\&NR^/.J'5/^$?ESG;!,/U2N3/:JK97
M.:5M5^A'#N!J8'B"G1J;I-_>CZV\ _\ (C>'?^P;;?\ HI:WZP/ '_(C>'O^
MP=;C_P A+6_7TU'^''T1\%B/XT_5_F%%%%;'.%%%-=P@Y_"@#Q/]M;'_  RQ
M\1\G:O\ 94A)P#@<9Z\5Y%\7/A7\4[']FGQ3?WOQNO-2TN+PM/+-IA\-:?&)
MHOLQ)B\U5W*",C<.1UKZ$^)WC_X71V]YX2\?>*/"UA'>VX,^DZYJL%N\L+D@
M$QR.K;201GVJQI/BWX=?%30-3T#2M>\/>+-)^Q_9[RQTV_ANHUMV7;M<1L=J
MD9'- 'S;\.;BU\-_%[]GG4O$)2/2]5^&L.D:'<38,=MJ7EVTCQ[F/#RP@HHZ
MMAAUKZ%^(WC[P=X;\9^!/#NM6*ZSXBUO4R-&M8;>.YFM)(XG+WFPG>D:*2K3
M*#MWC. :RDU?X)_%?18?AQ%JW@SQ;8PPB"#P['?6UV\:0K@;(@S,#&JY##E<
M ^]6_A7\'?A=\*?$&IV?@O1M&TGQ#Y"R7:PR"6]2%S\F\EBZQL4X!P"8^^,@
M X7]C.[L+'PSX^\-R1BT\5:9XQU636K:5L3/)-.9(;AD8E@LL+1[6Z':<&O1
MOAAXZ\&>,/''Q M?"VG*NHZ3>P6NLZQ!9QI#?7 BPJB=/]<T2KL;/*'Y?:L+
MXZ?"WX*:^]EKOQ4T_P ,VT[.MI;ZMK%PEC+(<%EA\[>C/P'.S.,;N,9KH_A)
MKGPQ72#HOPUU3PM/IEBO-CX9NK>5(><981$\DD<GG)ZT >B45%!/YRD@<>O;
MJ1CZ\5+0 4444 %%%% !1110 4444 %%%% !24M)0!YWJG_(Z7_UC_\ 0%KL
MM+_U8KC=4_Y'2_\ K'_Z M=EI?\ JQ0!I4M)2T %%%% !1110 4444 )5>X[
MU8JO<=Z .%\5?ZI_QKL?#?\ R+VF?]>T?_H(KCO%7^J?\:['PW_R+VF?]>T?
M_H(H TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *1AN!%+10!PGCC2?M-K+A<\5\C_%_P0FJ6
MU]9SIF&X0QL<=,]#CV.*^X]4L1=6Y7K7DWC'X?KJ3.1$&)]NE2XJ2:?4N,G"
M2DNA^6NB_LSZSJGQ"EO=:EA31H9\HBN6>9%P0"N.,GZ^E?9O@3P!]H\O,) &
M %V]/I7HEK\)3'<;O+./<#(KU'PGX)CT\#]W@G!)(YS40I0I_"CHQ&*GB6G)
M[&'X9^&D,<:,8<?A7H&E>$H;,#]WC'M70V=FL*!=O JV% K4Y"M;V*0J,"K&
MS!S_ $IU% %:\T^WU"$QW$*3H>HD4&N3U;X6Z5=JS6KR6+G[NPY0'Z?_ %Z[
M6DJE)K85DSQG6/AOK&GDM%&+V(?Q1'YC[XKD[J&2U8I-&T+@XVR#!_*OI';Z
M54U#1[+58C'=VL4ZG^^H)_/J*WC7<=&1R+H?-DK8..GUX_2JLG?TKV?6_@_8
M766T^>2S)S^[?YXQ],G(_,UP&M?#77='5V%I]K@'/FVYW#\C@_I71[2,M41R
MLXR3[U5)JN3*R2E&5E<?P$8;\C5.;IP0>W':B]]A&#XH;=HEZ.F8C7E6J:D;
M'3)CG&]OZ5ZEXJ;;H]T/]C%>&?$"\^R6:<X&-Q_"OBL:[9[0;_D?YGZ/EROP
MSBDOYU^0[X7)#>>*+C5KRU%U%:95%D^[N/&_W%>PW6J166FJSWPD,:%FR>$)
MZ ?A_.N(^'>AR>'?"-G+*%A%S:O-*MP#G<22.?[NT9J,ZI::KH,8EEAGNI4\
MPO;\H5#8R1Z <5XV)C]<Q,ZDG=?Y'IY?2>$PE-0T?4W/^$QGFM;6)8T,UT/O
M+T"@]>G)KJM4GVVH2-?-E5%7:#C)(ZUQ&BM%!8M.4C=U##:K#"+R>/>I--\1
M2+9QZBL4D2SH-RRMN=3C@8K*2Y=(H]*;<NH3^'=4O(%1I_+&XLV6P<>E<S?>
M&=.NI+9-7OIQ96ZF81V[NAE '.0O;CG)Q6MK7CJ&QW2SR;2J^9Y?))QQC'N:
MY&/Q:;Y_%'B6YM/.M-/L4MD4,T63*#N QR#M!''K6'+4W+HMN2YBQ\*='T_Q
M1J^HZS<030K"S):><A15C'&$4DDJ, 9SBO1+F]EL;#Y'7;(NX[!PJ@_>)[5R
MGPVE@A\!V#:/N,;+O>/?DIO.['3H <=\XSQTI^O74>LZC+H,EZD#*J,L2$AC
MDY R,=:[(4UU9TRJRE-\VQN7TD:VJQ)$L2R']]-(W 7'5 >6)J4S+9Z*]YI"
M7\MKY)5I;KY$E;!^4<DCIUQ7(Z?X;E\2>)-31-1@ M6#W<3$F1DQ\J)G[H^E
M:EK>-?>'1:Z!J#2/8RJLL<Q'DCD[E+MC!!!'?-*I*,/=B[LGE<E=EWP&[^(/
M#=R=9E72YM[H$BB5)B.S!CR1P#CFK\<?]J/)(&\]G?RVDC=0X# #(4@<EL=>
M/>H;/QA8^-[2?0=3BLX-0LXGPLAP\CHI&T8 .,XQS^E8OPNT9/%7@6_N8YKB
MUU2$?OXVXEB((.W!)Q@C')/KVKGC.HY>_H8*/-NM#H=,T2XN)HXK-0L4)8PG
M+*I4LV> <YSC/4 ]Z["'PW86.CR3:MM2!$,MPVXL,XYQDG)YP,9_I7-?#_3-
M84V-W<1-'?\ VB2&YM6DRK1*CM&4]#DY;'!]*M^+M4?Q9K2V%GDZ;;MM/RX$
ML@ZD^P)Q@<9%>S@Z+J2NSPLTQZPE%QO=O8JZ#)_:VI!K*T6QL]Q\J-%^;:>C
M.?[W7_/-;_QAMFM[;0588/DR_P TKNOAOX &8F>,]>I'KU)K*_:;TT:;>>&X
MP,#[--_Z$E7Q!!1RR:7=?H<'"-:=;.Z4JCNVG^1]0> 1CP/X>_[!]O\ ^BUK
M?K \ _\ (C^'CZZ=;G_R&M;]?24?X<?1'QF(_C3]7^84445L<X4V3.WCKZ4Z
MFR?=H ^-/B%=:G;_ +;GB%M)^&2?$T_\(7IX>TDNK.W%JOVN?$@^TG#>GR\U
MUWBK3;GQA\#?B%HWB'P=I?[/[:I:QV$.I7VIV!@N6ERBB1H&P%WE8R"0S"3
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M\8 ,+]JS3[76/%7P(L[VUAO;.7QU"LEO<QAXW7[%=<,K#!Z'@]P*YO\ :_\
M!NA_#/P7H_Q)\(>'[#2?''A_7=-_L^?3;=;>6\6:X2WDM9!'M:6.2.5P8SP>
M/3-=EXM_9W\5>-/#?AJ#5?BMJ%SXD\.:]_;=AXA_L:R1T(@>(0F!4$14>8S;
MBI/-7=(_9ROM4\4:%KOQ ^(.L_$&?P_=_;M,L;JSM+*QAN,8$[0P1*9)5RVT
MLQ"[LXS0![3'&$8XY[?3IQ[5+357;U.[C&33J "BBB@ HHHH **** "BBB@
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M5^?3I67\$/ <VOZ5XS@\F2-F2%?+V$>9@ECC<1T^E>G>&_A+/N,NIWDU_.^
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MOV<X\NW2XM#@K<$&-<<[B<DX QZ<]LU?T7]HP>0\D\4R/&NYHXV#,!G!R"0
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MY_XGTV1UX0?TI_ZT8'HI/Y"_U"S3I*/W_P# /N9F(Z#]:/,]J^&%^/WCIO\
MF.S''HJD?RIW_"_/'7_0=GQ[*O\ A2EQ3@8[J7W!_J%FJZQ;]?\ @'W-N]J-
MWM7PS_POOQYWURX'U11_2C_A?GCK_H/3?]\K_A3_ -:,%V?W!_J%FO5Q^_\
MX!]S;O:C=[5\,_\ "_?'0_YCT_\ WRO^%"_'[QV<_P#$^F([$*O/Z4EQ1@7W
M^X/]0LU76/W_ / /N;=[4;O:OAG_ (7[X[/_ #'9_P#OE?\ "C_A?GCK_H/3
M?]\K_A1_K1@NB?W#_P!0<UZRC]__  #[FW>U&[VKX9_X7YXZ_P"@]-_WRO\
MA1_POSQU_P!!Z;_OE?\ "G_K1@NS#_4+-/YH_?\ \ ^YMWM1N]J^&?\ A?GC
MK_H/3?\ ?*_X4?\ "_/'7_0>F_[Y7_"C_6C!=F'^H6:?S1^__@'W-O\ :DW'
M.,5\,/\ 'OQR< Z]-G/'RK_A7U#\!?$6H>*/AW;:AJ=RUU>//*&D;T#<"O4P
M&;T<PDXTEMW/ S?AS&9+3C5Q-FGV/2.]+3%^\33Z]P^5"BBB@#A?CE_R23Q3
M_P!>3?S%?/WP%TP:EX4\1+UVW$?;U0U]!?'#_DDOBC_KR;^8KR#]E&S%UX=\
M2@C/^DQ_^@&OD\4KYS1_P/\ ,^]P,N7AO%2_OQ_(\?\ BKX*^V17D,B$12*4
M8@#(SW%?&NM:/<Z'XTCTB\TR\O2S^8&L0?GCR.IVG:#W.3UK]3/'G@07RR$1
MY)]J\7O/A;-]I++$P(RH;'S 'MD=J]W%8.GBE[SU/G<MS2>67:5TSR?0= >Z
MAMX;>)[>$)\T"8$:9.0JC/( [GTKT_PW\+9+E4)B.#7H'@WX7^4R%H<#C"[1
MQ7M?AWP;%:0I^['Y5KA<+3P=/V5/8XL;C*N.K>VJO4\C\/\ PE554/%D>XKN
MM/\ AA;QJ,PC@=ATKT^VTJ*%0-BC\*N"-1T4#Z5U+0X+'G/_  KN'Y3Y7([X
M&?SJ*;X8V-Y \%S:1SP2??BFC61&^JL"#^.:],VBC:/2E8JYX+K'[(_@K6=\
MEM:R:%<$<26+?N_QC;(Q[+MKS7Q-^REXD\/J9=*>WURW'3ROW4V,9Y0G!_X"
M2?:OL7:/I3?+YZG'UJDVMB;(_/34-#O= NC:ZA97%C<CK%<1&-OP#8)_"HH_
MFSSE <;L&OT%U31;'6K4VU_9V]Y;MUCN(ED7\B*\I\6?LS^%]45IM->XT.<C
M :)S)$O.<[6;./8$#VK>,UU(DNQ\JK]S/_ZJD3[M7O$&EIHNM:A8QW4=ZMM,
M8OM$8VK(1W /^<BJ2*=G3_/X5U1L]F8V8Y>H^H_G6?K@SY0[$,#^=:*+NQUS
MGIBL[6_O0Y!'#'GKUKYGBEK^RJGJC[C@O_D=4_1C+O79-)AAGBF,4T0!C<$@
M@COD5O6O[1T_B2U?3=15VU=5^295XG XRV.AKRKQIJPAA=-WRA<D*<]*H?#"
M^DT^/4+[RL^<WDSS[-Q57'R[:]=R2H0]%^1XE.BZ^.GV4G?[ST_6_%4GA[39
M]3U2W2*-HR1(^&/WL#!_A)(QD5\[^(?VF]2&HSFV8BR!*_9H0.H[-(P))S@]
M!74?M#>*+2W^'<Z:8\L\L++"Q;+MY@R6('H&(.<>M?&%YJEXM\L$TWFAF#RR
M+_$3SD<BN!TI<O.?2RQ4:,_8PV/IKPU^TM?PWWEWZ27-G,,2J6'F(N<_*0!D
M  ?E7MMOXXE73X;ZTEC\J= ZS0,679CHH]>#D''2OA#R9]<NO)T]-T[,JJR\
MD?D:^G_A[\(YK?P38Q:M>Y:,/*$DS([%^<''0\]<#&2*N"CO-D^WG=QAJBY\
M6/&EE9F/41?M;S1(Q06JVYCO#CE7B+J-ZJ./E)+$?0^5>*M4U+Q)=V_@K1[9
MM-LKN".[U:9 8WNEP-J$AB %!Y08&[/7!KT2\T/P[I.N37>JV,FLW^CVDEU%
M;*H=(-L1822#.,%UC W #+ 9/0M_9]T:WOM/US7M2T]1=WKR3Q74LD<L[([<
M'S%'1G0]OX>>U=L)1C&R.;E<G=NQWGP[TJ[\/Z1;6^C0M:01A1]HN% C<@$X
MY)QW_,\UT]Q\39;5;AU:>&=5/^D*JO;AAW<!>%SWSQ7+>)-4DTG0Q=_:F>'R
MTEF,A .WDA0.-Q)&,5E^(O$EG'OT^2>UL!'F6[M8")9IU(^[C!"J.IX/ HMS
M.[1U2J^Q2BF==/K'BGQ%8'5HH[1! C"=1/YD@89VR0K_ *MAQD!^#^%:N@_$
MJ#5[=HG(\WY%::>,1A=S!<@8 SN;G:=HW8(-<?<6<I\,Q:OH>DQ:7:31@0[9
MTFEE+,P5BB*%*="HSG&<@5D>!;==)^',R_$B6]M)9?.^SJY:&,Q2?Q1E<D!L
MCCMZ'J,;):B<YW6OJ==KWCK[/=7*2VS2JL/DM/;QH#"%/)* 9(#;>^ <<8S7
M":LMWK$UM>6$A)F4O&UI@\C(V_=Z@AO7J<]16]I,MCKRSR&[CE6.XC62.X9D
MD\F3$8C)WGA6YR/O#(XSFK^B^'_[:U(6ZSQD0@7$!X9Q&Y<8. !N)"C( SM7
MCO5)J'0F7-.5KZ'C&MZ3XMBAGNF@DE9'W2.P^94P<_/C('JHX->S?LT^.O%.
MEZY%I=TT]QH_W<R,6^SMM##!(Y'WEQG@C/ (W>CV?AS3M TT2WJ1O'"F]MJ@
M%FQP#QSDDCW&:@\%Z7=ZA?&5XTAC>5GCMX5VI"I(P@]< #)[DGH, ;.JI1U/
M+QLH4(V>I];_  ]UZ2^MDWYR0"<GIGM7J5LV^,'->1_#/1WM;=-PP?I^5>N6
MJ[8@,5@CY^UB:BBBF 4444 %%%% !24M)0!YWJG_ ".E_P#6/_T!:[+2_P#5
MBN-U3_D=+_ZQ_P#H"UV6E_ZL4 :5+24M !1110 4444 %%%% "57N.]6*KW'
M>@#A?%7^J?\ &NQ\-_\ (O:9_P!>T?\ Z"*X[Q5_JG_&NQ\-_P#(O:9_U[1_
M^@B@#2HHHH **** "BBB@ HHHH 9(NY3@XKQ[]J;CX6R=Q]MA_DU>Q-]TUX[
M^U/_ ,DLD_Z_8?Y-7GYC_N=;_"_R/8R;_D9X;_''\T?'*J-N/?\ I2[10._^
M>PI:_ 3^N4)M%&T4M%/7N,3:*-HI:*->X'5?#?PK9>+-6U""_:Y6WM=.GO?]
M%95=C'M.W+*PP>1T[UK:I\-[?5-'\+7_ (76\FEUKSXQ97S1[D>+DXD4!=I&
M<9 ^[[\9?PU\9Q^!=:U#4'6?S9--GMX&MU#.DK;=C8) P",G.>E6_"/Q*N;?
MXB:7XC\13W.HBU+KA,.=K(1\H)&!D^U?08=X/V-.%;XF[/RU6OW7/B,9#-%C
M*U?#7Y8)-+^9\KTMZV=[]"M9_"W4+S4;J'[=I<%G:[!/J<UXJVL3NNX1%^[]
M,JN<9ZTD?PKUF/6M0TV_:QTIM/CCDNKB\O$6%%?E&# G(;''&?4"K&B^*M%D
M\'ZSX=U?[=;QW6H+J,-U8I&[*P&PJZ%E_A_VC][VY]3\+>(K+QU<>-M933[N
M[M;E;*R6PM4MY[LQQJ5#O#,#&%)YSR1] 379AL#@L0H<DM7TOY-V^5DOF>;C
M<US; JK.HO=BK)\N[;BD[[:IRTZ65SR>'X2Z])K5_IK+:QR6"1S74[W*B&")
MP2KNQZ# .>_2F:9\*]9U32UNTDL89I@SVEC-=*MS>H"<O"G\0P"1TR!Q75>-
M-7@\(ZQ\0]%N+Z?6+C6(;=8[F-4VQR*_F,D@#85ER1A1CY0,#I5[1?CF-/\
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MB.ULM&\N0LH^TWD&"".,(C#@C Y(^E9U(RBRGB*<:6NY3O&D\7:M'#$";*W
M1%4Y4MC:2?4 CY?7D]Z]J^'/P_\ +\N1H\8QCC\_SKGOAGX%SY3M%C' X^G'
MX=OJ:^D/#.@I8PK\N*#Y.I4=63DRYH6CK8PJ0N*WUZ=,4D<80<4^D9A1110
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M^W,<BB%95+1DN5"G(4G@G&.<9%>!_J[EO_/K\7_F?8+C+.E_R^_"/^1\S_\
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M[1>V_BV4Q:;<P*-AQ$9 S[B& *CC /OBC_5W+?\ GW^+_P P_P!<LYM;VO\
MY+'_ "/GS_ADOQ0P(:]T\\YW!V!_EC]*3_ADGQ07W&\TXG.?OO\ X5]4:CK
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M/^1\Z_\ #)7BC_G^L,?[[9^G3I2_\,F>*?\ G]T\_P#;1Q_(5];%E7.> /\
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M\^-O_/76O_!TG_QVOKQ5'^<T[:/\YK@_U?HK_E]4_P# O^ >I_K9B.F&I?\
M@#_S/D'_ (5Y\;?^>NM?^#I/_CM'_"N_C;WEUK_P=)_\=KZ^VC_.:-H_SFC_
M %?H_P#/^I_X%_P _P!;<1_T"T?_  !_YGR#_P *[^-O_/76O_!TG_QVC_A7
MGQM_YZZU_P"#I/\ X[7U]M'^<T;1_G-'^K]'_G_4_P# O^ '^MN(_P"@6C_X
M _\ ,^0?^%>?&W_GKK7_ (.D_P#CM'_"O/C;_P ]=:_\'2?_ !VOK[:/\YHV
MC_.:/]7Z/_/^I_X%_P  /];<1_T"T?\ P!_YGR#_ ,*\^-O_ #UUK_P=)_\
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MS_PD6E_^!L?_ ,51'XU\-Q]/$&E?^!L?_P 50(W=M&VL7_A.?#?_ $,&E_\
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M#*2R2.?/N;BX@E;!C=245)(B#GE@<[AE2 >W83;DQ+D=<8IOR;0?)&<<\?\
MUJ\-UZ?Q-,?C;#J&LV=WHMM8S)%9I9R)+'NTY678YG8* "=P"?,Q+#;]VIH/
M%WC#1;6STS78-&FTS5/#5W=VRZ<UPDUI)!$A,4DA*^<K+(F)%6%@0>.AH ]N
M7RV&1&I_"E"H>L0 S[5\]_#WQ_XMUS2/!_A_PK8Z+8"[\*0ZL+C5GN+I;9R[
MH(R#+YDBL57YC)E<$_/D"O2-%\1:EX^^"ZZO:0"QU?4]'D>""WF $5PT;!0D
MAVX^;&"<?6@#N_W7_/,''7:,XIK-&O6$ 9 YP,9^O],UXM\&/-\.WN@Z3XFT
MSQAI_BZ?36,EQK6N27]I=O&%\XHJW<T:D;E.2J'!X[TOQX\3Z_\ "S4--\3Z
M-<R7=KJJC0&TV:X(MXKN9L6MRJ$$#:Q8/M'*@<'% 'M/[OG*( .I[#UI6\M<
M'RUV_A7S?%\:/$/AJ35=!T-+WQ5)X0$-E?%M&U#4[O5;G:KSJ+F%1' 5W$ .
M&+8'"@YKI_B-\9M2\(:L&M[G3I+6W-FUQHWV"ZN;Q(YF56:>>-O+M&!8[1*I
M#;>O.  >SB2$X^10IZ-Q@_C3U6-F(V+QUZ5YI-XT\5W7C3Q;:Z;;6,ND^'HX
M9O)\J22[OV>U,OD)A@(R6VXD(?.=NSC<=#X/>.9O'>DWUU<ZQI^H7<,_E36=
MGIT]C-8/@%H9XII'?>"?O$)D<A<4 =]Y,?\ <7\J/)C_ +B_E3Z* &>3'_<7
M\J/)C_N+^5/HH 9Y,?\ <7\J/)C_ +B_E3Z* &>3'_<7\J/)C_N+^5/HH 9Y
M*<C:,'@\=:PO"*A?[9 X U*8 #I_#705@>$_^8S_ -A*;_V6@#?HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH SM4TL7T;+D
M D8Y%>7>+/@E/X@9O+ELQNZB1FZ?@IKV%AGVI&3/<T!N?,<O[*>KM-N:^T\I
MZ>;(3CM]Y,5UWAK]G^?1F4R7%D0#G$;-C\MM>W*FWI_*E*T[L#GM%\*IIJA6
M*'']W)K<6U11@"I<8I:0#5C"TNT4M% "8%+110 E+110 4444 %%%% !1110
M 4444 %%%% !1110 4E+24 >=ZI_R.E_]8__ $!:[+2_]6*XW5/^1TO_ *Q_
M^@+79:7_ *L4 :5+24M !1110 4444 %%%% "57N.]6*KW'>@#A?%7^J?\:[
M'PW_ ,B]IG_7M'_Z"*X[Q5_JG_&NQ\-_\B]IG_7M'_Z"* -*BBB@ HHHH **
M** "BBB@ K!\3?\ (0\.>VHY_P#)>:MZN6\>+*[: (;B2UD_M'B:(*67_1YN
MFX$?I0!TI;S!P>,]JY#2/ACINC>//%'BV&YO&U+Q%!;07<3LODJL*,B% %W
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M6<8_UUK_ $G%#7FJ-U\-ZD<<C=+:$#\/.QZ_G78[:-M4]=Q63W_KJ<:UUJ3
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M^)H_X3S1/^?MO_ >7_XFLC_A%T_N#\J/^$73^X/RH U_^$\T3_G[;_P'E_\
MB:/^$\T3_G[;_P !Y?\ XFLC_A%T_N#\J/\ A%T_N#\J -?_ (3S1/\ G[;_
M ,!Y?_B:/^$\T3_G[;_P'E_^)K(_X1=/[@_*C_A%T_N#\J -?_A/-$_Y^V_\
M!Y?_ (FC_A/-$_Y^V_\  >7_ .)K(_X1=/[@_*C_ (1=/[@_*@#7_P"$\T3_
M )^V_P# >7_XFC_A/-$_Y^V_\!Y?_B:R/^$73^X/RH_X1=/[@_*@#7_X3S1/
M^?MO_ >7_P")H_X3S1/^?MO_  'E_P#B:R/^$73^X/RH_P"$73^X/RH U_\
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M]G6C[.M344 0_9UH^SK4U% $/V=:/LZU-10!#]G6C[.M344 0_9UH^SK4U%
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M>%KCX>>(_#&H6WVNQ\6W%Q>:_-8SRV;ZC+<-NE)EBD$H0C$87S#B)5CR5 %
M'%6O[60GDTHOX806OEZ?)JMW#J@EB5+[49=-LYK!A'B\ADGA:02/Y&8'CD56
M9C$-9?VE%/A6SU!O#;0ZO=^*+CP]'HTNI0B5(8-4%A->N1GY%+1DJ@?#S1(6
M ;S!IM\#_A_HDEGKNI07I70H QO=;UZ^N(_)AE>X0W1GF*SK!*[RQ&?>(CAH
M]N!CDM%^%?[.WCKPS!I\,?A?Q[I%QK]P]J^IZP-<_P")G*?M-Q%#+-+*R.XB
M,DD2$;PKEE8%B0#Z#C<MU7:?2GU7C80H%2,!5& J# P!V[5)YN<X /.!S^=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTS2;R]TC2; V.EZQ<7T:/:WVIR3!I'@A\Q'@ODVJR85PPP!&CGV!OE5B.#O
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M[X7CT,ZB-5GMM4T>\!O"UY:PB!DE=A- <F6(@P9R<"N1\4_"'XOII>IMX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>eigr-20221231_g3.jpg
<TEXT>
begin 644 eigr-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 9P!G  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (8!5T# 2(  A$! Q$!_\0
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MDW4;J %HI-U&Z@!:*3=1F@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^'D$_\ T3Y/_!R?_D>G_9.-VY/R#_6/+=_:GVUN'^31N'^37Q+_ ,/()_\
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M/^2S>/?^P_J'_I3)7U/#O\6?I^I^><9_P*/^)_D<91117WA^3A1110,.Q/\
M"HR6QP!ZGVI=CJ<%&5OF 4CDE2<C\./S%(OWE('*G(.T$@CN/0^XK[A_;K\
M^(_%LG@D^']!U+7%MDO#-_9UH]P(RQA W;0<9 ;'T->=B,8J-:G2>TNIZN%R
MUXO#U*T'K'H?#Y4["X&4&[Y@1C@9/-*L;-CY3R<=/?'Z'^5?='P[\-ZOX5_8
ME\8V.M:7?Z3?K;WS>3?120R!"HP<, <=:UOV==7USP]^QV=5\/V']JZ];O=-
M:VJVSSF1Q.V!Y:'<W4]#FO/J9MR4YSBKVE9>A[%/(?:3IP;:<H\STU7E8^
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ME%JUK>=]CIGPYBZ=11BU9WN^UMSY2AADN98XH8I)I9&V1I&A9G;C"J .220
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M'#2;E8C$F1CH<)R!7YX!A@'MUS] ":Z6/XE>,HYKF5?%NOB2Y $\G]HS;IL
M@!_F^; .!GUKFE4\%@6.1]X9_GSS7;@\'5PLJDJC3O;8\W,\=A\51IT*<7RT
M[[N[=S[C\*^-M:\ _L V.M^'K[^SM6M7D6&X"(^S=J3HW#JRGY2>HJU^Q?\
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M./YG\?SI0P4\9VCL7ZTO[+I1<7"35K+UL$\[JU5*%2"DG=Z]&^Q]L:7^T_\
M#[XF?#G2M,\:^)O$7@;7;!$1Y_#\\\;2, !O5H5<$$#[K#C<0/6N$B^,7@S3
M/VC_  ?K5GXG\0ZGX-T.WE274=<FNKR3SGAE5G5'!8!OW2X50">U?,6[L#@
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M /Q%'_"F?A]_T(WAO_P46_\ \179[:-M7[6K_-^9C]7H?R+[D<9_PIGX??\
M0C>&_P#P46__ ,11_P *9^'W_0C>&_\ P46__P 179[:-M'M:O\ -^8?5Z'\
MB^Y'&?\ "F?A]_T(WAO_ ,%%O_\ $4?\*9^'W_0C>&__  46_P#\179[:-M'
MM:O\WYA]7H?R+[D<9_PIGX??]"-X;_\ !1;_ /Q%'_"F?A]_T(WAO_P46_\
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M[9($+D %BJ #. .<=JUA][WH /M0,[N<8J'J[LU2Y58=11104%%%% !1110
M4444 %%%% !1110 4444 %(3BEK)\6>((?"GAC5M:N$9[?3[66[D5>I6-"Y
MSWPIQ0!JTM,CYY_O#/7C\*?0 4444 %%%% !45PI= !Z^F:EI#GM0!Q'_"E_
M +-N_P"$'\-[O5M(MS_[)_G%.'P8^'_?P-X;^O\ 9%O_ /$5V>T_C2[:T]I/
MI(Y_J]';D7W(XS_A3/P^_P"A&\-_^"BW_P#B*/\ A3/P^_Z$;PW_ ."BW_\
MB*[/;1MI>UJ_S?F/ZO0_D7W(XS_A3/P^_P"A&\-_^"BW_P#B*/\ A3/P^_Z$
M;PW_ ."BW_\ B*[/;1MH]K5_F_,/J]#^1?<CC/\ A3/P^_Z$;PW_ ."BW_\
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M+^ 3][P/X;/_ '![<?\ LE=9INGV^EVL%K:6\=I:P1B**"% B1J  %4
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M#7B4?]QJ4?R%'_"N;/\ Z#?B;_P=S4 >H[AZ_K1N'K^M>7?\*YL_^@WXF_\
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M\U2/3KB33;.ZDV[()[Q8S!%(?,C^1W!'F)Q\PR >H4ULXXIL<RR_=STSR/\
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M)U.TBO;.ZC!VRPR(KQN,]F5@?QK5KRC]DW_DUOX.G_J3-&_](8:]7H ****
M"BBB@ HHHH **** "BBB@ HHHH **** $HI:* $HI:* $HI:* $HI:* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\OA[5?#VK^(G&E(_G0BUCCE^S,S8&460#?\ Q$T >[']G_13TUCQ#_X'@?\
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M-ZYHGB#78K[_ (2SP_8GS+P.CPW&JVMO,C#;R&CE=3_O9KZ'C5E9B3G/^?\
M/T%>2?M.?\B+X:_['CPK_P"GVRKU[O0 M%%% !2,,]*6B@#Y,_X**?"'1O%G
MP'\3^+-4NM6GN=!TT?8--BU"6.Q68W,)6X>%"!)*H!52Q( =N,X(^J44=2_S
M="P]?8=O_KXKC?CK\*X_C=\)_$7@>;46TF/6(5A:]6$3&+$BOD(2 3\OKWK1
M\2>%]?U;Q1X9O]-\4/HVDZ?--)JFE)91RKJR-$52-G;F((Y#Y7);H<"@#X[M
M;>/4/^"8FJ>*KJ..#Q'-IEUXU>^QB5=8%R]VL^XG=YBRA5!SN 55Z  _<FGY
M-O&S+L=EW%=I7!.,\=N<]>?7FO"X_P!EJ[CLY_"/_"8!_A)-JK:H?"3:8/M&
MUI_M+6?VSS>;4SEB8S%N\MC'OV\U[Y&A7JVXXH ?7RI_P5'8+^PM\2@2 6.F
M 9/4_P!IVM?5=?*G_!4=5;]A?XDEAG:=,(]C_:=K0!Z=^R;?6_\ PR_\'8O.
MC\T>#=&&S>,Y^PP\8KUS/:OSH^'?@F+]G_X*?L^?%.\\6:M)I=^?#T5]9S3Y
MMX(;NU4=#@!49E_X"#7W!X!^,G@[XE7MU:>&M?M-8GMHQ+)';OED4MC)'ID@
M4 =Q17(>+/B1:^$=4AL[G3=0N1)#YWGVL0=%YQM/.<]^F*W/#NO1>)-)@OX(
M9H(Y02$G7:XPS+R/^ _J* -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1NE+2&@#\]_V._P#D
M]3]H[_K\Q^BU]P?Y_05\/_L=_P#)ZG[1W_7[_P"RK7W#_G]!0 J_>%9OB)'G
M\-ZG;H,226LJ@MT^X:T&^Z?6H=:D_P");J*D<_9Y"!C./D-)NRN85U>!Y=\%
MWUC0_",MO'H7VE/M;GS%O8D'W$'1F]J[[^VM;;/_ !33'Z:C!_\ %5C?"=MW
MAF<CI]K?'S?[*]L5V:@[OXC^=.-5;&6']U.[,5M8UN1E7_A&V+]A_:,/3_OJ
MLOP=\1H_%WB;7M!&FW&GW^C,$N5FFC=23TV[2:ZN1WMXVFRQ93P,$BL";P!X
M??6+O45T\PZC=8-U<PW$B-,>Q.#6W-%Z'1S'2>4V[[IS2B%R<8QGN2!7.GP1
MI+?P78^E]+_C2?\ ""Z.P97CO&5@01]OF'\FI\L0N^AI3:YI]KJD6ERWD*W\
MHS'#N^9N">GX4_5-6M]!5?ML\<!<X&]A[?U(KSN\^ &@W7C*RUT3WR"U0@0?
M;IR3P1][?GO4OBOX$Z#XH@@59M0M/+;)4ZA.^[E3U+^JU7+#N3>?8]*95^?<
MP95_B5AC.<=ZR],\3:9K&FW%[97T$]I"#YLT;95,#)S],5DR?#'0)$==E^<A
MLDZC/U)YXWUQ7A3]FW0?#_A.;27N;Z660N%E2^G54# YRN_YOQHY:?</?['K
MMA<1:AI\%VLBW%O-'NB96'()XJEINJ6NM1L;"[BN?+<AU1@2N&*\_B#7*:+\
M'="TG2-/LPVH226BJAE_M&<9V\@A=^/PK/\ "?P*T'PPUR6DO+D32,X47LZ
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MF_WJT*S]%_X]F_WJT* "BBB@ HHHH **** "D-+2'M0!\\_M.6_G>)/"N?\
MEA8:E.N.NY(D(/X9!_"OCG]J3X<^-/V6/C'9?M-?#^V_M+PGK<$#>)-'081Q
M*B"5)5[QR'#=#AL?6ON;XP6@O_BEX(MRH;S=/UA,-TYMEK:^'NBV'Q ^!>D:
M5KEG%JNG:AI8M+RVNAN69,%"K?E^% 'S+\*_A?X;^-GAU/BE^SAX\NOAK<W[
M>9?Z+"@ET_[5C,BS6V<1OG'W1R!D=:[.;XK?M%_!W#^-? %C\0-#@_UNK>$Y
MQ]H*]W,#[3GV7/6JWPY^"NI_L9^.+;2OAIX-N/$7PY\37JMJMS]JWW>FW!)
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MRC!&>QZ^U '244SS!SD;0/4TJL&Z<CL: '4444 %%%% !1110 C=*\_\4?\
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MU:PM5>/2M%U"\9[33D8$$1KGG@G&>E>QJNUCEFSC!R?8?D?I4BL H&>,X!H
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M?T'Q3XAT+Q_\*KSXH:/?7GF^%]5TJUB9[:*6, P.Q(:%DD#8<?W@<BN0\/\
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MCUS(.*6N,\+_ ! O]<\1W&B:CX?DT:X@A:;<URDH;#A<#:3ZUV:_,VVLI4W
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M&0* /9&F"*S$851DD\"E60,2,$?6O@6^\4W2ZM>RGQ-J@_:+C\?_ &6PT/\
MM.86<FG"]51']E#>0;3^SM[M*5WB0,=^]0!]ZV^W=C^+'7UZ=: +%?*'_!4S
MS_\ AAGXB>44$>_3?.W=2G]HVW3WW;?PS7U?7RK_ ,%1O^3%?B9_W#/_ $YV
ME 'J7[)*NO[*_P ' Y!;_A#M'QCT^Q18_3%>L5Y3^R?_ ,FL_!O_ +$S1O\
MTAAKU:@#'\7^&+'QKX6U;0-4B$^G:G:R6EQ&1G*.I4_H:\G_ &,--CT7]GGP
M_IEN6^QZ==:E86ZL<E(HM0N$C7/LJJ/PKVZ1MJDGI7RC^SC^TM\*_ WPN31=
M?\>Z'I.K6NL:NL]G=7:I)&3J5R0"#ZC!_&@#ZPHKR_PY^U!\)O%VNV>BZ+\0
M= U+5;R00V]I;WJ-)*YZ*HSR:].5MP'&/;T]J '4444 %%%% !1110 4444
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M2PP=N#R5 X'KBD:XB6X> RH)D7>T6X;PI) ;;UP2",^H/H:/M$(N6MVE19E
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M]$L-<T^12&@OH!(!]">1]1@T :VFZI:ZM:17=E<17=M*NY)H'#HP]01UJT)
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MN#X(:M\4O!EIJM]K%C8:Q;-!/?RF1QYEG$[+D]LL/SKZ9W=* %HHHH ****
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M<TBI_?>W/TYP:]/^'/[7/PJ^)\T=KI'BVTBU)CM:POO]&F5S_"5?'->Q[#M
MSQ7FGQ&_9O\ AS\4[>=/$GA+3+R:0<7D=NL=S&?[RR@;@??K0!Z3',KJ&4[E
M/1AT/TJ3=[<5\H-\$_C+\ I!)\+/%R>-?#>>?#?BZ5VD@';R;@9) P!AL=?:
MG6_[97B;X=S26?Q:^%6N^'98R"=2T5/MUD4/\65^88^E 'U;2UYIX)_:.^&W
MQ MXY=$\9:5=&0#$+7"QR@^A1L$&O15NHW4,A$B-T9#D&@":BF>8./0]*=0
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\J_\%1O^3%?B9_W#/_3G:U]55\J?\%1V _85^)8)P3_9@'O_ ,3.UH ]5_9-
M_P"36?@Y_P!B9HW_ *0PUZM7E'[)K _LL_!S!R/^$-T;_P!(8:]7H **** "
MFMTIU(PW+[]J /BGXZ6O[1W@/XU^*+_X/Z%IVK^'/$"6=]<2WP)9+B.(1,HQ
MT^6):]T_91^*FN_%WX1V^J^*K)-/\46-]=:1JL$(Q&+BWE9'VCTXKU\KR.PS
M_P#7-?%]I\&?VD/AOKGBNT\":KX=;PSJ6O7VLVHOI2)E^TS&5E; /0F@#[39
MMM ;)Z5\<_\ "._M@!E/]J>$\ C(\]N?;[M>P?LJ^,O&'B_P%K2>.WM9?$NC
MZ_?:/<261S$_D.%!7VY[T >ST444 )2T4E "T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%(QVC-? ?B3_@K]X/\-^(M4TB7X8^,IY=/NI;5Y(UAVN4<J6'S="1^M 'W
M[17YY?\ #Y;P9_T2OQK_ -\0_P#Q5???AS6D\1Z!IFJQPR6\=]:Q72Q2XWH'
M0-@X[C.#0!I4444 %%%% !1110 4AI:1OZT ?GO^QW_R>I^T;[WI_0)7W#_G
M]!7Q)^R+"(_VX/VE(U&%74&0'_OD5]M_X _I_P#6H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "A>O_ -;-%'XT$ZIW&JNQ@1S@'Y2>#^%<YXB\$VVK
M1^=:F*UU!75Q<>5N8XSD'FNEI"@^4E<<]?\ #TK*5)3W(K4:59>^CQ:\\4^)
M/!'C"WAU/4[-M*NL2223##!5 !(&>F:]3T7Q7H_B"S$^G7UO< MM"JX#$^PS
M4'BKP3HOC6VGDU32X;F<QF%9RF]T'MGZ5X_IOAU/A7XOBAL/#=S=VTSQM%/)
M'ADQD$\=N:X_?I226QXZ=?"2LOA/?V4Y&!N'<^E(WR^Y[>]8<_B:2.&>4Z/J
M;.H)7="<<#./I7,V/Q,U&\T.>[D\/W:S*X5(_*.S!..:Z_;+ENSTI8J$8IL]
M!S\Q7^(=J7OC-<#9_$N]O)])A?P_>K#=0>=*RPG<G .!73>'?%%GXH^UK9I/
M'/$RK+',FW:Q!P!^ -.-:,D*&*C4TBS8HIJMP.>G#?6ESC@Y![9'6M+W.S1+
MWMQ:*.:*JS%?6P4#@T44ADAD'I2>9[4RB@!_F>U'F>U,HH ?YGM1YGM3** '
M^9[4>9[4RB@!S-N%,'2EHH **** "BBB@ H7K10O6@#8T7_CV;_>K0K/T7_C
MV;_>K0H **** "BDZ4C/M7.#B@!U%-+X[9I#( 0* 'TE(L@;MCZTM 'E?CG_
M )+Q\,?^N.J?^B$KU,]#7EGCG_DO'PQ_ZXZI_P"B$KU/KQ0!Y?#)_P (]\?)
MT^[!XBTF.49Z&: LI'UV%:]/5BQY_"O+OC8K:/<^$/$J\'2M51)&7M#+\C9]
MN%KU"(YR>HQP1T(YQ0!)1110 4444 %(PW4M% ##'Q7DG[1?[,/@?]I3P;+H
MGBK34DN%7%GJ4*XN;1NS(W4@>AX->O4UEW#% 'R+^PG\"_BW^SK<^+O!OC36
MH=>\#6LB'P]<>9NEY)WX!Y5,8^4]"#7USO\ F]O6F&$[3AL'!P?2OG7]M?P#
M\7O&G@73+GX.^(FT77-*NS=3V:D+]N380(\]^<<&@#Z-W;NQH7YC[5^;'PT_
MX*;>+_A;KT/A7]H3P/>:!=(PB.L0P,B]AN9>A'?(-??_ ,/_ (G^%OBCH-MK
M'A;6[36["9 R26TH8@'U'4'ZT =0T>[G//Z52U30K'7-/N;#4K2&_LKE/+FM
M[J,21RIG.UE(P1UZ^M7?,%.H ^?_ !E^SWKGA/0= M_@MKZ^!X]'O)+LZ'(I
MDL+Y9&W21OG)08SMQ@ XK<T7]I;0F^)&N^"-:T[5=$UG28)+@W%U9.+6ZACC
M#R2Q2XVE1R/?%>PM&6[U7N--@NGWR11N^QDWN@9MI!!&3VYH P/A_P#%'PO\
M5/#\.M>%=8MM:TZ4#$MN^2I/\+#JI]C73^<O)/ &<Y]J\<\8_LP^']2\+ZII
MG@Z^O/AO>:AJ']J2WWAQQ$9+D# 9T.001U48Y K(U?4OC'\+]5\"V5K86WQ&
M\-M''8:W?+^XODF9\?:0N<%%'4>] 'OBMNSBG5Y7X)_:2\ >-_%6O^&[#7%3
M7-$:4WEI>(872.-@K2?, -@)'/N*].BNHYXXY(F$L<B[DD0Y5@1D$'N.>M $
MU)31(&; IU #2N?:F36R31-$X#1,"&1AD$'L0>WM4U% 'C7C/]D'X0^.Y'FU
M/P-ID5TV2+C3T-I(K'^(&(KS[FO-;W]BSQ!X-C6X^&7Q=\2^';N%MT%GJLWV
MRT'^RRL"V*^KC2;<]\?2@#Y/A^+'[1OPO4Q>+OAE8^/;5>!J/A6["R2 =7,+
M'(..P]175>"?VYOACXAN4T[7=0G\"ZX"5ETOQ+ UI(C>S,,'\*^@_)QG;P/0
M''/K7+^,/A1X1\?V;6_B+PYINM(WWC>6ZLQ_X$ #0!K:+XLT;Q';+<:5J=IJ
M,+ ,'M9ED&#]#6FLH/4$'O7S)XB_8)\'V5V-7^'6L:S\-?$,9+0W6CW;M 3U
M DA<D,O XXJI%#^U?X-C6,2^#/'-M;_*'9&LYY@.YY(!_P : /J9)@WUJ2OE
M./\ ;&\2_#NZ@3XP?"_5?!>F2.(VUZR)O+")CT+L!D# 8Y]J]]\$?%KP=\1K
M%+OPSXDTW6H7&5^R7*LQ_P" YS0!U]%,\P;B.]"R;NU #Z*:6Q2T +1110 4
M444 %%%% !1110 444UV*KP-Q]* '44W>/J*3S,'&T],T /HIGFC<!W]Z56#
M4 .KY3_X*D1K)^PO\221RATQE^O]I6H_D37U97RK_P %1O\ DQ7XF?\ <,_]
M.=K0!ZE^R6@C_99^#H48!\&Z.3]390UZQ7E/[)O_ ":S\'/^Q,T;_P!(8:]6
MH **** "BBB@!",TW;^%/HH CD 5<GH*\$_9N\4:-IEQ\2=.N=4LX+^3Q]K
M2WDF59&W3#''6O?FSCC&?>O@?]KC]D'P7\.TU7XRZ3JFMV7BN?Q/I]\5&H%+
M823W\*RG9TQM8_E0!]\!@W2EK#'C/P^K?\AS3CQ@YNH\_P _>K6G^(M+U:9X
MK+4+6\E4;F2"=7(7UP#TH TJ*:&SVP:=0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M=2PX..]>#?M<_$*U^ 7P7U3Q7H_A/3=:\0R75OI^F6<EJA66ZN)5C4MQG')/
MOC'>O>Z^<_V^M3\'Z7^SI?OXZAUH^'WU.Q#WGA\*;VRD6=9$G3/]TI@]\,:
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MHHH **** "BBB@ HHHH *%ZT4+UH V-%_P"/9O\ >K0K/T7_ (]F_P!ZM"@
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M6U.;GI8ZJ-9R5I#Z*.P^GY45M8[+W"BBBD 4444#"BBB@ HHHH *%ZT4+UH
MV-%_X]F_WJT*S]%_X]F_WJT* "BBB@!K+N&*Q?$G@O0_&4$5OK^C:;KMM$_F
M)#J5G'<(K<@L%<$ X/45N44 9MWH-E?+9F>TM9Y+-_-MGF@5S!)M*ATR/E(!
M(R,<$BJ=]X'T#4]<MM;O-$TR\URU4+;ZG/9QO<PXR1LD*[EP2>AXS6]10!''
M&8\=.F#CC/3M3S2TE 'E?CC_ )+Q\,?^N6J?^B$KU->E>6>.?^2\?#'_ *XZ
MI_Z(2O5%H 23)7 P#VS^E>4^+&?P+\6-(\1$;-)UM%TO4)&^ZDF?W)/U;Y<_
M[5>K,NY<=*X_XM^&?^$J^'NM6"J#,T)FA;G*RIAD8>X(% '6PL>_7:.G\_QJ
M6N8^&_B4>+_!.B:N>9;JTC>7MA\#<,?7-=/0 4444 %%%% !1110 4444 %%
M%% #77<,?H:3R^GKCK3Z* /&?VBOV5? O[27A.YTKQ)I<4=^R_Z-J]N@6XMW
M .&#8Y'/0U\.3?LR?M6_LDL;SX9>,I/'7AFVRPTN=]Y* 9_U3>PQP>]?J0PS
MBF>7R#GITH \N_9K\>^+OB1\(=%U[QSX>;POXFN!(MUI[+MY5MH<#L#C->HL
MW.,\TBQ;5Y.[C&3]*^0OVS?@3\</&GB[1O&/PA\</I,NFVYB?17D*)*<YW#L
M>@&#ZT ?7RL/7-/#9K\Q]!_X*#?&?]G'5AH/Q]\ 7%[ K#;J^GQ;#MSCJ/E/
M&3ZU]B_!']L[X4?'B%5\-^*+9+\@9T^^80S ^@#'YOPH ]SIKIN''ZT+(&(
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M7_@J-_R8K\3/^X9_Z<[2OJJOD_\ X*FW(@_89^(:%6)FDTV,$=O^)C;-D_\
M?/ZT >M?LG<?LL_!O_L3-&_](8:]6KR?]DJ3S?V6?@Z<$8\':0N#[640_I7K
M% !1110 4444 %%%% !1110 4AYI:* &E?0XKF/%'PP\*^-KZ.[U_P /Z?K%
MS%'Y4<MY;K(R)R<#(]2?SKJ:* /"?&7[$7P8\<ZJNHZIX'L#<+&(1]G01+M
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M%% @H7K10O6@#8T7_CV;_>K0K/T7_CV;_>K0H **** "BBB@ HHHH *2EI*
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M'CEC8,KJ0"&!'4$'@]Z@U#6[/2XXGN[B&U26584:XE6,,[<!06/)). .I/%
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MG.5'/K[U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "48I:*
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M*WUDW$_*1@X.: 'U\J_\%1O^3%?B9_W#/_3G:U]55\J_\%1O^3%?B9_W#/\
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MPMXNUJS\4Z%XMFN+/3/$D.GK:W5A?);F98)H5_=,CK%<,K#G*X/!% 'M?).
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M=S^RU\'#_P!29HW_ *0PUZM7E/[)O_)K/P<_[$S1O_2&&O5J "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 5\J_\%1O^3%?B9_W#/\ TYVM?55?*O\
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MO_2&&O5J\I_9-_Y-9^#G_8F:-_Z0PUZM0 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@H\P4 /HIGF"CS!0 ^BF>8/\FCS!ZC\Q0 ^BF^8#T(_.A6W4 .HHHH ****
M"BBB@ HHHH **** "OE7_@J-_P F*_$S_N&?^G.UKZJKY5_X*C?\F*_$S_N&
M?^G.UH ]4_9-_P"36?@Y_P!B9HW_ *0PUZM7E/[)O_)K/P<_[$S1O_2&&O5J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+)4D!CVRH.#QQ5WQAX"\._$'13I/B71+'6]-#K(MK>Q"2-67H0#TZ#IV)]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>-B3U_>I_A3U_P""/GA_'S_&#QP3[3Q_X4 ?<OV6?/$,GUVFE^RS=H9#_P
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M"UAF-NW]I:7=:?)O"JQQ'<1QN5PP^8#:3D9R"!TE "?C1^-+10 F/>C%+10
ME!&>]+4%Y>0Z?:RW-S+'!;0J9)9I7")&@&69F/   /- $P7'>BO/OA_\?/ W
MQ1U633O#>M->7BVJWT<=Q97%I]IMF.!/ 9HT$\6<?O(BR_,ASAESWZR;F(Q@
M#U^I']* '8]\4 'US2T4 (1FDV^YIU% "8/KFBEI&;;VS0 4?C7.Z?\ $+P]
MJWB[5?"UEJMK=^(M*AAN+_3H9 TMK'+GRS(!]TMM.%.#C!Q@@GG-;_:$\!>'
M?%3>';_7#!J*3PVLLGV*X:TMYI=OEPS70C,$,C;TPDCJW[R/CYUR >B,N1CK
M]:;Y(;[QW'UI(YQ(Y7&"/U'8_2I: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!DGW>F>:\ _:*G@\(?%;X,>/\ 5V^R^&-#U/4-/U746.(M/6]M&BAN
M)3C"1^:D:,YP%\W<Q !-?0+#-136L=Q;M#*JR1L,,K@$&@#P;X2:A:?$G]I+
MQ[\0= N(-3\(Q^'],\.6>KV;B2UO[F*>[N+@PR#*RK&+B)"ZDKO#KU0X]_JO
M:V<=F L*)%$!@1QJ /\ /7\S5B@ HHHH **** "LOQ1KMGX7\.ZGK6HR^1I^
MFVTMY<R 9*QQH68_@!6I3)H5F78ZJRGJ&&01T(H ^1/@[\3O!_QT\6>$O'OC
MCXD>#H]8W^;X2\ V&O6SMICW"[(WG'F;Y[]HW"8P%C+NJ+EF9OKF&0,<#TR?
MQ_S_ #JBOAW3D*,MA:HZ$,&2!5((YX('L*OQ0B/W[=* )**** "BBB@ IDB[
MEP..V?3BGTUEW8YQ[T >%?M(>"?'OQ N/"VD:!HNBZYX+CNA>^(-,U+6'L'U
M#RBK6]J66VF!M_, :1<?.%"'"E@W)_L8ZIXGOO&'QV76M T[28/^$ZN7E>SU
M=KPI=?8=/5X #!'N0*J,),@DL5*#;N/T^T.YEYX%,M[..VD=XT56?!=E !8X
MQDXZG@4 3T444 %%%% !1110 R1MBY/0=:^/O'WA7X;:1^U)XYO?C-+IT/AG
M7]"TJ706\3SI'I<LUL;B.Y"^81%]HB$L17/[S;/+MR"]?83+O&#5.XTF"\4K
M<QQW"XPHF0/@\\X/!H \G_9';5_^%):2NK-J$D*W>H+I$FKAQ>-I:WDJV)E$
MGS[OLPA^_P#-@KNYS7LU,5-O?CL,=*?0 4444 %%%% "-DC .*\!_; N5?PI
MX0TG5G_L[P3JWB*UMO$>LB'>=-M526:.;S,'[-_I$5LGVGY?)W[PR$!U]^/-
M1W%NEU"T4JK)&PPRLH((]P>M 'S-^SE?:';_ !Z\>6'P_P!:/C7P-=:597U_
MXD>_.J%-64F+[-_:#%GN#]F$+%&D?RAL VB3!^GJK6=A#IZE+>*.",\E(T"C
M/KQ5F@ HHHH **** "HYON<=:DIK*6& <4 ?)'P[\)W7Q"^#'[4?AFP*F_UK
MQ3XJTRW;@8DFMUC7)P<<N/\ (JE?_$70?C9\+?@YX%\,WL=SXM.M:!=:OX>6
M0?;M$BT^:&XO/MD1(>#RS;F++*-TCQ@9#9KZ^^QHFXQJJ,26X'5CW/J?YU&N
MEV\=PUQ'%'',Y^9U0 MSDY/?MU]!0!9C;=GT]Z?3%3:Q;J2,9_/_ !I] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 1S'Y,>O%?)'Q8\867C_X
MOZ]X2^((\4Z;\-O#TENJZ+I?A?4KR+Q/,T*2E[JXM[=U>VC9]GV<-AVC8R;E
M^4?7,B>8N/?/2FK%MQSQZ"@#-\,:O8Z]HMG?Z:DZ6$\>Z%;BTDM75<]#%(JN
MGT91TK6IBQ_/N)R<8Z4^@ HHHH **** $89'I7BOQB^#_C7QU\0O".OZ'XF\
M/VFC^'0UU#H>NZ-/>0O?L"BW9,=S%EHXRRHI!"EW;KM*^UTUE##!H ^<?V+/
M#_C7P[H_Q'C\7FQC%SXVUNYMXK?2[BRDD9[Z5I+@>;*^Z"7*-$%'"]7?.1](
M5''&R_>?=U[>^:DH **** "BBB@ K@?C]X!NOBE\$O'?A"QEC@O];T2\T^VD
ME.$6:2!T0L?[NXC/L37?4R2/S,=.#GD>U 'R!HJV7C34/@;I/A'P+K/A7Q#X
M-U!9=8FO='FLHM(LHK2:WNK8W+J([D2N8T40O("%$F<(,_7L.,8 Q@8H,);;
ME_F#;MV!_GIQ2QQ[#G.>/U[F@"2BBB@ HHHH *BN/]63Z<_X?K4M-D3S%Q0!
M\(>,M#T^31_B8/&/@_Q-J/QWN=5U&/POK=AI%Q+(BF9_[(:RU&-3#:PQHT61
M))&499V<8;+?:_A%=67P[I0UV2*36A9Q?;FMUQ$9]B^84'4+NW$#L#]*U6A)
M4KO(!.?I2Q1>7P,;0,* ,8% $E%%% !1110 5%<*'0*0&&>A&1TJ6D- 'A-O
MH]^O[:NHZJUA='26^'UK:"_,+^2TPU*=S%O V;MK(<9SAB<8S7GVDZ[J7P8\
M.?%KX=-X;UO4_$VK:SJVJ>%_L.ESS6>IIJ,CS0A[I$:* QS2R12><RD+&' 9
M67/UKY?OSDFHQ;E5 5L8&!UQ[=Z .5^#_@UOAU\+/!OA)YA/)X?T6STEI%!
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M!P#ZX(ZUQ6G?!O0]+^*VJ>/K??'J>H:1;:.]J(XQ;I'#+-*'4;=P<F=@><8
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M> ;JZOO!NA7%\[27\EA ]PT@"L9#$A8D#@$GG';-=#3$C$9..GI3Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:[;%S@GG'
M%-\W_9Y],\T 244R.02?_KS3Z "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<FUF9BJQ2 .=CEE90IP200!D5^5'POU9O"'_  4/^#[Z3+\,[7^T(3:7MO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (;R-9K=XY$$D; JZ, 0RD$$'/J*^#OV _V3_&G@3]F/XI?#OXF
M:'+X8NO%MS=VPQ<P3.;::Q2 R!HG89!+\'!&,XK[V9=P]Z8L(7..YS_^OUH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)1110 4444 %%-9@N,D#)QR:%;<3QQZT .HHHH ***1FVT +144<XD4-@@$
MY(QU]*<TFT#(QSZT /HJ(3!N@^G6E68,V,$=QGT^E $E%1^:?[OH?P]_U_*G
M*^XGCC&<T .HI&;;CC/.*8LV['R^GX?E0!)14:S!N<8&!_\ J_E3MQ SM- #
MJ*B^T#C(QGH<C!.<4OG# .&P?8Y_$8H DHJ)IL?P]\>H]^E.63<2"I! R1^?
M^% #Z*8TFU<XI#, P&/3.>,9Z4 245%]H'?@>^1_.G%R"!MY/Y4 /HJ-YO+Q
MD8]NY^F/:D\[IQP>^>/K0!+14;2[>W/'O_*E63<Q!7:0,D'\?\* 'T4UG"8S
MWX'Y4T3;FP!D8S]: )**C:7;_"0<9.0?YTL<GF,P Z=?\_Y[4 /HHHH ***:
M[B, GN<?G0 ZBHXY1(3@''^>#[T]FVJ3_2@!:*8DF_.!P#C/^?\ /%/H **1
MB1T&:C\[K\I _7J?\/UH EHID<@DZ?6GT %%%% !113'<KC"[B3@<@4 /HIJ
MONZ XQGD$4Z@ HHIK-M&??% #J*8) >?_KTGF^@SSZ^] $E%1^:=H;:<$9QW
M_*A9=W09[<'W(_I0!)13%D#-CVR.:<S!<9]<4 +140G#$@=B!UZ9Z CJ*<LF
MX=#^/% #Z*C\[KQC@'/.,'WQ_GB@R8[8]>>?K0!)13%D#L0.@IS-M&: %HJ+
M[0.>, <GD<<9Y_\ K9IZMNZ"@!U%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!G>((+VZT:[ATVYMK/49(F6VGO+<
MW$"2E3M,D0>,R(#C*AU)&1N&<U\]6OQJ\6)X6^$NAIK.AVOB;Q=%=+)XIUZS
M9[$S6Y4+"EM'-"9)I]YV()%^6*1OG*A3])R'"Y_E7E/Q8L;:#0;/PF/@_+\1
MO"%]#)'>:;IZZ:(;=HY(FA4V]Y-"CJ27<,K$HT8.#G*@&I>?$3_A6'@_3KGX
MB:G9W6N7%Q):QKX;TRZE:_?<[1BWLH_/G8^2F]T7S-@1V+%5+54O?VEOA[8:
M'H>JR:U,]OKD\]IIT%OIMW-=SW,()FM_LR1&83(596B*;PRLI7<,5X5<? [Q
MG;>%?AEJVJ:7XEUQ=!N-81O#>C^,)K/6++3[Z99+2!;\74/VB2VCBBB=7N-A
M!8J\GEJ6[#PI\'9=/\4_"S5])\&ZEX?L-/U?6M4UFVUW7%U2^@DGLWACDFF>
MXF+R2?NR5220*'Y/4T >G6_[0W@2Z\3:OX?BU6Z.IZ/'YNJ*VE7:Q:<GV9;H
M-<RF+RX T+!E\QEW$.JY9& AL_VCO EYH7BC5VU&^TZV\,V/]I:M#J^CWNG7
M=M:XD/G&VN(4E:,^5( RH02C $D8KAG\"_$'P_IO[1&H>&;6.S\3Z]JGV[PS
M=32PL;@II-E"C?,'52LT,H42KC(&X;<&O*=9^!/CC7].^,3:9X3\565OXC^'
M4N@Z?;^,?%2:GJ%UJ)>YX8M=SQ0(PE0JJ.(QER0F<4 ?2_A']H#P/XZU+4+#
M2-7E-Q96:ZBYU"PN;&*:S+%1=027$:)<6^5/[Z(NF"IW?,N4\%_M ^"/'^MV
MNDZ/J-X;R]@:ZL#?:5>64.HPKMW2VDT\21W2 .C;H6<%75AP0:\U^.'P0\0?
M$[Q%;VE@ATW3KWX<>(/"\^HM*-MK=7AT\0)(BMN=,0RDE0<;#DC*FK]GI_C'
MXE>,_AG)J_P^G\!V_@RZFU2^N+B\LYXKB9M.N+-;:P^SS2.8LW3R;IEA(6*(
M;,L0@!ZOX[^)F@?#>TM)M<N9TEO93!965C9SWUW>2!6=DAMK='FE*HK.VQ#M
M568X )'FOBC]KOPGHFH_#Q--L=8\0Z=XNO;JT%WIND7T[V?D07$CJT4=N[><
M)+?RWMVV2Q@N[J!$PJI^T;\,]4\5>-O 7BNQTC7?$>GZ''J%C?:3X9\12Z+J
M#1W7V9EGBF2XMQ)L:V"M&\RJ1*6Y* ' E^%^H^%=/^%7B/PQX UX#0O%.HZU
MJGANZUV&_P!687-C?6IE>YNKLQR2%YH)'7[0P&YPI<J,@'T#XN\::7X'T.?5
MM7:Y2SA=(R+2RGNYI'=PB)'#"CR2,690%123D^AKS;Q!^T%8:IH?A'4_!TT=
M[!J?BVW\.7\>HV5Q;7%F6+B6.2"41RPS#8IVR*#M=6P0ZDZ/Q^M/%NH>%=+C
M\)V^J7<2ZM"=:L]"O8+/4KG32L@FCMIY718G+-'EUEB<()/+=7VY\1\ _!7Q
MO8:?.UUX=U+389/BO:^);>UUC7QJ=W#I2Z?;1F2:YEFD9Y%='#H)'VL&"-(@
M5V /KQE9%P&W')QD9]>O^>U>*? CQ;\2?B=H]AXMU?6_"B>';JYOHQH]AH%S
M'> 0SS0(?M1OW0G=&K']SR"5X^]7HGPT\<GXC^!=/\2G3Q8VVH&6>UC$IE$E
MJ)G%O-N*ICS(ECEVX^7?C+8W'YU^!7@.?X4Z5*TO[.]T?'L#:M,?%4*Z"#?%
MY;B:*,W O/M!\U6CBRZ  N-VU06 !Z'X=^/.I:Q^T)J'A.6PLD\%M)<:/I>K
M1NQN+C5;2&&>YA?YL%/+GD"X&0UI<%L *3'HOQ&\<_$3XD>,--\-:KX3TBU\
M(ZK;Z;?Z#K%A-=ZI<1.L<OVDR17$8M4F1F6+=#*#Y._)!*KYL_[,_C[PY\(?
M#&IV'C77M?\ '?A_48?%@\-RII4-C=:H\K37\*SBV6<"<7%Y"':X/^ORS,N:
MZWXO>&]?^)'B2T.F?"C4=(\;:/J4(T;XB+?:<D%E;B8%V,D=P;IHVA:0/:M
MT;LQ1\H?, !ZE\/?'VH^*/B1\3= NX;6.R\,ZC9V=G)"C+)();""XD,A+$$A
MIB!@#Y<=>M2?&J^^(UIX2MX_A=IGA_4/$]S>1Q>;XIN)8]/M(-KL\L@B_>2$
M[5C54YW2JQ^537GWA^3Q=\.?C9\3;\?#CQ%XCT?Q-J.G7%GJFDW>F>2D<>GV
MUNYD6>\BE!5XW.-C9'()R:I?MO0_&/7OA/::)\&M)N[S5=1U".+5[C3M6M].
MO+?3PK-*L$\K 1R.0B;P&VACA3U !Y%I_P"WMXM\/_ ?XH:UXM\,:)=_$/P?
MXG/@^WM]"N)#I6J7[R;(BF]BZJOS,ZD@L$'*%B%] ^"_[2WCX>,OB?X"^+7A
MC2W\:>#]*B\06X\!^=<1:I9/&2T4,<[;FG1QLY8!F;  ";G\GUC]F[QO\1OV
M/]2\!:'\&K+X,:QX7U.TUSP[I<_B*VU5-9N(@QD::>( "1QE=TAP24R549'J
MW[-OPW^)&M_'GQ[\:/B=X3M?A_J.K:;9Z%IOAF'4H]2D2&(+)+/+-%\AW2 ;
M ,, I!&%#. 7/V2OVH/%OQ[N?BL?%?@V'P?<>$M22RAT2W<S7D?[IV>.9RP5
MY,J,;50<X/K5/]F/]K;Q/\;/B]\5M"\2^"AX#TOPO::?=VUA?!CJ:Q7"/('N
M><*QC"/Y07,>XH22IK3_ &4_A#XL^&WQ5^/NL>(](.FZ=XG\5G4=&D^T0R_:
M+;]X!)M1V9#AAG?@G/2LKX=_#GQC\-?VGOVE/B-J&@2GP_KUAITVAS0RQW$M
M^]K9;98TBC<S9#C:%*@G/RB@#WOX9?%?PK\;O ]AXN\&:F-:\.7S2"WO?L\L
M.\QR%&^25%8$.I'('0$9%>3:/\4M?\$^%-<U]]4U'XDZ?J.H66E^$VU""WL)
M-4OIG*,(3# BBPRT;).ZNQ6.XD#21^4TGHOP%U_Q;XX^#OAC6?B#I=OHGBW5
M+/[3J.EV]K+;K;,_*Q^3,[NC*A0,K'[V[(&<5RGCG]FG0-*\,P2_"_POX4\'
M^)+'5+'5X/LNFI8VU[);.Q6"X:!-VQDDE0-M8IYF0K?=(!U7@]?B3I.IO?>-
M==\'7F@&TDEFCTC3+FRELY 5929Y;J5)D"^8"WEQ'@'@96H]'_:.\!ZUINOW
MRZCJ&GPZ#IO]L:A'K&C7NG3QV6'/VA8;B&.22/\ =2 /&K E" <X!P=6\=?$
M[QIX)\46?A_X=ZKX%\3?V+<MINH>(K[3)HEU Q%8%1;:XN-^).2TBHHV\@\K
M7B<GP7\=Z]??$2\M_"?BRP36/AIJ6@Q+XP\5PZE>76J2L"JA!=2P6\;\E?**
M1YWY2,!5(!](^!_C_P""/B-K#Z7H.J3SWGV+^TX1>:==64=W9[E7[3;23Q(E
MQ""Z9DA+J-Z\_,N:WA_]I+X?>)HM1N;+69TTJQLYM0DUF]TR[M--DMHG"23P
MWDT203Q LI\R)V7:0V=N#7 ?$;X*^(O&EYX(L;)9-+L[?P/K_AR]U&&9%:PF
MN[>SCAP-VYB&A<@ID H.0,&J?B[PYX[^+7P)U3X>77P_N?!^I65C9E;IM8MX
MK"\N;2Y@E6*SEMI&GCBD$+#S9(X60,ORDD[0#TJV_:4^'\WAWQ'K<^JWNDV?
MAZU6^U.+6='O=/NK>V;.V<VT\*3&)BK@2!"I*. 25..H\-_$#2/%WAU]=T^2
MYCTA3)FZOK.:T^5!S(HF12T>,$2 %&&2K$8)^9O$WP3NO&'PE^*$>C_#;QAH
M_BK5/#ITBT7QEXP.KSW8=F=H8?,O[F.*,,H.YFC8Y(V<<_5FI:?!JVFW6GS;
MO(N8FMW\OKM92IQ@<$9STP,T >/>#?%WQ3^*VBZ9XST&3POX?\*ZB\=WIVC:
MOIUU=W][I[$&.:2Y6>-;5YHR2$%O-Y8899CD#LIOCIX/L_&T/A6XU"^CU>:Y
M^P1S2Z3>I8271B,OV=;TP_9C+M4CRQ)OW KC=\M<+\+M4^(7PS\(^'_ &J?#
MN_\ $TFCP0:/;>*--U"QBTVZMHU$<<\Z37"W$4GE@&5(X90&#!"XQ7FOB[X:
M_%#Q?X^TVZU30O$FH7&F>/[755UF3Q1';Z''H4-^)(DAL([A?,F2'9O,\ <L
M)L2.%B0@'TA)\9O"$?A6^\2'5U&C6.K-H=Q<M!+B.]6\%D8MNS<<7!$>X K_
M !9V_-4</QK\*W/CI?"$%S?7.LFX>T9K?2;R6SCG6%IF@>\6$VZ2B-&8QM(&
M' QD@'YV\5?#OXDV7@GQI\/M-\#3ZG;WWCS_ (22V\1?VA91V36,NL0:C+E7
ME$PG3?-'M,:H1$6#DX5^ND\&>,(?C)-/X6\.^(O!FCZGJES)XHEO=2L[O0]5
MMO(FCCN+6 2O<07C-]F?]W%"C;7$IEVH2 >G^'OVAO ?BCQ,F@Z=K$TM[-]H
M%K<2:==0V-\8#B9;6\DB6WN60;B5BD<@([=$8B[X!^-7A7XG7EQ;^'+F^O1%
M$+A+J;2KNVM;J$G:LUM/+$L=S$3TDA9U((()!!/SU\#?@/<^$+/P3H?B?X<^
M+;W5_!D!CCUJ]\<2WF@220VTMM'-9V<E\Y1I8WVB)[6-(UEE4'"+N[O]G/PI
MXN\(^(+VR&A^(O!WPW@TR"*P\,^*M2M-1DL+I=JE;*>":>06FQ<;)Y"5)41I
M&GR@ ZKQ1\0/%WB;XAZCX*\ KH^GOHMO!<ZSXCUZUFO;:W>8,T-I%;12PM+(
M442.QE41H\?#F3Y="?XE#X8^']*_X6/J=G/XBOIY;6WB\,Z9=7$FHE2S!H+*
M,3W&1$ [JID"#)+8YKG-6TKQ9\+?BQXD\5Z-X7N?&WA[Q5%:F[T_2;NV@U"Q
MO((C$'5;J:&%X'C6-3^\#JZKA6#$QT/$D/C63QUX+^)4'@/4+Z:VTK4M%OO"
M\-_9#5+6*XGMI8KB-Y)4MF<?9%$L8FP/-&&?R\. =?=_M(_#NQ\(Z;XEG\0;
M-)U+4#H]M_H-R;@WX\W-F]N(_-CGS#(GE.@<N @7>RJ>9\>?M=>$O"OPU?QA
MI5GJ^OQ1:W:Z'/8KHVH07%K/+<01NMQ$;8RP,L<ZR*DD:F7,:IDRIGCK;X1>
M,=4U;1/$5UH*V,FH?$[_ (2^ZTHSP.^E6(TI[)#)ABC2GRH9&6,N!),X!<+Y
MA/B/\(_&&J6_QJN-,T5[Q]5\4^&];TJWBN80]_'8?V8\Z@NX57/V22,>85!P
M,D#D 'KL'[0/@NX\86/A1+S43XCO+2UOTTO^Q;X7$-M<%Q'-.AAS F8V5VEV
MB,[1)L+J#!H_[17@#Q-K]GHVGZS/-)?S/;6%^VF7<>FZA,H8F.VOGB%M._RO
MA8I6)V-C[K8P/"_@W7=:^+/Q'\2:GHUUX>TWQ'X5T2PM&N)8'N8)HFU(W$3"
M"5QOB^TQ<JQ4DC:S8)'$>'?!OCW5/!OPN^'.I^!I/#T?@Z]TJ2^\2&]M'TV>
M+3RFTV21S-<;IO+1=DD42QI)+EWV@2 'KOP3^(&H?$3P_KU]J4%K!)8>)M:T
M:'[)&ZJT%IJ$]M$Q+$Y<K$"Q& 6R0 .*P_C[K7QETVWL4^$VF^#'6.*:XU/4
MO&MU/';Q(FW;'&L!#%VRS;V9541MG[P(PO@I=:M\._$<O@?5-'\O4->\0>+/
M$OF?:4_<:>=5+V\N$#9,HNX=JLRG&_/*D5YU^W7X5^,OQ$U?PCX9\#^"+_Q?
M\-F\RY\5:?I7B2VT2?4_O*EFTTC!UA()9PJG>&QE2 : .<TG]N[QI\0O@A\%
MKGP?X5T6/XK_ !+OKK3[6TUB6;^R8/L;E;NY.S]XT;;1A V5W,-SF/YNZ^&'
M[7'BOQ/\$_'&JZG\/Y-=^)?@WQ'-X5O_  WX7E/D7=XDB(LL;R;O)MSO.YVW
M;%1VY&*X/Q]\)?B?K&E_ CXE>$_@]8^%_%'PUU"\MO\ A64>OVQCDL)E2(^5
M=J%A5@$W<C^,D[MN#ZC^R)\%_%GP[\%?$?6O&]G;Z=XM\>^(;_Q'<Z+:7"S1
M:>)N$M_-7Y9&')+@X^8=P20"E\ ?V@OB9^T%^R19>/\ PYX>\.R>/]2NKB"S
MLKB66WTRWVWAA$DQRTA5(QO8)\S[2!C<#6A^RG^T!X^^(WQ&^*7P[^).E^'(
MO%'@>:Q,FI>$)9WTZ>.ZB,BQ@3$N'78<DD9W,NU?+);QSX>?"7X_?!S_ ()U
MP^!?"'ADV?Q:DO+F'[,-1M!)8P37<LC3QR^;Y0<1E=NU\J6#  K75_LWWWB;
M]G7X:ZU::U\!9? 5P9[".+4=0\8VNK7OB;4KNY2WWW,\2;E??(&+%2H#-M50
M,4 ?6_BM=:DT&Z3P[-86^LMM6WFU2)Y;>(E@"[1HRL^U<D('3<0!N7.X>6>"
M?''CW7=2^(/@ZZNO#ESXL\-O9_9]?M=/N$T^5+I-YWVAG=Q)$$?,0G.X>4=Z
M;R%ZCXY:IXQL?AS?-X$TNXU+Q#--!;K]D-J9[:!Y%6>>);F2.!Y4B+LB2-L+
MA=P9<J>$\(VI\/?##Q!HEG\$O%$\$CHVH:9XDU#2;F[\1?:6$=V\DIO9DFE$
M9.X7#QJRA8U(4*  7?"OQPN/"\/CQ/B1J6ER0^%-6LM+?Q!HEA<16US+=K!Y
M</V8R3R1RK)<PH5#N,21OE0Q"V_%?Q8\6:+\>/"/@X>%[6U\*:Q+/"-=N[Y6
MN+J2.T:=A# F=B [4\R1@Q<.!'MVR'E_AKX?\8_#>V\9ZSX8^'$^CZ%>3:7!
MH?PXFU.TMA:8D*7]XIADEM;=667S/(B8AOLI;"R3MCMOB!X3U;7OB]\*=:L+
M)KC3-%N]2?4;@2(/(62RDBCX+!B2S ?*#ZMC H Q_C'\<M1\%^.O!_A?PW8V
M>J7%UJVGQ>(KBY+%=-L;JX\B(C:1^^E;>4S\H6"4D?<#.^,GCKQ_\+6D\5)<
M^&[WP9;7]A9OHKV,XU&X2XGAMBZW@G$:R"28%8S;D':%\P%B5X7XB?LL^((V
M@N/#/Q"\73S:IXUL_$6H0/'HK"%OM$;27"R2V/F-Y,<:"-&=P%B1-K*N!IZF
M/%E_\5[K5/%OPM\6^+;#0=2_XI9--O=(73856)5^WO%-?Q2273,92'>,^4FU
M8E5C(\H!UWQ ^+'BSPO\8OA]X6MO"]M%X7\0:J=-N=?O;T>;*XT^\NMEO;IR
MN#;*&DD93R56-L[U]=B<??/ 4;OND 9SGZ'CD=17E_Q8\'ZSXF\>?"'4=.LF
MGM-!\33:AJ,C2(I@MVTN^@WX8@L/,GB4@9/S @$ FIM2_9]\,ZQJ5S?3:IXY
MCGNI6F=;7Q[KMO$"QR0D<=XJ(HR<*H  & !0!F>,OBQXJT'XZ^!_!\?A:VMO
M".N74]K)KMU>!KBXE2PN+EEMX$!VJICC4R.X8D2*(B-LE4_C9\=M0\!^+O"7
MAOPW96>JW]YK>EP:Z]RS;--L+R[2U1AM8'S99&?RPW&()F(.T [/Q$\#ZMJG
MQ-^$&I6%K)<:3X?U&^DOYFGS)#$^FW$$;DLVYB7= <9)W9[$UYA\3_V7/$;)
M-?\ A;XA^,)[K5_&6F>(-1M771BL82[@+3+)+9"1OL\,*B.-W90(47:P&* .
MZ^,WCSX@?"V&[\7VUQX<OO!UE=64+Z#)93C4KF.>2*!V2[%P(DD$DI*Q>0^[
M8!O!?Y.;^)GQZ\7^%]<^(%WI5KHB^'? <VGPWFD7UI/)J.M?:4B<M:R+(HBR
M9O*B_=3>=-&R93!(;XB'BW4/BU=:GXH^%_B[QGI7A^_5O"D6E7NCKIZ[84S?
M21SW\+R71D:4 O'MB55\M58O(^#\6/A/XCUCQ-XY"^ ;CQ1XGU=E?P?\0(]0
MM8$\+HUO'$@!EE2>U,,RRS,+6*02B1=WS.Z* ?1>@^/M"\5:YXDT?3-0^T:E
MX=N8[/5(?+=#:RR0+,BDLH5LQR(<KN'.,Y! \EU#XI77PI^(WC*?Q5K.NKX4
MM-"O=>@LM4L[$[X[9[<.VG&UC$AC07"1LEVWFEI(=FY=S5Z5\/?&$OC"^\3V
MS6JK;Z#J7]D1:AYF[[<\<$332",*!&%ED>/ )R8B>.*YWXB?LZ^$?$G@7XA:
M3HFC:5X4UCQE9W$-]K>E:9%'<RSR;W6:5D"M,5D8R$,V6);GF@!/",OQAUB?
M2M9UR7PAH^F7#"2[\*PV=S->VD3 _)_:)N%1Y5!1C_HJC.4SC]Y6EI/Q\\#:
MMXRC\-VNL2R:A-=36$%PVG74=A<W488RP07C1"WFE79)NC21F!CD!&48#-\&
M_$3X@:A>:7I/B7X7:AIVH;_+U#7;75+&31LKNW2P'SS=-&^!Y:O;J06 <K@N
M/'?@G\ [CPC>>$O#WB?P+XRU"Y\-WQFC\2MXXN)M 9H@YANH;%K[<KME<Q&U
M5$+R88JJ[@#LOBI^V-X6T7X7>)-=\(/J.NZA83G38IX_#FISV,%[]H-N1-)'
M!M(B=69D#J3A%!'FQENED_:(\->"] TP>+]8N[[7&T_^TKY=&\)ZIFUMSG;/
M<V2+/+8H0#C[25)*28^XX7@U^$/BZW_90O?"']EX\23:_/>QZ>+B!%,3^(&N
ME;>'"<PL'(W9.2#EB!7475OXQ^%_Q4\>:QI7@74/'>F^+&M+VVFTN_LX'LIX
M;2.V:"<74T16(B-9%>+S#F27* @;P"[XR^-CZ;XJO;2SU32+7PRO@6[\6Q^(
M9+:2_2+RI(MDVV&5?.A",SE4(+C;M:MOQ%^T!X-\!Q64.M:C>7NHR:<FHS1Z
M%H-]?-%;D "XEBMXI7MXG((5IL!MC@%O+?'AMQ^SEXOT+P"_A^TM8-:E@^#N
MH>$UNK&X2*!]2EV%(8O,=66-L85C@*JKN*\5VVB:;XV^#GBK6]4L_ %YXYM?
M$6EZ<RC1[VP@FL+NVM5@>"?[3/$OD-@,C1-(03-\F-I8 ]]TW7M/UC1[75K&
M]MKS2[JW2[M[VWF62":%E#+(CJ2K*5((()!!!Z&N T7]I+P#XAFNHM.U'4;M
MHK6>^@V:)?8U*WA*B66P)A_T]%W(<VOF@AT(R'4G.\'_  ?U'0_V:[?X<WFH
M11ZG)H,VE2W=CO,44LL;+F(_>\M&?"DX.U5)"\@>?_ GX3RZ3K_AF?7OAWXP
MTK6_#MA(@UG6_'$^K:4)_+$#_8(&OIVVR L5:2"(JG8-A: /5?@!\;[+X]?#
M/2/%MKI=[HK7D,;S6=[;7$2QNRAL1230Q>>G( EC4H>><@BK-O\ '/P9J'C)
M?"7V^[@U6:XFLH6NM+NX+2ZGB!\V""[DB6":1=KY2.1F_=R<?(V.?_9?\/Z]
MX*^#&A^%/$6@WFBZCX?A&FF6>:W>*]"<"X@,,SXB((P'".,'Y1@5XY:_#3XG
MZ[\3O VLZYH/B9M3T7QE<WVKZU>>*(QH[:=Y-]!"UCI\5P$5?+> %GMXY@6;
M)EWR/0!] ? GQ_J'Q(^'_P#;NJ06]O>?VQJ^G"*T5E3R[74[FUC;#,QW&.%"
MQS@L20 .!7^/WQ"USP'X*@C\)6NGW_C;6M0M]'T*TU5F%J]U*2Q:780VQ(HY
MY2%YQ$>1U'&? &ZUCX>1Z3\.]4T,P7]Y<^)=?NIA<HPM;>36W>T&(PZLT\=X
M&'S#:(GSSQ5OXC_#;Q1\3?C-H%U%K6M>#?#7AG3I[FSU?2?[/GDN]1N6,4B^
M7<Q3A5AMU==QB!/VDA6P"& .ATW]HCP?#\(_#/Q#US45T/1]=CM503QNSQ7$
MWR_9V"@G>) Z$=0RD=3BIX_VDOAZ/!VN^*+O7)-(T?0;J&RU=M8TZZL)]/EF
M,7E">WGB26-6$\3!V0+M?=G:"1XMI_P-\;^'[4^$4CNO$OA[3OB)IGBK3=8O
MI[.*22TEF%S?AHH?*5'BN3/)A(T!$T>T-AL:OQ5^#_BSQ3JGQ5EL-%6\M=>G
M\)RV(,T*K="TO%DNR59QM"QJ.&VDX^4,0,@'M?@'XN>&?BE/JEKH5S>K?Z7Y
M1O+/4]+NM.NH%E#>4YANHHY-CA'VOMVML8 G:<><_%KQ/\5/#/Q,\#Z'H/B'
MP?'H_B_59].MDU+PS=W4]B(M/N+LL[IJ,:SDFV*_<CQOSDXP>GT_PGK%K^TE
MKWBK[&?[!NO"6GZ6MYYR?O+J&\O)&1DSN^5)D.XKM_>'!^]57XJ:+>>(OBA\
M&-2L8X;C3]%\07\]]*T\2[$.D7\ VJS NWF2*I5 6&&) "DA KRV.=O/VF;?
MX;_$SQ3X8\>W*/;:'X=TG5C>Z!H5_=/*\QO!>3M#!]H:&V3[+$0S\)YF&D8L
MIKT/Q3\<O!_A&;2X;F_NM3N=4M3?6=KX?TR[UBXEMAM'V@16<4KB++J/,("9
M91G) KB[7PO=M\;/BAX@>*WDTOQ!X=TG2=+N?M,+_:+FW;4OM,2H6R"HEBR"
M #SUVMCSCX-^'O%WP-M?!^H3>$;KQ:U[X#T+PQJ%CHNH6'VW3M2TV*82Q?O[
MF*.:-O.E!*2,4:$\$'<A=%\DNQ[5K?[2WPZT'3O"U[+X@-]#XIMY+G0ETBQN
M=0EU)$\LOY$=O&[R,HF1BJJ6 #G&(W*WY/CMX.@\:P>%9KV^@U.>Y^Q17$^D
MWD>GRW B,AA2^:$6SRA5<>6LA8,C*0&5@/&?AK\+]9\,^*_A#?ZB+!X[)/%L
MNJ-8W\;PV5WJ-['=+:1,S*\OE?Z1'N5>! Q(7(%<GKW@OXA^*O'OA^^U73->
MU'4M/^("WYU9O%<,.B'28;J4Q0VEA'<!7FC@50_GP!RRS'S'PH!=!R2['TC#
M\=O"%UXUD\*6UW?7FKPW9L)Y+72+R:Q@N0@D:"2]2$V\<H4@E'D!RRC&2*Q?
MC-\3M8\+^+/!/A'0[S1M!U#Q1)=+#KGB&WDN;.*2!8BMJL"2PF6>;S3L7S5X
MBE/S%0IYKX+WWB#X<R#P->^$I+^PF\0:I/#XQLM1L1I]Q'+<7%WF1'G^U?:5
M+/&Z")\O&SEPI)7IOC/JMM<:2-'U'X:M\4/"]]'(=4MH9],>.!HI8VA$L-]/
M$CJS"4AMQ*- ,#D$%T+EE>UCH]!\67.@R^'O#OC+4].N?&FJB\:#^R+*>&VN
MHX7!+JK-)Y6(WB)5Y&PS$!F S69XD_:*\ ^$M/\ MFIZV\,3:ZWAF-8["YFD
MFU-8WD^RQI'$S22,L;;0H.]MJ+EF53XIX=\%^-?A[I_PM\02:1>>(Y_#-UK$
M=SX:&M03ZEINE7S.;.#[1<S(DTEND<$3$R\_-LDE" M%X=^'?C&:^\.ZCK.A
M6^D7%M\5[SQ=>VO]HVTIM=.FTV]ACE9@^"V^6)=HRP))&0-U%T5[.78]B\2?
MM0_#SPDTBZMJ6HV9@T^'4[PMH=^ZZ=;RJS1M>E(&%FQ52=D^Q@ <C@UZ/I.M
M6OB'2+'4K"3[187T*7%O, 0)(G *M@@8RISS7S#\2H/%O@'3_CUIUAX2C\06
M?C"*74[37(]1MH;>R:338K1H;Y7E6?"M;;D,22;Q(%^3!->J? _Q-<W%G#X+
MET[R6\+:#H]O>73SEG-Y) 6DMS'MXV(L+ER?F\_&T;<DNB91E'='EO[67QG^
M.'P2L]?\<^&-#\"2_#?PW;V[W?\ PD-Q<C5+YF=!(;?RPL<8)D6,"0ELQD@$
M,H.'\4/VMOB3K/C+1O!WP<\+:#-XC;P6GC?5_P#A+YIS';6[85+-%A*L;@ET
MX; ^=<CJ5X[]ICP)\:OB-^T<;[4O@M+\5_A#X=6"30O#_P#PEEAIEA>7>Q6>
MZNX9=QG*EW14=0H7/7<X;7^+/P[^-GA[XX1?&3P#\.8/$VI^*_ ?_".ZQX7G
MUZV@?1+TE)-_VAR$G5& 3"XW;7((W ADEAOVX/%WQ6\/_!G3OA'X=\/OXZ\?
MV%YJD_\ PE4\[:=I,5H9(YU9H@LC%IH9$1AQ\G0YXV/ /[0'QS^/WP5\->+?
MASI?PZ\/Z_8SWVF^,;+QG+?&"UO+=D7-J8,E4(#NRN3L#HH9\%CYII/[)?Q1
M_9F7X ^*_ ?A^Q^)6O\ @_1[W0]>T&/54L/,6[EGN3);SS8&R.6=U)*[B!'A
M2"^SHK']G7XN?#_]@'Q7X-T/3;;4?BSXRNKB^U&QLKN**"S>]G07,:R.X3*0
M J2&(#$["P ) /9/V)_C5\0/CW\*[KQCX[L?#UG#<:A+;Z/-X=CN(H;VVC;R
MS<;9W9PK2!@N0IPI)49Q7<_&CQ]KOA>Z\%Z!X;_LVTUCQ5J[:9%J>LP/<6EH
M$MIKEMT221&5W6 QH@D3ERV3MVM7T%;+X&Z'\+/ASH>G?:XI@FBQ*)/+%K;6
MUG+))=O\K;N8D3DC<TRG=U)S_P!H+P7J'BR;PO-)X6?X@>$+.XF.M^#XYX%-
M_N1?LTC17,D=O<"*0;C%,P4;O,7,D4:D 9X.^.[R?"'5/%/BB&W-_I6JW>@M
M_8ZNUOJ]Y%=M:1BS5B6S/,%18]S%')3>VW<8_@O\>'\1>!/!D_CO[#HOC#Q)
MJ>IZ1;:?IL,SVTES9SW:ND;D'"B*T9M[E0=O;< >2\&_LY:UKFGZ7J&H^(O$
M7PXBT?6[W4/#7AO39M.O4T:VEB2&.%Q<0742O&%N-BPL4@2Z>*-B@S6S\ _"
M/CWX1^#="\/:E9ZAXH.I>)-8GU*^U*]L86T:VDN;J>"8)!$HF\]O*+("61KE
MB"J(%4 WO!'Q6\4Z_P#'/Q)X1UOPQ;>'M-LM)AU.P'VQ;F]N$>\N;?S9=O[N
M,,ML'$:M(0I4LRL3&O)?#GX^^,?$NN> =0U2WT1_#?C>_P!2TZST?3[68:GI
M#6HN&\RYF>9DF ^S&.51%%Y4LR+N?&6[BW\':XO[1^O>*/LC1:)<^$K'2X+W
MS5.ZYBO;N1EV;M^%66,DD!6W8R<&O)/AC\)?$^C^(/!#OX"N/#WC+2;@R>+O
MB,;^T<>)D6%TE7*2O<7'G2-'(L=S'&D&WY#F&,$ ]'F\??$#P/\ %+P9I7BB
M?PWJVB>,+^ZTZUL]'L+FWO-,>.VEND=YI)Y%NHPD#1,XB@^9T<  [:]?U#4(
MK.QN+F7B*WC:5V&,@ $Y&?I]*^=OA+:>*]6\3?VY\0OA9XRA\8ZM#)93:Y)J
M6D_8=#M7)/V:S\C4#-'&,#,RQF:1L%CA45/1=(^ /A?1M5M=0M-7\;O<6DRS
M)%=^.]<N8B000)(9;MD=3CE64J1U% '#>#/CGXPDC^&7BGQ2OA]/!GQ% _L^
MSTVWF6]TAI;*6]MA-,TKI=;HH'1C'%%M<KC>N2$\!_'+QUJZ_#7Q;K-EHB^
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M (OLHVD!F [#^[CD8'08-*UON(.XCZ<9^OY?YYR44 +Y)YRY/I[=O\YH^SC
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MS%V\R5Y79B ,L[DLV%55&2<*JJ,  444U"*U1G/$UJBY9S;7J;#6X9BV<-C
M; R!]:##\V=WTXHHJSG$:U1PP;D'/;U__6?SH6V5 0._J,Y]/R_*BB@ %N%.
M0?ID< X '\OK[T-;[E5=Q&/XNIX^M%% #EB"KCVQD<?2F_9QC X7MCC&<]/S
MHHH &MP3Z9Z\#G^G:G>2/4Y_/^=%% !Y9YRV?P_SVI##D8SP.@]*** !;<#O
MZ8QQT_\ KTJP[6SN.<D^O\^@X[444 .5 OU]A@>].HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>eigr-20221231_g4.jpg
<TEXT>
begin 644 eigr-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )L!$X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**0D 9
M/ H 6BD+ 8R<9Z4;AQS0 M%-W+ZBEW#UH 6BN9\5?$[PAX%N((/$7B?2-"FG
M4O%'J-[' TB@X)4,1D T[PK\2?"?CJ6XC\.>)=)UZ2W57F73KR.<QJV0"P4G
M .#U]* .DHI"P R2 *XWQ#\:/ 'A+5)]-UOQKH&D:C  9;6]U*&*6,$9!968
M$<$&@#LZ*I:-K6G^(M+M]2TJ]M]2T^X7?#=6LHDBD7U5@<$?2KM !12;AZTM
M !16#XL\?>&O 5O!<>)=?TW0()W,<4FI7:0+(P&2%+D9.*Q='^.7PZ\0:I;Z
M;IGCKP[J&H7#^7#:VNJ0R2R-UPJALD_2@#N**YGQ7\3O"'@2X@@\1^)](T&:
MX4O#'J5[' TB@X)4,1D"JGAKXQ^ _&>I)IV@>,M!UJ_=6=;6PU&*:0JOWB%5
MB<#(S0!V-%<3JGQN^'NBZG<Z=J'C?P_9:A;.8I[6XU.%)(G'564MD'V-7?#_
M ,5/!GBN^^Q:+XKT;5KO_GA97T4K_DK$T =312;AZUQ6M?&[X>>&]2ET_5?'
M'A[3;^+B2VNM3ACD3ZJ6R* .VHKF?"?Q-\(^/)KJ'PUXGTC7Y;55:>/3;V.=
MH@V<%@A. <'KZ5FZQ\<_AUX?U*ZT_4_'7AW3[^U<QW%M=:I#')$PX*LI;(/L
M: .XHK$\*^./#WCBUENO#NN:?KMM$^R2;3KE)U5L9P2I.#@BH/%7Q%\*^!?L
MO_"1^(]+T+[5N^S_ -HWD<'F[<;MNXC.,C./44 =%17!K\>OALW \?>&SSM_
MY"L'7T^]7:V=];:C:Q7-K/'<V\J[DEB8,K ]P1U% $]%)N'K1D=>U "TA(7D
MTGF*%)+  =3GI396&PY.* %\P>AXZ^U/KRC0_P!I+P#X@^,6J_"VUUG=XSTM
M!)/8LC+D$9.UCPV!C..F17JV1ZT +12!@20#DCK1N'J* %HI-P]:-PQG/% "
MT4W>OJ/6C<..1STH =12;AZT!@<$'(H 6BN6\5?%3P9X%O8K/Q'XKT;0KN5/
M,C@U&^B@=ESC(#,"1D4SPO\ %KP3XWU%M/\ #WB[1-<OEC,K6VGW\4\@0$ M
MM5B<9(Y]Z .LHII=00"0">GO65XF\7:'X+TO^TM?UBQT73]XC^U7]PD,>XYP
MNYB!DX/'M0!KT5Q>@?&KX?\ BK5(--T7QMX?U74)R1%:V>I0RRR$#)"JK$G@
M$UV>X>M "T4@8$X!!-&10 C,%I!(.,@C-17DWV>$R;&D55+%4&20!G@=^G05
MX3X:_;2^&GB+XN6/PV6?7--\9WI(BTW5M%NK-CA2P/[Q  I4$@]#0![]3%D!
M]CZ4[->2_&#]H[PI\#4ENO%-IX@BL(8O/GU#3]#N;NUA7(&7FC0JO)'4]Z /
M6E8-R*6N)^#OQ>\-?'+P#9>,/"5U+=Z'>-(L4T\+PL2C%6RK $<BNUW#UH 6
MBD# YP<T;AQR.>E #3,JG!IP.:\D^)G[3GPX^$/CSPYX1\5>(K?2];UY]EI%
M)]U2> 9&Z1@G@%L9->L1,K1J5(((R#ZT /+!>M-$@9MN.<5Q'Q1^+FD_"FWL
MY]6TS7]1AN-__(#T:XU#RPHR6D\E&V#'<XKF/@'^T]X!_:4&L3>!=1NM0CT:
M58;O[59R6S([ D##J">AH ]AHI-P/0YHW#UH 6BD#!NAS2T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&\5?\$X?V@]$\+7^K:EXF^"GBIA]B2_/FW&GL& =8W)&_:73.<9##ICGT?\
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MCUYH ^QO!_[1WPR\?:P='\.^,=/U/5?+\U;3<T;LI./EW@9Y&.,UH_$CXW>
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MS)MYR>V*^EFL49!%Y<?DXVE"N01Z8JE9>%]-TV2=[2PM;:28EG>.( DGUXH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,T-G'%,YXI7UL
M[<OK2;@343.(\E@%7WKRWXD?'C0_ OF6D+?VAJ>W*VT!^7/^TW;\JY\1B*.%
MASUI61V87!U\9-4J,')OL>G7UW%:PM+-*D42C+.Q Q^->3^,OVBO#?A>9H;>
M=M3NP/\ 56Q#(/\ @?3\,U\V>-OBYXB\;74HO;MH8<\6MJ2J(.P/J<=ZXWC
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M%69[2[O27;>'VH"1C()(K1^&_P );WXWZ')XK\3^(]5@N+Z8O!%8SA(EC''
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ME24ZCDI-->1\K^)%T7P#^T9=ZKXKL?+T:_ME-M?3(7CCF"@EN <$X(_&M/\
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M70G8N,8!]Z^QVTFUFNHKQ[:.2ZC!$<SH"Z@]<'M5&^\'Z-J5P\][I5G=2O\
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M!A1P!C&*FV]*\6I/FO)=6?7TX>S@J79(>O2EIJ]*=0:A124M !1110 4444
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MZ4[I7+R\JL>FER[[BT445)04444 %%%% !1110 4444 %%%% !1110 4444
M(REEPIP:[CX1_$N[\ ZY&@DSI\QVR19^5?<5PY;;S2;=R@ ?*._>NK#8FIAJ
MBE!V2/,S# T<PH2P^(C>+_!GZ&^'-?M]>TZ*Y@E#HX&&S[5M1*%7BOCSX#_$
M]_#NH1:3=R,8)VQ$S'(4U]>6%XEW;JZMN'K7[=EV80S"DJD3^7<YRFKDN*>'
MG\+V?=%JBDW#UHW#UKU3P1:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "DI:* "DI:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!.M!Q32VUCW_&DW<4:AZCN*=46[G@Y
M-.#':3C)]!0*Z>P^BDI:!A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2TC=* $/2DV@<T>
ME5;BX^SH9"WR]SVJ+K5O9#5W9+=G ?&WXA1^ _#,DD9S?7/[J!1V;&<_0"OB
M6>ZEO+B2XGD>2:5B[%NY)SG\:]"^/'CT^-/&5PJN#86;&*/C);'4CV/%>;E3
MN+=CS7X]GV8?7,0Z<=D?TEP?DJRW!JK47OS5V/I:**^6?8^_78****!A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (W2BAAD4@XX-+?1[$R5T$<
M[1N'CS',IRC9Z5]<_ 'XC+X@TI+2ZEQ<1C803R<=Z^1V4-U&:Z?X=>*I?"OB
M>UN%8B)F". >.?6OI\ES#ZKB5'[+/A>*\IIYE@Y5(1]^.I]^KM;!!X[4O"UB
M^&=635--BE5@1@'.?:ME<'O7[-%J24UU/YI<7%V?S):***8@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*3=3
M78+UIKW$<:Y8[1U]Z%KL#T)-Q],T@<G/!K@M2^-&@V5RUM EU?3<[?(1<,1U
M^\P(Q[BL?4/B7XAO+5ETG3;!II" DGVO<4SW8!>*I0E+9&,JL(;L]2:X"MMV
MDMZ?XU0U#Q'I^C^4=0O8+)9#M3SV";C[9KQ[P3=^,8[::35]0NDU!-P0W$OF
MV\G/79V]JY^Z\*Z[9>)+K7[K3[;7[J8B4(TQWQ8&..,8XZ5O&A)[F$L73BM#
MVNX^)>A6]I-=&\4VD0):X493CJ ?6JEG\6M$U*V2>T6\NHFQAX;5F!_*N0\*
MZ;9P:?)/#HO]E23G=)#(J[F/X$\5<TGPWIVAW5W=6%L+62\.Z7:<@GOQ6ZPM
MSA>/Y7L=*?BUH!:Y$;7,WV<9F:*!F$?U-2Q?$FQE^<6=X(-NX2>2<_\ ?-8P
MC15("]?R_+O5?4=2MM/M&DO'V6TH\IGP<$GMP/\ ZU:?5(I:LC^T)-V43HX?
MBAX=DD*3:C'9.O5+O]T?R-:&G^,M'UB<PV&J6EW,!GRX9 S?E7F>F?\ "+:(
MSI9RZ?"S#<^W:#SZ^M,O[.V\5-#!I$<\EU;RB5+JP(C6%AV9O0Y/3-8/#Q^U
M*QV0Q52I)*$;KJ>R&X9" P7D>N*>LA/H?PXKQY/B-'X$U#4;35;R\U.\54(M
M8QO6W^7[N]B,@GGI7/W?[06M:E;N;+3(M.=6P&E;S,CZ8%52P-?$.T(F6(S7
M"X7^)+4^@ED+=!D>N::TK;L <?2OFR/XZ>*[)O,N)K6:-?O(EN!G]:GU#X]W
M>H>'[J&]M9[263F.XT_[RXZ>E:2R[$4Y<LHF-/.L'4ASQF?1C3%>I'/2N9\=
M?$"V\"Z*VI7,/GP1N$DV.!LSW)KYTTGXE>(IK9Y)=1GNXYQL>VOF\Q=OT[&N
M9URW6\M;R.RBDM7E.1#-*9D/<G)QCV&*Z?[)Q$;.2T.)\08:=XTWJ>VP?M1:
M;<7#JNDR&$' D^T+C^5;^H_'?1_^$?O+RP9FO(U)CAFB.&.1QUKYITW1XI-+
M1;D;BPP5VX.:U1&/*$?&S&,$9KVXY'"23N?+U>*L33FX<B.MF^./B_6)#*S1
MZ4@;=LAC[#_>SUK)E^-?B?[7(H\0SDL<B-((R![#Y:R5^Z00 .V*CD:.UC,O
ME E>ZCYJ]1Y5AZ<4G"YXJS_&UYO5KYK_ "-AOC)XR9ML6I7Q;U\J,?KLK?A_
M:,\66<*12Z7;SO\ \])48L?^^2!7G2ZQ/<7D(6UN&M6_UC,!Q^&:N/?)"A>4
M2(O8Y KDG@<&U[T;,[J>:9A3?NRT\W_P#W7P1^T/8ZU(;77;>/1+D*<2O)^[
MD(Z[<_XUZ7IOBK2]8.+*^AN>,_NV!KX^TUEUBUU.?SK=8+2,-'N8EIB2!@#%
M=G\';2WD\8+-J1V"SB\R)HY-BH/]O/6OG<5@J--.46SZ[ YMB*\E"<5ZW_0^
MGXY&?.1BGEO<5SY\8:'#937/]IVQAA7>Q60'CZ>M<6W[0F@,"8[/4#M..8EY
M]_O5Y%.A5K.T(L^BK8W#X=)U9I7/5-_TI<FO.M)^.'AG4MWG2S:<.,-=1X!)
M],$UZ!!/'-"LD;;T89!'<5%2E.EI45C:E7I5XWIRN3+TI:2EK,Z HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z4
MM-D.%.*!-VU& G."*\X^.7BEO"?@*]GMW9;R8>3$RXRKG@&O1E;=NS7RE^U=
MXA^V>(M/T<-NCM8O-9E?J6)X(]1BO%S;$_4\)-IV;/I^&\O_ +1S2E2:NEJ_
M1'A+'S&WDDD\G/K1M_$^M+P>1T/-%?AG,Y/FZG]50244ET$I:**184444P"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1EW4M% NMQ-OO2*IC8
M.#SV^O:G4TM\PXIIN*O$4H\R:>Q]6?L[^-3JFCQVL[#S8QY;<^]>[)CC .*^
M)/@CX@.C^*DAWL%FY/IN[U]JZ7="ZLX9!R&%?M^3XKZU@X-N[6Y_*_$N 67Y
MC5IQ5HMW7SU+U%%%>Z?+!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %)2TF* "BC%,9@A);@#O0 _-&X<<U$W; R.O6L#5O&NF:'J2V-W(R
M3.N\$CY>F< ^N*2NW8EM+5G2;AZT;ASR..M<C;?$;0I9C')?BV?LMP,%A_>'
MM_A6=K7@>?4O$EKK5AJ@C99-TBRY?Y,=$P0!^(-7RLE3B]B_X\\7#PRJ16H2
MYU:Y7;;VS. 3[_\ ZZ\RT7POK>H:F-:U+Q'JPDG#.UCYD:K$_;&P=.O'2NP^
M*?@]]>M8[ZR@2_N(XO(:%R260L3E2#P0237':)K$/A325TQK9VNK8 RQ!"K$
M'^Z"3_.NO#QCU.#%3E]D=XGT'3+S$]];BUU.S#21WL4+^7.I!/[W8.W<GTKE
MH)=9AL[]M#O(XYHX!-*]G!;F'RR2 X(&<9!Z\UZAI>I+KNGK<>3)$LI*&.<?
M-L[C%<;XG\(Z;9VTL>BW5OHDR*1/('R54G*Y7N,[N*Z7'E^%G'&O&3Y:B(]!
M\32Z?I[SSZF^JW[KN:U2-ECDR02 S# QU_"KFG_%);]Y,:/?+Y9_U:QON;'?
M>/E/X5E>$_$\=A;V^@^)$622X+)]L7!@D7M@\$<5N:?X.O\ P_J#R^']31-+
MDC+?9)D\V-3D_=((/2JBG+2Y$^1/W4<['?>*/%WB":9;62PL8BIAM;D/#G.<
MEF7!/TSBO4;99?*4SA?.V_-@<#Z>GU-0WUU+8Z?+,L#7<T:[O)A&"WK@?_7K
MSW_A<":C->V$>E7<%S$5C1=X5U8XY/' _.M'[NYCRRJO1'IFX9 SRW0>M<;K
MT5CXJO)K)[RZN!&WV633[1BCLP_BROS*ON>*LP_##Q+XHTAH]8O;.)"^^(RH
MTL@! YW*RX^F*[GP_P"'M ^&6APQF=+<+\KWEP?GD;Z]:Y:F(3]V*.ZG@^76
M<K'C^I:+X8\(VJP3PVYOXWWFWMXQ<2L/[C2/D*?QJC)\3=3TJRBT_P /V\&B
M6,<FYE4>9)(#_>)SS7>>*)_AIJ$U[JDIL]1OW&66W9M[D#'T[8KPZSM(;=IG
MBC\L2N7 ).<=J]G+</3Q#_>Q;/DL]Q]3 _PZB7IJ7]2U+4-:U2XO]2N_M=S*
M%4E8U0+M&!T'/%0^X''UHHK[:E3C1CRP5C\SK5JF)ESU;NXTH) 5;HU!7;P#
ME>FW%.HK71[HRC>/PL$4*O0#%#,S>E%%)W:LPZW0G+<L.3T'I2T44W:R20)+
M5O4*.,'=T]***'KN)14=D(JXR%X!]3Q4-Q:QWD)25%,??K4]%39)617-.]TR
MI(G]GV[&UMU$@&%C ^6F6%E<*&:ZG>66<X,? 0+Z<=>:O4F-WRXQSG(/-8RI
M.2NK:'7'%58M*+:\^IGW>H16/RQVZR2-\K)$!A2?KZXZFNA\"^'K[XA3S6^G
MCR)X5_>>=N*J?=AQGT%3?"GP/'JUYJA;5[FWAA(>>-X0^4R<A6]:^F?".D6.
MC:39QV"EH60?O74!W]"V.]?'8O-9TVZ=*R/TG+LCIXBG&OB+M,X#PS\ ;'3[
ME+K6+N75)% *Q, L:GZ#[W_ LUZS#$L,:QQIL11@ 5/17R]6K.M+FF[GW5##
MTL/'EIJPB_=I:**R.D*3(H-,D!/0T>@#]P]:-P]:C&57K5"\U.TLV<7-RD.T
M9RY J)245JTAQ4I?"KFGFC-<!J7QL\'Z=#(YUFWF,?!6-LMGZ5RS?M1>#E89
MEO2,_P#/O_\ 7KBGF&%I?'47WGJ4\IQU97A1D_DSVC</6C</6O'(/VH/!LS;
M1)=K_O6__P!E74V'QD\(:@T2)K=LLLOW8V;!JJ>/PM7X*B^\FIE>-HJ]2C)?
M)G=;AZT;AZUF6>J6MX"8;J.?'/RL":OJ=W(.176IQE\+OZ'FM26C5O4DI::*
M=5""BBBF 4444 %%%% !1110 4444 %%%% !37.%S3J;)]PXZTGL!!*PCC9O
M3DU\!_$O5U\1>.]<OTW>7)<,JAFZ!>,8^H-?<GB^_ETCPIJUY%@S0VSNN>F0
MM?GS-,UU<33O]^5S(WU)R:^!XJJOEA2[GZ]X=X=2JXC$O=))"4445^8+8_=
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MK]&/QH6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYX?#K%17NIV/Z4\(N):>.Q-7 R?O.-U\MQE%%%?B3M?0_JA;:!1112&%%%%
M!0,YXHI&Z4A;Z&CX;OH--U[3KR<E;:WN5>3UX:NP\1>.+6^U;Q7=V$\J_;KR
M"6VD5""-@&=W/3BO/F;@D\D]:16+ -W[5Z6'QU3#PY8GA8O*:.,K*O4>J5OQ
M3/6_B1\4-,\:?#_3K.)9$U?[0DMR@BQ'N","0<]\UD^!?$&A7G@O5O"^K7,F
MG?:KA)X;KAE\P8P&'89%><@%E&3FD6,J1@\#M6SS*K+$+$/>W+\CCCD.&AA?
MJ<)M>]S+R9ZIX+UK0/AKXDFFAU>74)6M9D,\4.$5^-NP9Y'7)IW_  MR;5_A
MAKVD:S>SWFI3W$+P,RC[H<$_2O*L-T'3.:=N.X<U:S.K2A[*E\-G^)G+AVA4
MJ>VKS<IW3O\ X=3U7QM\2-*U[5A<6\CF+^P?[-!>/!\W:1Z].:OM\6M*U+X1
MS:%?/+'K$J+$9TAW!XU88).>3C/%>-?>'//&/PI<?GUK19Q7@Y.^]R)\,8*I
M"$&VN6UGUT_X<]='Q>L-+\8:3]CT^UETRSACM1>,C";RBH$A"YP#RQKS7Q1-
MIUSXCU";3<BQDF9K<-PQ4XY(^M9855SVSR:-H9L]ZXL3F%3%4E3D=V!R7#Y?
M6]K2E+:WJ.HHHKSCZ,**** "BBB@ I#2TWN:$]2962NQ8U#2+WW'%?6G[/\
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M@ HHHH **** "BBD[T 5[^\CT^TEN)76.*-2S.QP !7%-\0+W5K%FL--*)(
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MU8UNJH^Z<;>AXZB@'/0=>E:1A".D5<QE5;UJ2W,G4O#W]H3%XKN:S:1D,J0
M$3(ISM8'UZ9'.*98^&5AD59[J>]MUD+I;S8V(3UP!VX'7I6E>7\&GV\MQ<7$
M=O"G+2.< >M>->-_VA(K5I;7P_ ) #_Q\R=,\\@5Y&/S+!9=&^(DDSZ+*,FS
M#.I>SPL'?OT^\]?$=SIL@N+'4GLTQF2%B'CP!@#G[HQZ5RWB[XE:=-:AKJYM
M!J%J3Y=S8W"@@>C(V2:^:]:\<:[XFF$M_J$TNT$!68A1] *Q-S#!/WNYZG\Z
M_/,7Q>[_ .STT_,_9\!X;5%!?7*_JE_F?1%A\>]/^7[3+"FV4(Q$3;G7!)*\
M^PKH(?C9X2D@9UOMB#^]$1_^LU\KY5FW-\[ <9]:50(U)0;2W4CO7!2XRQT'
M>5-6/7J^&F5R5HSFGZZ'U;)\5-/NE!TQ/MJ-\H?S539G^(@].G>L?2OBO+;:
M@ME<+]NCDG\F*[5PH9F. H?[I(S7S9'<.J[5D* \GN<CI7=Z!\5+BUM%T_5[
M6'4].XRK* R\\X/M7T6#XPP]9J.(]UL^+S/PYQ6%3EA&IKSW/;=4\,:O:^(K
M,W.G7UWINI72Q&!)MT=O& -S$KR.OK5S4M6\0Z3X;GL+S1X=%\,6[;9+A;D^
M='"#QU/S$X /UK.\$^+-,U:QACT76+O2XQ\JV<4N!]<'O747&AMJD8CO=6O=
M0@#*S03.&C<#L1]<'\*^TP_+BE[6F^9=S\SQ'-E[>'J0M);G Z]=6/BZ&S@\
M/ZA?.5F1Y;.U&V94( 4KG.T8[]*Z31;![K4M6T>\FN'LD58_L4K!O*SG*&0=
M3QDT>-O"XO5AU"QLXFFM5<21YV-+&!D(&'05U&F6L5G9PI#"L"E5W*![=?K7
M;&G*_D>7/$1E2;^T<UI]U/X!U*>SL)7F%Q$!:V<S%DSN 8^V!D@#TKN/#/CB
MPU*XN[#4)K>*_LPOF[&'ENK9VGGD'((P?2J30HTD<FU5:/[KX^8=L ^XKE/$
MGAAY(;R.)8_LVI3B>XN"XC>%@ !ANX('3_&HJ8=;HVH8M[/L,M?!NEZMJ6KM
M/I%H^GW%R9[2X3'(8Y/2JV@>!=+FUPZ.D7]IV4ER3-(6(>Q(4,J*1T!Z\^M=
M58BRTFP@MXY(888E6)4)P!@<\]JL>%T>3Q3+)I^19N,7YP#'(0ORL"/XL8'T
M%%2T:7F3AW*51\JT.<_X4U=S:R+>"1M-T>TB=8V:3+74K8PQ]%&#Q[UQ=EXZ
MF^'5W<:+J7F:GY-T;?:&$;!B^$VCJ5P17TG>1B6QDB#&/>-B?4C@5YE-\*9/
M$"VUCK,$-M:P2><9K>7=)(PZ=N/SKCI5)1U;/3KT^>*AREK2=:@UBU$\,@(!
M\MOF *'W%8WQ!T6#4O#MZ@MI)YSAB]MCS..A'%5]-\,Z3X)\8"PT&\GN4FA9
MKWSW+JO/R[6Q][.<_A77KD%3_%T 4?-] :].$E4C=GA58*C,YGX%7K2&=GU6
M%G>(>98,")DVG:&;)]!BO9TDSG R<<M7CFIZ+HOBF1UB:$WT.422-OWD;?WN
M,=#VJ/1=>UCX>7"63VMSKFD2.!',9@TL?J=IQQ^-<$Z#^),]2CBE9)GM6XDD
M8XH9:PO"_C'3O%L<[63L)+=S'-#*N'C;T/;]:W6.*XNMF>GOL<-\2OAM:>.(
M(9Y;AK6ZM@=D@/RXZD$5X/XP\,^#=-T"^MK74)-:UAI8U)5%"(,C<!M&#QZU
M]#?$RZO;/P'K4UA&TMVL!*(O4Y(!Q^&:^4-'NH)K-O(+(B-\^<##'KFOHLJP
M]3$OV?-HM3XS/\31P,7/D]YZ7+BKM5%' 50-O<4M!!QR,>_<T5^A6M!1CT/Q
MIR<VY=PHHI%(;A>:KWGK:PN9)\LMQ::SA1R0._S''%.'S D'..M;'@GPW+XV
MU^+3H"PMU.^XF3^%1V!]37-B,13PL.>3/0PF#K8RHH48W.>74;8Q"1Y$56(V
MAF'Y_G5ZQT^?5H6GMK2;4!&=K-;Q&3GTXKZ&TSX&^#=/C3&BV\\FT;I)!EF(
M.03[YKM[73H+.+9!!' O]V,!1^E?(UL^YERPB?HN&X2C"TZE35]#Y_\ !?P5
MO?%$)FUEI=*LF8%(% $CJ#G:WM7O&B>&=-T&W$-A:QVR8 /EK@G'J:O>8JL!
MG!['K^%-AU&VFD:..>.21>61'!*_4=J^<Q&*JXF7-,^QP>7T,##DI(G6/;GF
ME9>*%D#$@=:JS:M9P2&.6YCB8=1(X7^=<B/3)V7Y37SW^UIKCPZ'I>DA5Q<2
M><&/4%>U?07G)(H*,'4C(93D&OE7]K343-XFTRR_YX1;P?\ >ZU\YGU65/ 3
ML]SZ_A.@J^<44U=*[^X\%4A?K01YF,\)GDFEW!:0X;D=J_%]$KO0_J'9M_B=
M_9>'-.T/X>0>);RVCU.[NKDP):S.515'0C:0<UOZ;X%T;QW\,M3U^RLTT74=
M.?F.-V9) !D@Y.:XKP_X+U+5M-6[NWN+70U<_OF5F!;_ *9J.I_*NBO/&4^C
M^#[KPWX<TJZMM/F;=<WDT+>9.>A/3Y:^HH^SC%5,1"T>5JW=VW/SG$QG.MRX
M2OSU>=-N]E&-]8[V9!X ^'\.I>'M1\5:O&\FC:?&2L,9P9W';\S2^!8?#7C/
M7'T6[T:/2FO%(AN[>9B8G[ AB176>!YHM2_9Y\2:=!/F^MYGF>%?O;3C'%><
M_"S29]:\=Z/!;_+)'(LKMCH%.3NJG"-/ZNJ<;J25] ]K4Q2QM3$3<94VU'6U
MK*Z?G<M6?POU.[^(<GA08CGCD*-(><1C^/\ *K/BJY\-^%?$DNE1:!'>16#"
MWFN)I7#RD?>/! ^E>AZ3KFG-^TMJ-RUU&MM.)+>.8'@N5 "_7->/^/\ 3WT_
MQQK5N[--(L[*6<'+]Q^=3B*,<+3<J"YFYM?)%8/$U,RQ,:>-;C%4D[:J[>[^
M1N_%'X>P>&8=*U?2R[:1J:;XUD8$QMC.W/TKO/ >BWFO_L]ZC8V,#3W,U\Z1
MQJ3[=_3WK"^*=N=)^&/@W3+B<"_7=.T+9+!&7@$?I6GX-OKG3_V>=2GM79)(
M[]I5D&?D((_2O0H48T<9.G!73C=^6B/+Q5;$8G*Z$[J4HU;)OK9NWJ<-KEU<
M?#^TF\/0++;ZA)_Q^SO&5<C'"IGJOJ:XAMW)^\V"QVCK7T!>-8?'OP698E6+
MQ=IJ9:/O*GL?0UXOH>JW/@_5I)C9QM<1[D>WNX\[3TQBO%S&C4IM/F_=OK;8
M^DR;'>TA4CR?[0G[R>EWY/MV-GP?H-GJW@KQ1J4\(>[LX5:)\XVG-<CU( _E
M7M_A'XG7=YX'\57+:5IJ&WB#!$@ 1^>A'>O,_$WC:;Q59Q03V%C;>4<C[/#M
MS2QN'P\80E"?3[S7+L5C)8O$1G3TYOYMM%]YS?-&">!T[TUE#'DXIT8"=#SB
MO!C>Z['UK;/H/]FW7F*FW+#Y3@* <U[OXN^)6D>!6LUU9Y8_M6?+,<9?./I7
MQ#\/_$FH>'/B%HC64KB*XD$<\*GJO<_A7U-\:)K?Q!X$C:QNK:46<@EEQ(/,
MVXZ >N37[UP_?$X.BY[/3\3^2N+Y/!YAB5&R>Z_,]%T'QMI?BB-GTN]AN2J[
MC&&PR_4=N:\R>\^)S>(KB:2YM['38I#(YD \D(#TSUZ>]<)\/-6T3PQ:W&N3
M7-W!X@AB<"V#8AGR,+QWK U_QKK/BM8QJ=[+/"F'2$L0H;.<'UK[2CE=2M6=
M*FO=[L_+\3Q#0H8>%2K+W^T?U/=?$GQZ\.>&V\N";^UKEDW[;1QLP.IW=.M,
MT[XYZ,=%CO-;ECLI97)CM;5O.=5Z@MCH:^;6AC4N-BLK?+R.@I%5 S84#<?X
M1C'M7K_ZN1BU>>IX'^N5>[_<H]T\5_'SPIJ4:6YTJ34[)V&][F,((^V0I&<U
MXQX@>P37[W^Q0\6F1N&@+,2P!ZX-4&Q]TC<OH:3.U-J],_I7IX?):>%FI\UT
M>%CN):V.I.G*/*_(Z'P_\2/$7ABZ$UCJ$DZ$_O+>Y8NC#\>1^%;&M^*-#^)-
MT7U*'^Q]<DBQ'=K*?)DV]%(/2N!==W XI-H:-U;IC!'MZUUU\JH57[6EHT<6
M$S[&4*3PU5\T9::D7F;6Y(\Q20VUMP.#C(/I7<^$[72_$W@N[T*69;368Y6N
M8Y)OFC\M1QC'?K7#1L)G1%ZL0BP+@ ]L5W^@SVWPWT>\N[R:*77KR)H8M,4!
MC C#JY[5Q9A5YJ,*=-^^F=F34IX6O4JS@E2:>K_0\W:0ED6+$D;?>E^ZI';
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M,%J98RZ_(-V.ZG(_.OEZV'Q-%VJ0Y7VML?>4<5A\0N:$D_N$PWK1SZT[G[N
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M[[-:S+,%3RV+6LZ=V4>OMTH\(M;>-/"%O-K,%O>REF1WD4'< Q //3CFN?\
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MH7&C2_\ $MFMEB194QL?'S$>XK@-0BEU3][?3->7!&&EEY)'I["MWQAX-NO
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M$+*I8(I(!)'TS^==<6Z5GZO8R:AI]S;QLL;S+MW.N0/PIZ739$K\C2ZGS?\
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M6/O[GWK4XW+WK\UQ>.GC7J]$?MF59/1RFFHT]9/=DU%%%>:>^%%%% !1110
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MCTW1Y;I)[2PU22+RK:6Y(&'/(7=]:\OV\JD_?/;>'A"*Y-CI8HUAC5%&%48
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M;AAMV0 A,?CS72"BEH&%%%% &1XDO+VPT&_NM-@^U7L<1>*'(&]AVS7+Z?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=L/!NAPZ+JFGNNGVRDQ3PG)V]ACN>M>_>!_COX1\=&(66I1V]S)_R[W/R/\
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M3 9;VZ6L"PPQB.-/E4#TJQ2;12U(!1110 4444 %%%% !1110 4444 %%%%
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M5]]H@DF)5;I;9BL5P"_S2%3T?!.:]24,&.1WI#)**** "BBB@ HHHH ****
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MUNI Z4 >T1MO4'^8IU1P8\E<9QCC=UJ2@ HHHH **** "BBB@ HHHH ****
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MM7Y9B*7L:CAV/WO!8A8J@JZVD/HHHKG.X**** "BBB@ HHHH **** "BBB@
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M>V_#?6K'5-#>WL]1DU.33Y/LMQ/(&!,@ 8_>ZCYAS0!UE%%% !1110 4444
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MU:\>4G+<^F^)\SW!5P3DYYI:6BH&%%%% !1110 4444 %%%% !1110 4444
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M&5H8UED5&959L MC@9KD_ ?Q*A\:+)!)8S6&HP[EEA?E<JQ4[6[C(/85UDQ
MD ZL1QD<8KR/X@>'=5TGQI8ZYH-Y':RW2-;RI<<1*Q0@2D=SR!QZ4 >P+(6(
M^7 ]ZDK@=)^)MG!HT$FL&:"^3"7""!\9R1N7CE>G(]:[I)DDC5U.58 CCUH
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ME2>%/!^D^#;2>VT>S6R@FE,\BJ6.YSU8EB3G@?E6Y10 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNQ>)#\H)D<;C)&3Z<I7I2KA?EX7'%4=$T>'0K&*TML^2G5FY9C6G0 @I:**
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M<;L#N:I7WP+\/:C;VL<L^H++"Y>2Z2<":Z)=9&\YMOS;G16. .5% 'H<;"1
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M[]%*L3TIEKM\E"OW2,CZ5,,5\O4FZCNS[^$8P5HA_%3J2EK,L**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCPMI&AR.]AIUO:.^-TD484M]3WKRY6N['T,4U%)FFO;/'TI])M%+4E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %,DD$:YI]0W#$=">A- !]H!; !SZ=\9QFG^8.O;UKRSXP?$#7/ J:&-
M(CTNW6\F:.>ZUQ;G[+"BJ6.6@1O+.%SODVIVW9(%1>"?CEI^L7'B&+4%$/\
M9GB"#P[%<6:-/%<32V\,RLA0$A#YWWFP..30!ZUFD9BO;/XUQ=C\8/"VJ37<
M5A>S7LUJ9%N([>TE<PNDBQLCX7Y6#./E.#@$XP"1%I?Q>\.:M'=20W<ERMKJ
M4>E226]I+(GGN5 ",JD.JE@&=250A@Q!4X .YW_+DC%-67<V,8^OK7E>G_M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJL5MY"998H8GRDT4BX*P(/NYXX-4]._9J:^\2>(M3\6^+-6\06-]?7MSIND
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>eigr-20221231_g5.jpg
<TEXT>
begin 644 eigr-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ),!$@# 2(  A$! Q$!_\0
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M ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW;6@WR%K1XB QED.P';\W3@  'S#^R_X"\+?\%"O"?QM\=?$JRNM6EUO7Y=
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M0;U$H&XB5P2<C'ZB:9_R#;3_ *XI_(4 6Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I"P49/ I::WW3QGVH ^._P#@J9X]\,6/[(/CSPM=^(M*M/$VI0:?/9:+
M/>QQWMS&NI6Y9HX&8.X C?) .-C>AK$_X)Y_M"?##PG^QU\/M(U[XB>$]!UF
MSCNUN-.U77+6VN(O]-G(+QR2*RY!!&1T((SFOK+Q1\*?!WC>\CO/$?A'1/$-
MY'$(%N-3T^&>14!+;0SJ2!EF.!QDFL9OV=/A=MVCX;^$\'TT2V[#CC9Z?R%
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MD7&YAY7(."^ >HR.:][\6?#CPQX^6V3Q/X<TGQ%';LS0QZK8QW*Q%@ 2H<$
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M4!N,D8]#7TE=7,5G;2W%Q*D$$2&2261@JHH&2Q)X  [URWA7X3^#/ ^I-?\
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MXYR/SK(TSXE^$]8U".QL?$VE7EY(VU+>*\C:1SC.%4'). >*\ \=:'_PMO\
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MJTE2?NU+;^;L=N'S)U:-=35ITKW\[*YII\4?!\DR0Q>+-$:61@JJNHPEF)[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:VEQJUUJ*R/M4#[OE-E<X/&&R#C/-?33 E<;<TNS\JF&/=.'(J4=[K?1_?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !129I: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDW#I2
MT %%%% !1110 44FX'IS2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCHO_ $"K3_OT/\*V** ,7P>FWPSI?;_1TX' ^Z*VJQ_"/_(LZ7_U[I_*MB@
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M )ZZA_X'S?\ Q5;]% &!_P (7I__ #UU#_P/F_\ BJ/^$+T__GKJ'_@?-_\
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M/F_^*H_X0O3_ /GKJ'_@?-_\56]N'!R,'I1G')XH P?^$+T__GKJ'_@?-_\
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MT4 8'_"%Z?\ \]=0_P# ^;_XJC_A"]/_ .>NH?\ @?-_\56_10!@?\(7I_\
MSUU#_P #YO\ XJC_ (0O3_\ GKJ'_@?-_P#%5OT4 8'_  A>G_\ /74/_ ^;
M_P"*H_X0O3_^>NH?^!\W_P 56_10!@?\(7I__/74/_ ^;_XJC_A"]/\ ^>NH
M?^!\W_Q5;]% &!_PA>G_ //74/\ P/F_^*I/^$+L.TVH _\ 7_-_\57044 <
M[H6GIINN:G:Q2320K%;R+Y\S2$$F4'EB?05T58UC_P C1JG_ %[6W_H4U;-
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M_P"@5:?]^Q_A1_PB.B_] JT_[]C_  K469)%#*VX>WUQ_.G%U4$DX H R?\
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ME0&'ECH>@!^C/P5\6:QX]^$_A#Q)K^F?V+KNKZ1;7M_IQB>,6\\D89DVN2P
M)(PQS@#-?)O@[XY?&;]K:\\1>(_AIXVT#X0_"[1=2FTBQU+6=+6_OM6D1(R9
M)%F(1%Y)&TY&65MQ7->^_L:_#OQG\+_V:? WACQ[<-<>)M/MG697N?M!@B,K
MM# 7.<^7$R1\9 V8!QBOCSPYX.\<?LO^#=;^$7C[X%77QT^'<>NSWWAC5=/\
MJ9 902JR0[2T;9>0ER $9W4,RX( /?OBO\8OBC\,?A'\'+K5-7T"7Q5KGQ!T
MSPYK-YH*":SN[&6>=6*"0'8\B1H6V\JQ8+@ 5T'[8G[16O?!.S\%^$_ ^E1:
MG\1/'NHOI.AR7@/V.S8>6);B;&20GG(0N",;B>%VGYUM/@)\6/#_ .P_\#M"
MA^']]JOC/PE\0H?$E]X;%[;QRBVCN[V<#S6<H-RR1#C)&_[O!KJOCKH/QQ^-
MZ_#3XIZ7\*KSPAXL^&?B-[C_ (1&ZU6UN)]9L9Q;B5H;A?D1L1R(59<X8LIR
M I +VO\ Q3_:$_9;^+WPZLOB-XBT;XI^!/&VIV^@R7UCHR:;<:7>2N50 )P5
M)=&W,6W!) %4@$\M\4OVG/BC:_'[XW6.G_%CPKX*\/\ P\MK:]T_PUKFF6TC
M:X3:O(]O&[.DN6:(@E"Q'G*!C@5O^(M3^*_[:GQ"^&&GGX9ZM\+? OA'Q-#X
MCU;4/$4D;O<SVA5H8(8P ^26D7=]TAB<G8 >3\??L_ZV?VC_ (YZ_P")OV<K
MGXN:#XJ6VBT2\2]L86M@D#I,\<DD@>%F++AE7</+!Z@4 >W^-?VL-=\,?L+V
M_P 7-0T3^PO&NK:5!'8:0ZX+ZC<$)$8D;>67EI5C;)9%P<5=_8=^.OBSXI:'
MXV\)_$F_L;KXD^"==FTC56LT$8GCR3%*JJB (2)$7 R?)+'K7S?'^RW^T%XH
M^&7[./PTD:;PR/"L]QXDU/7[R:'4;6PG2=WTVU>(N&E>% $*C,8$N 2%Q7I_
MP;^!_P <?@W^VK<>*?$FI?\ "Q?#GC314@UW7]-M(-+MK.Y@!6V+VXD+.52/
M;E1C-QST- 'L?[#?Q4\2_&K]G/P]XN\77R:CKUW=ZA%-<1PI I6*\FC0;$ 4
M81%'3G&3DU[_ %\0?L.W7QC^#/@[PK\+O$OP-U6QTF"]OI+KQ4VMV9BA6:>:
M=6^SJ68_>5.&[Y]J^WN^<4 .HHHH **** ,?PC_R+.E_]>Z?RK8K'\(_\BSI
M?_7NG\JV* "BBB@ I*6DH R8?^1LN?\ KQB_]&25KUD0_P#(V7/_ %XQ?^C)
M*UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FMDJ0.#
M3J2@#YD_X*$_''Q9^SS^SS)XM\&W4%GK2ZO9VHEN+=9E,;EMX*L".=N,XSZ<
MUQWQH_;(;1=>^ ]AX#\6^&]7G\3ZU#;>(;.PN8+QUB:)24(5BT?SL?FX/&,]
MJZ+_ (*4?"+QA\;/V:9/#7@C1)M?UQM8L[D6<,L<;>6F_<VYV4<9'?/->:_&
M;]B^#2]>_9\U3X:_"_2],OM(UB&X\2W6DV]O;2)$L4>3*VY3)APW3=SGUY *
MN@_&#X_?&S]K3XR>!O!OC_0_"ND>!Y5^R:=?Z!%=QW@R55))<B1<G[S G&>!
MVK.\;?MM?%.U^$D?BMM/M?!^O_#_ ,81:%X^T>.Q^VVT]NY'[R!R6=$"Y8G(
M.2!DCK/X%\+?&'X!?M=?'CQY8_!K6O&VB^++A1I<EAJ=E;HX5]VYC))N (/]
MW/'2N\^"O[+?C'Q)\$?C/#\4[6UM_$OQ6N[C4IM)AFVC3V,>((Y)8^"0RH3L
MR..^: .L_:$^-WB6W^)'P7\!_#74X+;4_&=Z-1O;B;3#=&WTB-0[2!2 JAB=
MI).Y<\8I_P"V]\:_&?[/NA^ O&/AZ>QA\,Q^(H;'Q-'>1J1):3?*OS$%EP=S
M%EQT';BO,_V(_@/\5;7XEQ^,?C!HEQI=WX4\,6_A/0OM6J?:GFP6\^X4*Q&U
MP%'S<^U?3G[2'PG@^-?P+\9>#)XFE?4M.D2W\L*7$ZKNB*EN =Z@9]S0!YS\
M8?C?XBM_VA/@M\// LYDC\022:SK4R10R(=(C3'RF0Y4EB#E1G&,9KY6NOV\
M/BTO[+WQI\9KJ.FCQ%X;\9KHFE78L(_]&MG<C!3&UR , L#UYS7KG[!OP5^*
M-GXXU;X@?&7PXNB^);'0;#POI:7#132200J=]P'1V",PVJP &<5X!<?L?_&)
MOV4_C?X57P/=_P#"0:_XZAU73++[5;;KBU#DF4'S-H '8D'VH ]Q^#O[2GQ3
M\,_M _#_ .''C+Q9H'Q5LO&FD_VJU]HNG):WFC-Y8;RYDA<J$'7<XR>V.E4/
MVDOVT/'GPY_:*D3PW)82?"GP5<Z=8>*S*J!I[B\<KY0F:(^6\:C<0K#Y02:T
M?A_^S?XJ_9A_:'\*^+/AQX$FN_"OB;PTMIXLTNWN;>*.QOHX5*,F\Y 9UY"9
M&6/05YUX7_8I_:'\:?"3XE2ZSXYM?"4OC^[NM1U7PGJ&EPZG>2XSY$;7OF#:
MQ4*HVX"C'N* /J[X_?%_7_!OQ'^ FG>&=3A31_%_B0V.HLL*3"ZM?LYD7:[
MX!.#N4@^]?038D7 Z&OS[UKPG\<;CX1_LTZU=?##5-?\:?#[67DU?1WU&SAE
MGCC@,4<@DWE K @#J1MY'>OL?X-^-/%7C[PL=3\7^ KOX=:LL[Q?V3>7\-Z[
M1C&V3S(N,')X]J /"?V'?VC/%OQMT_XMW/C2_M9(?#'B6XL+.:.W2$16J!B
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M"\W@HI;+&/#MP\3O8HGR)%F(E,!54C:<8(%=;0 4444 %%%% !1110 4444
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M?LQ_&/QUX!^/?C+XE74'A6[G%MXFN4>[T.[CL99HR$V!HW!;!*DHQCX+;,@
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MY%M9P74UM&&B'RB4-:M\PR2"23\Q% 'Z<T444 %%%% !1110!C^$?^19TO\
MZ]T_E6Q6/X1_Y%G2_P#KW3^5;% !1110 4E+24 9,/\ R-ES_P!>,7_HR2M>
MLB'_ )&RY_Z\8O\ T9)6O0 4444 %%%% !1110 4444 %%)10 M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C<J>],VM^OK
M4E% #.<].*?110 4444 %%%% "'I42QD..H7MS_2IJ* "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#&L?^1HU3_KVMO_ $*:MFL:Q_Y&C5/^O:V_]"FK9H **** ,?QC
M_P BGK'_ %Z2_P#H)K1L?^/*W_ZYK_*L[QC_ ,BGK'_7I+_Z":T;'_CRM_\
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M-SI%UXDTOQ9'XGUR\NIGMX;B3R9D8H=K'*J\,8X (CR0":]OT/\ 99O]2_:
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M@35OA[X=\>>$X?#U\=5F@AM]0UZQ4R&\ 623F0$QK&2&+W)(R<B@#]-J***
M,CPS_P @^;_K\NO_ $IEK7K(\,_\@^;_ *_+K_TIEK7H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:>T/X:^,OCW=>,?%MY?Z'X%FT9SI::0D;Z?]KMR8XHI%;-R\LA'!VA/E'J:
M/H1O#^E^=J,G]FV@EU)56]/DKFZ4(4593CYP%)'/0&BR\/:5I]Q#/8Z=:6UQ
M#;K91RQ0JC1P Y$0(&0@.#MZ UXEX?\ VR-!D;QA8^+O"GB+P%XD\+>'Y_%=
M[H>J6\<D\NF1$AIX7C<H_*XVY!!/L:J_"G]MOP;\5_B%X8\,VF@^)_#Y\4Z>
M^H>'+W7=.^SP:M'$':;RB&.-JIN!/W@0>FTL >WKX%T%KR6Z;0=-^T374=]+
M-]E3>]P@.R5CCEAN;#'D9/-7]2T*RU:2S>^L+:]:TG6X@:XB5S%*#D.I(X([
M$<Y K3HH **** ,CPS_R#YO^ORZ_]*9:UZR/#/\ R#YO^ORZ_P#2F6M>@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#'\(_\ (LZ7_P!>Z?RK8K'\(_\ (LZ7_P!>Z?RK8H *
M*** "DI:2@#)A_Y&RY_Z\8O_ $9)6O61#_R-ES_UXQ?^C)*UZ "BBB@ ILB[
MD8#@D8IU-?[O'Z4 >'_$?Q+=^+M8\#>'[G0=6TW0M7UN2TU%;]1"9TBMWD2/
M".<QNPR>0?W72MGX$W]ZP\::-+'C2M#\0W%AI;#<0MLN"(QGLA)0?[N*[WQ%
MX6T[Q98)9ZO81:C;+*LWES#@.N<.,<YYQ^-4[/X<^'M/ATR"WT>W@@TTR/:1
MQ@@0M(")".>2P)R3ZT >8_"/PR/AOXIT/1=8\,6=MK]]87##7K6^,K77E,AD
M#(0",^8ASDU[JU<MX9^&_AWP?J$EYHVBVNGW4R^7+-&"6*CD#))P,^E=30!X
MA^VH,_LN_$(>MB@_\C1UY=_P3TU\WWAO6+)E^9HX+W/^\-F/_'*]=_:ZTV37
M/V;/']I;Y:5M.,@ '.$D1CQ]%->"_P#!.F0;=4YP7TJS;'_ GKZ7")2RJNGO
M=?H?$Y@^7.\'+NI+\&?;U%%%?-'VP4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8U
MC_R-&J?]>UM_Z%-6S6-8_P#(T:I_U[6W_H4U;- !1110!C^,?^13UC_KTE_]
M!-:-C_QY6_\ US7^59WC'_D4]8_Z])?_ $$UHV/_ !Y6_P#US7^5 $]-;[IZ
M].U.HH \A_:._9T\-_M%_#O5M!UK2M.GUAK"YM]'U:^MO..F7$L903H,@@J=
MK<'G I_[/?[._AG]GKP'I^D>']$TNPUAM.L[?6-0TZW\G^T[F"+:9I.YRQD8
M9Z;S7K=% 'Q3I'[ =[XL^'OQ.3QWXHU2+Q=X^U.]U.ZBT?5)QIMJ7)-I&T1.
M)UA(4C<.F%Z+63%^S'\=_#GC;X._$'29/!^I>+/"'A!O"]]9:E<W'D3;"\<<
MOF ;V+1,K-GHX;L:^[** / ?"_P:\6K^U5;?%K7&TR**X^'D'AN]M+%W;9J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &-8_\C1JG_7M;?\ H4U;-8UC_P C1JG_ %[6W_H4U;- !1110!C^,?\
MD4]8_P"O27_T$UHV/_'E;_\ 7-?Y5G>,?^13UC_KTE_]!-:-C_QY6_\ US7^
M5 $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 8GA]=^E7 Y_X_+K@=_P#29.*POB'\&?!7Q=M;"U\;>%M-\2P6,_VF
MV74(1((9<8++W&1^>!G.!70^&?\ D'S?]?EU_P"E,M:] 'FG[0/AF_\ $O[/
M'Q)T+1;%[O5+_P +:I8V-E  &EFDM)$CC4< $L5 'J165^S7\+[7P7\$/AE;
MZEX9L=*\5:=X;T^VO7:SB6YAN5M$CF#.HSNW;@3GGFO8** /C[4?V??$?BW]
MAWQ-X0DT^[TGQK;:KK6NZ(B[/M,=Y'K-W>V+1MG"F0&-=V>%E-8$/[,OB[X]
M_LN_&R;QAI?_  C'Q,^*%^^I"QF5$DLTL7C32[*:09#(%M4)?KBX<]:^X**
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M\MTB![*8.ZF)D>,X?Y@5*GOBK$&D^-_@I^T[XO\ 'TW@+5O%7A_XE:3I9O\
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M\*>+;K-L=L6GZI,W*=A%*3V[*Q^A[5]:AU;H<U^5;*&4J0"",<BOI_\ 9O\
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MO=W&GB2,Q(90JHA8*O*H22>@/K7I_P#PJ:UT#PSJNE^$9F\-SW^T27D@DO\
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M;]BAX_//YU^E/[/'[/.@?L_>#X]+TU/M>JSJLFH:I*O[RYD]/91V']:^ O\
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MK!T5=9<O)>R6D]S#:KSS)CRX5.3D]SDYH ^]=P]?:EW#UKPC]E_]ISPK\=O
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M!V!1110 4444 %-D&Y&'M3J2@#&E\,:7=:K'J<VEVCZG& %OGMT,R@= 'QN
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MY FA2,K(R J#AP&V_P .:]5^%G@%?AC\./#?A*&Z:]AT>PCLOM$B;#+L7!;
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MVBEH/$N@/]KM)D.&9%Y9/QQD?CZUTWP9^)5O\4?!=EJZ[(KU<17MLO\ RQG
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MY\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&L?^1HU3_KVMO\
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M22-O,8;3U-,VD=J!V9^GW_#\36O^B1V'_@^D_P#C%'_#\36O^B1V'_@^D_\
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M(^J5*-+VG\MFW^&WS.K_ .'B?Q<]/#O_ (+W_P#CE'_#Q/XN>GAW_P %[_\
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M6C8_\>5O_P!<U_E6=XQ_Y%/6/^O27_T$UHV/_'E;_P#7-?Y4 3T444 %%%%
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M0/+F0;CD+NPQQR"V>YY[O]H;]F>X_9^D@DO]?L[Z+4IY%TVWMXG\YXD(RTO
M5-H8# +9)XR,X\SFT^[\"^(M*NM1@C34;.ZCNVT\R?OHF5E<+)C_ %;';@@C
M?\HR!D5M?$'XV>,/B@UT/$6L-?VDMQ]ICM'C4QV[XQB(D;D7'& 3D8SDC(\Z
M,J4:+C->\?>5*>:5\QHXC U8K"KXDM+ORW_3]3A****XC[0[[X#?\E?\,?\
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M3_P$3_XU7+:7G]R/K/:8;^>E_P"!U2?_ (63XF_Z,\L__!1_]R4?\+)\3?\
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M/U[_ *!:_P#?P_\ Q-'_ !#CB/\ Y\+[P_MG!_S,7(HW=,=:3^S]>_Z!:_\
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MV=,G_9I?^$;L?^>$?_?(K5HH RO^$;L?^>$?_?(H_P"$;L?^>$?_ 'R*U:*
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M_C'2;[QCJ7AJVO%FUC3K:&YNK=028HY-P3+=,G:3CTQ70T %%)N&XC//I2T
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MG*RG)P^$49/ Y-?I=\(V!^%G@SGC^Q;/'_?E*_-2*-I9DB56:1F"A5&223@
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M<?Z[KQ6A_9_B/_H-:?\ ^"QO_CU;,:@R;L#.,9QSCTS4U &!_9_B/_H-:?\
M^"QO_CU']G^(_P#H-:?_ ."QO_CU;]% &!_9_B/_ *#6G_\ @L;_ ./4?V?X
MC_Z#6G_^"QO_ (]6_2-]TT <BK>(_P"W/[..JV)Q;>?YW]F-C.\KC_7=:T/[
M/\1_]!K3_P#P6-_\>K97_6<XSTW=_7!J:@# _L_Q'_T&M/\ _!8W_P >H_L_
MQ'_T&M/_ /!8W_QZM^B@# _L_P 1_P#0:T__ ,%C?_'J&T_Q'CG6=/(]/[,;
M_P"/5OTUF&TX/2@#D1)XD_MY=._M2P/^C>?Y_P#9C?W]NW_75H_V?XC_ .@U
MI_\ X+&_^/5LK\K9(QQU[@?6I-P]10!A?V?XC_Z#6G_^"QO_ (]1_9_B/_H-
M:?\ ^"QO_CU;]% &!_9_B/\ Z#6G_P#@L;_X]0=/\1_]!K3_ /P6-_\ 'JWZ
M0D8H Y$2>(O[<73_ .U+$_Z,;CS?[,;'W]N/]=UK0_L_Q'_T&M/_ /!8W_QZ
MME%'F;L#.,!L<X],U+D<#/- &#_9_B/_ *#6G_\ @L;_ ./4?V?XC_Z#6G_^
M"QO_ (]6_10!@?V?XC_Z#6G_ /@L;_X]1_9_B/\ Z#6G_P#@L;_X]6_2,>#0
M!R6_Q&-<33_[5L6#6[3^;_9C8!# 8_U_7FK_ /9_B/\ Z#6G_P#@L;_X]6R.
M) 2.3P&[_2I=PR!GF@#!_L_Q'_T&M/\ _!8W_P >H_L_Q'_T&M/_ /!8W_QZ
MM^B@# _L_P 1_P#0:T__ ,%C?_'J1M/\1A2?[:T__P %C?\ Q^M^DW!AP<T
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MER53XYZO]!]%%%?/GVP4444 %%%% &1X9_Y!\W_7Y=?^E,M:]9'AG_D'S?\
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MZ%-6S6-8_P#(T:I_U[6W_H4U;- !1110!C^,?^13UC_KTE_]!-:-C_QY6_\
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MNO\ TIEK7K(\,_\ (/F_Z_+K_P!*9:UZ "BBB@ HHHH **** "BBB@ HHHH
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MA[>U:TZE2G*\)./H<>)H4:U-^V@I6[H\ ?\ 8Q\"33&5-3UA-Q^7%Q"VW/\
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M ,51_P *Q\-?] P?]_I/_BJ .IW#U%&X>HKEO^%8^&O^@8/^_P!)_P#%4?\
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M ,51_P *Q\-?] P?]_I/_BJ .IW#U%&X>HKEO^%8^&O^@8/^_P!)_P#%4?\
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MTW_I\_\  ^X_^+H V\T9K$_X0W3?^GS_ ,#[C_XNC_A#=-_Z?/\ P/N/_BZ
M-O-&:Q/^$-TW_I\_\#[C_P"+H_X0W3?^GS_P/N/_ (N@#;S1FL3_ (0W3?\
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M^+H_X0W3?^GS_P #[C_XN@#;S1FL3_A#=-_Z?/\ P/N/_BZ/^$-TW_I\_P#
M^X_^+H V\T9K$_X0W3?^GS_P/N/_ (NC_A#=-_Z?/_ ^X_\ BZ -O-&:Q/\
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M)_\ %4 =3N'J*-P]17+?\*Q\-?\ 0,'_ '^D_P#BJ/\ A6/AK_H&#_O])_\
M%4 =3N'J*;)M>-E8@@C!KF/^%8^&O^@8/^_TG_Q5'_"L?#7_ $#!_P!_I/\
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M5CX:_P"@8/\ O])_\51_PK'PU_T#!_W^D_\ BJ .IW#U%&X>HKEO^%8^&O\
MH&#_ +_2?_%4?\*Q\-?] P?]_I/_ (J@#J=P]11N'J*Y;_A6/AK_ *!@_P"_
MTG_Q5'_"L?#7_0,'_?Z3_P"*H ZG</445RW_  K'PU_T#!_W^D_^*HH ZJBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+M.\!#X@^,H=#T^\MKNW-L^GQ21+;O%)!"NRS""))((W4!-V<Y8@X'O=% '
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M5[310!XK9_LTZ9<:_KVJ:SJVH7XU'4KW4+6RC*QPV)N5C24K@%F=ECVG<Q0
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D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>eigr-20221231_g6.jpg
<TEXT>
begin 644 eigr-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'O ^,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ/[)\1?\^!_[_1__ !5>AT4 >>?V3XB_Y\#_ -_H_P#XJC^R?$7_ #X'_O\
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MMX,7Q?K&A?V/X2(>Q728Y3/<,H 0R[P%&-J_=XZC'>H? 7[/_BW0?B -;O\
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M"7[;&RHVU4 &S&YN22<CL*]9J';ECZ*_KU-->:7:^GH%%%%24%%%% !1110
M4444 %%%% !1110 4444 %-;[M.IK?=H Q=7/R-6!X/;/BJX_P"O9O\ T-*W
MM8^XWTKG_!O_ "-=Q_UZM_Z&E '>T457:^@1BI?!!P>#0!8HJM_:%O\ \]/_
M !T_X4?VA;_\]/\ QT_X4 6:*K?VA;_\]/\ QT_X4?VA;_\ /3_QT_X4 6:*
MK?VA;_\ /3_QT_X4?VA;_P#/3_QT_P"% %FBJW]H6_\ ST_\=/\ A1_:%O\
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M;_\ /3_QT_X4 6:*K?VA;_\ /3_QT_X4?VA;_P#/3_QT_P"% %FBJW]H6_\
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M\$5SI=LMY=HZ,/+A8,0^<88?(WW<XQS4-CX\T+4[70;BUOQ/#K@)T]DB?]\
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M% !36^[3J:WW: ,36/N-]*Y_P;_R-=Q_UZM_Z&E=!K'W&^E<_P"#?^1KN/\
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M_9N$_D_%_P"8?VGB_P"?\%_D?>?_  ]*_P"J9?\ E?\ _N:C_AZ5_P!4R_\
M*_\ _<U?!E%']FX3^3\7_F']IXO^?\%_D?>?_#TK_JF7_E?_ /N:C_AZ5_U3
M+_RO_P#W-7P911_9N$_D_%_YA_:>+_G_  7^1]Y_\/2O^J9?^5__ .YJ/^'I
M7_5,O_*__P#<U?!E%']FX3^3\7_F']IXO^?\%_D?>?\ P]*_ZIE_Y7__ +FH
M_P"'I7_5,O\ RO\ _P!S5\&44?V;A/Y/Q?\ F']IXO\ G_!?Y'WG_P /2O\
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M_P#*_P#_ '-7P911_9N$_D_%_P"8?VGB_P"?\%_D?>?_  ]*_P"J9?\ E?\
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MW_@XF_\ D6NBHH YW[=XL_Z NC?^#B;_ .1:/MWBS_H"Z-_X.)O_ )%KHJ*
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M2*6\TH)9[D \BYC4-"0.V'5?PR*^/_\ @FC:^(OC1\1==^*/C6#??^$=%L_
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M?9,^IVWF1JNY;9L,7&6R,<%5S@<C]'J*TYGS*:W7+_Y*FOQ38G:2E%[/FO\
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M_#^M:5 'G-K_ ,A[4?\ KZE_]#-=O8_ZM:XBU_Y#VH_]?4O_ *&:[>Q_U:T
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M,:Y'9RW^B^1(+[3D>.&:.92R@QLS%'&WD;CG.:OEW3W_ .&O^-U\B.;JMO\
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MWO\  ]3_ &A_'>B^./%FBQ>'[B2_TS0M#L]$CU&:(Q->F!2&FV-\R@DG ;G
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M4V[-R\HXRP XZ]*T/V=O%VEZ_J_P'T2SNI+K5/#DNN76HVR1/F"-U:1#R )
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M".BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME\HA5YB=@\O<L"@##8W,<G-.'UFZYMK^6WNOIW]Y?<PJ?5;/EWMY[^\K:_\
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MU@DHM6A1EW*S$Y+;NP&,=Z[ZBG<5M&AL:+&BHBA$48"J, #T%.HHI#"BBB@
MKG?"_P#R'/%__84C_P#2*UKHJYWPO_R'/%__ &%(_P#TBM:8CHJ***0PHHHH
M **** "BBB@ HHHH **** "FM]VG4UONT 8FL?<;Z5S_ (-_Y&NX_P"O5O\
MT-*Z#6/N-]*Y_P &_P#(UW'_ %ZM_P"AI0!WM8%S_P ?$O\ OG^=;]8%S_Q\
M2_[Y_G0!'5+6Y[ZUTF[FTRUCO=02,M!;RR>6LCCHI;MGUJ[65XJUB7P_X;U'
M48(X)9K:%I$2ZN%MXB0.-TC<*/<TGL-;G,:!\7M,O;^/2M=M;CPEKS\+8ZL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7O7["W_ "=1X(_[?O\ TAN*\%KWK]A;_DZCP1_V_?\ I#<5S8K_ '>IZ/\
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M:"UTO3[73;4'(AM(5B3/KM4 54T_P;H&DZE)J%CH>FV=_)G?=6]I''*V>N7
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M"?V_C.T?_ 4?0O\ PL3]GW_HDNG_ /A-Z?\ _%4?\+$_9]_Z)+I__A-Z?_\
M%5\]44?V/AN\OO8?V_C.T?\ P%'T+_PL3]GW_HDNG_\ A-Z?_P#%4?\ "Q/V
M??\ HDNG_P#A-Z?_ /%5\]44?V/AN\OO8?V_C.T?_ 4?0O\ PL3]GW_HDNG_
M /A-Z?\ _%4?\+$_9]_Z)+I__A-Z?_\ %5\]44?V/AN\OO8?V_C.T?\ P%'T
M+_PL3]GW_HDNG_\ A-Z?_P#%4?\ "Q/V??\ HDNG_P#A-Z?_ /%5\]44?V/A
MN\OO8?V_C.T?_ 4?0O\ PL3]GW_HDNG_ /A-Z?\ _%4?\+$_9]_Z)+I__A-Z
M?_\ %5\]44?V/AN\OO8?V_C.T?\ P%'T+_PL3]GW_HDNG_\ A-Z?_P#%4?\
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M_P"!%+/<:U=1C_X">[?\+$_9]_Z)+I__ (3>G_\ Q5'_  L3]GW_ *)+I_\
MX3>G_P#Q5?/5%/\ L?#=Y?>R?[?QG:/_ ("CZ%_X6)^S[_T273__  F]/_\
MBJ/^%B?L^_\ 1)=/_P#";T__ .*KYZHH_L?#=Y?>P_M_&=H_^ H^A?\ A8G[
M/O\ T273_P#PF]/_ /BJ/^%B?L^_]$ET_P#\)O3_ /XJOGJBC^Q\-WE][#^W
M\9VC_P" H^A?^%B?L^_]$ET__P )O3__ (JC_A8G[/O_ $273_\ PF]/_P#B
MJ^>J*/['PW>7WL/[?QG:/_@*/H7_ (6)^S[_ -$ET_\ \)O3_P#XJC_A8G[/
MO_1)=/\ _";T_P#^*KYZHH_L?#=Y?>P_M_&=H_\ @*/H7_A8G[/O_1)=/_\
M";T__P"*H_X6)^S[_P!$ET__ ,)O3_\ XJOGJBC^Q\-WE][#^W\9VC_X"CZ%
M_P"%B?L^_P#1)=/_ /";T_\ ^*H_X6)^S[_T273_ /PF]/\ _BJ^>J*/['PW
M>7WL/[?QG:/_ ("CZ%_X6)^S[_T273__  F]/_\ BJ/^%B?L^_\ 1)=/_P#"
M;T__ .*KYZHH_L?#=Y?>P_M_&=H_^ H^A?\ A8G[/O\ T273_P#PF]/_ /BJ
M/^%B?L^_]$ET_P#\)O3_ /XJOGJBC^Q\-WE][#^W\9VC_P" H^A?^%B?L^_]
M$ET__P )O3__ (JNL^%7C/X/:MX]TNU\*_#NST+7I/-^S:A%HEG;M%B)R^)(
MSN7*!EXZYQT-?)U>G?LU_P#):_#G_;S_ .DTM<V*RJA3P]2:;NDWN^QV8/.\
M55Q-*G)1LY);+JSZ<TVQ\.ZMI]K?6GPM\VUNHEFBD^QZ:NY& 93@S9&01UJQ
M_8.B_P#1*?\ R5TS_P"/UT7PY_Y)[X7_ .P7:_\ HE:Z*OSVY^HV/._[!T7_
M *)3_P"2NF?_ !^C^P=%_P"B4_\ DKIG_P ?KT2BBX['G?\ 8.B_]$I_\E=,
M_P#C]']@Z+_T2G_R5TS_ ./UZ)11<+'G?]@Z+_T2G_R5TS_X_1_8.B_]$I_\
ME=,_^/UZ)11<+'G?]@Z+_P!$I_\ )73/_C]']@Z+_P!$I_\ )73/_C]>B447
M"QYW_8.B_P#1*?\ R5TS_P"/T?V#HO\ T2G_ ,E=,_\ C]>B447"QYW_ &#H
MO_1*?_)73/\ X_1_8.B_]$I_\E=,_P#C]>B447"QYW_8.B_]$I_\E=,_^/T?
MV#HO_1*?_)73/_C]>B447"QYW_8.B_\ 1*?_ "5TS_X_1_8.B_\ 1*?_ "5T
MS_X_7HE%%PL>=_V#HO\ T2G_ ,E=,_\ C]=%X+ET[[+J%MIVA?\ "/?9;KRI
M[/RH8_WABC?=^Z9E.4=.<YXQVKHJYWPO_P ASQ?_ -A2/_TBM: .BHHHI#"B
MBB@ HHHH **** "BBB@ HHHH *:WW:=36^[0!B:Q]QOI7/\ @W_D:[C_ *]6
M_P#0TKH-8^XWTKG_  ;_ ,C7<?\ 7JW_ *&E '>U@7/_ !\2_P"^?YUOU@7/
M_'Q+_OG^= $=%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XG^T%\
M4KS0-!U72;#1_$]K=1O;E=<L[5DM #(C$"<,#DC*XQU.*]%\#>./^$VMKF7^
MP-<T'[.RKMURR^S-)D$Y0;CD#'/UJWXT\(6?CKP[<:+?RSPVL[1LSVS*K@HZ
MN,$@CJH[5N 8 %-6Y;/?_AB6GS7"BBBD4%%%% !1110 4444 %%%% !1110
M4444 %%%% &CH_\ RV_#^M:59NC_ /+;\/ZUI4 ><VO_ "'M1_Z^I?\ T,UV
M]C_JUKB+7_D/:C_U]2_^AFNWL?\ 5K0!>HHHH 6BBB@ HHHH **** "BBB@
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MY[ZXMSM:9XI0BQLP^\@&?E/!STK#^.&D6FE_%35(+2);:"8PSF&, !&DC1F
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M_P#)/?"__8+M?_1*UT5<[\.?^2>^%_\ L%VO_HE:Z*OR0_<5L%%%% PHHHH
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M.?M(*?=7/)K4_8U)4V[V;7W!1116AB%%%% !1110 5Z=^S7_ ,EK\.?]O/\
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M[M.IK?=H Q-8^XWTKG_!O_(UW'_7JW_H:5T&L?<;Z5S_ (-_Y&NX_P"O5O\
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M<HHI-\SNQQ2BDD%%%%(84444 :.C_P#+;\/ZUI5FZ/\ \MOP_K6E0!YS:_\
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M[S28%MK.58T'E1+G"XQAA\S9W9SGFI[;XD:_9S7S17%JL5\$%Q:&PMS;2;
MI\@Q^6",=0N:YBNN\'^"[/Q!X?\ $.LZAJ<^GV>CK 76VM%N))/-<J,!I$ P
M1ZUA4C1IQYIQ5MMN[T_%_>=%&>(J24*<G?UMLO7LONT*K?$3Q%)J]YJ;ZF[W
MMW:M8RR-&A'D,,&-5V[47'0*!CMBHM,\>:]HUGIUM8ZB]K#IURUW:B-%!CE8
M89MV,D$#&"2,=JZZS^"XO/%6B:?'K0;2M8L)-1MM06U^?RT1F*M$7&&RN,;L
M<]37-6?A2R\3:UIVD^%[R_U._O)/+V7UBELJ#&=V5FDR ,D\# '>LHSPLM$E
MMVV6JUTTM9[[:F\J>,C[TF]7_-NVHO376Z<=M]!FO?$;7_$FCKI5]=PMIJS_
M &E;6WLX8$$F"-P$:+R=QSZYR:;JOQ"\0ZW-H\M]J3W$FD!19%HT'E;=N#P/
MF/RKRV2<#-7-2\,^%K&:[M(_%DT][;JW[P:8?LDCK_"L@D+G)X#&,#\*I_#W
MPC_PGGB^PT+[7]A^U;_](\OS-NU&?[N1G[N.O>JC]7C!U%&RC=_#;IJ]NW8F
M?UJ4U3E-N4M/BOUT3U[]R"\\:ZU?6>K6L]YO@U6Z%[>)Y2#S9@20V0N1RQX&
M!STK,T^^ETR\BNH5A>2,Y5;B!)D/&.4<%6_$&NML? NE)X'C\2:MK%Y:0RZ@
M^GI!9:>EPVY4#;B6FCP.??I6EX;^#K>,/!.M^(=)U1I6L;EX;>PFM@DMTJH'
M)&';#;23M&[[IYI.OAZ47T5[/33HNWI\AK#8NM.*WD[M:J_5OK?>[\WYLYWQ
M!\1]>\3BT_M"XMGDM-@MYH+"W@EB5,[%62.-6"C/"@X]J-<^)'B'Q%97%K?7
MR/#<NLEQY-K#"UPR_=,K(@:0C_:)]:35O!W]E^"- \0_;/-_M66XB^S>5CRO
M*8#.[/S9SZ#'O6/I.B:CK]U]FTRPNM1N<;O)M(6E? ZG"@G%:1A0:O&*M%OI
MLT]?Q1G.IBE*TI.\DNKU3V_![&XWQ.\2R::+%M1!C^S?8_.^SQ?:/(_YY>?M
M\S;_ +.[&.*R/#WB+4/"NK1:GI=Q]EO8@RI+L5\!E*MPP(Z$]JZ/P?X!&K3>
M*K?5XKVPO-(TF:^2W*^6_FH5PKJRYQ\W3@^]:7C+X6R>$/"V@2R:/K<NKZG$
MLLDS)LMX'9B%@V>66,F%SC>#[5DZF'C+V22][TUNG]^ALJ.+J0]LV[0UW=U9
MI?+6UO\ @'%CQ'J(\.G0A<?\2HW7VPV^Q?\ 7;=N[=C=]WC&<>U=SX8^+4L<
M/B1M7U/5;'5=62V1=8TA$\V-8N FP/&,$ #(8'CODUPNL^&]7\.21QZMI=[I
M;R#<BWEN\)8>H# 9I^@V.E7CW#:MJLFF0Q)N406IN)96S]U5W*OOEF'XUI4I
MT:L&VKKR]5_DK^FIC2JUZ-1).S71NRV?>UMW;M>ZU-WXE>-+7QA<:5]F6YG:
MQM!;RZE?JHNKQLD[Y-I/3.!EF.!R34=G\5?$MA:Z?!#=6O\ Q+XO)LYI-.MG
MFMUY.$E:,NO4\@YH\:?#V?POJFDV]C<-K4&K6D=[8R0P%)9$?. 8\DALCH":
MP=8\/ZKX=F2'5=,O-,F==RQWD#Q,P]0& R*BG'#SIQ@K-:VO\[Z/Y^FQI6GB
MH593=T]+V[:6U6_3KKON3OXLU:32;W3)+UI+.\N1>7"2*K-), 0'+D;L\GOW
MK;O/B]XKO;B:Y?4((KV9/+DOK:PMX;EEP!CSDC#] !][M7&T5T.C2EO%?=_7
M9?<<L<16CM-KYOS?YM_>Q22Q))R:2BBMC ****!!1110 4444 %>G?LU_P#)
M:_#G_;S_ .DTM>8UZ=^S7_R6OPY_V\_^DTM<6._W6K_AE^3/1R[_ 'VC_BC^
M:/L;X<_\D]\+_P#8+M?_ $2M=%7._#G_ ))[X7_[!=K_ .B5KHJ_)#]Q6P44
M44#"JEKI-C875W<VUG;V]Q=L'N9HHE5YF P"Y RQ XR>U6Z* ,34O!/AW6M3
MBU+4- TN_P!0BQY=W<V<<DJ8Y&'921CZU>FT33KB_-]+86LMZ8#;&Y>%3(82
M<F/<1G:3SMZ5=HH\@\S$O? _AS4M*MM,N_#^EW6FVO\ J+.:RC>&+_<0KA?P
M%6_^$?TO^QCI']FV?]DF/R38>0GD;/[GEXV[?;&*T** ,O\ X1711)IL@T>P
M$FF+LL6^S)FT7 &(CCY!@ ?+C@5IGG@\BEHH P]*\#>&]!U&2_TWP_I>G7\F
M=]U:V4<4K9Y.6503FN=_X4[HU[XZ\0^(M9M;'7$U1;416=]8)*+5H49=RLQ.
M2V[L!C'>N^HIW%;1H;&BQHJ(H1%& JC  ]!3J**0PHHHH *YWPO_ ,ASQ?\
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MDM%0L&E*$N;X;:=-+^?GKN:/'MQG'EUE?7KK;R6UM+67KI8HHHKT3R0HHHH
M**** "BBB@ HHHH *]._9K_Y+7X<_P"WG_TFEKS&O3OV:_\ DM?AS_MY_P#2
M:6N+'?[K5_PR_)GHY=_OM'_%'\T?8WPY_P"2>^%_^P7:_P#HE:Z*N=^'/_)/
M?"__ &"[7_T2M=%7Y(?N*V"BBB@84444 %%%% !1110 4444 %%%% !1110
M4444 %<[X7_Y#GB__L*1_P#I%:UT5<[X7_Y#GB__ +"D?_I%:TQ'14444AA1
M110 4444 %%%% !1110 4444 %-;[M.IK?=H Q-8^XWTKG_!O_(UW'_7JW_H
M:5T&L?<;Z5S_ (-_Y&NX_P"O5O\ T-* .]HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \YM?^0]J/_7U+_P"AFNWL?]6M<1:_\A[4?^OJ7_T,UV]C
M_JUH O4444 +1110 4444 %%%% !1110 5\Y_%K6OA-:?$#58O$WAC5-1UM?
M*^T7-M*RQO\ ND*X G7HNT?='3\:^C*^)?VC/^2R>(?^W?\ ])XJ\7-LRQ.5
MT%6PLN63=OE9O]#Z?A[)L%GF*EAL=#FBHN5O--+\FS?_ .$B^!'_ $)>M_\
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M_B'O#O\ T#K\/\CVC_A(O@1_T)>M_P#?]_\ Y)H_X2+X$?\ 0EZW_P!_W_\
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M7_[!=K_Z)6NBKG?AS_R3WPO_ -@NU_\ 1*UT5?M)_,BV"BBB@84444 %%%%
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M;+X(7\TDL=M:^,H;F0PJSL B@Y"KDD@9P ,^E3?LMVH_:T^,&L_M)>*[Q/\
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M08)_<.'<-P."< Y &2<5HX^\HK5V3^]7M_7J)OEYF]DVON=KGT;17S#\5O\
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M?UK2K-T?_EM^']:TJ /.;7_D/:C_ -?4O_H9KM['_5K7$6O_ "'M1_Z^I?\
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M?^2>^%_^P7:_^B5KHJYWX<_\D]\+_P#8+M?_ $2M=%7[2?S(M@HHHH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !7.^%_\ D.>+_P#L*1_^D5K715SO
MA?\ Y#GB_P#["D?_ *16M,1T5%%%(84444 <1\9M2N]+\ 7LMI/-9B2:"&YO
M+?/F6UN\J+-*" 2-L98Y[=>U<%92>%M%\52:[X'@LTT/1=&NY=6U'3,&WNWP
MK11M(O$T@VNQ;)(SR?FQ7NE%+HUZ_BK?AOZAU5_ZUN?/_AGX=:?X5_X5:B0
M^);NX?4;_4Y3FX\L6\DDL8;J(]\JKM''.>O-.:Z32_AMHOCJ?>4'B=M;F94+
M-]GGF> ' Y.(9$X'I7OU96L>';?7+S3YKN29X;*3SEM P$,D@QL=QC+%3RHS
MC)S@D*1HY>]=::_JG;\$9\ONV>NGZ-7_ !9C?#O2;J&SO];U*%H-5UR?[9-#
M(!O@C"A883CNJ 9_VF;UKKJ**E^1:"BBBD,*:WW:=36^[0!B:Q]QOI7/^#?^
M1KN/^O5O_0TKH-8^XWTKG_!O_(UW'_7JW_H:4 =[6!<_\?$O^^?YUOU@7/\
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M* "BBB@ HHHH **** "BBB@ HHHH *Y[Q/\ \AOPC_V%'_\ 2*ZKH:Y[Q/\
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M;?A_6M*@#SFU_P"0]J/_ %]2_P#H9KM['_5K7$6O_(>U'_KZE_\ 0S7;V/\
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ME94D\LIE&^7Y<L#CD5ZG11=[A96L5M-TVUT?3[>QL;>.TL[=!%%!"H5$4#
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M1110 4444 %%%% !1110 4444 %%%% &CH__ "V_#^M:59NC_P#+;\/ZUI4
M><VO_(>U'_KZE_\ 0S7;V/\ JUKB+7_D/:C_ -?4O_H9KM['_5K0!>HHHH 6
MBBB@ HHHH **** "BBB@ KGO#'_(;\7?]A1/_2*UKH:Y[PQ_R&_%W_843_TB
MM:8GT.AHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[Q/_P AOPC_ -A1
M_P#TBNJZ&N>\3_\ (;\(_P#84?\ ](KJF)B?#G_DGOA?_L%VO_HE:Z*N=^'/
M_)/?"_\ V"[7_P!$K714@6P4444#"BBB@ HHHH **** "BBB@ HHHH ****
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MO^?^7XGHE%>=_!BZN+7PO>>&KZ3S+_PY<R::S-U>$?- _P!#&R_D:H_LT_\
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M ,A[4?\ KZE_]#-=O8_ZM:XBU_Y#VH_]?4O_ *&:[>Q_U:T 7J*** %HHHH
M**** "BBB@ HHHH *YZ;PE-_:5_>6>OZEIOVV59I8;=+9DWB-(\CS(68?+&O
M>NAHH%N<]_PC&I?]#=K/_?JR_P#D>C_A&-2_Z&[6?^_5E_\ (]=#13N%CGO^
M$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]
M67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?
M]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\
MD>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^
M$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]
M67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?
M]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\
MD>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^
M$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]
M67_R/1_PC&I?]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?
M]#=K/_?JR_\ D>NAHHN%CGO^$8U+_H;M9_[]67_R/1_PC&I?]#=K/_?JR_\
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M7_0WZS_WYLO_ )&H_P"$7U+_ *&_6?\ OS9?_(U=%10!SO\ PB^I?]#?K/\
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MF/G/^[;J3_"?7Z4 ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/#_&MJB@#%_L^X_YY_\ CP_QH_L^X_YY_P#CP_QK:HH Q?[/N/\ GG_X\/\
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MN?\ /O9_]\/_ /%4?\)AKG_/O9_]\/\ _%4 =W17"?\ "8:Y_P ^]G_WP_\
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MN?\ /O9_]\/_ /%4?\)AKG_/O9_]\/\ _%4 =W17"?\ "8:Y_P ^]G_WP_\
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M_P#R7X'TY<7"6T>YS@=@.IK#NKV2Z8;OE4=%!X_^O7R7KOQH\4?#_P 9>,=
MU#XCR^*M.7PYIVK6VMKI%K/<V5Y=7?V>.WBB@$43+*"&B\TG:3N=W7.>"\<>
M+O&'CSX4_$?P]KWB'Q)ILWACQ7X?CBGU2+1O[2*37%JQCN/LB2VWR.WF*4"M
M\J!\C<K*/O6MU_\ DE%_--_=ZHKK9_UIS+[T_O/NJBOD+XM?$7Q#\%M8^+FH
MZ48]>UW1_#7AV*'6+S3K);UVN+RZADGFDCCA60* KA&*Q*5/" L:FU[QU\:/
M"OPU\77%S/KVD1>?HL>B>(O%=MHDUZ);B^C@ND,.GR- \01T92RHW[QADX#
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MT6Y]:WFMZ=IU]865W?VMK>Z@[1V=O-,J27+*A=EC4G+D*I8@9P 3T%7:^)O
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MP!$JN@(C@R2&)956N^\#^.SXD^!+^)=.\3'Q/(ME>/#K3:4^GO*\32*"]M(
M4=63:P*@$J2% .!G*2C3=1[)7^6_XV3U\ODXIRG&*W?]?J_Q.Z\,>"?#'AR3
M3XK#P[I&GPV+S268M[**,6KRY\UX\+\A?)W$8W9YS70V?@KP]IL.CQ6F@Z9:
MQ:-N_LR.&SC1;'<A1O( 7]WE693MQD$CH:^+;7XS>*M;A^#:ZOXW\8:)#KW@
M)==OY_!OA>+5;FZOMUL"[QKI]UY:8ED^ZB+D@9Z"NJU#]HCQG\._VA7CUC5V
MU+X16.G:/I^IF]L4AN[&XO?.$.H2L(T8*9(DCE5@JIYH8*N"*Z)0:ERONU\T
MVOQ:LO5>=L5-<K:[)_>D_P GKZ/K:_T5>? OX;:A9ZO9W7P^\*W-IK%T+[4H
M)M%MGCO;@$D33*4Q)("S'<V3R>>:UM-^'/A/1[>Q@L/"^C6,%BTSVD=MI\,:
MV[3 B8Q@*-ID#'=C&[)SFO+/@[^T)H:_#?0KOXB>.M!TK7M6U/5+6S75KZVL
M9+M8=0F@C6*,E-Y51&OR@DG&<D\UD_:JAM_CKIOPZU#3] MY-3U"XTVWBM/%
M-O=ZQ#)'#),LMSI\:'R89%C;:WFLPW(&12V!E:_NKK^AI?1R?3_@Z_GJ>S6?
M@_0--&CBTT/3;4:-";;3/)M(T^PQ%0IC@P/W:E55=JX&% [5C:3\&?A_H/BZ
M7Q5IG@;PWIWBB4NTFMVFD6\5ZY<8<F=4#DL.O//>OC[X;^*OB-X^U#X'Z)+>
MW.J:)?3>(K^^N)/&%_IMW=-;:B8U$KP0L[I#'(NR(R;)"=K[%0%O;+']KS3;
M?XQ+X)\01^&-&AE-\/-@\76UW?V M8FF:34+1$"VL;1H[!O.?& &"D\/>TNK
MYON6_P#77\AJRMTT^_I_70]:\/\ PD\#>$=7EU70O!GA[1=4EEDGDOM/TJ""
M=Y'&'<NB!BS#J<Y/>IO%_P ,?!WQ"FL)O%/A/0_$LM@_F6DFL:;#=M;MD'=&
M9%.P\#D8Z5R/B7QEI7Q-\#2:_P""?B_INB^&=-DEDU3Q%X<>QU':D<>YHQ-*
M)88B,JS;HW.W@;<[J\N\#?M'>-/#O[-W@GQ;XT@\-MK&KM.#JWBO7(?#-B]N
MLC_9I92T<C+--$$<1QQ$9)SY8Q4WLFWIRV_';_@?@/?;K?\ #?\ X/JNY])R
M>&='DO[B^?2K%[VXM5L9KEK9#)+;@L1"S8R8P7<A3Q\QXY-1S^$]#NO#)\-S
M:-I\OATVPLCI$EK&UH;<+M$/DD;-FWC;C&.,5QW@[XT6GC;X"VWQ.L=/9;:?
M1Y-56P:=2<HC,T?F*""-R$!P"",'':O/_"7[5>IM#I][X[\$1>#],U3PG<^+
M[&:RUD:E(+6W6)IDG00QB.3;/&R[&D##.2I&*<O=<HO[._\ Y,_TD_O%'WN5
MQZ[?@OUC^!ZUH?PC\"^%['5[+1O!?A[2;/6-W]I6]CI4$,=[N!#><JH!)D$Y
MW9ZFF:'\'/ /AC1;_1]'\#^&])TG4(A!>6%CI%O#!<Q@L0DD:H%=07?@@CYV
M]37C6C?M2^+-<;2].N_ %IX>U3Q7X9NO$?A5Y->,\<R1*CF*\(M<VTH26-\(
M)UY(W9%=[^S#XT\8>/?@+X/\2>-K?3UUC4-)M;O[1I]V9OM:O C^=(OV>%89
M&8L3$@95XPY[.47&,W+96O\ ?)?@XO3_ ((KKW;==ON3O\TUJ=CX>^%W@SPC
M:Z=;:%X1T+1;;3GEDLH=/TV&!+5I1ME:((H"%QPQ7&1US7A?Q2_8BT3QMXL;
M5-%C\':;IKZ.-&31];\'Q:E!IJ^;+(9]/"SP"UF9IG+/M?+!3CC!I+^VIJ>E
M_!O0?B'XG\&:+X7T_P 47EO8>'X;_P 5JBRR2>86DO)GM5CM856-GW@RL1_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%)@#(^=<D9./;JW-+M_L]J"5"O(=[8[]@?R IQ?)\/E^')_\A'^F)ZN[W_\
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M;Z7UBVPPG7OPW]#_ )]JJZ?=?99\G[C<-Q^M$?=V\_Q27Y)"E[][]?\ -O\
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M &7?B6/%CZSXFU:PO;H>$]6T":]N/%.IZH]]=W7D[;H03Q+#91DQ-NA@&%R
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M'PG/X&M?!6H3W5Y);7ULEOYVVXAC6&1)BPFP59X]NW.6Z5Q/A#]DWQMJ6G>
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G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>eigr-20221231_g7.jpg
<TEXT>
begin 644 eigr-20221231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )D!+$# 2(  A$! Q$!_\0
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MKKO;YZ/]4#T:3ZZ_H.HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N>^(?\ R('B;_L&7/\ Z*:NAKGO
MB'_R('B;_L&7/_HIJYL3_ J>C_(WP_\ &AZK\S\]_P#@B'_R2OXE?]AFW_\
M1!KS/_@M)H^DVOQ=^&%]HJ1Q^,KNRF6Y^Q\7#HDL8MF.WYL[C*%/7C Z<97_
M  2S^&/Q8\>?#_QQ-\._C1_PJZR@U*&.[M!X6M-6^U2&(D/OF8%,#C ^M?;G
MPC_X)Z^%_!_Q+3XE_$#Q3K/Q=^(D922+5O$.U;>WD0#:\5N"=I4YVAF8)QM
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MKFA:A;ZMH^H0K<6M[:2!XIHV&0RL.M<]\9OAWI'Q8^%?BCPGKEK'=Z=JEA-
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M?\*=\&B?_A!?&GCC^TDGMO+\&Z1_:#VO[LGS)QO78G/WN>AKXY_X+#0QF^^
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MO8ML[DMY)(8KAE.X CYAS7V#165/W%-/7FM^%[?F:3][EMTO^-K_ )(^2/\
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M'FMJIY5'G36LE9^BUM]^Y/,Y<MG\+NO7:_\ E\S\\/V5/#-]_P $\_BUX_\
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MX+D@9-?5E%9\B]@J+Z-ROYMW_-&G,_;^V79*WDE;\FSX%_9M_P""B7ACX>^
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M'[*OBOPK\0C9Z+XG\0.]_IMC$%==&*NLEI;R2+Q(R[ )'']]@,@ GYV_8_\
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M!O&C>,=);P>=._L[_A($N5:Q\XV.S_7 [-N_Y=^=N>_>O?O^"FW[,WB+X^>
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M]HQ@MHJWXM_F_N+WE*3W?^27Z:^84444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGA$JDN?2G\6CTN[=M=>UST^BO%/#O[2T<WB:UT7Q1X6O_"5Q=,JPO=L2,L<
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MQ=^U!:>'?&TN@V6AMJL$5PMK)?B[\M?,) 90OEG.W/KS@U&'PU7%2Y*,;O\
MKN7BL90P4/:5Y67S_0]QHK@OBI\7M.^%UO9I-:3ZGJ=\2MK8V_#/C R3S@9(
M' ))/2N7\(_M%?VMXMM/#WB+PM?^%+Z\(6W^U,6#,?NA@R(0"> <'FM:>"Q%
M6G[6$;Q^73>RW?R,JN886A5]C4G:6G?2^UWLK^9[+1117">B%%%% !7EGC3X
M<^)?^%@#Q?X1O=+BOIK$V%S;ZLLGE[<Y#J4!.>%XZ<=\XKU.N)^*L'BG5-%A
MTCPO $EU"3R+K4FE119PG[S $AF8@X&T''/0XKKPLY1JI1:5]'?:SWN<>+A"
M=)N:;MJK;W6UO,\'TW3["#19/#][JC/X#\-SFYUS4(E(74;QF&+>,#DJ#@>^
M,\?*:]Q\!_%O1/%VJ'1+;3]2T._AMUGBLM4M!;L\/ #( 2-O(]..E8_CKX,Q
MW7P<_P"$0\.".&6W,<L7G';YTBG+%SZMSSZXZ"JG@WPGXJUWXH6WB_Q'H\/A
MQ+'3?L$5HEVEP\S<Y?*<!?F/!YZ=>M>S6J4,52E.4MN:VJ3O96=NO,]--DDN
MA\]1I8G!580A'XN6^C:2N[QOTY5KK\3;?D=9\:/^24^*O^O"3^5?-G@_XT6&
ME_!>X\$6VE7^H:[=I<0((XU,7[TMR,,6) .<;>HZ]Z^H/B=HMYXB^'^OZ9I\
M7GWMU9R10Q;@NYB.!DD ?B:Q/@-X4U3P7\-;#2M9MOL=_'+,SP^8KX#.2.5)
M'3WK#"UZ-'"2]HN9\R=KVZ/7T.K'8>O6QM-T7RKEDF[7733M<\%\16M_\.?@
M-I/A.^(L=6\1Z@UQ+%,P3R(04X<Y^7D1DYZ9.>E7O&&K>'OA[\4/ 6M^'M8L
M-1M(+:.PO38W,<N$0",LP4G&4;O_ '*[WQE\)M4^)7QLAO-?TTMX,LK7RHV^
MTJOGMM)QA'WK\['G X2HOB7^S)X=F\'WG_"(Z)]GUY"KP?Z9(1(-PW+^\D*C
M(SR?2O5IXW#WA[:6L[N5K6][2SUTLK'B5,NQ7+4CAXZ4THQ<K\WN^\W%6L[R
M-K]J-@WP=U @Y!N+?'_?P5U_PH_Y)?X6_P"P7;_^BQ7!>,/!OB[Q7^SW9:%/
MIQ?Q-&L"2VS7,9+"-\;B^[:25 ;KWKTGX?Z3=:'X#T#3;V/R;RUL(89H]P;:
MZH 1D'!Y]*\2MR0P3HJ2;4WMVM:_H?04?:5<PCB'!I.DMUL^9NWJNQX;^R[_
M ,BOX^_ZZ_\ LCUQWP#UOXD:7X>U%/!?A_3M7L6NMT\EY(JLLFP<#,R<8QV/
MUKUCX"_#?Q#X,T/Q=;:S8BREU"7-N/.CD#C:PS\C'')'6N'^&OAWXR_"O2[N
MPTGPCIUS#<3>>[7ES$S!MH7C;.O&!Z5[LJU*=3$J,HN_);F>CLM>JV/GO85J
M=+".49KE=6_*GS*[TZ/?TV.G_::FU&X^">C2ZM!':ZH]W;M=0PG*1RF)]R@Y
M/ .>Y^M1Z&K?"3XT68QY?A_QC;I@_P ,=T /YL3_ -_?:M'XI>%?'/Q*^#NF
MVMWHMO'XG^W":XL;:>-8T1?, (9I".A4_>/6NO\ BA\.YO'/P]CTZ#;%K5DL
M=Q92[L;)T'3=VSR,^X/:O/A6ITZ4:,VK.4U*SO9/ELUY)JZ]#TJN'JUZSK4T
M^:,(.+:LVTY:/S:T:\SA_P!EO_CZ\>_]A3^KU1\4?\G>>'/^O,?^BIJZ7]G+
MP'XC\%V/B&3Q+9K97>H7:S*@ECD+<'<?D8@<MZTW7OA[K]Y^T;HGBB&QWZ%;
MVOERW7G1C:WERC&PMN/++T'>JE5IK&U7S*W(U>^C?(D1&C5EEM*/(T^>]K.Z
M7M&]5Z&G\?OA7>?$[PS:)IDL<>J:?*9H4F;:L@(PRY['@8)XX[9S7'^!_CSX
MA\/^)+'PG\0]&:QO)F6&'4%79N).U2P'RL">-Z' ].IKT7XH/X^MO[-NO!"6
M5WY1?[797FT>=G;LP25QC#=&'6O-D^'/Q#^*GC30]5\=6NGZ'IVD2>8EK:.K
M-)AE8XP[_>*@$EN .!ZYX-TY8?DQ+BX:O?WD_)>?]=C;,(U(8GVN$C-5=%M[
MDEYOI;773]3Z%KYPU?Q-HOBS]I(MK&IV5CHWARV>%3?7"1)+-@A@-Q&3N<_]
M^Z^A]1DN(=/N9+6'[1=+$S10[@N]P#M7)X&3@<UX+\+?V;[.]TO4+[XA:/\
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M_ONNC_9I\/RVOP\U?Q#>9:^UV:6=I&ZLB[@#^+%S^-<I\9?@GXOU3X@:K?\
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M]-DEOZC526)S&,ZU.2C3;4?==KO1R;VMV^\M_'+_ ))'XH_Z\S_,5F_LW_\
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M]OQ/5OA%XTM_B!X/&MV^DQZ-]HN)?,MXW#Y<'!<L%7)/TKS/]L?_ )$[0?\
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M6XQ#9VZ0+[[5 S^/7\:Y?XW>&=2\8?#/5])TFW^U:A/Y7EP[U3=ME5CRQ '
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M<,"#F5^A&Y2 ?PKH_B=\/M?\1_&+P3KMA8>?I>G-&;J;SHU\O;*6/RE@3QZ
MTU6P\L12Q$9[Q:=[)W2:UUZZ6%*CBHX7$86<->:,E:[5I23:6G36YH?M._\
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MP;_T$]=_\"(?_C->Z44?VGC/^?K#^Q\!_P ^4>%_\,>^#?\ H)Z[_P"!$/\
M\9H_X8]\&_\ 03UW_P "(?\ XS7NE%']IXS_ )^L/['P'_/E'A?_  Q[X-_Z
M">N_^!$/_P 9H_X8]\&_]!/7?_ B'_XS7NE%']IXS_GZP_L? ?\ /E%#0='A
M\.Z'IVE6S2/;V-M':QM*07*HH4%B !G [ 5?HHKS&W)W9ZT8J*45L@HHHI%!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C,?[
M0&IZDOB :1X'NM3?1+F:.Z9;U$B6)"1OW%<ECAOD"DX'4UMM\?/#J>#-'U[R
M[N6;56:*TTRWB\RXDF4[6C ''!(YSSD>N*\F^'-YXOM[CXDV_AK0K;6XKO4Y
MX'WW:P26\A+@/AN'7!Z @Y%>H^!_@;I=G\+[#PUXFM(-3F5GN)&4G,4CG)\M
MQ@C P,CKBOH\10PE'XU;6.SU:<;NZ;TUM;8^5PV(QV(?[N5_CWC:*:E:-FEK
MI>^K)[3Q!XX73=6\3ZW;6FAZ7:6$T]OH<?[VX=@I96FDZ#&/NKZ\]*\6/A6&
MZ^!<GQ)DO;YO&?V@W U/[2X=?W_E[ ,X"XYZ9_#BO<]'^'NN:3'?Z)/X@;6?
M"EY:2P+'J"EKRV++M 60<.N"?O8(XQ7F<7PY^(:_#T_#8Z-8KIAN.?$/VU2G
MD^9YG$/W\Y_PQWJ\-5IQD_9RC'WH^7NZW6NK\UK?S1EBJ-6<8^UA*6D_[WOM
M+E>FB6]G9)=;,]U\&:Q)X@\(:+J<PQ->64,\F!CYF0$_J:^?-!\.V?QDM_B'
MXDU^2ZFOM/GFBTS;<.JV2HA92@! SPN<^F>IS7LJP^)O#>O>&-#T;2K.X\(P
M6H@O+V63$T112%"KN'HO\+9R>E>=0>!_'/@";QAI'A[0K76M*\03/+;WSWJ0
M_8_,!!WHW+8!_A_N^^*Y\.XP=25*2C*7PZI67-JO)VZ=CKQ"E.-&%>#E&/QZ
M-W?)H[=5?KT9QL7CC5/'?@_X8^&K^^NA#JU[);:A/'(1)<11R!%4MU.5;G/4
M@&N@BN(O@I\7M8T?0A-'H4VA2Z@-.DF:2-)D1F!7<2>?+/?^+Z8U-2^!FK^'
M?"O@>;01;ZCKOAJX:YEMWD\M+HNP=U5FZ<@ 9QQS[5J:+\.==\;>.-6\4^+M
M-AT)9]-?2[738[A;B1%92K.SK\IX9L?[W;'/H5,1AW&;@UR>_==VW[KM]UGT
M\CRJ.&Q2E352+]HO9V=KV27O*^RZW5];]3S ^%8;KX%R?$F2]OF\9_:#<#4_
MM+AU_?\ E[ ,X"XYZ9_#BO1_BI8GQE\$5\37=]?)+_8\4_V&&?R[9I'"DNZ*
M,L>3@$X]JY^+X<_$-?AZ?AL=&L5TPW'/B'[:I3R?,\SB'[^<_P"&.]=M\4]#
M\1KX#3P;X8\,?VO8RV"6IOC?Q0&#9@ ;'Y;(7/!'6HK5HRJQY9I^^VM5I#33
MR]-S3#T)1I2YZ;7[M*6CUG=Z_P![U5U;K8Z+X*_\DG\+?]>,?\J[:O/O@M#X
MCTOPC:Z+X@\/_P!BG38(X(9OML=Q]IZ[FPGW,8'!)ZUZ#7@8S_>*C3O=MZ.^
M_H?2Y??ZI233344M4T[I6>C"BBBN,] **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!&8*I). .237AVB_ME?#CQ1\<-+^%
M_A^ZOM?U>_6ZVZMI]N'TM)+=-\L7VDL!(X& ?*#A20&*FO<)(TFC:.15=&!5
ME89!!Z@BOD;XDZ'IOAK]O+]G+2](T^UTK3+70->BM[*QA6&&%!"N%1% 51[
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M[YB_^(H^P3_]!*Z_[YB_^(J[10!2^P3_ /02NO\ OF+_ .(H^P3_ /02NO\
MOF+_ .(J[10!2^P3_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\ B*NT4 4OL$__
M $$KK_OF+_XBC[!/_P!!*Z_[YB_^(J[10!2^P3_]!*Z_[YB_^(H^P3_]!*Z_
M[YB_^(J[10!2^P3_ /02NO\ OF+_ .(H^P3_ /02NO\ OF+_ .(J[10!2^P3
M_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\ B*NT4 4OL$__ $$KK_OF+_XBC[!/
M_P!!*Z_[YB_^(J[10!2^P3_]!*Z_[YB_^(H^P3_]!*Z_[YB_^(J[10!2^P3_
M /02NO\ OF+_ .(H^P3_ /02NO\ OF+_ .(J[10!2^P3_P#02NO^^8O_ (BC
M[!/_ -!*Z_[YB_\ B*NT4 4OL$__ $$KK_OF+_XBC[!/_P!!*Z_[YB_^(J[1
M0!2^P3_]!*Z_[YB_^(H^P3_]!*Z_[YB_^(J[10!2^P3_ /02NO\ OF+_ .(H
M^P3_ /02NO\ OF+_ .(J[10!2^P3_P#02NO^^8O_ (BC[!/_ -!*Z_[YB_\
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M (E>.K^3Q-?6EY=Q6EO%-?.'$DTC(S;(8O+W*@+':0HYXT?V._B!\2/'FO\
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M!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^8O\ XBKM% %+[!/_ -!*Z_[YB_\
MB*/L$_\ T$KK_OF+_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XB
MKM% %+[!/_T$KK_OF+_XBC[!/_T$KK_OF+_XBKM% %+[!/\ ]!*Z_P"^8O\
MXBC[!/\ ]!*Z_P"^8O\ XBKM% %+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK_OF+
M_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XBKM% %+[!/_T$KK_O
MF+_XBC[!/_T$KK_OF+_XBKM% %+[!/\ ]!*Z_P"^8O\ XBC[!/\ ]!*Z_P"^
M8O\ XBKM% %+[!/_ -!*Z_[YB_\ B*M0QM%&%:1IF'\;@9/Y #]*?10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >5_$SPA:W7C7P7+_:6OVO\ ;&LO:7L5
MCX@O[:%XDTV[D55CCF5$^>")B4 )*G.=S9]-L;./3K&WM(FE>*"-8D:>9YI"
M%  +.Y+.W'+,22>22:X[XA?\C;\,O^QAF_\ 33J%=Q0 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMXC_ )^/[V'U3#_\^U]R/GC_ (8&^"W_ $+=U_X-+G_XNC_A@;X+?]"W=?\
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MV]\#?'WQ0_X7!\9/'\-IXBL6EM_"GA&/1]0G@\.VS'#2.Z6Y26ZD &YP2%&
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M44 %%%% !1110 4444 ?(EOX'\2_'+XI_$E/"OQ[^(>@6'A_5_L$\-O9V/\
M9\5P4#O;6S%2[^4&4,6 P6 !;FM/P-X6UWX1_M$>%/#7BCXU^//%DNL:?>75
MA9:O:6:Z;?-$N)(B\8$@E1764# ! ^\<$5GZEX7^-?[,WQ \;:G\,_ VF_%K
MP/XNU637Y-&DUB/2M1TV^E"B?;)*"DD3%0P&-PY&.,F[\._!?QA^-GQR\)_$
MKXJ^%-,^&NB>#[>[_L7PQ:ZHNHWDUU<QB)YIYHP$"K'D!1@Y/(HH[0MVUOWY
M==]_>VM?UZA5WG?OI;UTVVTW[:^2/JNBBF2QB:)XVW!7!4[6*GGT(Y!]Q1Z
M/HKYS^(7@[1/"?Q<^%VG>!K&'2?%$NH-<:A)9J?,FTQ5/G&Z?.Z0$[0#(22W
M0YJ]X.\+Z+\:-0^)6K>)[*WU>XM-;N='TY[@;WTZ&!$ ,!/,3%RSEDP22.>!
M4\WNN7:[^ZVWS=OD^P[:I/K;\;_Y?D>_45YK^SAXJU#QG\$_"NJZI.]UJ$EN
MT4T\F=TICD:/><]20@)/<DUZ56DH\LG'L3%W5PHHHJ1A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5F^)/$ND^#]#O=:UW4K31](LHS+<WU],L,,*#JS.Q  K2KE/'7P
MM\*?$J;1I?%.B6^NC1KK[=90WFYX8Y]I42&+.QR 3C>#M/(P>:F3:5T-6ZD/
MPI^+WA'XW>$4\4>"=877=!DGEMDO$@EA5I(VVN )%5B >^,'L37#?%[]LWX+
M_ ?Q+#X>\<>/++1M;D4.;&.WGNI(@<8,H@C?RL@@C?MR.>E>>_\ !-?Y?V<;
MWV\4ZS_Z5O3/^"?^D:?XH^%WC?QEJ-E:WFN^+O%>KR:K<RHLCS1I</%'"Y(^
MXJ+@)T ;IS5VNUR_RJ7W\NGX[Z[;"^%._P#,X_=S:_\ DNWF?3?AGQ/I/C3P
M_8:YH.I6NKZ/?Q">UOK.4213(>C*PX-.\2>)=)\'Z'>ZUKNI6FCZ191F6YOK
MZ98884'5F=B !7S)_P $]S'I/ACXN>%+*+[/HOAGXB:QIVFVX8E8+?>CB-1V
M4%VP!ZU]!>.OA;X4^)4VC2^*=$M]=&C77VZRAO-SPQS[2HD,6=CD G&\':>1
M@\TI_"I1V:3^32?X)_\ # M)2C+HVON;7RO;SMYD/PI^+WA'XW>$4\4>"=87
M7-!DGEMDO$@EA5I(VVN )%5B >^,'L361X;_ &BOA]XM\70^&]+UYYM2N9)X
M;.26PN8;2^D@.)DM;IXUAN&3!W+$[D;3GH<>)?\ !.FS;4/V8-7M$E:W:?Q'
MKD0ECX9-URXW#W&<UQ>E_#OQ/\-?AW\(-.\?:,/"GACX-7\^M:MXO:^M7MM2
MBBBG2$6B)(TY:4RH766./G(!8D9?NIIRT5HO[U=O_MWMN[V06E[R6K3DON;2
M7_;W?9==S[%\3_$;P[X.USPYHVK:B+?5O$5TUGI=FD4DLMS(J%WPJ*2J*JDL
M[85>,D9%=)7R!\-?BEX9T/XA:M\3/BSJ5QI'C/5[2&.QTE]/N+B#PCHLTF;6
M*[GBB:*TEG;$DCS.N3A0<)7UZCK(JLK!E89#*<@CUI\K45??\O+U77STZ7:Y
MDY-+;\_/T?3RUZV3J***D84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!P_Q"_Y&WX9?]C#-_Z:=0KN*X?XA?\ (V_#+_L89O\ TTZA7<4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M!?7$EG8W$\5K+>RQ1LZ6L!023$ D(I=E4,>@W,!D\D#FIZ* .'\*?$RZ\5:]
M>Z7_ ,(7K^E_8+C[)>W=])8&&VE\A)U5O+NG=LI+%@HK#+@'&&QW%</\/?\
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M_L73_P#GPM?^_*_X5=HH I?V+I__ #X6O_?E?\*/[%T__GPM?^_*_P"%7:*
M*7]BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X5=HH I?V+I__ #X6O_?E?\*/
M[%T__GPM?^_*_P"%7:* *7]BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X5=HH
M I?V+I__ #X6O_?E?\*/[%T__GPM?^_*_P"%7:* *7]BZ?\ \^%K_P!^5_PH
M_L73_P#GPM?^_*_X5=HH I?V+I__ #X6O_?E?\*/[%T__GPM?^_*_P"%7:*
M*7]BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X5=HH I?V+I__ #X6O_?E?\*/
M[%T__GPM?^_*_P"%7:* *7]BZ?\ \^%K_P!^5_PH_L73_P#GPM?^_*_X5=HH
M I?V+I__ #X6O_?E?\*/[%T__GPM?^_*_P"%7:* *7]BZ?\ \^%K_P!^5_PH
M_L73_P#GPM?^_*_X5=HH I?V+I__ #X6O_?E?\*/[%T__GPM?^_*_P"%7:*
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M_ORO^%?FM15_ZN?]/O\ R7_@F?\ K9_TX_\ )O\ [4_2G^Q=/_Y\+7_ORO\
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M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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M#1/C-XWGM]1;6?%=OX'ED?1+&Z7;,WV@LR1;@%1B/F(V\D;>/H?X;_%CX?\
M[3WQ>\%ZVZ^*O"GBOPK876HZ;X3\3Z<+%KJ*YC6(WJ$AA.H0E0T<A $F2.13
MH>]"/71773X=6O62;TTLETN%;24NFKL^N^B?HK+OKWL?4%%%%( HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLU_\D4\.?]O/_I3+7S'$/^ZQ_P 2_)GV/"W^^S_PO\XGIU%%%?GQ^I!1110
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M^FG3Z[BN'^'O_(V_$W_L88?_ $TZ?7<4 %%%% !1110 4444 %%%% !1110
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M'0!W%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GA\4/\
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M*X?X>_\ (V_$W_L88?\ TTZ?7<4 %%%% !1110 4444 %%%% !1110 4444
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MHHH **** "BBB@ HHHH **** "BBB@ KA_@7_P D2^'W_8O:?_Z31UW%</\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLU_\D4\.?]O/_I3+7S'$/^ZQ_P 2_)GV/"W^^S_PO\XGIU%%%?GQ^I!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 </\/?\ D;?B;_V,,/\ Z:=/
MKN*X?X>_\C;\3?\ L88?_33I]=Q0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S-^W%/##X?\
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M?_%T 7:*I?;Y_P#H&W7_ 'U%_P#%T?;Y_P#H&W7_ 'U%_P#%T 7:*I?;Y_\
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M.I7T-%)<CC;4****T,PHHHH *^MO^"9__)=]>_[%N?\ ]*K6ODFOK;_@F?\
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MD<F%_AO_ !2_]*84445SG6%%%% '2?#/_DH_A3_L+6G_ *.2OO\ KX ^&?\
MR4?PI_V%K3_T<E??]?HG#'\&IZK\C\<XZ_WFC_A?YA1117VA^9!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M!8QO#96Z2'=(L:JQ]2!S6=JUF8W\] -C'YNV#Z_C_/ZUL4C*&4@C(/!% %33
MKW[3'M<CS5Z^X]:N5A74,FGW(:)L9Y4D9'TK5LKQ+Z'>G!!VLO=6]* +%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5P^D?\EM\6?\ 8O:/_P"E.IUW%</I'_);
M?%G_ &+VC_\ I3J= '<4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\&?\ !4K_ )IE_P!Q/_VTKX,K[S_X*E?\TR_[B?\ [:5\&5]UEO\
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M1_R,<-_CA_Z4CXEHHHK\6/Z:"BBB@ HHHH S-(_Y"&M_]?B_^D\-:=9FD?\
M(0UO_K\7_P!)X:TZZ*_Q+TC^2.3"_P -_P"*7_I3"BBBN<ZPHHHH Z3X9_\
M)1_"G_86M/\ T<E??]? 'PS_ .2C^%/^PM:?^CDK[_K]$X8_@U/5?D?CG'7^
M\T?\+_,****^T/S(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@""\M1=0E"2"#D$''-8]K<-I]PP=,=G
M'>M^J&J61N%$B9WJ.5'<?XT 7E8,H92"I&01WI:R=+O/+/D/@#/RD\<^E:U
M!12,P49)P/4UF76L=5@'_ S_ (4 7KBZBMER[8/9>YI;:X6ZB#KQV(]*YUF+
M,2Q))ZDU9T^Z-M.,G]VW#=/P/^?>@#>HHHH **** "BBB@ HHHH **** "BD
M) &3P*%8.H93D'H: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY(WXA_[=_P#THBK@S#_<ZW^&7Y,];*/^1CAO\</_ $I'Q+1117XL?TT%%%%
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MS?[1K]U]Q\[_ &_C>Z^X^OO^&O\ P;_T#=<_[\0__':/^&O_  ;_ - W7/\
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M*>(=<T[2K;3]92XOKF.UC:6&((&=@H+$2DXR>P-?&==-\,/^2E>$O^PO:?\
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M^1^3]%?K!_PP/\%O^A:NO_!I<_\ Q='_  P/\%O^A:NO_!I<_P#Q=']L8?\
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M4EVBJ7V"?_H)77_?,7_Q%'V"?_H)77_?,7_Q% %VBJ7V"?\ Z"5U_P!\Q?\
MQ%'V"?\ Z"5U_P!\Q?\ Q% %VBJ7V"?_ *"5U_WS%_\ $4?8)_\ H)77_?,7
M_P 10!=HJE]@G_Z"5U_WS%_\11]@G_Z"5U_WS%_\10!=HJE]@G_Z"5U_WS%_
M\11]@G_Z"5U_WS%_\10!^?OQ0_Y*9XM_["]W_P"CGKF*^Y=4_9N\#ZUJ=WJ%
MY974UY=S//-)]J==SLQ9C@$ 9)/ &*K?\,M_#[_H'77_ (&2?XU][3S["PA&
M+C+1=E_F?F57AG&5*DIJ4=6^K_\ D3XCHK[<_P"&6_A]_P! ZZ_\#)/\:/\
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MYB_^(H NT52^P3_]!*Z_[YB_^(H^P3_]!*Z_[YB_^(H NT52^P3_ /02NO\
MOF+_ .(H^P3_ /02NO\ OF+_ .(H NUYM^T9_P D;\0_]N__ *415WGV"?\
MZ"5U_P!\Q?\ Q%9OB/P;:^+-&N-*U6YNKJPN-OFPY1-VU@PY501RH/![5S8J
ME*M0J4H[R37WH[L#7CA<72KSVC*+=M[)IGY]T5]F_P##,O@/_GPNO_ M_P#&
MC_AF7P'_ ,^%U_X%O_C7Y[_JSC/YH_>_\C]@_P!=\N_Y]S^Z/_R1\945]F_\
M,R^ _P#GPNO_  +?_&C_ (9E\!_\^%U_X%O_ (T?ZLXS^:/WO_(/]=\N_P"?
M<_NC_P#)'QE17V;_ ,,R^ _^?"Z_\"W_ ,:/^&9? ?\ SX77_@6_^-'^K.,_
MFC][_P @_P!=\N_Y]S^Z/_R1\945]F_\,R^ _P#GPNO_  +?_&C_ (9E\!_\
M^%U_X%O_ (T?ZLXS^:/WO_(/]=\N_P"?<_NC_P#)'QE17V;_ ,,R^ _^?"Z_
M\"W_ ,:/^&9? ?\ SX77_@6_^-'^K.,_FC][_P @_P!=\N_Y]S^Z/_R1\945
M]F_\,R^ _P#GPNO_  +?_&C_ (9E\!_\^%U_X%O_ (T?ZLXS^:/WO_(/]=\N
M_P"?<_NC_P#)'RM\,_\ DH_A3_L+6G_HY*^_Z\RTS]G;P7H^I6E_9VEU#=VL
MJ3PR?:6;:ZL&4X.0<$#K7H'V"?\ Z"5U_P!\Q?\ Q%?59/E]7+Z<X56G=]+_
M *I'P/$F<8?.*M.IAXM**:UMW\FR[15+[!/_ -!*Z_[YB_\ B*/L$_\ T$KK
M_OF+_P"(KZ$^/+M%4OL$_P#T$KK_ +YB_P#B*/L$_P#T$KK_ +YB_P#B* +M
M%4OL$_\ T$KK_OF+_P"(JU&ICC56=I".K-C)_( 4 /HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QM:9&NHEY
M\Q$)]L,1_P#$U0JSJ<@DU"7Y,,@5-V.HQN_]F-5J "GPPF>9(P"=Q .TX(&>
M3GZ4RK^CP;[@R$*50<>H)_\ K9_.@#9HHHH *S-7M=RB9%YZ/C^=:=(RAE(/
M(/% '/V-Q]EN _\ ">&^E= K!E!!R#R"*Y^\MC:S%?X>JFI-/U--/MVAEW,J
M\Q!023_L#MQVZ#'LI- &U-,D$;22,$1>K,<"L>_U%K@E(R5BZ'U;_P"M5:[N
M'O)Q)(?E7[D8^ZOJ?<]L^G3&3F.@ HHHH *-V[YO[W/'O12)$88XQUR@;\QF
M@"6VC>2YA$9PPD4GZ @G],UTE8.F0M)?1,K8$>6;GJ,$8_,_I6]0 52U*S^T
M1[T4&5>GN/2KM% &+I]]]G?RY6/EG@9&=I_P_P ^M;59>K6(93,H'^V/7WI=
M)O\ S/\ 1Y"=ZCY&;G</3/J/Y>O- &G1110 5'--';QF25UC0=68X%4;S64C
M)2 ">0'!;/R*<X.3W/7@>G.*R)"\\QEFD:5\Y&[HG7A1VZ_4]R: .FAF2>,/
M&P=#W'Y&GUB:5=^1<&-V_=R$;<GHW_U^/Q ]:VZ "BBB@ HHKB/BU\1I_AKH
M>F7EKI<>K7>HZI;:7#;S71MHP\S;0S.$<@#V4FCLN^GWZ =O17CVJ_'+4M!O
M/%'A_6="MM(\5:;H,^NV(AO&O;*[B16_CV1."'&"I4<<@UW_ ,._$5SXN\ ^
M'-<O$BCN]2TZWNYD@!$:N\:L0H)) R>,DTUJKKR_&_\ DP>CL_ZV_P T=%11
M12 **PO'FNW'A?P/X@UFU2.2ZT_3[B[B28$H72-F 8 @XR.<$4SX>^(I_%W@
M/P[KEU''#<ZEI]O=RQPYV*SQJQ"Y).,GC)H6M_*WXW_R!Z6\[_A;_,Z"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN-\*?$3_A)_'OC3
MPU_9_P!F_P"$<DM4^U>=O^T>=%YF=NT;-O3J<^U<U/\ 'ZTL?CH_P[O=)DMH
M6CB6'6C.#&]S)&9$@*;?E+*KX.XY*XQ0M6DNO_#ALF^QZO17F^L?&(:1J/Q'
MMFTDR+X/TV'42XN,&[WPR2;,;/DQY>,Y;KG'&*O^ ?%GB[Q=8Z1JE_X=T73-
M&U"U2[62WUN:YN$5T#(#&;2-2>0#\_'/6A:[?U>_^3!^[O\ UM_FCN:*9+*D
M,;R2.L<: LSL<!0.I)]*BT_4+75K&"]L;F&\L[A!+#<6\@DCD0C(96'!!'<4
M 6**\W\1?$[7+?XH'P5X?\.V&J7<>D+J\ESJ.JO9IM,ICV*$MY<G(!R<#FN>
MM_CYK.M?#O5?%^C>%=/FL]%2Z35;/4-9>"X@N+?=YL2!+:1)!@ AMRYW=!2N
MK<W3_)V?XCY7?EZ_YJ_Y'M-%>/ZA\9_$V@_#2/QUJOA'3$T5H+6[,=CK<L\Z
M03,FYV5K1!\BON(#'.",CK78?$CXA1^ O"<6KV]F-7N;JYM[.QLTF\O[3+-(
MJ(H?:V!@ELX/"FK<6G9][?,E--77J=A12#.!D8/>EJ1A1110 4444 %%%% !
M17&_%;XB?\*Q\+Q:Q_9_]I>9?6MEY/G>5CSI5CW;MK=-V<8YQU%)\7_B(_PK
M^'^I>)8],;69;5H4CL5F\DRM)*D8&_:V.7]#TI75K^=OGI_FAVUM_7]:'9T5
MY;??'BQ7X,V_Q L-.:\CD>"&33I)O*>&5YTADC=MIPR,QSQSM[9JQJGQ.U^;
MXGZCX,\/>'=-U":PTZ'49KO4]7DLU(D=E"JJ6TN2-O4D=:IJSM\ON5_R)W5_
MZWM^9Z51572Y+V;3X'U&WM[6^9<S0VL[3Q(WHKLB%A[E1]*/[5LO[4&F_;+?
M^T3#]H%GYJ^=Y6[;OV9SMSQG&,\4NMA^9:HKF_B1XR'P]\!Z]XE:T-^-+M)+
MK[,)/+\W:,[=V#C/K@_2N%_X75K^FZMX9TW6O"VFV4_BB!VT>:UUIYX6G$?F
M"*<FV1HL@CYE609[4+5V7];_ .0;*_\ 6F_YGKU%>167Q6\<7WQ!U+P>G@WP
M^NIV%C#J$LK>)9_),<C,JA3]@SNRISD >]=3X%^(C^+?$7BW0KS35TO5/#UX
MD$D2W'G+-#)&'BF!V+@,-PQCC;UH6NW]:V_,'IO_ %I<[2BN2\#^/O\ A.-4
M\4PP6/D:?HNI'3(KSSMWVJ1$4RD+M&T*S;.IR0>G2NCN-5LK.]M+.>\MX+N[
M+"VMY)562;:-S;%)RV!R<=!1T3[Z_?J'==BU15;4KP:=I]U=LI=8(FE*@X)V
M@G'Z5XMI?[1VI1^$O"OB[Q!X3MM,\*>()HH$O+'5FNI[1I6VQF:)K>,!21R4
M9B/0T+WG9>7X[?>#T5WY_AN>Y45YKJGQ.U^7XGZCX,\/>'=-U":PTZ'4)KO4
M]7DLU(D=E"JJ6TN2-O4D=:FUSXI7^AZCHWAM="AU/QSJ4,ER-)L+\M:V\*-@
MS2W+QJ5CZ#/EEB20%.*%JDUU_P"#_DPV;7;^OU1Z)17->'-7\3W5_);:_P"'
M+334\LNEYINJ?;("00-C;XH7#')/"%<+]X' JEXD^(G_  C_ ,1_"'A3^S_/
M_P"$@CO'^U^=M\CR(U?&S:=V[=CJ,8[T^J7<#LJ*\OT_XH>*/$WC#Q9HOA[P
MOI%Q!X>O([.6ZU/7);9I6:)9,JB6DH &['+=JJ:5\?X+CXV7WP[U'1VTZ6%$
M2#5%N?,AN+DPI,T !12I"L2"3\VT\#I2C[UK=5?Y;@]+WZ'K=%<EX5\??\)-
MXT\8^'_L/V;_ (1Z:VA^T>=O^T>;")<[=HVXSCJ<]>.E=;1T3[@%%<!XT\?:
MAX=^*'P_\.6T-L]CX@>]6ZDE5C*GDPB1-A# #)/.0>/2H?AKXXUOX@ZUXBO0
M^FVOAS3=4N=)AM%MW>[D>$A3,TWF; "V[Y!&>,?-VH6NWG^#M^;!Z;_UO_DS
MT6BBB@ HHHH **** "BBB@ HK@?B1\2-0\&^(O"6A:5HUMJ^I>(KB>"+[9?M
M:0Q>5$9"69892<@8P%KCM;_:4;PWH7C0:EX:\CQ1X6EM8[G25O\ =!,MPZK%
M)'<>7DJ0V3F,$8QBA:[?U_5QVL>WT5R^BZQXJ$LTOB31]"TC3(H6D:YL=:EN
MF!&#\RO:1 +C)+;N,=/3F?#WQ1\2>/=._MKPGX1MKOPX[-]FO-7U9K*:\4$@
MR11+!+\I(.TR,A/!P!S0+S/3J*JZ7=3WNGV\]U9R:?<2(&DM971VB;NI9"5.
M/4&O)KK]H8V_PBU_QN/#^]]+U632UT\WN!,5N5@#F3R_E!W;L;3CISUHZV_K
M=+\V@Z7_ *[_ *'L=%><^(_B!XJ\$>#?$7B3Q!X:T>.UTNPDNXX=-UN6X>9U
MY"'?:1A ?[V6Q_=-9NF_'ZUU7X(:OX_ATATN])AF-[HDMP%D@N(OOPM)M..Q
M#;>0P..:7=]OZ_K_ ((UK9+KHCUBBJVFWG]H:=:W6SR_/B679G.W< <9[]:L
MU333LR4U)7045X5'\?-97X;:_K;V.GMJL'BB3PYI\>'2'FX6&.24;BS8#%F"
MD9QQMZCV;1(=3@TV%-8NK2]U 9\R>QMFMXFY.-L;22%>,=7///'2DM8\W33\
M4G^30WH^7^M&U^:9?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G R>E '.W3.UU,
M7Z[R!CTSQ^E14'J>=WOZT4 %:6D7:*Q@8;6;E6]?;ZUFX)X )/H!FG3VSQ';
M(A4@@CZ]00?7_"@#IJ*HZ?J(N-L<AQ-C_OK_ .O5Z@ HHHH J:E:_:("0/G7
MD<<_2L*NHK!U*W%O<<#"OR.GXB@"K1110 4444 %/DA\M87_ .>D2-_XZ!_2
MF5/<PA8[2;(R]NB8[_+S_P"S4 6M%AS,\N3\J[<?4@_TK7K.T6,K%(^3AC@#
MMQ_^NM&@ HHHH 0@,"",BL+4+-K68,I*C=N1EX*G_/YUO55U15^PSLYP(U+Y
M^@S0!5CUZW%N&F.R?.TPJ,LQ]5'<<CGH.^,'%&]O9K_*L3%!_P \E/+<_P 1
M_H..2#FH:* $50BA5 50,  8 I?J<#WHJ:QC\R[B7CKGD9Z<T ,O+4Q,T4F>
M1U4D?B#_ %K9TN\-W;X<CSH_E?W]&_'^>1VJ/5K4S1"51\R=1ZC_ .M_C6=8
MW7V28,?N'ANO3Z"@#H:*0,& (.0>AI: "O%?VJ5N)/"OA!;26."Z;Q9I@BDF
MC,B(_FG!90RE@#U 89]1UKVJJ6J:+I^MQP1ZC86U^D$R7$2W4*R".53E9%#
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MMU$_94_TP;2N)N/W@VDCYL\'%7[.S@T^UAM;6&.VMH46.*&% B1J!@*JC@
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M=X5T2PN8YC<)-:Z=#&ZRD$%PRJ"&P2,]<$UTE4VK61%G>_E_F%%%%24%%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>eigr-20221231_g8.jpg
<TEXT>
begin 644 eigr-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )Q!-L# 2(  A$! Q$!_\0
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M^T.XDO-%T^XF;?++;QN[8 RQ4$GCWIQ]Z+DNCM^"?ZA+W7%/JK_<[%ZBBBD
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M9$<@#<77/)K[X\4W?PMU;]E^?5-1T32;[X4KX?74DTPV:?9/L:Q"6)4B PI
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M+M2V1$0 +&"RDJ ,*I'!%?//[.>M? #Q_P#"72?%7QW^(?P\\>?$7Q!"U]J
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M<-\+OA/:?M._!7XN^*/$$3+_ ,+:FG&GM/&5:VTV &'36 Z\;!/[F3->'?\
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MDG^*LOQ/M?\ 8DUN\\0_LD_"B^OW:2Y;0+>)G;JPC7RU)_X"HKYW_P""SO\
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MXA>$?^$@U2RUYK*"?^T[RVV0B")PNV&9%/S,QR1GGK7ZO^*?^16U?_KRF_\
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MI_\ [#\7_I3?5^D-:RDYPISENXQ;]>5&?*H5*D([*3L?)/\ P4._8MN_VM_
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M>B0ZH8]-O6D8/()451(Z.P!:,R;#T*XXKZAM[>*TMXX((TAAC4(D<:A550,
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MC#X9T>S@-O:0Z;$BBV!!^90P92V3NRP;)Y;.370T4VVT[]=_,2LK>1\G3?\
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M_MK2666QTVVN=.@M;(2$96-5LLD  #<Y9L 98]:^HJ*))2=V$6XJR/)_A/\
ML[Z=\+_A[=>!KSQ5XC^('A2:U%E'IOC*2TNU@MPI4Q*T=O&S(5(&V0N % 7;
MSGR/2/\ @FK\.O!_B"ZO_!/C/XD_#W3KN0276A>%O%$EI97&">'^4RD8./\
M6< <8KZTHJFW*7.]_P"M^Y*]V/*MOZ^XX/0_@WHG@CX<OX-\#SW?@6S)+KJ&
MCB&6\61F#/*7N8YEDD?!#/(KL<DYS@CQ3X/_ /!/OPW\#?B1?^-_"_Q,^(D6
MMZI,9M4^UWNGS0ZEF3S'6=#9<AF+<C##<=K*>:^IZ*$VI\_4+)QY.A\V_M)_
ML,^'/VJM3M)_&WCSQLNG6,K36&CZ9/806MHS*JL4S9M(Q.W.9'<C)P0.*ZS7
M/V<;OQ%\)7^'U]\6?'LNES126MSJ'F:9]ON;5XPGV=YOL/W0 ?F $AW'<Y&
M/9J*CE7(X=&7S/F4^JV/ /V9OV-]"_93CN;+PAXX\97V@7,C3RZ%K5Q93VC3
M,H7S1LM4D5L*/NN <#(-:G[0W['OPR_::6SG\8Z1,FMV*[+/7=*G-M?6XY(
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M+'8YSP'X1N?!?A>WT:]\2ZQXO:'*C4M?-NUTZ= K&"&)6P.Y7<>Y-?->B?\
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MOW?VRMYIBM_J_+V^6+#R]FSY=FW;CM7UC15<S<N?KW)22BX+9G,>-/AOX?\
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M1QHL<: *J*,!0.@ ]*?110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5C+XT\/2:G_9JZ[IC:CNV_9!>
M1F7/ILW9S^%>3?M5>--0T'PSIFBZ;*\$VL2LDDD9PQC4+E >VXN,^P([U8T_
M]E/P='X8CL[N.YDU8QC?J<=PRNLF.2J9V8SV*GCOWKU*>%I1H1KXB32DVE97
MVW>ZT/&K8RO+$2PV%@FXI.3;LM=EHGJ_N/:))$AC:21E1%&YF8X  ZDFL.U\
M?>&;^\%G;>(])N+LG:+>*^B:3([;0V<UX)\9&U/7O&7@WX6Q:G,UGY$ O;GH
M]PW(+L,G.%0M@]VYSBNE\<?LQ^#X?!=^^D6D]GJEK;/-%<FY=S(RJ3APQ*X.
M.P'6M5@Z%.$)5ZC7/M9=+VN[M;F3QV*JU)PPU)/DM>[ZM7LK)[=]CVV]OK?3
M;26ZN[B*UMH5WR33.$1%'4ECP!]:IZ+XHT;Q)YO]DZM8ZIY6/,^Q7*3;,],[
M2<5\Y>'?&-[XL_99\41ZA.]S<:<?LJS2$EFCW1LN3W(W$?0"N8^"URWPW\<>
M#=0=F&F^)[-K>1B>!)YS(/R98S]&-="RGW:JE+WHNR7?3F_%''+//>HRC#W)
MJ[?;WE'\&SZ[U76+#0K,W>I7UMI]JI"F>ZF6) 3T&YB!4-GXFTC4M+EU*TU6
MQNM.AW&2\AN$>%-HRV7!P,#KD\5X7^T'-)X\\?>'? ]ODP6Z/J5\5/10I.#Z
M$*K?]]BN>^%/_)K_ (Y_ZZ7'_HJ.L89?&6&5:4O>;6GDW9/\&=53-)1QOU:,
M;Q2>OFES-?BCZ$@^)7A&ZF2*'Q3HLLKG"QQZC"S,?0 -S71 YY'(KY&\+_"_
MPCJ7[.]YXGU&'[-K,:7#1WOVAUW.K$1IL+;3D@+C&3FKVD?$K7/#/[,*SK<R
MI>37[:;97+$[XX<;B5/MAU![<>E;5<K@VXT)-M247==7U1RT,XJ6C+$P2C*+
MDK.^BZ-,^D-2\<^&]%NC:ZAX@TNPN1R8;F]BC<?\!9@:V+>XBNX4F@E2:)QE
M9(V#*?H17A7PY_9I\)WW@C3[S7K2?4-6O[=;F2<W,D9B+KN 4*0.,C[P.2/P
MK"^!TUY\._C1K_@'[7+<Z3B1X$D.=K *ZMZ E#@XZD#TK"6"H252-&;<H)MW
M5DTM[:_F=,<PQ$'2J8BFE"HTE9W:;VOIU\CZ!T_Q9H>K:A+86.LZ?>7T6?,M
M;>Z225,'!RH.1@\5-?Z]IFEW5I:WNHVEG<W;;+>&XG5'F;(&$4G+')'3U%?%
M_AY+WPOK&I^/+!6<Z'KQBNXU_B@E+ _R*_\  QZ5ZY\;-0@U;XD?"*]M9!+;
M7-TLT4B]&5I(2#^1K>>5QC6A!2NI)W\FH\UONL<\<YDZ%6I*%I1:LNZ<N6_R
M=_P/:M8\:>'_  _=+;:KKNFZ;<,N\0WEY'$Y4D@'#$''!Y]J-'\9^'_$-TUM
MI6NZ;J=PJ[S#9W<<KA00,D*2<9(Y]Z^:OCE_8/\ PT1IG_"4?\@'['%]J_UG
MW<28_P!7\W7'2O5?@YIOPMFU2^O_  %'NO;>(17$FZZ^5'.0,3'')3MZ5A4P
M5.GAHUGS-M7T7NKIJSHAF%6IC)8=<B47;5^\]+Z*VIZ)I_BS0]6U"6PL=9T^
M\OHL^9:V]TDDJ8.#E0<C!XJ:_P!>TS2[JTM;W4;2SN;MMEO#<3JCS-D#"*3E
MCDCIZBOB_P /)>^%]8U/QY8*SG0]>,5W&O\ %!*6!_D5_P"!CTKUSXV:A!JW
MQ(^$5[:R"6VN;I9HI%Z,K20D'\C6\\KC&M""E=23OY-1YK?=8YXYS)T*M24+
M2BU9=TY<M_D[_@>PW7Q&\)V-U+;7/B?1K>XB8I)#+J$2NC X((+9!'I3]/\
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MYI?VU;&YCCM_](ECV*3)D?(PS]T=<]*^JK"Q@TNQMK.UC\JVMXUABCR3M50
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M2]UK6+O%W5]'Y=0HHHKS3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$<@#[Q')_&L?X%V-]\0/BYK_ ,0Y;.2TTM]\=KYHY<D!0 >^U%YQQDU[G?>
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M/;3:CI=G?S6S;H)+JW21HCD'*E@=IR!T]!3M8T#2_$$,<6J:;::E%&_F(EY
MLJJV,;@&!P?>M*>:J*HIQ^!Z^=E9?<C.KDKG+$2C/^(FEY7UE][1\\_M;VRW
ME[X&MW)"2R31L5ZX)B!Q7H'@W]FOP;X+U:+4HH[S4[J%@\+:C*KK$PZ,%55!
M/USBO1-5\.:3KKV[ZEI=EJ#VYW0M=6Z2F(\<KN!P>!T]!6C7&\PJ1PT,/2;C
M:]_.[N=JRNE+%SQ-9*5^6UUM96?WZ'S)\4)I_A+^T%8>-;BTEFT2^4+))$O0
M^7Y;K_O  , >M:_Q<_:&\,:_X'OM%\-W$^KZIJD?V58TMI$\L-@-G<HR<$@!
M<\U[]>6=OJ%N]O=01W,$@P\4R!U8>X/!K+TGP3X=T&Y^TZ9H.EZ=<8QYUI9Q
MQ/CTRJ@UK'&4)1INO!N4%96=DTMKZ&<\!B:<ZOU:HE&H[NZNTVK-K5;^9Y;X
M)U33_@!\)]!M_%<<\+ZA.YF$<7F"%W!;#C.>% !P#SVKR/XJ7'@KQ1XHT!OA
ME#(=?FN07^PV\D$0((*D(RC# \Y48P#FOK_4--M-6M7MKZUAO+9_O0W$8D0_
M4$8JEH_A'0_#LCR:5HNGZ9(XPS6=K'$6^I4#-70S&%.K+$RB^=MO1^Z[]U;H
M98C*JE2A'"0E'V:26JO)>:=[7?H>&_%;</VDOAX'.7\J')]_-DKK?VI/^2/Z
MA_U\0?\ HP5Z7=^'M*O]2M]1N=,L[C4+;B"[FMT:6+G/RN1E>IZ'O4NJ:38Z
MY9O::E96^H6CD%H+J)98R0<@E6!'!KF6,CS4';^'^.MSK^HRMB5S?Q59>7N\
MNISWPG_Y)?X5_P"P9;_^BQ7S)\&?$7@+0=8\5_\ ";Q6,IEN%^R_;=/-UC#2
M;\81MO5?3/X5]A6MK!8VL5M;0QV]O$H2.&)0J(H&  !P !VK F^&OA"XF>67
MPKHDLLC%G=].A+,2<DD[>36M#&TX2K<Z=JG9V:UN8XC+ZLX8=4VKT^ZNGI87
MP#XB\-^)/#R3>%7A.D0NT");V[0(C#!*A"JX^]GIWKQ;]LA1)I?A53T:YF'_
M (ZE>_Z3HFG>'[7[+I=A:Z;;;B_DVD*Q)N/4[5 &>!4>L>'=)\0K$NJZ79ZF
ML+;HUO+=)0A]1N!P?I7/A\1##XN-=)N*?7<ZL1A:N)P4L-)I2:MHM/N/-/!_
M[,O@OPKJ4&I!+W59XRLD2ZA*KHC#D':JJ#_P+/2N!^.&BV?B+]HKPAIFH0_:
M+*ZMX(IHMS+N4RR9&5((_ U],UGW7AS2;[5+?4KG2[.XU&W $-Y+;HTT8!)&
MUR,CJ>A[UK1S"K&M[:K)R=FEY71A7RJC+#/#T(J-VF]-[.Y\X7NFQ?LY_&S3
M);'=#X4UM1$Z2'?Y0SAAN//R,5;.<X..:V?''_)V7A'_ *\T_E/7NNL^&])\
M1QQ)JVEV6J)$2T:WENDP0GJ0&!Q2S>'-)N-4@U.72[.34H%V17CVZ&:->>%?
M&0.3T/<ULLQ3<9U$W-1E%OO?9_+J82RJ24Z=*24'*,DNUM_D[:=CPF;G]L2
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M!;+;:IIUKJ5NK;Q#>0+*@;UPP(SR:LVMK#96\5O;PQP6\2A(XHE"JB@8  '
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MGA95*DVKSMI%6BK::+SZA1117F'L!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME\*/^A>\9?\ @%:?_)5?E?11_9]#LP_M&OW7W'ZH?\/4OA1_T+WC+_P"M/\
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MZ'P0_P"1:B^E>#FGV/G^A[V5?;^7ZGI=%%%>$>^%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?A/\ M&?\G"?$_P#[&C5/_2N6C]GG
MPAI?C[XW^"O#NMP-=:3J.IPP74"R-&9(RW*[E((STR"#Z&C]HS_DX3XG_P#8
MT:I_Z5RUL_LC_P#)S'PX_P"PS!_.ON*7PQ/A*OQ2^9]9W'P=^ .J_M-:C\#E
M^%=YI-U]GW6_B2R\17<KA_LZS_ZF0LJC!89);D#CGCR7X+_#F\\ _&+XL^$=
M,^%>E?&H:,DMJ'U2ZM[<6:)(P$P\Y2"Y& 53#94X(KZ.\1?M":AX>_;ME\"6
M'@#PU=KJ$MM87.O6>GO'K)AE@C9W>Y1B2J9S]T85!R,9J3]G;X=Z3\+?VJ/C
MKH.B7LU[8)I4%R#<3--+&\O[QD=V)+$%CR23@C))S7SZJSC1YY7:=-O5MW:Z
M[W6CZ?F?12I0E5Y8I)J<=DE9/IM9ZZZ[>A^>WPO^!/CWXV7EW#X*\,7.L_9C
M^_D1DBAA)R0K2RLJ X!P"V33/BG\#?'?P4O;:U\:^'+G0WN03!([)+#+C!(6
M6-F0D9&0#D9YKZIU**6'_@F/9'PLLKM+K;G7VM%*L%\Z3=YNWJN!;CGMM[5H
M:PT"_P#!.OP!#XY::.63Q! -/^W ^9]G^T/RN<'9Y'F8Y'RXQQBO4=:?M&E:
MRG&'GK;7\>VJZGF?5X<EW>[C*7W7TM\N^C:/FWPC^R!\8?'7A.+Q+HO@:]NM
M'EC\V*:2:&%Y4QD,D<CJ[@CH54Y[9KZ"\ ? *'QQ^P3J/]D>![;4OB*^N-;1
M7"V*?V@I6ZC5D\T@,BJH8$$@ 9SWI/\ @I ?%,7QO\"+X>.I+IZZ1%_87]EE
M\>>)'W>1Y?._'E?=YQM[8K5T75-8T?\ X)D^*9FN[VSU5]9EANI&D=)R7O(U
ME5S][+98,#UR0:YIUIUJ'M-DY*RZZ32U?YZ'13H0I5U3W:3N^FL&]%^6NI\C
M?%;X"^/O@A<647C;PY/HGVP,;>1I8IHI,8R!)$S+D9'&<\UT7@K]D+XP?$/P
MK'XCT'P1>7>CRH98;B6>" S)C.Z-))%=P>Q4'/;-?2/Q"CL]2_X)X_!FZUIV
MFM[?784DEDR[+!YMRC+ZX"#& 1P *],_:U\2_"_P+\9O &O>)_\ A9$=YIEI
M;SZ$/"8M/[+*K(3L42$,7.%#!2,H4%;/$3C+V?7GE&]NR3VOUOW[F,<-3E%5
M%MR*5K]VUO;I;MV/S^\'_ GQ[X]U7Q%IFA^&;N\U+P]"\VIV;LD,ULJDA@4D
M92S9!&Q06..!73Z[^QU\9O#>BV6JWWP_U-;2[DCBB6!HIY@SD!0\4;M(F20/
MF48)P:^Z?V=?B%9_$;]J+XR^)--T'5O# GT"R+6>M6HMKL2*@_>/&&;&X;2#
MGD8/>O)OV//%VN+^S+^T1JW]L7QU.*&6\CO&N',JSFWE)E#9R') ^;KP/2LI
M8JJH2G9+EC&37J[6_P"":QPE&52,%)OFDXI^D;Z_E_D?*WQ0_9M^)7P8TFRU
M3QEX5N-&T^\?RXKGSH9TWD9"L8G;8Q /#8/!]#7?_':QOX_@+\*YIO@[I?@B
MVE@7R?%5G=02W&M_N5^:1(P'3=]_]Z6.3P1SGU/P3<2ZM_P3!\="\D>Y%IKH
M\CS&)\O,]LQQ_P "=S]6->J^*(]+F^&G['::R8QIQU#3_,\[[F?LZ[ <D<;M
MM:RJ2;Y)ZVG%:7ZJ_??7T,H4H\OM(:)PD];;IV[;?CYGQG)^QO\ &:'P>WBB
M3P%J":0L'VEF:6$3B,#)8V^_S>G.-F:K_#O]DGXN?%;0(];\,^"[J]TF49BN
MY[B"U249(RGG2)O&0>5R*]1_;@?QZ/VNO$(TQM=%W]DB_LW^SC+YGV,VZ^9Y
M?E\[,^;NQQG=GO75Z;\"?"7PY\!?"/Q!\2/$_P 0M?UC7?)F\/Z3X1\F6+3R
M=LJHOG;A_&APF#G=@'&:JE7G4IQJ-I<UK*S>]]-]7IY=2:N'A3J2II-\J;;N
ME>UM=M%KY]#@/V1?A#+IO[76B>#OB'X5C:2&*Z:YTC6K598V(MG9&*,"KCH0
M>1T(KRG]HS1['P_\>O'^FZ99PZ?I]KK5U%!:VT8CBB02'"JHX4#L!P*_1?QU
M"B?\%*/ATZHJO)X7F+MM +86Z SZ\5^>G[4G_)QOQ)_[#UW_ .C36-&M*M6I
M2?6#_"=C:M0C0HU8+6TX_<X7/H7PS\,?A%X#_8P\,_%3Q1\.&\;:W?7KVLZG
M7;NPW9GF12#&Q486,#&SGUKE?VFO@7X!T[X%^!OB[X L+SPS8^()5MY_#]Y=
MM="-BLAW1R,2QP8F!R>05.%Y%>T:'\0H_AC_ ,$X_ ^M2^&- \71#4VB?3?$
M=D+JV8-=7&6"$C#C'#<XR>#2?M'6=MX^U;]GGXC+?2'X5:E?6,$N@O&@L],=
MG0E=J*HP0KH=V<>60#@X"<IO$R5VE[3EO?1*WPV\^@U&"PZ;2;]FW:VK=_BO
MY=4?*FA_L:?&CQ%X5C\1V'@*_ETJ2+SHV>:&.:1,9#+ SB1@001A>>U<=\-_
M@GXY^+FOW>B^$_#=WJVI68)NHOEA6WY(Q(\A54.01AB"<'TK] OVA/'OPU^%
M_P"UEI7B7Q'#\4KCQ?9Q0?V=;Z*EH^EW$93;Y42N1(P8DAU!&6)]J\F\/_M,
M:%X=^(_QM;Q%\._$L'PV\8W:VVIM':FVO=.F,;(R3 ,%5G+.2N\$'IG)%53Q
M56I%SC'=-KUNE:_7?RU5NI%3"TJ4E"4MFD_1IMNW2UN[T=^A\W:K^S/\3-#^
M)&E^ K[PK/;>*M44O963W$.V=0&)*R[_ "R %;/S<8K<M_V+OC7=:1J&I1?#
M_4&M;&26*;,L(D9HR5;RXR^^49!P8PP;L37U)X5^!UC\(_VK/@3J'A_Q+JVN
M>$-=M;N?2;/6G)GL(_LK.8P"!A3YH.-JD'(.3S6KX0;QM_P\\UD71U+^SA;3
MY\[?Y7]G_9_W6.VSS=N.V[/>G]9G*T8M7Y9/5/>+:M:_EW$\-3C>4D[7BM&G
MI+K>WZ>1\$?#OX2^,/BSX@?1/"6@7>M:E&-TL4("K",XS([$*@SQEB*WOBI^
MS9\2O@K96][XR\*7.D6,[;$NUEBN(=QSA3)$[JK'!P"03BOMNS^PR? O]JFZ
M^'^^76Y?$MV)#8IB86^Y,[2O)3!N2,?[5>>?!&26#_@G3\5_^$G\]=&:Z==(
M^U [#(?*V^3GMYWIQG=WS2>+FXNI%624';J^:VWWZ;WL6L'!35-MOF<TGT7+
M?5]]O*QX'HO[&_QE\1?V0VG>!KJYBU6R74;2=;FW$30, 59I#(%C)!X5RK'T
MKB?$7P>\:>%/'T?@G5/#E];>*972.+3%0222EONE"I(<'GYE)'!YXK[#_;DU
MO4=-_9W_ &?;:TOKFUMYM/AFDBAE9%=X[:W,;$ \E2QP>V3BNR_:Z\8:C\,_
MVFO@QXST?0)O$^JVNCS--I]O&SRW$(#"3!52V5221MV"!C/3-:+$3YTG:SE.
M/_@*;3O^#^_R,7AX>RYE>_+&7WM)K\;K[O,^+_B1^RS\4_A%X;37_%GA&XTK
M1V94-T+F"=49L;0XBD8IDD#Y@.>.M3^ /V2_BW\4/#2^(/#?@N[OM'<%H[J6
M>"W$P&>8Q*ZEQP>5!%?0WQ>\!^!OC9\'?&OQI^'VL^)_#T3:BDGB7P]J[G[-
M=2>:A; #8+*9 P^9AP  AKU?]KC6OA5X3\1?"_5_$C?$2WL]/L(9_#[^#/LB
MZ:H5@5'[XY\S:$X4_<VU"Q-2T8R7O-VVVTOWU\K-71I+"T[N47>*5]]];=M/
M/1V/S^\)_ _QUXW^(%SX'TCPY=3>*[;S#/ID[);O%L^^7,K*JXR.IYR,9R*Y
M'5])O-!U:]TS4+=K6_LYGM[B"3[T<B,593[@@BOL'X@?$CX@?%;]KX^(/@CX
M=UWPSXMFT6-'M=9M+:VN9(PF6ED29FBV,ACVECSA2.<5\D^+O[7_ .$KUG_A
M(/-_M[[9-]O\_'F?:-Y\S=CC.[/2NFC4G/EY[*ZU76][77E^IRUJ<(<W)=V>
MCZ6M>S\_T.W_ &:_^2V>&O\ >G_])Y*_9_X8_P#(LVW^X*_&#]FO_DMGAK_>
MG_\ 2>2OV?\ AC_R+-M_N"O%S+^,O3]6>WEG\%^OZ(Z^BBBO)/7"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /.OVC_P#DWKXG?]BQJ?\ Z22U^%-?NM^T
M?_R;U\3O^Q8U/_TDEK\*:^ARSX)>I\[FGQQ] HHHKVCQ HHHH Z7X=_$CQ'\
M)_%5KXD\*:FVDZU;*Z17*Q)+A74JP*.K*003U!]>HJ7XE?%+Q1\8/%#^(?%^
MJMK&L/$D!N&BCB 11\JA(U50.3T'4D]ZY6BI<8N2DUJBE*48N*>C/0_$'[07
MQ \4P>#H=4\0O<Q^#S&=$'V:!#:%-FTY5 7(\I/O[NGN<XOQ*^*'B?XO>*)/
M$?B[5#J^LR1)"UR8(X?D084!8U51CV%<M12Y(WO;O^._W]1^TG:U]-%\EM]W
M0]NT7]M;XV^'_#D>AV7C^^73XX_)3SK>WFF5<8 $SQF08'0[N.U<3X"^-OC?
MX9^-+SQ;X=\07%IXCO(Y([G4+B..ZDF#L&??YRN&)*@Y(SQUKAZ*7LX)M\JN
M]_,?M)V2YG9;>1WOP_\ CQX^^%GB/4-=\+>)KO2-2U%S)>,BH\=PQ);+Q.I1
MB"S8RO&3C&:M?$C]H3QY\9KS3W\>>([OQ#9VDJR+98CMH?0D1Q*J!B,C=MSS
M7G%%-4X*2ERJZVT#VD[./,[/?7<_1+Q-^TE\+_''B'P;XDT?XY^)_AEH^BVL
M$4O@:QTF[,<HB;=Y9:(^3R,)\P<8 Z"O!OC+^V;K>H_'3Q/XR^&%S-X6LM6L
MHM,F>:U@DEO(HQCS'5U<*Q[$<@ <]:^9J*Y8X2FG=ZK71^>_F_FV=+Q=1JRT
MVU7]W;R7R2.^^%?QZ\??!.YNYO!?B6YT0W>//B5(YH9".C-'(K(6'][&1ZUJ
MS_M1_%6X^(D7CE_&E_\ \)/%#]F2\58U00YW>5Y(7RRF[G:5QGG&:\LK3N_#
M&LV&AV.M7.DWUMH]\[QVFH36SK;W#(<.L<A&UBIZ@$XKIE"%^>25]K_H<T9S
MMR)NV]CU7Q-^V3\8_&6DZUI>L^-9[[3=8MOLE[:O96RQO%@@A5$0$9()RR;2
M>,G@5QWB+XU>,_%GP]T/P/JVMM=^%M$?S+"P-O"ODMA@#O5 [8#L/F8]:XBB
MDJ5-:**^[MM]PW6J2=W)_?WW^\ZSX9?%7Q3\'?$P\0>#]5.CZOY+V_V@013?
MNVQN7;(K+S@=NU3>#?C%XP^'_CZ;QKH&M/8>)IGF>2^\F*3>9<F3*.I0Y))Q
MMX.,8P*XVBK<4W=K6UOEV]"%*25D]+W^??U/2/"7[1GQ&\">,M8\4Z!XHN-*
MUC6)FN+]X(8A!<R,Q8L\!3RB<LQ'R<9.,9JSX]_:?^*7Q,U#2;SQ'XROKV?2
MKE+RR$*1VR03K]V54B55WCLQ&>3ZUY=14>SA=/E5UMY>A7M:EFN9Z[Z[^I[#
MXZ_:\^+_ ,2O"\WAWQ#XUNKW1YE"36\5M;V_FJ,?*[11JSCCD,2#WKW/Q#^V
M-;^#_P!EOX6:'\.?&%QIOCW175-1MX[-]J1".565S+&8I%+,A ^;L>"*^*Z*
MSEAZ<H\MK*Z>GEW-(8BI&7/>[LUKTOV^XZWXD?%CQ=\7O$"ZWXOUVYUO4E01
MQRRA46)0<[41 %09).% YKT.S_;;^-^G^'5T2'X@W_V)8_*#R0027 7_ *^&
MC,N???GWKP^BM/94W'D<5;M;0CVM12YU)W[WU.\^'OQU\=_"O5M:U/PQXAFL
M-0UF)H=0N98HKE[A2VXEC*K?,22=PYY/-1>!?C5XT^&F@^(]%\-ZVVFZ9XBA
M^SZG +>*3STVNN-SHS(<2.,H0>>O KB**;IP:::WT^2Z"52:::D]'?Y]_4]D
M\(?MA_&'P'X1M_#.A^-KFRT6WC,,$#6MO*T28QM21XRZ@=L-QVQ7'>"?C-XW
M^'/BRX\3>'?$U_IVN73,]S=B3S#<DMN/FJX*R9//S@\\UQE%'LX7<K:O?S%[
M2?*HW=EMY'J/Q0_:>^)_QFTE-+\8>+;G5=-5UD^QI!#;1,PS@LD*(&(SWS^E
M8?C'XS^-/'_A+P[X8U_79=1T+P_'Y6FVC11H(%VA0"RJ&?"@ %R2!TKBJ*2I
M0BK**M>^W7OZC=6I)W<G>UM^G;T"BBBM3,**** "OW0^"'_(M1?2OPOK]T/@
MA_R+47TKP<T^Q\_T/>RK[?R_4]+HHHKPCWPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<F]U74;A[JZN"JKYDCDLS84 #)/0  5F452IPBTTMO\ A_SU)E4G)--M_P#
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MH9=S9P-PZ\X;\4_V>[GP3<^$KGPQKMOX]\.>+6:/1-5T^W>!KB59!&T+PO\
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M?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /PG_:,_
MY.$^)_\ V-&J?^E<M>>5Z'^T9_R<)\3_ /L:-4_]*Y:\\K[>G\"]#X6I\;]0
MHHHK0@*^POV3/%&G_LY_#7_A9&MVT,O_  EFOVWAV 3(&*Z>AWWLH'<<JOU4
M5\B6-E/J5];VEM&TUS<2+%%&HR69C@ >Y)K[5^.OQ$^%?PAC\)_"/Q+\,/\
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MKWO_ (8M\?\ _/?2/^_TW_QJC_ABWQ__ ,]](_[_ $W_ ,:H^MT/YT'U2O\
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M_3?_ !JCZW0_G0?5*_\ (SP2BO>_^&+?'_\ SWTC_O\ 3?\ QJC_ (8M\?\
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MBWQ__P ]](_[_3?_ !JCZW0_G0?5*_\ (SP2BO>_^&+?'_\ SWTC_O\ 3?\
MQJC_ (8M\?\ _/?2/^_TW_QJCZW0_G0?5*_\C/!**][_ .&+?'__ #WTC_O]
M-_\ &J/^&+?'_P#SWTC_ +_3?_&J/K=#^=!]4K_R,\$HKWO_ (8M\?\ _/?2
M/^_TW_QJC_ABWQ__ ,]](_[_ $W_ ,:H^MT/YT'U2O\ R,\$HKWO_ABWQ_\
M\]](_P"_TW_QJC_ABWQ__P ]](_[_3?_ !JCZW0_G0?5*_\ (SP2BO>_^&+?
M'_\ SWTC_O\ 3?\ QJC_ (8M\?\ _/?2/^_TW_QJCZW0_G0?5*_\C/!**][_
M .&+?'__ #WTC_O]-_\ &J/^&+?'_P#SWTC_ +_3?_&J/K=#^=!]4K_R,\$H
MKWO_ (8M\?\ _/?2/^_TW_QJC_ABWQ__ ,]](_[_ $W_ ,:H^MT/YT'U2O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (>>#6;<^';"[D+R0*S>XK3HH QO^$1TS_GV3_OFC_A$=
M,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC
M_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3
M_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS
M_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^
M$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH
M QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[Y
MK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]
MD_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=
M,_Y]D_[YK9HH QO^$1TS_GV3_OFC_A$=,_Y]D_[YK9HH QO^$1TS_GV3_OFC
M_A$=,_Y]D_[YK9HH QAX3TP<_9D_[YK2M;.*SCV1($7T%3T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6\TVWU!<31AQ[
MBJ'_  B6F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6
MS10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\
M?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6
MS10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\
M?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6
MS10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\
M?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6
MS10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\
M?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6
MS10!C?\ "(Z9_P ^R?\ ?-'_  B.F?\ /LG_ 'S6S10!C?\ "(Z9_P ^R?\
M?-'_  B.F?\ /LG_ 'S6S10!CKX3TU6!%LF?]VM2"!+>,)&NU1VJ2B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/OC-
MI>N:MHNC1Z);:M>I'JL,NH6VBZB+&YEM0K[U64S1=RG <9KT&L/Q5INN:C;V
MQT#6X=%NX9=[FZL1=PSI@@HZ;T;'(.5=3D#J.*3Z>J_,:Z_,\'UKX@6DFG:7
MX2\,7?B3P[JFH>*+;1]9AUK4)[G4;&-XVD;RY9)I0F]$&UHW(Y)'/-=I\/;R
M^\,_&[Q9X*&IZAJ6AQZ7:ZM9IJ=W)=RVSN[QR()9"TC*2H.&8XYQBH;O]G3^
MTK?4=2O/$;R>-;O5K;6EUR.R"Q03VZ[(42#>?W00LI4N2=Q^:NO\$?#NY\/^
M)-<\2ZUJT>M>(=62&"2:WM/LL$,$0;9''&7D8#+,26=B2>V,5<>[^?\ X"E;
MY2N_^')EV7]>\W?YK0[>BBH+BRM[S;Y\$4^W[OF(&QGTS4C)Z*I?V+I__/A:
M_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O_?E?\*/[%T__ )\+
M7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %VBJ7]BZ?_
M ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_ -^5_P */[%T_P#Y
M\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X4 7:*I?V+I_
M_/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O_?E?\*/[%T__
M )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %VBJ7]
MBZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_ -^5_P */[%T
M_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X4 7:*I?
MV+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O_?E?\*/[
M%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^% %V
MBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_ -^5_P *
M/[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X4 7
M:*I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O_?E?
M\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^
M% %VBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_ -^5
M_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_
MX4 7:*I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O
M_?E?\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^% %VBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X4 7:*I?V+I__/A:_P#?E?\ "GPZ79V\@DBM((I%Z,D2@C\0* +5%%%
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M_P"?"U_[\K_A1_8NG_\ /A:_]^5_PH NT52_L73_ /GPM?\ ORO^%']BZ?\
M\^%K_P!^5_PH NT52_L73_\ GPM?^_*_X4?V+I__ #X6O_?E?\* +M%4O[%T
M_P#Y\+7_ +\K_A1_8NG_ //A:_\ ?E?\* +M%4O[%T__ )\+7_ORO^%']BZ?
M_P ^%K_WY7_"@"[2=.35/^Q=/_Y\+7_ORO\ A39-%T_RW_T"VZ'_ )8K_A2&
M47\>>&8[>"=_$6DK!.Q2*5KZ(+(P."%.[!(/85L37,-O;O/+*D4"+O:5V 55
MZY)Z8KXW\$'P-_PI_P 9C6/[/_X24/*+7[1C[1]T>5Y.>?O[L[?QXKO+7X1Z
M[XT^%_@B^0VTLUE;;IM$OM\4-ZFXF,LZ$'=LVXS[<CG/T-;+:5%^]-I<UKM>
M5]/R^9\O0S:M67NTU)\K:2?:25GVWO\ +J>NZ?\ %SP[K#:R^GSS7MCI-NT]
MUJ$41^S#:,E%D/#-CGC(QWKSB3XY>-+7PS;>-[C0=*'@Z>X$8MTED^W+&6*A
MR<[,9'IZ<8YK6GO+'Q9X!\2^&H/"C>&?$5OIDNW2Y+50,;2 T,BC:Z[B!D=S
MTKRS4-?T#4/V:=*T.TFM9O$LTZ6XL8@INMXG+<J/FP1WZ'(%:X;"T[V]G?WH
MK77W7>[NM->_0QQ6,J\M_:\ON3EHK>]&UHV=WI?;=]NA]9VMU'>6L-Q"VZ&9
M%D1O52,@_E7BMU\9/&&N0^)-9\+:3I,WAK09GBE>^DD^T7009<Q;2%&!SSV(
MZGBNSTB^\,:#<:'X-O7LQXC:PCVVWV<DOM3!;=MVC[C'DYXKP[P%JV@^#_A;
M\0]$UR>TM-=AN+J*.VN HF<M$$78#R?F!Z=.M<N%PZ_>2Y.:UK73U3E9OS['
M9BL5)^RAS\M[\S36C4;I>7<]1UCXXS7F@^$3X:T^&ZUSQ-D6UO>2$16^WARY
M7!(#9'&,@$^U2^%_BYJ=GXA\0^'_ !I:6-GJ6D69U W.F,Y@FA !.T.=P(!'
M4\\\#'/CNF>'AX'N?@]JFNQ1VFGNLPN99T 2,N[.GF$]/E<=>F#Z5L:UHUO\
M1/B=X\NO#BP7^GVWA][=)K50T33L@VJA'!)P>1Z&O0G@\/'FBE[MI/F[-2LE
M?T^^YY5/'8J;A*4O?O37+IJI1O)V];^EO4Z:3XY>-+7PS;>-[C0=*'@Z>X$8
MMTED^W+&6*AR<[,9'IZ<8YKK_BQ\2/$'@_PS)K&@Z/:W>GQV\=PVHWT_[OYW
M"A%B4AV.&!R2H&>]>)ZAK^@:A^S3I6AVDUK-XEFG2W%C$%-UO$Y;E1\V"._0
MY KT7XV1Z+X;^"<VAW%QIL&NK8VJK;[XUGDVN@9E7[Q'RMR/0U%3#4XUH+V?
M_+QQMKK%6UW\]S2ABZLZ,I>U;_=*3>FDW?3;3;;?L>L^"]:G\1>$=%U6Y6-+
MB]LXKB18@0@9D!( ))QD^M;5>?\ PA;0=9^'N@K:G3;Z>WL;>.Y$/ER-%)Y8
MRKXSANO!YKL_[%T__GPM?^_*_P"%?/XB'LZTXVM9L^GP=3VN&IS;NVE^6I=H
MJE_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A7.=9=HJE_8NG_\^%K_ -^5
M_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_
MX4 7:*I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O
M_?E?\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^% %VBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X4 7:*I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\
MSX6O_?E?\*/[%T__ )\+7_ORO^% %VBJ7]BZ?_SX6O\ WY7_  H_L73_ /GP
MM?\ ORO^% %VBJ7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A0!=HJE_8NG_\
M^%K_ -^5_P */[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/A:_]^5_PH_L73_\
MGPM?^_*_X4 7:*I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*;&BQ
MHJ(H1%& JC  ]!3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:%X3T]M&U>/3IUN=+NHC'>A_+(S)GYGY(^;)'(''2N!AU*U7]CEXC<1B0R&
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MGG;N$.,E<\9SCMUXKK/B!\55\%Z&-2LM$OM=A:V%YY\(\NV2,D8+2G@$Y&%
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ML0L+0G7DKJ*N>OT5\[Z/^S1J&I:397<GC[58Y+B!)6158A2R@D ^9R.:N?\
M#+=[_P!%!U?_ +X;_P".5W/"X1.SQ'_DK/.6,QLE=8;_ ,GB>^45X'_PRW>_
M]%!U?_OAO_CE'_#+=[_T4'5_^^&_^.4OJ^$_Z"/_ "5C^MX[_H%_\GB>^45X
M'_PRW>_]%!U?_OAO_CE'_#+=[_T4'5_^^&_^.4?5\)_T$?\ DK#ZWCO^@7_R
M>)[Y17@?_#+=[_T4'5_^^&_^.4?\,MWO_10=7_[X;_XY1]7PG_01_P"2L/K>
M._Z!?_)XGOE-9=RD>HQ7@O\ PRW>_P#10=7_ .^&_P#CE'_#+=[_ -%!U?\
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M/$]\HKP/_AEN]_Z*#J__ 'PW_P <H_X9;O?^B@ZO_P!\-_\ '*/J^$_Z"/\
MR5A];QW_ $"_^3Q/?**\#_X9;O?^B@ZO_P!\-_\ '*/^&6[W_HH.K_\ ?#?_
M !RCZOA/^@C_ ,E8?6\=_P! O_D\3WRBOE[1-#U/X2_M">&=#?Q%>ZO9W]L7
M?[0S ,'$JA2NXCAHP<_2OJ&N?%898=QY9<RDKIVL=."Q;Q2GS0Y91=FKWZ)_
MJ%%%%<1Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117B
M'QM^)7BW1?'>@>%/"#01W]]!YQ\V-6+DLRJ,O\H'R,:Z</AYXF?LX-+KKMH<
MF*Q4,)3]K--ZI66[;/;Z*^>?^,A/^H?_ .2M'_&0G_4/_P#)6NW^S_\ I]#_
M ,"_X!YW]J?]0]3_ ,!_X)]#45\\_P#&0G_4/_\ )6C_ (R$_P"H?_Y*T?V?
M_P!/H?\ @7_ #^U/^H>I_P" _P#!/H:BOGG_ (R$_P"H?_Y*T?\ &0G_ %#_
M /R5H_L__I]#_P "_P" ']J?]0]3_P !_P""?0U%?//_ !D)_P!0_P#\E:/^
M,A/^H?\ ^2M']G_]/H?^!?\  #^U/^H>I_X#_P $^AJ2OGK_ (R$_P"H?_Y*
MT?\ &0G_ %#_ /R5H_L__I]#_P "_P" ']J?]0]3_P !_P""7OAK^S[83VFL
M_P#";>'8I+IM4DGM)/M'S-$0,9,3\KG/RM^5>XV-E;Z;9PVEK"EO;0H(XX8U
MVJB@8  ["O /^,A/^H?_ .2M'_&0G_4/_P#)6NO$4:N)=ZE>%NW-HOD<6&Q%
M'"JU/#5+]^17>M]6>_-I]JU\MX;:$WBQF(7!C'F!"02H;K@D X]JX]?@CX&C
MU[^V5\.6HO\ S/-SE_+W>OE;MG_CM>8_\9"?]0__ ,E:/^,A/^H?_P"2M90P
ME2G\&(@O21M4QU*M_$PLWUU@GK]Y[3J'@?0]6\3:?X@NK!9=8L%*6UUO8% <
M\8!P?O'J#C-9'B'X,^"_%6M?VMJF@P7-^2"TH=TWD="ZJP#=/X@:\M_XR$_Z
MA_\ Y*T?\9"?]0__ ,E:<<+5@TXXF*MI\;V%/&4:B:GA)N^KO!:ONSVO7O!.
MA>)]#71M3TNWN=,0 1V^W8(\# V%<%<#CY<<5!X/^'OAWP#;S0Z#I<6GK,<R
M,K,[OZ NQ+$#TSBO&_\ C(3_ *A__DK1_P 9"?\ 4/\ _)6E]4J<KA]8A9].
M;0?UZESJI]5GS+9\BNOG<].7X(^!H]>_ME?#EJ+_ ,SS<Y?R]WKY6[9_X[5O
MQE\*?"WQ N[>YU_2_M\]NACC;[1+'M4G.,(PSSZUY-_QD)_U#_\ R5H_XR$_
MZA__ )*U?U>O=2^LQNMO?>GH1]:P_+*/U.=I;^XM?7N>P>"_AOX<^'JW:^']
M.^P"Z*F;]_))NVYV_?8X^\>GK735\\_\9"?]0_\ \E:/^,A/^H?_ .2M93P4
MZDN>>(@WW<C:GF$*,5"GA:D5V4++\SZ&HKYY_P",A/\ J'_^2M'_ !D)_P!0
M_P#\E:S_ +/_ .GT/_ O^ :?VI_U#U/_  '_ ()]#45\\_\ &0G_ %#_ /R5
MH_XR$_ZA_P#Y*T?V?_T^A_X%_P  /[4_ZAZG_@/_  3Z&HKYY_XR$_ZA_P#Y
M*T?\9"?]0_\ \E:/[/\ ^GT/_ O^ ']J?]0]3_P'_@GT-17SS_QD)_U#_P#R
M5H_XR$_ZA_\ Y*T?V?\ ]/H?^!?\ /[4_P"H>I_X#_P3Z&HKYML_B7\4/!?Q
M \,Z5XS-H;+5[E(-B1Q'Y6=4+!DZ$%@>:^DJY<3A98;EYFFI;-.Z.W"8R&+Y
MN6+BXNS35GW"BBBN,[PHHHH **** "BBB@ HHHH I:QK6G^'=+N=2U6^MM,T
MZU0R3WEY,L4,2CJSNQ 4>Y-9?@OXB^%/B1I\M_X1\3Z-XIL8G\N2ZT74(KR)
M&_NEHV8 ^U<G^T1X?\)ZU\-+N\\9>!M0^(^E:-,FI)X;TNR-[<7<JY50EMN5
M9B Y.Q\KQG&0*^7?V.9/!^K_ +6/Q"U_PMX5D^#D+>&[:U/PXU#2WTJ_GVS%
MCJ$EKY:Q(,;4'E,_W\L5)P5!WDT^B;^Y7_X&FV^U[$_=@I+R_%V_"]_/;U^Q
M/&/Q:\#_  [O;*S\5^,O#_AF[O?^/6WUC5(+22?G'R+(X+<D#BNHBF2>))8G
M62-P&5U.0P/((/<5^5'PS\5W?C#PWXV^+?B7]ES_ (7;;ZAK&H7.K^*M<O[%
MC8V4,K(D%C:S+)(ZQ1*?N!#N!&3U'Z6?"/Q-X>\9?"[PGK?A*,0>&;[3+>;3
M80H7RH#&-D94$X*C"D9X((JHINGS/?3Y75_7Y[/6P3]VHX>J^YV?_#;K0R_$
MW[1'PJ\%ZY<Z-XA^)O@[0=8M2!/I^IZ_:6UQ$2H8!XWD#+D$'D="#6YKGQ.\
M'>&?"MMXFUCQ9H>E>&[I8W@UB^U*&&SE609C*3,P1@P((P>>U?%'Q.^'WBCP
M1\=/BOXMUC]E'1OC7X4U>^M;^#7[R\TN6[MK:.SACE2&UF229SN1SM&W)'OF
MO5EU)/BM8_ GXO\ PP\+S>(_ ^CVE\B^$]/%G9W%N)H! AC2>6.!6@,;Q%=X
MP';;D<&8^]34NNE_*Z;LUONK7VWZ#E[L^7IK\[>>WG;<^EI/$>DQZ VNOJEF
MFB+;F[;4FN$%L(0NXRF3.W9MYW9QCFK5C?6VJ6-O>65Q%=V=Q&LL-Q X>.5&
M&596'!!!!!'!S7P3X9U"ST_PSX<^%/C*_F3P7X?U2XDU^ST>TGU)]4U%YY+R
M/0;>&VC>2>&VC=6N"B%<(J'"[P/N7PCXIT;QMX9T[7/#U[#J.BWL0EM;FW^X
MZ=. 0",$$$$ @@@@$5=E9R6WZ?\ !Z=UJKIHG9\K_K^NO9Z/5,V****D8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<#\9_AC)\5O"]KI$6H+IK0WBW7FO$9 <(Z[<9']_/X5WU%:TJLZ,U
M4@[-&-:C#$4W2J*\7N06%JMC8V]LOW88UC'T  _I4]%%9[ZFJ5E9!1112&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'G?BKX4/XD^*7AWQ@FH);C2XEC>V,18R@,[#YL\??/:O1***VJ5IU
M%&,G\*LO0PIT:=&4I05G)W?J%%%%8FX4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)IH[:&2:5UB
MBC4N[N<*H R23V%+;5@/HKAM)^-W@C7/!=UXMLM>BE\/6TYM9+PPRH#*"!L5
M64,Y)90 H.XD8S6OX1^(&A>.&OH](NY)+FQ=8[NTNK:6UN+=F&5WPRJKKD<@
ME<'M5 =%1112 **** "BBB@ HHHH *\8\5>"=>U']H[PWXBAL))=$L[41276
M]=J';-QC.>KCH.]>ST5TT*\L.Y.*W37WG)B,/'$J,9NW*T_NU"BBBN8ZPHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /&OCEX$UGQ3XT\ :AI-A)>0Z?>,]XZNH$2>9"P."1G@/TSTKV
M6BBNBI7E4IPIO:-[?-W.6EAXTJM2K%ZSM?Y*P4445SG4%%%% !1110 4444
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M8Y"!I2%SS@#/->A45?,];]?^'_/4FRT78****D84444 %%%% !1110 4444
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M>QG&7-%2:M<****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\S^.VG^(M?\/V&AZ-HM]JVEZC<B/6FTZXMXIUL
MP,O&GG2Q@F3A"0W"EO:O3**5KC3L?%6AWS6UGIOVC0KK1-!L/BNTLS7)M_)@
MSN1(SY<K;3&VP$XV?,NUC7N7A-1>?M0^.KJT99+2WT+3[6Z:,Y N"\KJI_V@
MF/H"/6O37\):')IM_I[Z+I[6&H2/->6K6L9BN9'.7>1<8=F(&202<5)X?\,Z
M/X3T\6.B:58Z-9;B_P!FT^V2"/<>IVH ,FJB[)7Z?_(J/Z7_ *UF2NW;K_\
M).7ZFE4%Q</!MV6TMQGKY908^NYA4]%(92^WS_\ 0-NO^^HO_BZ/M\__ $#;
MK_OJ+_XNKM% %+[?/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XNKM% %+[?/\ ] VZ
M_P"^HO\ XNC[?/\ ] VZ_P"^HO\ XNKM% %+[?/_ - VZ_[ZB_\ BZ/M\_\
MT#;K_OJ+_P"+J[10!2^WS_\ 0-NO^^HO_BZ/M\__ $#;K_OJ+_XNKM% %+[?
M/_T#;K_OJ+_XNC[?/_T#;K_OJ+_XNKM% %+[?/\ ] VZ_P"^HO\ XNC[?/\
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M+H^WS_\ 0-NO^^HO_BZNT4 4OM\__0-NO^^HO_BZ/M\__0-NO^^HO_BZNT4
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M.#CBB/O1<ET_6]OR82]UI/J=7]OG_P"@;=?]]1?_ !='V^?_ *!MU_WU%_\
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MU%_\75VB@"E]OG_Z!MU_WU%_\71]OG_Z!MU_WU%_\75VB@"E]OG_ .@;=?\
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M *0\\'D5\Z?M7?$?Q;X)\1>"[#PSXBN/#\-_:ZC/=-;VMM,TK1/:+&/W\4F
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MO;7S7B\V)AAEWHRLN1W4@UX?X#_X)Y_L_?#+QAI/BKPUX _LW7M)G6YL[O\
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ME@R(K6$LC%25AC0G!/+'FM8O77I%J_=N2:^Y:?\ ;J,VM'9;R6G:R=W\VO\
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MQ?U'#2Q'+S<MM-MVEY]SZ;_X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\
MP?6O_P <KX)HKZ?_ %<_Z??^2_\ !/CO];/^G'_DW_VI][?\-"?"S_HI?@__
M ,'UK_\ '*/^&A/A9_T4OP?_ .#ZU_\ CE?!-%'^KG_3[_R7_@A_K9_TX_\
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M ,CT?\-@?"K_ *#FI_\ A.:G_P#(]?&%%'^KM+_GX_P#_6NM_P ^E][/L_\
MX; ^%7_0<U/_ ,)S4_\ Y'H_X; ^%7_0<U/_ ,)S4_\ Y'KXPHH_U=I?\_'^
M ?ZUUO\ GTOO9]G_ /#8'PJ_Z#FI_P#A.:G_ /(]'_#8'PJ_Z#FI_P#A.:G_
M /(]?&%%'^KM+_GX_P  _P!:ZW_/I?>S[/\ ^&P/A5_T'-3_ /"<U/\ ^1ZU
M_"/[2_P[\<>)M/\ #^CZS>3:M?LZ6T-QHU];+(R1O*PWRPJH(2-SR>=O%?#-
M=K\"/^3@/AU_U_W?_ILO*X\7D=/#T)U5-NR.W \1U<5B84)4TE)VZGZ T445
M\@?>!1110!\I?MH_\CM\._\ L'ZQ_P"C-/KPFO=OVT?^1V^'?_8/UC_T9I]>
M$U^6<0_[\_1'[SP=_P BJ/\ BD%%%%?-'VX4444 %%%% !1110 5]?\ [(?_
M "031O\ L(:M_P"G.ZKY KZ__9#_ .2":-_V$-6_].=U7VG#'\:IZ+\S\RXZ
M_P!VH_XG^1[)1117Z(?C@4444 %%%% !1110 4444 %%%% 'G$/[./PNM_B(
M?'<?@'P^GC RFX_MA;",3^:>LN<??_V_O>]>C8'!QS7!^+_C%I/@SXAZ#X3O
MHI%EU+3-0UB6^9U2&TMK01^8[DG)R95  [ D]*^4?!WC:']J+X[:/K\6G>.O
M@]KNH:,^H>#_ !#;:W'<6>NZ;;S@.9[ @HF[SE.QQEE((88%$/><81VU^25_
M_D7IOH[7L$O=3F]_^&_S6OFNY]UT4@Z<\TM !17D7B[X@^,O OB[PM#J/]@7
MNG>(-:_LN+2[&&?[9%$0Q$_G,^U]H +CRE W8W'K7/ZO\=/%47A3Q#X]L++2
M6\':)J;V3:=/%*;ZZABE$4LZS"38AW9(0QMD+RPS0M?Z]/\ -?TF.VMOZ>_^
M3_JQ[[14<$RW$,<J'*2*&4^Q&14E&Q*=U=!1110,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J*ZNH;&UFN;F:.WMX4,DDTK!410,EB3P !SDU
M+65XJ\+Z9XV\,ZMX>UJV^VZ/JMK+97EOYC1^;#(I1UW*0PRI(R"".QJ97L^7
M<J-KKFV/GFTM9OVNOB=X3\5QP2VOPA\%WYU32+B="C^(]34,D=S&IY%K$"Q1
MR 9&.1\H!/E7QH^-&K:/^T9XPU+Q/\&OBIXETKPSI4ND^%;KPYX8:\TY'GAS
M=W[3&15+,"L0V@[41^<L0/3],_X)D_LU:/J5I?V?PW\F[M94GAD_MW4VVNI#
M*<&Y(."!UKZ:OK.'4;*XM+A/,MYXVBD3)&Y6&",CD<'M2J14J?+'M+[VK7OW
MMIMHK=E9PE:?-+R^Y.]K>NN^KOT9\<_\$W?C!H]K^QIH)U^TU#P;I'AF(P3Z
M]XFC2QTV[$D\C"2WG=]KH"P0L=N&XKZ.^.GQ<T[X)_"#Q)XYO=L\.F69EMX5
M.?M,[86")?4O(R*,>M4I/V;?AQ)\%5^$C^&U?X>K&(AH[7EP<*)?. \[S/-_
MUGS9WY[=.*WO&WPG\*?$;2M%TSQ%I(U'3M'OK?4K*U,\L<:3P<PLRHP$@4\[
M'W*2!D' K>O)5I2:TN_G;J_7>RV,:,?91BFKVO\ \!>G1L\E^"_[--JW[,A\
M'^/DDN]=\5.^N^)+F-@DW]ISR"=G1@.&B<1JIY \I>M>$?%J&#2F\=ZQ:7^H
M^.O#_AZ_L(?$6L^()(@WB/64ECAL=,;[-#%&+.U:823!(QN<[3D^9G[ZN;=+
MNWE@D+A)$*,8W9&P1@X92"#[@@BN2L_@]X-T_P"&8^'T.@V__"'_ &9K4Z7(
MSNK(Q+,6=F+LY8EBY8L6.[.>:B3O-S2LM++T_*R6EO)_9LZBK149.[ZOUW^]
M[_/J[KE?A#\1_$VJ?$+QOX!\8'2;W6O#4-A>+JFAV4UG:W,%TDA5?)EEF*.C
M1.#^\8,"I^7D#URN4\ ?"_PY\,;6]BT"TN8Y+Z59KN\U"_N+^[N650JF2XN)
M))7"J JAF(4# P*ZNG+425OZ_K^M HHHJ2@HHHH *^)/VN/^2^G_ +%G3_\
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M$_\ T$KK_OF+_P"(J[10!2^P3_\ 02NO^^8O_B*/L$__ $$KK_OF+_XBKM%
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M"?\ Z"5U_P!\Q?\ Q%'V"?\ Z"5U_P!\Q?\ Q%7:* *7V"?_ *"5U_WS%_\
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MM6MUNK.[6%8_-C89#;7B#+]& ([BOCO]HCXS?#_XJ?$3QOI'B'QWX:TCP_\
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M *&W1_\ OU8?_(]?:=%'UQ_\^X_^ H/J2_Y^3_\  F?%G_",_MG_ /0VZ/\
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M.!7U!^S7\1[_ .+7P0\+>*=5V'4[V&1+EHT"!I(IGB9MHX&XQ[L#UZ#I6O\
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MH_=]KYI=78^]****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#D@7PT_P"Q9TS_ -)8Z] KS_\ 9[_Y(%\-/^Q9TS_TECKT"OQ<_H,****
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MT_[%G3/_ $ECKT"O/_V>_P#D@7PT_P"Q9TS_ -)8Z] K\7/Z#"BBB@ HHHH
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M: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
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MGOZ7:[V;U.:T7XU:=;ZEX%\,^,X$\'_$3Q98RW<'A<S&],;0H'GC^TQIY3;
M?O$KNP=N:_-_PK\,/V>[7P_\:[3XWZ\VD?$CPWXFUB;3X;[Q%<6=S$LA\ZWN
M+&V$H61G)#9".20N>",_J->V'A34M>T[6[NVT>ZUK35D2RU*9(GN+59 !(L4
MA^9 P #!2,X&:Q_$'P_^&WBWQ%9Z_KGAOPKK.NV>/LVJ:A86T]U!@Y&R5U++
M@^AJ)1YFWM=-:=+M-->:22W[ZE1ERI+>S3];)II^3OV/ ? .GZ5J'[%_P[\9
M_'2/4QKNB:*)C?6^H7=EJC>:-D<(E@E29Y)T\E3%N_>,P!!-<IX4\)^*_#/Q
M2\&Z=-J3_#+6?%N@WUX9M,M+64Z%IMD(?L6BV_VB.2%0@F:6=@A9V#8( !'V
M+K%OX9\1+9C58])U,6=REY;"\6*7R)T^Y*F[.UUR<,.1G@U0\9>&? WQ$T^&
MP\5Z5X?\3V,,HGCMM9MH+N))!P'59 0&&3R.>:TJ2YYRFM.9OY73_&[^Y6T4
MI&<(\L(P>ME_7R_5WWBC!_9M^(&K_%/X&^#O%6O0)#J^I60EN#$FQ)2&91*B
MY.%D"AP,GAQ7I59]OJ>E6L$<,-W9PPQJ$2..1%55 P  #P *?_;6G_\ /_:_
M]_E_QIS:E)M!%621=HJE_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XU!1=HJE
M_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XT 7:_+#P7_R)VA?]>$'_HM:_4+^
MVM/_ .?^U_[_ "_XU^7O@O\ Y$[0O^O"#_T6M?6\._Q:GI^I\-Q7_!I>K_(V
M:***^[/S4**** "BBB@ HHHH *[7X$?\G ?#K_K_ +O_ --EY7%5V7P.FCM_
MCW\.Y)9%BC6_N\LY  _XEMYW->7FG^YU/0]G)_\ ?Z/J?H)15+^VM/\ ^?\
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M]_E_QK@?V@=7L9/@+\242]MW=O#6I *LJDD_99.!S0!^,E%%%?II^7A1110
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MR+O1/-(V,^W!*JQ905W ;AEV8'5T52_MK3_^?^U_[_+_ (T?VUI__/\ VO\
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M% !1110 4444 %%%% 'WM^SW_P D"^&G_8LZ9_Z2QUZ!7G_[/?\ R0+X:?\
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MR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %=K\"/^3@/AU_U_P!W_P"FR\KBJ[7X$?\ )P'PZ_Z_[O\
M]-EY7EYI_N=3T/9R?_?Z/J?H#1117Y6?M04444 ?*7[:/_([?#O_ +!^L?\
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M^0H\F/\ YYK^0I]%'LJ?\J^X/:U/YG]XSR8_^>:_D*/)C_YYK^0I]%'LJ?\
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M_P F?/<0?\BVK\O_ $I'DE%%%?IQ^.A1110 4444 %%%% !1110!][?L]_\
M) OAI_V+.F?^DL=>@5Y_^SW_ ,D"^&G_ &+.F?\ I+'7H%?BY_084444 %%%
M% ",NY2OJ,5\B?LF?#V+Q)^RS\1/@WK#&WN-+UG7O#%ZVW)432/(DH!ZYCN$
M8?A7UY7/:+X T#PYXJ\0^)--T\6FL^(/(.IW"2OBY:%"D;%"VP,%.W<H!( R
M3@8EQ4E*,MI*WXK]+_>4I./*X[II_<FOU_ ^()O@[^T3\2?@MH/[.GBGP'HN
MA>$=/^Q6.H?$6+Q!'<+>6%K*C*(+(+YJ2LL:#+_+D-]W(Q[=X/A@^*G[8?B#
M551I-$^%FDQ^'[!F.5.I7:K+=./=(5@C/^^U?259VC>&])\._;CI.EV6F&^N
M7O;O[';I#]HN'QOEDV@;G; RQR3@9-:\[YN:6^KOWDTHW?3X;Z*VNIGRKEY5
MMHK=DG?3YI;]-#QWXP?$;XZ^!_&#Q>!_@_I7Q,\,W$*&"XB\3PZ3=6DN#O$R
MSJ5=<X(V<XZUP7@?X6_%WX&_ /XG:_H.E:3XB^-?C+6)_$']CVMRJ6%I/.R(
M(TDF9 XBC!<[B S CD8S]845E;W6KZO2_6UT[?@O/3<TYM4[:)WMTNE;]7Y'
MQO\ LRWWQK\ ZM9Z/K7[-]SI::W>K/XE\=:CX_T[4+VXE(PUS+''&&< #"Q)
MA57 4 "NOM;;_A,O^"A5]?VK;K7P7X%CL;ME&0+F]NC(D;'L?*BW?\"%?3-<
M]X9^'^@>#]7\1:KI.GK:ZCXAO!?ZI<F5Y'N9A&L:DEV.T!$4!5PHQP!DUKS>
M^I-;7_%<MNR23=K>2VVSM[LHWWM^#YK]VVTM_7UZ&BBBH*"BBB@ HHHH ;)(
ML2%W.U1U-8MYJ<EPQ5,QQ#IZGW-0W%W)=,2YP,\*.@J&@ J6.'S;229.L+[7
MSQ@8!R/SJ*MG1=IL0ZIL+NV[W()7/Y** &Z7?&8&*0_.OW6/\0_Q'^>]:-8=
M];'3YE>([$8_+CL>N/\ /]*U+.Z6[A##AAPR^AH L5@^-O'&D?#WP_-K.M3O
M#:1D(JQ1M)++(W"QHB@EF)Z ?RK>K&\7>)-)\+Z#<WNM:I9:19[3']HO[A((
M]Q!PNYB!D^E9U).,6T5%7DDSD[3XZ>';OX8Z3XX$-^EAJTBP6-@T*F\N)FD,
M:0JBL079E./FQCDD &M?P7\2K'QCJVKZ.VGZAH>N:5Y;7>EZHD8E5) 2DBM&
M[HZM@\JQP00<5\P>"_$&FR?L_P#P?U*WO[:]MO"NOP7>N16TRRO80M)<*)9D
M7+(!N#<XXYZ5[)\.;RV\9_'[QCXLT6YCU#P\FCV>EIJ-LV^WN)U>21Q'(/E?
M8"H)!."<5T.*YY+I=KY))I_-NQE?W4_)?>W9KY+4]IHHJ"X:X7;Y$44O][S)
M"F/IA3FLRR>BJ7G:C_SZVO\ X$M_\;H\[4?^?6U_\"6_^-T 7:*I>=J/_/K:
M_P#@2W_QNCSM1_Y];7_P);_XW0!:FA6XA>)P2CJ5;!(.",=1TK\R_C=HWPFL
M?%_@[P1X;^#>I?!*?1?%]JJ_$_7O#KV%K((;@<6]\BR-<F;'RF=T7D,6[5^D
M&J+K5UIEW!9_9;&\DA=(;KS3)Y+E2%?:8\-@X.#UQ7R7X\^ _P"T[\;O#<GP
M]^(/C#X;+X NI(?[1U30;"\CUB_ACD2384DS#$6*\LG3 P.HHIZ5HR[-/[G?
M?R_7KJARLZ<HOJFOO5MO/]-UN?95?E+\3_#OA+PK)^T'X>UKX>V'Q/O]7UJX
MG3XL"R:]@\-FY^417UR(7DMVM<;BL&\8VAA'FOT.U#0_B:OQ<\.7NEZMH]K\
M-;72I[?4M#D8M=7%V2/)E23R"0JJ#D;Q]#G(^;]%_9K_ &E?A;X=\2_#[P#X
MN^'5S\/=9N[V>+4/$EO>OK-BET[-*J^6OE2LN\D-)]XGG P!E*-VVE>Z:[?:
M6C?2]KW73JMBX2LDGI9Q?X/5=[7M9_H=5_PJKQ#X5N/AGKOAVPD^+_AVP^'T
MOA-&M+RT5FEE$!6]W7$J(T,J1;6*,S@;<*X)KSWP+XJT.VTKX=>$?'6NSZAX
M%^'UJELL>FZ?=:C_ ,)'J]DJK/+Y4$3N;"P;:/-91&90I)_=C/O%C\"_&'@G
M]G/PM\)?!NMVME%:6T.E:AXBN+J1+M+/!^T26RK$P69LE4W'$8;.6*@&GXA^
M ?B7PIXR\-Z[\-=.\.0VFE^%KCPD-%U;49[:W@MY)(Y$N(WCMY"SJT?S(P&_
M/WU(R>FI-J<G'57=O7WY)^7O2LNS=].77"G%>SBI:.ROZ>[%K[HZ]TK:N5U[
MYHNLV/B+1[+5=+NX;_3;Z!+FVNK=@T<T3J&5U(Z@@@@^]7:\_P#@S\/KSX0_
M"GPGX+B:'45T/3H;$W<EPP,Q10"V-AP"<X&>!@5V?G:C_P ^MK_X$M_\;I5%
M%3:@[KH.+;BG+<NT52\[4?\ GUM?_ EO_C='G:C_ ,^MK_X$M_\ &Z@HNT52
M\[4?^?6U_P# EO\ XW1YVH_\^MK_ .!+?_&Z +M?!/\ P5+_ -=\+_\ =U7^
M=G7W3YVH_P#/K:_^!+?_ !NOA#_@J$UPTWPQ\^**+Y=4V^7(7SS9]<J,5W8'
M_>8>IP8__=I^A\*T445]^?GP4444 %%%% !1110 4444 ?K3^PC_ ,FJ^"?]
MZ_\ _2^XKWVOGG]A>2\7]EGP6(K>!X]U_AGG93_Q_P!QVV'^=>\^=J/_ #ZV
MO_@2W_QNOS>K_$EZL_2Z7\./HB[15+SM1_Y];7_P);_XW1YVH_\ /K:_^!+?
M_&ZR-2[7Y8>"_P#D3M"_Z\(/_1:U^H7G:C_SZVO_ ($M_P#&Z_+WP7_R)VA?
M]>$'_HM:^MX=_BU/3]3X;BO^#2]7^1LT445]V?FH4444 %%%% !1110 5VOP
M(_Y. ^'7_7_=_P#ILO*XJNR^!S2+\>_AV8D5Y/M]WA78J/\ D&WG?!_E7EYI
M_N=3T/9R?_?Z/J?H)15+SM1_Y];7_P "6_\ C='G:C_SZVO_ ($M_P#&Z_*S
M]J+M%4O.U'_GUM?_  );_P"-T>=J/_/K:_\ @2W_ ,;H ^7_ -M'_D=OAW_V
M#]8_]&:?7A->X?MD-<-XV^'OGQ11?\2_5]OER%\_O-/ZY48KP^ORSB'_ 'Y^
MB/WG@[_D51_Q2"BBBOFC[<**** "BBB@ HHHH *^O_V0_P#D@FC?]A#5O_3G
M=5\@5]:_LDR7B_ G1Q%;P/'_ &AJV&>=E/\ R$[KML/\Z^TX8_C5/1?F?F7'
M7^[4?\3_ "/;J*I>=J/_ #ZVO_@2W_QNGPR7C2 2V\"1]V2=F/Y;!_.OT0_'
M"U1110 4444 %%%% !1110 4444 %%%% !1110!Y[IOQR\,ZS\4)/ =@;R[U
M:**:26YC@Q:HT1 DC\PD;G!8 A00#P2#Q5+5/V@O#^E7&H2MIVK7&@:=?#3;
M[Q%!#&UC;7!(4JV9!(0K$*S+&R@G!-<5XJ^(GA6+]JGPF7\3:.@M-'O[*X+7
M\0\FX,L8$+_-\KD@X4\\'BN!O-3M[7X#^.?AG-(O_"=W6MW5K;Z.>;JZ\Z[\
MR.=$QEH]AW%P-H"G.*4=5%[W3^;4K?E^A3LI-/177R3C>_R9]@A@P!!R#TI:
M@L;=K6QMX6;<T<:H6]2 !FIZI[Z&<6VDV%%4O.U'_GUM?_ EO_C='G:C_P ^
MMK_X$M_\;I%%VBJ7G:C_ ,^MK_X$M_\ &Z/.U'_GUM?_  );_P"-T ?._P"U
M3J+ZQ\9/V=O [C_0-6\52ZO<[L%7%A;//&A&.?WC(WU059^.DDGQT^)%G\'[
M)F;PSID,>N^-9T) :$'=::=D<9G=2[J?^64?^W67^UQ:W_AWQU\#OB7+!;QV
M/A?Q4ME?/YY*Q6^H1FU,K$H JJ[1Y/;=6A\5/V"_@W\9O&6J^+O%GP[L]4\2
MZD%-Q??V_J$ D9(PB$I$ZH,*JCA><<UDTW2?^*5_6T;?AR_-6>ERW;G7?E7_
M *5*_P"%_2]S"_X)G7$5C^Q9X3FE=88(;C4W=FX55%[.23[ 51^$/A6_^+GP
M+^-WQ$L;62ZUWXJKJ7]DPRLL;&PB@DM-.CRQ 4,J[^2!^]SQ7E6C_LYWW['/
M[*5SX&TZTTO_ (6E\3=3B\+3:II.HW4R3>?-*$D5)47;Y-J\I)55Y7)SUK[/
MO/!>O^'OA.GA/P!/IOA>]T_3H['2+R=3<PVWEJJINB*#<N%P><\D]:WQ"C55
M66Z:Y=/1.7_MMGYL4).G4C_B<OQ:C\G[WW)GQY\%M?T_]GW7_AKI?Q2_90T3
MX77US):Z%I_Q!TUM+U%GU Q^6'GDMXP\!E(/S%V)W'.0":^@_P!HSX4_ [1/
M#OC+XB_$3P/H6NWUS:+%-=ZG:"ZNIW$8B@@MB^YHY&.U5$6TECGKDUQ,GP'^
M/?QG\4^$F^-6N?#Y?"?A?5H=;@TKP5#>++J-U#GR3/)< [%4G<50?-DCT(K_
M !D^#?[1_B?]H&/QOX9F^%FK>'=)BC7P[I/C*;4G&FS%!YMR([>-4,[,6 D8
ML57 7;ELJK^^5I[MO5=FE]S;OY;7)II4W[NR2T[M/:_;9_?8?X4^"NMZ#_P3
M5O/ 7C%I(]:B\)7LCPS/EK)L23P0EAWB_=K_ , KWC]G7QI<?$;X"_#WQ/=G
M=>:KH5G=3MG.96A4N>@_BSVKR?XN>-OB=X#_ &0O'VH?%"#PE+XOFL;G3[5/
M![W1M99+D""V14N%+M(9) ",X]*]8^!_@?4?A;\'/!/A$V]N[Z+H]K8R,UTQ
M)=(E#'_5_P![-:RDYRJS?5Q_]O;_ #C?Y&=N6-./;F_]L_R=OP/1**I>=J/_
M #ZVO_@2W_QNCSM1_P"?6U_\"6_^-UB:%VBJ7G:C_P ^MK_X$M_\;H\[4?\
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M[4?^?6U_\"6_^-U^+G]!EVBJ7G:C_P ^MK_X$M_\;H\[4?\ GUM?_ EO_C=
M%VOB#0_VOOBGK6B:?J&/!\/VNWCG\O\ L:Z;;N4-C/VT9QGKBOM+SM1_Y];7
M_P "6_\ C=?F=X&_Y$GP_P#]@^W_ /1:U\QGV-KX.G"5"5FWV3_,^ZX4RW"9
ME6JPQ<.9))K5KKY-'MO_  U7\4_^>G@__P $MU_\FT?\-5_%/_GIX/\ _!+=
M?_)M>6T5\9_;N8_\_/PC_D?I7^JN3_\ /C_R:7_R1ZE_PU7\4_\ GIX/_P#!
M+=?_ ";1_P -5_%/_GIX/_\ !+=?_)M>6T4?V[F/_/S\(_Y!_JKD_P#SX_\
M)I?_ "1ZE_PU7\4_^>G@_P#\$MU_\FT?\-5_%/\ YZ>#_P#P2W7_ ,FUY;11
M_;N8_P#/S\(_Y!_JKD__ #X_\FE_\D>I?\-5_%/_ )Z>#_\ P2W7_P FT?\
M#5?Q3_YZ>#__  2W7_R;7EM%']NYC_S\_"/^0?ZJY/\ \^/_ ":7_P D>I?\
M-5_%/_GIX/\ _!+=?_)M=-\*_P!I/Q]XH^*GA7P]K:^&Y=,U:XG@F-AIMQ!,
MFRTGG4JSW,B_>A (*G@GI7@]=5\&6D7X[?#HQ(KR?VA=X5V*C_D&7O?!_E7H
MY?G&.KXNG2J5+IO71?Y'C9QP[E>%R^M7HTK2BKI\TOU9]\T52\[4?^?6U_\
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M'LY/_O\ 1]3] :***_*S]J"BBB@#Y2_;1_Y';X=_]@_6/_1FGUX37NW[:/\
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M **** "BBB@ HHHH ^L_^"9__)?=;_[%FY_]*K2OTSK\S/\ @F?_ ,E]UO\
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MX?L84444 %%%% !1110 5UOP3_Y+W\./^PA=_P#ILO:Y*NM^"?\ R7OX<?\
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M5%&6/&237!Z/^WQ\"/B]\3+'QI\2O':Z+HWAN[>3POX-_L>_G,<X)4:C>/'
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M_P F?/<0?\BVK\O_ $I'DE%%%?IQ^.A1110 4444 %%%% !1110!][?L]_\
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MN!7P3_P5+_UWPO\ ]W5?YV=?>U?!/_!4O_7?"_\ W=5_G9UW8'_>8>IP8_\
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M_8PHHHH **** "BBB@ KK?@G_P E[^''_80N_P#TV7M<E76_!/\ Y+W\./\
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M:>7WWU_ [VMC1X]L#N<C<>X]*QB0H))P/>MV/3XWM(8Y58%1DA9&&">O(/-
M%RH+RW^U6[)T/4?6H?[(MO27_O\ /_C1_9%MZ2_]_G_QH _,+P3_ ,B;H/\
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M_K%3_P"?;^\^7_U4J_\ /U?=_P $_/*BOT-_X5;X1_Z%S3O^_"T?\*M\(_\
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M/S2OS6_"_P#F:5%4O[(MO27_ +_/_C1_9%MZ2_\ ?Y_\:]$]XNUY_P#M"?\
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M]?Y'P)17WW_PK#PG_P!"]I__ 'Y%'_"L/"?_ $+VG_\ ?D4?ZKU/^?J^X/\
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M^HI[KF6Q.UDQ]%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5.^UBPTN2TCO;VWLY+N86]LL\JH9I""0B GYFP"<#G@
MUXS^TQ'I4FK?#!=;T_\ M72CXB/VBS^P/?>:OV6;CR$1V?G' 4]*\\M= O\
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M]D_0](A\ ^$;Z+X;#2M1;2U+>*3;:>OVC(Y^>.4SG=_M(.G.*J*NK_UO)?\
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M[^#</P>EF9M<7Q'_ ,(C(<_/]A1_.,V/[OV48KZNM;:*SMHK>!%CAB01HBC
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M?ZV3_5?>=A1112&%%%% &7XH\/V_BSPWJNB7CRQVFI6LMG,\) =4D0JQ4D$
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MM8^!;[6]0CO[_5]6UJ5)K_4-1>,R3,B[4^6-$10%XPJBL6\^ ^@7SW#27FI
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M **** "N:N/^/B;_ *Z-_P"A&BB@!E%%% #X/^/B'_KHO_H0KI:** "BBB@
MHHHH **** ,_6O\ CU3_ '_Z&L>BB@ HHHH **** -K2?^0:GU?_ -"-3V/_
M !XV_P#US7^0HHH GHHHH **** ,_6O^/=/][^E8]%% !3H?]:G^\*** .FH
MHHH *R]>_P!3;_\ 7;_V1J** ,M?]=!_UVC_ /0Q74444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>eigr-20221231_g9.jpg
<TEXT>
begin 644 eigr-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &:!1$# 2(  A$! Q$!_\0
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MCMU$<[QKM61W;HHSECSGI7NE;3@Z<G&6YG&2DKH**^(_^"E?PS\5:+\']?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#.3-\</@O^TA^Q-\/[KXJZ-^TIK?Q#L](F@.H:1XECF:)XGE6,;4FN)U;+.
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M67+SF\12GS$A5C4^I-?3-%3**DE%[+;\_P ]?74<9.+<EN_^&_+3T/)?A?\
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MW<H&.V.E>ZK\!? ?_"H7^&#^';:7P2]J;1],ERX=2=Q=G)W&0O\ /YA.[?\
M-G/->@45<O?3C+6^_GZ]R(^ZTXZ6V\O0^,/ ?[ GCKX&7ES9?"#]HC7_  5X
M/N)S.^@:CH-KJXC);+>4\S!8R1@9$>>,DMTKZ!^&7P.MOA/HNNRZ7K%UK7C;
M6QYNH>+/$@-Y<7<ZH5B,B(T8\F//RPQF-0,@$$EJ].HHN[6OY>=O7<+*]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP+[F.<MG!/>N<U#]GGX?:I?7-Y<^'P]Q<2-+(PO+A068Y)P) !R>@%=1X/\
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MVJO^IT4<MQ6%5*I1<7.,>5IWLU>^CM?\#R/PO?)\5OVG&U_25:;1=+CYNMI
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M:>]]%VVT9XEX%U0Z7^SKX=E_X0P^.LWDR_V=Y/F[/WDO[S'EOTZ=/XNM9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_\ &*ZNB@#E/^%F:1_SY^(/_";U'_XQ1_PLS2/^?/Q!_P"$WJ/_ ,8KJZ*
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MC_\ &*ZNB@#E/^%F:1_SY^(/_";U'_XQ1_PLS2/^?/Q!_P"$WJ/_ ,8KJZ*
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MC_\ &*ZNB@#E/^%F:1_SY^(/_";U'_XQ1_PLS2/^?/Q!_P"$WJ/_ ,8KJZ*
M.4_X69I'_/GX@_\ ";U'_P",4?\ "S-(_P"?/Q!_X3>H_P#QBNKHH Y3_A9F
MD?\ /GX@_P#";U'_ .,4?\+,TC_GS\0?^$WJ/_QBNKHH Y3_ (69I'_/GX@_
M\)O4?_C%'_"S-(_Y\_$'_A-ZC_\ &*ZNB@#E/^%F:1_SY^(/_";U'_XQ1_PL
MS2/^?/Q!_P"$WJ/_ ,8KJZ* .9\/_$'3/$GB"[T>TMM4BN;:UCNW:^TRXM4*
M.[J #*BG.4/4#/.W=M?;TU<IIO\ R53Q%_V!=,_]'W]=70 4444 %%%% '*:
ME_R53P[_ -@74_\ T?85U=<IJ7_)5/#O_8%U/_T?85U= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .4^)G_(N6?_ &&M)_\ 3C;UU=<I\3/^1<L_
M^PUI/_IQMZZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KR#]I+X&_"'XN>$3J7Q>T*QU'1?#T4M[]ONKF6U:SC"YD/FQ.CA2%!
M*YP<#@D"O7ZY/XF_"SPQ\8O"S^&_%^FMJ^AR31SRV/VF:!)6C;<HD\IU+KD
ME&RIP,@U$ES+3^O/^OO1<79ZGYM>)K[5/#?POL_CQX?\-V'A'PW8WUOX=^%7
MAZ]M=UKH]M<S;9=:GB)PT\O)4MTRI.[@GZB_9;^*?Q+A_: ^)OP;^(WBJU^(
M4_AFRLM2M/%%OI46FO(LZJ6BDAB.P8W#&.?E;).<#Z)\<_#/PM\2O!-YX/\
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M_P"A=\/_ /@^G_\ D*C^TO''_0N^'_\ P?3_ /R%0!U=%<I_:7CC_H7?#_\
MX/I__D*C^TO''_0N^'__  ?3_P#R%0!U=%<I_:7CC_H7?#__ (/I_P#Y"H_M
M+QQ_T+OA_P#\'T__ ,A4 =717*?VEXX_Z%WP_P#^#Z?_ .0J/[2\<?\ 0N^'
M_P#P?3__ "%0!U=%<I_:7CC_ *%WP_\ ^#Z?_P"0J/[2\<?]"[X?_P#!]/\
M_(5 '5T5RG]I>./^A=\/_P#@^G_^0J/[2\<?]"[X?_\ !]/_ /(5 '5T5RG]
MI>./^A=\/_\ @^G_ /D*C^TO''_0N^'_ /P?3_\ R%0!U=%<I_:7CC_H7?#_
M /X/I_\ Y"H_M+QQ_P!"[X?_ /!]/_\ (5 '5T5RG]I>./\ H7?#_P#X/I__
M )"H_M+QQ_T+OA__ ,'T_P#\A4 =717*?VEXX_Z%WP__ .#Z?_Y"H_M+QQ_T
M+OA__P 'T_\ \A4 =717*?VEXX_Z%WP__P"#Z?\ ^0J/[2\<?]"[X?\ _!]/
M_P#(5 '5T5RG]I>./^A=\/\ _@^G_P#D*C^TO''_ $+OA_\ \'T__P A4 =7
M17*?VEXX_P"A=\/_ /@^G_\ D*C^TO''_0N^'_\ P?3_ /R%0!U=%<I_:7CC
M_H7?#_\ X/I__D*C^TO''_0N^'__  ?3_P#R%0!U=%<I_:7CC_H7?#__ (/I
M_P#Y"H_M+QQ_T+OA_P#\'T__ ,A4 =717*?VEXX_Z%WP_P#^#Z?_ .0J/[2\
M<?\ 0N^'_P#P?3__ "%0!U=%<I_:7CC_ *%WP_\ ^#Z?_P"0J/[2\<?]"[X?
M_P#!]/\ _(5 '5T5RG]I>./^A=\/_P#@^G_^0J/[2\<?]"[X?_\ !]/_ /(5
M '5T5RG]I>./^A=\/_\ @^G_ /D*C^TO''_0N^'_ /P?3_\ R%0!U=%<I_:7
MCC_H7?#_ /X/I_\ Y"H_M+QQ_P!"[X?_ /!]/_\ (5 '5T5RG]I>./\ H7?#
M_P#X/I__ )"H_M+QQ_T+OA__ ,'T_P#\A4 =717*?VEXX_Z%WP__ .#Z?_Y"
MH_M+QQ_T+OA__P 'T_\ \A4 =717*?VEXX_Z%WP__P"#Z?\ ^0J/[2\<?]"[
MX?\ _!]/_P#(5 '5T5RG]I>./^A=\/\ _@^G_P#D*C^TO''_ $+OA_\ \'T_
M_P A4 =717*?VEXX_P"A=\/_ /@^G_\ D*C^TO''_0N^'_\ P?3_ /R%0!U=
M%<I_:7CC_H7?#_\ X/I__D*C^TO''_0N^'__  ?3_P#R%0 ?$S_D7+/_ +#6
MD_\ IQMZZNO%_CEXV\3^#?AIJ'B#5O#VD_V=I%S9:A,MEK,LLKB&[AD"JK6J
M#+%0,EAC.><8/@W_  ]"TC_H0+W_ ,&2?_&ZZ*6'JUDW3C<YZN(I46E4E:Y]
MPT5\/?\ #T+2/^A O?\ P9)_\;H_X>A:1_T(%[_X,D_^-UO]1Q/\C,/K^&_G
M1]PT5\/?\/0M(_Z$"]_\&2?_ !NC_AZ%I'_0@7O_ (,D_P#C='U'$_R,/K^&
M_G1]PT5\/?\ #T+2/^A O?\ P9)_\;H_X>A:1_T(%[_X,D_^-T?4<3_(P^OX
M;^='W#17P]_P]"TC_H0+W_P9)_\ &Z/^'H6D?]"!>_\ @R3_ .-T?4<3_(P^
MOX;^='W#17P]_P /0M(_Z$"]_P#!DG_QNC_AZ%I'_0@7O_@R3_XW1]1Q/\C#
MZ_AOYT?<-%?#W_#T+2/^A O?_!DG_P ;H_X>A:1_T(%[_P"#)/\ XW1]1Q/\
MC#Z_AOYT?<-%?#W_  ]"TC_H0+W_ ,&2?_&Z/^'H6D?]"!>_^#)/_C='U'$_
MR,/K^&_G1]PT5\/?\/0M(_Z$"]_\&2?_ !NC_AZ%I'_0@7O_ (,D_P#C='U'
M$_R,/K^&_G1]PT5\/?\ #T+2/^A O?\ P9)_\;H_X>A:1_T(%[_X,D_^-T?4
M<3_(P^OX;^='W#17P]_P]"TC_H0+W_P9)_\ &Z/^'H6D?]"!>_\ @R3_ .-T
M?4<3_(P^OX;^='W#17P]_P /0M(_Z$"]_P#!DG_QNC_AZ%I'_0@7O_@R3_XW
M1]1Q/\C#Z_AOYT?<-%?%NA?\%*M.\0:M;Z?;^ KI)IB0K2ZFH48!/.(CZ>E=
MG_PVI-_T)2?^#<__ !BG'+\5+2--F<\SP=.W/42N?3]%?,'_  VI-_T)2?\
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M (-S_P#&*/\ AM"?_H2X_P#P;G_XQ5_6Z'\Z.#^U<%_S]1].T5\Q?\-H3_\
M0EQ_^#<__&*/^&T)_P#H2X__  ;G_P",4?6Z'\Z#^U<%_P _4?3M%?,7_#:$
M_P#T)<?_ (-S_P#&*/\ AM"?_H2X_P#P;G_XQ1];H?SH/[5P7_/U'T[17S%_
MPVA/_P!"7'_X-S_\8H_X;0G_ .A+C_\ !N?_ (Q1];H?SH/[5P7_ #]1].T5
M\Q?\-H3_ /0EQ_\ @W/_ ,8H_P"&T)_^A+C_ /!N?_C%'UNA_.@_M7!?\_4?
M3M%?,7_#:$__ $)<?_@W/_QBC_AM"?\ Z$N/_P &Y_\ C%'UNA_.@_M7!?\
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M=,****HT"BBB@#E-2_Y*IX=_[ NI_P#H^PKJZY34O^2J>'?^P+J?_H^PKJZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%_VRO\ DV7QW_UZ1_\
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MZ3$****_,C]K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-7^Q+IBEA;^5YNP)Y/3[O?&>^:X/XM:?9Z5\2O$EIIZHEI%>R!$CX5.<E1[
MY'X5U4,14G-1J)+F5U;Y:/[SCQ.%I4X2E2DWRRY7=6[ZK[G^!R5%%%>@>4%%
M%% !1110 L?_ !]6_P#OG_T%JTJS8_\ CZM_]\_^@M6E7\V>(7_(X7^"/YR/
M[(\(_P#DGI_]?9?^DQ"BBBOS(_:PKUN;P5\/O#?AOPS>>(;CQ)]LUBT%R6T\
MP&*/G!R&7=CGWKR2O>?%DG@N/P/\/G\41ZY-<+I0,$>EF(1LN1D.7Y&3_=[5
M[&!A"5.I.2C=6^+;6Y\_FM2<)T(1<K2;OR[OW6_S.5'PCM+?XK:'X<EU"6ZT
M;5HTNK>]A41R/ ZLRG!! ;Y2.GOCM4'B*S^%^FKJ5I:'Q<VIV_F11&;[+Y)E
M7(&['.W([<XK;\&>-#XX^/'AF\2U%C8VY6TL[16+>3"D;!5SW/4_C6'X^^)G
M]J3:UI/_  BGAFSW7$D?VZUT[9<C;)]X/N^\<<G'.3714^K0P\ITTM932NFW
M9*-O3?J>=3>.J8FG2JN5U"+E:25FY2NWWT6MM.Q7\,_#_2(?#$7B;Q=J=QIN
ME7$C1V=I91A[J\*_>*;OE50>,GC/IQF#Q)9?#V70Y[CP[J.NP:E$5V6>KPQL
M)@6 .&CX7 )//I6[\4(#=>"_AWJ\$1GT>/35M'VG"B9&/F*2.A//Y&I+RW\'
M>*OAEXGUC2/"7_"/W^E26JI)_:4USN\R3!X; ' /8]:56C&/M*,%'W5UYN9Z
M7YD]O1::=S6GB*DN3$U)3M*?+:/+RQ]_E49)ZN_5I-[[:'EMA MU?6T+DA9)
M%0E>N"0*]/7X4:2WQV;P5]IO1I0;'G;T\_'V?S.NW;UX^[TKS71_^0O8_P#7
M=/\ T(5[_'_R=\_^^?\ TCJ<OHTZJI\ZO>:7RL;9KB:U&4_9RM:E4E\URV?R
MN>8^)(?AK;Z?>Q:1_P )6=53*P_;?LWD;@<?-M^;'7I7077P6L9?A/9>(=.O
M+F;7FM#J$]FY7RV@#E7* +G*Y4G)/?U%<_XP\5>#M0L[^UTWP-_96HM)A+_^
MUYIMA#Y)\MA@Y (]LUVVJ>,)O NC_"?58P9(4L)H[B#M-"SJ'0COD?J!6E&.
M'J*HZO*U9*\4TE=O75)Z==-CCK3QE.%&-#GC)R;M-Q;E:+=KIM6=K;W3U//M
M'\&V6H?"_P 0>(Y);A;[3[N""*-67RBKD EAC.>>Q%<;7T%XP\(P>$OA5XU_
ML]O-T74+VROM/E7HT+D$#_@)R/P'K7B'A>RO]1\1Z9;:7@:E)<QK;EL8$FX;
M2<\8!]:X\5A73K4Z'+9M*]NYZF78Y8FG6K\WNJ6E]++EB[/M9WOV)+KP?K]E
MIWV^XT/4H+#&?M4MI(L6/]XC%=-H_A73K[X/:UK36AEU>#4X;:"97?(1@,KM
M!P<D^F:]H\#J?^$TOM*U?XE3>)=0DM[B"\T(VLQMR=AW!7)V#;CL!W%>6:"[
M1_L^^)&1BK+K-N0RG!!P.:[7@Z=%.6Z<7V=FFNJ;7^1Y7]J5<3:&S4Z>JYDF
MI-_S)-K3?9HT]1^'NG^"_AMI]WJ?@S5M5U>_MYI;B]+RPKIA!PFY ,=P</CH
M?I7F,/@_7[C33J$6AZE+8!=QNDM)#%CUW 8Q^->G_%+Q+KES\/\ X?PC5K^0
MZC82BY3[2Y^TG>H'F<_/^.:[;PNNI:'X^T:Q\1?$^;^W%>))/#UO;2R0,&48
MB9E(C4X/7;QP?2NBI@J6)Q/LH^[%<L5\*U?S3D_+63U\CGI9AB,)AG7J-2G)
MS=O?>D6UHDI<JZ7T2TO=MGS'16WXXMHK/QIK]O @BABU"X1$7HJB1@ /PK$K
MY9Z.Q]O3FJD%-=5<****1H4[O_CZA_W'_FM)2W?_ !]0_P"X_P#-:2OL,'_N
MU/T?_I3/XN\2?^2FQ'I#_P!(04445UGY@%%%% !75?"WPG:^./'FE:)?2S0V
MMT["1[<@. $9N"01V]*Y6O1?V>?^2P>'O]^3_P!%/75A8J=>$9+2YO0BI5H1
MELVOS-NV^'?@/QE<ZEI'A74-?M?$%K'+)%%K"0M#<>7G<JF,9!XZG\JYZ3PM
MIB_ ^/7_ ++C5SK1M#<>8W^J\K=MVYV]>^,UT=UXZ\%> ]0UF[\*6&MW'B.<
M36XNM7DB$5L6)#-&L?+'DXW>U4BK2?LVP*HW.WB0@>Y\FM+1G"7*DWRK;OSK
M;Y?UN>Y4A0YY1M'F2J;;62]WYIWV\C@K;P9X@O-..H6^A:E/8 ;C=1V<C1 =
M<[@,8K-L[.XU"ZCMK6"2YN)#M2&%"[L?0 <DU],>%X]4\/\ CC0++Q)\4IH=
M;5X$/AVWM998&5@ L3,I$:D@XR5XX.>AKFM*QX3/QBUC1U%MJNGW'V>UDC7+
M6\3SL'*^G '/;%5/#1CK?3WK[7]VW9VUO\C'^S5:.K3O9WM?9RV3T>CT=NAX
MOK'AS5O#LB)JNEWNF/(,HMY;O$6'J P&:E;PCKJZ2-4.BZB-,*[A>FUD\G'K
MOQC'XUUW@OQ1JGCWQAX7T/Q-J]QJFE?VBC[+Z3S3N)QC>V6P>F,XYKU34OB_
MX5\,^.K][W5?'EQ+:W$D$VF2/;&Q(!*E!%D#9CIT-3&A3E'G<K)MI7\DM_O_
M *V,J.%P]9.HYN,59:VO=W_R^9Y/X-\)Z=K7PP\::I-9M<:I8/:+9R*[Y3?(
M58!0<-GW!]JY#6/#FK>'FC75=+O=,:091;RW>(L/4;@,UZ[\-?$4V@_#CXG:
MMH.ZS9)[9K7<H9H4:1P/49"GKV(JE8>(-1\9_ WQ<WB&\N-3;3;RUELKJ[<R
M.DCL590[9.-O;MFBI3C*-UHU%/R_X<T^K49T:<;^\U-W2T?*Y/5[[*R['F6C
M^%=;\11R/I6CZAJ:1G#M9VKRA3[[0<5G30R6TSQ31M%*AVLCJ0RD=00>AKV3
MXK>*]:\"Q^%=$\.ZI=:3I$>D6]TGV%VA\^1P2[L5QNR>QXK+^.TG]I+X/UBY
M"#6-2T>.:]*H$+MDA78>I'\JSK48T^;E?POE?X[?<<]3"PC"24GS12;[:VV]
M+KUU/+****Y3RPHHHH **** /I/]B_\ X^O&G^Y8_P [FOIVOF+]B_\ X^O&
MG^Y8_P [FOIVOLL)_ AZ'ZWE7^Y4O0****ZSU0HHHH Y34O^2J>'?^P+J?\
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MF@7MXN^&S$$UU.R<C>8H$=U7((W$ 9&,U^>EE\%/C3\>/V&_!VA)J_P)\/\
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M_#O[1WPN\8^&-!MOC%X8\'3R_P#"3^$>/ML"QCY&;!8.JS;E&5Y+#8A%>5_
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MC_X^K?\ WS_Z"U:59L?_ !]6_P#OG_T%JTJ_FSQ"_P"1PO\ !'\Y']D>$?\
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M?ZDY_&MY_P!H/79MMQ-HWAVXUA5"C69=,5KSC@-NSC./]FO,**7MJBO[V_\
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M12?;+==RL,@X,@(X/>M'X<_-\'?B6IY7R[,X/3/F'FL[2_\ A5']FVO]H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGK?_ (3^H?\ QBJ/C7_DHWAK_L$ZE_Z.L:L4Q7)O^%M>'_\ GGK?_A/ZA_\
M&*/^%M>'_P#GGK?_ (3^H?\ QBH:*=@N3?\ "VO#_P#SSUO_ ,)_4/\ XQ1_
MPMKP_P#\\];_ /"?U#_XQ4-%%@N3?\+:\/\ _//6_P#PG]0_^,4?\+:\/_\
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MP_\ \\];_P#"?U#_ .,5#118+DW_  MKP_\ \\];_P#"?U#_ .,4?\+:\/\
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M(/\ P!?_  K]EZ*/[8Q'\J_'_,/[&P_\S_#_ "/QH_X9A^+/_1/?$'_@"_\
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M%G_HGOB#_P  7_PK]EZ*/[8Q'\J_'_,/[&P_\S_#_(_&C_AF'XL_]$]\0?\
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M/^%;>,/^A0\0?^"FX_\ B*_1.BC_ %AQ7\L?N?\ F'^JV"_GE]Z_^1/SGD\
M^*;6\L5F\+ZY$TTICB5],G!D;RW;:HV<G:K' [*3T!K3_P"%?^+/^A2\0?\
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M/^%?^+/^A2\0?^"BY_\ B*_06BC_ %9P?\TOO7^0?Z[YC_S[A]TO_DC\^O\
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MY_\ B*/^%?\ BS_H4O$'_@HN?_B*_06BC_5G!_S2^]?Y!_KOF/\ S[A]TO\
MY(_/K_A7_BS_ *%+Q!_X*+G_ .(H_P"%?^+/^A2\0?\ @HN?_B*_06BC_5G!
M_P TOO7^0?Z[YC_S[A]TO_DC\[+KP+XH_M*VM_\ A%]<%P\4DBPG2YP[*K(&
M8+LR0"R@D=-P]14G_"N?%_\ T*/B#_P4W'_Q%?<FI?\ )5/#O_8%U/\ ]'V%
M=77I4\HH4H*G%NR].]^Q^8YYA89_CIYABFU.5KJ.BT276[Z=S\\/^%<^+_\
MH4?$'_@IN/\ XBC_ (5SXO\ ^A1\0?\ @IN/_B*_0^BM/[,H]W^'^1X/^KF$
M_FE]Z_R/SP_X5SXO_P"A1\0?^"FX_P#B*/\ A7/B_P#Z%'Q!_P""FX_^(K]#
MZ*/[,H]W^'^0?ZN83^:7WK_(_/#_ (5SXO\ ^A1\0?\ @IN/_B*/^%<^+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ%%%% '*>,O^1C\!_P#8:D_]-U[75URGC+_D8_ ?_8:D_P#3=>UU= !1110
M4444 %?/7Q4_:&^*?AGQ5JNF> OV?->\?:;I)"W>L76LVVD0RG8'_P!%24,]
MR "02H'S @9KZ%KPG]H*/]HR;42GP@;X?IH#6&)SX@>[35?M&YMWV=E5H!\N
MS:9%(#9R"*SFVM5_7J7%)EWPK^UAX-\2?LWW7QGFCOM,\/6-M/+?V-Q$/MEM
M+"YCD@* X+[QM R,[E/&:\K?]N3QOX3?1->^(?P"USP/\-=8NH+6#Q0^N6MY
M-!Y[!87N;)%#PJ<C.6)'  8D"N0^$?C/X26__!/_ ,8:5XFT'6;#0M%N+S0O
M%.C7<Z7&HRZL\P\Q4E0(KR/-*FQP% XX 6N)\5>'_C5\// O@C5_CZ1XK^!_
MA^]@O;[2],NHVUFR5)5^QOJ9$2K=I#\F]8&!+<L7"\]%H^VU^&\?2SU>OFK<
MNMM5?<RU=.R^+WO73;3;?XO/8^I_B5^TWJ/A7Q)XXT_PQX/A\5V?@/3(=5\3
M7$FK?8Y(8Y$>416L8AD$\PBC:0J[1+RHW9/'5^._V@=!\'_"#3/'EI#/K::Y
M%;?V!I5OA;G5;FY4&VMXP<X9]PR>0H#,>%-<'\2?V?QKE]X_\7:!X_M?"GAK
MQYHL4'BDW6F_:@]M%"R"YM9O/C%N_D.REG65>%.T8Y\B\'^*'U#QU\-O$MAX
M6CU-+R*;0_A/X5U2[-A!;:9;VX-QK-U((I6C>6-%5-L3,$9!@>8Q&<5?W):/
M2_=;W\M=.7RYG)>ZRY-:3CJM?1Z*WGIKS?))W:/MO0[B_O-%L)]4LH]-U.6!
M'NK.&?ST@E*@O&LFU=X4Y&[:,XS@5Y9\>/C)JW@#Q1\-/"'A>VLKOQ1XSUL6
M:+?QO)%;V,2&6\N"J.A)6, +SC<PSGH=SX'_ !AA^,GAK5+Q]+?0]9T75;G0
M]7TMIA.MM>0,!(J2A5\Q""K*^U20PRH.17B7B74GU'_@IMX-TV<;[?3?AY>7
M=NIZ)++=['8<=2J 52UJP71Z_)1<_N=K>C)VIS?5:?-M1^]-W]4>D?M%?M0:
M9\!=-O(K;P]JOC3Q1#IDVL#1-)C*K%:1!B]Q<W##RX(@48;CEF(PJL>*[+X9
M_%*U\>?!GPY\0KZW30;+5-&AUF>"2?S5M(WB$K R;5W!03\VT9QT%8G[5/\
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MH^(7A;P/I46I^(_$NC^']-FQY=YJE_%;0OG&,.[ '.1T/<5^?UU\*_!FJ?\
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M+/>;:QURTGO%12<Q$2("?0!W3]*RKRY(^Z];I?>[7_4J@O:2][;?\+V_0T_
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M]W7YZ^:V9Y7\=/VG_BWH_P"UIHGP6^&FG>"S-J6DK?I>>*X[LJ'VS.X+02#
MVQ8 V$Y/7'3VWX5:I\6-$TO7]0^-EW\/["RM8UFMKKPK)=QPPQJ',SW+W1 4
M !2"#@ -GM7QC^T1X?\ $OBC_@J'X0TWPAXL_P"$(U^;PXOV?7/[-BU#[/B*
MZ+#R)"%;<H*\GC=GM7T?\4O!_CCP7^R#\7K/QY\0O^%CZI)HFH2PZE_8L&E^
M5%]FP(O+A)5L,&;<>?FQVK#F]GAG5ZVEOUM)[?)=3;EY\0J71\NWFD>Q7'QJ
M^'EK_8_G^//#,/\ ;*A],\S6+=?MRDX!AR_[P$\97-=%KWB+2?"ND7&JZWJ=
MGH^EVZ[YKZ_N$@@B7U9W(4#ZFORLT'X+^![C_@E;JOCFX\,Z?<^,7W3#7)XO
M,O(S'?B%%24_,B",!=BD*>XK2^+'B"Z^)_AG]BCPGXINY+CPQKJVS:I%*S;;
MQTD@A D(QGY21ZCS"<UTN#]I[);\T8^7O)O\+/U\C!27)[1[6D__  &WYW^1
M]&_&7]I[6[7]J3X$:!X"\8Z=J7@3Q5)(FHC31:WD%WB3;\LX5F4C/\##WKZ<
MOOBMX)TR37$O/&&@6CZ'L_M99]3@0Z?O&4^T M^ZW '&_&>U? GQZ^$W@GX5
M_P#!0KX!+X-T:P\.C4ITGO--TQ%A@5ED*)((5 5"P!!( #;,]<FH_A!\,_"7
MQ1_X*4?&VQ\8:59Z_962M>V^EZBHEMI)AY2!WA;*R%5D?&X'&XFLJ/[R$8+=
MNH[_ .%K3\[%5?<G*3Z*FK?XK_TS]%/#7BK1?&>CPZMX?U>PUW2IL^5?:;<I
M<0/@X.UT)4X/H:P=4^-'P^T/Q&OA[4?'?AFPU]F"+I5UK%O'=%B< ")G#9)'
M3%?G5\$->U7X*Z_^V;I'@$7$6@^'[6ZNM,CM<E+&Y5I44H#GE5W?40#KBNB^
M$_[/WPT\1?\ !-;6?%VK>'=)U/Q5=:-JFK3>(KB%'OTNHY)2F+@Y=<&- 5!
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M"D5%.TFI/9QO\U)1_KU*J>ZFENI)??%R7_!]#]%:*** "BBB@ HHHH ****
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MR#ZG12_SO\_Z_K5A_E;Y?U_6B//_ (*_".#X/^&]2LSJ!UC5]8U6ZUO5M2,
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M@32]+92-PN[EU@C9<]2I??\ \!KVRODO_@IM#.O[-]GJ"!OL>F>*-(O+QE.
ML(N I8]L!F7KQ42BIN-.6TG%/T;2?X,N,G"\X[I-KU2;7XG;ZGXX\$_L*? +
MX?Z;X@6YBT&UELO#QN[.-"(YY%)>YFW.N$++([L,MR>#5'X?_MT>!?'GQ!TC
MPH_A_P 9^%7UUF70=7\3Z"]AI^M$+NQ:RLV6R.1N5<Y ') KB/\ @IAK%AI7
MPA^'6J7ZF?3+;Q[H]S.L<1F+Q*9&8! "7RH/ !S6!^T]\:_A]^T)J/P/\*?#
M?Q7IOB_Q1<^-]-UB%-#N4GEL+6#<\\TVWF'"'[K;6]N#6\).M4<IZMSY7Y)J
M.ORNWZ)_+*453II1Z0O?NUS:?.R7S^_V+XI?MZ? KX+^.-0\(>,O'/\ 8_B+
M3_+-S9_V1?S^7O177YXH&0Y5E/!/6LR\_;P^&'BCX)_$KQU\.O$"^*V\&Z:;
MJ>&2QNK51,ZN($/G1QY#.N/ESC\JT_BE_P -3?\ "<:A_P *X_X5!_PA_P"[
M^Q?\)3_:O]H?<7?YGD?N_O[L;?X<9YS7"_%;P1\??B-^RS\8O#_Q-@\"W>K7
M6CEM#M_  O2TKQYD=)1==2Q2,*%]6SVKEF_W$Y2=G;T_S.B"7MH);77G_D<'
MXK^"_P 7O!_P*N?C@GQZ\:7?Q(L=)'B2ZT2:[0^&Y$6/SI+5;$)M5=F4#9ZC
M. 3Q]G_#'QI%\2/AOX6\5P(L<6MZ7;:BL:G(3S8E?;GVW8_"OD?XB?ME?"WQ
ME^Q3?6FE^+M.U3Q=XA\,_P!B6OA6UN$DU9K^>#R!";5?WBD2$Y8J%P,@\C/N
M/PW\7>%_V?/ OP7^%GBS78=.\6ZEI-OI6G631R.;JX@MXQ*H95*K@G +E020
M!D\5VR24JD$M%)*/_DUTN^BC^?4XXMN%.<OBLW+Y<MF^WVOQ['D'QN^(TWQ4
M^-GBKP-?_&)_@C\-O!5O:1ZQJ]AJMOIFH:GJ%RGF1PQ74O\ J4CCVYP,LS8P
M>"/:?@7X/D\%_"S4E\)?$_4OB_;W9DN=%U?Q5K":B QC 6-KR%,O%Y@R2 2
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M^MI/YMW(E:UX[<Z2^<977_@2_!6T2/J^BBBLRPHHHH Y3QE_R,?@/_L-2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLV.W1;;RB"#'Y8&W:02-N,<UI44NC71CZI]CRK_AD_X(?]$;^'__ (2]C_\
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MQ1_PF-K_ - WQ!_X3U__ /&* -VBL+_A,;7_ *!OB#_PGK__ .,4?\)C:_\
M0-\0?^$]?_\ QB@#=HK"_P"$QM?^@;X@_P#">O\ _P",4?\ "8VO_0-\0?\
MA/7_ /\ &* -VBL+_A,;7_H&^(/_  GK_P#^,4?\)C:_] WQ!_X3U_\ _&*
M-VBL+_A,;7_H&^(/_">O_P#XQ1_PF-K_ - WQ!_X3U__ /&* -VBL+_A,;7_
M *!OB#_PGK__ .,4?\)C:_\ 0-\0?^$]?_\ QB@#=HK"_P"$QM?^@;X@_P#"
M>O\ _P",4?\ "8VO_0-\0?\ A/7_ /\ &* -VBL+_A,;7_H&^(/_  GK_P#^
M,4?\)C:_] WQ!_X3U_\ _&* -VBL+_A,;7_H&^(/_">O_P#XQ1_PF-K_ - W
MQ!_X3U__ /&* -VBL+_A,;7_ *!OB#_PGK__ .,4?\)C:_\ 0-\0?^$]?_\
MQB@#=HK"_P"$QM?^@;X@_P#">O\ _P",4?\ "8VO_0-\0?\ A/7_ /\ &* -
MVBL+_A,;7_H&^(/_  GK_P#^,4?\)C:_] WQ!_X3U_\ _&* -VBL+_A,;7_H
M&^(/_">O_P#XQ1_PF-K_ - WQ!_X3U__ /&* -VBL+_A,;7_ *!OB#_PGK__
M .,4?\)C:_\ 0-\0?^$]?_\ QB@#=HK"_P"$QM?^@;X@_P#">O\ _P",4?\
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MQ1_PF-K_ - WQ!_X3U__ /&* -VBL+_A,;7_ *!OB#_PGK__ .,4?\)C:_\
M0-\0?^$]?_\ QB@#=HK"_P"$QM?^@;X@_P#">O\ _P",4?\ "8VO_0-\0?\
MA/7_ /\ &* -VBL+_A,;7_H&^(/_  GK_P#^,4?\)C:_] WQ!_X3U_\ _&*
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M_/GX@_\ ";U'_P",4 =717*?\+,TC_GS\0?^$WJ/_P 8H_X69I'_ #Y^(/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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M9.!UQ(#E"P7#YA9H5)/94KHO$^\02/D8-!XP:J+Q@CWTWI#DD@Z?*3=R@(R
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M91'P:;E:NZ%0@^NN>;8D!?ZW%XJVNGTB;01/M*OP#;S<,:H1(/(GB46I^CG
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M%XLA9DI8?R%0@YO;_-;VSH=+DJ?+\A=BU8I,M>-T5ZIU,#H $M -T&/=7E^
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MV!P.P3NITVR-G;19OD5/P'9U!Z-&LP\>I^ SCG$F CU-^!S@$C<.)!4.>D.
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M#9JMCYDVRS4Y#@Z*_:$M&(5<'=&="5<;C\,75R*]266RZ;9=I7I[0#/]$3,
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MR[.E05@(>31ZG-QL2RGR,%PF@A>0ZGUOO?-Q//YR\/S5I/\7+4U"<$'V0P@
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968628880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eiger BioPharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0971591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2155 Park Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">272 6138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EIGR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,107,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,158,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Part III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2023 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2022.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001305253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968527856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, CA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968864960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 25,798<span></span>
</td>
<td class="nump">$ 22,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Short-term debt securities</a></td>
<td class="nump">73,150<span></span>
</td>
<td class="nump">66,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">2,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">2,853<span></span>
</td>
<td class="nump">2,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">9,361<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">117,535<span></span>
</td>
<td class="nump">103,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrent', window );">Long-term debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">4,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">120,139<span></span>
</td>
<td class="nump">126,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,975<span></span>
</td>
<td class="nump">7,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">15,655<span></span>
</td>
<td class="nump">13,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Debt, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,809<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,121<span></span>
</td>
<td class="nump">29,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">39,625<span></span>
</td>
<td class="nump">23,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">64,829<span></span>
</td>
<td class="nump">54,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2022 and 2021; 44,074,284 and 34,568,821 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">492,759<span></span>
</td>
<td class="nump">412,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(437,193)<span></span>
</td>
<td class="num">(340,417)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">55,310<span></span>
</td>
<td class="nump">72,399<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 120,139<span></span>
</td>
<td class="nump">$ 126,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968679328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 13,484,000<span></span>
</td>
<td class="nump">$ 12,142,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">1,837,000<span></span>
</td>
<td class="nump">745,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">75,282,000<span></span>
</td>
<td class="nump">64,436,000<span></span>
</td>
<td class="nump">41,590,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">29,105,000<span></span>
</td>
<td class="nump">23,900,000<span></span>
</td>
<td class="nump">20,559,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">106,224,000<span></span>
</td>
<td class="nump">89,081,000<span></span>
</td>
<td class="nump">62,149,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(92,740,000)<span></span>
</td>
<td class="num">(76,939,000)<span></span>
</td>
<td class="num">(62,149,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,132,000)<span></span>
</td>
<td class="num">(3,559,000)<span></span>
</td>
<td class="num">(3,594,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,082,000<span></span>
</td>
<td class="nump">158,000<span></span>
</td>
<td class="nump">704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(963,000)<span></span>
</td>
<td class="nump">46,487,000<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(96,753,000)<span></span>
</td>
<td class="num">(33,853,000)<span></span>
</td>
<td class="num">(65,051,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (96,776,000)<span></span>
</td>
<td class="num">$ (33,917,000)<span></span>
</td>
<td class="num">$ (65,051,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings Per Share, Basic and Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in USD per share)</a></td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in USD per share)</a></td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">41,628,207<span></span>
</td>
<td class="nump">33,944,342<span></span>
</td>
<td class="nump">28,143,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">41,628,207<span></span>
</td>
<td class="nump">33,944,342<span></span>
</td>
<td class="nump">28,143,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 12,734,000<span></span>
</td>
<td class="nump">$ 12,142,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eigr_OtherRevenueMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eigr_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eigr_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968511344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (96,776)<span></span>
</td>
<td class="num">$ (33,917)<span></span>
</td>
<td class="num">$ (65,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale debt securities, net</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (96,927)<span></span>
</td>
<td class="num">$ (34,058)<span></span>
</td>
<td class="num">$ (65,101)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967014928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,523,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 56,480<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 297,863<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="num">$ (241,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,267,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">96,760<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">96,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement', window );">Vesting of common stock under Product Development Agreement</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on available-for-sale debt securities, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,051)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,878,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2020</a></td>
<td class="nump">95,035<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">401,509<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(306,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement', window );">Vesting of common stock under Product Development Agreement</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on available-for-sale debt securities, net</a></td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon release of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,917)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, end of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">34,568,821<span></span>
</td>
<td class="nump">34,568,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 72,399<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">412,930<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(340,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,528,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">66,110<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">66,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">47,367<span></span>
</td>
<td class="nump">47,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement', window );">Vesting of common stock under Product Development Agreement</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain/(loss) on available-for-sale debt securities, net</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender', window );">Issuance of common stock to lender (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueStockIssuedToLender', window );">Issuance of common stock to lender</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon release of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (96,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,776)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">44,074,284<span></span>
</td>
<td class="nump">44,074,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 55,310<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 492,759<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="num">$ (437,193)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_StockIssuedDuringPeriodSharesStockIssuedToLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Issued To Lender</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_StockIssuedDuringPeriodSharesStockIssuedToLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value product development agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_StockIssuedDuringPeriodValueStockIssuedToLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Issued To Lender</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_StockIssuedDuringPeriodValueStockIssuedToLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972936368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 2,068<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 3,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850969944912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (96,776,000)<span></span>
</td>
<td class="num">$ (33,917,000)<span></span>
</td>
<td class="num">$ (65,051,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_GainLossFromSaleOfPriorityReviewVoucher', window );">Gain from sale of priority review voucher</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(46,493,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_IncomeLossRelatedToAssetPurchaseAgreement', window );">Income related to asset purchase agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(281,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">292,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write down</a></td>
<td class="nump">1,043,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of debt securities premiums and discounts</a></td>
<td class="nump">682,000<span></span>
</td>
<td class="nump">996,000<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">1,144,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense</a></td>
<td class="nump">1,238,000<span></span>
</td>
<td class="nump">776,000<span></span>
</td>
<td class="nump">804,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of right-of-use assets</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">523,000<span></span>
</td>
<td class="nump">478,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued under Product Development Agreement</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,317,000<span></span>
</td>
<td class="nump">7,901,000<span></span>
</td>
<td class="nump">5,973,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">828,000<span></span>
</td>
<td class="num">(2,576,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,367,000)<span></span>
</td>
<td class="num">(2,424,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(196,000)<span></span>
</td>
<td class="num">(701,000)<span></span>
</td>
<td class="num">(3,563,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(1,265,000)<span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
<td class="num">(1,392,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,152,000<span></span>
</td>
<td class="nump">3,234,000<span></span>
</td>
<td class="num">(1,899,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,957,000<span></span>
</td>
<td class="nump">2,309,000<span></span>
</td>
<td class="nump">1,491,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(628,000)<span></span>
</td>
<td class="num">(576,000)<span></span>
</td>
<td class="num">(534,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(83,010,000)<span></span>
</td>
<td class="num">(71,342,000)<span></span>
</td>
<td class="num">(63,185,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of debt securities available-for-sale</a></td>
<td class="num">(75,101,000)<span></span>
</td>
<td class="num">(84,647,000)<span></span>
</td>
<td class="num">(128,295,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of debt securities available-for-sale</a></td>
<td class="nump">85,073,000<span></span>
</td>
<td class="nump">99,630,000<span></span>
</td>
<td class="nump">83,766,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProceedsRelatedToAssetPurchaseAgreement', window );">Proceeds related to asset purchase agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">281,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProceedsFromSaleOfPriorityReviewVoucher', window );">Proceeds from sale of priority review voucher</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PaymentsRelatedToPriorityReviewVoucher', window );">Payments related to priority review voucher</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(48,507,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(340,000)<span></span>
</td>
<td class="num">(225,000)<span></span>
</td>
<td class="num">(258,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">9,632,000<span></span>
</td>
<td class="nump">61,532,000<span></span>
</td>
<td class="num">(44,787,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock upon offering at-the-market, net of commissions</a></td>
<td class="nump">66,402,000<span></span>
</td>
<td class="nump">3,040,000<span></span>
</td>
<td class="nump">96,779,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt', window );">Proceeds from issuance of common stock to lender</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt</a></td>
<td class="nump">39,841,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(33,277,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon stock option exercises</a></td>
<td class="nump">234,000<span></span>
</td>
<td class="nump">361,000<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock upon ESPP purchase</a></td>
<td class="nump">157,000<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(1,116,000)<span></span>
</td>
<td class="num">(175,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock offering costs</a></td>
<td class="num">(286,000)<span></span>
</td>
<td class="num">(316,000)<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">76,955,000<span></span>
</td>
<td class="nump">3,167,000<span></span>
</td>
<td class="nump">97,463,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">3,577,000<span></span>
</td>
<td class="num">(6,643,000)<span></span>
</td>
<td class="num">(10,509,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">22,221,000<span></span>
</td>
<td class="nump">28,864,000<span></span>
</td>
<td class="nump">39,373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">25,798,000<span></span>
</td>
<td class="nump">22,221,000<span></span>
</td>
<td class="nump">28,864,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">2,885,000<span></span>
</td>
<td class="nump">2,783,000<span></span>
</td>
<td class="nump">2,791,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrual</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_OfferingCostsIncurredNotYetPaid', window );">Common stock offering costs included in accounts payable and accrual</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 458,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_GainLossFromSaleOfPriorityReviewVoucher">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from sale of priority review voucher.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_GainLossFromSaleOfPriorityReviewVoucher</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncomeLossRelatedToAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (loss) related to asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncomeLossRelatedToAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OfferingCostsIncurredNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred, Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OfferingCostsIncurredNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PaymentsRelatedToPriorityReviewVoucher">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to priority review voucher.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PaymentsRelatedToPriorityReviewVoucher</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock In Connection With Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProceedsFromSaleOfPriorityReviewVoucher">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of priority review voucher.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProceedsFromSaleOfPriorityReviewVoucher</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProceedsRelatedToAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds related to asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProceedsRelatedToAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967539120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">44,074,284<span></span>
</td>
<td class="nump">34,568,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">44,074,284<span></span>
</td>
<td class="nump">34,568,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972088176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on November&#160;6, 2008. Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV), the most severe form of viral hepatitis, and other serious diseases. All five of the Company&#8217;s rare disease programs have been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Lonafarnib is a first-in-class, oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III, interferon.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA approved the Company&#8217;s first commercial product, Zokinvy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (lonafarnib), to reduce risk of mortality of Hutchinson-Gilford progeria syndrome (HGPS) and for treatment of processing-deficient progeroid laminopathies (PL), collectively known as progeria, with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, on November 20, 2020. The Company announced that the European Commission approved its Marketing Authorization Application (MAA) for Zokinvy, under exceptional circumstances procedure on July 20, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing avexitide, a well-characterized peptide, as a treatment for congenital hyperinsulinism (HI), an ultra-rare pediatric metabolic disorder, and post-bariatric hypoglycemia (PBH), a debilitating and potentially life-threatening condition. There are currently no approved therapies for these disorders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal operations are based in Palo Alto, California, with subsidiaries in Delaware, Ireland, England and Wales. The Company operates in one segment. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had $98.9 million of cash, cash equivalents and short-term securities, comprised of $25.8 million of cash and cash equivalents and $73.1 million of short-term debt securities available-for-sale. The Company had an accumulated deficit of $437.2 million and negative cash flows from operating activities as of December&#160;31, 2022. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and until it does, the Company will need to continue to raise additional capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the currently available resources will be sufficient to fund its planned operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if the Company&#8217;s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic, among other events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972245840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#8217;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two customers accounted for approximately 58 percent and 42 percent of the Company&#8217;s accounts receivable as of December&#160;31, 2022. One customer accounted for approximately 93 percent of product revenue during the year ended December&#160;31, 2022. Two customers accounted for approximately 66 percent and 34 percent of the Company&#8217;s accounts receivable as of December 31, 2021. One customer accounted for approximately 94 percent of product revenue during the year ended December 31, 2021. The Company did not have accounts receivable or revenue in 2020.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transaction Risk</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger BioPharmaceuticals Europe Limited</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for 2022 were $0.1 million. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at the subsidiary. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation Risk</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign currency translation risk relates to the translation of the foreign consolidated subsidiary's assets, liabilities, revenues and expenses from the subsidiary's functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the foreign subsidiary, which has a functional currency other than the U.S. dollar are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation losses, net of tax, for 2022 were $0.1 million. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. Long-term securities consist of debt securities classified as available-for-</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale and have maturities greater than 365 days from the date of acquisition. The Company&#8217;s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of accumulated other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net on the accompanying consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of the property and equipment are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of remaining lease term or 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2022, the Company has not impaired any long-lived assets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent amounts billed to the Company&#8217;s customers, net of an allowance for doubtful accounts. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The expectation of collectability is based on a review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for doubtful accounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no allowance as of December&#160;31, 2022 and 2021. The Company had no bad debt expense for the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval of the Company&#8217;s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company wrote-down $1.0 million of inventories for the year ended December&#160;31, 2022. There were no write-downs in prior periods.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021 and in Europe in November 2022 . Prior to 2021, the Company had no product revenue. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy (lonafarnib) through a reimbursed early access program in France. The Company recorded revenue of $0.2&#160;million from sales of product under the ATU program for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company&#8217;s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt payment discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory milestones. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying consolidated balance sheets and within research and development expenses in the accompanying consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use assets and current and noncurrent lease liabilities, as applicable, in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in selling, general and administrative expenses in the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in selling, general and administrative expenses when incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing costs incurred with securing a term debt are recorded in the Company&#8217;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#8217;s consolidated statements of operations over the contractual life of the loan using the effective interest method. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#8217;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Stock-based awards to non-employees are recorded at their fair value as of the grant date, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions for Black-Scholes option pricing model inputs. The Company accounts for forfeitures of stock-based awards when they occur. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#8217;s unrealized gains and losses on debt securities and foreign currency translation adjustment represent the components of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,262,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,119,341&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,933,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,815,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company does not expect the impact of adopting this standard to be material. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. In October 2021, the Company amended its Oxford Loan to replace its floating interest rate with the LIBOR replacement rate (see Note 8). The Company adopted this standard when LIBOR was about to be discontinued and the adoption did not have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972030016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). As of December&#160;31, 2022 and 2021, the carrying amount of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimated fair value due to their relatively short maturities. Management believes the terms of its long-term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company&#8217;s debt approximated its fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company&#8217;s debt securities and commercial paper consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were no assets or liabilities classified as Level 3 as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 of the fair value hierarchy during the periods presented. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no financial liabilities measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the estimated value of the Company&#8217;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized loss </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized loss </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically reviews the available-for-sale securities for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">other-than-temporary</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i) it is more likely </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">than n</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ot that the Company will be required to sell the debt securities before recovery of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">their</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the year ended December&#160;31, 2022, the Company did not recognize any </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">other-than-temporary</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> impairment losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">T</span>he unrealized losses of $0.2 million as of December&#160;31, 2022 include debt securities with unrealized losses of $21,000 that have been in the loss position for more than 12 months. However, the Company is planning to hold these securities until maturity and expects to recover the amortized cost basis<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972028784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,216&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2021 and 2020 was approximately $0.3 million, $0.3 million and $0.2 million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract manufacturing costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,167&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract research costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972061904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Product Development Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProductDevelopmentAgreementAbstract', window );"><strong>Product Development Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProductDevelopmentAgreementTextBlock', window );">License, Collaboration, and Product Development Agreements</a></td>
<td class="text">License, Collaboration, and Product Development Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the University of Pennsylvania (UPenn) and the Children&#8217;s Hospital of Philadelphia (CHOP), under which the Company obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain Glucagon Like Peptide-1 (GLP-1) receptor antagonist(s) products to treat all human and animal conditions. The Company also obtained an exclusive, royalty-bearing, sublicensable, worldwide license to certain data developed by CHOP. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for the development and commercialization of the licensed products at its sole cost and expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consideration for the rights granted to the Company under the UPenn/CHOP Agreement, the Company paid UPenn a one-time, non-refundable issue fee of $1.0&#160;million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, the Company is obligated to pay UPenn a specified annual license maintenance fee, up to $2.5&#160;million upon marketing authorization in one or more countries, and up to $18.0&#160;million in commercial milestones. The Company will also be required to pay UPenn a flat royalty in the low-single digits on net sales of all licensed products by the Company, subject to specified reductions and offsets, and specified minimum annual royalty payments. The Company&#8217;s obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. No milestones have been achieved as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for the Company&#8217;s failure to achieve the specified diligence milestones within the specified periods, subject to the Company&#8217;s extension rights.</span></div><div style="margin-top:18pt;padding-left:23.13pt;text-indent:-23.13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Development Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2018, the Company entered into a Product Development Agreement and a First Project Agreement (the Product Agreements), pursuant to which the Company will receive development program support services for its HDV program. The services are to be provided from July 1, 2018 through the new drug application (NDA) filing. As consideration, the Company has committed to pay fees of approximately $10.0&#160;million in cash and stock over four years, including approximately $0.8&#160;million for expert consultant fees and pass through costs to vendors, plus certain incentive-based regulatory milestone fees up to $1.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the aggregate payment, the Company issued 115,526 shares of common stock subject to quarterly vesting requirements related to successful performance of the services and achievement of budget timeline set forth in the Product Agreements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Product Agreements can be terminated by either party due to material breach or by the Company without cause with 90 days prior written notice. For the years ended December 31, 2022, 2021 and 2020, the Company recognized research and development expense of $19,000, $0.2&#160;million and $0.2&#160;million, respectively, related to the shares issued under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2022, the restricted shares were fully vested.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progeria Research Foundation (PRF) Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the Company entered into a Collaboration and Supply Agreement (the PRF Collaboration Agreement) with PRF. Under the PRF Collaboration Agreement, the parties agreed to collaborate with respect to the development and pursuit of regulatory approval of lonafarnib for the treatment of HGPS and processing-deficient progeroid laminopathies, collectively called progeria, in humans. PRF granted the Company a non-exclusive, world-wide, royalty-free, sub-licensable license pertaining to all intellectual property and data controlled by PRF to prepare and file any NDA for a product containing lonafarnib for progeria. The Company is obligated to: (i) exclusively supply lonafarnib to PRF for use in clinical trials and non-clinical research in progeria at the Company&#8217;s expense, (ii) prepare and be the sponsor of any NDA submission for lonafarnib for the treatment of progeria to the FDA, (iii) use commercially reasonable efforts to file a NDA for progeria by a specified date, (iv) submit a Rare Pediatric Disease designation and a request for expedited approval in connection with a NDA filing, (v) establish a patient support program in progeria, and (vi) use commercially reasonable efforts to develop a pediatric formulation of lonafarnib for use in progeria.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PRF Collaboration Agreement, the Company is solely responsible for any additional studies necessary for obtaining an NDA for progeria and is also responsible for any additional costs for such studies up to $2.0&#160;million. The PRF Collaboration Agreement continues for an initial term of ten years and automatically renews for subsequent renewal terms of two years each unless either party terminates earlier.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Bristol-Meyers Squibb License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (peginterferon lambda or the Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $2.0 million and issued 157,587 shares of its common stock at an aggregate fair value of $3.2 million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $61.0 million and commercial sales milestones of up to $128.0 million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In the fourth quarter of 2020, the Company recorded in research and development expense a $3.0 million milestone, triggered on successful demonstration of proof of concept, as defined by the BMS License Agreement, in a Phase 2 clinical trial. In March 2022, the Company recorded a $5.0 million milestone expense in research and development, which was related to the initiation of a Phase 3 clinical trial, as defined under the BMS License Agreement. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2010, the Company entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck &amp; Co., Inc. (Merck), which provides the Company with the exclusive right to develop, manufacture, and sell products containing the compounds lonafarnib for the treatment of all human viruses except certain specified viruses such as hepatitis B and hepatitis C alone. As part of consideration, the Company issued 27,350 shares of common stock with a fair value of $0.5&#160;million. The Company is obligated to pay Merck up to an aggregate of $27.0&#160;million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. In May 2015, the first regulatory milestone was achieved and the Company paid the related milestone payment of $1.0&#160;million to Merck. No additional milestones have been achieved as of December 31, 2022. The next milestone of $1.0&#160;million is due upon successful completion of the Phase 3 study, which is expected by end of 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the Company entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford progeria syndrome (HGPS) in humans at no cost to the Company. On November 3, 2020, the Company entered into an amendment to the exclusive license agreement with Merck which expanded the indication to also include progeroid laminopathies, collectively called progeria. The Company has the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to the PRF. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria or any royalty payments for sales of a specified quantity of lonafarnib to treat the currently estimated progeria  patient population worldwide.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductDevelopmentAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product development agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductDevelopmentAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductDevelopmentAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product development agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductDevelopmentAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972113504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreements and Related License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract', window );"><strong>Asset Purchase Agreements And Related License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementTextBlock', window );">Asset Purchase Agreements and Related License Agreements</a></td>
<td class="text">Asset Purchase Agreements and Related License Agreements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EGI Asset Purchase Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2010, the Company entered into an asset purchase agreement with Eiger Group International, Inc. (EGI). Dr. Jeffrey Glenn, a founder and director of the Company, is the sole owner of EGI. Pursuant to the agreement, the Company purchased all of the assets including the intellectual property rights related to the use of farnesyltransferase inhibitors as anti-viral agents and methods to treat viral infections with those inhibitors and inhibitors of prenylation, prenyl cysteine methyltransferase and a protease as anti-viral agents and methods to treat viral infection with those inhibitors. The Company paid EGI an upfront payment of $0.4&#160;million when the agreement was executed in December 2010. Additionally, the Company will pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, the Company may make a one-time payment of $0.5&#160;million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product. The product is currently not under development.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avexitide Purchase Agreement and Related Stanford License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, the Company entered into an asset purchase agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig, (the Sellers), whereby the Company purchased all of the assets related to the compound avexitide (formerly known as exendin 9-39) including any related intellectual property from the Sellers (the Exendin APA). The Company also entered into a consulting agreement with the Sellers as part of the agreement. The Company issued 15,378 shares of common stock that were valued at $0.2&#160;million and with the option to purchase 46,134 shares of common stock with an exercise price of $2.06 per share when the agreement was executed in September 2015.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 46,134 options to purchase common stock, 15,378 shares vest monthly over four years as services are provided by the Sellers and 30,756 vest upon the earlier of the first commercial sale of the product or the approval of new drug application by the U.S. FDA (the milestone-vested options).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2016, immediately following the closing of the merger, the Company issued additional top-up options to the Sellers to purchase an aggregate of 48,544 shares of common stock, pursuant to the terms of the Exendin APA, with an exercise price of $17.25 per share. The top-up options consist of both time-vested and milestone-vested options.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the time-vested options is recognized as stock-based compensation expense as the awards vest over time. The fair value of the milestone-vested options will be recognized as research and development expense when it is probable that the earliest milestone will be achieved at their fair value as of the ASU 2018-07 adoption date. During the years ended December 31, 2022, 2021 and 2020, the Company recognized $0&#160;million, $0.1&#160;million and $0.1&#160;million of compensation expense related to the time-vested options, respectively. No expense was recognized for the milestone vested options during the years ended December 31, 2022, 2021, and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also obligated to pay development milestone payments in an aggregate amount of up to $1.0&#160;million to each Seller. Additionally, the Company is obligated to pay each Seller royalties of low single-digits based on aggregate annual net sales of all products developed based on avexitide, subject to certain reductions and exceptions. The Company&#8217;s obligation to pay royalties expires on the expiration of the last to expire patent assigned to the Company under the agreement. Additionally, the Company has assumed the license agreement the Sellers had previously entered into with the Board of Trustees of the Leland Stanford Junior University (Stanford). The Company is obligated to pay a royalty to Stanford in the low single-digits on annual net sales after the first commercial sale of any products developed based on avexitide. As of December 31, 2022, the Company has paid a total of $0.1&#160;million in milestone payments to each of the Sellers related to the successful completion of the Phase 2 trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Purchase Agreement with AbbVie Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;20, 2020, Eiger entered into the AbbVie Agreement with AbbVie to sell its rare pediatric disease priority review voucher (the PRV), which was awarded on November&#160;20, 2020 upon FDA approval of Zokinvy. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. </span></div>In consideration for the PRV, AbbVie agreed to pay the Company $95.0 million. The transaction closed in January 2021. Such consideration was shared with the PRF in accordance with the terms of the PRF Collaboration and Supply Agreement, pursuant to which the Company and PRF will equally share any net proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained $46.5 million of proceeds from the sale of the PRV, net of related payments, and recorded the amount in other (expense) income, net in the consolidated statement of operations for the year ended December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset purchase agreement and related license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset purchase agreements and related license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972245840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Assets</a></td>
<td class="text">Sale of Assets<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company and Theragene Pharmaceuticals, Inc. (Theragene) entered into an asset purchase agreement (Theragene APA), whereby the Company sold all of the assets related to MYDICAR including any related intellectual property for a cash payment of $0.2&#160;million and 475,000 shares of common stock of Theragene. At any time after the Theragene APA execution date and until Theragene has received cumulative gross proceeds of $4.0&#160;million (Proceeds Date) from all equity financing transactions occurring after the Theragene APA execution date, if Theragene issues additional shares of its common stock without consideration or for a consideration per share less than $6.00 per share then Theragene will issue additional shares of its common stock to the Company concurrently with such issue, in an amount such that the per share consideration multiplied by the aggregate number of common stock shares issued to the Company will equal $2.9&#160;million. Additionally, the Company may exercise a put option at any time after the Proceeds Date, where upon written notice from the Company, Theragene will repurchase the 225,000 shares of its common stock held by the Company (Option Shares) at an aggregate purchase price equal to the greater of $1.4&#160;million or the aggregate fair market value of the Option Shares as of the date of the receipt of such notice. The Company is also eligible to receive contingent consideration up to a maximum $45.0&#160;million in cash, based upon Theragene achieving certain specified future milestones. In addition, the Company is also eligible to receive up to 8% royalties on net sales of any future Theragene products covered by or involving the related patents or know-how until the twentieth anniversary of the Theragene APA. To-date, no consideration has been earned or is expected to be earned.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the sale of the MYDICAR assets qualify as an asset sale and not a business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Theragene APA, the Company became the owner of 475,000 shares of common stock of Theragene and held a put option for 225,000 shares of common stock of Theragene, which were recognized as a cost method investment with carrying value of zero.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Theragene entered into an Asset Purchase Agreement with a third party for the sale of MYDICAR. Under the terms of the Theragene APA between the Company and Theragene, the Company is eligible to receive 25% of any upfront, licensee fee, milestone or other payment (other than royalty payments) received by Theragene from the sale or sublicense of MYDICAR, within 30 days of receipt of such payments by Theragene. As such, during the year ended December 31, 2021, the Company recognized $0.3&#160;million in other (expense) income, net. The Company expects to receive a de minimis amount subsequent to December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850971961520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovatus Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022 (Closing Date), the Company entered into a term loan and security agreement (Innovatus Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), providing for up to $75.0 million funded in three tranches with a maturity date of August&#160;31, 2027. The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) the Prime Rate published in the Money Rates section of the Wall Street Journal (or any successor thereto) and (ii) 3.5%, plus (b) 3.75%; provided that, at the election of the Borrower, up to 2.25% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through July 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. 2.25% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 6.5% of the aggregate principal amount of the tranches funded under the Innovatus Loan. The Innovatus Loan contains customary representations, warranties, events of default and covenants of the Company and its subsidiaries, including a requirement to maintain a cash balance of not less than 5% of the aggregate principal amount of funded and outstanding </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan terms at all times. The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was funded $40.0 million in June 2022 on the Closing Date under Tranche A. The remaining $35.0 million is divided into two tranches (Tranche B and Tranche C). The $17.5 million under each of Tranche B and Tranche C will be available for a period commencing on the later of (a) the first date that the Company achieves certain development and regulatory milestones applicable to each Tranche and (b) November 1, 2022. Both Tranche B and Tranche C draw periods end on the earlier of (a) June 30, 2024 or (b) an event of default. The Company believes it is currently eligible to draw the $17.5&#160;million under Tranche B, but has not done so as of December 31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified a number of embedded derivatives that require bifurcation from the Innovatus Loan. These embedded features include mandatory prepayment upon an event of default or change in control and contingent rate increases. However, the fair value of these embedded features was deemed to be immaterial on the date of issuance and at December&#160;31, 2022. At each subsequent reporting period, the Company will reassess the fair value of the embedded features and will record a liability if the fair value of the features becomes material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the Innovatus Loan, the Company recorded a debt discount of $0.2&#160;million and capitalized debt issuance costs of $1.1&#160;million. The discount and issuance costs will be amortized over the life of the loan. Interest expense for the Innovatus Loan for the year ended December&#160;31, 2022 was $2.6&#160;million, and is inclusive of non-cash amortization of the debt discount and debt issuance costs and accretion of final payment. The carrying value of the Innovatus Loan at December&#160;31, 2022 was $39.6 million. The carrying amount of the Innovatus Loan approximates fair value given its recent issuance. The effective interest rate for the Innovatus Loan was 12.86% as of December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with entering into the Innovatus Loan, the Company entered into a Stock Purchase Agreement with Innovatus for the sale of common stock with an aggregate value of $5.0 million. On June 1, 2022, the Company issued 749,053 shares of common stock to Innovatus at a per share purchase price of $6.6751, the preceding five-day volume weighted average price per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the loan proceeds were used to repay in full the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $33.5&#160;million of aggregate principal amount, unpaid interest, and exit fees in connection with loans outstanding owed to Oxford Finance LLC by the Company. </span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oxford Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into an aggregate $25.0 million loan with Oxford Finance LLC (the Oxford Loan) with a maturity date of July&#160;1, 2021. The Company borrowed $15.0 million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan and borrowed $5.0 million (Tranche B). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;3, 2018, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowed the remaining $5.0 million (Tranche C) under the Oxford Loan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $35.0 million and extended the maturity date to March&#160;1, 2024. On March&#160;5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $23.3&#160;million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $6.7 million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $30.0&#160;million (Amended Tranche A). The remaining $5.0 million (Amended Tranche B) was available to the Company provided that certain milestones are achieved by February 2021. The Company did not draw down the Amended Tranche B.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;23, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by 17 months until September 1, 2022, followed by 19 equal monthly payments of principal and interest. The Company paid an amendment fee of $0.2&#160;million to the lender on the effective date of the fifth amendment, which was recorded as an additional debt discount and was being amortized over the remaining term of the Amended Oxford Loan. Interest expense for the Oxford Loan for the year ended December&#160;31, 2022 was $1.5&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2021, the Company entered into the sixth amendment to the Oxford Loan, which amended the interest to be the LIBOR replacement rate which is the sum of the alternate benchmark rate and the LIBOR replacement spread. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of final payment, the Company was required to pay an exit fee of 7.50% of the original principal balance of borrowed funds, or $2.3 million. In addition, the Company was required to pay an additional exit fee of $1.0 million. The </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $0.9 million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2022, upon entering into the Innovatus Loan, the Company repaid the Oxford Loan, including (i) the $30.0 million outstanding principal balances, (ii) $0.2 million in accrued and unpaid interest, and (iii) other final payments consisting of $3.3 million, for a total payment of $33.5 million. The Company recorded a loss of $1.1&#160;million on early extinguishment of the debt related to the unamortized debt premium, discount, and cost of issuance, which was recognized as a component of other (expense) income, net in the consolidated statement of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the amortization of the debt discount utilizing the effective interest method. Debt and unamortized discount balances are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum payments of principal, exit fee and interest expense under the Innovatus Loan were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: exit fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972251936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Company&#8217;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the convertible preferred stockholders. As of December&#160;31, 2022, no dividends had been declared by the Board of Directors.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by the Company up to a maximum aggregate offering price of $200.0&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of its common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0&#160;million of the maximum aggregate offering price of $200.0&#160;million may be issued and sold pursuant to an ATM financing facility (the 2020 ATM Facility) under a sales agreement with Jefferies. In December 2021, the Company completed ATM offerings for a total of 565,938 shares of common stock under the 2020 ATM Facility. The offerings were made under the Company&#8217;s effective shelf registration statement and resulted in net proceeds to the Company of $3.0&#160;million, after deducting commissions. In January and March 2022, the Company completed ATM offerings for a total of 5,841,786 shares of common stock under the 2020 ATM Facility. The offerings were made under the Company&#8217;s </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective shelf registration statement and resulted in net proceeds to the Company of $45.6&#160;million, after deducting commissions. As of December 31, 2022, the Company completed the sale of all shares available for sale under the 2020 ATM Facility, and the 2020 ATM Facility was terminated.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2022, the Company entered into a new Open Market Sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies, pursuant to which the Company can sell up to a maximum of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$50.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our common stock in offerings that are deemed &#8220;at the market&#8221; offerings as defined in Rule 415 under the Securities Act, under the Company&#8217;s effective shelf registration statement (the 2022 ATM Facility). In April 2022, the Company completed offerings from the 2022 ATM facility for a total of 2,686,288 shares of our common stock resulting in net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, after deducting commissions costs. No additional offerings were completed since April 2022. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$28.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remaining under the 2022 ATM Facility for future issuance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,143,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,262,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options available for future grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,976,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,327,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted and performance stock units outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">641,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for issuance under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">788,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">671,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,549,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,884,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972038192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restated 2013 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors adopted and in August 2016 the Company&#8217;s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Under the terms of the Restated 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restated 2013 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than 110% of fair market value, as determined by the Board of Directors. The terms of options granted under the Restated 2013 Plan may not exceed ten years. The vesting schedule of newly issued option grants is generally four years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2022, the Company is authorized to issue up to 8,127,807 shares under the Restated 2013 Plan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Inducement Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company approved the 2021 Inducement Plan to reserve 850,000 shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals&#8217; entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of December&#160;31, 2022, there were 380,000 shares remaining available to be issued under the 2021 Inducement Plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity, including restricted stock units (RSUs) and performance stock units (PSUs) available for grant activity, under the Company&#8217;s stock-based compensation plans during the year ended December&#160;31, 2022 (in thousands, except option and share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Available for <br/>Grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,262,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of  December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of  December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,726,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock of $1.18 as of December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised in 2022, 2021 and 2020 was $0.1 million, $0.1&#160;million and $0.3&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021 and 2020, the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> weighted-average grant date fair value of options granted were $3.65, $5.58 and $4.78 per share, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of options that vested during the years ended December&#160;31, 2022, 2021 and 2010 was $7.3 million, $6.9&#160;million and $5.6&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation of stock options granted by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizes the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. The fair value of stock options was estimated using the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27-6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27-6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00-6.08</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.71%-88.51%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.96%-71.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.00%-77.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76%-4.23%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62%-1.35%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39%-1.37%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected term represents the number of years the Company estimates, based primarily on historical experience, that the options will be outstanding prior to exercise.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected volatility for stock options is based on the Company's historical stock price volatility.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, the Company&#8217;s board of directors adopted and in 2016, upon the merger with Celladon, the Company amended and approved the 2013 Employee Stock Purchase Plan (2013 ESPP). The 2013 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code and is administered by the Company&#8217;s board of directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock initially reserved for issuance under the 2013 ESPP was 100,000 shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 165,000 shares of common stock, unless a lower number determined by the board of directors. As of December&#160;31, 2022, a total of 948,831 shares are reserved for issuance and 788,057 shares available for future issuance under the 2013 ESPP. During the years ended December&#160;31, 2022, 2021 and 2020, employees purchased 48,115 shares for $0.2&#160;million, 37,619 shares for $0.3&#160;million and 25,645 shares for $0.2&#160;million, respectively, under the 2013 ESPP.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company revised its non-employee director compensation policy to approve the granting of RSUs in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for at least six months during the prior calendar year and continues to serve as a non-employee member of the board of Directors (the Board) is granted RSUs. Each eligible director who has served on the Board for less than six months during the prior calendar year and who continues to serve as a non-employee member of the Board, is granted RSUs which are pro-rated for the period served during the prior calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director&#8217;s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. The RSUs granted to employees will vest annually on the one-year, two-year, and three-year anniversaries of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company&#8217;s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSUs are also available for grant pursuant to the Restated 2013 Plan. Each PSU, which is a stock award, is earned through the achievement of performance-based metrics over a defined performance period. The length of the defined performance period, the performance-based metric to be achieved during the defined performance period, and the measure of whether and to what degree such performance-based metric has been achieved will be conclusively determined by the compensation committee of the Company&#8217;s Board, in its sole discretion. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022 and 2021 the Company granted 30,000 and 270,000 PSUs, with a weighted-average grant date fair value of $6.87 and $7.92 per share, respectively. The performance-based metrics include the achievement of certain revenue targets and clinical and regulatory milestones. During the year ended December&#160;31, 2022 and 2021, the Company recorded $0.5 million and $0.2&#160;million of stock-based compensation expense related to the PSUs as it is expected that all milestones will be achieved by the target dates, respectively. This expense is included in selling, general and administrative expenses. As of December&#160;31, 2022, no PSUs have vested as the performance-based metrics of the PSUs have not yet been achieved. During the year ended December&#160;31, 2022 and 2021, the Company granted 298,150 and 371,500 RSUs, respectively, with a weighted-average grant date fair value of $5.22 and $9.16 per share, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to the RSUs granted, the Company recognized $1.2&#160;million and $0.9&#160;million in stock-based compensation expense for the year ended December&#160;31, 2022 and 2021, respectively, which were included in selling, general and administrative expenses. As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested RSUs and PSUs was $3.0&#160;million, which the Company expects to recognize over an estimated weighted-average period of 2.0 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and PSU activity and weighted average grant date fair value for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares as of  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares as of  December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested options was $10.1 million, which the Company expects to recognize over an estimated weighted average period of 2.70 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972032016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes was approximately $23,000 and $64,000 for the year ended December&#160;31, 2022 and 2021 respectively, with an effective tax rate of (0.02)% and (0.19)% for the year ended December&#160;31, 2022 and 2021. No provision for income taxes was recorded for the years ended December 31, 2020. The effective tax rate in each period differs from the U.S. statutory tax rate primarily due to the valuation allowances on the Company&#8217;s deferred tax assets as it is more likely than not that some or all of the Company&#8217;s deferred tax assets will not be realized. The tax expense recorded for the year ended December&#160;31, 2022 relates to state taxes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Section 174 Capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(96,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(71,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(128)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s lack of earnings history, the deferred tax assets have been fully offset by a valuation allowance as of December 31, 2022 and 2021. The net change in the valuation allowance for the years ended December&#160;31, 2022 and 2021 increased by $25.1&#160;million and $10.5&#160;million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had approximately $292.3&#160;million and $25.4&#160;million, respectively, of federal and state operating loss carryforwards available to reduce future taxable income that will begin to expire in 2030 and 2028, respectively, for federal and state tax purposes. The Company had $10.8&#160;million of federal Orphan Drug credit carryforwards available to reduce future taxable income that will begin to expire in 12/31/2041.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company also had research and development tax credit carryforwards of approximately $0&#160;million and $3.1&#160;million for federal and state purposes available to offset future taxable income tax, respectively. If not utilized, the state credits can be carried forward indefinitely. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if the Company has experienced an ownership change under Section 382 of the Internal Revenue Code (the Code) of 1986, as amended. The Company&#8217;s merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#8217;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. The Company assessed whether it had an ownership change, as defined by Section 382 of the Code from its formation through December 31, 2021. Based upon this assessment, the Company experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to the April 20, 2016 and October 18, 2018 ownership changes, reductions were made to the Company&#8217;s NOL and tax credit carryforwards under these rules. Additional ownership changes in the future could result in additional limitations on the Company&#8217;s NOL and tax credit carryforwards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2022, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions based on tax positions related to prior year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions based on tax positions related to current year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reductions based on tax positions related to prior year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reductions based on tax positions related to current year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the $3.5 million of unrecognized tax benefits is recognized, there would not be an effect on the effective tax rate. The Company does not expect the unrecognized tax benefits to change significantly over the next 12 months. As of December&#160;31, 2022, the unrecognized tax benefits for uncertain tax positions were offset against deferred tax assets and would not affect the income tax rate if recognized due to the Company being in a full valuation allowance position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to account for interest and penalties in tax expense on the consolidated statements of operations. The Company files income tax returns in the U.S. federal and state jurisdictions. All periods since inception are subject to examination by U.S. federal and state jurisdictions. There were no such interest or penalties during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972088176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">From time to time in the ordinary course of business, the Company may be involved in various legal claims and litigation, including those pertaining to the defense and enforcement of the Company's patent or other intellectual property rights and contractual rights. The Company is defending all current litigation matters, including the litigation matters discussed below. Although there can be no assurances and the outcome of these matters is currently not determinable, the Company currently believes that none of these claims or proceedings are likely to have a material adverse effect on the Company's financial position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The Company records accruals for outstanding legal proceedings, claims or investigations when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company evaluated developments in legal proceedings, claims or investigations that could affect the amount of any accrual, as well as any developments that would result in a loss contingency to become both probable and reasonably estimable. The Company has not recorded any accrual for loss contingencies associated with such legal claims or litigation discussed herein as they are in the early stages and an estimate of loss, if any, cannot be made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On November 8, 2022 a putative securities class action complaint was filed in the United States District Court for the Northern District of California alleging that the company and two former executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleges generally that between March 2021 and October 2022 material misstatements and omissions were made to shareholders regarding the TOGETHER study of peginterferon lambda for the treatment of COVID-19 as well as the likelihood of FDA approval of an Emergency Use Authorization for peginterferon lambda. The Court appointed a lead plaintiff on March 2, 2023. The litigation is currently ongoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On November 15, 2022, the Company received a demand for arbitration (Demand) from claimant The Progeria Research Foundation, Inc. (PRF) asserting two claims under a May 15, 2018 Collaboration and Supply Agreement (the PRF Collaboration Agreement) between the parties. PRF has alleged that the Company breached an obligation to supply quantities of a drug as requested by PRF. PRF also has a claim for declaratory relief regarding the grant of licenses under the PRF Collaboration Agreement. On January 18, 2023, the Company filed a response to the Demand denying PRF&#8217;s claims, contesting the arbitrability of PRF&#8217;s claim for declaratory relief, and asserting a counterclaim for declaratory relief related to the contractual provision underlying PRF&#8217;s original drug supply claim. To give the parties an opportunity to discuss a potential negotiated resolution of their dispute, the arbitration has been suspended through the end of 2023. As a result, all arbitration activities are now on hold, and the final hearing, originally scheduled for May 9 &#8211; 12, 2023, in Boston, Massachusetts, has been taken off calendar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LegalMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Matters [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LegalMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972030016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into a non-cancelable operating facility lease agreement for 8,029 square feet of office space located at 2155 Park Blvd. in Palo Alto, California. The lease commenced on March&#160;1, 2018 and was to expire in February 2023. The lease had a three-year renewal option prior to expiration. The lease included rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $0.3&#160;million. In February 2023, the Company amended the lease to extend the lease by one year with a one year renewal option. The extended lease will commence on March 1, 2023 and expire on February 28, 2024. The Company accounted for the amendment as a lease modification in accordance with ASC Topic 842. The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense recognized for the Company&#8217;s operating leases was $0.6 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were $0.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating cash outflows for the operating lease liabilities were $0.7&#160;million, $0.6&#160;million and $0.7&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, the weighted-average remaining lease term and weighted-average discount rate were 1.2 years and 12.82%, respectively. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. However, the amount and timing of these payments are not known. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Service Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, the Company is required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture 80% of actual manufacturing volume. If the Company orders more than 20 percent of manufacturing volume from other manufacturers, the Company is required to pay 70% of purchase price to Patheon for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive two-year terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#8217;s notice of termination to the other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972211584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsAs disclosed in Note 6, the Company entered into license agreements with EGI, which is owned by the founder of the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972038192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Event<div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Departure of Directors or Certain Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, the Company entered into a separation agreement and general release with David Cory, the Company's former President and Chief Executive Officer. Pursuant to the separation agreement, Mr. Cory will be entitled to receive, (i) $1.5&#160;million continuation of his base salary and target bonus for a period of 18 months; (ii) $0.4&#160;million cash payment equal to Mr. Cory's target bonus for 2022; (iii) reimbursement for COBRA continuation coverage for Mr. Cory and his eligible dependents for a period of 18 months; (iv) accelerated vesting of 50% of Mr. Cory's unvested stock options, performance-based restricted stock units, and time-based RSUs outstanding as of the separation date; (v) reimbursement of Mr. Cory's legal fees associated with the negotiation of the Separation Agreement up to $10,000. The Company accrued $2.0&#160;million related to David Cory's separation for salary and benefits as of December 31, 2022. Expense related to stock options acceleration will be recorded in Q1 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Silicon Valley Bank Closure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 10, 2023, the Company maintained two accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at Silicon Valley Bank (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVB) holding</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash deposits of approximately $8.3&#160;million. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (FDIC) was appointed receiver. The FDIC initially announced that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll insured depositors will have full access to their insured deposits no later than, March 13, 2023, with uninsured depositors receiving an advance dividend a receivership certificate for their uninsured funds. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#8217; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its full deposits with SVB. The cash was subsequently moved to another financial institution.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967622128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#8217;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Exchange</a></td>
<td class="text"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transaction Risk</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eiger BioPharmaceuticals Europe Limited</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for 2022 were $0.1 million. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at the subsidiary. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation Risk</span></div>The foreign currency translation risk relates to the translation of the foreign consolidated subsidiary's assets, liabilities, revenues and expenses from the subsidiary's functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the foreign subsidiary, which has a functional currency other than the U.S. dollar are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation losses, net of tax, for 2022 were $0.1 million.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Debt Securities</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. Long-term securities consist of debt securities classified as available-for-</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale and have maturities greater than 365 days from the date of acquisition. The Company&#8217;s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of accumulated other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net on the accompanying consolidated statements of operations.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of the property and equipment are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of remaining lease term or 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent amounts billed to the Company&#8217;s customers, net of an allowance for doubtful accounts. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The expectation of collectability is based on a review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for doubtful accounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval of the Company&#8217;s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.</span></div>The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021 and in Europe in November 2022 . Prior to 2021, the Company had no product revenue. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy (lonafarnib) through a reimbursed early access program in France. The Company recorded revenue of $0.2&#160;million from sales of product under the ATU program for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company&#8217;s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt payment discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div>The Company&#8217;s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory milestones.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of SalesCost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock', window );">Accrued Research and Development Costs</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying consolidated balance sheets and within research and development expenses in the accompanying consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</span></div>Research and Development CostsResearch and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#8217;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use assets and current and noncurrent lease liabilities, as applicable, in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in selling, general and administrative expenses in the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in selling, general and administrative expenses when incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text">Deferred Financing CostsFinancing costs incurred with securing a term debt are recorded in the Company&#8217;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#8217;s consolidated statements of operations over the contractual life of the loan using the effective interest method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based CompensationStock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). Stock-based awards to non-employees are recorded at their fair value as of the grant date, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions for Black-Scholes option pricing model inputs. The Company accounts for forfeitures of stock-based awards when they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#8217;s unrealized gains and losses on debt securities and foreign currency translation adjustment represent the components of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per ShareBasic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company does not expect the impact of adopting this standard to be material. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. In October 2021, the Company amended its Oxford Loan to replace its floating interest rate with the LIBOR replacement rate (see Note 8). The Company adopted this standard when LIBOR was about to be discontinued and the adoption did not have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972047824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of the property and equipment are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of remaining lease term or 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,262,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,119,341&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,933,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,815,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Estimated Useful Lives Of Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967478096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the estimated value of the Company&#8217;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized loss </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized loss </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967657296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment and software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,591&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,216&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract manufacturing costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,167&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract research costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972020656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-Term Debt and Unamortized Discount Balances</a></td>
<td class="text">Debt and unamortized discount balances are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of debt</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum payments of principal, exit fee and interest expense under the Innovatus Loan were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: exit fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of term loan</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972147968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CommonStockReservedForFutureIssuancesTableTextBlock', window );">Common Stock Reserved For Future Issuances</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,143,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,262,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Options available for future grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,976,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,327,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Restricted and performance stock units outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">641,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares available for issuance under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">788,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">671,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,549,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,884,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CommonStockReservedForFutureIssuancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Reserved For Future Issuances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CommonStockReservedForFutureIssuancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968441776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity, including restricted stock units (RSUs) and performance stock units (PSUs) available for grant activity, under the Company&#8217;s stock-based compensation plans during the year ended December&#160;31, 2022 (in thousands, except option and share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares<br/>Available for <br/>Grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,262,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,061,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of  December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143,183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of  December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,726,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted</a></td>
<td class="text">The fair value of stock options was estimated using the following weighted-average assumptions:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27-6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.27-6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00-6.08</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.71%-88.51%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.96%-71.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.00%-77.00%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76%-4.23%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62%-1.35%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39%-1.37%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected term represents the number of years the Company estimates, based primarily on historical experience, that the options will be outstanding prior to exercise.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected volatility for stock options is based on the Company's historical stock price volatility.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and PSU activity and weighted average grant date fair value for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares as of  December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares as of  December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Non-cash Stock Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972939744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26.75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">60,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Section 174 Capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">96,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(96,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(71,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(128)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2022, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions based on tax positions related to prior year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions based on tax positions related to current year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reductions based on tax positions related to prior year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,907)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reductions based on tax positions related to current year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968611744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Leases Liabilities and Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the Company&#8217;s operating lease liabilities as of December&#160;31, 2022 were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966136352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 98,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">25,798<span></span>
</td>
<td class="nump">$ 22,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term debt securities available-for-sale</a></td>
<td class="nump">73,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (437,193)<span></span>
</td>
<td class="num">$ (340,417)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850965787568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax', window );">Aggregated transaction gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_EarlyAccessProgramTerm', window );">Early access program term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,484,000<span></span>
</td>
<td class="nump">$ 12,142,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,119,341<span></span>
</td>
<td class="nump">5,933,344<span></span>
</td>
<td class="nump">3,815,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment, Long-Lived Asset, Held-for-Use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_OptionsGrantedToEmployeesAndNonEmployeesMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,143,183<span></span>
</td>
<td class="nump">5,262,185<span></span>
</td>
<td class="nump">3,697,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (unvested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,407<span></span>
</td>
<td class="nump">623,000<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,751<span></span>
</td>
<td class="nump">48,159<span></span>
</td>
<td class="nump">81,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=eigr_CustomerAMember', window );">Customer A | Customer Concentration Risk | Financing Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=eigr_CustomerAMember', window );">Customer A | Customer Concentration Risk | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=eigr_CustomerBMember', window );">Customer B | Customer Concentration Risk | Financing Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,734,000<span></span>
</td>
<td class="nump">$ 12,142,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=eigr_AutorisationTemporaireDUtlisationMemberMember', window );">Autorisation Temporaire D Utlisation Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_EarlyAccessProgramTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Access Program Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_EarlyAccessProgramTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Foreign Currency Transaction Adjustment, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_OptionsGrantedToEmployeesAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_OptionsGrantedToEmployeesAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=eigr_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=eigr_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=eigr_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=eigr_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eigr_AutorisationTemporaireDUtlisationMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eigr_AutorisationTemporaireDUtlisationMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968511200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850973569600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 88,664,000<span></span>
</td>
<td class="nump">$ 97,376,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Other-than-temporary impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized loss</a></td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, unrealized loss position for more than 12 months</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_FairValueTransfersBetweenLevelsTransfersAmount', window );">Transfers in or out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_FairValueTransfersBetweenLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value transfers between levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_FairValueTransfersBetweenLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966075856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 88,664,000<span></span>
</td>
<td class="nump">$ 97,376,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">28,642,000<span></span>
</td>
<td class="nump">41,511,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">8,913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember', window );">U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">39,563,000<span></span>
</td>
<td class="nump">42,345,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11,546,000<span></span>
</td>
<td class="nump">13,520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11,546,000<span></span>
</td>
<td class="nump">13,520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11,546,000<span></span>
</td>
<td class="nump">13,520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">77,118,000<span></span>
</td>
<td class="nump">83,856,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">28,642,000<span></span>
</td>
<td class="nump">41,511,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">8,913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">39,563,000<span></span>
</td>
<td class="nump">42,345,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850965798752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized cost</a></td>
<td class="nump">$ 15,514<span></span>
</td>
<td class="nump">$ 13,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">15,514<span></span>
</td>
<td class="nump">13,520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">73,350<span></span>
</td>
<td class="nump">84,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized loss</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">73,150<span></span>
</td>
<td class="nump">83,856<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">88,664<span></span>
</td>
<td class="nump">97,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">28,759<span></span>
</td>
<td class="nump">41,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized loss</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">28,642<span></span>
</td>
<td class="nump">41,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">28,642<span></span>
</td>
<td class="nump">41,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">8,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember', window );">U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">39,646<span></span>
</td>
<td class="nump">42,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized loss</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">39,563<span></span>
</td>
<td class="nump">42,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">39,563<span></span>
</td>
<td class="nump">42,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermDebtMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">73,150<span></span>
</td>
<td class="nump">66,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember', window );">Long-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized cost</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="nump">13,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="nump">13,520<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="nump">13,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">15,514<span></span>
</td>
<td class="nump">$ 13,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized cost</a></td>
<td class="nump">3,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">$ 3,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and investment securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CashEquivalentsAndInvestmentSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966891248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,703<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-progress</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 2,853<span></span>
</td>
<td class="nump">$ 2,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968711216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,591<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(895)<span></span>
</td>
<td class="num">(603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850969832992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PrepaidContractManufacturingCosts', window );">Prepaid contract manufacturing costs</a></td>
<td class="nump">$ 3,542<span></span>
</td>
<td class="nump">$ 3,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short term deposits</a></td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PrepaidResearchCosts', window );">Prepaid research costs</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PrepaidMarketing', window );">Prepaid marketing</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 13,985<span></span>
</td>
<td class="nump">$ 9,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other prepaid expense and other assets current classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OtherPrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PrepaidContractManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid contract manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PrepaidContractManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PrepaidMarketing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Marketing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PrepaidMarketing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PrepaidResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for research that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PrepaidResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967639296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">$ 6,167<span></span>
</td>
<td class="nump">$ 3,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AccruedContractedResearchCostsCurrent', window );">Contract research costs</a></td>
<td class="nump">4,188<span></span>
</td>
<td class="nump">4,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ContractManufacturingCostsCurrent', window );">Contract manufacturing costs</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="nump">3,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProductRevenueReserves', window );">Product revenue reserves</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 15,655<span></span>
</td>
<td class="nump">$ 13,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AccruedContractedResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contracted research costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AccruedContractedResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ContractManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract manufacturing costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ContractManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductRevenueReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductRevenueReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850962012000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Product Development Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2018</div></th>
<th class="th"><div>May 15, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2010</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,282,000<span></span>
</td>
<td class="nump">$ 64,436,000<span></span>
</td>
<td class="nump">$ 41,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,110,000<span></span>
</td>
<td class="nump">$ 2,685,000<span></span>
</td>
<td class="nump">96,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,074,284<span></span>
</td>
<td class="nump">34,568,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2022 and 2021; 44,074,284 and 34,568,821 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember', window );">UPennCHOPAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_NonRefundableIssueFee', window );">Non refundable issue fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_ProductDevelopmentAgreementMember', window );">Product Development Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProductDevelopmentFees', window );">Product development fees</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PeriodOfCommittedPaymentOfFees', window );">Period of committed payment of fees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ExpertConsultantFeesAndPassThroughCosts', window );">Expert consultant fees and pass through costs</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_IncentiveBasedRegulatoryMilestoneFees', window );">Incentive-based regulatory milestone fees</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock issued subject to quarterly vesting requirements (in shares)</a></td>
<td class="nump">115,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember', window );">Progeria Research Foundation (PRF) Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CollaborationAgreementInitialTerm', window );">Collaboration agreement initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CollaborativeArrangementRenewalTerm', window );">Collaborative arrangement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | UPennCHOPAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_LicenseMaintenanceFee', window );">License maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=eigr_CommercialSalesMember', window );">Commercial Sales | Maximum | UPennCHOPAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,528,074<span></span>
</td>
<td class="nump">565,938<span></span>
</td>
<td class="nump">9,267,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_UpFrontCashPayments', window );">Up front cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Merck Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Merck Transaction | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Research and development | Maximum | Merck Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DevelopmentMilestoneObligations', window );">Development milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contract-Based Intangible Assets | Merck Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2022 and 2021; 44,074,284 and 34,568,821 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember', window );">BMS Transaction | Common Stock | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember', window );">BMS Transaction | Licensing Agreements | Development And Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember', window );">BMS Transaction | Licensing Agreements | Commercial Sales | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember', window );">BMS Transaction | Licensing Agreements | Development Phase Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember', window );">BMS Transaction | Licensing Agreements | Development Phase Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CollaborationAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Initial Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CollaborationAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CollaborativeArrangementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CollaborativeArrangementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DevelopmentMilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Milestone Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DevelopmentMilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ExpertConsultantFeesAndPassThroughCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expert consultant fees and pass through costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ExpertConsultantFeesAndPassThroughCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncentiveBasedRegulatoryMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incentive-based regulatory milestone fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncentiveBasedRegulatoryMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NonRefundableIssueFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Refundable Issue Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NonRefundableIssueFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PeriodOfCommittedPaymentOfFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Committed Payment Of Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PeriodOfCommittedPaymentOfFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductDevelopmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product development fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductDevelopmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_UpFrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up Front Cash Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_UpFrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_CommercialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_CommercialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_MerckTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_MerckTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=eigr_BMSTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eigr_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967340064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreements and Related License Agreements - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2020</div></th>
<th class="th"><div>Mar. 22, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,317<span></span>
</td>
<td class="nump">$ 7,901<span></span>
</td>
<td class="nump">$ 5,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember', window );">AbbVie Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PaymentForAssetPurchaseAgreement', window );">Payment for asset purchase agreement</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember', window );">AbbVie Asset Purchase Agreement | Progeria Research Foundation (PRF) Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | EIG Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_UpFrontCashPayments', window );">Up front cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement', window );">One time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issued stocks (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_OptionsToPurchaseOfCommonStock', window );">Options to purchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,544<span></span>
</td>
<td class="nump">46,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.25<span></span>
</td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_VestingOfOptionsToPurchaseCommonStock', window );">Vesting of options to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_LicenseAgreementPotentialMilestonePayments', window );">License agreement potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issued stocks (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issued stocks (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement | Share-based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issued stocks (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement | Share-based Payment Arrangement, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issued stocks (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset purchase agreement and related license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LicenseAgreementMilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Milestone Payments Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LicenseAgreementMilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LicenseAgreementPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LicenseAgreementPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One Time Payment To Be Made On Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OptionsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options To Purchase Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OptionsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PaymentForAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PaymentForAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_UpFrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up Front Cash Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_UpFrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_VestingOfOptionsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Of Options To Purchase Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_VestingOfOptionsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Period Of Options Issued For Common Stock Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eigr_EIGTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eigr_EIGTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=eigr_ShareBasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=eigr_ShareBasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967316512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Assets - Additional Information (Detail) - Disposal Group Not Discontinued Operations - MYDICAR - Theragene Pharmaceuticals, Inc. - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Cash payment received for sale of assets under asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived', window );">Sale of assets number of common stock shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares', window );">Maximum cumulative cash proceeds of counter party for issuance of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares', window );">Maximum consideration per share of counter party for issuance of additional shares (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AggregateCommonStockConsiderationValue', window );">Aggregate common stock consideration value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare', window );">Shares repurchase by counterparty based on exercise of put options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost', window );">Cost method investment with carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage', window );">Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived', window );">Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue', window );">Shares repurchase by counterparty based on exercise of put option value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementContingentConsiderationReceivable', window );">Asset purchase agreement contingent consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_RoyaltyReceivablePercentageOnNetSales', window );">Royalty receivable percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AggregateCommonStockConsiderationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate common stock consideration value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AggregateCommonStockConsiderationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset purchase agreement contingent consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum consideration per share of counter party for issuance of additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum cumulative cash proceeds of counter party for issuance of additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_SaleOfAssetsNumberOfCommonStockSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of assets number of common stock shares received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_SaleOfAssetsNumberOfCommonStockSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share repurchase by counterparty based on exercise of put option share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share repurchase by counterparty based on exercise of put option value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentsAndSecuritiesAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=eigr_MYDICARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=eigr_MYDICARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=eigr_TheragenePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=eigr_TheragenePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850960435200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 03, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,531<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,132<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
<td class="nump">$ 3,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,625<span></span>
</td>
<td class="nump">23,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,110<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">96,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan | Amended Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentExitFeePayablePercentage', window );">Percentage of exit fee on principal balance</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings from loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedAdditionalExitFees', window );">Loan final repayment additional exit fees payable</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan | Secured Debt, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Repayments of loan agreement exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan | Secured Debt, Amended Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Loan agreement, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember', window );">Fifth Amended Oxford Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentInterestPaymentPeriod', window );">Interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_AmendmentFeesPayment', window );">Amendment fees payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt | Innovatus Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of common stock issued during period</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares issued (in shares) | shares</a></td>
<td class="nump">749,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 6.6751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Innovatus Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentPercentOfInterestDue', window );">Debt Instrument, percent of interest due (in percent)</a></td>
<td class="nump">0.0225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentExitFeePayablePercentage', window );">Percentage of exit fee on principal balance</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent', window );">Minimum cash balance of face value of loan (in percent)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Capitalized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Innovatus Loan | Secured Debt | Variable Rate Component One | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Minimum prime rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Innovatus Loan | Secured Debt | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Minimum prime rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Innovatus Loan | Secured Debt, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Innovatus Loan | Secured Debt, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Innovatus Loan | Secured Debt, Tranche B and C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Oxford Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Oxford Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Oxford Loan | Secured Debt, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Amendment | Secured Debt, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Amendment | Secured Debt, Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Amended Oxford Loan | Amended Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Repayments of loan agreement exit fee</a></td>
<td class="nump">33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Accrued and unpaid interest</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_LineOfCreditFacilityOtherFinalPayments', window );">Other final payments</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AmendmentFeesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendment fees payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AmendmentFeesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentExitFeePayablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee payable percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentExitFeePayablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentPercentOfInterestDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percent Of Interest Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentPercentOfInterestDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument principal and interest payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedAdditionalExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized additional exit fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedAdditionalExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized exit fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LineOfCreditFacilityOtherFinalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Other Final Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LineOfCreditFacilityOtherFinalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MinimumCashBalanceOfFaceValueOfLoanPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Cash Balance Of Face Value Of Loan, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MinimumCashBalanceOfFaceValueOfLoanPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_SecuredDebtAmendedTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_SecuredDebtAmendedTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_AmendedTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_AmendedTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_InnovatusStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eigr_InnovatusStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_InnovatusLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_InnovatusLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_VariableRateComponentAxis=eigr_VariableRateComponentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_VariableRateComponentAxis=eigr_VariableRateComponentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_VariableRateComponentAxis=eigr_VariableRateComponentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_VariableRateComponentAxis=eigr_VariableRateComponentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheBAndCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheBAndCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_SecuredDebtTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968647824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt</a></td>
<td class="nump">$ 40,531<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Exit fee</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</a></td>
<td class="num">(3,506)<span></span>
</td>
<td class="num">(1,482)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">39,625<span></span>
</td>
<td class="nump">31,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">$ 39,625<span></span>
</td>
<td class="nump">$ 23,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized exit fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850967212896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Maturities of Long-term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized interest</a></td>
<td class="nump">$ 3,506<span></span>
</td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="nump">40,531<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember', window );">Amended Tranche A | Innovatus Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Long-Term Debt, Maturity, Year One</a></td>
<td class="nump">3,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">Long-Term Debt, Maturity, Year Two</a></td>
<td class="nump">3,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">Long-Term Debt, Maturity, Year Three</a></td>
<td class="nump">4,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">Long-Term Debt, Maturity, Year Four</a></td>
<td class="nump">4,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">Long-Term Debt, Maturity, Year Five</a></td>
<td class="nump">48,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total future payments</a></td>
<td class="nump">64,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized interest</a></td>
<td class="nump">21,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DebtInstrumentExitFee', window );">Less: exit fee</a></td>
<td class="nump">3,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="nump">$ 39,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_InnovatusLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_InnovatusLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850965985568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DividendsDeclared', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount', window );">Aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock upon offering at-the-market, net of commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,402,000<span></span>
</td>
<td class="nump">$ 3,040,000<span></span>
</td>
<td class="nump">$ 96,779,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CommonStockValueAvailableForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount', window );">Aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod', window );">Maximum shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,938<span></span>
</td>
<td class="nump">5,841,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock upon offering at-the-market, net of commissions</a></td>
<td class="nump">$ 45,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_CommonStockValueAvailableForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,686,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CommonStockValueAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Value, Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CommonStockValueAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends Declared</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Debt Warrants And Units Maximum Aggregate Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Equity Debt Warrants Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eigr_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850965781312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Common Stock Reserved For Future Issuances (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_OptionsIssuedAndOutstanding', window );">Options issued and outstanding (in shares)</a></td>
<td class="nump">6,143,183<span></span>
</td>
<td class="nump">5,262,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grants (in shares)</a></td>
<td class="nump">1,976,460<span></span>
</td>
<td class="nump">1,327,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_RestrictedAndPerformanceStockUnitsOutstanding', window );">Restricted and performance stock units outstanding (in shares)</a></td>
<td class="nump">641,407<span></span>
</td>
<td class="nump">623,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram', window );">Shares available for issuance under ESPP (in shares)</a></td>
<td class="nump">788,057<span></span>
</td>
<td class="nump">671,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">9,549,107<span></span>
</td>
<td class="nump">7,884,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options Issued And Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_RestrictedAndPerformanceStockUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted And Performance Stock Units Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_RestrictedAndPerformanceStockUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Available For Issuance Under Employee Stock Purchase Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966762480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ClosingPriceOfCommonStock', window );">Closing price of common stock (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="nump">7,884,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,549,107<span></span>
</td>
<td class="nump">7,884,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage increase in number of shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional options authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,728,441<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grants (in shares)</a></td>
<td class="nump">1,327,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,460<span></span>
</td>
<td class="nump">1,327,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,317<span></span>
</td>
<td class="nump">$ 7,901<span></span>
</td>
<td class="nump">$ 5,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,115<span></span>
</td>
<td class="nump">37,619<span></span>
</td>
<td class="nump">25,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee option grants (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_PerformanceStockUnitsPSUMember', window );">Performance Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee option grants (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 7.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (unvested)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for grant (in shares)</a></td>
<td class="nump">298,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1', window );">Period of service threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee option grants (in usd per share) | $ / shares</a></td>
<td class="nump">$ 5.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (unvested) | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of new grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (unvested) | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of new grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units (unvested) | Share-based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of new grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember', window );">Restated Two Thousand Thirteen Equity Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of new grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available to be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,127,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eigr_InducementPlan2021Member', window );">Inducement Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available to be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember', window );">Two Thousand Thirteen Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restated Two Thousand Thirteen Equity Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice', window );">Threshold ownership percentage of shareholder for grant of options at pre determined exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restated Two Thousand Thirteen Equity Incentive Plan Member | Holders Of Ten Percent Or More Of Voting Power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employee holding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restated Two Thousand Thirteen Equity Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual terms of options granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_PerformanceStockUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_PerformanceStockUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eigr_InducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eigr_InducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968702224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_SharesAvailableForGrantAbstract', window );"><strong>Shares Available for Grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,327,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional options authorized (in shares)</a></td>
<td class="nump">1,728,441<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted', window );">Granted (in shares)</a></td>
<td class="num">(2,061,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted', window );">Restricted stock units granted (in shares)</a></td>
<td class="num">(298,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted', window );">Performance stock units granted (in shares)</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited', window );">Forfeited (in shares)</a></td>
<td class="nump">1,132,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited', window );">Restricted stock units forfeited (in shares)</a></td>
<td class="nump">126,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled', window );">Performance stock units cancelled (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,976,460<span></span>
</td>
<td class="nump">1,327,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,262,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,061,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(47,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,132,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">6,143,183<span></span>
</td>
<td class="nump">5,262,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">3,726,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, beginning balance (in USD per share)</a></td>
<td class="nump">$ 10.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted (in USD per share)</a></td>
<td class="nump">5.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised (in USD per share)</a></td>
<td class="nump">4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited (in USD per share)</a></td>
<td class="nump">9.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, ending balance (in USD per share)</a></td>
<td class="nump">9.00<span></span>
</td>
<td class="nump">$ 10.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and exercisable (in USD per share)</a></td>
<td class="nump">$ 10.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning balance</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and exercisable (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Cancelled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of performance stock units granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of restricted stock units forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of restricted stock units granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Number Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_SharesAvailableForGrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Available for Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_SharesAvailableForGrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966914832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">68.71%<span></span>
</td>
<td class="nump">68.96%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">88.51%<span></span>
</td>
<td class="nump">71.40%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.76%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember', window );">Non-Employees Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850969743168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail) - Restricted Stock Units and Performance Stock Unit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares, beginning balance (in shares) | shares</a></td>
<td class="nump">623,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock options granted (in shares) | shares</a></td>
<td class="nump">328,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(132,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(176,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares, ending balance (in shares) | shares</a></td>
<td class="nump">641,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 8.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee option grants (in usd per share) | $ / shares</a></td>
<td class="nump">5.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options vested (in USD per share) | $ / shares</a></td>
<td class="nump">9.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">7.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of options ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 7.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_RestrictedStockUnitsAndPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_RestrictedStockUnitsAndPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966904864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,317<span></span>
</td>
<td class="nump">$ 7,901<span></span>
</td>
<td class="nump">$ 5,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,158<span></span>
</td>
<td class="nump">$ 5,649<span></span>
</td>
<td class="nump">$ 4,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850966972608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="num">(0.02%)<span></span>
</td>
<td class="num">(0.19%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">2.39%<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_IncreaseInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits impact on effective tax rate</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties associated with uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">292,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Orphan Drug Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Deferred Tax Assets Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=eigr_OrphanDrugCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=eigr_OrphanDrugCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850973167200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.99%)<span></span>
</td>
<td class="num">(31.07%)<span></span>
</td>
<td class="num">(26.75%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">12.14%<span></span>
</td>
<td class="nump">6.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">2.39%<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.98%)<span></span>
</td>
<td class="num">(3.02%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.59%)<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="num">(0.02%)<span></span>
</td>
<td class="num">(0.19%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968518752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 63,069<span></span>
</td>
<td class="nump">$ 60,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">9,985<span></span>
</td>
<td class="nump">5,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DeferredTaxAssetDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,920<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,429<span></span>
</td>
<td class="nump">3,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 Capitalization</a></td>
<td class="nump">15,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">96,546<span></span>
</td>
<td class="nump">71,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(96,418)<span></span>
</td>
<td class="num">(71,291)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DeferredTaxAssetDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DeferredTaxAssetDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850973823264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 1,950<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 3,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">1,586<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions based on tax positions related to prior year</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions based on tax positions related to current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 3,492<span></span>
</td>
<td class="nump">$ 1,950<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850972194496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Matters (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_NumberOfFormerExecutives', window );">Number of former executives</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LegalMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Matters [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LegalMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NumberOfFormerExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Former Executives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NumberOfFormerExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850965747696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense recognized for company's operating leases</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease payments for operating leases</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows for operating lease liabilities</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (in percent)</a></td>
<td class="nump">12.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eigr_PatheonIncMember', window );">Patheon Inc | Master Manufacturing Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts', window );">Percentage of product manufactured on the basics of annual forecasts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PercentageOfPurchasePrice', window );">Percentage of purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eigr_PatheonIncMember', window );">Patheon Inc | Master Manufacturing Services Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts', window );">Percentage of product manufactured on the basics of annual forecasts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Palo Alto, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Total leased space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue', window );">Security deposit of collateral for lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Palo Alto, California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Product Manufactured On The Basics Of Annual Forecasts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PercentageOfPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PercentageOfPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the fair values, as of the date of each statement of financial position presented, of securities that are restricted as collateral for the payment of related debt obligations, primarily secured borrowings and repurchase agreements, and that are reclassified and separately reported in the statement of financial position because the transferee has the right by contract or custom to sell or re-pledge them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66007379&amp;loc=d3e113888-111728<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eigr_PatheonIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eigr_PatheonIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_MasterManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_MasterManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850968549328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted payments</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liabilities</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139850970011600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 06, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 10, 2023 </div>
<div>USD ($) </div>
<div>account</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,798<span></span>
</td>
<td class="nump">$ 22,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=eigr_FormerCEOMember', window );">Former CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent', window );">Salary continuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_NumberOfAccounts', window );">Number of accounts | account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Silicon Valley Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Former CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent', window );">Salary continuation</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_BaseSalaryAndTargetBonusContinuationPeriod', window );">Base salary and target bonus continuation period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Cash payment</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_COBRAContinuationCoveragePeriod', window );">COBRA continuation coverage period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold', window );">Legal fees reimbursement threshold</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs | Former CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eigr_PostEmploymentBenefitAcceleratedVesting', window );">Accelerated vesting</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_BaseSalaryAndTargetBonusContinuationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base Salary And Target Bonus Continuation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_BaseSalaryAndTargetBonusContinuationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_COBRAContinuationCoveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Continuation Coverage Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_COBRAContinuationCoveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NumberOfAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NumberOfAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PostEmploymentBenefitAcceleratedVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post Employment Benefit, Accelerated Vesting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PostEmploymentBenefitAcceleratedVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post Employment Benefits, Legal Fees Reimbursement Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eigr_FormerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eigr_FormerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=eigr_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=eigr_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>eigr-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:eigr="http://www.eigerbio.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eigr-20221231.xsd" xlink:type="simple"/>
    <context id="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d807711b4f64b30a7b7788c5e328d70_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5b0214e5e20a40479ca62fa1f0e66c24_I20230313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="i38d8baf64e8f40a288b32a28a3c7522d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i965b044302dc48988da35b57cfb58274_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide6769059acf419584a1d5e087c7d813_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabac5190f6fd4b358ed63396e06def66_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iecd62fc9b3a24432b3e2aae65a93e3a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id179859417824997b40e168360961323_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2dec7376c9ed41ca8bc576d43df8f8c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib76f8832abac4cfea3d3116b0eeedbe1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b2d5cecd217418582eec551acd8d836_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia386820e405b4bf383170b67729d1511_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8cfaed52a2d473ab12f3b5530650c41_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i380647f21fbb4f4b88a32a72fa283b95_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i99f3f456db4f4a55a3d22861cea918c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49673d67a34044e3a750f2b9178048a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c1713a9ff0046649a86f61420a19003_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8b36575981b4572bcb7ca1dc5769835_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i430636db1f0f42f2ac9906c42783a48f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5569a83205404b1ab3e0541a2035e937_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd0e307c2eab47c5a18cefb7aad66078_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5bbf3a04c3844a28b4b670e4ceca7a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac7b5637f1bc435fbeb01ba1c65e4e8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ad1535391c54ca0a4cf8079da469538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i607fa35bf31f4c78b9dd13096251e2ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74ea87a513d646d09871aebfe33508a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f351ad36ff44a06a963475dcfb18d78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec887a30f3da48368433567628e641f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63379744fdd040ef8ba43ddec4a1793c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf88f13c190f43639edfd10e3b5f87b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic47d708618bb4821bc17b74b8bd55ef1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6a49e4c035a341fba613eb1be522b4a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i284faebef99d43ad8a30a1beac1378bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78b0e05eb8a74058b915db9040827fd8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42d24ef6e4884de5be511fe91960c05c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1651d333e874061b4abfcd49f5976e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c0ff92a272442afaa01f8a3b8e72b36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i243c690d5ce3462c865847425d9c4b48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie052ceb522c94669817dae862de6dd4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44e1792926524fcb95997fa9f9ef3f47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i606a6b3724044b869c02652034594518_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibfcec53252b04308b81a3cceadbdd73f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">eigr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia328cb20d25e4fab95b8005fa9861f94_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55f52fce331b4f66a6e112c7e3be3f98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i822a4e7e22674f7bbb06ac44f94c3932_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0d8abc424bd4f599a92cdb29f6579f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20f285951c75439fabaef052cce22e5c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9b8e4b3a3c1f4746a43ddffd760f8621_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6001d47ec21d4e1eb84a3b4279669161_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:AutorisationTemporaireDUtlisationMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i394cd5e381054e4889a9aad84ab79747_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d5d0c2a8148487aa4d0984dc7e1f99a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0ac15c5f9d74de499a4fe9278a01e7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9f5cc5d592e405dbec8dfa432ab7e43_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ca1a86dbf584c8a9e5686d5ab7063c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ffc44f911d84c7e8b5688da7a44b998_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b5485fa3aad4734a238db7b097d944e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib58d979ab27f4989884fc5e44ee5ba47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ad646a38b894ce5a9b00244c2be3b71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idca3d92946644292bfe24473fcc4be04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29e2e430ce08456580668540fb412dad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i723c7034a80843358bb376fffac512d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i046e24627cb54f7189bede6e1170857e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i552f64c943e64319a4ce95e39943680e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iceddcfeabe854c64be9f9598bcbb3de0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfe8063b179f430aa2aa6b702e9b306c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9eef20e8a0334e0ba1d0d3ca4318cddf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5ec97ca82ce4eaab0fe2d816a068638_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4afe7b4dbf6b4c01a3a293ce9ee8ddf9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6dda2ffdbb7449b99003a29733a4d967_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3710956fd50341c98bf6174e70730c41_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i564ce4de58c74e4b8c4230bf90320a01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcbf0466704049dab4b0a5022b8f1e03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97feebbd9cc94ec48c7937f8f4950348_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7631982a357a40a69c633f5518769a9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib532a65e081b47d0a19d3b35f518a757_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ab1c22a221540b9a784d77e13b63afd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedcaac54148842f482fb9f6ab25e2ed3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ecf5e8208174b24a163cd9c86a1f6a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i230066a3071c4132b69848eae00a92eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36a17f8d193244e19ada1c34fd6361e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i232fe125fe24498fa3256c6f183ee314_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i968a09cb75864d2bbf238de4188016c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cd42c9f677f475ba44a739bbcb8d569_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83c955bd8cca416686ce21b475131066_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee904f5f9d1a470abe8bd130514c72f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c9339f160d84eebbc7070bc3bddd479_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1af0f8a55164e0eb8dcc387d8ee162c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib672ffc131c141c89ec35e1cdc6d0888_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib149a8ec14b946089462bf96a8cb0335_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d031ec06fa747218f0529c0d926de3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70fa2af8a8064c0b96426610b6658882_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fa03a6d5dbf4539a01f114da77c480a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id78913e7ab2e4303a5543c869a3218e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6eb2b8528634735a6af7527a73a9128_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c4688b49a6540e98c724acb8b04a2ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2171cc598bbc4faa9d1dfb89113cc454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0faa0526436449a8d5aedef9fe5142d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5464846d99ce4aafbbb96b5563f1dc1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62a60c80d69a4de39ff38d8b55aef975_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide1b1828296e40aeb62b7b75b1921d5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26381ba35f554000928e20baa54aaf82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6182cf377fb42d5b55072fb1f5fcc4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5e14c606c1641bb863e16722c0cbc4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4960562ae1a43d5a1836ee70a2a0ced_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia72e03af8e4d4e029c34f04f781a6afe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia401dca885444fa3b7a5f036bf820425_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia921678878f04db6adbca4595688a360_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0af19da2c6184c899e48459eaf368c09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6a349046f334530a41f51eebfe060e1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice98876375a746198c11b6156223c890_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i40856ef0109745e6bca5398e2deb59e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i806febb1a3f14a009905147c299141c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-11</startDate>
            <endDate>2018-08-11</endDate>
        </period>
    </context>
    <context id="ic8e9958c1f874287a316e0d40a1ee557_I20180811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-11</instant>
        </period>
    </context>
    <context id="i215c0c22884741439373b4bb5cf353ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie01aaeb68a154d89b511aa445e1f10c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib38883ca632644fd93eb6fb8b5632ec4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1093f397da6f4ccbaa4327f49cc99f6b_D20180515-20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="i26693b4f07bb413dbe7693e3a8733d02_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="i312ccf68285749298fc9eaba96fdb15e_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="if8b0cb8cbbf34f3a92bae7940e633560_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="i98b448fdcc72493fa8f472a5547e9c5e_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="i522fba7c7f6b4899a22248daae63fdef_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="i53c796ad9f4d4cd8b485cdc08c8eea06_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">eigr:BMSTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a015d0ea8614264a0d243ef6aad2068_I20100930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-09-30</instant>
        </period>
    </context>
    <context id="i6b02f365ff984634a4f599eb3ff0b476_D20100901-20100930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-09-01</startDate>
            <endDate>2010-09-30</endDate>
        </period>
    </context>
    <context id="i31cc6fec54de49cbaac8df50f262c636_D20180515-20180515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="ia0a31c2673294cd7a5b85a7f0ceb46ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i424ffec162f345b6805146b3e1859078_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i4a1f282e249c451586adac7467c9a9ae_D20101201-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i121466ae35884ba0b24b9f6d9978e273_I20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-12-31</instant>
        </period>
    </context>
    <context id="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i070111655a2d458abdc58cce6fdf5362_I20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="i2ff02c15b30e423587839d54ad95f618_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i78240c9a110c474c969a366314c34f1a_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i9da09837945d43e4865652c607fde425_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i1d316f19952e4069af11841afd2c9639_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="iba57b158870e40fdb866d4b2678df531_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i6368f25382834801a6682e48b0981e29_D20160322-20160322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-22</startDate>
            <endDate>2016-03-22</endDate>
        </period>
    </context>
    <context id="i53e59300f06d44a9b0494eb5cc7fed9c_I20160322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-22</instant>
        </period>
    </context>
    <context id="i290212954c99401aae042a9ef1f88723_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6901de3d60ff4db1916a73b9d096e7a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9b1a8da043d451197ac210c2a30510d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a5c0da13bd14c669d92be3294f92711_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i8114b95ec2a24e868a25140a3f0158b2_D20201120-20201120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-20</startDate>
            <endDate>2020-11-20</endDate>
        </period>
    </context>
    <context id="i2f59d99d10d04de492abcac7063c4d9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ib87cb0850d4c413db472e1cfa4e0516f_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="id8ab44b29d644c6e854e9000bd3ea4dd_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i5efa461c8d184d5bbf8fae9a20d47978_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="if57d9437106f448c83d0afbcf0114df9_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i812e7a0b79e5490fbf8cc0469a5ce008_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib19f9a06b61e4ddfa40008408ebc9e74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0abd73b32db44aca977bb76f57865f5_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">eigr:TheragenePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">eigr:MYDICARMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib4a7a59d419a456a86819f0db13f903a_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="ia94b90e55cdc4829a94a8b1e45fbba04_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eigr:VariableRateComponentAxis">eigr:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i9713023dded64c8ea5adac4bda00c7e2_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eigr:VariableRateComponentAxis">eigr:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="if6f055c598d7454da7696030a389cafe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i98c422a139a345809437127a7479b57a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBAndCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3899d90a98f843c28f7608b176abbecb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2913f5ce26fd4b958098cf5381ee746d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac8c23ec655449c28e8237fc61998863_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24dada1a3b5242b5a75afa813589f088_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i788faa633fdf42068abaa39dc2edf9d3_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:InnovatusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i16fb4c62472c449a9b7982be7439e638_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:InnovatusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i53c72d39d32d498788a5ca7d700ec4e8_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i92c6b12ce519418c8440d547c323d70f_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i19d31eefba974ecf8d96ae66cc576d69_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="id8ef2a5a94d44cb39fe45dcedfee9769_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i442e61d07b494a89af46c51bf3c39c99_I20180803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-03</instant>
        </period>
    </context>
    <context id="i10d5cb28ee524a039c68d61469c0487f_I20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-05</instant>
        </period>
    </context>
    <context id="i87edad638cf242f0a34985f29b06a8ed_D20190305-20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-05</startDate>
            <endDate>2019-03-05</endDate>
        </period>
    </context>
    <context id="i43c59ab4e6cc45cab9946e312f152846_I20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-05</instant>
        </period>
    </context>
    <context id="i676ed4dafff44a7db6aea95716fda14c_I20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-05</instant>
        </period>
    </context>
    <context id="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanFifthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-23</startDate>
            <endDate>2021-02-23</endDate>
        </period>
    </context>
    <context id="i054ac64c0a9a48f39f0672426b1763f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="ifed09a12b16a48eca75c2639c1883cb0_D20211006-20211006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="i062780bfd6314b9aa885ba2d25702a18_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i911bf9268d42447e85041ca1379f6928_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i9d011b31a4674517a07eb189e6e48b8a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:SecuredDebtAmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e876d14531242919ba3e7c51a9f6620_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:InnovatusLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13530243d7b34f1c827b988b0901189a_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3b089476acf40c8a5b5c34b133005bc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2cd0a96271fe4fe19e51825f3a419589_D20220331-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ff52c712c8d4b55877e2745e77f4a16_D20220325-20220325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="i8b3390cbd84f4e9b830a1dae02e73f6d_D20220325-20220325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-25</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="iedce0e0e2285449bb203fa52f3e4b81a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1ec4a30b09349279833954d224dead9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a28c62f12bf4413a513b312483af157_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eigr:HoldersOfTenPercentOrMoreOfVotingPowerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id7aafa6247ea4c65a7c5873f86ff4fd6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09207d695d8c4253a8e427f8c6d035d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4028eb882514f05b6a41d5478817cee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief5a5c4c1ae64fc4ab9b4e7b4056be2a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:InducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie2dd632aefc143bb8b84aea6a35fcbaf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:InducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73059116eb97484196f938499f7d5281_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ec04d4ad35c443b99bbe1aa326e6d2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c049d0b7ef5404389a868b354fa749a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaac2aed31bb54cc18cb6ae41a4a4024c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71407d30e650431da3d0986454f2222a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09b3e189eaf243f4af6da3f36cd256b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i51aa14a7322841a28eb8b15ffc596162_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79074ea06073434787ed7105b645d332_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic09b60b6370048899551663b184c6f48_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icdaee817ecba4432b442ecd4baec5196_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5e793187f544593b74da04cabc2339b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if03ebee97bdd465fb594bd07b6658cd6_I20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="i94322c77d52a4ebc957caaa8538856a0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if1c1d057c3104eb38128ca6d2e56cc34_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib0d49d00344d4c8d9255a8ab257ddb21_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i50b559f643dc4ebe82779e55c0713860_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:PerformanceStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4545b7ea67d340b68656d572237dd471_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:PerformanceStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia26ed6605602415ead8fa34aa2933308_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea5fd9f65a07451c9c163efc7530542c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96530fc320b84544b9696cf29d5efa21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:PerformanceStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4234b3566e684a2bbc69705bd15492d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78457377acd944119ee3cbc487a296cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77186ca2509745eb8c68fb8c32e77418_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i891dd7eeeb804b7180c764a60670443b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bf58d38de1c412a9467e8c815412e01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8e0daa1d8724811b59a7c133d069b57_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea11b6251f7c49fbab31dbf60503d7f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d45e0236dca466d80b365de652362f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10c618b5c7b3487e9779d512b4de6cb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6193b2da2c0048398fdfab50bdd10c98_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b1c32c7c8074780b2a2e9572bb98ea4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i038017cc1aff4f5b802f302a04651e70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3f6e0f47b76477398971584c280e787_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">eigr:OrphanDrugCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefd9ad44e31d4bb09abdd6c03737db5d_I20221108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="ie6112fe6606643398b7e891f4e07a185_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i88df8041ee074c629e1deb74604adbcd_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i9e22fa7313ce40ddbecce4a6177c2baf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54e4723198e54d37b6163a5733e2bfed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bd59ee561b343dab5061b07e80ba9b4_I20230206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="i2f726335e506438cbf098a44665c4473_D20230206-20230206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="i8892b34c54854c50ad3eda9fa1852d3d_I20230206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="i4934175f59ca42c484533a305704b3c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eigr:FormerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1325efe242c2485cb3654887aef1a15d_I20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="id907190c69db4635b5b4ed706d83cdfe_I20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">eigr:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>eigr:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="account">
        <measure>eigr:account</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-36">0001305253</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-37">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i10c618b5c7b3487e9779d512b4de6cb1_D20220101-20221231"
      id="f-888">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6193b2da2c0048398fdfab50bdd10c98_D20210101-20211231"
      id="f-889">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <dei:DocumentType
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-3">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-6">001-36183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-7">Eiger BioPharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-9">33-0971591</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-10">2155 Park Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-11">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-13">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-14">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-15">272 6138</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-17">EIGR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i5d807711b4f64b30a7b7788c5e328d70_I20220630"
      decimals="0"
      id="f-28"
      unitRef="usd">274107513</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5b0214e5e20a40479ca62fa1f0e66c24_I20230313"
      decimals="INF"
      id="f-29"
      unitRef="shares">44158437</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-30">&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Part III incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2023 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#x2019;s fiscal year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-31">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-32">San Francisco, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-33">185</dei:AuditorFirmId>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-38"
      unitRef="shares">6143183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231"
      decimals="0"
      id="f-39"
      unitRef="shares">641407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-40"
      unitRef="shares">1976460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i965b044302dc48988da35b57cfb58274_I20221231"
      decimals="0"
      id="f-41"
      unitRef="shares">788057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-42"
      unitRef="usd">25798000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-43"
      unitRef="usd">22221000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-44"
      unitRef="usd">73150000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-45"
      unitRef="usd">66594000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-46"
      unitRef="usd">1749000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-47"
      unitRef="usd">2576000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-48"
      unitRef="usd">2853000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-49"
      unitRef="usd">2612000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-50"
      unitRef="usd">13985000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-51"
      unitRef="usd">9361000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-52"
      unitRef="usd">117535000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-53"
      unitRef="usd">103364000</us-gaap:AssetsCurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-54"
      unitRef="usd">0</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesNoncurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-55"
      unitRef="usd">17262000</us-gaap:DebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-56"
      unitRef="usd">696000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-57"
      unitRef="usd">613000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-58"
      unitRef="usd">561000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-59"
      unitRef="usd">653000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-60"
      unitRef="usd">1347000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-61"
      unitRef="usd">4510000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-62"
      unitRef="usd">120139000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-63"
      unitRef="usd">126402000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-64"
      unitRef="usd">8975000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-65"
      unitRef="usd">7765000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-66"
      unitRef="usd">15655000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-67"
      unitRef="usd">13699000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-68"
      unitRef="usd">491000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-69"
      unitRef="usd">628000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-70"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-71"
      unitRef="usd">7809000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-72"
      unitRef="usd">25121000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-73"
      unitRef="usd">29901000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-74"
      unitRef="usd">39625000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-75"
      unitRef="usd">23986000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-76"
      unitRef="usd">83000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-77"
      unitRef="usd">116000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-78"
      unitRef="usd">64829000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-79"
      unitRef="usd">54003000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-82"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-83"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-84"
      unitRef="shares">44074284</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-85"
      unitRef="shares">44074284</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-86"
      unitRef="shares">34568821</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-87"
      unitRef="shares">34568821</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-88"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-89"
      unitRef="usd">35000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-90"
      unitRef="usd">492759000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-91"
      unitRef="usd">412930000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-92"
      unitRef="usd">-300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-93"
      unitRef="usd">-149000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-94"
      unitRef="usd">-437193000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-95"
      unitRef="usd">-340417000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-96"
      unitRef="usd">55310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-97"
      unitRef="usd">72399000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-98"
      unitRef="usd">120139000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-99"
      unitRef="usd">126402000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="iabac5190f6fd4b358ed63396e06def66_D20220101-20221231"
      decimals="-3"
      id="f-100"
      unitRef="usd">12734000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecd62fc9b3a24432b3e2aae65a93e3a7_D20210101-20211231"
      decimals="-3"
      id="f-101"
      unitRef="usd">12142000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id179859417824997b40e168360961323_D20200101-20201231"
      decimals="-3"
      id="f-102"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dec7376c9ed41ca8bc576d43df8f8c3_D20220101-20221231"
      decimals="-3"
      id="f-103"
      unitRef="usd">750000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib76f8832abac4cfea3d3116b0eeedbe1_D20210101-20211231"
      decimals="-3"
      id="f-104"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b2d5cecd217418582eec551acd8d836_D20200101-20201231"
      decimals="-3"
      id="f-105"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-106"
      unitRef="usd">13484000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-107"
      unitRef="usd">12142000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-108"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-109"
      unitRef="usd">1837000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-110"
      unitRef="usd">745000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-111"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-112"
      unitRef="usd">75282000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-113"
      unitRef="usd">64436000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-114"
      unitRef="usd">41590000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-115"
      unitRef="usd">29105000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-116"
      unitRef="usd">23900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-117"
      unitRef="usd">20559000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-118"
      unitRef="usd">106224000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-119"
      unitRef="usd">89081000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-120"
      unitRef="usd">62149000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-121"
      unitRef="usd">-92740000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-122"
      unitRef="usd">-76939000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-123"
      unitRef="usd">-62149000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-124"
      unitRef="usd">4132000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-125"
      unitRef="usd">3559000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-126"
      unitRef="usd">3594000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-127"
      unitRef="usd">1082000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-128"
      unitRef="usd">158000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-129"
      unitRef="usd">704000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-130"
      unitRef="usd">-963000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-131"
      unitRef="usd">46487000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-132"
      unitRef="usd">-12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-133"
      unitRef="usd">-96753000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-134"
      unitRef="usd">-33853000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-135"
      unitRef="usd">-65051000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-136"
      unitRef="usd">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-137"
      unitRef="usd">64000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-138"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-139"
      unitRef="usd">-96776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-140"
      unitRef="usd">-33917000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-141"
      unitRef="usd">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="2"
      id="f-144"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-2.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="0"
      id="f-148"
      unitRef="shares">41628207</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="0"
      id="f-149"
      unitRef="shares">41628207</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="0"
      id="f-150"
      unitRef="shares">33944342</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="0"
      id="f-151"
      unitRef="shares">33944342</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="0"
      id="f-152"
      unitRef="shares">28143391</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="0"
      id="f-153"
      unitRef="shares">28143391</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-154"
      unitRef="usd">-96776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-155"
      unitRef="usd">-33917000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-156"
      unitRef="usd">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-157"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-158"
      unitRef="usd">-141000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-159"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-160"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-161"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-162"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-163"
      unitRef="usd">-96927000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-164"
      unitRef="usd">-34058000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-165"
      unitRef="usd">-65101000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic8cfaed52a2d473ab12f3b5530650c41_I20191231"
      decimals="INF"
      id="f-166"
      unitRef="shares">24523381</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic8cfaed52a2d473ab12f3b5530650c41_I20191231"
      decimals="-3"
      id="f-167"
      unitRef="usd">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i380647f21fbb4f4b88a32a72fa283b95_I20191231"
      decimals="-3"
      id="f-168"
      unitRef="usd">297863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99f3f456db4f4a55a3d22861cea918c2_I20191231"
      decimals="-3"
      id="f-169"
      unitRef="usd">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49673d67a34044e3a750f2b9178048a1_I20191231"
      decimals="-3"
      id="f-170"
      unitRef="usd">-241449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c1713a9ff0046649a86f61420a19003_I20191231"
      decimals="-3"
      id="f-171"
      unitRef="usd">56480000</us-gaap:StockholdersEquity>
    <eigr:StockIssuanceCosts
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-172"
      unitRef="usd">3231000</eigr:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231"
      decimals="INF"
      id="f-173"
      unitRef="shares">9267760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231"
      decimals="-3"
      id="f-174"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"
      decimals="-3"
      id="f-175"
      unitRef="usd">96750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-176"
      unitRef="usd">96760000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231"
      decimals="INF"
      id="f-177"
      unitRef="shares">25645</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"
      decimals="-3"
      id="f-178"
      unitRef="usd">186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-179"
      unitRef="usd">186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231"
      decimals="INF"
      id="f-180"
      unitRef="shares">61700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"
      decimals="-3"
      id="f-181"
      unitRef="usd">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-182"
      unitRef="usd">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"
      decimals="-3"
      id="f-183"
      unitRef="usd">217000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-184"
      unitRef="usd">217000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"
      decimals="-3"
      id="f-185"
      unitRef="usd">5973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-186"
      unitRef="usd">5973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if8b36575981b4572bcb7ca1dc5769835_D20200101-20201231"
      decimals="-3"
      id="f-187"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-188"
      unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i430636db1f0f42f2ac9906c42783a48f_D20200101-20201231"
      decimals="-3"
      id="f-189"
      unitRef="usd">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-190"
      unitRef="usd">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5569a83205404b1ab3e0541a2035e937_I20201231"
      decimals="INF"
      id="f-191"
      unitRef="shares">33878486</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5569a83205404b1ab3e0541a2035e937_I20201231"
      decimals="-3"
      id="f-192"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd0e307c2eab47c5a18cefb7aad66078_I20201231"
      decimals="-3"
      id="f-193"
      unitRef="usd">401509000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if5bbf3a04c3844a28b4b670e4ceca7a1_I20201231"
      decimals="-3"
      id="f-194"
      unitRef="usd">-8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac7b5637f1bc435fbeb01ba1c65e4e8b_I20201231"
      decimals="-3"
      id="f-195"
      unitRef="usd">-306500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231"
      decimals="-3"
      id="f-196"
      unitRef="usd">95035000</us-gaap:StockholdersEquity>
    <eigr:StockIssuanceCosts
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-197"
      unitRef="usd">417000</eigr:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"
      decimals="INF"
      id="f-198"
      unitRef="shares">565938</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"
      decimals="-3"
      id="f-199"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"
      decimals="-3"
      id="f-200"
      unitRef="usd">2684000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-201"
      unitRef="usd">2685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"
      decimals="INF"
      id="f-202"
      unitRef="shares">37619</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"
      decimals="-3"
      id="f-203"
      unitRef="usd">257000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-204"
      unitRef="usd">257000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"
      decimals="INF"
      id="f-205"
      unitRef="shares">53028</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"
      decimals="-3"
      id="f-206"
      unitRef="usd">361000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-207"
      unitRef="usd">361000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"
      decimals="INF"
      id="f-208"
      unitRef="shares">33750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-209"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"
      decimals="-3"
      id="f-210"
      unitRef="usd">218000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-211"
      unitRef="usd">218000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"
      decimals="-3"
      id="f-212"
      unitRef="usd">7901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-213"
      unitRef="usd">7901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i607fa35bf31f4c78b9dd13096251e2ce_D20210101-20211231"
      decimals="-3"
      id="f-214"
      unitRef="usd">-141000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-215"
      unitRef="usd">-141000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i74ea87a513d646d09871aebfe33508a1_D20210101-20211231"
      decimals="-3"
      id="f-216"
      unitRef="usd">-33917000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-217"
      unitRef="usd">-33917000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7f351ad36ff44a06a963475dcfb18d78_I20211231"
      decimals="INF"
      id="f-218"
      unitRef="shares">34568821</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7f351ad36ff44a06a963475dcfb18d78_I20211231"
      decimals="-3"
      id="f-219"
      unitRef="usd">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec887a30f3da48368433567628e641f8_I20211231"
      decimals="-3"
      id="f-220"
      unitRef="usd">412930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63379744fdd040ef8ba43ddec4a1793c_I20211231"
      decimals="-3"
      id="f-221"
      unitRef="usd">-149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf88f13c190f43639edfd10e3b5f87b8_I20211231"
      decimals="-3"
      id="f-222"
      unitRef="usd">-340417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-223"
      unitRef="usd">72399000</us-gaap:StockholdersEquity>
    <eigr:StockIssuanceCosts
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-224"
      unitRef="usd">2068000</eigr:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="INF"
      id="f-225"
      unitRef="shares">8528074</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="-3"
      id="f-226"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"
      decimals="-3"
      id="f-227"
      unitRef="usd">66102000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-228"
      unitRef="usd">66110000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="INF"
      id="f-229"
      unitRef="shares">47367</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"
      decimals="-3"
      id="f-230"
      unitRef="usd">234000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-231"
      unitRef="usd">234000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eigr:StockIssuedDuringPeriodSharesStockIssuedToLender
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="INF"
      id="f-232"
      unitRef="shares">749053</eigr:StockIssuedDuringPeriodSharesStockIssuedToLender>
    <eigr:StockIssuedDuringPeriodValueStockIssuedToLender
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="-3"
      id="f-233"
      unitRef="usd">1000</eigr:StockIssuedDuringPeriodValueStockIssuedToLender>
    <eigr:StockIssuedDuringPeriodValueStockIssuedToLender
      contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"
      decimals="-3"
      id="f-234"
      unitRef="usd">4999000</eigr:StockIssuedDuringPeriodValueStockIssuedToLender>
    <eigr:StockIssuedDuringPeriodValueStockIssuedToLender
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-235"
      unitRef="usd">5000000</eigr:StockIssuedDuringPeriodValueStockIssuedToLender>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"
      decimals="-3"
      id="f-236"
      unitRef="usd">19000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-237"
      unitRef="usd">19000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="INF"
      id="f-238"
      unitRef="shares">48115</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"
      decimals="-3"
      id="f-239"
      unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-240"
      unitRef="usd">158000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="INF"
      id="f-241"
      unitRef="shares">132854</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-242"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e2095c2f0bc403dacd40a193fc687a9_D20220101-20221231"
      decimals="-3"
      id="f-243"
      unitRef="usd">8317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-244"
      unitRef="usd">8317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic47d708618bb4821bc17b74b8bd55ef1_D20220101-20221231"
      decimals="-3"
      id="f-245"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-246"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic47d708618bb4821bc17b74b8bd55ef1_D20220101-20221231"
      decimals="-3"
      id="f-247"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-248"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i6a49e4c035a341fba613eb1be522b4a3_D20220101-20221231"
      decimals="-3"
      id="f-249"
      unitRef="usd">-96776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-250"
      unitRef="usd">-96776000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i284faebef99d43ad8a30a1beac1378bb_I20221231"
      decimals="INF"
      id="f-251"
      unitRef="shares">44074284</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i284faebef99d43ad8a30a1beac1378bb_I20221231"
      decimals="-3"
      id="f-252"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78b0e05eb8a74058b915db9040827fd8_I20221231"
      decimals="-3"
      id="f-253"
      unitRef="usd">492759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42d24ef6e4884de5be511fe91960c05c_I20221231"
      decimals="-3"
      id="f-254"
      unitRef="usd">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1651d333e874061b4abfcd49f5976e4_I20221231"
      decimals="-3"
      id="f-255"
      unitRef="usd">-437193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-256"
      unitRef="usd">55310000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-257"
      unitRef="usd">-96776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-258"
      unitRef="usd">-33917000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-259"
      unitRef="usd">-65051000</us-gaap:NetIncomeLoss>
    <eigr:GainLossFromSaleOfPriorityReviewVoucher
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-260"
      unitRef="usd">0</eigr:GainLossFromSaleOfPriorityReviewVoucher>
    <eigr:GainLossFromSaleOfPriorityReviewVoucher
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-261"
      unitRef="usd">46493000</eigr:GainLossFromSaleOfPriorityReviewVoucher>
    <eigr:GainLossFromSaleOfPriorityReviewVoucher
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-262"
      unitRef="usd">0</eigr:GainLossFromSaleOfPriorityReviewVoucher>
    <eigr:IncomeLossRelatedToAssetPurchaseAgreement
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-263"
      unitRef="usd">0</eigr:IncomeLossRelatedToAssetPurchaseAgreement>
    <eigr:IncomeLossRelatedToAssetPurchaseAgreement
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-264"
      unitRef="usd">281000</eigr:IncomeLossRelatedToAssetPurchaseAgreement>
    <eigr:IncomeLossRelatedToAssetPurchaseAgreement
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-265"
      unitRef="usd">0</eigr:IncomeLossRelatedToAssetPurchaseAgreement>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-266"
      unitRef="usd">292000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-267"
      unitRef="usd">276000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-268"
      unitRef="usd">167000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InventoryWriteDown
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-269"
      unitRef="usd">1043000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-270"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-271"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-272"
      unitRef="usd">-682000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-273"
      unitRef="usd">-996000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-274"
      unitRef="usd">-124000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-275"
      unitRef="usd">-1144000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-276"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-277"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-278"
      unitRef="usd">1238000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-279"
      unitRef="usd">776000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-280"
      unitRef="usd">804000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-281"
      unitRef="usd">550000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-282"
      unitRef="usd">523000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-283"
      unitRef="usd">478000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-284"
      unitRef="usd">19000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-285"
      unitRef="usd">218000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-286"
      unitRef="usd">217000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-287"
      unitRef="usd">8317000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-288"
      unitRef="usd">7901000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-289"
      unitRef="usd">5973000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-290"
      unitRef="usd">-828000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-291"
      unitRef="usd">2576000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-292"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-293"
      unitRef="usd">1367000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-294"
      unitRef="usd">2424000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-295"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-296"
      unitRef="usd">196000</eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-297"
      unitRef="usd">701000</eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-298"
      unitRef="usd">3563000</eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-299"
      unitRef="usd">1265000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-300"
      unitRef="usd">607000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-301"
      unitRef="usd">1392000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-302"
      unitRef="usd">1152000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-303"
      unitRef="usd">3234000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-304"
      unitRef="usd">-1899000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-305"
      unitRef="usd">1957000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-306"
      unitRef="usd">2309000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-307"
      unitRef="usd">1491000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <eigr:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-308"
      unitRef="usd">-628000</eigr:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eigr:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-309"
      unitRef="usd">-576000</eigr:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eigr:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-310"
      unitRef="usd">-534000</eigr:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-311"
      unitRef="usd">-83010000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-312"
      unitRef="usd">-71342000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-313"
      unitRef="usd">-63185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-314"
      unitRef="usd">75101000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-315"
      unitRef="usd">84647000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-316"
      unitRef="usd">128295000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-317"
      unitRef="usd">85073000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-318"
      unitRef="usd">99630000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-319"
      unitRef="usd">83766000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <eigr:ProceedsRelatedToAssetPurchaseAgreement
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-320"
      unitRef="usd">0</eigr:ProceedsRelatedToAssetPurchaseAgreement>
    <eigr:ProceedsRelatedToAssetPurchaseAgreement
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-321"
      unitRef="usd">281000</eigr:ProceedsRelatedToAssetPurchaseAgreement>
    <eigr:ProceedsRelatedToAssetPurchaseAgreement
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-322"
      unitRef="usd">0</eigr:ProceedsRelatedToAssetPurchaseAgreement>
    <eigr:ProceedsFromSaleOfPriorityReviewVoucher
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-323"
      unitRef="usd">0</eigr:ProceedsFromSaleOfPriorityReviewVoucher>
    <eigr:ProceedsFromSaleOfPriorityReviewVoucher
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-324"
      unitRef="usd">95000000</eigr:ProceedsFromSaleOfPriorityReviewVoucher>
    <eigr:ProceedsFromSaleOfPriorityReviewVoucher
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-325"
      unitRef="usd">0</eigr:ProceedsFromSaleOfPriorityReviewVoucher>
    <eigr:PaymentsRelatedToPriorityReviewVoucher
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-326"
      unitRef="usd">0</eigr:PaymentsRelatedToPriorityReviewVoucher>
    <eigr:PaymentsRelatedToPriorityReviewVoucher
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-327"
      unitRef="usd">48507000</eigr:PaymentsRelatedToPriorityReviewVoucher>
    <eigr:PaymentsRelatedToPriorityReviewVoucher
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-328"
      unitRef="usd">0</eigr:PaymentsRelatedToPriorityReviewVoucher>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-329"
      unitRef="usd">340000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-330"
      unitRef="usd">225000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-331"
      unitRef="usd">258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-332"
      unitRef="usd">9632000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-333"
      unitRef="usd">61532000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-334"
      unitRef="usd">-44787000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-335"
      unitRef="usd">66402000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-336"
      unitRef="usd">3040000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-337"
      unitRef="usd">96779000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-338"
      unitRef="usd">5000000</eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt>
    <eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-339"
      unitRef="usd">0</eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt>
    <eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-340"
      unitRef="usd">0</eigr:ProceedsFromIssuanceOfCommonStockInConnectionWithDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-341"
      unitRef="usd">39841000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-342"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-343"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-344"
      unitRef="usd">33277000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-345"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-346"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-347"
      unitRef="usd">234000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-348"
      unitRef="usd">361000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-349"
      unitRef="usd">520000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-350"
      unitRef="usd">157000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-351"
      unitRef="usd">257000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-352"
      unitRef="usd">186000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-353"
      unitRef="usd">1116000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-354"
      unitRef="usd">175000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-355"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-356"
      unitRef="usd">286000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-357"
      unitRef="usd">316000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-358"
      unitRef="usd">22000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-359"
      unitRef="usd">76955000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-360"
      unitRef="usd">3167000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-361"
      unitRef="usd">97463000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-362"
      unitRef="usd">3577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-363"
      unitRef="usd">-6643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-364"
      unitRef="usd">-10509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-365"
      unitRef="usd">22221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231"
      decimals="-3"
      id="f-366"
      unitRef="usd">28864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8c1713a9ff0046649a86f61420a19003_I20191231"
      decimals="-3"
      id="f-367"
      unitRef="usd">39373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-368"
      unitRef="usd">25798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-369"
      unitRef="usd">22221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231"
      decimals="-3"
      id="f-370"
      unitRef="usd">28864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-371"
      unitRef="usd">2885000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-372"
      unitRef="usd">2783000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-373"
      unitRef="usd">2791000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-374"
      unitRef="usd">64000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-375"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-376"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-377"
      unitRef="usd">36000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-378"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-379"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <eigr:OfferingCostsIncurredNotYetPaid
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-380"
      unitRef="usd">6000</eigr:OfferingCostsIncurredNotYetPaid>
    <eigr:OfferingCostsIncurredNotYetPaid
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-381"
      unitRef="usd">0</eigr:OfferingCostsIncurredNotYetPaid>
    <eigr:OfferingCostsIncurredNotYetPaid
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-382"
      unitRef="usd">0</eigr:OfferingCostsIncurredNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-383"
      unitRef="usd">458000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-384"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-385"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-386"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-387"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-388">Description of Business&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on November&#160;6, 2008. Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV), the most severe form of viral hepatitis, and other serious diseases. All five of the Company&#x2019;s rare disease programs have been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Lonafarnib is a first-in-class, oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III, interferon.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The FDA approved the Company&#x2019;s first commercial product, Zokinvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (lonafarnib), to reduce risk of mortality of Hutchinson-Gilford progeria syndrome (HGPS) and for treatment of processing-deficient progeroid laminopathies (PL), collectively known as progeria, with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, on November 20, 2020. The Company announced that the European Commission approved its Marketing Authorization Application (MAA) for Zokinvy, under exceptional circumstances procedure on July 20, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also developing avexitide, a well-characterized peptide, as a treatment for congenital hyperinsulinism (HI), an ultra-rare pediatric metabolic disorder, and post-bariatric hypoglycemia (PBH), a debilitating and potentially life-threatening condition. There are currently no approved therapies for these disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal operations are based in Palo Alto, California, with subsidiaries in Delaware, Ireland, England and Wales. The Company operates in one segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had $98.9 million of cash, cash equivalents and short-term securities, comprised of $25.8 million of cash and cash equivalents and $73.1 million of short-term debt securities available-for-sale. The Company had an accumulated deficit of $437.2 million and negative cash flows from operating activities as of December&#160;31, 2022. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and until it does, the Company will need to continue to raise additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the currently available resources will be sufficient to fund its planned operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if the Company&#x2019;s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic, among other events.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="0"
      id="f-389"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-5"
      id="f-390"
      unitRef="usd">98900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-5"
      id="f-391"
      unitRef="usd">25800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-5"
      id="f-392"
      unitRef="usd">73100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-5"
      id="f-393"
      unitRef="usd">-437200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-394">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#x2019;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two customers accounted for approximately 58 percent and 42 percent of the Company&#x2019;s accounts receivable as of December&#160;31, 2022. One customer accounted for approximately 93 percent of product revenue during the year ended December&#160;31, 2022. Two customers accounted for approximately 66 percent and 34 percent of the Company&#x2019;s accounts receivable as of December 31, 2021. One customer accounted for approximately 94 percent of product revenue during the year ended December 31, 2021. The Company did not have accounts receivable or revenue in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transaction Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eiger BioPharmaceuticals Europe Limited&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for 2022 were $0.1 million. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at the subsidiary. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foreign currency translation risk relates to the translation of the foreign consolidated subsidiary's assets, liabilities, revenues and expenses from the subsidiary's functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the foreign subsidiary, which has a functional currency other than the U.S. dollar are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation losses, net of tax, for 2022 were $0.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. Long-term securities consist of debt securities classified as available-for-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sale and have maturities greater than 365 days from the date of acquisition. The Company&#x2019;s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of accumulated other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net on the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The useful lives of the property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of remaining lease term or 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2022, the Company has not impaired any long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent amounts billed to the Company&#x2019;s customers, net of an allowance for doubtful accounts. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The expectation of collectability is based on a review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no allowance as of December&#160;31, 2022 and 2021. The Company had no bad debt expense for the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to regulatory approval of the Company&#x2019;s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company wrote-down $1.0 million of inventories for the year ended December&#160;31, 2022. There were no write-downs in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021 and in Europe in November 2022 . Prior to 2021, the Company had no product revenue. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy (lonafarnib) through a reimbursed early access program in France. The Company recorded revenue of $0.2&#160;million from sales of product under the ATU program for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company&#x2019;s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt payment discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying consolidated balance sheets and within research and development expenses in the accompanying consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use assets and current and noncurrent lease liabilities, as applicable, in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in selling, general and administrative expenses in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing costs incurred with securing a term debt are recorded in the Company&#x2019;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#x2019;s consolidated statements of operations over the contractual life of the loan using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#x2019;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the employee&#x2019;s or director&#x2019;s requisite service period (generally the vesting period). Stock-based awards to non-employees are recorded at their fair value as of the grant date, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions for Black-Scholes option pricing model inputs. The Company accounts for forfeitures of stock-based awards when they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#x2019;s unrealized gains and losses on debt securities and foreign currency translation adjustment represent the components of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,143,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,262,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,697,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units (unvested)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,119,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,933,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,815,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company does not expect the impact of adopting this standard to be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. In October 2021, the Company amended its Oxford Loan to replace its floating interest rate with the LIBOR replacement rate (see Note 8). The Company adopted this standard when LIBOR was about to be discontinued and the adoption did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-395">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and follow the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-396">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-397">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#x2019;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c0ff92a272442afaa01f8a3b8e72b36_D20220101-20221231"
      decimals="2"
      id="f-398"
      unitRef="number">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i243c690d5ce3462c865847425d9c4b48_D20220101-20221231"
      decimals="2"
      id="f-399"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie052ceb522c94669817dae862de6dd4c_D20220101-20221231"
      decimals="2"
      id="f-400"
      unitRef="number">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i44e1792926524fcb95997fa9f9ef3f47_D20210101-20211231"
      decimals="2"
      id="f-401"
      unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i606a6b3724044b869c02652034594518_D20210101-20211231"
      decimals="2"
      id="f-402"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibfcec53252b04308b81a3cceadbdd73f_D20210101-20211231"
      decimals="2"
      id="f-403"
      unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-404">&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transaction Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foreign currency transaction risk relates to changes in exchange rates on monetary assets, liabilities, revenues and expenses held at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eiger BioPharmaceuticals Europe Limited&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Gains and losses on foreign currency transactions result primarily from monetary assets, liabilities, revenues and expenses denominated in Euro. Aggregated transaction gains for 2022 were $0.1 million. The Company expects the foreign currency gain/loss to continue to fluctuate as long as the Company continue to hold monetary assets and liabilities at the subsidiary. Market uncertainty could potentially lead to significant volatility with foreign currency exchange rates, which could result in additional foreign currency gain/loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation Risk&lt;/span&gt;&lt;/div&gt;The foreign currency translation risk relates to the translation of the foreign consolidated subsidiary's assets, liabilities, revenues and expenses from the subsidiary's functional currency to the U.S. dollar at each reporting date. Fluctuations in exchange rates may impact the amount of assets, liabilities, revenues and expenses reported on the consolidated balance sheets and consolidated statements of operations. The financial statements of the foreign subsidiary, which has a functional currency other than the U.S. dollar are translated into U.S. dollars using a current exchange rate. Gains and losses resulting from this translation are recognized as a foreign currency translation adjustment within accumulated other comprehensive loss, which is a component of stockholders' equity and comprehensive income (loss). Aggregate translation losses, net of tax, for 2022 were $0.1 million.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <eigr:OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-405"
      unitRef="usd">100000</eigr:OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-406"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-407">&lt;div style="margin-top:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-408">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. Long-term securities consist of debt securities classified as available-for-&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sale and have maturities greater than 365 days from the date of acquisition. The Company&#x2019;s debt securities consist of available-for-sale securities that are classified as Level 2 because their value is based on valuations using significant inputs derived from, or corroborated by, observable market data. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of accumulated other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other (expense) income, net on the accompanying consolidated statements of operations.&lt;/span&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-409">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The useful lives of the property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of remaining lease term or 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-410">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The useful lives of the property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of remaining lease term or 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia328cb20d25e4fab95b8005fa9861f94_D20220101-20221231"
      id="f-411">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i55f52fce331b4f66a6e112c7e3be3f98_D20220101-20221231"
      id="f-412">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i822a4e7e22674f7bbb06ac44f94c3932_D20220101-20221231"
      id="f-413">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id0d8abc424bd4f599a92cdb29f6579f8_D20220101-20221231"
      id="f-414">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-415">Impairment of Long-Lived AssetsThe Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-416"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-417">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent amounts billed to the Company&#x2019;s customers, net of an allowance for doubtful accounts. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The expectation of collectability is based on a review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-418"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-419"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-420"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="INF"
      id="f-421"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-422">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process, and finished goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to regulatory approval of the Company&#x2019;s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.&lt;/span&gt;&lt;/div&gt;The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-423"
      unitRef="usd">1000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="INF"
      id="f-424"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="INF"
      id="f-425"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-426">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021 and in Europe in November 2022 . Prior to 2021, the Company had no product revenue. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy (lonafarnib) through a reimbursed early access program in France. The Company recorded revenue of $0.2&#160;million from sales of product under the ATU program for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes product revenue when a customer obtains control of its product, which occurs at a point in time, typically upon delivery to a customer as the delivery of the product is the Company&#x2019;s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s product is subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt payment discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides a discount to a customer if it pays for purchases within 30 days. The Company expects that its customers will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and records these discounts as a reduction of accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s other revenue consists of milestone payments from the Marketing and Distribution Agreement (MDA) with AnGes, Inc., which was executed in May 2022. The agreement provides AnGes with a right to use the Company's intellectual property (IP) and seek regulatory approval for and commercialization of Zokinvy in Japan. The Company will receive additional payments upon achievement of certain regulatory milestones.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:Revenues
      contextRef="i20f285951c75439fabaef052cce22e5c_D20210101-20210331"
      decimals="0"
      id="f-427"
      unitRef="usd">0</us-gaap:Revenues>
    <eigr:EarlyAccessProgramTerm
      contextRef="i9b8e4b3a3c1f4746a43ddffd760f8621_D20210601-20210630"
      id="f-428">P1Y</eigr:EarlyAccessProgramTerm>
    <us-gaap:Revenues
      contextRef="i6001d47ec21d4e1eb84a3b4279669161_D20220101-20221231"
      decimals="-5"
      id="f-429"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-430">Cost of SalesCost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories.</us-gaap:CostOfSalesPolicyTextBlock>
    <eigr:AccruedResearchAndDevelopmentCostsPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-431">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the accompanying consolidated balance sheets and within research and development expenses in the accompanying consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.&lt;/span&gt;&lt;/div&gt;Research and Development CostsResearch and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#x2019;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</eigr:AccruedResearchAndDevelopmentCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-432">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use assets and current and noncurrent lease liabilities, as applicable, in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in selling, general and administrative expenses in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-433">Deferred Financing CostsFinancing costs incurred with securing a term debt are recorded in the Company&#x2019;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#x2019;s consolidated statements of operations over the contractual life of the loan using the effective interest method.</us-gaap:DebtPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-434">Stock-Based CompensationStock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the employee&#x2019;s or director&#x2019;s requisite service period (generally the vesting period). Stock-based awards to non-employees are recorded at their fair value as of the grant date, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions for Black-Scholes option pricing model inputs. The Company accounts for forfeitures of stock-based awards when they occur.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-435">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-436">Comprehensive LossComprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#x2019;s unrealized gains and losses on debt securities and foreign currency translation adjustment represent the components of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-437">Net Loss per ShareBasic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-438">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,143,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,262,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,697,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units (unvested)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,119,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,933,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,815,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i394cd5e381054e4889a9aad84ab79747_D20220101-20221231"
      decimals="0"
      id="f-439"
      unitRef="shares">6143183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d5d0c2a8148487aa4d0984dc7e1f99a_D20210101-20211231"
      decimals="0"
      id="f-440"
      unitRef="shares">5262185</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie0ac15c5f9d74de499a4fe9278a01e7d_D20200101-20201231"
      decimals="0"
      id="f-441"
      unitRef="shares">3697075</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib9f5cc5d592e405dbec8dfa432ab7e43_D20220101-20221231"
      decimals="0"
      id="f-442"
      unitRef="shares">641407</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8ca1a86dbf584c8a9e5686d5ab7063c7_D20210101-20211231"
      decimals="0"
      id="f-443"
      unitRef="shares">623000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0ffc44f911d84c7e8b5688da7a44b998_D20200101-20201231"
      decimals="0"
      id="f-444"
      unitRef="shares">37500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8b5485fa3aad4734a238db7b097d944e_D20220101-20221231"
      decimals="0"
      id="f-445"
      unitRef="shares">334751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib58d979ab27f4989884fc5e44ee5ba47_D20210101-20211231"
      decimals="0"
      id="f-446"
      unitRef="shares">48159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ad646a38b894ce5a9b00244c2be3b71_D20200101-20201231"
      decimals="0"
      id="f-447"
      unitRef="shares">81169</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="0"
      id="f-448"
      unitRef="shares">7119341</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="0"
      id="f-449"
      unitRef="shares">5933344</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="0"
      id="f-450"
      unitRef="shares">3815744</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-451">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Updates (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company does not expect the impact of adopting this standard to be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. In October 2021, the Company amended its Oxford Loan to replace its floating interest rate with the LIBOR replacement rate (see Note 8). The Company adopted this standard when LIBOR was about to be discontinued and the adoption did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-452">Fair Value Measurements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). As of December&#160;31, 2022 and 2021, the carrying amount of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimated fair value due to their relatively short maturities. Management believes the terms of its long-term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company&#x2019;s debt approximated its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company&#x2019;s debt securities and commercial paper consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were no assets or liabilities classified as Level 3 as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 of the fair value hierarchy during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no financial liabilities measured at fair value on a recurring basis as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the estimated value of the Company&#x2019;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company periodically reviews the available-for-sale securities for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;other-than-temporary&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i) it is more likely &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;than n&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ot that the Company will be required to sell the debt securities before recovery of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;their&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the year ended December&#160;31, 2022, the Company did not recognize any &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;other-than-temporary&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; impairment losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;T&lt;/span&gt;he unrealized losses of $0.2 million as of December&#160;31, 2022 include debt securities with unrealized losses of $21,000 that have been in the loss position for more than 12 months. However, the Company is planning to hold these securities until maturity and expects to recover the amortized cost basis</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231"
      decimals="INF"
      id="f-453"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231"
      decimals="INF"
      id="f-454"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="idca3d92946644292bfe24473fcc4be04_I20211231"
      decimals="INF"
      id="f-455"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idca3d92946644292bfe24473fcc4be04_I20211231"
      decimals="INF"
      id="f-456"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <eigr:FairValueTransfersBetweenLevelsTransfersAmount
      contextRef="i29e2e430ce08456580668540fb412dad_D20220101-20221231"
      decimals="INF"
      id="f-457"
      unitRef="usd">0</eigr:FairValueTransfersBetweenLevelsTransfersAmount>
    <eigr:FairValueTransfersBetweenLevelsTransfersAmount
      contextRef="i723c7034a80843358bb376fffac512d9_D20210101-20211231"
      decimals="INF"
      id="f-458"
      unitRef="usd">0</eigr:FairValueTransfersBetweenLevelsTransfersAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-459">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i046e24627cb54f7189bede6e1170857e_I20221231"
      decimals="-3"
      id="f-460"
      unitRef="usd">11546000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i552f64c943e64319a4ce95e39943680e_I20221231"
      decimals="-3"
      id="f-461"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iceddcfeabe854c64be9f9598bcbb3de0_I20221231"
      decimals="-3"
      id="f-462"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icfe8063b179f430aa2aa6b702e9b306c_I20221231"
      decimals="-3"
      id="f-463"
      unitRef="usd">11546000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9eef20e8a0334e0ba1d0d3ca4318cddf_I20221231"
      decimals="-3"
      id="f-464"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5ec97ca82ce4eaab0fe2d816a068638_I20221231"
      decimals="-3"
      id="f-465"
      unitRef="usd">8913000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4afe7b4dbf6b4c01a3a293ce9ee8ddf9_I20221231"
      decimals="-3"
      id="f-466"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231"
      decimals="-3"
      id="f-467"
      unitRef="usd">8913000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3710956fd50341c98bf6174e70730c41_I20221231"
      decimals="-3"
      id="f-468"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i564ce4de58c74e4b8c4230bf90320a01_I20221231"
      decimals="-3"
      id="f-469"
      unitRef="usd">28642000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idcbf0466704049dab4b0a5022b8f1e03_I20221231"
      decimals="-3"
      id="f-470"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231"
      decimals="-3"
      id="f-471"
      unitRef="usd">28642000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7631982a357a40a69c633f5518769a9c_I20221231"
      decimals="-3"
      id="f-472"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib532a65e081b47d0a19d3b35f518a757_I20221231"
      decimals="-3"
      id="f-473"
      unitRef="usd">39563000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ab1c22a221540b9a784d77e13b63afd_I20221231"
      decimals="-3"
      id="f-474"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231"
      decimals="-3"
      id="f-475"
      unitRef="usd">39563000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7ecf5e8208174b24a163cd9c86a1f6a2_I20221231"
      decimals="-3"
      id="f-476"
      unitRef="usd">11546000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i230066a3071c4132b69848eae00a92eb_I20221231"
      decimals="-3"
      id="f-477"
      unitRef="usd">77118000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iafbbdf437b5c42dd93fbab0482b0cb2f_I20221231"
      decimals="-3"
      id="f-478"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-479"
      unitRef="usd">88664000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i36a17f8d193244e19ada1c34fd6361e5_I20211231"
      decimals="-3"
      id="f-480"
      unitRef="usd">13520000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i232fe125fe24498fa3256c6f183ee314_I20211231"
      decimals="-3"
      id="f-481"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i968a09cb75864d2bbf238de4188016c4_I20211231"
      decimals="-3"
      id="f-482"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231"
      decimals="-3"
      id="f-483"
      unitRef="usd">13520000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7cd42c9f677f475ba44a739bbcb8d569_I20211231"
      decimals="-3"
      id="f-484"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i83c955bd8cca416686ce21b475131066_I20211231"
      decimals="-3"
      id="f-485"
      unitRef="usd">41511000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee904f5f9d1a470abe8bd130514c72f9_I20211231"
      decimals="-3"
      id="f-486"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231"
      decimals="-3"
      id="f-487"
      unitRef="usd">41511000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1af0f8a55164e0eb8dcc387d8ee162c_I20211231"
      decimals="-3"
      id="f-488"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib672ffc131c141c89ec35e1cdc6d0888_I20211231"
      decimals="-3"
      id="f-489"
      unitRef="usd">42345000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib149a8ec14b946089462bf96a8cb0335_I20211231"
      decimals="-3"
      id="f-490"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231"
      decimals="-3"
      id="f-491"
      unitRef="usd">42345000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i70fa2af8a8064c0b96426610b6658882_I20211231"
      decimals="-3"
      id="f-492"
      unitRef="usd">13520000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4fa03a6d5dbf4539a01f114da77c480a_I20211231"
      decimals="-3"
      id="f-493"
      unitRef="usd">83856000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idca3d92946644292bfe24473fcc4be04_I20211231"
      decimals="-3"
      id="f-494"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-495"
      unitRef="usd">97376000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-496"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-497"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-498">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the estimated value of the Company&#x2019;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="icfe8063b179f430aa2aa6b702e9b306c_I20221231"
      decimals="-3"
      id="f-499"
      unitRef="usd">11546000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icfe8063b179f430aa2aa6b702e9b306c_I20221231"
      decimals="-3"
      id="f-500"
      unitRef="usd">11546000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="id78913e7ab2e4303a5543c869a3218e3_I20221231"
      decimals="-3"
      id="f-501"
      unitRef="usd">3968000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id78913e7ab2e4303a5543c869a3218e3_I20221231"
      decimals="-3"
      id="f-502"
      unitRef="usd">3968000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-503"
      unitRef="usd">15514000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-504"
      unitRef="usd">15514000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231"
      decimals="-3"
      id="f-505"
      unitRef="usd">39646000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231"
      decimals="-3"
      id="f-506"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231"
      decimals="-3"
      id="f-507"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedcaac54148842f482fb9f6ab25e2ed3_I20221231"
      decimals="-3"
      id="f-508"
      unitRef="usd">39563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231"
      decimals="-3"
      id="f-509"
      unitRef="usd">28759000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231"
      decimals="-3"
      id="f-510"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231"
      decimals="-3"
      id="f-511"
      unitRef="usd">117000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97feebbd9cc94ec48c7937f8f4950348_I20221231"
      decimals="-3"
      id="f-512"
      unitRef="usd">28642000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231"
      decimals="-3"
      id="f-513"
      unitRef="usd">4945000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231"
      decimals="-3"
      id="f-514"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231"
      decimals="-3"
      id="f-515"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6dda2ffdbb7449b99003a29733a4d967_I20221231"
      decimals="-3"
      id="f-516"
      unitRef="usd">4945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-517"
      unitRef="usd">73350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-518"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-519"
      unitRef="usd">203000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-520"
      unitRef="usd">73150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic6eb2b8528634735a6af7527a73a9128_I20221231"
      decimals="-3"
      id="f-521"
      unitRef="usd">15514000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c4688b49a6540e98c724acb8b04a2ad_I20221231"
      decimals="-3"
      id="f-522"
      unitRef="usd">73150000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-523"
      unitRef="usd">88664000</us-gaap:AssetsFairValueDisclosure>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231"
      decimals="-3"
      id="f-524"
      unitRef="usd">13520000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id2b7d0acc06f4ba4ab2cb74692f7c611_I20211231"
      decimals="-3"
      id="f-525"
      unitRef="usd">13520000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-526"
      unitRef="usd">13520000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-527"
      unitRef="usd">13520000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231"
      decimals="-3"
      id="f-528"
      unitRef="usd">41576000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231"
      decimals="-3"
      id="f-529"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231"
      decimals="-3"
      id="f-530"
      unitRef="usd">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c9339f160d84eebbc7070bc3bddd479_I20211231"
      decimals="-3"
      id="f-531"
      unitRef="usd">41511000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231"
      decimals="-3"
      id="f-532"
      unitRef="usd">42429000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231"
      decimals="-3"
      id="f-533"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231"
      decimals="-3"
      id="f-534"
      unitRef="usd">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d031ec06fa747218f0529c0d926de3d_I20211231"
      decimals="-3"
      id="f-535"
      unitRef="usd">42345000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-536"
      unitRef="usd">84005000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-537"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-538"
      unitRef="usd">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-539"
      unitRef="usd">83856000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2171cc598bbc4faa9d1dfb89113cc454_I20211231"
      decimals="-3"
      id="f-540"
      unitRef="usd">13520000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0faa0526436449a8d5aedef9fe5142d_I20211231"
      decimals="-3"
      id="f-541"
      unitRef="usd">66594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5464846d99ce4aafbbb96b5563f1dc1d_I20211231"
      decimals="-3"
      id="f-542"
      unitRef="usd">17262000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-543"
      unitRef="usd">97376000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ImpairmentOfInvestments
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-544"
      unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-5"
      id="f-545"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-546"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-547">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2021 and 2020 was approximately $0.3 million, $0.3 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid contract manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-548">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-549"
      unitRef="usd">1703000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-550"
      unitRef="usd">1056000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-551"
      unitRef="usd">884000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-552"
      unitRef="usd">1468000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-553"
      unitRef="usd">266000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-554"
      unitRef="usd">88000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-555"
      unitRef="usd">2853000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-556"
      unitRef="usd">2612000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-557">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i62a60c80d69a4de39ff38d8b55aef975_I20221231"
      decimals="-3"
      id="f-558"
      unitRef="usd">736000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ide1b1828296e40aeb62b7b75b1921d5c_I20211231"
      decimals="-3"
      id="f-559"
      unitRef="usd">669000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i26381ba35f554000928e20baa54aaf82_I20221231"
      decimals="-3"
      id="f-560"
      unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia6182cf377fb42d5b55072fb1f5fcc4c_I20211231"
      decimals="-3"
      id="f-561"
      unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib5e14c606c1641bb863e16722c0cbc4a_I20221231"
      decimals="-3"
      id="f-562"
      unitRef="usd">101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4960562ae1a43d5a1836ee70a2a0ced_I20211231"
      decimals="-3"
      id="f-563"
      unitRef="usd">101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia72e03af8e4d4e029c34f04f781a6afe_I20221231"
      decimals="-3"
      id="f-564"
      unitRef="usd">271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia401dca885444fa3b7a5f036bf820425_I20211231"
      decimals="-3"
      id="f-565"
      unitRef="usd">271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia921678878f04db6adbca4595688a360_I20221231"
      decimals="-3"
      id="f-566"
      unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0af19da2c6184c899e48459eaf368c09_I20211231"
      decimals="-3"
      id="f-567"
      unitRef="usd">59000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-568"
      unitRef="usd">1591000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-569"
      unitRef="usd">1216000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-570"
      unitRef="usd">895000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-571"
      unitRef="usd">603000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-572"
      unitRef="usd">696000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-573"
      unitRef="usd">613000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-574"
      unitRef="usd">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-575"
      unitRef="usd">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-5"
      id="f-576"
      unitRef="usd">200000</us-gaap:Depreciation>
    <eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-577">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid contract manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock>
    <eigr:PrepaidContractManufacturingCosts
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-578"
      unitRef="usd">3542000</eigr:PrepaidContractManufacturingCosts>
    <eigr:PrepaidContractManufacturingCosts
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-579"
      unitRef="usd">3695000</eigr:PrepaidContractManufacturingCosts>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-580"
      unitRef="usd">4542000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-581"
      unitRef="usd">54000</us-gaap:DepositsAssetsCurrent>
    <eigr:PrepaidResearchCosts
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-582"
      unitRef="usd">2822000</eigr:PrepaidResearchCosts>
    <eigr:PrepaidResearchCosts
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-583"
      unitRef="usd">3253000</eigr:PrepaidResearchCosts>
    <us-gaap:PrepaidInsurance
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-584"
      unitRef="usd">586000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-585"
      unitRef="usd">631000</us-gaap:PrepaidInsurance>
    <eigr:PrepaidMarketing
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-586"
      unitRef="usd">753000</eigr:PrepaidMarketing>
    <eigr:PrepaidMarketing
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-587"
      unitRef="usd">469000</eigr:PrepaidMarketing>
    <eigr:OtherPrepaidExpenseAndOtherAssetsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-588"
      unitRef="usd">1740000</eigr:OtherPrepaidExpenseAndOtherAssetsCurrent>
    <eigr:OtherPrepaidExpenseAndOtherAssetsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-589"
      unitRef="usd">1259000</eigr:OtherPrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-590"
      unitRef="usd">13985000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-591"
      unitRef="usd">9361000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-592">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-593"
      unitRef="usd">6167000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-594"
      unitRef="usd">3131000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <eigr:AccruedContractedResearchCostsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-595"
      unitRef="usd">4188000</eigr:AccruedContractedResearchCostsCurrent>
    <eigr:AccruedContractedResearchCostsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-596"
      unitRef="usd">4760000</eigr:AccruedContractedResearchCostsCurrent>
    <eigr:ContractManufacturingCostsCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-597"
      unitRef="usd">2101000</eigr:ContractManufacturingCostsCurrent>
    <eigr:ContractManufacturingCostsCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-598"
      unitRef="usd">3288000</eigr:ContractManufacturingCostsCurrent>
    <eigr:ProductRevenueReserves
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-599"
      unitRef="usd">1373000</eigr:ProductRevenueReserves>
    <eigr:ProductRevenueReserves
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-600"
      unitRef="usd">1846000</eigr:ProductRevenueReserves>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-601"
      unitRef="usd">1826000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-602"
      unitRef="usd">674000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-603"
      unitRef="usd">15655000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-604"
      unitRef="usd">13699000</us-gaap:AccruedLiabilitiesCurrent>
    <eigr:ProductDevelopmentAgreementTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-605">License, Collaboration, and Product Development Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with the Trustees of the University of Pennsylvania and the Children&#x2019;s Hospital of Philadelphia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the University of Pennsylvania (UPenn) and the Children&#x2019;s Hospital of Philadelphia (CHOP), under which the Company obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain Glucagon Like Peptide-1 (GLP-1) receptor antagonist(s) products to treat all human and animal conditions. The Company also obtained an exclusive, royalty-bearing, sublicensable, worldwide license to certain data developed by CHOP. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for the development and commercialization of the licensed products at its sole cost and expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consideration for the rights granted to the Company under the UPenn/CHOP Agreement, the Company paid UPenn a one-time, non-refundable issue fee of $1.0&#160;million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, the Company is obligated to pay UPenn a specified annual license maintenance fee, up to $2.5&#160;million upon marketing authorization in one or more countries, and up to $18.0&#160;million in commercial milestones. The Company will also be required to pay UPenn a flat royalty in the low-single digits on net sales of all licensed products by the Company, subject to specified reductions and offsets, and specified minimum annual royalty payments. The Company&#x2019;s obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. No milestones have been achieved as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for the Company&#x2019;s failure to achieve the specified diligence milestones within the specified periods, subject to the Company&#x2019;s extension rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:23.13pt;text-indent:-23.13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Development Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 11, 2018, the Company entered into a Product Development Agreement and a First Project Agreement (the Product Agreements), pursuant to which the Company will receive development program support services for its HDV program. The services are to be provided from July 1, 2018 through the new drug application (NDA) filing. As consideration, the Company has committed to pay fees of approximately $10.0&#160;million in cash and stock over four years, including approximately $0.8&#160;million for expert consultant fees and pass through costs to vendors, plus certain incentive-based regulatory milestone fees up to $1.0&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the aggregate payment, the Company issued 115,526 shares of common stock subject to quarterly vesting requirements related to successful performance of the services and achievement of budget timeline set forth in the Product Agreements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Product Agreements can be terminated by either party due to material breach or by the Company without cause with 90 days prior written notice. For the years ended December 31, 2022, 2021 and 2020, the Company recognized research and development expense of $19,000, $0.2&#160;million and $0.2&#160;million, respectively, related to the shares issued under the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, 2022, the restricted shares were fully vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Progeria Research Foundation (PRF) Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2018, the Company entered into a Collaboration and Supply Agreement (the PRF Collaboration Agreement) with PRF. Under the PRF Collaboration Agreement, the parties agreed to collaborate with respect to the development and pursuit of regulatory approval of lonafarnib for the treatment of HGPS and processing-deficient progeroid laminopathies, collectively called progeria, in humans. PRF granted the Company a non-exclusive, world-wide, royalty-free, sub-licensable license pertaining to all intellectual property and data controlled by PRF to prepare and file any NDA for a product containing lonafarnib for progeria. The Company is obligated to: (i) exclusively supply lonafarnib to PRF for use in clinical trials and non-clinical research in progeria at the Company&#x2019;s expense, (ii) prepare and be the sponsor of any NDA submission for lonafarnib for the treatment of progeria to the FDA, (iii) use commercially reasonable efforts to file a NDA for progeria by a specified date, (iv) submit a Rare Pediatric Disease designation and a request for expedited approval in connection with a NDA filing, (v) establish a patient support program in progeria, and (vi) use commercially reasonable efforts to develop a pediatric formulation of lonafarnib for use in progeria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the PRF Collaboration Agreement, the Company is solely responsible for any additional studies necessary for obtaining an NDA for progeria and is also responsible for any additional costs for such studies up to $2.0&#160;million. The PRF Collaboration Agreement continues for an initial term of ten years and automatically renews for subsequent renewal terms of two years each unless either party terminates earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Bristol-Meyers Squibb License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (peginterferon lambda or the Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $2.0 million and issued 157,587 shares of its common stock at an aggregate fair value of $3.2 million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $61.0 million and commercial sales milestones of up to $128.0 million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In the fourth quarter of 2020, the Company recorded in research and development expense a $3.0 million milestone, triggered on successful demonstration of proof of concept, as defined by the BMS License Agreement, in a Phase 2 clinical trial. In March 2022, the Company recorded a $5.0 million milestone expense in research and development, which was related to the initiation of a Phase 3 clinical trial, as defined under the BMS License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2010, the Company entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck &amp;amp; Co., Inc. (Merck), which provides the Company with the exclusive right to develop, manufacture, and sell products containing the compounds lonafarnib for the treatment of all human viruses except certain specified viruses such as hepatitis B and hepatitis C alone. As part of consideration, the Company issued 27,350 shares of common stock with a fair value of $0.5&#160;million. The Company is obligated to pay Merck up to an aggregate of $27.0&#160;million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. In May 2015, the first regulatory milestone was achieved and the Company paid the related milestone payment of $1.0&#160;million to Merck. No additional milestones have been achieved as of December 31, 2022. The next milestone of $1.0&#160;million is due upon successful completion of the Phase 3 study, which is expected by end of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2018, the Company entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford progeria syndrome (HGPS) in humans at no cost to the Company. On November 3, 2020, the Company entered into an amendment to the exclusive license agreement with Merck which expanded the indication to also include progeroid laminopathies, collectively called progeria. The Company has the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to the PRF. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria or any royalty payments for sales of a specified quantity of lonafarnib to treat the currently estimated progeria  patient population worldwide.&lt;/span&gt;&lt;/div&gt;</eigr:ProductDevelopmentAgreementTextBlock>
    <eigr:NonRefundableIssueFee
      contextRef="ic6a349046f334530a41f51eebfe060e1_D20190101-20191231"
      decimals="-5"
      id="f-606"
      unitRef="usd">1000000</eigr:NonRefundableIssueFee>
    <eigr:LicenseMaintenanceFee
      contextRef="ice98876375a746198c11b6156223c890_D20190101-20191231"
      decimals="-5"
      id="f-607"
      unitRef="usd">2500000</eigr:LicenseMaintenanceFee>
    <eigr:MilestoneObligations
      contextRef="i40856ef0109745e6bca5398e2deb59e6_D20190101-20191231"
      decimals="-5"
      id="f-608"
      unitRef="usd">18000000</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="i806febb1a3f14a009905147c299141c6_D20220101-20221231"
      decimals="INF"
      id="f-609"
      unitRef="usd">0</eigr:MilestoneObligations>
    <eigr:ProductDevelopmentFees
      contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811"
      decimals="-5"
      id="f-610"
      unitRef="usd">10000000</eigr:ProductDevelopmentFees>
    <eigr:PeriodOfCommittedPaymentOfFees
      contextRef="ic8e9958c1f874287a316e0d40a1ee557_I20180811"
      id="f-611">P4Y</eigr:PeriodOfCommittedPaymentOfFees>
    <eigr:ExpertConsultantFeesAndPassThroughCosts
      contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811"
      decimals="-3"
      id="f-612"
      unitRef="usd">800000</eigr:ExpertConsultantFeesAndPassThroughCosts>
    <eigr:IncentiveBasedRegulatoryMilestoneFees
      contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811"
      decimals="-5"
      id="f-613"
      unitRef="usd">1000000</eigr:IncentiveBasedRegulatoryMilestoneFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i734e8594827447d2aa043ebe2459fce3_D20180811-20180811"
      decimals="0"
      id="f-614"
      unitRef="shares">115526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i215c0c22884741439373b4bb5cf353ab_D20220101-20221231"
      decimals="-3"
      id="f-615"
      unitRef="usd">19000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie01aaeb68a154d89b511aa445e1f10c5_D20210101-20211231"
      decimals="-5"
      id="f-616"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib38883ca632644fd93eb6fb8b5632ec4_D20200101-20201231"
      decimals="-5"
      id="f-617"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic6a349046f334530a41f51eebfe060e1_D20190101-20191231"
      decimals="-5"
      id="f-618"
      unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentExpense>
    <eigr:CollaborationAgreementInitialTerm
      contextRef="i1093f397da6f4ccbaa4327f49cc99f6b_D20180515-20180515"
      id="f-619">P10Y</eigr:CollaborationAgreementInitialTerm>
    <eigr:CollaborativeArrangementRenewalTerm
      contextRef="i1093f397da6f4ccbaa4327f49cc99f6b_D20180515-20180515"
      id="f-620">P2Y</eigr:CollaborativeArrangementRenewalTerm>
    <eigr:UpFrontCashPayments
      contextRef="i26693b4f07bb413dbe7693e3a8733d02_D20160401-20160430"
      decimals="-5"
      id="f-621"
      unitRef="usd">2000000</eigr:UpFrontCashPayments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i312ccf68285749298fc9eaba96fdb15e_D20160401-20160430"
      decimals="0"
      id="f-622"
      unitRef="shares">157587</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i312ccf68285749298fc9eaba96fdb15e_D20160401-20160430"
      decimals="-5"
      id="f-623"
      unitRef="usd">3200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <eigr:MilestoneObligations
      contextRef="if8b0cb8cbbf34f3a92bae7940e633560_D20160401-20160430"
      decimals="-5"
      id="f-624"
      unitRef="usd">61000000</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="i98b448fdcc72493fa8f472a5547e9c5e_D20160401-20160430"
      decimals="-5"
      id="f-625"
      unitRef="usd">128000000</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="i522fba7c7f6b4899a22248daae63fdef_D20160401-20160430"
      decimals="-5"
      id="f-626"
      unitRef="usd">3000000</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="i53c796ad9f4d4cd8b485cdc08c8eea06_D20220301-20220331"
      decimals="-5"
      id="f-627"
      unitRef="usd">5000000</eigr:MilestoneObligations>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a015d0ea8614264a0d243ef6aad2068_I20100930"
      decimals="0"
      id="f-628"
      unitRef="shares">27350</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i6a015d0ea8614264a0d243ef6aad2068_I20100930"
      decimals="-5"
      id="f-629"
      unitRef="usd">500000</us-gaap:CommonStockValue>
    <eigr:DevelopmentMilestoneObligations
      contextRef="i6b02f365ff984634a4f599eb3ff0b476_D20100901-20100930"
      decimals="-5"
      id="f-630"
      unitRef="usd">27000000</eigr:DevelopmentMilestoneObligations>
    <eigr:MilestonePayments
      contextRef="i31cc6fec54de49cbaac8df50f262c636_D20180515-20180515"
      decimals="-5"
      id="f-631"
      unitRef="usd">1000000</eigr:MilestonePayments>
    <eigr:MilestonePayments
      contextRef="ia0a31c2673294cd7a5b85a7f0ceb46ce_D20220101-20221231"
      decimals="INF"
      id="f-632"
      unitRef="usd">0</eigr:MilestonePayments>
    <eigr:MilestonePayments
      contextRef="i424ffec162f345b6805146b3e1859078_D20230101-20231231"
      decimals="-5"
      id="f-633"
      unitRef="usd">1000000</eigr:MilestonePayments>
    <eigr:AssetPurchaseAgreementTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-634">Asset Purchase Agreements and Related License Agreements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EGI Asset Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2010, the Company entered into an asset purchase agreement with Eiger Group International, Inc. (EGI). Dr. Jeffrey Glenn, a founder and director of the Company, is the sole owner of EGI. Pursuant to the agreement, the Company purchased all of the assets including the intellectual property rights related to the use of farnesyltransferase inhibitors as anti-viral agents and methods to treat viral infections with those inhibitors and inhibitors of prenylation, prenyl cysteine methyltransferase and a protease as anti-viral agents and methods to treat viral infection with those inhibitors. The Company paid EGI an upfront payment of $0.4&#160;million when the agreement was executed in December 2010. Additionally, the Company will pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, the Company may make a one-time payment of $0.5&#160;million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product. The product is currently not under development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Avexitide Purchase Agreement and Related Stanford License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2015, the Company entered into an asset purchase agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig, (the Sellers), whereby the Company purchased all of the assets related to the compound avexitide (formerly known as exendin 9-39) including any related intellectual property from the Sellers (the Exendin APA). The Company also entered into a consulting agreement with the Sellers as part of the agreement. The Company issued 15,378 shares of common stock that were valued at $0.2&#160;million and with the option to purchase 46,134 shares of common stock with an exercise price of $2.06 per share when the agreement was executed in September 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the 46,134 options to purchase common stock, 15,378 shares vest monthly over four years as services are provided by the Sellers and 30,756 vest upon the earlier of the first commercial sale of the product or the approval of new drug application by the U.S. FDA (the milestone-vested options).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 22, 2016, immediately following the closing of the merger, the Company issued additional top-up options to the Sellers to purchase an aggregate of 48,544 shares of common stock, pursuant to the terms of the Exendin APA, with an exercise price of $17.25 per share. The top-up options consist of both time-vested and milestone-vested options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the time-vested options is recognized as stock-based compensation expense as the awards vest over time. The fair value of the milestone-vested options will be recognized as research and development expense when it is probable that the earliest milestone will be achieved at their fair value as of the ASU 2018-07 adoption date. During the years ended December 31, 2022, 2021 and 2020, the Company recognized $0&#160;million, $0.1&#160;million and $0.1&#160;million of compensation expense related to the time-vested options, respectively. No expense was recognized for the milestone vested options during the years ended December 31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also obligated to pay development milestone payments in an aggregate amount of up to $1.0&#160;million to each Seller. Additionally, the Company is obligated to pay each Seller royalties of low single-digits based on aggregate annual net sales of all products developed based on avexitide, subject to certain reductions and exceptions. The Company&#x2019;s obligation to pay royalties expires on the expiration of the last to expire patent assigned to the Company under the agreement. Additionally, the Company has assumed the license agreement the Sellers had previously entered into with the Board of Trustees of the Leland Stanford Junior University (Stanford). The Company is obligated to pay a royalty to Stanford in the low single-digits on annual net sales after the first commercial sale of any products developed based on avexitide. As of December 31, 2022, the Company has paid a total of $0.1&#160;million in milestone payments to each of the Sellers related to the successful completion of the Phase 2 trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Purchase Agreement with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;20, 2020, Eiger entered into the AbbVie Agreement with AbbVie to sell its rare pediatric disease priority review voucher (the PRV), which was awarded on November&#160;20, 2020 upon FDA approval of Zokinvy. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. &lt;/span&gt;&lt;/div&gt;In consideration for the PRV, AbbVie agreed to pay the Company $95.0 million. The transaction closed in January 2021. Such consideration was shared with the PRF in accordance with the terms of the PRF Collaboration and Supply Agreement, pursuant to which the Company and PRF will equally share any net proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained $46.5 million of proceeds from the sale of the PRV, net of related payments, and recorded the amount in other (expense) income, net in the consolidated statement of operations for the year ended December 31, 2021.</eigr:AssetPurchaseAgreementTextBlock>
    <eigr:UpFrontCashPayments
      contextRef="i4a1f282e249c451586adac7467c9a9ae_D20101201-20101231"
      decimals="-5"
      id="f-635"
      unitRef="usd">400000</eigr:UpFrontCashPayments>
    <eigr:OneTimePaymentToBeMadeOnAssetPurchaseAgreement
      contextRef="i121466ae35884ba0b24b9f6d9978e273_I20101231"
      decimals="-5"
      id="f-636"
      unitRef="usd">500000</eigr:OneTimePaymentToBeMadeOnAssetPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930"
      decimals="0"
      id="f-637"
      unitRef="shares">15378</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930"
      decimals="-5"
      id="f-638"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <eigr:OptionsToPurchaseOfCommonStock
      contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930"
      decimals="0"
      id="f-639"
      unitRef="shares">46134</eigr:OptionsToPurchaseOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i070111655a2d458abdc58cce6fdf5362_I20150930"
      decimals="2"
      id="f-640"
      unitRef="usdPerShare">2.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <eigr:OptionsToPurchaseOfCommonStock
      contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930"
      decimals="0"
      id="f-641"
      unitRef="shares">46134</eigr:OptionsToPurchaseOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i2ff02c15b30e423587839d54ad95f618_D20150901-20150930"
      decimals="0"
      id="f-642"
      unitRef="shares">15378</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i78240c9a110c474c969a366314c34f1a_D20150901-20150930"
      decimals="0"
      id="f-643"
      unitRef="shares">15378</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i9da09837945d43e4865652c607fde425_D20150901-20150930"
      decimals="0"
      id="f-644"
      unitRef="shares">15378</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i1d316f19952e4069af11841afd2c9639_D20150901-20150930"
      decimals="0"
      id="f-645"
      unitRef="shares">15378</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase
      contextRef="iba57b158870e40fdb866d4b2678df531_D20150901-20150930"
      id="f-646">P4Y</eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase>
    <eigr:VestingOfOptionsToPurchaseCommonStock
      contextRef="i4c6591a11b4f4589aa6dc2b50acc5000_D20150901-20150930"
      decimals="0"
      id="f-647"
      unitRef="shares">30756</eigr:VestingOfOptionsToPurchaseCommonStock>
    <eigr:OptionsToPurchaseOfCommonStock
      contextRef="i6368f25382834801a6682e48b0981e29_D20160322-20160322"
      decimals="0"
      id="f-648"
      unitRef="shares">48544</eigr:OptionsToPurchaseOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i53e59300f06d44a9b0494eb5cc7fed9c_I20160322"
      decimals="2"
      id="f-649"
      unitRef="usdPerShare">17.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i290212954c99401aae042a9ef1f88723_D20220101-20221231"
      decimals="-5"
      id="f-650"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6901de3d60ff4db1916a73b9d096e7a2_D20210101-20211231"
      decimals="-5"
      id="f-651"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9b1a8da043d451197ac210c2a30510d_D20200101-20201231"
      decimals="-5"
      id="f-652"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <eigr:LicenseAgreementPotentialMilestonePayments
      contextRef="i2a5c0da13bd14c669d92be3294f92711_D20150901-20150930"
      decimals="-5"
      id="f-653"
      unitRef="usd">1000000</eigr:LicenseAgreementPotentialMilestonePayments>
    <eigr:LicenseAgreementMilestonePaymentsPaid
      contextRef="i6901de3d60ff4db1916a73b9d096e7a2_D20210101-20211231"
      decimals="-5"
      id="f-654"
      unitRef="usd">100000</eigr:LicenseAgreementMilestonePaymentsPaid>
    <eigr:PaymentForAssetPurchaseAgreement
      contextRef="i8114b95ec2a24e868a25140a3f0158b2_D20201120-20201120"
      decimals="-5"
      id="f-655"
      unitRef="usd">95000000</eigr:PaymentForAssetPurchaseAgreement>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i2f59d99d10d04de492abcac7063c4d9c_D20210101-20211231"
      decimals="-5"
      id="f-656"
      unitRef="usd">46500000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-657">Sale of Assets&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company and Theragene Pharmaceuticals, Inc. (Theragene) entered into an asset purchase agreement (Theragene APA), whereby the Company sold all of the assets related to MYDICAR including any related intellectual property for a cash payment of $0.2&#160;million and 475,000 shares of common stock of Theragene. At any time after the Theragene APA execution date and until Theragene has received cumulative gross proceeds of $4.0&#160;million (Proceeds Date) from all equity financing transactions occurring after the Theragene APA execution date, if Theragene issues additional shares of its common stock without consideration or for a consideration per share less than $6.00 per share then Theragene will issue additional shares of its common stock to the Company concurrently with such issue, in an amount such that the per share consideration multiplied by the aggregate number of common stock shares issued to the Company will equal $2.9&#160;million. Additionally, the Company may exercise a put option at any time after the Proceeds Date, where upon written notice from the Company, Theragene will repurchase the 225,000 shares of its common stock held by the Company (Option Shares) at an aggregate purchase price equal to the greater of $1.4&#160;million or the aggregate fair market value of the Option Shares as of the date of the receipt of such notice. The Company is also eligible to receive contingent consideration up to a maximum $45.0&#160;million in cash, based upon Theragene achieving certain specified future milestones. In addition, the Company is also eligible to receive up to 8% royalties on net sales of any future Theragene products covered by or involving the related patents or know-how until the twentieth anniversary of the Theragene APA. To-date, no consideration has been earned or is expected to be earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that the sale of the MYDICAR assets qualify as an asset sale and not a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the execution of the Theragene APA, the Company became the owner of 475,000 shares of common stock of Theragene and held a put option for 225,000 shares of common stock of Theragene, which were recognized as a cost method investment with carrying value of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Theragene entered into an Asset Purchase Agreement with a third party for the sale of MYDICAR. Under the terms of the Theragene APA between the Company and Theragene, the Company is eligible to receive 25% of any upfront, licensee fee, milestone or other payment (other than royalty payments) received by Theragene from the sale or sublicense of MYDICAR, within 30 days of receipt of such payments by Theragene. As such, during the year ended December 31, 2021, the Company recognized $0.3&#160;million in other (expense) income, net. The Company expects to receive a de minimis amount subsequent to December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531"
      decimals="-5"
      id="f-658"
      unitRef="usd">200000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <eigr:SaleOfAssetsNumberOfCommonStockSharesReceived
      contextRef="ib87cb0850d4c413db472e1cfa4e0516f_I20170531"
      decimals="0"
      id="f-659"
      unitRef="shares">475000</eigr:SaleOfAssetsNumberOfCommonStockSharesReceived>
    <eigr:MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares
      contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531"
      decimals="-5"
      id="f-660"
      unitRef="usd">4000000</eigr:MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares>
    <eigr:MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares
      contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531"
      decimals="2"
      id="f-661"
      unitRef="usdPerShare">6.00</eigr:MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares>
    <eigr:AggregateCommonStockConsiderationValue
      contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531"
      decimals="-5"
      id="f-662"
      unitRef="usd">2900000</eigr:AggregateCommonStockConsiderationValue>
    <eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare
      contextRef="i92100717fcf74430af9c50c3cec2a181_D20170501-20170531"
      decimals="0"
      id="f-663"
      unitRef="shares">225000</eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare>
    <eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue
      contextRef="id8ab44b29d644c6e854e9000bd3ea4dd_D20170501-20170531"
      decimals="-5"
      id="f-664"
      unitRef="usd">1400000</eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue>
    <eigr:AssetPurchaseAgreementContingentConsiderationReceivable
      contextRef="i5efa461c8d184d5bbf8fae9a20d47978_I20170531"
      decimals="-5"
      id="f-665"
      unitRef="usd">45000000</eigr:AssetPurchaseAgreementContingentConsiderationReceivable>
    <eigr:RoyaltyReceivablePercentageOnNetSales
      contextRef="if57d9437106f448c83d0afbcf0114df9_D20170501-20170531"
      decimals="2"
      id="f-666"
      unitRef="number">0.08</eigr:RoyaltyReceivablePercentageOnNetSales>
    <eigr:SaleOfAssetsNumberOfCommonStockSharesReceived
      contextRef="i812e7a0b79e5490fbf8cc0469a5ce008_I20211231"
      decimals="0"
      id="f-667"
      unitRef="shares">475000</eigr:SaleOfAssetsNumberOfCommonStockSharesReceived>
    <eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare
      contextRef="ib19f9a06b61e4ddfa40008408ebc9e74_D20210101-20211231"
      decimals="0"
      id="f-668"
      unitRef="shares">225000</eigr:ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="i812e7a0b79e5490fbf8cc0469a5ce008_I20211231"
      decimals="0"
      id="f-669"
      unitRef="usd">0</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <eigr:UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage
      contextRef="ib0abd73b32db44aca977bb76f57865f5_D20200901-20200930"
      decimals="2"
      id="f-670"
      unitRef="number">0.25</eigr:UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage>
    <eigr:ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived
      contextRef="ib19f9a06b61e4ddfa40008408ebc9e74_D20210101-20211231"
      decimals="-5"
      id="f-671"
      unitRef="usd">300000</eigr:ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-672">Debt&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Innovatus Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2022 (Closing Date), the Company entered into a term loan and security agreement (Innovatus Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), providing for up to $75.0 million funded in three tranches with a maturity date of August&#160;31, 2027. The floating per annum interest rate of the Innovatus Loan is equal to the sum of (a) the greater of (i) the Prime Rate published in the Money Rates section of the Wall Street Journal (or any successor thereto) and (ii) 3.5%, plus (b) 3.75%; provided that, at the election of the Borrower, up to 2.25% of such rate shall be payable in-kind until the third anniversary of the closing date. The Company is required to make monthly interest-only payments through July 1, 2027, after which the Company is required to make monthly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. 2.25% of the interest is payable in-kind for the first three years of the term by increasing the principal balance. Prepayments of the loan, in whole or in part, will be subject to an early prepayment fee which declines each year until the third anniversary date of the Closing Date, after which no prepayment fee is required. The Company is also required to pay an exit fee upon any payment or prepayment equal to 6.5% of the aggregate principal amount of the tranches funded under the Innovatus Loan. The Innovatus Loan contains customary representations, warranties, events of default and covenants of the Company and its subsidiaries, including a requirement to maintain a cash balance of not less than 5% of the aggregate principal amount of funded and outstanding &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loan terms at all times. The Innovatus Loan is secured by perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company's intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was funded $40.0 million in June 2022 on the Closing Date under Tranche A. The remaining $35.0 million is divided into two tranches (Tranche B and Tranche C). The $17.5 million under each of Tranche B and Tranche C will be available for a period commencing on the later of (a) the first date that the Company achieves certain development and regulatory milestones applicable to each Tranche and (b) November 1, 2022. Both Tranche B and Tranche C draw periods end on the earlier of (a) June 30, 2024 or (b) an event of default. The Company believes it is currently eligible to draw the $17.5&#160;million under Tranche B, but has not done so as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified a number of embedded derivatives that require bifurcation from the Innovatus Loan. These embedded features include mandatory prepayment upon an event of default or change in control and contingent rate increases. However, the fair value of these embedded features was deemed to be immaterial on the date of issuance and at December&#160;31, 2022. At each subsequent reporting period, the Company will reassess the fair value of the embedded features and will record a liability if the fair value of the features becomes material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the Innovatus Loan, the Company recorded a debt discount of $0.2&#160;million and capitalized debt issuance costs of $1.1&#160;million. The discount and issuance costs will be amortized over the life of the loan. Interest expense for the Innovatus Loan for the year ended December&#160;31, 2022 was $2.6&#160;million, and is inclusive of non-cash amortization of the debt discount and debt issuance costs and accretion of final payment. The carrying value of the Innovatus Loan at December&#160;31, 2022 was $39.6 million. The carrying amount of the Innovatus Loan approximates fair value given its recent issuance. The effective interest rate for the Innovatus Loan was 12.86% as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in connection with entering into the Innovatus Loan, the Company entered into a Stock Purchase Agreement with Innovatus for the sale of common stock with an aggregate value of $5.0 million. On June 1, 2022, the Company issued 749,053 shares of common stock to Innovatus at a per share purchase price of $6.6751, the preceding five-day volume weighted average price per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the loan proceeds were used to repay in full the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately $33.5&#160;million of aggregate principal amount, unpaid interest, and exit fees in connection with loans outstanding owed to Oxford Finance LLC by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Oxford Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company entered into an aggregate $25.0 million loan with Oxford Finance LLC (the Oxford Loan) with a maturity date of July&#160;1, 2021. The Company borrowed $15.0 million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan and borrowed $5.0 million (Tranche B). &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;3, 2018, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrowed the remaining $5.0 million (Tranche C) under the Oxford Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $35.0 million and extended the maturity date to March&#160;1, 2024. On March&#160;5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $23.3&#160;million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $6.7 million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $30.0&#160;million (Amended Tranche A). The remaining $5.0 million (Amended Tranche B) was available to the Company provided that certain milestones are achieved by February 2021. The Company did not draw down the Amended Tranche B.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;23, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by 17 months until September 1, 2022, followed by 19 equal monthly payments of principal and interest. The Company paid an amendment fee of $0.2&#160;million to the lender on the effective date of the fifth amendment, which was recorded as an additional debt discount and was being amortized over the remaining term of the Amended Oxford Loan. Interest expense for the Oxford Loan for the year ended December&#160;31, 2022 was $1.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 6, 2021, the Company entered into the sixth amendment to the Oxford Loan, which amended the interest to be the LIBOR replacement rate which is the sum of the alternate benchmark rate and the LIBOR replacement spread. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of final payment, the Company was required to pay an exit fee of 7.50% of the original principal balance of borrowed funds, or $2.3 million. In addition, the Company was required to pay an additional exit fee of $1.0 million. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $0.9 million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2022, upon entering into the Innovatus Loan, the Company repaid the Oxford Loan, including (i) the $30.0 million outstanding principal balances, (ii) $0.2 million in accrued and unpaid interest, and (iii) other final payments consisting of $3.3 million, for a total payment of $33.5 million. The Company recorded a loss of $1.1&#160;million on early extinguishment of the debt related to the unamortized debt premium, discount, and cost of issuance, which was recognized as a component of other (expense) income, net in the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for the amortization of the debt discount utilizing the effective interest method. Debt and unamortized discount balances are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, future minimum payments of principal, exit fee and interest expense under the Innovatus Loan were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(21,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: exit fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601"
      decimals="-5"
      id="f-673"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia94b90e55cdc4829a94a8b1e45fbba04_D20220601-20220601"
      decimals="3"
      id="f-674"
      unitRef="number">0.035</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9713023dded64c8ea5adac4bda00c7e2_D20220601-20220601"
      decimals="4"
      id="f-675"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <eigr:DebtInstrumentPercentOfInterestDue
      contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601"
      decimals="4"
      id="f-676"
      unitRef="number">0.0225</eigr:DebtInstrumentPercentOfInterestDue>
    <eigr:DebtInstrumentPercentOfInterestDue
      contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601"
      decimals="4"
      id="f-677"
      unitRef="number">0.0225</eigr:DebtInstrumentPercentOfInterestDue>
    <eigr:DebtInstrumentExitFeePayablePercentage
      contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601"
      decimals="3"
      id="f-678"
      unitRef="number">0.065</eigr:DebtInstrumentExitFeePayablePercentage>
    <eigr:MinimumCashBalanceOfFaceValueOfLoanPercent
      contextRef="ib4a7a59d419a456a86819f0db13f903a_I20220601"
      decimals="2"
      id="f-679"
      unitRef="number">0.05</eigr:MinimumCashBalanceOfFaceValueOfLoanPercent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if6f055c598d7454da7696030a389cafe_I20220630"
      decimals="-5"
      id="f-680"
      unitRef="usd">40000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i98c422a139a345809437127a7479b57a_I20220630"
      decimals="-5"
      id="f-681"
      unitRef="usd">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3899d90a98f843c28f7608b176abbecb_I20220630"
      decimals="-5"
      id="f-682"
      unitRef="usd">17500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2913f5ce26fd4b958098cf5381ee746d_I20221231"
      decimals="-5"
      id="f-683"
      unitRef="usd">17500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="iac8c23ec655449c28e8237fc61998863_I20221231"
      decimals="-5"
      id="f-684"
      unitRef="usd">200000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="iac8c23ec655449c28e8237fc61998863_I20221231"
      decimals="-5"
      id="f-685"
      unitRef="usd">1100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:InterestExpense
      contextRef="i24dada1a3b5242b5a75afa813589f088_D20220101-20221231"
      decimals="-5"
      id="f-686"
      unitRef="usd">2600000</us-gaap:InterestExpense>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iac8c23ec655449c28e8237fc61998863_I20221231"
      decimals="-5"
      id="f-687"
      unitRef="usd">39600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i24dada1a3b5242b5a75afa813589f088_D20220101-20221231"
      decimals="4"
      id="f-688"
      unitRef="number">0.1286</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i788faa633fdf42068abaa39dc2edf9d3_D20220601-20220601"
      decimals="-5"
      id="f-689"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i788faa633fdf42068abaa39dc2edf9d3_D20220601-20220601"
      decimals="0"
      id="f-690"
      unitRef="shares">749053</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i16fb4c62472c449a9b7982be7439e638_I20220601"
      decimals="4"
      id="f-691"
      unitRef="usdPerShare">6.6751</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i53c72d39d32d498788a5ca7d700ec4e8_I20220601"
      decimals="-5"
      id="f-692"
      unitRef="usd">33500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i92c6b12ce519418c8440d547c323d70f_I20161231"
      decimals="-5"
      id="f-693"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i19d31eefba974ecf8d96ae66cc576d69_I20161231"
      decimals="-5"
      id="f-694"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id8ef2a5a94d44cb39fe45dcedfee9769_I20180531"
      decimals="-5"
      id="f-695"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i442e61d07b494a89af46c51bf3c39c99_I20180803"
      decimals="-5"
      id="f-696"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i10d5cb28ee524a039c68d61469c0487f_I20190305"
      decimals="-5"
      id="f-697"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i10d5cb28ee524a039c68d61469c0487f_I20190305"
      decimals="-5"
      id="f-698"
      unitRef="usd">23300000</us-gaap:LineOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i87edad638cf242f0a34985f29b06a8ed_D20190305-20190305"
      decimals="-5"
      id="f-699"
      unitRef="usd">6700000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i43c59ab4e6cc45cab9946e312f152846_I20190305"
      decimals="-5"
      id="f-700"
      unitRef="usd">30000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i676ed4dafff44a7db6aea95716fda14c_I20190305"
      decimals="-5"
      id="f-701"
      unitRef="usd">5000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <eigr:DebtInstrumentInterestPaymentPeriod
      contextRef="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223"
      id="f-702">P17M</eigr:DebtInstrumentInterestPaymentPeriod>
    <eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod
      contextRef="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223"
      id="f-703">P19M</eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod>
    <eigr:AmendmentFeesPayment
      contextRef="i1d7c6a4e9ebe48f3a01d633d6e1202a2_D20210223-20210223"
      decimals="-5"
      id="f-704"
      unitRef="usd">200000</eigr:AmendmentFeesPayment>
    <us-gaap:InterestExpense
      contextRef="i054ac64c0a9a48f39f0672426b1763f8_D20220101-20221231"
      decimals="-5"
      id="f-705"
      unitRef="usd">1500000</us-gaap:InterestExpense>
    <eigr:DebtInstrumentExitFeePayablePercentage
      contextRef="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601"
      decimals="3"
      id="f-706"
      unitRef="number">0.0750</eigr:DebtInstrumentExitFeePayablePercentage>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601"
      decimals="-5"
      id="f-707"
      unitRef="usd">2300000</eigr:DebtInstrumentUnamortizedExitFees>
    <eigr:DebtInstrumentUnamortizedAdditionalExitFees
      contextRef="i6e0db16a8eb64b9bb35375c5f4e9fbd5_I20220601"
      decimals="-5"
      id="f-708"
      unitRef="usd">1000000</eigr:DebtInstrumentUnamortizedAdditionalExitFees>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ifed09a12b16a48eca75c2639c1883cb0_D20211006-20211006"
      decimals="-5"
      id="f-709"
      unitRef="usd">900000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i062780bfd6314b9aa885ba2d25702a18_I20220601"
      decimals="-5"
      id="f-710"
      unitRef="usd">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest
      contextRef="i911bf9268d42447e85041ca1379f6928_D20220601-20220601"
      decimals="-5"
      id="f-711"
      unitRef="usd">200000</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <eigr:LineOfCreditFacilityOtherFinalPayments
      contextRef="i062780bfd6314b9aa885ba2d25702a18_I20220601"
      decimals="-5"
      id="f-712"
      unitRef="usd">3300000</eigr:LineOfCreditFacilityOtherFinalPayments>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i911bf9268d42447e85041ca1379f6928_D20220601-20220601"
      decimals="-5"
      id="f-713"
      unitRef="usd">33500000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9d011b31a4674517a07eb189e6e48b8a_D20220101-20221231"
      decimals="-5"
      id="f-714"
      unitRef="usd">-1100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-715">Debt and unamortized discount balances are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-716"
      unitRef="usd">40531000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-717"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-718"
      unitRef="usd">2600000</eigr:DebtInstrumentUnamortizedExitFees>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-719"
      unitRef="usd">3277000</eigr:DebtInstrumentUnamortizedExitFees>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-720"
      unitRef="usd">3506000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-721"
      unitRef="usd">1482000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-722"
      unitRef="usd">39625000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-723"
      unitRef="usd">31795000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-724"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-725"
      unitRef="usd">7809000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-726"
      unitRef="usd">39625000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-727"
      unitRef="usd">23986000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-728">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, future minimum payments of principal, exit fee and interest expense under the Innovatus Loan were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(21,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: exit fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-729"
      unitRef="usd">3686000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-730"
      unitRef="usd">3780000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-731"
      unitRef="usd">4407000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-732"
      unitRef="usd">4814000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-733"
      unitRef="usd">48185000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-734"
      unitRef="usd">64872000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-735"
      unitRef="usd">21741000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <eigr:DebtInstrumentExitFee
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-736"
      unitRef="usd">3506000</eigr:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6e876d14531242919ba3e7c51a9f6620_I20221231"
      decimals="-3"
      id="f-737"
      unitRef="usd">39625000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-738">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the Company&#x2019;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the convertible preferred stockholders. As of December&#160;31, 2022, no dividends had been declared by the Board of Directors.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by the Company up to a maximum aggregate offering price of $200.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of its common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0&#160;million of the maximum aggregate offering price of $200.0&#160;million may be issued and sold pursuant to an ATM financing facility (the 2020 ATM Facility) under a sales agreement with Jefferies. In December 2021, the Company completed ATM offerings for a total of 565,938 shares of common stock under the 2020 ATM Facility. The offerings were made under the Company&#x2019;s effective shelf registration statement and resulted in net proceeds to the Company of $3.0&#160;million, after deducting commissions. In January and March 2022, the Company completed ATM offerings for a total of 5,841,786 shares of common stock under the 2020 ATM Facility. The offerings were made under the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective shelf registration statement and resulted in net proceeds to the Company of $45.6&#160;million, after deducting commissions. As of December 31, 2022, the Company completed the sale of all shares available for sale under the 2020 ATM Facility, and the 2020 ATM Facility was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2022, the Company entered into a new Open Market Sale &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with Jefferies, pursuant to which the Company can sell up to a maximum of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$50.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our common stock in offerings that are deemed &#x201c;at the market&#x201d; offerings as defined in Rule 415 under the Securities Act, under the Company&#x2019;s effective shelf registration statement (the 2022 ATM Facility). In April 2022, the Company completed offerings from the 2022 ATM facility for a total of 2,686,288 shares of our common stock resulting in net proceeds of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, after deducting commissions costs. No additional offerings were completed since April 2022. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there was approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$28.7 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; remaining under the 2022 ATM Facility for future issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,143,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,262,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options available for future grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,976,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,327,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted and performance stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;641,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;788,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;671,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,549,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,884,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <eigr:DividendsDeclared
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-739"
      unitRef="usd">0</eigr:DividendsDeclared>
    <eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount
      contextRef="i13530243d7b34f1c827b988b0901189a_D20201201-20201231"
      decimals="-5"
      id="f-740"
      unitRef="usd">200000000</eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount>
    <eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod
      contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231"
      decimals="-5"
      id="f-741"
      unitRef="usd">50000000</eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod>
    <eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount
      contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231"
      decimals="-5"
      id="f-742"
      unitRef="usd">200000000</eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231"
      decimals="0"
      id="f-743"
      unitRef="shares">565938</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3da6ebc9c2f54835a8a53c1b40b98c1c_D20201201-20201231"
      decimals="-5"
      id="f-744"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic3b089476acf40c8a5b5c34b133005bc_D20220101-20220331"
      decimals="0"
      id="f-745"
      unitRef="shares">5841786</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2cd0a96271fe4fe19e51825f3a419589_D20220331-20220331"
      decimals="-5"
      id="f-746"
      unitRef="usd">45600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eigr:CommonStockValueAvailableForFutureIssuance
      contextRef="i1ff52c712c8d4b55877e2745e77f4a16_D20220325-20220325"
      decimals="-5"
      id="f-747"
      unitRef="usd">50000000</eigr:CommonStockValueAvailableForFutureIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8b3390cbd84f4e9b830a1dae02e73f6d_D20220325-20220325"
      decimals="0"
      id="f-748"
      unitRef="shares">2686288</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8b3390cbd84f4e9b830a1dae02e73f6d_D20220325-20220325"
      decimals="-5"
      id="f-749"
      unitRef="usd">20800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <eigr:CommonStockValueAvailableForFutureIssuance
      contextRef="iedce0e0e2285449bb203fa52f3e4b81a_D20220101-20221231"
      decimals="-5"
      id="f-750"
      unitRef="usd">28700000</eigr:CommonStockValueAvailableForFutureIssuance>
    <eigr:CommonStockReservedForFutureIssuancesTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-751">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,143,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,262,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Options available for future grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,976,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,327,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Restricted and performance stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;641,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Shares available for issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;788,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;671,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,549,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,884,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</eigr:CommonStockReservedForFutureIssuancesTableTextBlock>
    <eigr:OptionsIssuedAndOutstanding
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="0"
      id="f-752"
      unitRef="shares">6143183</eigr:OptionsIssuedAndOutstanding>
    <eigr:OptionsIssuedAndOutstanding
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="0"
      id="f-753"
      unitRef="shares">5262185</eigr:OptionsIssuedAndOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="0"
      id="f-754"
      unitRef="shares">1976460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="0"
      id="f-755"
      unitRef="shares">1327645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <eigr:RestrictedAndPerformanceStockUnitsOutstanding
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="0"
      id="f-756"
      unitRef="shares">641407</eigr:RestrictedAndPerformanceStockUnitsOutstanding>
    <eigr:RestrictedAndPerformanceStockUnitsOutstanding
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="0"
      id="f-757"
      unitRef="shares">623000</eigr:RestrictedAndPerformanceStockUnitsOutstanding>
    <eigr:SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="0"
      id="f-758"
      unitRef="shares">788057</eigr:SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram>
    <eigr:SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="0"
      id="f-759"
      unitRef="shares">671172</eigr:SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="0"
      id="f-760"
      unitRef="shares">9549107</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="0"
      id="f-761"
      unitRef="shares">7884002</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-762">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restated 2013 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s Board of Directors adopted and in August 2016 the Company&#x2019;s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Under the terms of the Restated 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restated 2013 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than 110% of fair market value, as determined by the Board of Directors. The terms of options granted under the Restated 2013 Plan may not exceed ten years. The vesting schedule of newly issued option grants is generally four years.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of December&#160;31, 2022, the Company is authorized to issue up to 8,127,807 shares under the Restated 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, the Company approved the 2021 Inducement Plan to reserve 850,000 shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals&#x2019; entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of December&#160;31, 2022, there were 380,000 shares remaining available to be issued under the 2021 Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity, including restricted stock units (RSUs) and performance stock units (PSUs) available for grant activity, under the Company&#x2019;s stock-based compensation plans during the year ended December&#160;31, 2022 (in thousands, except option and share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;br/&gt;Available for &lt;br/&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of  December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,262,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional options authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,061,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(298,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,132,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of  December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,143,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of  December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,726,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock of $1.18 as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised in 2022, 2021 and 2020 was $0.1 million, $0.1&#160;million and $0.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021 and 2020, the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; weighted-average grant date fair value of options granted were $3.65, $5.58 and $4.78 per share, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair value of options that vested during the years ended December&#160;31, 2022, 2021 and 2010 was $7.3 million, $6.9&#160;million and $5.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records stock-based compensation of stock options granted by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizes the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. The fair value of stock options was estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.71%-88.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.96%-71.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.00%-77.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76%-4.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62%-1.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39%-1.37%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The expected term represents the number of years the Company estimates, based primarily on historical experience, that the options will be outstanding prior to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The expected volatility for stock options is based on the Company's historical stock price volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, the Company&#x2019;s board of directors adopted and in 2016, upon the merger with Celladon, the Company amended and approved the 2013 Employee Stock Purchase Plan (2013 ESPP). The 2013 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code and is administered by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock initially reserved for issuance under the 2013 ESPP was 100,000 shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 165,000 shares of common stock, unless a lower number determined by the board of directors. As of December&#160;31, 2022, a total of 948,831 shares are reserved for issuance and 788,057 shares available for future issuance under the 2013 ESPP. During the years ended December&#160;31, 2022, 2021 and 2020, employees purchased 48,115 shares for $0.2&#160;million, 37,619 shares for $0.3&#160;million and 25,645 shares for $0.2&#160;million, respectively, under the 2013 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, the Company revised its non-employee director compensation policy to approve the granting of RSUs in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for at least six months during the prior calendar year and continues to serve as a non-employee member of the board of Directors (the Board) is granted RSUs. Each eligible director who has served on the Board for less than six months during the prior calendar year and who continues to serve as a non-employee member of the Board, is granted RSUs which are pro-rated for the period served during the prior calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director&#x2019;s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. The RSUs granted to employees will vest annually on the one-year, two-year, and three-year anniversaries of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company&#x2019;s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PSUs are also available for grant pursuant to the Restated 2013 Plan. Each PSU, which is a stock award, is earned through the achievement of performance-based metrics over a defined performance period. The length of the defined performance period, the performance-based metric to be achieved during the defined performance period, and the measure of whether and to what degree such performance-based metric has been achieved will be conclusively determined by the compensation committee of the Company&#x2019;s Board, in its sole discretion. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022 and 2021 the Company granted 30,000 and 270,000 PSUs, with a weighted-average grant date fair value of $6.87 and $7.92 per share, respectively. The performance-based metrics include the achievement of certain revenue targets and clinical and regulatory milestones. During the year ended December&#160;31, 2022 and 2021, the Company recorded $0.5 million and $0.2&#160;million of stock-based compensation expense related to the PSUs as it is expected that all milestones will be achieved by the target dates, respectively. This expense is included in selling, general and administrative expenses. As of December&#160;31, 2022, no PSUs have vested as the performance-based metrics of the PSUs have not yet been achieved. During the year ended December&#160;31, 2022 and 2021, the Company granted 298,150 and 371,500 RSUs, respectively, with a weighted-average grant date fair value of $5.22 and $9.16 per share, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In relation to the RSUs granted, the Company recognized $1.2&#160;million and $0.9&#160;million in stock-based compensation expense for the year ended December&#160;31, 2022 and 2021, respectively, which were included in selling, general and administrative expenses. As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested RSUs and PSUs was $3.0&#160;million, which the Company expects to recognize over an estimated weighted-average period of 2.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PSU activity and weighted average grant date fair value for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares as of  December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares as of  December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense recognized was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested options was $10.1 million, which the Company expects to recognize over an estimated weighted average period of 2.70 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice
      contextRef="ib1ec4a30b09349279833954d224dead9_D20220101-20221231"
      decimals="2"
      id="f-763"
      unitRef="number">0.10</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i0a28c62f12bf4413a513b312483af157_D20220101-20221231"
      decimals="2"
      id="f-764"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id7aafa6247ea4c65a7c5873f86ff4fd6_D20220101-20221231"
      id="f-765">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i09207d695d8c4253a8e427f8c6d035d4_D20220101-20221231"
      id="f-766">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if4028eb882514f05b6a41d5478817cee_I20221231"
      decimals="0"
      id="f-767"
      unitRef="shares">8127807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ief5a5c4c1ae64fc4ab9b4e7b4056be2a_D20210401-20210630"
      decimals="-4"
      id="f-768"
      unitRef="shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie2dd632aefc143bb8b84aea6a35fcbaf_I20221231"
      decimals="0"
      id="f-769"
      unitRef="shares">380000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-770">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity, including restricted stock units (RSUs) and performance stock units (PSUs) available for grant activity, under the Company&#x2019;s stock-based compensation plans during the year ended December&#160;31, 2022 (in thousands, except option and share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;br/&gt;Available for &lt;br/&gt;Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of  December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,262,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional options authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,061,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,061,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(298,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,132,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of  December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,143,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of  December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,726,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-771"
      unitRef="shares">1327645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-772"
      unitRef="shares">5262185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="2"
      id="f-773"
      unitRef="usdPerShare">10.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      id="f-774">P7Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-775"
      unitRef="usd">530000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-776"
      unitRef="shares">1728441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-777"
      unitRef="shares">2061100</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-778"
      unitRef="shares">2061100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="2"
      id="f-779"
      unitRef="usdPerShare">5.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-780"
      unitRef="shares">298150</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-781"
      unitRef="shares">30000</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-782"
      unitRef="shares">47367</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="2"
      id="f-783"
      unitRef="usdPerShare">4.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-784"
      unitRef="shares">1132735</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-785"
      unitRef="shares">1132735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="2"
      id="f-786"
      unitRef="usdPerShare">9.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="INF"
      id="f-787"
      unitRef="shares">126889</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="0"
      id="f-788"
      unitRef="shares">50000</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-789"
      unitRef="shares">1976460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-790"
      unitRef="shares">6143183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="2"
      id="f-791"
      unitRef="usdPerShare">9.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-792">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-793"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-794"
      unitRef="shares">3726809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">10.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-796">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-797"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <eigr:ClosingPriceOfCommonStock
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">1.18</eigr:ClosingPriceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-799"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-800"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-5"
      id="f-801"
      unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i73059116eb97484196f938499f7d5281_D20220101-20221231"
      decimals="2"
      id="f-802"
      unitRef="usdPerShare">3.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6ec04d4ad35c443b99bbe1aa326e6d2a_D20210101-20211231"
      decimals="2"
      id="f-803"
      unitRef="usdPerShare">5.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4c049d0b7ef5404389a868b354fa749a_D20200101-20201231"
      decimals="2"
      id="f-804"
      unitRef="usdPerShare">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-805"
      unitRef="usd">7300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-806"
      unitRef="usd">6900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-5"
      id="f-807"
      unitRef="usd">5600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-808">The fair value of stock options was estimated using the following weighted-average assumptions:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.27-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contractual term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.71%-88.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.96%-71.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.00%-77.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76%-4.23%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62%-1.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39%-1.37%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The expected term represents the number of years the Company estimates, based primarily on historical experience, that the options will be outstanding prior to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The expected volatility for stock options is based on the Company's historical stock price volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaac2aed31bb54cc18cb6ae41a4a4024c_D20220101-20221231"
      id="f-809">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i71407d30e650431da3d0986454f2222a_D20220101-20221231"
      id="f-810">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i09b3e189eaf243f4af6da3f36cd256b0_D20210101-20211231"
      id="f-811">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i51aa14a7322841a28eb8b15ffc596162_D20210101-20211231"
      id="f-812">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i79074ea06073434787ed7105b645d332_D20200101-20201231"
      id="f-813">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic09b60b6370048899551663b184c6f48_D20200101-20201231"
      id="f-814">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icdaee817ecba4432b442ecd4baec5196_D20200101-20201231"
      id="f-815">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"
      decimals="4"
      id="f-816"
      unitRef="number">0.6871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"
      decimals="4"
      id="f-817"
      unitRef="number">0.8851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231"
      decimals="4"
      id="f-818"
      unitRef="number">0.6896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231"
      decimals="4"
      id="f-819"
      unitRef="number">0.7140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231"
      decimals="4"
      id="f-820"
      unitRef="number">0.7300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231"
      decimals="4"
      id="f-821"
      unitRef="number">0.7700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"
      decimals="4"
      id="f-822"
      unitRef="number">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"
      decimals="4"
      id="f-823"
      unitRef="number">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231"
      decimals="4"
      id="f-824"
      unitRef="number">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231"
      decimals="4"
      id="f-825"
      unitRef="number">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231"
      decimals="4"
      id="f-826"
      unitRef="number">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231"
      decimals="4"
      id="f-827"
      unitRef="number">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"
      decimals="0"
      id="f-828"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idf806ddcd0e24a74b911855e055c2d7c_D20210101-20211231"
      decimals="0"
      id="f-829"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9898d9a85d6b45a08f3125925c3e1878_D20200101-20201231"
      decimals="0"
      id="f-830"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie5e793187f544593b74da04cabc2339b_D20220101-20221231"
      decimals="0"
      id="f-831"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if03ebee97bdd465fb594bd07b6658cd6_I20131231"
      decimals="0"
      id="f-832"
      unitRef="shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="INF"
      id="f-833"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="0"
      id="f-834"
      unitRef="shares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i965b044302dc48988da35b57cfb58274_I20221231"
      decimals="0"
      id="f-835"
      unitRef="shares">948831</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i965b044302dc48988da35b57cfb58274_I20221231"
      decimals="0"
      id="f-836"
      unitRef="shares">788057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i03ee8ecd9ac8450ba867acb206224e82_D20220101-20221231"
      decimals="INF"
      id="f-837"
      unitRef="shares">48115</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-838"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6f0af6d5a5ea4cedb2861dd74451038b_D20210101-20211231"
      decimals="INF"
      id="f-839"
      unitRef="shares">37619</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i876a85cbf4fb4e23ae7caa7d09ad0e13_D20210101-20211231"
      decimals="-5"
      id="f-840"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id6e0957246eb427da4b2bef52269a5ef_D20200101-20201231"
      decimals="INF"
      id="f-841"
      unitRef="shares">25645</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i74d7c3ecf9db4947bf177241914557a1_D20200101-20201231"
      decimals="-5"
      id="f-842"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
      contextRef="i94322c77d52a4ebc957caaa8538856a0_D20200101-20200331"
      id="f-843">P6M</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1
      contextRef="i94322c77d52a4ebc957caaa8538856a0_D20200101-20200331"
      id="f-844">P6M</us-gaap:DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if1c1d057c3104eb38128ca6d2e56cc34_D20200101-20200331"
      id="f-845">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib0d49d00344d4c8d9255a8ab257ddb21_D20200101-20200331"
      id="f-846">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i50b559f643dc4ebe82779e55c0713860_D20200101-20200331"
      id="f-847">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231"
      decimals="-4"
      id="f-848"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4545b7ea67d340b68656d572237dd471_D20210101-20211231"
      decimals="-4"
      id="f-849"
      unitRef="shares">270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231"
      decimals="2"
      id="f-850"
      unitRef="usdPerShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4545b7ea67d340b68656d572237dd471_D20210101-20211231"
      decimals="2"
      id="f-851"
      unitRef="usdPerShare">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231"
      decimals="-5"
      id="f-852"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4545b7ea67d340b68656d572237dd471_D20210101-20211231"
      decimals="-5"
      id="f-853"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231"
      decimals="INF"
      id="f-854"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia26ed6605602415ead8fa34aa2933308_D20211001-20211231"
      decimals="INF"
      id="f-855"
      unitRef="shares">298150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231"
      decimals="INF"
      id="f-856"
      unitRef="shares">371500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia26ed6605602415ead8fa34aa2933308_D20211001-20211231"
      decimals="2"
      id="f-857"
      unitRef="usdPerShare">5.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231"
      decimals="2"
      id="f-858"
      unitRef="usdPerShare">9.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea5fd9f65a07451c9c163efc7530542c_D20220101-20221231"
      decimals="-5"
      id="f-859"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia9e1d4b42250476fa5702ee998b028b7_D20210101-20211231"
      decimals="-5"
      id="f-860"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i96530fc320b84544b9696cf29d5efa21_I20221231"
      decimals="-5"
      id="f-861"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i4234b3566e684a2bbc69705bd15492d7_I20221231"
      decimals="-5"
      id="f-862"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iea5fd9f65a07451c9c163efc7530542c_D20220101-20221231"
      id="f-863">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i382c9c9de96c462b95e1262c30084c2e_D20220101-20221231"
      id="f-864">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-865">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PSU activity and weighted average grant date fair value for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares as of  December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares as of  December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i78457377acd944119ee3cbc487a296cf_I20211231"
      decimals="0"
      id="f-866"
      unitRef="shares">623000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i78457377acd944119ee3cbc487a296cf_I20211231"
      decimals="2"
      id="f-867"
      unitRef="usdPerShare">8.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"
      decimals="0"
      id="f-868"
      unitRef="shares">328150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"
      decimals="2"
      id="f-869"
      unitRef="usdPerShare">5.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"
      decimals="0"
      id="f-870"
      unitRef="shares">132854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"
      decimals="2"
      id="f-871"
      unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"
      decimals="0"
      id="f-872"
      unitRef="shares">176889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9ae767dd24e8443f80ef9fd1c68d9ab4_D20220101-20221231"
      decimals="2"
      id="f-873"
      unitRef="usdPerShare">7.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231"
      decimals="0"
      id="f-874"
      unitRef="shares">641407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i58c4f8b33420498dbaddf6374b2ce8fa_I20221231"
      decimals="2"
      id="f-875"
      unitRef="usdPerShare">7.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-876">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense recognized was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i77186ca2509745eb8c68fb8c32e77418_D20220101-20221231"
      decimals="-3"
      id="f-877"
      unitRef="usd">3159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i891dd7eeeb804b7180c764a60670443b_D20210101-20211231"
      decimals="-3"
      id="f-878"
      unitRef="usd">2252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bf58d38de1c412a9467e8c815412e01_D20200101-20201231"
      decimals="-3"
      id="f-879"
      unitRef="usd">1494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8e0daa1d8724811b59a7c133d069b57_D20220101-20221231"
      decimals="-3"
      id="f-880"
      unitRef="usd">5158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea11b6251f7c49fbab31dbf60503d7f5_D20210101-20211231"
      decimals="-3"
      id="f-881"
      unitRef="usd">5649000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d45e0236dca466d80b365de652362f6_D20200101-20201231"
      decimals="-3"
      id="f-882"
      unitRef="usd">4479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-883"
      unitRef="usd">8317000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-884"
      unitRef="usd">7901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-885"
      unitRef="usd">5973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-5"
      id="f-886"
      unitRef="usd">10100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-887">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-890">Income Taxes&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s provision for income taxes was approximately $23,000 and $64,000 for the year ended December&#160;31, 2022 and 2021 respectively, with an effective tax rate of (0.02)% and (0.19)% for the year ended December&#160;31, 2022 and 2021. No provision for income taxes was recorded for the years ended December 31, 2020. The effective tax rate in each period differs from the U.S. statutory tax rate primarily due to the valuation allowances on the Company&#x2019;s deferred tax assets as it is more likely than not that some or all of the Company&#x2019;s deferred tax assets will not be realized. The tax expense recorded for the year ended December&#160;31, 2022 relates to state taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(31.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Section 174 Capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(96,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(71,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s lack of earnings history, the deferred tax assets have been fully offset by a valuation allowance as of December 31, 2022 and 2021. The net change in the valuation allowance for the years ended December&#160;31, 2022 and 2021 increased by $25.1&#160;million and $10.5&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had approximately $292.3&#160;million and $25.4&#160;million, respectively, of federal and state operating loss carryforwards available to reduce future taxable income that will begin to expire in 2030 and 2028, respectively, for federal and state tax purposes. The Company had $10.8&#160;million of federal Orphan Drug credit carryforwards available to reduce future taxable income that will begin to expire in 12/31/2041.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company also had research and development tax credit carryforwards of approximately $0&#160;million and $3.1&#160;million for federal and state purposes available to offset future taxable income tax, respectively. If not utilized, the state credits can be carried forward indefinitely. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if the Company has experienced an ownership change under Section 382 of the Internal Revenue Code (the Code) of 1986, as amended. The Company&#x2019;s merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#x2019;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. The Company assessed whether it had an ownership change, as defined by Section 382 of the Code from its formation through December 31, 2021. Based upon this assessment, the Company experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to the April 20, 2016 and October 18, 2018 ownership changes, reductions were made to the Company&#x2019;s NOL and tax credit carryforwards under these rules. Additional ownership changes in the future could result in additional limitations on the Company&#x2019;s NOL and tax credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits for the years ended December&#160;31, 2022, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions based on tax positions related to prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reductions based on tax positions related to prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reductions based on tax positions related to current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the $3.5 million of unrecognized tax benefits is recognized, there would not be an effect on the effective tax rate. The Company does not expect the unrecognized tax benefits to change significantly over the next 12 months. As of December&#160;31, 2022, the unrecognized tax benefits for uncertain tax positions were offset against deferred tax assets and would not affect the income tax rate if recognized due to the Company being in a full valuation allowance position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to account for interest and penalties in tax expense on the consolidated statements of operations. The Company files income tax returns in the U.S. federal and state jurisdictions. All periods since inception are subject to examination by U.S. federal and state jurisdictions. There were no such interest or penalties during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="0"
      id="f-891"
      unitRef="usd">23000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-892"
      unitRef="usd">64000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-893"
      unitRef="number">-0.0002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-894"
      unitRef="number">-0.0019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-895">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(31.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(26.75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-896"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-897"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-898"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-899"
      unitRef="number">-0.2599</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-900"
      unitRef="number">-0.3107</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-901"
      unitRef="number">-0.2675</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-902"
      unitRef="number">0.0415</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-903"
      unitRef="number">0.1214</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-904"
      unitRef="number">0.0643</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-905"
      unitRef="number">0.0239</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-906"
      unitRef="number">0.0073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-907"
      unitRef="number">0.0033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-908"
      unitRef="number">-0.0098</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-909"
      unitRef="number">-0.0302</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-910"
      unitRef="number">-0.0100</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-911"
      unitRef="number">-0.0059</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-912"
      unitRef="number">0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-913"
      unitRef="number">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="4"
      id="f-914"
      unitRef="number">-0.0002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="4"
      id="f-915"
      unitRef="number">-0.0019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="4"
      id="f-916"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-917">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;60,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Section 174 Capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;96,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(96,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(71,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-918"
      unitRef="usd">63069000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-919"
      unitRef="usd">60273000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-920"
      unitRef="usd">9985000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-921"
      unitRef="usd">5486000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <eigr:DeferredTaxAssetDepreciationAndAmortization
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-922"
      unitRef="usd">2920000</eigr:DeferredTaxAssetDepreciationAndAmortization>
    <eigr:DeferredTaxAssetDepreciationAndAmortization
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-923"
      unitRef="usd">1863000</eigr:DeferredTaxAssetDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-924"
      unitRef="usd">3429000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-925"
      unitRef="usd">3004000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-926"
      unitRef="usd">15581000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-927"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-928"
      unitRef="usd">1431000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-929"
      unitRef="usd">646000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <eigr:DeferredTaxAssetsLeaseLiabilities
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-930"
      unitRef="usd">131000</eigr:DeferredTaxAssetsLeaseLiabilities>
    <eigr:DeferredTaxAssetsLeaseLiabilities
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-931"
      unitRef="usd">156000</eigr:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-932"
      unitRef="usd">96546000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-933"
      unitRef="usd">71428000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-934"
      unitRef="usd">96418000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-935"
      unitRef="usd">71291000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-936"
      unitRef="usd">128000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-937"
      unitRef="usd">137000</us-gaap:DeferredTaxAssetsNet>
    <eigr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-938"
      unitRef="usd">128000</eigr:DeferredTaxLiabilitiesRightOfUseAssets>
    <eigr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-939"
      unitRef="usd">137000</eigr:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-940"
      unitRef="usd">128000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-941"
      unitRef="usd">137000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-942"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-943"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <eigr:IncreaseInDeferredTaxAssetsValuationAllowance
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-944"
      unitRef="usd">25100000</eigr:IncreaseInDeferredTaxAssetsValuationAllowance>
    <eigr:IncreaseInDeferredTaxAssetsValuationAllowance
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-945"
      unitRef="usd">10500000</eigr:IncreaseInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i5b1c32c7c8074780b2a2e9572bb98ea4_I20221231"
      decimals="-5"
      id="f-946"
      unitRef="usd">292300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i038017cc1aff4f5b802f302a04651e70_I20221231"
      decimals="-5"
      id="f-947"
      unitRef="usd">25400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id3f6e0f47b76477398971584c280e787_I20221231"
      decimals="-5"
      id="f-948"
      unitRef="usd">10800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i5b1c32c7c8074780b2a2e9572bb98ea4_I20221231"
      decimals="-5"
      id="f-949"
      unitRef="usd">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i038017cc1aff4f5b802f302a04651e70_I20221231"
      decimals="-5"
      id="f-950"
      unitRef="usd">3100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-951">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits for the years ended December&#160;31, 2022, 2021 and 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions based on tax positions related to prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reductions based on tax positions related to prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,907)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reductions based on tax positions related to current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-952"
      unitRef="usd">1950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231"
      decimals="-3"
      id="f-953"
      unitRef="usd">451000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8c1713a9ff0046649a86f61420a19003_I20191231"
      decimals="-3"
      id="f-954"
      unitRef="usd">3277000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-955"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-956"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-957"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-958"
      unitRef="usd">1586000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-959"
      unitRef="usd">1499000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-960"
      unitRef="usd">81000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-961"
      unitRef="usd">44000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-962"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-963"
      unitRef="usd">2907000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-3"
      id="f-964"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-3"
      id="f-965"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-3"
      id="f-966"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-967"
      unitRef="usd">3492000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="-3"
      id="f-968"
      unitRef="usd">1950000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231"
      decimals="-3"
      id="f-969"
      unitRef="usd">451000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-970"
      unitRef="usd">3500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ide6769059acf419584a1d5e087c7d813_I20211231"
      decimals="INF"
      id="f-971"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="INF"
      id="f-972"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i9ad1535391c54ca0a4cf8079da469538_I20201231"
      decimals="INF"
      id="f-973"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-974">Legal Matters&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;From time to time in the ordinary course of business, the Company may be involved in various legal claims and litigation, including those pertaining to the defense and enforcement of the Company's patent or other intellectual property rights and contractual rights. The Company is defending all current litigation matters, including the litigation matters discussed below. Although there can be no assurances and the outcome of these matters is currently not determinable, the Company currently believes that none of these claims or proceedings are likely to have a material adverse effect on the Company's financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The Company records accruals for outstanding legal proceedings, claims or investigations when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company evaluated developments in legal proceedings, claims or investigations that could affect the amount of any accrual, as well as any developments that would result in a loss contingency to become both probable and reasonably estimable. The Company has not recorded any accrual for loss contingencies associated with such legal claims or litigation discussed herein as they are in the early stages and an estimate of loss, if any, cannot be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;On November 8, 2022 a putative securities class action complaint was filed in the United States District Court for the Northern District of California alleging that the company and two former executives violated Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The complaint alleges generally that between March 2021 and October 2022 material misstatements and omissions were made to shareholders regarding the TOGETHER study of peginterferon lambda for the treatment of COVID-19 as well as the likelihood of FDA approval of an Emergency Use Authorization for peginterferon lambda. The Court appointed a lead plaintiff on March 2, 2023. The litigation is currently ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;On November 15, 2022, the Company received a demand for arbitration (Demand) from claimant The Progeria Research Foundation, Inc. (PRF) asserting two claims under a May 15, 2018 Collaboration and Supply Agreement (the PRF Collaboration Agreement) between the parties. PRF has alleged that the Company breached an obligation to supply quantities of a drug as requested by PRF. PRF also has a claim for declaratory relief regarding the grant of licenses under the PRF Collaboration Agreement. On January 18, 2023, the Company filed a response to the Demand denying PRF&#x2019;s claims, contesting the arbitrability of PRF&#x2019;s claim for declaratory relief, and asserting a counterclaim for declaratory relief related to the contractual provision underlying PRF&#x2019;s original drug supply claim. To give the parties an opportunity to discuss a potential negotiated resolution of their dispute, the arbitration has been suspended through the end of 2023. As a result, all arbitration activities are now on hold, and the final hearing, originally scheduled for May 9 &#x2013; 12, 2023, in Boston, Massachusetts, has been taken off calendar.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <eigr:NumberOfFormerExecutives
      contextRef="iefd9ad44e31d4bb09abdd6c03737db5d_I20221108"
      decimals="0"
      id="f-975"
      unitRef="segment">2</eigr:NumberOfFormerExecutives>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-976">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company entered into a non-cancelable operating facility lease agreement for 8,029 square feet of office space located at 2155 Park Blvd. in Palo Alto, California. The lease commenced on March&#160;1, 2018 and was to expire in February 2023. The lease had a three-year renewal option prior to expiration. The lease included rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $0.3&#160;million. In February 2023, the Company amended the lease to extend the lease by one year with a one year renewal option. The extended lease will commence on March 1, 2023 and expire on February 28, 2024. The Company accounted for the amendment as a lease modification in accordance with ASC Topic 842. The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense recognized for the Company&#x2019;s operating leases was $0.6 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were $0.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating cash outflows for the operating lease liabilities were $0.7&#160;million, $0.6&#160;million and $0.7&#160;million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, the weighted-average remaining lease term and weighted-average discount rate were 1.2 years and 12.82%, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. However, the amount and timing of these payments are not known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Manufacturing Service Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, the Company is required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture 80% of actual manufacturing volume. If the Company orders more than 20 percent of manufacturing volume from other manufacturers, the Company is required to pay 70% of purchase price to Patheon for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive two-year terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#x2019;s notice of termination to the other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="ie6112fe6606643398b7e891f4e07a185_I20171031"
      decimals="0"
      id="f-977"
      unitRef="sqft">8029</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie6112fe6606643398b7e891f4e07a185_I20171031"
      id="f-978">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue
      contextRef="ie6112fe6606643398b7e891f4e07a185_I20171031"
      decimals="-5"
      id="f-979"
      unitRef="usd">300000</us-gaap:PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i88df8041ee074c629e1deb74604adbcd_I20230228"
      id="f-980">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-981">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-982"
      unitRef="usd">528000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-983"
      unitRef="usd">84000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-984"
      unitRef="usd">1000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-985"
      unitRef="usd">613000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-986"
      unitRef="usd">39000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-987"
      unitRef="usd">574000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-988"
      unitRef="usd">491000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="-3"
      id="f-989"
      unitRef="usd">83000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-990"
      unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-5"
      id="f-991"
      unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-992"
      unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-993"
      unitRef="usd">100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-994"
      unitRef="usd">100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-5"
      id="f-995"
      unitRef="usd">100000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      decimals="-5"
      id="f-996"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia386820e405b4bf383170b67729d1511_D20210101-20211231"
      decimals="-5"
      id="f-997"
      unitRef="usd">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9f604c27efee4a6bbd8fc92b03ed1aa5_D20200101-20201231"
      decimals="-5"
      id="f-998"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      id="f-999">P1Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i38d8baf64e8f40a288b32a28a3c7522d_I20221231"
      decimals="4"
      id="f-1000"
      unitRef="number">0.1282</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts
      contextRef="i9e22fa7313ce40ddbecce4a6177c2baf_D20200101-20201231"
      decimals="2"
      id="f-1001"
      unitRef="number">0.80</eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts>
    <eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts
      contextRef="i54e4723198e54d37b6163a5733e2bfed_D20200101-20201231"
      decimals="0"
      id="f-1002"
      unitRef="number">20</eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts>
    <eigr:PercentageOfPurchasePrice
      contextRef="i9e22fa7313ce40ddbecce4a6177c2baf_D20200101-20201231"
      decimals="2"
      id="f-1003"
      unitRef="number">0.70</eigr:PercentageOfPurchasePrice>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-1004">Related Party TransactionsAs disclosed in Note 6, the Company entered into license agreements with EGI, which is owned by the founder of the Company.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231"
      id="f-1005">Subsequent Event&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Departure of Directors or Certain Officers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 6, 2023, the Company entered into a separation agreement and general release with David Cory, the Company's former President and Chief Executive Officer. Pursuant to the separation agreement, Mr. Cory will be entitled to receive, (i) $1.5&#160;million continuation of his base salary and target bonus for a period of 18 months; (ii) $0.4&#160;million cash payment equal to Mr. Cory's target bonus for 2022; (iii) reimbursement for COBRA continuation coverage for Mr. Cory and his eligible dependents for a period of 18 months; (iv) accelerated vesting of 50% of Mr. Cory's unvested stock options, performance-based restricted stock units, and time-based RSUs outstanding as of the separation date; (v) reimbursement of Mr. Cory's legal fees associated with the negotiation of the Separation Agreement up to $10,000. The Company accrued $2.0&#160;million related to David Cory's separation for salary and benefits as of December 31, 2022. Expense related to stock options acceleration will be recorded in Q1 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Silicon Valley Bank Closure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 10, 2023, the Company maintained two accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;at Silicon Valley Bank (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SVB) holding&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cash deposits of approximately $8.3&#160;million. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (FDIC) was appointed receiver. The FDIC initially announced that&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ll insured depositors will have full access to their insured deposits no later than, March 13, 2023, with uninsured depositors receiving an advance dividend a receivership certificate for their uninsured funds. On March 12, 2023, the U.S. Treasury Department, the Federal Reserve and the FDIC jointly announced enabling actions that fully protect all SVB depositors&#x2019; insured and uninsured deposits, and that such depositors would have access to all of their funds starting March 13, 2023. On March 13, 2023, the Company was able to access its full deposits with SVB. The cash was subsequently moved to another financial institution.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206"
      decimals="-5"
      id="f-1006"
      unitRef="usd">1500000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <eigr:BaseSalaryAndTargetBonusContinuationPeriod
      contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206"
      id="f-1007">P18M</eigr:BaseSalaryAndTargetBonusContinuationPeriod>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="i2f726335e506438cbf098a44665c4473_D20230206-20230206"
      decimals="-5"
      id="f-1008"
      unitRef="usd">400000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <eigr:COBRAContinuationCoveragePeriod
      contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206"
      id="f-1009">P18M</eigr:COBRAContinuationCoveragePeriod>
    <eigr:PostEmploymentBenefitAcceleratedVesting
      contextRef="i8892b34c54854c50ad3eda9fa1852d3d_I20230206"
      decimals="2"
      id="f-1010"
      unitRef="number">0.50</eigr:PostEmploymentBenefitAcceleratedVesting>
    <eigr:PostEmploymentBenefitsLegalFeesReimbursementThreshold
      contextRef="i3bd59ee561b343dab5061b07e80ba9b4_I20230206"
      decimals="-3"
      id="f-1011"
      unitRef="usd">10000</eigr:PostEmploymentBenefitsLegalFeesReimbursementThreshold>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="i4934175f59ca42c484533a305704b3c7_I20221231"
      decimals="-5"
      id="f-1012"
      unitRef="usd">2000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <eigr:NumberOfAccounts
      contextRef="i1325efe242c2485cb3654887aef1a15d_I20230310"
      decimals="0"
      id="f-1013"
      unitRef="account">2</eigr:NumberOfAccounts>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id907190c69db4635b5b4ed706d83cdfe_I20230310"
      decimals="-5"
      id="f-1014"
      unitRef="usd">8300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M, %Z_\BY.D_, 5V'3O\"4$L#!!0    ( %.4<%9;.]**Q 4  (\7   8
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M@-\WG*N7&WTFVY[!+_\'4$L#!!0    ( %.4<%;4H9ZUY@4  "<>   8
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M2#E/RXV4=U22,8 D$?;4K-Y3<:VQ(W9C=X[^P^%FRX#IV_HR8"+[,F BW\E
MZP:)W0U*&Y%NYF+WO:?7!MIISAY$@WXM&XJMF\+6=1)OB*^-Q.I=S\[@D&SQ
M4&S=#+9>EMB][+N?')OX[J?$T 6V]B 2_.@(('ML'VE-++&;V'IIL@FQQI]=
M!$.RQ4.Q=7/76F9BM\RG#J-!7?&@;/%0;-T,MJZ8V%WQ^\/(-+*A#WQ) G#&
MZ+%!ZO:/#T[0"EHM]4DDETOLIA3UR=3^[OZT\UZ?\1W=?\ W<7UFV=+41ZB?
MDVJ9E1SE="$IG>M0MJ>J3R7K"\'6^ISNA0G!"OUS19.45@H@GR\8$[L+]8+]
MV?#T/U!+ P04    " !3E'!6] ZN.#L#  !H"@  &    'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;*U6;6_3,!#^*U9 "*1U>6O2;K21M@;$)%XFQN #XH.;
M7!N#8Q?;;0>_GG/2A;;SJGWHER1V[GE\SYWMN]%:JE^Z C#DKN9"C[W*F,6Y
M[^NB@IKJ4[D @7]F4M74X%#-?;U00,L&5',_"H+4KRD37C9JYJY5-I)+PYF
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M1.\>Y,W_#%1M#JI&0=48E)K\(^A AW<FZ7@"9=AE!]NMPPP_\&,<J8D%BC-
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M?]*CYJ(X,,IQLDA_HT;R;LPO\@D CP:C@4ZZ_7VQ)(D1YN&<?EJLV;EV8<
MQ@&7%#E6$,0+%3:),4CQYK,7TXNCDXL9D$TL [Y+KU(A$H)@]H@S8WF>?I\-
M!#K3]Z"?M-]:VH,=WP0CQ[:*):>7\8L^=_9DS_CAXD;"O2@0ACO,6NXY]?*D
M?89T."<EI!H;KH/F5$1?2BE>2\IBE/REP5+?D+>9'C<^(A=ZE;[-T'T+F694
MJOE^J;%--^07D)VF%=\V.9>8;*4M[F$+*!O0 T3O(M6\J_X#58;JXUI-N5HN
M4=+QV:EOKOCTY$^L>(]N^(=(?PY%3[2#P']^<7:8>7YQ5.A&273.UV!S)+3"
M*DF:9TUBY18XGRL0$,T9Z(98YQ!XR5T2?!<!UZFD5AV\!U1;;FF);HJCCW(=
MG+<VLPA,38<=5>C]J4O9_.+PPRD+4T +I!?+1<,H]L'?!\%B^\ Y6CBR^V1V
M=L+;_I/UM]A\ J_HUZ9=1P8_W['$02]%*=-*F.:?).4?3@BH.,(N;,.,7"UK
M948@JMWLC90O$S3FHSV^5?.N29HN]M(36ZT2"\<X@R(W?_%R/+ =/(#O10@X
MY%[Z0P,UP[L<1Y&]N1$&#F?WMQ&$L_T^MN,WZ=O+FRNUBA?/3@BU!*0SN"^:
MA,%7J).N5[X!YYY24FP.^,/4T)[;2XV&\'SB=! _\J7OVIF5WF=0-UPR1XYK
M< 6K5D)W6U,DG9:<*9'[JI..%3?1K\$B#>T4$35JAK;0,Y3#10J"2+F$K;FS
MX%#U#4OS%8X$>?'1E2 .C^T#CI%DN6S;T[.98-!NWWU0O,<_YETS?:K5NS @
MSH]?:2ZRFJ@Q<KZ&KYKCKQ95(SMTV+$2#F:]?_?JXR?_AH2O^/[ 64L&A'YZ
M?CC*0<,^<94\-4^<3Y2Q$$>9.<(RL5DL1SF=7 3ABI5#H#VXJ#P8N& 0];+\
M;_W=D>.I/]SS./F#2VO\S9DK/J_,DI6_O10^S?Q?KKJ4/]@4'Y<_>T5"XTMJ
M*KN@5T^.GSUY),U2_I>NV?"?;YHW7=>L^<<5>5S;X@'Z?M$0,_473!#^GM=/
M_P]02P,$%     @ 4Y1P5I0XWP#$"   ;AD  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&ULO5EK;^,V%OTKA#LH$D");?D1YPEDD@Y:H ,,.IWV0[$?
M:(FVV9%(#4G%\?[Z/9>49,FOR2Z*_9!$HLC+^SCWW$OF;JW-5[L2PK'7/%/V
MOK=RKKCI]VVR$CFWE[H0"E\6VN3<X=4L^[8P@J=^49[UX\%@VL^Y5+V'.S_V
MR3S<Z=)E4HE/AMDRS[G9O!>97M_WAKUZX#>Y7#D:Z#_<%7PI/@OWI?AD\-9O
MI*0R%\I*K9@1B_O>X_#F_9CF^PE_2+&VK6=&ELRU_DHOOZ3WO0$I)#*1.)+
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M@5I7B(\RGZ=R-)7BM%3+SH.,'XB0^C[&.4" /P/O83B#["Y+5<.-?/71<EG
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M4J$W*=&%T6T8KE,<RN&?&QZ^Y F)G,WGWZ2(-S$@![]AIM2T*JD[:+R_V8%
M:-9QXWYQ=&Z$Z8P28@-I"A0#8YAE&,@\SF1C"0L$,U";E<%!$XH"@[G]_"V0
M?(E04*\,4R\FXI&%D6@1^>FRI7^:>ZE7FPBO1[;2.1CE[>K[7SJ,61$NU?"]
M;MY0:>GF0^ YA5*-%Y?4]RN9*+1<-"PL4$(7NL2>'J)D(6NI0[;OQG'4N5P.
M)(NNT%T\3\9[YO9K>TL_BY?3V^7QBA_D;DE^*;' UO'P_'00KZ>:%W"=<%4-
M9@/'PV,N.%H)+<#O"V-\\T(*VO^[N/XO4$L#!!0    ( %.4<%8DIN=9>P8
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MYM "@Y-GPIRZ.GJ<^Y50%XE9?D%K<T?-#8-.ZD+<R;2LJM"@<I2S";6Y26
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M(A$-[J<(7T@F\4Q2:I4 X"0UX[K+DXHRW)<$%6!I<77<=BI<"?E.VC:N.?O
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M+R>QR_&F9BY/H*?M!B?'.HHZNQ]>]K U9$IXQUX0#;T@'J),AN,0GT:MRZ$
M-,A7;K]F@7<Q&7O1V,>G83CQQM&(/0*VGDALLPR>0]PME(#NA):."0?+HS)'
M_H2-PZ'G^SZ;GY*>-MV:W+OYPP.;Q+'GC]!Q$GC!)&2?7>-=>*/HP@LPX,2+
MXPA#ANS4:7[0N8$5H%?NGDEM5$E;7\;:K^U5=E;?X/;F]3T816DED*P<ENCJ
M]R>C7GT\W;U85;K[W$)9O!VZQPROXZ#) ']?*CQI-R^T0'O!G_X#4$L#!!0
M   ( %.4<%;]580YW X  .TL   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;+5::7/<QA']*U,,Y9!5((AC3UE2%74X42IV6*1E5RJ5#T-@=A<1%EAC
M *[H7Y_7/3,XN <IJ_R%W 5F>KI?WSW[:EM6G_5*J5I\6>>%?GVRJNO-R\M+
MG:S46FJ_W*@";Q9EM98UOE;+2[VIE$QYTSJ_C()@<KF667'RYA4_NZ[>O"J;
M.L\*=5T)W:S7LGIXJ_)R^_HD/'$/;K+EJJ8'EV]>;>12W:KZT^:ZPK?+EDJ:
MK56AL[(0E5J\/KD*7[X=T7I>\$NFMKKW69 D=V7YF;Y\3%^?!,20RE52$P6)
M?_?JG<IS(@0V?K,T3]HC:6/_LZ/^ \L.6>ZD5N_*_-<LK5>O3V8G(E4+V>3U
M3;G]N[+RC(E>4N::_XJM63N*3T32Z+I<V\W@8)T5YK_\8G'H;9@%!S9$=D/$
M?)N#F,OWLI9O7E7E5E2T&M3H XO*N\%<5I!2;NL*;S/LJ]_<UF7R^>(MY$K%
MNW(-76M)<+VZK$&=UEPFEM);0RDZ0"F,Q(]E4:^T^%"D*AT2N 1;+6^1X^UM
M=)3B>Y7X(@X]$051=(1>W,H:,[WXD*PK6:F+.Y;U6C[ M&IQ556R6"K^_)^K
M.UU7L)/_[I/>T![MITV^\U)O9*)>G\ YM*KNU<F;[_X23H+OCW ^:CD?':/^
M55KZ8Y3$C=*UK/$T"L)8?/BMR>H'\;%(  S<1ESGLL!7\8^F4+1DXHEZI9B$
M+!Z^^\LL"J??:_&VE%4JRH5XGU7PN[+20J;EANC*(A59(:Z:):R:2>REH(G!
M59FGBO9N-E5YC\VT\@I*2BVAYW![1IN&"^GYN2\^@4[%-&M5K37QNW_M0$BX
MW8-8PEQJPZ2 7$!.>_8K,:N2S,!9433 *]A"764)4>55NT]$4V2U9JE*G%8)
MN06&6M0EX$JS^RQM9*[%=E4*F"\Q5 BUWN3E@U(XH%PLL@18>:(HBPOW0J0M
M_F4E$G")* 7.6UFM3%^%A967<;A3!@K21PWFA?JBJB332FP@G (SM<B5AA@K
MO%S(K,*VZC.RS+W,&^4+Q-1.#$$*SXJE6)<L(K:$P0O'RWU9TSL#*3V4>2Z2
M7&JM^*L%EI8.N= "60LH.K,@C DE$JT!. ]#1;)@Q#B$ZW@/+2<[,GA":B0
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M-^NR]D%<;%?*7"<6;+];:L=2M:3NA>\4#G) T>^.1FPM$ZYS@R=U]R*[=<G
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MD_8(#/ DF$S9OS0IW$7Y?-J?8.LY4,(9^[W+7[%D')"K8%$XAQ]\49"Q$RT
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M.:2+LMW60W]XM7 #UQ=6W78U>)1Y[:"N0"@C_1'4O]* M,HI,Y%[Y=^=UMS
M4R&T7-L0?.TDXI%G,G=Z4!Z)TY+BB516:5EIMW39Q0]<KD0+ZAP5Q825*^^2
M2-\Q>3[LYYO4BA,KXG4N8Q"&6(>6/ES0YI:H""V%2!%T%R7U1X@+VIIR) =C
MZ\44$SNZO(;8M4)38IV)H?ID1*-T3-6F8@2[%L)KY.?.2NUF0D2!L*F@ !FP
MKPWY9)B/#?DW3M(\1MKVVAZ9?<N\I9'=L^U+>BT?PW4?,6(N?(^.+"^</6]Y
MZCM'Z\L\-:8DORL2)VCYYR#MA(TG 3XC3"OG38"8EBGWG+%V!4OO2214<V!U
M@_ST^S5P<8D.&=9S@ %&EBD-)?,YP^SR:9<77B77Z7A\U@ASBJ&*1N57@>U)
M=4S-%M&P;XMB3&CS\ G5]]Z!T-E,VEW><0>2IA4M+I4CZC<N/54O5IH78G7H
M';X%V:]5B4*^H\U4"V*?+HX+0#3XTFLDGB\1T[FE 'OP^15#QZ-%VXA\1"]R
MO],U/A\IQY*@*P=54\=7>&ZZQS:*H!TWW+-"QSY][8*NJ"5'<C#95;F#,K\;
MT#KGJ%J^[A:G4*F,MV0_0%/#0KG,O_1 VG+Y#=)BGN>I&TLKI>N78I4MD7V0
MD&7B/-)UI%G]!J2:;[!@W[Q+F3JXG<8"-2UO2IQ[MWC82?]9:FD2&5>(-U#:
MOYTT,#RI2Q^%IT#O=4JM4D+]S,OPOWA'IH]<^7:O(08D[7A)L ^F>&T2'72]
M2Q^V_N=P+2CUCH8YV_B_/)J[S1]&-_Y_DMUR_V_3;RA2\$.6BB6VC@;GDQ[3
M_A\<_\.JPOUKLE#6JLQ=K@4Z&DT+\'RIE*U_T '-WVC7_P!02P,$%     @
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M&@=I(P%531LDGP"$)V@$>. : +V/)P,  VL- *,P<\D:UVGL,9XO1G%^M_
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M>02VZ]7.(-.$_M@8XFX+PXJ?-[0^@/VEX;WH#;_ \&!FOP%02P,$%     @
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M33'MYZW _"HD%/ZE'S^%??$0S)KK=T+J2)] #T^:MB';A#>*OJ5/[VUAX[Y
MHO%DS[:"PWYM^L(LEV1PE*J@! %@-E$ZZ'G;RZNU,PM7)PI7SI=UZX?.Z@E
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M>C$*C@/(,"<5T_=B^1.;@'J6+Q5,N2<LF[51 &FEM"@:L%%04%Z_R4N3B U
MW-\!2!I XG37&SF5ET23\5"*)4B[VK#9A@O5H8TXRJTK4RW-+#4X/9[6;H#(
M84KGG.8T)5S#69J*BFO*YS 1C*84%7R'J?DFLHJA77VE-#5)P0P>%.85@UN3
M765G)M)\,U*_ N$97#U5M#0N:OARB9I0IKX.0VV$V^W#M!%Y7HM,=HB,$[@3
M7"\47/$,L[<$H8FX#3M9A7V>>!DO,3V"3OP-DBA)/'R=-HT=Q]?=P7=+9H"K
M4+<%Z(7;HW>J2I+B*#!G2Z%\QF#\^5/<CWYXQ'5;<5W'WMDA;F7(-Y@P:^Y;
M7_[<FN5PH[%0?[<I[QY >:]5WO.FM?FT&,UQFS0_N >O2*3RR.BW,OI>INM*
M<JHKN56$%_K._ Q:88,#.CLX@/+C5OGQ1YSU@_<[>]+*./&?6S1_](5@&="B
ME.(9;>+4-D5>GG<F*X[6?^GH@$8WY/]9_,85$W_$ZSWH_6;'R5I)XN6Z$$59
M:93K?[7+I!*Y7I+MQ]O/^-[<K>^5N'-(XP]Q[<3K>R?V7@Y[C?>C.[N-#S<*
MG@+EW)5U"ES-4M<^[6A;.I[5!=-Z>5UWWA$YIUP!P]Q HZ.!N51D7<K5'2U*
M5S[-A#;%F&LN3/F+TBXP\[D0>M6Q&[0%]?@?4$L#!!0    ( %.4<%;=>L,'
MC0,  !4-   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;,U776_;-A3]
M*Q?:,+1 $GW8EIW,%A#'"Q8@:8-D[1Z*/=#2M4V4(C62MKO^^I*4+-NQK':M
M'_IBB]2]A^<<D5=7P[60']4"4<.GG'$U\A9:%U>^K](%YD1=B *YN3,3,B?:
M#.7<5X5$DKFDG/E1$,1^3BCWDJ&;>Y3)4"PUHQP?):AEGA/YWQB96(^\T-M,
M/-'Y0ML)/QD69([/J-\5C]*,_!HEHSER104'B;.1=QU>W80=F^ BWE-<JYUK
ML%*F0GRT@[MLY 66$3),M84@YF^%-\B813(\_JU O7I-F[A[O4&_=>*-F"E1
M>"/8WS33BY$W\"##&5DR_236?V(EJ&?Q4L&4^X5U%1MXD"Z5%GF5;!CDE)?_
MY%-EQ$Y"&!])B*J$Z&5"]TA"ITIPSODE,R=K0C1)AE*L0=IH@V8OG#<NVZBA
MW#[&9RW-76KR=')+J(3WA"T1'I"HI43SC+2"<[C.,FJ=)@SN>+E?K.^O)J@)
M9:]-Q+OG";SZ]?70UX:(A?/3:M%QN6AT9-$P@@?!]4+!'SS#;!_ -PIJ&=%&
MQCAJ19Q@>@&=\ RB((H:"-U\>WK80J=3N]IQ>)VONGH&UTJA,93P#.XIF5)F
M7$6U<3L#X^D3IDLI*9^[J#>"RWIB3!15\.'>+ !W&G/U3Y/=)9MN,QM;":Y4
M05(<>>:H*Y0K])+??@GCX/<FJTX$MF=<MS:NVX:>W%).>$K-GB/.MB:Q)4+/
M(=@JM4H&@SCN!D$P]%>[0@X#+_N=?KP;N$>R5Y/L?2-)MGV@34Q+F'B'P$N*
M;1%[W.*:6]S*[:U>H#S7"\+/S6XIA#2U&6A>F UI#S8P87QM)!M_E6SKRM^Y
M,?JUKGZKK@E.-2A[+)S;9[ TAX0P^MF<(*NI25'_0%$4= ZWR6%8V+T\NDD&
M->'!#Q&&0BA77\'45LB%1+!/#4QMS%UM;%(T.%04'@IJ)?:=S^FREGW9*OL>
M5\B@TT2^-?'_%JD3@>UI#(/M2S/XJ>I[1>=$WIT*;=^\G8XC_.$:7T&T5:/6
MD'UJT99:=)K*7N&T\FL+V>>W;2O"UI=O\I<D7,U0*J <3-DP?3F(&;#CAZX"
M[+41;0LIB?H[#6:.<N[Z;@6I6')=-FGU;-W;7[N.]L7\V/;\KG'=PI0?# ]$
MSBE71LO,0 87?<-'ECUX.="B<&WL5&C3%+O+A?EN06D#S/V9$'HSL O47T+)
M%U!+ P04    " !3E'!6(#C.]3(&   M-@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6RUFVUOVS84A?\*X0U#"VRQ^";;F6.@25!T0 L4#=I]9FPZ
M$:(73Y*3%MB/GR0KICC)UU1U]26Q'?+X'O$X?LAK+U^2]"E[U#HGWZ,PSJXF
MCWF^NYQ.L_6CCE1VD>QT7/QEFZ21RHN[Z<,TVZ5:;:I)43AEGN=/(Q7$D]6R
M>NQSNEHF^SP,8OTY)=D^BE3ZXUJ'R<O5A$Y>'_@2/#SFY0/3U7*G'O2=SK_N
M/J?%O>E191-$.LZ")":IWEY-WM'+&]\K)U0CO@7Z)6O<)J65^R1Y*N_\M;F:
M>&5%.M3KO)10Q:]G?:/#L%0JZOBG%IT<G[.<V+S]JOZ^,E^8N5>9ODG"OX--
M_G@UF4_(1F_5/LR_)"\?=&U(EGKK),RJG^2E'NM-R'J?Y4E43RXJB(+X\%M]
MKR]$8P(5)R:P>@)SG<#K";PR>JBLLG6K<K5:ILD+2<O1A5IYH[HVU>S"31"7
MRWB7I\5?@V)>OGJO@I1\4^%>DT]:9?M4%VN49^0/<G=86))LR;LLT\5C*MZ0
MCX&Z#\(@#W3V.F%#5$X:.F]N=:Z"\&VA\?7NEKSY]>URFA>EED\X7==E71_*
M8B?*NM7K"\+I[X1YC'5,OW&?3NWIT^("':\2.UXE5NGQ4U<IB%6\#E1(5'4I
M+KL<'21$MT3Y<KS,=FJMKR;%ZRW3Z;.>K'[[A?K>GUW^D,0LM_SHED/J+;==
M9@\*LE(H_U4\K^9SWQ>>YRVGSTTC[8&+&9_YS8%6D>)8I "+O$G279*J7!<O
MVON<9'J]3ZM8=E4+2O5=&B0QR[4\NI;#@R@QW2*)66[]HUM_<! /"GXC7VSN
M"]8.8GN@H)+2DT&<'8N<G0EB%.FTJG*G=CKM*A)4Z+LB2&*6V?G1['QX_N:8
M;I'$++>+H]O%X/PM6K&:+RAOQP]\II_T03WS+N^!3KY>W%V0A^19IW'Y_D[N
MDWC3:0?6Z;MX6&JVZP;;T.%IK36P'".IV8X-IU 0#)P26TLT(\L7TN_(;,=(
MP;B0)_]G4H,8%&:,3TFL?Q0@FSX56Y7M_E0:09'>:X.D9ELVP$(%0AI1405+
MS79L8(6"=."61MG*&*52^!UI[!C)9?E.?RJ-AC,H#!H?];,.">VL#YS9>T&0
MU&R?!E7H#"&"J+2"I68[-KQ"04!PB^#<.8(=(^$(&M2@,&O4$23_DEX[&UBU
M]V*-02G,4 KS$+;9J(2"I68[-H3"0!YPBF<MT0S=_W,)#K%+:QQYP"C1#.3Y
M'0XLUGM5QCC^8 9.&$?((2J;8*G9C@V;,/@TQ2F'XGP.Q^ -9GB#P;QA(NN\
MWX$5>Z_B&*<ES& ,\Q%RBPHT6&JV8P,T##Y\<<KM['QNH2%V:88\&$P>)HQN
M>QU8KO>ZC'%NP@S-L 5"$E'9!4O-/C(W[,+A$Q:G0W//%32[1H*@R0UR<!@Y
M#KGL:JI<PS/[+@B6FNW3\ M'Z-EP5&S!4K,=-]HV"'T;W@K6;$;IO"."[9%S
M/I>G.S?<T :'::..8-^]#JS:>['&8!5N6(4C='(X*IU@J=F.#9WPX=T<[MS.
MZ1@)]W.X@0H.0T4SGN=W/K!8[S4:X[B$&VCA"/T=CDHJ6&JV8T,J?'B/A[LV
M>>#G^DDOPC"(@!G$!-=Y_P,K]FZ-CW&:(@S:"(1^CT"%'"PUV[&!'#&\WR.<
M^ST=(^%^CS!L(F V,=%TVPW!<KU7:8S3%='XJ I"YT?@?DAE#+H1AF[$\,Z/
M:/=S6H&$AMBE&0P1+KT>WED1ZM$(EIKMTU",0.CU"%1XP5*S'1MX$<-[/:+=
MP6F%#AIBEV8H0[AT=WC?'0^LVGMYQJ 3:>A$(G1W)"J/8*G9C@V/R.'='7F^
MNP,.L4LSX"!=NCO<<8\#B_5>E3&.2:1!$8G0W9&H_(&E9CLV_"&'=W?D^>X.
M_"P_ZZ+QT5>7[@[OL[N!%7NOXACG)]* BT3H[DA4A,%2LQT;A)'#NSOR?'<'
M'&*79EA#NG1WN/-^!I;KO2YCG)E(0S,2H;LC4=D%2\W^'+IA%W]X=Z>6D$ 2
MP2&'TJ:-[_*47Z3ZI-*'(,Y(J+?%'.]B5DQ.#]]-.MS)DUWU]9[[),^3J+KY
MJ-5&I^6 XN_;),E?[Y3?&#I^0VSU'U!+ P04    " !3E'!66O9M@C<&   <
M*P  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R]6EV/FS@4_2M6MEJU
M4CO!'Q#2S41J9_HEM5+5V>D^K/:!29P$%7!J.YEV?_T:0G&(C0=8)B\S$*Z/
MS[VQ[SVY>';/^#>QH52"'VF2B<O11LKMR_%8+#8TC<0%V]),/5DQGD92W?+U
M6&PYC9;%H#09(\\+QFD49Z/YK/CL,Y_/V$XF<48_<R!V:1KQGZ]IPNXO1W#T
MZX,O\7HC\P_&\]DV6M,;*F^WG[FZ&U<HRSBEF8A9!CA=78Y>P9=7),P'%!9?
M8WHOCJY![LH=8]_RFP_+RY&7,Z()7<@<(E+_]O2*)DF.I'A\+T%'U9SYP./K
M7^AO"^>5,W>1H%<L^2M>RLWE*!R!)5U%NT1^8??O:>F0G^,M6"**O^"^M/5&
M8+$3DJ7E8,4@C;/#_^A'&8BC 9 T#$#E -1V "X'X,+1 [/"K>M(1O,99_>
MY]8*+;\H8E.,5M[$6?XUWDBNGL9JG)R_C6(.OD;)CH)/-!([3M5W) 5X =X(
M&:LPT67YF*W 520VX,WW7;R/DL(JRI;@FMY)<$,7.Q[+F!X^>\>9$. V4PLK
MB?]5$.]9LHRS-7BG%M;!Y*.R4-9/KZF,XN29FO#VYAH\??(,/ %Q!O[<L)U0
M=F(VELK-G.QX4;KT^N 2:G#IFBXN (;/ ?(0L@R_:C\<UH>/57"K"*,JPJC
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M/R*8T)6"]RXFB@T_',4\W$BV+4XSWC$I65I<;FBTI#PW4,]7C,E?-_D!R>I
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M5OO5I'^_FF.0\=$><(,P" XH1Z+\\/+R@-,>' SF4/Z"Q88PB2CD6N=<1-I
MM ==VU&\:LZ*-5?ZY&F:A?XW &$"]'C.N7KJF..G_]M(_@!02P,$%     @
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M@N+GMTF2/W]3SN A2;]MW\[E_P!02P,$%     @ 4Y1P5O(#U"C6"   NV(
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MR-G7'^9]A1W3S>O[12=N\DZX1SKAD#NL/93D^R2 H,7>>\?>[1#H(]$2JWO
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M7.(G!"@;@.MS*<UV8D^IYJ,D_0=02P,$%     @ 4Y1P5CA4<PF6 P  . \
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M%[GT9UR-M6T^U+)/]>%HK\^W6B=8+F14#Q+F0\("2%@(!&MXS.AMUP%[^F\
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ME.9@Y8[@\D305;&_])$*0=/B<$FP=+,J('^?4RI>3U2 >E_VY =02P,$%
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MQ'<_$\_QO![X^.-P]RW<1E<Z:[S.&L_D\_=9HV6<ZCV2D0E]P:VKR)40M%R
M&?^^FDDE<!_^Z9/:Y [Z<^NS>2$KFL+(PL-GC+62HT]NY%SV"?]/R=[8X'<V
M^(>R)]\J?=XD85AK=(*6&<%N(!4.6+D@QZQL"W[29T.3.S*Y=4=9)9$;^.[
M']JK386[<:$7>>X@[.+>D \Z\L&'R-,5;DXZRX%@XR/S9O<NL)9*OJ<@V&'F
MGL=1$#E;"GKB? \#]R@(.P7A005X[)1@J6JMKT"8UHV'CDAS+NN2H8A_*$FX
M6Y+ #9QX2T]/F.<[CM,O)^KD1 ?EF$.U70_6MA'4@GV(W$XGD_=$1#OLXL'
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M:&5E=#4S+GAM;,V:77/:.!2&_XJ&[>RT,PFV9+ A2Y@!TN[N1;>9I!_7BBW
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M9##[VC<6I5Y!9KW2&HOJ<T,'Z&PTZ%07Y=!K0!N=Z@M=RAQD%!7MT.2LP'3
M=IK8H^&TOF.9W>J+76H=9-8ZK=CGSQP=L$=-[.G01M/JOWH,+J&$4*F$D%D)
M_=S:UU2N#E%IJJA&$,8M>\,Y72F,D%D8M=(=7JYL'<!<G=>-)+^$ED*EED*>
M^15JY0TU Y77;G<A\Z.4[<6@6KA7$DQY$"XAOU IOY!9?JGWR/(D(ZB^OU]0
ML9=O2$P2OGPNF]SC9WEK<<0TR.-6D6^GE,JUP@.1YT#B_BI-.,4^W^/H,Z&Q
M[N7YLL5+%SP33'6SL6KIZ64]@0-B=1Y@"EJI^I!9]2TV&THVF!,0"K0P8:$/
M#CC:$XT&T-)FYL?5TN?4GYS,/O1,#*?4?H[Y9=/_)#%:O#0D1DO/GT@,I]2+
MCEDO&A+CO$!H46$C*^HYH6E239QSKTMEYW13=N!4"^AIAH!?3A&(PK6Y+JB
M:NM!BP.C?"Y<[5SDZ)<0@D[EN,TL! TSJX^(-@Q.^PR_JO"S*D>[,:$;=>+-
MQ*SN$YX=?19WBU/UA3I+KMU?PIM5=C9>FLF.ZC]B*G8\!B*R%B;MH2?H:';Z
MG7WAZ4X=(#^EG*>QNMP2'! J&XC?UVG*3U_D ,7_09C_"U!+ P04    " !3
ME'!6*S^E4ID$  #1&0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6S%
M66UOJS88_2L6DZ8[Z;9@R&N71&I*IUUIW:I6N_?#M ]N>)*@ LYL)VFD_?C9
M0"$PXR:]EOHEX>4YA^<<O_#83/:4/?,U@$ O:9+QJ;,68G/ENGRQAI3P2[J!
M3-Y94I82(4_9RN4;!B3*06GB^IXW<%,29\YLDE^[9[,)W8HDSN">(;Y-4\(.
M<TCH?NI@Y_7"0[Q:"W7!G4TV9 6/(/[<W#-YYE8L49Q"QF.:(0;+J7.-KT+?
M4X \XFL,>WYTC)24)TJ?U<F7:.IX*B-(8"$4!9%_.[B!)%%,,H]_2E*G>J8"
M'A^_LO^2BY=BG@B'&YI\BR.QGCHC!T6P)-M$/-#]KU *ZBN^!4UX_HOV9:SG
MH,66"YJ68)E!&F?%/WDIC3@"^+T.@%\"_%,!00D(6@ \Z #T2D O=Z:0DOL0
M$D%F$T;WB*EHR:8.<C-SM)0?9ZK='P63=V.)$[-'01?/%W/I7(1N:"J[$R=Y
M@UR@;[EG$%V0'3#9!Q#ALG=LU%V.M@H09VB>$(E_7*QI AS=T0@2)"@"+F+9
M*("6)&9H1Y(M(+I$7#T-T9)CQ4@F^=&G$ 2)DY\FKI"*5%[NHLQ^7F3O=V2/
M??G(3*PYNLTBB)H$KK2B\L-_]6/N&QE#6%RB ']&ON?[FH1N3H=C#3P\'>X9
MU 15ZP8Y7]#5NFO" &E:]YI)[U<@![! \P,ZCKLGA_SR]9ZP"/WUFZ1$7P2D
M_&]=^Q3/[^F?KR:M*[XA"Y@Z<E;BP';@S'[\ 0^\GW7>VB0++9$U?.]5OO=,
M[+,;V2F9G-*V1(X&8"GZ)(?* 0CCVDYN)AL42)UA9N"P *( I?D@T;ED9'BG
M2_W*I;XQOWSN07\4LX'.%R/\W,YEDRRT1-:P;5#9-OC@03VPZ;M-LM 26</W
M8>7[T-A=O])$^IS$XO!9O8GC=)OJS"M(L)>SJ+)K-_,N!Z.A?!WLCGWIB!L/
MFG%A$3=NA V#*J@A951)&9TNA;QT21GI4AR-^FTIVK@A[K64C'1*AGHEXTK)
MV*CD(>;/:,D 9#$B9UI9=R FZPYC"XUUZ7IXV'+^1A_G#?R6KHZX8*R7AKVZ
M-O/>*:Z[S4K*=C8]/VBIZPC$0;\EKS.PH^GP4>V)C?K">!='D$7H$$,2:=7@
M__>9MHXW0T)C2#-WO\[=/_WEA?Y%=]W]S<QT[GQJE2VTQ=9TL:Y/\4<7J-AJ
MA6J5+;3%UC2_+E*QN3Z\?=G(U;=T](02]0VJ?JO41$,4D8.V9K7&%)[&9+*J
MKE3Q&:6J&NV&"=AJU6J5+;3%UG2Q+ESQ1U>NV&KI:I4MM,76-+^N7K&Y?#UK
MM)NIRA4I\L?=H_Q[&<+O86A:5%?%V%P6_TZSB]MTD] # $?'8UYKDI'L[+YF
MDRVTQ=8TLB[*\?BC![IQ67"V^3;90EMLS0W,>M7@FU<-9VX^O<'F=>\^O1L9
MOH'$6FAAAWNTUYT"6^7?##A:T&TFBFW>ZFKU7>(ZWXUO79_CJ[#XNE#3%!\[
M[@A;Q?(UG\!24LHUJGQKLN+[07$BZ";?47^B0M T/UP#B8"I 'E_2:EX/5$/
MJ+[BS/X#4$L#!!0    ( %.4<%9P@A<\G0,  %P,   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;+57VV[;.!#]%4);%"E06S=;DK.V@#C9=O>A11 C
MR3,CC6PB$JF2M-T _?CR(LM.+0MQT<U#Q-L,SYD;Q],MX\]B!2#1]ZJD8N:L
MI*PO75=D*ZBP&+(:J-HI&*^P5%.^=$7- >=&J"K=P/,BM\*$.NG4K-WR=,K6
MLB04;CD2ZZK"_&4.)=O.'-_9+=R1Y4KJ!3>=UG@)"Y#W]2U7,[?5DI,*J"",
M(@[%S+GR+^?^2 N8$P\$MN)@C#25)\:>]>2_?.9X&A&4D$FM JO/!JZA++4F
MA>-;H]1I[]2"A^.=]D^&O"+SA 5<L_*1Y'(U<Q('Y5#@=2GOV/9?: B-M;Z,
ME<+\1]OFK.>@;"TDJQIAA: BU'[Q]\80!P)A<$(@: 0"@]M>9%#>8(G3*6=;
MQ/5II4T/#%4CK< 1JKVRD%SM$B4GTX5DV3.:*UXYNF:5<K; QEP#M% 1D*]+
M0*Q 7QG=@)#JT)WZ<)+IH96]IT0*A&F.;H&;,*$9O-J[TI8G\L4<>C1V4M)7
M&^#*[^@SQU0B!1[0)TPX>L#E&M#%#4A,R@\*Q]DW3EVI+*/YN5ECA;FU0G#"
M"GZ OC J5P+]0W/(7RMPE4E;NP8[N\Z#7HTWD U1Z']$@1<$Z!URD5AA#J+Y
M]-P0MIX+S0WA*<]U*++(K-RH6TZG^:6H<08S1^6Q +X!)WW_EQ]Y?_>@&K6H
M1GW:T_M=G%B>']$3+ FEA"Y5\I3&41>$-KL?T(].>U@:]J+(7*2+RR:-@M#S
MO*F[Z0 X;@&.>P':,&&U#G*!ECKX%-JW8AH?80J#Q!^?P!2UF*)>3 _69&\%
M$1V!&/@*QGC4C2)N4<2]*%25*X"< R3N !)'23+I!I*T0)+S8@AH_CL!E!P'
MT,@?>7$WNDF+;M*;=[L"-NBO8%V )O]#8OK>OM)[O69M*R]N<)O@'^0:=Z%Q
M;TSE5=5^EQW=N7N_N$$U<&MX[8%]=>NLO!95?."&9!CI1&[__&Z/^ >/F/\F
M:H-7U% '-:CJDKT -!SM06%XK45^%J_F80T/B(V'X8GH\H,]E^ /NVFS+Q_G
M^B8XYC 9GJ@C_OYE\GN?F-^@4+RJ/>>R"(]9Q"K$3M#8/V5^_UMV/HV.0G4N
ME]%1ML1#+_F%BGO0\%7 EZ:M%2AC:RIM[]>NMJWSE6T8]\=MW_T%<Y7D I50
M*%%O&*LGCMM6UDXDJTW[^,2D:D;-<*7:?^#Z@-HO&).[B;Z@_4&1_@102P,$
M%     @ 4Y1P5K-+#4)D P  . X  !D   !X;"]W;W)K<VAE971S+W-H965T
M-38N>&ULQ5==;]HP%/TK5E9-G=0VGWQU$ E(IU5:)U3:[6':@TDN)&IB,]M
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MC.75#I@*D,_GE(IM1TU07A;]_U!+ P04    " !3E'!6F*TE^-0$  !\&0
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MY+4J*8-[@61=543\O(.2'U=>X+U,/-#M3ID)/UGNR18>0?VSOQ=ZY'<L.:V
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M?;J@Q XS-SAHVMCGK4$_-=&L_9J"#0'^OC0&CTX8G6GQ\[]02P,$%     @
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M(_&'.R"=4QT(,JA!!IT@<V/)%-I@FH,YW)?EV4V+,[OK%0WVP(+^[C[IG/M
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 4Y1P5OVXZ:#N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M4Y1P5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !3E'!6NN==&MD'  "(+P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M4Y1P5L;]WTLR @  K04  !@              ("!'!   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %.4<%9;.]**Q 4  (\7   8
M          " @802  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !3E'!6U*&>M>8%   G'@  &               @(%^&   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 4Y1P5O0.KC@[ P  : H
M !@              ("!FAX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+
M 0(4 Q0    ( %.4<%9-/.!?!PH   99   8              " @0LB  !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !3E'!6-=#2$XL"
M  "[!@  &               @(%(+   >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&UL4$L! A0#%     @ 4Y1P5IRB0U3C"0  6#(  !@              ("!
M"2\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %.4<%92
M#*"3H (  %8'   8              " @2(Y  !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6Q02P$"% ,4    " !3E'!6L%*>(%8(   8$@  &0
M    @('X.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M %.4<%85_+4<HB(  -MK   9              " @85$  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 4Y1P5I0XWP#$"   ;AD  !D
M             ("!7F<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !3E'!6# L6W7 $  "9"@  &0              @(%9<   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %.4<%;60+>=]@T
M #,H   9              " @0!U  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 4Y1P5A[&W1[Z"   QQ@  !D              ("!
M+8,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !3E'!6
M)*;G67L&  #3#P  &0              @(%>C   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( %.4<%9T5Y>C*@T  (TE   9
M      " @1"3  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 4Y1P5C9C/"KV!0  [ \  !D              ("!<:   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !3E'!6_56$.=P.  #M+
M&0              @(&>I@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( %.4<%8;"^V,J D  %(;   9              " @;&U  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 4Y1P5BHCL%M3
M!P  O!   !D              ("!D+\  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !3E'!64C&,4O8&  "5$0  &0
M@($:QP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %.4
M<%:+7"V93 (  #P%   9              " @4?.  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 4Y1P5K:?V%R4!0  N@P  !D
M         ("!RM   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !3E'!6RO.T!?L?   /9P  &0              @(&5U@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %.4<%;'%* _V0,  %X(
M   9              " @<?V  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 4Y1P5O]V*ZV*!   BPT  !D              ("!U_H
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !3E'!6&EER
MF'<$  "Q"P  &0              @(&8_P  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( %.4<%8P<ON#G@,  $P(   9
M  " @48$ 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M4Y1P5MJ0H=[T @  / 8  !D              ("!&P@! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !3E'!6:C8ZT/ &  ",$0  &0
M            @(%&"P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( %.4<%;^:_+G"P4  -\,   9              " @6T2 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 4Y1P5G;@D<G8 @
M9 8  !D              ("!KQ<! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !3E'!65].;43\#   V"0  &0              @(&^
M&@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %.4<%;F
M@*7TR <   Q!   9              " @30> 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 4Y1P5ON)2_KP @  7 L  !D
M     ("!,R8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %.4<%;W11N=?P0  '<;   9              "
M@<@\ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 4Y1P
M5K-'<1,6 P  (0D  !D              ("!?D$! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " !3E'!6I(S,./8"  !Y"   &0
M        @('+1 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( %.4<%:)'!@4N0\   O@   9              " @?A' 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 4Y1P5O(#U"C6"   NV(
M !D              ("!Z%<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " !3E'!6[J3;48$%  "V&P  &0              @('U8 $
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( %.4<%9S%8R0
MB!,  -H^ 0 9              " @:UF 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ 4Y1P5@)DRP80 P  H @  !D
M ("!;'H! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !3
ME'!6.%1S"98#   X#P  &0              @(&S?0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %.4<%8?E>UTN04  *,M   9
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M970U-"YX;6Q02P$"% ,4    " !3E'!6<((7/)T#  !<#   &0
M    @(%^I $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M %.4<%:S2PU"9 ,  #@.   9              " @5*H 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ 4Y1P5IBM)?C4!   ?!D  !D
M             ("![:L! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " !3E'!60XQRTXH#  !(#   &0              @('XL $ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %.4<%;Y)7ZJP0,
M /0,   9              " @;FT 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ 4Y1P5EBIN_EG P  8@L  !D              ("!
ML;@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !3E'!6
M/M_])^P!   $!   &0              @(%/O $ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( %.4<%9&,R]L&@8  -,K   9
M      " @7*^ 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ 4Y1P5NADLODA P  IPH  !D              ("!P\0! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !3E'!6]M:]0 P%  " )
M&0              @($;R $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( %.4<%;#5@W&7P,  +(6   -              "  5[- 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ 4Y1P5I>*NQS     $P(   L
M         ( !Z- ! %]R96QS+RYR96QS4$L! A0#%     @ 4Y1P5L5LGA+M
M!   8RH   \              ( !T=$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( %.4<%;22;QM$0(  !<F   :              "  >O6 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %.4<%; B&UTZ0$
M 'XE   3              "  339 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !( $@ KQ,  $[; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>256</ContextCount>
  <ElementCount>411</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>96</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - License, Collaboration, and Product Development Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreements</Role>
      <ShortName>License, Collaboration, and Product Development Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Asset Purchase Agreements and Related License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreements</Role>
      <ShortName>Asset Purchase Agreements and Related License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Sale of Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SaleofAssets</Role>
      <ShortName>Sale of Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/RelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail</Role>
      <ShortName>Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - License, Collaboration, and Product Development Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail</Role>
      <ShortName>License, Collaboration, and Product Development Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Sale of Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail</Role>
      <ShortName>Sale of Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/DebtAdditionalInformationDetail</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail</Role>
      <ShortName>Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail</Role>
      <ShortName>Debt - Schedule of Maturities of Long-term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stockholders??? Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders??? Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stockholders??? Equity - Common Stock Reserved For Future Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails</Role>
      <ShortName>Stockholders??? Equity - Common Stock Reserved For Future Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stock-Based Compensation - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail</Role>
      <ShortName>Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/LegalMattersDetails</Role>
      <ShortName>Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eigerbio.com/role/LegalMatters</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="eigr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue in us-gaap/2021 used in 1 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. eigr-20221231.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 -  eigr-20221231.htm 4</Log>
    <Log type="Warning">[rq-1207-Period-Type-Preferred-Label-Mismatch] In ''Stock Option Activity (Detail)'', element us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 has period type 'duration' but is given a preferred label periodStartLabel when shown under parent us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract.  The preferred label will be ignored.</Log>
    <Log type="Warning">[rq-1207-Period-Type-Preferred-Label-Mismatch] In ''Stock Option Activity (Detail)'', element us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 has period type 'duration' but is given a preferred label periodEndLabel when shown under parent us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract.  The preferred label will be ignored.</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="eigr-20221231.htm">eigr-20221231.htm</File>
    <File>eigr-20221231.xsd</File>
    <File>eigr-20221231_cal.xml</File>
    <File>eigr-20221231_def.xml</File>
    <File>eigr-20221231_lab.xml</File>
    <File>eigr-20221231_pre.xml</File>
    <File>eigr-2022x12x31ex1041.htm</File>
    <File>eigr-2022x12x31ex1042.htm</File>
    <File>eigr-2022x12x31ex1043.htm</File>
    <File>eigr-2022x12x31ex231.htm</File>
    <File>eigr-2022x12x31ex311.htm</File>
    <File>eigr-2022x12x31ex312.htm</File>
    <File>eigr-2022x12x31ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>eigr-20221231_g1.jpg</File>
    <File>eigr-20221231_g10.jpg</File>
    <File>eigr-20221231_g11.jpg</File>
    <File>eigr-20221231_g12.jpg</File>
    <File>eigr-20221231_g13.jpg</File>
    <File>eigr-20221231_g14.jpg</File>
    <File>eigr-20221231_g15.jpg</File>
    <File>eigr-20221231_g16.jpg</File>
    <File>eigr-20221231_g17.jpg</File>
    <File>eigr-20221231_g18.jpg</File>
    <File>eigr-20221231_g19.jpg</File>
    <File>eigr-20221231_g2.jpg</File>
    <File>eigr-20221231_g3.jpg</File>
    <File>eigr-20221231_g4.jpg</File>
    <File>eigr-20221231_g5.jpg</File>
    <File>eigr-20221231_g6.jpg</File>
    <File>eigr-20221231_g7.jpg</File>
    <File>eigr-20221231_g8.jpg</File>
    <File>eigr-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="816">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eigr-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2021-01-31": 816,
    "http://xbrl.sec.gov/dei/2021q4": 37
   },
   "contextCount": 256,
   "dts": {
    "calculationLink": {
     "local": [
      "eigr-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eigr-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "eigr-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eigr-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eigr-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eigr-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 648,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 96,
   "keyStandard": 315,
   "memberCustom": 55,
   "memberStandard": 39,
   "nsprefix": "eigr",
   "nsuri": "http://www.eigerbio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.eigerbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.eigerbio.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.eigerbio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.eigerbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:ProductDevelopmentAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - License, Collaboration, and Product Development Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreements",
     "shortName": "License, Collaboration, and Product Development Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:ProductDevelopmentAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:AssetPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Asset Purchase Agreements and Related License Agreements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreements",
     "shortName": "Asset Purchase Agreements and Related License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:AssetPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Sale of Assets",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.eigerbio.com/role/SaleofAssets",
     "shortName": "Sale of Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.eigerbio.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.eigerbio.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.eigerbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.eigerbio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.eigerbio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Legal Matters",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.eigerbio.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.eigerbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Related Party Disclosures",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.eigerbio.com/role/RelatedPartyDisclosures",
     "shortName": "Related Party Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.eigerbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.eigerbio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.eigerbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.eigerbio.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.eigerbio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.eigerbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.eigerbio.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.eigerbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Description of Business - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail",
     "shortName": "Description of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "eigr:OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "eigr:OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ia328cb20d25e4fab95b8005fa9861f94_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "eigr:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ia328cb20d25e4fab95b8005fa9861f94_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i7ecf5e8208174b24a163cd9c86a1f6a2_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "eigr:CashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
     "shortName": "Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "eigr:CashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Balance Sheet Components - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "eigr:PrepaidContractManufacturingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "eigr:PrepaidContractManufacturingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - License, Collaboration, and Product Development Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
     "shortName": "License, Collaboration, and Product Development Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ic6a349046f334530a41f51eebfe060e1_D20190101-20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "eigr:NonRefundableIssueFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "iba57b158870e40fdb866d4b2678df531_D20150901-20150930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "iba57b158870e40fdb866d4b2678df531_D20150901-20150930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i92100717fcf74430af9c50c3cec2a181_D20170501-20170531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Sale of Assets - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail",
     "shortName": "Sale of Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i92100717fcf74430af9c50c3cec2a181_D20170501-20170531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Debt - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
     "shortName": "Debt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i054ac64c0a9a48f39f0672426b1763f8_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail",
     "shortName": "Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail",
     "shortName": "Debt - Schedule of Maturities of Long-term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i6e876d14531242919ba3e7c51a9f6620_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "eigr:DividendsDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stockholders\u2019 Equity - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders\u2019 Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "eigr:DividendsDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "eigr:OptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stockholders\u2019 Equity - Common Stock Reserved For Future Issuances (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails",
     "shortName": "Stockholders\u2019 Equity - Common Stock Reserved For Future Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "eigr:OptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ide6769059acf419584a1d5e087c7d813_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stock-Based Compensation - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
     "shortName": "Stock-Based Compensation - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ie5e793187f544593b74da04cabc2339b_D20220101-20221231",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i78457377acd944119ee3cbc487a296cf_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail",
     "shortName": "Stock Based Compensation - Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i78457377acd944119ee3cbc487a296cf_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Summary of Non-cash Stock Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i77186ca2509745eb8c68fb8c32e77418_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "eigr:IncreaseInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ic8cfaed52a2d473ab12f3b5530650c41_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ic8cfaed52a2d473ab12f3b5530650c41_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "ide6769059acf419584a1d5e087c7d813_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i8c1713a9ff0046649a86f61420a19003_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "iefd9ad44e31d4bb09abdd6c03737db5d_I20221108",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "eigr:NumberOfFormerExecutives",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Legal Matters (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.eigerbio.com/role/LegalMattersDetails",
     "shortName": "Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "iefd9ad44e31d4bb09abdd6c03737db5d_I20221108",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "eigr:NumberOfFormerExecutives",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "us-gaap:OperatingLeaseExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "us-gaap:OperatingLeaseExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail",
     "shortName": "Commitments and Contingencies - Maturity of Operating Leases Liabilities and Future Minimum Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i4934175f59ca42c484533a305704b3c7_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "eigr:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "eigr:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i5a2fea426e7d432dbb6a46a1103f6994_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "eigr:GainLossFromSaleOfPriorityReviewVoucher",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-20221231.htm",
      "contextRef": "i38d8baf64e8f40a288b32a28a3c7522d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 96,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.eigerbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "eigr_AbbvieAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abbvie asset purchase agreement.",
        "label": "Abbvie Asset Purchase Agreement [Member]",
        "terseLabel": "AbbVie Asset Purchase Agreement"
       }
      }
     },
     "localname": "AbbvieAssetPurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AccruedContractedResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contracted research costs current.",
        "label": "Accrued Contracted Research Costs Current",
        "terseLabel": "Contract research costs"
       }
      }
     },
     "localname": "AccruedContractedResearchCostsCurrent",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs.",
        "label": "Accrued Research And Development Costs [Policy Text Block]",
        "terseLabel": "Accrued Research and Development Costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsPolicyTextBlock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_AggregateCommonStockConsiderationValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate common stock consideration value.",
        "label": "Aggregate Common Stock Consideration Value",
        "terseLabel": "Aggregate common stock consideration value"
       }
      }
     },
     "localname": "AggregateCommonStockConsiderationValue",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AmendedOxfordLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Oxford loan.",
        "label": "Amended Oxford Loan [Member]",
        "terseLabel": "Amended Oxford Loan"
       }
      }
     },
     "localname": "AmendedOxfordLoanMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AmendedTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended tranche A.",
        "label": "Amended Tranche A [Member]",
        "terseLabel": "Amended Tranche A"
       }
      }
     },
     "localname": "AmendedTrancheAMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AmendedTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended tranche B.",
        "label": "Amended Tranche B [Member]",
        "terseLabel": "Secured Debt, Amended Tranche B"
       }
      }
     },
     "localname": "AmendedTrancheBMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AmendmentFeesPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment fees payment.",
        "label": "Amendment Fees Payment",
        "terseLabel": "Amendment fees payment"
       }
      }
     },
     "localname": "AmendmentFeesPayment",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement and related license agreement.",
        "label": "Asset Purchase Agreement And Related License Agreement [Line Items]",
        "terseLabel": "Asset Purchase Agreement And Related License Agreement [Line Items]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement And Related License Agreement [Table]",
        "label": "Asset Purchase Agreement And Related License Agreement [Table]",
        "terseLabel": "Asset Purchase Agreement And Related License Agreement [Table]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementAndRelatedLicenseAgreementTable",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_AssetPurchaseAgreementContingentConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement contingent consideration receivable.",
        "label": "Asset Purchase Agreement Contingent Consideration Receivable",
        "terseLabel": "Asset purchase agreement contingent consideration receivable"
       }
      }
     },
     "localname": "AssetPurchaseAgreementContingentConsiderationReceivable",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AssetPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset purchase agreement and related license agreements.",
        "label": "Asset Purchase Agreement [Text Block]",
        "terseLabel": "Asset Purchase Agreements and Related License Agreements"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTextBlock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreements and related license agreements.",
        "label": "Asset Purchase Agreements And Related License Agreements [Abstract]",
        "terseLabel": "Asset Purchase Agreements And Related License Agreements [Abstract]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract",
     "nsuri": "http://www.eigerbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eigr_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.eigerbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eigr_AutorisationTemporaireDUtlisationMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Autorisation Temporaire D Utlisation Member",
        "label": "Autorisation Temporaire D Utlisation Member [Member]",
        "terseLabel": "Autorisation Temporaire D Utlisation Member"
       }
      }
     },
     "localname": "AutorisationTemporaireDUtlisationMemberMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AvexitidePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avexitide Purchase Agreement",
        "label": "Avexitide Purchase Agreement [Member]",
        "terseLabel": "Avexitide Purchase Agreement"
       }
      }
     },
     "localname": "AvexitidePurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_BMSTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS Transaction",
        "label": "BMS Transaction [Member]",
        "terseLabel": "BMS Transaction"
       }
      }
     },
     "localname": "BMSTransactionMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_BaseSalaryAndTargetBonusContinuationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Salary And Target Bonus Continuation Period",
        "label": "Base Salary And Target Bonus Continuation Period",
        "terseLabel": "Base salary and target bonus continuation period"
       }
      }
     },
     "localname": "BaseSalaryAndTargetBonusContinuationPeriod",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_COBRAContinuationCoveragePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COBRA Continuation Coverage Period",
        "label": "COBRA Continuation Coverage Period",
        "terseLabel": "COBRA continuation coverage period"
       }
      }
     },
     "localname": "COBRAContinuationCoveragePeriod",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_CashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents amortized cost.",
        "label": "Cash Equivalents Amortized Cost",
        "totalLabel": "Cash equivalents, Amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAmortizedCost",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_CashEquivalentsAndInvestmentSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and investment securities.",
        "label": "Cash Equivalents And Investment Securities [Line Items]",
        "terseLabel": "Cash Equivalents and Investment Securities [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentSecuritiesLineItems",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_CashEquivalentsAndInvestmentSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and investment securities.",
        "label": "Cash Equivalents And Investment Securities [Table]",
        "terseLabel": "Cash Equivalents And Investment Securities [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentSecuritiesTable",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_ClosingPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing Price Of Common Stock",
        "label": "Closing Price Of Common Stock",
        "terseLabel": "Closing price of common stock (in usd per share)"
       }
      }
     },
     "localname": "ClosingPriceOfCommonStock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eigr_CollaborationAgreementInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Initial Term",
        "label": "Collaboration Agreement Initial Term",
        "terseLabel": "Collaboration agreement initial term"
       }
      }
     },
     "localname": "CollaborationAgreementInitialTerm",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_CollaborativeArrangementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Renewal Term",
        "label": "Collaborative Arrangement Renewal Term",
        "terseLabel": "Collaborative arrangement renewal term"
       }
      }
     },
     "localname": "CollaborativeArrangementRenewalTerm",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_CommercialSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Sales",
        "label": "Commercial Sales [Member]",
        "terseLabel": "Commercial Sales"
       }
      }
     },
     "localname": "CommercialSalesMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_CommonStockReservedForFutureIssuancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Reserved For Future Issuances",
        "label": "Common Stock Reserved For Future Issuances [Table Text Block]",
        "terseLabel": "Common Stock Reserved For Future Issuances"
       }
      }
     },
     "localname": "CommonStockReservedForFutureIssuancesTableTextBlock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_CommonStockValueAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Value, Available For Future Issuance",
        "label": "Common Stock, Value, Available For Future Issuance",
        "terseLabel": "Common stock available for future issuance"
       }
      }
     },
     "localname": "CommonStockValueAvailableForFutureIssuance",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_ContractManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract manufacturing costs current.",
        "label": "Contract Manufacturing Costs Current",
        "terseLabel": "Contract manufacturing costs"
       }
      }
     },
     "localname": "ContractManufacturingCostsCurrent",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DebtInstrumentExitFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exit Fee",
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Less: exit fee"
       }
      }
     },
     "localname": "DebtInstrumentExitFee",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DebtInstrumentExitFeePayablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument exit fee payable percentage.",
        "label": "Debt Instrument Exit Fee Payable Percentage",
        "terseLabel": "Percentage of exit fee on principal balance"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePayablePercentage",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_DebtInstrumentInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest payment period.",
        "label": "Debt Instrument Interest Payment Period",
        "terseLabel": "Interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentPeriod",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentPercentOfInterestDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Percent Of Interest Due",
        "label": "Debt Instrument, Percent Of Interest Due",
        "terseLabel": "Debt Instrument, percent of interest due (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPercentOfInterestDue",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument principal and interest payment period.",
        "label": "Debt Instrument Principal And Interest Payment Period",
        "terseLabel": "Principal and interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAndInterestPaymentPeriod",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentUnamortizedAdditionalExitFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized additional exit fees.",
        "label": "Debt Instrument Unamortized Additional Exit Fees",
        "terseLabel": "Loan final repayment additional exit fees payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedAdditionalExitFees",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DebtInstrumentUnamortizedExitFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized exit fees.",
        "label": "Debt Instrument Unamortized Exit Fees",
        "terseLabel": "Exit fee",
        "verboseLabel": "Loan final repayment exit fees payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedExitFees",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DeferredTaxAssetDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset Depreciation And Amortization",
        "label": "Deferred Tax Asset Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetDepreciationAndAmortization",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Lease Liabilities",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Right Of Use Assets",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedTerseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestones",
        "label": "Development And Regulatory Milestones [Member]",
        "terseLabel": "Development And Regulatory Milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DevelopmentMilestoneObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestone Obligations",
        "label": "Development Milestone Obligations",
        "terseLabel": "Development milestone obligations"
       }
      }
     },
     "localname": "DevelopmentMilestoneObligations",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DevelopmentPhaseThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Phase Three",
        "label": "Development Phase Three [Member]",
        "terseLabel": "Development Phase Three"
       }
      }
     },
     "localname": "DevelopmentPhaseThreeMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DevelopmentPhaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Phase Two",
        "label": "Development Phase Two [Member]",
        "terseLabel": "Development Phase Two"
       }
      }
     },
     "localname": "DevelopmentPhaseTwoMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DividendsDeclared": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends Declared",
        "label": "Dividends Declared",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsDeclared",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_EIGTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EIG Transaction",
        "label": "EIG Transaction [Member]",
        "terseLabel": "EIG Transaction"
       }
      }
     },
     "localname": "EIGTransactionMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_EarlyAccessProgramTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Access Program Term",
        "label": "Early Access Program Term",
        "terseLabel": "Early access program term (in years)"
       }
      }
     },
     "localname": "EarlyAccessProgramTerm",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member].",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Debt Warrants And Units Maximum Aggregate Offering Amount",
        "label": "Equity Debt Warrants And Units Maximum Aggregate Offering Amount",
        "terseLabel": "Aggregate offering amount"
       }
      }
     },
     "localname": "EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ExpertConsultantFeesAndPassThroughCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expert consultant fees and pass through costs.",
        "label": "Expert Consultant Fees And Pass Through Costs",
        "terseLabel": "Expert consultant fees and pass through costs"
       }
      }
     },
     "localname": "ExpertConsultantFeesAndPassThroughCosts",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_FairValueTransfersBetweenLevelsTransfersAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value transfers between levels transfers amount.",
        "label": "Fair Value Transfers Between Levels Transfers Amount",
        "terseLabel": "Transfers in or out of level 3"
       }
      }
     },
     "localname": "FairValueTransfersBetweenLevelsTransfersAmount",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_FormerCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former CEO",
        "label": "Former CEO [Member]",
        "terseLabel": "Former CEO"
       }
      }
     },
     "localname": "FormerCEOMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_GainLossFromSaleOfPriorityReviewVoucher": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from sale of priority review voucher.",
        "label": "Gain Loss From Sale Of Priority Review Voucher",
        "negatedLabel": "Gain from sale of priority review voucher"
       }
      }
     },
     "localname": "GainLossFromSaleOfPriorityReviewVoucher",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Holders Of Ten Percent Or More Of Voting Power",
        "label": "Holders Of Ten Percent Or More Of Voting Power [Member]",
        "terseLabel": "Holders Of Ten Percent Or More Of Voting Power"
       }
      }
     },
     "localname": "HoldersOfTenPercentOrMoreOfVotingPowerMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_IncentiveBasedRegulatoryMilestoneFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive-based regulatory milestone fees.",
        "label": "Incentive Based Regulatory Milestone Fees",
        "terseLabel": "Incentive-based regulatory milestone fees"
       }
      }
     },
     "localname": "IncentiveBasedRegulatoryMilestoneFees",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncomeLossRelatedToAssetPurchaseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (loss) related to asset purchase agreement.",
        "label": "Income Loss Related To Asset Purchase Agreement",
        "negatedLabel": "Income related to asset purchase agreement"
       }
      }
     },
     "localname": "IncomeLossRelatedToAssetPurchaseAgreement",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in prepaid expenses and other current assets.",
        "label": "Increase Decrease In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncreaseInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Deferred Tax Assets Valuation Allowance",
        "label": "Increase In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncreaseInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_InducementPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement plan 2021.",
        "label": "Inducement Plan2021 [Member]",
        "terseLabel": "Inducement Plan 2021"
       }
      }
     },
     "localname": "InducementPlan2021Member",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_InnovatusLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Loan",
        "label": "Innovatus Loan [Member]",
        "terseLabel": "Innovatus Loan"
       }
      }
     },
     "localname": "InnovatusLoanMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_InnovatusStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Stock Purchase Agreement",
        "label": "Innovatus Stock Purchase Agreement [Member]",
        "terseLabel": "Innovatus Stock Purchase Agreement"
       }
      }
     },
     "localname": "InnovatusStockPurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_LegalMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Matters [Abstract]",
        "label": "Legal Matters [Abstract]"
       }
      }
     },
     "localname": "LegalMattersAbstract",
     "nsuri": "http://www.eigerbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eigr_LicenseAgreementMilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Milestone Payments Paid",
        "label": "License Agreement Milestone Payments Paid",
        "terseLabel": "License agreement milestone payments paid"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsPaid",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LicenseAgreementPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Potential Milestone Payments",
        "label": "License Agreement Potential Milestone Payments",
        "terseLabel": "License agreement potential milestone payments"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestonePayments",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fee",
        "label": "License Maintenance Fee",
        "terseLabel": "License maintenance fee"
       }
      }
     },
     "localname": "LicenseMaintenanceFee",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LineOfCreditFacilityOtherFinalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Other Final Payments",
        "label": "Line of Credit Facility, Other Final Payments",
        "terseLabel": "Other final payments"
       }
      }
     },
     "localname": "LineOfCreditFacilityOtherFinalPayments",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MYDICARMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYDICAR.",
        "label": "M Y D I C A R [Member]",
        "terseLabel": "MYDICAR"
       }
      }
     },
     "localname": "MYDICARMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_MasterManufacturingServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Manufacturing Services Agreement",
        "label": "Master Manufacturing Services Agreement [Member]",
        "terseLabel": "Master Manufacturing Services Agreement"
       }
      }
     },
     "localname": "MasterManufacturingServicesAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum consideration per share of counter party for issuance of additional shares.",
        "label": "Maximum Consideration Per Share Of Counter Party For Issuance Of Additional Shares",
        "terseLabel": "Maximum consideration per share of counter party for issuance of additional shares (in usd per share)"
       }
      }
     },
     "localname": "MaximumConsiderationPerShareOfCounterPartyForIssuanceOfAdditionalShares",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "eigr_MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum cumulative cash proceeds of counter party for issuance of additional shares.",
        "label": "Maximum Cumulative Cash Proceeds Of Counter Party For Issuance Of Additional Shares",
        "terseLabel": "Maximum cumulative cash proceeds of counter party for issuance of additional shares"
       }
      }
     },
     "localname": "MaximumCumulativeCashProceedsOfCounterPartyForIssuanceOfAdditionalShares",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Equity Debt Warrants Issued During The Period",
        "label": "Maximum Equity Debt Warrants Issued During The Period",
        "terseLabel": "Maximum shares issued during the period"
       }
      }
     },
     "localname": "MaximumEquityDebtWarrantsIssuedDuringThePeriod",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MerckTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Transaction",
        "label": "Merck Transaction [Member]",
        "terseLabel": "Merck Transaction"
       }
      }
     },
     "localname": "MerckTransactionMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_MilestoneObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Obligations",
        "label": "Milestone Obligations",
        "terseLabel": "Milestone obligations"
       }
      }
     },
     "localname": "MilestoneObligations",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MinimumCashBalanceOfFaceValueOfLoanPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Cash Balance Of Face Value Of Loan, Percent",
        "label": "Minimum Cash Balance Of Face Value Of Loan, Percent",
        "terseLabel": "Minimum cash balance of face value of loan (in percent)"
       }
      }
     },
     "localname": "MinimumCashBalanceOfFaceValueOfLoanPercent",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "eigr_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employees Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_NonRefundableIssueFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Issue Fee",
        "label": "Non Refundable Issue Fee",
        "terseLabel": "Non refundable issue fee"
       }
      }
     },
     "localname": "NonRefundableIssueFee",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_NumberOfAccounts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Accounts",
        "label": "Number Of Accounts",
        "terseLabel": "Number of accounts"
       }
      }
     },
     "localname": "NumberOfAccounts",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eigr_NumberOfFormerExecutives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Former Executives",
        "label": "Number Of Former Executives",
        "terseLabel": "Number of former executives"
       }
      }
     },
     "localname": "NumberOfFormerExecutives",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "eigr_OfferingCostsIncurredNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs Incurred, Not Yet Paid",
        "label": "Offering Costs Incurred, Not Yet Paid",
        "terseLabel": "Common stock offering costs included in accounts payable and accrual"
       }
      }
     },
     "localname": "OfferingCostsIncurredNotYetPaid",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Payment To Be Made On Asset Purchase Agreement",
        "label": "One Time Payment To Be Made On Asset Purchase Agreement",
        "terseLabel": "One time payment"
       }
      }
     },
     "localname": "OneTimePaymentToBeMadeOnAssetPurchaseAgreement",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OptionsGrantedToEmployeesAndNonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options granted to employees and non employees.",
        "label": "Options Granted To Employees And Non Employees [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "OptionsGrantedToEmployeesAndNonEmployeesMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Issued And Outstanding",
        "label": "Options Issued And Outstanding",
        "terseLabel": "Options issued and outstanding (in shares)"
       }
      }
     },
     "localname": "OptionsIssuedAndOutstanding",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_OptionsToPurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options To Purchase Of Common Stock",
        "label": "Options To Purchase Of Common Stock",
        "terseLabel": "Options to purchase of common stock (in shares)"
       }
      }
     },
     "localname": "OptionsToPurchaseOfCommonStock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_OrphanDrugCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug Credit Carryforward",
        "label": "Orphan Drug Credit Carryforward [Member]",
        "terseLabel": "Orphan Drug Credit Carryforward"
       }
      }
     },
     "localname": "OrphanDrugCreditCarryforwardMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Foreign Currency Transaction Adjustment, Net of Tax",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction Adjustment, Net of Tax",
        "terseLabel": "Aggregated transaction gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAdjustmentNetOfTax",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OtherPrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other prepaid expense and other assets current classified as other.",
        "label": "Other Prepaid Expense And Other Assets Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenue",
        "label": "Other Revenue [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OxfordLoanAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford loan amendment.",
        "label": "Oxford Loan Amendment [Member]",
        "terseLabel": "Amendment"
       }
      }
     },
     "localname": "OxfordLoanAmendmentMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OxfordLoanFifthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford loan fifth amendment.",
        "label": "Oxford Loan Fifth Amendment [Member]",
        "terseLabel": "Fifth Amended Oxford Loan"
       }
      }
     },
     "localname": "OxfordLoanFifthAmendmentMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OxfordLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford loan.",
        "label": "Oxford Loan [Member]",
        "terseLabel": "Oxford Loan"
       }
      }
     },
     "localname": "OxfordLoanMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PRFCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PRF collaboration agreement .",
        "label": "P R F Collaboration Agreement [Member]",
        "terseLabel": "Progeria Research Foundation (PRF) Collaboration Agreement"
       }
      }
     },
     "localname": "PRFCollaborationAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PatheonIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patheon Inc",
        "label": "Patheon Inc [Member]",
        "terseLabel": "Patheon Inc"
       }
      }
     },
     "localname": "PatheonIncMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PaymentForAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for asset purchase agreement.",
        "label": "Payment For Asset Purchase Agreement",
        "terseLabel": "Payment for asset purchase agreement"
       }
      }
     },
     "localname": "PaymentForAssetPurchaseAgreement",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PaymentsRelatedToPriorityReviewVoucher": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to priority review voucher.",
        "label": "Payments Related To Priority Review Voucher",
        "negatedLabel": "Payments related to priority review voucher"
       }
      }
     },
     "localname": "PaymentsRelatedToPriorityReviewVoucher",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Product Manufactured On The Basics Of Annual Forecasts",
        "label": "Percentage Of Product Manufactured On The Basics Of Annual Forecasts",
        "terseLabel": "Percentage of product manufactured on the basics of annual forecasts"
       }
      }
     },
     "localname": "PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "eigr_PercentageOfPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Purchase Price",
        "label": "Percentage Of Purchase Price",
        "terseLabel": "Percentage of purchase price"
       }
      }
     },
     "localname": "PercentageOfPurchasePrice",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "eigr_PerformanceStockUnitsPSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance stock units PSU member.",
        "label": "Performance Stock Units P S U [Member]",
        "terseLabel": "Performance Stock Units (PSU)"
       }
      }
     },
     "localname": "PerformanceStockUnitsPSUMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PeriodOfCommittedPaymentOfFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Of Committed Payment Of Fees",
        "label": "Period Of Committed Payment Of Fees",
        "terseLabel": "Period of committed payment of fees"
       }
      }
     },
     "localname": "PeriodOfCommittedPaymentOfFees",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_PostEmploymentBenefitAcceleratedVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Employment Benefit, Accelerated Vesting",
        "label": "Post Employment Benefit, Accelerated Vesting",
        "terseLabel": "Accelerated vesting"
       }
      }
     },
     "localname": "PostEmploymentBenefitAcceleratedVesting",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "eigr_PostEmploymentBenefitsLegalFeesReimbursementThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Employment Benefits, Legal Fees Reimbursement Threshold",
        "label": "Post Employment Benefits, Legal Fees Reimbursement Threshold",
        "terseLabel": "Legal fees reimbursement threshold"
       }
      }
     },
     "localname": "PostEmploymentBenefitsLegalFeesReimbursementThreshold",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PrepaidContractManufacturingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid contract manufacturing costs.",
        "label": "Prepaid Contract Manufacturing Costs",
        "terseLabel": "Prepaid contract manufacturing costs"
       }
      }
     },
     "localname": "PrepaidContractManufacturingCosts",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PrepaidMarketing": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Marketing",
        "label": "Prepaid Marketing",
        "terseLabel": "Prepaid marketing"
       }
      }
     },
     "localname": "PrepaidMarketing",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PrepaidResearchCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for research that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research Costs",
        "terseLabel": "Prepaid research costs"
       }
      }
     },
     "localname": "PrepaidResearchCosts",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProceedsFromIssuanceOfCommonStockInConnectionWithDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock In Connection With Debt",
        "label": "Proceeds From Issuance Of Common Stock In Connection With Debt",
        "terseLabel": "Proceeds from issuance of common stock to lender"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithDebt",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProceedsFromSaleOfPriorityReviewVoucher": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of priority review voucher.",
        "label": "Proceeds From Sale Of Priority Review Voucher",
        "terseLabel": "Proceeds from sale of priority review voucher"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPriorityReviewVoucher",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received.",
        "label": "Proceeds From Upfront Licensee Fee Milestone And Other Payments Excluding Royalty Payments Received",
        "terseLabel": "Proceeds from upfront, licensee fee, milestone and other payments (excluding royalty payments) received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceived",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProceedsRelatedToAssetPurchaseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds related to asset purchase agreement.",
        "label": "Proceeds Related To Asset Purchase Agreement",
        "terseLabel": "Proceeds related to asset purchase agreement"
       }
      }
     },
     "localname": "ProceedsRelatedToAssetPurchaseAgreement",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProductDevelopmentAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development agreements.",
        "label": "Product Development Agreement [Abstract]",
        "terseLabel": "Product Development Agreement [Abstract]"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementAbstract",
     "nsuri": "http://www.eigerbio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "eigr_ProductDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development agreement.",
        "label": "Product Development Agreement [Member]",
        "terseLabel": "Product Development Agreement"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_ProductDevelopmentAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development agreement.",
        "label": "Product Development Agreement [Text Block]",
        "terseLabel": "License, Collaboration, and Product Development Agreements"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementTextBlock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_ProductDevelopmentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development fees.",
        "label": "Product Development Fees",
        "terseLabel": "Product development fees"
       }
      }
     },
     "localname": "ProductDevelopmentFees",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProductRevenueReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue reserves.",
        "label": "Product Revenue Reserves",
        "terseLabel": "Product revenue reserves"
       }
      }
     },
     "localname": "ProductRevenueReserves",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_RestatedTwoThousandThirteenEquityIncentivePlanMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated Two Thousand Thirteen Equity Incentive Plan Member",
        "label": "Restated Two Thousand Thirteen Equity Incentive Plan Member [Member]",
        "terseLabel": "Restated Two Thousand Thirteen Equity Incentive Plan Member"
       }
      }
     },
     "localname": "RestatedTwoThousandThirteenEquityIncentivePlanMemberMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_RestrictedAndPerformanceStockUnitsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted And Performance Stock Units Outstanding",
        "label": "Restricted And Performance Stock Units Outstanding",
        "terseLabel": "Restricted and performance stock units outstanding (in shares)"
       }
      }
     },
     "localname": "RestrictedAndPerformanceStockUnitsOutstanding",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_RestrictedStockUnitsAndPerformanceStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units and performance stock unit member.",
        "label": "Restricted Stock Units And Performance Stock Unit [Member]",
        "terseLabel": "Restricted Stock Units and Performance Stock Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_RoyaltyReceivablePercentageOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty receivable percentage on net sales.",
        "label": "Royalty Receivable Percentage On Net Sales",
        "terseLabel": "Royalty receivable percentage on net sales"
       }
      }
     },
     "localname": "RoyaltyReceivablePercentageOnNetSales",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_SaleOfAssetsNumberOfCommonStockSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of assets number of common stock shares received.",
        "label": "Sale Of Assets Number Of Common Stock Shares Received",
        "terseLabel": "Sale of assets number of common stock shares received"
       }
      }
     },
     "localname": "SaleOfAssetsNumberOfCommonStockSharesReceived",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Estimated Useful Lives Of Property And Equipment",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of prepaid expenses and other current assets.",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTableTextBlock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_SecuredDebtAmendedTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended tranche A.",
        "label": "Secured Debt, Amended Tranche A [Member]",
        "terseLabel": "Amended Tranche A"
       }
      }
     },
     "localname": "SecuredDebtAmendedTrancheAMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_SecuredDebtTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Debt, Tranche A",
        "label": "Secured Debt, Tranche A [Member]",
        "terseLabel": "Secured Debt, Tranche A"
       }
      }
     },
     "localname": "SecuredDebtTrancheAMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_SecuredDebtTrancheBAndCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Debt, Tranche B and C",
        "label": "Secured Debt, Tranche B and C [Member]",
        "terseLabel": "Secured Debt, Tranche B and C"
       }
      }
     },
     "localname": "SecuredDebtTrancheBAndCMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_SecuredDebtTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche B.",
        "label": "Secured Debt, Tranche B [Member]",
        "terseLabel": "Secured Debt, Tranche B"
       }
      }
     },
     "localname": "SecuredDebtTrancheBMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_SecuredDebtTrancheCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche C.",
        "label": "Secured Debt, Tranche C [Member]",
        "terseLabel": "Secured Debt, Tranche C"
       }
      }
     },
     "localname": "SecuredDebtTrancheCMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Cancelled",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Cancelled",
        "terseLabel": "Performance stock units cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsCancelled",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of performance stock units granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Performance Stock Units Granted",
        "negatedTerseLabel": "Performance stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPerformanceStockUnitsGranted",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of restricted stock units forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Restricted Stock Units Forfeited",
        "terseLabel": "Restricted stock units forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsForfeited",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of restricted stock units granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Restricted Stock Units Granted",
        "negatedTerseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant options granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted",
        "negatedTerseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number Of Shares Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesOutstandingAbstract",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price",
        "terseLabel": "Threshold ownership percentage of shareholder for grant of options at pre determined exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "eigr_ShareBasedPaymentArrangementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Tranche Four",
        "label": "Share-based Payment Arrangement, Tranche Four [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Four"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase by counterparty based on exercise of put option share.",
        "label": "Share Repurchase By Counterparty Based On Exercise Of Put Option Share",
        "terseLabel": "Shares repurchase by counterparty based on exercise of put options"
       }
      }
     },
     "localname": "ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionShare",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share repurchase by counterparty based on exercise of put option value.",
        "label": "Share Repurchase By Counterparty Based On Exercise Of Put Option Value",
        "terseLabel": "Shares repurchase by counterparty based on exercise of put option value"
       }
      }
     },
     "localname": "ShareRepurchaseByCounterpartyBasedOnExerciseOfPutOptionValue",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_SharesAvailableForGrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available for Grant",
        "label": "Shares Available for Grant [Abstract]",
        "terseLabel": "Shares Available for Grants"
       }
      }
     },
     "localname": "SharesAvailableForGrantAbstract",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Issuance Under Employee Stock Purchase Program",
        "label": "Shares Available For Issuance Under Employee Stock Purchase Program",
        "terseLabel": "Shares available for issuance under ESPP (in shares)"
       }
      }
     },
     "localname": "SharesAvailableForIssuanceUnderEmployeeStockPurchaseProgram",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_StockIssuedDuringPeriodSharesStockIssuedToLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Issued To Lender",
        "label": "Stock Issued During Period, Shares, Stock Issued To Lender",
        "terseLabel": "Issuance of common stock to lender (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockIssuedToLender",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value product development agreement.",
        "label": "Stock Issued During Period Value Product Development Agreement",
        "terseLabel": "Vesting of common stock under Product Development Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueProductDevelopmentAgreement",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_StockIssuedDuringPeriodValueStockIssuedToLender": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Issued To Lender",
        "label": "Stock Issued During Period, Value, Stock Issued To Lender",
        "terseLabel": "Issuance of common stock to lender"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockIssuedToLender",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_TheragenePharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Theragene Pharmaceuticals Inc.",
        "label": "Theragene Pharmaceuticals Inc [Member]",
        "terseLabel": "Theragene Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "TheragenePharmaceuticalsIncMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Thirteen Employee Stock Purchase Plan",
        "label": "Two Thousand Thirteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "Two Thousand Thirteen Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandThirteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_UPennCHOPAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPennCHOPAgreement",
        "label": "UPennCHOPAgreement [Member]",
        "terseLabel": "UPennCHOPAgreement"
       }
      }
     },
     "localname": "UPennCHOPAgreementMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_USGovernmentBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. government bonds.",
        "label": "U S Government Bonds [Member]",
        "terseLabel": "U.S. government bonds"
       }
      }
     },
     "localname": "USGovernmentBondsMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs",
        "label": "Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs [Member]",
        "terseLabel": "Unvested Stock Options, Performance-Based Restricted Stock Units, And Time-Based RSUs"
       }
      }
     },
     "localname": "UnvestedStockOptionsPerformanceBasedRestrictedStockUnitsAndTimeBasedRSUsMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_UpFrontCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up Front Cash Payments",
        "label": "Up Front Cash Payments",
        "terseLabel": "Up front cash payments"
       }
      }
     },
     "localname": "UpFrontCashPayments",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage.",
        "label": "Upfront Licensee Fee Milestone And Other Payments Excluding Royalty Payments Received Percentage",
        "terseLabel": "Upfront, licensee fee, milestone and other payments (excluding royalty payments) received, percentage"
       }
      }
     },
     "localname": "UpfrontLicenseeFeeMilestoneAndOtherPaymentsExcludingRoyaltyPaymentsReceivedPercentage",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_VariableRateComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component",
        "label": "Variable Rate Component [Axis]",
        "terseLabel": "Variable Rate Component [Axis]"
       }
      }
     },
     "localname": "VariableRateComponentAxis",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_VariableRateComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "terseLabel": "Variable Rate Component [Domain]"
       }
      }
     },
     "localname": "VariableRateComponentDomain",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_VariableRateComponentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component One",
        "label": "Variable Rate Component One [Member]",
        "terseLabel": "Variable Rate Component One"
       }
      }
     },
     "localname": "VariableRateComponentOneMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_VariableRateComponentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component Two",
        "label": "Variable Rate Component Two [Member]",
        "terseLabel": "Variable Rate Component Two"
       }
      }
     },
     "localname": "VariableRateComponentTwoMember",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_VestingOfOptionsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Of Options To Purchase Common Stock",
        "label": "Vesting Of Options To Purchase Common Stock",
        "terseLabel": "Vesting of options to purchase common stock (in shares)"
       }
      }
     },
     "localname": "VestingOfOptionsToPurchaseCommonStock",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period Of Options Issued For Common Stock Purchase",
        "label": "Vesting Period Of Options Issued For Common Stock Purchase",
        "terseLabel": "Vesting period of options"
       }
      }
     },
     "localname": "VestingPeriodOfOptionsIssuedForCommonStockPurchase",
     "nsuri": "http://www.eigerbio.com/20221231",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r365",
      "r394",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r321",
      "r581",
      "r633",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r416",
      "r523",
      "r537",
      "r558",
      "r559",
      "r578",
      "r587",
      "r593",
      "r632",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r416",
      "r523",
      "r537",
      "r558",
      "r559",
      "r578",
      "r587",
      "r593",
      "r632",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r321",
      "r581",
      "r633",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r318",
      "r525",
      "r579",
      "r591",
      "r633",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r318",
      "r525",
      "r579",
      "r591",
      "r633",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r408",
      "r416",
      "r499",
      "r523",
      "r537",
      "r558",
      "r559",
      "r578",
      "r587",
      "r593",
      "r632",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r408",
      "r416",
      "r499",
      "r523",
      "r537",
      "r558",
      "r559",
      "r578",
      "r587",
      "r593",
      "r632",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r268",
      "r269",
      "r365",
      "r394",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r319",
      "r320",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r580",
      "r592",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r319",
      "r320",
      "r545",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r580",
      "r592",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r620",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Palo Alto, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r53",
      "r590"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of debt securities premiums and discounts"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r57"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail",
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r124"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r239",
      "r533",
      "r542",
      "r543"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r68",
      "r71",
      "r197",
      "r538",
      "r539",
      "r561",
      "r605",
      "r606",
      "r607",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r614",
      "r615",
      "r616",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r146",
      "r148",
      "r183",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r148",
      "r177",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r240",
      "r322",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r384",
      "r471",
      "r576",
      "r577",
      "r610"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r211",
      "r225",
      "r265",
      "r309",
      "r312",
      "r316",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r449",
      "r451",
      "r461",
      "r590",
      "r630",
      "r631",
      "r652"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r16",
      "r18",
      "r65",
      "r265",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r449",
      "r451",
      "r461",
      "r590",
      "r630",
      "r631",
      "r652"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets",
        "totalLabel": "Assets, Fair Value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, Unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "verboseLabel": "Debt securities, unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r325",
      "r338"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Debt securities, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r115",
      "r323",
      "r338",
      "r528"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r114",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r149",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r12",
      "r102",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrual"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r13",
      "r48",
      "r95"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "eigr_CashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r95",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r204"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r265",
      "r286",
      "r287",
      "r289",
      "r291",
      "r296",
      "r297",
      "r329",
      "r353",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r392",
      "r393",
      "r396",
      "r400",
      "r461",
      "r560",
      "r604",
      "r611",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Total (in shares)",
        "verboseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r614",
      "r615",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, end of period (in shares)",
        "periodStartLabel": "Balance, beginning of period (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32",
      "r590"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2022 and 2021; 44,074,284 and 34,568,821 shares issued and outstanding as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r72",
      "r244",
      "r246",
      "r253",
      "r529",
      "r534"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r200",
      "r201",
      "r321",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r200",
      "r201",
      "r321",
      "r544",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r200",
      "r201",
      "r321",
      "r546",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r222",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r106",
      "r107",
      "r200",
      "r201",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r200",
      "r201",
      "r321",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Contract-Based Intangible Assets"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r582",
      "r584",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r76",
      "r265",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r461",
      "r630"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r105",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r263",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r378",
      "r385",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r212",
      "r213",
      "r223",
      "r270",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r472",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Minimum prime rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r29",
      "r213",
      "r223",
      "r389"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total future payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r206",
      "r208",
      "r362",
      "r472",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face value of term loan",
        "totalLabel": "Face value of term loan",
        "verboseLabel": "Face value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r59",
      "r206",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60",
      "r270",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r472",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r60",
      "r139",
      "r140",
      "r141",
      "r142",
      "r205",
      "r206",
      "r208",
      "r221",
      "r270",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r472",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r205",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "terseLabel": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r207",
      "r374",
      "r390",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees",
        "terseLabel": "Less: unamortized interest"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail",
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r328",
      "r340",
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, unrealized loss position for more than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Current",
        "terseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Noncurrent",
        "terseLabel": "Long-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement with Individual, Requisite Service Period",
        "terseLabel": "Period of service threshold"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Capitalized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r194",
      "r642"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Section 174 Capitalization"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r194",
      "r642"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r192",
      "r194",
      "r642"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r194",
      "r642"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r194",
      "r642"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r187",
      "r641"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Short term deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r93",
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r307"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is not classified as discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r11",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Sale of Assets"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r254",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r284",
      "r286",
      "r289",
      "r290",
      "r291",
      "r293",
      "r455",
      "r456",
      "r530",
      "r535",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings Per Share, Basic and Diluted [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r254",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r286",
      "r289",
      "r290",
      "r291",
      "r293",
      "r455",
      "r456",
      "r530",
      "r535",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r266",
      "r425",
      "r443"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r639",
      "r643"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r639",
      "r643"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r639",
      "r643"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r639",
      "r643"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r639",
      "r643"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r138",
      "r236",
      "r248",
      "r249",
      "r250",
      "r271",
      "r272",
      "r273",
      "r275",
      "r281",
      "r283",
      "r295",
      "r330",
      "r407",
      "r417",
      "r418",
      "r419",
      "r439",
      "r440",
      "r454",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r538",
      "r539",
      "r540",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r199",
      "r457",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r376",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r458",
      "r496",
      "r497",
      "r498",
      "r574",
      "r575",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r376",
      "r409",
      "r414",
      "r458",
      "r496",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r376",
      "r409",
      "r414",
      "r458",
      "r497",
      "r574",
      "r575",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r376",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r458",
      "r498",
      "r574",
      "r575",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r376",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r496",
      "r497",
      "r498",
      "r574",
      "r575",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Financing Receivable"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r341",
      "r342",
      "r387",
      "r405",
      "r453",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r571",
      "r625",
      "r626",
      "r627",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r93",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "terseLabel": "Other-than-temporary impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r93",
      "r121",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r210",
      "r217",
      "r233",
      "r309",
      "r311",
      "r315",
      "r317",
      "r531",
      "r570"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r266",
      "r426",
      "r432",
      "r437",
      "r441",
      "r444",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r267",
      "r282",
      "r283",
      "r308",
      "r424",
      "r442",
      "r445",
      "r536"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r247",
      "r422",
      "r423",
      "r432",
      "r433",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r89",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r207",
      "r219",
      "r251",
      "r306",
      "r470"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r258",
      "r260",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r118"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r14",
      "r63",
      "r590"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail",
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r64",
      "r294",
      "r343",
      "r345",
      "r346",
      "r524",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r42",
      "r118"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r41",
      "r118"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r78",
      "r305"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Common stock issued under Product Development Agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Total leased space"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturity of Operating Leases Liabilities and Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r265",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r450",
      "r451",
      "r452",
      "r461",
      "r569",
      "r630",
      "r652",
      "r653"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r214",
      "r228",
      "r590",
      "r613",
      "r628",
      "r646"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r265",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r450",
      "r451",
      "r452",
      "r461",
      "r590",
      "r630",
      "r652",
      "r653"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r29",
      "r213",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Loan outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r54",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "auth_ref": [
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period.",
        "label": "Line of Credit Facility, Increase, Accrued Interest",
        "terseLabel": "Accrued and unpaid interest"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r54",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Loan agreement, aggregate borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Loan agreement, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r29",
      "r213",
      "r226",
      "r375",
      "r391",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: current portion of debt",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r133",
      "r270",
      "r380"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "Long-Term Debt, Maturity, Year One"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r133",
      "r270",
      "r380"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "Long-Term Debt, Maturity, Year Five"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r133",
      "r270",
      "r380"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "Long-Term Debt, Maturity, Year Four"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r133",
      "r270",
      "r380"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "Long-Term Debt, Maturity, Year Three"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r133",
      "r270",
      "r380"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "Long-Term Debt, Maturity, Year Two"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtScheduleofMaturitiesofLongtermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt securities"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Debt, net of current portion",
        "verboseLabel": "Carrying value of debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/DebtScheduleofLongTermDebtandUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r60",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r74",
      "r94",
      "r218",
      "r232",
      "r238",
      "r243",
      "r245",
      "r250",
      "r265",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r288",
      "r309",
      "r311",
      "r315",
      "r317",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r456",
      "r461",
      "r570",
      "r630"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r309",
      "r311",
      "r315",
      "r317",
      "r570"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense recognized for company's operating leases"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Less: current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail",
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesMaturityofOperatingLeasesLiabilitiesandFutureMinimumLeasePaymentsDetail",
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r475",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Reduction in the carrying amount of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r481",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r480",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r57"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofComponentsofAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r241",
      "r242"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale debt securities, net",
        "verboseLabel": "Unrealized gain/(loss) on available-for-sale debt securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestmentsAndSecuritiesAtCost": {
     "auth_ref": [
      "r24",
      "r215",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method.",
        "label": "Other Investments and Securities, at Cost",
        "terseLabel": "Cost method investment with carrying value"
       }
      }
     },
     "localname": "OtherInvestmentsAndSecuritiesAtCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Repayments of loan agreement exit fee"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Common stock offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r81",
      "r113",
      "r256"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchase of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributions": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.",
        "label": "Payment for Pension and Other Postretirement Benefits",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r149",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the fair values, as of the date of each statement of financial position presented, of securities that are restricted as collateral for the payment of related debt obligations, primarily secured borrowings and repurchase agreements, and that are reclassified and separately reported in the statement of financial position because the transferee has the right by contract or custom to sell or re-pledge them.",
        "label": "Pledged Assets Separately Reported, Securities Pledged as Collateral, at Fair Value",
        "terseLabel": "Security deposit of collateral for lease"
       }
      }
     },
     "localname": "PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [
      "r216",
      "r231",
      "r635",
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.",
        "label": "Postemployment Benefits Liability",
        "terseLabel": "Salary continuation"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r16",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail",
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r15",
      "r17",
      "r572",
      "r629"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock upon offering at-the-market, net of commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r84",
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings from loan agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r113",
      "r256",
      "r257"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Cash payment received for sale of assets under asset purchase agreement"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SaleofAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from sale"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r83",
      "r180"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock upon ESPP purchase"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r51",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r50",
      "r123"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r25",
      "r26",
      "r125",
      "r230",
      "r532",
      "r590"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r125",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r25",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r25",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r255",
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r33",
      "r39",
      "r229",
      "r234",
      "r590"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegistrationPaymentArrangementArrangementDomain": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies and describes the contingent obligation arising from a commitment made to the recipient of the entity's financial instruments to endeavor (a) to file a registration statement for the resale of those financial instrument (demand or \"piggyback\" rights granted to the recipient) or for the resale of equity shares that are issuable upon exercise or conversion of those financial instruments and (b) for the registration statement to be declared effective by the Securities and Exchange Commission within a specified grace period.",
        "label": "Registration Payment Arrangement, Arrangement [Domain]",
        "terseLabel": "Registration Payment Arrangement, Arrangement [Domain]"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementArrangementDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RegistrationPaymentArrangementByArrangementAxis": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertinent to describing and quantifying a commitment or performance under a commitment to a recipient of an entity's shares (such as to shareholders of an acquired entity) to register the recipient's holdings of such shares, by payment arrangement.",
        "label": "Registration Payment Arrangement by Arrangement [Axis]",
        "terseLabel": "Registration Payment Arrangement by Arrangement [Axis]"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementByArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r415",
      "r486",
      "r487",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r484",
      "r485",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/RelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r186",
      "r235",
      "r660"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units (unvested)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r143",
      "r227",
      "r420",
      "r541",
      "r543",
      "r590"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.eigerbio.com/role/DescriptionofBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r236",
      "r271",
      "r272",
      "r273",
      "r275",
      "r281",
      "r283",
      "r330",
      "r417",
      "r418",
      "r419",
      "r439",
      "r440",
      "r454",
      "r538",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r252",
      "r265",
      "r303",
      "r304",
      "r310",
      "r313",
      "r314",
      "r318",
      "r319",
      "r321",
      "r329",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r461",
      "r531",
      "r630"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues [Abstract]"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r479",
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r321",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt and Unamortized Discount Balances"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r148",
      "r176",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Non-cash Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r22",
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units and Performance Stock Units Activity and Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r51",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponentsScheduleofPropertyPlantandEquipmentDetails",
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r149",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r156",
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r588",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of new grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of options forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Common stock available for grant (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of employee option grants (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested shares, ending balance (in shares)",
        "periodStartLabel": "Unvested shares, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant-date fair value of options ending balance (in USD per share)",
        "periodStartLabel": "Weighted average grant-date fair value of options beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of options vested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationSummaryofNoncashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional options authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares available to be issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "terseLabel": "Options available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail",
      "http://www.eigerbio.com/role/StockholdersEquityCommonStockReservedForFutureIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of employee option grants (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending balance",
        "periodStartLabel": "Aggregate intrinsic value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r158",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, outstanding, ending balance (in USD per share)",
        "periodStartLabel": "Weighted-average exercise price, outstanding, beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage increase in number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of common stock issued subject to quarterly vesting requirements (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r147",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.eigerbio.com/role/StockBasedCompensationScheduleofNonvestedRestrictedStockUnitsandPerformanceStockUnitsActivityandWeightedAverageGrantDateFairValueDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail",
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual terms of options granted under the Plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r174",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "periodEndLabel": "Weighted average remaining contractual life, ending balance (in years)",
        "periodStartLabel": "Weighted average remaining contractual life, beginning balance (in years)",
        "terseLabel": "Contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationWeightedaverageassumptionsusedinBlackScholesModeltoestimatefairvalueofstockoptionsgrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Employee holding percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise price (in usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt [Member]",
        "terseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "ShortTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r138",
      "r265",
      "r286",
      "r287",
      "r289",
      "r291",
      "r296",
      "r297",
      "r329",
      "r353",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r392",
      "r393",
      "r396",
      "r400",
      "r461",
      "r560",
      "r604",
      "r611",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r62",
      "r138",
      "r236",
      "r248",
      "r249",
      "r250",
      "r271",
      "r272",
      "r273",
      "r275",
      "r281",
      "r283",
      "r295",
      "r330",
      "r407",
      "r417",
      "r418",
      "r419",
      "r439",
      "r440",
      "r454",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r538",
      "r539",
      "r540",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r295",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r31",
      "r32",
      "r138",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock upon ESPP purchase (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r138",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Issued stocks (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r138",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r138",
      "r143",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r31",
      "r32",
      "r138",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock upon ESPP purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r138",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock",
        "verboseLabel": "Value of common stock issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Stock issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r31",
      "r32",
      "r138",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon release of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r62",
      "r138",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon stock option exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r36",
      "r37",
      "r112",
      "r590",
      "r613",
      "r628",
      "r646"
     ],
     "calculation": {
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets",
      "http://www.eigerbio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r264",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r468",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r490",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/DebtAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r326",
      "r327",
      "r387",
      "r405",
      "r453",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r625",
      "r626",
      "r627",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/FairValueMeasurementsEstimatedValueofCashEquivalentsandDebtSecuritiesandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.eigerbio.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesMeasuredatFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/role/LicenseCollaborationandProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r421",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "terseLabel": "Reductions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions based on tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties associated with uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits impact on effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r298",
      "r299",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r477",
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease payments for operating leases"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/AssetPurchaseAgreementsandRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r285",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r284",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eigerbio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16242-108621",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001305253-23-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001305253-23-000005-xbrl.zip
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M*FL8]3XX9K#4U#T<,JW8!UX<R7Q4*F+J4M4_HX+JX*/'*%#+HY+VX4C6O?K
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MKZ4VELC(=-JNCT7' _!$X-8,H@[GX7/&2M0)-:GOB:'**LU<X$9;A ACCMA
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M%1:,",3( /**:TB>!4H/6-]"*B45R(RWPGCK#.,Z[>9BJ!A F\>O KK].CO
M+O7>/ZC@UF,P'X:BE)")6'M#'%A\S"FM U- JF B%<JA 51CK3NM%B=73AC*
M-&(B4LHX18:!/8Y#L#$@@4+>T +KONTVUNM,M$29MW&O:4QU'*XGS-^%JMK_
M]>V[/2!.6 [NS??7QOK._;7ATD7UUW9! T(**KF13&"M',968+ /"04Y1-\K
M,;_XUK3A[V%Z4_>6]/.U^5B>3DX?(ILPI+@($?A 2\:# $W*J5:!^& !IL6&
M3;[PUH/*U:?A: SSGQ[[JG9YDYRKD;4^37UD1M]>T_U]\:="(@9KL:$1,X.0
MUJGL7SJB=:H+%0/:[F/#GTOESQ5M54)94%PS121CTA-C$*/!!@)&;G0A[T2+
M%5(XXV?^8XC\"9:L!ZOV>2J"JKOTP#T93VH'J1U\)]2Y=NFW&$\J:,W!9(I*
M,J*DH5@$Y!DR8 [SKDW4AIA?Z:E<I\\W%81PAQPA2C'),*.:2FJ9M=Q%RJFQ
M#T0KK$SJ5H.E 6&3DJS*8,Z\TI9C.,# +,41(\<'M.W3>E)U)1L]6:J4HLX(
M2@1CT6M0CR+:M/DR)<&Q 6V3N9Y47<D6E^ OTDBU]$9$YIP%.:5YAUSGM(["
M]G8/QWQG^L<@J7KX<K\>C8Q-RRV3V7Q_5@_?P?R.5L_\I=] 4R*$!C4:D;26
M8>IMD' @4*,DI1Z13%.!6!<+@#\H6E>:OBRK<AQ>E>?!'U1@91R7=A3VVC:,
MVV<7K\V_ZF9_9-IK!9BO2I>>4QW/J+R$R.T5,HL=Q.[H4N=+*5H F2DFSD6A
MB.*2::)5=#H8:[2(WF(>!D3FHXEM2U^:YB*YKF]CWEUX7GS[C887[E7/_.F4
M#1A?I.*IN@JWKE"HJSRJ1;WY/<!4:W*"X5HF[]GKH[F3#Y%SHTK[)RMG;:0L
M4J.)-4%JAH*@E LT(,[]<EAFWI*H_&$XGHS,N&XN7I>CT(Z!VQ:W&O1^P'+#
MXG=@<:TL8RIZEU:>@(EE5&22I/5;,F@W*' >3N1Q(RD#E!1.2+1&.IEV]E):
M&T((4]X84 ;1A_B@)&5.&;Q+!LW[#_6&IQ\@3U,GM3!>1^:9\Z +%'?>(>54
M" 9-LUVTCVLBNKZQDC_!TR? 2ANN7G9<E]XYK@N7+B16) S"W*-@E,","&:0
M)XR&*(SQ!(F\XADCI-<7H#\7(GH-%LSO=Z?@<CEX'^:]@7$\ WFZ<=M2DSMH
M!^DY$/R617(6D4@%CU$K)B@S+'*M@Z4Q(LMD5Y("[-(I]K7DF^5;HH/AR"5B
MZF=5S/2BP]"&U.(#?.@YA?/BXQD\;0D+VZ[8$%DF[F9#7!.?;PKO.2=B<)SY
MP'2*S#OE(T>1".($%0\D,C]P)A]D@L @ ]Q%A*1$@WDJ#;>*&QF1"Y8)%QY(
MVOW[9JW5Y/X981% "PM0_8Q;D7")"4L#5EPCJ3)KT2EKT0UKK;=J3HF9\,<D
M:=IS^.?F0HEK%RR9I>G=69HNCJ4-CD210$ +,]"R"AQ[XR03TFFC31?*19CT
M=NPZL_1A&,$D^'<P;1=SW#O'V"\.?EDU6^=QY)-?F_;[=CL/DSO;>0NKP"
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M741IB_2H-UIL(U /5:!6K\44)D$:9*4.G&D408LYAYC0AKN D%K_+68V0O?
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M1L:,]!8<&:.YQ")Z@YD;,!M\K1A_.S=<98$OF;'KP@+82R<,"SK8P%2D!F$
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MT[@3(/'S<!Y&]5FZ]L7'%!KZ4A1HD 16&GLO0P#2(F:!VLA)P8Q 0J*T]F9
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MUA/8:QZP;4.@^Y(G,QXW)DU]/1J!X@<X Q.\:\4Q)T';0,KCR2B=O+A!PXR
MR?Q*8:@V;$BW+-)EURK)3*+ <5-_ "+-[//.-D[N2&J9U^:F_;?+5F<V7]=O
MJ9ET;USWC]@0\IYDL+;9 (SF'.0OA7' ?SBUDZ:]K"$^ V]AV@0G43FOYTH_
M?$@-=!+Q.ZH5QKEP-LXZLM>$&W1=H7%?39*'ESS.*1FJX,!-32W8DMB!T9_\
MLWEX/8,KSTW?7 0<_0!>P6D(XWG+LPE_3,JF<]@VU%P6->>H,J<,>Q\[%+_M
M'NUF(@'6PJ.J(M>B->5&P):K R]UWE16$M3]=PJ%G%\DXOQKTI1MBD[E8% ]
M&;>E#U,%F:AV/6#Y8I(VOH8O_*V"6S;46RKU0I-[E<QIJ/%)V?B=LUQVGL,@
MY70IS1R -ANI6JYE.7%),26:N+1 <]P+1V/. -$NPYE@5W;ARA0U+<RY*4?)
M:-D0YYX]MB0>3<B6X^\!Y,:5.71=NHY"LR5H(&]M755AM*'0,L4'[.X)T&46
MP)WF:-IDVYDFJYKD(U<Y0=1G(9J4AIBD PZD;'S-L,LDKD+PG3>7WIPT6LH:
M="FNZCBGR39T7:+D=3FU+LH[1\K;7;A.9?4!_91W&XW@YI2'.4L&1M)O\,>X
M2X]^QD7?O5,>^[/U$TO.!W\^.P83%=.7Y\\[O9F]S<G.V#'X>1D^]!&G)K1I
MLG.<]TJ:+EV7=(\U;? I]7PI7?E4VTY.SSH2F79JZ$6@#HPJ36AWZ$96;/K8
M=F+_U;\7#,??NX=>Y@U!_>VF3*_O<L[I@R[ZE\ L='< O<$13VD9<!7@KE&1
M"SEN2W#/DL>OP6U(+5FVBP^ASR6$W!JW@(,74RT\VRHA*6(/OJ!+370SG%3G
M95-7:69W,V6[H<!4-\?P^4U]FMW']%GIO[O%P;B .4BIO[.Z;<L4:ICRX)S"
M@,O[Y&YA1J/NH=MP5Y,8- T5ICL9"FF.R].SI(M@,M*EL?O 1*#T3-MG^Z=I
M7 ";_OD?3LJ4%H=I[&[93I? ]UK M2P:*5%K^KXV.3-O4DK==++4](E\>) O
M8PS-+!\&L]-]=HYC7:9DLVA>?(YA/^1$/OS?[S!/O\"45SUYK[#!=G%13XHN
MF=W-X\BX=(V?)# ?E9U56]TA??SB8XK3)';M(=\7]J(8F0^9&S+SC&$P\!8
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M_G-3R;GRL:Q_)>?J3,FW(((@LTF3CI,VFI8J@7K_D-+]39L\E!TW,IW)T2,
M:/1W:1OI@EZKC>DC%6/XN!0R3]M*IW-@$(R3=*<01[[]O!Z==Y8! $<V*LY
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M])Q.-D7K.[)"@G;JTM/%LIY@;5Z0Z.PT B2(0>T?W;7+ ,*\W$;-_%\NQ9!
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M%+S=4,-D42@-/;6%F*0>T 6")J&7[ZW5,"@DJ %[>W_0=6_/BZ"/FP\[W3!
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M"\DO9*[RY4*6V@HY:>BUSK:8)9TL^BJYEL78)OZ/XP]GW(PVAW*I$9I/"O;
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M]GX?.^G>KP1)WP>+\=95VFO:U0\6XX/%^& Q?B>+<:_WZ%%@_!SL;9O%>-<
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MZ*G?!)G3.!W'CL8/M:_"FU203^-*QY>H^V(B)_H[" ]1]0B"P[G<UOK0Z+]
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MI\.'"8? %EHOX?(?5G@D]RY4#YP(DUHT?P"3S_-41:\<<-B%,&3F&3?P=6.
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M]_*;D&[<$<38^V->WGXZ'+3.&0!\D;FL 4K$05("H\50!RAV% UL4I A?TL
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MI!G)L?W#7A0=![ F&6;,YY =3Z0U+("JB"X-5W@'3=XM5@X=-%U>B8:+W@8
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M<-4UJO/ -,.?3=+3!%-GJF6<QG+DODVZZ QE'PM7A668V0H1^<3:*?L6"/Y
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M-;Y;5".(RRMHL(17B)5CRM4W2(I=Y14<"X'!]GT07H%9)%G*^5@5]\O5&$6
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MGG3.P^66& H>P%59I1TB:2=XIYA91>!HA,$AU4Y[I'T/M3XK* K+'4-ZDL^
MSXY+2803GOMDD7LM;D.@C=[L8(9$51.)6#5!R'$L]HOUH*WUS^)=!"OW'*"3
MUZ8\"S-#O"%/K6WK8?L;KR&A^[8HMO&$5KYHIZAK=;6D7,;@Q7!L:LL)N1^N
M.43;S/K'QR0_>CQ.<)3X[ERX%S&9Z#@J)JB5,[1W,LC[0.^CE5Y6B:VR#LVD
M'\Y79B'J[2U?[:P=/05WY@R:OLV1$[,CS:=^@\Q><$L;L^TDC)W&M>OM8QM>
MAK*1K!GB+N_L G(\)FC)V07JZ,&/8<4.R>-?.7YAMBL*F.#'+6E@Y]Q\3GPX
MO>D'F(@Z<+D_('S:CH9-BI]4'G.]/)_;H&I4QVOHU_+"ZZJ\JNJN8J4^(V+Q
M&+<#5X[Z>_TNR[JZJKDP/^H9)\<7#5YR,G+:>XPB&J^!I>#<9Z9:8YH]6^T4
M!:;'EIQ)#*-(SB&N@T3?.&$*2'P="0/@Z&EU8<3=&S(?P6]@QRXU"LMZT:&;
MT3>&\7>0PO:)+:X/TLR4S?*,#HU]0F+MZ_M.ID#)5VIN][A8B.CW.F6S;4;6
M.-"?2Q$[#KN^$-[!L.E)+40Y("C=ZT(0'2BEQI:.8RZP<(/M*%E4>\CC=QE5
M%\OT%Q;\#%WH>4KQO:NC7MRZN"+SV?CK\*D?JUX]OS\3<5LCL/4K-/RQ*/^!
MIC4;!EKDOW45=[1H4:>)S\".M84@Y[-?X28IF[UL.4SI+3?#=2;U#+^-PX'I
MU: ^64G_,(I7$7_I#Z^L6;<+C$!1-[/;)\-0]^7J7_&4QN,S_I2]L"\]4$B&
M&7<?'&2ZE[M6()I4YH]U6>S9_K$R3$M;AX(=,Z_=XF$F%X2S%LK9-0:MZIE1
MV>J?^*E:KRD>3VL] +EW0=)?L:];3&>L5(8O;#BA 2,"*>;@F.R%U/F&ZFA@
MBF -"6MT3ZD:DBIV3PACA:-C%Z+K;<X"TUR0F46 V8+;57'-B?#CS^#*_H@]
M\EUD#_D^OVVE)]ELW&NW:A^V0_MRI-DMP[;RN9RF2 G)HFL130@Y$9)1R-AS
MX,-#9*K<AG&R;@Y1H>3=TKZC3H=1J]#"(JF<R#7$]N I'>L-I[A> <W9L&O'
M_RC#6Q7-3;E0_:$?J10'P_V2/:#PO;]SRZ@E X#8?T9LZ#L%S_",X\+?0=8X
M7E58Z<M>/N#]+C+QC?_J6HAK<"9"6U7YDQ>[\.SAD*;,'5W$N(S#I4:OD@"9
MQ+FS&;HBDU&)>8<$D<U!0:XO/024VPMN"R*U,6\RQN:'3,;9VW+QEMH]A-IQ
M39I;H*:02R"R#Q[<C4H-4F8)QD7^SO B&H7H3/&?D(JZWK<@ 2;T(F?/J)&
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M@R;/R*2*N"RI\14'A&\2IXGP4 <I0DOQB*O3FWI9K$?.3RQP!N=Y&QQS<VI
M;QRL"^_'RV=1LE9$48'=QL <XV^OH42O-B5.@L9%-\4Z2]$ZJ-DG4#TN; ^"
M* ]B\KP,1S6R?UJ-;'9)'H/"!L8%D;C :M0_C61%T,86^T!]M543NL/"9ES5
M#$E(V+WZB)U$ABDUD/X:+.G@Y3V$/I< @QB)>8'-+GT2PHE7*'%$)GB\F7(S
M2C>F;^FD-@E*Z8C7_- P4\-$A(>_?0CX5+B2^NKLW?3P5*XA*/O7@*D>&O#(
M$Q&/2X?QAF\/#HU+N7BA($.IW@%N#BN7I#J%@8A7!W8HK&21-IW> 7..O3)K
M7BJ5%+7<:9%\U2&"><WT<W*\0C3=0<!=L[0C8*E[@+LTP$V3?3&S)Z<=9^K"
M/EZW_U3:S;OO#RCG)D9HX&O$.G)8$]=@T8-0"O=\>^C:%!E!;5I+FKU,M^P0
M=*J86,^^#G/3[=(]SWM]5E?#0W@(8^U:<#U$BSZJ&B>)?[T>,\(+:'9$)D[4
M(<WL(-P-CDXKC=M<E.4EI$EK$/&ZGOFK$+E2RL#*D-ITQE],$N6C7%*:60BK
M2[VI++I2D1/*G1=9WZE)QRN)^76BJ%S-K X/W;@^0_<?+_^I1=:"&+CE8CI2
M$ZEK8Y(^)*7C3SX*MKJB6O0,X:!688H<AC,IFP//$U>*NIWDVBC%R] WT5.:
M%#")Y*<A8);CSM :2"]^E'"@VT#5_@UY@*E"JFHE<NE9,BXAEF%;#08J?0 .
MB'A#)=V7$#&8%Q%]M=[+P055I05HHM(%AV&T.A&3<X?=Y3@?_<=K-Y)&L ]W
MUFAWHH]*>]WKO@)W5Q@LKJ>+YY-4TKH2QW/0?I-T@P[.8ER#&9L350<[Y,YG
M/V+5;;Q0#Q[XB"@X(@J.B(+?3_B/YBXFZA-$U:I\)T:8N! DP9:*5\T[0OX&
M#Z9N$DLLA'\2S D>;QDN<YLWR\0/\79ZT,D(+OZVWW^=^-X$?(TH*!"*(<XL
M*)_#1SP9HP+NE,2^L>TFR958@!\9H!9-W;9GL[G@T1#<2S@;ANL,8[*T$*-X
M5U"=Q7>^IBX7&V#A43-"TH?N'(1!>E8LV.!R'25E4S_%;__ZY,G?GM!K?O?3
M!8+-\%_WP0RE6(FQ>3VD'Y#N?M"*YS+&CY]$_" !*0E[D@1(@@3A)@BE^N?3
MEABL<7CB;S?!=%=@AZM"H"#-!N8L)/1,6HZAE1)[$Y#3;&>_$9%D/ (C_3ZY
MH_B;JY# ;UCOE#(.T8$4CR*%<SB?&[3%RDZ(LF_Z,/'9'16A\02,O<3H^.;E
M)B$BR%VDM9,0DV4N?$^& P7;D^W]>\>8@Y^VW/%, G8< I'H5BA5 KL'J6>0
M,_TX$XC2R/MAD'SK B3 U0&7<+[ODV?-XN.+$W;OIK$/OMO&&\)>!U\,#4M(
MDSO9C>?OB!RT:!\VQ=Z/+! >7\$KAQ3R"K-;RBC\Y:LOSC]3UMEL]I<O/S__
MW$AHZ:M_^?SQ^9?V&UWP#*UGY+;9I<\8@O$D2S#WCY :WJI+_="G_CFW;LB"
M_Z[;$.5T<'MW4;OV84[Z!5S[D<FX%:*'8'=VG*S^XDOPA)Y!X;JP%YY,AC#W
M=C;[[&O.PH93 8LG&($--TDP?01273'A$^W#Q%*,(F5LMAY_E5[?755B>,E!
M6'HD+2>=SQX_UL[Q^%I(F@E/;9B65^?/SIEC]O*:?OP!;>?]+W'2010IN4N0
MXM4Y=^!Q]M\K;QN#/"7HPG)0$#B%A,P-I*0;5<$:.B3'5* #D9PTV/DVK*"M
M-@<E9 669N-B7/JLW-MY5=?+>VVNCVN7KK&C%KRC1/2 I0U5B3SA)L_TM-Y+
M@FS1=* >IY\%:@]O% J)Y3]TS9'7>M6P0@E&2[L/>-58.LY&D8_KL*(K4BY9
M)TTON "A.O9VIP(B6[Q.:/YW.\J4Z4-QYK/><0-I6ZS9#[:;9>:65))!YMHG
MZ$5=BP]$CX18/2R.Q=LS=J@2DNK\%MHC6#-Y>RT?$;93]!O,ZZIKY7,/W?X^
M-0GXEY% _F$OZ["S8:Z"XW=55LR%69F4/6-R\W49WJ8J<_J7\^0?/:+U_K18
MKX-;3MA=_A:\>OWM*6-[PMI<4S-F,.GV^>!Z]>[T+%B*6ZU,D]TOX1Z6J%^*
MSBV4OB0Y^J*8-W#N 1AY_/DHQ&:>+]Y2PK=:GLF@KO!_W_Q10_RQ.ZBD?1VN
MS>,OL]GSDG"AWY9URLX<-O;+:G$^.[F4WG%\[E23=P7/!@4;X=LGK_#?4S;I
M-J432A7DMEMEF;\YNXBGRR6!U7+FB!G[A%LS\J<WW9R?EKC_PID;ENU9?4OU
M(8)XE<M2%H5][R1^\93?8:FZA((J2]XZ4T(H]SO.*3#>Y#ZWU# PQ!$WY0T#
M!N(&208C[)'-!HJ(Q=KKF<9/N"%0;@":C2IGI;T[IO0EP"J5<!78M.BEZ8B@
ME /)PY"A)O@/Z4 W^5*:.NAX^2%OE_G_S/[.<@VO6-@P3G&Y>$OYU/UF7J]G
MSU_^_35]3Y;>9[STSF<_HGZJQY1KUR.:(/%<P*O/<.LGC[_X@E _;V??KF]@
M(2[S=3V[6%,5T)FEKS__[-&7L6,CC&*QO2;72)!'93O[\HM'9T^^>G+VY>//
M_L;/8:8G&, P@;M"0;;T\=O;V_."!G5>UN=A;$0@7#)Y>J[:%YM"Z3R]/<-R
M#A>[8!37:U84"L/R@DJ&CQ^=_;<]<E.@?+(P0.K/K[^WBK/>QDLU"R<&;3EA
M0:.T98>ZDEZ*B@(//3?TTQT#)"P0;7PM;E6D:0[KLZ#4F=2Q:_^;>4'X=ZFH
M2VN0B"90$69=2'4\7/^FJ.#,9H,KTC^QQ^3VPJFE_&73C^T1..OZJJ88H>&T
M400<W)1MQQKTP1W;@]<;9.34%:5-5K04_L__?OS5Y]^0T_[3*]E@5/"F%JP.
M,F8V,'$=QE4B7+%<G(>WGE-7E,CHF?P")62:7:;+CT(LTI='B_-.ZD[1LZ6J
M*-L-%2-KI!M(I<D ;G&?#]N;R 3D^FUQ8*P1;@CK&;\)[@0^RT:'"UM0ZH>2
M<M9V"3]M=;),6(Z%\H-I[9]&&RE'UL:PBI<P(. SI(Q#0AP"Z'&W'MMCY?+_
M^U]W5PD>?_;H?_T>\B$N4829#<_YGV<?EH[HH,/[\J?GKV:/+\Y)!.C1-\/_
M?4WR(2]80^6C^\&3Q$KCENG_KSN2 R;\%!475)PD]H6[@QHR*:(5DS2<T<=X
MK?24YV! 6&-.TIXB$<)8)/9U5R5!;22\JQ><GQ;J^<J:*M/': 7S18Y TK\X
M*CER@'29U,F"WWR[0ZF9-4D I\M5[H$2)3AP^ I P8($6.F>E0&8*^)BRMG5
M#X-!(=W9NB:>U2LNQ K039(-$%Y+ATJ<*KJ:J/J@JX%O4K(OQ/1^?O9TSAS+
MMI\P A>)F 8TG0K*(\?HV_H_CP7B8X'XDR\0?\2Z1#P+0ABV"0^U_^A'PL$#
MX-N"*MHE-['B>1E()E3V:CU$@_RM>..>9WT06)$5[:3+BP">84B(_94QW\P"
M!&NG]S-*<PU->B:L%2(UP:OOC.GCM@#CAB=2!52]8_').R[!MP]#M8SV-QI,
M?;KDH)/NGGL\4P; $LE]44Y&7$OI)_'^@G:2(.H+IO]E"&:I+/OX@A^_[X#S
M*3G'I.GXA<_\3T=Q8LFO0C$SA0$-4?#.I?$2H%'-<O1&B3WL\;=*#YEQ%V%J
M0.*1\R][?_2W"QQMCZROG&/\)G<NSOOFW^]R1_\0$S.^8S%D7W[S\?)MZ=@\
M_OS\"QJ+7SE#X'$=P1FE6LF\K'LH1@6^<'+*0V\'"AW43:TX@J0RQ?A$0I$3
M?H&=.L('E"WQ%L9J#A0<*::MBIWJ09+(,"D$4)%TUI;P-J$?L2BV7*;2;U-^
M!5W,+^J:,:_H=+U(FZ1.7CR[.'6%N%SZR8'^N>"&U9/GKRY.H^B)ONJ('%=F
MM/PG(;S/5WE3E?/33$&S'%\RQ,35J[15A*M5>GD5'&6@]UX^RS+3*VZ"/6Z)
M#[PE6$X-T;;0!; ZY[0NC<+)!0"OA%+83FV"+DW$37ZEMJN*3M(K1M@"@B*4
M5DDRQ/J*(*&YNE,GIR_&,BTO!PXOR>N,_=VG8RBW)XU.# Z;N/W]2&F.2_1W
M+-%+M2>2RFJ4N8]F @VV9.XDQ\6V[@>R=;1DQ$J]YRM=D%\Y\2)?G?_M7F\R
M"#]I_L\^/Z<V<>(7I*UQ%CRBJ^H_J=;*$11G&#]FF2JQY[R1(#5EL3IYWN0D
MK[F0/?ON[Y=OE%C :[> @^C^RAU\S@K XIKP9?4_]E=D4;Y_]</%;".2KZ(K
MPOH@U1DI7]*_=@47O+J-@10)+E9O]")\@FWAZ"97_[^O+M_\]/S)YW:'UK N
MM/W;;AY.;SZQDB4&>Q35& 2K'SZ7R#2HU1)[ ?/G]:;$L@C0/U5X6'DVKK"@
MZ2[?*GW3['OD<8O9A5_VWWXOR_ZPR>;>YO#WZW(.>;78EBD(F*,M^T"V[$<O
ML W?K+A"=,1XBVY+,4)D?X1'5!K]]H_-EC@/X-YQ(UY<C%/'TLL5K6<6BNVM
M-P* JZ[9U*5C]Z,_(K-4*9P7%&1&/'DZ.=0$$3ZNI@^XFL1 J+_&CESKA7&1
M(8YLNSV449;"C&*4'L*5EFK5ZP_\UN\ILW ,!3Z<GS40(Z1,!9'R4^J-F"EW
MUR*8!/BO=#!'>@\2HM3L"G&E4.N'Z:YH<2/$L^L2'5_=4GO4Y#S<$E?S0H (
MMK+#YY0F[7[ L^/L_[Y 4.7*HY*A3-%TT.5;!JU=<7!<F-^S*KFO@,I3U/JQ
M8\X-HD6)$G":$NL_!06,')QJ2L7QV7A%060<Z'/+LJ4&;J\\/O$>L=V([W9O
M$.QQH;WO0GNY>I\%MLK+-0J:1L==B');9K)M&>%L13F.BJ4@D&#* 68^W)4M
M9<Q=POT%^]-M6$C4ONK7K*.-"":,,L@C@';"/S P(K+=\].[]F&Q69F62)'F
M\[E$;I.K/9";I2PXIRC-NH1-)L3X>E=N&)@V]\Z<)LRY+:F??QPX]]-C?5SR
M?X!M!0L)M[X5VI+.^K8C)B^A(9TT797AM*7X$P64?DQ=OVD+/4[/,W&WQ/=?
MJ.]/M,TE%(1B'_H:S0X*94 ,(H[JJKL?E<)QO?T^$TNV0!.68 WM*K9IT[$B
M)JC=$ >YD.O=HHQ7%GR<[F=@U[B-*8Q-(?E03>$SBY,2A'Q;,$0%9!%*VE)O
MC;Q#6H7D,0\\F*@OXMGX 8B@TB50XJ(BV+ST>D2G (68!=,@Y".<0K/V6ELP
M%M=XW92["EPD0. <U^P'M)%4E-9.\83A%!%$OBV7KIET8=2A!O .!V]KLC)0
MHN'**JY#" %:1W) .J(^YARCM<_>0":$K,L;UG93-=$HJ(3-$2Y^/#(_Y'*(
M]"%PZ-7IC[Q_X-L"2]$BW_)>50LG9"='U^=CS^-/R43XLJ*KYFF_?ST@H7*'
M $IRG-[B/"F[N]2;PG @6'(BB-RRSM,\G #7^Y:(I2KPL?%ID(TRP2D8/)Y*
MPNY&#T]GY_Y\]@9KK2<JK(^4IC[E\02U'0X6CCZ53>=0Q*,LAEMBL,*AV'@*
M7>N,!]&&ZV2MFZN\DI6.H&*""P^[HS\ 1TSE$5/YR6,JCP;Z]P- XF$K :D>
ML$R%74<%8 U8^^QA!_SWR3Q*RHX:H@<"E+,N/0/V6"U-</2$%XFP3^$P%+=,
M"QT19!\;?_A2Y7CO72[D;[O\;5&I-/!K A[FU->Z5):6\/6?WQ)C,?N;;1@O
MJB9CF(C$Z'QVK'-]P#4Z4C573WY+'.EA4:R*)LS3.M_,EXP7>OKC+R^?G3W^
M&GX%T;(S%[KJ<N[1R21'XS\<O" WU7N?*0%$[N@H?L YEAXS@$[8AP)2<UY6
MYKX7[YC8B$(\-)M,U:TU3Q6\/E!,<C_<^Q;*K3P^N*\$&/[9..F%C%J^N!:^
MW4'YE>/1E"!2*A[*/B;ICF/Y_ ^(3438@2RX$F'I(?#\U87'YY^I%L0\7R.^
M</@R=]CX]C*37EJ)J(ME$,CR^,*GE S2\W!=Y$OFA2%TI>":VJY%[95;QF[J
M11+:NN XL6N((4R3%)R W3K8Q(1K770$O4[%T=Y]P!SM 7-C"X7HMYNR &G<
MG48,=2*146D7]58Y86%9P2S4,8)]"X%C .?8'2I;@;LIAI:J3,&.+;-!$HW7
MIAZ^_1K3:.BN939Z.B1GX3;6QQ3:'^$US=.J"PX;0Y@Y"!C+U:@<L:PUZ? ?
MF5-E&$)>G6/\5OIGS[C)/!ZJ6L1%J5):*KP8CJ1<C.<JY5>^U:[UJ74<._EU
MA_ )[2MMJDN*2JTOMY9MTVTE!*C3TI9O37><6=I"SX5=,=44N.A3ZMAI7KG4
MMK+^'8YK_X^)&-+53XE'4:<%$8&4BS*=/Q&DN2%&%C5S@_+HP8Z@X[Q^J'G]
M+J8^A]*'40F&YO[]\@6'A ZFC5A1W90AZ&2%@DSY2;DN01B54=$"9S:$'=EQ
M *[0CT4@EB*L+35=C!Q!YOBXMCYT!3(J->G.-DU7%9!:>9.R6(.0%Q R$>O.
MB;JQ)<6D'OC'"Q]&I5AVHHZ3^T?VN:&$Y(,U1XJL*@_ #5 31MCZ0. 0MF;!
M6#.J0!">4%J3]2M]G2=G@**KH0Z/!VM-%X1,4MULE><'B9W?3NEKE^\Z9*V8
M6 F ;^@7.J>K[Q'%U*LMS.-R_+21^\?Y^Z!E;:E:6YHY/-NRV)0+"!]H-[,O
MG8S++@W)@(8HNX3)B'8J,P_X *>*X9*F3U.DDV-4SF+UYI!U>>@TKZ]1V'D=
M-:!HS%[8>#Z-Y$HOE<E7!E?(N,-W+2EV+UZL#TO0]YZM, /Z *$.&&$+R-0=
MGF0CB N(%BJ2H;V"&I^&NY(X(W>]9FV_RL73<6M/GDN!.51=:8L"62\V@@^<
M<OKW\T9\./:'%P=(])GS;8))GPT$920@GJXW)8OREZ^_//^;X_'_[+/SKU,>
M_R^_.'\</Y!0\L]2[OC^,RB!O.O3A?PEY1OA_?SE\\^^.G^B%S>*4BACMBW3
M75.]10EC&6L:_B7GJ'X*8\JW&EI@W@751# (^I7K>KTL&B,Q%,INE,+K!A1I
MPCO^T!D]?_7H745#CDARA5D,?UHXZ%%*I0"=-?BFZ[RJXEI6&>MPZ74(O'>B
MM?)N1VHOF_!XUVV/0K=LB5YX 4J'1*^L:NLUO-VE.PXC$YT V<.W-R)KKW1,
M(?!?LV[L"/SS=K1LK!+",]H"KG1BY.[$?Y[A?S'Y-_G:0,3M=?C.&;$H:R
M#J'.\T/$;*2=YWUU3B/D??P(V^,S[MUX(;*SSPK4@\*AI<08":/WBV<OGYZR
M",]V2THUT'$&W05ZH=Z$(0BWGOU"2.[][-N\>CL[>?/+MZ=472**<8R+5!H(
MR&JFB2BC2:A<;)<6NC"8Q;M%48#*%.TS+Y^R,@L^ "-W3G3 UQ3_9D9610K+
M7"JET90RI]REI84S]JPA[F'*T6!(Q4=R*TZ*'^%+J,BBQ,9SC;WMEJ[* _@E
M?/^ERUD:IBH)JT>[&D5Y$!9')GQ1-TVQ2(,J-_>12\2]D/?J!1%)+_6>*R_L
M"UM)3_Q* AW03PW287M:3\%)9 )OO\Y(H*:YB?CI(P;PB '\U#& '_&\A5&$
M=!@=K\%P=&@?**B\R]95RDQL0@@F+!58L DNV>I3B96,^"_?RK[,A5[:_?W6
M >+8>I =,4;"LH'! QE3 \/^*E@C8IL66_$9VPIDMB7X"X:7#4T\?RF#6>XZ
M?F@2L&GLF&$BYB:J^[74)<YT=CN37&>=<W W%Y+;[D>ZK43"ZB'0<Z +EY7?
MT@<2?$QVP(+^_D-<2J6[:V*P*:K[ F\^KII?E#P<"\14^=4GG7WW:3P?[5M)
M%Z)+3V9I_L"7-)(V0JVKH2G1\NC#3HPHVA3<!@A50 0ROD=5<$3?Y)2>?(\W
M&#_MF9,RWXCC01NKW(@FCM.^7@FBTV%ETL8#%@#?1XKI"/P9+$KN))LB(..F
MN$4Q*#Q-S( .;7 E)1MMHZ/#(%DG<"=7<-;@:J[RFV#(X?VR_ ?\'FZE\\A:
M4SI6/Z6Z,S_EWM<JI;^_P>;CQDH8A? 6]:[H=W.(:4U'(X9-21%9^@PSKU,V
M"=>)JR?=7IX^K^V(XDGDGA29/>B@9^)%TH.$^2S6:Z3Y5/&L+W,&3QE]H08G
M2C9+C1 M,[>:7[L8.-%1O,TK3E%3%M":'#L[*\N#,M_1!I)^+;\U>]O1)43<
M)LPT19XIP*Z1<-)]%0PE8;6B'#RR7*456C>\/KT\,;7WXREYMJNK,/K"U@0U
M4-_7#- 5-+:HY760#]J.L:I0^$EZMV'</!,Q_*Q=_C;JCQG[BK> L>F)<(E(
M)'$R1 >+DW#D_A><.=9FQFGK0I1J3;YI/9?CL!T]D6RED7]V]OW+7U[/MN4-
M9 '!U9)Q1RZO+N:2G&]*8_(-FYO8S%9(["C5G.B-!6,9=K4$9QT /_3Y[Y[]
MHO(9RGS*1*&T4UV>T1T-<7=ZBI+\ZHK8FT66O::NPD./ (WCI+<XD:*-#,5M
M["=X\>P"ZK;:LTQDIN%YD*9#Y;@ L&1.B(6"D0!">*R#.+JWV48?I*$UWM95
M#ZT21TV6"=8'41 GH\<^(]1RDF7B05^UK21-W3"I'NO1VH$_Q@'SP$\ !GD<
M8$AP#*!584W!!Z<D\Q9)>^1'^QA;4"YP4Z3"P,OJ,&<-K3"E.8W$;".V3ET1
MEQL9=$MF*L:;]91X(Y8N:1B4<L R&$PRODD?_8%.(,0'=:M?"!;S.9'ZE'[P
MW_>BM)D<T8 MPO<91T>N<H@YUL@NPA[>>SX"1UN,B"A2%U-7PI9$HR+H$N%<
M\G),4&"=J[T6TU@JR-=MS3!)28+3T7G);)CYS 2'7]"6%%1#S93X"E2/:5\6
MD.9OGA"+I_H0]^;L/(T,"Z)+1(T2J((N-2B3<T7)^?>2M56D0EA,"DCOR+7E
MK=)O+5,E:6O9I\5@#R]N$??&ID51"#G1F/D[RB-#<(K#8ZSQ:#&Q"*SA5D>.
MQPN+1X2WE^8V]!\X^O1TRW5]6QA'1JL+#(_;?0J><3PU#I?Y3!2:?1<X(/!F
M+<%\9R'0S%<4F"9S:=Y,ZI>7*]XYY.+\YQ'K\(&P#G'2KXMQYW$2N_3-<5(^
MT*1$E#WB>26W.>2-'"?C0TV&QFV%\!DEH7RC(EK&Y+4\[I8_>()\^.LB7<(Z
MYBR]R@P_1FO:C\&.4_/A#!FI2N\2VU51<9<G("+5LEA<U<!X.B8XSM>'\P:2
M-AA+.Q8#US_L+O6=U>%+Y $.QQR7WQ\;GS_8GE.&/)^C'BO7I-R!&4>NP=V>
MS)IETVP,WSW[19(&-\6[<+TEQ_3?O<0O+[_][KAG/]1\AQCK;9+/J!(:-<EN
M:-B:9'^.%O8/GZVBI<11V1($"_1V69PL*2M1%:><=])+LFKR\.^.66*Y0RTQ
MT:8_XHFP)6LE.;?A:G"+!'W:!14BCI/^0;=H6D@$!CLM*/X5A2FI*;) \7%C
M_F%SA$1JN%?8H'45)J2I]_F:JX4R&9S-U'2HSYIKL!Y[W(_S]*'FR7-3D'H5
M11=40I2"P/3 'W&.1YSC)X)S/!J&?^*05?1[I@#,3%5MM/PP09@38J%5O2[K
MH^W^T%,DO:X2DL!';=^684I<>^MQ%CY8D@<@6)^2&T89BO#I(<)RM-9T(8!9
M6"^<D?&-8*&0 )+&(JD!#N&B@GW\QL2GA+V'+BZ"*=1?4Z&Q)'A>U&A4.%#.
MX(:6ZUB-"]P-D)B)T"PG083B@^^5]6K E 1K.M3)Z/$R2IE<A2?CAJBS;LLU
M;'EQ UBY$=_DO]5-_ ODWC'B .])!C02-KD9&09S#[W(_*)KR('.I \GHOZD
M.Y+%H]:T^"  %(O.:^%C_)\NN-D,\M(?::+1/QE^1_^5]!73,I$5*>ME>/$S
M_HD7:U.VL2-LE XF:2FC1DHJ85<[0<X:2*T'1Q2!%BI"/("FZO?L,[Y,!;UO
M_S Y[X\,!B:<E[[587"=]CV@[XI>_/G/G/.^K0E:U.1G#=A'1(^,(:^KLFF!
M!94L>91G;=XB>WY2GKZ'_.Y)&3Z.!/NGJ;M[;M4":6WD\18R3A+L"O?Z(?P.
MFF_H9*;77N==M;@NEBE^Q\]'^/F_\JHC(\D+6*/S DV-6VTF*)OP'BT06"W7
M));4FCY[&;[?K??2QTR;^M7%1<+^.?; SY]F$2U*A@+/I["L2#'*:^&5F>R+
MA+?SY-7%*2T1QQ EWY/^Y-8P.>0GW91A!P"?K\2FX1%* U"I8)IGJ/(4.+S^
M&+D*&)NAQ0924J;.[H')?NN/*^DHR<F0W"0L=LE%8JW?G:Q.CKXTY1E968W)
M^;<N;!^(2P*RG:\%Q(EU/0'M!HPLO&;K-UA/;,C0NT,^'\%B_HM>2DK4!Z48
M;<D3X?78BP-)*,)UCLI!)A/81(?GZEOT _P-D\NCI^>AE])U<%WD-R63E: !
M7[AP2FFS ;.Z:Y,(6ZK;X>F55V%7'X%?'[#4*P*$Y HQM-15#(_0KX\S+4X?
M/$8+>4\J7,F)[F%SCC6^CU%*\!BQ"9U%*P1J/Y"?8+2%Z:3ZBXVPUO9$)P'%
M)ND^MSB2CD>-U^4>U&<#F^P:"$*05>U*%;'$U:18N"PV:-L]@-<GW*ZX2\<E
M]N&6F-6,V4?65>3=BHG5EY2)1WIB1BU)IF'$LB0^C/7>_*O<^54L:&45[+HY
MKH /M0*NQ%0,I=&FO4@BF(L@+2;&/L[0A\.E+AN.U)%"$9K]N">/0__!AE[%
M#\0H%A0&+[2/?[S\P[SNOFN;U65(Z:7)E]3LN6A 4$%7?%O5MV?7]>UQ"C_4
M%%;%54W88;1P]4@.RFK@,?$.<_&],KZ7HK#.((Z\:4A5ECTA8,03P!2(4(YS
M^N&#FQ2(B(8_-*@>:B\5MAR40=HT]83:T7':/M1!QN5:[*00;!A2D4NW-&N_
MEY[X(U:EQEJ3!_U5:1SMI6[S-1-HN$0;4WWV\VRL")NW;;TH44Z!T]QWTY$/
MTR3S8.US!DZC_FVY+>A]R-$;V2;$3SPOZ.6LBVPY)IH"-AGI6$=%Q/.\Q*ZS
M-/Y,M)@]^8+U$4Y78]]'LGEV89-!Q$&EZ2DAN2D=SBY-;:&KI3-5QTWI2L9&
MN+VKO_O3*^>]SLNVESU2!B'0I:*5?EFN.VT@[U.C@O@UA&^CY(Q*.B4JGK0,
M22#H6KRG!U[Z^ZE.=)N%69)IEL:(IR9);Q(O,9QBG<C_T">ID#2[^.G5[ 63
MX.PS9IN)_4V1,$>[U&D]PQG1R^\Q]+>5D+&AYX(8/93#%1-(#%!*-B7D3TJZ
M2O4@=Y\C)O*(B?P38"(_DMD0@9>PWXD,-^S0I<DN*DR_6(7]B=(R U#Z4@#8
MSZ(<!@P5G87$X1\-KR&/:#M_7^<<XKQ119(+A9:3R4*84BPE@"%_XF55!3]E
M1Y7]<E7,WBQ*?ISO"Z; >D$U^I?9[/O+V8E]]A35\ZX2HW5"=W87"L]PR@7L
M])=<$9_]Y:LOSA\Q$;BRB*>T6C[8ZC\EN(J)NZ68A8"MJ6^%>YAA$SMB'KXN
MF#C\4?\NX-59K.M6R-2X.)O<V;_7Z"M0U9V&EDOZ!. 1NG'<'\SD)8#]1!:E
M]>RV!:G-V.5X>02+WH4IW5")E_P0AA<MBU7>K7?^T%A%EK\ML9@(=>&R"TXE
M:\\4^"H)E56Y9NUO,:#<K#>E?,6WS8S2>-'4D!_!(_!E?NN65QO^%'-Y,+_G
M/?6//SJ+T^"\9FHK8VOI\;?%\G]P)4O&?]1-3 ZD*8%A1<5<1/61G=<3(H..
M6=9Y:T\+*M8#IJB6,K%,V A^.6TBP7+CX]PT!LGI=3D0IM/I%>4GW1CA*HLV
MB1D@>>7?UN%W".&NUO6<.#Z#3U)O ):(+*ZH*\"_IT_V5!7IKS<UN0P*6P*5
M2-A:Y6Z<X]70#%XM7DGXU\M;ZAYE>)[Q]]#'Z^JJIE\,)%D ?! V;^*1#R,6
M#&ZJ8>$XXH?AGA(%"N6,<&PZL(:1CE(H0X@'Q8I/Q&!:-9/5\!L;%P*$3FA1
M]Q@+@2K:A;W#K'1E7(7S0IWP)0=LZWPO-9?(\^HHS"3$&F4#%,3':%SF07_I
M.I[[YW:H^AZ-NZE/R3H$!UKEPD$G29.T(7N19+5RJ:A.5"T9H2_5U,28V-\G
M%\T]-?LO6Z9W[B2A6J)VZ&9#\3;D2+/%QP(4I)"7*D\D7,'#+[?/ILAB#T@K
M1CZUOCM4+!]ZH#@<:>%!$/+*+:W]$0>H9-,]6X>OL'1$^.5%=Q6\@IFHI7R5
MT3#Q(B?GYHO!%8+W45%*:4U>2MWM"($'JY ?T& A@88(;)=,$:RO4&_!><G$
MZ^'U L>+^$\=:#)][5%G1^Q/:P;6+QOS.Z+G0@RWBWAR>3\H.#YD[>!%[ZZ9
MBC5^4U>W'#H:;=)GKNG(QM*.QB!,>\[G>.9BY]IMC+4(JM.'"Z*&:2W399>F
M-/ \+%&^9G"+NLT<0AAMEK1FXZ-$L[FQ(E'5*@L\%\97JW DVMG6=G,P88LT
MSAQ]2?NX&$Q<\,X=W:-J[6$MF90=IX,;IN1R#/@&IY'HPH/8PXYT_ 6T.M!!
M(D=4IG7<:$<"0"#!@9GG\TD=%>?P^M4B \"GD$[[4&51W-?)99H>&F&<-B63
MTZY).JEI^:1<K,'&N(8L&JOP\3GG]YC;%.%+<^++W@1/AMDCEP)_#3X[XV;'
MCO*F()>>B3#%L<^2AYEZ"WU\ B?3?(C,* _.FB25B&L6SB(/;OC+!IA5WM.8
M!%U8VNGF%D;'=&*\DT2A!P\)TR!TX60QZZY=D[\;#%DB:#U+2.G;:WR!(CC_
M^GYZE4969Y8%[.GLD0FM6;"Y)]8S/A_I("XH0";R1]+?II>8!6/\'R*LNW=)
M3*>A$!V^4=.WUJ#;9$"MGSLS$L\U9YR9"FS''W,Q:###Z%HZO%YEK,>]&TXQ
MJ"R5F[\QG1N!_#!*V<LXC9-6&LB'+!.]_:V>T3WNQ1 BD(OY #RF]],(!&WU
M$,%Z*9[L4_-D/[H#\IZ>X$#B5KF%!50]64I1VYBS9(?2?T/AKDVXZ%V,<#Y[
M*@9_&DR$>)A_7T07$"TC.2ME!K.R4TO*HF -UW=QWL=V*IP?RAT<G8I@YL+"
M!E.]U*HDQKL"*3+5<UH5J4IB/:L+A9LR/9&<,Q-ODBJB':((EH-4-YE[!>OO
MD6#3@C3A @^OO(?1FJ<!U\/WA?MJ >SU'))1\#HA_X2DPN$86_R*5&:W;-,=
MTG.-5MR)J+?)#C""P]'/!I#*07#-1]S4XRD7OJ,9OG_/%SHR/*?:>[5^G5Q^
M?_IP^K^RM(VJW^QU/K,V1&MST3%S57>&NM*WK5F1M"!A$ZQ=,:D @V*IE\^(
M\KW6O:C.BZM_]WB6#G&O]APCW2B<Y2]WRH&M5'KC#'I&78W),/J\R^\?TB32
M@U8UUG\X-#;(!+12^B3CK2_QT#/)O])8B<!I*F[@5EL"$HC:FIP'OB:1CBF0
MDIRUE]?$:OW9A.;287T,$.K]#KJ]D41?\$F33UU^^QU (NHW+N5!G_2=1B]U
MP4JT<I@Q9D#T*YJH<B$%:52?Y<_* +KDQ@!($QT0WSH6I(\%Z4^D(/UQ:?OU
M,*&M>%70/M]>T]:E+$7)%<%(<USNM!?\JJY=;+@%K&_!!T4=GIY[2*75&*=D
M79$JH>!F0ES<PVWQMV8B0&S!12D]J[FR>R#_@,A]QY"5NBW\]QO*(C#^DR@T
M2*#O)\C9BLM<U7UG'Q$W^?>WACF[0YMDPG,?$T:60Q%1=5$Q"J@^X"V>S[X/
MYRV5.Y"EN-=S\]44FZ<=O3VB$1M)XP2I=TX3PY0YV"DOKW(E60[SMVRZ*\V^
MVLG_\H=G6:R(H6F$_3%C?(&(D_O:-(M*N'/2SRZZ3A\&OOKD7CMC]O&PL\1V
M';W7-V6X :5GL_>>;<]!HA,TWTO4K-_T$\*3H)#,?]U$2M$I_)#VF=_7L!Z1
MUN^+M/XU@EPYBRUI+:5JA6G;U+OBCHQ&%" [E,VPRCKQ;XC)RQEC<'B964(F
M!E%Z'Z"81F^6IF$,S#P23?TZJ<U]^*VC(5<.!UK! \6UNCDT*J13)'Q%!R2E
M6.AH>F@+09<C[9,W=SV35A*D)GO@RH<ZNB.:6:R'I>2= .RG7 [_=?3UY%BF
M1>P9OJ#DRNFA'WA]?_O]Q8'1NY\D\,<M2M]#O9<:@N<%"X1N\\7;_ H_MF$5
MA5 F U=-LWQ;%%ONXU@"@<QM4FQ<X"H4[^@0R5!>:7:9[PCN<U2CV,1 R+IM
M 6:."L#2L4XJG/7[,LMG+KQ%L%OMIXB1+0%,ZT/=P52OFG>A,>T !=ZZ7>:9
MGCPPJ9>;ZI/(_6M3? \KW>/R:Y#YW#$=V,"I\)Z$.3K)?E3K+Q/WX.6W+Q)#
MH@8DAPDIV0N_ZG*48CT,W]Y74K40@ZV<] Q]D)3C^4S33UGYG$OR7E64$1@8
M2UXO_6.Y4*8&5$.1G$KD9,N6VE;=XNX_(]^AZI",Q8OLMYPSW09;,297VJ\M
M\M[K%SZ2A4&18:')>4&X0="QOY$S%5^%(IPAU%2;VD*HH05 [I\ZKZ022-H_
M.YN9N,G[B!0L2\-3C#5?/2,'OF<^P@OM&6D<]M"6.N',%JI'I4<5JLC\Y*E"
M+UTV2NG>Z=[@"?(5+R*#;1EQ$W4RURWCJ)M\"XEB\N+#\XM()1I%RDUA1)L5
M5_^3SK1[3GIFD Z*=.L%\3C*&Z"T&&MVJ#!']L[PF&'@%=W:;RC:%CF[N4RI
MF.;=AP]6-T,YR4A=F*!AKXL-'5K[,;%[<I :RD/0E"3-/3(+;>0X"Y] OG]+
M61*NI J)Y_.G?P\^246$:](@=TN9@'H>;) 4/5#?MT,P)FC]'F\Y<K2][L,[
M'DR /C-FR6(UZRHE-\W']I46/9P:JM1CD@V%%'\.2'Y:HU6^CZZ*4&1U-<0$
MX.F"QU!(8FH46>IN]M#+!!>)J5Q";IPVON#6L*0;VR"<AB$L_5BY:$?Y&5EO
MGMHIU6V7U!NSEB90N:G>:>"1I'G:UZG;@B@.HA3O3[KY/7Q8H="^O@W'([[:
MAL8C&.1@;QJ-&./&74XXX'R_L<C(3L:16[E&&RDGJP\U[*!-W N(A*[QWSBV
MF4+1PDKOJMBH&\YK7/)\]GJBQ%\5\E1AO]>2= O&DN'[HU_)JYIC1J*PR\TV
M8G.N\5K)!-YY6PZLKW(!YC)DO\\SV!_*9+V8]VD'SX%0=E[$VBS.;<BRQKU/
ML\U%?S[@T(A/H!)]?!5$CP<DK).:#C[LY8J4MU2A6 9->/LC5^)U^R 02.\9
MI/[HD9;2?4)$TD(8BNXEQ_+6X['XL=D2%N89Y6[9G8EN]F& #[N: ^?RSIU8
M:-^HG4 C>2!_")$?LBZJJ]UU.(1@4L+YV78;XP4H*TJ!R[[;4B/(8C>-EQ3K
M035E&8?)09C(7QX:FP3W.H%V(Z3C@\?AH-V'WCA?7'L$C87D'/1.<'X))6<&
MQ6KRC.'R9B,8&3T2W+J<7I1T'$QGHIGDW$X@*KK7G;CO5G!7JAYU#LHVB6[>
M!7O64BYASSLG\I%M[D@&8JYC&PJ9N=^Z%LIX$;@=GNJZ7"-3RI),O:=;641[
M:'-*3(*],()?X[ KHLPGFH;$8::(@N';T@"T*GDCLLEU][VSUJ2 .)G3 ]LJ
M?/U8DS_6Y#_UFOS',\]ZFB7\T>@![#EM"1>GDZM1^'[<EB9P,87I/I3+?A$;
M+M['HBLP_6TQ"99-Y!G69#*%V6ZG"2XSGVOV+F_*G!DNK%T&C]Y#8[(YOEC3
M(7%U/8*Y.N0:M<3;<I ^>T-Q[Y8F"8FA/GK7-:@LBQ#=L>.6,/G,BZI84<1-
M]:[B7=DZ@DS'*8,6KO*FIM[;_HR1<[LN<E?32\(V"AYNY91D2J6]<F+YEW='
M)@5Z-8*Z*VEW%A:!\(?G'7';/?08^UYQJ=,)N(>#6K:IWYE12E/ ,91A;=EW
M8$@; TXT8F(>_T6A^?C15)CRF\,AJ;I-T5 >B%)*==,'@T9ONUX3N 3\.I:*
MS#3#23E73@V@8RC%Y5.>,&E'ODH&![P^Z/2:+3FGQ6]"*8*);%#4%Q@I*%FF
MR*4Z>@S[44M "(58IJ>?89:7"V=)\'QHK&J$AIIV2BL)J/NR-(>6$*+BQJN+
M:<\_"GED46T#<0@$.*PH!0-;U55Q=PUZ)N6*'L&]=R^YU*2*5EIR@KN%@O@!
ML- #WY$OI%X6I^;042,Y2;*?=W5/K! -5'0&YJUT4&JZ8DC]+VH$LCN/0@ ?
M"G/R>P @7&8M6RYM."4N.B_#(81&B8;25FN8TH3NK6]3CWR;'W)JM_56J]L\
MWDNCZ(@P4)0A?#8P8B&)@:*I@\N"Y$LBB+6KE6[#Y&:DX+Y>^_LFA..PF&H2
MCE/_P'>U\B6[$B<Q&J&OCI(_?6X1U?([SNL'G%<,/[6$"V<53<2P-#H9#(UN
M\P3R3.?T/4+76+LN&!_2ML8>0Y")C. 2CGS9?Z8Y#*@>IPB:4C[ZYK[0K>-Z
M^\/LR*JLEAI5&_Q^H(S"!8B,F+245L_56E$.9X**A0N85LRLZ5:Y%V./]R">
M %@Q.WQ0Z,^ERFU;)FWR9&&4A-7"6):DY#Z:,7^_RL21L?I#K]I!Y.W*1UR5
MC%6O]U[=:19,HF]PE6PH5T<WHJRI2@ZH,1RUA67ES+!'33WT0/&G:RL$]H!M
M!\J-F2_6T_B[5 UO*2W[1U*I_N&680XB0TPM##,",QT2O(T]3X35'RXD\5$U
M[PO3PB;HZ8NN]W?43>KBY5A%BD4K%0$%U4IRO0'=2C9.JY4)XJ-&\^H@W>32
MIVDNY5#V=$7>_"&FN)V2 -RCN>F]]Q-S-H #$8VE@G]J=^!+41-JP%\&N?G'
M[*&4)B#";0Q/H&KXR0$++#6NHTQ-O$H'])J*ZI=@*FK*Q>R9 "C]3%.XEC0"
M(_'HT<<+DK&NP!IYO2<,4K!,M/7:308(;'*NH53;#QW-;2S6Y54I&WH1)IJ(
M;MBX1795 3O=U-TBS-BG4'^WX8L8ZKS5G-?D))R\OGQV.BR<ZS2.3L73.!7?
MI5,Q._GNY6F$#!(31$6^T@QG\:-O($:\M8<0*"W^^/@;9A\6DB?V:%;%&76S
MD]B-$*WAH<O*@7,.?2&,;/A5JY8OS&Z8KS)R&AFQ061#$E*QQW_C''S&QH-8
M+G,/_>W!?OEZP2(4M[A.3C00C[(P[;  -^6RHQK+6.20,7I;'L7G)J[P(H/+
MC00?8 5E^P<$N&0Q8>&<[8^&$-0(X/\U9 9GUM_B1U7?3=!/XW<V:#51:35Z
MZ#"WQ>@W>$E1/9',/=7WR[!-KC3;PQ#\-^I90V)!9R=N:IH-HI)KD;ZQU&XK
M>7L'[!_<1GY]KQ5)ID.*7?(U,0C\!G+6A+<F*JZESS$/30FJ'03N(;Q:M4MK
M;&G+@D :7?Z?]Y2^,2XU_N1.\)8>!)>?LFH,ZR=N0,)/GKB$]QX3>(K9LS>N
M%4FHS\$/Y2\V+ZQRJM=M1*5=0/SD0,'T1>XANP+5QEJT+! =(I-*[MQKR^ID
M>R1/33:.C/N^\'T@XF/'\HU:)'I(-".$D:C?%M+W,3XZI?AZA\<Y10KJ=\$H
M<YLW2TII\A,J:C#12Z80,/S[B&\YXEN.^);?Z_Y0V90.ZUZ]G&G=5C%D3<,1
M/MHFMC[A@LE-D"T,VS?[X>ES^EKP-8@N)OI9I6./8I)^;BESSK]Z$=QT,V53
MI,K/5W6I4'98E<*3#QAG;1Q0T$(JI*?J]?*.UVP[A?WZ'HT_8[_@/>&(@Q9M
M!X=._(K#T<IW+P4^0;[AY/CK'64>/%13FH03)/M#S[E07$"JHCB4>?\(=8,<
MR1,QR*4.SVL>GE]D>"XE@.NJ7;F>O2&V"?@0GST"K_3GY[/OZEL"-#!_TTC?
MG;F%(<I)@ASQ/H;7S 29,;;E<N\:\,=LWT]=\$O/<#76T@#X$'G#R&'4C?!0
M84_)JJ4K]_OGD<_3X]TGEB87VU8[A4- 4#;]EB=VJKL*H#F;2'7FPM+6F6S]
M-QY\K^Q/+B:*.UXW>YS822=O/!TPNP@^I,MH37RNM=X3LL1UZA0#19*(>?@
MSCIX!^8I<CD+_5^UA]A'(?S%:.P#\S+E,?^IC,;#3#%I^M!2&]^2.ZH:*S^A
MPW3O=SN&MHS%144Y4B]4NTM1GMDL*2IRY-:,98H9Q&4]6"%Z:NP0IR-L75X3
MH5788C$4&\%5CK;U/^QTTZ_O.P$X(UUO*;+$4_R!P[-4"07O=>XR,^6WWX4]
M.OY<Z,5>L9-$":>=_%X]-.YQ0!BZ%D)5: 9LYJ4'/R=<JQSQXD*\DVM^K'OF
MLWP^27/H!=7S*D(Y6H6A(%8ULE_:K-;&A(Z^!9<$'4C8]=N7&YPY/%8)4-@>
M'4TW[LWTWNNDK#0+ [2M2[#'*ZC7WRA.22%Y,6LT+B +X&EF$HCUB]J-([\=
MEAI$0W5%\<S-_>2ZL<>J8L$ JYYVE?KA\V)W6W"RS""[NS2UPHL*A)MA;UT7
MZZWO:<*?-Y0^*ZPP1KRV:=G6EP!NX9R#E)0%57>1TX"Z;30'N5WG"TX/A,5I
M+?32_VUT).>RD)FRX.X!\?ADRW[XF +EH-XAD3+*+S\9#_29;WRBS3TR)K
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M\D=73J10 ?.%$>33+.:R%H]7(HM=#'34A1=?A8%Z=M.OV&3J!-@"$@V5WAY
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MDRZR^'CDL-:1-_I2&*[:34$R;T+K<K8X3TDVB@,CS,TQ$)$&0[VGKI>$Q/3
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M_?\XI8 Y59RHW)B%HLK1)CUR6H#0ZH(ITP( WT,?,]B-FU&Q"96.X:<9ER_
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M/]+H0XHJ+K/*BJ*",H"(=BD;HDP#*'S&U<M]HKR,N)5?!<Q*JA[N)KRN&.$
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MN1 @*'KI&,@L#9G 7=?^[UW##^C2O_1V$U4])2H/4>NI!GRJ 9]JP+_Y^$$
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ME6CUZB5W@I-09O3<3,@#U!3Z-B0S0679)_5PV6YQ:ETVVWNZ1]B!S[#-.+]
M ZK_G5SO:05KKZ\OG@5O4$D%S2M>Q$4DA01ZQ=N)]YH.@^\#GF;<)9--!B2F
MA3*XA9N!A.)X72SUI <T+_5^=.P.Q^Y=_N(IWAU-FXZ!;E)60B-10=8Z]-J'
M)B$7[9K:6%JO*[-3A]W,423(/JN98-MN6C!\Y,=LB+%2YVI[WII,CK92)@XI
MR:3P;IS,DO=$.E>*X"4VYB\/1ON+]O]PA8W)^FHR>Y=:J@FCI7S8-'AP+$NH
M->0G(Z6^\%>+=/HA334A;Y@E^3J8N_6HW\ECBB_I7X6/84Q8F%U'FIH!IY1&
MSON[0C<O(?"1HW=?>YTXYCRY EZ!W"]6+>M*TQ&QL7.3+-M%CZW(#OBK"4Y9
M1'/?#YO5G,[VH.4_(NNZ+2T\7D244\#!-A*P.N5$%[.U9C4AD6&-?+I<3]PV
MD@&AM1X.2I8LHQIR,Z0X+)K?"3=]:4F^WD7V3T95PK2Q)(1RG0'_+>E\I@H*
MH;U4@#TP?"I)X)=R4IZ0;143QN57BD-T2.5DDG/.L4.R96])E8R"RUS.X0N!
M*_\,/!>-@E_3YTLIUE#ECNGX!7_K8BL<0,G/PCG0 J-5:)Q<>!$_1HYWNNP)
M)DG;!9F3 H"7F-H:DSY[_M5751B4XNPQGK1T#551>/ 2$53,$,6N]SDW)U(9
M$4=*0Q%E%))@4*OJX7@44!U,,/?>EQXA)C=0# D/'#X.-WS"H<=3GIL7K\X-
M,G$!XM=MP_&OS E0>BTE!][H>?[DXO6K-T^9>&:<-6-L&FYZZ=O+Z()CX5@5
M'VRZ8Y]M?=7UH@]!+@+/,WUJNFG(/FS:=?-L>XVYX7YW2MX.?2<@LA"8D2E@
MP6%7[..CAP(+4A+M!Q&X6HO>R-<\O2P=G01M:5'8OW3DXTGA@/^^EZNHKD^Q
M2OYBC#!!% .CS0/@WC<L23H=A)JPA<X+%<PJV6^[;M-^:!2D9.)M!GN+(;OQ
M2:>YYE]W(P3GM@G%;PH9RE8W+LPJ0"ICY;(NTTTTAG<=F7!Q+\P?G"9X<#0K
MQ0PP,E-_#"DL2:K?\%*/@JR$07/88D7((QRFF$:+OIIT=&BR,E1X;J_0 V]!
MHK'@+#5R.%J?CE,58:4315TLNP71#S._)D4*8RYQC! AO&S]T9&O55+5;(9G
MZ[#W[^OV#DR9B5.1M B+B\ZZH.MV"*.5H#-TD4<XH7-[6HY;9X:B2HP>Q24\
M-#@%_&_<"6[PQP:I*'?BH$U DWP4JC((A=5RU$I9HQFU.=_$F^M;X(_9J]1.
M#'I$^+)OZ@&P'O#5N-:#4^GW5/H]E7Y_LV^Y;(?E[F9$FZ_380N3=\UB(UX(
M?MQA6S*'X5TS9!X4"2.P"?'^OS]HG#8;^?ZC"XAKSKD4:.;_]XYZ#+;[HZ^[
MA15S!35<UL(%C(\5[CDVE3RO-[.H6(VJ(LVV]>)<ZITAIAQY;%2OPT/&K>/D
M(H0Y\&;.;X,?NHE,*E]_'6;D@B884+MN;S7WPT\BV7T&TT$>(#\.178LN#/M
M=2]F6J+)5C/"<*9FCA1&!N$V'O)5DCK5)$!50I3-H- I"SQ>+]:;_MY"8 2%
M1Q_JN8+IO\V90>(SQFA,[^9<$:[OZ!GK:+N3A)2I#QWP*6,]\#WI0<L9+@D7
MSK_"T1C;CW(SSDK.ONMR:+$ZI"F1U+%)'C(XEPD=.'NP\&?(;+FHSWDZT;)L
M]I91W33:9J'>M>OE+ _%L2^A;YIEO1L;W_4*:/0R[(^8E/(IEDG+.]=B%R/5
MMY80GH]ZV_,+D[Q)5]"[(9M1%_ 3C\_1N58--'A:_[#7:;G=U)U/__)[QY4K
MJW WET1)&CAJ4Q.C*%5]0$WA"D2[D+N=LW/Z[M@T- W372,QNEP;Y5K&R!0D
M%$M*;.&56+PS>M.XFZ5U[,\Q5AW[OM,\2[MFH9!53(D>LMK, ,^@II@TP=8^
M]IWQ@J7.56X-0SVS L>)$'VQ>7\V.:D(V30['^.YF#5U]/D^O@-H(<(^Q*]R
M89)4P-!"8DVY2/F.8[]LD1&&2^92 C-R1V%WJ:*2EHKN-4%^<&5;R%KQ&O:?
MZVO["H3/95L82&DV+\M^*?:+.Y42.A-^'_M[S2#GF[YM6/>**[M6'$TB3)<\
MP#H0T$^6'!T=]DDCW7"5%Z_.<77J>&W^]T[@-A+Y3B);$RS!7_U3[F>>2<]!
M?[N>>PS'>)AMD!SU1UJ];E18WBF$P#!]@(? 50V4KY4W%!U>G'KE]N Y(]R)
M_EDX4@?".$SRC% U0V75$O_<4B.?^)Q&A"QUE$VQ],;T<UKYECW1'3:]13_$
M#?.%=#[](C9G) NT]<6=O%"A!P_Y^>L6:F5:.8G)E8=1EEEEJ% NB^EA.Z[E
MRU&]BWTYZ7B34G:4Y4JE[4JRGAKA@;E.O?%FN=MR_VQ,9:+7>6P9)5%Z7ZY1
MQ$0_Y_0'IEH7W;PP2^%HTT9T[B+LQ[%E6!Q#AW%N*84<E][6>[DC+EQSM! 5
M3V;DR/O=EMH9+M%@)![HMN^Q4YV-GYSDQ[Y2WU_;!-A2#&/QH")Z1,G%AI8P
M)(37H2*IGE-2O[OK-V0&&"[Y<;%IK@3JA0Q!^+=VTGF7D;\EA! 4!@D;V*X;
MZ7(K!G.45H_.O@@YAE'FHF;#(8JNAP@Y!B1/_3 Y?9:;NKU1N;J\E\[OK.+>
MY+7*:5*E8HK('0$H<2H^!R=11ZNBT@$QWS1D(VDD0,^R%;Y35G_"0\ES,\1J
M.AZ&X%J')UAIEG<)-R-85;'&^E.46Y#[CW_#V4VC1'?%?U#BEE/DTSO*P=M:
M79Q\WH3A!0/.)D0=$6Y2E^\?&G#AHC/=6>D'1!MI(VA-O!4RVDT7AG_92!$;
M1R8"),MU)]CSY"$8N]?5P]#?DYN T2.=8[WDIN%YUC%<F7]UD[0A H[#J!![
MT%7UJ*FSY+O@UIUOI4*ADZ)Z9?#H4H!2&E WY2(CASEF'X'Q:GAW1"78%YQE
M,IQ*,(^$D=2,$E&)M4-.*Z>W\#Z@P%_<?/J)89J"SN@)A*),$ MV<!VYC?VE
MH1P&@R_8H43[_143?' VU0,O*GYO.D5%2H8FM[ XL$MH>A1UF9UF)3Q(),OK
MP0\ )TPMD'+M8 :X5M7M*V<7-QO=NF3RJ,2QVEZK%)7;/)(+YBI1MY\:6 XG
M>4?)!N+J6;Z[]*M:N=4BH5LQO!:=ICAE,4?KTN85JK=6K"7W4>H?[^6ZO4X#
M^U([[9F6MZ+7$.(C6N9A2@?RCKBY0A!DT<NQ"" ^V50T3<9NSF,3!TM<$1>_
M<>C6=#A4&E$6'A<I.L=T%*4::*4V^'*KW<!)-4@;ZTLIQ7#!8>?,RC2MM-0R
MMJ8'%E[L7.2H952]X%]B[>E1G 3%3N22U)$@HR&3*IG+[9;&(29K<!_IR&@*
M3SEO #-6L0(<%6!Z!BO'/[YY^QV9R&4(N!A=]H8.YY=5\$B;F\4?%S_"@7E#
M_G2S@F;099C$^PH_!"['9&1S&@0]OZ(@M+HP*-/(F$S&CXOO-H;("M'?/1M:
MB?CL;/%C^Z&Y;\?P]J<RZZG,>BJS_N;#_D9%D*[3,Z=X;J>)X8FM;,4_"C%%
M!ZI.^9CQ$,ZT:9.KW#>#K[V/Q!BU2RK;(1;UQ)&K(@]9:"O55.+QN%&$T<;F
MM$R,Z;$[8Q=B.S,72<:<FW:,D]=HQ3*F4S[8A_H6X3#]A@#EA7C")0##\47.
M#@<5,NC6SN#X+E>.)4SJ?O?781'HZNAZ:S'C(&E0ST/$PR6/DP4V3$\39JB.
M'9IT(*[7K%!'!Z[)+==;?W_#-4Z60Q=..,GX2B$WSQSFKV=.S]Q)S/47=5$+
MO">1%<=O@ +VG_,Y$:GL6'IGX-481E]O+!1F#H51CT;H5U9@,>3[/&.*@00I
M _/8VLLQ]6Y0FB;,YPY-]K$35:$-E ,7PT7Z+<\4'7A9;YAG-\Y'2V;P1M:0
M[JYUHZQ+LBYVY,;0/"F5GIL4]D(H=[X)L8OD4&H$4 *;&W<CLIZ,.;CKE\F2
M?77..N^;$)UM#%SJ&G^U_[6_W+17M71O'GD'1K?X^RYLX>=?5>'_GS_'0J8-
MN$/;I54E#/\,?/,(>,J3%Q=/#:E+*.=S5W]E#!\/3 (_XB3SBF! ?IZLD!EU
M[(@$[.OGU&"[O18&G,U*HV9S:]_\R,G %Q=*F_Q/A1AN  W!:2Q3OZ 2&8/0
M^;&5'?:'5V_(5+ZJ]Q@&,>@<H]H@E)9H\A*M)X9"EA'V3[@+<$]!6]4T6K5&
M2KAX75*-53AF>()PS_N:2?5BKMNRSQ;\9/M$'TT"/@0S<1MJ367*B1<>C^XF
MP?NGS6O-]-U*,))#Y&,'GU9YF*B3S<0E\Q-Q@ZS2J?$E^1SS+QC/76G4C6""
M(_=%N-WCG&J_81Z__M.3_WJZ>!N94;"W?NH7__G\+W]X_M57?ZI*P I,)CN7
MJ/-U7CQ:L]<WMT-S+:4<<@$63X"K[9H8W4I;.'<C;8@)F=HD:3^<AU#XX^(E
M3<>WB%?I*N%YOO[#?_WQ#R\NF&+C!JC\ITZ(P<@DGD@!VTPCUW7P$LU(:6EQ
ME#;-53ORNS\5"M9+QR6_MJXM9"23?<YK<W9=BDNTW3,P)OUM.\H:A 6C];?9
M"X\G-LGLMF>;DY\%E(J*) BR'<8_N/, );B1.VR45&=[W?S6ET/U*RS+U2)"
MH1C@1Q=^])&9Z3H=/0:3RWYIQ6_[+WD:O\71>,C/D)4G\BQ-;1P G^)Q),=+
MQ U2LE*N6/) ENA"NM$(U" (6MB0A?LE>I2_1$>;Z^P.2\PN.W&X.K]]TMC+
MU*L%Q,HG%Q9^/[_MC:07A,S9HM;PZH<H]D$'),V;M^T0T] QR^V*NL^_$@ G
M)\*Y\HW2A,OR:OU!> P=SZ/3EH");]>-OU=EI$Z^$70KTB04BXWZ7M.BHJ51
M#HA&*M*M8KKLF)7A1Z'**$9!0$0.YW1O5&#!Z>UB(.?J5ABEL-.8*%9\_:3;
M!]W"5C6807'LDT6KV*85X53).P7K 679)7,AF7Y@I\QY-1?@R?A4)7O2^[R)
M#;GOJ4F93IO%:]HWS>+)S^_>O'_]-,N#UZ7G4G#OXQXKK5H1KIU=T!A8 Q_R
M!0 EWKBA<,L\.L4_U-OE];-?ZH\D_D!HTUG,#O^&Z*&9 Q8X(%=-"0.*3KFM
MY^"<;"CC#5WYD29D#3EX/AM"SSRF/)N_9/W3FW!TK.NA:R^?\<0.P1<+ST9]
M@.%?5&%:-T-/?>,WEZN:H4=WS<>PS%=8*5XA@O!%D<7 4>PYLMG8:+#G$I^T
M3"JV][8XW 8Z$C=3Z]Q9$=-(7GQ%,I\Y+2P:%K86^:^QY^S!=7\/&'H6&)63
M/&5NAQ(>&DTSTL0J!3EEW9G4[;06SBD@EVW30OBC,D@9J/G B3EF(+]D%4U
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M)B7]).-'^8RVEX0%QV'B+56:L1H,SL=])9#<[H<"@9KO@)#/:,%Q#HBRC5+
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MWM3/PT -=RWIB83_=F;*:"'=J#F#!7OU^),^WZ&N:N >3=I2FY65Q+BE6R9
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M5\TW>2(\SP:!M4%@?>L(K*_GS-'F%5Y%')!L 1PNP)+5RX9%3^G3<JR=7N_
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MV;'"5C0$5V=5*U%,V RA+09AYPEFDEP9NCR]8YF/@K'8O5%F\NNR_W;4W;G
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MZ2P+J5MM^!VV4;,3Y_VD>=YS0#C"\"!)*56MI8:SJ]YWS<&XITJ!1L[Z0_'
M<KB79D_,8[FHM$UHG%U42E"=N2(_^5A;-UIHNLZVE>"-H[:8@/J1/(0Y7^S6
MH2Y;5EI)U/NA<,^Y!<X\2R1N.T,8/6#?Z8\GL+UT[#_8L^WRJF@&](,/@.$L
MG-&BEW0W0\C@;N0I! ^58G<W.1''398JF9BB@K-P1M-'_WZ9#^J8D5=U.\3
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M0:HX(&,)'UH3Z\:MXB-8\9RK\FR'1G&Z[JO_9&Y(UG3U'L 0,$"'ZYUSX8D
MP 26=<SD?#B<X.*)&5^VALPR;T1MDX5&QKAS?2&G%PT>>4A0&AS&??]R3NT_
M?%(C0PX[C-G.+HW/S??,:MNZX,]<9XXN%-[E5?B2NH7\FS5DP;)Z-_FUNLQ9
MF,1J-T%,0+?!DBR0_Y>&;GSI7?!HK^C(V'J77U1!U\<[CBJWDZ=8=LP)I*1.
M.".EAI+K9C&V,H']2$C=F!/(BKC1*&C BUV377*CDS$Q&LD47J,PY7%REN M
M<I*$R5Z<S'KGNMY!(V^"'88SQL;6X1()AM98%H.N;K\=Q';T!,M?S;%B1  '
M:FQT%%.+\*@6 D\LGU'(<HC=[!(=OU7<&5@FITBRT[M"C:.BYT^V^./3M]MI
MQ YB^2?RQO[P08([Y[<98R,>R=*UV;T07/)8$U5<]G7\U_0"!7PNBK1!YS!G
M$I:R6U+4&6T;LXT)!U)>09F^S^WP3O:,#W?Z?D4OSCV>SM$XBW<$\P '6R)+
M!D:\1_MV]6!A.\3;N%A>O[IR<VW<.P];F?#H;5EP_I8/+#H?U<<)*35H/H*.
M<EO0'4J,8%WGY4512PR/)=Q] ;\WZ"P^.^,]@3!1?NS8*;(S'$!SLR)N"00&
M)G1)#X3I^-"9G9#3H'3>=9"YE(*2,$$KJXQS'&%XG%*%G+M*UAK1,-OHT*HD
M.T2KZZ59?0H$3CC7&:9C_Q:A50I+"\K%$64RQX!?]Y'ML7%WM%O#C(S_#HI<
M=HCS*C-C)R,-H%FC @H!_8P^CC?>;OJ2K=>_OH/3;'E";;\MM,ZG[@AS<KI?
MV\:Z/*\F<F'> BGNJ/@/0&_D^Q'W@R4S^Q:*L8<:8",&'ZD!AYXY>=AX/?ZS
MF/(4IU'/_=Q;61@RIAE'SRJJD<Q5899XZ6'P__\"0T).4 %C[SJ<D2?M6W:<
M^407E! ^JMOD8KFK+2&?==Y^+BTPM5E%$RX8U=!9\C57.2,K!UU-7%M:,9:"
M5JC6GW=7JU([F;6Y37#&E)^R=O2) 6\.B(XTXU8+:U//RTB3 <8 BP2M1Z70
M>W-)XO*<Q:@6_K+2C6K:;<ZB2?6C=%DALOT%F24'85NB]]X4D#<%Y&^U@/P5
MHZ5G#D>*&*#,C>$M0"!1I$FN!^PP&9!@SPNX*<HKN'1FG+7L,?KTY<AP)ULE
M70>U%6#$^)S\PZ4(W@^KN7HIC9TQWJ^U.+W'<&X+83E\%M0WT\X]>YBPO7@Q
MZF@U/_]H54:CX1*I>=I+_G7P-$")V3&2WNS20CE:19I]0&&=E?R[_K<]H=_T
M';$RD6:X;W!_<;SI3Q4*W2(800\#T1=9(O%(KGR+(*%IV3.>DLS":/9GZ?A1
M!:[5J3NX0)I>1^,UG$$C7%%>DBLJXDHV'J9M,@8<K'I]#?/"D6(@P:@5D92
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M>1 GXI_H&"YP.E3Q- +TCQ8,1_UGO;TWF=^T=W(9^DV7A(IV\MK/K1Q-R"L
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M^;2E>"JL5VT$BK#@C3 &-ZQWR0UBA@G&KS04B.!XWAK'7'29!_5@Z;? :H
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M(K^0,\O@%LL)&29DY/HZ0\*X6M]$+%]0L3-^*;Z6Q5!.7\&C=S23K*42*^X
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MDVCMI5#HI480@MQKX=OK82_>6K#AP!44/&*Q0PN-%HDV0JW(56?,U3+'NIF
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MR]9&'LA_D8EULB$Y1*J3J0/+P1Y_B\?.=O%I5X >&4.05+5*)83P7C:RZ*9
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MV6(B=L"'TO[$C2?2N4N"3U-&=4@%S?/2"MV=*XX0T\'RA#-[YR-@,[LWF-T
MGQ:UZ 8-J-&Y'3B__4'*MP!'F(#T21AJ%!:_U"7N!@,,$5&_/M-%>(2. 6H[
MGG^8T%KAJV9>S0M19.R/&E^0&W ]$\.B^G7QXF[R:W6)QFF&0*A<H6WGFYZ/
M/E>R;)K3:^UR7YJ0&3:7&M<JT;E@1V 'J'> C(7[I$L"S,*Y#%!OKO9!(AMT
M)[J"9(MKEE5+2V[4;-_(+]#%K4]I-3V6,X:V3#9K\I_M/YZ,BF8VR18_%R4O
M5?[1$[V8%@(?+!>'V:K)Q[[ A:8!%+E4FE[OK!_O\D<=26GY[,'Q[O[1P<J/
M <9?]=E5E]T_V-T[7OW3JRY[]6='>P\W#WM\=*/+LM*T+H@><>YK=;SW'RQ]
MMT=W6PJZ7T9XNPNT6$I_L^[V_T,K\XMHGX.L9UF%^S/&)M XOXM8^?H-&NQ?
M5WS^3F_[;S5D^YLAN^V0[=UF'RYW@ R'>3X>7_76\'&[[SPM1J-)_A6 ,4<!
MI,X[/#_?9-FL>O4_9SU=-["?<XWO[@EOO4JU3ZFS2A/^WR,DX-9ZP7J^@>XZ
MO<T+[R7?PN;\\;->,7RU&E==JW<[>) ^/#J4&.=S7M.6[BU>]U:;LG/+[L;>
M++IO:=$='J2/#@\VBVZSZ+ZLI=M[L/_U%MV?Y,9^*P["VZ@!Z!4W *UT:0]N
M-PR]FVD-5]Q^^N#A;<_6*V;]OLS<39WF[W.6]A^EAP>W/8PVL_2%9^EANG]P
M_/4FZ=\LNG,Z(G>RV#=U?]9OE3U.'SQ^^,W[I=_Y)!VF>\???O#PG4_2?GK\
M^-MWMM?:2)_>K$#_;^9T[Q^G1\=[&W=NS6=I/SW<V\S2FL_2<?K@X"M.TI_D
M=*^U$?_ %#'7(91N>X1J[4H!0H<T_J.J!=R(ZU<W*Q1_IQG+/V5HUGO;/GJ0
M'MS50_XSAF?-T_*;S?'OO#D>'J5'AW>,\3>;8[,YONO-<;2?/GA\6X]O#38'
M>XH_,3AZ;1L+O #:]7ATYH+UDF45^(-#'GEIE5F84)J73V0)/]4_$VF85:)D
MP/=7RIDH=%;H(V!JT+.\VZT@5%YMW;1YKUY/K\)9%E/?1]T0$>VQL2&.5G9"
M+'?(]_<_,+V7$:RFG5&YS'G,E#V1QH7OVY;27\3B1/+@K/&^8VTMR@BR/(!1
M&TSA.YQP$Q%V$"+ULRO;,=R<J[!2W 5;CGZBIUGFT5D#\?7] ^V648HWT=5F
ML@)N:NFLH#+'ET"-!CF[ :NE]JGL%<+4,I'>^CD]K+ I3)FU]0^9PQ)=*V@\
M&>8J34#?HY^$^N]@S679#*'D[=7S6TGFH>\UR :%*4SSW9IF-06(JNHF&8L@
M2 ]JV4[S&NI*6,Q5';?]..&L;)Z)>D,^=RMWGK-X<RLR3K,<9#9L">D:'=:;
M;&:/J<(4QIQS4>@'K*.9Z:ITFN=M:6H+(PA,3\&XRX0G;>W;<E5$'O^4]AQ]
M_X[:%Z2+6;1:-<ZY ^P2'<.LG#MW#-?2YLLZ#4(8Y1BA-C1YCB;OT88F;T.3
M=[\T>5_GO CE4KV- <.7\%HOKF)8@E%V],$SI;=.E.8I(E:OB^:C,8<.R72B
MJ[CH894(SHM1W9XUK@'HSQV;@QN-3:_FX9>:&'(9C1Q^E#?#NAC(P7HZSZ?)
M_DF:_/".QC1Y*<?8#W<6"3Q^L+Z<:.]-B_F70(OY_V?OW9_;1I+\P7\%P?7>
MV1>0&N^'>Y81:MF>]7Z[VSK;,QU[OTP4@8*$:0K@ *1DS5]_F56%!TE0(D60
M+)(5,=.61 (H5'XR*]]Y-3^+^3C:HWU;8ZKT4D,QUK5[H?E"4]S?U/'/5<WF
MLREV3$=^32@;7H+-<K"+=43GM)TQO25CN"'\!AH(B2(P(9FBV/YR.6-=>EO%
MS-VSKT>4J7A@DHQ 7ZYZK^N+^D]E&U0KOM1NYE^P_>X;=I8 E6II;]JWVZ@9
M0JMGXO*.K]DA0>]LC]!Z>-7"Z%+#=MCM5F9L#4L]&IGFE[('U8,1BME8O)#0
MJ%D',]& [MO':_;1[Z2,R;]:]-2%]<?>0UP$VTRR/\4XE/8>K8*IZ":]C#)F
M%0C3&H^.=4:JUW?EP\B[C&AAC_%6EWSGBS_%^*6FX4VMO2Z?;*M/LE<+ST!>
MX<FR$;!IPL>%D)64 K)>;<4F[;:U:?6AZ*?7S#,9Y47!>@R\GH:A>00T_)SA
MV)4C(6'*%MM-04J*C$]>04(V/BC6:SZF(^P>%<V*1DY'I+S3T('U 'S?Z6A9
ME\Z.O'3F'9O?"NR_$SO()B+(3?-G%M[JS]5& HIFG'_.)F[_0.D]2\N[JI<K
M0P!V;2VP$T#,_2E5(Y!G^X"\OBMPZ,L+C&OD!'1)737ZV4T^QK$-G#T^EM,4
M7:^2Z[^HX,!-".^>@^WU3/_GLIK64YF=?,95RG"2U.-8T(>9UJ9I-:$7#_-F
M3@M<4X]T0L&"B,.(!F^#5=\*1SE5_7NXPL?&Q[,.0:"J\6&M((A0&R[B1M-J
M6N'A?(L)FS+6$ 2 #K>?C%<,S*B<E[PKGE!$IJ)OW@O+K'SWI39CJM$]^1-T
MI8KF;$/^.8MO^7=Y/T#F[!0#M\2,+G*/2V5[!HH[Q;<?"T]DREI$,<>?:+C=
MZ.9?<,?KZ4VLLP]S5=8.>_X2*Y;#M, 1FPJ'VFW]I3QKM6=B3P,E'W>::9R9
M]@ R QVTL-+9O9ANM#BGC =@4$G,N<N4=_UE:E]:1+-[V,$LHG5_PODEMN^,
MS1'9=>SUF&8/>XSOV^PK&8%1Q6].BN()/\0=H*T-Y6/66GM:S;[BLDST4Z\V
M>FZ?FS:.V.T)WBE&D4DF"$80BDR?%?8";"1[J2ONAJY8 =W<<0IT+^HH#'91
M%8IP^_4Y3:I-O!-#O=M0KF2+X$QTFM-Q_LC6%U7""+:?;3CN<EQ- FP1%5]/
M*.VB_R0W.GB';5A0_1ANW=0-Z/-B(:R&)$8M(1^SJ$&'"&F1"3>U>=.CF]@)
M(K[ P5TK.\%?SV4/2RGG_V!H*C"*D#=,'S>1BG6Z9HN@%0_8M(<+" ,3+;@'
MG JW9+8OC I$Z[N*Z<R%+'%L8#UA8%6,L]66[8^*D7D#Z=>]%C^@9A,Q^K*Y
M2V4W5^\%[PWR!J7!$V5QVCS%J:6\,QM[T;(^/W@G?;'I\R*HGK3=.F-&9,Q.
MM?*.5E(+#S@6^GLI'MIUO]9)-7<@LRUK(:&]W/J@%B&XNE]=ZXS@>N)C7OQ9
MQ;OJ#5@ZG%N]WN$.<!R /MGN4OPL@D0$$T[5%8*$VR4\&E<IHUV[7>TL?)V2
MZ$X<ODRFLMD5/.+'!;?8!\K,I#^S_#'C(< 8Y\:P-7<\X?A&$']N9GG(+;5:
M"V4''4,UX&TJK)5'.%E9,+V<ZDUH-FZ0W*8KFWG6,#=:0G"*H1,*%16F..B\
M>6*2P@EZD0+Q^4^H98C^B>T5M7R8!7FLCW@4?L ?</V%"/AS<9:@6PT9X#;/
M8^F[>]X ;Q1X_G<E!*QTV.ESWM)ZC$@CP.OF\9R@M45)RA<%G="1;K%%*)DP
ML/];,'[9]GZ6]:R:)R[4.]Z W8OSOVA&JF+J=4P]4#%U%5/?_^BYP\DZ-!7+
MLC8+'T!9:K*9*G=H5H\Q :$VBVB'W5FI1\W768Y/"IH8%W>M(XI;RCD*!?@C
MGEYLD.^#2*H#>5;E4(&:1B/"YCWS$(MP/0AC_G/S,!S8=8$#N[B]S&_1NK48
MW"6>V7ZK!5%,V(E9SR]CTO*QR,7=M3?FI8&I=F/A,VG-!IMK$/R"7_ [V,Z8
M;,@L[+G5I^CUP?.'B^@C5+$6)O_*K6;-#>1:F/XKTM2T"#1@T(H+D9%8<NLL
M7]0%*L,OC^#T+U%3(QH;>%_E'NK:]&DBSEQV.L=T#-#DV8ZMQ]0CQ<2GU:QV
ML;J4-ZS.,[A-RY4!JX/3282=O]VEDSK#\0[^,UX(22+LD]DX 20OVH0@/^^8
MXXK@RU>#,U8\BCNOVCR49HL<)+VZ-T_UM&P)!*YNH\+,!1#P)KS_6S#.LU*,
ME&=_>K=@]B]8CNA 9 =+-3R>;Q[WEK'X-GK&"CKBFB20^GXRK1)YF>.+>4LQ
M ?2B^BN([I3[%'4AFT')1#/W2KA66V%Z9LXVPK@Q!?CP,.YK@*7324W4V21N
M6QP4Q6?2;4<RN=DD5J49 PJ[$S<HX>,'DHYQ![CGF7M_G]D9D2:+?X3%L6.#
MF=IU*D)<V?Y+I."<40_68HFE*6,;GJP[%F[&^=1SI'Y1<@4_FMW/N));@Z(6
M$C'/4$5/"&-T+B3P44T6V=-2+@I^ON)-&=S@6'K R7[/8A&5QOKBRNY/[R>$
M>Y;FQONM>EKE=B<8KV[65N_SM*(W2ZIN_,/5!C#5ZE63- YT1JT:#3F:ZY][
M"+FCM0?.I^AR&OV3A4ER,),!C!GC<G@,YT,A')B6\1M%VRT%_:*8W6K\91 [
M?) Y_Q38_(844^T#?,"2]3AKLRM^$<.3ZDN:S)K6H^\H&>.<0E(TTY4ZHTGM
MZYF@*IB'4JRKAEQ!V_[&2NR@DZ+E+H.W8UE@<ZH>!ZI(Y"HINNCJ 5#S;K-9
M207?3UA^_0773N_I] [D5,L!W)C/U<;6GA-TM<R8<E@)7CP36R$2Y@>>3=,J
MBX?+M*Y/. ?Q^Z=E2^[6#ZNOXLKW+6.Z%$?-@&2B.*$6#F6F[=9AU9;WLKHW
MF[C%7'5PR;]F0'=:<"$(IL^X"K[=X[D,C,SK:VHAW?8EDV6_+1]^-\LF"+CJ
M@:VSI?9J)"RS'P_!2D'"N2=\U D*Z8163I%&V5E+O95;EMRL.*P/*US^J!W*
ML-LUCN<5S33!@Q$6SFDWF1414(R6E?_=-K08/FSGSK&3DT6SQ4U$'1KFT*Q4
M6[@^(3B3@7"<_LE&L7$UH)L[F<Y2WV.Q.@5/W29V6;1/:#ZIAC*YRG/U8(&-
MQB%TZ>Z5\@@EZ[>P8 U4&8U5R*6D[1?D:VN-AA0!3'9^T_2!J3['C_7K+O53
M&J!W*L=,1 DA"K#)>7I%*P&XR2AF"9P4='VAR&E@@=VF0@C.NQXV/6JZE]:<
M FUC09RUB"?*<P+@6:S\@$Q)*R W'XAL):_F1==QL6(-+Q\=XI!NTB+6/#!P
M_?2>'6U=#U9'2(<)RDRX@S-4SA(WQND]4_(F<ZL3!88+XS@Q(_VQ1IKX)L>R
MD,.$*;DQN0<=)T8UK^6;0ZKS(X=H";S&/:SRKA2.,%&!/)MPLK<^YQ91VS<"
M&$V%I<.'>?[1&$"@.#ZP5.\JQIO.!;V%W)[D:#"F<_*?$:5=I[#PF'+115.B
M^P4/(A:K>VX;]3D>9@P.RX+W2]&IB(+CCK!2A,9C.<;X$(Y-NZ/C!.Z>T(7'
MM]5Q8#+Z@/:M>.GC<R=^8[45OS!)>=VJK3@BO^+<4+NE$@I6/*+EDV;0.V8E
M%VG$DQGP0ZP_;QDH\ZD:"4F+>2<\>21%7%;?A+,$59R*':H+%SY;N,W<HO16
MZECEL'II:)\NSBR\ZI<Q@>]^B^YR=*'QFUZ@KX;E3^4Q'7,+:N5J\";M!XH7
M!'G22*"6AX9%LID_ PAR@<01J71H8HGW@,.\!+9LLB^8)ZOVXK7OS)PWN&V-
MPTNL";9C(D(7?$GMDQ&$84)3#/R6M9/HB3N-9(^ ?U^+:'.9/RW74RN7\01<
M11\K _T[+>XO#U5_69.E]A>P6I."UI6MS$\]8T/J )U\2&65HUKQO"YD2&M,
M]8K,5[U)Q:PD$[/S,' WF]9)EO4)37^@-HV9"NM"^QA(_O<<W<"\.8(TA'^H
M%\7TK?GC(UTX)JYYU>/_W9X_*R[ASO*'CE=4B2!!J!)!5"+(01)!)):+6-U_
M\:F@5*OKZKXRM?+0LA%;.5PDN+"ZJ(_%K!>EX=\NOX&FB0G\,S"D_DT++&!F
MT8@4=!:>6$MYL<I"&(RKIDF3EP$7%JC^Y?P@K"-I\^<S2T!F/O93.A8_I.B!
MRN+#$AXT;>;*XWV>6'0B%@LKFYJK^WL6T<$#C^="/+"4F\F89'R*."M4>>8R
MD:R#J4C,L3QC!D@K<%-=K3VE=,Q, P26["I^RX'9CL0QU"XU>\I ]:?WDW'^
M1"M+1Q2[M TUP3)M>_-[U^UKIBCY=S%D5M=*W0!AD&]-@^NPO!'!+SD\$R_\
MP)H@H/>FG5!VMV@PLC2%\@Y]F_ ;/P&>N!^V!8@YV1"-\U*HM+QKPC)^RJ9\
M;<3-0M[%0/OK.!_!V_W&BO^K&S([MA(=1P"'.<? _':NXY"H]H]W0'AF&[NV
MYQ4.ABHW8M\VOS#T):?G]V=<1+@/&##@3A1FYR&/8L"CG>15U[CRT#7?];C9
MSXJ7ZTT!&D2L@R(3LG/\2;I3<%8\KK(TD> E1L%?7T@-^K*\E=1?F[KA+W69
MDBQ^S17%WVA/@KI55PQK_\L\#1^?27=ES#TWY%Q*E^WW.2<6ZQ.KE;-[=)3\
MFV4\=!5YMW-^RV>3?NM=T-ZRP$,^@\7&Y;NU7&1"DHA%5>8UZY8+VS,FDY*^
MKW[X.4Y+4&^>WJ<9>TEVT<_B9L(F1X-RH5DN,YOXQXVM>6EP>U,,6!!/%A]?
MLH\66O_RSQSGTG:=E1\;E^;*SYZ[K6E=&L'J2Y^[[?.?.8:G%GM<BW77NJT8
M#[+@R*K8J;-=^HMS7,*EKW:T,N>^H44FX_S5MX +7A+=C(E14"_(:0V%T\K9
M3QML"7RUR!_YS]9Q;L\;C3EKKN](=DO5IO!-^<_5F[(+SFK-+%BW%;S<^X<'
M_QI0>OEMSVK+S)ZX[[FO[FGXWVYV\F6-UNBH;)GOW;7FC*Z>IWD<=#_6G^:Q
MV<N_.(CBH&]M6KIO.Z^;T-;W1(YZ(_H<L*<@? 80-IU7CE]7$%80EN"MW?"4
M\;O[&:>')=X^YYL>]$W_L\O&V_5PU8.^\1>1)SW?K&!O ]@/^NZ^^\HY;OL4
M/2\,*SQQ$K$XN_6S(I/<9#HI3MI.PLM'G/]GNT/MF=/<]B4_W:K1X:\_W;:W
M0.0#A&GK3G#*+I'SI>RI>PK.E[*ZK0A[O":T:2H;^F1MZ.MZ%)M(C>(UTJPK
M[?MUXI\OS O?,C"Z2T58K7!']]A5@);]GF;88>E]N)P&=W ^JALG;J.M'^,!
MH0>V?Y S0IWBZ[LYG,.XPA6)-N CX[6A)D6DO1').8RH.UUU6.9C_>N*\0YG
M%VW2K6!3T22QF_PTJ>0YNF-[BDIR4\DT],!15)*=2IN>\OU0Z A/^1,PWK^]
M/%+^S$QZ*]1-0QF,LE/)UD-CT^P%1:5]IR#JEF(EV8ED'<;Q<H3G_2NL>LN7
M[,#GN371,[&O;0S\TPK>&YYN69MFW&RT$T=DR9P4:8-0-X)-@_N*LD= 6=/7
M3<=6E#U:[T.HO \G6]O]:UZ*:37Y<NNH<\\5?!M:NN\8[\X^4?"TJ.I[>FB'
MBJJG1573U0/#5%0]0MI9*JGW=)-ZZQ[?PIMQ9MD*;QW=M*WUQ9(*KNZ;0+;N
MNAMH XI ^R:0Z]N*/-*2QSQ,^L@1'MY'Z!ZH#^\TB_+[<TL\,'5CXT1#%2S=
M-Y'<0)%(;A*%&X?L%(GVG1<2J.94IVN#\^94;X4%_DZ<YIV-7$]<6WT;>LJ8
MD)<\CJ<[P6&RG165-O!I^;KC;A 74Q3:>S3$V+O/\0B/\B.TR%G ?L3F".(4
MK(>TQ&%F.#^('^K:E/S8KNC_M,*"H:?[[@9'_JF&!4^+JK:M!XJJIT95S\(2
M$D75(Z2=&6P:!E#^@^-1.F[Z532.5Z^V7IG'K"R??5'(>V5UB*+0_KP'&V3I
M*>KL70ESE./@%!T'O].I-L[+I1-[3>U:3/RU@;QQ/L/YP4S#5A.%MMT:N?F$
M^4]\[[4VV59;<V"+33&&8HSG75"AZ2O&4(RA&&/1BQ=LDE!].HQQ\CZ^L\X1
M^FE* ([P;YP^#/\"_ZG6=$^*VS3CV.1SR_>\8HM-)[JA!8[A)K=4R_*I=D])
M!IN>S,9:7O"_D"G<FHPOFPGLS[U*L,M787=\GTZ!U-'<RRU-\[9>'$']S$MX
M!R-'UXJUZ(YD0)Y'4FK)F$R9-W5Z1[4G2@J-9C&-M0\THO<C6G!.LTU=P^'O
M.J_1QN^6Y)YJ$UA4'F./=YQS?KER*\22'!?6/,G+%.N[WQ=TS-K(_?R8QM,[
M ?CV54(&&\TE9 02=S9=?4F+F?DL^/UON^EBJJFQ<B]6+7'XEU'QTW#^LO9_
M[XKJ#A/@K8M10<F?%R2!&[PGXT?R5 Y^FH<?8*^][ZNV;&VQD20[PRD7PC&-
M<E[[_QZ$-RWP6[ <(LU:M+N")O\U^(_4=1/+\P(G=@W+L4UO1!/'-3V/>*9#
M+</\AS\8?D<QC:QQ#0\$0I=_^8D,UY)X#1568^((A&7W*-*-I.1*5]^^Q.?<
M.R QWQB7@08/&E=1*)2%U<L=0L"CS.YZ_L&W3APDA]R;[D,,R)F,:30M&>UF
M$SC2LJDV(4_8Q!P^C"@<2C$_Z:ZRO])2USYGT:7&Y "[!F3N?8EHP%]^^W"E
M:X]W:73'#E3Z@T9P0L5:FFF_D2?VQ%=K.OL@XH9<W3W4Y;BX>NX=,(X,9VD)
M)!L]:6_,2[/F[VF.O\O'[\_J:%(* Z$X@O3TEW:SK4D"TS!-4OL.'U2$87PU
M*5( %:Q,BT$2 V4(&!,9O$X&][G'-H4C,@4>!+*F&8CK:5X\P>U!N\6K'XMT
M"H<P?)K ]05^709"2DDK:06WE+NUVNB152];-;]CN<^G;!:M::VS_$6!WM;8
M4*+[[J6U)(36-7UEPR#;DC>><^E4KW0@OF4+V5ZFO_$NO9HX]9?A%G>4Q!'L
M,6IH8X(*5D5O';\WGJ%K#]XWC_Z\&#'B1_D]?H$9<=67&6BF!0'4-'BI;@@+
MF!#T_:43?A$\MHQ2P%::I)&&1PTM:!;A(V&E[J7=N=((]@7]A^Q9L*6SA$13
M?N:4\,28;1+\*7U(I^G\XZ\>Z _X8TRUFSN\FPT?$G@Q6E:/-.I'PK\47C>C
M[1O@WE>7_OKYM^\7%FS)+'["8W%"@7E!=867@,O'Y'X4$[:6__[P]Y9R^\MO
MW[1?TXCMUM5M02DR5Z7AYE$T*XI*NT4NY+P!:[,:",YM1\Y,J'PV+?&] %@/
M</,2-J# $H))D=\6Y+YLT1#VN9R-6>=A/G/@(2WQ,&\NQ;^B+M&]_W4'02!!
M_D +1 [K:\P06#88!+6 8OD"TIR,Q[A)24FG*#7@]OZE6]\^IBO("VL%-$73
M!3HS:,4I_ 8/@>M_A<4DI,C2D8:PA]6A0T K\O&8QDPI84S#*"5VI'I+JZ6/
MSBV#-VHNRSQ*&?4?T^D=O\UL,LD+IN"2C"E#Y32]): 0 ?Y@;W.D'W\64G\E
M+*Z__/WSAZ,ZWI@,6F-PA?PGG;7F"(Y5AU[[B,,SSPI;,#KV,X]MSAO+O@P/
M?.9Q=7G[,\]JWF1>DBT(3;U32NJ-B&0 B=@QR8Z;^KH%0;+>P?JBH.62?:E/
M/#QN/,97JR01GL0D>]( ,(_3N_E->5X(&RND'[?<^0%;_$G;CS_"L-+*WG12
MBJ7%U2Z('J.EP#'"%XUJ\EH6F<<=W@E98PKT1\+#]S/4V<;:B(P)Z&=X].6S
M0AOGV>T%.NNT45X ]N#+Y:*V]#G+\@<RG97P;9(=U7$W3XV%UDAR0T?4;BPB
M)]P#<D#W+S XW<+*/6C13T*2: F<:4+T/9!TC%&<"Q#Q%RAR0**"_LO5=N%&
M8AYE@DCC&MC"$]/JC4%&TO+XX+5.RPXIH?;,PD7\FX/.:>OY:Z.N%4%?PMP;
MQVO=$I\'*GU$:5PN!!?X$\:UN"H('H0T!GV^ 'LS3DN&(GA #IA[PC!4"IOS
MD,\B?#>T%T>COZ<HPZ)J>=69W79C8[HU6B&@[L$JZ0\\+6=I><>\)B**\>4'
M8#QF,E#<RCH^L*Y1'R8E5E>ONU9Z!%A-'5;2#TQ9((O\J$_QUKD()^M4+$#E
M=#0Y'6;O.1UXBS3^K\'+"06F80]4)H@T:SGS3)!GI?"OZ;]F:8P'%IY%UV2"
M\EO[2DLXXR()1/&&A\HWOFRD7_UF1QKWOF)OH0)[:X:L'ZEV1V+M31BT#!/8
MP(B4=SK[KT8!$ ^@PF5B:%YYEQ=3;G+&=#1MV0LZ.[6+M&0.7^V-Y;;"4N*F
MW*7<==\WOMU2Z#!U8>6#.LP6G6N%&?J&9O<S?L['-$FCE"F ;QS;;QR&Z^E]
MA\LP_I)I_S/+J%8[*8%.[-!E80GF46-J+*,'WQ80154D@UMIC=7_:YI0[1M&
M>9#)?Z7<I? )<*=]UK5?;[2W]7??Z;S5$?L&:FJS2150;,(R:#[R^,@4S@B*
MP:8,U/526(>8_<Q7%*..!9M_-;N=@7TH>,&_U/Z@W"4F[O3&,5JW3\7+<[-S
MRK2X"!1\Y@>$N_$P#9G 0G^DF&D-"M\;V[X4*?/5;5 CG)55S.NI#D$(,^!7
M=(7@0@H\_' 51%@1"3,MYF_V@FG!\-DD2.$M;S.@=XRQ$,+8 NQO_OWGK#9A
MOZ/C$\LN&(B9IEH]K!D=)6(SP&_T#FZ$CG)<_J5V53)/8[6T5:A@F$)KK$!&
M%)KV/0%TP?]QS<BC+0<"IK6/:8D990 \]S^;^\,#;I'0C8^*W#-G*WQ#$)@-
MVVRYLQA3(X)+)#!SI2+[,'K@FE@$+IOB?H/&F:)N :N+"_+(GOG&;%NT/*[W
MG8-0^T771K,I2+4'GIP?8_BPS)$0L)Y*.%=87#=O[7"BX"J.4Q[I&S_I/"J6
M931BP5M&4287<%.98)CW]R'(NX3'-XPA:S=PZK- ZM4JR='X_;EV!WB[SS,>
M@JY]00T"0)R+%-*6N+C4NJ196I8S6(_OA+KAVB#K2<$5D+E'P&*;Q2!2T 3D
M7]8FU>H!=QRB&%CW7?/5)#WX>?RECCB[JP5_!L_Z K(#OXK.O&](FT,J/#5Z
M=K(([]+QUS%DENUSI/*%?>F F;!4\ 2XX0;7M]^DU,PX<_T/31*X'C4K0'LY
M(\"A@ %QT("8Q!53D)[\E,:3%T[$V?VA5> W;NL\EW-_A3]R3MJD+'F2"=.2
MYU6BG(D1W+'V?_U'8%G&ST(?X8YT]C?SY]95I&1*9\;5HZ\S8$W'=%NI)]\:
M)?8JFNKBDX_I+1H,@67Z/Y<:4CUBH>_RCHX3.*%O132<+;52!][B_9B2=/7]
M-^T3B=(Q*%WO+D%D:E<@%,>-"$$]84RG/!%#++7VS]:W2,0M>/8.( J-6BQ\
MTKW TZT@:(GII<V#OXN,EG3!(WQH,%JM[#@IP0BV"WJV #E8Q\8CW_?W<$(R
M/8]EP5QJOP-_UZI BXQ,CV[H"UHR'(8-^9D^J"SB]4F!VCEW)\];&(>%<- D
ME4NY;\#^:#L@=AM9MR2;F&!)9I@SQA1 M"V.P!2OC08S8- UF$Q-TC$S&I^5
MT?#+IQQLG6\7MO;V$UP!?'RIV;9]8;FF$_KOFIRVULF YM+''R*R<5W+ NWM
MMX_7[]J5.#&-QBQ*TAP9HR=^MX_7^/!%>\=@]P8E^CX5Q4%,DN@U.;A+ 55*
MN!$HW8N:1:/L5R*HI7];1MN.[S@ET+M X3*>GL?^L.3:@><_D@*L.91ZGY?M
M'5PT[#T^69B@W7O?H3MGRXKSKI57=RO=U=U<=3V0AJK]^NNU]K;^]=TJC36?
MC>.5.NN<WKB!BE;N4$73WC*V65:QVKG!<RI6VV!&UX90FFJ?Y;R$G+\U=V-V
M?L08'ATG:89^H=?*S8,?%7^ : $$4Y!5C(#,X57[>YI=*JIH"B -=G&$6;\)
M^G,IQQ2ZEAA )F.2(35;OC&FP**_BI3\ 1G],=5,"]-@IG?X^7C,<J78A[7L
MJ_R5T[L4:)]E,Q;4X9G&0I";QL7_N=3^.W^$]:/8Y!@%F/.4^F89<&^N$I<,
MHNB*(M$=OC;#G3@%>42;.^/F=J5ZJ;DTZWOR!&_"774CW"'0%_&)!5[^R%AK
M-._0*TA:<C>KT,Q9<Y>Y[6NV#73%.6<3>[,1!U]]KY82&HFX%RYKA)_ EI2H
M*Z7W$Q)->4!_DF,\,(6O/>;P*5,1;L?Y"/Y 0;3G][SL@-^TK.&/:21 YS@M
MB]F$?S3-.7<\Y"@DV:K23.?X@==-I^Q3X&R@9<J6A0*@K)RJ?\M27-(W/!_$
M,9,7X_@1LT\;XZ6VBEAJ^(49:L [,855ZNC6Q$.'^6^Q7'JZ9K*3A$SX!?F&
MI4O@*2\\;RP\4] &'1UIKTUV;O%LD5(%61ZA6#/)6UQTJ5WC4BKG_8JU -O.
M 8TE>Z3W0B]XO(.#_I$RS_^4E42T4G?+JCZZBF+4:20B([GR4XM$8_2H/S&A
M)+*/BUDKA[@#!.LF/'@#:4/<G[B ^B1$QU<N5.YY;%_N3*,T9Q(.<X3J""?*
M7PZ_*8M'L"*4=ML8%GL8DQD&$;A@3-*B9(G=][1@ D5<H6O_7_YGFCUP=_S_
M$#@FBB>1D?0'QQG<%N]00Q56,U<^M:#2,C&<W>:XT6U.6JZN:FJJ=%'(-1NS
MN!06 +/ $? ()C\Q$<H95&_?4V_=D,.Y+O:98L<BE 2ZX%J*7IU;C*6RQ'LT
MAQ_@>WBXLG-7;&"$S!*OG_MY0%NN4^KQ0PP$'W_OQYJ$3.]HMA3/7+T^2WG8
MKZ&5T%:7-T7OS.3GM4VXE0W TG]S$P9N)1#& V?LP.FZ\5SY'WYUN6[P+N6X
M:4YM$&Y),E=F(0"@MRH!]7:)F3X/0KTY8_4*HN26V[LJE:Y.I;-Z3Z5327$'
M7XO\27&'DZX@,$H\V(14Z*[>;/0XEADQF8W&S !@U5/M\Y,?F2!1R]D(]3%F
M0LRIED)SP_E<<%:QO196516V7CQ+&UND4^@>YZ$&6X;&(FY8^ZQB6C-FA% 1
MZEE,'1'G7G6>92Q6,[T#J^3VKMI(5/IXDN-/><%==4+V9[=<D7Y$5P[F7M=;
MVS80P<PFH[QZ+%;GHKY/;X'DJ+V .E;>I1.1.,3/.0Z%E/),%B),,R1/A[G8
MF!2+)B7H<;3 5!;TJ4QRL!:9CB/4_.98Q5,-[%*F)\8Y4Q/_S/)'M!_8YQWF
M;N6.:%P5S-C #:2QKC'LD2GS#=1?8?>O+Q3Y+/F(Y]HL/P+PB,HB_(U]%7LQ
M76J?DRIE9Y95MUAID[<RX(6]3*L]6K*0FUWLVCY\H>6]:KLB@$OAJ^/:9S&G
M%G4I.(T6RW/X:V]9\QX<>6TUI>U/[(PNZ/QA&7.8XOXPO'*/HT#1_&['*6@2
MHGP8>9^Y&._R,0C[LJZ\8IXI[M].,[PCC;%7@7"W-/<5?FQ6C0J4'6,Y>BM/
M:_[++2G8N"R85@BV"'J^15N?ZC(LEIDN>6O^X!D /&$/74PH;6<%<V6QZYL;
M+V.V*A6[YP;N(^7D1&)GHOL7&+IT,JV@ABEC"&F6K]5&(W-MB2\Q1SX"$NB'
MSK36;E>"1H!GQ,1TQ!$4@R+XA&KFG\*KQ;<.JV G/%U1Q\P[["Q1-3'C2V2"
M VMPQRE%9(Y9^C)[,D@^?"\6S@/UL4Q'(DL415DYXWTJ$#$+Z*W:-8#\R9Y$
MB %Y3*R)D[)J\ J6UQTI[AEI1K.2M;&0H*CHA?9FO*$#>C>_+ "5)R>RD--4
M#EM_PU3V7UG!]<%7_4*)J/8%)"F&Y4!3]#N3O+#O%S(R9]9&7M0Y&F/F3&BR
M.YF4Y<R>5\$)%O,S T994)U2D2:H?:*CHG):V"R8,?<7[E.]%A7MY)[W3\"_
M\8?""@4S-G\; :MDHM^"2 .N?P<!2A_Q5&..7"Y9^0W@MOQR86JS5Z ++V#9
MS0OP7B/-:GE UN&)H^,RYWF?[42)>N?&O!2_#AJAV,)$6Q"=+!P)YAA:OGC"
MH/X8IR4F'8,TN]2^8LP27_MWT'(TTVY"4ZT\W>98K4.05<L7H?S"SG^&#[1@
MC1B#R,&):1D5Z:2MH48M]IT[9U8DN!Y>&FW(PE<HN1G)EWKT2,[8(GM94*5*
MJ?ZSMDO$V55R%28M8N[#@P7PD" [LYK$5MR"L=B"FM'G??#Y$QG78?/F]HCQ
M$64UEJ@(B@^Y*!'G/H]%5:XKH>TM64S+NEO=DZE<Y M7Y_]Z[$KVH\\=ZD?"
M*<?75:-J??ZA1;9C898O65478HISJNL@?/8-127X)^:HAV_^$QT'S:<L0;*Z
M0;,MJW(3V!DDRM?G&*%J5U7U>JF[=%5^!NPN)KXD#)JZCU<A',>5EB[JXO]G
M!IIC=3Q71C</5#]J<3&[17<[8(#SW-O?/UR]$TDO_ '+;\5,@1%M90C@F4Q3
M[CP&,5-715>ZJX8.1&QX5HA<'^2\?(:^CQD[DN$4#PTM)D\E+]"O6XS"T0EO
MM\3_>SL66R8<1=V]7)]UJPD9%SCAYKWM59- T+;+IN\O;)F4V:;VX3L6S& U
MA_0\_5+=6EWZLZIX[>U\^<J[I;JE?12H(8\EL$JF.6+-"=B&L_OY5B=5^MG\
M>C$LC<;ON.Y<P'.;WI)W[%=X3^0_]J>4_^FF !IH7UD-%?I#R[LF+OT;Z]OR
ME>4LE")F*)[[!R87?9O""TZU_P&^0WYXB^P!2GLY ]N]++E\*N@T?\>V^VT*
MC[0OW?^$71S#@M^.\%??_<^?&_G$G5<B,8>.YY_Y"VLRA)DO?-^M2XN7@L$#
M[_BNE'>$^QHJC0-0^2>PEX8=N\8\3,]T']C2%#-&4)$7MQ=E?HPN57$>[R;R
M3(F@T&BNQ;4?<!'S-6%7G*!-CNH;NPT7H!@P4AI7()T^Y@UDWM:%96P'J]^N
MW_%[=I6B<:F::"NN['#&<!5&M+>8M^28B54C1H"(AZ89>KFCJ%;H5FIRK4AN
MH\)5IXSPWK"%5^MD> %\_)X_B.S72DWZ)9_>K7PY5J0GTIHTYF+A[X#EDVGS
M%HQ\ML'--SR"\%' /2RO!K\4TX3,QE-5GR=%?9Z*Z]9Q75O%=55<]YSBNGW6
MYG+7X@2/=:[!@92X  L#@U2S>^P*@ _&#"W1PH[?H+[S>L?!X13@*PU-EI;"
MQ#3=NA2NW9.@H)B;R%*!QTPMVDTVO[5>-O\A2PE>;.6 H<&5;0:PAG)"TKA6
MSG7A+DZG6D)YGD!7PAUO/]#.]@3%EE%&=(CXQ"Q7BI4-BZ9N<$!3]^B<5+_-
M93!^$R'2I<(;.1GZ<]94?"TH:;^1$M7RSM<KVVZHWW[[=L7MKR6W#8?C#0'V
MSS,QA.FM^/5=K=[-YX "=,9-L_6(3,K9N/8 1W^26_$E5++&=#')D.F*E]K?
MNB<]M=W,'?U!JE"S6&&E8C(("PF.Z3@1P=0?GES9+*ZY:#R>RT(-#!3PD5#\
MA<-V_IWYS:NH,R]BN,\+RKN16',WZ+I2I, P9UCKT<6*UP3![,_=<^% @^]4
M;U.KX-BM*&&A<9XYD+)LF/DY6@"$%3@0EM*B4]H56SP#=1ETEJB.I24LB,V,
M?'17@LEZP6)M['DH$EFOELKH:CD%%],HZ@4RXX\TTQ"8;P7[WK1<B'6).O<
MLO<2MQ9Y%*RD$"\X/CGU)4DN?A$-;[[=H5?E"LL0;X_!F?ZA&?A4V=X33(L#
MB17SW*:4Y\!C?%2'GPK,=GIL5U[Q3PC+>4@NJLX_)=L(TMJ(=@%=4\E6,#87
M.,?B4U85DM?/9#?&W!I6@P?GX ,I4N$>JGIM9U.>$_3Z>HI0WGH*5M+R:9P_
M2HXDYOELRN,8B<K9/396_3=2&)4>?)4$7Z66?A7H4M"D(B9GWC('9CZ#M<3E
MN_<;F$?BF96G@$TC9YF$DY*^KW[X.4[+R9@\O4\S]@[LHI_%S81[H:-ZEEF
M_&-A-H?A9> $:#GCY.EFQ+8PJB^94;TP?IM_YIN701"N_-BX-%=^]MQM3>O2
M-%9?^MQMG__,,;S=+-99Z[9LLK?8XXX1\"].>@^7OMHQRIW[7?8SWSQXB>^9
M0^9_\53^.#>!A!WNRU//M]B;YJN"7Q@[3:8:,TXT?,G%T?!R[UJ[0<A6;WM6
M6V9N JKE&E30)FF2//?6&#3=SSN_?%JQE_X=6]W7Q:+SF;5UDO$BD%[:@/4
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M^:>X9:;:LHVX"KT+/8D,F8)Z[-U>*I ZA]SN<TOAEK3<R74V+W<Z0/W$2_E
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M<@HI*BDJ*2HI*BDJ'8,>Z-B&9WOQR$R,Q+$2BT1A:'B18_F!39Q@G9:<*_1
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MO<Y+IK/7^OO&2@8&''7+#B12Y)4Y*;N2L3X:EP$7#H9=_0T4W$X&;KWK$UO
M+3 &P\!0;HH#H>8KC6<<+RGVDZ1:1(J"-2 F]T@R=%BP/;O(DXL9UG-@9NWK
MHB1GH:OWKEC4+;I^I:2D7W%57Y*_E92E.+<9[R/7^;IXS,2FWWUU_%8FHH2P
MZUV#Z -V%L#.4ID^)PR[WC6)/F"'@\G\K>TEY8QX'7KXB%AX:A[]J:5E.:.Q
MQGJO:S=%CLJ&]H$^T'$^8?&0JZW*0\]"6^\_BQ.(@A.8OR1LG@@HZ'^ TD=
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MO?GEEGJ$ WJ$K5O^-H%R91_**[U[5R'60][S,EO**EH%/=D5ASZ@UU^)J7)
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M^8'WQ5P&&#R\>*.]2EYKJM_DICE">H/JD5*O4[-R>?O&7^&;BU]5KZ7\6QZ
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MP%I]U2!D2+77)G.;9%1OX33$>ID"RGY%*@4K-R6WP[/5ZU?=$SB.*>/J4H?
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MH#//#/0P,.-_?EA5E/_AT_NEHDKBZ16)J&&A9)S\%-'QOT61KZJ1M&XI#7W
MM;=7TA\[<;SG3MA..XE";D6^Z3/'8<STS2 6)F.N%8<A"X3.:"=+E=^/LQ/[
M:7:R%WYRCDZS?*G8]@X_6*.R5VD!2UT^;,B<'8#^OH,Z,7UA"F;IH= ](+_M
MZ8[CV4R/ V:8$8\V-/OT^ #64G1Y[>\J<5'^)E,)1.JR_>FJDNS;.</=B:M=
MTPI=W6+<@VU9ENT%@>4Z<1SST(9]^1M:-!YO6]YV#-\F@M#+!<\%7=F:K%_#
MP\N^2Y<U69H5T,/M7RQK>"RT\Y:D4F^<95%/ ZJ[BNAS]K7)#.(0AO([6M$5
M]R1+]QZC%,]%H//V%-:?G+QA79E/75-H^TI6P]2PUNB9(HTS=F+9VP%7/V_P
M[FFQ#[58^U%@T4UC;+#HWLZHZ-H2[O<+@D;?CEP+V?L7#_2]"]4F2/F[4,V:
MJ+83U9;!)%X"_-=B_]6;;;CF[CBSV[#3G0%UIA6.<84O 8CFSZ4<^7W@"E?B
M 8QNS_]QKRT>*-3!<I9)9XXPF6.Z86"SV#4\/Q"1<(1AN!!"N&)U/OO8NF/J
M=!UF@=4F0AS]Z-0P9C9S1H2DN2=DCDF*GJD4V;89.RSTF24<9AD^9Z'P;6'Y
M\!/'T_<M12ORL3T!,HY.58?_)$&3!!V(!(4BBL)8\$!X-@L=%@@_]FW?"\(@
ML"*A/ZH$F9,$31(TBKWM(D&Q\'3'"@S7CYFE<VYR[@2N;@H_L'0G?'Q/SAJA
M)_<2DB)O%RJ-)GST=3+CPQY-77A<MRPF]( ;D1Y9(0<?S@NC:$TUSP-9';8W
MJS.A1H^7Y0);8.,A]\Q0,,%YH,?"C#S#X;KC.9;W^&K:/CKU9KZQK[F+$]>-
MD.L8CX4;L"B(G8"%NL$M;OH6!*E">*#G_$=5=,ZDZ%X RSE1Q,TXCH+ 9<P/
M?%_7D>E<R^(L\AWW\16=.SY%]Q)N%][FQ9Q*R1?+XJ>A@^MDQW(-W;>=.+)U
MBQFA[X'>-EPF7-VU]) 9CZJNO6><#9E8KDUA.PP<TDC87@B,Q@(O9*:E![&O
M6Z;.]7VSW!;JVC\Z-;V9P\R)[9XOVT5A$.O@$KHZTYD?\8 %.K>!TP(O-H1N
M/::F<_5)T[T EO/=6(@@B/PP])D(&2@\WW)C+V8^FMO'C\!=8X2:[B4D2O\Z
M^7:BG>>PI$P"[>0K2E^FB*[M2'(LP_=,;MDN9SIW_-"QK-BV#<]U?.[O^X;A
M=EV]OSNZ*8DP7I8+;,ODCBUTSPB8&^G<\",KL.P8F(Z[]N,G$5SKZ-3R9[8S
MIBS"Q'9[9CN3!T9HFAQ8RV9ZX'/78Y'K"L,*'(O'T:-JNNE>Z"6PG(A"SD.;
M&<SSF!DSSXP#/W9X8-K"%-&^ Z$M-)T]0DWW$O*E*\>";MK@@PUR&QUY=B[W
MV0MIGHV><448V\(SP:-R66 R;CA6"+&PYW #U(WY^'K&V7.9T#,8X3A)^R3M
M^W%D+5UW'&[IKA$RPS(#Q_>8)[C0=>Z;(GA\:7>/3EV<:NQ-TCY)^R3M>Y7V
MNX&3/5#8NO=KXTG2)TF?)%T5B'B1%_#88<*+F<Y-SPLL$_[#K="U37/?":HM
M[+I_=.IY,\=YIG.F)]BI9P6.-"UV@IT: ^S4$%%I@IV:8*<FV*D)=NJ J#;!
M3DVP4],*)]BI"79J BO8)7_A<,.-O<CP+9,Q8?@\XD9HL3AR+,<0]FK(_@?,
M7W@(.V7-;%,?40WN!/DQ2='MMWMF+ S3IGD7OA=SR[2=T(D-SQ+",M8,OGB8
M?+\WP4Y-$C2.O>W2"^)X7/?#P+4]AT5F$,2FY46"&9ZG&T[XN!(TP4Y-$C2.
MO>W2P&<&6)<?AKH3LX S'I@@3LSQS=@-'<-X?$_.&J$G]Q*2(OOM\W\11=]N
M&#$S]&/'=6/FVB ^C+N6'P1AX$6VXS^J^9GZ#%X"RWE6Z-MV$'EAR)GA.)X3
M"A.;JVS#,G3'>7Q];1^=,F-F&\;$=L^7[83P=1;;L1\9G+DZXKP&D6'IML%"
MUXP?5]-- %0O@>6,T+<L/X;SC#R&'?^AJ[MZ$%I!%$7,W3?+;:'IW!%JNI=P
MT;"_/O]MH]6#%AQA\%B//6[;AL.$+L 7#4/+<R-/",,QPT?5U1/ZU$M@N< !
M)R .P04-#6:$GB]"RQ9&&(5.I'N>]_BZV@==;<XL9D]L]XS9SF ^]P3P7. S
M1_?@#S.(?8=[8:!;UKZO(6_5=/Z$/O426,Z(=,L0F"WE+G--PXMUV_1#/?)-
M)Q)6].B:SC=&J.E>0KYTMS[_81G1U"'T0*1Y-GK&U6-N<O#B/=UAH1[X#C,=
MQ] #Q['!H3(?7\^8^[J7V>-Y/W&R9I+V2=KW(NTLYKK%G<B.@IC9EL]U(S8,
M%G'7#9FG\\>7=NOHU+-FGGUO5(])VB=IGZ1] 3296Q O0+3J,&;Z$+)B :!K
MQ6'( J$_:M62O_=KXTG2)TF?)%U)NG!<Q]=MGX<Q,WS;8]R($ [5#=W(,ZS'
MM^OVT:GOSBSW.=CU%7W^:E.?ZDLXVW!#W_\C,X])68,+40CM&O]X<+R(#Y_>
M+S)2V_GV,>%!DE)]UUT,B-YQE/,($O$X.W&/3K-\22Z6?J#%;?M@VKU;NQ0<
M7QAIO-)B6(AVA2O1@!Q<*["8K@!^UP)>)J7&2RV/M::;7$J>:BDW-9Y%U%M^
MTLIBR]I(RB2KN5Q8C[D5CS%$H)CG98(?>%.(%#YY)3K@"=1>O6\IJ=6[K_
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MPG"#P C,(TV /IHC[Q6U.#I5K]+H7:0S\DP65BWF2?H'O-*V;G[U<*F1'EI
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M'+DALT44,6 \Y5RPHL;$-E8AU[8!%A+T.5%6IG<W(/'5^@OBMZ%95M4FM2W
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M55:JOLRP&@B>_MY-WVRKIF]X>%7_U5[MN@Z KCF;VI_6YS:25G] K_F1CN:
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M.X+K4YW94HU.;2PL>ONJP]>3,>":$ALBB(=<%^^:T4/9FU6_ONIVP[='R^W
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M.?EU-KW"\CLJDM_+WMW>QX-@VD''^30A.DH:-3.GRT1"%*&_U1KBO&Y^KN!
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M'3I(?"0B^N;9PYX.(+<ONF)R.8W51\W)J?K7[[*W*^9B47G$[#:"T-N^3MB
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MC$44= ) G:NOL>IWL@/\T^:O7KI5GW#B1\01@4N#)!:Q;T>QP\(P#(C'V5'
M/V%N!(_,@@,G!CK+^C3%[AF<IO@RJ<$D#A(5"@?"%U/L-76\4>=L2!L@R!+Q
M[+9(%J=3ZW)QM<CGZA*=5VB"0F'W\YT94;P$QH[-A;8@I1Y :7X07W\[MOXH
MNV9Q*K$$A&I_MCF=@H 4JD9J$MTS74P=F5_Q9L%<:"[74%,C[ LMLN4&.V7Y
M%9,O5PT[V/=M":R6J$E7T'N(R;0 $V?=7\_4U ]\9&I)$U#!%\R2)(TD0EZ!
M!)X7;UAQ2?\93H1,<0I$3.?+:%[CSI;R9^]P7G% S]G^WF2.05)-<ZSAR@(^
M13$L2@T.5EOR;YE%:2X-WLQT-K<F,E=#95,K$6EF!L@T@NL8D:0J9E.(<-AU
M?C-3C A_LM*WFZIJWY)O%SHRHH+8H1T0&KA^P D)&(U=E\92Q,&&L0"WG7/8
MI1")VXUR?!3UME8UG^^G($/7Z>T7H ]\4%QA$N-+)C](/;@LXY\-Z;X@Y4J'
M\-RM#"Q!-Z'E"OZCX-Z[F1JKJ4#H<-8ZFH@\U_WB1C_@1YO'I*$TTE*[H:I
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M+^ !CP/!6>R%E F;)\1Q6>"R"'-Z?G?8/5CY<VW@,]*%W-57_HZ1+JOESW6
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MYG8R>P!%I& OK"^++ )>D]87X+0M5< SP:I\0N1-AXPZD57#&3 $\G*<9L
M,_#!10R:S4# *M1.QQM92I?B!6YD=@7BJ-3B>SF9P*>G3<$!)E7#\0HHY?8V
MF]U)#?6ZD8[6&_V1;U^^O%5R:96_H\9'$Z"N#'+][P4<7O* 6*HHH\5%C9=8
M7!35 $AE##?\36H9I2XI %:4T5 &;PH.YE=0,^ ?P&/$4C\[D@*\%?!!04$H
M8)GM*'@,.#M5X*7WK^!/#64*SSU/Q62"4#SP/7B&:"31G*HU]9JJ\\89(?!*
MOSTOB4UD*&4 OEA,/9:$+*!A;/O@NS$>Q1Z"\CIDHRJL(?&^%[<HV'H![5=S
MZQ]GV<?%?)')3^;V>VYQX00; >SN/>P%!95(P&F*!80'H-TB^&6*4R_I-$+/
M!"'8-#J0_KPB)>*X=)'2?'0RN]>G]"9]V]/<[ D4=LA=.E\@RH:?(3SXG-0&
M -1YK2FZ$ )$;U=<"O'5@'8;&;D>^,.+-<B.XD*W(+=2O8^W,(U%IK(1(Z4%
MWJ3K*-_)U'M2_G"&OMC&? F>)_Y)(1:7B_DUA-7_D7%O.:!P)!Y;*P=+!P"V
M8SJ1.2A3P\WFQ&*)CC0HIU*S=FA2ZW(-5C8<D&&"=;Y8YQ$%'@MM"A&<&T>4
M!YS'@C!$;P(-Q%V?=H.!/X/>86<7 >4C8*&5](9_5NAHY-]GH<M ]H=SXIU=
M^)R/;-:NW);D*[Y$T2Y1Q[76S(VM_>"%"V<E+_V4OJ<$1E-R&<6!B#AE=BBX
MYXLH=&W/=:GD[H9(HDNU(PLCDT($H!Y.PQ/J8RA<-O6APF%#?RWO?1[^V05P
ML^.T6UB*X\!#>%[8T&Y2J(!I)27ZHC<2CDT6[>ZF)?3&?FSA)3:B+3#!@"!@
MT4*7>TX<^Q!M C5XN(/%?R*V",XNB#_RG';3R:YLP7U/<!:%"4U"*ETBI!\)
MX<=V(&);.J0_3.I3L 6UMX!BWT&MQYZT ^:[U),A=?U8T- -9<)<UPN 6Y(-
M];WGXPSJ0/C-1AX]G,+P:>Q'1$9)$(<TH'Z8.."942=P*&.^</HCPCX)9[A;
M*8PZW.NHTWAM%9L.*?L"OM0\2U4&3J<,_IAB#@^%  BMJ(B&NO;>X-,Q"HPT
MS?(YIC&RN0Y?RMT#-0S<.[TZ98XYS>EYF>4H_.,F(N[M# CZ@)&CR;JHBZG\
MMHI]$NOKMS]4)EQ$"*ZKR%:FMY',"B]5L\J_%UBK^S3%N VXR:1GVA_$U]^.
MK9]%=&W)27J5HB-5WM_]]4QE9&O.J9A;$PB&YVO1:P.PY&[DXXH!0648@>X"
M[0T*G7#./&$OR:A-VH/J'V0BLVRE _HO>.Y/4Y72A1#]JX3GS=.Y_ 8WFD92
M2W WT,<]XA++:269$*7FZ=\6! +SZWQY KV.H:[+SHT84[%Q49I2"6M%*I76
M:I[YC2SBW$:H]*%,VZG#>8>OO\7458$WC&>^[?F8%)^ZB#HL%;?-K^'H7\QI
MT7U/"VFVPXDIHHZ63P:NEL+)8 @'(GN>*<%"RJL[T'#0YG#6W]HQY!S5 Q=/
M#X3KU&FF8T/M&S/\.(.+&?)/01=EN<@>"K)6^PQ&5KX(_R]6^$SNK,7NM75B
MZOAF"\WYP$+(Y=EL<:5U88''K2^K#KV\)U"?R0)^40EQ88%!!Q[%5_&BV6PR
M0DZ(9:(2&Y4!;FM-G>!>IDD5'%9?J=.(NNT%K[5.%A,G<F((=R/BV""+A#LN
MCX07NY)Y443H%K*X<_"N_OE3TZZ73+*SB^*,ER5RM/9I0SO&Q2(VP1I^Q./
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M8AFHR-?&067D7OWA=#8'[31OQB8'T5V[N:S"]63L>3;S;)<Z3(J8)X)0(=R
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MF]/\5AQFX\.=8: '3 \&??#K8I[CQ/^QC?;L6_$]R<\3I4V>1G[\D_R<Y&>
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MLB$Z308?U<49A#*VQ.UM-OL;Z#.'9^O'Z:$3$3?R(V[[U.=V" ZB#)COAF'
M0016^(ALV6;LBV)8.TX/&#IPQZL 4G;E:)MPV_&CR!%)0A,6<MM-B.T*FWK,
MD;[]#$_J*]%=-=K?R;@C9(M$@I43$T6"? Z'OA;ZUQ)W(IVH50)@"3)<1@SJ
M=#%?9&HYG7JCV%5W+>;6/7PO:/DK5,8S2_Y]FV9*,[LVL0O=RI?O"M5S^[;0
M=MPNLMM9+G.M[.M<V^?T8E"\TDZH'_H>]7T2\,!WP,.)7&Y+G_O;GEXG0-OE
M#7@:6XZ/UXZ/*[VSJINBX-/:>7W.;L'.61^RQ97!B7R<DW+<'XCS@VM39_QB
MU!R<YTQQ36:FK16;Q=6\M6*V3JK"-_R_]KZTNVTDR?:OX'C.S-@]%(V5!%UO
M_(ZLI5I5EJ615-5O/OF 0%)$&P186"2S?_V+B$QL)+AI(R1F?7!)(@@@,R-N
M1D1&W-@]0&XL> T&=47F!N\^JS7Y6I"^G0'C$ZJ6I;[[;*RU:9HQ)\>;NC()
M4W6),CD_Y\V#LY$21JF2I>#W_(MY7!;Y P3#*PA9",I'LN:#B2D&#/<$T]F'
MZ7X-9L9-@U_ ?;T9SIH8OO+MXNN\3L5*A UHN7N0IK$_S%*6=)0D0]5,2C4M
MU1(^]7'?GA7SC\:\,G%F.(^!/X$Y@_D;S9DW"2(;#(^!;0BF#B#J?<CB9.Q/
M<[<!W$1XDYRJQ;#UO%O/&7:I"$$\K@ GP@SOZC'E/;^_QS[@==K [G7PC4&8
MT:NH[5/%I(!_=PO/N/?3L7+$@L#QX$DPQBR@=P[%N!M>#B03;N^ZX)K"_HQ[
M9?[]XN:+TXOB[((OZL"=F^8YAWYX[/"?,&Y<K%$6TY4TD;RSFQ*10^7'2I:P
M^@:,+EV"KM']F-'7 #;)E%P< LT."37WI!HFFN9U%$<3!36#*[M/#P<G_G:\
MX ."ZT?T2$HVI:O\1+P0(GD=^*N+/_]F-,##:>P'<%.\L09+>>&F$3Y*L^DO
M-DWF_ NH7:7B&M=O05]8N,O"LSM\A^83?<\ 5B:.M]3;QC7&^R[=I;@0PU<3
MIL19@ ;3H>=1BS80X,61"U]9()H;98$G!)*TK/SJHCQL_7)M-R.0>'LHN+>X
M&&9AKCYD@XI>=[PW5\S<Z#9$6$?A#U'R0?XF48P@] ,-A!3--,1_,K-PQO([
M5!0OP=OG(LQ^PKA"FF5$.3?(4-MQ0;"W'I_[$6$?=>ACY+,Q9!R)4&-3_Y8K
MS)13RJ!T<8Y"L6(I<\<A1J80B6"47)D=VEVK \*!@*>=8>0&M!:_&L 2L23-
M+T:-+:>+CQ"^=0L.>DH""$.W5 64#IO\Y#,"WQHR/B*'=D0Q[+S)I *[:QHP
M5-\Y89$]#.L]#/6ENO2J>QANT)-P"6S8SPD;=,=/1-OFUI9GH8L4 <D?!6P@
MI%SFL%&?A9?JK?A'6"HVO$Y.+G@5!<$I!^8E[14M;</VBKW=.7X$6J$+]B47
MHFC4N#-EE3FHXE:R14"86QQYZ$)5R-C8I_:,EMW53%VV9WQ=+VN^2"])S7J=
MS23_%UW'DYK6DVTO&TO*QI+/VUA23MD&4Z;N5R_.+T[ 3[Q3'H_' W4T:= X
M>9Z"MK>=T2-S=K;,V5GB*VQ;5F_I2)4YL![=(N4UE0A+A90*62CDP/$TR[",
M@>9:INNHCNF.;+4_\,"/'UB&30JI/D(A%W7.>/?9M)Z*G%9JG-2X%HQZ"XVS
M7:VO&<Y@-%)5L]<S!X[=&_4T4U<=;:"JM 5J@Y?; JE%C-Z7_ 0+EG5S-$SM
M]BE\S^]X@%^GH"Z_)QZ'A^FG@\$N0HT4<L]/T9+*B4KM3"@_D4DC91K[45RW
MVGG@>S_(H5XP1793]<U31['+0A9@BMMI'$TN<9TN89 17EO$Z;=(3;>L-O9<
MD!QF3RRFC\UCWKF8]J28[H&8#D8]U73U/ALQ9CJ]X="S1^Y 'ZH&\S3'L4A,
MU5Q,'^Y^/)N8ON4.-M(XXL:1F\4QIH0\TCQZO=0MK\8\.N(KM4ZE-W"&J'6.
MU:I.Y))FZ$W92$\GJP-J\S20O5W?L*SNUE!:(:L+XMA3WWU^?&?)]C%HO65K
MZ*I,Z):QHB?D/GHI:^B8;>7>+.JL]NZSN5B/*>GL6RN%+31SMA3"C7WLWM.1
MYT@Q;3%8OI2)\P@Y76^,]XQWG_7.0'T"^CD9"6J?[2-#0:_%^-G0O5Z]\YA/
M3>,D?>L6"NIN#:0G$=2G.]25@MI>0=VMA?0D@OITQ[JO-4*TXS1]%GI;)^C7
M^9 E(><S3<V;P:FG(N!]HLS&7A\S&\V!_D3A@]? O;LF["!57:KZ6ZSCZ=E/
M5,<C55VJNE3U'5<(]09/4B'4 EU^C13:9YR99!M*Q6<V_&[&3OH/)/PZFTSA
M94YR$B:XY,I)MR90[A/;XB)_LE*A,%W.P^(G%?XIHFZ+F7)/=&3(H#5$!CS!
M$Y63696L47BG&%ZYSDWG1;!Z^&7D?G,Y =?R%\!P-*?:2T#@_!$(7Y@B9=4=
MYU-30E@71=.5"2S1&&G5UI*.KF:=6<8M1AQP@FC2N87/D\9^+T1$4TZ0PZ<&
M'UO24=*D(!5BY3V\!2IW0<F%=&_$R-Y(G)Z_7^LYW!K8?Z: /NX,10P&CAR*
M2&"&2^ CY0&1FL%<3EGH!-B<0!%+@F(3)BP7-U!-@C$ZO" .3Z0I(R$0O,EP
M05T"1WY MRO7@Z59'!:L>W]TK[L-W*/_S&(_\7Q7W/$0EF1*8:($9!,7 _^9
M\@6*:^2-%?XXI%C<[/XW7-?PGV<W5<^^G6Z>.@6SAH&Q?%T.0^],+-BAZ\89
M\]:&RM02G;07\+EW-SK]!6R/W8W.>/<YC!8VEO5_X'2JA9:#QI=*[H$2 .H]
MB/MK(VY"XK.SK)'>Z]FF9ZFZ:6B](1N!"=;K.3W-9##%W_O8XV\UF-KSY[U&
M;_Z\UW@)"K9FKCM-[_*Y6OSWF2GNOK);)SAW4EA=E*\C6H%;%KJPO(ML=GV3
M*P$L$O,.4>P&?5M#X1_V^O!H9@W88.".=,_6;6:P47^>_8Z>IX@'+AB<&VR+
MY2(UL2(V\B&N?<=EU(__S)+4'\U>?A=6#1 */.!04G_"30W\O]CQB+[8B6?(
M-!OCWCI2AAEL:BQ)ZGR]@L[9#^^BX(YS(]\YL =FB1+0.KB!XT^X%502GU9)
M4]-Q! ^8<AN+_A 5+6EP6\=OLA! R*6-?(XZ\#_!;("],DQ+CFK$D2" G3:#
MQT]CW/33F4+NBJ!:AGE!Z,'/^9_KYH"?\(?3ZX%I5>0_5)A;)UR\Z@-A#5<H
MGI^X&7$O#QE8:6@G( 'A[5@8SX)8/(S08,QBM.+X:](Z9"D9)7S0"2ON"N\H
MW@IL7S0L/09_1Z,"G*WZ$I77P0OX[(XEG 86M*)R8[%.B+U(2LL\:A+D5%AR
M(]X1R,%W '%#4\4#HSMA<_9^N3(C>!U0<UR&M6;I4IUHTL$VZE)5@G"W)6)O
MW$.1]A>M6%A+L.NX5''=J,QTI[( H$RP#0HY2JJLQ?"%(>>XQP5TBD[!LX*H
M&,01EQM)R(4(E43 HED(B1N>=$8H+#,%GX5+6N="5QAW+UBM[0*9Q-N\/+TH
MIZNNN#[E.Q$Y.9\E(AZ_!]4E>G9T#*O/Y2TPYGFOQ9B*+87$=,A(9X8 !^6,
MX70L#!H^F&]4PEU1OH!$0%^\'RWBW//00@&UC4#(<::(,)Z,F1KXU4F?2T!
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M55JU'V.W.I=+GD.O6ON,HW_E"H\A:3W?'!CM?&4+.3_DQBR/NY0)9$-6R6L
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M'FZ-/29AZ^E]2 3RP>N'*DE:L)JTP% E:8$D+9"D!9O8"[:,X>RKO:"K*GA
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MG_87D"122Z1N&/Z+Z8@\TWGY,QWSR<]T/@XC;P;_&Z>3X//_!U!+ P04
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M) ].RH14%,F&D_"1&C_'9:0DP.5OPDYU71;CO)6Z764QHJ55$^."IQ4UR7T
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M& (2<43:]3<=.I/U"6:S/+-(+(L>8TA8+/#G4/SE3O MC5GSU&V)Q(8)75U
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M>&UL[7U9<UM'DNY[_PI=S^O-5NU+1W=/R++55Q&RY9#M[IDG1"U9$L8@H#D
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MV=8!J1GW%8![<K885M/_6=/I,LFRH#-):9J36!-(=(G@LJIK72<E@]1*]2E
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M6JY5PO^OO6]K;NM(PGO/KTCEO7?G?JE*4B7+]D8IV53)LEUY0O7<1&0A0 N
MLI5?GQX I$@(( ^ ,P!XV:VB"0+"Z<LW,]W3MXZCL]>_^@2IV,<%QMUHQ4&2
M[;L8?KD$ZT[^)U;VY[-7X_0[R7_V"_Y=2]9>??PXS1]QGB]*R=-O05HMM"HQ
M)(AHR(SGT9,;KA1HZ[BAWWPHW:)2^U+PO%!S%#WU;0*M2/N>]AIUS>G'JTKG
MA\O\C@B>I$$.W/OD"S!T9#:8DLB%YPG(<R>?/DHNUDOUMT!JM^<^+R UU$D#
M]WIA+=RF;$G60CJS7_-?B[=F@Z01"T<)Q@E6QXA(\$4$T$B6IC=2N497+=WH
M>S8(:ZBV!KF%[Z:3F'.:_4SBN\X#N2@DL$^3\8*#012H=70!//UK4-XX\&3<
M B%?6TGNJ<^V":X>).W90:I?9?7= ^X6'7_@Z"J_^D+>2[WN_'DR_?EJ?C7-
MUS0/(C(NN8Z06!2@BN00DI6 .JK$A)?1=.LOU/V9SP8L+771(-/P=D7H514H
MO5ALD<NM\\WX5H7H@&<L!7UM*JL5**$]('<.L$2I"B]!IC;5=KM0^6R0UER%
M;5L]O)Z,9^2%3A?">I]C'G[)Z>(.L29KP9-TH)*D[91S2QMK2D2Q8MX;8D2W
M*='8B<SG#+B>E=@@"?*Z0'FU*.Z3VFR;V)910QYC=,QHL@TY@JKV8K!% [DG
M)6:O3&2-+/R^6#A6HMVI\7D2E9]+)M\][3TLCS[39D_;?JB]%Q($Y!E2%MRZ
M:+)C;69]GUUKI1,AI'M#IATT=9JF.ETH?&G(M+]2]VC(M(=&3M20R;N0!*T9
MGPW9H+1&R"(P$HJ47!D3%'=M$HL?7T.FMI#911&]IQW./USF7W#Z[SR_#A=<
MC[Y@2GB.Y PS50<RLWK?*^G\-XG(#-*;W"W*M_41Y]EX:1=E3'J79(]1O;L-
M1Z-G0A<O:KFV)OL?JR67%7#KC6)D_PO6Z0+S<70_/JUEL;_D>PR<K#<L[4+&
M4^V9O),*MG3;W4=^#7LF$Q5!.(-T$M7Q-9SVDQ!2S1<0@G&KM%F?M';.:NS4
M,[D/+>XBMKY[)B_CK=<M\3'[8%"#DV8QQ=,".AYJ.V'F-'.UF7!O^KOSZ-/U
M3-Y)^),^)'?$-,#OSYCMV6RSO7,!=WM*7PF!!_"VEA7H24>*,"!=T,H4[Y5V
M7MO +%G29& -]GC>R5,#38S6EEA#1G7HGR4; 3UG8 GB14GDI5$+MA.G!N[]
M^-JO:E93/Q=O+W- +_X:Y^GL<OCY'9EY]$'\6,-T[Z:9U)RGGXC@]-/?]-9P
MEM]-AS$/?!:15K^ H*ROEIDD^?M4.W$SLM2%\:[C!+Q3LO$HPQ:[ /[N2+Y'
M@Y@6W?8KZ>%AYL,Z\]==?!=<W$EU6'$^<#:ALLJ!")Y<S.#(:S5T,*HH(A>V
M,-W-&MQO!VK"T[-9&&<&CQ:7D?MR]M/?GX?+H.8J"5$76[@16+N"U5 FU^!K
M2[HD+0O2.A-UH^!?7RR\P/HHRF^1@;JO'!<__LBS^4WZ(Q^P3/_CJ0#S2M"*
MY JPV#KC-I@8M.5!^_,R&3=P\3RQ? H(-,AYW9N7N]E-KZ[FEY-I;:M&DE4F
M.F<7+8VA#L>N@YHM)"&LR=J+HAL:(7VR\@+LHX*A03O/O1E:ED-\*V:=7<PO
M\_3#)8XO/M>OF/UK62-Q?2C%G'3Q)H%6.I%!%0*$+"T(+;ER7C*I.]WC'0_T
M.W+XLA;. 3H-<HY_^O1Y-/F:\V]Y^H4<A\UL_SH9?Z%C*R]/L-F'R1Q'M]^O
MW3)_G<S_3YZ_SW'R<;Q8^]):%[-24$(-FBO,M0=Y;<@2<Q0E^2AXDS71C*5G
MMPC. QQ]MU5]/9K,J@7VG:-,'K(7LN0(,6I=&Q58""@SY)0L9E$',78K8MWZ
MB&<#H1XEW2(1>5^AK/;PZQO%FVU\@?HWX_ET.)X-XZ+.9(#2R>QT 2$] Z6U
M@E *@BVZ,#)^9&%G9@GOP-VS ?+90J9!<]I#>;QKVOQ)>\!E/1>^Y"E^S(LW
M?\1Y_AF'TR6[,A:>ZP15CZJ0[9,D.%$LH!7>)QL$LC8SLH[,Z,MB.2,@?;]N
M_,FNME?L_K&PGZ[9O6&+#ZQFZ)*))'1%QZ0H@?SGK" '%;74V7ML8T.WXNAY
MKH130V-#-.?@..8M:^XU?A[26;:\_7F?9^0MY/1]=:V.5A8OR-.-B%!SM< +
MC^ 44ZP$7PIO8P_M3.JS0VE;96Z 7S_1Q'T$]BU-X*)<7,UG<QPG\E$6O*]2
MS 9&^,",+)"ME&2&9>++%0]>Q2I-35*6YV67=.#JV8'Z;""R ?^GBT->W]5_
M2Z;[[M9>>2)>A )&R#JDL@I=!PXV">T<L\9VRTH]?@AG.U,OZ#\10#: _VRB
MEK<Z@2R<BH'C@?D0(FBN/:A 2]NES BG)@D45@C5J,E!(XY>8'\*:&S _.&Q
MS/MZ:-U<U"_RO:XSP48XG@UL<=$F+8"7B'6@CH.@%+T,AJ%23,=&LWOW)/CY
M(?8(BMT R,.[%6VF>^&>;B5[(%6N+8'IZ' R@')$L,\V0&+:)>Y,D*'1C<8^
MY+Z L7>E;H#BP9V,?LPE3Z=;1?;G<'[YADSX+\-TA:/W^3]7P]EP?AW5O,[$
M,CDIP:RC;;TH4,990#1U9?DL;?':V#8=.?J@_MD!]>@JWX#;TX4A=TPR>?@"
M'76=#:\"V%@SPGG(@-%J\#[D@@P]FC/+1.U;!,]N!9V-Y'<"WX9E>'#8\]5H
M\9F<-HODI[_KKWE0:H$Q=Q%,8@R4L!ZPGG*T;\04H_91M.FXV(V^9P?@!FK;
M@*Y^@H--UMG=V-" 5A%+9&D!4SZ"RAX!+1JPAA5:8L)E/+-\DQTY?'8(/TOH
M;"BJ.3B8V"S1<!4VG4Q7?ZJ?XX,4BI=<:A#%D]U'KC(XFQ/D)(JS4B2#;?).
MCLOGLULO9PRC#:OF\!AH;_V-8E")6\W!>2M!U;9FWB8/5CN? B\Y-#)MGF,[
MU8-.A).H_-3M5.]V "(H,8:A@-/(JJ\N 17G@,:R9+@(6#J-07YN3<QVTOC&
M)F:[2+YAUZLN9#S5)F8[J6!+^ZM]Y-=0G<X$%Y1F((PEXS,)PB4S6%]*XPQC
M7O>\GD_>Q*P/+>XBMKZ;F)&DOK7BRIY)#+2E>%63;UG6$+Q/4&MXLG&!H^AT
M=]BMB=GM1Y^NB=E.PI_T(;F>>X+>[:;& HLN& U9,ZQS 2(@<@G9\,*%<HZ+
MV)\*SZ,/W=XJW%MR#9JJU/!;;6*[VE6D4388,!@S**,\'?!*U_,>D],F:-VF
ME_-M*IZGG72P/AJT*KFF9=73N LU3;O$WZ7G-!WA]]?/%D4?(-R&V\&**I^T
M,JCI?)%U!%JR#H*4",@R(=JYPF2;J-XQ5/U (_=6FMY%IGWW:7^?9_,:\/CP
MU^3#Y>1JAN/TX7(XG><\OK[QK8G+PR^+M(SE";4ZIZ1&I6O;).2^MK!7#+RN
M;:QU<@)9(IMS+:=W2VGS_C0<_SKR$-5-CB_WOH<YOQFGJ[@X\2I9=:FNB.):
M!96SA)*EIA..Z'$\Y7K"632N:&]<)S!L>\+C574O,NM[W6_"W;9DK.O^R#6D
M7K2%G.J@WA(4A*0LZ"(3,YY;V7$\^^[/?KS*;RSG)@.1:5^J:'T]PMGL]K@2
M.M%8$'6XH)7DWACZS3'N(3BAE%1*9-\HHV<;2<_;,^A'4PU:P-VF9[6 NE#4
MU%7XGJ83#9#J1VGKU9;]2+R!_["!LI2,K DT8+TFRG3MU))0@8J>J8"2MMA.
M5T-GBX&'!D(="P*["+IO ^-_+5II$T$?\GA5_7@Q_64RI3WSC\FB7>7DKQN3
M-O!HG"$C*-A A/+B 1T=><2N(D<JB:18)]-BEZ<>WZ@X5$638\BW08/RY7E'
M'UZ W#*5HB-H<\83@;Q(0&,X%.>YID,OH&HS\OX.&<_;=-A?(Z?HJ;E5$-_8
M&*<UB[T+3VTG6#;@ZC0FRP%@V37[\%B:;M6,OF_>-!IMHD]@BR^T<2<./BH/
M"5,L,@:?4Z= ]A-&[P/&UIF#=Q<%MP!M-466";PK4T'E8H/*##*K,4S%$*IL
M())9&GG!X$6C>O5U4LXPU[2YAC?53NZMGKXO?\G,7,S(&L?EW=7OI(_9N]]^
MO\X!2E%GU F2KW%K8R0$6F:0A76<RZ!%*)V,^/N?\XQAT;<6&FPH-:XQ'<9:
M0G-#W/L;XEB*DE8_[;PY"?H1"FV_.8",-EAI1>"^S9B5>\EZQHCJ7VTM;Z27
MD;$JLLFX"FEQI ?%;4X<H41%.R)S=0HRBR!H3U%9:&5"HT3S^\AZWNYE?QIK
MT9_^+DVKU=.%J*;^XD:R3GQ'?;CZULMI>I-]@[-K,W%&U=2](L"+.JC;,PM!
ME *>\\A$1*$;-7$X(B"Z7E@?"0^[B+Q%R.);Z\K5 6@S\1&"!E:2K;WE/3BL
M'8&C$BQG57BKB,4Z*<>W57I0T?;6H'O(M\7]]$U?NG<X3&_&JX:EU].E=8H)
MM8-B%L1E U@,!VVMYZEP<KG:]"Z\EZRG (3^Y-Y@%UA-55ML<2::K',48#@/
MY'5S :YD!&.RY=ZA%K:-WW*+B.=M4>ZKC1XGO:R1<HW_#L0TM1OOD',:>W%O
MY6Q6\@&2;;</K(@J/)D88H(8?4W[S;3QR;K=J6QM9E*A;A.\/(*:'[ "VVAY
M%X$>+VJSV+1H7Z.][V)\7=X3HI;*L "!6SKJ;,'E@>2B1N4S)PX:CD[H1N3Q
MS8(#U-DMP'*P+EJ-7+^7U ]_3:Y)U5S5LC#(R$1-OJB31,A6DF37)H]&QW34
MUN^;B'S:L-E/%R?9;3X0 JXQ[AU3'!,G ZGV$E0$[^ ([9PII:74ENE3[3>W
MR'SBT-E3'UNOP?_[/]?D])9>+MY8_+W*X7TN_[7^]_?W;VYD]M=??_TC#S_F
M:1A._A$GG_ZY$-C"A_Z._NOV>+ALCX>SV=6G98^F*_KD</S#".._R:RG;YC]
M,DF$B$F5Z"><DS$UG'ZI'?0F95:_>[+\=Q]KA[V<?LQS'([NLC@;?OH\6LM!
M^#ZN=QI"__E-KG?EO:+V#BK/5L+Y[WD>ITQ>]##]C_\V%,4(%@TGQUL2Q!F2
M&295TBX@,H5R<!J23]31[NU-#QPOK=9&%'!)8%V=]0Y"!S"VI$P>)F&QS1W=
MX;2?;%C83</,5]_@4)L<UD#@ASS]Q >8@W:JMCKD.9*=Q4B^BB<(0K+@51"A
MI?'2A*<S#/?VB^[>!H;U"X]69O@!H]!NC>)9ZRG[/E?-TM]?3\;S*<;Y%8XJ
MRV(@LS22,X2 N0;#(P?49$QFKHAA4D\V#0=Z')?9EZ5R9H Z1=[J-HG?MSO\
M,1G1UXR&\Z_OR8!8M:@9:&>C,F1 :R7JK1'R.HN6$>"9U*B+5=W:,AWOB-Z9
MQ^>Y8LX//BW2D([ Z6H47*'S$V-Q4)![XC0Z\C0-@BZHK#"T630*.1Z/QY>%
M<A[P:5#^VRNG[X>S?_\\S?D-^9I3\DAO;P@.4V:J!"CD_H+RP4.0PH.(23/I
MM#=X9K/5=N3P99&< W1.4?)V,)^KK4#9Z'C!#(IG27P6!!]T FD1911"^N,&
M'WKG\&6)G -T&J3I-CDO?ZSCF_(X53X'P3*KT'*PKB106BCP)BK0,=M0&#K!
MSNS&L"MK+XOBI&!ID'347Q96L9:I4#+D+.O)1RSYDB1DFZ(U!C6/C6:Z/,/&
M_ =A^B0J/W5C_IO<T#MUNR)Q[S0WA*E$JP^U!>=" K3)&4E>3F1M;HZ>6,^(
MG9!P;\^(733R6*KMN_#TTC.B4TKH 6 Y1MG]/II^+"@N+(?$R4C)N7:FU9GL
M]CI(B"?O$YJL3*,4U<>#WIUZ1IP=>'=1<(LRN=O]*^\T)Q )LR[1@ ZL@#(I
M@$]*0\S<!AMKHDJ;:^NM))VA(]1<X]LFF!VDKKY[2?PZ&6\G3%LG39W>BM*2
ME>*D H?> O>B2"4<+^L]2+9TDKCO*<\8&OUJH,4<G\7&ZS%:R<G1+J:6EA5O
MP!FM@2GFG1<VAM+I>O^Y3>7:Q\C?7_(]1EK7YZET(>.I3N7:205;YCGM([^&
M4[DP1]3*%4!FZ;PIV4*0S('-B;FLE9>FDV%Z'FKL-)6K#RWN(K:F4[F(V.)$
MT"!-J&'EPL#E%"%8228PK_VG7&_Z.Y.I7#L)?^M4KETDUW0J%QHF;"V;RF0>
MU/H7!Q[1 BO"HO!,R=#I\O<Q3>7:6X5[2V[K*CQ"\<>U&3$I-U.)-S5WPG':
MV$CL59P/OPSG7^G]M03&?]5T_Q]QGF]")GV7@QR?]&8%(B?6PEK)"/%FO+$Z
M)S(,8Q8N8(PV2L859TJ(+24CQV?BY$4DJA[75B<(C'ZH:#)@S!YDX8G+S$EN
MC9J)G4<1R3X4$#B6ON/UX"*"R-7"3;F5#?U^,AK]/)G6SP^<05]RRF!";>QA
M-;FL)AC@W!L6A2NIVW3/XPEY5Q;/\&ZA7^SW%G]O"I[C%7X_S.CW_,TO\_3#
M):[XG]WLL;]>+<=\J1S(;)2 V1@@^R4"FF) )&F%=9*S<F:K9%<6']$J:0O3
MOA934XR=4^G)@XPN+(S9FSH98SA)@^*L%\E)8%;[6B-.VN!)@<C<2NT*U^NC
MR\Y^+=WE\&4I'7LI'8"P<ZI->9#//Q;[Q0V?0@LFM>' #9.@1*J! <<ABL"L
M38X;>68E7#MR^+*2CKV2#D#8.16O/,@G::'DX6U6T0MK S+P-NMZ,Q7 1\[
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MAH9Q=E%>C<=76&=/Y(@SVELSG: ^R 3!9]I;C2O@52E@9=2+2E7:9#O='A]
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M^Z].:&BI;8[2,=#1,;"S,+&P_[<O2BUP\CA-_]$\6II+P)&3-+0G:2B-  @
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MCX*#[E#U4*$'VTVW.'F]#_MU<)4\!F7O4-"8K_)Y>IQ>2'51K]2_XYI6J;R
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M\9I>;*;ZP]WK7SWMU!/?^2.A\(8QV#D*\!.)11[.CU& J!ZJ(70F4+'=A$?
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M@ =HTB<!V%.SWOM7V=W8?1?\D3+O;5<>K+@;E>;#$%2;T/7+5]U$O8)OTE.
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MX/ZM!>]9F%#+>Z*4 )].86KP\I$=M4XVC:BU]1H RON3D<U5[>[&2SJD'(N
M<KA_T6&W5KZ=83Y']8#WU@C,F=1,8C>XEZUOH,9.@X674(!Z9=",;/BGQ<2)
MSIV"?*Y3-J+#=U[-#=P$M-.9']X:^S)?XTL!0ID(< J@BC@%G]9!4P!N%$KE
M$KQE\@-Y=JI+80ZZ5'00\X8: >[?;3\9YU_: Y*E  UT1# %^-@2#L9=GJ(
MD084@)D+1P'(P;S\5+!)<+(D1-/ )J$4Z=&Q^W3UU_+X'^LUB%<A#13@@-DG
ME@(<^;4FWQ0HH,8[&-@PTO!UR_7/M2!<'9R-.DDDL7I$AE^+F!S;<>S^%GML
M]JPMG>@_5K+#_RBC6:^QP9K]N'*RXC^/0*,4^?0O^?^?E_\0!6LDT^/IMLW,
M%%"O3MU9<RX (K" [*TC-\/>ZPG8&@:V+?464P!,$)F:?OZT;4023O]:]19=
M$A$6B=5J>U,O-I$^/T6XCZ;FH-O<>$'RT5\[-A'@?Z_!H<4>5W&8[3]YN]!N
M\3IO%P\B"?['2J%_1[4R/J>/=G_SO^ZEXOSGVG0RMP0U32$=4]*D "^H@T1\
M6!.3AH"J8%8QP_OE?ZY%_$G" ZT(Y?S#L+_$_\_%!U^!*1 D[A)L\5!K7&&"
M<F=37%CT7)O/<F\*3N/BN(FQI\=/5DD3%4%X:YL]!;BOPT<!= 8'4(?6DM1N
M/^,_KI%#*$"&OBFX<6/_S!7T*D,&?*EBM"*GK=W M9C$[*2FSB*^LB.O()16
MT?7?><?KGTR>D&.U\&:K@-L4 /49O!U_EE2&:D2--9!UAWXE5*J_+8+DQ5.
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M.G*T). $U0)]Z4%C?BU7OZ  #$BB=A5R5>(+!;"'YY,&-^3V4F"[BL\*D*]
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MB,AM'E^7[+BLGY=O]XC?RXZ?>W0N:UJS/<N,[XRR@L2;J5*YX"JKP_^#O?<
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M\'[M>',K\9EEC&M0=FL3 M^+$;Q  X0T3]( G]RA9,<R=1[8/6(0@6T*&*"
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M:_A/P^_^4\1@]_(7T)1T+7TW^G%&Q^??!\$-+7?21:,U@?4WT9@_W$X#1%)
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M%<&']<U?-=-^F&H$3C(ODJI.%?3SD*.4H,KS<4#B:3#9CWQN=P%*<C!024.
M&*6&7FU&49ZY(^A"9.BL-:@)O,-I1@,,"^@RJLC6/.9;,*0>]>.:':2>J3%C
MN)@&_U47TY].=(NN_:E$[1VZ_5L#G'-$!U(@"X]N_CN&*./MOT#\7R:EN>/_
MCH^()'G(_1QT;DJIU";?#?K[->B9'\4IIF?@/XI3\#C3I?<A"%56.P"T).-
M V1$5W269F%KK*M5<,?D3'1>KMIY\'V-B-P;^W"X^P&N-B\U6A\A8[3V0H?"
M3<FK/48^-X1V7 ::$(#-:*)FM0[B&]64;LGO'Q^8?5MVO97Z*ORPJ^HC=9M-
M5]PV?;/80[:@?")?GD0+SC?@%DWQ!5<TJTG7>Q1+<:+OCXOFN"8\OETO>.EL
M-^@8S)V2(3REW<K&&9R/):27OBMM21Y"W#]TRQFSJ%JR2%T5V>SQ:IS:JB L
M;N7A$1%DQ7<I/%"E)_QE%O!1]:]"5U\QO3TOT3[Z7DM9$,4=R9$?(:E;2D"6
M5WG<&2*K[(B,/[@K+M47"IXLHVZFC'CVX:'R+HN3H$!U 6K[+BJXVBE]!W-8
M48Y;-WU>_>Z7'LK;VS%WOG =E5X_.O9>- YUGS!;'_5M$=N]S(F%!VY#.175
MM,!\5_;):E6X'15R>%7B]J;_K+?>Q>A1#-OKISZ0 _3E*$6,3CU!_)9&O#8P
M92G'/AJ4(@J2K$QY&<VS6J)-C+$I)UE1OZ8*$94(LXWEE4&-:DK-M<?[2NZ[
M*D0X;!Z0N5/JZ0#AR"OX*'G\W',F(TMFGM=<*==>91E!ML=*#$8D,PNW'\,Z
M4BZZ?S=*=E[)RH<,M._N2G2LJ79C[9=4,FQ@3L3B;,<G"1-2/3#>MBUVC@F"
M3';_Q)USEWECN-, EP./HR0N &Z-$[M)HL3'E_&81@P?8@\8CUL@-955GB_$
M7O# +"M/!YK_(J;W]/L'C36F(^-?[22:JO>2;+Q>-$(/PUQQG(?O;ZG+]I(=
M"T6JTJWE-7GG/QL* ZXY&]WD%GZQ^%S2*V8JX7DBJ5%_$OTRT?Z%C'N*!;N%
M/;4OD;HUG_X@N+9/ZKNH6O_IZ;TCE;?!/-WZG7.QKFM$5!ZF9V-X)N6ZDHR-
M9E5<+9R]Y$EYWGK%$@8(X\$_QGJVZ@.QK0&J['#G(MW\^1B]HI0GWS43V\[<
MJ>?U#;EU8_:+K*#Y)]6#&]97MOR(\"GP2"-N*PJ7=,S8M-<]BGT4,]JACO)T
M\SR4>M/;[<R'^"> Y#/A[<I'FF$)!.C6<[H2DT:Z7$\ D?:2Y-LK/E10VTGV
M28B/+X5A&!G_K:XJKVZ?C4]H%U>Y*=8HL@=]]AO L=(],3HDUJURLL^R)EC^
MRYHZO"JE"H*RZ!BVY3MB029_J*VQ,%W\OEMC_J$PT /I^\B&OR_=,P&\>#<[
M((H/=I9H3)#;HB^K)M1>+RU2O1 BT$-GR48EPM02ZR>LH%>SC2^XFO;^*>"R
MX,DJM2M;CXFN]G@)W2%5>3S)B!CCY)%>VI4QQ2X I0&N][FJ5L>>%QQI+^R_
M%<?T,?J<OR\>L<Q"IQ.]-(M;#8 . QVH&'0DB62YG*0:D<U3WK[6M;2CYAE5
MTQ?IM[>>!B@S",#/ZM94XA,:]"4:J>=K^K22W(HL%AZS0:R8T$LJ&OL^LZI4
MSA;I%.;U%&4H]U4-***V(99(%Z?-'<6T"*F2HVE2\0:=:J":['B'*F]87S^2
MX#2Y^A(F3SI#%B$\>9M)26CR/_XI6NW:]K(\*/5=K;K6H["O?@/'I.=DE":W
M7U+9J!CZ1J40Q3H?D>4P=%%LZ%'#$'=WI3%[;_R7\*8[4H1DM]Y:#SQ\V0%I
M1A;M466?D@L2<HV<PF_V6<^5>R;T6A9617]A+DY'7+ALMQ9O(@IX$3Y86TQR
M 1?Y]XAP$7/=)HF#^JS7+_HZN"TH"QPRNGON@"KJU;T'RR-NY8*SBIEIUOW1
MD._5NQNQSGQK<+&[@E]OQE%ES0I+*Z.K=E!O,8X37._[:UFH?97]O0O2OO:X
MG5[ER?X5V[+;6V]H@$'+S.>G.;]XN]LJ;_"A<*B7:*9:H44,ZT:*,78PK0A*
MG&AI.W5VT?.PY:A" %\1@,-\K.3%=/N[O9%.#<"M' Q^B-$'>Z25+&'1L8!Y
M0/U* T3)]&;L^*JB)OS&7-HWY[6;7$>2J/RLH;6\BU!\N-\+ZF$S9]LU4(EJ
M=[FWG+"]9ZQJ]8[7W' WS/3FP\W8#$%K+4(-0M.@VYZ,F7&VY-)L>1217$.R
M]GBL[X*.IP$27J]"#_H#[HNP4-+4+WAI3"R:7K2)P<Y\^GB^LK S.>G.U5=B
M$<PA,SF8"-0KMVAIMLG6)1)^M0G$I #F&O;B7L7-U#Q:8_=1 S4!;]?T7!+C
M/#7\"W?RK0 7L\E(#E8^>Y(S)6&*LPET#-X@B*9R+XN[HY=H@&4KOY@']U/M
MWTZ3:8#'RB,U/H.0!N (HA%XX(&[$PG^LO)N=Z1"&*2TC,!7FZ^8]_D(5Z6O
MN_6',DZQY-2+1C?=;+HGT$IG+FY:#2U4Y9<,=0T>,&WT!3\9K*YT=^2?(UUK
M[_1VC$1A00V(@"?HCW+AU)->'0T6V<6>[X@AA2?*]79D9,7"MJ6/5;\[WR^<
MN3,LB^U2.;BL>AO?.LGY8@,=D/H+/,BB9AP5%;_?%D\<RK9T.C:JVG:]8MVZ
M_O4EZWJ# SL^D!=Z)+#U I!9U752FG) 5J[:I.A\A7KQL:'X8IW>JTO/V8-$
MSZ9ZAKO,MTI$H!U,"4'/:WGFV+ ]=R;VC&BVU:RS$$2@>&^[#AH LC#NE^^A
M59*=/*KWUH.DFDA7&3'J.?6#&4<4>6L%W4E6W0GX'?>[P)%1K$@,'C(57XY-
M.9!%;;T:.#-R(;FJZ8/6D32[MOJN [-'NL"*4_5.?33 ?50$$(^NE;3Q:B0)
MD]B6#U]A':8.;$746BQW44*2*=*=YX?N\=V,.)*'YBN]<-8(*=7K7LN5Y*!!
M,B;HE55V7:YRN(1T1C(K+$F'CQJP+1N=\3C9:F+KXE]"5U^)E/A_2'P4 )NB
M 9A)PO"[- !'U*[/[P&<ZV,04C,C']*[V^AG8$;]>5[(Z=X?VAS?$-FG<W0:
MU)Z5XPJ:ZH)O"^_<8$V=4^=^76 ;;,.G@WD8J1/O]>UR^XN9/8T R<GP6[:5
M_7VK&75L2+ZM\MLTP$>A-"SIE7/,U]#Q]:Z16W<P#KUC9^6M9F2J8 $A&DP8
M5N$:%1R*>&]0^AA'[PCSVF2 ZJ<A,:PVP-^$98I_TJ23Z]K\^Q=#P,&G<CV:
MO$__G83SO[]W2%L-Q';_?43HY:&6",HG%]F)#OKD=B2IC[>AGRQ'(3:]6E0V
M<;77X$3)S8;BO=@B^(H*#3 VL$P#_/2\36DKZMKN4EFL?9#^MGWKO;BC9V6\
M11=H *(7I9O" R87T0#;BD \@838/878L:8!5AQWKMS?R+B_@8(L$%:\;<:W
MU%$T0%#4& W0HT #M*_2UQ7#F1I800.DTU6^. QU!A5[/NH:_9\Z2@2[C+'[
M2^ SZ-!%_@O\_Y7 O9#+QT@:W21-*Z_;28T@?&0$+QT:?;\9@:VJM-, V0[E
M(I!:SR>MZIXE/H8E/C?>$R[3P>01(ZL\2,?A<VR_QNDY_BE.K\VT!!T$O&IO
M28S>O,TXG/O+-?C^DX, 9Y?;Z=?\_W;-5Q#Z(WF7J/ROR;M&'33Z<MV@1K"Z
M) >'>OJ7]T7R#L@'R)[K&LY96:/7^)^Q9XV"1_7*<B!" B,)SB"&1P)?"\L6
M?1=EO&Y;W?KAH?##1X%QCI# N__7P_8TO[P"Z0AZSTRS^<5C)@&/CF<G%_<W
M7'QMA[1UT2CN&[SX1MO 9(//]-2TTS%E\6NBR +_ :O,=6 ^ @^F 7;. SGA
M0P.SC'1?@M"+U#H[X$>)H%:*F@U\_LI0C\E.BQP%AR0B9OQ# F@ 3R25[T=F
M.D8!=L7(@5-/CQE::\]:MB='M$,BJT/CHY^JBK3>_!1EEG0]J:F7> _'=_9]
M]7#.-U:GEMY\:26#E\_&G?R[&]652A,''51]CWVOG2396][XJ)V\9C0.!J^\
MMMS-"AY"9;W,JK2,B=B^XF6WA*;X9"DUHCETJC)](?Y[Y2\AO-Q:CQH+AN$X
MN:RC^"R\+<8#NMYHQ[DYW?81BX-*B%U]E: 6>/V9EG>KQ:8,\XNL.A-KB,NE
M5]_1/(M6=X."G,E*Y^H=G<5UK3ZT\EIR2H@E'^(&^TM7%7=_BY$NH0'<M]YI
MADIF9N[I^=,4\=YN!8>](O,2X:#@)'WG>TMC5QP<LK658H>,=; :^T:&E<?\
MYTFEAF&QL::KX&JCZ-!'OC+^4U_OHY2(>PF)G)&I "C7J<01F3%/8W/K>10H
M>;"W!>->-M!U,]^O9^A8?J]4GG'<:65]QV"DD:(MDO4=?0Z_?6=XL[1&PUI"
M$UWSO,M9P^F^V-LS="DP:-">^1+Z1'3OHHV*!PFLB06^2(1&J7I,=GHVH'SA
M6_MZRLXDG#TK5_HYIEU%1\,;L%XG&E-PN@M9A\J#*A4G+V@AFDCHJL>C<RAU
M(H(@9X&7F0VXW0/CR?-J4+/=<7:YU]?&AFQZ0MV]+NJV#N<RV3$P@_@II%K)
M$KL&3J4;N@6IC$+K<MJN6>7[@;@V(*'^[4#A4E24"-. 1^>CKH;VE3[3^&8>
ML/;-LWE:=:]66CV['G<ISTF/+"STQ@E^ KMK7GR=+^*UC)I<HDOU.XZ_'V7
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M 25@-C/XO7G1YM==[P],)\UZOBP>%Y5_O-E\.9.HITF<)6G"[!)PLEF>>[W
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MF\UR?\7 Z@)CS"-$XK#SMN7B+ED_"S6]\..C?S[6TG^I+'_+BVCG*.?HO];
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M@2B/HQKA4NU23$*5JU51MO>_\:6].*7T.9,P%^KX]08Q4CV*YX#_?!BE'8Q
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M0:&2^R'+=4C<6!C! U9/)-I3 2HL]0BB7"D5,#G/4/DWJ /\B[:_TO8G_2)
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M2RASIP)$1D-=WS'\E/I!#)HT#W!A\Q)&35Z YOFN+34]0#(6?=A.G.M"L]C
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M.67\.$F6$)KN/J7.5>*H:=@G(B:2CU,>2AX[^]B^]+7('8_#JC=41PQW+R^
MV16/D2[T5_/B.S"3+]*XOH3*E(4UBWZH#?<^ESGG\X6]]9& .W20"Q#:#NWU
MW'LZ[\="NK*;]"R0;9@(;*H5BC'9%'4+\)K2[7RC*<<OEO,9^R8VYD#+H1.@
M[U60T%".+'&1GY"$K/GD4OBC4OM,;TR3_NQL:/:&A1]J+6<4:[@*[Q4/ILA6
M$616M C8!WO2*1F++D0CAFA._3VHL*1KRS>$]9&'=QB/2QC&N,9/(O#:V+?(
M:B6"W^RDJ9C857Q)8YPF'X>=]8Z(^J*Z F0J%572NWEE>49+ =>V4%NULS+M
M'N"YT>SH*.8,#M.J+ML8)!\C(RA,1+.I"60#F,.<&#@UZ3D-2@O8;%J+Q&JB
M\*5#D<5Y2L]PM=;E5V+,/QXG (F"DUDDJ:NH;YQSA<76;>/;?(@V]@V>81<-
M[&(G=L].#*D#3D6S&+"':T1^^IBK#NX>VPLL7;%ZG6Z_9P\IQYWC2&);R?P]
MU3)6DVXC^15'8.6?X@@L"T<S:98B2E^+7C_)M$+_E,0&Z$+1[33TA!.!Y; Z
M!> ?<D<J9E,!%Y<0N[/CWVMI&EF0/ZPUG^A.J47"?J8OS5N8K/2*A4\<3=DY
M1Z("V$E^:<@-Q;V3I..!D>ORO4TPF9#-A[Y'!FB[,B9Y!UQW>RP[VP<.*NKS
M0'V)Z)A50;VU$9Y5YA<*2ZMX<"%BEV6*(V\ >!P*5D UR[U!585%)_&'GHX[
MV@3E_138E;P*OWQ,S*HOP<2*^RBPC0IXG/,Q+-5CA)FHEZ#B@P"-+K@XG&2Z
MW\/ H;'CQKXHX>>9FU@Z.7#TPXD?19_O=+BU,' )5""3KI(_E4"\=)-MWZS*
MEXTP*O[P[ZMT7E'(D\ZWVR(>M*>X[5"TF7Q]=PJE-YO\6$21D->%_?DYBBU$
MALG'A N!0B,\XD4.X$>GOF682K^_M=WA;FD_):KL29!&NBUPQI/374^)+%=@
M)3^6!3(ZFZT '^^U95\BN"]J!)F67$EF>H.]/H)%:5A[;&%; M^L6"H1-,T(
MH2E3^8%MZO@4A\H[M8GW9^.&,DVYL/X2%ZD W\&',=*;LQ45;+DE;'&]R+A;
MV=U)XGP)X^Z9Q;751M&/BLECMYZT%:TM"F.AO"[F.(9O2@9;YL6H35[)=Z"6
M;1X)8A9W84DO]-C6/;Y+B?U=UP0$  3,#J8??7)<S_G9EHUA^.6!1[U7(9$N
MRL]O,HK4^.R$9S<9;-G+.,=?ZTF0RJV8'-@^]P*49M9RHN<BU_%E9J_@7H&^
M@8$4^9[%<VYM3MUEP^]%1AP[D]^!CAW&-$(\H\K")LK?JK5=>FZR&S 3WU-"
M8AV[U2=O\<BS1EI.2Z[CY2LV06/62U.S N^E9M0D7@QG?>O]"0N?4ZYT*TFK
M5>L:Y\C ?ABB*2V"L'E12_UD_?R6M*0S415>\$"]8BQC64\IS,&9$QA&NOZA
MY',H+@/=P/_"YH4U"U]1DP\'@M"SWF6U?/GB)C:>"BBVKA!^?!8J3TXU'_4]
M8\ZE$:VM_E,!T@@ZYQ3V:621DZ!\,<2MZ=6%C6? ,\\?!$Q_ 3MXW="(*FX[
MX=0U]X(_[O[VA8@L*H!)K*5YC(UPN&0L=?;HBK="T73U(]P[%I5O\FZW^P)/
MEE?NG0"\J%G_+59%2)I!F=\EB@E6_'RIR8^MB,U5TC=;#MUK2\R"Q1H6'<\W
M5QH3!1,4"_!AK3@+05CO%YA05I[T&@?1?U\U0S2P(DE\MW5';FZ9E'?N'<QQ
M<*QJJN6E DK'][2#NQ4^C),U H2#")UUXLP^O4WG["*&^Y]6@S(9.7;?G07%
MFDE'M8CSWK;JM%2SOL584T8%Z",TXG)NO.:>7+855/V 2NA>3ZQ!0A_BESLG
MS$4/]NJG4;Q\"BCME:>9)TS"<,KKZ)NDMMBN*9[1"7A(::7&PFY:F7W6"#&.
M[4#F%W4.-F<CYF5UWK&IP>-K\]F-JHF7]=XM-"_EEZ#G7:U<8,:5[FX6XMTP
M"VW&29G&[&I.J.B*B#XY'Y5"=MNT^.Y85AKEJ"*+FX[M.JATP*B#^; %FEB!
M4^"8[>@UQHC\Q"Z]M'Z#;1?831<8N2$M\2SMP%.["R ^@G_#;O3<2V?C[T,%
M:B^APME/) J_'O-%M1Z_+B_HN5%K\_PU0_GG_)\L9WQ 6H3'L2POT+BKE%$K
M21E]"_/\<G''"Z(GN[Q92DX\8CC7^OJBS>7*UQ<GD>CLXG=]".>[Y1A%81^U
M!K_<A<HTM)U=P/D<S1-1[J<?9OSVXL1%.<R)048%>\^UB+33^%J49"JHD</X
M=N@IU(U6N,BM>BZ6>R-^3GP*N=$]BIP.9L &*N#E.>'&),QP0IRI^8.;@I"O
MR48UA2+J$USZVN<SU>?=C4 -8X+X,?B4 C/O<=[35(!SZY7&<\$TS9XKF3WZ
M8R4SCL!E\?Y#ZVNF+H+:%44XX2>O_"[RZV#85&GD9Z@J%?#"K6/UZV!=EMKG
MD4493N9GN7D_#MD\'A%JJ'G[]H[QV=8.Z9^(J+&C&'F<[:0Y5_+99%ROK_%Z
M M>/9Z>.:>6TN$Q,3&!2-?%AC:!AGOS'CKA0T^HK[^T)(CW9$9#<6P6VR:-;
M<<H2/EVE1R_?C9J(*)I:86A"L'K*W9K"/TJ6]$J6SGYBBZXNL4^#1%J_C'WY
MR75FE4&D\4+"SIU#_;<]L-T4Q7O9?:6Y^ VYA=H;Q*MC(]IC5XJ>)-N+3CT9
M0:?P^\LW10E>5:["R+GW[5XP),@TK=Q4Z<*8%B6V&/?R%^Y!W57\V%IY4]G,
MP[ZKULU.E_I</.$>>S5I8FB9!)K =A8V<&?&XO;R%2)6R(T%6^9Z=Y:-N6Y=
M@):O"G?(Z^&3&BM#HW/,S>R]BJN[' A-AQOGBX"(O/P?0B/OA)6/R;OV<DU^
MN)ZY@MS,=C)B_TE!R=7H3*F&PW"I[KKXM'2[22;R5<R>RK)1!&IKWFU6?LK+
M4 +$9='DKH*HHQT#2Y:2P2UQ(^#%;7WVJB\QB],U)15"QZOU)FRB3L?YSA4(
M)Q+#72<5K!Q+,/C4L8A=Q53?$[I:4M4]XZ,CS1=#AZ^?@.]]6,[[L>=[3\Z'
MWP\3XN&.&V>:WS4 OAF0=AE.XFTJ.CCW,W<NX>Q82K&WCF4JNF#:+:>CGWTE
MIQ<)6RK*56$#<0W\,X;"%?B'#,C]T'\&LV*Z)V!!T%HK$HR>\'F>Y^'_9MS"
M_]?^0$R$*<I][T:=/4XI7O+5N*H<7* \K)69'C/&>O8C393OT96JF$<4=Y)>
M5CJ3_5NH@/<1FP[KB*$YRCT+&4K-%!70I>)7 K7:5@)'C)?15(FH0F+(+TN#
MI-2> 3@26"9+*RSXMT*CI1G8OOGA7>>^^2%HA9Y42X-SN/9#RX^3^[)1Q,.+
M9A:H\JS#658/',\[:*%0C?24WO3,VZQ1!G07E<*"FXYRSB5TG);<F7U/E+J
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M7Y#<HH,*4S;D(#)Q'3 -5]B-\_V\%?,V]WP1<\?@I]%&=XDGB7JG/HM?W-4
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MJ1?>/+6D(P"Q_['H^\A=O8X<>[PQ8$>(R'M4Q4?_?XKH_\'DDH2FWKN&WO_
MW9O46)G:3E$#[WGHX7P#@.T!\YW"+LVFQW)AZ4=F7< +16Y#T/'$\0U T^/B
M]6UVU2)3WYTG-R&Q_>9<78.V4S,;(1Y-(H>+<6A0TDI=76:G(?/#PET>IK_@
M>TVAAN 0#\S%BP3D1^^[!R^T=1HK@UV[]Q&;".:U6T_G76[M<E#YYMHXDC2K
MR<&6R4)N:*=2 I>?PV68G85!G^QF%9K9N CX9@T/@NQVY[%T.'OI]+Z(WVX%
ME8C5#-/$:XL;10Z)Z&20:)*26%5J)IQO=M@'YY&[ <E;+4*^PCWFMLXNTT9\
MY>M$GPZQD,]^<#)Y_O5MT*LT.Q'(*X39,C?6; T(L!5-W9XO3I,EA\B?2PU%
M)JF0FBB=&^V\N0:B2&:B\*2>/$23K0- RZGVR> WQ>P10XFJ7T]=-M&GBO.*
M/V@_EO1M^^B(]SXI]ZRK%#H][+D!+*0]QG[%D"*ZL\@BY>)+O8NEBB9E':4X
M_GVVVABPIMYHMIM'+N#OV/"5JL!K=?!QJ8TW@-F(54NL1'<-I,<HPKNFO.1*
MNGE?TO*?)*+XDX; G$[%.V#=Q%JGI1'XTPW +0&^4BK2.?: +/3']K9SB +E
M9-:HH'9]0P;B$_[W_%XN-_93<TCG'$^QFQ-GB_SX_0_P)3L<Q.P;?MJ6_PH4
MY==&ST;6VBBC%TIQ].>M6I.][Y[G$,X,+/&^ L^%_3%UQW*<RND[-D<2]_?L
MFJ79CM5&!_/R+'1<%DN75VQ%'@9&"A:,PL<.\";HJ;+1#!M5JLSV12_8!,B@
MSZ'$=,1]XR=+,?E@BU=0$$R\SV[.>UH+^_G'@MZG]62#+^8\<="M,#LHO64N
M_W5ZT?C)%S-3=5[&!X4O;0+M'+OLRUJ\H;_][)X$[!VSV26KBW0-72A$W #X
MG4#3[:'8V!O ?;I8\AM OO\8/L[C].V>F*BV[9JIBI+_'N3SLDM,UZ8><D4X
MJ]C?9>9O8!X0!\3J"/0E[ZMEY9UYSL9DJ^MD<<)0#R\R0U_&79:MGO>\1+?T
MS' XV25J;31YI@GWK(>EFRPDCEQW+;=&G,GU'S(G%7L5XZ<KBS*>8<]^[D50
MZ2&_QGFN!)AUZ.?"63?8HI,KPIY-??N;GNFR_M9#) YSV#="A.R=]O%D>)IJ
M(R+K21V,?4$PMB'RT6X^NXNLO*$ OS02G"Y#+2;T=O3;TPMK=:/DOI=GM8)#
M1@<I>\POC5N2ND?U/U??CV%U)% $.)]L-!X2XMS1*[T&+[Q >JG(GXXQO[O=
MXFCRPV9VNEM4=LWK1)0JBFW0OR/YK%/2>8F=S0R$__1JSAL%Z#"_EGLJ9N<2
M%Q&_TYPGB'/ GOJLC0CO/D&?EJ/=ND*;VWSJ%DG[%]^]T-VLK LJWBLWQ EO
M14EVN']([HV(*\ ,=RL;OE>GVC%M-DF0?Q[XBZ9*G.)ZYU3-P/8Z'8&S/ &=
MG$O= /[ N]MU*"A/:CS-\F2+."]X3ZA=GC[PY@)3&*8+QWJV3+X+IE+4H-C.
M<?V@2^=TX1H+V]KD.J\$H*^+$?77Y:T:\T6C23"2+W*TV>3T['W]LUU<$MD;
M8 ;&IGHO7G9%HGW#$<,0=PHBCQQ_I;6&S>WY]L?8Y*M7T,=8WRM-B"=2;*R;
MAN?0 B-=VZQ=V"[E7_>9("US),QM@3[G)SD[5V[=Z:16%U]*TEO:$%!WAQKH
M]1CC-OXV@\+C86,<TR7BH)J]D]W/_%?,'V=\[;/#COHH59/>ZE 6GLH2["X+
M7S?6T87? )A4%9 2"2NT"YWUL/M./-DH,1%+&S/#5]1AO>5_.K=KFR..\EH;
MB9V37ITE8:LPKU9O /M.:,.>:5N5I,TN=;7I+*I$X!7/E)X7T]M'E<"<YS6D
MC-22/2Z>[Z_+H!(HX,(AHH-.E7MUC'+WTBRT5N2\?;K5#D5SWTL:*!8N+I:!
M--6Q#\-2JGLU=1(G@K""P3N:9_G7J;2)W*W-73,2IG,27(7:FF*AFKS"J:P"
M FZC,@D\;D2'A?85X3!OF&TAW9$0RA[215:Y.='.BZW#4*T5[XUAXI%:9QT8
M,GW,2CC4$Z582Z.I;4BG6<R?)SI*V-8BHIJ0S\K[.R7FZ&*I8_UT;-X*L<)T
M0L<,E4(7]X#I;$:<4"'&\[NYP@W55V9GW-]JG7X#2A,MTI<BAM@UWB<6-@"
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MT;'J4K!A=3),9H(<P0](ILE5P/S!-'D^0V# 9!]PD.$'355_1"@%59[EJFK
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MS($AODR(A=3"=MD8DNK,>L?[*9/*+,&1]UV>O^C*LT3TJ_YD=LA5-YXS]\C
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M\GPI@>P:U%5-]$5^3=;/<P.ZQVFR?MIO9%D0:5YO?B,R!W)+CLE5N$Z!N]X
M[D!R=_L"\NCK.O:I/(-M]"TF]K\E&^C9/!_D,TWIY3;;X$W(=&;O X3H5I/V
M*QT^6QH56?>2/T;)E_FOTM'CU+'3'<PXH&^Y91]*,?/9Q(I7612=*(-5=Y2<
MZ4*SPO(JT?'ZD[Q2AQ>-+X(DGOK="J(G@(S_PSVB_QO+0A0I9_4HYCL_6Q$!
M5D#5OF&1[5RXVPR%5V5/6V5_:LU3&.:326M1,>1*^GLND!%8PM(OMW0D-#A8
MR2DYO)Z4KM0-K8YHW@FA-<Q&B$9Z^!:/<<3R5WK19:]=_WJPAA=ZFI.4V;N6
MOW5_HSU^\A!4*^IU\"[0]3&#UZA/RBYV*K&XOQ>_HQJB5$XUJ*I?6&,M/;OS
M+BZPOK[!K9AJ3'CDGBEO$KGUY9DRTFVF9V7!>//"?*-ONMMQ_U19??"T-;OI
M2&#?#NTJ08U%X!ELY.DDGOZ-=4^5ZTQ:]0=J7V3O&-;Y@(A@M]=.]P!FO:YB
M2,7]7:_U"F/>J?WU&)9^X))4_?-57I^E_&?,RRZ%=X0FJ52%PJE>]Y#IAN>Z
M0]4I ZJGY<#W[21U6-!J!G["#=7ZZ6*FQEF2C(V<[DV^UUKIY4RV&871&M/D
M]<K+I:+/?RSLJC_"86U_-UIRTSPYK#2YI+Y/F5#^*   % E;06?-:YV7#U5O
M +T#]@$W )-[B'\T0:\9L6G6#@$>KT^RM:]2;!=4:Y2#ZN=8'=2BU7$SNM/M
M?D^J48_(U#_? -1/MU%H#,)A/7I.SC.7U"XNT%4Z5P+E$U!U')W0*NT/G\OL
MF7SOY%.L0WT#$#Y.V',XZ7F%+L^;D]#P/+SCR;%8.)11/PSF^L3'\HXOY8"0
M #LSE><R]"/]1=EX,*7?NV^JZ2:F<IMPITGS.$@VCD(DH/[WV0RCZ67D:\JD
M=+YUV$R VT7$6="+#AY5X^+U^YR_:?^%?!.'&]G> #!W\K!F>+Y;^?W)'X&/
M]]AB^.LD:J(A-AJRHYW\-MW[X>J,*Z.$N;7JKQVK^L.=0(LD=]$>3B[G D_!
M,G@4XO=*57-U0]PG0N.*GVQT'W.&4W+33VJ$G)+F1N@MR_D^FK!S80SG%\VT
MR:A.A>GSO^PY9;LRC$C5227)OZW/C>LWK4(F"M@>C187S>WPF%^HCQ,.-JCY
MI%A4H#>["R+1TQ_5VGOH;P!SGB4F:IV%],=9NWZE#8%:\H&87M/W@;SRF6FN
MZLE(-4;-QL"3)1Z$X9=,]XSE.5['5BYGVARZH7J"S?DO#7^,ZG](&L^(,J=\
M+%9.W<QN.9XZ L_;J^91^'/_^/UX7(J20I%!J 3DDJ3.FC_J$R@)^E1IG;OD
M:E!D$EU *QC.R*+LM\DM,@)163,5OA8-EOK]KWIL;]E&J:D2:PZMB.0ZWU]N
MI>JY =2EM]==64 B5J-Q]SGZ6IN?936L+(Q$A;]XH<!KSTZ/TOCV]*@SG(RT
M[5)+-)\H*5".H_O1VCH0N6U;BJ+BBR.E8U=DOU6IIS,;X'T]S"[R$*<:L?JN
MO%UB8N4)>DK&TE,!8QT5WNUX3NZ4/O/>A8^4[." L\KNN[K>FHKA'WO?+E34
M^_2[^][1.:=C,T<G^90<ZG7%D#2]ZK^R95A_;NDSXJ;:]MH4YRCS15(S'793
M8LF[2?F8+!SNNATOC'TT?-9]_>G%6N_\4PED2%#@Z>)2/[PZPT+T"6<.<,G%
M*'L30:2F5#D.$M@8V+[$^XFZF/MV;I$ H#0W !+>6Q%;X@\,?;>"_KC]TGH.
MNZ _\],A:M_9K7:=NG^]FS$F1HD:XI J3="-G\MC7<&SPKM*ZL;N+,W#1BS7
M6QLLZUOREP:FLQ('+: E EG4OQI0BVLJW,X?5O>&KG?/3&;O .[8DW!1TSWU
M0S04@89?IR)4T4%.)_ET(W0<D#7D>3@<# K+59PXP;;RHK/4:*^>U,ZPZGMR
MRP='QVW!M@(]&UW=,G^+U#6':_"WF:%FXM0IH![8KVLW &)<"'KTBT,QUON2
MRH"LGW5\S G,]W;.:K&NQBZ:0)Q^0]3156-H'$FQE%</S9A?@XO.#8P!*R].
MOM=2#R<ICBKMCAG:PZ_-^P"P("C%=9Z_'?UM3U>DS@%QLIVJ2WZ?]=YH%D+U
M?(;/B3B3?REWM7?AH?SN&P>#G:)G_8(6#0<-5\*X-UC]56"D,K"G(R&7<Q+'
MBE'H\8&[+FTWKT3'YEX;Q<2YL3N!5:M?#UK72#H2D.C#PF+>5=T]@IP52N:^
M"100R'E5;'>\/Q&J:!=A&=E?NGK:D=9-M9IM51;K_&M\7HJFLV[IJM3['F7[
MTY\=*MIO!]-->UQT/L-F\^H%HN'.'=1;OCNF+SPL-V,>I')++XV_IUA_?>SZ
M98JA#)B5)QP^:J'1N;A]HOHFY?Q7$&/"Z:COOD8#9\\=:5*ES63$EB#1T8'A
M@LJ9%V8SYJ22$6J.L8M5Y_6X- [WI!$WH*BH55.V3FOGE-S\[?W&-B ]ANB[
ME%U!'@WLGML-@%&5["NV13/57=; <5HE6[LQ>3C-B8MF&">0CUC/VLF2^=(3
M3D:8?09C\CE"@ZQ]\$%_R/I6T"8KL<N,$S< YQL *T3^L%?9CT?T;]07M8R8
M&4KOS5CP-U_A7MI#47+G"TR#H+9O'QA'=%VM3HX%GWEA?;Q*H4;HI<B#;&2B
M\O+!J.??J\?2?9X<NE' =G/EE%!IGWZM$,=?[1M\I5LZ/$MT/Y5/#S6M<G\K
M;W:L!IVR,1%<P#'@LUYL!";[S!UCEZS*'?C3K9T^#65XQM>@K"HLX;=$(.K
M;S#PM<#=Q?7MW@V 5SG_M:\9R /,"KT7@5SIV@<C;5./L2(:F+.4LEV8\*3?
MYWGB*"G!D;[AXFS5WE>@D"BR3R:YDC> [XE4W*T)(LZTBFS]RB&&WCU%I(2^
M __H;&$=F=L:P!P@VHPN/I<*T["WL"H2PMA[Z5H0$(CR]+*ETO4V&TL=]#K\
MID H>GB$&\M\)Y6K//,5WF70+@$!]MI5\?S*,HN7]3+"&8B5CK-,G"G!:U6S
M9RU]628" AV>K8U;>>3("(*\R\7"T@80VJI7C#/)TYE#KYT"+H##Z'RZR!L
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M%]EI?SZ ++'9>,I!C$IWL]U>#0I(NN19+X6M-,TTS!C6/IY:TN=8*OA,;']
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M(!R_/T%=X-1P99L&;;,;<I'+4!!40ZDV;:PP/E_96'CV<\5,H-=IC.<>^J)
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MR^H6\]Z0FQ(E5JC6A%W4-<X\0BS)F%F?]*M ,]_SSX=29?'H/FM'G^..WM(
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MS)1K]8$#2__I)BN0CZ8T4-!?,WM--]QCX4:*QG.AY59S125JZK#OQU&ZB[P
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MBA(8]&-<7L)YZ39T$W=.H_ZR7<3RT^IC4$@MY+&M>%]Q6$ZK60.5+F&W81"
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M3BP7+K2^#2%.<;CTM6NYN]0)GJO(3Y4?=B#H:K#V4EB"Y<\%GZAQIA^S]C(
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M3/I\RLY+FO?/.3"FF0+ZV3/6#$1E/,"0M%M+JO]#JBIB@"F%:#*Y4^MKFUP
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MMK\.CX.&GQ^8J=Q(E!CGB+B5-7Y_X@(L?>0>>@&#Y7X7EG9 +60KQP02%#V
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MG'<-YI]A"-*7RI@=Y'6:(WM_DGYE^AI<>'+*4KEE>]!HD[2JYOS!.'<GWG4
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M>^/*\;R'#(TW'':J]'A3^AS7W=0Y*4H%QWZU40MM!A\<D$(F"ANTGY]:]UT
MKFK?)@S@NBL[?>*R3!-0%P!&J(%-<\Z6-?[QX3LUJZTBE^Z2NH_/;&8#=+^O
M%ID)QM/0:^?O0(#:GEA$-(*AMI43:G=_3,7S)_>LUYVUN2<M(6Z#* 7M5,[G
MB;_25N@Y2ZCK911TA1*;DW)S.9?4*5)O*32LCZ$#SI$@,!1WE$E$N."V(9UH
M(/X"$%E[73L@Y0]DV!?V/.Y%;$N7VV-.]H3;S L-:S]%<*@<'20&& ?&V.BY
M@+M8JNN/'@16Y(&5?_PZZ7-H9_!:VMN9:TX8H877\V?SFQ:?7 !T-CU608*_
ML$K+IBS@!"=4=+>)*]WDL_%Z%52@"VW6#=&T'ZJ^P_"?945*C.P4HD(1:=MC
M86)Y>6H\O?T/C7I%2.[<RTH ?1:TP7CM91GN'H5!&0Y6G"*S?]^Y7TWHT]$#
M&#6$(OC4Z(G[6.OM9P1KS 5@6P$#C"A=7J)U6()6:'BCRO5JRZKX=-'>VH2C
MEV4I#*^^]HID;8#$2:^(JW@DF6UNVZ\-SCIQ(&A@4SWF(T<"?W<T50EK^.BT
M_UFT5N\/P]MF]7E+MKXO+$5CRZ!7+1'A%(-2@Y];0G?ATMU>2SC!X^UKV,^@
M]3.UAT05\6@^]Z;$AMA:L=9G4:DJ6B>,$) '9T=O&!R&;ZV93@ )S\$G+@"\
M< %B<Z\U2&VT1<NER'&#?=&]+J"F*_/Z0OH@RCSZJ6KX'\!V'\,G,]I)9<L[
M3C912\W3:T(?+P :!6>Z+TXLJW%:T:9#8>)Y>?M)6-7<4FS:-I6Z]'"Q+]&,
MNO4^<JAC1^K.Z04@=\O$O?,F_\-@9Q$=4&TWS FDXA.Y*'%9YC<9LCA$%?C(
M]"B%D@JD/BS\G'%[X;_JK0X" K9 .ZJY'845\A@M:#4BBLR7V6M5-T6^Y<D#
M>5Q?#6Y,6O?9I11(23AEU\0E6#O61/=0;"4(1)SP 3+27GT[C7>0RWTS=9,Q
M,T_\EFPG5\*O")0&(+FQQY :5U69@A8BCU\ ^$'"L.>$Z4[#%H;E4#4'?/A=
MV=7NJ9]0K^*D.W=0#^JZ8W#J+H]T@4^]>7N""KTI5/9A0'Z0#-$5%QVNS89#
MTD(=YPP(ZHUGJC68<P_L^O/DHJ-87"K/']4QYB![H48L.IXCRO'#NONZ.BC7
M%@ :W8^4"L*-'Z@7[C?:R]W>G3Y!V.Y= &9I30G*%P &__.['8[*$]I,Y1NJ
MUZ[A%V9F;!9ZM0S8? 52[/7$K5?_1C(_?!UL'063(11WLR0L_4!G$BC!L;;1
MT; @YLR@$G2Q9Z'[7G? Z!6IU':Q1H>&!RS2 QH:HCA.BB.1!USAN+2Q@DJ!
M\S1M_W*2\7D66I"8WY59_&C:WT%**WNN\J;(_G/1U3K]KP8/V^@/+P#JKWU[
M)"GOW\QY$>*Z\6#_Z!  U_GI1NF1^(*Q#? ZZ*# ,U* (QQ*U7AJ'4&B2\-U
MY7* 1!$=$_4C^7B/)1:BWIRIBY)R$([?='X.>=B0%@3NC ,<STH!48+? EQB
MS_(KM^*8>@';;4,@YSA 5ASR]\EM^H<A].82@RAD=H72W%084$_LWC0-(D(;
MQ_N%SD,E6X)G?<0ZD3RZA+IW :#&XC/2\Z!^9/9A7FBSI8.(WM@*VEC]00'[
M\RPKZF^2M'FII@*N*NVD!\1I N3(!\+DB097X8<385S?'.TV@M.GH[Q>C,NA
M0F(+'AO,^/J"9W&BZ2>P_)%D6EV64O><IW^OBOH#QK-WLHC'W8A:2'?K5?(X
MGT0'_](5J%P?,5Q##A7Z^@S2E#2U*29QK'N>+8X#L,C>9?H-<)X* [4O&#YO
MHRTY^E5)=_X-X9&H=&2%%XJM])CUV)R>K2N\\I$K:SX;>JRFV/=B;UXJ[XJW
M[D*"KRT"Y=K#PD:2)ZJ5P'3QWA_SB%F]#VJ]]%=5&#:NV\7K?HV80YGW"6:+
M4-2%,_MM4OS[6C.;T3*W7!FG'80=II[=<M0<04&8%Y:ZN0;+D]*"E+<%'KX-
MRQZ,TZEF#'M\EV)8IVR4^L2),K>"6>.X&V#X\(J'@NIN4W-T?;"G@[QP@E]]
M6MS^!2"!#"0(U2[+FI!NXASNMLT.)K9,LR[._)EU%$VHJGJ<)?TA]_5SJCU.
M)X/%+RQW%9??)GG<Q[?^:<5*Q(!DR+_!+"0;;//NM@^K1]WKP:# 58-K61U!
MK!P"'B7J9NJV1[O@45-:VLKU'4E*#ZF6P#MWV_K7=_W(@A[! -O[B<6SB@8C
M?FD]P5; )))/$4P'']",=7!RJ1L["-'P\7X!PYAS5H$E)00":"N# ;-V7_XL
M)WRB#'8%KN^7/@AC/!2:4=F[U@9AA;TDGN23E(BM1= STS&21(6C_?Q6SM7F
ML64WKW]6UG&2VW+<\CJ%0M:_QPRYXG<H'M]SG6EUEX]UE"8:X(MM"9F1!Y_Y
M[34%6^J/IYIJ_]5U;^<G- ?IJ^>^B0;0>'TYG-<THRW;Q:F?4G5KMC </22.
MXI"S5)B==-Q@B"[^* )3[C&S.IX_+K_>T,Q8C7HI;OV6C;:O5VI[;NKG'WN,
M_N&LT=R$<UKO":E&EV/4+#[<=X^-;$HTDZ-P4B"N'YR.4$]8FBA8M=O+']><
MAKKM-U G-@Y3)QQN]6).1BC6A4 6'K;$? MB(P'8?@' FU\ :$ER/@)+6XZ
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M?5OP3(!T _^@9C-W=G:H]EI4;7QDW"+E5(9ZSA9M^N,SQ1L1]4'"A!S/OQ>
M/P,84!7>YR@4OQ:-]063Q&KDY_R+&IO5'GA_HF%H204]&1/M2+TRSV)+:)UQ
M/=*8A#/!)Y>NM7B5VBE"K78(17B<H[V!4DLF4/N8H:HU0'_C1J=4E155RB_
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MSS#^93 KC)/@OU:9UZG\R+1H,XO#KC%H)9G+=<*\29TL-+G<R@>G(8\M"8"
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M3&S;N\_#L6.*S;#.6(:;%'X-ACQXD%.0CBG3 VTNH"=-B,_J>:#.2U50<_<
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MLRLNB6:O^@7T%1(8"=.?G#-&'XL\-&DT0N5Z!FH*!<:^%W-DBS,S]W)8-+D
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M))WHILS-[MB^G+9-G%K-G-I7)S1<>0?@T!Z<OR]&]/I0;) 1F.['.M*Z_&?
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M5+9U2+9LU&'70[VZZ#A/Z*G#X^EZ_T96(4Y.*:7*B.9%#'+)79D.YU$ E;'
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M9Q^[2*5O5,Z=]K,'==^D%O=?P<8+-H\JFN<0#'XK"V^F3I;GV*<*4U[=>>7
MP?4PB"/GD;LV.<N0TC5K'?(P;V.SG>\[\%\+T%_/P00:B9^VYUF$YRU<OP_[
MU:O/M3E>WTM;U*OXO%H]TZS^GF^4>2NMV YC=:(W+N*)IZ'%^>O7!_=IKIFS
MU?,JO'C?FR!Z!_?';>QEVIZ72V069_5E30M\_#L XF8'C-A9X^OLT$YZXC#]
M*#)M/DCA&<O/N6N:)0$&O_51P'='<==G%W%!=K00GYG IEHWR]-8AN+B,O7>
M^:0;LB1!3PJ7T(+2"$O8_L< FY2H\YYXS27_6?A5<UP9)%WV;9E(V@B;*>_=
M-6.+78%/;13QOJCZF>.AF>#-?C4L6>K2^5T^Q&AU':LOMT!=DD,\ZA3?53&9
M!\WT-?DNEF.<1+U>$%XL<%B_PGBXOIVP.#D 7P>+38XB*]6P\$ECHM?F"GQ/
MBYVE]I-GX"M-=4UP0,!+/1FN:#/5U6=?:%+@#C1A1#%<+Y9.2:"C(\4O-=QS
MY^JFTLSXXK3P2E/=J>&25[21>#>#ZR-J&&;+HCQ:F8V@BALMP-&H3C0QY<V9
M_\EBSU+2F+3ZO+-S :CF =_AY*>30WPP7*PNHU;[)3BG+(2;[5:^,<95-XH>
MSAMQME*PU^KT8 DM<4N=:7T[*!8/JU'5B9G)#FMRXHQ!LWC&"#ZIHM=2JG;/
MSHA=DJ#O64[#"MCB_ PM;Z:9]1*.I2\ QILH[ITO>X/I")Q3H")2O^-(YR;A
M(?PFSNP8W<XI\ ,;EQ]V'N\%IY!J%.[J?/->Q=_!O9U?^-E,WTYC$;Y9L 'G
M\!U7L*P36],]WL(!,2N9Z2I+H23>1M1*/U!\X>LN.B3Y\IKUL I)AEN0U611
M@!XF*X(WR<KQ&%LS$AYCNW:J\ZA+Y:9RKB$XQDJV'@,.L9XX[$+4?RY[%1:P
M9'E3;NLCU[D<8:LL7SY,7J\P/RVZ\5#N_LKXO*-;V&A*])9WP' >E+Z[H3MI
M@>POQ4RJO;%H:-A1\= =H=<U]*<YE#P+OQYV,^I8W2@O)'*;;U7R9@Z&VCF4
MHAM$2843%#QY!,Z7P^=4C-9)/:4>]\!$6GY[*MTDSN!UJI-V47?NC]'IQ3)?
M-;P:K"*W=V84"F)HDE#T+CW/250:->UN>7P@?@1N[%9R3)&/J';-&'$ KWB^
MZ/\^$O+A[OQ\[;;'&:P>;2IT6 SQ9XS?%#19:L$[9<1>Z[]&<A*6[.E(HB!.
M1IIAPSJ+(9:BG%[[?VP(7GP>+F?*[:5NT5N#F=-(I/W(3<IO)6M;,$-X@<DO
M_FYETE'R6&H@4KPO*BNDB!0SU>.<-9ZSG,UAGR49;S<B.G%^YZ9ECNJ2M-N8
M%ZI,]I>2FKV6TMFQ=-;M9BG?MKP_9QE9I2@:IHT&V+<S[PSGH_OEFC7-<_1"
MCZ9^L*&3)).%8SF^B+%G?C'*6,2\W^2D'V=[$9>N%Q]X_,)A]8O0]T)7ENPU
MGE2V=,<L9<,NWZ<7@!WA[U,;9]5\.M6!1@L[$^.A+BN2]SLEE,VYXLG)D8Y'
MA3 1J/NX9Z.6O@FB>FR/*]HH-+E6VHOTZEQ8K^R5>"W?J8!UDBAWW;03GXW3
M3%QL 5N8[H>EH]GRE1>8W6PX7\C>3H=C)>_JK\JO377UP;OLE:C[)\\&&5U5
ME[FL\MQS#4 TN9.E2UA6:#"']J/1G\,#*7/(K1NT5SO/%X5(@'WJ ,!C8Q4O
MK$+[<18W*_O,0)-?]/[OC!W]V!WAN*_-4>1;%J1(3NIFZQ*XG51\LD?!8L=5
M]8 1=09LU?;KARKA@P 6);^)HZKGPFQ/QXQ]MF:-K-5$NHR:T%JS.CU/M'*'
M"K7(/GM&='D4:]XQ=TA:DZ!D9[GK(:!J&KW/T:UN:S*U9.#G.;,ZGAVR>Q@V
M62K*2F1,&C6 ;*L4[)&M\CF,"25=:Z.Y9\X;^K;5YK@8Z]\.GNG0(DY%+DHN
MVHF=.H/\S^=V6B\[6?*0\)(9QZT7S?MS@1E=K%7T?"<J).3Y$EDY:=/6F 3'
M8G]GA/A9"I^+G0A>*7XWNJ# $3ASF^B2S*.86*L28M3;Y7,OJX=-6^27V?UO
MGR+QT83."T!P*+RW$W0>5 K*J#GSV0!_0F)>))S*1EP ?D@5'*2UI$; %X<W
MWBSV*#LC:*NQ-Q#7?0J3^_&S'H-*V+0SF>-W.'/,20>\ZN0=P7S)GP('KW6Q
M"=N3XI\N<^8V2&5#4UKKUY//OY ]"SGXV,"32LN3Y*M;5>@@O3N3NS^U%S0H
MN%D>PWD?IUL&&^1DQ]R+P7+CU?0Q7U/VIXT?-4;@M;!\N^$&U]UM\+/I!1KX
MM[V#4O=K!K *TTHM:O61'W)D);V)-#@2S(P6L+UJ$4KK)4IN\0<TXY<:OXH5
MZF6G+['Y67I3O,P@+N3=@P>PC:'.&92)V99?AIG!GE<^;V?P(.KM:=+LGK)Y
MRT.GKH?K]KORL<8S,!;<T9(@Y )P==,;S"C2)+I\3J\9/[+>FD($9IGP!2(W
M.*V[&UD^';XN(!>B-ID<E%_?H4>=-H'*H6JJ8Z,Z&*GMU"BR^ :O:EL%!QMW
M;NLJOUI@58;U:/1!Y63L<>5:#*Q,\T 'W+K6@;>R'42JGT<3'(K+4BJV8$SA
MZT8_$EZ,.MF-?;[7%)=SP&*M(^IFH]=8-YL"%%N)M^X!5H&CFBB6H@)T1?*^
M;$D;3:I;!Y+%%99V3C!1/CK5I[PVQQYZAR62K^ZT>+Q)$-O19N:RPX^Y '2E
MLDY;DFMAXFH_^OH>FV)2;[C<E33W=H%_3GU_$S])BJ0_O!Y CHV?]J*;":]!
MQ6CI:R-,5G6]2(W=-7Z9.].O<$?,3N8Q8%D2Q-VU9P)3Q[=PCA:.*-$B7L2V
M"]JTU F5;("9+X@2$8H[M**O&ZMUW/[TFCQ)_TJDGJN)-2G[K8>=PW#; 6]\
MFS?LWOC1!8 *)]]WYE"Z\Q++>S S(-C5".U)Z:/6[;Y!+AA\I=P+'+-(OHP;
MRV9%+DLVQQA!Z Z@3QST65A79C_LCVS=C. JDWCOZMO6.HC3Q#:V)SI,WD G
ML)ELPI@F;)N1C1CI@B]S5A044;8.=TU$KLHC>*35;^8F,=#7O3F:ZTB9""0R
M(0T1EP6.%)AV<E_9!*,3MDOP094R/:Q(8A8Y,B_<1B7]J51-4G!Z@;L6 =J>
M+(9F'ZMA(\((@B@E1RW]CH80G-?SM/S/!9O*3O,EUGS^^:T,#)PO2<,%?]NM
MEKDL*9CUX]6@G.8*WH@J.*UY<[6$7"(Z9I!-WW73T*WW<,!?)NJH/ Q,98Q^
M,Y&*FE<SP^I$W6T:27U4-VHE6JF8+);\ZT-YZMVH*R^GF6.M*2&-'#%=HYW^
M DSFG@?2I49N17WQ)!W(2K[HFGF91W79G9P,O_=JZE+\J8"&XY0^"%J$@)Z4
M*KDK-XG<.CECR#)\>M9JLEI)TV3L"$D-!>E4C .?^A(>%_D*G$2Z\6A8&^,S
MIY:LWYO8)-B!.0*XL0GQ+>P!JF--/C+A1Z+4&\</YG!> 4J*[WH=-:_1]7PP
M?)L4PN,T ^T60': $\QX)Z.:5,J@Z3W2WLHLDS6-44>BUQP7.-*.Y9RDWT8-
MHZF#[:XPAN_4/^IQO:)#,RE!;;1]2-R2.+YD0:X-U./X^;!7^3OY@ABV[@:M
MEGKJ'-X28YWB7#_9)Q^MKZKN][L$B&G#7F(Y)7I" F1'A"ZM@%!K[3%API9"
M/QZZJJ8@P_U3_(KLTLKA(5JN_$N3*!:TC(QJN490P?E^WTJ"WEO4PS*DU:;S
M-+Q%.+YTT'L2R>/+HGO=B*5]EWE0<) @@W\&1;QHPL3'H>(";3!EZ?ZOU^:W
MA=N"N!*]/WI%2AN_W!OP6N:+/]]^XV,7Z()("1O)-!SX%0VJEGEW6$Y.@&%%
M0PD@2GFKSRY>I-*8N?EL 2[,D\[JRHH9&0GZ% Z(OM5YJM2 :.O98G0UDA'W
MN.O,.XZU/R"+;5QK[L?7=?^ H(< "??6][GO_(S=L-DO<#*HO1B9;%JFGBIH
M\,*!;G7:5COFC['WCE3#Z8O!:_T?6&ASI)6M/NU9QM=C^Y=K4Y>0,6DBZ>7V
ML5EW1VUCU*M^-PG?2V?7J&!\DO4H*$U-0HQR\6ZH<+W,6_8+@&77=T]K=?4:
M9Q>OPU/:G>^J#U:USST5JYZ<QP:\*;WLO:^4X<P&+3UT$G1'=G9K[JGOT5[*
M$'=,_X*9E" R+L=O*<LM#"TZ[=,%NX$Q*D*QS6L^;)!7#_*R%-1!XI_N9HR\
M9[1[V&APD,5\R&/C8154$F"'"9OL @7Y5?L-$32;Y/),9AQ'(ODXGR1^=]9K
M]+AW'>3C>D3J9M( [X)3="P#9UB[M5Y0E#,Z6L&BD7:IY[P!6^&]=P#:/(\/
MT.5RBJ-Q;[LWJL\\X0-$LX\[;AS:B.X+0&7S7J?F4,0(U&JO/8L-[Q,JN1X^
MN+GLQ#=6EL+G'Q%]_W=59;&J*>;ZG)PBNK>)"2^%2^UJD*XHMMS, F+*LO,<
M17.'0)%>M,ZEWA$T-S\:G7[8(9<EA\Z89_C#DM'($*8%<=PKM*4.BF,UO'@Y
MD*Z]>TLC1K/AE22FZX,NETXJM8FTBI%^;&S:R@KN\Q(P%DQ5HT.%*^XR5KZ6
M F2RQ(4/S&JD' Z0KNFO)-*BGAZ82%\GX8];E);C?RTVAMJ8GO9:]6-Y5 /=
M&/T=@CYI*W90%H8:MQ^/0B&MJ;10^4%(KY1F9#7>I9HLD:?_R^F*D-A^L/8-
M%D#B:C8#\<;F!>"FYSF-7L.XIQ/\V40HTGKLD"*_OM::Y4K;^V_E%H=\"CJN
M#T\LS5'(=BHX6C7YNY7%4Y_E61W2MKR-*DB:YL+3-X6J8+L9IS'1M"=O#78H
M\[#515>*XW#G?X\!W,,I+($I-UB/LFJ^_YFD[_6_EYTGG6[_//H-F6RHVY>'
M-M,9@ARY.]?BO%Y"7J/U/LHP.3=(F$D)='6IVSO ^L[4.FBB9KH_+^W EWMF
MCCQKZK("H1"$[FF73QWG(T:2U?9S]*CR&/)ZB3)K !C+%YGW _=4T3M-]+*2
MN'](X>1WO*:)STL""@G&BB>Q?'@I[;->2T./YX=> %1P$.QK#I=.F<67HW1]
MJ-L9*D(Y'D^\8^\F#P8*%&R?8F_V+'^'GJ'6#>N&CZ@>M_N8P3ZZ.?.84FU5
M:]W,X>J3-EA*^BXV-C%5H@0=1%1Y;#B]&=\:,W082M.646)"\[4M7B_O2 !
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M 9Q&A/KYTL$CP'Y/,<3<!]2?/8V+@+;.Z@#@<OGP/X,"+9O_ 1^@F<[W^2\
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M:Q-D^\H,&#(WVW2V,;K-)]%-_G:,5Z;P4ROJ9XN.RZ9FBZH+.9E\Y-J@HD&
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MJVUL;[(X:1'PO<'=)9U2 PSNB\4TV)*DF6&);@##J6:\N'PM"BW5+]=$2U=
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M\#%G8\"&,CLMZX@7"+"<MBW4L,U=_ (X/Y?'OV<;?"7^S/'!KN?\('@?O=;
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M(! <;E&E&]0X>4WH$B<]!<:XH>,^_:+<HA0]1L9J4$^8E=2I#3OI5)=5%?N
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M!'+&_0[M:A'.:O2(X<0!M?'SL6RLF[(BR_GS&D'2Z939C*$UUP_=MC'@(?)
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M?H:6ZKRU;7D%=UHRZ=@RTQR%N$[V6SL<3=2!<ON("8QDM.%Y02Q[QF#<);M
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M8T+$9P=A9#! A&^%>GB_KM'.7MND6-=C?U@B[;?M5!^L$\Z>]AV*8&'"K['
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MZ5E5<'/\$=*L5+)NNTG2#FT6[J?_>E$5(EV\,@S>0SC8B*1A-FM& )1@0FG
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MKJ&6/S6U71;&RX?&Y#IO@%[O/7M/*.R,LWW5(_-!N].D\*'>[0.G9/<K6T"
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M^VAM=HN+X\8CQU;:>!)FP?IZ^NG%4?8/YWG^C=>?-/<?HDLRYCA:Y#JG"1)
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M'E4LW0GP]46S&"/HCL4)<,P3J-D:,)=[R$%K05CF,"J([S:FPJ0N;YU8['Z
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MZ/T0+B8I./Q\>GOY2KJUX_F"'X\:N)VT]@:(*'@EW?L/$(CR!MB.^P]2\\^
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MT?*[5#JONQ%F%-X''T!0VH?I&IN#+?'6#3Y^3F"2U2+%4'=$R&UF%#T3\?]
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M&:'=F3"SCS77FW5PYVAD3\:0N@ BK9$'-B803'5L$!:QZ=:'""JU.0F]$+]
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M84^B2RA?"U91T8;NB?#\'<))N?8YE\5X%1+\!X6Z_O*G:?9#:B;S)<!"/]L
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M%E>A<VA+9/\AG2'<8> S]3ZUN"([K%3@Z7!OHCGP.UN*;5Y][-S.ZWNZ/Q:
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M(X RGR[9NTB!"/I5:9G50VU#'T>2_;R904>3_G7W'HD1LDW-,S7B?2.VJ1M
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MX.DF%^ITD1B;B=+.+JKEQ WDP$:V?;^,(T];_77.[X8O35W.S*<)6EP%JY$
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M4;5\^OS&M($/6$,K[4PP %-G@P95=BA];N&QK'W1*K,49*?9<T2."DFY\8;
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MEP6QWFCU=$NSN>USWQHC-MOJ&*J11N!&F!Z)OX]2Z0@^BLG8?_MM_447:H[
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MO 'MRROLU9,R&%)FA*>W9RI97L65N>)HZ?*N-<"D!+./^4E[C$?88FQ;S9F
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M9#$X95<"P-J:L07[Q3Z<\GASEWJR=@8R[W]3@^M%)-$+!GPMUN)G R/T?Z@
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MSM:$-1[X\R=(H1XD3&^#YE9RY&<3.-PRF[?B&)N70[1,* 4.4GYW2N<JQ:E
M>^H?\Q<J$D?^.>WJ6YL1^<+ !&4DH9ZMS-K4[D'A5>M!UP/C6N9^*GYSH4*S
MZ0Q4\]*N<JJLU%7]^^=]*G^FUJ35W@S!8OWYFW(34=1(@3K=@!^L!T,AW-9R
M+4,(_IP- *%+>8:5$**5X#^%C9R@84M+7V;GVS#=-;GX4KFI"D)=CD3%+@,+
MN &2/4#54#<EK^^R;27+>CAY-NY@P8G2M1J:#%):*YA(/P)96>[@9^Q=QZES
MN&^,C5N:[7@?5"&Q#40J-</PF5-*OLXQ?-J,$NL/XLMF%8DC'[YN4-6,2<!R
MF6D2+AB!Q994.<QV>EJ6*E\M,Y]BFRFJ-#997U_["$?'4#Y_U/(UZK:2-;?
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M(1-D(J!%I J)_!KZ;R(=3D0!:/Z!*Y)0-!F&YTTQU[$)KC68IE%Y9;0.875
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MVQQB$_]A0E)&X8BNL>(@9^0BI5W=E\Z&32N?DK8.&/10E89N5;AV%GG5^XZ
M^5&4#H(KQ;G^;\T;P-W3^;R*3U)S+Q+#50QC6\*YOEW[A]FC9GF.12W3A+N1
M9I'C3UXGF$O@>;U[2,X))!^F!<DQ<2)CEHWZ>(SO2N%75UFCVK_6<D@*W*^
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MO?D&9TK2WMZGMFTWI0=\OKT%=GDW/_[<P -UP&2D%1"\FG"Y-@SPP5#V0[Y
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ML3GJ!A%-UR5CIT)%"0 1LZ.U)4<A_;C8P/K,3=(VZ1YXELG(_9&L)\"G9 (
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M%Z-30>$5F:53=M,R^+4V,-[4^\?RS5]!EY!SVVE-0Y<^UB0*]K'(+#Q:>?Y
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MI3'GG4ZJFI9F"I:9\4G#[O%0VU:#9*9VHW@Q5Z_8M,96_:&@2S[I>!I(%+-
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M,!7&0RHKL0X" ":);B,N:$$V[A"";@#]=?/T&D_K>[>S+" !<+6NF_J<7H
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MX4OR%5E$&CQ=,LX ?!]V_Q5WPE8VP?A- #6NXDY*>_';=P_IG1#ITM^KS$0
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MXRT/F:'7RU6,V/<CUR#31&0\&NN73.LW<Z>LR"@IP!27O=<B@N[I2(NK*[<
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M*B^'4-)"A[DPSK766,_:/[,U+^LU/+J3/'U;^7%<>8<TS_V^6T#I!EQN"W\
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M1O'_&HG[=\/P9@L' = G@_3&!;NT'F<]V@)GH1,( $YXUS+J4@L!,.;+QQ=
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ML*%F:TXHPB5W?C?R54(+-J+4*#NJJSMJG:C[W^4I*F@W4A*XQSW0U8W2>ZM
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MT]>1O_.)Z,T#3VBK$ ED %X*_O=-Q):X9C5J'EL!_TR^PS^T,?\AWQ#KEM4
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M^@D9( "Y1P:<>I?=<U:^5F''(#*@VVRP>19^ AC/23IU!J=NYK(2US%)#8K
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MOO(9^H8 Q<]*I?V^)7]=-/R3Y:R<'J?#UY,TP>'PM8A3]]216WWEIT^+WJ%
MTZFE0UI;-KH#SX,6D@@^I,80[UWE5L6K61$W:/^BSPF!+!%_OI_E?Q4*U[J
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MGS%:\_XNK'\]L_X.K(]^X?J[L![^AO5_-ZR_E<#_1;K58 <9,,/U=6N^H7C
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ME$-5J._$>\JN6U^KZ#U5:.X]?6T(]A/Y><55"C#$@L!AM$<^^,M#&K?JS&M
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M?7C_>9WC:#_Q'0F[?77?;>6UT)BG%P,T>4!E04U1/HZIVB+=GUANG(OEBC?
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M$VP#EUR_D,8V*< TUP]=_J7NDJ^K1[8?2L8(#S.=@D.&H?*B X)>S)ZN7#2
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M;4I48.7 QT*':^>'F0Y!!7X2:]T*Q6OU!\E-( -B\WFU'G%&IQ]<1W=A#.E
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M\>5C+G>"@_V3CM ^:][)P*Q[@*QXS*K0?-6;Q"3_L/S94&@9&H&0&LN_UH.
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M$U&H[(-Q!A$.(E?:^$\U=P^DQCS/JEF#M9MG&JSS^VND^H!^J4TDZ-#X4FX
MGKI7L)LH1W+"B _KWM@4R/1WA3]V.:/>"2FSVOHQQ$_56X4ZF1J[2?B!?L,3
MS;J:'[^$8OV*]S\PMC@Y.@JXX>:#;0ZR>7JEMVAPH=5=>D=8I)3N,OCNHDY
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MWTT2^*9-XK)2DUQA$GU="^5)CF7^>-;X#E=M,,-DRDY;4_VL^+"O@:&&2B<
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M+NU5U)T^JJW^+W+W$11V172LPR=48F^K+%>L(,;G<3A>FW3!_'-[;:'Q[@D
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MIBO1Z4^R7PZ..!MU&0U[;T4^(A_^5Y (2&[X+R6]4F9!^28KD)VT8'H3:]O
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MK!3B+9&:^G&CQ9K@9429S@=I3BO=+5B#4G=-/,,WA28-Q&X[E!=,=%C<-S#
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M6Y?*I(X\LB,[LO]JD(/I_P%02P,$%     @ 4Y1P5D_,&\73I@$ $.@! !4
M  !E:6=R+3(P,C(Q,C,Q7V<Q,RYJ<&?4NV=84]W7/ABD=^E-0"G207HOZD-7
M$*G2@B!-I$D++:$HO0@(2.^]1*3W3E"D]TY"$Z0DU$!"&)[?O#/O^V$^S,Q_
MOLS.61^2LW/.OO=:^U[WVM>U;Q=N-P#W=32T-0!X>'@ F[L/X'89\!R ?^_>
MO]==([B["$D("0D(",F(B8E(*,@H*,C)R,DIJ6CO4U+14)&3WV>\3T-'S\#
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MFL*W22$BA_LP6;'*YU4]=D<%].'![O;K?$Y0=<SBPZV BV(Z[GM/QY2[]6O
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MV0Y\Q,@Z[7ZR3'SY7XGJ^N<.W!_,EUD*-34 V[;-+.-"HX#@OA]",GB[4SE
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M/3\$:20^%-]TQLF!["X@:%D?>\?-''OP9!4HS%M[*-$E[/=K63;SEZ'9X<D
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M^&/2M%2:0[&QLJA5^2K:%O.'U 0OJM].4&NG*UXF\#O[\P#OGO/#\>TKPS1
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MO!"F^B+>-"A?JIJCE,UABM'7SD 3]8@D8#.'-#K7O?/5%%1W1'GJ;.^F6NW
MSLJ%IN+!_>?&A0IM3/=\Y/-+O&U6A]5.Q#F4P&\;FV+*$HZ79$_X,%WO!?<S
MX-T^ -@4!>^<YVE1KH##EJCA%SE%VCMB7QP7+6KY]12(%>AV7&T6F3YJ)T1S
M8ATF"<[^YOW7>[_^LV&\>&FTC"K<E&)Q7Z,/1CV8DE!TL+PLVQGU*+&CMN%)
MP(U8@1UY:O&L@".B2Q#!M+B@X\FC+]6A^Y#WP=2A:^GDM6H88#Y"FEII[-?O
MM"2EOZ6ZK)57M5*Y@_4:O S$#<9=</.GO5Y9N-V-#A9;J-#+>$H:N :),'Q\
MO!PL*.E0723Y=EYI?DLF=T%&HCV4G83-KLG>';@H]=WOX%2^E#KOI!A,@ A1
MABM'_['AR+ND\XX?3XWC +AH31R,G3]R7Y/PBR^ONUZ/;FZCR<?"E]P"'DO4
M0<GFT_8O<=_^,'YG @3G8?W0/V0KUH1#0Q)^K>WOS1E5U\;U)SMYT/5!*.>&
M4[%Z388YW$<ZX3L<A36-N:4)(QLE\,:(EWI,-H1I]7T29M4,0B]D5U/=2AF[
MT0"*)HY5+FR5R5(7>1Z!FYNN\F KRJQXQ?)VID-,2S3@R0CMGO$?=/SUH [2
M1:5/-A3^K)_Y[&U$9 <O<P,-#5T(R7[']C9;<3B0?%LW_EI[SDK797(O+[GF
M]V+/"3_8G4V4,;UJILEL]>H\>,QD6F!64,,FTKC6(6FR&<]C@;#F.=X,*PD6
MMI^3MA(LFD"1B;<7NJ.FPF',%K0ODWHX[R?L]$N.MH>#L1T-(),0A0&?[(G1
M)7E"P3E#'V-H8;>'8E5&?)Q9(JPD;0?FF6$O__NEI,)+7!F6584FAY<$F7'V
M6?8_M<C"E#HB._SJJM1L26Q)'G3__3$W%TE*$'40AH-Y]@+; AMN^!U*=O6E
MONYS81QAG'MKHPIUJG7OR?]_"+[K_Z!7]4Y(LM9KLC"V7 P9DO?_T9*Z 7_@
M*7\^^(\UA(G=.\>)8CH&?A5(T7Q3WSI^R/7,0N$AG?PLN0-M14>+33-<MKX4
M25*%,+!9\?$%DH:+5#G:VK3^3AQ@IQSN79Q3DYS=UP/$8OF6Q+B5\D$N5#Q-
MGAKQOT",,T.X%[UI<=>@U+J+VQ66OW>6\ (&51J2EQW[Q>9)U/PB!)+HUC]=
M3_]$T'>T"-0?VW6V?UQCJS)@'Y$KCU8;LW.N3K"8_?"(?,@8ATP_3YE7R8N@
M9]>-V+]7!0U0S7GH9D8/V5->-8%%FG1>4H']I800MN,=8C^FN 45N(MM&<<5
MPO14JN:O''I9"%26C IY :PE+F@ :0L=U/]\! .T/:=T9DA1KC#FD+$SNCB"
M/_B&]+-[MB:!SDNU;@5J%885^EQ*O9^_E@M&3G-PO"+0@-11^PTIC:8HT .$
M</N+;3'#5J?,X7S0L&#W90BL;J)J9N:><=BR[82.-I#9*SK'*=:=7/4W"L\;
M"-$Z;LEP<\I"),BV5(0-*3ERH<8YXA^2'.D'N(MLE4Y!*[JLQ6]52IYU^?#U
MB*SXH\!I-.T#WM,E[F3+7>F"B$D?\&I"?12(<%8HA7DC2B7I0ICYF8BH43^=
M]!9>5EC_: OEKJX74C#NY5BI@,_GFPZWA(;(==4JG;2#BN#5ME7D%E?<+UDO
MAW/UY_.7KM<PR"D:,)TSWQIAZOE8B:9C0TH+P;-Z5S (^W-52P*[$PR?_C9)
M%I(=S:@MT]%E(1:(*WP>KYW KLBWX+00%[\*"N'?67Z$HK;41%&GSW>5(UH8
M'1QKWM6&6K-^YW/M6:5/^,JO_!!WGV,/R7\B>DZ_JG1R<3%"T;\./Y+CO5+!
M09!_) R68O.6'CWT%O0Q\7$J,@#-[LKVDBV;2+V7G_)-8N5\[$J7V7R8%<&_
M_J2WU (Y42-0S$6B^K(C[#D;AGGVXAW=_UCBJ6XY?_\",38A)A]SJ-7"1NA(
M$T&]-J](K6!7NEDK$[7T<"AJ:_BUW\]/TY1K4+^&^.DOR%=%%BB&R6HPA8&Y
MB7)9+$HC0J\[WN-II.H'_-6WR,5?!/Q*7GN!M137L!+!+)&;QF:/6P?E]>J"
MDYK(['GW+<-C[5$)_")WU_G.!H,)L;[DH7F!,@E\JODW6UB?N?4CC,Q2HS@@
M-<<MC6L\(2TBQ[G1F2"#;=<Y7:$4IY(=7%,/S%[N,[_'PLK25Q#>H[8]T*<K
MLR@L&6I0%+^82[>4T8:$2;N0X5,X3R"2QVU52=8.P\(UXV/SF L7OL3.(M,]
M6>I?&_BG@,43?$=#JM_C'2@61.?/X56KNJ/J^RW-X]4/B]WT?.)7 -(541A,
M6X-TYV?)/0,43G&0E&:>A%G*G?&HY_JN4NJ3+;1+%L!'OJ2&\^;3"1>>UN%>
M)?,S.DR7D2_>D++PRF>_W5VA3R62?!XG)QSB32UX&7QF]WA)=]>02:]$>DOW
M&&GG8,H0"O:Q,2_$(J"XIX6C< #2*DR;Y0CPA("/?X8*W\.V!H>0''*KKUT<
M!^>XK !)EFI#!+WJBI$V5@6<Y%2..>.Z-J^?R[\'N.'="SVY<3#(K5P5!U)[
MOYQP^7)<TF%>LC)M(X5;="^8$D>H>_;R3> W$L<\J>JSWU^@QNX=I^/1ND_$
M(@O%;[8DS>LE\@:E'B,<DY]Y8TX4(R6Y$K)/Q'<O%<P'N6'6#A>!$?Z-N3 =
M""Z2:G0O63D0JN=>*3_-Z;)S]+2N9NRCE2GS;"!U1_&- =84]8@^ <=>2>3(
M_<!I28<=98U/JNDJW@XR ^7PZNB.V2R$C54^!'>HY1F=<.0<J+Q1.:%C/;;M
MFXY)#S5CV#GAEP9V=W78<K3UH;>XDQU+AFASV416Y7!AAX8B3UH$!Y_HC"1A
MCE=/SQ9]P3 G^X"REMT-P[HO22D9<V;8<Y+_2%]C?G>!?Z(*H"I#\K>FKD>Q
MF:;D$/^30'U-JTM)>!4<#-*?5%M3E$EZ.F_MO^Q$0_"(QE=P@_YXSO !&@"1
M-(I:WBY  WK9+P\B(0BU4S/H_$'K&2,(9WIAW8.;GJ]3;'*^^2#C"D@,%Q)F
MZRFD^%0RD-YB [%! SHMW,E1WM40))8*2E0.*93H#]X:U$$#VCZA ;!X."WI
M&?UN*>;(D93<K=<PN/&2WA;\5Q 2<&$=(; ).-TT?=/J<+'UIQ[?_U4 Z,FH
MW'61W^E-Y_]C"E "O@+_<S9UHUH^%VD-_AM&4?.JQKZD._MD_^K^DV^O^IXE
M7D,3E^9N-]  J&A+,I=W="UPM:H)%PV0TAU!8;*B 319*&K%MM;3C6(T8(4?
M#!] A'L>+-:1[LLQW$I:>'*KJ!A.H &3^EASM^M@:%()]/"V=Q[R'S/.988&
M8,2A 5&J: !^S@KHZF0*?$P)1&QX*T2E(]6*;??#\H=&!OSRTB=:)ZV;W6X&
MT ##2JL<\[UUG^H_0>C_+%.KN_;:X").).!Z8'/ $?-AZ4?SA<!4[V*,?3![
M81>/&O;$F#Y/8C\+]#)*WR5%6K]" ?CZ8 1APW,/#1A)J$0#_/KON,B&!@2/
M'?,@KZR "#P(TK&%-7E)ST4VF344%&]!DF^7:RDD[@O'_26ZHDI'/KA>"K7[
M0!CEY'REJW4FM? G;/2?A7.L"8JW' TO;VQ=J>M^,)A/>VF8)X%#C[NQ8[!\
M1 PKGA5*CDJ7FU_^2W?)/F1D"!#GE:"W]PK3IS'#/BE$ S3L.9Q1<##4 WKI
M"SMH_<N!<9:/VYXKYM145">?;%2\$8(GFOC'VF/G 94M&_%;O3:D(MN1D8JK
MWLWBXLL3T/,MX0WUBMJ,B^6_X""1T0%7]'>W$@/"CN3IT%SWJC3V4U7W=IX+
M=YV %;.X"(*T$<E"LTY1&T&/FF9==@CU%BF$2R07&3]2WOI75$MP7YI,8Y$-
M@C$;,#W0>2C"$-@G2KL+% 2VY&T[::"*-J[MH,DO[CAS"OJ#=G_M1WDIDZ"G
MT3>L IY1V30T3A\06H#X1=3Q'Q+TYA=OHFO0@+^R*0Y1<WF6K49-P;#^R:3N
MXOS@ZO>=E+0T%+Q4;#BGEF?!I_XOF=L%0;6BFBE$^BC1 %8D_M]#%^NM][ F
M\F[5_Z7'W3 9)<5&1R1<AX'G6IA6L[<P;X_DDJM_BP5,1X'MOT1AR:]&Z.;K
M86'1YR">ZO.;=H=-RW/]?R/B$(')"+$!R 67W$>J7S'\F6!P6/2$K[,4^6#"
MY<UO6*].58WJ373M7\YL9(O^5@1>S/()DG#C[< '(G?,5LN\CKH'S2@XM\2P
M0<D@-.:O_7 @ 8^P=^JU'F/C?$FS&7VNA5'3ZGZW($JAB^-]-W9_TOGGP 8-
MWQSC.:A"V&V6-03WF-1P%#"XA+T>P5DW2B=\/5>(5]9'\X&;8C"GT.Y(-A86
ML8;_G*E%;A[\UVO5G9(!-DTWB]+( /^TI#*,SMVM=2VQR[-49-35;^2>_6)7
M#O\E2P%+]5+EIAS,'(NSO+&L/GL(;W%0XWX?9F&7VSO[U_%3WMTX+_BP&0U@
M9_\C^F)#ELQ0S9N-7O\.?53_-9']=79E_E,F^_^^AE>W=W-=!2G?D[R+#G1_
M#\5OI87O\:7"U1!ZF#8\E_%T8L-Z"B>WO;N$0=ZJIFO#[(.JY9]O)"<X)"P8
MY@:*,0#^Z59NSYJP+TQ;DV&=GMZV&_%<F1K]^X^U6HRNM3;.,R@TTP1'9VYA
MA)HYUI)BE;K]K!EWM8 VK?\_BEJ=Y)Y"@9L2]H4>T,&E[ ROR,P;?D4(,B2Z
MIVHO%KXQKKWDKNM<G7X>]\&8H4:#'WA-.X);_]ULUQPS7Z5I 08YSHL@.!_Z
MXPI6YQ(TX%E+G1=DL?UN*!;@5=Z[&).AIX\&M-J#X7. G5I"76%"W<W6/_T!
M^%\ZNOV/=,18JH<BWG&#MS6G@4<+]$C7F";07:4J75/?"]Q=N9N6*HQQ6](1
M]\ U,O]5&VE<24W$[+!0!^7/;ST9R\:)WYY_>!#,WX4S%:7#;3VFZ;_*S\!"
M64:IL#_#Y.DLN &DJ!Y^H=NH@K7[//]5SL+7O$D>X[*Z>"JF;[S^5$Q <5+]
M]+"D7E8_PK=3$J"L;;'<N#S0<J^-3Y'\J,[+MH2T[UA&O.+W1*6J+6%ZY=63
M7 *SI63B\W4YR0_E16,8V6BB^-IC1/9&:/'=M2+/5,B@T0)I'YN -OD8I7J]
M)@+D1PT<(@>'I*1Q \_X1YA*?RG<](4$J8F#(GJ.7H\Z0\AG=VP*EMUMKVR'
MXQM>#$OP,[[B5#VXOT7$<<S[SN198=?"WB>$_RKBK%GQO5BL8&Z*L[7M[)/9
MS%1YQI,!_[JT(4";:%^WG4=1M;(]=1ZMU184'X&M<7SYM2KZ85F"C=15U:*=
M:D,PS9O/-:&Q1I\8D,."S1$I*D-NHN>%+?C5<(U?]3:"4WGX>1$)BN/V);F&
M#/5.-)D4FRD.01E:)[/R-.QL&(XR9+B05^Z!NC7'A^'YEHG1%7,]<XKU*IFR
M.3]0TB5Z?254%8Y?\!SV.3;I"78\JWL#D8K,OS+LKXO325JB5<>#T[Q($H5E
M26_7H4_Y) K=2DUVZ3'9,QO$!W&__'8Q;WIE+]M*EQWIP]R3XN1D K;M9ZO]
M*D<G_X4#T\^Q0E;13-2XW6D9V0WLDGSN1F"%VUY+M(C0DTNW$CV[RJX*7?JU
MJ<Y9%IO%=OB24^X=+/5SSF1UOW/*ERA)\O<3F'A7"1:4JOMN8JD3WZUMZ:IL
MZ:J'P1T?G?Y&+S3 ]V_T^B\/,,8._X>Z$A%Z_AM<%SG/'MBBQ*J[->DBUZU)
M<C 7("32H4PTKZL^49,?,<Y6G :&E,IH(+1@N$>D.H;=^?/]%Y%B)C87MV'E
MB_[(EQR\>&)"8[)RV&6 ;0G2 GTK.M(QN](^86&R J9B+ QC<<W-U3U]\D"7
M?F?( W=7D2H#N??X)I2GG&/\1;W2.A-3O4@6<N 9AQ7D\I 0)?Z2EGMU3_8.
M,?TOC^7^EW520 ,>!?7#4$]\[,%M#']?QQHVZA^J1IVOH'9YBE;:6DZ#3U?
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MZN5OB@\RGX?)$^LB KK\(XA>XJGH'@,)$5$@?$2ERC37>XF$Q'#7 E; :F4
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M["@6X2@RHI)SWV:O5R3OLSAO9@1Q!$$S&X/?HVU/M<>J<OHQ?;0WSL, ,DI
MS/X+E.=[#!F6U1'&:$_@E_3. C0 ^%:AP)K.>/3E5;"<A%F8I.0O[!;+XDM
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MF+T3RGV9!/N5LJ!B,=+=)+3],9WLF\NSL\5['T2FJM-FLVC,S+;I.A4TN$=
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MEW3^+6_B60\@DQLI.$ !O=UI'UI^EOM:<[.3^>0\'[+=/=,@ $&*W*AWB_#
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MJ7(INZ;RK:/&1J%P@!45,AS@#A$.D/ QZ[K)" =0]#E/K)]$ %&OH.<2]W"
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M1(*.SKQEG<(=W&T\#HQL4<M?@[^\V >6.K6(G[JE>VY XN6S)':3+]\R7+I
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MJ=!Y[EG+H9S!,MS:_]XFQ]BEKT[#Q]S'@M%-!-*Q;_:!!O_E\W\#R2@.8"H
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M+HBUQ\!V3CD'BLGJI;9$1V\+$8JN3S&=L17ETPL"]G 'D<PV+>/[G:;2-&?
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M*7@I!WHQ#DNV(7^T1^_N@,..@!\0N$+8=0I@4!DO1J82HP#8U4F"X'#XGFZ
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M+(*(S!3 V4,*($%4C$A,.HH\[D Q_E>+%.-_6:18^6,+W.N?(P&QCS>_+5,
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M\SA-I7J%M7LO]5^G\K^D,#XPY<O[/L>>>R3AQ\D2AU36Y1E-R;$Q2=,V;+?
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M1I=9X5..:@E6KJ:.?FF4TZ6D5X#Y.DJ6&!_4#*^=SPA%\82LC@BL<#K&VK'
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M2P]*EG+R4_T*[5HE5VPYEQ7-(M\RO9G]1L^$RXLIZR>_"%6O#&14H$8:8VD
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ML9:?YV.!&X[:R^JW&2SH0US]3:I%$V/#3B0]=#X/KPC[A"JE ;;(L:J#9AK
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MC[L_;!VQ_BV+._[6G+3S???F-<'*P"SR2:)5-3Z._:?XT=)WX-!DS1$)6=%
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M>96^+,._@QOW!_[4B3/3%_5^8/<'Y"(XRN$5A\8I?]%M3;)P$65])(ZD;7J
M+0$\:8 #=!U>\2?"T_31N/I[ANDS:TQO?4L ,YY";P;ZW::R%=&L@YFF//O]
MO7=ZZ^^,+G^PU/RCB2N(D(#:Q9B#<1=_\SLT\7]/Z  E%T$W4M"?V/TA^Q=<
MYA"QH\EV@@8<O49<4DE-H09S^5-V0OKHU@Z'D2^F6D!)ETUC/8Z%VH30@(I;
M2:]?*9R>9>1&5=* /YA7+B^(Z[QP]=JUWA,4-(0-%N3E-TI\6Z4._5;NSVXA
M]">).FCANQO8$F_-&L^5E[5T-96=#X'_I) 6B5Z/FS>ZE(BEK\VNW.OY)9KA
M@U[;VF^K1)^,]5XR?]W)QZ,TP"/[EQXK&RYP[\HP_X^-7E4A2F8%D/GDS+G3
MJ5QH9S-_T:9Q?_<V*(>2R[-IL5&9>N5KCF9.3B]' T^Y1+R+P#(GN"D[NL)!
M*P9^6$(ZK &T3Z)W9\[A8;=U9.8%CPOSQZ>L.E!K@A7.@I5S8 +* [,OZ >E
MP]4;&'*,)EETRH4:ACQ+ V;T4#1 2/]]?@4=RZK0 $Z?'=R*!F[%2HT&,.W2
M ?7[Q38:0.)PI &=0XCFQA$:\-.;B* >&:<!&[*\C/]#]C]D_T/V/V3_O<FT
M>F\DIFY(D$SKL!0V%0DZ-D^#4C5RJ%S4JK<NI'M^T"9&JHJX/V)E/.98OO$Z
M6YM@;:V91V?>0]?(O;X6*V'BV5#$LS'R%7>\N*D9'7?@SO*^KA[Z=JU;LGYC
M-U1KD 3K4';\&66O]-,:H:^M,X=;^4AT<LZ(^)D=F?.O'CQ^)>'&&:2^KNX+
MJ>T3KUP)\$>JH,"^+=0[&F"_'LZ[^\JB9>6]0X)]-J[T;K.L"3;P#+:!3:\=
M'3,\\21Q'2I$'1GP3H39C95BWLBNS[W!F0IP#YEJ?G4U-G_K5UJ!$_4NZ9-,
MG#6-%>ZE :<GK_,CI^C#UFH$)=3XV4[2L;BJ*W)_GIXI.!ZB4SY 2AR2??P_
MBDY9WOUTIWA"U5/Q5J]F*9AW:YB2 A=*T.Y_W^N+5:4!;;Y,E-L5;I/2.I\C
M]T"!.%$[V-"TH&&JU?,%#,Z%U$<-98X[V ;1N6J2Q6D #PWXWN1* ^ Y- #O
M^($&A%J2XFC K6=@PDTVZM4XD@TVG [9C@73 (8L>I.BM(DY"M[+'QJ.2<B?
M[K6CGJ$!T?3Y?51# S#TDHHH@VC&$I$4EK.@W64P]5*=RU]S*/@;&2Z)N^'_
MB0S/,OXUOYD_^('_??QJ_X/Y_8U^_]']_;_*+VX&9(J7F"O<+:=[3TC3+'B?
M^QIX?0A!U@,1:I3LFW@I34U]^P5U.THHZV"2J1X-8*DG@J@!WQ$S+T%D8Q&R
MU&XKW4ROF[%1T/3JO>U^&0\8%C9,"ED_0?FUT-<.X9,4)D4N*FM+MGNOIZ-0
M>5I(/B4/9A98[$^N)OSE,&J7)2-9FJW5M6]'&&3HR\I(57*W>B#FQ*S+YU=<
MW&D,X1& "*B_Q"W-_X@ /\T1%?2\BG8/K!ZQD\<Z]=7!C\(^TET3RKH5-66P
MA)*85-E# LBT[X_@2<LGW0_21T/AO1NS./1K\$H^-=3QQ[?\+K ..9CWC:MT
M3#'J/47\3:^QV[YA8KV]U6(?IJJC->X469&D+EB(BS&Q!!DZF4\SN++G2,8D
M&'2'&BA<;:PW;3: #V//VD#3.DQ[L%3E57H\'?;WH@-MAK1O)%$F&C!D^X..
M.A6*9NBC/7UX""Y"FM4BE"8*GW:XF1O#*?&BS=J@H-?MEO+KT<%YSD)_O=YB
M0^TU/T\OBU-E7S.NR+ZLN+E *501DX/R04$'CUUH0'LAAC $Y<+\]$#39_H4
M@OAQ&T/R K72@#WJ=]4^2.4-%8QG',GK[.]?Z%$#0;B"(:6N[^RY>.P*>@UO
M.@\<] G3E<DFT<.[6LDNA40WB!BZQ9Q4)UI0PRS6#XB,-( 794X#PES](#0@
M*Y3>() ^TZWTN,V*)R%I@.I)>I/#:30@(F>%Q\MCEVUYK-K>?S&!!K3H^YG0
M$\O( 95,#W+M!7\CR+0$T5*#%J$KID9O\(4>R?#/_@E)V]'U=0?!_S]DN_<?
MPK;I?]C^B6VAYJHZT8S@Y^1W:.7@+9@TY=-'5HS"(RA'9$!D)A?JI;_P! BE
M48Z>3W7_,%GFY;W?')/D5G6)CW.8IA4QCQ2:0EGL1BF6DA@'B<C&!B<_Q&H,
MYK<KF-'5>D&^1P.0J_]@]U2!%B*8BMAB^T-*2G4W#7CGW[3]<,S17E#W+YQI
M\[<SY4''H_!H&+%DG;)730-FC5? A#6)"'HT/O5G_Z3[WY'9WZX%WF>C'OVM
MIO&?._Z'FHELXRGX.AKP;=6;C@'$?T<9R-E5"Z+W"\,.N1Q^1$<C/<V->RS3
MV8(BIO1V@N-^8P2\8S/\FI_X")P)-N#"[)A@WEVH[L354IGF?%OX2& "XUWC
M?MC5C?E@TRW)XG)^&>]%CTVP(=@6<];!2HPD/;,*?=#@NVJRT?2TMC;>^&Y<
M;6WS#&MFTFJRF\M]_Z(%[-BU6:\OB,,L=+5DI6F OZS_V0]5UFU^1Y\5#*=;
M3U(@S%=T3]XSF.[>D#5=&RPLW+4?_O;R'[:ZR**7\@WD=""/E"2:L!MF*I=<
MD5L3(,JIX56"!MI\7E.'*'$,T?6(1,]#T"KP_OFBR?,TP 2C<[HID'IX&Y%V
MMANZ%O<U3AQ1![[JP=E+1-,#UDNXD;<CI7_/L"#KV-[O&_UYU*[F_+WL +X_
M;C23,5.@I)N1@,L?-X)_(EF^?.B_@!CYFS@^]F;Z?0:_"NK/G&[(6B2^P9N8
M\X6>0UV*Q1H,\9:*:G68HR6XAK="6H> ^,PQH<W2G@QCGT!LZ>6+VMHU^1\%
MYM]33^O^P?&A*FEXYBF10#"$Y=R#<*V?SKCRX;!3FUS(Q+)INH_):(R2!VX]
MK(Z_#A/AD:;,<3<ZQ#%M[)5]33IP8AF2=^1 ZT%]D9"[@P^3$EV;4F8<M@-R
MV,\D%:8DBL]0?%!;S9=75?WVA#74(,-UW7R:F92$BPN7<NB'>5F4CP@/E)ZL
M7!Z7MSX2\%H_X*=;,9CAED;N14=MAY<'' ?9 >$^AQXBX]!78;HXFXR\OLCM
M%?'#XVMJG.Q66J<MOTP:^:0?=I2F]QN$YB=K#X/+&V1GQ87,AHR]TG0=\Z16
MMR?2XV]EF+NFB";4_A3\B]'57Y HV,[Q6>3AR1I2JJ3^)!=LC![D;.3E_>^#
MGBO"G_D&R/P+0H.![PQ^?T$@QF@8.Y06IA1[\^#^H;^8W6OJ? '+SP[]!>^<
M%T(*LR77<(-*WP][_Z,,'>[3KS4N3]ZT#>#XPP[C<_3RYT%)*O%U]QE[S0?B
M2,^+HMGVX@=I@&Z;/R/=%SN*$3I[NP]H0.)7NJN6"8"W9D1_BLM1E:WWC=3L
MEKUA;'N^U$L6V9%7^^[_:_6.3BRDT<#(S7^].4"!XKZ&V5N%7H"/'/&>YM_N
MZ=B(1->-JJS0@,SA#="J)7V0!07V)Q&7BWZZ@79)2+YVT,:ED@VE.!R&_ 9"
M!R@_S.E*:N;!8ZI1M=2DO2X"EJHC$H+X)6Y/ W(2,)J**&ACW)N9S0"%_7BK
M43KJYTW)7_:K#D.LU<0149TWD&I:6 F1V&TB:G6TZ(<F,6KF6!0>!'*@8P4R
M7Q$$A7CND'JO8ES_D#@>5JVC MVNOR7&ZF6-=@PD\1P\(D7AXEHD8GQH0*3$
M.E68#";8163UDQ7P3OTR*3L]<J]_)'&*U5\PLYGJ<I?L4N@DJ6V7;XG8+P:W
MNY,,6'W<![=1X=0+?BY#9.W9]2!IV$%3ICS)R;^(]!DF(WI2HI79^9HXTP,]
M_M3HJ_GPNU%\JATI5<9B[N;PFS0@*-B!RH7$7QP.:W:"FA+66V@ NW:VX_C&
MM/!]3::[K]]=$$E)>A>XX7/U<T)WYBV5+I<D74%..Y&ED= ];<9@Z#4RF%(I
M0DQI=SD*,UG!]9:]AQEVF+A;PC1;1Q.R:<"S8LGZ^H9S\*4'IS[/I8@*WS56
MBRSY"!]3D21@HOS$_+0)/NLMF<>)K-4NN /_VP?F%;SI7G(LW3S)K3?F]#I;
MD_T"I$<C@?W2-U?$LEB2?RH[+EJZ[^02.>#??3#-F!-D&0Q1>23*-T_ SMPB
M+VBDMWU#/FI2X5SBA7?RX6P9UJ^)U9D>8!?+J] Q>N0D[A$RMJQ$/A'/$<H(
MSP.IPY<*;%H]<66[W]2^S7A8-CYC6*Y4)%:G!V@H[QNLRC,R'D/[4AK]#(MA
MICL*I(B2G]6[J3>*3L:@XKV<KD3"_+J[85A'5J,DSX>QWO@&OATU4B!A5)M0
M6CMKR8<'M;KPPS"JA.?['\IP]&3F8"KQ2.?VQ90NCCL?+5ZJJAUS^CA-!OQW
MM)@38-D:9OH9/RY<TY7F/Q1;NX6*(=.3R='C&"(GDM6C%L[IF QB\[/Q/1;!
M&+&0<2+.P.W4G0O F5>25X5M^:JT SQ/WX=_AU:V%Z',R,\)7D%PWN5I<4)'
MZ,L8-0VB2(2XC59J[YJN??:%RV;'4N73!*WMKG[LV;QB\ 5D)QQQ@5'3]+84
MSSU5P:Q!3(L7;@4J0&+;B:PE"1THP;]1!0?)H(^PP0?$N%!\Y6"Q3*T&#5#A
ML_"ZWQ1[&"137B9O'%VM&CE$<"%S,MYR"0.Q;V,$20Z[S8*725XOQ3WZ6">^
M5E][FFP2>=[EROAG::?'O=?U(_9>M#*LL(ZMCKPI- RZ[A[K[[B "D54>D56
MLD5.<Q,TZ6@E9!3*YDR&.H^J\#;H#F."-KMO;ZA+1A_B?']L(TR^3]C&?1'$
M G:P!.' OZJS8;.0?C_[668]ZW8)'.DE!6JH9VB$%4Z\?+K6&/OMCIC?TQJ>
M++8J&D Q\J&X0@6MX&-4\6$E,#&GV2L3J"5 VA!,)#=+:\C A$'HBY&2XX_=
M%SY)1EPP9:]X>NH%)[N[5<0!!_D^<;$M+A -&FGPR.DZ^FW$51E=>W&J 3G^
M!=4CD72&103<_%5^(E+- GE+8AID3NX< L]NK%#K&N%IJ&EH"?SI,HBXYT$#
M+ 4QJCA0+*:3[-(J@<-1GOI['2C&TP"F16T:4(7<YT'96!\D;J'.4C+HA5/&
M$GB''I_49']A-SII0#T41"]8?9%%8-TNS)REY@ X?@.Z2J$!PK82!RP3B)\<
MIE^191WD]-V6]?T#.E#3MD71*T*7]3TA2<2/WV] ;J6BC2BQX+E%- @Q.HG=
MUY7U%V2DJI?3@&J,VMRFRQZ?(?T6,NIY,/2F9+=0=!8*-=RZ_*L1<+O%GZCS
MU;1 :%FT$^-H2T21I1%QICC\-"9:\(OFDSH'ESK%7-5SX8\2IA_ TV.UFH#1
M/F19W._9E%RJ6ZO.];M+"BF !>M]GV\8];LXFV%<.A]X_O:&+B=$T();J?W'
MWA>E&8/+!XA!;!YC+!MF:02M3+!;G2]T$+Q N-@7T<#H2/>DPZ2-E5_FEZJ=
M2MI\7\;.,;M[/X\Z0%T7G(M/]Y3'$B"K7K.@*"N5X43<:/.[!GW"A,[(Z)T&
MHK3C*8LIZ6/&"5HE9@S"#A:>[AGOZP0O,RRKC*U&]V,%5F;!G'"LX"5'$"^L
MI0EQ8J(-S*0D G]>">*$%&O:RTQ8&MB?J[(1OQ!$ ZZQ'32]N+6LY'I@XV@
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MOXIE<:GM63P@^[H,*:Z&[[&MBR*#M8X'>&4KA.'749&D%B>]S_WH;#'3:<7
MPE'E6)DB5-O#NULS2TM.KW2"4^JU2 =:__KZ3/36TCQ>_&N9"!.JHBU_\R%*
MC_MA[7>L.9%;OOLYD[A627O!VL<F#\GAE,&-M5LM)X[DSU!513_ GE%=9R%+
MI6@.ZGVMB?RQRE;UB*ZL#W5UM"S7?UZL>E>7WNCG\JNO)]ENE46+/-LW2=>>
MD?I::%'>V!R=G\V;\$;8,(KL_MCNPJWYP_BRA95A@@8&:8Z/1W%]-%6OL_>Q
M^0$JU6Z=,'B19ORFH:8!M*IIFR"5F'OJ9#$;5T.7PW#MC"D2?J7U#+Q^;&4^
M^S.#G2NH?537I2V5S"C"PY'QXMVM+L)\-#+U!7T-Z<_O[I]J(]\I^\Q 5@\J
M(#L:>A>/;Y]1Z%P"H,;$U,.]*[0BD.IS";"5AVQV&(V9>A""^H^*(W\?8+@.
M3@C/&]3H#7/R_JODVU3VW&!,B:"<\@GJ"3NNZ<2*@*M,O 2X[./QF/V9E5,U
M*TO7W"O6/^IR2O/W.T"A4.H+=^ GPR,YFG."7OP*S2G=ZU-.C7]R.JIG5:V$
M!84%4_IN5 @=IO^/KDJ^T/A+0#0Q==?+ UL2%%KT"Q1 W/YX"6 E0&G_[E,*
MZZ.)R[VEJ!="#2T&N79.;E5O!>F6D^7B.GW<JWIXXO+5YRT8VL&T<0E/& QP
MWRZRD.B3G94?!#&,HCS3A]X>K)8'5Q+.]4'];[X4\MMW6J)].N0<>.&MXU:W
M0NO!Y^=/B2/-EX#>_:LI25LU"ETR[0LJWQU'2U,]%9KYI.7%%I*[%N52;W8B
M<A)3R5/O&CL#LT/2N^2270*<*LE%Z_)%]GLJ&<RW$6_W)D[]?_Y2O"NH]_&
M_5:"OSL+S\WV^AT]FYF4>XX"!0#PXE?B[W;NB3K@7!#JV$UD$J6<'6#_(R*0
MPE*JGG:>U.TSYHFOP$D$2'K9E(M -]DW-N]LJK,+#<O2GU2T((O>5[YO;F5A
MOH4X*-N]'Q'>97J'=CY@-,I7-4S+Y8+FVSO%<-1&9[9!)ZQ6KQ?VT<AH1M)9
M^5'=>%YUW0>YQHBRW4P6Q3$C=^9$]0EOR8EVK2GEVXCMOU\$5SI,\WPZ/ZNK
M?IV&:WN)\^Y(DFI)/[/QYQU4H<0P1\?JM0JC66),$ASX$?<GL+.?A6BQ%5'Q
MOF!VFS6AW*UP3N7'%K=T&RQR\6[P5U8T4!K;A M[&LG[8)D5<.B!R$=1EV"W
M<2%8R#LIUVTA*@/3R*7'HL=4V[?IFR)?B[[4VJ0EO2W'$[-,8,*4KB2#>::)
M;/@:0PQ[.U=Z%Y/\S5RO[VTG"$;4[H<[K4MOK .MF41JW4<>R<,G IG)%#D_
M-2HI89]P\6Q"JO9CCI!SE<OP[OJ96H<9,.T*%;#'")[4BG3,O,6?,<?]6R7N
MP[-'+$]7V7]60'JM:KCZA\EZK9B/(%$YO)A@$!W:;7&]R$?V(_?GA<U#\V*M
M%36UMVFO!=G6KZM3TW\QFN?,(<2H1 +B& 9VD^;9 W:?<%T'O\%#5G(C@^ [
M%LN7@-N63B(K;3?AKWXV-+8=FNEF&OO.7L] D**FS:^]8J_>B,E!XFYB83W[
MD9< %M%0'GRX5AT^"GN7./_BPV;9A+'S^GRP&AM55E6&_?-261*:QV\ON@-1
M%V+ZTU*[ZN?/:]K:)F65LJ=F!J7J(][=9<YH>C($4 BA*7 "_#;P7!@>VQ!X
MO,&)1#WA$L+K+6_T 3]>D386T#P:G,,Z)@6+\C^A13@CJ'K2]5T"O'ON!R=;
M/N*.GB3[)3R2168Q/8)WQ#W NH>?*^,I.B1=@^@S<Z/:[YGAZ]'HAP*/M#TX
M>B:DG#^'!V:],7_CQLOINE.)6B0HUT)RX?0DAS2QL#>[D)Y+0&UES^A'.].)
MY3&"T7(P]':GVWFW#_W$DZ3 BA9_^AODJ)JPQQ7A.!F\#Q:(8NI^=<6W9#"$
M---;9ARL*VK)&LGK-P1.DO>8-VO%L-;>-X)/&L!HZ,L%OSQ7+Z-]L1F8A!\-
MGG!U6RN@5H6_3M*WK3+DHPBA%A"X1N788XV5\@,@&Y8"#X*8<)F'CEP"#G2/
M<L^O5-#73)S'Z1O(8B7+__M.R*(TPJ:D%1MRZN*V@I@J%%]5 !HUQBBM*@-F
M?"\H>C6QPZX^/SHF3=MG;N0G/A!FB Q\H<>\GW0(^P"QYXH.%<(WH4<_ AG!
M+U'\T](0\@6\/C.!PT9"+%U^U[E0\H;C&]*UZS^5)/)(K,R#8MC6SA=\$ISI
MP1X8&IPV]@JLM<!N;09M1!')MX@<XPYJN4;AW1,<[FCFJ<_SOT%A&0T?;,];
MV+WE&C PG!U^]!R(C[48;^<$_>K2PFP885E=WTI_%+6?+O\J6BXEGJKW(,UP
MOO$L)V-E>_(@F>:ZW[=WRDSM%S'MXG\X;V"17;!;(&27%T$(JUY\HLU?1_6[
MN>[#7<U*08%/8?QOX^)R=-7503CH]=#?=\$*^#7,1D^SR'$3!AI.H!/X,#&Q
MN; T>/^S_-"CEMNT<)'$H-MG).WFCG$'#_KU0C^18( 1D.4<94G,?J?>71 8
ME-^]B1Y4=".+\W7MU5JM58\"J#Y^4"$YE?IZ\SV<!X9![M1A?<SQ:Q"L&)HK
M05%6M* 8I'O>'<\4*;)WWXR<C\0VF>:1NR= 0ESXNUQ7'"4<KA04Y!#>;_5\
MC*P+20FSH6'%R_9RD>VYIZ-F<EV7%0;=Q:256-E22EPCNDN2G3EI(P&5 \85
MZ'[/32MU CD>6 86PN;V#MN>[8ULB3'C"W6">D4R8E4IU.EY.Z< IV1[:?UD
MTMLY4_&1!G] (R3]E638/)I1O3FCY>?BQ$48@S0S7YK'#=!-W!85A5XF2R8"
ML;=YHEE5&Q7-<R/:)GN^DXRYLACH6AG6SHL_QE3JCH&%2C8S+9N*MNM-IYA8
MX9^M+[H5W+BE'12KL0GO#H00)S>V.Y4"MYX<=1#ZG)U(UVF8"3P7><H28&8\
M=!GR,?0>/EBX>2^+HR+)*Z\W^*[JHPP+Q/+ ]QU$/AO)AJ)M,Q=3Z"CKQL=6
MYW/@]B,74[ _DMI>K%A#2*MY->2+VOD[NI1&1[&&A(Q-2T*H>7B?_/CF<2\
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M)K! NU#%GOK+)OV@4/W<>,>LP?IF=F^XEW;&EVT64UW![U^L^(ZV]J>V@>Y
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M@9WO0NA%A3)N00N=ZYLAV5X>K?,])2TGI7# ZN&F52[$V>%GCLBS,JN?1OB
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MNI"Q:H69$@;_/?M>*>3D%L&O76-EZ3Z$AF:;9QLZAR1J+:5< MR 1Y*6PY<
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MH+TJE&NY\A[;+^=[GS646J)>*XRQT\(S]XUP)IC/'4RF/\WM.(.H'U\""D-
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MY'?#S*!K#"'!%2%]EP"ETE4]1/>%1Y1R _"?\Z?N_\_RIQ[_(W_*;L[/[+7
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M@?_P/^:01SXW;W1[RT(O83IV8<'#^>Z\!HP+8,V=9?:;$KFNWZB>#8=>)2A
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M QR"N QDJ&LCM10A.FAI'5U?"=\%.P&>D$0'E77O9C^GN6XRDD4MJ)@5)1&
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MH>!]IO^_GQ %&A:R>\UCCLA+!R83(-8V/8@J+"4^78OZC@X0L['][G1@F_\
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MAI"*XA[M3\MZU/O#H=4E>ECW18$;FUB*V>,7J<RSC?I5U$K]RQ0A:HZN$GX
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M8E[P<)SHWF,W75H&)(K$"_7[3!M OI ]ZP#-?(3'8FK1@2/83$1? "9,R/^
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M'S^WZW&7#CAS[]#>"86:$_9H)I V<[*(/R_U?%*C$P,LSP,%%@<V=_!8FM!
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MB7D[HC*-<MX)A/Y8-1M)!]CDPA,FL9Y,,-)T^4N#+LFRV<IZ3[P\A #:"F"
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M+40YLB7*_\G91E\>V^T]TXL/;YT02/SZB0,ASH!-/)*I/I3\C)31<@R.]5.
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M;9O2_."+I2C XJ;O!'R!#QRNYS!5$]:@G&=O)&T@T^4(HRE)ZR9[YGS3;>]
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M[DW.O#OJ9W6FAL_6&B;(NR\69Y1R33M>@4W1R""[-]^Y2..0;A@2(- =?)4
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M-WL<68%Y#B]!U1)X7K=T-+Q-_\F>6U_C+7>.$I%\RZ?3T4/QI(I<>\MS2+&
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M=+L.H?+@'V,;_J=$FX%4\#8*34UM+%:=B)5^-2(P65,I[K'_/.@[F8KAKW[
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MW3.+\B,!1(+PS9A6(CTJ>.<0L0/:1G&N./GML??WTR4[28".Z]:J/*0<$;B
M#*@M2^_MYS^<.D0J+Z4'T%F'-X^E%Q9IG!5#&C9T>(K*RLT.]%!Q3R!A<]>
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M4//Q%V^GU+1AFI7$)5H5E:GZ:.<DIGZIU+VB(N4DC0>OXQ/NFBO2ZEG_1U]
M0AY-L,;GHE$W\%O-1 9,:77,H[G&U1@) \,7MMWZP,T_MY_(QMA78!!H7#%:
MZS8^OU5.H/S[B/L -1TT(D-.Z8PC%H%FZ=>_0AX_B.O@"S[/%F7 <G52!Z6^
M:T"-*';5:E7;E9_HWWE3^ A(;G?<+K*DU>P+OTQX.,K0^GG3J"39**IQO-Y9
M)LK9U_]R?+WK+<O+"JP *81/@?%DOF ILJ/K]"$7W';4AX,$H R ?=M+98@D
M@-%ACV*4)MQF3=%,L0XP]O3\41[)@LYH@NA$<G5@FY1V7;E2W.8E7X:4R]P]
M(F7;!5<*)=O]9K,&%L',?O88=Q*@959TRJ[.L63-J&YDFWD<S)]'S]E=MB83
M>1 GW]7)""1W)(!A6!&U05%C"C"37;Q8U\^X,R5?1V4UJLB29.$[Y;H/4E3>
M_L)=^:#;XR^#V,+;G;LG2_.=PLWRAR&4 :)>%N@<3_"?X[?2!8_B1"S<^9\M
M)@JEZ-+]^=)E'IQ/4,2W+PX$'?O(5E>]TW/47'SS/&RIEU=39N.*U$XD6VD_
M7PO89E9PLL3O]:+&0QR0G*!2/5H&W.G+*FT;G R)=.@I,/V$8?"LO;=YO'-E
MD6* &@]K-JJ)!"UB??]L8>\I&SAR<JM-QB-XAD02?LNX<1SV\QB:46?7+,&V
M]N[-YM05$QF(34OK-YH>>NG-<21![MIB.S 4N9ZH4+)/U4/WI7]JS#AM9/(Z
M:G6RL0Y95T5H8\F2S06F0FK4B_\LV24<<C,%+[A(Z?>C_F3>Q0[L""Q:U0R7
M[/F!0,&*?8G%4]X>*PI=E2?\7RWBFTU\]3/Q6ZU)=?!V:A9#?$V;D)<AC),B
M+ZR!ORYU9MIQFGGZ)U-HT0XDGC7Z)ZVQ3OT\QJ.FP-5V'AK  ZX]TS?"BL<N
MUBO6C1T9W^.=C*:'3G\*NG%XJ^WF,L$;6]^"H"9(FY>:SG<63,ZKL5<3^U)Y
MC+1G)P2O/,3&W>A0]%O$WF ?+&EBLI.JW,JSN[-!58C6\&Q%.2;0J!K(_5Y5
MU&OYNL9AZ7+-)<F'J>$\_6@KS$%NZA0<7L-DU/=*Y3YOIO5=IBC5Z416*I'A
MU/"F4RZ\*S<)T$PL$_2TRBN%[Y22 )!AN<F(3B)C*LN3;"Q;'-;L!O/D^.E#
MSAO$[]]F#QR;^Z4L4FT(_+";E!SV(6VGCT>8M3C,X+:*R\G$W?,_ ]6N$"F_
MIX'-35+8M6;;2FD*U89'WK)_U U**2L%K^0MKB2:25S)?.R]E8K,(DA@J@9B
MB$_D!0/?8NR2WOQI,6<S_6%K^J6CD79%Z3H3XQ*=>*4)0A-&2$0>\(A/J?>0
M )P_C]@*T:;L"B/ZVJ/NQ@)@+<=ZI]TR&LEH'_,_'P:<["6P'D%L$6S?3\<S
MZUX$/8-4C;XEXUBXQ.F1GDDNAKVVDK@\1X/7*MR2*K;+I(O0K T\4UI29<YM
MK)SS"Z1Y]JMPILF B9S%BU4/$5I)(0O">6(M3\U^N)=M>*:NE'2YG J-./8
M&P8[:Z-">"5U 66 XG<5T/[Y$S'40CS33^,^" 9%N+)M*^.^6%\(6@II8S89
M-F!7]8B=Z^ASRBY6N>+WWI.+[@-F8DDY6(Y7V?4\QH.][J,AN[C$JS9!IM=,
MB=JF89%)C/;[]U[_RF3##.Q<P\QK#E="I?E8=M@V6>IMLRY+)^Z;O-4>.IBI
M5MU+3<9IP*C6C^<X,(13/_$ \4I4G8W>#SYA(Z?(:P<>"YS;YIZ^'^82WJ:=
M@)NGB==_SF468_7E$K+"^43>_/?7B/TG(JW1<WM&8DG:M5_6;A3POYZ6^W\>
MACU(8W!H[M#3^)W8J=Q%Z0"-R.W ]*-NYJ%_.3+WGPL^AC8VL4$_WI]C1[ZR
MLC]B64>X70_-\C%T-.EV97;U[&IN:WHF">CI[2KQ B1P'&P/N697HC<ZOYDO
M2>D(JX(_N8D8_LFR-WWS$8>AE^F,A_?>,^('Z@,D;Y[S^]R<(F3B_(KK.C=F
M%6IJ)LI\5$Z8^MN#]DW@4V=Z_!YXGSY]F2O2\3'=2:"I,QV]WLQ[%>Z'QL&O
M3Q8F)' X"($$""0!V&O.7_61 &M3),"O;*+-J(Y^_Q1\YX/M,L4>I<;UW?'C
M9UJ#16?'99V*YWD-U,5TAF5E;C5.$TEKP%2G*UBQ,2WQ7V/#8OH#6OV="..0
M"A.IAG5P<N.)R5$X'T@1*Q>/EI39 ;VJ0D74&W<C8\JHZ0K-2BQSD QN7L*1
MA5T=]GW7:+5UGOX[&;QT(37[WI  M=3$&7TK,U>TM*S>'KJ]Q$<SGSY9>CVZ
M3W0<97M-S_W$8]<LM[D?'C)7!5YDPR+/J<0A^$= @D]!?'E6[3Q>N0%* BA$
M)1-O*), ;-G$.WO,),#@DM6%JM$F 3H+;VT7E$G\]6K!A6CT[4 =2D["%Q+@
MV$W /PO])Q<J@@I0M _.R3\:"-\1=$Q2M#,WO?\@5GY%P3O_:K1(8#A@BZ]'
M3LKKS "S&R.8O&B8!+R=]J2*Q\E(+-9AY\&K@0=Z5VEZK]I?WVS#(5\CP?@/
MF$!UK#LRU&DG:*P,56@@]K4VYG7=1ZX'3!8T'+"JS_3+=.SQS7W/D8Y@Y$;R
M/1( N661@/5L<]17'"("9S=3E^?8!L74[W#F(HVFVCDB7,SUHJY[S=XQ27[R
MQ^?-VWI0D%%'(SHF1/RXKJ$D^9C-<[)LZEJTZH.9%J94<%V)/I2NX\G&U,_0
M@#N;IY1[@7N'6/,RN:C<:H0@HA2B^99&\M6((A]'"95.V7#MS7?BAV45B^ /
MNPU7%E.VG59K[)Q -HUGLIE[%5-A+)[Q]-OW(@[O:5VN0?"MJ@\<D  "I;F5
M,VLAPBNHY!6B;^E>66>L5\225D0I\=9Z_,8(?Y.8Q 1]<N_#&,E*&ME61[Y*
M*PNS^<Y.^YTJK8CP)J'AW=<OS[B"'&7DW!O5[Q2G^*WJU,CO)\UFM%UCY[J2
MJD&]4#6'P ::8.G&QJHZ@W>S,]4UP AAZ;#Q1QE?'#L8E7P1C<,_]RB)?:=1
MJ%84/=[78*S4NG'LECA.WYE/Y8>Q\6?'H=9KNU0KK*ZCH[/&*7NH^6R( +-@
M/\[8<;]QY*PL95V;\&;8T;HQQ/C'J)^06.F'49Q](9MES54R=R&5I?N?;]*P
M<#@;- G@RY+-Z+#7/H\<Q5#:[]M*^ 1G'O>P.@ISV(!8E-GIK!YICD^ULH=G
M!=SL*O."&@Z7$:07J6^J^N>+(:8(8 <SZ\^)TCV,Z&DV'6L9<:^3VJS.14HL
M9K?X[1PC1B_0USE'ZTW-E QY7ZHA^Q_6FH1@CEW]XT]K2-:VX94X4\06"7"%
M4*_#LAKA3P+T$*E/CA'-8.;*-/CEZ1ZOT^"O=7)ACNY%F[\S'52%PE3#TJO7
MOJQQ )P17\(/013X1((ZE+_<]C0I$EL>PZ6MTOQ.Y[&5[>Q0,+7U L;9S&X!
M\4GN/MX[>\:.V:1.#!?EG]^)*Y5X=<#Q ?2QJ/OEM9.LA"N?G2L7@F1*W8$W
M"92%7J S2U/_U(Z634M? ?J.3>,T7SJ=UJO>=%J]WE.TW#O&6HG=&G C$D!O
M7SA$./(UL9*(7/6LU&'X,2"6CIU^43TAP,+_6AAVYP>KD$GDPD%DY 0/"7#]
M. J^[EQ^(0LOI.'26%CAI+8)C, ^)T8"?.OXVT/5LDF &.V_EAO]]5^ -?[_
M5JB8QT\[#W%'/-CIF?W'!U*_-O5]V#956BU8EW+-X2VR2Y!35@<41@V,/_*>
M;YOE:F/.Q65D*2.GH7(<5#7T0U,;;V_PCS[N+7V<< +%LV*$-%L<#E6(6I&O
MCVELA9:F'5M) "P\UT-W=;Q:JLYKDT_573*ZO(GE^E3(Y'ZP5J7+G)E20 HP
M1&WB/U)]!6E>OJB_7/L?I^SW__>4<$B+=+@=Y/>N5_C2J9YRB-NY?>L.<)JY
M5ZKZO$D_WE*@H<'&(\!C-CWFA<5<E?7!56'&9Y7UFK^6@P2BA94=1AN#8WBE
M!L((?%B;EDP@HDW8*VG>H+HNZ?2&P^(GH^NC=$E@ 05>>NEWVR3 *ZBP5MC<
M_?$ 82^?^1=U!C)TLBOC7_2[E* ;WS[,J5Z)_1RZ<']*2:U&VVCN$@824>D/
MU1YM4,Q?3TW*+WYBO*-':>:/E>___29TFK(@N^;+C2>/*K0A?I=&2OT4%R8/
MGX#X*S.8O7-2QXZ*T;I&G+JW Q_<.&![I\]^?YE5[T<Y-.T4=2( 7HQ-+QO]
M"2\%ZY_;]\V'S7&/R3PH\1+&S:WU#)6)Z8X<<:L]H*K@,9CYP61:1OY,)-/5
M)"8X +3I"6%JT,[;?%7D]4HR7T,H_"N;8X%6)>'/3,")3+I?@R=2'I^[L.'G
MOR!K_+PF5=IW<HD2*IHRS?J[>>GM4PY M\B'=/UDKPA<P,01*(AX;YB_RI@/
M3FLXX"RP^[67:)*UKB+X\7/*6N_2??^AX2S9 .A>%:)KEM"3K+4%K3E>;U+:
M:]V+, KJ##JL*#38-./ TF?#.$L<*O]\U:NJ\&;IFC',AM177HK;=FTNBP-'
M&LGEDL6YJ<LJM$D8)1:;M5OE=S+WL/).&RX?F-(]/C&A[[K_GHHO'2O1K,T5
MR7]4"E; [(4Z+ TO#4^K8R\[JCRW_+(<1BA\]^Z=/HR]47]<[GH/9_VWK<?K
M;'?&FGKRQ3-<O\T9G6>V7_K\NUS^[*?'8^O[*]Y7,T5T3LQFY[=@(]B)2D$H
M%$6X($9CN'XNTL]R!+XHA=&KJVOLBPE^-"+&XU2Z8AW)Q,Y=S\9/&.:S>KJ\
MC!VO5Y5[;,PQ3E^XV!A@JK;9MJF5_Z@!8EM=/?]=)MR*B8,$N$P/UR4/7Y;1
M/I-#1>P2A-;R8K.F[)*2[2V&'D*='9W9BULYKI-1C9O$J2TO+Z539/+CW9=
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M",)SUYAE!\A(=_,Y[[YF<Z7!N5?BYL35C U+^>/7+C'(<<HQI,S7/*\*8.+
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MR3\H4\I::$W@!U\DH".JNY ^/I9XN>U3<;U;Z?:';UTXW)Y_SKE%7N"N9P/
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MM62576U*Q0F+;#DWR(H)AGQB!"-=KA2H350-(?L0#)4)!L6HAFDG0^QH9/-
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MCN\E^BXP8&1^."0DCT/8ZB_<B;]>()QMGVC)Y!E) T2GX&5RX#2T=Q4N[D:
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MGQC])T;_B=%_8O2?&/TG1O_K8+2@^X)WNDHEH0MUP;@N(KHNJ3TT_HK1VSL
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M6>@HLT[QDO[2@TY=P;<V$>FG [7I_78DS1$$LA+\W6^'[';&I0RHG@.M2QY
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M"'T5Q5Z=M?N9'>P2K8X>*#&KR(';M0\"233 F!SF$H%CX3^8E">*^GOX!=*
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M!P],8;[$\OB9Q_B: :<72@H4BQ]/HTY,7G,>]/.LNLQT0LG(C2,BJ2HZI.Q
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MF%%/,YJ[DB':;Q6(U:A\X'L]+@*8_(!YTVTPC%SFW2V%C1'=?_#45@,-_/M
MSM\K<P$._FJB%<B#[<*? 3I%JD&[I.^!?SJ4;3RI2(\@#XC@W1H?/4BMWL-*
M*8%\CG#OOY="W9W%N0+66H]?Y//<=*98'<]*\;3=G5^\@?.**+.[KN7]S<IV
MH3?)Q;TFJ?2RO%ZWH:=%<NR[+(>M87FSF.292$[+ 30J&FNPDAAV!N!K90C4
M>3A>$SMTK\>F;_SHEA]O85!>XG!=XNU/20]K;SBFL:H*!G\CC<<K-6>GEX!?
MFFZEP+V/N#A-=&EB)+[^GV.)RD?VQ8&Z90RZN(4O3_%8->&&_KHUUKR8=(4-
MO6:A^9+$"9+ R#MY3S;UW]-<7J#G-+G_W\)R2*0R$:NT IF5_[M2IGE]_#"3
M'E?\07QT-R&=\YM3I$&8,T9TG>J@CQ4\Y)0+JFF4(E>D[[S=2@G%$E5.%;:#
M)<K. )<]TF"\O_QD'$V^>.XJDMQD]\2]/O#?>@D*8R@R-3$RG;ETJZ^@3E$"
M&8]VQ! E-K))%E#]W\U"WDL?FGG>I+%]VZZV<P>[47]]<)J>!M_0** !TC>J
M@&1"4VQ4ZPLP8.*+IRF>LF^UN/[J8*M)AH&9!(]JHJ=*U"'E!J59;T7W36S;
M]RZI<^!9]50][CCE2-IU#W#7F 4K[T970:H@>Y::Z?\%/R<!R\?_K@,W; %]
MF<ILOSW[V($'1XC+B"Q<NZ,OY_"PMN #;^\3Y.DCW&5A1@T?G<6,HKIJN$\3
M8X'=8C\FMO*(BZN-B%E%O*4*$E?;-2_CN>L; ]XW6TL]R+<6L"X@F94\Z0B^
M]GA]:C^546GQ"<IN '(PK^P?<HZ!+@0/:*EP-B"**NK>2D>TQ@UT(OC5=0K4
M$DWLZ>T]EYW%[D8EW,J.20KWIQ^^[QB3X^PG7.;O#\DE9'/]!>ZVD'S=$#4J
M<4=R-'\<&/&,'?#W=_UR6^M_'=4GL#Y(M2I-U>Z5;@#ROPX<427("?P+B0Z$
M8*!.N_#U*1XC/$^LN*NBAZB'(L+=3Y(7\E@BJY%R\'6CQMNM"ZZ\"$-XJ_</
M$3 #O_<E\F*2(O]?@D9>&+,$,@OD*3=' Y[AZ:!RMM;BGK:J-N,9ODY>GNZ
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M?U)/2F/OYVI_AA=-&7Z(=Q@] ]"=6(E14&CW/J7[MIT>9?+MX\_J:TGVW4M
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MFMQQ>>)WM-O^K&4'N&JD@X]LO\*[WIJZSIWAG_KJIV&HS\_4>+VMVTPR$6%
MNB613[:$,@IJSO@\XSZXBP87%+A.09(T*@1(EKW=WG58S9?4,P >FP4'!K>?
MH[2Q^+VL>BA)W=8U .>6+N^A0C-V0*&U>1#HA+JB)R&Q]#TEF;E.H%Y#JO@,
M$*ER3G6L9X \+.X,< 8 /#\#K)O[MA]$E$QB96=M]^&%3=76A3R\)_;'$^@F
M2"LEL9!Z$3:1<YDX@[L$CZG-\4\O=,/9Z97.S$/_NAW<S]R(KSS^4?],YTG_
M:Z:?)^!'%!3(?3^!6V95) )-HWAO)%I&.M;3NWRQI*G1:B'UBZ\?\*8;K]4\
M YUSZ<09X 5\^K@+3 ?C)>OA1KJ$C!_C.0+'GZ2M[ BQ%9#4$JR@#=6-$K7I
M\S#S)P!:X8@!3Q@C=0S\(RKZ&ZA=P]> 6(ZKZM:3TWF'FHX+CBQ[G/[Q8;_V
M:APB]<3K\>/D2RG>\3JW[DG=:"R@3IS.O"'KAG_ZFL\5$+ S9? &#?]YNO\3
MS2>[1J1E[(1\X&?% &4]WYP@_;)E__IJ?/R0!3)G?<#4H"W_Z%*+<<^L,;:/
M9$R&&HRP0UF(7(6+1(;%H.LQI,YT@+$_)V5M:!"0<\F<[O--/C%?."&/DG^5
M4@1?^@R3Q.]'O=I31*):4!7YQ34YCK-5#@^KM>WOS]=?W:25[+CZ!ED$?X$:
MMR3\0S2D)(MRPW$),RGKCL*0-/7Y5?07M.9)Z;J7^<O#=3?QG4QT1BTFB%GO
M88;-7X?]L?Y%HWU3D1DP(6I2\RZ1UO8W&;PT@(Z&B>*H^3>^?-\.V&US?!,O
M]I>SL839XGZ08'!2.,SG]QD (A*/$&PV*;>F#B(NEC6#EUOXU^8,5R!7#-=M
M[7_\66?(H1=Z0#OX<O:!9,/JSOYLC,'T&> E)L:XF(]^A^AH<H<71MVOUAM?
M1"NA7X"BP2C,![A+.??QTG%7(CW1I4W&U^?'=G!\@;$O:Y[%7_7V-R=Z8N0.
M69AIRUW6<4*J>.$GT[FFL?T!P^8A?L*;E?VR3!O"><G"T&^/CG='2*Y$9#><
MJXCX )__$XZK@-V4*6FNL0V0<2[1_II^4#42#GC)&V#*U?K,DE&.4$%IA:"=
MT;.B'=3++3CRW:G((Q&@9NZZ=9OHCAE&,;F'[DXM)29N])N:-NB.Z(\*GI_H
MRA'L/21L#'-)\P;T&3%Q"<,^1S2RG)U]ZLDUDMP_$V]Q3\*\RAA?!\@*%H +
ME6'WT4OE"!K3C8M[5Z JZC%57Y\)65!2PS3: !'38>[8$4E]@F??/7^3%.,I
M2,:N=E*\F\W.+278L:4#(O]VLP?)#W8^YQ=EGN$QG<"9,X#!F":/@22CKM>
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M;D7XG!2A^M?A='/0*G!F<8C*JQN^/J[S*=YF<?KO1HWGZSW_(KT%&MIN_9@
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M:(/M)B&#@GH%>85:""&\&=U3Y_.5Y' KG-\T2^!Y'O[47I<4OJD6YOM;)O1
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MKN"HE!)WGMG=V2P?U[$!,0..+G; /TFY"Y^'M>_T;K1FYM7Z>OF63-J 6L\
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MKEP'KY)C<JJ 7(D-@N^/L<WP5W*6!14@G;V4 ^\IO(&.^!W*$*^F^%VR+S>
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M_3Y&O'#[!%1F4GSRYA]TR #+#I)7@\L-=EM-"%*\9HJ>_?LHN/$RG">#]FV
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MYYG;&E;A18+X_]IA;H%S!(O@ OJ:6K)BU)P\7M;,]G)/!24\T5MO>OF/D\\
MQVE1I8L-_-2ROMB"SA(B104,EX"SJSB3?T1TU7.FC2L:'( '=EQ=UCXG$PIQ
M1_';:HY^"S#.&8G01>/[F@&<T5+F08YOR"7 G\X=^&(_*J#Z].%1A(RKCDI\
M)E,O@O)WH) <!L?:([OYHC@+8\GV03@J@!6B7TE*\9<IC=9)47M]_5)DP14
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M#=Y4P" 5P+ 'LA6%#X!(GH4I?/NJ5,"2<#\5D&1\SM!1Q&Y*+(S\]0\50$P
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M:^,]#VOKPD1VPV3,N\V^P*4.=UZVR(J+?FDQ?/HE013POV T^]V4ZX54@*"
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MS%S@ )U5&QP 5!:64X^L>L8!LM%43_U!+G5:68SX2H,R;L ?<6>H@)IR9G(
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M*4>3/6X:M #_B?(JI&"E$.XT=+NZINV \9&BTA+?]W,BWB&O'SLJU-0_>Z0
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M*!*1H?B&H#R<QE9%R87F$-O2\UX=KA@;\T.7G5I^?"AX##:,E4=^DU-@>-)
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M/C;(T0<JJINI18%4U^#J'I.&R!N"IV!3WC?AQRO..NZ<%%,650Q3>H;5A")
MC#IZNB^HQ5E](S%H'W&OE[^/3.F[J*WUY6,QBK4)!4FVRIM'CO*WWOO>,<T;
M,8D9Q\)?$K=LV66>FL&V:!@N.06R#"^;8W]!MSI;U[/JI7V"X24M?C4!WD7W
MHJ8.WU']_&JE]LCMZY+QPGL6G75IOZOH1FT@'K 7/(Z@39\,@SS31(!I^!^_
MQ;G\M=K?O6-]EO7IYDM+YV.$-@@5]*@V"&_B,%'0@0:%MI#-L]_.;XEN)<9]
MF+6%ZE7!)DI@9YY8U9Y]596T!MA/&#;XIO(+>QC$W[H>.WUQ',XPT.P$(S,J
M139D(+Y@,8G-;XBJI0A9,U%;H%2;[:._R0&R_DA(#J KP^( /=+ PLQ_XF?1
M_^JQ7(;7IIPG\K+V!*D)\'. 5N?!>=WJ[-L>.U*T']PEY<DOO>6W5.K[Q-Z)
M"*BE2RSTO$=8T <'J_)R^ER*-G//B'H)O;J^G^DQ[UY.43/'T-Y7'/*7*H"I
M#.G8C;7%WP5X!J;%EB6X#=<3<@AAO8UF\4W\TNQY K]+32#D>A0[@:D4)]F7
M*O)&+C+5U8*NEWDYP"XN5RV!M1-D&+WD[1 ;*W69YF<5L^GWVZ:ZRI^_$#XY
MY[IH.EID-:&YJ$N7<&1DDD '6.?Z5_/+Z=CH[88<5^^'48_THH0N"%ZM3(R8
M_XHQ8IYBN=+%J(LB;^<%!$>"XFXER 9V5$5?J[W0^P[F>>KRD^NV.^2/U6N.
M$,_1T:V0!"B_)IPE4!IJ9<T((D$78,P2GU]?-#3.'@^-!D<@K:?'?FI3P[3M
MJFQ,='TUEMKM V-_2T3B]52_:#V_(/]NN@0!SF4$ST]$+VY/"/+,R,D/WZ$1
MRMZ.N1-&?*2?INT[_D@C.*5V5<XY:4E9:,/NGSPQO$OL$M'Q4P.FOO+Q.@%6
M=#:'O&?*/M1J_X<@/K6DKSW.5;^5-M)6WO)=L5D1879M]O[M3\<L5?HU=[%^
M2@-,X-PU0>6X;WV+SN0SSR^1B[Y"TZ36Y(?JH PW<0ZPJL+@-CS>Y)]\.;WN
M01Q@7PZ1'0F60$TD.X-)@2X<X&<!F<H2MCHM%V?V8)BE$8?:$F5Q&^9C2R]N
M@^N%<X"SV7$XFJ4Z$*8NUL.0:-_R;(7L'YVO/V=]]WVRX\/:R)PD=P-I ['4
M.E[#$RRUM__G)V?\KX0!5E&JW4I<-O"&KG=Q /-_+S$V# P#;1K"X[/7#>;!
M6VZZ#^Q0=J*7^5*1WXC+,/!N;M^V[L6M1DFO[?O@_'O(R_Z/1T/=$C%+F$U*
MZ'IN;N%^1FY0733=UM[CTH_I-*[0K\A^NH $(#1$QFC9OC'O?N_^,=<+"2&:
MZ4YYF6\.0W4:*I9&$\8H51YE"[DD<4;F!$[.=<YP?*F!%&$H8'K2WU\HBM4B
M6M[B'YAS!'M+I/.<RI4TXWLG%W7L5DS]D#@:!_C=AGG@3IR&;:];H+UQ%9=>
M<T%<&":QQ1=O[$+JEG <R' 8,-;-)[2(Q6]8AU@>K7LZ=J[QX?%/WV,[:I1T
MCG. 6V ^1\83&[J"\\M:8Z@G605S@:W / _VJT^V6YZL3L64O/_5*@Q6L;M7
M7KKG<,J2Z+6.\:IZI+/W; [S.3AL8YX#\+&(A-"GQ,^0R.$O6TK1=X.(![T#
M9K+DL]L,[U3 ="O<G0G=.GU8WN<ZUMFXI&",[W+2FZ3TM#;P9]13C+=F?*EN
M@I5+_8#QE>TT];9E5S/1H1K#,#+^]UC>:85WV/O/.R$R9Z=@^ ^YOK@2W+>(
MK_HAJ,%15 8JW-AT>-V"5O*CA+P(:<43GV'\P\F-0H$"[C9A<[(5+FH5&JV/
M)5\>D_ED_"GWX:\Q*[D*$JYI$RDWYH)A&]-#XHY45C'%,DL;'^R((FBF)7PZ
M(_'FB_).2TP'SZD;*=GG<]*#1[>(7.=:UXA;(\BXI3-<C)9T^)_ O##/96+I
M"6S4=,*_,P;NX&9J/UDPRE1FUM_'5(V^^S6I:^_M@Q;W"]T4,? CO$_W3^Z\
MM[?CK>Y/AZ_@2G14(.H9M KWT-B /+HOPJ5EW\3VG45?S>>2]C?U*I^8R-I=
MBYJKY;V^<AKDZD1PF=-[/NX,D1TLGOELIJ,AJV"K)>5X[\RAQVHJ+'_2# L*
MBG1Q+H>*6,+6!_L$FK<_-"5CX6F9HP%[?IQL0RQR:[%W *XK."+8C(.]M(QL
M[%XXJ//TS7D-$/_>A;V'PSQDBY[1-AY+-(%I5Y\]&M(U"9B^1KN&3VT;^JC:
M$ 5+.R.]R^Y:@K".W66C6\F6"E)KUME2F%V@!!1)$"4UHT(N.W%N.Q8??Y;Z
M7552*;4AF+SG5/N#TDZ<.O)(*.0R]%EZ=FM+SHPPPK2*48_U*WXJ*+S9.W[\
MDKAOI-FG5$M'[#HPNS&_IOIHE]AR3PP'\,'%$'9P07E;I)4+Y>UI)/7PMF"V
MY">Z!$M!")SN^3I9!9.:\.J.KK?>F\"FZ[ YG_]$WZI%"2/N,^ 3XS<CE*",
M)R0W0;LG\ R/CS#[H96.YY)^%O=:#C_6,A0Z+=LF]CN;U@_EP\T4_7$;(K\1
MF&U@P=(9;J)NJ;*YC+\YD2N'$R_SY?>Z<RM?0)<6SH[%/>( M-P*#D!Y@6JQ
M0<AQ@)RR"11+>8$#,*: ,+?_FJ]T@SQ!RC.LR KZVJ%7VZ0U8\A5MRTG>ZOV
M^ T=NWXQ^F0Y_M(![=G3LF+_; /YWPU%=5' H1TD IY2AN[E@J9]'1?KX;"%
M+48+V9.5OX\$WHX=!F\)+/*8]N3$*A^\8B8*7'%WHY>Y#R\$:>[TPN\NVX[6
M:"C6?;%1Y)=B:%Y=815I3U',=88R[+'&7(\_HKA=(@Y*>RMX.0>#8XN5H<$S
MA5 .,)$SS%+F]@X8I6=+-8T;$>4J;@R -7ZU:0X0F[95TY2]%T+6%&5Y8,O[
M*==C)2RJO!7O]PKYK^CM.+6Z^Y,N^%E/+B/%[.<26\NG%^I3[M(EP;J@_OW>
M]EODQ,6F>Y%;0'@LL(6,W:PA]<11356Y2 N/QI[T29,0C^WCT7@"EX9(?_7P
M/GJS-NB 5(#1$_=([O6'.[)7[32YRW8%QA;=,2?JP)U9<Q5]>EO,B@.P1)VY
M$P;12A /.("9+8>K9'>)XTBG1=F'69?I+S/IAJ--60=HO].*W605?"IZ"J&-
MGPM?.Y\HJI)14K;YX]W'&93L[;UR0AR@:97(NE,'Y9\-(W)I$JSI=C$C$2YL
MTO'D:<Z#18^'[>*+7RZ+/-:R9,%FQEN&'F49_/%K8P=X2]A8G@,\F<4QND&T
ME#^V&=[)-X,9IAD<('ZX?$FNTD^N<@=)NJ:5&I<NT)V)S2>5\3CVA++=,"%R
M\DG2]JN7;TRN7,@6-56W_.#V2S,:P3]<'?/;U04M;(E59*\(*CU:*T6M?Z<]
M)9S\U%L22.1SA]7_2C8XOK;/,3=)+/G6?5^5F](*$6]?2V2GR<ZW8,[1P&2Y
MCV6A2X2>EII[\VD"I:Y=1>9"PNL$RC>]H?EC"^7-6A.K'8U Q,E<Q'E&&UE-
M$=/'4I_(/#L8<T6WYEE>X-<YK2-%Q#_[,@1>>$T*IPK.8D_6IYW+;G&^E%^8
MMQ7\VE^X]6N<K[#17=NS44'P4FU"(_7>VEO!0W\76C3#$FOPQYV^)! +9,,!
MVF&_-@2=]06= 9KF2'^K\WH5W8K,DE/L/[[:>+./"G&Z\:G.F]3B(EQ[LQ B
M-T@=7'&/Y+;L5CQ7-\3ILP_1WV!E7.(2P#V1=V_6'F@>!:;J_5GSW%J)]*9K
MLF,Q1,:QFK<6)7T.R=Q\J61PL\;,'<X2<>GEYE0_&;HM]@!'LX&?EE.CS[<Y
M;T2CO$:MNMQ\8$R=V/8^08%?<QOV_<6)?=F5#_8RZQQ.C3=\CJ5W"Y)#X@KZ
M\VM0DK">'.*H5W]HU&;9+6+!6/>#HZXYED-"Y=?$7*_?[W#>8D,?LPTRKL79
MII#/!_B<U/A*E3E=I7TTZZVI%E^USQ&:?OM9PO(.^NZQ,Z&CI1[<8(7UWUV<
MHX!.;OW4ZEB((PN$M!)Y*C.(!R$FXT2\7T[4[]]GEVW\4NJ;%SJ2+^Z:'*YP
M0.-9*HP8#_@A<:)H.F%/^T"BNO"(G<5;X)XJM]*SA3G 3%$WM])A8;QAX[K8
MQ0?Z+#5(#&K5[C=W170;CS \Z=QJ[W;@KB[OT"JW<D90;$L%U+K4$'AUZKY[
MA6MT,SJ:0D(_6C0&;[_3*%*XZNIJ^4!+5>>SC='W:1^:J;<@3U70*O _\.=_
M,QS^P\9 <%![: ;;0EV-/8*::3DMF\F%.SD#NLQZ/+H%J0?G"=5O=JYI11]J
MX7=U]TZWLMA5G2&RW='0\*+87QQ(M:YXKETCJ9L"9T)\3$7H!]+>(ZXQ0@H1
MNE6#I<)]+>[)6\0K?>DA7R_<R1)Y)8O>]UO9%A5;B&P[T>8_ 9+R&79Q:0N+
M3JBBE#4($M2_ARRW'?*LW>OW?)=[5[S#6W:OM/F34A8?(_(V.?(I VFS>Y6@
MV[3#5C<R QDN=OB$R9G+%A>!5<-$,DG==RK+AN#JXU;]T>.AUCU (?M&][WL
MBJ5W13[$':;21%C/\?JIX:C D3(":BWAWE#Y:ZMPJGIV&'76:-2F'?,#!&$,
M3Y1<):FQ;*J'/5*^S'H<R\/7)*E&UJ"#UT^FKNR0<?0=;9"7[!$;G*EO*WNF
M$RYKVX:W4OLE7_=H,B;W3L* 5G(BCTK3H1.\(6*;&X6;]9 XQ!6FLKGL4;I$
MXN'!NY3+IZ$'7)=P&#L.</O68R_4X@>Q MJT,Z.<KO4#*MU$]@6UA&5&)]SJ
M+]70A<I!G4>YH4'<8'?['G26<<4<5A5_WOE]CMETQ*QY4+HZ9G2*1MA>F$PK
MOMWP^1ARBE6V0DRC7H%/RZ5YCH .L-6Y<D-$-UO:N]ZN<4&; 7'T%=XLI9A9
M*CGF/J]T<4Q^E63NJ/+5.$1_%13C+D/73S"V(:GK7V%"GAGKKGL4CFP**XU@
M5K7.K7R.C.C<N[FW R'-T'?M"Y*5: %53;<*@-K<Y7^N]0B$5L/&M4PTK[W$
M#QZ+)8QT6?$?K-G1+O3R^GPEXIVEPBI1W%23T65%1[>%JK/L/GIM7<,7/*[<
MI![-[/1:#WE;,OESY\4O+H<E+N]1.#2Y\YC<JO=&<C11409L58-L26M06;\$
M#73'19:,9]] 7&3DYR/4T2WPPE&"JT"X2]5/7V3[LU&E6@5YT]^NA_$!YI"W
MNK^&O^+D,-JYH5J"T=*F:'*F"W09J>0E;.-1/)_L4S$[5?,<>^O[2F'MYL.D
MT>TW!]1Z3.7F<>)8%9>Q4#)8U%M.;K"8Y:N1?3^H*'1]"T\@["F+!X^4Y<2=
M@]61=URKC++W="#LY9<%HR!4ERD?5#&6:G3L_6;0,C1B>LN"NEE!Q2OG/&_^
M-W'V;YN5PYZNGJP!^ H',/;BJ?B_GT9QBM'&!#,T*7F& 8S29K+3*I>#^Y8N
M^$U590K;C1X/IUR_> K0RCJP*\Q$= <E+'LAA4:\#-J?B[Z8#:EF!/FOE^PD
M_)A*/9K2'6M[ZX?UZ] K,1[)5L(!-D$K+!"MNZ.M"Q4#\5:A^V)?!@;6KXQ>
MK];HJ>GZ,;;D\4/;K41T!RD=O>!"*[.C3[*/U_5I9JU'7(,ECPC8DN[F8??+
M],#N,?<):X4V30HEJHW-Y#PT]=FNQOWF,K41IY_@]<8(-:@N<A2Z<IK+A8IG
M0$QW;.J_RU*U[UB=T(I6PP,%-.8%VN):Z6M_L@UB-H7@YAQ1T/G,<7SL]M4P
M5EO)P*VLIS_YWO>Z<TG"GNQ6^):R,XHM$L<!OHFBFI7H,NQ8\6PN!),YP+(9
M$"8K-IU-BV&9<YE29 $'()W"L9(L6$=10KB9=UPBR;C$)2,*E_G>];I+%85V
MV?UDG2F:J2%*5JI%6%CT$9T&<N""'YFR.<_W)R>9BI2>-GZ^ET>LI8MI[1V\
MM5\:@Y,^3G[LE!^]L!QZ;,HO=YEB>3MIL6LS1MI,(4!*ZNS3((,FT1UK7"(Z
MA 31V;F>N\;+6B.TR/C0(<=\=$NA76^4W2.FQ>'' C9_Y\N.F4"'K+]S"/1G
M7TX+,2CD;6(DRQ=&<I-I,B3&!ST(7/GX-=VM[<7>_4>AQ\5AK\F\+Q?JBKG.
MNF2=XMK*DJDLZ9EL5K8K)/(.7>XUT]LJ=Q[?75WK\L>N9Q]YG^!G40X0\\RF
M]L#(TGTJU/PGWPM4\QB]8_L@50(U,7R> TQN@4E^H13VLY X' V6@UJ."&L4
MW3$%HM48^W. \T9M1(9N+WC3%/WG2[H7(U^7]2RZM+ 5ZWH1%](=GB)\8;15
M1I=% _U ZL>2D0'/2KDP'W_5I:32W,[1BSU"1\T"WK(P0 27WNV[WP%:/8=Q
MXS(T-Q$.D#+#I0=U%/36$8(&MPF6<G72M[7EBE '\KY09A/DXZS<R;KA7;BG
M*!((>R9HTIMFH6)8[UJ?_*S=).[PJRDZ,1_Y\/)_VK7:[/^+M_>,:NI;]T87
MTE2:(D@O H)*ER8U*%U$4*0+B( ($1!I00)!E-X$!!2$T$$I$6G20@<!D0X2
M:D*7EE!"A)2;_SYEG+WW?<^X^YP[W@_K0S+62M::\YF_\LQGS3G=_8SHOY24
M$'B\]J;GPR=8A_GIE$[+1!0F^+GB@-)9!_%DUMOI?ZR3W@=^1Q2 5X<BYKEP
MFE/=0XF^!%BW\O'E)D@Q9PI?PA7[=-C6@/(LWX\[;'#N7@_@*(EPDT@55]HL
MU-@$"B@ A@K*;X0ZX0? *%4YGP61Q1M@!%VR*&SDUACUBX^.9,,"\GE0],*!
M60U514MP48"4*[2E_W@1TIM4ZK_MAAZ*WMII!J&W-2"@V\,[M2$A!RNCZ20+
M%^W*M[-E"I]+4W=RF:U9%G$.(_\8E)R]A#6\S[B6N,/&4:CD9+,*ABE! UYM
M!$/K9CP2DW=P6S&R4+^K_X#?1UN0!HQ+M6D</[B<X'?5"2>%*A<T'/$,=#?V
M1MPLZ1:!?A#KE)1GWZ&/A/!;M88.!J93@//-? A3Q--,DXGY5(R)N5XBSF_=
M645N9E;1YWM_*9?/O=<U-&\A M=BR?T>]?.76NQ:SU0L1(M":HTR.LY'-EIZ
M[G#_H4K*1=6>ZPOR:YD;1%%L7'<H[;"T'XB54*\[4I/U[(]E0"B7X=)]HR<W
M+NP9B:4$B:6\,*'5I"6?@['"AFFI'J2-JJ((F2 T(W:-!"BV$D\E48="I>,_
M-2^U<4TQ*B0.:1#5.713PR:6SE\(^YK@2P[C=233&%!O9"H;PFA</0IS=XQY
M^PMUT_4,=BW*NM>;O:=A_]#K.:,#XXI=ZS\.9W,(&QI9@(9S$Y*Z>:>B&5K*
MP,KIEK(KUA7E]_0\IIC?FVT97_ 7-]+,2#)CQ?__LMMP%ZXD0=$[BLS;.E6[
M2:C9END7SW0O?@0 ;K3C.9TM02>AXUJGZ@FRWKC;FV8Y0QT9W.?Z%%G6#+MC
M/Y<[BZ48G K3](K%P2);:UL[%V)&P*L_]_8-LW1J3_P/ZVJ?XK_V>H=#9U4L
MVK8-VJGPLH3>[=F]8)P+>;ES+&UFE_7-:?Q9SL*V&6V2LLA"$,P6P,?^HS,.
M@3NR0"U'=F5 BZ4PYCLONW^<<F3K4Z,S''H7FV&7S^-@@:\S6EN[(1I/J[62
MGY+^ZB_C+0C"C9)G[N!*.M2S!J(]I0MP_%FKV1TBJQWK+TQI,P_8"-8.%ZF6
M*(/:4VV$5L+GT8D:39!#O;42WQ79/,OYJEE]?H:-MVRA)JZPCF_8>A(3RIM\
MJH1@1DOM*2>('3G27H@"T%)!&4,=:!$1:.]C'C\8D8TZ3&*+_^Z*OZ9"ESH6
M#F3=6PEGX6CM(552 <,KG,[B4"Q4LW@S1ZAA8E>J,+9W6P4;863]2* KNYE=
M8=>!#S/T1H5W*,G/W;/9"-VZ);GN9SE1*601;?(4S[^=X+L?I>$6[]P2XO/W
M/V] E$QB@@VW%%. Q6NP" #:>R)-U,Q &\3Z8F39(<_<;04SQ..*3#T_=8TZ
MZ!^9@K)$PD^=XY91[:-;1<+_\4D^OXP*;^8LM.GS#RE8QP>,D/Z4A"OJ':?(
M7?T+N=DJ4:22NZ,'=B?/TO8K\A-UJ6:304&;ZW_;0H)7*]:U> A%)Q:7@KO'
M']5BXX-=QKRG ZJ:,H1K3#8265X:$*\(G8'Y/J#"?NT0!>"R3TQ%VPMI9QKY
MS<F,]A@!5L$0"R::879ZCV'1GS"T-L'X)+.$S%()(S2"_N[3@<<5VO\+)WS
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M3RH8XQA-%AN;[0TNAO 9A!AM?V0_JQY>%4EWSBK@)AW__<:6*#<P7'_$49E
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M,:X)7PKCRTZQGF;$5JKC'4>V%!VGJ9K?O63:[E<A2K-F3[K&F#N(][+4,LW
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M&X& I,_<G*A-P[$6H26#Q^VO[1&O5WT8&UC8ORXIQWI=>_T&(K?T7\EV#U
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M RHTY2=]X3ZV.!G=!#HWTS)89N2#+_Z&.B/5+?>-WE"[+7X'$8IXU;J8(RA
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M5+/5L!:ESRSF!2@Z\H>EIJ$M;RG>CDF*2'+'Z(#\R PQKCTH]T+FW:%W@%.
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MG;SSAN42/]Y&F4KJ&-&%#++O)<TAINM:5@8QAI&UXDMSU8./V_6(!P14^BG
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M@/$$9]^AH4'IILQ3>DY )'W**,%=<>!'-/ @ ^BF-H?V6G53^@59!$^)$@C
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M\O)51B10F7LY@?J=ZN3OVSK?B\T?;?B7,(;9V9[HW>C&!3TQ??3UNW7PUYN
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MD4[I%VP-@D$'4Z2(87CK18X$S(6FZ\2:AY%=/._-CJMF>1I;DY8?O)$2O(W
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M@X%S[C$"YT?V8T#,#+\7TZ%W-]L)O>5^3??"GM_7V/4P9*E1+TG (R+M%=O
MES?$BV9^%J.B1:/F2F^\O&A#JL?7<PO%'G[1$"8]K7%64]4(*ZDNQQK<[!DA
M)E;NU]P^3^-ZF7T]U#_^5K>)#7,8WKH3P97\.%#6(FEL@[5R$J 3BQ3R?GKQ
M7?YQF:K_D^>O:P-Z8P_L",42$KOR4'^/RH-]UU&Z%.PRUW/Q,K,?7LG.398#
M]2<U>F<0&1$GL*78#F9!P^\/2:T.(Y-XW9D9UN6(SRXS? R#M@>?-U);'7KY
M P1H+X _P3\TV4 PCN[W[)] /J8R*7"$\JX:9SR_H219_U9)69F;"]O0NX>-
MC':O&@!99%A^K%*E;X@)^/RUK'B0CGKEEZ&OH_)*T;B&S%D0FI"LTD?Z8%"N
M%00_H2>QUV'N*9HFB:T]*[F6\1PF*X^</14ANM:- B=E,W[;7EJBW5W9$E\R
MEK_#1VQ0\XTI5<9U]3Z0@C\)NE4)NL0XW*K5A#SPPOJQR*^4@'.:TU+%P;/G
MO9F806^_O3YXUK*3LXAB7M,0PVT,8N94[T9J11"FIZU+ GRKQN1V?WW!OD)O
M*JOCXQL.4-?QHITH3M@/:)KIQ$JMOA_-L+!3HM@K#U[ZSZRJ5T:2.X$<:I:+
M4@JJ3/:6J=L#7#??Z"1&".5 HQ7MT?*L_3?+6&/"]VU9ZVWMZOPA&Q_S;\>Z
MNMQU<1'7J_?4^U($91^I'SFN+? I'=Z9OS9$X5V;#D>'NRV,8G>W7O,W-H5[
M'&[,W!8^,5Z%;2"V5:^THE(D:M(6'>.O#QN^IUS] 9$%OD<\V;MXS*VP SH<
M?\W>^@%;_+RPX(&"?B^Z9&9YS=]2 QS5<A=R6>/E%@%5O8.)0YT"W/V_G2'
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M-(8:Y!N8B/MKBA(U2U7GM1A%LK@WFEMX'Z<3O^\-R=\<N/M<>S_G:RSK%$&
M]I*,V=$D F,4V,.4..)N:U21(=[26RJLE\P'CC;KB(Y?]9W(=*^^BWN3U9V<
MG.BI24U6YR('S,SUMM8#6;39H^?3]1$JO:];!#98=&5OUS^N]TQE*!0K[&8
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M!5.SX7@_]F&(*>,QCI=7).J(\."I&9G6&+2H=6#2$<G-7X;<'CK#\<]4DG2
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M'-B8,Z)4\!/K(P3PP*M+W=;/&^YBC?7VO2QM;,##PD[9CPYQFV)28Y6WF_/
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MA!>2 MJ51T*H,0%EOXP*.$_VI]SLR:NX;O-#_<-\X:'KKB!%4)G2IVC,'^F
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M-"92X^'S[G1 -8B*!"N9#8#*>RG=4SL+OSWKY#?,K+W^X=</%;/D8MJ=;3J
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M_&>(R7R%+?'LU[=/_!\LK"TKS!@<Q[)3H0ULQAS3%,D3KR'.99LD-M$!9N9
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MQ;*W-?!!![=E:HQ7(;G@;D.-$M?.<1%OTYB0N;C.8  CV!_?P$Y2F4E-R*.
MR&/%L)O#VQ+L9\F%+\8QK T?QK1=)-PTXT4VPEG;<:&Q 0O]&(>$5QA>U2-E
MKHK9<F2G@GIRKD5OI*J#9VF3IV_GXKB)5HEAWS/%!.L1X$NX R;6@#LTB(L<
MJC<P?>A'X!RLSK[QS"@9'Q:G:VUS3L\>_UI(,/K$N'BU3 RO%*5JC -'U*7L
MALJ#R#HPW0U-IR?6PFO>S.@HD;E[^D+^3(0PQ8=2_"%#+X\?5>>C(H(NPNX.
M@>RGHO<G>BI\2GPW#1N&'K^<GX'+-PD_@Z$7CMQ;$T=?%S 3/)"!^8^NKL'
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MOA__=B"-[YUQAFEAA72,\8.AUG_=R]J= ^ ]Q@&X,(SW9FS]G0/8B@JG9'$
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M@"Y?.!=.=T)+(P0Z=YF&]C(-M1,$!H%HZ&G^:X#^IT%S[FR/YQDN7&1D.EN
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M_D2?%Q7XELR3^Z@C0S_L>0J?-5D0,,=!Z/_@%4\$/K)D'7"SW_G,2@59> \
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M\<^DUHXTA6L:^AZ& 96%(>$'"4FV[3F-NLO)R_DRTM^?NC'VZ:_[T#"4%B-
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M)0DF\/SSY43:B<;JEQG?1V/X[2739AQR^+DE!Y6; CK[!H:33Z#0H0IEZ%2
M5<K#88J@IZ5H#J^.P5N5E6AK*XJZ!>(UC*V,,A)\+3^NQ;(2>J]8Y\6S^NK:
M%^>^\[3'T#\1?RH7862L68]UDV&9WUI@A0N^,KEB:&TS/96?-+3:F]]Q1V;+
M N$*>7M-*?JEM'&'P/76V <8=,LK2_R.H,5/QCZ#I^=-2R.W'&*$<Q3\%-RE
MQNP2FO7[#M6WE:3UK?2M8CU- WDW/J[!T*=J'QVD $093 & +%><G_11\.;!
MQ?W1\=?+FO7M*-"XK3W_GC^$G[R%RV_WC<&($^ ?PZN EK]- ]U$Z9S-H&%.
MP:DGSU_>O -2/YFL)ML1,9%+"U$4N4CM<>D#I=H(B$;EQ]!;?\\OO(>5[N1%
M[2/5  B.+0I-H1N1:=$)*.ZI2L/?;IJXQD6G.Q, S@$=WS]<J^F8J."[N6GN
M;^H/9;0$PCPP:W]^:? XEID6%HE_[9L=V"/;CQ].=V)1BBF<&1"VEU8K&=,/
M,6-7GUI]W7O,T2V7#%0(*)_FL748L\T!Z6UPP?%*W[I]TH/4 <ET(1GIB/C6
M\T87KN])+* "9]D]'4"->D5AKEEZ5UV>/J[:,%H,=>);:X8D(JZI2Y<"#):H
M[Q/;@8;:)U/XSS'=@?G9] :RIO=?7U0_L7BYN>04VR&I!!NTM%B8WP)RQHLB
MLV2N$*_JR\9*M5;NM&)I2\_D2!E&"*8Y>N#UN9 D33\X_N..8-M3C6ZV93MD
M-]OK$X:$E0EULU>ORAY^?>@\6-UVT_%F#\],V_VP@ $/RJ# M6;"4'NEJM2?
M:=Z$,H'=/K^(\O75H?&[D*0@C"(5E*KD0 4A+YYEM*UEJDWIN%]MB)M+4-V!
MQB]IT<0?IE8-_Q33@\E#'^ T9(;?FD(AQJ0 TY:QS\TQQX5/4%D*]Z\(,\?<
M#T@+FUB(10U .J@@E&6\3Z#A_1FC^CU[]:W>"9'!/]^59&G57QY6U1YJ4T%I
MMGY4T#,)Q/Z%K6@4P2=E&3D=V:7JT^AVN"7(:[#Z"@G^=?4F7P%#XR[TGNK@
M%QD.QA%8=2(&RK(-0ZE>+LG&>?Z.7\_4)4^OH?K!=>CX.L1EKWD&5<UJI[+W
M/LYWPF/^BN[UNE?G%B\7D,L@'B0U0\LE9.3S0*DBCR\#[#KJ\T_OL<MWJOGX
MG&<(Z.',)I)PR!B*P%8>"Q44A3"B#)',.XX7L&F&,S8:V/!D3>+?+5MP74E]
M_BMB9-MMSVZ%41'=D8U^L:P(8166K)_3LGG^LN;1AUZ;F%X,=-ZWP4FCUFK7
M)UMII[X5_:]Z"B8)Z!"..B@W4\P)/?$B$RA>JX7;MPI\5:.?U659_>8+V)IH
MA7;1I;!X=KZ ]RI17GO% 0&?8;<)\RA!0OA\1J#!^T1O_JIR'^>7=+(TCY(V
MV&A10?/B9W%SLSR+FPIVGQ8JEU@FB4I/3Q_%2\EM[4W+%CWLEHV?W&ZNRCW)
MNT>ZGDX%,4Y0091V?\1&PY;<<L=E8@<N'[)'!%-2;!(.K8C9L60- N5PQGSR
MY=P='(J'_UE+<[*8U&KW'=I+?N]>'18M!XYQ+?!@N&9G#/F[6FK:B0,<YW7,
M5-_=X[ND$WKTR;G60Z]2@0H:L?YWN8SKW=?2<C0E*QY[Z4 J7.RP[+>OKYAM
MF&V8:)JUW:)0W)K(>#Z=!SH?K'D#?&W3I-<7%RY@G^/23%Q3_11YC'M_@GO5
M]@T;3Q&H);KA%8K^<FTXC.SU.KZCC;B3MICRXH7." I.#Z3]P^4GH< Q>=<S
MHOX9_$V',':N+(8I'[_>GN(WM/BC.YA-Y-2 = 3_FLS?>)1+'"VU!8R^8)=6
M[<J.H<39%<WK&]? \520A[VM,5&Q_&6N>&=T55+G"[S0'&/2R+DBL7JI/Y@K
M9"5"< 0>54$%7=P:\8H(@7W(Q[^;%;K$1$-"<:L?(<6)%MFX5J?#@O'*%JM#
MXL8 ^X=KFQLS7W ^'_UQV7RDR0: S8!P*[IX<\*!L6ET5<=,H3/()G8Z3DV7
M;O7/FYZ11B+*A8]?7$SZ&3_[$=P72Z:MO57$LZ;@J2\;5"9M"UL016$7\\))
M?-6:C)-W$&O"5%#=Q.?3DO<I<?DLMW6IH$=B5)!0AS455).=* ]F!72L8BTF
M]O%W/&30Q<'9?NV_,#:)KSN=7;_!AY4FIK.3-;GFK&<?!GHI3&RLO>DH0GYD
M$XREL]BY8STD9^-%!17+)2L( >%=&B^IH-$XMQ[2SV^:*F3-AH9<:3S.W?DL
M@))""<E6Z3^X=VT1=;')+2I5,"ELW2A,JV23RUA=Y)Y7&%_5W1=ZT]^,.8?@
MPS8N]2ABQ8_0\&V'P)+?\3Q%LY;^\BN7S])&8%RF9RABGID [0@;L-0>QO0@
M^'X7#AR6%?]P Q$&=8P]XS5[TAGPO&N8+!3F5M/')0'AZ>73>+MZR^9@0-4:
M[@AT+#D4+?J^AE^L'1%U#[2W&51.PQD/7?&,](-J'V?0SHBUVJ-/T[V1\ADM
M8^IZY> K31>O[8;6>=RBX;O<LDC,72[U7*)(_>726ESH8(%?F%H:Q8^+"K]K
MCN 4FQ'7#N\*&T#V^-(9XU 3X,ZK)C*9:PI%C[ >9LEF?8-+ 3VT^X5U%28E
M0U$V?0%K'O:[A:2FRS%)S _-C:^=_AF-E?3I-]^%V/X-&-($D4W'%H?)ED5
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M5%U"21F*'7XC',P=C"E:I-IJ.^<MW;MV?4J\U_&%2D7Q^H#1M_URG-H19>M
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M*_@N03.3I!^BI$7DBJO:71R7=@R3@+>)N"?WK:\)IG[7O4Y,1B&)S<M<T4Z
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MD245MF@R*'@!\&^6$52S&J,W@S)I!HQM\G\X,%9O"GB)TR>(=K"W_3"E$L:
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MY1R>VV[9 "EQ.C/&5W#'V,ZPPP9$#.7I^!29S'HEL6:N\$37W:1H49,#9NK
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M!D@[[X2-@6X.7 D;\U$$=ZCL@4WKGS8N;:)7;]( Y=!5O##QX0A5B#1QHY;
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MPGPY$ANF&H"^?(VZHR4?-B:+"&H$]3;MWSX0P+&TB6CAU-K,CI)D;S7\4*:
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MZ!$Z7&FG?&%A-WD#T8K9TUK:CR<<Q]RNP:\M#Z(\BH<]7+::!AA2 KH[SQF
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M?($(C(/ZRG,+2#?*\%T2+<M1?O.Z><Y<0HPM^%&LG[+P==]/N:[?C1KLOCX
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M1/8N!"#G!X74UY)\GT$^"_:A(WH!4O]]5:MVQX@0DA0!TKYYT=:O2P^K;D+
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M#F@JCM"R13";:7U"I%G[UBS8#2I5KNZ86G?/F\9\J]"Z[?3?!H.&DO>]<!G
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MB^03[Q_^-L]J3BDOA&@PS+(!<<S#&L :I"#U6L#.. 5%33H"S.:DOP^^@23
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MNFMRL>OS5/HR2N%0@ZS4YEG>NAQZL,.745HC/7]P "H8>&!1\M6F>,S?2<%
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M_8> )8'V1[F6SJZHZ!X@^1Q_ ')DWD?QJ\T#W)4HWT:!9I9D.[-#NN_J%O^
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MZS;P.01:T"6M@:UT+J*!6%-:,#UM**^XQ93X06=A_:[__<EF%C;N$]%4<02
M6J$IY]>#ZX3/8I@IJM6#CL3^> 786I#JHJT42>*6L+-(ZBU4#>=C-G\-WHLJ
M/7.Q.<B&VNGJG2#]*SOOK0?[C@!>V!'WA$3,LPGP:]7"]8^X(!V2!\&]@":
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M2U(#S-/VWW"R7ZQ($@7P(\=C *80/ -J75$@&NF#"#V_$\(W;#-/^]A$#13
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MR;N3?/EB:62;[-_A],I\YX\V:!DXZFKP8IA$@2ONFGK?:ZG*+P6N')+NDB-
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M",]\#.#)H7"-M_#M,HX> [;:0"2?1JV/C71DVTY?&X_#Z<.,))\4RJE@UV,
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MDON'2,> O1TG*BY'?_PD/8'8\8_/XOU!#2%^&'-A!NR-PR8>U<LPSWX/:4(
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MO.D!FK[V..\B+ANR9A+BNH+\+2UX<&*F\&,TKK_XE[J'0PV"_#'@0SUEXAA
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MZ!?I0HO\$BUWKC+DYI>,/E=ZE,#==^IVH3C1X!Y.79YM1=T!-I<4-F%KG]$
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M.Z:3M'^4'/8:/7O]PE;%LZQ$K('U^0R5]%[3'4$+,_(@+H.WQKJBAI<5C]O
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M%YJ*=1"=9'U']YTO?I"W4R+Y8\6J"Q6 6#^U+H.TREKP3\?$H7FMKQ!B19K
M"#;KNSM*UZQU_=.TQS,TOV68*M0A[01,RVS?KV;U(JC8O;S*K':0VU^:JPYV
M73D]Y8_!O@U^4_WE$260.3B+$C_D.PEPWGN0VLR*<\4DMDF;/ZPLZ#[EFW<E
MVAPG?2P057<EKH'0&.DY6YLQ)0 V8@6V \?9.P(I\8%H43ULZ3()<,4!5O33
MZ27\P]25@YR^3BK>Q+O@.?5&K619?8 L2R^9_X8%05&9&!.LHM<24@G(A-?
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M3\_?N>/!/)!]%5^PF_3C5$]MOM/YZUKF4A6+JX,C7!(*PE(/+K(J2?JW+_:
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M3^.KZEWPGR&F3H1Q(07%Q5#%[/]O @!02P,$%     @ 4Y1P5H.1*IC.ZP
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MX]*##O=9=<(S+UWQC^FQ$A)'IIB":=BOF[U&T<2G& V-.J)'-"GL+ 7AB(@
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MF->F5Y!O1JDLT_!!>=CC,]<EI98RGOE]W<;RC3G81-KEVT#6B>'ANT1YY_W
M+%_B#=(K"B#LD*A*$.D:[$4WA(64X9Z&;,J^RL#-Q^I4<&R9X@Q)+)6V=4UG
M&3"=G%G=)I=Y\;IPL=^](IT,6/+I;00O<;H!SWD4U^WL?%Q"+I07N]&=9%V
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M8^PK_]GV,$HM W+K:I*P]PF0Q>4)>8S28UWY^QRZ;0NADO=U;-X>GI:!+E
M;=?(S!)A</JM5A:/6]C*9GQ-SKYU.^^'[U,_=R-+DK]PR9+/@?>B=\MVISEK
M=DY[YLZFI1.[#:VK=E-RFD5RB'.8_I._Y,OGJ&(,C >1?^Y0 -GY.D3Z26LW
M9(5A.P/PMTA#5=V?]W*:LN&Z+)_;@1?::%CI4,[XX[=50M&"3.---Y>"F'?4
M+IB^GYFW_&PGK2"KV77@Z+BN9,PD_;:)-ALF@_-+7@0Q3C+)W1_YRCGA%V*>
MUAOK\*YYZG-#ED6RS;#>.'L+6GIQ -$_;][$NS% V)_9UU"G %XU?D,X2L^
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MEZA;]* T]@K=M1I-VNK7&]/Y615NM0I<;^QF%.?2Y[42F>%T]W*>KW$$B'_
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M0;"QVJ:QF>@-BFOFM53EJR@.I+.\OYUYS-3Y[0=)I YK[&S<BG9SD#M5 L[
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M1+608H(\RQ^::V_SIBN/ 3O. 9&PJY2[1!/"IK<OGG9J>GOZ_9Q"03+PCC,
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M>09%L5_.'J(8[ZZ?7"V;852Z#_!A=Y@/[]6+>#9V9;CXK&Y=&*OI(EZNJ7.
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MG7?6)OB2[ P"<M8X>)_^J6K$+\#G)<9%E+L=Z=4AJ4;]]/*6,4]KLG0<>S=
M&KSQ8_#PW7EA-O9C\3H/I\X.;.&.!PV!]M7><\,;!;7IV9S%_TS=;7CY_95^
M14Z#39?HNK;IZ"Q4@\C8:&$"I:KA0=(+*2BN6LC,@?)5"S<]_2%E47!9PZ6
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M*(.V"$K54H_KYA-GC(F!W\+NT#]LK8+:>#YV*%NFA!>]ZGM@WPZ^&Q\7__R
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M*:C=?#%7+[2]W$,?]\W=8@(GJS[J\5QJ6M7W6FRO6]Y1+F,"RO[(Z'HP!=Z
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MQESJQ@1"WT +>RN5)O*/'_"_F^.D(N&0B-3A8 *"G0+6KQDI="M_E>J_HZG
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MVF7O^AW_MK=/AP\P^5_[<]NS(;BZ1C)LQG)I\WTWQ,=8NHFLLT;52NZGPE!
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M3Q$(1.+*4;2779;#>K2M.*#" < C7I)3#YH+BOY;&<-OP731< $C@)DU*#L
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MA7UD%C;=R[PJ4IS>C:H]M';&KTT%TB>[:1RARD&Q'E)5-8'?J*PF*K;EM%U
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M4OSGT4GG;-O&=KDDA[.X&@R$"-0^$[E[U-BY)('<<X/^!IP,DBV#*7=8,]X
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MZ$WB3VXF^ Y&QZ>RZQ]V?RA)C74GWK82"%O[IA=-J2I"<V61I'?Z^[V4$J.
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MR5)M+Q"M3<T$VRIAX^CQ:8RUTXJ.RDFL1D8[ZHJZEU"?5&][) _,T/K97#@
M]VA.0S;[ O5[-8;L=>F\J]%8/4?'$:.DBXWC6YR(W8N5R-O9/Q[C-WC60J?0
M;$LU/^%4.3>>X<.R<J\7>T997%&06I-X&;_S?%"GXIJ2%OD[T^' K#94F6T1
M;A53 -?H7=U6.4]P3IO0CM(/M:ZZ>IMF<)?+)(A/Z<NA639<^P&@3+>B-HNB
M1FR):SDS5:^I/P"_7I%#?J![9VFW1*+;,#.A3]_H51Y#""5P?2'>LC*3%'P
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M0CRM2!PZYU*%WL2:Q&H5"5GBG(Z^?.+K6F37^VLFB+&8(*6;=<[=9>9MTP'
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MJ#9Z0UOU3#H#7A9:E983IB9MG+N:"MTE8F$>"9!NB"D^,U*J\>=#:C?_%88
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M@H\2O]OH)";O8%$.CL=R-(^Y>ANG9CX\T8#KU1KW9B8Q<I\S$ NY<N2YP?(
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ML71^\=[R/5'#M<)(:+5"?@W]?ZWXH;[3CAT<S\JZQAU%:PNDX']0#C"HF'U
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MX?L8,KC.*=&% 6"0>B5LT:!UEKE:Z46X3@@*DE(688L.!="BOTS<MC+)8A,
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M15PH]ZZNCW.JNI5\].+)1TNYM69L"7-*$%L%)CSH69L8NOE<Z-6%49@BJI/
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M2I':X:CF'(27WVV&;%' 3)87YC(,.(5]T55$"X ZIIDDZLK+8-Q8Z<Q8H"R
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M-T'>ES%\04S6%;8^0 W%VRT8SG/=V:MT%(K]^?GRD?( KVRG6^'O_+NF8\0
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MC,7\:RS>X#Q&C]I&4N\ BU155>"(M4([?W]%+MT]A'RU,E?N*E(>S+ V5_6
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MRK>6F3J>TNCQ8;7[L^V%TG<?U**MS_PP*/(J5")9Q /+42\0JM/-8V/EPUO
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M1*14 '>M)!E3M%+60E3Z-P((4NPY&!&YHET@X9@N5_'&89FTVQ?KXCL'@+.
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M)DK#5Q89@[QTX)H=+C%G&.K7.C=IV@:NTDH(+0[1LX1-Z9GHUV??DJ]B:/;
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M&KE;?<FZW],;)8++]USX34W&E:J)(-%UCH^;: _+7J6[PK=!>W^1HBT^6S'
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MW_.VJO#)!^+EWJ"7+W>[8?G1(9MN]QX$)FL)V]N\,T8C]5JJHM/+?* 2-,^
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M7J(A8.FFA?OE4>6=8D@TG+7Z<&/;;8*.43/URYE-@_S2SD<1$W&1U5]QW7A
M['4,8".XS(9-V1_I@U<?@(+1QY I,XGOY=K _#9(;\MJ!ZA!@U5;UZ?F'=R]
M"HU4<J>;Q@%(.%KO'#7F; [U-BM H]^]>#V$^U"18J#WZZY,\:"K]$NU? '>
MUPTC#RB$X"8!%&\%Y>AD&6#UL%3WPG1DW%FC=^&SZHHT+]0EBN';392Y*PMY
M^M?YL],Q/_>$/;Z5YW<)],C31'.Z)3WBZYA.>&/SWP<@,"LX9,*/0\60F<+L
MNI2K<M_<\JD??DE!\G$YS]+5\HR?I-E'A9C&SW%K2\<:5T6BNE(2]V-*$&9
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M62#:"DA,@[FM7&\GFP[-M]?^TO97^OQE7W!_//%;\N,F+LX47]Z<?#V"9NF
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M([,0X__B<$P^^QI_>!OKQB<(G.!814YHT/>F2TB^!T "25B_-;GEUO)XL)9
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M5S1D!AD$KI!5PTU&Q]O*S;"["'T2+!PIMGWDSUHMN''KODI=*F4_P3[IO>=
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M(,LSU>+07X5'PTL40^IV#[5X3Z1<_M@#>3ZV>U7<(RW6A7-\>=&3M#P9GJ&
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M#--FI<X^;#AGG;SRU0<S>+>Y-S5E?D61P@15=$.)Z7(WZGAPXH.-P%UNV>&
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M]XS)O.IG6UKOD"HUXWAK>G/_ YBI\[#IR]JM5]^1*;%.U[$G>#:.?5A58H*
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MS'A6*E00W=<-X*BJ#(()\@N4W<<CW%:"Y$:=C[QSV?=!#B<7Z.,Z3:H/-9X
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M@M=B[-L;VS,/X9+UOG!9I&0^/<PD]:?!.3?>':O;O#,<48^'-"R#G;8V'BU
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M5QNGR1Q*.6,$/]5G,!;O AO,7E&DJ:DVH=>V5^75L?RXB C_XNW5=!O]V]\
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M0MLRO!*C8]M14RG([^@)XD/4L$D+>:H5Q=F$;A@Y13MJ?U UISGTRWA;C+I
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M1V&1&"2"HN]G(MEK>&C3(Y8'3Q_G'+&&"OL+R%B^'KDT[]H'T,8)NU#C5]N
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M'R2+B[ F'5YO-<,^TAJHGCE0H_R30D79U\??+WXQTPF*O**E"3,[&3L8#\X
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M;(L/_R"V ZU@:!:=(Y-:J':@CYXIG>4XXL$^RD7TJD /5N [TI"NS51?_K9
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M8\PSLSR\EBTYZOI^2G.3\H-(T$_W$XQL+Y$KX'J:FVPG,&[V".(B1,:@@<\
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M5M;[S/F^LRAY6 S9+P.BZ\D,>/(BJ3QL:T93&[0[H%>4(%3K^<)&,\$E^W@
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MYQFHK9F^C%T]A_<3]102;G)=\JCU;XIZ.ZX2&S?\HS)-3U@I'^PN$ALEB78
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M^EZ7M"%X5N.,DWA4+RC]GA)U!F: ;",4<_D6@?V8^U!'X%&U7;#*DBOC#\^
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M,U0^U9ZUX&@%!\/>$!KP_LJR/8IV).<&#RG^[A#YSMO/PRKDWW'6 +*F@QQ
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M*_(78*?KB=9FYYJ*%N8J"HN#IOV_]\;3C0&?F^>!\P;]V9;+--;.%/?1+6E
M;4]/H:,_6; P?RF&KC:@(F%9Q[YQU&$=#Y@[47&&N*=21H!]-7G^C[ H;ZT^
M88,P/.>Z.NT2@IN:3C-D]OI=[BV,A^E0?1SD(BG^[_W'=EH'WHUA6&"E&$G*
M4+@'Q9O$.?6D:-!?5^)*P#YZI_(%D+'B9P5#0<NT+*6+!7#7MD,INNJ25>@/
M^($YRH/.3= M\-.$W=U,WCGCWJ5A3=\[UK&2]6=6%F#:7WETH%]I4 HX_'-S
M\H[5&9&%SJI#4FXV_M(&F<(^3F G-]&/:%$>!S8RA0(<I';;N:X_W[WS5'L_
MJY)#)VH$:ZK7Y<@\5N,D:S+P(5^,,O;(U#"8F:T6>F).?OASRN#D$9^X_/!X
M_B06CV$-YR5%6CV,I.O#6[L)>JM)OU;<(\-!U2$^A!5FBS1'X 565T7F!6DF
MTP7(MG(+?+WN(;,9CWM7>S-=,[1*6MG>U4 U9Y''KX8QWZWI=(JE4\[1/U=/
M8S]X Q(O0EZ<[R(F$1>.KIDMN<D_2WUAHP*VO,(Y4V>N=BZP/R3&HOR.Y_V^
MO?[UT-#K=M4SV9AB**D/PP*=3IK&4 ]!EHR9K'5DWCKPH6KY:2^TOUNVQ?TV
M)7%UH5YTF6')@U8$@-KWC9%5F(^5/#9!( P=$D$V]BU:W $3QCR1CJT26.CS
MJO,\&!*T,=*W;0!9^I^;OLOY/9?"2N3OJOX\RZ)I\3 U3QX<S=^95+ L\)4#
M]R[JGH]H#S6)_F7+0?Y3)L"O=! W@,W(H\8S'7"K$PR'\=G?!30L>[69#-WN
M#0$PX'A'2NFO6 :=QG["$_X>*E7Z<R*M-2F*+V!,(&-2M-TM]&Q2)^$+> V]
MC)V5 MR^(3)J%!9&JE0EU[5' ?>;/C_VLX0PQ[]1+T'0+S^L\?RF, .>^WTR
MLEJ/R=#J 8LVH)9.-J)\U6>*@(WAP%/4?U01?$>*%L3LQ>RAZY)+B)(I1-@^
M^^<S'A[9;S72A+971RX8:IGT2DCS2TY=JWXEL2#1WBP4>N_(_K0W6&X==H-!
M>HB=SK68>T/4DI'%>=@(H1]+<2.SX^K9M 5O=.\[U^*2H7% :-^](PFJB+E-
MT,Y"C5QE"$*EN] F3%'82?BV>7P\V810B&G""R"',)SH.HX O;9J;E^4V.3L
MH<O5^]G.KF"KH;:X_F>:C'CEO4-P#]T0V/72(BN/>RFOA""MSJR12O%WW;3E
M$\<X"6V-,C=WSHR,95^_'K$PCF"C2<"=M:AS-&\X3I_\*UNNF9FV5(2SNUPZ
M_P6H9@0E@C01.$^C><&UC$E%A0I7Y99/%E6]G?^%#03GM*)LN_, /.C7&&/=
M\L3I:H&C^DA"$72A7P@)890BV%_?8#*_#,,_AJ4+(=[U$!D?RNS3"TS7%[TC
MGJQ%6>&[G&L;"%0QD2>OR>D-4@'#1\*)#<&3(@F<4(B38$;>((7!B*?S)B(_
MQ!S-3+X3Y663E*:ZSW=V^'@X](-"6&]E%Y-5!?!L:J& FC[7+>G*62'.:E&^
M[R ,\*!J5"M5;]K2P)\"XW4')8A7]D"])_@A^.B*J.6Z40JV;]3HHAWM$_4R
MC.,M+*)L'+5[$S22:<E-E2*UU WSD"TC,F9C4G.S=K@X^*:ZO)NJ<L>0-J0"
M8"OB#JCPOO?#AP''Q)FN2640^7D;3'=2CL8\H&1D\L]%(EE@J?:HNCCD.52[
MNLK6**VJH1KAI_%H\ [FXHYQ GJ+^Z(:0K]-ACU[,.<I(5[DT%L6Q*.\E-FT
M&P?_7<3G(>RP,G@6RDKWS(7K&MT9U.O,.S;@>O##%X%(&NWWX]"6V\;^%<7R
M,BE&L^=UDBL/3[)O@@*]6M/]$8XILWUZBR6%I286QGG;L.:,;*;L'=@QMQ"Q
MJ2N^OQY],V\E<MVAYG1>OY68+CL?A*J/^[ARC[KQR5[F=)W=-#X19[,)&H#3
MA4-]N,Q*% (#\TKA^>&5MZI"P<&P;0@I.%/P34=P.9IPP]UWA]O,*C;@SH 2
MI#/4[4GPK1@=/:/KQ9G\I5='BX^&)W:^,,J4\?82B"7/C5EO@AKQAWD''][J
M(HX.$]Y*>/K6<5L+L[!(;T#J]*.A%[V&I^*#&HT:#=VR+Q;[0$?Q W)UI@3
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M3YEN&R4!T"4]X(/LPPG6M&V"AL81SH!RWNK&^5E&Z,TFJ&D" R",K[DQ(A6
MTD)K=;C5,0ZF+X3D]5.]B)*'U]$5P3DXE84+'EZ!VL#CEN4I?W<H)Q>_)V%9
M6_RN,X(JZ0:\5>-NYOH(85V$A!K9LB5/?'ZX6\.?!4V& \E6LZZW<(^V*HGG
M);\A8>EA_X_,.G:Z'+4=VB9&J(_.!CYASD_):GYH[W^OZ QI>G^(#R1R_&]X
MX'_# _]<>.#/%O/>3X>WD __G*KJH?+C;\'C"/IWI.,^*7_4AN_/X]?6-T$6
M'#6E$4PU-^6OO>TCF#,_;!OXB];3_6L2Q^4SY_]8[N9GE0&[?A;[]VO_F5I<
M;VD$$T<8UAM@N[J*;H4M2/\*7_(W"8'*H;YU:W'(;[OI:URQ:QO5Z6OXW8#Y
MA (O>:L]I%)E_H<[_=:M%8O_CN9X!?H,K!_+26=-0"]!;S[XQJ_-N/--,SU*
MM8MZD.EBQ!2JNJ'W)[3&_]#Z=Q_]\2?K#RHN(GL.3!61HD=*  8,E^MM(D=;
MA>I/PU%,-8,JW8XMF;&"HO[V&177_KP*90CWIU@PHQ(X1*[ ;WV*5*\E<S5Q
M7#8%[I>(#_V9VZ$\_R?X[@(@[W\H61EU/H@;?UV/&L2%0Z\UXX9&@9.&M/&^
M^16,?5./XI7Z/?YK"-T$N7VE*1M\#]AN.P! \*&DD49_U7<!74REKAE]X^7Z
M$F@'H!)$?UPY\M]()/)_6/__F[WP7ZRAYV0D('_*,?=ODPX%+AX%_W"KG-\[
MM@:SW[/QE6PER.(^84<,5E!A-+9O?5N5;ZCXYC8D,>_0RT$E9.'9VJ#3V3\-
M /QQY:&:+.4[E?GA-FL6?9)C!5T+URK#Y9MT>LZ]^*WL]8K8V?N(_"%"*M:O
M$$>%$&I;U1N;$XM?90P.5#*O= ]A(_MXJUQ@3G#;^@'G9RL.CL8:%:&41N*.
M)FG;XWZFIYMK#+14Y(1Y:')EV?^0;M50_Y<R_/T_$CS<*-C"F Q5X*S2$J3H
M6DO*7$^J+W@=VI+UW8A[/W%LMJW9_@$XKC<!%B'C^V9&U&$X(%?"IP29G^EA
M&P':S*D#R4&0Y?.#7Z7@NT;%GN_!99ZX!RU75WU=8%A]:R:;''5L/66I^"\*
MU4#V+S6 N 3A,N83X"=?^:&O^(^SOI[_UZ%);#SJ+G8 K\UXJ;A?DI+;6^'Y
MXFW1K$F%"^PP@-%8]<@M[P8F([/I>B2/?D6NS L'VHH33,1T=\IZCJ8%1WJ6
M-E5A.QE!F5PZ8KIYQ7-.4W/L$C?A(@V]EA=)>;%Y,_CJS@W.5_+3>]H@[H4O
MS,V"2]1<PN,,4@J@<1P_#TC2?_WS<":-!<W8T_WB'V@/Q"S@]P .A/B6(D=V
MS7QM$%R%?INHT11UQVC*8C1)'"\/!5FD=X:D=S[\S_WC+_[]K'9ZYZN3\2FA
M8^L]ZE\CFTWTWT<V<?^/1#:'_T\JG^\_H?(=_I3GX#3V .V'_NE/2^6K.$:;
MNB?_VRKEO\*;*5LZYV(3EZGS(X02,=8[\SC:J'2O6%+C!-Z+<0C[$4,5MXF:
MA&Z?_?5, %O<1:M'K2ZCAU[,J)G)"Y:P50Y\5H.%Y8^A^U7>N4/?\)H/W#&R
MRU-)SVWOKLR?XGH']<YU(0 J<Z$U"=D&+= )5;P771Y\W5)C%[9?;1+D+K]A
MW $^4*EZDXM^>')T$X0W+G;D-U!(V/N.&_M0^0CS?;4<(P-J\YD3(1!%S%GE
M,=6'TX[XQ3G*+-0QYGA92-D^:XK&S+''F92XA"I'JWD"%;&50-O8,8=96W!8
M[F.RLM&TX0Z49&IF*AQ==S3:Z/_C[;WCFMJR]O%848JHB'2BHM($5$ LF(@*
M"%Q >A.B E(B1$ D0$A4I(A ! 44A:@TJ1%I2HMT 3'2!022T*0$$DHXD,+O
M..^\<^^=&>_<F7>^OS_.)\DGYZR]]MK/6NM9YYR]=^*M4N@U_PKQJP-%R7,X
MZA><-*XB'4>YF,:3X6,VL<OU>9OX*:>,28 \GMY'0?4AJ&N02 W371ZK86V#
MW*EO^@>2[ZX/:]R&G%;[75LC:L!-:!-T=A(*[ *C;H0.QX<W&[<&N7/V-JP-
M_-W, 3G6"]A[L$SNP?__>J7>7ZZL)+"203<C8(X"#8S&B;I5DX2<IL#].5.]
M_.MOPQ*H",9W>"Q\L /.4# #B^908(0[* <6:6'.]H^1G3>SB@[7FX4??/RZ
MJ]]>_9,8ZQZ#<1'6ZF.T!A$2HLZM++TCFOQ. ?ROFBE/D+H_";LM$Q1YV6-5
MA*% /$=#*X(TT4/# ^XH81PYOR$H@'-2> 2_?!//X=^%JWO! RN! +!*_O#2
MB'OI PN'QN4$HMR64YW_UEP:3U*L;GAAVL<IY7?:0G_3#5[!Y6!X);Q;NZR(
M30;KY/!PQC)G]1O8/2&!?Z;SBVK00/H<[\X9;]5TX_U-&[V4-Y5OI @2QO17
MW]^9X3'6();S0^0Y[1&>I-1?&M?G:*C]I2?5-[L.N72B9KT.TAP")>6;EA^#
MGJ^TBJ @."*M-#Q]$T4*)89VO;D&F<D>=?_RS63'?8O0!NC4.%\1NXYKT0KJ
MF?7;ODG]'_KVK\8#1(K-X=.$(>A4JD,?=^+)&J3N'#J8%^*M\#<Q-EF_&P3]
MWXY.[A-9\ISPDJG*#&_A$X[ZLA*LN6!EHO0UR%L<?9B"N,,[VK7DB#+I.GAW
M:KC%M.CVA1-M?L,_0]=-ZKSV0<E7N<:GB.JY G5/I&7<>]()1Q?^ ;]_%OE5
M"U/"13CJ/(X/)(7"!;CADC0>5)Z!X]U>G>"R[8'6W_@Y_%?W?_&?791=K8"K
M<<"* *W4N4@-(V,Y.S$;%G[CM?,7*R)'-%<JQ!K:]FG6W/5.YY7,$7YF@Y#,
M<PU/\=LL4K0%#(P'!R\M^ 2&2"--B.=J2%34)'2AUA/^U\]EPL^Z79W%VQ>Q
M':>!8XB0>34U+%P@99A1MHA?H6I"__H93/Z9D^ES=+?MX;F#U;<<K_8_OG8O
M-RP4Q,0?*JT\BH]"""WA[CG!>K3E"O*0.9-^@6+KC[7,-CG_@R30'<-(Z3CR
MUM?_^R6WG;=]#5*CR3O$\01"TH&F,\;'/4X^QKK(AGRP5G[NJ_SV[T ?):W#
M:0?5/,<6X .Q'HJK'>Z 3]SK^NMG]QS\9X,"9>XZ'KJ2M@:Y'<':+0PZV>9_
MU&;H)_D#3E/PX5L N?$ZX9E#4#!N":U!!'"@N5)%S/[VS0:L3G[J9/47:<+C
M>-YZZ%=;&'E."WX5-U#T8;BH.HMFA-]NZRDF\/K5(83KQ0LUS9^1TU  D_3#
M-38B_]@U2"?;BB[I^3](U!+U#D2AY/KJOH1+)F>9NH0\ \E./ "6+&=B_'C<
M?"ACY<<-ND6^7OA<?V_C3U,#>D*'A>+ ?K <[KHE,IM5C*L;Y0F#] IZ:0U"
M0B(D?AI&UOWMPO6:X(4EC9S+8/ MQ"@RE^M2D&??=OB'553>;I*Z$+5+9!IQ
M]&=R1%,,/?.D#Q2=O/'U/A5YM@H>I:(Y%;L3VN]<9U8;Y>7]=O,IBS4(-;,2
M+#1@2;B, .C/^H(AKA*38/@YN#68[S/JH6U0#A]O:QTX1B!_X(6HKD$,X7]&
M#G2JU+&/"Y*&'4:1\&0X(,P1B0#C:C*CE[/JR'N,^U7<+/PGZ.F^7@%F!=Z^
MI+_X,Q20!RTJI$DEKBQ6<!5^E97P[7=6N8"C/"1(GY'W_A_H+SFH_B5C_=J7
M>MP_[0IF; 2_!0%L:.@OB] \D_O:(TG(Z_BYN"J3;<K].#>UKSB://TTM>V<
M ^-NGY2R1$-EYM3EB$")$48:U[JU LQ!-,6_@AT<P)L$1J>3Y!J$8$3JP ,>
M1"$<.6-XTK'II]%C-3_I%IC>Z\W_@O<-8)5*_>UX07\55X'_&:[_25__TW&C
M_3.#>8,R%DW[V*Q^AFGMW'T6=F_W(=184?@Q\S>W'0YF_Q2;5=MD/E"G]/)$
MRA>.%P[)N3T-E\S<680_U)V: OW$UOIMAH'_-O<0HTG_'!FK?O,COZ>X[G_'
M#W\\D/])UM_PW[H2.;@&<1T>,*TAE/CWE*"H#D;3=AH9>D^<%"2$.L6)K:3?
MA'LZ$3C8-.,_0NY#761BAHZPQ?&6L0=NV[=(CYF>>"%<\;.-V?_HX#P%@?;,
M,]2)FU&Y*>U2#.O-);U;LA&'E(?AE%=#4IUS<&?V^B_[N+%;G 35!D_I&S*&
M :5;]^'W>,< L8:%@3+6Y11,WP?JC;KL@@46&(%>:$/SL2TG95/2IJV#4EC9
MNX[DEU2^3(&9=6U+F$@?2]#;#E3E+@W*#%PS-*6R<&GOY]<@H3A*!G0'R6T-
MPO>]>M>7F44V'3;49W>@^NS<QTF"82]HS$\8QQ_6!;T?*Q0$9BT2<( 0@=7$
MJ(-(C=(VR_>4-,GP]XR88;4<"VOB2UWJ S&;B)4&H^= WAID6!FA\T2#J5Y(
MI> &*5@CS$4@[#7&FLDJHPU:R1F?LWZ'?)JX-TPP1'D*=P_!L"3=)_!A9=Q3
MMW7<'#P8<LH@]..=B<@DY?A >$Q(&(AT.\!O#7+.&RR(,6!\'R-$P!>/3<.7
M6WI3 Z#'P);'>*H_XO:/26^;0:Y%:AA>W? =MTSI[4#\YNSVOY,$P0R J2,)
MJ !31X@PCR,) GD-(H;[+OP2[$(HP@#WNR[I<TZX4<E<H7(R=[YXW0*8 A"T
M.>ZZ13B;\0./K9Q?+19RX ^4_L)72Y B45[*G@:F?3+;\OL\>L9K;/54TOJW
MF9X@_J##T4P^SGPH;X7820!\R76$52E_ GOL1R.'."? 0KO,;@U2;5TY]?[6
MSLI!P\>=U^>1KL>ESP_:%S]Z-(4%ZXPZ/70H+U ';!GLLY $37AEC(^[@,B"
M_H$UG+EQ=\!@=:&.+: "?BIPFGZC"<CJU>NA"RW"['&2"9S:"M^&^^[5@YM+
M2.-)%S$F>.&#;KP5>_C;P_"%23[6;@<P8)FMX'_3-EALN$7")QY#E]NPS__
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M'R>F5Q_Z$84&:%GUYYG+=RJOR-]3\7>UF\U/&RH8>"^GS$5.0^\@BA!AU5N
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M(R(A=P"U8&FH%;;X5(.P\YNC@,+2UJT?!'W>V0S#=C"M"2.H;;9(>Y=6']?
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M0X#L?D8J?D0 6CA]TK\Z _E\Q6:+A)_%=RRTLU(SJ\DYHZ_NBH=X[;GU=#/
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MB_/?(B!*\C=4U!>HJ2]P,C$P<?Y?V_D/@(T.< 3]H 1= BC80)1LH/,N  P
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M8#Z?.WJEE?0G)5[2+.]UKBE$Y:Y'#2U#<Z!5ZT1.C:60'CCZ6ZAO=Z/99H0
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MY&%4$IJWA'R5/CAY.?I*8--D7PFC7(?;BXOOX%,W>CZ=I9\#KD,\$6-0=NG
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M%H-71))\$I3N60E%\E+N<8(>I]76+5=(<X)NFHU*!WD]KO]>'[LY<^Q>FNS
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M:H 0CM]WW7O>]ZQUUVWKG//7;[)GK:P]>R;S9#[[V3-[[]OYVS4 C9::IAH
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M>GN4T;I?%-@IR-ZCM*^PDT)*RGE4>+EG\'L7/I'AO;8IM2]=_7_6UN92((/
M^KDH)1=R\AL?11;-=1%2,_'%@0KS?2?/Z67!1S8:S[3F[_1F\++@J>GZCE\K
MFU'' &F]K4C:Z_Q8J3_6!<%8G0\\ $DL"/X#[Z:NM[^-+<>3XEX?<,D:!!S?
M C \5MC,D+>\.1 ,E<)<Z$%V)N#:?0RT[K6[>'*:/_X;?Q,GLVMU#TR$:=Z
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M&/N7BP_+&6[$8M5K&UMR]]@<N5JR(]*]HU6:V2E'X[+QU17KWVH8/G?;(9'
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M1@^7U?:B88X*MP MBIP6V.%.YJ/6N-2?^1ZG93A_>2U86] M0,^J._>8Z$T
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M$V"K,Z+S^Q]7]V4][XB#-P6S'M]I[OSGQ<@7@3<XR2%"RW +Q+!IZS-OE7/
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M<N(+9XH<T/$)WQ!B+SR11>_,31G,J5T?I']R&X_:F*Z(SM/9<MDQ'8L3@6C
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M[\0E2[QMDR\]+&YE=+!B=$MGBEY$*>:AS,?NN]M7G#8-G<=FZ_AK!=YTMZ4
MM?#*);F;$C<U;[3]BDMUIM<+=_JDH\8K=-4E=%\]:>K]>SD5LY\"V-(/^;3S
M/)7.:=19_L!+D^+(FJ[^1NQ"=-+@ENO:I6XX%N2:LXG2WI0.KZ.*SR/CS7BL
MJFH9$_E$>*+^GJ:;M49^GRY\AC5^1+FJX-:SLL?!1Z.JL^3=KRCBN+-$^%-#
MCQ(5(/W0I5A;AZ9GL:4([5[.'%,#SAR" ^06+$;WV=CKR^,!<QT="<S"NS^L
M_R"S[(SGQ8Z"E8K]<D61EKR%9;]4HJ5DOM9;7KFI A_)>]@^%U;/$]MK%@^_
MNH.AI9Y->:<WLC*_=NMA+#=G^5505(OD2DDW\#"C]ZZC; JQ*EKBY:(0V3U5
MMKAN<]D-5C"3(6%^Q(="-W206F&0IZWGPZ[T(U9E@.2@\-"Z83-EQ5N\@9_C
M'\M$#.K5)P1)'&,8<G>[E8>)DRUF<[H6*QUA3@JZ 9HIH@G6&!80X([@$Z.D
M?Q#.\SC_5;GU1Y=DK*R\[&9I<+L[HS0HQFY&YXHB?[O#8Y$(IVAGSY8NWRP7
M".W^@(7FE[D.S0MA/<T5M#*>V5?Q/&+XZ[Z4U/L//KP+894J^'<558R>TO;U
M]F"!*S]I,D\O._EU*7E+2@MD%@]1BG87/KC#.M<86D>5-CT=">53*BN?A><.
M(^QS,J1(1Y"] 4>B1174VY[<\/7QDW. :/$FNOGCU3?6X0<;*B4Z4+[#I%'E
M)$]T34O+J>C"R2T]_!5ZY]ZL.40PQ;6)E/=_ON;+5*4M^3Q=I$.2$2ZXP^$Y
MX(0?BB@%_<4NP,'(XA0'WUV6B3.?!T!T]S"0.80D>@99N="E[UT"Q36VL259
MTDD\<]]IO\C=,[-S/P=4K8:8J!'>IMW6(M[S@GFK"11N=^:?%<-5Y48^S*<)
MBJ%@!9JU^."6A1!CB1 X>Q9I:#O?N-N")LLG;Y))P-CTQV>6JRUFRY9W(W]Q
MM3 75W># 6X#EIB#!221'\]QVNH5NQ)U-0ITT]:].HQ+6(TKX5=KV9ZJ]*5P
MMU4&45_ 01KCFM<Y(!C!!5=L(@2@SW2&MK9SAK*,)D5O.>H;3:B[ZL^+$W.^
M@P[H+V',Y5+V!2]/K34S-E%4?R**?.^%/FB.D&.?>^K&F,2E\>6P)N-AO'A9
M'@57AH4S#=J\=S$IM[@9B@RY+;\)TH%I*;M%@QAXK1ON!5S:NTRC?'U]YGZN
M.>*7'!]>/'6>'>_1Y7@3%M^R4\DS M3\65W?\-FIBB^L!TM[/^6[\"6C5BD'
MJ&7G.0 @=CKT.;[I"2ZXPV2(K-\[>]K697)J[3!>N\%]AT\%*67B !H1^OY!
M!O^12G"Z7*MR J2'NS]X.,$Z(P5WN]'KZ,($FT-TNK7S47$$!\S>6#D'0,\!
M5]=\J8AW,HAJN.#@+=$T-IBOV:AO^>JH_<2\26<BFG^I,E*E,BM"=?F#)8A#
M5L0L/LS7VI<!-MJ.8 G0(Q3EFA)BVA./#N>"0WS+"J-^AW#<N^[W\MDKS_"9
MT)@!LQ&P-=^V;B<+8SV>#$-3CK_J2SMW5J]15E=>\;,L",MTNT+H6;:: 7]%
M^<WZ\O#?%!7=3,J2J]6C.1SC_&(&CKKUX6]'<__E)<#,K,SOM#)_WS W=?C/
MM1/ 2%9FUC^Q@BOY1^P;G08U._)L@J'-XV"L&3+H'+!D/@K>G :?73%@_Q=_
M[W#!9OX?7G.^_.1/?KDM?F!,K^XAR^]!,T9R+NQ^P<NI[AMH96HMI<NWXO[V
M3@]F#UUX@ZLE<7U?APQHA$N-P5SKVV 4FEWR6=&06.'[B&JZ8J)!E:BYU]+B
M1#TTV"ROHM6#*A@UM HTCHEH^RD')J3C=CKD[HP(9-65/C$AYYI50$?2(K!X
MAMW5CBG.6T:/TXEQZ#;<C!J %'LB@U^,)5ABGDB!K1Q7I%$=+C ##3Q/\)\[
M+W^JIPEHETU&]@F]>$(-3WUB.C7 >N%EXM#PDW$'UH[FG9)>=NI?E[4M+^C)
M^N&0(]M+XYY..;,,&\L-P-5:LW=KG;E:EE<TJ4=;\I:FR=\"JE0MJX, =*'+
M("LL[9:9^:#J:O3#ID'["88'K5@;BM_XH\8ZE@%<<=4S00M[F+YZGFE%5-S;
MI/ E-FNI@T[/;X:Y.=P^;(_4A@.:G[EY.)\AM^F>"3BJQ/(DV;.\72QMO:?"
M=#!@OWE'7_I%"M01"M)6SK\I+-7*>3<9RY-81AT;$?SC6)-F6\%F;(@^7)$N
M8E&"6?9SL4@GRZ=XL%4UX_Q[I\O,1LIM6DI7PO'=P"+K@Q!UM$"@@.U4LDJ(
MV+4)F:H:W<.0IK>T\3QY_+N'6,FC8HE7>/I>G&*GX&I/? DLC/.NU:QXU5SM
M@8[+?G% -TML59@EMWW1CGW9RL_MP2[FQ9O7#SMA33$>3L4P8)>=O5[,MK"Y
M1'Q4Z<W>C\*_8\S&MG7"HN?7#JPTE?/5R^7B"<*YW9G$1\/\6]FVC@Y%1_=_
MN50$]&A/(MS>#7HFF=_6>G@KDF4%ZT#E[?60;:6A9-$Q7'^H53\(&O(CFEGC
MPQ_-7W<VTXS7=T"ORC:B&;2]/9Q/GSFM6LL1WU4EZS1&];\8@?^TMLPF1$S;
M6_ID92VEOOTE2'DY2)M((3O&4N*-H;XZP5>@)S()R?JSSFP6>4UYPK[_]Q)P
MT[3"*[O<\</$"'U9RJL&C8':.+G@\#T5XOV3M+"5L0-O'YWYW;4K?>+T%A0*
MU_>!$7RAKLN"7GRZ/T371^,*UQPK!^Y5$MS8.4T>5Y7Y'?K()\]J<EZ^-7O$
M3"$U1);+IM_=-@04C\)LAF1%,\0;)R=L'QZ_ 2W: ])>:IEG-W"OOC(3-'T6
M,;=J8JV3:EEPO_2*D*DK\]5*;KS2?'F)T<83H[:N&?>>MT ^A\UD2]F"XJ"K
M65 I#GVKA->EPD[.*S[Q&SY%V#/SD0D^30DU7C?F5V&?,]Y_H\=7T!&?.:4I
M0$W0:7[/1I2W&:6 JT0?34]PZSF P8;C;B)329BMA-)7\MJ[S[2T#L+E@;C'
M7L[0;3 9X;G,0TNK&WWR]^*;1R4'?,1N4-(4V6OU.GVK?9/OTK_D #-H+YN<
M*>D-Q:5-'U^&FK.1A9N\ ..72K*WEZLCGCIP:8$=S@$\'D/5V>X'7= 5R P%
M> ;!MG@.Z*ZX0-Q;!F$=TLOCX.+<$P?:<T#4'#!M:>@'_"\,%OPGA0_>O?_7
M]N?$7]N?B,9I<-L_5.0S>=AM9F6AELG&4($MKW>)HS\.WK_2@2@'[ CFK59[
M 8Y-6IOHDS#=VP_PJR\FB'K8:Z)G5_?4D)KE(W"M7,.G#C^GXC^4M3XI>7P)
MY&+0P(EG/ <<>A.*L"7DL/*.DYS/H-M9!!/2;4I^7>/X;8D).JZF5X=%=\U&
MJ6+?OGO0')Q:Z:N,<^PH"?9ED^,EY+2?T 95GO%U2;"XXLX!-@1_Z/6B.$K'
MASO/*I+NEG.< ]IW.M614TD00G+SK<JA$./L>%L,DG&-'YW$Y'J/:R)1Z:.[
M&WGFU&I99$&T]B7*\)M.\NPT8:<:A%#6$IH%0C,Z\.A3 Q C$V+O>F9U8.CP
MSE_=_\>XH_T8F>,*(UEP)"<#E3+, PFV&6(F6($,\M<AUP[8U=O,F6W)#_/R
M[*#9IB_*BM??5E9%/WD7+JCRV*_GGDLX*A5&>>B&*CS0NC$%(;(0%-// 5:F
M\M/QH=OVV-I4DF3WKXE22IOPVS( ]?K('"? DH$41G!*HBOUT1C($UH,4VF3
MXQ^O[*]'C1)],.QOO'-&B[@=Y]K9 UHVHI_ED%G>3[;F3+_J7@7A #EBAJ;5
M%7X.-TBX"7ZL=*3@+B%3RVN_?E/C</MP)9@\H+.AXTTOC]-=%#6.XC ;'_^Q
M^1TM.:&^LXEV J2$5E4WV9@7:D!EI.['-\8)\[9TSK]5L%0P5WKO?WG;K'NT
M01#GVVU.CH]OY]>9T1@Y@)H(7FE?W(:RA,F_3S">^S)F\4/."WDO:+3B;![*
M+3@5W^F$:#OTO28WG 5D>$K3+I'<A0K#2M#H>LQ*GC;<#KWB8UQ4#W)=',U_
MV/M$3@71> X8%-9!T ,J=/Y%1>%_5#7AWUE,S5^L!$3  XG&S;>J(?O*I#=-
M3W$'";6X^4RGR)^YX*/>DC*$M #B-B'Y'#":Y"L,X8=+CY+&T68V9]OE)8Z'
M%P#+9[H22MHD#C6WG -ZQ4+/ 2S$J+V2B+AVS:;0$9.$[;=O#$.$:R(6O,.M
M2WR?+^\#;\HWW369N'/;5OSNC,14!O<\V^NXN<A!9Z<6+I;]G;";G=GH/Z++
MC54>='TSRH2QU%J>]/7?9WP]#?8%/,'[AZE]"]N)(,<D0_NLL]E.9>9,2',-
MA^3=U_H,N6<0.EXS6E^^SC,H^=4F?N0/1Y!6=KM=9B_5<H;^=']]E3P75346
MF>5Y#@@56TW3"^G]4,#BLESA[?,U/ K9/=KHR1/P&@4RR*X<.&OZ[EIC<EG2
M2L@O)K(^2&TS;=/8=M&7^1SP/L;2DTN<*OWVKZ\BO*>W*!$-J #%2SI%:KLR
M*9.%>FS9VK%&#H)(_^Z<V2K^:VQ"@37'$4\H#%9'LZR(-W%LTZ18K"0H@?.=
MJD'_I$J"OR'6B5TN=GV>E: NAQ7(\10C[GRTA,PI?72^I'<Z>P[P%AMM;O%6
M[_+DOY?V//5I4/P+%SJ+/Q17FTK(XO2R7FBG;AV'0VXK3N<\-?.04_[MVDQ0
M!"D]%KXM6U?^R#;MO9,0C]3F CC6BZ,,DV=,6_J_F'OOL*:Z;E\TB(*(@"@=
M*0I*$Q#I-2K21$!Z)TJ1WGL-18JT" A(%P&I >F=T'OOA!IZAU #A.3$]]OG
MG.][]S[[GN<^]WGN]\?\8\&::\PQ?J.NS#F6[MS++W8%.ZQASV=6]TXOU^NA
M[F?J4[N3"BX]6>,(@ZH>F.NC(9/85U*KX<=01<2O<L15<)#ZF-VSU<'7BK3O
M%_<W#GQE9;R.6CBL'#]ZI+N4#)"\4[+6J8<U5=<&RFE'"4E\+(N4K%E)KOVU
MG=S@:-!RJZ^%<OC]]O=-4D?]9/>@[#B[5[,9RZT!>X-<OT<:"*OOF@Q).G;8
M*A+=L9J4:# G7RY5FID!LCK 53[K61+;L):RICI/UE\3-L-<OK&>;AD60Q :
M 9X&?I03>I8CK4'$X2=9]!8^E;,3C>^XJ5N1>K;.-#>]G2^F"E%DR^9A/C=*
MNWXM\L_DKP^NVH=!7HJ5+,DXQ712:/36@MYN1JH_5IK;.05]25[(6>%%*<2N
M[";V0)X]$F=1G1#=_I6X$MHN+_5(#K$3<[NZH3K08__G>[<L._5XX+S(@)-B
M9&3D\? )4"\3NF&C.&YKWSCD=1']--(D02EG^BJ=V'TP'_33?&$!SUB"'#'1
M"5[6MXW+N#2MK&<-(%#H\&3#F4N$$..3D6<N"H%PJRJWGCO2]5]B- #:(AL
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M 7Z^+$(UC1_IW%-^6RPZ! )/C88@XYND/7\(>7:-8P'2D,$FPTFT0M'F)%1
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M>[U)Y&WC*(<7RO*L<3VYQ)+JJ1X0M6X,$^<8\/)IXJY7[O7=Y,3J?2@0>"I
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M'S?4MRT2GQ:R^]#>6BNRIDHJ6I@WY#EM5A"FL'_MR5 _9?;G#/AE:.AI"?6
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MDF8=DFOGJ&VW3^M])4[#9'."CZJJX3APT(CFKY"\P[C%P"4.C(6IQ*-2.[:
M+2)9(&AY<2WN7*34,JP*VX5D9(2?3XCU.9TF("E1AHYOE1\]%6&R$5[B,=\W
M)E%B-:G&.SQ\KR6T&,W0:IW'6QYPIY0GWO#,(%.G'MX6'8B.U5QTO9[\RXDL
M2=742832\:*(GF ZJ.])V?"D9?ZMH)P\>Z)@T<WT!U'&#'367^_]IF]P^$+6
MT4_+0()N*YZ_1N3X&V:QB4IC+/)]=(UEUM.ZM2FY)]:L2<77^4/%YO6J_4[G
M.4YIE^,%>]AP^%WBP-R3W1_,H2($&RQ*M1OC=5Q=MGGMQ17'^%B"EZ)1$1CI
M_;[-*:I)2X/FSS"]$0\XO2,%'/?/TPHS2XQ^=)>+Q/@E'P4%R31"<W5-&G 0
M.;BF1&M@((ZM<W"X@UF$+[$L8SOB#EEF(>=ABW[#%1[$-K\R-J?YK2&K&S,O
M@Z3P%I('-0O+"$! FAE'6>C+785D[XJVTL .I9ILM;?WCAYM(S2XP$RKT[_0
MWQKMS00_:;^47$Q815&268^>ZQ7BW. Z^,:B8NMGF0R3&3X"0X,L%.4%97R]
MR@ME]T^'2/^L$-^0R':]MZ-;C/)HVW[B%"''HG%1OI5M-NQ^KOQ)(0(>@0[B
M/?CU==^ IUY;33^%>/@">,Z-OP08OZJ$L7@6_&W#A.99LC+=U!E%&,@?5?"+
M[XK3%CRM].$I-:.( O\>ZHVA^G%['W#_8V7(L3\!NN3J[CPF?B.DF4UZ77(R
MXR2 X40$EU60W4?;Q8FA[6 I=WZ5HI7ZM9XW>9>L+9QC?$M"YTG[]@AQA,3#
M2<?P0(I_36ZERD?J]'FL!;L*-]&>P9\;UCET/2"O03VB8=,,A9[@K4<FZR+'
M'6!K>J@X=;!\6^-;]5GJ*92^&654A'E$/KQW#..:?%N3(?'A&V<;&O52*R"Z
MOK.^D"&D<NU#T$C0<YH],A%6C;OC;Q>JMM^!"!P+.]3JP4C4BR1/\;,P/@M.
M=.[#,SFZAMTOHAKW[O'X>VVHK'%(7:/1W.5J.W![ CD\QJ6/]T=S,L$W+5NS
M'#HAU!F.KG&YMBRBMU:H'AE%_.P"N(+.#8>JY$Q<%ZLE%_W*TU*7WFSYQ!72
M8.EA[ED%-$T&<D&X64TVD]?[P^%C-G>.@"&:PX=6_HHT\VZ,NZZ+XC!>:O'/
M"UCN-_?=>2<,TF<"R5B"V$8#.=3"0G0FX$,Y>CI)@94/13';&;9,*3=F&WZI
M<.A[(Q,<UF#)QWZ[<J(J*U,;J9;3-BIE%E.J5?-%E0E[C#\A^71Q^$G:[\72
MZ0;I;VOX(Y480B%[R(XYBHF%W?.ZACG>I@0]TK0>;B?S9S58[O('3S_HR<ON
MORI(\2Y?O@2P]B],4\I9K(MN,E>5!*,@B5^^ON62Y4)E%=V>,S9/6&FO9:4L
M_&AJ^FF7L2VX.DD0;150U*_0XAO)\W%^)B[N+VK)=N[]M*4Y:JU2;C42;F<I
M.>7=3(V]@)BM!GG_,]"8X<@O:_52U?(7YG/QL5O2N>-+OHL_;6]7W1%1HJ9Z
MAS-]Y[8;^-DRC.4%(EHSQ!YR_.Y#QV_O9B Z]CKX8U!M9)UP5XZ9BWTC2IZN
M*T/A <RW7OO;K@"$;V9*Q\,L.-;@K-,F^[IC<-EBA)S9@R6AJ>5O1,%)M>J*
M]1-<XE)[#>=@^1R3P;-4#:V.M2"WK>/=C!3!M:D#AIY!G2("F<;PPZ *AHVI
M7^@F3*KJU@HWW =EZBN$B)0G8=);)%=BY;X$-/"\)XPLZS18,;E,B+W S<[8
MN.'O%(D/.6@U@H*5N69B7NKG#,.^1=\1UE.&[(VVF9F>&%':?S_CFY.KM;;4
M\>2K+#D/A<'NO^3:P7IOFGA@G#'7;<#PQC*%O"!N5'XF7A**FWS=B4ZHY.YS
MX:4N[!JVZ3>F)=5OBZ(8Y[>9>K=XA(!;-.:464]5XSY,;S!O?_*':;]BU9.-
M=X8<U*1^RZKGC'U@?AN "3M3#B37_=J$:-JC1)NE@(J6+44U5YFL:)\YZ!=^
MU^KCZ,W.%N5;YKY=7AX^W'I[E,N7..+7+#OR:'NKJG)9M#39UY-+-<;1];/9
M"T8UN]O;-YY6;RTO)-=GN]Z?\  RC^#Z\8)RJF7:'GO3'W[P? YYG;!AEWR2
M0/Z1M;:G/TO1&0,8K'!#Y73'')?GZ-K[>+-UK736W *IIO]ZRYB")9?MCL%)
M&)XQ>M^_#7BW;-8UC8D.IZP=']6HQ[2@T$D_ND)*Y2LKKG=QPS2Y>ZY7UYH^
M/*L5D?/NMU,]LP@D[5./7;9N^3IT)%13>=2=>2RSO1*OD?S@.0VJUT?<_J:V
M8WL*DVBR$IH04. &NCE<;;I_HG<&['H/'"CPX4ZF[S54VA>/F4GG)G42P+2K
M>N/>;"TO#M;UNWZVVFAEJVUM>JVC.X(U;C;W6(X+&U,6M@QBBNO3NVEAGM_'
M"@>,[V&[/AP*Q3Y9>^?+$@*TUA&5\JS9R'SEVOS+D"0RZU. IB;?EUBY#$=K
ML1=BX6-SNDA/BEP&_U%>9"L5IXU[,[*Y+DFJ.=;<,4G<6/6]PLOT^)_S]Z7)
M:B<QSGFD@>_:B:R[1YW,B,;LQ?6,91WBX"2"7.9SFC/M/=L<:S66;(JM3@\[
M&=YL[[,G!-YM(6HLL+BXISK^QFEB@+Z)IS#)XX1;EX!7#M?N#$,$%?;$24#+
M2]LMSE_.91O?=\"-AP++O=(K_9"N$"65A]FT\G4"P]=QYO7=RX$D+*0M:C*A
M[6H33#NX)@C=0EZLG&*9*V-&AUG:NN0>;@HT#T9.FM94N-:R6O:)/7,DQ\*-
M,6<657CCTFZ?HTVE.__1?RK_W5;1_ZKMZ#KB63>M7_J^N:/R+R^9P4\;8B#?
M'H5#Z Y418E#^%R#H+*7U\U!+2'[$ZU>,$^PQBV-G&D->THP(%Y;5!Z%B9[R
MN!34!3W@Y&?Y #?+7?/I:>&,8>I$+A*4]U2TZEM&?1-5M$;QU1(V=-#B:7"F
MEPZ$M*R4!]^RWW[?I0C5R.M+C>GM\.!5YHZW457>+X_\1I%/I7M#'#"I>K.7
MWLZL=C5"CKQ[_D8K-Z%NWC!V=(EG->V$.>;<V\WTI![[:QVV?OK9$H*T*G5^
MO6D0[1RPPU6#3$&A/E<K+WJ^L09"X^ E"8C"4?'LOEDNS1K))]:UWF',\I7'
M)=QMA8$/#F@66G6^],1X=0#4DL(B6TWLI&6_G8L^-L[I])]13 <$6G_=Q6!/
M,'?1>E6"&)Z3-\PWMQO".,^LIYV0!CWVC]01EG\-\TMDV2CB:7^'NR?4,*0>
M#!/JVZ'4$I[QX;3C#2T>0*D.AMKNT^*\NWOJJ>-Y7@XAKJ&'CWG'?TY4%=)Q
MZ7P8$=*]!&3V8]I+;UIW5"H/VV'W^.BV Y)<K@U %UDF)Q>!@S%Y':>F13Z.
M$->2GT]QL_UIC%HI[2!H0Y?'/JY.<_7#[-T9IL]>W_OWO?PQ-\.!,X$P5\0E
M@'T&?&J,TDF'2>0VX)Y@I=ZSM:Q\>STWZIU6B#QY= EPN;4JC_J@_%JFX)0G
M[18 0(+EV.7S!8C6<LGX#R[H_LD^-W/7J"MU]OE)KO0$9/[,/\R %SGA49RD
M'3"^A-(V?:U[UW!@8&[LYHR@H$>/"CI+9G,GZA) [XN)ULYW">>TLNR21'F-
M5B):;+K@'_GE$FWY%#Z)74^'JW[]FA/-6O8,"?E[J+O\T 3;X^EKMO) DPG?
M[2;:J;M "WB<W/EQB"RU?V$G7K+.!6H_MO4YCT@;A*!\N@^QVW@&D=%6@;@W
MCCR;LP4;%HT[1!KZTCG9MUA3,80^W%N+1SLN229W!X"@,3NC^F?<DLPQ78C^
MZ'IS<UP;7]!+LOTL/YE&,<@!;\Q>BTI)O67.--(G(X7UE/0;/=:$42 "D$TR
MG20S#P?L0UD(_%C<8"+B0T..UL1D>_!.S/+0P&<)"SQ"AWV7I7TRHR;NBO_0
M*;URC(LB?>7%G[JGU\[Q;KUH [)X58$7Y(,$C;GM']J5-TT:)L ]H<B@"L%V
M#78\U\_AOGMO!RB;F9Q:$S(SR<^Y69.PZ:5&*U-)BJ%]!!_L2(1<[MEB7CPO
M ;BL=WNV$A/OQ^9=75$093@I.$(Z6F1_7031UR60JB%PO.V8B'S.]J%>5F:M
M.ISIW"@#?.&&-:L9V=G96J7ZM'Y:/JT"\5Y9'[:L:974'66**1K++D*X7Q3T
M\NF;#=&4^K_WHCP(N+?>KRY&8[=UATE0)6!=B4,N,'DQK]L5,4@WMTX4CK5!
M=!2W5!9L>KK:[7<>V[C_16+//>$JX'_RJ")3[-'!++KFAPYOV6[RTE8J(79>
M>Z_ G$W[F0M\7\?? LZ_AI:B!3:\ DE-Z:M+=*'T6IV,&?I7Q%0.PJCG!>+(
M !H ;/%<.E]W402?<#X-5F50G.27#3F:;AE#2:B2.9HUP@??&UY^O2\[^\K*
M,"11Y8=K898R JD1$>3P/)]OKX*$$VE^C)0I)H@M]2+C_G2$4P8R;%IC)NPQ
ML7/+G5*9#(D>C76@BI>("!<K+AJ1Z18'YX_$OZ6QS;A:<%PD=]0=C2.93;W,
MBQ>8;<S?-P"A4PN#4Y-=\U1^])FZ335[E*WQ[(V^/1*4;DL3:P;O3="QJWY-
MN?S^8$^NGD=U:CRB[V$URV33"I0$A>6KJK=? L@)3CM]4D]T<VZ\_RT:%)^F
M)%R]@D5#$2O%P7CK]+''O\TN5BX!0SY&:G_]Z"5E=%GPW5&B'?YW7:[_RXSD
M<NI? %!+ P04    " !3E'!6X"Y!CA U 0" 7P$ %    &5I9W(M,C R,C$R
M,S%?9S,N:G!G[+P'5%/=TC]\D":@($J5$A4$% $1D)[8Z (" @H(*BJ]26\)
M6  1B'1%("(@(B72.P'I(+UW0N@UH80 *5]\;OG?Y];GONO[UOJO];V'[*R4
MF=GSFYD],_OD'"@CE!G@A+:ZECI 0T,#V%#_ ,HX<!.@/7+DUX-ZT%$?]$?I
MZ>GHZ)D9&1F.'F,^=HR%F87E..O)$\=9V5E96$YPG6 _Q<')R7F,C9N'BX/G
M) <GQR\A-+14'CIZ)GIZ)H[C+,<Y_NN#4@>P'SW"0_^ EN8<<(2=AI:=AM((
M@ " AI[FMP/X\T%SA*HC ^-1)F86*D')"> (#2WM$3K:7UI3OPVD?@_0L=.?
M/"M]G>&4P2/&<VX<5X*CTXX*W2BHYS3LQ0K+/'[^@HF9BYN']_1Y$5&Q"Q=E
MY:[**R@JW;REIJZAJ:5M=-?8Q/3>?3/K)T^?V=C:V;M[>'IY^_CZO7SU.B0T
M[$UX3&Q<?$+B^P])G],S,K]D?<W^5EA47%):5EY1^:.AL:FYI;6MO:]_8'!H
M>&1T##V+F9M?6%Q:7L%M;>_LXO<(^P>_<-$ M#1_.?XI+G8JKB-T=+1TC+]P
MT1SQ_D7 3D=_5IKAY'4#QD=NI\Y="3[*<2,ZK:">24C&$,OY^'DO,Y>P+/H\
M[A>TWY#],6 O_D?(_@KL_^ : X[1TE"=1\L.0 "2T>=P,> /C9C(J0&@V,C;
MWZ!J+-C"DV-R:L 9_TE2*=QYTU[>_PZW@)J\=PE?S5>6J,\?J\:HQ/0M!KJ3
MZ^J;]D<P7[]LX-.]2VC<!O[$'U2^<J&JYNOD^K7_H2 /I7#=@3O2MI_# ;$_
M/&*"N*A<SI_H/\=Z\GVEL<V85%\!S"[(&U3^O_=%$F F]CF(^0^/C/\/M:FJ
M:+Y@R]E$]1Z/@1H'\-\,0\-^LR &1Z/[P:M:YS8M:,,)V\V(LH%:%MP7U">I
MX(0U.[/734'EY*$+"_N&LOZE^XS.7HN\J@XY;*]SPIT,3&VW<>4'/$>;C>>?
M='\O8]NRG8"T(=_ T'.G*$ O6)_(CR!KI),%KT-(I^8H0'T;!9CS6R>W-5,
MT3E?JU5!<PH T2_]@XR00C=4VS[C04L"!>CN7\]K(";)LVTYS%H1?.DHP(Y^
M+ 5@%*4 T4L4(/2=/@6XM0_!/H?M"R;B3>3W(6<I0.Y]!PJ0F#5N'KHOZPR:
M&VY$8;>8*, 20I3,2J47ZJ4 ;&<0Y#=;L!GJI%NJH-%[TW/$5^5P"=C6SJ&#
M*P40B:1.2DC\>\5^IW86*39R/':+;1<N,3V&<*).U%L.B[4Z20$:6JGJ?0Y
M$!0A1+@&4>4%[$"4*N E5?'6'=@3#"QV"W30]%^B@Z\ENVQ!;U" >UO3^P>!
M)=2YU-%DW0"=OP?S=UBI6I+U6R%#*F5DZ'^KY2]L-379^"'J1'RA^W(XJ?]#
MEOX;V>^%X/6H#CCS2\4!Y/H?]C>74:3]"N@=+-?7A4@"CU$YTG^YH/;\WUO@
M[RRT#'MJ[03]'V![:DW%QGW0EF Y-8RE $%_V)C]?PYI"-4N% #QIPA+"X5@
MK$[^WA*:L)F,4XC]K!7(QI6_^NXZN6 >M;USZ WSN^LZ*=-]!B^'8R2J>$'=
M9NB['5<UJ)!6EU"CW1AKHB\VD *$\6F>%ATM8?Q^J%"QO4<?)7^\ZC$U9O3>
M$QV81Z&B;*Q^!85*V _-;'Q&HP;Q<WXU' :6ONOT' ;7_M"X<I_K?$=*^JH^
MDAJ),Y]Y( P>*A$4H)$,(HF4YR>K@G)-(L7'UM MCZ%9(:GGAN=-"W:FQZG+
M*_7E-D=@(6A_"2)M%7YH>O@Y,H?4:Z5/SD?M[Q-@]6!:DCL%R +M2Q\:X%MA
MBY^(32#'4+(?VT_3V=I!\E*Z/07P@-ZE (,M9<5$R R<]-R[[#M1?PQ>>I,"
MJ#(NB!T^@6SW0!^C./'(/34^TUXUT J&:FY$*)$=E@_;H;X6@=B#1]F(.Z#W
MZ>OOJ#:YOA].-!VK)N8@;AN4P"HO4("<YV18 _DH:EC_P(U  >K^*0-JDL/)
M:B,<L>M-3H6"L%3O6U@1J=1M\'^IS.%GQ$'Y-+&:7+L%&Q87/V0COB=]_3/-
M7WC$<5:_,/[21(P"F I.]5.C[ 5DEQJ!W?!_36^X;K4!;W_=$%EU\:]0<1 [
M\C_H_<.+1?V7(4GF#GY4RA,!-ATU?T /$)%H-?P3MDI=! @0G$B+_ZO(/YL&
MV11(]>3^+WK(1<C@,#5I0]@(9\K;:K["YEK6-?ZE\S4.2BG XB*: M!9K::4
M45-#+*CDST[_2PQ Q:GPPJ]2C2C7X$0!.KI7-T$'<\/$\G]E[BQ##C:CI#O?
M7*_FZV.H,XR7%9-KJ8:T2$&N0;:L\8B_:*]>0YU(:M'J+9\I\)H.9*]2[/B"
M03H*0?*S6L%8;6W_,OY-C([X(:B1]"UD1?$]W4,]F<U]J-!VMONV:8<55I\>
M@OVRF^L**?N"*=4M*75;$E\Q1B8@-59VGVKM0&[4/P:7A4;Z!]S\^CE\4?E&
MN-BG(W]D)"W:+Z08/+!N<XR($$1IR_=\4!9I59N3](G7P.C@1]Q?GEM<M7JK
M_X;//?(GK*9+6= O><;("[FG,6]E)0AR#T\$+RYL8\YS8=9*]"O^S5HRAN5$
MPCJZ&\A,D-78\9'_Y*I?T4M==F])SV';_W(I_7EE0 9;' [UJ>MHF%>^Y#^'
MF,DTD?B;:/<^<L-_%NWO_TOTOUW25.)'0!LSL.+JDTG.IP#]37NP>NZ#99?]
M?[6J[VTUKSE9''ABAO-$N.'QOG/^\"[XKG?6KU03>K!, ?0@6RX$QG]C(GV2
M!6S[MZ@QPHB4I?W[8&8+/3WUF5S[..#)4&T#CEI,H -_%OB7"3@)R%_6^04%
MEH,D0Z$TY HJ$'@+F>;?.-7HK]8,/:"6HL46\NU_*;D"$-&:<:, P]D6RH'?
M_IE\(<MZJKNXMY%-\-@(>@BUECV@IK+TK<\6"E332S&2*Y2M1LBBZ\J6MZH_
M7,=WZA[KN/BBADV(Z(#3_'9@O:1)<M@=GM$N(UZ TT@[+EXK4-E=F *7S"WP
M6M>)E8E/'%Q"J-XOT:J_,?%UD]J<X_2__?&6^<_#P2@[[QK3R/"<5'/W_J4I
M50KPG4RU?>85T]5A:ZMW*#[(7)'/'KGA()0<UV9EU(!J0F2M0'V;877I9-%]
M_J<<!E8^4#T. S5:UD8*P!R1T +X(>P?1&71\YHOT&C.Q8L*83';'&_WXH+;
MDU\6GSRZH<I6CBR'.:,  KRIT$>8 +L^4-)4JM,@C_=,GSC:P7-MLIC_"4-+
MSW!*6/-%N>P^?YWL%?3SX;<- WF,N7X@MGAEEN XOMJ'Z@J\*GVYCB/[^J("
MJK@#T+R51X R=@J)MAI);+ZJ-)0(RYC.J]GVE>_5.A;,',%_F5' P1SO.;C;
MS09ML3'&DD+Q^37.>[H.]J7=BM&-Z\'S:1.3^C>3ME>>3<0M*N2,F5B&%NB?
MQ<=F,8P]A\OT&\];SP!9SK.7:]J6%&D/X%TAD>^>9-,N3_>ODN7V4"WKCT&G
MH!V]JR#V'64I5D+SD\Z4G#/;L\G:P);WTT0Q&O$!VM5[,$YA"#_D\22H<=1N
M]P'GHZ15/IVBIO>2\D_U&(;LE 7CEA;<<W@4U=O:.^.MA")%#:6_CALL: ]5
MX,XUKY?3/1/?B[\; V'KWI)-N<O>JGIT22,?!FFO[2<H>TS3H:SUV7VJ$:(F
M0\(?UO8DM5NOO9#XE&HJ]J0E350@9[9/7IZN8.F*MZ#,-/+ZOH2?@H51D[;]
MD,'J5$MH1'WN>:4K-1,8KRJK1V+(= _]$8U9KJ+T\>FK:9_N5?>^H<]KF@@Q
M;NUBTAQUWW$T99FA *,M35!)0MHWPE&YJ%BDW7>YG^EWXE_=#K?F55=SG--^
MY18!LKR0Z\6[;>8P.?&\'5<P5R._N;[@^U2P9.<I<DT(=WJA>0NS?EI6WT7X
M:^F6A:;P>R'.8^D==6P1^;.L1ULY%R$L9!J?JMGAL%T!/JWBJ"$GN7 K_8#Y
M<Z6NFB.-1W2>" *RZ*@?G8H7PUO/QV/.*ORXFS+OSY__<L:*G?!ES#^%[_K
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MU";DB^AW9A(+M9)Y4[NLT\.0-8@4.=;<=/$3L@=%$(41H_/<R0U;%&!9KB2
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MEN"%,RB,R8[5AXE>-4[LX@I:C>,.S7\S=.T]Y;[2*)\FOB:,4H#S'UM0>-
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M93CG5W]31_)R?][ZT]N,WXI-T?FU(Z@;%& FA0)LJ9=T'[)U4.OBT.#^"N,
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MK#15H #@%T%<+VY\-YF)3E)Z)PYI-(_]<5 E?H("6+_/L:$+" 7ET;5;?%N
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M@7!2(KP90>W@&&]-PM<1[+3_#VOO'=94U^V++D !$42:=()4$1&0+B6@TD1
M47H3D"Y$I 4(A"*@M @(* J(@* (B/0:.BA*+]))@B ED$@+I)V\[[>?O?=W
MOGWW/?O<^\=XGCS)S%QSC3G&'+_?FF/,57!$_NNFUY!/0/4A56>2\7<I7+[)
M((X"1J_JS:\?UZW^V'4&"\54GS7D!RGT;4?Z[!?T(Y*7V'3$".%+:'.2^!]"
MA"7NH HM+6 !SF.N2].(^O[])[_^<QK1[3$%(JK)!7MWQVW^4G8,C5I.N3=T
M@9D6H;&;UQ)[[7IRVSZ="E;)W=#]*F1F9"@.N78/L^XD2-2,FIU&<K3+>.5*
M557\OEI7D%04]O!3K<T:USIKDK!;HX>N(%34?]C9WW<<QOV2W-(NSDD'(5P+
M@C7PGUAP##ARC=;,)N?OT9"J(O)L%.\2.56-PG^H/W2F"7TV EZ:!L?/[JO]
MU@YT+@#QTOAXL3-'%(AD@F=/5$;$7DTK+_5N,(7P;"$N'OVD*#X=Z,3^ ")]
MJ0#KX3LJ,!+: R8(4X&?8Z"90WW0KA">Z6\S4L$-D[3-T9\W<8R[%"I  _)]
M'ZPI+!_P]@T=@F.1YVP1<*\RAFUG@N</7M"??S<^>+?./VQ1&#Z.) HL$+0Q
M<P5)(%:2"KI\02"2<=.REO?*>H/A8?9*AFK!X#[/,JB>"9N._ONLCUPI! J9
MH$9123L8Q%HL&3BZIF3?/\MM==3N1-BXP/ 3B2H(LAPFF9&N1>50 7)JF&$2
MS!AGW1FED]C9W-^3:C#LE!ZKS.F37"\M :3][*J6A.K4!1YHD<NU#(E&U]'G
MT>:)A^W,F3<?7-CU5QSZI/'KA7#W7!)Z)RC"G 4&QN\\_;2E[/S,F;%5/S2R
MTB?GFIM(D7_%>;7SQDS0IT4<V1:J,;HB"[ZXQ"[KV:RI/ @ZTL>>J&_8V.!H
MQ/O,@;XXM8U9*WR2"A \R;SJ5Z>?T@TQ'4/7J(!P5;J6O&K3,LW.0"1?U,Y3
MJP,[R?R<]]I/PK.J?2$7(UP./"34OH\6TEF#%+70#>T\41-.\KC+"'PV.Y>3
MCY-$':XTT14OE1=1OM[U;=4@Y[NS7-$9S"#K1[T!<(0Z-]W>'\KPL>P%"!;)
M04>9/  ?V D>P$=Y0E6;T!Q]< R1"E17Y97@EWKAL4BN5DFU9!*$*2E(V[S;
MKO_IY4LNGVUNFK,J(E\4JWU/LKU6W1=H0P5J0%@7M+D0S HW65GXR2?J_&?\
M0POC0'?5A*D1KXPP?0S'+8>CIS>QTJ!>79%^]!PH(8JY%:_]O@HC'#Z%Z0Y_
M$-Y>G!I!>3]K\,"0V/KK>=+4"(QK&<P%K;' 3>6AVT(PUN-8N9W2&$B3C0=_
M:OM. &ES#3G;%DO8/,A]V#"(ZS;&9BB&!L?L%*SZ3NO0?W">K4$K:%MWY=*+
MY!7J3- UX#U1&S#%,9A:I5>^Z+0K+=X^J>D^D/[>>@;!UE?N"[FB,#?@]2L8
MO./1GIAJ:_M,8_B("H#UG(R)9O"!9%05441+E@J4SEW<W]X#:N_H ]PI2F/9
M2<"1$H5%!I=H@/?L@',1:NXU3Y8VC02-'K"IREVSV;)R"SQEGQC/S'GS+8]%
M3[1PXQ#S<0EWL/QNT"7MR$0(I5TVE;")JP2G+ITBZ2^'U9T;<YLZ;V.W[\+%
M5RW6?HV3#BQ?%3Z*EX[?)]OWBO CQV&WCU4S2W\HY[Y_D7WG6_,797T+U9!5
MT;3KOQ[;%W:\94_#^F$FP,LO<TN3*HO2V#E^O'>$3NY4/[.VX94/J=F6#GWY
M)?YV8.-)R]\ ^+'WD2J^YG*_^[RUMP-7"G[NS?[:="ZND0JXES=NK>$0)"DZ
M"J?IQ_HRF,3L?:+!5 %6SO-@6.WU70U7-T7_/S_[D1"5G?1"IXI&=#3(^2*\
M\\Y/^2TY_ 5..K?W=)D35,![=GHR^$\IB4?8$ND"?R:9$)*G@' CE_KJBN01
MI9;LJ4"W/$DX>0CQ0X1M-.$'1H/(JN7:%JA=OEN$6HIU)1=06**&"[AWM&S+
MC4N6"MCU(SV5CQIB!5LLA<\ ]SR<"<PJATS145>@FFA+[&1I0AW1U#7"J^>+
MH?_1 XN?7T5>B=YF"M!_+'*)D.Z+$K80U,Q3N]W$>7TM[*":27]-T%QC..IE
MQ?"9S5%HIG$LA=DC5D/OO+1CI<+W5@2!G;:&F/V?YCG_?Y7T9HLQ 8!T2$ZC
M BO[8*^=8U+_[[I#IB/R21B82%MPOVY$C2[MTUSS2T5D-P6NI\N"A%I!GJ:O
MX19+_>,XC7TOQB[HH"H8B:53A5/%5."9_[OBP(,P9KXAG>O&+;(OK:UC?BV=
M7+(9(8G+M8;SSM[%^L-ZVYXQS>N-OIYMV<%6^-% %O<XZ'T1;6'FL5DZ-1>:
MX"E>.KL$4B/*SO',E&DBGU*",)8/W1,/[[8HVMM,K;@[$PQ^(EW(1>SFQ(TO
M)&&\ )@7^MIIQ.!U0.G2[^^<OSQRU2S,35N,*RL-(Z"S#ZO=M5@Y9>DA #1R
M/[E-/VCW3%%P7' @6\_3<9&>Y:GYT7!AH7[C7ZH[S8$WSS\.2/%L$K6^"N,H
M;L Y(DKVD!AC*L!\.:TS"]/J?E\/!'D)ERH=/-ORV]NTTON@N=C.H>%Y!:E(
ML;MEU?_4.N'NOJG=DIXE\2&^PV$9XH(E&U5IMA+HWBY OPTZ<BV)UET[ ?)_
MD]D)BHB*F&B7)7"]);QCYO&8D-.J_WJWS(S8='<"^7'R<7>36H';V"OKM?G.
M+/@S&S>-_O#!<2W3][X"?KW8K#VNV6OLKY7]LFZQOB$KVEZ!*8Y(&#KFK)W_
M8E8$M@C#1 8X<9-?!X'8"69^DMN0DNQK*'>3]<G;"AK?=HZ0 AK>A^SPZLUZ
M7@X? 1BOK]B\_0^1WZ]L'I]"?_!N+JFL$Q0\W5@):S@_R<?9Z-I*$9V6>4<2
M'JG-$S>O82LSEGSWD1]>Z\D_-W ^%(/[1 5.D5A&8 K3DL6M35Q&0]Q.0]'N
M,S&H8U)?VLW(KMVM<,;R"ENOD(K@,K/Z;/QGJS S1G/ZPK'@0;;'7*H%H<(3
M'-E67D-A)SS__'A$!<[JG/SMI#ZR5LVY:#?P1_P3TB^ONG:-;\G!HP"79!X?
M)34&N20^I1+!MY9A$A\;IF'U+/&"3:S:0Y5/7N,9;?T_+I<=MI6^8<7PD[R$
MUOY4"28?Q&68/S5%+1%N[&=ZI)_2VJEQO;7,Z@:VPXH3\FA&]/[GPGISW9N&
M+Q6M; &0:,>:6B&0F\VW9+MW33LE:5U)MUA3TX0XWC ,E/JIQ.?W/M/GTWGA
M-L_^@>8_FAC1 C?C]$VCD^\R1=WR:XMYU-5)S.!O-*I'!;0O"!V LP#NV]#B
MX>D_;T_^=P<&%(:/7MM_RY;*2]%^3=X8^43^MP__[*O/Q\9$)NAVA[$:D#5H
M9E<3%<@^)_!B,ZTE0T*4PL^$JTJ#^Y@GZBB3LW449Z+&G=FQR-I6Z8I.!FBF
MH=Z3@(NB69).^(%'"V<$07;$UYB3;Y&$DN7DQX6M"V";6VIF?MGU[2*_ZT&T
M&5@7L&KR/%=>ZB-@4]M:WRR8_:#S6L51%#?=KGP7,IXB2)A!31!*B.K0/YNH
MBA_$L)SC2Q<DQRF3*0,U]IX<[0&'AJ(/@BN'($E+M<Z=\^!4&)T;GN%Z'-F_
M J71/\MR&,B U3APV/^X=":*90->79 F5UN5D,_62&.:!5Q.Y3X-8)^ET/?S
MG+KW"W8'1($"%V== A.&-XXBO>1SX"0P[1?,=MTH#PNI<'-9TQ.K'V\*QRR5
M:GLQ9!/N$&U)*H3&0=_WF^7O-V_"FI3]7 3&L"!BBP1#Z&2@4U>-[ 67D>EL
MF 4Y-TJ(Y)&*1$GB?K5.S]WL_V#K7]^,*$"E,VL,[*3W0O^0A @8(KBFH5O^
MG'0/F-7S$6XMV>%TV0LXJ[4XQ%]A1FN$:6I0[/. !G<3SY]B<'U[X?('%S!/
M.P\ALT,U_LEC7T:N4#?0ARMOCZSGIT=%V C/4 5/[7Q\= 2F@\B/>SMD5.*[
MOBD81(BT3]"-W;FURZ0AJ+NO_+&S^;&F !#\GX[*95Z0'2;14+5D9@=R'_61
M"FC:[3&N.\'1B*-+^2>I0!7;W:/9$:;PCU%YGV5^ZM3*PW=G\W39.O>+F*;R
M] $U;TQNDB]<5<WP:#+FI/USPT*^/C!+_BO9APX8];^><Q_![Y#3@DM>W\8-
M(?!B-!Y)N%/NX##O(\)E\L"M/E1>I=4BWTKJ$L:K@V[HI"V^8<O=#^T8V$<%
M7/ G<IT36N^6V-K]*#8\V]OV*U?,WBQU_F2JFLPRNOV%TN5EC:-FH4?0_7<:
MV=<"YJKJ %@U^]9P&0%TBQ"#KA+8G$WL%:R(Z.HVG%2>LS=:#K-0T#TKMOS@
M@W^C1F^86@><:1'F1)A$$<L1'%!$GQ/W"$GSH[<U>&Y6<_VK+T]_%G?(*W>1
MAS&WLZ,2&4Y,_V9P/UA>]I1ZS=/ZJ')"7U_KLS[ I2M"AX,<.$Y$\4*_R1*K
MSKVO>KO^O*X]N:3R%5M+QQ..5R5WF@V 9:Z?UF^]X*? U11- @(M.G$ZU?E&
MS2BENV$[C/.'*(QX5!S%\QNVECE=)S9PY8KB)E:74TV<!Y2AYB_*E>(OZI%?
MU:37*=)?<=F+KIT&3$7O_$I;B(HMT ?T?\&ZA;6OP%D,$A_'WR\.Y5L^I 2K
M2 (WIH@YOB<OAL=TJ.RV-Q&Y":%6>)65 XH4GC$'97ISP_Z'2=>YG+3FX(D,
MQ3"%5T<\+[,O,IZ2:D]9L&E&IB@[LR_8ZWWTJ0\/FC;]PKR]9I1KM7>[AVN\
M#H!2@52XV](IPG1/_L6)TM:VNB_XRYEG7I=Y*RC:NTE</+?XBS'*6)PN '%S
M8!SN_IMRSEM'!<]3LEJ-5^J9'4ZT-VZOF88$DLMX ^[-]Q^&63WH4#^J<38X
M-1ZRT*&J%!L13K[@<4:QOPJ5SP; Q(E788+->,^^/'GGUT;XDM+$(.&+Q%M0
MF)^"_V75/CG1VRNU 6_!K8<\>^9=-/Z4/8A")+^VCNMM%YO\)&>)&:MUO(;/
M'S<S.,$AL)9_JB_<NOHCUBW[(89)^F>4X;J%+/#6,V59 , CGR[5G(G'2UOA
M%PLCRA;LOJ)WV.>@X=OJNG/<"C\D/G[=OO4)S/*[E1]G;8)S[O'S[3O7D,/E
M[)/KGI\C<<7-M?]ARYW$)F'?JDDMRV*OACOV/@*I=5D]'7SH?-V4Y>:WHB)%
M@67'G\MS9K,J<SQ5%G[UA-1_KCR2>A7[3OZ#]-NW[)?(I? 5?=PT&2'"0P7&
ML5GA^] =K.(5!^CI;G9!)@,\,I[?)DAT,]M&])!GZ]X_P/I_$IZ_'H4+4FY9
MHSW)W>"]-5]G2^MO2-P]R)&B\[."0U9:GWD50#"(B<)'@&.8MLQQK[L6+WQ&
MW!VM)($*E:?&T@3=BUEU$L5:ZW>[D(PT]V-/;>>:7/:%T/^V.WCV879Q^!EK
M*)=$/>0L.(*)T7Q@NIWRE48F$JP)&FE(7(+7TO%UMA 1%0($5?4T9&H$FFE0
M.R76$"@A&\SG(GB6;F[]^04&=I1\OSD=*;@&V8H#/WU(TCN9$BN8V##DYGJ%
MCI5N';O81B=^:H1NK^IYK3P73(6<2P5\Y45F-@32<I8C96DK2*9<6^N0:%+8
MC6F]!;WE>OJXK7/M;4D/7O%@[O_N?N2N<4(D(1KT/RU]_[\5(V]O-B J@M(/
M_Q->4!M*CJ("6^7.-)A1,&+=O52]:GTP12Z*X0/[@=_>)":2*+'19_\POW>X
MEG/;A+5,1(/76[J2N?/#A9+VV(!5*T^E]X1SPB+GD@;O3<BY>5RV4+WU@ IT
M^"SCYN<22>8J7!2\.46J_H/&AQ4#IU[)!T,AF.[0.[/?IF;S"R6.0&);D@F!
MZUA++?DRGP-5^7-5I1MWS=XP_J$;^+K-5,@S#1>HIY/M%Q6P<IUK$.XY%+TS
MZ.=_K4CV]_>82ATT^$NPY*'J&H^],;XDNZIRP6N=9X+WH/K3EUYER4=\]$S3
MZ31.T]OX!A5'-X>P6]:*+)K[K58-;9\ZQ?:KY4.+5X%WAD(C*8S^W<'$M^+R
MNY-Y.!?QRU>4-A23Z.;5@K#W]OSLY"(,&R9<4?[I[HX]Y_C5^WE"$0IG>(S[
MC(7U561?$XW4G8[C1=IK+UR*B19UTTIQ>R.@F6Y7$:+\I"D[9EU?5/2-1P[3
M6%ZE3=X1/RG ;& .\9)A>E5CTW0GR0XV='' /KVNHL7Q=#<]N4&"WUP:XI+I
MX-Q+YMX0X<V\FW#@>_J'E-$^LX<^VV[?8SJA1X&._4P5#,+\U^6#_1-_IJ%K
M4PT:>&56PL%8=E2%6F=]SO%V$X/S5_D<,0.%1^X7$_T5.USR?:N=D_+/+ES6
MTO/ITVE-)\LZW\,-O:K\65%!SFI-?W9.[U=7>6RQ"*-VH'5\'E*CKDZ([D]7
M6\U0P(ZEC(%]QCMB?BA:?E:\@R+8.HXJL$]8<=:4\(-DLQCH');:]=(<J19'
M__6B'+'&4/DY^\)S_N</,+-M('N<3B):MOST:[(.;V-U:$3(,QYN3[[YQDXM
M*Q,2")=.U'64"5 >,YO['!7*(!'0;Y;5)N,RW9?RBY^<&5U'_J(CLJ1?^LVS
M*54^)RCBG435@/,J'R9F>OV.&C8'MTOAE%&.T^YS2R_RS6IPX[O84I-/X\D"
M6"SE!/3BE/!5]=KHY-*,^R</[V?)9$O EF1^>TL0F);#M&QIP%S0^]9Q0>XX
MK[>.A5&G8$"*&R@K*'#Y^$::79OMCP:L-^X/.X=A<>7[WJ4=AZ<_;\3Y-$B#
ML&<64J^S8R-QQQ!.!Z_-X*M'BE]E6J$S+H^2&[&8?,WI2.FNJM-?T29^8;5E
M0Q_\=8RC'"([6BOG.?I++!.7&^+\2":A5>^?5WQ8O/1,J5J0I1E[GXMOO>#F
MT-WNK738%PT/<KD6?;G7$N1Y2?_KNEA0SB!Q+O&.?;,TEFXY-<*4^-!N0E&_
M,59J0'RI-'PD$\4>[Y[19:Q<MN*K\D(*K7 K;FU8B&BUB$#)27<?/ZH>WT*G
MS8MD&*2N=QZ%?7CQ&>L5EVUXWH5X'<IUN[$]03MDP6D$^W %HGG=!;H6=VQ9
M!9 >X^ ]$;+>>VVVXA$Y7NB&QB/)QQ6UI-+%9E]SEG55I47CDRFBBY^5<O0U
MCJZ1BH2"5-!PGKTJ-I+T=+N@;2?G^K&/3W738JC0JU!%N:74!1]NF4&4OD^=
MYXA>G%(TTT!(YI(6%8CG&7*"&8S*U?FF7MV@R-?K<<U?*612E &0(O'1))_%
M0C16W&0,->$O+YXVY/I.XQ1Q+L$0=(MB^>+S/I<=#U9\?N9=31"8PWM13/Y
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MC7,3::RZF'/@@4M9XLE!GR^PHP)/GEG[CY:;'CP,DP+MV_8O:!SOWH5)D]_
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MGZ,YNW&FOJ79NSV4LU-5*A*X@KA:X:MK1#539'X_5FWZBP/EV/A^NM"3I)_
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M59Y^;/N^T,=?]-FMI(S4]C>@OB^EMGY2802'!PYA'EN04=OC$&2IS]C-[)R
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M$,&R^;D8MA_0V?,R#I9]N8C*Y?,I407;@Z*;:/05>0D]:X>SPCQE!*Z4_M1
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ML5]S5DX@XETOH0EVW;P3(!A$*!JU\!%_S:]N=F.JV!I2'CWKO.Y>D!USPX)
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M3#RK1+5+7+;XH@#E.3=*!PEB!/B2<F1.<SBO;MS:@#V'I89T8EN/B3NK'>N
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MA9TZV&5WHD&UP-Q1.Q]Z-\>4(PPU*;S$IW[QL/R2QZXDQ9"!H8$J/V^V7(P
M90_)\P2X@</$'GN,@7?53 J$_$RBIWQ1;J%T,8J?_P TR-\DYS'CX*OQ21%
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MG;8^3&UB706D?3<JW:HABKM2RG"XHC[P:M=LSS#X]N2L5*C +[U1?68-"#]
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MV6"E!NO% UD4@MR,T>H0F6W#(3/V#G&GC!)ZQYP\I"Q6383.QW+,#%A[9D_
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M[\?WLN+B46>1Q='-3ZM947HSS1;D<XD9T]2RRY(47*F2/]]GWN.ZZ^>:(;Y
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MG**KI^+0G@EZZ6X@BEU;NNB^2D=GQ$.9LFXMO3J)T<-#ID]'FIF(8G?B[R!
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M7<,G[N* F\S+\N-.?QZF0M;!^(*_B%^A 8#*_CU\R2X/I8!Z+HA9GR".Y)+
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M(&[LFRS)%SZH&(=:;2H&[SFEDB4AV$:(R^O]U-W[HXI#T8[T871AW* ,>](
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MX"PB9QA8=SD\<WWC/WZF&!]U3UV)6=A&1=OQCS;ZEA UT7=>++;7ZU>J91S
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M?OLNN4U:JFO6L!*B00/2S=#==I.JEQV>^+9T!B]!$VA M5H;A)?:AZI$Q\#
M^$V'FGZJ+IHK+F!3]=?@@GM7^_><;\9B":\YIQ5:)E,8#FQ(JM2A'#Y*L388
M,8=@=;5>0.99VU6%UXZ6Y47T)=^^%_=0'%8TE9N:<$.+?P>EEAR)XY/X7-Z]
M,:$U)UQ!T@QJP()7.V8%^KA=A?F^#N0UC7J161SDM*\4?57N$:FVC5/BS3%P
MU XN?=*BFE.XZTO$$L0N#5+57.%:([JB08'8F8SWQF%8C!#9H#]'UM+,]^6/
M.K'37>P??SR-UH4*!#YA.%!PV.8C[^>[[F9S:?1YAB82N(B4<OB0L"+1! >-
MTE7$U\3#E5;@/*-5ZAX;B\34Q]'YR^F]RR;C%["WDU+RV6<C.A7"!'"H:+AB
MT"25U;@(=@$OT4ZQ:K%V>I??681R33'14D_($78]-:5N*0]ZP?N@74'JUDF&
M@Z"OIYB[OR\*(31]JN?TX7>I@S/:Q&*\S5SY,[( 06(.W"XK@#V1]<YZHAN'
M./;NQ8I%$^?#A9Q N<#*[(M*V4 ^8XH9!O55KNI#4,1L^0LO/X3 -,QHR)KO
MCOQIC/.:VH/KN--'&&8BCOLP7:-CLI"W_^(4"(+R: [WCF8!HMF<!_3;Z!U-
M9(P?2:W^:\7P^V#1N@MJROKF U]^\+*K66ANEZ?"E&C ,=$H"TJ4OU><U:BF
MK9W*D.>D@0>WO()U=>Y/=D RC'HO\GGA0N\I/1#7WJT('YQZ>==]DUWH@ P-
MF"U2@"GQL.< P^6IG;XN#4;AWP65KE5X]*INR#5]3K#*]F$XD,<WX&1GD'C[
MUF9)8E]QD/.W9K%1C_1E=V//R/A&K>\.<6'OG;3:0]78*6LC2VT=]8H#EG>I
MPU^HZ"#RR+#N(-+9@8I/U?+>R+::CT*#3KO;2=& 9['D2T-D0YZVT)?;#>>^
M#JS"%4R4K945@I]\=KDLE&/O&7B,J#65F.6IJEQ^<A+>#:V QLK ;+7!A(C+
MH]JN7#FQ!7\F"GIF8CW44B0<4PSUY5EYS:M%'_P,650'*/IX1(<\,^PRR8Q\
MMEFZGVRV^SB8!ORJ?Z66<\<W?L9&=8HTBB#+0Z)"_<7HFG[Q!63NGN8D%+26
MY>/AY"158<3X-N'>O<O9IRX!#E:_#5LI]QI%Z<,,(NH>7$>QKR$J154SJND/
M3I@7<*5KO,K/3RD7^5'#'"<J(L@Z3$E .&TPP?LQ5= UUAGEFL;AQW[@DZ:^
M'O9<4TD&6TT[O>/0;I$&D?CJB,W?DR(+X1#+QML$WQ;A8\TU%02U.!@$V[ 2
M.<WUJ?QCB[M,A/J/DEIQYP3IHIIZDS2K^+2!#)\OGT7B&)-"XSC[FN#&\'X(
M^T[?. IGV-X7)ZR EW_>K$F6)PB7B5_L^6A;6A-BL'1#=B@ QYX\WY$&VFPO
M_+T$+4(<A^E_(#9@O2*JIKDG;&3!E@.E&X_+G!\W*GQGU10#W[YS$_Z*X=>_
M(G'3WXKEO6H<ID SZVQPS*UM;7!A"+#0>(F@U H_-5*Y)FU+4(W/<PM)9G.T
M+UI6F.P+:(]D.^/9DITN\N!$/BLB5E<\R.8;PD'W/$$X&3O2F-3AYN].+(/W
MX_BN;O%Z:B<PA21:[WM16<-($%N8-1&@7NC'^>) C#_]LR3+B&]SS;->]B<$
MW;ZG)[APDMEZ/PL+:2]&>"(3<P2)63@;Q!>8.E$-&U1E>O='5MG"\"A$U?FV
M6+C=1=(-N(UCWTPN:&0X*P@B#UELDG^MOK<$S;2.(G,)=/H&A5H0D_/_($ 9
MW[@#,8Y0MF4[4<FYAM>- ^#LS](G2^JBCK&8I_Z(']F&="9.F'0>>$9BP2?)
M.AG8F7@Z/G7!N^%7D*>JT!7&VL-RG]'L'G6_#.P?71*38U8_'Z[[X:('FN\[
M^DRLJ)A6J#/Y<%7<BRZ61T>H9^'=-("GT4$;\OX2SBRJ:,#69O+GF.9]G&J
MT7,%A&Q,%\#N6WER:DP'#Z6R,A)".Q$G/)O/$S.P]^-1;?%@@V&Y*@Y[TS=Y
MI/OD&]1;-Z5_]@GJ7Q93$L.V96]; Y1C6Y<ZF0QO2%J83C<XB\Q;=:*^6*VI
M$&)W$X>509Q32Y 30]C=]WN2P4R)13\/%I(XQ8^/<39P";P]^40IFNOSL;#4
M$]Y]MC>/OOJ?N?[W?Z.H/'W8T@%;)!G NU+((<0!?""Z>*Z@?PR[6Y29/-2;
MXZPVZ?D@RXD&J, :7ZHNNH>MXN+ >46YH R4N]<OYQN4#[!+6 SW$EQV6)L1
M-\VD>"RGJ5#4][>TTOLO45=>!2:52$L*VSMKV[.UHC[+DI',S>)$^3F)CKY3
M9 ,4H:SJ;6-]\_N^^N[5+\:R==%VQ@+1@DI'B![AWE"HN1XX>PR#-]9QOH<O
M?.'79(_+*?]DAB4539KQQS]/O3<^<8$&)(:&^OJ22I/>>*!?#@-:E",(^V";
MW0D(N"_6ZKOJY3XJ)V85ER,+BY]!9*ULX;IW]\H_7,@%T1$0:!PYA^B4M6J_
M4R_?.0Z3G46>M([5VCAA@OTE7]WYB--DOG>=_RS.^UQH-;PYBZ1-9AN .(.?
M'X##R1!OW\#"I1)1-;4X_GL%R3]3--",,FC@"1-S4XCIOTX1_".&8MG V\[=
MGZ1!/+&!NP7FMC%*"CH0N&(O7"0O 5RV=_FQ?ZD=X=_5.[7'JSWVP5Q/6(50
MO@LA&I.NN*D>)"9J@]U+W0((QRVH&HY5M;]81*V-[MU[=>I)J1&?^K*K#;WF
M90PS!AM(%E45:^& 3-" KQ'&M;;VPH%9#3]/V<=C:^SCQK[0R3)CO7[9S!8^
M@YE@(2==[-@334;(,L<'UV4WY)C3;\"#F=]$0Q<T7-5.$]G]D6PH)U04ADG;
M9@YUB@BY&B9]CW"5!KB.K/-O!G>T[2>*:CD$L&Q=6V0%%B>:+L< ^V.V=.L7
M1F8FJ"54@7C<FIGHWJ#-L+S#L&>F.^E#34XP;V/"[H(EYU1[BJI]3MHVU]LX
M39CDL49WCD:W4^IYO+=N*IPY$0XP ;.W_U_P@P6Z1MT#$ZZ>,OA6D@=<D3QZ
MTG=9>G;C%VC7C%#X%.($B8&>H)YW\2$^6NFH40MHXU&XOC#A?B:\BU_B89()
M_HF!4@QI/./)W@<94=^$10@590V08_!JJ\&DR["SS_:^I:..P,\0#[JFC#RT
MW>=D=7L7C-+J5>WTDY[^(32S,!:$H-:X2%)D: VE4%L-)P\0F5NH.O@R5-2:
MG[2'6+LQ:-?IY=G[;[A_)T6:-7\0,9IJ\W*C"&_";3UUB;A]"Y7:!]^RN84,
MO;R7], 9R&,TP-XK=H:5J$6Z%Q1JA<\V+B:V:MU5/O8U9_""/TC.IE.67Z;@
M@:T))^OORR\ /Y$P:9(\68E  UI0OR0,\0%YLY.F)FA5[OH8M<@JK=?\;.6:
M!]AV"Z/2@;6@ N9/&BW;Y26-.<82$KR]"J$T(%[8>.H$+K&8!H + +@;^0PE
MF8R@ 1S!6$1TB%>K#72<!K2&/' >WBZ"71%^K\+"JG[V E:+T\A1 &!53?U>
M/EADN)AP:5E=T.+UTXT$GR>:0VE&CU-S="[\4[3*_U_^CQ9+<9^&)Q>-T;:6
ML-7(UA0;_.'UO.55@(F^"C10SSMN\WCA?\Y+,NJ1IWZ87\]I,^0$O#+^?+\Q
M[P$-@!30\;7A(J"40%S92%PT^EIRX8'!S+S@T\[@7!:7#S)96;SHX017M,X+
M%P:7(O) +< R*_Q6R7C1>R]0;<^*!I1OT^L5D7OUQ)@'T\0QD\)O-W5<&+8M
M[^_:/_/Q[E#JY>B'3>'-"@?#S[W/%%@0B0L)'2KZ]XENX-'T58]-7ZD'?*/I
MP/Z3J]AKH_83,_OKAMO*#.?^CDU&']1^9Y00S.2J.8T6KOSWG!OY3I/T)_4%
MY_0YGC$ \W'^VX7*67I=:-U*X$!*5,$S8FDTS8G]5XM09YCN*X9S7.!,1 /=
M04*,;19*KTLD*&;W,Q;1:20H]4K&JJ["FI%1AW%UYJ4M=9U,S#2@9-^RYJ12
M);U247._>E=GB&#<Z6R+_38 ^SDL <$9 Z3$1'] X_?017M+-^ZIG6)-TOL.
M1A(/,X4H9UFIYRL!W^R'-'!\2X=$PW(#9T/G$9K>/L<%@B%I@&Y,_,(F(3G1
M<W$IT<U,JU!0>!^WHG=JP+RR(=07C=HLN*>F>"P@Z>(E,N+P&FJ5[/-*F*?[
MEE<GLP '>X@UO>WX@DFRN*##/'C11##'7H&Q$+I%#:4W_M?V4^:Z&)"S"'Y+
M?]<)&E>?SPHB<D!-.EENJ90+#"X?Q+.VGGY3[]NG =J'BT/)T4),;A"M\A]Z
ME! DGN)RQ%HRN4M\:>?OFVUHG]K6=?%9GV/T;KLUKX?C^.8Y;^0>B9$LG30(
M(^B=>/]:G!E);9+(^J/45]YT*$P+;]]59W-F!Y*+[@7Z\:VU[(D=T%TP2VZ]
MGL3'":X_6[R1MC>/#)BSM)UB?L1L]^;/\67)[O/8?JHVG8$B\GJC?;AOKT(8
M@1J4^SWAU\XBLHQ.5-'A1/N)9]D]E8<9Y6+7&',4F"62T7R'MZ%FAE2O/_O?
MRQ7V_W!A"GPITE0_\ D[Y.E1NL-WUK$Z9W-J2B\E3>MZ,G-<5SA.2LB83^"%
M+U3'FNQ&>!1D@Y5[D?E?BOOR1RB_Z/]1LF0G^S)"*%NR598AVT@(V;<DV4WV
MP3#*OH<L6;,K6_9MLLW80K(SPBPHA!G"Q.#K_?D#OC]^/C\\OSSW//=YW7/.
MZ]QS?[CG?(_UP$$XM?T;H97V32X-<C:9=-=M=.5%]2I7 @73PBW+(/E5IG_S
M8^F*UNU-B2\&T0Q4$_U.&'(/"^)F&'W:BEMGR&8);V *.)==\3CC44I9]NMO
MJ%(=1D;?CSS912P@K"449-A!BO^TN.R1S<EJ/=C-.RU=[G'\<X>KK3%UHB U
M/6^9<VR!9:'!3,I,!NX&B6WE$8C]/%+[Y.AD[0#M]L-FL\W/;L*/1M0#WB2B
MXWB/W=DU 4)?4QY$;Q%M"V,D%K1%AW.[HRNR<78^_KS)CKS($%"2:-.<9//I
M9I8^F(-LIWD4+U6:(%Y@CW>\EH HM,[ZHW*;$&@'&@#1*82)]75FQ_Z1/W.P
MGE7(\PJRM3,YH15K@CJENQ7B7NSKG3::B;P3#S<R51<H@)QJ0EFW4>B>6-RL
M=TIEZ=#&5@+:##U0*;:8]5MAK$)&&O#CB_,!=Q#S5L?+YS>;SDH1M,'%T%(+
M+YU3PU;">.I15BUC?>G*YGS@7/N[?X-HW(W,4K5G$?>**4L!>EQUW&0Z(C7R
M!++#4@5]-:<,8MM&5RXAY +DOS2TWRY;?)1\0&TF(7\OFK7N'A6VC0I1:45B
MPR?##4DHM$L4V<P9@@/%FOQ^&-:3!'N66U@<4)7=@4VTF[A!T__L3A5.-EM$
MU$<=J$_2/8H@@%):I!XAP;/K2ASF'E4=,Y+2GB]RQQJ, RBS64IL;=:-]DJD
M<^X$P4;?$QQVKF)2@=N!G8:I52N\HPL\6[VK;A993[?NUBU/H0U4]/BG +^7
MBEVNV5F^UJA7(&$)FB@@&T(;XO8\UF"Z/IP/&ME_L"4EON01 /4G7@$G+!7(
MTI=E4O,R@K_E]KA4DH9P%DGGW"/59+6BWL!S^LZ\9]WM[8BF0HGX/,/V)AL/
MIJ9QX9PF_WWO#XXW7\1YCC)'"-3C>^)SJ9&A^GHMHQ^F;!:?<)B;*_JMVJV
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M;A[R4R(\M7FIUO014;38IP)Z/F]F]\KHABZD>*A8,UPD_N:7%"QL))T_;XQ
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MBPPF<Q+Q.^4).*7T9ZTNP)?&DB\\F>0=BT:1$0''\.949!>09K/[5A&*5[Y
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M@XG-/5R" "0+=PY%_YJO_1C&^O=]!AS-%U5@'/%$6LG+E^8GS<LLWB,,,6@
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M!:)WDW.)3,2YH"VO![_:W,K+&?_R7&YI29="S!CQ>^,0:W7) '?R+C/5Z]A
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MA9[[S\:ZO^-M?0@W?&^L3K>6DH-O/'A#>GISZ%$H\-LE?J<D'=1;PS"??Q>
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MW,F\<A860_WUX?]]#8"K%XO_#U!+ P04    " !3E'!6)Q_J')9J 0!E? $
M%    &5I9W(M,C R,C$R,S%?9S0N:G!GS+MW-%SA]R\\>O3HW21ZB!*]CQ0]
MB-X-(6IT8C &D>A=D!!$CR@3O?<:(GH;=8Q>9P@F#%[?N]ZRWK7N6O=W[_O^
M<?<Y^Z_SG.=Y/F?OLS^?/6O.[?SM&N"^EIJF&@ /#P]@>W< ;A<!SP$$^/C_
M.>^,\.XDND=$1$A(1$9"0GR/@HR"@IR,G)R2BO8^)14-%3GY?<;[-'3T# P,
M%-1,S(STS+3T#/3_F02/X.X>0B)2(B)2>DIR2OK_:;OM M#<PW]+J$N QP7
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M%059UD\!R:2[Q^8V?)AW46OMHE?:X-G'?M8@2-*AZ04I17"B5^OG\+2(P7J
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MED@=*99^_/QJ.;#PL!,2LC\$#71B2,(QQ'6=3ZBE+ Z6"*JRBC 8V_6$*0
MWZ@GDBAW&#F9)@[K*@4G%3BD)Y\PM+>!_>G?X?^\$88:3"A38!DO^F$/K_3.
MC8M^/N=?X*;5;#%/Y>E)E3B5W\Y-UT/Q]VMT4&&Y0FE&"UQ7'IHY&%U1);R=
M6E+V'7JE5+YVC-@_WYBZ$8#>FU4$,?6"@,YP[T [?L29#JM&Y=Q(6Z1.19^7
MI>/$G@8]WJ5"\1[I#S/+%95BNZ88WB2O?PT_AX8.YV;KA-:3R$.[7]2UZC!I
MUH#NP7@]S;@B1JV)#:+(B->\A^#U#]/^?.3IMAYFHYQV>$62!1L'W<.)8I*0
M6V6%6+AVDF&]&4]PR&@],LVE+Z41W700."#/BA6](65#E_=<3&%1?9D6+P."
MME*^5S#*-!+^XJ'9[":#;*PYH'[")_,8CNYB'F!,INSKSJ=$/>QVTGA#.H($
MQMGP3,&X--';@_).'PX*9V*7GH>4JOM-2F]W$Z54)X;* ZY0YS58!21U+) $
M9QRR;DV[:-0V\==RL9P\!H_6<CA9H?P1R339O^<W]U;7W(E12&!TF]GE6W'L
M%_^%BLCO/I-%^,R6(R3?6!Q!"4'P_K'(SKJ<TIX\5KT?.)OQX[JAOY:S+0UQ
M3S]:.'^@LL:C<:!M9CG,6@]=2W@2 W+,HY5Y(!K+OP:\#&B\=B;X= MXWXGC
M0F=&PNAV.Q2FZN*"11G!^QB+Y3UOVAH=MN<2]T-."CIBL.I7 C@^C&<WB,#*
ME9.B+G@QAVS6M#5AF>^4D^CQ543(D:^-SBV *!< ^PUC[]I?SX;> M:D^D."
MT:3J.(&QJ)$P$ASW.?<MX $_/1[:L17#U@]&ZP(1U"_0]3>599#LM=+8SR$Q
MHF/9WJ4_;3GL?=2NBZ?D!IY3?=Z>N)NI**_F3SA&:.U=,^J8PMD!.Z9C=CRZ
M_'Y+NXF8,/O/@;O9B++ZA=M8YUJ]OLL)A!^Y=5AJ<F4]5&_=*?=2O9-DO_8O
MO ;DU(ZOY'MNC*9*J'@NFA:,5-!6F.?EM2I<%&S)75O+"P*< K%\1X5(:GK8
M: MQ/?)02'>J'C(^O[=;^M"Z-I_?C5:3WTTHM*L\[;JNTPE(#'V-S4>C>M^Q
MXO>N+]N;WDS/U&N;D?^<>FAR&I\GABQR-KTAL5&]!1 >8Z0NND"(J/6 +G?;
M^OILJU_?7<ZKT_W"PT88WV[S<5-O@BVA-,\Q$BC^I!L^;6^.E3PW;_[(.E'!
MS>)$V8=0/4'JYAAK[K=PZSJ\?3 UC!5KCP1'3:FA<Q/<"UR<%_O;OSW4#N"7
MJQ!-!)/BN#':72T)C7&2"M:N0@J:)6%6!)^_/E3()($3G,#5(K;BI9?H]N24
MSU)03V\!]+F-'[</F)A!YZ/?"4Y.;TB5T '=8"9%-@S_#>V=?D%@HPXNB[QZ
MYK(3^TY.ZVS1CUKJ.^JO6.X*[XLV422(T,T 2 H91\34N66Z/(PDY?4[&;",
M-*CH;O78<<W$T2898+\X(>'1WA!J+?3F=?E>=7;)7!5_=/E!%^EF&8K]%&R(
M8[N.]8_ C!AC?V$B+*=PQBBG;/DW.9\<%EPP8=*?J JI%&R]Y\HD\?ZNQM\\
M@#@A5Y*N\]>M'><TZD@V4]\I7M-3Y'6Q;D,)KIY"%;'%%58NRG08C[R*/>DA
MSG4$DQV/[5]>,WRWW@XI*&EB*&*Q^Q; @C/', X^1V=&N8_-_]5YML/-EB2<
M\D%K"=J5^@S7%]X-_QSJHA=G YP!K7T#$4*UT=<BCT6.B^MKIH_9-'.[CPF6
MF;/YS":*B1\+V*6$$4.^41?<96D)N(ZJ&!VZ%M&_=@M@DHEJ\T(DE%>\2PWW
M/7>D]7A <Z%)_L_T^\WOU3JFR#9?=%)77"A*2%BO?XZ5GFXUZA-+KO\'R=^H
MZ?M]UY00((Z1H%N9(^W<PY.>@T[7DY:OVLFYI7,A[? 91RU0='3@L/GPJVD]
M; B$?\-ACB/"NJP+*%(BL?[[G906; DZDO.J?27:7CS+?,N#7HXD_%^S 'U8
MMX*;/XC,0\,*R$BOLF#M+$QP[Z?X+^=&&]L8?9640I5"%VYG.?MQTXD;+HQT
M&E*)#V4XZ\_F+MW#P'LD G8-OPGVA_\>^\#)/MEV]RH3A6/XT@M<9EMTOU!^
MNC'.^21$K_F9F]_U.\!'LVK[O 3[T6E=='&L>X4*\R'3$$O2TU!6I5F$V$W;
M(PWPVE$1[Z;W;'5Y&\F=9.-,<.!)<C.Q2M$64L$![.UX,G6F9#IR:C+EJW90
MA-I<(0YD1DD58KA1 6$WM(N/5\0QNME([,95GD=RU?&08\==IK[_@&WMZ616
M)$ NNR$'TM?-%4.1V7TATFY@4E?I4QZ[<#(>-W\\H\VP/Q+6)#@&A=Z[-NN*
M;<>&?UHRS@7Z*M/B+;]A4R/05=6Y2"1[:.E;LKC"VBN26>7'UV4P>HB0YF2]
M<.A@D/*7TKW97P%VWHI]Y-&?WU@!)"*F39U*<"KHK7(D$*MU4#^BW4D5';^M
MKRGSHBS14NDC%'4E?3,"I("Z78E#R#QIL-IZ&*KB'Q"/U=$9J6B3HZ,G/  \
M]AK\H6@JFJ=X ( ]0W]HMQA4M%03';">]T'4/<UHW+W-.M"V(:!P-.8;S8"T
M>,-3=A^E'?R5G"N+W<JK@#V$Y"W@_J$E\ANZ8)2"S_M</[!%\:?LU;SP2D?3
M)#0$N6S9$]67$33SM868I;.N;6(CN2CBE-VO'\J"!(6#J#PZUTIR!=%U*T3H
MOQVL$3WX6\(/_P[I_-#>>B$3W7!(^3YP(+#JZH:,>XU#K[L3@'M"W=MYS](*
MJ_YTUKY]!OJHU,*]OC5,UHZMF_E?<D. +;M#F@KG/Z<K<QQ/1TO&"C6G2X>?
M=UVQ@TBLOKE1LKE:X!MVI\J@GJ%:04T6$ZJP2([I6"P5"*%]'G3=U '<O2&?
MY6M Z\56+O-,5?J[A0K,C[#Q09N]-\-@.]8+BM[](9CB@8?UC=%B7BD_CH:4
M /1XIZ*'_ZX4L?;K<UVW +K]3(1M9C^KR-<+>?_KEKPZT<R,D^ZQ!VEC#-L@
MM&8G5MT?OG"B9"+,I%.-$<[I:V *,!E6[1MFMMODR?O2^G<7[+=L&9?M\EHQ
M,-I4]HP9/I(T#[(!+\#/L[ 7Z%FDR?ELCU#EJ]6A%4O-\]<:QNS4G^5PW_%N
M 6A]:@0W&!UP^&@M1T\SVR2B)Y>DLS'"]$HQ3-5;P;W)@;/"[@W[W XP\:XQ
M),<98+7]15I+%EU;*+=R_:EK;=A+% OV-#D&W%"B'+ _AQBA<QK,14P]N< W
MC%-TE8BB'>^?XB=-SH4OZ[39H(O4R=%--K);U<J$./=F;,P=RVS5HD<3<F8+
MU\GCL(J<*=GIM!HGTL<2OC+DU>P^ZEJ ,R"6'WS0BUPEPN*+QK!&1>778]3J
M?:66/ZW8I0B__3*66DTEO?GDZW8:6!=[@<H,5V;^Y4X=B].S+]+Q,G_]WN3Q
MD0HA[@<I.\VT40#C^9VHA9$N]1=;J+N31$F2LLXRLJ4K?B87_'JVZ;:AA^5=
MC<@<S!*-4Y:"5"U>F0X@;LJYGOZP&G9,57A+G>ZCNZ+);A]&X@JX G6!Z!6%
M,,^U0Y[WM)R5U+^ML ]H@.E'$;H_$,.IOK[;R45O7B2B+L@IMLVN9"?S8#AE
M<46.RKS%%F]5"J-WF%,E>E!Z!89*8L.1S!^_YHI\7MC/<F_@BCP+^.$)M67D
M#7\<R&-X5YTK<VDF^=!CO3H^BSKU/^>.S_H;,TUB&;13(Z6ZQ/&:PN<=PY0G
MVZ[S8>PN'=)3BKS>*&%>1>VRCVXZ"F._:XE9B%0(?<_@\3!1RVYJ'$,K,GX$
M>+Q9W1=?2+B^T#56&323AZ,[1I[GKX,^=LA.%&4_G6F33+%:4A2LD2YZ1_#E
MZ]=MGM.YK!-XO!8(>;!*]OZO)5WB_"U /?1/&$BEGE)K3JTF=?UDBTV6[EA'
M,IRIE(6O3:$?7-?90\T!D>FSX,A+D,PQ63_5:7FO$$A.G]ZG^R[R#9FN.MSU
M7^T-F11JY)@)%XQ]BGZV_SNB)VMS0R8HV])*7&JX+IOPY;?KF<6O5UF7G2CU
M+C ^).X\9%:1+@!9#L2J^UV+&]H[$6J]7UZ/^<+Z&*\ZW*:0)&U?A5/B+J4P
MF'<I:_!YS][+V=:RY\6[)HV9)=KE\?^<.UV\)&(O";I"ZV1Z0V,04R[*3!B/
M["I79<N7#><^F>X1Y7YKOC;4=U/,C?]=#C[G1:^DE\U;[EF\G9.9T'8+8$Z5
M,SVD$C.*ITD<:-,[YQ[W R_,G2.QS>CF0P^VP_'ZE>Q0J195=B^UQ566 28J
MP"!0& !+5B^S:$=9\/Y6.S0,C(.(NY\-6L$8NB"=YW%8-_0MH(]VIX,+D_&E
M<&_D_6R @?B0!-87:[IMVD\=:R. !A_F(%>3?![&=2$2ZVX8[.Q\?E&,]ZP\
M:XO7,#$9^](M=#(WVTD/ V+U4'.'QFO[Y#ELJM/N4)DBZ=;  $DW(9O'\,W>
M^P_8/SJ(C@%EZ/&R,2C5Z\_*?#@K-*P5=4RW^VN]7=JL/ST/,2R\Z, \:32O
MR?(@/ 5L(3E"6? K/9(^R>OUF@ @Z-*^'?;F3C_IWM'U*CG4#PO\OH/@S"L&
M[\F7[(]D*SC$:K^O4<-+^80_SUF_UXDVU(OEY)K$L:R!(SEI9E;59MJ\ SD^
M]I6EC[;:21^SAYFMA4^_(NG$9I[G8PU972])<'R7X//4?N%6R[)W^,_9H-GO
M#\=08.#=DNR.T8LX!X&1S89J-GZ.CK? XI O=U(E#$:-]403X4BHPDNUB_M+
MQ)>[SO<P2R^Y%7(BJ#\?L?PZAR?<]0_)@YZ>F$1ZE>J26EK![VMX;7A)6H"K
M_<$\^C9>])A>[$6_\H/Z"=ODC^"Z:MZDFN^/84T_5JEA3[!"ZS^;0\D@J;U6
M;CX&#O4^//&)_68$EZ;;VUW )$X@1N8P!6,_D$?K?@SW\(N\^37QL';B6.I%
MM=GF@\]]^G)Q7NQ_1UUQNG-U;F.+H<B OJ1("U#L!]/3;$]Z;3?D_K[ BN)]
MBEP'#39^%OZI+, U7Q2?%'_\>=FCY(:=F>9_D8',I>-XJO2O_K=RG0":*CT"
MV:T<';MF+P&"M3RL8.B 'N'JS9@R+UJG,\;O*H_I>9E%1<MC">*6)&R-817
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M'708F=@V._K+D)2<DMJIHV2>C(EX7%1XKE;\'/2G3Y+1-0M2739BA=(E1/]
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M*LWC0OHT^>2A4:_'4?"-5 1&&YG8B=;3B>KO8,&HE0=S?*$,I,J7R6[7'"0
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MJ<%9N]+UK@OR%574X<8DL>*5U =7!0-#P[> A=%TN_>R4FL@(D<LV!/YY1:
ME*BOR32P_ )P*W<,X/8>5'$[J*^-75EV+PBW_Z@VDV!$1##%D*A(@KP>7IVW
M@*'^P'Y_&=LTUF/CU(J!)RP--QC+R8OKP XMW?\J/D=M59<B7,$44K)FO85/
M@[<>A[.YJN&?#Q8[0M]BVX']')S4][#2B/-+]V=(^V!X;0IIO,-7&0^5/9+G
M8 U73K:I>FWGM9:?[R'Y<C&\\>+P<0.SG0P+U:;$/\-L+_Z\Z[UO$YQ+='_
M\'U$0[5$Y:?U'[H_/KYAUIV;O/*SCKTAGMP:;^,M-ENJJ>]OK_/6,"U9^\9N
M.DP'58I8ESE46G<'O4H\4F#_]3!W.=Z!IA$HTPE*#XFAL.->$U,*"IIFO-0I
MDC&P5G5G-S4(^6<,<+S,&J..]^,UAC=4O$/5?+9_-%&2UTR<MQ3X+A\-5)M0
M9L#&]2(>TY**<KE !QYN9CT]%7@<M!$F- HCQ05-PMBQBEC[OO, BS=;6>:O
MF)N2_1$22=ERYQ?PLC;XI_?DOBEF68WO_:QA;YJFZ^(4=J<^!,?Y^9!,Q_Z
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M\#ERNK1V0C7E.2(B!A@'75R?5@E3+DUE<2U-Z ?,9YL^R.Q:DMT 0@YX(E+
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MNR^R[=5V%['$^8.AO3H[<Z/8=BY3,G^B&Z8M8Y1%6(+*4)[-33ZLU*>) !
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M3*_994456DD LJY:];FXZ4XQ($:SF,-X9'QQNI/K\E)P\3C;59<B^]VDG;O
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MT9C+HZ6$1=L.Z6$A0@,*GX+FA%LY0.^O3X,,_W":9CUW-FT/(![5&%G0CZN
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M]WFYKV'5W(*&R"F7PBN_N"MX<CO;U0VF;W[]@"[<:]OTGH9Y*0C0%M@0D*'
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M/1M0$/AF@A=+7H.H5STDC##F>\-@>L@N([!%WGL>9^ OV"EVV"^YJ%=M=EH
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M!VV%NRW G;3HEN5#TNY++F5;NA/ \=%W?M$E/HQ^(KC"ZP?Q+"*#Q>7A<&)
M%(!OK/$>INJ72JY]<7<9M^Q[X'RT[CG#VE8X,B7X?=[A(H104'CKE'R:OWM.
ME)?A]/;C="Y*(R\22F5I8P/<?[2+5Z]^'&*,F+SS*T"Z"BN27;HC18(*GGR;
MVC%1()BQ_] 0E?DK9O1UUTQIN,/H"[M\8+F71Z.4\T%S+&M-<WB!I+Y]AKM<
M*"11@U$[W#@NQ^LEL>JW)OD?<,VK:+ORJPST*-R.:&C!X4)XHQ)_CKXFQ+\Z
MF"E0$X&RCM28<F75$!I\\WCX#SZ?0!/?"K#ILG)?Z5DL0:)G*F1OTZ\I<.IU
ME!?G9(R%B%YA^>1MX)B\6>.4*][*HHZ?%1,F0:W,.-_L@/COUC5T^\Y[M37^
MT5[HIY:F.+3!-[9G3.]HOS*+8@+$=8A#;(*+)]1)U;*,QCWJ"C(:$U?.N*\4
M@"$D>X*?PLJD'S%9 $QN/+NY_N&\(MN9:!?!OKN<C$>/?;1P(0XAN";U9!PF
M9BP*:N/>M9BK[1$[V1ZR9-&67_Z2#8!CX5,2N@+0Z.[&[6!^-+&&JEYQ>J<C
MU@[AX&]>E.),U%8@V$MF3_J83T[[#[GO$+W[R'OB0^')"D\+WR'8Q#5EU[5V
M)-Q>'3Y?B#A5^2[YL>SE3V*I9^=E!L'D\0I3KE.J]TOW7=+1I2%;N50Z*YKR
MC\R5IC*G/CEJ"CB>$S%L):\8[YI8A&$BC:>IEA8MGKT<DOL$>3]LM="Q]JGC
M^,;1':$+-,^2S3TE2O"H%K\UJHQ$YQDWQ$ N_N& IJ'O&B!?70W&M+=QZ*#%
M+M;V5F<J0OM/J\<9?L'_ S[64@QZ5S.CQH:(#WWYY\:Q&[3E*&5F'0'9U#BD
MQ T?<VPNOG+M]*^?!A64[=Q\CQ>XC_;25/(#*C/+*JHWQC" J!'1 'HCQ"7;
M)/Z^;9VJ7DAYRH^^ +M02-FTGJ&(:O>LMT5M=F_.JT#)::@#_VKV_,F$$:T?
M$V-[/.-NQJQ<^WGS<<C[AZ[CHNYB]<(!&1CW_.!MP^NYH/\&MF1%^7BK\Q6B
M,=9/MHYWO0US-_L*PT3GGRU101(9+-16WTY!<] UP)9_>^L0=>UKM1F_0$UU
M!XI<ALI:YP(^^B?&9RSG:/%V7>>2+$N6[C%KE36J)!XIFZ]%"!X8E,*H7-HX
M01.0@>VQE =.,!_FC\E)DY;U!+_IRRJZGJU$J@N&%.0_'(>%H%*8S(PPUSH<
MC^&:'K3?9JI0,\LSC[I9XOO,PLC;ITS/'7DRVRE+TC,OW6WE3)P6B.AU)W@4
M>A27UYZ/EZ7778A?GK_FR4==""GEFL:>RE!VF1" ,Y!0\EKDUG-KH18?+D%4
M>ZN1ML_7WT^I&+H0:6N,G1DKN+N-4MGE 40'$S\4*'\^UWK$SBZ[-WOR!\XM
MT%.A[^(5<"WW=%5@-S/U-X*8TP&/K'XS>_5__.O)SO2"ZHHXXI8WOB-/B)N*
M=4@3WA'-5TA2DV,LZK8B+0R."1L3#O[A?/BIAJ0+WW:_GJT]J.!_Y2"X!]78
M".NO499QIEZ:RC%9ZYN(>QNV,U0F2]?ZFH>-+PM\GQKL5[QT7FR0]@-K?">/
MYKX76R-H0U2TY_"!1=-:-_](WABNUG,,)B7;7'C)5Y88Q+W-=%309_D%NP10
MH]MCLM'FW'K?3_$_>2+7?O?O^E$A]RPD<Q3&3V;)?30\=9*.+#X!TM:W?.]J
M'XXFVW@ZZ,_%V6:.7/]<WV$X4NW7'#P*H"'"VQE]52?L71UDX(;A MV5ORR^
M;O#W0I\IV)M%MU9J]^RT3K1/-;J(V !+?2KLV:%M?@B:D?O*[ N!90WZ@O05
M@N;G/9=O\R?/U9=H;%,'#T'&1LZVX8.)LD2^8V*ZI9H%^<<KKL)]A=W"^:$]
M:U]$KN<W.C["FG<9GZU'R;%]9*[*T#"HA@H^7:@5]$!\;K0H%'\_<20CO3K&
M8.9H$&O_7( ]ZS3-Z>)\;QXQZ0S2@>Y*%W=D55K=)E%*I^8$P1U-DOF)ENY[
MIS47!H?>?,G1WM&E&TTRJXF>O+C.T%N[&2W/M*%5593%;OA.S0[?:"Z?_0=9
M8>6=J$N5@;)_.%_0HZO]@5FWRH19]^41+9/GL@JKHS '9\(D"^4*F33!WLNN
MPT,I-")" _C@ -M(/+5+G?OP9R/."O?WL^+&$S882+1G8M>0D[=SN*+FI>F>
M^>M1*[$,@&T[-FW;;6+-I,EW!+]WC](VJS(CQ*>X2H/N!O#U#K]X5SIWAABV
M1<4BCR!-I7(M9(]'@(JN GH8V*;V-7K[\DM'J\UDAG[DO5->HMX#B@=4K.P*
M*_..K)\-,"[:_4QLPF+++@UUEQ?K>\YD:@4'$N*,<LRFU26UH\,Y?&8GC);I
M^#E']&"B,W.\?$L/Z_YC?;7THU60%OWUV1#+T'LIMA".+V!:?P;N_J:-%A\L
M^P)YP3('"BBF/,-7\$'LP &?"EM13[T1*3D:,)L4UQOD&#Q^0Y?#FVVJ\'>@
M>"=DFA+&)_VZ4U)>S76D8[YLCS+*KEAM?36ASE".EOB$/%]-JL%WTZC_LUN]
MX&L?;8V8XTR+>>";IDS"O/:9B\=MEJ(+..1==^*3)LLC=B&(;F_?& $)^($,
MG* *+.65]C'^[(4\$C$D! ,",,ZQ1;H[*7LY8O^)?I/,)0>8"2SJC:.:0<'O
M5#'H]"Y(]V.L8WB9;8DI3#I1"5LA9Z)<Z-KZZ;FU>3=#?6B)B6A=9T<8=,6E
MGFCX[1I!PFP;V*]/5UFR$T!BNK&W> .D0Q,:$EJMI7]A*)V[ )5)+E--E4G_
MF!]UY7O_+2>E[!/][U#H@^RHD,DUWYN)BCK_XL5_.*I-H"B!0,6O$?PDO/Z5
M8S>[9+JX@7^/ '!<4[.;XSP(!]7_-@A#5648L+0^!=E\N6O]E7-1<T8[48-?
MVM^FH]5(3J8.I?N1UP9'[-2=M=.Y-3BT&6[(.[1K2XY1@B[=+]N-;C6/T"4]
ME3%7KIGPE>B@VCM"QZHXH&SB<DA[*MI8'+'Q8?+XWJ[TCB^*=]S[\D2&DP8U
M>[$#!\O-1Y'R)-90D/$A+S]+C5"%IYFI<NJG;+?G?8<><O4WO,=)G2WR87?4
MUE#]L-0/:-'4+QZ_TC,8D4<6T\ER\&XPU1<!=>!#T-AJQ2=W&;OT:>2F^'I[
M]%">W/NK]&-NG2NK_/F579.PUXK"?N PNLB]&$QQF\$Q8U>;[;75[!&V+_Y#
MH_-I1@63#:X,[FSCEH79G<L)9?B=\!JX,E#=6I0*96//BV?H]OXN4O? XBT(
M*#8;S \>X$'=WLKU[?20FO:LOZ>S*GIWYP'JP/MEY>[%.E;8F): MC66TTY%
MK^TS^\G^;L5V)&S=I*Q.U^.[(,*_&<\A?C49U6;RR>)ARS*_M+L(_@R8G0@F
MOT_&G"BER6YT1#&UQF99Q8&9I8TB&+[<TY(?^'34LG]SPB:XWJ?28 9.1[HE
M!YP\_M[,YC5%XT<4TXBLC2QE?VSB%QAV'&SS*Q$O4S^5(_A.S5<0^S9JTY:)
M!W0YZO_9%QYT3+D?#=O3*%X!^6H;_U63Z0LWNNY4626-JS_ZAT,08O</A^1.
MNIZ?M4 J(G^SEG5ZJ#E%^/3;#N1<GL/]8!)AAOQ1-HL0:-^5*V9?K9 C]\18
MR.1H_C@UM9B#_S%HD?[[#\=*65H .;\NF;9+TS+V^$YVHIUV.__3Q,%="?X2
M2XRO<&.I[%[%K=2#R!&/#SPQR[\6>%<9'*F,%]%=M_.>FTB_*][$8JVSV/GR
M-Z]5\RQJM>PI_8[/!$3LD?W_33D!R*[1Q GBTS Q4,I%VRQ30GVL M3\#_W>
MT<&CY!BV@_F:(1C]*O76'W_TDW@$?F_]EMML7J$%6W1K99TN'+:#C11 +ZRV
M^IX4TQ-\5PK:X^]9(:\?T9$UX,??.1N\"*1&Q&3>A'\9?&C&F\]:&\,!26%]
M#*4P+]R;;7_V]0RX/4[8:/<G]D06@BC0-MIG?*:._.'8A<+JNDD1L!6WRV\-
M=^' ,I6!+_</JJ)+8(M.]ZO@^8W"C .I6-2*W!$5?\RJ516U?);3CK]S0[KC
M3Q/3PCKU"7)W2-N=,D2?G9-4#5*\J_1&NC;3/>ZI/$BW Y):*_4<D5_OM^Y_
M43COZZ&AJL@D^1_G\FN>V&0H!! </> G$_4'D!X!7Y]8K6DT=H^]R-+5F.&+
MYFX9Y*,2>/O!PPWO$MJ>XKIV,YMY%UPGWO'"^\=@.>//^,[I63FN@M*U353#
MI_T_$[%FYAQR-1;IQU."?G+:R!//G+ZV_ M=G967_!%^YF*?&%:"N/M.I;#7
MU;W^KIUCC&#?M7887[G7[*6XKJG(LY?1U1X*;B&KHE?MIL:ZO7T%]PLY4W[G
M-/5"9;],R!8S5+FI3:P%S0+MXB2)IZ4ZV=WZK3:QR%R1HSA?P]>!:BCF)AZ#
M9?.?Y20MO]V4&]EJ E5A1N)1M(;CQ2WJD9E+)'4<.C&F;CAQ?U!;<3(V>8'O
MH+/:"-,,60U2'7>:B+A/OEL=\K'>>C!\;?C3<H^.LOIXJ2PN[(F$TZ<=.7UB
M@Y;BW+\[*,&5X*'_CGM;]W.QM6]8TL"AROWH.T@<_4(NYUBYB^)"LP_EFU T
M+]B6]E15[G>266,4(HA\-GP?P9^+E*'A;3QB/:/=2M4=HOB'8R?YI]Q?OB?Z
MQ5CDZ96ZV;>"1E7Q^3$77"E?I-SY#(\WM;QMH]M&AT\\5[9A3.$0Y,(7.#>6
M5A8]]8#??"M0+A]W].;+)I(OBZN_$OS7V--L)=+Y;>W5A,,K/J9X@[\0*:XH
M">0:X+@QMNX?#LZ.?TR+E(9<JR_E'.):B^M#9"H3<3-RS?CAT:P(C++GI^/-
MU+)9&P)MK?+.N8?N5,-S"OY<IWMM@Z6@T.>6>:(\$B[U=]&T:-J.G*QEX%(6
MJ8?Z3^3%DX/AG5)A"H"6EB:VY6WWS7:)Q: @N:)VGQ/#"-? -S! T>Y+&8\_
MO;IN:[/5#+]O9A5/7O="#:,"]>4Z\D47*5^IL-ID$I4I?R(=!16?B/?*$P>^
M.VY+:6\K7NRN-.U[:;[PU=]_JS)(VE"3KY*1GK-1W[.W52[61Z(&(<;/GL*N
MF9S)EICIWV>PY$<7'&FU1LT#R]&>AA\<&4=@XU8\X@+H9HOO?&J/LY"Q%!K*
M6FT-S6(_#^.HQ$NU$)[08P<:Z8#OECP3SYX:MU]::*9,!WXZJ0N6.7GEZ.""
MZORLTK E.2\(M!:<* XM5>T3;]G9VPR@RJRL-^N+M9_.:K:IA#K;5 ];\,C;
M)YL*@L5S>%(ZN1?>ML C;M:#Z5"?IZEJ[K,5+<L 7)HD9Y7*3&?F_-U(URL5
M9O/6E#B"[)1MM\6",T>O&^E_..F=2#)T#4UM0-?8B<JMQPH2^K:75G3W1_\_
M'..Z%,9"UX7E][XO4ZD-]&2I-4$C(M,&U3_V=3+):<']J[8Y+FDWLIBQ(@"=
MV%9:?4*P00C<Y+[!R([V[X-9G!3O7#:TEME+)BY_$GI*>+ZTSQU;>W(2SQE4
MI$Z+1*DH;8]-M3EO YFK3EXM!L49^'SK4JDH5$M\A)MC9988&K=52)"0/0Q#
MQQ,M7(7K@*U/O;F#NJBG[Q<Q7$%Q>!MF11G@R_&!K<=\;U+RDNAQ.3MQIVU+
MKH+9CGGO_SH#MWK\PV=O6JTE/U*S5+N$5LGN'F80'B.9EX2B-A.*N/(W=)"L
MRI4D_H?=;'[@2_H7*4\WRH!S0RX8@EVK)Z=ZGV-"]W0G@$GU%6/DXI3@S)GB
M4)(+Y_K*W!(S1PL[;S "\[/5E,D2=I7_+LAQD/3)/QR;U'F *+5AT[.&4JIG
M!D1=JW?+*= 8I_W8H+KI)*>_5[YH!;0&!36?=<Q*%Z%N'MU:I.=.CMI>(\&)
MAKQV]!I=-&M]K9E]8YIQLXTNR[@T,8#NI^DI7'?B3K]P+T-NP(\N_NV&)3O1
MM3><HD#2.HB>H*R SVE"5=V8_HU*MUN?^W]P)6SWNUAGXO_WD\:;G?\VF/5-
MZT-J!RUQ!NH;RMU>6,6C8'I"_<PZ^YU66NJ"^YP.M13E>H&^MRKVC>KH(;_E
M'F7)FE<69ET>WVJ_XL,9?@0V[_M18>%%<K+@E6Z+EUZ\ZMT7AL3SX2U1Z):8
MX/TJ>5_F4GA&:M_-\J+H_C-.X?KVSW-.WIC"8(>>.9'2CLKW 6V Q2;V'_D_
M\N]SM&\G%L9CO$7JLG9 9_?WZ\'=;GD0SO_1=H3_5ZK9""_.&XD">:')JD5!
MU4O*^43_] $G%$:_VR;@V\B7)KFWJ"\- .@+SRO!(]T]D]Q&UQI3OKWFIK'?
ME8U_@LG%!"HF^4<U :@.YU5-NHNDA_'*NNT0_JO:/JU<)6.E9\ SE,6ZMY0L
M9&Z>"T.GORG/R\VW+*T+4'N(5$]A"Z$>:>18<:\;#!(J^09#0:<Q*.A,[A->
M5;5I,</0SB(&!<Z*XDI.Y&&J##],'WKZU.S0&& 3GWK/Q2I*[EZFSW;P2NG+
MWEBQ_X_,*<(S'#AK10)W"*UOJ2D=#51?[Y*KD*NN/SNE_8 E2[E#S6#'=$DV
MAJ<_ R9:8X@+<2_(6YQGIH9)LM=R+AD7KMNP,"H8O>J[$!(1>D5VCSHPE]8W
M'=)K"2L(9:\^LI#.7J?Z=$:XK6_P<&D;U(CO[B(>5EW=L\8^PE =(&)9_KBC
MR&$H^QP(MIVT'IWBK=X%:.MTBWA66CIW3S7!-V1N(T[FZ.UHHJ$YJK[RXW*O
M,8&U$+?=(@:SVCV*\T^)$ X9;W3[QWLZCH)%6?N"QQ.*9 3;_]W/9S)M15P"
MC@)V>OM']@6%OY_<SM&7Q&]\QI,L?1.A7C1'<&2U,^*/]RV8>FG/D#0MGKMS
MYPC8A\?98ZMK_C8^=53XCDU;]=;PR$N),>R.W!T.Y!"D,)#M4PQ27&4,2S5H
M$! ]K_,L8>3QX'@3= V#/[H3;QA_H_"6Z&I,[0@E&B> \X?\]AD>?W%:KU+B
M;//=5J8=^1D$<9Z=P;JN73^^[Y2/3Y0IB/SI4_&9\.8>-"HG&@B*7I/+>66J
M0'YPA^!M5?T>6BVZV\P8'HA_^V&W%L1((5J4O&ZJNLXO^<=L=G9#0L+J)"'<
M+O<:3FJK,W!,7$]U._*W\RKAA-OD*K;TOE&_B45)WMN5$I\A(%B6N_CJ!5A^
MC2U)\6&XMCE2ZXUMZMIW*LP#$VRO'\[+)Y5**SQ;&#"V?W9LH7;UK:BRYJ8
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MK,^C'0O9'&L_'S:YR4*R];&ZU666T2I1?1XYUA)>$Y>]$YF^LZZ6E"1+=0]
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ME$]135X2<C.3@9)707!PC7IR7>/I_INF^49Q]J]-U N[BFZ&,'6");7XI3N
MQ=-PV"_E.6V#D&^9L&](JIVZ&'16;--V ':4N_DDK<OOCKE@)-@[(R#WV<2%
M.P-JX'RSR;J;:5YI!2VYRH ]_C4HT0NFNUI\QL_MH!][]%?INN64@_D[Y?K6
M%5A>#>9=:FJ,;#%.\?MC=@JH*L4D#<=(&L3/F'V.AWF5OF\C-J3Y&2];9[6=
MJ[3Y9T^9^;N@J<>.9[KQ[<#==PA'@<#OP#8)#%V(%$?GP1AUT<4T)6)?-!@
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MJXG+=;/ZFM-9W5VC25M](R/?BCF5S71FI^>EN4>\G#$R-&*K6Q6J>.I4WJ9
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M*U'&SW=^R]"\@JV_.X.$^)UAD'T_?25-U^R9MU6FDD9K<SSZ,_KVU3DU"O4
M;]M"E7A*5$)VW?)4^GJ%U'2IA4M2%S>K9^M5'>;??PV( %793*/SPMQ8'^AG
MO-(4,D]*<A.Z'%V940O"IGU+:\V'MBOVFWF1G +S(6RKNI86/C^ITTUI0DS
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M'-;K3;4>ZM[]$K DQ!H[;F >?7NT9#\V*E^@79-"00VXL(MJT\_'BH"D/P)
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M ET06<#:ZV:OK-CX-XEN;N[2+#*G)&I^;AT/,5:0I9Z+S%&7+,B1>HK20;T
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M-)&OG^';SZ"LX[)WR&#$<5"HT#()K0'U5%E[]4"1:$%OU\\&5M!J@QH !%Z
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MM&B "&])N+84E<6.4.$/]3IT_TGG?T+8[$Y>0GCG<7(_TV-+VWE)P#ER/[T
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M7EWQG1+<K8)D">/#X@<CC!3I)[>^<49/MX"IG+K;F$4C&&UDDC$_K5?X#D4
M3JDE5\3\:+,5LA61[F$NN^6;\;8J';;M:YZ\IZ>+6X3)+-F+!U19;$;.*YS1
MVY>UZ2QA=>U8RL5\3D/S5+$E_2)"S.;Z9K'LU0%1@'FI4<%7_7"KGP08R.\'
M":O^9+,[4%CIOHB/B ^V/8-!+;[=N*'(=VM3WV\"GI&?12'.@>%<DN;M>(-E
M>C:Z7@7%%I[6Q8LV'#O0B>MEJR9PVFM[ =(N>[,K@=^TO<9(68 G;6_EW"-
M!57I6;@,+?;]9:,+WLPH%Z'4I[ *'.J3[>$)0..0&R/XXZ1.MC@N06R=SNC'
M$3&Q=3,_V1/#.$/RJZM,6ZF,.9DA>NA(;3U>BNX3?M+RN!2-_LGVBF]AE\F3
MI9TEVJDO#6W)ZN)<%^80.<]$-$JEUWI7 <32#Z\Q.;-L'G)/ALYT'@'?#)=1
MS?H>?)X4!LTZ!OXL'\VB< -,A3\*=VBURCD;A_]U5IKH6\E=+Y\LQJ2+UB]7
MMZ9K:WO+, _Y2\,$8;=;(850[@,#KI;,3QNO\&B([S/.U?$\(F F(FWE17MC
M"TO&RIZNC)\+D]>P/L5EOF:]34:N6Y'1W<Q4_75:ZA*_(3\B>!NM=1MI4_MT
MNI&@@A'%LOY9PF$0O1COT<* 3E7\$F]\:VGM2667+V&7_]QI489&>QT775M+
M-XQQM-GXRZ=GAI5##H . )K1(1':.BBFXU5397B=+U>/H(DMG 7<X'*OQEKP
MN[;!-D<QGE_6MQ?-,$4(1KU?*TGP]77]R4A^8CV%7=JOW]R[E_D^X3H?-,T<
M.N)+%#X'X>LX0]BK<@+$9-8D#^I7_6GWK(OYEW[E[H&+AXOO2WIM-YCU34-9
MAE2)(H-^T]TVK@?KG!_/%5>V**YQJO>V<4RW2)OY^GH[%^P"\G33O?Y44E2'
M&!V^[F>H_-,KX7QZWM_ZUP6\6*[V_UZ \K9<=9MQ[7;] H^Q7WOFX;>,!4U5
MMJ=(H$TFQM)X-KJP<6:P?X(_<VMB.&7GHUII/%S4AM("!C!%4C<OO:C"J[$%
MI G>FO'O$VE@QN_3 LY'#+2G[%BF+G 7!=:&P&!_@@61OQH9Q# ')U7"$UD@
MTW0&?6;1XFF($$/:1/N7X1%2]<8W:UR"^NFX1F_%OWA;@"-M)4C<%7)I'92B
M.3*HB@$OL$QY3:0TI6@,D)0KT3$Q$M0@#[9^@^D6ZMR.\<T624;-H6':UZ\G
MY-:_."@ +&G2,"5F+OU?J*[6I_2U,3>ITNL*KZ>5)[DRZ>-%O$5_CX8AZJ?:
MSHK>&A$!N'X$R-\G'IS?+A,K>ZX?D]K _1CU)68LO/F+I/X,#0T-HC<ELI]&
M(^34J68*[H11OK3=M]B?$_2FQ.2+#07VHPUT3J/_K.#1.5.\7@7B<.<&B,Q8
M_@>TQO\/X?\X]V]02P,$%     @ 4Y1P5J_M#+8_D0$ .[H! !0   !E:6=R
M+3(P,C(Q,C,Q7V<U+FIP9ZR[=SA<T?<^.GKOG3""D"!$%VV(:!$1$D2=1"]A
M],X$0?0@2!"=$$%$KX-1HY,0?6:(7F9$Y(0Q?I//O;_OO<]][G.?W[W?N^>L
M?^;LL\]ZSU[[7>L]>^;RQR4*Q'Q/UT 71$)" GI*_( NET#:(#)2TG\'L9$3
M#PIJ"@IR<@I:*BI*:GI:>GHZ6CHZ!D969@9&%D8Z.F9.9A8V=@X.#GHF+FY.
M=FY6=@[V?X.0D!&O(:>@H:"@86>@8V#_?]TN>T LU*3WR?7)2(1 I"PD9"PD
ME_T@, A$0D'RGP;ZWQL)*=%'2BIJ&EHZ8H<F9A I"1D9*3G9/Z^)9R.(YT'D
M+!2L5V6T*-E,GE$)^;#+1J474PO?J>_E,)W&BLC9^T;3T')R<?/P7A,5NWY#
M7%Y!44GYMHKV71U=/7V#>X\>FYE;/+&T<G!T<G9Q=7/W\P\(# H."8UY&1L7
M_RHA,2/S359VSMMWN26E9>45'RJK/GYI:&QJ;FEM:^]#]@\,#@V/?)V9_?9]
M;O['PB(:L[[Q<W-K>V<7=_SKY/?I'^#OV3]<)" RDO_9_F]QL1!QD9*3DY%3
M_<-%0AKTKP,+.<55&4I6+1.J9SYL0K)1U.QWTHOK>VF$Y4RQ'/:^T[2<(O+H
M:[A_T/Z#['\-6/3_)V3_!>S_P+4(HB<C(4X>&0L( KIX5))X'?0?>[=9=__7
M-I6Z'"&RL?@;+A<4P&ZB2?%?9BI'P2-&^H(SL1^GE]*ICDJB/NK4J]WI!G_)
M,(N2"C L:TXI?WIOD&>8(I61JZKWI,8ZK!5V-?7)-<N2=.VR]/=?O^IJD7MK
M%=%4EB2"KO^S,C'7D5+O(HJ2^M]'W-L:'"E0Z[F3"WYN3O-O4AD@S:,<H0]3
MG3KEP:7W8TRFFR2,K(WSV3A6WNS)FX*\ []D,#)=>4B9\A_?>L6OX%=/NNU/
M)N5!NQ)<=KBZ^,Z;K*,U'NU>:7P,O4UTK0>#ZI&^XH>9-6YGA/>>E6XY<V<I
ML3,T3]L;LYP2'86OIG][C5R^\I!B\7K)"]K_J]V@&1)]K?^IC4JX5@>DD@A[
M^Z%X$JW_12)BMF#Y(=GV_\3SOV)E%7]?A=X2^S%%MET1,K+RX@QW3\3<GF0C
MX+2(RL1H6>6TC%7"@2'_I(AJVN@7NX,8STXN?6+7 XW.AV25%2%5K;4A_'KE
MU[T7>L>)CMB/93!S1(FE&Q>1)KKD1S5G]PZZ_GJ4EE<Y_.]R2X[/6L/J3.Y6
M(*L;Q3'^MP\,6T.G2*>-&+E1 J&SE?_;I"?>(YY5HK4B>O?Z=:E8E":=CMS8
MH_PK!/:"4"\RD0SO6Q4O1$IR1<RWPS#O_T_10#2.,8]"=C4^]+M<?H>!7($L
MV?<5$@>ZW#9L4\QCC!'59:EFZ=H2C@):OXG.Z+"#3/Z;9GIK>. F.PD.CF<O
M1&H(8^MZX<QX2^Q\?QTOH/<(>U'S_J/KF6C5:83B^AA"?^S+72Y1VQ:&7W'@
MW?7UQ$("31L:Q@(DH;;B-,2!0HQ%JIIUM<><DK=1V9Y5;]NLX%+P<(8>FQ1.
M],=C+ZE(?+ZO1-$E*+H$/I*(-SIS0YSY-59#L$:<+ 3D)8@^B;_(>I4UC.1T
M+Q%T%I[O&_HH?$!2\[9PC=\EB*73TPV[A;X$)> MP]AG%UQ5;.>JU<Q1/ +*
M0FZ6CY3Y7MVA?""KZX&9_-&"1N 5CF*.NA7QOLTMN+GB6G<E$R!,^YM!ZW2C
M-;M3PMSB>&^JDIN@^$20G*1,QE*N:0\XA"?=\G'ANW;Z*Y>@@L+WU]_1D'F/
M\) M57B@I.,CA;Y!'"%+#;H TP?W'(M+$ W>K0SNNAVJ41Q\K!1?=D/F&)-A
M-&%2UO0^O*LG\H+O6E8+%MZH%^4\ T=]!%.?K-%Z6,5%A=6Z9>RV<,USR>XR
MD']YK^42+-SFHO]CB.>Q9K?I+>V?KWF>D)UL31@?,;[#0R:/2\?L0B944,X(
M:3BJ!-SP)Q[A!*$!(.MZ2.L5N#:0XH)Q117:%%JV=N6>C[>\6W7KGCJ&P9=C
MA5\Z9>@$!(AS'4PNBL]BF%+@SH6LVMCVO7/(T%EV'LULN>'+1!TIW+OLVU#:
MU&>R'Q&C38FOOWIK4C4<0>T6*AKB;#\N/3D9OO"!OH,W0WHO07%K9!#'+HWU
M1]_D^<5.DV<\_0]L%;H@YL<!X\:F86^SCW&.U[RD2&"-RH%4;J:Z,Q7=", 3
MG<>T"#NU!Z!AZY>@YET+I3/=]Y^6QQTB%-\>KS05K5WUT'OU8M"2L2<0OZ(,
M H4CSZ4!NKXU[,,Z&KPG;KZ_6J+&RA8&S=&<T9C!O<.K?]"ZXK>DY[P;\S7
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M&:\&/!*1 48'SZCBQ'(ABM<5C'2O7\N2:PDMO>5L@WLMD]N  B<+4 !5],>
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MM(J$CA07[_I6(25]V5HQLONM=%U_UT:>,DVO( L0Z:7!Z[E_]="3^]+87T\
M8UH ,P?C!K;LFN+^/,)U%TLTUTJ],\NV]HB3/,7(<KE?I3M.Z6V;I#KG(DRM
M,3M.$>3"Y7'>K3A82B1G4I1+A.C.H0+W-_VK<1;<(>5KG"M+VK>$;WNYDAV6
M>R]L?:@<D$*/1P80^B]!U.'@<\=P,"XG54-*"%@?RB64^WU8,ZJ4[1J,?K76
MGCAMC ]]RMPCGKQ!EO77G3AK3-$GEZ!7J_PX*02&<[Z)WZ\O4KAUUO_ %,[B
M+C81/]IW]-*&FKO2ONC34W]U75>R$YOA(E9CLH(W*>*ULCZ#H18_YW*PSRTO
M0;V/.[51ER"&X#P[[&&.6-S ]Y\SNW(KT$ZIUP;R,K9&P@8L0<)_7AR:+7.1
M1ZO_0A7N^ZPC%MZ$^W9C(8G/-Z&L5'E][3<7"H(]14G>.16.^_*:ZAL-!0;>
M<!86!VF,_'J3O)567.RL.S&WDMH14C=A%'0:@H7'0!R)J>\TZYL_'2RY9<IV
M]R&0>FZN.Y>[>6O2@]Y",JC-./V^3_9]9BI-O?K('CNA.;@KTX\&+0&5[TWJ
M=I@0J<:1H])O8LV=&=P5XE&U0@$Y@>RDZ!B6;_FYH+,-_4_>3/(%X>'1N]2#
M6LJ#H<X(";@#,8C.)I]<U%Z"7&$DB,1P0W#,25AL2V=#O&EP;5-P^(*94&M'
M\J=>=L[AE)Q(37O-WJ[*<$'$13;<:XT^7 9PPKRW[M,@ ;(^R.09-76$K/93
M. 6]&K,)0;1=%7DZ8#;I30VZT%V6*8A.0>(3\;T7+1HTKHCZ^>1NWG ;X%E8
MS7;HQ5Q[L]7&+P\+I0;W]#9S/XD'AY;YI-QLC?A.1^=N !A'7;A@MH@9CM55
M@'?>&9O=4.O6\?SW$UODDBK%LVQ=<]!Q615*1EF=FJKD;W6G:*3#5- 'MD8V
M.^ES$;PP#MH+CN;E>MGIAHG#P5]YVAFX=/\JSQ)F7'CB$/)@,X4*]+K[J\2/
M0[1UGN6S"+2(:?RH?4VT#)*46F,]%[2%=\/)]14RUNR[X""OY"\H5??>-#0J
MS7[2Q3@+2OK$C"KJHRP,6AW4"+J(:W!4$92TDP^;=IH*7(6C.^A&PP[\K%HB
M[FR9?/?Z3>-%NZ+3XK=L>)6;"D1/>\%]\:'S*J9.()P,MQ:/9_/V5'M4Z9:A
M_4Q\.<_74<3I;F&?99"T,EA)A'Z*%$@ZK0*4T/R!1ER60#F:7\DL49N].8=W
MO+U3BI%V6"ER/TUW()0S!G-38L!*O:*FQ-T\=S KN,"SB5"H,DD^<K&13F,N
M@)I/(8S"J?5ZH0MA?=V,.+O"TA^3#A5*I]^\2V[6.U-4R,G\M3E0#E2[(K \
M/PS&ZMMJ][,%MZQ+%;HHO<<NKIFL/'W]U].#?_3^)6BW/H,DR:T/W]J[IPDN
MMM, :E"3L:'A2MVR.+LTM+7ECS)6#Z[I)9JW]%EI(7P_&+W;%+B(2C=9@!*H
M\50CT.,BDS!O43UYYT($B4P:=;*7]@\+=4F[KUS$2!U!7&&+UNM< VD\7;7E
MG[9SMNY.'XB8CE;<Y8_;YGC[AL*"_"QS4KD2@2J=-R%,(O@TZ,.]IEQ4-#I$
M2Q8U/DW5_JB3C)M[ICC%:_PZJU?D*:-R$=/TG=X<,L'"ASKAU<0J#H3U:O'
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M=\TBWN6>6!AO/-7;S3J&@VF:&<1CNMC"C@QB54@+).Z$B_  ")H*N4L@;/>
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M_^;4752)B.PAO[M\('L^E0Q+5//AW.HKG%5(7$N*7$Z"1WXN=AR:=_(<ML>
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MU-V[&^MA!!'NXC?<'4P -RN'FR.O?HVO@HFWI_4KM^X;@9B]W]YC23(,,'W
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MT7>;U:KI%.G2*F,JJ#$[X7+B4;,[:3PKU-.7?@M'@-XGPCM6-$I&*@:*G]E
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M6-P U$^$)SEI)5<VMJ0PE\?-QPWY:RP!Q.C*$>1FM<)JPN-8N5=3V]._1*]
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M#ZW=-<"W!Z=?U%LFFO\XK9XU6)P@YF\4%E5RD <1::\+<P## /W7@"^JRM>
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MH'/.^!;5GG\#01AT#4AO#+XB&;P&=.F%(%8_-EP#RNF11U;QY<_HV3"!F]>
MP^DW-R3M#(DK4D21C5\#-LJRK@'^APBL'E(9\ [13G>C:-CLQ36 </T:@"[X
MSUKU+VD(_&_@FV=< ^3=J/!4-QPY+/OJ7HOBE=<6&XY-ZAI :W+TAI@$S^Z%
MP!]/*&(4'*_XHG%*1]> L^T"Q#)\":_G./K_4C3LTNM^3Q'_NO;M?UY7[/'+
M7&9[?#%NT-16FA7_AICM[] YG(4'N/S,,:)N?,HQZ_?T)I'^K7;3F'0?N7'+
M=!F7BL_D*S=5].!?/:+Z+_;J/*(4V^/^\9:63(\X0?"_\V:0E:FUW_#KT0UN
MY_I_ ]W1@9DY@O6;+7/Z$T*2OX4 []I(3_,I!'8M1!QN+OYW=NDR>+-+5; ]
M4>\,>Z5\ 2'5W^IGM#+7 ,A[:]^ ;DJUO:F)9_2(?Q/Q>DY]:1+N;Z]R;LS4
M -[_^^!O)#=T>QYUL7ZR90IR"0-T_.</M/^S9TN'130L@1LT33VE_QW]RS%:
MGIM3B;_,.FV_BJKF_G>6_(G1>NIUE/__U6K\/X0&A%/:D=,L(+P&@/\!9D3[
M&?->8'Y>2IF]>X6:^-<2_0/A#+%7S[G?>%KXW';5B[2\!G"H%%X#S*>6SFDF
MJ_XG=Z&_NLGQ& .#FU14\[;%:3ZW1<FSE++;C.UJB$,2#KI!M(H1B%7=*<7M
M,? ET51D--[3Y!HP+7'UEB#M;WI<A3+@QMH_M]_L?VZ@'V\,7P/^KNL=I5L$
MS=7;COF)(OZKAG5CLP8^07_;CR?/-^DJ*&XX&G+_Y^V+WRMLQH"!O^N#$T:Q
MRN2E]=X^SOC-KLGGG,ND@+Z_Y2&B?"O<,=8J;]K\6<1P*VQI &O$?[DU^Y+>
MWP25JMI7OM_NQC2RW6P ^7<;J"-?D3X?V[N)X>0S!K:_\TBI*#_@%TV<?[J8
MUKS\!T*._YJ06(3][_& KG^$RPIF>_7\$#&]-GWU;<#X. :5<?:/[ 4G@L]U
M!2'_DWO?DG1/)<]0/_,X0>(VT<.?KP'W6@%_6ID:@J8&NJY$:L?<WHO?%4ZR
M'U.*"*]G";X?U^"D,GL>U2I[#0CP@XM@KP&10&T,3V<Z$<9M.)*MK?6)F<-Y
M]]06D[M(%^=]H@5^ )GG1P+ 2GTF9?9)(^YXI3SX_+1C*1A,)CXH>XBFBA8J
M*RUUJ.'YQ>CZ]&6IP$X#@S4E)Y/_;0OGFBB"PX'H2$5Z11NV64(4\HN",*SN
M%2X&)1P2QR('FG2]9'"]*)4\NQ,AG,C0P5'35<_U5^I#/CH[JABLU_2*1V0S
M&).R4I:(T5]1QTKYU<@KM9^VU25WM71U7:4Y0QE30G*4"G)(ZI\]U=K-AU!]
MFV@>O>+\QYV,4FW7@/M;UP *B>@@,*4OVY)FJ<1BS:=03V]8*7E,=P5M[RU#
M"W.#V^3Y[NYA@,\HQ&[7R@!B=K^SE0Z[/[.$"KP&1!RS$7VHJSW)DQS;WYV_
M<U^-FA+EQ$*W :PUI#6<4]C$/%@Y*2Z#04X"L'11;BSG(#^X<]GFB-KM(O[G
M>4;*S&'UVH>5A2YQL3Z0[A)%BP4$VK$#/.O2OL@S2J?2@I6*EF"[#],Y1QM>
M Z:(%^R<(II^V9]96?JU<3F12/R$*2ZS[5(5^?:D*V#T*U!)KDLL>'5<S$F:
M_>[>(U"EW2FO(]?@R>-$AV'16T$2?7P[MT9(\GUO>DH-J$LXC.V!&Y@<;E%3
M,[Z!9?6GBVAFIZA^VD4]SAG_-=.:ZZ][H_%4B:11)KG.-\4^RD9[Q>4[NL30
M+.R(G6M7)#E2)+$?_6UWTG@2;RO2%%'=ZP[\5=(%3^N)NZJG).8;OJD2:[9H
M1<I67C@=+M@:+<B#9DZGG'@_>@VH@LNCPN7Y((*TH]EINJ[^G"_#O1X_B+=[
M;OI)%811/!&OFU:T \VR=2)H6QDVD\L"2[:?SN,<MHWKZIJ,+$7-&,S9&\*L
MQ#E7A6!'F<2^\QDU/9V(+TO4T&IP8%[WN3#QGQA8?M>FN)WS2;B=X[LZ#:5;
M8DJKBLD]?/!"L@!)\M-K0"U5SS US&-YHWWI/IX?JU?V%0Y!E_*\#C9.[Q)B
MES3X^JL=+/1.^LS2P3U52%04T@WGO^"[&E&D;5;##G<E7O'7X0P<L0_/S80V
MGD^):YBIHZ&/I8WYP8NJO(;]'6+*!ZEQK&@0;<H_[NFDAUM?L,.9<&XKB@0+
MYO;F]W#1[X1+A1VAZR9II.PRAR:G*?!<M4Y60ZX*^A46@'SPB2?N%$O*-ONB
M\QI #(2@D>1X=1,* "Y@KLN8^2[D<8R =DTUIONU?5OJ,F'J$T[\#/C)923"
M89@-=MAQ)3;FRS/P89$S[ED+5OB+&TEMP&_AS%JQ%T!KF@(N;O\0)@_:^W$'
MF1+;;,1(VTO$B>-E<3/"&@4FK8(S8?,26;.(:B/2S:,+'UE[^Y0_L593<#^[
M5S#82$[$"8N<WK'&<B'?1P?E:XSL52,B?6\C)ZQJQ]'UD;8-E<W-:;8UHIS?
MG[+R:O<).!5MR;@\>UB"@.Z'16*N 2=J$X-7&=Q96+I. UG'$*L+<O#FTQX$
M1241P$)41^=3?1OA//.@Y4DWKJD ;G:9F5.#RUI>(OES#2!WN]N=AC)S:)]G
M<9<V1QG?6;,Q:NY^B-\1\/B5"272TW#\+8Q>]05<1KJ>P>D^"0,?H$T&7W1J
MYTXVR,*%BTRT2C9^G54QRL%36O?D^2*056R1XAGAX.KT7#3X=S<B5+]5=-(Q
MHX,Q;M%0>.9+G!FU+ /G$BM60#.>(#A!EM6/+5OQ-MRH!':*4OP"5"O?S)AI
MW"O/,3%?VNSFB3 9YGR?)-D@ .",$!D"#,)3EO>CP Q(".0FO:)1^9'55%\4
MR:K-U*&/>W2F7&N0K9,Y+R.2.(U"7IJK,6FI&)DXFTZW7G4C*?&V&.2)'48J
M".CM-,W*/;Z;9F/0</$\@(._^BF=S'#B TZX%<5?)/3ET4"9Y7UFWX$KBJDK
M:MC%LMYT#RC8>;MJ"6:I-XXO_,KPG*_R174U-/%KXB,B6S?R@0" _ 4:V2T<
MIDCN2XUG;IR4\+D%IH5DW',=IH1()9/>+=G;L4YWLPAXY@X,97PXUU_QKAY@
M\/S"PG?4^+1-3O$V#O3S_*UQ1B>(=4LXY\\G<\(3.4E6PP3T1ZNOZ9_NU7,P
MA:+<,]*@"K?@AC>!WE'$R"D%HRY/BE<4[\*5@CL3%YGH:K']@ME-+:E4$JF9
M\Y4OI?N8KO:)&\NC&JEZV"*W,>/H]$1,T6$[JP#.%BU5?]/^5+;U:NHSC"I2
M34*-F0+/J"N80_02I2WZ/]WZ2C9[0\L49Q^<F.!:,%L#:*F0:L<P7R)L;;YC
M9I^/939WBG/NHOK:&T J+==HG0BTC9/@K1]($*MQDHK+AF O5MRB,K"6[:VD
M-V [!B"0!<4.X_4D* ?DRVQSM"-354Z#34C FPK63_Y1MQUQX;JX\@M[N!+N
M?7Y&D%==^](MG&KG""Y:?P*HS.EP*C9+^^%=T%/"U808#Y\Q^M0T/U90SU+5
M52WBPS4@RNL:$(JTY<\(3Z8*2Y@5O(\5_O@>\NZK[&ML'Z<_RD:@WMJL8X"D
M@(9@]TKBLD1BB=RW_>0:0"=!\>""K+NQ-I[(G?%%&=F6%!&G"B=T+3$AWO)C
M@G);E]EEL*\LK@J=$+SB>!>OAJQHQ,4MI[E#.?0@XM2A*WTBZD4%?NR/7YJ2
M9W!6;(.E>BX$KT;,G^"L+Z3QXC%YF%Y,R2DKY\3Q15_6!/0CC]K"T9Q!2+V=
M.0T!:40W43U18)<7H@UYPWJ9?2FN9NM8>;'<N=< ,KJ.=/%1'0H/\#CTT=AN
MR=Z[V]#PN5 RF;?1#F\MI9B/Q EV$#^6ND#W\?:7J7AY]#X=F#N[W&QABUK3
MF9GW5GS8P8>1C\]HWE.K:CG'Q9G?T)-[OAUU8/HK<IQ<.Y*L60,CI5<Q]JZE
M-7:[2[/T]U]91OG);HY5A3:*GKI!^QGV%]ZMSL\H_^/HC?"?CS;X_Q?G'+DY
MF>1__<O9A=&]:T#O;Y<;"BV"^-/';_X?1W[_1B!6A82?M7(RJ9(4E[,4F>%&
M%\"K85%875O=&Z-MC>+?LZ$.@E/6(@W0Y>);,G,1*PJITRS8[)->*)TYCNK]
MLN)#G*-!1N?YA.0B>]6/A@#L%'>HFA)MN.IAQ5D]T%*^^(:)!GR#/\8&=P__
MS@-1P#A>IH"GF0RK&AXZ#3!#U_(N!QM^JS*P' YZEG<[SK12")M?9DB @I!D
M1RVB%Z^FV.NQ@E-QCH[0QR\K5./X'72YF:4TYS>FOY(V4G5312\Q*4) $>G$
M&,?H(T7235:2>-^^?/ ?:K,>F*B>CMHG3M.,YI^IMOZS5<W0"RA<MP:GQA8V
M!ZK!^")ORJ.;^H.YPNA*Q06T^F1/=?_1)Z/16VNAO3*/K**J<'3M2_2^!+[3
M8%:@IR4&8HRM#4</!#*:)C"FQ3=*&RPT1,0Z #Y?SF/'FH8#D)5+$7 UC.H*
M4)%F%PK%:V"-]U9T4M2"H-D@2]9'46J6RU_[O^STKK1^("RYS%*0@B4LH57;
M$ 1XB8GEV@F\K9<$TUQH=8<K]"AD0NX5C5\1?5I.7(-+-^]-,S_M1C)<#3>R
M^35;HC9WWF-^^3X.ZND<753)4;.3ZD>*W$XD<7EHZLI27RYV&7)%B->KP26R
M1?@^_9#(:+84"!1Q1,F3[1KGSZ9_?'BX1\-/7?-3^]!E%ZSE.\9V=QDWC1'N
M-B=/YXX_%I1]67?0GOB@:"^DT(%@,=-V?H0D%?\>MX3F1\P^6*[K&+XU9!7=
M>5^M9%N7\TUO\*M(D8,DRK<)C]94G"-L6O4;+YL5!(5W6K#YW9""S>Q.<R9L
M\I]DO9D?T9>,O^<C:+JG'Y'?^GF\(;&=\<.Q#1PFZ2L]V?H(;HU!_VGEJACY
M"!3.S>U0%H]]3IIV2C ZP_%TM@3 T 6[W;.#P(8BK14CKVC!A LWD]OS<MP6
MB\'KR@N]VNWP-ZM)SP\E_4@LGI]D4CGCY"[4X;J8X5W"F_BB>B*:C3+A>I78
MO+C+HNE9H=2$NF0QS_?-#;%T?/?<YE=X:F7UJ&8U3D:P&QT9LWPO,?,)]^&\
M&+VAM/?H*KY,NSUAYO)OW!^B$[ %\TH_SIYS5_NR70U>\5W^A?B (,55H7K\
MN9LPY:'-XK7I F.[>U!T5/>Y]-ML[L.O#--?DQ@L1PS28. 3WLLLO!TF#OVV
M<3@*"N<2CM[;JV$Q:/<*2J3,]Q026U69;GTWVZ54,.>7S8KV4RC#76(18(QC
M)\(OV2/(35I7%8L(I8CZ/D#Z6JC4=\C*K.SG\H//#:\4CH\>6"C__ ,YW#?&
M9/0P17]!5&G5N&$ZWD[?F+LP\I3P83EFDK9.EUX647T4Y_FLY YA(9,GR_8.
MXK.O.-8@NEG 39$.1[J/FBJI:@;_EDK$+#:IB-2"1(6>?H+=>//N93#BP_!#
M/'3\2G >-W8U]0HN@C8))Y/)KGOU4K^ WF_NV8)?"TBB ZZ(B[]0OIJ>NN+!
M!G<@Z&$05'F @'"9ZR#C&)1/7LM,.^NC9VSORBK12CQ]A\^8"HCNXBG.8 6\
M<U$ U\1<96'8#+&4X2O"]T&NL[FU3=8?']7$I(M>D(E85M19AB4N.X:V/O7M
M.'^(Q)1>W;5?E*Z&6FQM=# .A;N7.[IR?2R?O9G8B]](IOVBRZ+??\8ZC &=
MC#O2^_[RE<0NA>U"2YHUEA5K?F_7SKJ?/8:$/+_[F!<0^$EA#]96HC@C=1*!
M2\+R=/H^P=AVAXRQT:G:0M 40M*EF6$B>?-4WP@95E<+&8C\)]:;[=EFIM&8
MR]2/S0S$\9!\6#0:%*%5A]Y,4$Z@H)SC?C7ZM1<X.4SNU_J\I\4C_$(,[XQ[
M?Y./@KA$A89<O)J)A2N%P0591T*RQN_-CW^1_U3__JSY-B'7LY]'F>1@?R03
MPLYQEJX3\; &>1<WT*'OWDHY;?VC$N.>E<5>A]03KN1P+>&*9E? \JP[9+J>
MEY\8X#85=ZDQ>50TX$V29]."0GOBI2"-0V!779-_;2_-:FP#T&JZ=ZG*_#-V
M[L2D$=?#4O>SQ;*+SIP'2SX;E.3F6#33=BMO4ZEJ[VNM@O5'RX/R0H3%?H Y
M)XX-8^:*I#>=G8=EZ$^4'0\J?S2@?B$Q0/PA^+1VI6 EEH20D["G.H/6=P1)
MIR"/MQD'/L *OQQQ!1-"[AD;_3$N#T;5:]3 B *D4BU>F@:0?5+9B8KO@PV<
M'&,1(4@KQ0>X8I4XT$V.(\EAZ4L=R<C?*#K]F(?U,U;*?['%?)-:[&," :>-
M4&>MPO@[N#7LMM&H[UT(JU0UUJ'B]EZ<#Z3H?W#WWF%-==V^:! 1I!?I)2@@
M*$TZ A)%:2(B*D50(M*D1D4@0$CH(%5 0.D*4J1$:JBA@XJ(= DU"=(#"0@$
M$L+)N_=W[_[>?>Y^[CYGGW.?^YP_9O*LK+G*''/,,7Z_D3'6FIJ^.B#&<(JX
M#0%4TS:AR(N3H"<6L<W@#7>\J UQS1/!2_7&#8!Y/?(D1C>EN*?[:C,OE9MT
MOO@TU+AYY>K7/A/F.G( GCD!S@F3(RWW# G#O(GM?2% XQ&KA9&7XCHCHU_;
MGK#*#S"B%+\1M'?%Y:\O<%$U!!/MN]JYJ3:X=C:[ISJ+J[Z!"^HCZ1Q5^9('
M#KH],M_?F_@9*7 ^&_SU0B2_PX)L#ZX]!O1 H@]E-VCSIWS\.%1%RX._%M<D
M<1C0>-E-C@%N 3Z<^ P\\UPS<JH;3T=^G< (FBBY9$&@J7 MZ)9F,[R\4O'/
MA1+[Z4\G[:.D46^?%:J4J_P()%P5R?\\1&#"<R5ES@L^(7G/MF'(OKWWW+,"
MHV?/JDQ'/ROU#VM,+$P;DLTZ. 1.9^-RC@&,"'=E/OWWCD?(A7G>XK0/#Q4C
MH75A2ZEZZ5*\W-PO#M8\G?;LAFG:M.\T57*ZNW)'HGU/EEM<JXU2H4#9J28W
MK\_3[QXRRSUXA[;F2)*/B-@S(K=S=0 QOMWSQ*A9<?M>!_GH8X ABF+>I-6P
M_EQ>/0[V70[S#?Z$ZXH<8VO]$5K/O9+6KS5WCM=^)5^ "JIP;[9&0JY\R.E]
MKNK5Q*/*9"D-Z6, '!GZ(43UM6"FV7M5;>20]U07XGR7!<<TV6'45E!"<M1K
MD]=TT=\ZT<[5P%0(T@IU2/_=7A^S84:2M8W!+L?2Q%=06EJ'#6E%JW1 ]SB/
M9=_TZ>?6%TVNK+UVJD7A+ZS,@T!]0^'-X_V$0 1>T7-!GNI,3)CCJQV5O";S
M*HFM+N7=+\6>^&'H%V#O5> 3JF+]I *,^;TASH+7CMQOMZTULSZA63U]/<@V
MPU1 7>;^&?D$,3&W-G^-KS"U/!RE P[,0+ -+GS(&! B$KI[MIZ\VJ83HC<=
M5G<U<QZ'/?+^3U?F.-G2 =WP)\1D/8H6I>$UH9%,310I.0JV1ZS<LQ[\UR[D
M?IKA%2=:F\PQX*?YTU_'@/[T]B-?\.\'<RK'@!0+V[]"IX@_?'::(-)OR#'@
MX>3!G9-__G%^*3?W?G#0 2-NLC\YMIV.'MT+B:(+<[5%9+<[PW^0A'Q>:,G=
M.LK+#(]IO<9S81W6TF:GG8;XV/E_=1R%R*I\EM)[B8R *Y#5^H\!M3:$[$HJ
ME(@,4Z9)DRUZ@\[XB_RNRG[6[C6Z:!2F92BABLV8.P%@M]BZ-KV=!5C15X#!
MR/T4/9@VL3U28V"(#=J/ETUHM3B*PF:O6!$4B^O3!J8#G[.(6J4L;C=<F-ZY
MT=,@?-LM'JT(@QREZCDN<%C@VI/^<,7F<^F9EU]_[R$H<'@KR!ES8U1>]7;Q
M)5@/@U@.T> S@)<53_N9QT9&4:Z3 [#MO019K.%<%!X9@U8V(VAUZ127L)DB
MBE.\Y6_V<#.^^V!95Y-N,E_6YP$S@KP"HN9?Z8M#[QX#%O:JB3O88T ,S)"S
M&B=NTV-S_O+OIU9I&Q-8_VKV5!.]#I:9^^'O;R^PZ2L<5<//P;2.FG:W.#U0
M6;#V4Q4:!-%N06YSL4L#+OJ%3URC%[[?U^R%%KO._&+KNWSR&@4*GYKGIG%3
MKX:P81/V,B;@?*/>?LJ\#A:N*$OU3!N5;J8(%Y:P/9_L+1\_'Y5:63?<T$8Y
M;N@5IH20R/_CE=\9"86(JVABY7>U:[D&FUV#;XU:7OW26S3YU?@P1OO*^K?Z
M^2E=O%O\,<!I/M8N)JZ.+1&"=TNB6CJ5KFD.!'#E>%4*.Z$2T<]9O21\ 3&;
MK8__=(6&L)'B>_.%]2PH3Y#=7#$2H%$JST<,603$9[I'8!6_:JX\781R'G <
M4WU[J'GJQSN-W_KB=*2?0J[M!]8F1T#JS!F-DG'[\3"[.8[12M?4&]6JR1<2
M5^YEJ)0VA;%F=*3LOR@H^S.?< RHX4#1]6?Z@<:6"-3_<!^[(0%(^B9N,'0W
M^*J&S)AXC_&W%&=0<TJR%.3*"R87^#C]"/'-^(7Y\,.A3A#+]+P'F%7C"\1+
M3UWIY+FUF0&QU-3O\$ [6T=__\??V4MDDEB8+(1@MN1YBA2TO4.DI!<A\13$
M@P:2LVUBKHW)QIC$FV4;9[BXFDX.,'^_6B:E";V8 &"*4-)H)YPEN>&U"!HD
MV0ZX*#D"NQ4)),:"#1T_0MUZ=&X%J)%#8]ZHAYNR:N]H&G48<6TN)529*(S#
MI5 ]D.GU'C G52J$&&!##B12NFE2,;8DB3+<Y;U!>8.J8@R3J.F_:(V0RYO?
M5W6;D-/WNFB7C@J5-1"L]K1!S!L0KR2:SJV9>T1%OPA<4"?[Y$@CY22CH&;P
MW_-GBS@2Z)3Z#R*!)DO>WMGK;R>;8@E!\X8CFV@1\PK;&5-'L6. \[C(MLFY
M1N]NWT^ D@%9]^D$WRPB\"1Y>J^0E$QX@!\*-R.AC.N;B,79G"5*-7/<=<Z-
M.[Q372R-\LEU20' QA#/:3TVHE/_(1<A$\LEX)EB7N'N#V15A%TN@[XUB5+:
MO=&LK&25_WT@A/K:6"]GW"(*S 1S+S@&=!KKJ\%NC+T4KFSE0T+A$T,6XQC;
M.(N+UQ]7A#$*GA1R62N Q4Q+2AA[4V[ ;,BY]$\WXBRJ/YF%"OQ)!588EZPV
M9.VENUQH27AG&:?^(Z'WUMGLM.\SWD+,?^1-X[;GS>MB[C0E;1Z=N]'8& =2
M='G-T-2U2&!_\7Q:XZ#[/6T(<PR(0CQ-3M(_2T)M#"GWY@)[LG S*S8UIL6-
MT3*I$)6.K#LVWWF-G@$H.;AVXY?OW-#5-<UY&$]AERCIX >_!%_%)11ZR[S0
M$7-V%A,!#/]30@RCU-\R7"J2V>D66A]R2&T^!HR\\_P'Y;YIYY4?0#>\<0 C
M1]1HFU$MG'1-DFN9!J\G@0DD7*6G.7F0H@]U&,#I(XD#=.5HF3@[H?%(WM)>
M3/HYILYK\Q@@R_268WY>J@V*>H5P!P)7Z 861;A>Z [BVVP%NQ%I.X9UQ.7D
MRLR!UA0EB*72.<^HCG=XR\]?VH.?/_:O><RXRP;%4^5V!/W5AC["'U*?'+5[
M^6U-E2R@\Q<0<6I<<35K.D(D!7^50;'%D'>TB1H50VN)0/-.TQ_!29XS[1 0
M$/J7KZ#R$R.P$JC2%;36N((?%^_L[-/-55_QRLJ*8I: $P6*WQ=ZA#YW?W"+
M^,*,B3_7<,G]@_-C$R\<6IH40]#%0P00G>J9N/:PI<;LOGXS5/*=UKA!O5]*
MO%C%K663.Y< JM\[0C4+(5WXN'QFJGO10_AWA!#5;P&8#*>C#S_F*)]E@;GS
M3<8M/S?QU1E/OYB'%3ZS/UDFUZ?/YO4%0"G\_I O!U\I^S:'VET% MZD3M'M
M3P#UYBA<9DV">4SO.L48.N! ?KT:>&4K%+*59R]\XEWAG0##Z!Y#F8[7KSN"
MN/5GR</$Y1[$&74V#JYNFLZX'@,SIB<KZ?V'B_&KWN-B"G>^=1S<&/B<T?FM
MG%/+-?2*\K,OPLO"17^)=1!F?@PXB2.GX)'BIB2$\62K92 =OITB0WI4W><D
M2*Y%.%.D?UW>D\P?)CQ'N7U&S#E7]9[;[+T>JP?RP#&'QN%(FKKG/$OK.3W&
MH_IE]ZP>:QX+:'-""F .\J6GK[_!),'_5*@^?D=P$GWA9.DWH4L7C:Z[A>O7
M'^CBD!@4+CFN_<D5T1Z[Y$1(G>Z*_OE>;"%>4=BNR]OXEL!VRVU_:F7TM]]&
M7*EJ&>P6%3 V,J&*S(4;ZA$U5\9%UY-&L;(QK7P!.'<-LQ6]KY6[+'H-FJ[[
MKN+O3B:5:K/)+;R1#H5'UH5E1N07#%[*ZPR]HC.Y/-DU#Z ^/ZJ LPR2HJ?Q
MX%@]85R;AV=\)6.WSJWP>4-4](6X;O8OJD.M4B[[;IP?([@[AK/W<.1$W-!4
M_@+,3F%"$\0/E_:L(3_?37&5#A_TWK0^O0FKW3Y($)'%G/HI<@M@L,#XYU[
M8".>;?=*F^Z]V>C1B-&T.#)JH2'=>P&<B)&(!'D,@OOG+H2;Q7,$=!X2Q@(L
M'^ETGDV1O.5ZFM=D?]F7N_0;G(3,AIF2:A\F]^?7<7X,IAA"\SMIBL3V> BA
M50;+_V9V:DU>;.BW?;QY47,MEQS (/S^Z^?A#(?=P&\=?$--7ZE#$_0I3LE#
M#)'CR.OXDGZ0Q JH&AQ:]3C/7!!'A_,L?T).C5,_-@2;&Y'N?!\4Y9H%G(SO
M^*96UJ&12Y&E>I*"J SD%BQ8@!RZ=@PX Q<T+W_PR". 3V.L=N.!<_CB0:B/
M.19_)RCV<@%7?4)<(U.H[&LU@R\5SX3XP%E@XJTMS+U^.]0K)=AEDDV?ELXN
M,D[] <P"2VE[<O"H( ZSYFE6.IO/?OJ2(,OI.]6ZSQO'P5.(O30ZA[786QK5
M$#?KU1JAZI&*\S^!5]#BJ8Z+]@\Z_33J'#\ Y=YHE,.ZI<--02IG& Y]_^^,
MQ3-W3H$B$8L/1HX!Z[.@="_KOVW]:R=3,].KPI?^'F&L.4O'F#7+M-8GQX#A
M5.NV_Q[%WK6\RO9/E_E_:R>T+@:/:J+6U^G'L2]?T2X9_K=SG5VU5'#67A-$
M@4:*_Q-QS?^'IE*!6'PZ#EK'3!\##+(:/$7Z:4:)]VAME>U_+I2[_FL7JM,Q
MX%Q>-7V(J<> E?-U7@C\MWE:$W*[8DN(/OB2"L1D4?OAZ4I1('D;=0RH\J26
MG@CZQ_FY_Y0"/4BO&\5]$PO%+_I3BM%"1^WZYU 1-!4J[_ N. XM2;98J+3C
M>+HN@HJIRI.=/Z-)./7;*F3^,JMJ4=C9U8E0?9S3I*3880[[;H$SRN',H<VR
M11_!L\?.8F. V*G/"X.2W.(LDM!GIU<;\M3&JM[.Q'Z,@]H!# H#S330A"(W
MF18>ZXUC@">$GVI"!A.%+,IFH;[]&2"!.B0S=-JB_K7!=LT![G[*F9Q>.4/I
MQQ=>IESM^LF\@GB+KE.(F^6$IQ/SJ6?SN=&Z\/'\NO,I1=2GI.2P#\3@E9(;
MU:,^W>XXLUS0=WTO=GWG'2EVJYN;<S,[63O) O!)('?],>#7*+X^J1P'WMB*
MR^?4,_?^\) <<QU<?3"L62)F=M%+\H*C^#?^.Z<ZBI;/AX)N31CZQ*A/O(,_
MOJR?@Z?N@//AI\G84BKOT2?U_)@)A"!27Q6FV48<WVNK\@CJJ5[S79F[<>^+
MM. E]HOY9P6= M+&1[*):IT@X78OB\A]L) &.,E!BBBSU#SIC3UBZ]IF>;DN
M5YAA4O@ W^?<$]NQT_@IW%XVE.NG7L9C5=VC"V&=F  7^'Z5$8+N(:%;>S@2
M?6DK_T)@\Y/5VYZL=Z-5D_N)T("'S:."7\QF,[8'0\O'Q=F9WCSVL08\:4"K
MT4;SS^AST::!/-2;69OORZ@7B.:TJ))UN,@UM)"7,N%>R/?GFW=<3$VF9^KB
MN+YQ .!9[_B#/@/!Q>YZO3_4AD;0VL2<.4GR+FEH[RW1.[]GB/NIOE@-A-7\
M/9CL<Q3PH%LC_O8QP/6)L-5Y75/Y_1B8#0=%C'J9--2C+ 2EW)] Z\*,T#$=
M(&Z(NMS+KQH:J?-W&^I26..C7"[OJ%J%+SS.<:H$P,-\F%?-P+E 9B\ZOWL*
M>EJJ(1YPBR2M+]&H(VWWYNZC7^+7%*,&]T:#Y5#<0R+)]<("\UYA,K6BK\3@
M\3__>6V>,HY&+ *UCN"/$*NWZI$/)(2/ :]A\[L'?L> CZH3_UC\":K%&7&
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MF#V4Z"D>@XKK+$Z/M;Y 7_1P]+.CRRD!GVF_CK*)0;!'P\PENJX%7.56W2]
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MM'<,*A7.T<HO3+Y^*> :]: #<E4]M6. Y$'[^O;Z,>"F"QVM$(>H$4MT%SF
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M:2([@G6SHE+/!H<0G"+["XQ)FGYPU+N7?J^1N^EE<HZ;< $7'19'R2Y<AH4
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MZ>QKG]-,J(323HTBD,<OV#7B9!=<D:C5W2X,_07-PBQM]_7]^*;K9O(X]US
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MFAG1;7K,TA VO/?_>Y3S;W7_5KEXX,&9W>3#/W3=N:912/=>$M;'@-U!1#K
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M]8HM+9L:=#T8)-[2K$7XP^XK#T\;\Q8",IE:#DW2*;5&9%SGK-\I1VWQ WU
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MGEI3XI]ECH%?<TL\ )2$U^PN:K#R)Y;=TMG#]@@LVK\C1[S;\#: P*7&;-8
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M12HZOZX:P2A\H6UL;A5L=W:V,XDM@+J6Z&B'>O K-]36![-92[WCT]J&40S
M)G;^=.U5.6!N\PMD%)"$VP\:W,A/RQO&/$)4BG_1MWB:*'/KEB]P+A)K=V""
M/!H[7*UK48H-N& ^;^V$JSE(&>YA[,=$BQIVO%WN?7?Y*%CDP*^MX4]SE*)"
MP9J,:T.??G74)CUM6S/H$^VI"+YJZK*TG8DG6 ./4<T2-DA5?1EU!_59^>=_
M?P[X'_HM:_\YDOV?;6;_7WZ)*8F!X/N*?J?.U=5T:L#*$\"R^G>7$G)71/$
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MI3!7X#W2.635P^OYE/?6!MWBL?7Q*K':H,\=\M2EN1+8T>BG$)TZLL[*GN>
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M;#(P# P=UU;PY?[T7V;ROY1_8;63?^6\_UC#0^ 59*SPK5Q$)ZAA]XL 0*3
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MJP[(X3UP,_Y"GMC7" % S8">O[AFQD\ P%\0 !A/+?SMBFD.?)@+.0$PWT
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MP(*A7<.[6 \"8$:&.+H[_@@%@8K7\"SXD5A$#E0G8I8 N'RNNY"P,X*YTTT
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MTP6M4\"TZSCUBCD0##SFJT8G1 OOO)XX(G6WO^=Q1[TTZZMNXDTO[M: S,4
MF<,+_FOF>^SO'=?=MF741;B9(G%"">XXX,U5&@P#W2D'FZ&G<UG,O^6YF]#T
M_R.>JVLBI2DY5OR9 G1KG9[M;K4)6*1,Z[G%.6RDL.;9LR>Q0$$Q!IR0D;'
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MSEHR@J?9-/"M;SNOMBDD %YS AWK_6@;Q&[01"6V<7*G''9?L946*J+EXB,
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M&ZY;T5_1QH?YL\?/?#<,7OD>==V41]4_V<Q]GW55I3UY'F5 .DEE( GA$%.
M$I$_^R!+VVE*<NK0V;@5MA$6S//V9PHDR*8"K[GR73ITD'XLHY9<PZ!3\EA#
M#F7+UZ<E.?982QS%4,7X*$^ ,IFZJK)HPBP*6U2E  L+5[".4TV69"M;Y7_B
M$4:8!_Q((T*Y,9^CN <418",'"](1O1]1*$7V]-)HP4E*7(6%F?4YA&<0(SI
M[+&,>P#60(_1.0[=Y340^3Q -+-G6JW1*W*[8UT; 4)^#D+> Q3O 7UJ_RWW
MWW+_:3FEH+NT5@+_V9]>_IW%J$K=K$CVBA?N-Z+^S^=+&TA5]QH<=?4&MKNP
MPC<-&U5?/-;]FW=,3$D(W>X#F+WJ01(-9_EO_\WA[M1<X.,M[*>^VG"22B>0
M3ZMDC@I0W 7A7!1+K>-.^>^=W0-0CZ40S8#%48IR(.*UZ^JUSSV@\R8.R1WW
MIUR X)D<Z"F28%D(F2T%E=Q\@$EY?\KEX+9.I/?> X*%'D!"T?@M?N,]8./W
M7_.H#OP6U7^N^K]Z0ZSCAIP&S\N9H5E1M/7%(/;<O;WR?8**BIV<AH2HJ/#W
M8J:)RBV9Z"K$B>@JCZ7^K?JPCM8RT8'8X- ,Z<G%'CO\A8YJ2#^?A;&$Z8M-
MBZF[)5-(3@<"M*YLU.V(,+SIAG"MAAHO;/\&4[KB6]).?5G$9I>I.Y4T?'X/
MN&5H=KB3]%_S'7@ -O)_RDECL@:[ZC!9^%)V99:/?1N%:Y_:>:5A#EQ_]P\Z
MOM&XDQR2D)RE EF9-C0$/]D()>]^)@? RI4'  #DFZ@%:O_OS,M_-^2_>$,2
MM+.AH7L=YU?W@,^7=+<&#%#[S*"X!M1[@-%#UCF J9H1213S/OOJT]\_;(Q.
MGBLI,Q> K+;D4JE6%'7EZ)]^3F&Z8#VK>/[W;QX!7.O*^BA)<$6I\Z=:AP9^
M?0YG^!>@54BFMR5>KJ5 ?:^?[5.&V#>L5%^B"?7G;CGP<4F7[Y(#O7:L\9'C
MTC2&Z_ML2Q*RSJO0<A^!>X!TUSW /_]A1(KO 2&FZU77Z/@W=ZSW !)I&I7_
MVY+L-78>"]J!3[HJ39$D<:$=O\FE3LZS;S7H_GHS[B7*&AU^?66R]5VJ ]SN
M^9O&FC@' M&DNBJ?V Y5CES?TI 7@@GC7KM_\97J_MW5T+D[5(P[9-(](++4
M)0GQ]8OU^R)H;][Z:K ?$;2R$=*?^GUQ8:7:F4(GLJ]UNS6?U=;SY >WR^@G
MFYYJ&E]0^C\UO#)[X5_[W^$>>:2QZ3].L ^IG+ECN99,*K\2[# M?>@^55AQ
MI=Z_V:52994BQPMB>]KO30X(34G*>T#.QS_8<?UA'_[<YAR\_R_DM+C^O-J(
M!.S_9Q#@?\7T;K,"J^L+@0Q&+G&B"\7XVS-<O8V&@OS;=_50:6@O6#3D;'&T
M:(5K$=O:-E+!_IC)+B2A8H6.*^%-5/-I)\73(Z[M *_0!YW'9NM7H%ASF6T]
M44)LKQTY (-4IRY$JHYVI_A';1C0LYT-*@0PS4*'# )Y5\7>K%4*L4R.%8N(
MI-P#J.I&W_=#/J7F1T6-"@W.JI^>W/#^?M'X(^7)=BS+0L03]V0%Z9%1"NRA
M!H"$T8A!+ABW*'><V,'H!'\<6B7QH,=3:R>"&W1'ULR-D1P+N@N<1=X1*3-K
MBH%OJD\2+@WT@M^@#>X.;(<M<<3/25E%.2!4CES;<!97K29^KSQKGN;F.3JN
MV"33-3_*S.NO];1DJQ(8:I_?8OI.^#FPDW:[\2-U-.V7+)/8<@P59!M'"+2J
M'Q_'HT<_]>T4]PESJU+9#9'%%'=.R$Y-\K/F6)'\&,8DL\3'0XGD^2U*G@[@
M5-CE$<,Z$-M#JS\58C=T ,D.<VT#J=D)\J<(9)[/&-7U6CS14$B8P7-)VB'
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M72N66>C^Y"R*_?HKA1BNGD?O'3FJ3PG!M'?MS!Z?)'@WU<B2%'%$,W[/ZXE
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M- RZD?9PZ,7<$#M/E(/"4VF^3>P[]G"N6NF%C*'9A'1I7KW=9$2+?V&#?0^
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MJS MI%K8!C'6/O]N%^-6>4MH[EEE!:FK<+5WS>#(H'+50J%@.7V=LBD6%A]
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MQ=CCQ5\UX(1BR^Q"$L&49M\P4@OW#]]IMM<P F.W^!$6\DFJ\X>:ORB+;?E
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M8>'K*1FY:??(<7L#,M* (EFDD(03'&6B4 %M*M!A^LWPMJ _.0D'.L2##X[
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MAB;M4H$N ^(CQC1)U'_?-21_<Z,":F#"$(63SCZJ]!]VX8Z65*#/@.1%!<(
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M$]%!.J^PR"^I8Z!;+7__I:&J OZK:,\MN:@GITPO%57["*K8EVRFFFSL(*F
MM$Y=99 T/)FFGL81MO-)G#V=,Y?Q3.O%1:M-/&/>H#/.H485[R!.I@8N*MDZ
M.W3"9YLO>H;^* )78$)AY\B-.<30>^0<DAU!U@HU2!D)Q,9H=+UR'NUINEXV
M:'EI2D$6;X;_TR=_W5G793F;8GJ1_/O)*&3)=BU-:FX-0I3D;EW;8D6_NT:2
MGCN>%AZ%BSQN0/:GF'E];NJ %IH8\YU<I:^\(5!Q&V%&K#RV@H&)VK,(9F+B
M9I!&NP2N#W3,H(\G?ZMM'#XH^GZ]77<IPJ!!^QJ3$:-ZZBXD& ._,SFSL(;
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M[N.2YMA&B1EIXKFY.(;E@XF,RFRQQMRWW6Z!\QC+*1TGD:6G:4KS#M$^2C*
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MP?G'S#;\2E$BN6.&LI2Q@K&A K^:>I AU<DE]3UXYPF?]:,]-=VHJX5__[/
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MI>Z&SE7]_6UA4D%)U^)3):92+\RIO;A3,"F""9*<.V>M^&2H03L+XX@(RK*
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M4X 9J NT;VD@\)7ZMG'(D+M8:SD(+\.^QGR.3'P:\5E)<, __N5123 U 1Z
M$0U//RSQ<0#;82P8;\;.?*9<OLDHAJ]@JW7V:F4_V9NMT\0^0X=,FG4  [UI
MUGW2U0+(-Y_X6/&IIWH$=B0UWJU25Y30Q#\;T;FR)CDK#(N-@Y2L@29.&OBT
M^J\+KW!/QK4%,>O* KUW:Z&PTPN  4WS8HCL"2_L.#C+KIA@UQV^LV"8&@UW
MHZQWD<6B+M,8DO75A5U-VE]"@EHO '\ NV/FQ[;.U*W ^4XUPO10L#,S7X*X
M%0;\-7)PEFS:.'/:?(.UNQ423J0>3D1:&)N%,CT(-%%:>IIMO"=Y-J5^HX##
M7=FQG2_V[#Y>O_UD)SJU?=VN1/20K2;<KFNQ04TS,@1]];)B4U"),0.6IPD-
MPLE;AKLE';H%&X>@$AM/XSU)D/>*QW][$.E_RD^@\5_\!#[^*S\!AD.RKG]W
M6?J_>@6@MH3_=$R?CS\-_M,Q/0H'_*OW9G_4!<"G:.T"P%U"3L3KC ?;;1C_
M=;,G\^^8/M@[.*KF%G_VA_]0SO]WK,)OD&^RN>@-.&GV^99AW^HE*LF0J>J/
MB67=.!G;?T4FA+C5Q,!V'42V)M#K?F/TSE6NTY4&S1(U4:AM37VX;+3#YVX>
ML>\V7MS7U$CVSUIO6.7DX92!._Y,$&<N)ECP29S>ZVYRZLOW-*K/J-#KORAN
M<)/H@-2T2F PYTCVB&)5TLMJ+5$'4 6TX<9#;;7)V+J>08VWL0N9W.WO-*GB
M\TP='OURW[1V_ARND,O/(E&@S''6%;C)MW4!P" J9QTHR3[L;&T#M=#G1 A/
M>@U[(LA':U$N<'S'GRJQ@2JBP"%2<"#%&S\5:7,Z0/MLZ33#\$2@/K-41P#Q
M*)8O]$Q>XKQ_/YTJ[:A6;7C0'>GV];X1LZWW5,K5=TJ;1F Y^3Q'&:!#JK]M
M)C(]JKC&PRRG[3+N^UWFG]ANAA_*.@F6ML)\ST>;%.V%/9L54%IPLGML:D8\
M@V7C $,MQ=:&ZTE%ZH4F:_XNF6=?Y[S #NSN-?[+/WL&D37\!3YUT*$^,+E]
ME8E\M ,CI<U>T ]H;!4SVF*J-KF+W'55WJ/?E%4^="-"G]%H4>^1W_6]7M"3
M[HRMN1CLX),!@1GZ</WJX2WQR;)E6&4-/ 5[-A41SJ#RE31;EJC33M/S\GU%
MVT^$]V;73QB_607P^DP#)[O98[/J;5]I.[V- D1MCY"?FKJ46<5A9FT>]5#\
M8N%0:]6CODH[,:Z,VTYF1]*5?7U;M;YF7?W9[+N3#;>#R8""TH<8"C<@_:MK
M:IX!Y$$:02J"@KX'-X>M4];OZ0I%R0@JB#W=NIGS:GA+XFV-%-+H*!RM*W<=
M<S^I][.GUZ]C$_\XQQGZ2SIZP[!S:]+G U?6M)S*9?L&C][J65:3D5EB?WC
M/L[AU*K @;\_,KUQ<CVUV%S STD"F^'QQ#P)QJCGENA[!"WFOUP#R4<[2":@
M)]#MMB[,;<_!S+%,:]]?&_C(\&;Z%:(WF!@9J^?0X8Q'>L^@0M+,LLPQ90&8
MLF&=WW*AQ4HY$\ -)BG<I%EGD#N#74/<?5/;6P]_I%%4<%2/0(?5*'H"17-T
M*,_$UAG%E LE3W^A)V]-5ZS9,!\/7BGS-_P&Y>TZU7)16!F8Q;0F]3F9OC'Z
MHW M3ZU+OM*H\/LMQEFND:U\>,J<5G6HF4GP()CGW3W8([=3V)W DI_'JNP&
MZ2E)UJ5MGS<8C8Z&<DI+.'YKWHO03W[-S*FT1NJ<#GK23$^7^>= '"/7^ N
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M'4%W?\C+_H"2Z_D(K,A;G1[?>1AIW1#;Q2K-: H1")EL/2I7*!4X5>_-VG[
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MXON86Z^Z=_N<2OR>/C-M#A+ITX8->\:*#8SJ:1ERPZ) Z;:#L\+<=%3^=A6
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MG 6\5BWGH@@4(L07Q2ITZSN%,$PSU(S]V/O!,TC38QZGXBX]_\$@IUBG_ +
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M;;>*FK 7/3>68)>,E17'4P:??G728EHDNQ;IB"\M52XF\4PY\%C8A02NN0O
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M5S;+[\]N?SP3/W.&Z%I1%+.CR)4C+"IBBJQO##$I?#_=>FU)+(([VR3L1UE
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M<]^3.P;$ACXY8HX SML\H] ? [1B%T?TU4(=0Z?^_ +)6I!/=GA!9,\^2BL
M.8?J*@U432HU27YT<)3KIU\P@:^@Z%UP2/*SN64'9-UPOI,W9<J\/)*=":C/
M*>DU'&[A[RQ<@\YXA'%%3+0F=&A?5D>K@?TK8;B4Q%YC9/=%]BB?6+C]T-P0
M[,O(N&)Y^O3/]C-"MQ.FE4M\DBZ!5;@9N8TUD<-G&QB/JB=PF'@'KK!^": "
M"4I'SM<ABG=8R-"99;K-#@?+2L>C4Q^I3K'&5F-?O [/E64(3>NA\ U[<R %
MG< V'AZE$FI*O[J+)PKJ9>DX'%OH[H1M2?;+GZGP0UR6O=7%A))T/G"!NF)F
M D2DRJ[V^UBY:6Q+.\ ZQQTW1LUQ8L'L.#IEX,8X)UO!N<1IC%-*OUH23U/<
M'&M.T4I=('QH\@6Z+\"S)2UJ1I+OW2DAP"7"*6"DGR7[T"(QI[_9YP3): ,9
MU>Q\_+PK7-^G,00/9BK-8F0?TKXTH)PZ!J04%$+&N:!'0BD-^5'/RG05;P<4
M[7.GW1LJ>(B8_EA2AN[S=J]<TQG\X61YF7B^"4S*D54=@=.Y=BJMF6D*Z+07
M_XB0-%PD;):Y.WCYB&4&<%?4=,T$S$RWJ=V2N]47+^(IIS2>)Z7P''-FYU3I
MS(Q)ES0X)\'!,>-<8N=L5+I2J'TC?33U^G -[YLR<'$4M/V@*$;P:Y,3@\@%
MTVG?GC#=H7+6>J'/BXWY846WY;S,I@V:Q[;TJ\%YB+K0(NXG0S5\M[NNC64G
ME)-T9@;LUVLL=I1T764VT?WH3;!)'KQA>EZ7^"YE0\ZU_#$7S>O$-,OF#%ST
M:U [DID@$UD,FGQQE*NC0=?3D< LGE6>< CW;3]]H44YH-*AC<I<9:9C3_4=
MDG95^-X&11NG3G<ZQN_O!]<DV/O*;83=]?HX+OV$)=]PJ+D\_4A*!U.ZJ["\
M^'X52ZT"%Z*-5ANF#+.KFV;&4;:>"GK1NY<]+S\$BT!4%.F\?#PG1WT?7SC7
MP*>4W-)3@D<(E#IEB1:6^5WR)66 D:<$.JQ-V/G=&-UFC*]3)CWPEFTSG,,(
MH3+_ XSV Q('0JS.B6W/SF)11IC.*FZI,*!U\1/1]8W*G?'@BT5JV#5Y/W(H
M7>&DG]0I/L/W[\5^MCQ&^5,*^N\U9:VGF^;3R>(W%D*=NFMG\$O+ <1^.X78
M+I5%JN^\P=B6UL%!J$/4Z+3(HQ&?M=?NA2\LG"7#ZSO!=%J_=]LBP+\0H-GI
MTWJTRYS-"3-IA?#1*5(&.YNK/PER_5)%K&$!31W@];L0\(=!BFS):M8L@11>
M4EE<UQJ\6.64'U8L_S/BD6KD6DH]=UDXUHZV]".\N19L5@8;".*IN?>K0FTD
MJ0F,R91*R\DY\$8O 2%%TT[&GJ8SDSH./ASM[1X<ZL\VO]@:!I+H&>'0#MY8
MMEHC_>[*%\N-!I,Z 1Z>KG/9/<^0 ==.=TH$>=Z?W<YJ(R=A<WCU"+ HGXI;
M)OG.ESU8YG2#HNILN&Y=@CH>S<K)R<\E"I?.3O$IO$OQ>+L/#P(-4>VE) 7D
M#0J,+NN"YW.ROZU6ID[S!*BQ&'\,>O#G)S?+U$/Y8T"/+6'O" %948(OCO[I
M/GL?<KC 2U3?5D_-/@9\;V*F7CP&K-PYF/O/>-\X 3/9_L;-4>G^G)R&Y:9_
MFMZM3S1Z6X1Y=#\%O:8?)<_P[L(YD_!K#!#.%9$."IT/C@X2AV%AUQB6FESF
M>@;?SCW43YE(/>(.72UG.C\W$N>Q5^ N\C=:QP7C[7^A=;STZ?6[@+-&TDOQ
M-2% 2U<VW';OR%CG+C/-^Z4C;C.PRNR]UHV/A\89D#9#7!*;*>7AF$NPEO?5
M8-D #P<'*^YR)K4;X6<DIZ1B^E4_)B6GGAFK<J&HR;Y%WG0*G.ZLAT.?D@-$
M>]L:VB2UOH3G3HTTH==.E.F6L<#^Y3]('?<E]+:5Q]L/CJ+CO,V4S;2A&Z8A
M\]8O!'_W-.NI1@&2.HPB@]<(T Z%KHJB8!6"?7:9YB?3I$L)1HM;,U>_U&?L
MY9IVY3HW%E]+\4T=+C 'Q?&(#+N$#@<4"XP612.,I"R,-A7]6YIK0DKY7[)?
M6!X2]'WIL%510*?3Z7<,F&R 2-X:F#((09%FW+_OK5:4./L&*L>/U^V]>C'1
M)JOIX74]48KGQ-BA&4,&9<_IQ0YU=VIE5,$7RXE06NNS^_J;,R/T3=O)<-O]
M;^V!QI]"?S'H0D]1]%FJI7^NO%3J\0TSCVC*!KST%DH4^9>@FZ:2<A^HT.Z1
M2O0G#)B-TP(A.0,R,U65BF4QT)/(^[[^JO1+KN8ZC6F#)9!8,>9^FLS/1R.Q
MUFB<SK($Z:?G07AIRI3@4,R4I\2Q:#M<@Y2HHGH-/&OT975=<D?*H^Y%)\;J
M3//D^)UV\<"4!1V2.^$/YD;SL;\Q-_YVK%3$TK^MI 00, _'W><T\&ZS@NYW
MK+1%6._0O/1=(E9VQ:IUUB-?OUW4_*_%V)@@^<<K$.+8(_47"'[3WY/-'4V!
M:8;\X?C.5X/D]LX#BZ7(2I\/WFG5XY5C(ROI@YJD; GBMQ))#MJ>&J&?9\'C
M$1Z]IDT0TW7!==@:V<V/?49H<*?98%@',5KN*LV%(N]]RUU@<FKH_OYFH6&'
MM<C2A% Y8#*B!)JC9YAQYO3I0QR\7L%:#<_(:TV&<VYX29Y[.F-O[-33\[W_
MM'\=+KU22;/4<>8:W/K NE3[U8' XJ?4*0D:AI(W>>IAW[65H-U[KR35U18K
MN4&I5<L'775%_H&=>!^S0PN)O@N7/0(D.CE37IVROWXIJQ I03C$O)BH;"B$
M+U"LP=H>?KR9K][82H$_UE]G3DZV=*U0/SDDP0\)AC4I*X&&G>E9!WV="7VI
MTW1!$6QWV$S>R1[TR"0G%&CN5]][_8E<9T;X&+@4ZR90-2:NI%K16V3ZP.'+
M5$#E+V:&U/D4]7LW547VG=_,0S_80\4A:V:AMMN^U!K4?,@IM0 U: >,V>E
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MBO?Q>@VJL43]0WV %X,?S*(V,%?)(,M#A^2CJ'%1$D3$+V>Q^QO>C<MC_/,
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MLCC\(:W0B1H?,[PU!.,QK3*P=#X&9#9?TPF^TT#8?N6N73@&Y>M#88THPL>
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MWL"XQU6(CB*3.V]I:VWQ>/B%7E7"^A$.Q_<TZ-.+I&EAM>8GM^Z:*\FT2AB
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M@ 6 5_].GNO_MO8?W>K)5*ZN_1<4][ICRC4VIO\%%'<JQ2JR5I+"'+E$O-1
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MA3"5 %%:!_F>K=7G#RSX$Y6/(Z@"O7E*<7N]OK)EKE:^%"H+H;.+N3_?<F;
MQ'%/_57Y^X2+;UTB:E @JBM56M$:D]GSM-[\#W(>OE0 #P7*K:,S^+Q5;W_D
MRU9ER_NY2A'GG1KQ.V2[):2(+]JA/1J]G&&[M7#EPYOVK>!$HW;*+DR\<[R,
MVG\E32/58@E:.3>16S3'UQ\R<+:GB('VSQ$O /$?G&+\O]K^%B/._\J0]52M
M;R(:&^PM%+4"@?8W,%,"087UD4$9G=?<%;%%;Y_4/47=$7&X<D1^0FN@Y?DG
M(,<\<:L=1,J#$DTM&VUA)X!A>@WR_@F 8@KPES>G.P'019R2(O5]Z,&I%T8T
M@;;9ET.'FW*."?^IB\\_N_RSRW^SRZE(G1(8TG? UN]R 8@U+/N'%70>>0+
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M@-A./[3(U#?KV-\+]9I,.<+WB#0^3I+%\XWV*6]:'AU)[Q_.@'6<CUURUD/
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MN5P7JC QI#L*TVYLM:9^S3I+4,]L?+9ZHSB?YM-#0/)#OO:P3+E!,>[KVZ5
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MC%9;P[X6^+'(>:'GH=TI.R[+>@X6!L G[Y;H$_\-F(0_S8_]N%];GY+/JQ/
M_@155-,+PPJ3@>J0C6+5BBYXT7EPKO4DG9PWFYE6DYO5]T.Y6EP48(X?\"\\
M=%B2B[PWT>=I5\=U>2G,-F.UR,\(FGFM=^CTRJ?*F9FPEXH;8SDNO _ZN"M^
M )Z;S&1.=A@F!OI!<>OPGAV]/E!;G<I_O PUWV)-+-X6?7T"<",DN/2D55/R
MK;YVM(I<G&AD0?AI/ZY<2XL,!2]MM'*9\V#=+JNH_WUVR>$5V[RO>_'1)4B^
M TDO096MP]^D,=.")!,'U?(-8,E^"MQ0-W'S ,NV1.5^8BSH]ON1>G/OF+=V
MP^W8MI\>"+,/D:_%X$Z3XW?$:I'*FEX#* DFZP UPVE#Z**CX&%>B*4HV^_?
M?S4>S\W840UMK5;_9%QZCRD0_VHA^IT+^C.L%HC5JR.D+9(]L',N(-RN?#)>
M^'%?--XD%RG_65FJO8Z?FG#W?H:#\-'#\4OGT/TE'T *[R;7_7OH?EN#2M\M
M'7Z]C-#;!I),I'9. ZR4WJ]9&T5FM [;'0#Q4ZPMR8\AN:YMY'UDN9!11%9S
MYR@Q%0B,3328K?Z93RJN2YY,@@V? 'A\G4=I\EX!1%MMX0K(,M2NM?1 0\*B
MD'_<;F_CYQE116$[HS/F*C%O'EG<L(F\:R"K^_ ^>K!F&XG>?+IR.!MT_$>-
M/K&UTW$"V*U80I2E%>EY)FB;<?8BHF] 'LZ8=$SR;%FY(2=KI5"H+-WNT,IL
MU?1/SS4ULN=%B6I_<D3K$$EZ"W<7LL<5E*%N'*@:'\W"S I(G.6O%TOT$<^!
M/O;CDN-B:/$%Z/OOF2NS5>EI=9\K38?6X3MST']QL *]>;5#S%I?-$1YGN\@
M#FG^!M5T:)5+_*VM$58-\K:#AN^MU \K+AAK=[>U)+CEYLZVY9Y9#& ,N>VQ
MX3J]X @5\6<WJABH0:2*^7CN6:<K%KQ)697[%Y5[][)0=!,+LX\+,^'S%]^6
M:R%>QX,J1@92<VH'Y9C'*[[,^_YD*%ZVB1S2%O2QLQ9/.53F7[/2A&[WGS(<
M?X'4NT=8B?LUJA\^";@F\]A'1>6BY6F,Y)4*,MN""'*^GW9;MXC,B'T$B7@L
MN-=-&BAOO.<JP*7P\KO,N=L$E9L&.W(%%&ET9DE9CZEVBM?,0)8A(= I,O2:
M2640"$2?&CA-Y+ "==W(L1. QV!H%UI^;'ZT; PIRC(\[P-B\KXXYV3B&_DB
MFQXR$^]BXVJ2Q/+U::%.6U#VJH/Y:SU7@I"W7>@KJ-[B:6[@G/:$,9(V/Q&/
M-7>P.V:*DV7[^?[U+,NIQI_L ]^^,I4?:.G7>L6WU\.[O%5YS6<P@D;%4*]%
MTDW'1 .'-.TFJ9(8V:K#\"*E.=@PAH?F<:0Q1Q,G\^%>-^;+"_/@S$;W=.1\
M\G-:"R>-IR]7I!HO<O7>EQ.1NI%A\Y9R217J<W03>H]2XT%6=B#SX@5&:-8+
M(([?E, ^\]$M/R6%XE2VV(*5[%!4RH#6[:YX]*./;@WI>V_X_!Y:!D5TP/Q#
M=^S">4H^\3&AJ+9EVUYPLY044\,OX:^8-!/ESF5EO?W/RL#_:9G'_Z>=3/T7
M4$L#!!0    ( %.4<%;\T8N!N20! +QD 0 4    96EG<BTR,#(R,3(S,5]G
M-RYJ<&><NG=44]W7+AJ4)E60(E*B@"#2I'?R(M)$09$F+2HBG8BT ($H"$@7
M$%!:I(D(&*F1&NE=!*3WT*0G@&%#"B?O;]QSSAC?/>..^YV5O?[::^^UYEQS
M/L]\5O;IY.DBZ/QM0Q-#$!T='>@1[0<ZG0'I@\Z>.?/O16OTM(N!F8&!GIZ!
MA8F)D9F-A8V-E865E9V#^SP[!Q<'*^MYOO-<%WAX>7G9./DO\O%<Y.;AY?GW
M)71G:<_0,YQC8#C'P\[*SO/?;J<_0%S,9Y[25YZE$P6=X:([RT5WV@$"@T!T
M#'3_::#_I]&=H:V1D8GY' LK;4#M>= 9NK-GS]"?_7?5M+MAM/L@>BX&[BL*
M>HP7[C]F$O7E47R5DL\L=K.RE==B&"^N].1%Q#D6/OZ+ I>N2DA>D[JNK**J
MIJZAJ7_+P-#(V.3V TLK:QO;AW;.3UV>N;JY>_CY!P0&P8-#(E]'1<>\B8U+
M37N7GI'Y_D-606%1\:>2SZ5?JJIK:NLPW^L;VMH[.KNZ>WK[1D9_CXU/3$Y-
M+^&65U;7UO]L;!+V#P[_$H^ XY-_[:(#G:7[G^W_:!<7S:XS]/1GZ9G^M8ON
M3-"_ [CH&:XH,'+KW6=Z['M!5/$5,\_-E/S*UG-B2A9XWB<OAEGXQ)67KA+^
M->T_EOW_,RSB_\JR_V78_[9K&L1VEHZV>6>Y0! 0Y4%!W,%0 HK_:SBGFW<Y
MLHT!AQ78^-8N?N0'=Y+6R!J[]W0WSO-]D5<":JZ,,IKC^^'=.ZNIVW)F/8>:
MTLN<9T]!K1;:P@35\;6MUE,04[@B_.OT6(??8#[P1+ C]DV/C=M76RFQG$O;
MNIRTH08MY\F.A"I 86V\B1-WE+T][-9R8Y3:J9U*>,W@^$MCB'G@(I&W(!Z6
M[O-L)74M%&P^;,![E8%W"567V9W,'3YX"@(%H(7@-NV50+)5=<;%UT'7]F!>
M29/N:Y97XN3-!((?]_ VD^00UA-4-00C/CFQR?PC)[NG76VUJ4Z$])?GVV6B
M3%<C-#\'T*=%"^45);<434RY0_+RY0,Z=3&8_A-JC8YUW+6/9_Z/_7B&F$"I
M549.A9M($I+;DT4&/QZ7LCE=&2G?]I&1"'1X*;CS^!>^G5N4V^:E'CUA'GP*
MBDC<<)(9KE )N[ HV7W7U:317''Z%&2.?V%.WT]929%C^7;$^,XNM4'03&[@
M9#/N6*P5B;= G8$W+DO$X-NV?D"XFB1Q@TY+WK@Z@EPB0^8[6^X*T>R(S2*.
M_+MA,"O7ON+AM(!PIWP#'HN+]PV"CSK_Z%Y#.F>CHD-*7N\$,%])R>KNO.0X
MV.<(83@SR#[@=&\Q\EV:AK#"0-]MZ0_;%@X_NS\.0R_3=D8+Z[EPB3H>PI_D
M@_ L=K-SG'\5RE NG=^N;-PZU@\[N)HFSK,8H3DQ,594@-LFH^:_/BL./59M
M67]4$'?]-LNU@I<LTJ^ 8P*K-7 ?[]E)E?]U**5M6N9V@L@,/'D:FIS3I[6S
M\B6ALEO]0=P!9-*4&$^ [4#P&@B794[V&7CH?1)BO%(EX861=S!WE*A;AN&S
MLS(]X<\$]",GN8YF4TE2:@>!YT*_R/[U#NM;'[:\;P#BN>^P$$65@.MWG7PJ
M^P0$==I)8#]O* ;;1>5E?F[W4\G>=9E1%+L@T/>MG:XO93KY\H'F[7^7>5TK
M_DWYSFJ>.]^U)Q9[8D(,]Q1-=-^C52@HI!N*B3HJPMI(@$1*U*>9U?Z6&'4Q
M[1G7L#;N66<94*VJ:LC9+U>DZSDS5M/@>7)V6.)DXR0OUX#G'IW!E9\<ZBKX
MS!TIDBTBD/*!JHI0Q7\M: $1Y&.TG<.$:T(2Z^)#W7TO'BPG65Z#%=UK=;$0
M%!<ZO-C)=51RR3-82_Y>R,T'&[Q!?\+F_O,^!(Q02!P HO![Q'&\6NL.>.G0
M#A6MD@];WU3L5JC/%7\BGL5DS5S*O'HD'3;:A_?<CA/;T[.T5YV8^VXZEQTY
MWTLA,?#<_^=_=RM9#V'#99.F9..&VLJQ2Q)\$VIU@WYL+YQ776.?)N;J;>;_
M1MTW=IF67ES@HTZ@A*C<X9-4.D #1S(';4Y+QJYCGH[5>*L2YP,Q&48)N56.
M/6)O%=68X!M#VF&K5N 0EH*INA;/%RZ[@Z.A1:C>;9[[!E>B_IV9ES"QTTMR
M0>A1/I##\,MZ>-C+QP0#S)LU:9W.WP\T<B.C2++8C':O#N$I[W9Z1$G6"=GA
MNMWQ 6[N)@RI\))9(2UM-(Z_F=-]9"=L)O+(M7=\@G0*0F]9>$CGXLT[8.?(
MMT?7L?B8V$,8KVVK?(KL>.QG_6">%X^$$X:K09.7%P\BI%>@,^W$/&"5=&4C
MQ#7V$ G\0S99<K2Q"+VXU#0,>]Q8_:2<4%BUP)MY+3&3)2>Y0>FV>7K1";4Q
M;-50+FB56E%/7.7]L)1[V]&S/<0L7[-@,,B=9[<R@D?I\A-&DV7)\9K-57X!
M]99HW]0<RXR!:P75""/<7>FV2[S$VHI-OFFS%.<+Y@&AP=>2KCG?3QWH?GE=
MT,0Q(\VG9Z2@Y78]#292 (G-^2T+?'<[,JY%"]_9J(B);5);,LR^JV7"'OLT
MA?/B^G7-N.T6>NH<F!7B=@H2EH_29@TN]=!,W7BQB>'4B=<3KA(OY4KL?WOG
M=4^Y:K2#JPPG[WTSLW[D1II$81FU :PW#!4.GT75V72 IU#="QS*8$: $<QC
M#T]Z4CWK:*#T85(=6C5S[*4ZH#>7,7O#J"\8_2T_I2A*^&W7P,=W/E]\1]Z%
M_?&K^#HQZ*,16K422L,QY%^*A^[_@D?I920+=0IUOO84-#-C"XA!VO]4-(%=
MA$I(YOW9.V[Q?(>-07.K[Y]Z77_YD;R\)DD+V+L/[&L6_@W8R.PI>X)N3T'I
MUJ7.S)C#[+D']^N3ALRK7NWZ^%Q5-RXTD!DP_PA"M;5H$H)V' EEW2AZSD[L
M*RK]2, >>Z*9O:?W!<NJAH:Q &GUV:Z)%''%[F_'<3_TZPQG#ER__#Z0150@
MI1OEM\:V<\O2-]8Q>9G4%L=A8B(O/N8'<@:+6^_8F_XYNN0:%WX>'5G3/6HP
MN&T1FW72VC*T=F[E[=MH2<1EQY<1BWSB7-"@\219 U/L\<RADL7=[\134 P-
M_(H^%L1= _V_>FJ+.B45ZS7T!@I&NB7'AC,0Y-N!)HU\N%<_,?3S\@?7.O_W
MHNTO?G8^G#/Q_2;)#!?+$MLS3X$]HYH^SVP4":H=(1%I3OF?KVMR);ZA?*I
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M*3-MM!]3Q8KMH./ (MJ2>)35K\.[%FNA>SR>(\IVD!C_GHZ)B>V/:97G6+Z
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M'N_03M GIM1DJ>\@FGW.C'^[[1(G>;"GS_#DBRW;(X5[QF=?C=0F/,CY6.N
M,5\7)->.C@;Y:9A\]JMU'?0,UII9_]32*/8'FP3%=$=A76%@]Q9>0LG+I@!7
MN5)(6HE'!C%#<<HI<;-XV3>H$5256OYED2M=H+1%/GQ!EP&XG9EINH04 D;U
MOP7&G8(Z='E_W?V9[B[Z5D!DWRA)5$]=2^";'A-3W'$WE?6J*T<^^,>6_9N.
MNH,M#)>)P)^^^7_$]E5..+_ _>Y S\Z[23V&B212<H@W.\7.7.',>-#/.NHS
MK[#A\--,/<BFW"&S(A4I2RM:ZU2KB,,QAFF'C9[KF/Z!;D"+D-R&%-%F>+P,
M9MATMAR65[O><Z];_(54>[>HB-7OOTR3"1'L3\G_G2.<Y61 M+D#BR]"(#V>
M!F(B.UYW"VB<RX8?O-I[=6S-3[ZPUY$)$<3Z)"=#SR/TI)T\0D)T<TO.:?"-
M=ZVF<$$:7T?9)#6^SS/Y6JH7&G!;2_T 44[+ <_WGY9O/\BH,,U<'Q@[!;&B
M'G>3; !/(R#J(PW"3_B:\:,=3E?F*(E,L0:%!N$_7EIH5,A))D)E&"=<Q-^"
M>@6V=:^3O?&9K8UA\E1:+<*87S;+>E?:N/+5+JQ6( D21,_,JK'R=/'ZRM.$
MB>3PWY!O1!3I#L(&"%KV1/,[N<DO:=S/ZY(V^""W_###\<O,[XZ5!+YV0G)F
MW'&\"6$]OD44V6JG[>2_(VE,8%]_K1Q;KAP&<1HK'JW8*;2,?9HBGC2]F"GA
M;J;Z0HC<[L9T'=GD&SEB_@&+[[:<R)[I#_67<\*]&R]],4,V-PV1)1.;A]!D
M$])C +G43$P$=Z"9@.JEZ-SR.W7$D*$W'ZLS.HL?&2>9>.VZ[MN^--^[^?S<
M'PX=G)2%VXCQW-/$'RX!&FR<-SF+$9FDAP@!8(AD0>8=TZ:#1.F"X6&[)9CZ
MF >Z-YH;5?=X7E6)47OOK ;)SX/A%.E9K"N4CH:@K%1&0+)-]UI+W>_:'?X[
M<5V;FS^-4@78G#UV7*V>J$8)?=ZP$G:6E+T4$EP6GJQG:F(XHX).PVXFE76%
MRU7BP='H@+G;LC=#I5461-U#_(\.4M[JVCXR2FG8O[G(EO;R'/H2A8;5WGLQ
MX)KNI%H4"R"E4@KSS^8*"_#];!OO9AD<H721;>8HPE#O'X4%;9M?O,>-I//Z
M0F"\A?FTNYA!HII#[I<;BK![:<=I#TSGT=NKU0DHZAGL8A0T,+G&_L @;/M$
M<#ESA[ $FYKIGH9%(=P7Y84?]G\Q7]F8+FXN3JBS*0PIA<\Z[OZ0*2J[_IW>
MQ= #%K^ &7H5SEV\.@) NW65?VT+%V )G%'^%_R*[8R+&(V:4I;?O#7CZ/(Z
MK]>*:_&EE2R]#]L_&^$UQW$*LDTG.QT6AB&*F+?,Y,3PR,T\H5'^'T=9++;V
MW85(5YVWE<8_WNBOOMMO.YS!)(18F_V7M%3^OTG+P-KC&1KA67_/I/(D)^_<
M21K'P]^]7Y:\H@03>:Z#AURG<']MJ+R?7EAM0MF _&[CL/:P_S0Q.ZTM2=RD
MD20$P)R"GE"Z]]'_'A/HTT1=]@:6*-!R"OHUWASZ7X;$019SL54.2 'L,VEO
MFJ^PO @Q]J["8*\3M2CMVS(UE"__R*Z\SUY[%.Z<Y\FBME[A0J0)JF*EV^,K
MQ<BU3&KJ"QJ(0U_/X%S)O(5M1!3[(O=FEO?/S*"O<Y-L%4UOU8-7TV- Y3=5
M-#:?-YM);T"!ZQ,[*E_(K(!T">#9KI:Z,7^5\+K*GG4F:.9J;='C.]NO7Y3/
M#-,)GU6@/R_=J_UP>8\;V7I=5PP(,OY>-TS+])).L]WI.'=KHN;*70&]:QEN
M5@;M<G^?CYR!^@I8*#G$D/FR^":R%X?BM\75PD6:JAIMY?AWN:FW/B,7C?U&
M 4^UBWU1UTU(7^^J337;80P*3$/+-KT%*4\"Q)MWK6#*-<TGM:$MW;.0;\G;
MA,+P(53U0K2W;+ES<H==9XYF7BW"YFATUO@544DDL$OPD5,D_;*,WP962)<-
M\*-I&QW/UCS)RKC=[GNO,C2$Z4+=OR'J"R%MF\'TH4FOXQ;P(L7>Y7!P.X9H
M5O5PSGW\H&WK5^&M8F,R<\7T1J>!9<ZR+!]6'O")D> S4UY2:4ZC-IOWFP,2
MF(XY9*>=?"=TRJ\SJ_!J%^HQTKMHWKC%O>;NH+?O>8;H59N  (>DKXJ,"B=T
M)$WRN5_89Z>@UR'\K_S/5W4^YO-!OW:RGY_%*/Y<EF1(]LK]R/ 3A!X8FF1A
M))B3>99Q@9CBM;O7S]7.9'PPZG-.W7OR0GWEF]@&%/U;2F.XQ(K\( Z;FXWY
M.Q'H4%!H5ZR";S.;M[F]OBJ_??\4)&4'S%&)];2@&+99  MAGR6R+KLFZ K!
MOX9&C9#U%W-]V*VGCV4[*K2OM1;5PCX\_WKS[>R.=([0VW F2AQD51HJB)V?
M@!PV7*?8?2[Y),AZM2'.<\PDT][!4%3>50)5: R,4EFF3D$2CCA.TCF:?#_1
M\1R%/((>*R&CP$1&<PK[UL IZ+]^9_"=<XJ3J$1S HGH#H3BP( 3\I*V!B7_
MD\S"E!U3?$N_L_?!C2DV)Y/))O_>30\W:"H&6*8I_KC:^@UD-/3D_AX$?Q]]
MK(B-@_Y=XJ>^,W"P(7,[4^]@VI%$KM^0P_RR?JRW^>06E7=B&[N\P'4*:ML#
M>G'(;W9&__XQ1+8G-K(F#%[:R9(7AYW5Z#*Z?.DO&!#O)G^ 19^"ML4^(S?T
MK>[5;IT8'?!Z[H^<@GBPAVG;'M>^.N."DFM.05%8#K(1CF)5MW$B^WIBY-58
MA-05HT8ANEV#6T7Y_)*_OG?VW98.#(?31,]M;<ZOU%%6 LO!S?H/-9#(C/-:
M,_H'LJN'))=&(<YC9^]5U!-;FU$DWBPY\12$;\*Z(%GFYQP$$V'ZYMLZMWI(
M.;T@.N%DAYIGJKV[=^&9/\#3%C 0^<KW7TTV)&V$[T3 PGF'>8\\T88:O))*
M[>K@3'4?3\V/FL</G2W^Z?NXZ(_FH.',8_+->N *C;K[EU0KBK?R!$80%FC=
M#Y_@&9WE>P49LB/VQY4*6@([4P<1>M>_2\:-OW9P^$:A,?[.:GF+70LT)===
MZNK#L$P8*> /5GRA],29,+%LB:0C\_OBRA:8X6F=FCHY,!5RGF#<M&M5[#\2
M)MSNN"??AZX)7A1?]'-2R:=YPJ2%!QZYQ-8"J:TDZ+<E^B4R"BOXJ"CQ-I29
M:AFQ):6TJ7'.]_RII^>6GM751?:R K$T%-RE/5DT8M-%<XT)-*;E$L%HVQ,G
M?=?&H+HYLN-2\T[2YRJCP=DSUWX;;FM<9O+RZUJ.ZQ(:#7C2,O# J6)R!/'-
MLHCZ.RL\UN%(&C)3W::Y_L,M7!X>U$I5))B_MIQE-R)='_DUYVXHQ$^Z9>&0
M+\:D5: (HA-/NBY_AKIP"N*@BI)E8[I"^.)Q.X;VV1]VO+45G(O", \;W&YF
M^F,PP:#DM;,#@59,$4:\OX&TQ5-0))4QO%]$&X]Z56-[*'QF06],PM1V-?5!
M\\Z*S,"^DA9W:+4(2!B$SJ,E16((1ZXS26;S4A'?\\[/"YY'4G[^9:1>:^4$
MT<I=?K]'_H+)I17.'NG7N[0,I=#9U:>@EZ[2;3RKLK-9I/3A;2@#$C84A13X
M.XB\>1  .P-/UD]ZN.</NV3W"?4BY9:2]"FHW.68T53JT8\SQC\&_:B:M$A(
M0Z@"ON63!FC !L>7N]2XT90-XW>$/[$/DW#N'8!)BZ>RL9%3ZO1Z!A$$0G];
MELX>F4]Z*<%&T[MV0&W:02U(X>[YIQEN2XV3V\RM8GW)]*>@YR'_QJ]%A=R$
M)24N7#S^LS6L>L9^]I;MTZ)X/[Z+(2+8#^6NNG8*:)\CIZ2AO1U@Z]-PC$K0
M3=+T$-G4O/'$D9H\'% &YG8C:M9E!O%2L\/..,PX_C-3F"5YKV<S-((9DAC\
M%%M3EUX&3W,<UKZP9,Y--FGX)<?^J0(2(U9CZJGU4O&1TMRLGE J6T+1G56_
MG]+O_CW:<##_'-Z)8KT4G&<"J<JZ(B;TMDPYKA!_#W3" J0M8;N1L5C\G;M^
MG>'G@"@\[A34">'<J_U0*VW.8YMQ=T=B;+XJ7:''5B8X,4ZS4D/RLO5?L4OP
M6 N?7J=Y;^6*(\?C]Q9II3=5+!H#L85F>WN5)Q?P0<0</*9K2!".;@M1S4:[
M9RU$+;^JM0^#F:LFGNT;88CW5,7],/K^5O7MIE6VI$@C5#F\'RM 9:>.Y&D1
M^#NP,=/IT_"JK=LUHRJ)@O<,(N!/8E?@1? ?6MF*/ =<4\^_:,:=.,4:=$J7
M0;9@\EOW/V4CT.8 *S*W+>[:YVO7"N) _U]=NA_KADH0.0<8X2?L45VZUT;(
M.L1!S0V9I99ZRZR=UW!IMN YZ3-;;U\N/Q\,2>1--PXU5@_Z-9+3G/.;!'X'
MQALN)#HQX.6CR;Y+2&YXV6T\%5.ZF5%M:^^1:>)-_':OBT]TA2EL4E!O2.P,
MUN9/0<,7\VGEG8I44GH27#]U:X(0I&M,VY@<\AU\2=0IR 4L!/>S(C#FNN"$
M/7Z*C]9\D#OO.(<L,LHPKO[^>?K%Y(]NB2\TX% *5X*#.[#5X)<(P1)XF>EW
M0F"FLZ*3&]3=JCG>:]<T6#Q:.OK!]S.ZCP?#(@U<S&<?F#MYAO-CUMPAH1ES
M\L#T*2CUOSUQ-78Q!RNL"U;;]ENREVIR+IB<A]NUZ56TAH4)L9>@I\4[4F/$
MO%Q?+ WU^26LQY%$X^XU64X<V..;L3HWK=-BCF#_F;?R6)]TD8P 0C_1#-%O
M4=_B;Y$9E?%/YC'UY4C\[&@FBFGR"XRR$O>2LV7[:CPWHS)*&^<6+@E_< \(
M6Y)G? C$F#<1K)*:,)E9=YO;>GT]^:>*Z(H-Q+M1"LSL$7H]..S=/\6>#XKO
MAL4CMG?C$RJLBZ'KC8<-F)5@R=<0M[VHB5,0HU<3#)S<I-O"&W%QI^3W*C9)
M?0G5_V!%%\?2'P$)-%Q.>=6#CD0NO@7S(X0_ ?$X= RZR<"Y9"O\\OB5AA$O
MM,3Y7@2JI>>-JAIF0%?OX-$Z[TFV@>= <_FF?RH&AUIK6680M$A4&2XYDL!*
MA%LCS C5X336QUO&+\1"^6LH>@CVSW:"WA><[!]*8FH-ZVY9O-+KO7G5VH A
M>G]28Q6R^)FJV4+YJ,L%&'7JLN$SL,'X4] _OQ..1"2;OF4,2B@:O7R"2;=V
MYM[1^N1B.=M'YV-,L2RHBO.-4D=>K=@/FL NP@9)O9903V3#=.#A1,^Q33>X
MCJD-)A3>0Y4AZ*#BKWP;A=68#JJ.!<"?5F:M;4^C9O])N_YADA_T'O/5;XBQ
MR9S*3"%D_R!"Z6C*X&PCP3K395E 9:;T\;#/5VOI[-?^":6Q%R,E668EC*?]
MH 6_K2L]5*Z;+7";[@:13T%G^<%SHR7D1&RS_3[Y)E81N9@/9=7VQN\1:X''
M!/,E6]46,8(?F*U?L;V>C_"V+>D4M*=_96MT^W@':D6=@M:=H?9H@J-5XE'T
M'DXRHRKVXW6-#=4Y^KRO/7AVGUW[T>AS?'Z'O;;E<1PT1NV()M\Z!L$XAX9G
M^9\0VOA9SE,0<W-+A<?XZ*9-M<04>EKR.$-]6>(:!F02;.M;D[/$:^&;MRD/
M-?5 ?0ET"C?)ZC/+<7#:MPL[@:39A)L.BO3BAW[8(=L68EJ$\4GOF+\-ES^I
MBLW>T^T$-894"U7J]*J,WC=P*%J7E&Q42K"TB/L3CD2VVK>HPMFH/Z>'VH$F
MF^(Y^+CC[8%<CO'59PVOQ<H37 S$._<?)0(_#96R>BCQR,5"\)D6D? !*C.^
M)*')7BU&6[_ 3E ZWL0_N__EC&-<0Y."YEO+I"*A]3C*Q8*"W(TN7^HSU&RY
MPXZ&(;0OBS0WU+\PTTYE"5@$"R"$?B-8\?&VWR<"P.=+)O?^ZCOKE%O7)2A<
ME\]Y,["K:\9/]S#)+XZX,+/7/<^#!V_+?H'K6TX<DL#G-^W8$^MRBTQ>H#P;
MIO$1O7Q!BHDEL@EL+SQW[*Z[,%RW*"$/JI(S;Q:J77I;2L9@RMP7\+K_?K#L
M37;!JQ:3+@,/3&,Z[2P\G/A'GWG[C'@6Q=W55<DR5.PKU[,EYAS'K![A6AR
M(-)-A'HE[;$J^'*7FJ[BR&5\1F%)'<H3;>)?T&4255NU_//GC\:"YT*Y)<+!
MO"?=!OZW$9/)/B13<P+L% 1J4UC-W[;)7/I"3A[" M=L?H %ILF6 ))DA) ;
M*2;(52^Y1I),32H?B$_P$8R?)MUB3=VTFA-TDW2WH ,M3R!83T$,'( OP=F$
MQ/]:>>C"5HNV6YW)XJ2R_:L &.1RMTK[94RL_MG,8!#HPD3<25Y<>^:13QI@
M#QN$AB$70R[U'IB8[SR4E_2NV?\+N4XK59*Q/-I2B\TV..1KA!%.6$F?(%=:
M-A,68][28)RUTYJA^#;CLC'I/7O9@5"2M#FQCY" I$7E8BF4\>_QX8Z^%:9J
M>&?:T_OZV*X/HOHJKK'(F%6W\VK//3.>B8V=S@[KP/TA[5)Z+JG@JRD17ZX)
MB*?]  6A>X>FI8GQ@#>$S'.T9)XHJ^U<O.ET8=A+=@?VMT)WT6&Z74P0?>PN
M8OEJ[9.Q.%O.H4J1Z^";_#F5C2([:NTY^5D<V$2"O+N232T/JR"D$3OP!MCV
M1(^9I?EZ;P)3]\1XZO2&DR"^/ZR![%"U_4!;8771\AE#0KYOA";!%HHW1T])
M;!&] /;@(J!"-+-31/+=O*?J9NLXKU2E[!&'H$=&+WWBSTGQ1Q,C>9R$DACJ
M%7CXC".^"U,"Q!@T#*5]=L^4\F5=7'KI+_[TO)ZP'KV(IT=)NE&N2GDZJF!\
M(7SE0./%%%EN:\+S%)0Y0,93TK65PDY!] = +4WKT,/_BE<"CCBM]-_:D&57
M?0KJ@I3+OL^GKIF@:WU*5ZP&7.FC&3%8[SU><](3^(-;@ K>VJWI64-+,?O/
M>IRW[.L3W6Q/KKE8N0F%3/G:IMHGDS<54AG"E@TX%^Y9J:QB?LY =VUJOUH@
MOEI$YTP<0T/#Y7\?CRXS3+R"N"Q,DN[AHXMQ@L*7VH;:,)JJ[QNB^HQ4R&4>
M/7S*DHK& R^L]$CSZ0=8,M<![BA2%NF::]1Z%'YUU MQU^7+O ?W1F:0%,^"
MR_ZRLV*TV M017T,:V2.S9]<WML6Q/3KIC8J,%I%_X%#.C57I4;X%,0:;K2R
M'/YK@9U60$=\AR0*=H7HX9%$&#&(>#);9GO<U2%YLK3OO;"_]W/V"%V 7/R"
MY&T2=B6) _'MYKBP:T"D@SUKHIIITJY:?4/,SGUL3DKD]^XZM6,")L%5A3C&
MFY _:,B#S23/8M6.!&\BTAVMQA<B3/>AP0?RY O=N)C7Y "2+,!J_ NA][C4
MXX0O&>;^Q?W7ST]K/_72.U(HJ_2E[5S1K:TJ!,SV**'Z)B4!Z364?$FM\W^P
M=QYQ37SANX^B8J&*@'05L5!$>@O$AC0!Z9VHB)0  >D0B$I36J0K+=([$2%$
M:J0K56H@E$ B(CVA!E*X_/YW<7=W=9=W,>LY\YGW>9_O,V?..:6;= 4H,4'?
MH$J=ML8S<_V+PQ,*KVY23KIVUJ*SJ?QW5=2$NE2^A7!%8U^Y&XIB1Z^[&V_N
M2A,S@$\7B[UK=BFBWR</I&/ST=-N&;$#+&!K8V<I0-?KYSD7M058!4R2WLF?
M55J"U\6L&\S+3F6T[3>6Q**G596<(-?Q =$2[,'A\UP5P@__XNT #2=T7DM-
MWJITO_-RS"'AV8'#GVK8,>J<(E%;YD&78;RCE=(P<)$[B&LW-&L6WBEH_=V\
MA6:_S[&%2>X)UC[-[WWJF2QP8I-^Z07IAV#)6MLQ#[,'C7;9&L?(HM9R-Q\G
M,A<L0^,J7G^[$@W<A-6/:=S_D9*+WCU]:;7+TDA*^R  4YR^<U[>KZA_=W5U
MCMEB/ "F7M]?CUNPT>+#P\0I\/=5=0CN94P57W1C*M.6<%_!2]<I8/[G-X5;
M3_Y$/_TR3V*U.3;]6.Q\#J@^)E9+0HQ])?<J58ZD ,R,VDOQ>*7NG6ZLAHE:
M$+S-PMUTHL IXKMP>*&)[:"7!:\SY?KHVJ@E'&X5UE_ *_BZ<#<N<,=M-JRG
MGXLYI0[M&1#^=P2HW0)349W\/6OKJ%G7?66\932'BK&/-"7_YT\.RTLS#F^$
MV3(/^)GGX11$&T9,I)7%]CZQ!6333$ZLN-Y(L^[]EG4-P]<462$: -HHO %J
MEALM"J\<?MJ"_U@F]FWS& %&*=N3+0NW6LM06#AROLDKZ+_5O3P+1<@?87;=
MLJ2<T\U*96[[3R?=+Y0^<FK.ZH7/=&S#MA9UMWKZSUY)9(?Y'K\M,#5O00,<
MF7N5K-3S7EJFV4$+J[3;B@"N9/!S";D^IJ9N7Q$U6_+2O9#R%ERD:'*F;+ P
M?40O;/ (\*DDN)N;:4F8JPQ_RL2+B6F)_3<7RDD50]E2:Y^,^8'9T'4AW7G/
MO3%<-AC\'^GJ?[J]$>DL:9M@F_!9L1//&76@5ZX];_W90;;C,C<,7>XWUS?H
M8)HE*U&"O875(@)OU+KG&ZZ\Q(VG6L+B)B5E"UYCLP+IPR4*>\RI /TY/;LM
M#RK_GN>Q?C\$.2ULOO$#Q6!%JI0(,5@N18V@G0X19D+@W3%+H+9PTOL7 3,!
M\XO>NM=YLH^3(VOXE: .XE"L$IBGKV"6"E[ 3IE.:]=,>- 3=$PS I9:_$#'
MH?OL>X("6\V%[K#PV#DSWY1LIFR'8STS(VW=P^GTV2T=:(]1!A.9NT^G'H^@
M%B8[OK8#!\ \R>_TQ&)A N4/60;.\T%O+[*S<*E'?3K= U?%X0BUV([/3'[8
MU=]^80^,ZR"CXN[J \-BBH=1'0+5]D> :9UGFF]XEQ4MO1DS$J?'":.-!RW@
MOAK?_44!K=BY%N0O#5GQ[57F>0F:9M#&$+'G+<@5$85_E+G7M/"0:VRGPD(6
M6//P:K(:+T"B6_"1=X,'[Q5AX9"8M\>V6 P_2_<L[H% H<2WI):LE\>^%+.Q
MX<^M^L/UK6X_.(CDJTY;7P;;#NN+KCF :@/HHZ&K3+?$\)W4PRG9&^F$$=>#
M"J)*FZP <TSL&RJ6+D4Y._6O]2:%I869Y<1EY7"YHC(]?4NW6;?OZSEA>-B;
MGP!D#M;I^)'.]^W9D$4RVJ!X%H,)^CFBR$DW&;^*Y9VFN%*E6VR1Y9W/$OIX
M9>MX3^NO=[C$,D3SR[76BOIJT;CBH0F\PQQ#6S;DMN;X&B/0,=>!\^<1 -]$
M4D8&'Q?:*2H/A<5N5$F,E:H^H:'\CN;X9MI \YN#ONWR%U!S-+ !H,O[WJ'K
MWC6L%5"!F,/?G2E2C5Y8=^QQ&-YX"PE[:-A@$!?\1D)/CRO-@TN'M?0:^E8^
M7Y2$GI\GXPB HY_0WRY;%S//F.$]"*89A ^%K,#;=!4O&'-*30>%$NMS:U:K
M!'.J(!>N8N-);QM5KZEI+NZCQM1OZ\Q6""+[X#D3<UG@EMB0T50-)KL&8>P
MPSS/3M;64@[O=;PSXOELMMR5#/=TJQ#\<U"_8IV/V"O8YF&>MM^G\X Z0MJ9
M WNB2A2E/D)01C='AN_L$U"09Q71P,#B)G;C"WONWP>AN D_LQ)::VA81;@0
MXS!L[F7?W%-P'[RG)!^WN062QLZC"'QTL3 B./)0 O'>CV%@36;6: Y6.3EY
MUQJ\^-+165ZXYE2W8,>:F':HL4 0#@HD\7=,[<+/0!KA[^LJ:,%7H[?:_=,U
M%\]*=H9-G(HO^Q/(.VEBLU7RV-QY'+-?B/P#5K!P,M6\"/:%[H)N'%=8)J$.
M&8EUUA 3@=VF5C:BHH!/_8?JIJ=%KFVLZ$UVUM0]4+T6R ;\^B.MX\Q/)1R\
M[;F6?)!"%_@43&1A0!:,_D[A6;4\+,Q4\$H\Q$]524AN3W^_>$\W'2@=6[7M
MMPHN'K,8\RI'**]F' $DT-CKE_!%MU77-H_5UU';P^1G_B:P[<+?-EK%/Z/,
MO6D5J*G%U+>,E6 3;U7=V/H=K, GWI=RG3TA6B.:]5KKN6/)6M%=R$9("HF4
MD',$^""M.(WB6^4VSNL*E6^']N#OO+?&/%- *@.O'"1NG&A#C;M+&85.I%F-
M*T$MD7_CS66T31QD4,5M8 "\3;_9F(2-.0((PET(O'35D4VES4O+WU:V= JG
M[)HW \_W>(UVF\AW/0EM^_%S1>UDZQ$@OP:7J1!7:W0$B% VM"FNSH1L:@')
M"#KOP_GHHJ(.L3A9?]0):NEI P3[2J;,'YQ<K\Z,&=N32H['(P')9W^*2,53
M#<E9#HPBN.<>(Q\-8EMQY"3?B7I9[R@685^OC,-75@AUWQ'DV;[NU!]PND$5
M(7!0LX_FS7<S-*\OWUNKK@JG.>(_U\T(RQ80!J#09;%T,-EJ,RZ<LY4BVQYV
ML:=3/;RH,@ANG;MD65/SW::HYNESHH5I@!S>NRJB1Y]F3'+IE'$AEJQ5$ E<
ML).XM=WU$&)G@CS-H$'G:H1L=NE4^Q-QV3>35VM^*&U:D)?HO"QM3'6*<@)Y
M8DEO!(WDIBN/[B:!XOT,SXG:5,M$=)HWZVVKG^)AF>0[17IWUX>!^PHEIM,D
M!IQ1Z=$4IF1Y1GO])J0II D)@DDS6K"OQ*)M1=_RQX:SN%O"N7<^7=0T,!<5
M&:V&"I+O2'RN+OY\TR5@IBO[3)_P4E58'TV9.0,_#W>'?-@Y K"N8"P;=[@8
M^0Z<UAB^_1=:4:EG7GJ?$Y@<B(\G74-1%?9*&<A*NH:;2S[]$1D<4UF%^Q7W
M./>073GT-6@QJ>YCX?L?E+HO:C^[(3_HLN1WX'@D^6D%9X(H+WF])YK.NC @
MMU[M7U'!6J-U!?LR4]FUP-\RZ5[:_4_Q*FEOC,\T;@Z9I1OHA 74)ZQ/-4D%
M5PC7+Q8O\I?79Q'L;(\ J J7F/ I@FBKV']_NG/]CY5B#+##0/D)RJI@5$+[
MS/U7[2L/>C<^"SR]_TS-D8JJ!7F $PB<QT\VI="-2:8./51FWB O[@@*Z<!Y
MC@#N&@^>7G@F)$\?;)C*=LFV&E&TDHHZAAZKL#^;3)ECU8I(PKY'O7>X9('M
MP-!YYK'4ZZBNH=.8M2:W!66*UF?6#XJA6:M]ZW>(B]=RA7SO' % 3EQ/GMWM
M0Z2ZG(HE'Q>?EM#T?^O:A+H32"(2S:)^F\>2U+VX:-LSJ*P!PK'4>ATGC?"
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M.,<))0VIL 'L /+8/<B/0;&Y%T=A,B3PF3GJN_:>+L'T.EEIOZ:R]-O5I"W
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M67*=)#)5[]9$6A;NU1'@^E!>:;6!,36GP)W 64()*XP_]%#>>O*/:F5YSU=
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M;):[W'AP-6YS*GM7P4-$L>CVOR- TYWU@(W/.S*\?ZHHVS3^']M!$9W,RV-
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M^AKFX,*=3EB3=PS+_LZ>:FHK_]C[OJF"(15,&J+::'&@<>$=C)PEX(<]N,K
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MN5M&B*V9G9/VTRM]-S,P:AQ%)]06@I9[8,06H^_(V*]!)>;#ST> L@ ]_W/
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M$5D#XB/NHN(J&P*D JHU<:A;3'+$D.6TOIG[JHEEQ0R.N0"%_G!88=]1-/[
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MJ_53 ?DCU)>Y5D;2>OE>P)631Z&$?0+*OL0<ZHIO2*0"+A\NIG\E>!JDW;F
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MDZ%//EF[)\&GN9DLC)U[,^EJB9UNR'@9<!UD[,?>77+-@]5*M[*/7V?]V$=
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M+'7'U926*IN+" XK13%PE2+;N86-TQ)'+&]#ZLNX&@I.N"99WM2="CA7AN1
M_L*H<L&0C)1$F1P5PD5/#(R9 +$FN.:S) \''9M2 <Z];NWAG\!YG!]"8'0;
M% &H*HJDB8_M4,1&1.86; ZQMV0.QT/;:M) 0L\,N$/&3;[][C;NU@CL*0H4
M\,I V;:8&^?')+ R163)KL6E5DX6\,Y:>DVM16*5J !>5W,JH#*-"CA5$.E'
M2"P:,.ZLX$X7:*\]OB-EAYC^& *3@M$=40$)B)L3) ?<R).QND#7^BUF9='W
M)S&9#=_+_5_0_!F0T3NA>FUH>2_T%!11?[<EN,+!F9DGF4M-4?R>3O+EV^_=
M M>:[YG'G)T-S\"G;2USJ1 [Y+W.J>X7I<*0 #%PP4E.NM+>Q<VC%H.W7A!=
M/I/ZF#&^Q-?M/*_7\=L$5"B)-T(&.>O9>S]-I&:PH/<7N 7D%WGP0MUV]#EA
M&W.+0X+18M/2-L_9)>RRK!!_?(9,[R7IN[\$-YMI5]I\P!>"K\Z35!03JBL6
M"O.651ZO^5]+KBY1BGFGHNVB?<1V*/ZSLQ>^:J2;+5.^N["X5P\?1/K'G=8+
MCGT(RM1K*$]-ZS]$)F%R@+B7% %<>J(L@Y+'-@=WC0267?7XAW43-P% ?FIF
MLN+*KK:R=QW*.K7<#HDM?QQ.X+/(NXH\_@EZ)S*J>MZ/T0IGO2BN./F^SHI(
M!2BBCTL$/GYR"39VGW!S@X2T$AB6@P26IU+NI[Y.(6B@3&PTA)0)J)VMP?B[
MSF*M\2%7SL\MMK$M%X]<GUBKN/4$D=$Y%'0$\U^;Z%@66MK3O[KOK&UE(ZR@
M87K0<O#ZU GAB8^,KLME#A[CL*DL*K&8?DWAB&KM#U14YQP)F;X8=6%7,@[V
M#;(1&^FWE)2?.)3T-#7QMHO\TDO4"!5PA0IP\#O,Q;99+:O&KVVA&N-%W<C5
M"'60]/WG*32B?6%^<[;<8&$9<H%EY92I:?V>F'AZ<O.!_U?(U-,-P_B3 M_
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M7T2B70EQ2CX].[Y:S_\%/I?].Q@NVO0]=U 9G'M[+U^+R)3=$)H28:@M?PO
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MZJ74EJ7)ZN!QM76UB76NJB9/A.W;9R$!^[;-ZKS)B7?G(/X^G,X#G_::EZB
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MAI ==T5(. 4SU?T$=N72K;S=2LNHJ-OS+M-ZQLK<=Z%?2JSA^T? $%?KQP.
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M:\?JP#' :W7$DIU\E!@?O!Z7'NG\AXRI[@6/SI<YFDE7WFHUO0B(F@#F@1R
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MI3:98=.Y9&-HDOK_W13QKVO.$2$B8ER+6UMF 5DGB36KWQ5]<N.AY8%U!/$
M+"=8U4J77PZ?Z3)4QZ QF7_F"]UF 3S@N LUA078<"$V'3MGWQ3 1A;IT01>
M<.YZZ-:&O8#_T(:]?VSWX;)W/4\8;B]S%Y8/=-6J.DQVS1#I2D9%%.>JDGQ<
MGB@EKC5?^+$%)<S/H/_\BG,YC?9E@O :%TBW5XI1%1[5DSA/V1?[+,4<68<1
M^Z+JI\A U%U_9J=1>E]/7+"E]&>:35_:PZ@GAA3.-75*U5O*V3J+Z,1@5?D7
M7Y-+BSW/\H2O)T]TJ91&L\6:W]"UBPJ\<<F0_^H1+M<&BZJ(-M"^7YX-K67
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MF[YJ1ZNOY;* G7W]8FOKEQ0KPZSMO-@EKYRT,]?ES@3N2-%_Z%*54*H;/*.
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M@5]._OKJ,Q;@;L@">'18P$L[%I#  IB3&30E 3HN8NM309TU(&(8HKZTSV_
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M[N,TIL](H[M10AN$+BL9._29A<G*72\ME=UI_GRR0W%PXA&[N_>TOLP@PB'
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M 1& _^C?\R'@L9 S6%:/6Y-W8 &;QCE$M^^*VCC<_LH=J\:1+^,WGB/7>5E
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M6("WJ-Z7.!;PWEAWF4BXE+/8G&+O!4VQ> J]"D(#HS_]+E4!3 M2_?[15II
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M/[8NGY3UT3>,5J,M<B_=?18<C#4L A6N";#V>D+OW:6=!$/B],4!TK)_<K\
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MZM-![:"YB4$4^1Y6_92X;BT+CJ@X[K$'E^2=Q  K 2 1QFIB.X@XT1];E[.
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M#Z "+''_=ZJ<_[_2SE!'_PM02P,$%     @ 4Y1P5K>__XSHI $ H/<! !0
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MV20H'.'\H2R[O>T4!)6+@(JKI*JC@BLL"/16G[]IJT=]T?5AM^,"L<UV7C:
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M&V-9#@35E7;)&B](#G96@(6F3!8HP3_3W;_7> L[;12:H.U\, IW>EX>3^M
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M@9O,43$6G9CYM[4PE]AY=&TQ%5P]42FGW&XV[2&+O_?4N+=QDE/NZ>&LBK=
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M)=S^#\7R3>D,;"$U5[J/YS@-S.1 <A(;:QP.23H&YA*)AN=;\^_U&HJK;#
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M^*\-$K_N""^ O+P@\^ NY"L?\AP)1FR,@$D2@5T'#8/>:):QC<(F3$2>1-K
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MCWS>X[]4*_[NS@?7JX\]N-XAKR\1^O8]HH6B=(R.SNCH4</F_=E5%I3H&9]
MG;0-A)7'[N#*K'KRP"D<#+#"UV$'I,B+88JXH-)?PL4)WJD3*6X;I54&\X"P
MF:GOC7=E7<KNT@4FK=^2%'B*\?W5STK& :(V\&,I._?%LPEMEOBB 7-GTLJA
MR"$*FO"^9?KIV@RV!$6D5V:.[0K:]'8O^VODCL)]160TDJ\?3B]N-K^&MTTZ
MA=\ *%&+'_=GK\IKDC[5G*,$G!)XI9J294R3/9:KO!'=^U/UZ),([%NH4@>+
M.,XZ?O'LN?)^B9M26<B%0GQ\_)I-E0>12V"U8*@/\KT/(562!C>YU3]/>Y-M
MUPZ_N]?]?ZX'KQE!9%#7)5 4\E+\'F6G0_:VX.8IA5%%+*SGIV&Q?Q'EV\07
ML2ZYC0=.>$ZGD%S\P"U+FS?S7*K>XGD@RO.D;\XN?'[KLJG9X,_!R><S#\AT
M]/AQ%+7)0'\ZTD5+E9_8VI5%".^T> ,(\R.JQR9&"N$;09ES;_[,RN<_7X-9
MK$O>W85%M7[G)^>)YED'/;P!M(I<WEGP"2NIE&6&:8Q*O9"L&%BXD*51<\I1
MI3./CQ4VI&,YB^.4=N[TM5+@2TYTWK9BZ29&PLBQ J'-3P:P(_OM'O(M!Y@(
MV1WHD[XPUGO44S6$!B])Z)CVZ <=.OQH;T<0OV:Z%(@VE0$^P1^:85-B?R$"
MCQ&/*VQS(AS/=C\I3VBF6%G-D=U?<-@*?Y$[EG+^YX*;F>*0X];EWKO N]]2
M=90^G!+&5X)O;Z,]37R^M:_P3SB];+.&#^5ER/J.;#AAI1ME ZE=RH>]OZ4_
M'[SG$KJ33W0)&-K,=:F4V&ED_&S4<==):-OY$T5_9D?!)\"CC@,7$.X)6%=3
MQ:>Q^D+2RYL G70#<("_[FU^ ;N3N+3>+H25*<,Q=M'46TZ4&VYY&CF/9M:/
M6\#N<KI:O\4^N.KK>/")S('VQ.Z6G=.G;-03E; UT5+FA7A(?X^0M(>/^&Y6
M?"C'NQ?VL2^6?_OF.;.KM+*L*PB=&3N4W@#0Q^;26A&;98>H;H%)I45X-YA.
M89FQYQCQ$(H1_ 9-;O.\ 9@WL7^A#N/N,;A3XV4ZN2Q%X@Y\< .PFG]TR3X^
M:NJKWY$F@;/\4E7IQXZK1G(4P*EX72S"THDITZZ-2IT''2:Y<H#.1A)D9B?E
M4NW+W3MH[.G)#^P.@RRB\L&Q0<G/II(QQW\SF+*N]RX%)'=:>C:^")(1>GD&
MRBZDFSW _O68D$!'W3+3#:#=HSB**%C*<$F_;D3;G%VN*HI5Z0,\J%V 66)]
MZQ$7HGX?N#V$_@ML+.Y2H)1G4&+@=?[]*#_KSIL-P%'>\/]95//_;__O&W5D
MLQ#V*"G]Q'Z[WL)>LOKJNYFBU5#NP-30HIGZA2YT],,_V.M<V_K/R'N8CN)8
M%?IVNC'^#RS3$9$7=R7'HV1/M+%N?G31@WN2OX0MZ.8+NK_T;7.(<_^:BCSA
MAN[/-:E"C30S&/!A0MD8/?UIS_I_N"(+GGX*7A&:A[79*]/E:*M,;U3M21B;
MLH4=F]4[S;I?T0"" HX_NS#?Q>2+5AO(DC3'TDYJYAS/1M+[Z&EY&^&%='I&
M;72CU<)\4)F]JW!Z#*"I;N.4M(>_G5-,AR]PMFZ0)P?7O=.]@(?1^ITK9)]X
MYY14#%#WUGD*"A:(?>DH)9.\,U%E($&U^% _'RTS82K@T%!5%]?]J7 LY>58
MW$K5WGF5#P]GC2\"TM1<,PIAKV^H#9_ 4,^SC8J]4V!6L6@!&N5EXK,4<9S)
M5W%%!EMI>E)#92;9TZ]')54Z8:N+\W1S^(H30]P[[V_[KLYYP/+B$4K#K%E&
M?I"+*,71W3I$ )H/.]_-0CK&_-.NF;/"P8LN[5Z:Z]/+7Q:RBL+_RM,]"G\T
M;32PSVLX=3*Y#$EO"49*]Q;53,]I7C+*-(R[1Y ^^CN[I3^!\2W\GNM3D,!V
M[XCQY]</4_ADY;'*.G<>=;VN;8T0Y]@#QF]0;=M^J]:6ENVX3BAXET@H30IW
M&@(C=XHCK)?)@>D<?<A>.']<.'\Z6>JS"+J\A:EH^'9.]W5X=%DPF-X\WDYM
M#F*W,AMW23^N+?3#&:47Z425UFSG*HS/VE"688<J;EF& ZDVROO6B9F\(WG_
M^@)(!]S>K,?T(&,:!;"H-HG$G7VO)5]%8(7#JYQV)9^3$-/!XG=V?ZI'8^\N
MTXL7890Z2ES;92L>#=8(YJR@=W.G3,HDET,8P[1W0S[X.&\:Z_8M3$<]%!G[
M88K6'V>J?!V>$%GV4E4P(K:B.2+K_;F\%FXH^,@XRR$?&JCVIX[IIZ/3IZCN
M2\*?#),UM>%[5$D/M6Q3K"RC E^<4YA18]=/[+"IIP%"%P/>([[R>J@:XU^<
MHH**G_@;_#]DDPG*8,59L<4"7T?-8)+X822>:-=E9E,L9D&%S.//HZTY_Q]B
M8EMOCHK9 S+8M82L9WXG>^JI\^TBU]RZ7W;(C12$YO[@%HI/Q3@Y;*)[SHE
M..N0(GO*28-M"=_5(\-#/LA>K(HV$1$WF2(YM?!U4ZZ=IUY"37U43NK ].>:
MX"5WI5_E]RE4^IEB1L?T.Z]9U.:)MQG2$;S4*1O>N/ ]X6LN=E[R YX;  %+
M_'8ZH_ #8:<PX ,DQ))RVF26=UBYB=Y(65DVIF0]ODLX@Y"G@!/.D37@5-\M
MY?I+@MI>E>:'4?E>2IW3@><EN?V$E-TMBY//\E47E6[60]KY<:2K*\[B6LI$
M)'+=1.GV0G!Z/+Q#5!V2XU#OF/>EJ+'=QI.IE.JQX-M8YUCQ4V12LSC\XRU^
MO[-+Q_Z ]Q#M./L67=G,=OR\ >@?NG>K'H,#DYS:IJK4MF\ =Y3J3^:>47<D
MES;KN'Y_]:J;7=);C_JESN9BEN&AR/B1V=9FD<2SG[H%D0G,+NRT$'#C47,X
M)BTL#U\A/U[U\#.O>ZK,P3GO64+UJ0I;06!@/!$K4?AMIIJ-"C44J1G/*HX,
MKNU6&[<[2V3]G2)XD+T:K;RYQ;-TNSSV_:#C*%!WPJ-!-VEHIR?##8"*,H'H
MC/H&\!6A>CP4E?2-H:8#\4V_NOPAI-0QP3;;++*$C0W8,W'8M\SP+R!^+ X5
MI[E6,VN1)OXW]5$5.[$JGZ&GADG-F>0UT9]9F"(V-6JL&BW#.5RR]_Q3K#Q_
M!F7]2[&G 5/WO+6/;@"A++3CR.>5Y3B.&"_W%]-,-*<XR;JC1XP<C8$G@7BE
M16F>EN9G.+[2N%4'"/=[Q^;A%V=S5F0>B=.#R]--MC#:VRY!6% (#.24C;QD
M@UL=CFR6LG<GR0%^S-<<E3H5+<J4'$?;.4$23E"^*"!KR5(9RN2\,%)DK6F^
MW<=C'GLHK:^'2P\Y8LR %&S?VI OBN]$/9T[UK&?2!WDA3PI>,LD^AE)BC+N
M46P]0$;*T+8OJ,L;3NSX<>1T>%^BW]-L[=E9O'.4O\^MR.BA 8Y.1TQ<$V/7
MTA=EB2?MC-XC15+O/KD7O=C/\PJV1W /-N.CU?UQ,5!5U-$L;7LTJ\[0SUR;
M^85*)]=VSM7*:$UCR1B&C8L-RT/H]Q1JNB_3U<PVPK#O,5\1L='X]QPRFX)&
M^(W.L8XAW4&D>*!ZK8/5A"6XLCR6N$CLG39B<7!)"?9H:DS6"DPH&VQ9455=
M&Z%C$*K^;J;.XSL9\0O)EZ /5,[:)'QTFE&?WV/6FHJ1-?H%NJ]^AL>OA[3)
MB1*;UD".56S/6;J%<-/R;*/*9?(,B5[,_KH?!%4X?W>ZIF,KI1AO /*.03>
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M*TX<<JV,\C8EL-TE$"TTL M>/ENUU,][V.[!YTZ?R#Y'Q4G2C3(X\#E,.\[
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M[)WU[WNYB61EGQ,UL"&!!H@)X'809$8+WEB9CDE_CGL3]=)4<N^*?ZH&+O;
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M-:^[1V_??4CWP3S^H_R<=0\-0-B7?4\#_)4%]=$ @'+M(PE$)"4?N82FBM,
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M^<ISFIN;R/=:2H1T%"SZWY_ C&"]8;(YUO3J,SHHX^;,O1HSD]N/_)\G;=,
MG),.#!<>37TGGR?(9!-VV@1K<J/W!VSMB!<:',$C&QE%T0>UE?YNPSOZ\;]1
MAPF-+W7$L^<RUDIC4L7-O[JSS^Q9&QX>;90'^(^VMY>Y3V^*I>PV>D\>N>VX
M@&\1;0]"2#$$/74#L"<V-)L3O5Y[WW^E2T/JSR!&3LR9Z:W)J/];4!D-P$WF
M)A:]U1#%8M@VC]D;@R(7+Y+GE?"%"9V;-;=%+>/$+,+/O7VX#M0C->&4.W0I
MG\@&A,/6&>9.8U-CZG#4(K]M%V?MD%=1OW-";,APK?!OJW9\CPP:OG3:-1+K
M3P.T%Y)"3G'R5(,@L1=.M,GF$)_I@R.(#4X+N"-?[8U1SG+EW\!:Y3OLIS>G
M-=K;'$NV0'N^]J8J4&:1@2V*U28S:S7;H')V,WO4Q7_ZUGH[NHWYB#/OV!H;
M!ED#7Z4!/GG(%H)4B_X<4:-;4L.0Z1MO[-G-'%AV(O\?V (4/(7R&E=REG@G
M#7!R3=&4(IF6-+W:?@V8A% ^)=S&.:; @@VUK-OV=ZL47![V^35]#I<?$XI8
M<Z/D:R]AM?[M_HV40-?MX-4GIS5&3S]8A0;XU2\XB%A,[V##2I"?'.4^FP/S
MD\Z54,=LDEJ72=8A!?-AN8'(&*EFW6#)Z!.U(>J/>[WY=%$&WG=Q.1KI"\B.
MS"$ ^26I&LLOCW5()?YTZY'^&?9D SWW+.]AZR.-9:$&;CISIE25&XA$(A?^
MTD]0Z $^O35- $"8F-E@G7UJMSGY)A15]L4Y7"DX]/-+PQ_^AWH<],(\Q=JN
M/M%O3-LQ,_FXBH@\AX'0YQD67$)SC\:,>/M.NO6#1"KIDD12PN4,!L#'I2HC
MJZDS ;,3=4&-.X'YZT>YNA*/4QV>%F1D!1D\T\I\MEEQJFYS, S4\Z1#G//R
MG-9E0M=@]8'CR1%+\LT7XB*21I(2Y]Z^9G :T[I%9B)BVHQF/8'72'ZK]T,_
M/F)5%_G5%\_*^73ZXZ=/'Z_HA<!* F\6GDJ_)">P5%6347G#U,R(X2^@FC':
M&UWZSEL57P=W\V0ZY=PV-?(9YD0;M^64SJM,VOC6HUS7D_N[#6W32R%?EL#U
M*&Z8V61NC;M-KV]T3NT4$5^R$9)K'2TZOXV[%38UBI$Y5DK*! N?"(%?$*?>
M+Q)EXA8\9\L%GI+__$AV>Q%BSL/XZ??&]L4U2Y-0%T0X@;[U)MCWY/R&]K0
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M0,,AJJ0&V/P:@HTPCRXO?A;NG7?TPA;RL#/INN7]CWK<X:_#)/\R'+PG[G0
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M*FA$8XH^$?0[D.\1MTG5B_0C&J+?[#=M/CL&5-X[6R:LTI_8*<%(3+M1AY"
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MRI,SFGO-01GO)P=K#QFCKU3^UIN4>//61/+'X\BCI=0#Y)J_GG_=#>_9/_M
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M]9/_STVIT"LAL$:$*.24SSG(;(0EL"S);&':N\9V(M&'%91C;-C+ R]N_9W
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MYG(]2+^FE1@0XU.0S.55V5Q1$<>)B_=66:W0.==/ [@Q1]H$MP%C,J+?*]
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M>[J_Z[G7FX.\1-.#T :"\=#["O"=BEG284>.M$O2@XF D^!W%:+/SGLQM-,
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MDK%H6%.ICR=P*#2@LN=: "5:,S/HS4'P;"BX#&/.=6 P3#:H %5W7\+FLM,
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M3J/4VL6Q5#92/>PICFT#RSX.D<L)$<:HIMIP'>(26)&3R+Q\TOG%D[S3/MU
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MC=FIE4W('C3M3<)/ G)VE6Z<D(#\'8,&O^=D2?H<Y2=L>Y,!)%V@J*&V=QE
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M<,$'M'!P"FL)_%>2\_>LDZ"E? *("F 819'<D8PY\;L>E"SX/ IWA_R,UHN
M!_(TJA*X3@6P,.(J*%'@$"H %PBAT>^+5$#82X(I%: FV4P%$%2J?N5KX[0Y
MX,59.S3"3V/HP<!5>_(-&K9%$0TV7?^M@N>2+6@OQ1Q(DDY3 >:@Y4Z*-A6
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M<^\I</1.<4_OB7QX>?Q@.S)W^MZ!^\ND^H+1'83>]UT)^5F&=53 ; D#.-X
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MPR%K9]?U^WH>5N$VPR0V/(M/5K^\PO;#XL8)49N''CT)E?),UW<EUWH"W6@
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M'* /CR*92EB:]X)J92E@=Z;_F% 9? 8V!MP"ZY*C;\(I;\!CDU[_=Q!P[^^
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MC2:.*GH:+_+,E3PF\9$12#;8=W:G 5_VCH>KDGD=B=,'HR9R3T7<FW5<+L0
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M6EVG98;U3=?_8>^]PYI<VO71*"H*"()2%"4J("H"BA25$E$!$3&B]!85D4Y
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M$C9AUZ'*NV$Y]=-69E-T5=CF):X V!H3Y,8$?6KY.I:-H7 S06([2/,,W!)
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MN(92]9[^DD[+7E)FQW<S+#>"__H%H:^H972)4BYT"NG>?@JR.85[F]H<QO!
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M1@*S,Y&/:\7/V=F=?*FI=44Q?\?UL\2)%]1!LIEN*J/-;22_?2'MV:C]E2[
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MHWRXPBL77%OF$^G<],AZX<&!TFLJ9PT=G:)8A6H[B_\$S:./LL^I6NO>Z@,
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M2$&0L+@.TG 9&%I4WF<O.V#/UJ9>4/(YT++DAWG$S5.G#&K\+]_S:-S%$C=
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M84<6>/OS-CTO]U(/)QM'7E6D#+0"D^H!#W3U;!/Z<SV;3E%SCK.*658*JDW
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M&$S?W&X H]^]=:X,1I5= KSH<I#,"08_-%9K-S%=I07*DJ]>)H79QC[P%3T
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M.;34A_*,BQRYA><FBOM%AD2ERIJNR@]T78R8X+%K/E"R/_EB%-&F U4GQ5;
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M_;@[5WJ48O%ML,1A9J/PUVW;$0Y!CH&OO\2=SK/PL[[TV40STP'/6\T,2'0
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M)CWNQ_M.$+)0V)S(="_W[)W>, V"2QPZJ+S]^T(H<NN;I,C;N/DAT6W+]ZZ
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MZ3XM OU*V.L7O0SC6,,CAB$D*7!B58MZ&?01Z58Y5H$J?T0VO1&_QE5)#/G
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M/M+2N3M0N)32\\!4MRQ^Q71NTYM*.;!_<TGV]_)FR'3;0DC WN3FQAN+#CI
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M3K6B7N"*3;&*4![5P@.,@OO&GWMGRF[.8KG);*!CN!:X,+D8_D GF"D9Y-H
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M&0QRNH .:)<NRW^N9DJQR]:C[E->T@',C7IT0((9'<"JH$\'P$%G87B5$CJ
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M9*3O+/C]51G=NW]PC(G%67S-Y>XH.<DU=-I%%BR[1SWG1;P;,("JH@,T(CR
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MZN_>=,"MS1@Z@!@.H@,NWF.RT?&!3SBIT@$? S%T $4;3@>\*:$-DCJ.6)N
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MO]4IR9]% CTZ7L&3IGI[FQ^W';'1_O$BRB*Z2P9-J*'%CO1 F:_EIGDY#@G
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MAYEZ)@2(6(!L6#8RU&;%UY%_T:0&I!QQ@GKGB*'TW;UBX4+5!,ZY:J?35<2
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M6AS #_F%LQJ]3U^L&5C/.)7^=IY/3;)"772DU<QJ]S.M?]RWR;')L5'S%5'
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MH'2D1$5 Y*4+2(V*@-2(M "!*$J5HB"@@$2Z""%TI"5 * (BTIL0$GH))-1
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M4H\U+(HNG@T1L>O(_:+XU,,\))5/O4:\0;SA:VAO<5&*\..R'^."C[,RIAB
M5Y,4^ME7Q/+$7_?E]J?:<^Q_;*L2.H.<+^SU-_OM6,1G69K3&^B1TBG&W=J.
M#(!0OWD=+5=+SV>T#CC1P)51?2HF(%B9Z#.O1^>![HB^?,XQ6$\0P1?6Y9#K
M+,<(X=^O#&?K-U4ER^T-R=3BXU\M^9B6A:TEY=8&K&I(:7@@R9O[N]?%X]OO
MCF4.6:TV?$R*0TEZZ$A&=?ZQ0Y"Y65>523BGFSO)%G >!BO6H'H&,W&O=J!W
M'>>3&:&OH]RW$EP=K]EM)Q[S^:&4M.?Y7;* \$6&PN0*<[3S$5?6NVGL2L4$
M1 '?63^KJ6V!_9.GB'+WSGRV44Q=2G5*'=]43=W9FZPO.Z6@+B3[>Z3$%'!^
MIIR2WN##E!^4,TF>\[>W8&%1)L:^[RP"7.>^S;PJM0K@<"TD(.=*?KL#UAOD
ML=(GDW*%Z4$%RZA+M54,0)(NPC8LAQ"=JZK/.J;-\@PE37(JFC/V\+:T_DK1
M^_5<_E;D/?.!>V< PJEO]:2&/QI?V?BS@MN-Q<0"6E*TL.^_SEQ15[_(_WA#
M2L20WL$ D';G3/=E81_[PC1!U\+_\L#E%?VX-L?H%G)?VNFW,[1=_=U8L+"
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M582WU%:1I7^L;'I7K_AL..(^=LM=-GF\G9J(5P^/%E)'>N=F[B/#:ZFJE(9
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MGJ!_APKD7)I,W7^NW*QKT$1L(?%]K6M.]'Q1&@9_&&MB@E7X.'$,R;V&4F,
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MMM\WM.5 NN@W#\&TJ&HD3:$.:55&5;U>>$Z]52*<.<@2/+9EJ*-&JA8Q1;]
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MQ4%B<&04+#'[89RWB75#XNO;Z?:HC_W]'&0;'04FI0;_Z #\\ S (1?T/SV
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M!^!2;B^2;\,^@((O/#J5C55827F2(9\R^]Z_\234F(AN#9D7%B8&P@,4=1F
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M>;.I03IY I/3L =3*R"7FT]S4KQD=>>W4X:XS/87HBTH%D';HZ QXTC[Z<C
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M).F&ZGV3JU=LIFI43Q]W>&@@.)^RR#^V;DIBQ3_V?2+"Q0 \\?;K IZ9R]:
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MG7]6:.R98:OO>IMX<MDV]SQLZWS[.ROLK_]7/CVU @7NP/BP+8:)\;]O6,/
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MZ&06CF"%3)J5'T-X)7! ^C/=YR$LD4(R/CLDK[2$ I$"""UUNA.8##),:*&
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MQ:K4[I;VY2]JOVO_L'"<1GRIN=0M5W\(IQA^ P-AC\ON8\RTRL@U)Y(Y( G
M:GW([:L?5F16U;EPX8K*HEU73^JG'UY67RY(/U&*WF5 SSU%)6V:(5%V^5LO
MUKJ1LK,;Y][Y2,2V%A@Z">V%G10$20_Q+.DQRL@;2[Q%+,%=3X4%S^%5&0:]
M\6OCMX]\7;8(O*?L-+;:HS'AW RI&[4?#;=OOE9E=&)^;!.6Y'&>54K*Q9[*
M!U]+-Y_C(]7?(J(7TWII3-48&*[P8UD86VM ]S>JJO3N:P9BS59Z>K*9!BRV
MXYH-+.NXA(!5"MW,[G/#3H.^..KU9'9KF0SZ/&,O4-(@59#QAIS4/C]XY4OI
MT<LS1K*7SU.GOD!/]@.[)Y5_E]GQMN=P0 >I?ZO]YH#JM\58"E B@0CQ"=C,
M,EIFLQ<1;&GWE\-\#/LF" 0CA^F&BC= &1J">\?GA^VT$0*DCWO7*LMD77U3
M'/Q.69S.";'7*TY%;HBD9&8V0C_/ACD2>1%^,VPC'@HAC ,2:X#03\Y0P]!!
MC'Q2:ZR,/"IIX4KZDF#D#X/$+TF#]RXAK$92^+->:W$SF-@6B*0!0XY,B&BP
MV7O*QS/(H3JW_,TG,PV%D%KF>&(SW@AXO.V&5F:D+5J&P/.!^FN#N@X4R"$.
MZ+8=8#U$EA],9Z-T'_)6P29.'!9)/2G&=73EW#*4G^5 QHZL?B3L8XNB*ARB
MKC&\\O-&Y^S\DHWD,HJCE:F'B]PLBL.\^9YQ/]EO!AZ53WE[4?E(4B+;U+=^
M]O7FNA9E-$*[FU)Q?_/^")[DR5@,Y&FG1?>C;P CE#(N&.LV-@S*WP!&PF7+
MB[][5&_=R7DS+W9BVNB0C04'].8J=?3EH0J-TR@YXJZGTC?;QSHUD-8,$UE7
MC65NW#')%+-A6+]/CS[DLL?%\Y.EJMCSLU>Y0UOWM*%Q/)&8@X FDP(,9<OX
MT@[D;:T%^9>1>RZW/VUB:B,:PJ7G)&IVOOK\#@I^Z?.M'O;=G2U<HDE17>*E
M".Z5<C@W&5=74CPGTO9<C>$#KMWV?<_UZ.9EQ&:DV,$S'\&])G;6C652N!D_
MWQTIN']50\^\PXW&ZB1C=*7GH,>._8H\ /-CG&O!XBHQ4HR.5J7>(WPTD/&[
M6W!_YQ+?8)/PH/((7'4G&>S_6%Y9SC7)T#^!P'R/AQQDGT*+ ,6([=1$1]B!
M^:4O"OVT)B[,^>CI!$W9Z89F+%&0[(EM,E36_4-? 74!\$5K>8H4QP<-+X91
ME[8;LG4^CTPC-JMGM&; $]@FHV.)U@"$+*/RS6DCB!2O9F(O&AUY6,>L02B0
M&V'QH ?.-RJPQ"Q9\7.30E.69D^FG^_>QFV_*<2F5*VX#]VP$$BI^L<'^/O9
M(M ?MRI^=NTF<T"%4D'S"RG +OW\?2I[)[(R>T=K=/A_!C&<M;40GS 6E[_+
M=^[,1Y"?VE8/0_W=,%YZ$+%$H%(\C5T2>2!G+O% [;K>O3S19>+[PCLF)05F
M.8W\3KN5V"K+#^0PJ%;\#U1CJS)&N_WC+SY5RY"AVS77'O4N_S3N;3*#]X@G
ML(X,DR-SR*.J0G-X<0:[C-P><6Q0O5&SI9W2?7D\_ /3]<E;+>[#<JJ)9> 7
MVX=Z."#)F:I*;^OYCFM#)5XNR$;I8KTO4\[?5[1T5QT#MC4P Z3]#7*[9'JS
MBLZNI_0<Z[#I;]#S<PLDCZ;=+"MU2[EJ=1OG7.>L^+S&SQJ6D=Q44HR9&S ?
MM#3_L%RB (R@1TX[?C.?[L^R)*06K]1ORBW 8K*K IJSP_!@^LQC71?*][4>
MP583PA^-D5^FEU32;M>XK<C=WS]DF9Q0U<72W'67H6ANH):*4&W6%V',,''1
M?IIWETYQ0.4T\JKXB?N:G7M?;=[(NCIW"]L,X6,%T]T7X^D/C  _2!B9 <8G
M0YB54"']T>C7;J0C/K'(YV<CB9>]02 ;9SJ)+5G/%D&HLD4X(, 22X]&(I<$
M 4,.J I/JH"/3@62ZK\LU8Z/ZBW87C2LG&M,]L1M/F^_=L-%OP0V'1@5Q5*B
MT$8MVV'"52-X9:"73 O7U2P; Y 7O['XBU2R5CKO@>_4UJ8HJ>6,UUP#<165
M7=N)8\NA"ML<)1AECQJ0Q<<(E.P]0,),2__"GKUZK./@R<P!;^G7D]32B?OW
M/;L);AQ0')MG)]LO,0XK@/\=56%"OU-> /2:#RY9MHKYC,1V2^5^:#FE\.FP
MJWM$YUR'.I9IQ9B):A";A"9 9!H,@H]%34)$4!]F;I83ZG')JDX/?TOPD7QS
M7SYD](*%F;2U6OIUL\5M-1+0^*5Q/8TZ:OKVV(]A1_\T(&0!79DXN96)6S*G
MFH$]\%# C?Z@"2.?T43,CB]HJ!E 7[P;,VP=%/+NXI20%]GUR?OKP*:WJ<]Y
MT40*:>0<,P'P(</UCP'%%,50S-&,;IZH#LE00N-[?*3PJ?L&^H,ZTGOK3X,Z
M=5]*)C.C&>R(25(BH:*LO3CSBFI+<0;B\A^UP_X4XC@2T;?D]N1IBJ'2 %5\
M!BS6"HF6/;+SFN")?$@T:EG"=+1]!32":<*>0:F/O=.L4WW$=8O,"^)25%:D
M$3Q'!7RLC+6Z#A)KC4WZ8,N5"(69TA\#'N9I7C>H"WVLJ>7-8N482/7Z<%LO
M7[Q@:S>522=%&L7Y9IZ[]K5!Q37,I$CA.:\\OE;+7_%0KCA#'(*JU0UQ8\BU
MI)-B&R2*YF1E&6H3@H->8?)!@XUO;YEXU0]\,I=>FKA^-E*;>%-#X Q,@0-J
M,F2KHD380EA^ ,D6@0EP0,T&!<"H84WC-VB5T[;#.[C*3* SJ1%\(U(A%"3D
M.5LF@48 9@_HNVF4;!E53_ Z@$5U&-</+JI&].3 L?XN\%?*E9F HIQ74$S7
M^:]P3YI.X/;[:CR2E>9BE.]*6BG;.1FBF[:)G^D)*GS$LMH^B^G+/K"6+8!V
M8PRW!J*=WW3"2P";=LD/'@KW'EVC!1Y>M/1Z^C0[Y4'HN8<Q<VBD8 P!3B#&
MMI,.D8%X"C*2S4]7>>&L.S<YFN/RQL,FX(]O/)H*-]]=+<;=%9=G.TI0=N-!
MQ\?$&,C!4:8E _$.KSJL:X0HG,=(TF>B78?NE:U-RX_I=55^B&:"3H]8[+\J
M?5AO@?F<KOG13!AMA;!O)4F4LOE91A7]U!@*!]3"5HZ]3*BMT(F[R[YS)?8E
M]>[X1XGV?8XORU.JC#O]9TN\YF T_-#5Q"IYG$]B-G%H)^./B=1E.+O'KC"Z
MD@.*AHKBN5"TU@!]: 7]AT::Y)VR=\^"1QLU5H[METKEVHA[!%8)1(PQN2XS
MA1G\GZ$":'/Z\I9_33V I)B0#AG(/TH+UB*%%&M@YY(CQ!?#&C@@)@_@EZO:
MFAU#.JQ[(KAL09]_,#XK,<]S0KX^?9IFJS'?/K_Z.>W0IV_5@UJ@Q7LN^;ZD
M\EW2?)=U;Z=(O4@:G^U#M?H07].4RN?]@9K0%KI@9\@:2ET6P[PU-]XBFDV/
M?WI6@EKZDK39;@,##K/ E5>W\/\[WU#;3 +[J6,2NLUOS $5+!!W0\NOBD?_
M5W-K%/-+ U+*D\2KS]]Q_";Z 06<9IT8/@U/56)F1']:B%*2W/*369B;WX0P
M(Q,04"9]Y_FZ]H9*QBF[J9A/UX2N#;UZN]I^=6Z,\E*]V%2? TJZ#PLV1C?-
M7<M+G5=E$;AI*WJJ5+,EQ*3J"*W=3C%"UURT6(994M@=Z*2V<,:[0GS<Q=[7
M 'FFP-\);'5@\D><)7L_>W!"%)BC*,-:KM_%'*?;Q/K6B"Y36[+.?4O(Q#+]
MM6R']#Y+G+WP25M"0CJ& 2&Z4%0CV&#VQ&[$85VD\LWZEHBJ"LP_J<[QD;A;
MDO=T4'@\5-]N*E3%>__RU1(9U0Y'"8#$ >WCIN/+Z!MVE0R53#*,9Z*EU%-2
M=T$ORTL!5C&Z^<F_WOW!Y.'].D)PBXT!^^&,[*GN'F2GXL*8E=X7UTJ<8F]&
M*@>4L5TOH[)+9?=I[*179EZ:;Z=1S)[Y>2I=/H7];I>!\%.XZ6KO-!G^[>WN
MBRU6;H#3;9K22/O0)B(D]&6&O"SXF^Y%];B84R.9CU:CW6_<-G?QWG/+-;S'
M;H! WMV8E2KXIEUV++6H[QF2O00==42F)>,P6N-Q[M)W:@C$(+-HQR. "SV8
MHMHF7JFMCN0&IH<M&5R BDY4>;B9B[RAE4BX8E=I1F-GV_&5SLM$/V^"J?0S
M#DA0C^\996IQXP_KA;>Q.*I7.E,)&&W"J.W$H2WIV^VB6'&T)W67GWMB?JN@
M<T"/U;#2'B8AHJ-)GW"BI*,K&E =FZ*/\@]CMH/P)W;>X%508LS$&L"2/DHF
MQ:P1)#WKLF,K=^S\OJI\8]R[AWC>K;M:Z?8();['GCNY/V;+S!QH?.69=99A
MUF+&CXKL98MZ9>1),0IOM:ET^_Q.D9!A(I1JGSRSN+F?.\% 'QZLZ!<0:.L'
M-U0U,^J9>SMKD%9I'60+&^PR@3TC",QT8G&];00)H.PB8_H%G=JZA8M0@T4.
M\16AHAS[5+*(]O&&EV*1A?)%EYW-B;;>P>V%^QL+J;AVK!!:<R>;=0@OVQ"F
M*@4T(S0O]*OKF8:W>?KX",%5IDD;C^Y^@&IW[WD9-]P)D<0?9O=#]OU,<F6
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M;7]3"<N.8PL#4A3U\<SA6%TQ,NW(K9$X>],2^'6'!NF9'W#AF-5></D[ &;
M$(N:^5J%^+WEQM>9Z(LJ&8'WDNV-Q=N%<YUNE'&%G6GS,#?)K^.Q?V'#!O>I
MPP0(433?8+Z>?9.B/?EC=J^)SR^ #&_+>7T%2?DDG,P.8\N@+,GX;.6H1^@S
MKU%V[3:K\E5]OL [BC^;<7/PHO[ZUSZK03QE-LVE5]=X^SSZ.".ARN_= @=T
M2%>JU&/CGBSU^D #%.[C<PX$4I5KMTT 26>%VEPDDR+9A^F)D5/TY0@R0LR
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M%WF8#GSC3T(?&.U^J7?D_ 7&4G(<4BAC3O2.&84$L12F7*(XP6$:$:N3 ;8
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M86'U7\36:+NQ:N+7PVP$FV^GCSRN:5-N@/X3[%AT W:JFKSN^OWP9WLW-"2
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M#ESPU.$%^1:PQ;+W)9X-MA(<LC>R:N\2MX$*[D8ASF*/P"&!$^T+#"?2;A_
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MUGPLLKQH(YC(MX]YF37A&XSZ%#&/0.Y3-1]G@82$8 %IQ&,4)SX)8JNSIRY
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M*JO/V*.PK-Z+!W[U&J=>$=+J_BDK_Z&\'OT#\B#\!8Z3*&"*..KI>37'!.*
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M7LJ$=JL"/\3-*5?B<0Q3&G$OCE%4ASKE"J/!^D]?2U;JM6EOS(]H/UGX#=C
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M4&_-A@/UUYH%EUG*)NXXQ[G/ID(_<4:UB3OE.$_;U "&E*S-E^KO>=%@ZX[
MOU]E54:6.LG<(@Z(1V2 8!@%L9I+I@12[*GQ3" ?183A,#0Z%F?6W-RFC'N
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M5NYD,WEJ$DE'1"CUIA&4:1Q 1$D(L408<A+'+%:_2H75D>HS[<Q-M>^J1U'
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M9T_YJHZA7% >2,1P#$-"4XA\'<9#"85)J(1#(!DFPD@?S)N<FU*TH/7Z8][
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ML1I&[2',;?#;0:X/J=D59[NB)\P&JG'Y'7EXZ<"#78[UY+?&K]G>M0!\T3:
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M;J0 1HP;T KRTO:D,"P[*ANOM;'40T,C/K2*N@)L=S5U#5AA-9@7)^,JMVO
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M]BS#B8-QSS)\P#DZR_!ZB$=,\:!,:>\P^:NF_"==?)?EXRRFO,A)Q*!@4CO
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M<;#7H+:N@C]DOLD):/C7>DUJ\B&3I?SP"^O8N;$PKK?G!<^1"^CW%(\#]#8
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M*R281RW"@C[<]\R4E\;V_2";___4G,<^K!;Z&94)?*Q?OJX6"\VB*0V?%;'
MD4HR&&-AAJ)& F*")*0Q21F32"0)<SM*=:(_->.V8Q_\U GP-S,0;U^&_P4:
M*< ?1@[0"N(87W5=)CNU/"#X RO@ 7#W.-GU0B_P@:\;#R.? WL!='P\[/<8
M-X4HY'SVH75E/LXK3A?_)6GY4?^FFD5)P?+8%'6*7%NHJ120ID4$B39/>4)(
MQ*E5:7@/C:DIMHY-T/ )#*.@YM1.<?7!V:^< H$TM 7HCH^U@K% X(02T8[!
MW^]7S_^A[Z[UQ[^1^1$V/]9*H^^YHR@&"\&ZC]_F4L_CXI-M<6:(IYQ26D 2
MF2(DHAU0$A&AO_$,%U3%65Y(I\/ADV2F]IF':6)Z!E([(^1ZH ;^U"\V@/A-
MO_6T>NCZB08\Y.V%)NR1[FE2XQ[@]HI[=%S;?[6?<OB\6MZ;UOC&%>OF)B4R
M+3*BU4&!.40QYY"E$8)9AHB*4DQS5K@HAF,24U,*AD-HAH8 <1AQ<M,*)["T
MTPC7(32P-MB!4P>!PN>(GY<^Z =_@LRH'_MY,5]_Z#U7>AS,W6XT_/-&67R7
MCT^KDLY+^>'W]:+]94.B?6&3)):<,0(YC<U8Q01#5L0$YCGG,LF+A#M,+7<B
M/36EL,\\V'$//H =_Z!AW>$ RVTU+,[]!L-X8+7B *_/0:$;S@[GAX/A/=*Q
M8HC7VNW T0NQWG-(MR>.=SSI)>G!J:7?$SP/,X68FT?2Q1<Z%Y^6[^G3?$T7
M[2>12JD(B1E$-#4A()5!C%($>4%X@2G+8^[44*>7VN1T_Y998+B%GY:@Y=?Q
MR+$78LNCQ%# #:W07V$VWV(V@,UH!4K8L[Q>BN.>T=D(?W3V9G639U4QK1YN
ME\+\GXE./].%*62^7;^G9?DR7][7O<%F<82C7+ (,E$HB"3/M8=92$BX2A,L
MA8@C)[_2BNK4-(OAMDZ5KP,H<L>W8RFR%>)V"B8XC@,KFBV$]0][+-\ N@8=
MUTU3P8"5S"XHA:UNMJ(\;L6S"QA'5=!.-_L.#7LJ)9^W]CQ32:;B#+)82(B*
M)-6F3(XAEUC)+,MSD3D.^]H]?&KZ99\WU\%<>Y#9:0Y?((8^JK+!P&-BU;&P
M@2=-[1$8>4+4L6C'DYU.7.,?<UZW\:WO^A$?5H]TOIQEN9GJ*2BD.3)N!T&0
M)HS!A*8RC45<I.YQYV,R4_M@#\.K-\!P"OYH>'7,F3F#JWT,^CJT1HU#VP+E
M%8T^CT/PB/0)4J-'I<^+>RHRW7-UJ(R\XU&BLTBIC!/M,D0T+?0>GFOG(6<"
MHHBH."$DP\2IZ[@-T:FIBJN'+5LA;:<N0N,WL/(XDSYW8G[PD.ERYR$:.$?N
M!.$W3HP[#\7E;+B>>_TT4-=Z[?OJEFN/I)2O$Y5W2<I&\\TD+@AF5$&AE8]6
M02J#-"L(%!H;3E,>BZBPZW;IR8'5ES5NYTO]H ?S@:W4ZT/TW1"W;:V F]IR
M71X[#38$Y",WQ5RO0,L[L"C0"*?9/*$+JN1<>1A5WWD"]%KU^3[&\SQHE^)5
MW2[%;ZOEWMS&O4JZJLL3BE :4ZY@QA2!*$$II"RA,,(ICF*:()DXF62.]*=F
MG;U?+;0T*U->_2P/QJ&:6.7^O^_6#[($ZP=JAFKOW>1XMN2X7):G3<,MPM!A
MX:OQ'\";](0S[,F5(P_CGF7Y 71TNN7Y&&^/M>FZ+BMSF#:3DF4LXBD4*4<0
MY;F"C%'MH:8)3JEIPH6PHW.Z__RI:;JV>=S:\ >>-(/.7N@!>M8.IR\FP_N6
M[;@%#<>7/CA\7,A30H?V%@]HC.T8GA+PA ]X\C)/=Z]<<2E%]5&S\WF^E-6=
M:B8ES'">)D(5,<0JX1 )QB!#,M=?,V:"YRJAV*D9]EE*4_NDWZW*<O7G?'G?
M=LY<K/3F2.]+62M01W?M++R6CED(T(9VP5H>&[1J+HWGV_ 9T-&Z!$58E^HL
MM7&=ITM"'[E)%V_P2)O^8";8K>HF>%],8./[GZMN;J[$6CUD N8J9Q#%%$-:
M8 &53$@1%2J3A=4Y53^9J6F(/49!S2G0K#HDY)['LU\KA$-I8)5P$B"?U.7S
M2#FD*0=!;*249+=7RRWY^"(.O8G&Y^\>+ZGXH@0'"<27K_9LXFE\9NU6K0Z[
M&;<5@+-<%31)<PYC@K$VG!)M,^4B@SR.>5[0*,H2IXEV_>2FIAN;@,)/LN'N
M;^WT@1NPE(ZFTP64[>RG<-@-K#$;V/8YW?8E;YD-V9K<"I6P[2+[28[;+M)*
M_*-VD79W>9E7;/UI6:W+>H/Y4NI/9OY$%[=+T0U#:(/?7V0Y7XD99DP4@J<P
M9TIH!9-AR"*60Y4FJ6!%QB.[+L$^Q*>F;K8,UY'->3?SY*DMU7ZJF78R.-S6
MPLI@&PSAP<TX9J:C=*R#'=B:^>VXE&U=_)>AP7:R^08#?31+D)G9/5OPGVS>
M]%!SZ3SANV! NCUS3+/22]I7QJ;?,WSFD'[]N'=6LUK>=K&ISC7B4::T\0F)
M-"D919Q#+'*]/V""BX@3@6+[_>$"L>GM!ZM[#3 %7V4E-:P/X.-JLQ1-*>=/
M6IB_@0-QP*U;8,]J 2PVA8"P#AW> U_!QW.@^?CT%U]?AU&CX5 <:\;HUX^
M'V"YC2R#8$-%[5#IGR9ZX1DCCA&UD^9P?JCE/;YG)O*IKANL-B75 LPH5S)5
MJ- :EB80\2R#%$EJ?D(\X85*A%/[J-<$IJ=D:_Z,==(PZ'HH\@H_V[,0?U0&
M/P)I /ET$1"/8X_34@<^[7A%9.1#CM,B'I]MG+DN4*;KV<D_LR+G*(X*!E.2
M$(B,LTUBIK]RD7+.8X$$C:Y,<CU+W.HU?[/\UJ>6[=HID1W/5^:TGE\(2TT1
M%MRWRV1]-5?LYG"PV(!)K!<!&S9_]3SYMTU=O0C+Q:S5RT]P4V95N9[]2G_,
M'S>/K?F<,<3S3%#(4J&]/RES2"G)H"!(921C,:=6S4J.GCPU*Z1ESD[7'./4
MKTJNDGY@3='R%;"5R%EI^SYS?=/>)Z[_]?KS/G[J*%_O66&ZC_/\!1[!F%TG
MRO9;OSU,MN0/\J->^?:E*Q*)E.0*FI;2$)$$F3QQ E6,""4\25&46H=FG$A/
M[>N]V%BUE<#$;UR:RKFMAT6D9C"4!]823@#[Q''<D':(Z@R&^$@QGC"OMEO,
MQPNSW@B0VQ/'BP=Y27H0'?)[@F?SE7G%%ROML,H[M=^J^*NLA[N\7U7KJN:'
M[?%3W;)J75*^GD59G*,TR;2[67 S?$!!JF0$<Y[3(F>9=DR=LNFO8^<OMH>
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M0BYDK3ZW4:<'&<:!67)0T44[0ZAAW*2':<[!<\.Z0T:4[1KTJ[/@N(ZCQFI
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MR&>Y6#TU!Q]NB:I^ZV-I6PR%^M"61\NW<6:;=H>FBK#C':A5"3KN3:^:AO^
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M9NJ:%<40Y1)#PD4"<S-8)T4\C3)EHT;/$9B:#FUYK*WBEDVG\8EG@>S_WD/
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MH=L),,DJ>3T]BWIZMG_UE>MV,9*=.]/^3Q]OCWHQ GN[U<N?YB7->/O\.E)
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M?Y(O<K%Z-@^]?LAE65AS&\2=("13E2"888HABB-M=V<DA2B0<9+2!*?2/L?
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MZ8T,#_1&QL L6)"(2"2$B]EZM::+D1'>#OF[(WSAH9PC;N]Y'*<M^P[D_!W
MM2 9Y^C-##B-0[>6ZM;';>U[^M2>I&S[J'](8R3/(A$'B"<!#((LA8AR 0EG
M'*(T$F&81#3B]L5%WCY_:DRL'[^C!Y=BAV^1LS!*+\-CX._?0-$Z?J_D<[%"
MCV#B4NWQ(FS&*NW8QLA7^<:3BG?7:GQ[VXB%&4_*O%^%\?1E?4HFK>\?9=7K
M]48IF<^7#_5KIK(P0)0BF-#$E /7_T-"B:"0B)&4Q7%*['LVGAQF:MQUO09:
MTKI3,&AD=2F9<Q)0"R[S M/ E'8<H3[<=AHJE^)!/B ;JS:0V\OE6/CG'!#=
M=7U.WCUBV9YS&NQ7Y3E[M;^B.Z7;)R(L15(I*#G1A)BI#.K=-H:)S+C@ 6&$
MHDN+[4S1]UC7@/E37^+D13L+J-U.SP=,0UMY]@AY*93SUFTV8(&<\;QLMBK;
M%,3QX&G;;ZCT;9M]@M,L%2D/H>)Q"!$3 :0H9I DD50$<T(#IXCM$^-,C08.
M.GM=D"IT"E@[/O  U\!TT LI9V(X@X-77C@UUJBT<$;A0U8X=WD_4KB335^,
M&_5MM7RXE_F3&6E&5!IF*@A@S' $4<122((TA4&2""0B(7C(>L0SGAK/ZG5_
MCQC%6EP3K2"TG&[,<!)=.VJX"*QQN&$GHD'(" DU>3^!3UU8.7/#.2"\DL/)
MP49EAW,J']+#V>O=^U?<Y]2DE'U_?6*KQ2QA04*RD,(L,F=Q(4>013R )*)1
M$L>$29G:-D?<>_+4#(-:.%!)9]^A8A^N[B_\(A &_J0M]7?J0W%4U][])_:?
M-EK?B:-*M/M-'+^@AQ?S3NIU?L[U(G>]%+<R5ZO\J<P)7:_X/W\LY^MV19M9
M@@.]/F,)199%YA"&0!QH7DL1HVDB@I@@^Q BIZ&G]NGNA"]/)I]WXH/"R \V
M1@&P:M6C<@XX[3%!%I[2P6 ??/W?(FYJ-[0D!Z7HH)2]70%L,)0=G*R#H3V2
MX]4CZFY.V5[ =3IJW9XXGO.VEZ9[#MU^3_ <1?5'OBJ*6413'*99!EF9"\M%
M!'&$0Z@("42<QBA"3@5LNH>;VJIP;V*)P//1:!]/@3X5S':[.G_@#<SM9X)]
M2G%'"/?9@V6<@)]JR&F$_.RI;QWTLW]77]]0F7YY2_4 VK1=%I2WLK\)5H2&
M&86:SDVW61E AK3]&6EK,PPTI5!*7#BE<[2I44K3F*:4%K3$[=FBH1MJ6V^1
M)P '-QE[8]?#<62!B6?O4=>(([N0+)1_ZT>RN:G'GO:+-G]D_O'S31T3$88)
MS6B40!4S!%&(),2QP)!$81PIEI 09=:[UH.'3XTN*O& EL]A]W,(F,4N\@(8
M!O[H=PCTB:PYA,)AJW<!)"-MYBQ>#K=-V@F5.[=AA_>,M]$Z(>W>5NK4-7WM
MFA>YW,ABQ@5A3(3:9J&F"#,)$TB9PI"QA(8889$PIUX S8.G1C_5!BBOI',U
M3&JL;&T0=P0&-S<JD7P:%?M*>K8?ZH>/;"KLJ_36*CCX>P\#X./JZ<F4 U[Q
M?][)0N8O4NCO^LMFO<GEUZ+8&-](419TVU6TPW&@D H9##G#$"D<0<)H!E,<
MIUFB4"+"V-I(Z"' U+[D2H7:R=<H8;HI@$H-L-7#877M,S$6QLC < ],&_9(
MNU0A] .^@_DS\"2,9")Y>.W=3*@+8.LTL_H\=SQ3[ *M]\RU2Y[CV?_]]>F9
MSG/STXRB.!$493# 6$ D]?++XC"%/& \50F.9.)4L\=BS*DM'SO)MM$ZW^;F
M4RI;PEJN&2Z87^@1[X?D^[K%6QC_O%TMYOQUY/JT;T$;QVG>&G<:GO.W0%B[
MSX_<VL/B_7.U_/STO%B]RNK0K^I&5/LPDB!. ZE-6\0B;=J2A$*:1 A*R2(5
MQ1E/'))HNT::&@EI66$C;%&OZ96\#F93)[06QJDOP ;F&BTF:.3<@ZJ/%ZT3
M,P>;TA=V(QF/!D/98%B% 56%YWQU"+7!H],J['S >.:?C1Y[=I[5#5Z+-YI*
M7>94@C_*>PVIK%_>E"NAE&20\T1S*4<I))F*((FCE B*HS"UBH#K-?K4^/5H
MY;U= ;0K4*L 2AV\5%D\,2UVUM]@8 _,S6XXGR=L7W4-NX$;HU+A"0FF4'NP
M&QS+:H)G'M+#4OPNN=X;"Q.P7S_XNOZ&I$H#@A"&4@7:5J09A2Q"!"8AHH0K
MR2-B50*K>YC)<5@E:)E&LON0KAV,G=.(6EB'7G :FGZ.0]3',#R-E8-5Z 6S
MD4Q"U]?+S1X\BT2G,7CZ[O$LP;,:[)F!YZ_NP8@WZT>9&];-Y:,FWFV/R6^K
MHOBRRO4URX^;/)=+W@Y3N1;_9U.LZZI7-^J>_IKA6" I"($!SSA$,<X@B;2!
M&-.$!Z;J'45690Z\2C4UOKU^>,BKK$JP;@5D/=!Y1^W^ 2?-@J/?8RH&IO12
M);"G4]-0]V]&K;]?@5HST*BV%S^W4ZXLQ6=\O%K!]Y@_AW7C/>9QI&5FY/ET
M6Z5\X]ZYJ'D;;+PUT#<^>TNF]X?W\[(T8CS-RZ>V6M*R@"O"34>+1(40!4Q!
MFH4"!BR@0<A"):E3Y=V3(TUM)=Q^LXVD%Q0&.0VOG6?$"VACK5EN>#D[.\YB
MX=6Q<7JT49T89Y4^=%B<OV'D7CJ52[B=Z?;?FMP>35+<B\SI@_S\2^9\7LC;
M?,[E3 6,HRQ$D 7:3D>)Q!#'&$-CP@L6JXQ@-'LN.P5]7]-\?9$[U[?T+E_E
MH0[#?:"-Q)!6(@-9RVQZJG%YU<Z&O@),/LR72Y,8S>HVVR9!^L?W3R:9NDJ4
M'JLQC^NKPQ6F4K\P$NGW!\F$0F8JF>,$R0@3E.#MJ_-Y*7[S%Z?18"JOC:R2
MZ7^W=^:B XKW? M&/-KHV>2IUOVJG81^!1K]00T :!  )003Z/G4;\ZFT?_)
M4?8IG,<,-2'>^D+U'+Z?F?5Q5:P+$X?TRX@HBVM6K'.]]YNE41H+1AB4F53:
M+A(QQ"+!4"5I'.*0LPQ9Q<&?&VAJN[%2SC+"S@1JT;+5J*QE_B^W->4DMG:+
M@ _$!F;M'5B-D.!G(Z;'G=@Y)+QRX<G!1B6O<RH?LLW9ZWN6<F[5=?M32UYZ
MB-8SGDH5)F7['M-Z.DP32&-%H0P2)D.1$LF<JGL<'V9JU%"=W2TKMV@M(WA>
MY>Y=[D_ *B+."5(*)D' 392FAA6A&"8(141O*5B0X)E> ]AJ/&#;PPU()#3/
M7PW5OM#%1O8K?7D"5#NRO1RH@:EVO]#EE29<OMB46Z"/]9OX#[K>Y//UW&?B
M83<L?BMG'Q]JW+K9G>J^J9K=?76?H)P+;<:FI6C52+1E06Y-CQ@%41*0$$:9
M"$QP#X,T"5(8X31$&$4BY5;,/8ZX4UL!=GV$:PU<0EX&GUN+(^Q)S=AOY%*H
M)_Y&-5VC6ZK;F+SO\3JX1%)-Z;48*R)KI-?#5XC76%/4'2HVN!0CAIR-A>A^
MZ-IHH_;;\5TORA=1BN."UOO+&4M8AE*<0!EQ"E&"$20X0%"2()(XBE(916Y;
M%;N!I[=U*?-0:G[@;1ZIO49NFQA+^ /,8\2S!&)N@B5"E4&F=X>0!#P,XA0'
MG#AMP/V#/UZ5F>(])L!N5^D?UA%MIJ,9)I_/8.J\PW2#R.N.TW+H47>@;G <
M[D@=[^Y_9*#7'[J0195MOBL3PE/&-/DSF,H@@HC@"-(@D#!+42H193BVZWAY
M?JBI49&1U.P+2UG=CPE.X&E_4' Y2B,<%1B _EBM1'5D\%WF+W,NAZU9<!X;
M[X<')X8;_?B@6^UC!PAG[K@@D(N=-WC9"8.W/NTTM5L.SD'OI*D0JDW?CZME
M:?INZ,+XX\(9YUF:<*:MTY!D$.$L@DP0"K,8*YDPF2KE='CY#CI,C>"V<11-
M=$[>2*Z-KJWH8#%7\@J\R*+IB"%WJI=!.J^2YK:-+][S%7((U)GNB_$;>=A:
M2!P)VMFB 5IP (.'YP">]YE+_\$\(^LQ?F#/^TS4T2"?=Q+%O;W:Y^5ZOGZM
MSPOO9'ETO7SXOJ;K33'C21HK%!-(21) )% "F<HXC-(@UG9]FG&>V'9;ZQIH
M:@M;)>OV%'4K+:C$M>_&UHEN]W+B$[.!.;\O7$[-VVRPZ-W+K?/AH[5VLU&Q
MW>G-ZOH>1\ZWVNZO2NJ4="674LW7UYS+A8E^D^(O;<J97E<D%@0%<0(CFDI3
M/ Q#&LL$QA*%,D)"A+%]75S+0:=&%2T)2Q/7K;>8+=(6Q[@#X#<P;1B)P4YD
M4,M\!=J8_C48I@YGH0-@.]*)IA>,W4XE'<'J/%NT?=9X)X2.VNV=\[G>V\^Y
M\IGFQD8L;F7>N'SG_'HI/LT7&V-+-K$ B&@C+@LD3+B)VB1,0)*D(50A033
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M^Y2/4; ?/KH_JQQ O%W Y-6<GD;BF'[!G\(Z7+ U,;D4KH4%';,!%9F&Z)(
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M)=Q;>8(H;)S&M.U@<[B,#P?(8AUF#7SB7Q?S=,%'-"4'H2P(%1@H'@/94E5
M6I6"U(II\UC;P*'<XFN*>O",!PG:!Q%Y![;E[7+Q&9?KKV]GH0Y\R#50_%P/
MQNI6+'SPKJ &HR0)R%@&H;:QBBB**SRBDX_=-QZS;^VFJ@<?>1 (#2;Z#F#T
MAC@)M1KY-885OJNCK-Z4WVC_K>*:F&!C2$Z3IGFL#G\$3^X<;;\\."V",J*-
M__,H63UXT8, :3CA]X"D:W?MAE5E+!I%3AMP+6HS+?+=G-7DL?'(BR]D6]5C
M_6B.0-!#Y/3@,P^#G*.%W0%BMO1/M)):.I_!VD(;;]V"'=+N6\AIBV0SA8F/
MM<$]UB_NP2$>\#KB2>+LP 5^/0UQ.MLX8[25;NI*/BUF)/15W5;77Z]$HXOP
MA7,!B,F JLD_/@8'PN>,4H9H=!N8[$OAN"YR\XO1)HKJP K=X.MN7*J2CTS7
MN@->;UB02W"A1$ NDC/9&92/5?X, KFN+D_;8& WT(Y12 ?0>I92'7RQ>AN^
MUJ/TJ_L7*:/"HB#:D$DX@BRT<!XX$G>H>9"A37#_,#W=0.HH;=_=#(\7?1\
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MV3E%%==M=-!KSJ,@MF2L4X0SD,,@(9>,R H!/[9)!MF3P/WN8]AW JD66NG
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MN0D2;S+]\Q^U[!(GBDL4I7C0+B$H@;'>Q5+4F+SQ04MN;9LC^Z=2.FXG@^X
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MK$%)<! L,MK6G0_"):.=."WFKHGKU&T_$ _[PNU Y?1Z2? R3)>;,5^_D ]
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MU0A!$ :3%[9.%"UBH-S<TT0,UT)X?U<(;W:$L$GV$)$5)%JA,%T#<%O IYB
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M553+'*TR0@QB*?NG9<3Y+'T#[>D6):,(OH&S?H> FT8(45H>O-!@>92@F(F
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M0.,]&K8JZX-2: 6"<5K4V;H(Z%B-ZPM+3.I@S3"O9X]N9^2;M?[$/>^;]PT
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M1ZCW//IZ:-R=SY-&=P/ZCO@QG2VG<3-W@PGGM# "3.18YVY0[!M5 AZC*Q0
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MZ11YH\N@X^@=;K"QL3T]57=#<SP7;VIES:VXQBC(8$RMW)<B"!)@5N"<ITV
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MG2\>$!:ZU-ZL(U$.X-#Q9CPE,;VD!X^7/X>TOJ)<+QM!;JT)9(:#L72XEJ8
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ML43IQU'0+CPA>#9!.G"RR]$CDUW.LW3[-"XPX<&83N#3:9)_S\65Z10)DTR
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M0-;".@O5B$F5$C8,5P.D<B,$&BW\747?PE8R),P((8.<JF@!>).R: 'V#0#
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M4D/P6$]C]D%-ML1/L/N&19 ,MN3-?1WAYA->:A87D=1>F2PGL!(/Q4 AP+F
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M$@*KLI>F<I%CIJ[1 $54;0K8,=1>!XOD(8'<@%#:,U.)ZKJ@^&4TY,&QH%N
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MUA=]9:>8O'Y!0OJY5(V"B1&4>SN[3V*R5G@%47RA,YNGD<"930Y1DEUE^"<
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MZ,]>VW^:..SLTLGL/*/_@:+^: 0PMV"E$ K8.> R;"6BK*!(%[^.2-M!U,_
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M$,9#KJ<>,@)N_6%ELV)>6;%"5 8VG@*R'4"4L]N(.B/"1[P8[MV%4!6?'2K
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MI6=/^)9DZT2<BA:0;B,W,L=NSYGQ'#(\<;H_05TAN(8<-^K:9:OM9@)?RZ/
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M?]X!S-\GBOD.B98,182YBM(E61'.GE%VK)6O"]<XEK!.&[M0>O\#FBP*Z1S
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MQ:N&S#-QE$">PZ#/!X-NRCEP&'0SZ*6)X >'_TG0R Z*QS[.SQ2\:A12M\9
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M,#(R,3(S,5]D968N>&UL4$L! A0#%     @ 4Y1P5@BDPZ3QUP  ,3X! !0
M             ( !WU@$ &5I9W(M,C R,C$R,S%?9S$N:G!G4$L! A0#%
M  @ 4Y1P5@'&4$ARJP  VKX  !4              ( ! C$% &5I9W(M,C R
M,C$R,S%?9S$P+FIP9U!+ 0(4 Q0    ( %.4<%:2K;./3,T! "?? 0 5
M          "  :?<!0!E:6=R+3(P,C(Q,C,Q7V<Q,2YJ<&=02P$"% ,4
M" !3E'!68 .<4C^G 0#S4P( %0              @ $FJ@< 96EG<BTR,#(R
M,3(S,5]G,3(N:G!G4$L! A0#%     @ 4Y1P5D_,&\73I@$ $.@! !4
M         ( !F%$) &5I9W(M,C R,C$R,S%?9S$S+FIP9U!+ 0(4 Q0    (
M %.4<%;V^/CPU-$  (H4 0 5              "  9[X"@!E:6=R+3(P,C(Q
M,C,Q7V<Q-"YJ<&=02P$"% ,4    " !3E'!65!=:!#NA 0 'ZP$ %0
M        @ &ER@L 96EG<BTR,#(R,3(S,5]G,34N:G!G4$L! A0#%     @
M4Y1P5FS3QI4EBP$ <<\! !4              ( !$VP- &5I9W(M,C R,C$R
M,S%?9S$V+FIP9U!+ 0(4 Q0    ( %.4<%:#D2J8SNL  &@= 0 5
M      "  6OW#@!E:6=R+3(P,C(Q,C,Q7V<Q-RYJ<&=02P$"% ,4    " !3
ME'!6*T@Z/D74 0!87 ( %0              @ %LXP\ 96EG<BTR,#(R,3(S
M,5]G,3@N:G!G4$L! A0#%     @ 4Y1P5@*DB97**@  -2P  !4
M     ( !Y+<1 &5I9W(M,C R,C$R,S%?9S$Y+FIP9U!+ 0(4 Q0    ( %.4
M<%:[Q[?.E=X  , " 0 4              "  >'B$0!E:6=R+3(P,C(Q,C,Q
M7V<R+FIP9U!+ 0(4 Q0    ( %.4<%;@+D&.$#4! (!? 0 4
M  "  :C!$@!E:6=R+3(P,C(Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( %.4<%8G
M'^H<EFH! &5\ 0 4              "  >KV$P!E:6=R+3(P,C(Q,C,Q7V<T
M+FIP9U!+ 0(4 Q0    ( %.4<%:O[0RV/Y$! #NZ 0 4              "
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M2P$"% ,4    " !3E'!6"+2S]-TZ  "U$P$ &0              @ $S\1T
M96EG<BTR,#(R>#$R>#,Q97@Q,#0R+FAT;5!+ 0(4 Q0    ( %.4<%;N  A[
MP@D  $)#   9              "  4<L'@!E:6=R+3(P,C)X,3)X,S%E>#$P
M-#,N:'1M4$L! A0#%     @ 4Y1P5IEY3L=[!   YQ,  !@
M ( !0#8> &5I9W(M,C R,G@Q,G@S,65X,C,Q+FAT;5!+ 0(4 Q0    ( %.4
M<%8 GH]#_0<  !DG   8              "  ?$Z'@!E:6=R+3(P,C)X,3)X
M,S%E>#,Q,2YH=&U02P$"% ,4    " !3E'!6# OLF0P(   P)P  &
M        @ $D0QX 96EG<BTR,#(R>#$R>#,Q97@S,3(N:'1M4$L! A0#%
M  @ 4Y1P5GZ^=-K"!0  @!@  !@              ( !9DL> &5I9W(M,C R
F,G@Q,G@S,65X,S(Q+FAT;5!+!08     (  @ &<(  !>41X    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
